PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HUYGHE, BG; KLINMAN, JP				HUYGHE, BG; KLINMAN, JP			ACTIVITY OF MEMBRANOUS DOPAMINE BETA-MONOOXYGENASE WITHIN CHROMAFFIN GRANULE GHOSTS - INTERACTION WITH ASCORBATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; ELECTRON-TRANSFER; NOREPINEPHRINE BIOSYNTHESIS; VESICLE MEMBRANES; INSITU KINETICS; TRANSPORT; ACID; HYDROXYLASE; CELLS; MECHANISM	The role of intra- and extravesicular ascorbate has been investigated in dopamine beta-monooxygenase (D-beta-M) turnover using adrenal medulla chromaffin granule ghosts. Resealing of vesicle ghosts with high levels of intravesicular ascorbate leads to viable vesicles, as evidenced from the high rates of the ATP-dependent accumulation of tyramine, V(max) = 14 +/- 1 nmol/min.mg and K(m) = 20 +/- 6-mu-M. However, the D-beta-M-catalyzed conversion of tyramine to octopamine occurs slowly, V(max) = 0.50 +/- 0.13 nmol/min.mg and K(m) = 29 +/- 18 mm. When ascorbate is present instead in the external buffer, the D-beta-M rate increases 3.6-fold for a final V(max) = 1.8 +/- 0.2 and K(m) = 1.2 +/- 0.3 mM. This relatively high rate of enzyme turnover is retained in ghosts resealed with a large excess of ascorbate oxidase, ruling out contamination by intravesicular ascorbate as the source of enzyme activity. The synergistic effect of intravesicular ascorbate was examined under conditions of 2 mM external ascorbate, showing that the enzymatic rate increases 2.7-fold, from 1.2 (0 internal ascorbate) to 3.2 +/- 0.4 nmol/min.mg (saturating internal ascorbate). This result confirms that high levels of internal ascorbate are not damaging to intravesicular D-beta-M. These studies demonstrate very clearly that external ascorbate is the preferred reductant for the membranous form of D-beta-M in chromaffin granule ghosts.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIGMS NIH HHS [GM 25765] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025765, R01GM025765] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1989, J BIOL CHEM, V264, P12259; AHN NG, 1987, J BIOL CHEM, V262, P1485; BEERS MF, 1986, J BIOL CHEM, V261, P2529; BELPAIRE F, 1968, BIOCHEM PHARMACOL, V17, P411, DOI 10.1016/0006-2952(68)90251-7; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; DHARIWAL KR, 1989, J BIOL CHEM, V264, P15404; HERMAN HH, 1988, J BIOL CHEM, V263, P666; INGREBRETSEN OC, 1980, BIOCHIM BIOPHYS ACTA, V628, P182; JOHNSON RG, 1979, J BIOL CHEM, V254, P963; KELLEY PM, 1988, J BIOL CHEM, V263, P3799; KELLEY PM, 1986, J BIOL CHEM, V261, P6429; KENT UM, 1987, J BIOL CHEM, V262, P8174; KNOTH J, 1984, BIOCHEMISTRY-US, V23, P2011, DOI 10.1021/bi00304a020; LEVINE M, 1985, J BIOL CHEM, V260, P5598; LEVINE MA, 1983, FEBS LETT, V158, P134, DOI 10.1016/0014-5793(83)80693-0; MENNITI FS, 1987, J BIOL CHEM, V262, P7651; MENNITI FS, 1986, J BIOL CHEM, V261, P6901; PHILLIPS JH, 1974, BIOCHEM J, V144, P319, DOI 10.1042/bj1440319; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SAMUNI A, 1983, EUR J BIOCHEM, V137, P119, DOI 10.1111/j.1432-1033.1983.tb07804.x; SLATER EP, 1981, ARCH BIOCHEM BIOPHYS, V211, P288, DOI 10.1016/0003-9861(81)90456-2; STEWART LC, 1987, BIOCHEMISTRY-US, V26, P5302, DOI 10.1021/bi00391a013; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STEWART LC, 1991, J BIOL CHEM, V266, P11537; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TERLAND O, 1975, FEBS LETT, V59, P52, DOI 10.1016/0014-5793(75)80339-5; TIRRELL JG, 1979, NEUROSCIENCE, V4, P181, DOI 10.1016/0306-4522(79)90227-6; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9739; WINKLER H, 1970, BIOCHEM J, V118, P303, DOI 10.1042/bj1180303	29	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11544	11550						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050665				2022-12-25	WOS:A1991FT76200023
J	REED, KE; CRONAN, JE				REED, KE; CRONAN, JE			ESCHERICHIA-COLI EXPORTS PREVIOUSLY FOLDED AND BIOTINATED PROTEIN DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYPEPTIDE-CHAIN; CELL-ENVELOPE; SECB PROTEIN; SEQUENCE; GENE; TRANSLOCATION; MUTAGENESIS; REPRESSION; PEPTIDES; BINDING	Biotination of proteins is a post-translational modification that requires a folded acceptor domain. We previously showed that an acceptor domain fused to the carboxyl terminus of several cytosolic proteins results in biotinated fusion proteins in vivo. We now show that proteins encoded by translational gene fusions of two periplasmic proteins, alkaline phosphatase and TEM beta-lactamase, to carboxyl-terminal biotin-accepting sequences are biotinated and exported by Escherichia coli. Expression of the alkaline phosphatase fusion protein in wild type strains resulted in inefficient biotination of the fusion product. This result was due to the rapid export of the acceptor protein before biotination could occur since a very large increase in biotinated fusion protein levels was observed in strains lacking the SecB chaperone protein. The beta-lactamase fusion protein was biotinated but was only stable in strains lacking the DegP periplasmic protease. Both biotinated fusion proteins accumulated in the culture medium in strains possessing defective outer membranes. These results indicate that the export machinery can accommodate both a post-translational modification and a protein domain previously folded into its mature conformation in vivo.	UNIV ILLINOIS,DEPT MICROBIOL,131 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER DF, 1981, J MOL BIOL, V146, P469, DOI 10.1016/0022-2836(81)90043-7; CAVARD D, 1989, J BACTERIOL, V171, P6316, DOI 10.1128/jb.171.11.6316-6322.1989; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; CRONAN JE, 1988, GENE, V70, P161, DOI 10.1016/0378-1119(88)90114-X; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FALL RR, 1973, J BIOL CHEM, V248, P2078; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; KADONAGA JT, 1984, J BIOL CHEM, V259, P2149; KOHL J, 1990, NUCLEIC ACIDS RES, V18, P1069, DOI 10.1093/nar/18.4.1069; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; MEYER DI, 1988, TRENDS BIOCHEM SCI, V13, P471, DOI 10.1016/0968-0004(88)90233-2; Miller J.H., 1972, EXPT MOL GENETICS; MURTIF VL, 1987, J BIOL CHEM, V262, P11813; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; RADFORD SE, 1989, J BIOL CHEM, V264, P767; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; SUZUKI H, 1978, MOL GEN GENET, V167, P1; WOOD HG, 1980, J BIOL CHEM, V255, P7397	29	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11425	11428						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050659				2022-12-25	WOS:A1991FT76200006
J	BLACKSHEAR, PJ; HAUPT, DM; STUMPO, DJ				BLACKSHEAR, PJ; HAUPT, DM; STUMPO, DJ			INSULIN ACTIVATION OF PROTEIN-KINASE-C - A REASSESSMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; GROWTH-FACTOR; PHORBOL ESTERS; BC3H-1 MYOCYTES; 3T3-L1 CELLS; CELLULAR SUBSTRATE; GLUCOSE-TRANSPORT; PLASMA-MEMBRANE; PKC-EPSILON; PHOSPHORYLATION	Although insulin is known to activate several protein serine/threonine protein kinases, its ability to activate protein kinase C remains controversial. We reinvestigated this question, taking advantage of several technical advances such as the development of fibroblast cell lines that overexpress normal human insulin receptors, and the development of antibodies to and expression vectors for the myristoylated, alanine-rich C kinase substrate (MARCKS) protein, a major cellular substrate for protein kinase C. In HIR 3.5 cells, a mouse 3T3 cell derivative that expresses about 6 x 10(6) human insulin receptors/cell, insulin (70 nM for 10 min) stimulated phosphorylation of the MARCKS protein by approximately 2-fold (p < 0.005). This phosphorylation was not further increased by different times of insulin exposure, different insulin concentrations, or longer periods of serum deprivation. The insulin stimulation represented about 14% of the response to phorbol 12-myristate 13-acetate and about 17% of the response to 10% fetal calf serum. No significant stimulation of MARCKS protein phosphorylation was seen in four other insulin-sensitive cell lines, in which insulin is known to activate other protein serine/ threonine kinases: HIRC-B, BC3H-1, 3T3-L1 adipocytes, and H35 rat hepatoma cells made to stably express the MARCKS protein. In these four cell lines, serum and/or phorbol 12-myristate 13-acetate exerted a large stimulatory effect on MARCKS protein phosphorylation. We conclude that insulin may activate protein kinase C to a minor extent in certain cell types that vastly overexpress insulin receptors; however, we believe that this effect of insulin is unlikely to be of physiological importance.	DUKE UNIV,MED CTR,DEPT MED & BIOCHEM,DIV ENDOCRINOL METAB & GENET,DIABET & METAB SECT,DURHAM,NC 27710	Duke University	BLACKSHEAR, PJ (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,BOX 3897,DURHAM,NC 27710, USA.		Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BLACKSHEAR PJ, 1987, MOL ENDOCRINOL, V1, P44, DOI 10.1210/mend-1-1-44; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1988, AM J MED SCI, V31, P231; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHU DTW, 1987, MOL ENDOCRINOL, V1, P53, DOI 10.1210/mend-1-1-53; COOPER DR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P95, DOI 10.1016/0167-4889(90)90210-5; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; EGAN JJ, 1990, P NATL ACAD SCI USA, V87, P1052, DOI 10.1073/pnas.87.3.1052; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FARESE RV, 1989, DIABETES METAB REV, V5, P455, DOI 10.1002/dmr.5610050504; FARESE RV, 1985, ENDOCRINOLOGY, V116, P2650, DOI 10.1210/endo-116-6-2650; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; JAMES G, 1989, J BIOL CHEM, V264, P20928; KARLSSON FA, 1979, ENDOCRINOLOGY, V104, P1383, DOI 10.1210/endo-104-5-1383; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAI WS, 1990, J BIOL CHEM, V265, P16556; LEE RM, 1991, J BIOL CHEM, V266, P10351; LOBAUGH LA, 1990, J BIOL CHEM, V265, P18393; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MUNSON R, 1982, J CELL BIOL, V92, P350, DOI 10.1083/jcb.92.2.350; NEMENOFF RA, 1986, ARCH BIOCHEM BIOPHYS, V245, P196, DOI 10.1016/0003-9861(86)90205-5; NIEDEL JE, 1986, RECEPTOR BIOCH METHO, V7, P47; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5595; OPPENHEIMER CL, 1983, J BIOL CHEM, V258, P4824; PATRICK J, 1977, J BIOL CHEM, V252, P2143; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SALTIS J, 1990, J BIOL CHEM, V266, P261; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SHUBERT D, 1974, J CELL BIOL, V61, P398; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STANDAERT ML, 1984, J BIOL CHEM, V259, P2337; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; STUMPO DJ, 1991, J BIOL CHEM, V266, P455; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; TAUB R, 1987, J BIOL CHEM, V262, P10893; VILA MD, 1989, FEBS LETT, V244, P177, DOI 10.1016/0014-5793(89)81187-1; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WITTERS LA, 1987, METHOD ENZYMOL, V141, P412; WOODGETT JR, 1987, CELL MEMBRANES METHO, V3, P215; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	63	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10946	10952						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040611				2022-12-25	WOS:A1991FQ77400040
J	KLEANTHOUS, C; REILLY, M; COOPER, A; KELLY, S; PRICE, NC; COGGINS, JR				KLEANTHOUS, C; REILLY, M; COOPER, A; KELLY, S; PRICE, NC; COGGINS, JR			STABILIZATION OF THE SHIKIMATE PATHWAY ENZYME DEHYDROQUINASE BY COVALENTLY BOUND LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LYSOZYME; DENATURATION; TRANSITION; SITE	Reversible binding of a ligand to an enzyme active site can elicit a variety of changes in the protein, such as conformational changes (close to the site of binding or communicated over long distances), changes in the ionization state of surrounding amino acid side chains, changes in the interaction of the target protein with other subunits (or other proteins), or even changes in the thermodynamic stability of the protein. Relatively little attention has been given to studying these effects in proteins to which the ligand has been irreversibly bound, yet this can be a convenient way of studying the effects of ligand binding in the absence of association/ dissociation equilibria. We report the dramatic changes which occur to the shikimate pathway enzyme dehydroquinase when ligand is attached to its active site after borohydride reduction of the mechanistically important Schiff's base intermediates. The effects of this modification have been characterized by limited proteolysis, circular dichroism, guanidine hydrochloride denaturation, and differential scanning calorimetry. The conclusions from these studies are that although anchoring the ligand at the active site does not cause a gross change in conformation, it does increase markedly the conformational stability of the protein. This is conclusively established by three separate experiments: 1) the modified protein is completely resistant to proteases, whereas the unmodified protein is very susceptible to proteolysis; 2) the concentration of guanidine hydrochloride required to unfold the ligand-linked dehydroquinase is 3-4-fold greater than that of the unmodified protein; 3) the melting temperature (T(m)) of the modified protein is 40-degrees-C higher than that of the unmodified protein. These results are a very clear example of the thermodynamic link between ligand binding, conformational stability, and proteolytic susceptibility in vitro and will be a useful system for dissecting the contributions of individual protein-ligand interactions to these parameters.	UNIV GLASGOW, DEPT BIOCHEM, GLASGOW G12 8QQ, SCOTLAND; UNIV STIRLING, DEPT BIOL & MOLEC SCI, STIRLING FK9 4LA, SCOTLAND; UNIV GLASGOW, DEPT CHEM, GLASGOW G12 8QQ, SCOTLAND	University of Glasgow; University of Stirling; University of Glasgow			Cooper, Alan/F-7813-2011	Cooper, Alan/0000-0001-6709-7343; Kelly, Sharon/0000-0002-3516-1387				ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; BUGG TDH, 1988, TETRAHEDRON LETT, V29, P6783, DOI 10.1016/S0040-4039(00)82454-5; BUTLER JR, 1974, J AM CHEM SOC, V96, P1617, DOI 10.1021/ja00812a069; CHAUDHURI S, 1987, METHOD ENZYMOL, V142, P320; CHAUDHURI S, 1991, BIOCHEM J, V275, P1; CHAUDHURI S, 1986, BIOCHEM J, V239, P699, DOI 10.1042/bj2390699; COGGINS JR, 1987, METHOD ENZYMOL, V142, P325; GROSSMAN SH, 1976, BIOCHIM BIOPHYS ACTA, V452, P392, DOI 10.1016/0005-2744(76)90188-1; HARRINGTON WF, 1959, BIOCHIM BIOPHYS ACTA, V32, P303, DOI 10.1016/0006-3002(59)90601-8; IMOTO T, 1976, J BIOCHEM-TOKYO, V80, P1313, DOI 10.1093/oxfordjournals.jbchem.a131403; IMOTO T, 1974, BIOCHIM BIOPHYS ACTA, V336, P264, DOI 10.1016/0005-2795(74)90403-6; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10929; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10935; MITSUHASHI S, 1954, BIOCHIM BIOPHYS ACTA, V15, P54; Nozaki Y, 1972, Methods Enzymol, V26, P43; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; PACE CN, 1980, J BIOL CHEM, V255, P3862; PACE CN, 1984, BIOCHEM J, V219, P411, DOI 10.1042/bj2190411; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Privalov P L, 1986, Methods Enzymol, V131, P4; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SHRAKE A, 1990, J BIOL CHEM, V265, P5055; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; UEDA T, 1985, BIOCHEMISTRY-US, V24, P6316, DOI 10.1021/bi00343a042	26	25	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10893	10898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040606				2022-12-25	WOS:A1991FQ77400032
J	NAG, B; GLITZ, DG; TEWARI, DS; TRAUT, RR				NAG, B; GLITZ, DG; TEWARI, DS; TRAUT, RR			PROBING THE FUNCTIONAL-ROLE AND LOCALIZATION OF ESCHERICHIA-COLI RIBOSOMAL PROTEIN-L16 WITH A MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL TRANSFERASE-ACTIVITY; LICL-SPLIT PROTEINS; PEPTIDYLTRANSFERASE ACTIVITY; SUBUNIT INTERFACE; MICROSCOPIC LOCALIZATION; ELECTRON-MICROSCOPY; 50-S SUBUNITS; L16; IDENTIFICATION; PUROMYCIN	A monoclonal antibody specific for Escherichia coli ribosomal protein L16 was prepared to test its effects on ribosome function and to locate L16 by immunoelectron microscopy. The antibody recognized L16 in 50 S subunits, but not in 70 S ribosomes. It inhibited association of ribosomal subunits at 10 mM Mg2+, but not at 15 mM Mg2+. Poly(U)-directed polyphenylalanine synthesis and peptidyltransferase activities were completely inhibited when the L16 antibody was bound to 50 S subunits at a molar ratio of 1. There was no inhibitory effect on the binding of elongation factors or on the associated GTPase activities. Fab fragments of the antibody gave the same result as the intact antibody. Chemical modification of the single histidine (His13) by diethyl pyrocarbonate destroyed antibody binding. Electron microscopy of negatively stained antibody subunit complexes showed antibody binding beside the central protuberance of the 50 S particle on the side away from the L7/L12 stalk and on or near the interface between the two subunits. This site of antibody binding is fully consistent with its biochemical effects that indicate that protein L16 is essential for the peptidyltransferase activity activity of protein biosynthesis and is at or near the subunit interface.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Davis; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIGMS NIH HHS [GM 17924] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017924, R37GM017924] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAXTER RM, 1987, EUR J BIOCHEM, V163, P473, DOI 10.1111/j.1432-1033.1987.tb10893.x; BAXTER RM, 1978, EUR J BIOCHEM, V91, P49, DOI 10.1111/j.1432-1033.1978.tb20935.x; BAXTER RM, 1980, EUR J BIOCHEM, V110, P161, DOI 10.1111/j.1432-1033.1980.tb04851.x; BROSIUS J, 1976, FEBS LETT, V68, P105, DOI 10.1016/0014-5793(76)80415-2; COOPERMAN BS, 1975, P NATL ACAD SCI USA, V72, P2974, DOI 10.1073/pnas.72.8.2974; COVER JA, 1981, BIOCHEMISTRY-US, V20, P2843, DOI 10.1021/bi00513a021; Dabbs ER, 1986, STRUCTURE FUNCTION G, P733; Engvall E, 1980, Methods Enzymol, V70, P419; FERRIS RJ, 1984, BIOCHEMISTRY-US, V23, P3434, DOI 10.1021/bi00310a009; Galfre G, 1981, Methods Enzymol, V73, P3; GARRETT RA, 1981, TRENDS BIOCHEM SCI, V6, P137, DOI 10.1016/0968-0004(81)90051-7; GODING JW, 1982, ANTIBODY TOOL; HAENNI AL, 1966, BIOCHIM BIOPHYS ACTA, V114, P135, DOI 10.1016/0005-2787(66)90261-9; HAMPL H, 1981, J BIOL CHEM, V256, P2284; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; KENNY JW, 1979, J MOL BIOL, V135, P151, DOI 10.1016/0022-2836(79)90345-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LAMBERT JM, 1981, J MOL BIOL, V149, P451, DOI 10.1016/0022-2836(81)90481-2; LITTLECHILD J, 1987, BIOCHIM BIOPHYS ACTA, V913, P245, DOI 10.1016/0167-4838(87)90336-0; MAIMETS T, 1983, EUR J BIOCHEM, V135, P127, DOI 10.1111/j.1432-1033.1983.tb07627.x; Monro RE., 1971, METHOD ENZYMOL, V20, P472; MOORE VG, 1975, P NATL ACAD SCI USA, V72, P844, DOI 10.1073/pnas.72.3.844; NAG B, 1987, J BIOL CHEM, V262, P9681; NAG B, 1986, J BIOL CHEM, V261, P13892; NICHOLSON AW, 1982, BIOCHEMISTRY-US, V21, P3797, DOI 10.1021/bi00259a013; OFENGAND J, 1986, STRUCTURE FUNCTION G, P473; OLSON HM, 1985, J BIOL CHEM, V260, P326; OLSON HM, 1988, J BIOL CHEM, V263, P4801; OLSON HM, 1986, J BIOL CHEM, V261, P6924; OLSON HM, 1991, J BIOL CHEM, V266, P1898; OLSON HM, 1982, J BIOL CHEM, V257, P2649; PESTKA D, 1971, METHOD ENZYMOL, V20, P502; ROMERO DP, 1990, J BIOL CHEM, V265, P18185; SCOTT JF, 1968, METHODS ENZYMOL B, V121, P173; SOMMER A, 1985, J BIOL CHEM, V260, P6522; STOFFLER G, 1985, STRUCTURE FUNCTION G, P28; TATE WP, 1987, EUR J BIOCHEM, V165, P403, DOI 10.1111/j.1432-1033.1987.tb11453.x; TERAOKA H, 1978, FEBS LETT, V88, P223, DOI 10.1016/0014-5793(78)80179-3; TEROKA H, 1978, J MOL BIOL, V126, P185; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; Traut R. R., 1980, RIBOSOMES STRUCTURE, P89; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; ZIMMERMANN RA, 1976, BIOCHEMISTRY-US, V15, P2007, DOI 10.1021/bi00654a031; ZUBAY G, 1966, PROCEDURES NUCLEIC A, P455	45	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11116	11121						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040621				2022-12-25	WOS:A1991FQ77400064
J	PHILLIPS, WJ; CERIONE, RA				PHILLIPS, WJ; CERIONE, RA			LABELING OF THE BETA-GAMMA SUBUNIT COMPLEX OF TRANSDUCIN WITH AN ENVIRONMENTALLY SENSITIVE CYSTEINE REAGENT - USE OF FLUORESCENCE SPECTROSCOPY TO MONITOR TRANSDUCIN SUBUNIT INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; NUCLEOTIDE-BINDING PROTEINS; ALPHA-SUBUNITS; AFFINITY-CHROMATOGRAPHY; INTRINSIC FLUORESCENCE; REGULATORY PROTEINS; GUANINE-NUCLEOTIDES; PERTUSSIS TOXIN; BOVINE BRAIN; PHOSPHODIESTERASE	In this study, we have examined the interactions of the beta-gamma subunit complex of the retinal GTP-binding protein transducin (beta-gamma-T) with its alpha-subunit (alpha-T) using fluorescence spectroscopic approaches. The beta-gamma-T subunit complex was covalently labeled with 2-(4'-maleimidylanilino) naphthalene-6-sulfonic acid (MIANS), an environmentally sensitive fluorescent cysteine reagent. The formation of the MIANS beta-gamma-T complexes (two to five MIANS adducts per beta-gamma-T) resulted in 2-3-fold enhancements in the MIANS fluorescence, and 20-25-nm blue shifts in the fluorescence emission maxima, relative to the emission for identical concentrations of MIANS-labeled MIANS complexes. The addition of alpha-T.GDP to these MIANS beta-gamma-T complexes resulted in an additional enhancement in the MIANS fluorescence (typically ranging from 20 to 40%) and a 5-10-nm blue shift in the wavelength for maximum emission. These fluorescence changes were specifically elicited by the GDP-bound form of alpha-T and were not observed upon the addition of purified alpha-T.guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S) complexes to the MIANS beta-gamma-T species. Conditions which resulted in the activation of the alpha-T.GDP subunit (i.e. the addition of AlF4- or the addition of rhodopsin-containing vesicles and GTP-gamma-S) resulted in a reversal of the alpha-T.GDP-induced enhancement of the MIANS beta-gamma-T fluorescence. Thus the MIANS beta-gamma-T fluorescence provided a spectroscopic monitor for transducin-subunit association and transducin-activation. Based on the results from studies using this spectroscopic read-out, it appears that the association of the alpha-T.GDP species with the beta-gamma-T subunit complex to form the holotransducin molecule is rapid and does not limit the rate of the rhodopsin-stimulated activation of holotransducin. However, either the dissociation of the activated alpha-T subunit from the beta-gamma-T complex, or a conformational change in beta-gamma-T which occurs as a result of the subunit dissociation event, appears to be slow relative to the G protein-subunit association event.			PHILLIPS, WJ (corresponding author), CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853, USA.				NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NEI NIH HHS [EY06429] Funding Source: Medline; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BAEHR W, 1979, J BIOL CHEM, V254, P1669; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CODINA J, 1984, J BIOL CHEM, V259, P1408; DETERRE P, 1984, FEBS LETT, V178, P228, DOI 10.1016/0014-5793(84)80606-7; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P25; HO YK, 1984, J BIOL CHEM, V259, P6694; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KATADA T, 1986, J BIOL CHEM, V261, P8182; KOHNKEN RE, 1981, J BIOL CHEM, V256, P2502; KOHNKEN RE, 1989, J BIOL CHEM, V264, P20688; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; RANSNAS LA, 1988, J BIOL CHEM, V263, P15348; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135	27	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11017	11024						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040617				2022-12-25	WOS:A1991FQ77400050
J	JOHNSON, MR; BARNES, S; KWAKYE, JB; DIASIO, RB				JOHNSON, MR; BARNES, S; KWAKYE, JB; DIASIO, RB			PURIFICATION AND CHARACTERIZATION OF BILE ACID-COA-AMINO ACID N-ACYLTRANSFERASE FROM HUMAN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLYL-COA; GLYCINE-TAURINE; COENZYME-A; RAT-LIVER; POLYACRYLAMIDE GELS; BOVINE LIVER; SUBSTRATE; PROTEINS	The bile acid-conjugating enzyme, bile acid-CoA: amino acid N-acyltransferase, was purified 480-fold from the soluble fraction of homogenized frozen human liver. Purification was accomplished by a combination of anion exchange chromatography, chromatofocusing, glycocholate-AH-Sepharose affinity chromatography, and high performance liquid chromatography (HPLC) gel filtration. Following purification, the reduced, denatured enzyme migrated as a single 50-kDa protein band by sodium dodecyl sulfate-polyacryl-amide gel electrophoresis. A similar molecular mass was obtained for the native enzyme of HPLC gel filtration. Elution from the chromatofocusing column suggested an apparent isoelectric point of 6.0 (+/- 0.2). Using a rabbit polyclonal antibody raised against the purified enzyme, Western blot analysis using 100,000 x g human liver supernatant confirmed that the affinity-purified polyclonal antibody was specific for human liver bile acid-CoA:amino acid N-acyltransferase. The purified enzyme utilized glycine, taurine, and 2-fluoro-beta-alanine (a 5-fluorouracil catabolite), but not beta-alanine, as substrates. Kinetic studies revealed apparent K(m) values for taurine, 2-fluoro-beta-alanine, and glycine of 1.1, 2.2, and 5.8 mM, respectively, with corresponding V(max) values of 0.33, 0.19, and 0.77-mu-mol/min/mg protein. These data demonstrate that a single monomeric enzyme is responsible for the conjugation of bile acids with glycine or taurine in human liver.	UNIV ALABAMA,DEPT PHARMACOL,BOX 600,VOLKER HALL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,CTR COMPREHENS CANC,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [R01CA040530, R37CA040530] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHERSTEN T, 1967, BIOCHIM BIOPHYS ACTA, V141, P155; ALLEN G, 1989, LABORATORY TECHNIQUE, P58; BARNES S, 1991, OXFORD TXB CLIN HEPA; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BREMER J, 1956, ACTA CHEM SCAND, V10, P56, DOI 10.3891/acta.chem.scand.10-0056; CZUBA B, 1986, J BIOL CHEM, V261, P6260; CZUBA B, 1981, BIOCHIM BIOPHYS ACTA, V665, P612, DOI 10.1016/0005-2760(81)90278-2; CZUBA B, 1980, J BIOL CHEM, V255, P5296; CZUBA B, 1981, BIOCHEM J, V195, P263, DOI 10.1042/bj1950263; ELLIOTT WH, 1955, BIOCHIM BIOPHYS ACTA, V17, P440, DOI 10.1016/0006-3002(55)90394-2; HARDISON WGM, 1978, GASTROENTEROLOGY, V75, P71; Haslewood G. A. D, 1967, BILE SALTS; Hofmann A. F., 1989, HDB PHYSL, P549; JOHNSON MR, 1990, BIOCHEM PHARMACOL, V40, P1241, DOI 10.1016/0006-2952(90)90389-3; JOHNSON MR, 1989, ANAL BIOCHEM, V182, P360, DOI 10.1016/0003-2697(89)90608-8; KASE BF, 1989, J BIOL CHEM, V264, P9220; KILLENBERG PG, 1978, J LIPID RES, V19, P24; KILLENBERG PG, 1978, J BIOL CHEM, V253, P1005; KILLENBERG PG, 1976, J LIPID RES, V17, P451; KIMURA M, 1983, H-S Z PHYSIOL CHEM, V364, P637, DOI 10.1515/bchm2.1983.364.1.637; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; SCHERSTE.T, 1967, BIOCHIM BIOPHYS ACTA, V141, P144, DOI 10.1016/0304-4165(67)90253-X; SCHERSTEN T, 1971, METAB CONJUGATION, P75; SHAH PP, 1968, STEROIDS, V12, P571, DOI 10.1016/S0039-128X(68)80034-0; SIPERSTEIN MD, 1956, SCIENCE, V123, P377, DOI 10.1126/science.123.3192.377; SJOVALL J, 1959, P SOC EXP BIOL MED, V100, P676; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESSEY DA, 1979, J BIOL CHEM, V254, P2059	29	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10227	10233						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037576				2022-12-25	WOS:A1991FP08600037
J	KRAUSE, G; LUNDSTROM, J; BAREA, JL; DELACUESTA, CP; HOLMGREN, A				KRAUSE, G; LUNDSTROM, J; BAREA, JL; DELACUESTA, CP; HOLMGREN, A			MIMICKING THE ACTIVE-SITE OF PROTEIN DISULFIDE-ISOMERASE BY SUBSTITUTION OF PROLINE 34 IN ESCHERICHIA-COLI THIOREDOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL 4-HYDROXYLASE; MOLECULAR-CLONING; BETA-SUBUNIT; REDUCTION; SEQUENCE; GENE; PURIFICATION; RESOLUTION; INSULIN; T4	To mimic the active sites (Trp-Cys-Gly-His-Cys) contained in two thioredoxin-like domains of the eukaryotic enzyme protein disulfide-isomerase (PDI, EC 5.3.4.1), the Pro-34 residue of Escherichia coli thioredoxin (Trx) was replaced by His using site-directed mutagenesis. The mutant P34H Trx was isolated in high yield and was stable. The equilibrium between Trx and NADPH in the thioredoxin reductase (TR)-catalyzed reaction revealed that the redox potential (E0') or P34H Trx at pH 7.0 was -235 mV as compared with -270 mV for wild type (wt) Trx. The higher E0' value made P34H Trx more similar to PDI and contributed to prominent changes in Trx functions, e.g. improved activity with TR and slower reduction of protein disulfides. Compared to wt Trx, the P34H oxidized Trx was about twice as good a substrate for TR from E. coli and four times as efficient with calf thymus TR. A novel fluorimetric assay permitted direct recording of the reaction between insulin disulfide(s) and reduced Trx. At pH 8 and 15-degrees-C, second-order rate constants for wt Trx of 2 x 10(4) M-1 s-1 and for P34H Trx of 3 x 10(3) M-1 s-1 were obtained, and a different equilibrium was observed consistent with differences in E0' values. Also when the reduction mechanism of insulin was examined using NADPH and TR, P34H Trx behaved differently from wt Trx or PDI. P34H Trx may be useful as an analogue of PDI for disulfide formation in vivo and in vitro.	KAROLINSKA INST, DEPT PHYSIOL CHEM, BOX 60400, S-10401 STOCKHOLM 60, SWEDEN	Karolinska Institutet			Krause, Günter/A-1858-2012; Lopez-Barea, Juan/K-7258-2014	Krause, Günter/0000-0003-3905-0921; Lopez-Barea, Juan/0000-0002-2280-3379				BERGLUND O, 1970, J BIOL CHEM, V245, P6030; Clark W. M., 1960, OXIDATION REDUCTION; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4219; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FREEDMAN R, 1987, NATURE, V329, P196, DOI 10.1038/329196a0; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JOELSON T, 1990, J BIOL CHEM, V265, P3183; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; LANGSETMO K, 1989, BIOCHEMISTRY-US, V28, P3211, DOI 10.1021/bi00434a015; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MOORE EC, 1964, J BIOL CHEM, V239, P3453; NILSSON O, 1990, BIOCHEM BIOPH RES CO, V171, P581, DOI 10.1016/0006-291X(90)91186-V; ODONNELL ME, 1983, J BIOL CHEM, V258, P3795; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; RUSSEL M, 1985, J BACTERIOL, V163, P238, DOI 10.1128/JB.163.1.238-242.1985; RUSSEL M, 1985, P NATL ACAD SCI USA, V82, P29, DOI 10.1073/pnas.82.1.29; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALLACE BJ, 1984, GENE, V32, P399, DOI 10.1016/0378-1119(84)90015-5; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	241	246	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9494	9500						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033048				2022-12-25	WOS:A1991FM45900028
J	OHYAMA, Y; OKUDA, K				OHYAMA, Y; OKUDA, K			ISOLATION AND CHARACTERIZATION OF A CYTOCHROME-P-450 FROM RAT-KIDNEY MITOCHONDRIA THAT CATALYZES THE 24-HYDROXYLATION OF 25-HYDROXYVITAMIN-D3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D; LIVER MICROSOMES; SUBCELLULAR LOCATION; BIOLOGICAL-ACTIVITY; PURIFICATION; "25-HYDROXYVITAMIN-D3-24-HYDROXYLASE; METABOLITE; 1,25-DIHYDROXYVITAMIN-D3; PROTEINS; 25-HYDROXYCHOLECALCIFEROL	A cytochrome P-450 that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3 (P-450cc24: P-450cholecalciferol24) was purified to electrophoretic homogeneity from the kidney mitochondria of female rats treated with vitamin D3 (Ohyama, Y., Hayashi, S., and Okuda, K. (1989) FEBS Lett. 255, 405-408). The molecular weight was 53,000, and its absorption spectrum showed peaks characteristic of cytochrome P-450. The turnover number was 22 min-1 and the specific content was 2.8 nmol/mg protein. The N-terminal amino acid sequence, Arg-Ala-Pro-Lys-Glu-Val-Pro-Leu-, is different from the N-terminal sequence of any other cytochrome P-450s so far reported. Upon reconstitution with the electron-transferring system of the adrenal mitochondria, the enzyme showed a high activity in hydroxylating 25-hydroxyvitamin D3 as well as 1-alpha,25-dihydroxyvitamin D3 at position 24. However, the purified enzyme hydroxylated neither vitamin D3 nor 1-alpha-hydroxyvitamin D3. The enzyme was also inactive toward xenobiotics. The enzyme hydroxylated 25-hydroxyvitamin D3 at position 24 but not at 1-alpha, indicating that the enzyme is distinct from that catalyzing 1-alpha-hydroxylation. The reaction followed Michaelis-Menten kinetics, and the K(m) value for 25-hydroxyvitamin D3 was 2.8-mu-M. Both vitamin D3 and 1-alpha-hydroxyvitamin D3 inhibited the 24-hydroxylation of 25-hydroxyvitamin D3 in a competitive, concentration-dependent manner. 25-Hydroxyvitamin D3 24-hydroxylase activity was significantly inhibited by 7,8-benzoflavone, ketoconazole, and CO, whereas it was only slightly inhibited by aminoglutethimide, metyrapone, and SKF-525A. Mouse antibodies raised against the cytochrome P-450 inhibited the reaction about 70% and reacted with the P-450cc24 in immunoblotting but did not react with other kinds of cytochrome P-450 in rat liver microsomes and mitochondria.			OHYAMA, Y (corresponding author), HIROSHIMA UNIV, SCH DENT, DEPT BIOCHEM, 1-2-3 KASUMI, MINAMI KU, HIROSHIMA 734, JAPAN.							BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491; BURGOSTRINIDAD M, 1986, BIOCHEMISTRY-US, V25, P2692, DOI 10.1021/bi00357a061; CHANDLER JS, 1984, J BIOL CHEM, V259, P2214; CORVOL MT, 1978, ENDOCRINOLOGY, V102, P1269, DOI 10.1210/endo-102-4-1269; Cuatrecasas P., 1971, METHOD ENZYMOL, V22, P345; DEXTER RN, 1967, J CLIN ENDOCR METAB, V27, P473, DOI 10.1210/jcem-27-4-473; GHAZARIAN JG, 1974, ARCH BIOCHEM BIOPHYS, V160, P63, DOI 10.1016/S0003-9861(74)80009-3; GLASS WF, 1981, ANAL BIOCHEM, V115, P219, DOI 10.1016/0003-2697(81)90549-2; GRAY RW, 1989, BIOCHEM J, V259, P561, DOI 10.1042/bj2590561; Harding B W, 1969, Adv Enzyme Regul, V7, P237, DOI 10.1016/0065-2571(69)90021-1; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HAYASHI S, 1986, J BIOCHEM-TOKYO, V99, P1753, DOI 10.1093/oxfordjournals.jbchem.a135653; HAYASHI S, 1988, J BIOCHEM-TOKYO, V103, P853, DOI 10.1093/oxfordjournals.jbchem.a122360; HENRY HL, 1978, SCIENCE, V201, P835, DOI 10.1126/science.684411; HENRY HL, 1974, J BIOL CHEM, V249, P7529; HENRY HL, 1985, J STEROID BIOCHEM, V23, P991, DOI 10.1016/0022-4731(85)90057-3; HIWATASHI A, 1977, FEBS LETT, V82, P201, DOI 10.1016/0014-5793(77)80584-X; HOLICK MF, 1973, J BIOL CHEM, V248, P6691; HOLICK MF, 1972, BIOCHEMISTRY-US, V11, P4251, DOI 10.1021/bi00773a009; KNUTSON JC, 1974, BIOCHEMISTRY-US, V13, P1543, DOI 10.1021/bi00704a034; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KULKOWSKI JA, 1979, BIOCHEM BIOPH RES CO, V90, P50, DOI 10.1016/0006-291X(79)91588-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM HY, 1973, BIOCHEMISTRY-US, V12, P4851, DOI 10.1021/bi00748a007; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADHOK TC, 1977, BIOCHEMISTRY-US, V16, P2142, DOI 10.1021/bi00629a015; MASON JI, 1985, BIOCHEM PHARMACOL, V34, P1087, DOI 10.1016/0006-2952(85)90613-6; MASUMOTO O, 1988, J BIOL CHEM, V263, P14256; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OCHI K, 1977, STEROIDS, V30, P795, DOI 10.1016/S0039-128X(77)80025-1; OGISHIMA T, 1987, J BIOL CHEM, V262, P7646; OHYAMA Y, 1989, FEBS LETT, V255, P405, DOI 10.1016/0014-5793(89)81133-0; OMDAHL JL, 1972, NATURE-NEW BIOL, V237, P63, DOI 10.1038/newbio237063a0; OMURA T, 1964, J BIOL CHEM, V239, P2370; ORNOY A, 1978, NATURE, V276, P517, DOI 10.1038/276517a0; PAULSON SK, 1985, J BIOL CHEM, V260, P1488; PEDERSEN JI, 1983, J BIOL CHEM, V258, P742; ROSENTHAL O, 1967, METHOD ENZYMOL, V10, P616; SOMJEN D, 1987, J STEROID BIOCHEM, V27, P807, DOI 10.1016/0022-4731(87)90153-1; SUHARA K, 1972, FEBS LETT, V28, P45, DOI 10.1016/0014-5793(72)80673-2; SUHARA K, 1972, BIOCHIM BIOPHYS ACTA, V263, P272, DOI 10.1016/0005-2795(72)90079-7; TANAKA Y, 1975, ARCH BIOCHEM BIOPHYS, V170, P620, DOI 10.1016/0003-9861(75)90157-5; TANAKA Y, 1977, J BIOL CHEM, V252, P1421; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRULZSCH D, 1973, BIOCHEMISTRY-US, V12, P76; Warburg O, 1929, BIOCHEM Z, V214, P19; WIEBEL FJ, 1971, ARCH BIOCHEM BIOPHYS, V144, P78, DOI 10.1016/0003-9861(71)90456-5; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	49	87	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8690	8695						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026586				2022-12-25	WOS:A1991FM03800012
J	BECKERANDRE, M; SCHULZE-LEFERT, P; HAHLBROCK, K				BECKERANDRE, M; SCHULZE-LEFERT, P; HAHLBROCK, K			STRUCTURAL COMPARISON, MODES OF EXPRESSION, AND PUTATIVE CIS-ACTING ELEMENTS OF THE 2 4-COUMARATE - COA LIGASE GENES IN POTATO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE AMMONIA-LYASE; CELL-SUSPENSION CULTURES; FIREFLY LUCIFERASE; ESCHERICHIA-COLI; MESSENGER-RNAS; UV-LIGHT; PHYTOPHTHORA-INFESTANS; BETA-GLUCURONIDASE; FUNGAL ELICITOR; PARA-COUMARATE	4-Coumarate:CoA ligase (4CL), a key enzyme of phenylpropanoid metabolism in plants, is encoded in potato (Solanum tuberosum L.) by two structurally similar genes (St4cl-1, St4cl-2). Computer-based sequence analyses revealed similarities at the amino acid sequence level with other enzymes dependent on ATP for activation of aromatic carboxylic acids, e.g. some bacterial peptide synthetases. All these enzymes have a common seven amino acid sequence motif containing one cysteine residue. Using an assay on the basis of the polymerase chain reaction, we show that the mRNAs from both 4CL genes accumulate to equal levels in suspension-cultured cells and whole plant tissues, independent of various kinds of activating stimulus applied and of the overall transcriptional activity of the genes. The apparent lack of differential expression, together with the fact that both 4CL genes and proteins are nearly identical in structure, make it unlikely that 4CL isoforms in potato have specific roles in metabolic channeling. Constitutive in vivo footprints in the TATA-box proximal region of the St4cl-1 promoter define putative cis-acting elements which may be involved in the responses of the 4CL genes to various endogenous and exogenous stimuli.	MAX PLANCK INST ZUCHTUNGSFORSCH, BIOCHEM ABT, W-5000 COLOGNE 30, GERMANY	Max Planck Society			Schulze-Lefert, Paul/B-6707-2011; Schulze-Lefert, Paul/A-7746-2008					BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BENNET MD, 1975, PHILOS T R SOC LON B, V274, P227; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTT VS, 1978, 12TH FED EUR BIOCH S; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COX RA, 1983, FEBS LETT, V155, P73, DOI 10.1016/0014-5793(83)80212-9; DANGL JL, 1987, EMBO J, V6, P2551, DOI 10.1002/j.1460-2075.1987.tb02543.x; DELUCA M, 1976, ADV ENZYMOL RAMB, V44, P37; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOUGLAS C, 1987, EMBO J, V6, P1189, DOI 10.1002/j.1460-2075.1987.tb02353.x; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FRITZEMEIER KH, 1987, PLANT PHYSIOL, V85, P34, DOI 10.1104/pp.85.1.34; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRAND C, 1983, PLANTA, V158, P225, DOI 10.1007/BF01075258; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; HAHLBROCK K, 1979, ANNU REV PLANT PHYS, V30, P105, DOI 10.1146/annurev.pp.30.060179.000541; HAHLBROCK K, 1987, INNOVATIVE APPROACHE; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; JEFFERSON RA, 1987, EMBO J, V6, P3901; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; KNOBLOCH KH, 1977, ARCH BIOCHEM BIOPHYS, V184, P237, DOI 10.1016/0003-9861(77)90347-2; KNOBLOCH KH, 1975, EUR J BIOCHEM, V52, P311, DOI 10.1111/j.1432-1033.1975.tb03999.x; KNOGGE W, 1979, Z NATURFORSCH C, V36, P389; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; KUHN DN, 1984, P NATL ACAD SCI-BIOL, V81, P1102, DOI 10.1073/pnas.81.4.1102; Lipmann F, 1980, Adv Microb Physiol, V21, P227; LIU J, 1989, J BACTERIOL, V171, P791, DOI 10.1128/jb.171.2.791-798.1989; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; LOIS R, 1989, EMBO J, V8, P1641, DOI 10.1002/j.1460-2075.1989.tb03554.x; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Maniatis T., 1982, MOL CLONING; MITTENHUBER G, 1989, J BACTERIOL, V171, P4881, DOI 10.1128/jb.171.9.4881-4887.1989; NICK H, 1985, NATURE, V313, P795, DOI 10.1038/313795a0; RAGG H, 1981, J BIOL CHEM, V256, P61; RANJEVA R, 1976, BIOCHIMIE, V58, P1255, DOI 10.1016/S0300-9084(76)80125-3; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; ROHWER F, 1987, PLANTA, V170, P556, DOI 10.1007/BF00402991; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALUZ H, 1986, GENE, V42, P151, DOI 10.1016/0378-1119(86)90291-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P87; SCHRODER J, 1989, NUCLEIC ACIDS RES, V17, P460, DOI 10.1093/nar/17.1.460; SCHULZE-LEFERT P, 1989, EMBO J, V8, P651, DOI 10.1002/j.1460-2075.1989.tb03422.x; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; ULLRICH A, 1984, DNA-J MOLEC CELL BIO, V3, P387, DOI 10.1089/dna.1984.3.387; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; [No title captured]	54	111	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8551	8559						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022667				2022-12-25	WOS:A1991FK44100089
J	MURAGAKI, Y; JACENKO, O; APTE, S; MATTEI, MG; NINOMIYA, Y; OLSEN, BR				MURAGAKI, Y; JACENKO, O; APTE, S; MATTEI, MG; NINOMIYA, Y; OLSEN, BR			THE ALPHA-2(VIII) COLLAGEN GENE - A NOVEL MEMBER OF THE SHORT CHAIN COLLAGEN FAMILY LOCATED ON THE HUMAN CHROMOSOME-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL DOMAINS; VIII COLLAGEN; X COLLAGEN; DNA; HYBRIDIZATION; LOCALIZATION; CONTAINS; CLONING	Type VIII collagen is a major component of Descemet's membrane, the specialized basement membrane of corneal endothelial cells. Sequence analysis of a cDNA isolated from a library made with mRNA from rabbit corneal endothelial cells has indicated that type VIII molecules contain a polypeptide chain, alpha-1(VIII), consisting of a short triple-helical domain of 454 amino acid residues flanked by non-triple-helical domains of 117 and 173 amino acid residues at the amino and carboxyl ends, respectively (Yamaguchi, N., Benya, P. D., van der Rest, M., and Ninomiya, Y. (1989) J. Biol. Chem. 264, 16022-16029). The sequence of alpha-1(VIII) is strikingly similar to that of alpha-1(X) collagen, a product of hypertrophic chondrocytes. Also, characterization of the alpha-1(VIII) and alpha-1(X) collagen genes has shown that they are quite similar in their exon organization. It has been concluded, therefore, that they are homologous members of a distinct subclass of collagen genes (Yamaguchi, N., Mayne, R., and Ninomiya, Y. (1991) J. Biol. Chem. 266, 4508-4513). We have given this subclass the name short chain collagens because of the relatively small size of the triple-helical domain. In the present study, we report on the identification and characterization of a collagen gene encoding a polypeptide which is co-expressed with the alpha-1(VIII) chain in corneal endothelial cells. This collagen chain contains a triple-helical and a carboxyl non-triple-helical domain encoded by a single, large exon both in mice and humans. We conclude, therefore, that the gene encodes a novel member of the short chain collagen family, and we have given this chain the designation alpha-2(VIII) collagen. By in situ hybridization we demonstrate that the alpha-2(VIII) gene is located in the p32.3-p34.3 region of the short arm of chromosome 1.	HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115; GRP HOP TIMONE,HOP ENFANTS,F-13385 MARSEILLE 5,FRANCE	Harvard University; Harvard Medical School; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille					NEI NIH HHS [EY07334] Funding Source: Medline; NIAMS NIH HHS [AR36819, AR36820] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036820, R01AR036819, R01AR036820, R37AR036819] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENYA P D, 1980, Renal Physiology, V3, P30; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; JAKUS MARIE A., 1956, JOUR BIOPHYS AND BIOCHEM CYTOL, V2, P243, DOI 10.1083/jcb.2.4.243; KAPOOR R, 1986, BIOCHEMISTRY-US, V25, P3930, DOI 10.1021/bi00361a029; KAPOOR R, 1988, J CELL BIOL, V107, P721, DOI 10.1083/jcb.107.2.721; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KIMURA T, 1989, EUR J BIOCHEM, V179, P71, DOI 10.1111/j.1432-1033.1989.tb14522.x; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; MANN K, 1990, FEBS LETT, V273, P168, DOI 10.1016/0014-5793(90)81076-Z; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; SAGE H, 1980, BIOCHEMISTRY-US, V19, P5747, DOI 10.1021/bi00566a013; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P16022	17	78	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7721	7727						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019595				2022-12-25	WOS:A1991FJ34200064
J	HAYWARD, CPM; SMITH, JW; HORSEWOOD, P; WARKENTIN, TE; KELTON, JG				HAYWARD, CPM; SMITH, JW; HORSEWOOD, P; WARKENTIN, TE; KELTON, JG			P-155, A MULTIMERIC PLATELET PROTEIN THAT IS EXPRESSED ON ACTIVATED PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; GLYCOPROTEINS; FIBRINOGEN; EXPOSURE; RECEPTOR; SURFACE; ANTIGEN; IGG	Platelets respond to a large number of stimuli by undergoing complex biochemical and morphological changes. These changes are involved in physiological processes including adhesion, aggregation, and coagulation. Platelet activation produces membrane alterations that can be recognized by monoclonal antibodies. In this report we describe a novel activation-dependent protein recognized by a monoclonal antibody, JS-1. The platelet glycoprotein was designated p-155 according to its apparent reduced molecular weight. p-155 exists in the native state as varying sized, large multimers held together by disulfide bonds. p-155 is released upon platelet activation and binds to the activated platelet surface. Although p-155 and platelet glycoprotein Ia migrate similarly on reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis, immunodepletion and isoelectric focusing distinguished p-155 from glycoprotein Ia. p-155 differed from von Willebrand factor and from thrombospondin in its reduced molecular weight. Additionally, immunoblotting of immunoprecipitated p-155 with antisera to von Willebrand factor and to thrombospondin confirmed the unique identity of p-155. Evidence for a soluble, nonintegral membrane-associated protein was obtained by Triton X-114 phase separation studies, membrane elution studies, and by the demonstration of the protein in the aqueous phase of platelet releasate. Both radioimmunoprecipitation and direct binding techniques demonstrated the activation-dependent nature of p-155. The protein could not be detected in other blood cells, endothelial cells, HEL cells, liver, or in plasma. The functional role of p-155 in platelets is not yet known.	MCMASTER UNIV,DEPT MED,RM 2N34,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA; CANADIAN RED CROSS,BLOOD TRANSFUS SERV,HAMILTON CTR,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University				Hayward, Catherine/0000-0002-2843-0817				AIKEN ML, 1987, BLOOD, V69, P58; ASCH E, 1990, J CLIN INVEST, V85, P1372, DOI 10.1172/JCI114581; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BIENZ D, 1989, J BIOL CHEM, V264, P507; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRASHEMSTEIN C, 1988, J IMMUNOL, V140, P2330; CHILES TC, 1987, ANAL BIOCHEM, V163, P136, DOI 10.1016/0003-2697(87)90103-5; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; FUJIMOTO T, 1982, J CLIN INVEST, V69, P1212, DOI 10.1172/JCI110560; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; HANDAGAMA PJ, 1989, J CLIN INVEST, V84, P73, DOI 10.1172/JCI114173; KELTON JG, 1989, BRIT J HAEMATOL, V71, P97, DOI 10.1111/j.1365-2141.1989.tb06281.x; KELTON JG, 1987, AM J HEMATOL, V25, P299, DOI 10.1002/ajh.2830250310; KELTON JG, 1990, BLOOD, V75, P2172; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARKER RI, 1986, BLOOD, V68, P732; PISCHEL KD, 1988, J CLIN INVEST, V81, P505, DOI 10.1172/JCI113348; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x	21	53	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7114	7120						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016319				2022-12-25	WOS:A1991FG72700074
J	MAK, AS; WATSON, MH; LITWIN, CME; WANG, JH				MAK, AS; WATSON, MH; LITWIN, CME; WANG, JH			PHOSPHORYLATION OF CALDESMON BY CDC2 KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE CALDESMON; PROTEIN-KINASE; FISSION YEAST; CELL-CYCLE; F-ACTIN; BINDING PROTEIN; PURIFICATION; TROPOMYOSIN; CALMODULIN; EXPRESSION	A recent report that mitosis-specific phosphorylation causes the nonmuscle caldesmon to dissociate from microfilaments (Yamashiro, S., Yamakita, Y., Ishikawa, R., and Matsumura, F. (1990) Nature 344, 675-678) suggests that this process may contribute to the major structural reorganization of the eukaryotic cell at mitosis. In this study we have demonstrated that smooth muscle caldesmon is phosphorylated in vitro by cdc2 kinase from mitotic phase HeLa cells to 1.2 mol of phosphate/mol of caldesmon. Tryptic maps showed three major phosphorylated spots and approximately equal amounts of phosphorylated Ser and Thr were identified. F-actin or calmodulin in the presence of Ca2+ blocks the phosphorylation of caldesmon. Phosphorylation of caldesmon greatly reduced its binding to F-actin. The phosphorylation sites were located in a 10,000-Da CnBr fragment at the COOH-terminal end of the caldesmon molecule known to house the binding sites for actin and calmodulin (Bartegi A., Fattoum, A., Derancourt, J., and Kassab, R. (1990) J. Biol. Chem. 265, 15231-15238). Our finding supports the model that phosphorylation of caldesmon by cdc2 kinase at mitosis may contribute to the disassembly of the microfilament bundles during prophase.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary	MAK, AS (corresponding author), QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA.							BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1990, J MUSCLE RES CELL M, V11, pA434; DRAETTA G, 1988, ONCOGENE, V2, P553; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EATON BL, 1975, BIOCHEMISTRY-US, V14, P2718, DOI 10.1021/bi00683a025; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KEMP BE, 1979, J BIOL CHEM, V254, P2638; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LIN JJC, 1988, HYBRIDOMA, V7, P273, DOI 10.1089/hyb.1988.7.273; MONTGOMERY K, 1984, J BIOL CHEM, V259, P5555; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NGAI PK, 1986, BIOCHEM INT, V12, P89; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WATSON MH, 1990, BIOCHIM BIOPHYS ACTA, V1054, P103, DOI 10.1016/0167-4889(90)90211-U; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0	33	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6678	6681						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016282				2022-12-25	WOS:A1991FG72700006
J	SUN, GH; OHYA, Y; ANRAKU, Y				SUN, GH; OHYA, Y; ANRAKU, Y			HALF-CALMODULIN IS SUFFICIENT FOR CELL-PROLIFERATION - EXPRESSIONS OF N-TERMINAL AND C-TERMINAL HALVES OF CALMODULIN IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTIC FRAGMENTS; CYCLE PROGRESSION; CALCIUM-BINDING; CENTRAL HELIX; PROTEINS; DNA; GENE; INVOLVEMENT; STIMULATION; DISRUPTION	Calmodulin (CaM) has been shown to be an essential component for progression of nuclear division in the yeast Saccharomyces cerevisiae (Ohya, Y., and Anraku, Y. (1989) Curr. Genet. 15, 113-120). To define the functional domain of the molecule required for cell proliferation, we constructed plasmids expressing a series of N- and C-terminal halves of the CaM under the control of the galactose-inducible GAL1 promoter. These plasmids were introduced into a cmd1-disrupted yeast haploid strain, and the growth properties of the cells depending on the half-CaMs were examined. Plasmids expressing the N-terminal half (Ser1-Leu76) and the C-terminal half (Leu85-Cys147), which each maintain two complete EF-hand structures, complemented the growth defect of the cmd1 null mutation, whereas those expressing shorter regions of C- and N-terminal CaM did not. The half-CaMs that complemented the cmd1 null mutation were found to be approximately 6-fold overexpressed relative to expression of native CaM by the wild-type CMD1 gene. The levels of expression of the half CaMs with the true CMD1 promoter were not sufficient for complementation. These results demonstrate that half-CaMs (either the N- or the C-terminal) are capable of supporting growth of yeast cells when they are suitably overproduced. Cells depending solely on half-CaMs all showed a temperature-sensitive growth phenotype, suggesting that half-CaMs cannot carry out all the cellular functions of the complete CaM molecule.	UNIV TOKYO, FAC SCI, DEPT BIOL, BUNKYO KU, TOKYO 113, JAPAN; NATL INST BASIC BIOL, DEPT CELL PROLIFERAT, OKAZAKI, AICHI 444, JAPAN	University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)								AULABAUGH A, 1984, BIOCHEM BIOPH RES CO, V118, P225, DOI 10.1016/0006-291X(84)91090-8; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHAFOULEAS JG, 1984, CELL, V36, P73, DOI 10.1016/0092-8674(84)90075-8; Cohen P, 1988, CALMODULIN; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; DALGARNO DC, 1984, EUR J BIOCHEM, V138, P281, DOI 10.1111/j.1432-1033.1984.tb07913.x; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P129; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HIRATA R, 1990, J BIOL CHEM, V265, P6726; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUZNICKI J, 1981, FEBS LETT, V130, P141, DOI 10.1016/0014-5793(81)80683-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU Y, 1990, BIOCHEM BIOPH RES CO, V166, P681, DOI 10.1016/0006-291X(90)90863-I; LONDESBOROUGH J, 1989, J GEN MICROBIOL, V135, P3373; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; Maniatis T., 1982, MOL CLONING; MATSUURA I, 1991, J BIOCHEM-TOKYO, V109, P190, DOI 10.1093/oxfordjournals.jbchem.a123344; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MEANS AR, 1980, NATURE, V285, P73, DOI 10.1038/285073a0; MINOWA O, 1984, J BIOCHEM-TOKYO, V96, P1175, DOI 10.1093/oxfordjournals.jbchem.a134935; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NEWTON D, 1985, BIOCHIM BIOPHYS ACTA, V845, P533, DOI 10.1016/0167-4889(85)90222-8; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; NI WC, 1985, J BIOL CHEM, V260, P6974; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; OHYA Y, 1989, BIOCHEM BIOPH RES CO, V158, P541, DOI 10.1016/S0006-291X(89)80083-X; OHYA Y, 1989, CURR GENET, V15, P113, DOI 10.1007/BF00435457; OHYA Y, 1984, MOL GEN GENET, V193, P389, DOI 10.1007/BF00382073; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; RASMUSSEN CD, 1987, EMBO J, V6, P3961, DOI 10.1002/j.1460-2075.1987.tb02738.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SHERMAN F, 1986, LABORATORY COURSE MA; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WOLFF J, 1986, BIOCHEMISTRY-US, V25, P7950, DOI 10.1021/bi00372a025	51	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7008	7015						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016312				2022-12-25	WOS:A1991FG72700058
J	SCAMAN, CH; PALCIC, MM; MCPHALEN, C; GORE, MP; LAM, LKP; VEDERAS, JC				SCAMAN, CH; PALCIC, MM; MCPHALEN, C; GORE, MP; LAM, LKP; VEDERAS, JC			INHIBITION OF CYTOPLASMIC ASPARTATE-AMINOTRANSFERASE FROM PORCINE HEART BY R-ISOMERS AND S-ISOMERS OF AMINOOXYSUCCINATE AND HYDRAZINOSUCCINATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITION; DERIVATIVES; MECHANISM; ESTERS; SPECIFICITY; SUBSTRATE; PURITY; SLOW; NMR	D- and L-aminooxysuccinate were synthesized and evaluated as inhibitors of cytoplasmic aspartate aminotransferase (EC 2.6.1.1) from porcine heart. L-Aminooxysuccinate was shown to be a slow binding inhibitor of the pyridoxal phosphate form of the enzyme with a K(i) of 160 nM and a half-life of the inhibited complex of 8 min. Kinetic analysis revealed that inhibition followed a two-step mechanism in which the last step was rate-limiting. D-Aminooxysuccinate was not inhibitory up to a concentration of 0.1 mM. These compounds were compared to D- and L-hydrazinosuccinate, which are potent slow binding inhibitors of aspartate aminotransferase with K(i) values of 1.5 and 0.5 nM, respectively. Models of all four analogs were built into the active site of the closed form of the enzyme. The energy-minimized conformations of both L-isomers bound to aspartate aminotransferase show better geometry for hydrogen bond and ion pair formation than do the corresponding D-isomers. The aldimine double bond formed by the L-isomers is not coplanar with the pyridoxal phosphate ring in accordance with the spectral properties of the inhibitor complexes that are characterized by broad absorbance bands. This lack of planarity was not evident for the models of D-hydrazinosuccinate and D-aminooxysuccinate.	UNIV ALBERTA,DEPT FOOD SCI,EDMONTON T6G 2P5,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2P5,ALBERTA,CANADA; UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2P5,ALBERTA,CANADA	University of Alberta; University of Alberta; University of Alberta				Vederas, John/0000-0002-2996-0326				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braunstein AE., 1973, ENZYMES, V3d, P379, DOI [10.1016/S1874-6047%2808%2960122-5, DOI 10.1016/S1874-6047%2808%2960122-5]; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COOPER AJL, 1985, TRANSAMINASES, P533; CRONIN CN, 1988, BIOCHEMISTRY-US, V27, P4572, DOI 10.1021/bi00412a052; CUBELLIS MV, 1989, EUR J BIOCHEM, V186, P375, DOI 10.1111/j.1432-1033.1989.tb15219.x; DALE JA, 1969, J ORG CHEM, V34, P2543, DOI 10.1021/jo01261a013; DALE JA, 1973, J AM CHEM SOC, V95, P512, DOI 10.1021/ja00783a034; DELBAERE LTJ, 1989, BIOCHIMIE, V71, P449, DOI 10.1016/0300-9084(89)90175-2; DOONAN S, 1975, BIOCHEM J, V149, P497, DOI 10.1042/bj1490497d; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; FASELLA P, 1967, BIOCHEMISTRY-US, V6, P1798, DOI 10.1021/bi00858a031; FEENSTRA RW, 1987, TETRAHEDRON LETT, V28, P1215, DOI 10.1016/S0040-4039(00)95329-2; GEHRING H, 1977, BIOCHEMISTRY-US, V16, P4832, DOI 10.1021/bi00641a012; HAMMES GG, 1968, BIOCHEMISTRY-US, V7, P1519, DOI 10.1021/bi00844a039; HARRIS RA, 1982, ARCH BIOCHEM BIOPHYS, V213, P414, DOI 10.1016/0003-9861(82)90567-7; HENSON CP, 1964, BIOCHEMISTRY-US, V3, P338, DOI 10.1021/bi00891a007; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JENKINS W. TERRY, 1959, JOUR BIOL CHEM, V234, P2657; JOHN RA, 1978, BIOCHEM J, V171, P771, DOI 10.1042/bj1710771; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JULIN DA, 1989, BIOCHEMISTRY-US, V28, P3815, DOI 10.1021/bi00435a029; KHOMUTOV RM, 1968, PYRIDOXAL CATALYSIS, P631; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KITAGISHI K, 1988, J BIOCHEM-TOKYO, V103, P585, DOI 10.1093/oxfordjournals.jbchem.a122311; MASON M, 1959, J BIOL CHEM, V234, P2770; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MORRISON JF, 1988, ADV ENZYMOL RELAT AR, V61, P210; OEHLENSCHLAGER J, 1975, J CHROMATOGR, V110, P53, DOI 10.1016/S0021-9673(00)91210-X; OVERBERGER CG, 1955, J AM CHEM SOC, V77, P4100, DOI 10.1021/ja01620a040; RANDO RR, 1977, BIOCHEMISTRY-US, V16, P4604, DOI 10.1021/bi00640a012; SCHNACKERZ KD, 1989, EUR J BIOCHEM, V185, P525, DOI 10.1111/j.1432-1033.1989.tb15145.x; SCHRAMM VL, 1985, BIOCHEMISTRY-US, V24, P641, DOI 10.1021/bi00324a016; SCULLEY MJ, 1986, BIOCHIM BIOPHYS ACTA, V874, P44, DOI 10.1016/0167-4838(86)90100-7; SEVERIN ES, 1968, PYRIDOXAL CATALYSIS, P651; SIZER IJ, 1961, METHOD ENZYMOL, V5, P667; STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041; SUNG MH, 1990, J BACTERIOL, V172, P1345, DOI 10.1128/jb.172.3.1345-1351.1990; TAKAHASHI S, 1980, J ANTIBIOT, V33, P1220, DOI 10.7164/antibiotics.33.1220; TESTA E, 1963, HELV CHIM ACTA, V46, P766, DOI 10.1002/hlca.19630460309; TORCHINSKY Y, 1986, PYRIDOXAL PHOSPHATE, P169; VELICK SF, 1962, J BIOL CHEM, V237, P2109; WAGENKNECHT JH, 1972, SYNTHETIC COMMUN, V2, P215; WEINSTEIN S, 1986, PRACTICAL PROTECTION, P337; Williams J W, 1979, Methods Enzymol, V63, P437; YAGI T, 1990, J BIOCHEM-TOKYO, V107, P151, DOI 10.1093/oxfordjournals.jbchem.a123000; YAMADA R-H, 1988, Vitamins (Kyoto), V62, P117; YAMADA RH, 1985, BIOCHIM BIOPHYS ACTA, V831, P82, DOI 10.1016/0167-4838(85)90152-9; YAMADA RH, 1986, BIOCHIM BIOPHYS ACTA, V871, P279, DOI 10.1016/0167-4838(86)90209-8; YAMADA RH, 1984, BIOCHIM BIOPHYS ACTA, V801, P151, DOI 10.1016/0304-4165(84)90224-1; YASUHARA F, 1980, TETRAHEDRON LETT, V21, P2827, DOI 10.1016/S0040-4039(00)78618-7; ZIAK M, 1990, EUR J BIOCHEM, V187, P329, DOI 10.1111/j.1432-1033.1990.tb15309.x	53	20	22	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5525	5533						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005095				2022-12-25	WOS:A1991FD37000028
J	KAWASAKI, K; TAKAHASHI, M; NATORI, M; SHIBATA, T				KAWASAKI, K; TAKAHASHI, M; NATORI, M; SHIBATA, T			DNA-SEQUENCE RECOGNITION BY A EUKARYOTIC SEQUENCE-SPECIFIC ENDONUCLEASE, ENDO.SCEI, FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC ENDONUCLEASE; MEIOTIC GENE CONVERSION; YEAST MITOCHONDRIA; INITIATION SITE; INTRON; PROTEINS; GELS; RECOMBINATION; MATURASE; AGAROSE	A eukaryotic sequence-specific endonuclease, Endo.SceI, causes sequence-specific double-stranded scission double-stranded DNA to produce cohesive ends with four bases protruding at the 3' termini. Unlike in the case of restriction enzymes, an asymmetric 26-base pair consensus sequence was found around the cleavage site for Endo.SceI instead of a common sequence. We analyzed the base pairs that interacted with Endo.SceI on the recognition of its cleavage sites. A region comprising -10 through +16 base pairs from the center of the cleavage site was shown to be essential and sufficient for the sequence-specific cutting with Endo.SceI by experiments involving synthesized DNAs. Methylation interference experiments indicate that bases in the region comprising the +7 through +14 base pairs is involved in close contact with Endo.SceI in its recognition of the cleavage site. This +7 through +14-base pair region overlaps the most stringently conserved sequence in the consensus sequence for the cleavage site, suggesting that this region constitutes the core for the recognition by Endo.SceI.	NIHON UNIV,DEPT APPL BIOL SCI,FUJISAWA,KANAGAWA 252,JAPAN	Nihon University	KAWASAKI, K (corresponding author), RIKEN INST PHYS & CHEM RES,MICROBIOL LAB,WAKO,SAITAMA 35101,JAPAN.							DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; HARRISON B, 1986, ANAL BIOCHEM, V153, P307; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JACQUIER A, 1985, CELL, V41, P383, DOI 10.1016/S0092-8674(85)80011-8; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; LU AL, 1981, J BIOL CHEM, V256, P3200; MACREADIE IG, 1985, CELL, V41, P395, DOI 10.1016/S0092-8674(85)80012-X; Maxam A M, 1980, Methods Enzymol, V65, P499; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; NAKAGAWA K, 1988, EUR J BIOCHEM, V171, P23, DOI 10.1111/j.1432-1033.1988.tb13753.x; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; OFARRELL PZ, 1973, J BIOL CHEM, V248, P5499; SHIBATA T, 1984, J BIOL CHEM, V259, P499; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4746; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATABE H, 1983, J BIOL CHEM, V258, P4663; WATABE HO, 1981, J BIOCHEM-TOKYO, V90, P1623, DOI 10.1093/oxfordjournals.jbchem.a133637; WATSON N, 1988, GENE, V70, P399, DOI 10.1016/0378-1119(88)90212-0; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WINBERG G, 1980, NUCLEIC ACIDS RES, V8, P253, DOI 10.1093/nar/8.2.253	26	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5342	5347						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	2002067				2022-12-25	WOS:A1991FC21700096
J	CHEN, WY; BAHL, OP				CHEN, WY; BAHL, OP			SELENOMETHIONYL ANALOG OF RECOMBINANT HUMAN CHORIOGONADOTROPIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN CHORIONIC-GONADOTROPIN; GLYCOSIDIC CARBOHYDRATE UNITS; ALPHA-SUBUNIT; DISULFIDE BONDS; BETA-SUBUNIT; CRYSTALLIZATION; ASSIGNMENT	Selenomethionyl and high mannose type analog of recombinant human choriogonadotropin (hCG) to solve the crystallization and phase problems has been obtained by gene transfer methodology. SF9 insect cells were infected with the recombinant viruses containing hCG-alpha and hCG-beta cDNAs in selenomethionine containing methionine-free Grace's medium. The selenomethionyl hCG (SehCG) was purified from the culture medium by one step immunoaffinity chromatography using an immobilized monoclonal antibody against hCG-beta. The presence of selenomethionine was demonstrated by amino acid analysis of SehCG. The amino acid composition indicated that more than 84% of methionine residues were substituted by selenomethionine. Its sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis yielded a single 38-kDa protein band under nonreducing conditions. The carbohydrate analysis of SehCG was consistent with the presence of four N-linked high mannose type carbohydrates and four O-linked simple disaccharide chains. The in vitro immunological and biological studies of SehCG indicated that selenomethionine substitution had no effect on the immunopotency, receptor binding, and steroidogenic activities of the hormone.	SUNY BUFFALO,DEPT BIOL SCI,347 COOKE HALL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BELLISARIO R, 1973, J BIOL CHEM, V248, P6796; CARLSEN RB, 1973, J BIOL CHEM, V248, P6810; CHEN WY, 1991, J BIOL CHEM, V266, P8192; CHEN WY, 1991, J BIOL CHEM, V266, P4081; CHEN WY, 1991, J BIOL CHEM, V266, P6246; ENDO Y, 1979, J BIOCHEM-TOKYO, V85, P669; GREEN DW, 1954, PROC R SOC LON SER-A, V225, P287, DOI 10.1098/rspa.1954.0203; HARRIS DC, 1989, J BIOL CHEM, V264, P6705; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; KESSLER MJ, 1979, J BIOL CHEM, V254, P7909; KESSLER MJ, 1979, J BIOL CHEM, V254, P7901; LUSTBADER JW, 1989, BIOCHEMISTRY-US, V28, P9239, DOI 10.1021/bi00450a001; MISE T, 1981, J BIOL CHEM, V256, P6587; MISE T, 1980, J BIOL CHEM, V255, P8516; MORGAN J, 1975, J BIOL CHEM, V150, P5247; SHEN QX, 1990, MOL CELL ENDOCRINOL, V72, P167, DOI 10.1016/0303-7207(90)90141-T; STRICKLAND TW, 1985, J CELL BIOCHEM, V29, P225, DOI 10.1002/jcb.240290307; SUMMERS MD, 1988, TEXAS EXPT STATION B, V1555; YANG W, 1990, J BIOL CHEM, V265, P13553	19	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9355	9358						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033036				2022-12-25	WOS:A1991FM45900005
J	LANZ, T; TROPF, S; MARNER, FJ; SCHRODER, J; SCHRODER, G				LANZ, T; TROPF, S; MARNER, FJ; SCHRODER, J; SCHRODER, G			THE ROLE OF CYSTEINES IN POLYKETIDE SYNTHASES - SITE-DIRECTED MUTAGENESIS OF RESVERATROL AND CHALCONE SYNTHASES, 2 KEY ENZYMES IN DIFFERENT PLANT-SPECIFIC PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; CELL-SUSPENSION CULTURES; FLAVANONE SYNTHASE; PETROSELINUM-HORTENSE; NUCLEOTIDE-SEQUENCE; SUBSTRATE-SPECIFICITY; PENICILLIUM-PATULUM; ESCHERICHIA-COLI; CLONING VECTORS; MALONYL-COA	Resveratrol and chalcone synthases are related plant-specific polyketide synthases that are key enzymes in the biosynthesis of stilbenes and flavonoids, respectively. The stepwise condensing reactions correspond to those in other polyketide and fatty-acid synthases. This predicts that the two proteins also contain cysteines that are essential for enzyme activity because they bind the substrates. We exchanged, in both enzymes, all of the 6 conserved cysteines into alanine by site-directed mutagenesis and tested the mutants after expression of the proteins in the Escherichia coli heterologous system. Only cysteine 169 was essential in both enzymes, and inhibitor studies suggest that it is the main target of cerulenin, an antibiotic reacting with the cysteine in the active center of condensing enzymes. Most of the other exchanges led to reduced activities. In two cases the enzymes responded differently, suggesting that the cysteines at positions 135 and 195 may be involved in the different product specificity of the two enzymes. The sequences surrounding the essential cysteine 169 revealed no similarity to the active sites of condensing enzymes in other polyketide synthases and in fatty acid biosynthesis. The available data indicate that resveratrol and chalcone synthases represent a group of enzymes that evolved independently of other condensing enzymes.	UNIV COLOGNE,INST BIOCHEM,W-5000 COLOGNE 1,GERMANY	University of Cologne	LANZ, T (corresponding author), UNIV FREIBURG,LEHRSTUHL COMMUN ARTS,INST BIOL 2,SCHANZLESTR 1,W-7800 FREIBURG,GERMANY.							BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIRSNER U, 1987, J CHROMATOGR, V402, P381, DOI 10.1016/0021-9673(87)80043-2; CHANG SI, 1988, BIOCHEMISTRY-US, V27, P4753, DOI 10.1021/bi00413a026; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; EHMANN B, 1988, PLANT MOL BIOL, V11, P869, DOI 10.1007/BF00019526; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; GIL G, 1986, J BIOL CHEM, V261, P3710; HELLER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P617, DOI 10.1016/0003-9861(80)90395-1; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HORTON RD, 1986, NUCLEIC ACIDS RES, V14, P5112, DOI 10.1093/nar/14.12.5112; HRAZDINA G, 1976, ARCH BIOCHEM BIOPHYS, V175, P392, DOI 10.1016/0003-9861(76)90526-9; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; Kindl H, 1985, BIOSYNTHESIS BIODEGR, P349; KRESZE GB, 1977, EUR J BIOCHEM, V79, P181, DOI 10.1111/j.1432-1033.1977.tb11796.x; KREUZALER F, 1975, EUR J BIOCHEM, V56, P205, DOI 10.1111/j.1432-1033.1975.tb02223.x; KREUZALER F, 1975, ARCH BIOCHEM BIOPHYS, V169, P84, DOI 10.1016/0003-9861(75)90319-7; KREUZALER F, 1978, FEBS LETT, V94, P175, DOI 10.1016/0014-5793(78)80931-4; KREUZALER F, 1979, EUR J BIOCHEM, V99, P89, DOI 10.1111/j.1432-1033.1979.tb13235.x; KROEGER M, 1984, NUCLEIC ACIDS RES, V12, P193; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANZ T, 1990, PLANTA, V181, P169, DOI 10.1007/BF02411534; MIZIORKO HM, 1985, J BIOL CHEM, V260, P3513; NAKAMURA K, 1982, EMBO J, V1, P771, DOI 10.1002/j.1460-2075.1982.tb01244.x; OHNO T, 1974, BIOCHEM BIOPH RES CO, V57, P1119, DOI 10.1016/0006-291X(74)90812-2; Omura S, 1981, Methods Enzymol, V72, P520; POULOSE AJ, 1984, ARCH BIOCHEM BIOPHYS, V230, P117, DOI 10.1016/0003-9861(84)90092-4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER U, 1989, J BACTERIOL, V171, P847, DOI 10.1128/jb.171.2.847-854.1989; SCHOPPNER A, 1984, J BIOL CHEM, V259, P6806; SCHRODER J, 1979, J BIOL CHEM, V254, P57; SCHRODER J, 1979, PLANT SCI LETT, V14, P281, DOI 10.1016/0304-4211(79)90083-X; SCHRODER J, 1990, Z NATURFORSCH C, V45, P1; SCHUZ R, 1983, J BIOL CHEM, V258, P6730; SCHWEIZER E, 1987, FETT WISS TECHNOL, V89, P570; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SHERMAN DH, 1989, EMBO J, V8, P2712; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WIESNER P, 1988, EUR J BIOCHEM, V177, P69, DOI 10.1111/j.1432-1033.1988.tb14346.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	46	149	171	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9971	9976						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033084				2022-12-25	WOS:A1991FM45900094
J	STANDIFORD, TJ; KUNKEL, SL; PHAN, SH; ROLLINS, BJ; STRIETER, RM				STANDIFORD, TJ; KUNKEL, SL; PHAN, SH; ROLLINS, BJ; STRIETER, RM			ALVEOLAR MACROPHAGE-DERIVED CYTOKINES INDUCE MONOCYTE CHEMOATTRACTANT PROTEIN-1 EXPRESSION FROM HUMAN PULMONARY TYPE-II-LIKE EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NEUTROPHIL CHEMOTACTIC FACTOR; FACTOR GENE-EXPRESSION; ACTIVATING FACTOR MCAF; HUMAN-LUNG CARCINOMA; GROWTH FACTOR-BETA; HUMAN-FIBROBLASTS; ENDOTHELIAL-CELLS; SECRETION; LINE	Many acute and chronic lung diseases are characterized by the presence of increased numbers of activated macrophages. These macrophages are derived predominantly from newly recruited peripheral blood monocytes and may play a role in the amplification and perpetuation of an initial lung insult. The process of inflammatory cell recruitment is poorly understood, although the expression of inflammatory cell-specific chemoattractants and subsequent generation of chemotactic gradients is likely involved. Although immune cells such as macrophages and lymphocytes are known to generate several inflammatory cell chemoattractants, parenchymal cells can also synthesize and secrete a number of bioactive factors. We now demonstrate the generation of significant monocyte chemotactic activity from tumor necrosis factor (TNF)-alpha and interleukin (IL)-1-beta-treated pulmonary type II-like epithelial cells (A549). The predominant inducible monocyte chemotaxin had an estimated molecular mass of approximately 14-15 kDa and was neutralized by specific antibody to human monocyte chemotactic protein-1 (MCP-1). Induction of activity was accompanied by increases in steady-state mRNA level for MCP-1. These data are consistent with the induction of MCP-1 expression from A549 cells by TNF and IL-1. MCP-1 production from A549 cells could be induced by lipopolysaccharide (LPS)-stimulated alveolar macrophage (AM)-conditioned media, but not by LPS alone. The inducing activity in AM-conditioned media was neutralized with specific antibodies to IL-1-beta, but not TNF-alpha. Our findings suggest that the alveolar epithelium can participate in inflammatory cell recruitment via the production of MCP-1 and that cytokine networking between contiguous alveolar macrophages and the pulmonary epithelium may be essential for parenchymal cell MCP-1 expression.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV PULM & CRIT CARE MED,BOX 0360,3916 TAUBMAN CTR,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Phan, Sem H/A-7033-2009	Phan, Sem H/0000-0002-3711-2159	NHLBI NIH HHS [HL02401, HL35276, HL31693] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035276, R37HL035276, K08HL002401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1980, LAB INVEST, V42, P518; ALBLAS ABV, 1983, AM REV RESPIR DIS, V128, P276; BALIS JU, 1984, EXP LUNG RES, V6, P197, DOI 10.3109/01902148409109248; BITTERMAN PB, 1984, J CLIN INVEST, V74, P460, DOI 10.1172/JCI111443; CHAUNCEY JB, 1988, AM REV RESPIR DIS, V138, P928, DOI 10.1164/ajrccm/138.4.928; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JAD, 1986, AM REV RESPIR DIS, V134, P108; DAUBER JH, 1980, EXP LUNG RES, V1, P23, DOI 10.3109/01902148009057510; DENHOLM EM, 1989, AM J PATHOL, V135, P571; FELS AOS, 1986, J APPL PHYSIOL, V60, P353, DOI 10.1152/jappl.1986.60.2.353; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GRAVES DT, 1989, SCIENCE, V245, P1490, DOI 10.1126/science.2781291; HUNNINGHAKE GW, 1984, AM REV RESPIR DIS, V129, P569; HUNNINGHAKE GW, 1980, NEW ENGL J MED, V302, P594, DOI 10.1056/NEJM198003133021102; HUNNINGHAKE GW, 1984, AM REV RESPIR DIS, V130, P476; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KAZMIEROWSKI JA, 1977, J CLIN INVEST, V59, P273, DOI 10.1172/JCI108638; KESKIOJA J, 1988, J CELL BIOL, V106, P451, DOI 10.1083/jcb.106.2.451; KOYAMA S, 1989, AM J PHYSIOL, V257, pL130, DOI 10.1152/ajplung.1989.257.2.L130; LARSEN CG, 1989, BIOCHEM BIOPH RES CO, V160, P1403, DOI 10.1016/S0006-291X(89)80160-3; LE JM, 1987, LAB INVEST, V56, P234; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; MASON RJ, 1980, BIOCHIM BIOPHYS ACTA, V617, P36, DOI 10.1016/0005-2760(80)90222-2; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MITCHELL DN, 1977, J CLIN PATHOL, V30, P395, DOI 10.1136/jcp.30.5.395; MORNEX JF, 1986, J CLIN INVEST, V78, P61, DOI 10.1172/JCI112574; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; REISER KM, 1986, EXP LUNG RES, V10, P331, DOI 10.3109/01902148609058286; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROTHMAN BL, 1990, J IMMUNOL, V145, P592; SHAPIRO DL, 1978, BIOCHIM BIOPHYS ACTA, V530, P197, DOI 10.1016/0005-2760(78)90005-X; SHELLITO J, 1987, AM REV RESPIR DIS, V135, P78; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SICA A, 1990, J IMMUNOL, V144, P3034; STANDIFORD TJ, 1991, CLIN INVEST, V86, P1945; STRIETER RM, 1989, BIOCHEM BIOPH RES CO, V162, P694, DOI 10.1016/0006-291X(89)92366-8; STRIETER RM, 1990, BIOCHEM BIOPH RES CO, V166, P886, DOI 10.1016/0006-291X(90)90893-R; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; STRIETER RM, 1989, AM J RESP CELL MOL, V1, P57, DOI 10.1165/ajrcmb/1.1.57; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; STRUNK RC, 1988, J CLIN INVEST, V81, P1419, DOI 10.1172/JCI113472; SUWABE A, 1988, J JPN MED SOC BIOL I, V19, P78; VANOUDALBLAS AB, 1983, CELL TISSUE KINET, V16, P211; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; YOSHIMURA T, 1990, J IMMUNOL, V144, P2377; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956; YOSHIMURA T, 1989, J EXP MED, V169, P149	49	318	324	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9912	9918						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033076				2022-12-25	WOS:A1991FM45900085
J	DAVIDSON, AL; NIKAIDO, H				DAVIDSON, AL; NIKAIDO, H			PURIFICATION AND CHARACTERIZATION OF THE MEMBRANE-ASSOCIATED COMPONENTS OF THE MALTOSE TRANSPORT-SYSTEM FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; MULTIDRUG RESISTANCE; CYSTIC-FIBROSIS; ATP HYDROLYSIS; GENE-PRODUCT; MALK GENE; IDENTIFICATION; RECONSTITUTION; SEQUENCE; OVERPRODUCTION	Maltose is transported across the cytoplasmic membrane of Escherichia coli by a binding protein-dependent transport system. The three membrane-associated components of the transport system, the MalK, MalF, and MalG proteins, have been solubilized from the membrane and maltose transport activity has been reconstituted in proteoliposome vesicles (Davidson, A. L., and Nikaido, H. (1990) J. Biol. Chem. 265, 4254-4260). A modification of the reconstitution technique is presented which permits reconstitution from the detergent dodecyl maltoside. Utilizing reconstitution of maltose transport as an assay, we have purified these proteins in the presence of n-dodecyl-beta-D-maltoside. The purified proteins catalyze both maltose transport activity and ATP hydrolysis. In all experiments, the MalF, MalG, and MalK proteins behaved as a multiprotein complex; all three proteins were immunoprecipitated using antibody prepared against MalF, and they copurified, eluting from a gel filtration column between markers of M(r) 160,000 and 200,000. Each complex contains two MalK, one MalF, and one MalG proteins, providing two putative sites for ATP hydrolysis. Chemical cross-linking detected specific interactions between MalF and MalG and between MalF and MalK.			DAVIDSON, AL (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,STANLEY DONNER ASU,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011717] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09644] Funding Source: Medline; NIGMS NIH HHS [GM-11717] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BAVOIL P, 1980, J BIOL CHEM, V255, P8366; BERGER EA, 1974, J BIOL CHEM, V249, P7747; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; DASSA E, 1990, MOL GEN GENET, V222, P33, DOI 10.1007/BF00283019; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DEAN DA, 1989, P NATL ACAD SCI USA, V86, P9134, DOI 10.1073/pnas.86.23.9134; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FROSHAUER S, 1984, J BIOL CHEM, V259, P896; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; Miller J. H., 1972, EXPT MOL GENETICS, P431; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSEVEAR P, 1980, BIOCHEMISTRY-US, V19, P4108, DOI 10.1021/bi00558a032; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHUMAN HA, 1980, J BIOL CHEM, V255, P168; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	29	143	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8946	8951						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026607				2022-12-25	WOS:A1991FM03800046
J	BRANDLI, AW; ADAMSON, ED; SIMONS, K				BRANDLI, AW; ADAMSON, ED; SIMONS, K			TRANSCYTOSIS OF EPIDERMAL GROWTH-FACTOR - THE EPIDERMAL GROWTH-FACTOR RECEPTOR MEDIATES UPTAKE BUT NOT TRANSCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CARCINOMA-CELLS A-431; CANINE KIDNEY-CELLS; EGF RECEPTOR; MDCK CELLS; RAT-LIVER; DIRECT VISUALIZATION; HUMAN-FIBROBLASTS; PLASMA-MEMBRANE; DOWN-REGULATION	Madin-Darby canine kidney (MDCK) cells polarize and generate distinct apical and basolateral membrane domains when grown on permeable filter supports. Under these conditions, they transcytose fluid-phase markers. Recently, receptor-mediated transcytosis of epidermal growth factor (EGF) across MDCK cells has been reported (Maratos-Flier, E., Kao, C.-Y. Y., Verdin, E. M., and King, G. L. (1987) J. Cell Biol. 105, 1595-1601). We examined the role of the EGF receptor in this process. Transcytosis of EGF occurred only in the basolateral-to-apical direction, was time-dependent, and inhibited by the addition of unlabeled EGF in a concentration-dependent manner. In contrast to previous work, we found that only about 5% of basolaterally bound EGF was transported to the apical chamber. The half-time of transport was 90 min. A mutant cell line of MDCK, MDCKII-RCA(r), was used to study the expression of the EGF receptor. Cell surface glycoproteins of these mutant cells can be efficiently labeled with [H-3]galactose by exogalactosylation. The EGF receptor was found to be expressed only on the basolateral surface. Addition of EGF to the basolateral medium resulted in rapid internalization and degradation of the receptor. Testing directly for transcytosis of basolateral glycoproteins, we detected several proteins transported across the cell. The EGF receptor, however, was not among this group of proteins. Taking these results together, we suggest the following model. Internalization of EGF on the basolateral surface is mediated by the EGF receptor. EGF dissociates from the receptor in an endocytic compartment. A fraction of the EGF is then diverted nonselectively to the transcytotic pathway, as found for other fluid-phase markers previously (Bomsel, M., Prydz, K., Parton, R. G., Gruenberg, J., and Simons, K. (1989) J. Cell Biol. 109, 3243-3258).	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAMME, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	European Molecular Biology Laboratory (EMBL); Sanford Burnham Prebys Medical Discovery Institute			Brandli, Andre/N-1620-2013	Brandli, Andre/0000-0002-8932-3644; Simons, Kai/0000-0002-9231-9996				BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRANDLI AW, 1989, EMBO J, V8, P3207, DOI 10.1002/j.1460-2075.1989.tb08479.x; BRANDLI AW, 1990, J CELL BIOL, V111, P2909, DOI 10.1083/jcb.111.6.2909; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BURWEN SJ, 1984, J CELL BIOL, V99, P1259, DOI 10.1083/jcb.99.4.1259; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CASSEL D, 1982, J BIOL CHEM, V257, P9845; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; GATES RE, 1982, MOL CELL ENDOCRINOL, V27, P263, DOI 10.1016/0303-7207(82)90093-4; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HAIGLER HT, 1985, J CELL PHYSIOL, V124, P322, DOI 10.1002/jcp.1041240223; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HERTEL C, 1987, J BIOL CHEM, V262, P11407; HIDALGO IJ, 1989, BIOCHEM BIOPH RES CO, V160, P317, DOI 10.1016/0006-291X(89)91658-6; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; HUGHSON EJ, 1989, J CELL SCI, V94, P327; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; KRUPP MN, 1982, J BIOL CHEM, V257, P1489; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; PRYDZ K, 1990, J BIOL CHEM, V265, P12629; RICHARDSON JCW, 1979, FEBS LETT, V105, P201, DOI 10.1016/0014-5793(79)80611-0; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SCHIFF JM, 1984, J CELL BIOL, V98, P79, DOI 10.1083/jcb.98.1.79; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; STHILAIRE RJ, 1983, P NATL ACAD SCI-BIOL, V80, P3797; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x; WELLER A, 1987, DEVELOPMENT, V100, P351; WILEY HS, 1985, J BIOL CHEM, V260, P5290; YEATON RW, 1983, J BIOL CHEM, V258, P9254	49	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8560	8566						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022668				2022-12-25	WOS:A1991FK44100090
J	CONBOY, JG; CHAN, JY; CHASIS, JA; KAN, YW; MOHANDAS, N				CONBOY, JG; CHAN, JY; CHASIS, JA; KAN, YW; MOHANDAS, N			TISSUE-SPECIFIC AND DEVELOPMENT-SPECIFIC ALTERNATIVE RNA SPLICING REGULATES EXPRESSION OF MULTIPLE ISOFORMS OF ERYTHROID MEMBRANE-PROTEIN 4.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL PROTEIN-4.1; MAMMALIAN-CELLS; BAND 4.1; VARIANTS; CLONING; ACTIN; DIFFERENTIATION; HOMOLOGY; SEQUENCE; BIOLOGY	Protein 4.1, a multifunctional structural protein originally described as an 80-kDa component of the erythroid membrane skeleton, exhibits tissue- and development-specific heterogeneity in molecular weight, subcellular localization, and primary amino acid sequence. Earlier reports suggested that some of this impressive heterogeneity is generated by alternative RNA splicing (Conboy, J. G., Chan, J., Mohandas, N., and Kan, Y. W. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 9062-9065; Tang, T. K., Leto, T., Marchesi, V. T., and Benz, E. J. (1990) J. Cell Biol. 110, 617-624). We have now completed a systematic analysis of 4.1 mRNA isoforms expressed in erythroid cells, and have generated an "alternative splicing map" which summarizes diagrammatically a multitude of polypeptide isoforms potentially generated by combinatorial splicing of nine alternative exons. Complex 5' splicing events yield mRNA isoforms that may initiate translation at different sites and thus generate elongated or truncated NH2 termini; elongated approximately 135-kDa and prototypical approximately 80-kDa species were detected in both erythrocytes and T-lymphocytes, but in very different ratios. Among the functional domains of 4.1 responsible for interaction with other membrane skeletal elements, four variants of the 10-kDa spectrin-actin-binding region and four variants of the putative 30-kDa glycophorin-binding region are predicted. Developmentally controlled alternative RNA splicing in the spectrin-actin-binding region may help regulate remodeling of membrane architecture and mechanical properties that occur during erythropoiesis.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	CONBOY, JG (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,1 CYCLOTRON RD,BLDG 74-157,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 32094] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RA, 1988, J CELL BIOCHEM, V37, P269, DOI 10.1002/jcb.240370303; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P204; CHANG H, 1976, P NATL ACAD SCI USA, V73, P3206, DOI 10.1073/pnas.73.9.3206; CHASIS JA, 1985, J CLIN INVEST, V75, P1919, DOI 10.1172/JCI111907; CHASIS JA, 1989, BLOOD, V74, P1112, DOI 10.1182/blood.V74.3.1112.1112; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1985, ANNU REV BIOCHEM, V54, P331, DOI 10.1146/annurev.bi.54.070185.001555; COHEN CM, 1982, NATURE, V299, P648, DOI 10.1038/299648a0; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; CONBOY J, 1990, J CLIN INVEST, V86, P524, DOI 10.1172/JCI114739; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CORREAS I, 1988, BIOCHEM J, V255, P217; COX JV, 1988, MOL CELL BIOL, V8, P1327, DOI 10.1128/MCB.8.3.1327; DAVIES KA, 1989, TRENDS GENET, V5, P222, DOI 10.1016/0168-9525(89)90086-3; DEEN DF, 1986, CANCER RES, V46, P1599; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; GRANGER BL, 1984, CELL, V37, P595, DOI 10.1016/0092-8674(84)90390-8; GRANGER BL, 1985, NATURE, V313, P238, DOI 10.1038/313238a0; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HORNE WC, 1985, J BIOL CHEM, V260, P9073; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LASKI FA, 1982, NUCLEIC ACIDS RES, V10, P4609, DOI 10.1093/nar/10.15.4609; LETO TL, 1984, J BIOL CHEM, V259, P4603; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MACRAE TH, 1989, BIOCHEM CELL BIOL, V67, P770, DOI 10.1139/o89-116; MARCHESI SL, 1990, J CLIN INVEST, V86, P516, DOI 10.1172/JCI114738; MARCHESI VT, 1990, BLOOD S, V76, pA12; MILLER EJ, 1987, METHOD ENZYMOL, V144, P3; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NGAI J, 1987, P NATL ACAD SCI USA, V84, P4432, DOI 10.1073/pnas.84.13.4432; PASTERNACK GR, 1989, P NATL ACAD SCI USA, V86, P9712, DOI 10.1073/pnas.86.24.9712; PATEL VP, 1987, J CELL BIOL, V105, P3105, DOI 10.1083/jcb.105.6.3105; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TANG TK, 1988, P NATL ACAD SCI USA, V85, P3713, DOI 10.1073/pnas.85.11.3713; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TATE CG, 1988, BIOCHEM J, V254, P743, DOI 10.1042/bj2540743; TEMPLE GF, 1977, P NATL ACAD SCI USA, V74, P3047, DOI 10.1073/pnas.74.7.3047; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V25, P156; WESTIN EH, 1990, ONCOGENE, V5, P1117; WINKELMANN JC, 1988, BLOOD S, V72, pA35	54	135	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8273	8280						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022644				2022-12-25	WOS:A1991FK44100052
J	HORIUCHI, S; ARAKI, N; MORINO, Y				HORIUCHI, S; ARAKI, N; MORINO, Y			IMMUNOCHEMICAL APPROACH TO CHARACTERIZE ADVANCED GLYCATION END-PRODUCTS OF THE MAILLARD REACTION - EVIDENCE FOR THE PRESENCE OF A COMMON STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NONENZYMATICALLY GLYCOSYLATED PROTEINS; NON-ENZYMATIC GLYCOSYLATION; LOW-DENSITY LIPOPROTEIN; DIABETES-MELLITUS; SCAVENGER RECEPTOR; HUMAN-SERUM; CROSS-LINK; GLUCOSE; INVIVO; 2-(2-FUROYL)-4(5)-(2-FURANYL)-1H-IMIDAZOLE	Reaction of protein amino groups with glucose (the Maillard reaction) leads from early stage products such as Schiff base and Amadori products to advanced glycation end products (AGE), structures implicated in diabetic complications and the aging process. We have prepared the polyclonal anti-AGE antibody and the monoclonal anti-AGE antibody against AGE-bovine serum albumin and made an immunochemical approach to characterize AGE structures. Both polyclonal and monoclonal antibodies reacted with AGE-proteins such as AGE-bovine serum albumin, AGE-human serum albumin, and AGE-hemoglobin but not with unmodified counterparts. Treatments of these AGE-proteins with borohydride had no effect on the immunoreactivity. Moreover, fructosyl-epsilon-caproic acid, a synthetic Amadori compound, did not serve as an antigen, indicating that these antibodies were specific for AGE products but not for early stage products of the Maillard reaction. In addition, these antibodies were also able to recognize AGE products prepared either from alpha-tosyl-1-lysine, alpha-tosyl-1-lysine methyl ester, monoaminocarboxylic acid such as epsilon-aminocaproic acid, gamma-amino-n-butyric acid, and beta-alanine. Thus, these results strongly suggest the presence of a common structure in AGE preparations, regardless of whether AGE products are generated from proteins, amino acids, or monoaminocarboxylic acids.			HORIUCHI, S (corresponding author), KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,HONJO 2-2-1,KUMAMOTO 860,JAPAN.							ARAKI N, 1989, SEIKAGAKU, V61, P1171; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; CHANG JCF, 1985, J BIOL CHEM, V260, P7970; DAY JF, 1979, J BIOL CHEM, V254, P595; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FINOT PA, 1982, MODIFICATION PROTEIN, V98, P91; Galfre G, 1981, Methods Enzymol, V73, P3; HAYASE F, 1989, J BIOL CHEM, V263, P3758; HORIUCHI S, 1988, J BIOL CHEM, V263, P18821; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P683, DOI 10.1080/00021369.1987.10868106; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; NAKAYAMA H, 1989, BIOCHEM BIOPH RES CO, V162, P740, DOI 10.1016/0006-291X(89)92372-3; NJOROGE FG, 1987, CARBOHYD RES, V167, P211; NJOROGE FG, 1988, J BIOL CHEM, V263, P10646; OHTA T, 1989, CLIN CHIM ACTA, V179, P183, DOI 10.1016/0009-8981(89)90165-4; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; RAHBAR S, 1968, CLIN CHIM ACTA, V22, P296, DOI 10.1016/0009-8981(68)90372-0; SCHLEICHER E, 1981, FEBS LETT, V129, P1, DOI 10.1016/0014-5793(81)80741-7; SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198; SELL DR, 1989, J BIOL CHEM, V264, P21597; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; STEVENS VJ, 1978, P NATL ACAD SCI USA, V75, P2918, DOI 10.1073/pnas.75.6.2918; TAKATA K, 1988, J BIOL CHEM, V263, P14819; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V986, P18, DOI 10.1016/0005-2736(89)90267-8; VLASSARA H, 1981, P NATL ACAD SCI-BIOL, V78, P5190, DOI 10.1073/pnas.78.8.5190; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; VLASSARA H, 1984, J EXP MED, V160, P197, DOI 10.1084/jem.160.1.197	32	285	328	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7329	7332						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019568				2022-12-25	WOS:A1991FJ34200005
J	LARSON, JR; COON, MJ; PORTER, TD				LARSON, JR; COON, MJ; PORTER, TD			ALCOHOL-INDUCIBLE CYTOCHROME-P-450IIE1 LACKING THE HYDROPHOBIC NH2-TERMINAL SEGMENT RETAINS CATALYTIC ACTIVITY AND IS MEMBRANE-BOUND WHEN EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; PHENOBARBITAL-INDUCED CYTOCHROME-P-450; LIVER MICROSOMAL CYTOCHROME-P-450; AEROBIC RESPIRATORY-CHAIN; ENDOPLASMIC-RETICULUM; SECONDARY STRUCTURE; TERMINAL OXIDASES; PURIFICATION; TOPOLOGY; CELLS	We have expressed in Escherichia coli a cDNA encoding rabbit liver cytochrome P-450IIE1, the ethanol-inducible P-450. The expressed P-450 is located primarily in the bacterial inner cell membrane and comprises 3% of the E. coli total membrane protein. The partially purified cytochrome exhibits a reduced CO difference spectrum with a maximum at 452 nm, characteristic of P-450IIE1, and solubilized membranes or partially purified P-450 preparations reconsituted with NADPH-cytochrome P-450 reductase and phosphatidylcholine catalyze the deethylation of N-nitrosodiethylamine with a turnover number equal to that of purified liver P-450IIE1 (approximately 4.5 nmol/min/nmol of P-450). A modified IIE1 cDNA that encodes a protein lacking amino acids 3-29, a proposed membrane anchor for cytochrome P-450, was also expressed in E. coli and, unexpectedly, the shortened protein was also found to be predominantly located in the bacterial inner membrane rather than the cytosol. Like the full-length protein, this truncated cytochrome has a reduced CO difference spectrum characteristic of P-450IIE1 and is fully active in the deethylation of N-nitrosodiethylamine. These results demonstrate that the NH2-terminal hydrophobic segment is not solely responsible for attachment to the membrane and evidently is not required for proper protein folding or catalytic activity.			LARSON, JR (corresponding author), UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006221] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-06221] Funding Source: Medline; NIGMS NIH HHS [GM-07767] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BROWN CA, 1989, J BIOL CHEM, V264, P4442; COON MJ, 1987, ARCH TOXICOL, V60, P16, DOI 10.1007/BF00296940; CRESPI CL, 1989, CARCINOGENESIS, V10, P295, DOI 10.1093/carcin/10.2.295; DELOMOSCHIARAND.C, 1987, J CELL BIOL, V104, P209; DING XX, 1988, DRUG METAB DISPOS, V16, P265; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; FUJITA VS, 1990, DNA CELL BIOL, V9, P111, DOI 10.1089/dna.1990.9.111; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HANIU M, 1986, ARCH BIOCHEM BIOPHYS, V244, P323, DOI 10.1016/0003-9861(86)90121-9; HEINEMANN FS, 1982, J BIOL CHEM, V257, P4988; HUDECEK J, 1988, BIOCHIM BIOPHYS ACTA, V955, P361, DOI 10.1016/0167-4838(88)90216-6; KELLIS JT, 1987, J BIOL CHEM, V262, P4413; KHANI SC, 1988, J BIOL CHEM, V263, P7170; KHANI SC, 1987, P NATL ACAD SCI USA, V84, P638, DOI 10.1073/pnas.84.3.638; KITA K, 1984, J BIOL CHEM, V259, P3368; KITA K, 1984, J BIOL CHEM, V259, P3375; KOOP DR, 1984, ARCH BIOCHEM BIOPHYS, V235, P228, DOI 10.1016/0003-9861(84)90272-8; KOOP DR, 1990, CHEM RES TOXICOL, V3, P377, DOI 10.1021/tx00016a017; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OZOLS J, 1985, J BIOL CHEM, V260, P5427; PERNECKY SJ, 1990, BIOCHEM BIOPH RES CO, V172, P1331, DOI 10.1016/0006-291X(90)91595-J; PORTER TD, 1987, ARCH BIOCHEM BIOPHYS, V254, P353, DOI 10.1016/0003-9861(87)90111-1; PORTER TD, 1991, IN PRESS METHODS ENZ; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR HK, 1988, P NATL ACAD SCI USA, V85, P5463, DOI 10.1073/pnas.85.15.5463; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; STRITTMATTER P, 1988, J BIOL CHEM, V263, P2532; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TAKEMORI S, 1975, BIOCHEM BIOPH RES CO, V67, P1151, DOI 10.1016/0006-291X(75)90794-9; TARR GE, 1983, P NATL ACAD SCI-BIOL, V80, P6552, DOI 10.1073/pnas.80.21.6552; TRETIAKOV VE, 1989, ARCH BIOCHEM BIOPHYS, V275, P429, DOI 10.1016/0003-9861(89)90389-5; VAZ ADN, 1990, P NATL ACAD SCI USA, V87, P5499, DOI 10.1073/pnas.87.14.5499; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; YASUMORI T, 1989, MOL PHARMACOL, V35, P443; YU CA, 1974, J BIOL CHEM, V249, P94; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074	42	157	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7321	7324						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019566				2022-12-25	WOS:A1991FJ34200003
J	MARTIN, PT; KOSHLAND, DE				MARTIN, PT; KOSHLAND, DE			THE BIOCHEMISTRY OF THE NEURON - NEUROSECRETORY HABITUATION TO REPETITIVE DEPOLARIZATIONS IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GILL-WITHDRAWAL REFLEX; PROTEIN-KINASE-C; NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; NEUROTRANSMITTER RELEASE; SYNAPTIC DEPRESSION; CALCIUM CHANNELS; CA-2+; APLYSIA; INACTIVATION	Habituation in response to repetitive depolarization of PC12 cells can be used as a model for memory processes at the molecular level. In response to depolarization by high external potassium, a triphasic elevation in internal calcium levels occurred. Calcium elevation was maximal immediately after addition of the stimulus (phase 1), followed by a 2-min period in which the calcium level decreased (phase 2), leading to a new steady-state level which was higher than in the unstimulated cell (phase 3). In response to repetitive depolarizations, the calcium level in phase 1 was reduced by as much as 43%, and phase 3 was reduced by as much as 40%. By measuring the relationship between calcium elevation and secretion, it was shown that measured reductions in calcium levels were correlated with neurosecretory habituation. One of the components responsible for the reductions in calcium levels was a tetraethylammonium-sensitive potassium channel, and the habituation of this channel was reversed by addition of 4-beta-phorbol 12-myristate 13-acetate.			MARTIN, PT (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.			Martin, Paul/0000-0002-0674-6191	NIDDK NIH HHS [DK09765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALDRICH RW, 1979, J PHYSIOL-LONDON, V291, P507, DOI 10.1113/jphysiol.1979.sp012828; ALDRICH RW, 1979, J PHYSIOL-LONDON, V291, P531, DOI 10.1113/jphysiol.1979.sp012829; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; CASTELLUCCI V, 1970, SCIENCE, V167, P1745, DOI 10.1126/science.167.3926.1745; CASTELLUCCI VF, 1974, P NATL ACAD SCI USA, V71, P5004, DOI 10.1073/pnas.71.12.5004; DIVIRGILIO F, 1986, J BIOL CHEM, V261, P32; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P9189; GINGRICH KJ, 1985, J NEUROPHYSIOL, V53, P652, DOI 10.1152/jn.1985.53.3.652; GLANZMAN DL, 1980, BRAIN RES, V189, P377, DOI 10.1016/0006-8993(80)90098-0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1977, BRAIN RES, V129, P247, DOI 10.1016/0006-8993(77)90005-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRIS KM, 1986, BIOCHEM BIOPH RES CO, V134, P1298, DOI 10.1016/0006-291X(86)90391-8; HILLE B, 1984, IONIC CHANNELS EXCIT, P99; HUGUES M, 1982, P NATL ACAD SCI-BIOL, V79, P1308, DOI 10.1073/pnas.79.4.1308; Kandel ER., 1976, CELLULAR BASIS BEHAV; KLEIN M, 1980, J EXP BIOL, V89, P117; Koshland Jr D.E, 1980, BACTERIAL CHEMOTAXIS; MCFADDEN PN, 1990, P NATL ACAD SCI USA, V87, P2031, DOI 10.1073/pnas.87.5.2031; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; SPENCER WA, 1966, J NEUROPHYSIOL, V29, P253, DOI 10.1152/jn.1966.29.2.253; Thompson R., 1976, HABITUATION PERSPECT, P49; THOMPSON RF, 1966, PSYCHOL REV, V73, P16, DOI 10.1037/h0022681; ZUCKER RS, 1972, J NEUROPHYSIOL, V35, P621, DOI 10.1152/jn.1972.35.5.621	27	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7388	7392						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019575				2022-12-25	WOS:A1991FJ34200015
J	RAVAZZOLO, R; KARSENTY, G; DECROMBRUGGHE, B				RAVAZZOLO, R; KARSENTY, G; DECROMBRUGGHE, B			A FIBROBLAST-SPECIFIC FACTOR BINDS TO AN UPSTREAM NEGATIVE CONTROL ELEMENT IN THE PROMOTER OF THE MOUSE ALPHA-1(I) COLLAGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1ST INTRON; TRANSCRIPTION; ACTIVATION	We have identified, in nuclear extracts of NIH-3T3 fibroblasts, a factor which binds a sequence between -339 and -361 in the mouse alpha-1(I) collagen promoter. A 3-base pair substitution mutation introduced in this promoter element, which abolishes the binding of the factor, increases the activity of the promoter 4-fold in DNA transfection experiments. This suggests that this element is a negative regulator of transcription. The factor which binds to the -339 to -361 sequence is present in type I collagen-producing cell lines but not in a variety of other cell types, suggesting that it is involved in the tissue-specific regulation of the alpha-1(I) gene.			RAVAZZOLO, R (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA.				NCI NIH HHS [R01-CA-49515] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049515] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; LEE W, 1987, CELL, V51, P773; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Maxam A M, 1980, Methods Enzymol, V65, P499; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; SANDMEYER S, 1981, J BIOL CHEM, V256, P5022; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	21	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7382	7387						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019574				2022-12-25	WOS:A1991FJ34200014
J	JANCSO, A; GRACEFFA, P				JANCSO, A; GRACEFFA, P			SMOOTH-MUSCLE TROPOMYOSIN COILED-COIL DIMERS - SUBUNIT COMPOSITION, ASSEMBLY, AND END-TO-END INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD TROPOMYOSIN; AMINO-ACID SEQUENCE; SKELETAL-MUSCLE; RABBIT SKELETAL; PROTEINS; TROPONIN; HETERODIMER; REGISTER; MYOSIN; ACTIN	Subunits of gizzard smooth muscle tropomyosin, dissociated by guanidinium chloride and reassociated by high salt dialysis, form a 1:1 mixture of the beta-beta and gamma-gamma homodimers (Graceffa, P. (1989) Biochemistry 28, 1282-1287). The homodimers have now been separated by anion-exchange chromatography and native gel electrophoresis, enabling us to show that the native protein is composed of more than 90% heterodimer. The in vitro equilibrium distribution of heterodimer and homodimers, at close to physiological temperature and ionic conditions, was calculated from thermal unfolding profiles of separated homodimers and heterodimer, as monitored by circular dichroism. The results, for an equal proportion of beta and gamma-chains, indicate a predominant formation of heterodimer via chain dissociation and chain exchange, although the proportion of heterodimer was much less than the 90-100% found in the native protein. However, the proportion of heterodimer for actin-bound tropomyosin, determined by analyzing tropomyosin sedimented with actin, was greater than 90%, which may provide a model for assembly in vivo. The end-to-end interactions of the homodimers are about the same but are much less than that of the native heterodimer, as determined by viscometry. The greater end-to-end interaction of heterodimers may lead to stronger binding to actin compared to homodimers and thus would further shift the equilibrium between heterodimer and homodimers toward heterodimer and possibly account for the almost exclusive population of heterodimer in the presence of actin. The greater end-to-end interaction of the heterodimer may also provide a functional advantage for its preferred assembly. This study also shows that the two-step thermal unfolding of the homodimer mixture is due to the formation of heterodimer via an intermediate which is a new type of tropomyosin species which forms a gel in low salt. This tropomyosin is also present in small amounts in native tropomyosin preparations.	BOSTON BIOMED RES INST,DEPT MUSCLE RES,BOSTON,MA 02114	Boston Biomedical Research Institute					NIAMS NIH HHS [AR-30917] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030917] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRONSON DD, 1982, J BIOL CHEM, V257, P3937; BROWN HR, 1985, P NATL ACAD SCI USA, V82, P2359, DOI 10.1073/pnas.82.8.2359; BURTNICK LD, 1988, ARCH BIOCHEM BIOPHYS, V266, P622, DOI 10.1016/0003-9861(88)90295-0; COHEN DM, 1978, J GEN PHYSIOL, V72, P369, DOI 10.1085/jgp.72.3.369; CUMMINS P, 1974, BIOCHEM J, V141, P43, DOI 10.1042/bj1410043; DABROWSKA R, 1983, BIOCHIM BIOPHYS ACTA, V743, P331, DOI 10.1016/0167-4838(83)90390-4; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; Fraser C.M., 1986, MERCK VET MANUAL, V6 th; GRACEFFA P, 1986, BIOCHEM BIOPH RES CO, V134, P64, DOI 10.1016/0006-291X(86)90527-9; GRACEFFA P, 1989, BIOCHEMISTRY-US, V28, P1282, DOI 10.1021/bi00429a050; HOLTZER ME, 1984, BIOPOLYMERS, V23, P1811, DOI 10.1002/bip.360231003; KOBASHI K, 1967, ARCH BIOCHEM BIOPHYS, V121, P178, DOI 10.1016/0003-9861(67)90022-7; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU SYM, 1985, J BIOL CHEM, V260, P7257; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEHRER SS, 1989, SCIENCE, V246, P926, DOI 10.1126/science.2814515; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; NOWAK E, 1985, BIOCHIM BIOPHYS ACTA, V829, P335, DOI 10.1016/0167-4838(85)90241-9; OOKUBO N, 1977, J BIOCHEM-TOKYO, V81, P923, DOI 10.1093/oxfordjournals.jbchem.a131557; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANDERS C, 1985, J BIOL CHEM, V260, P7264; SANDERS C, 1984, CAN J BIOCHEM CELL B, V62, P443, DOI 10.1139/o84-060; SANDERS C, 1986, J BIOL CHEM, V261, P2774; STAFFORD WF, 1985, BIOCHEMISTRY-US, V24, P3314, DOI 10.1021/bi00334a036; YAMAGUCHI M, 1974, J ULTRA MOL STRUCT R, V48, P33, DOI 10.1016/S0022-5320(74)80043-2; YATES LD, 1983, J MOL BIOL, V168, P123, DOI 10.1016/S0022-2836(83)80326-X	30	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5891	5897						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005125				2022-12-25	WOS:A1991FD37000083
J	SHILTON, BH; WALTON, DJ				SHILTON, BH; WALTON, DJ			SITES OF GLYCATION OF HUMAN AND HORSE LIVER ALCOHOL-DEHYDROGENASE INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN-SUPEROXIDE DISMUTASE; DIABETES-MELLITUS; PYRIDOXAL 5'-DIPHOSPHO-5'-ADENOSINE; NONENZYMATIC GLYCOSYLATION; 3-DIMENSIONAL STRUCTURE; TERNARY COMPLEX; ALBUMIN INVIVO; ALPHA-SUBUNIT; IDENTIFICATION; CHROMATOGRAPHY	Sites of in vivo glycation of human and horse liver alcohol dehydrogenase were identified by cleavage of the borotritide-treated enzyme with trypsin, followed by gas-phase sequencing of the resulting tritium-labeled glycated peptides. A blank sequencing result, i.e. failure to detect an amino acid phenylthiohydantoin after completion of an Edman degradation cycle, was ascribed to an N-epsilon-(1-deoxyhexitolyl)lysyl residue, which represented a glycation site on the original enzyme subunit. In human liver alcohol dehydrogenase the sites affected were the epsilon-amino groups of lysines 10, 39, 231, 248, and 325, which were glycated to the relative extents of 10, 5, 75, 5, and 5%, respectively. The site specificity of in vivo glycation of the horse enzyme is similar; 70-75% of it had occurred at lysine 231. A computer image of the crystal structure of horse liver alcohol dehydrogenase was examined. As a result, it was proposed that the high rate of glycation at lysine 231 is due to acid-base catalysis of the Amadori rearrangement by the imidazole group of histidine 348. This hypothesis was supported by showing that imidazole groups were close to sites of glycation in several other proteins.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada			Shilton, Brian H/A-6667-2011					AGARWAL KC, 1985, DIABETES, V34, P251, DOI 10.2337/diabetes.34.3.251; ARAI K, 1987, J BIOL CHEM, V262, P16969; ARAI K, 1987, BIOCHIM BIOPHYS ACTA, V924, P292, DOI 10.1016/0304-4165(87)90025-0; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; BAI Y, 1989, J PROTEIN CHEM, V8, P299, DOI 10.1007/BF01024951; BORKAKOTI N, 1981, PROTEIN DATA BANK; Branden C.-I., 1975, ENZYMES, V11, P103; BRANEN CI, 1979, PROTEIN DATA BANK; BUNN HF, 1978, SCIENCE, V200, P21, DOI 10.1126/science.635569; COLAS B, 1983, FEBS LETT, V163, P175, DOI 10.1016/0014-5793(83)80813-8; EKLUND H, 1987, EUR J BIOCHEM, V167, P185, DOI 10.1111/j.1432-1033.1987.tb13322.x; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; EKLUND H, 1984, PROTEIN DATA BANK; FERMI G, 1984, PROTEIN DATA BANK; Fersht A., 1985, ENZYME STRUCTURE MEC, P47; FERSHT AR, 1973, J MOL BIOL, V74, P137, DOI 10.1016/0022-2836(73)90103-4; GARLICK RL, 1983, J BIOL CHEM, V258, P6142; GUNDBERG CM, 1986, J BIOL CHEM, V261, P4557; IBERG N, 1986, J BIOL CHEM, V261, P3542; ISBELL HS, 1958, J ORG CHEM, V23, P1309, DOI 10.1021/jo01103a019; JORNVALL H, 1987, ENZYME, V37, P5; KONDO T, 1987, CLIN CHIM ACTA, V166, P227, DOI 10.1016/0009-8981(87)90425-6; LANGE LG, 1976, BIOCHEMISTRY-US, V15, P4681, DOI 10.1021/bi00666a022; MCPHERSON JD, 1988, BIOCHEM BIOPH RES CO, V152, P711, DOI 10.1016/S0006-291X(88)80096-2; MORI N, 1989, CARBOHYD RES, V189, P49, DOI 10.1016/0008-6215(89)84085-6; MORJANA NA, 1989, J BIOL CHEM, V264, P2912; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; PLAPP BV, 1983, J BIOL CHEM, V258, P5537; POLLAK A, 1983, CLIN CHIM ACTA, V133, P15, DOI 10.1016/0009-8981(83)90016-5; RAO R, 1988, J BIOL CHEM, V263, P5640; RATNAIKE S, 1987, CLIN CHEM, V33, P1807; ROBB DA, 1989, BIOCHEM J, V261, P871, DOI 10.1042/bj2610871; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; TRUEB B, 1982, ANAL BIOCHEM, V119, P330, DOI 10.1016/0003-2697(82)90594-2; TSAI CS, 1983, BIOCHEM J, V209, P309, DOI 10.1042/bj2090309; WALTON DJ, 1987, ANAL BIOCHEM, V164, P547, DOI 10.1016/0003-2697(87)90531-8; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WATKINS NG, 1987, J BIOL CHEM, V262, P7207	39	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5587	5592						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005099				2022-12-25	WOS:A1991FD37000037
J	YAMAGUCHI, M; HATEFI, Y				YAMAGUCHI, M; HATEFI, Y			MITOCHONDRIAL ENERGY-LINKED NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE - MEMBRANE TOPOGRAPHY OF THE BOVINE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; POLYACRYLAMIDE GELS; RAT-LIVER; PROTEINS	The mitochondrial energy-linked nicotinamide nucleotide transhydrogenase is a homodimer of monomer M(r) = 109,228. Hydropathy analysis of its cDNA-deduced amino acid sequence (1043 residues) has indicated that the molecule is composed of 3 domains: a 430-residue-long hydrophilic N-terminal domain which binds NAD(H), a 200-residue-long hydrophilic C-terminal domain which binds NADP(H), and a 400-residue-long hydrophobic central domain which appears to be made up mainly of about 14 hydrophobic clusters of approximately 20 residues each. In this study, antibodies were raised to the hydrophilic N- and C-terminal domains cleaved from the isolated transhydrogenase by proteolytic digestion, and to a synthetic, hydrophilic pentadecapeptide, which corresponded to position 540-554 within the central hydrophobic domain. Immunochemical experiments with mitoplasts (mitochondria denuded of outer membrane) and submitochondrial particles (inside-out inner membrane vesicles) as sources of antigens showed that essentially the entire N- and C-terminal hydrophilic domains of the transhydrogenase, as well as epitopes from the central pentadecapeptide, protrude from the inner membrane into the mitochondrial matrix, where the N- and C-terminal domains would be expected to come together to form the enzyme's catalytic site. Treatment of mitoplasts with several proteolytic enzymes indicated that large protease-sensitive masses of the transhydrogenase are not exposed on the cytosolic side of the inner membrane, which agreed with the exception that the central highly hydrophobic domain of the molecule should be largely membrane-intercalated. Trypsin, alpha-chymotrypsin, and papain had little or no effect on the mitoplast-embedded transhydrogenase. Proteinase K, subtilisin (Nagarse), thermolysin, and pronase E each split the mitoplast-embedded enzyme into two fragments only, a fragment of approximately 70 kDa containing the N-terminal hydrophilic domain, and one of approximately 40 kDa bearing the C-terminal hydrophilic domain. The cleavage site of proteinase K was determined to be A690-A691, which is located in a small hydrophilic segment within the central hydrophobic domain. This protease-sensitive loop appears to be exposed on the cytosolic side of the inner membrane. The proteinase K-nicked enzyme containing two peptides of 71 and 39 kDa was isolated from mitoplasts and shown to have high transhydrogenase activity.	Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024887] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24887] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISSON R, 1986, J BIOL CHEM, V261, P4373; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARLENOR E, 1985, BIOSCIENCE REP, V5, P483, DOI 10.1007/BF01116947; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; FISHER R. R., 1982, PYRIDINE NUCLEOTIDE, P279; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HATEFI Y, 1961, ARCH BIOCHEM BIOPHYS, V94, P148, DOI 10.1016/0003-9861(61)90022-4; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CP, 1989, BIOCHIM BIOPHYS ACTA, V1000, P371, DOI 10.1016/S0006-3002(89)80032-0; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P915; WEIS JK, 1987, ARCH BIOCHEM BIOPHYS, V257, P424, DOI 10.1016/0003-9861(87)90586-8; WU LNY, 1985, J BIOL CHEM, V260, P6361; YAMAGUCHI M, 1988, BIOCHEM BIOPH RES CO, V157, P24, DOI 10.1016/S0006-291X(88)80005-6; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1989, BIOCHEMISTRY-US, V28, P6050, DOI 10.1021/bi00440a049	27	44	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5728	5735						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005110				2022-12-25	WOS:A1991FD37000058
J	GREEN, AR; SALVARIS, E; BEGLEY, CG				GREEN, AR; SALVARIS, E; BEGLEY, CG			ERYTHROID EXPRESSION OF THE HELIX-LOOP-HELIX GENE, SCL	ONCOGENE			English	Note							ERYTHROLEUKEMIA CELL-LINE; HUMAN-LEUKEMIA; MESSENGER-RNA; DNA-BINDING; ERYTHROPOIETIN; TRANSLOCATION; PROTEINS; DIFFERENTIATION; GLYCOPROTEINS; ONCOGENES	The SCL gene encodes a member of the 'helix-loop-helix' family of DNA binding regulatory proteins. It is transcriptionally activated in some cases of T-cell acute lymphoblastic leukaemia by a reciprocal translocation involving the T cell receptor delta-locus. In order to gain insight into the normal functions of SCL we have studied SCL mRNA levels in human and murine haemopoietic cell lines and normal tissues. We have observed high levels of SCL mRNA in all human and murine erythroid cell lines examined. Foetal and adult normal haemopoietic cell populations rich in erythroid precursors also expressed high levels of SCL mRNA. Our results suggest a previously unexpected role for SCL in the regulation of erythropoiesis.	ROYAL MELBOURNE HOSP,DEPT HAEMATOL,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital	GREEN, AR (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.			Green, Anthony/0000-0002-9795-0218				ANDRE C, 1989, ONCOGENE, V4, P1047; APLAN PD, IN PRESS MOL CELL BI; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, IN PRESS P NATL ACAD; BENZ EJ, 1980, P NATL ACAD SCI-BIOL, V77, P3509, DOI 10.1073/pnas.77.6.3509; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CONKIE D, 1975, EXP CELL RES, V93, P315, DOI 10.1016/0014-4827(75)90456-5; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GEWIRTZ AM, 1982, BLOOD, V60, P785; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HARA K, 1988, EXP HEMATOL, V16, P256; HARRISON PR, 1978, EXP CELL RES, V115, P395, DOI 10.1016/0014-4827(78)90293-8; HASTHORPE S, 1981, CANCER RES, V41, P3985; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; KELSO A, 1984, J IMMUNOL, V132, P2932; KIRSCH IR, 1985, CANCER GENET CYTOGEN, V18, P159, DOI 10.1016/0165-4608(85)90066-4; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MINOWADA J, 1981, J CANCER RES CLIN, V101, P91, DOI 10.1007/BF00405069; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; PAPAYANNOPOULOU T, 1987, BLOOD, V70, P1764; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TAMBOURIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6269, DOI 10.1073/pnas.80.20.6269; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485	34	119	120	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					475	479						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011404				2022-12-25	WOS:A1991FT34400020
J	LAMMIE, GA; FANTL, V; SMITH, R; SCHUURING, E; BROOKES, S; MICHALIDES, R; DICKSON, C; ARNOLD, A; PETERS, G				LAMMIE, GA; FANTL, V; SMITH, R; SCHUURING, E; BROOKES, S; MICHALIDES, R; DICKSON, C; ARNOLD, A; PETERS, G			D11S287, A PUTATIVE ONCOGENE ON CHROMOSOME-11Q13, IS AMPLIFIED AND EXPRESSED IN SQUAMOUS-CELL AND MAMMARY CARCINOMAS AND LINKED TO BCL-1	ONCOGENE			English	Article							HUMAN-BREAST-TUMORS; ENDOCRINE NEOPLASIA TYPE-1; FIBROBLAST GROWTH-FACTORS; PROTO-ONCOGENE; INT-2 GENE; PARATHYROID ADENOMA; MOLECULAR-CLONING; CO-AMPLIFICATION; MESSENGER-RNA; SARCOMA DNA	Approximately 15 to 20% of primary breast cancers and an even higher proportion of squamous cell carcinomas of the head and neck show amplification of DNA markers on band q13 of human chromosome 11. However, known genes within the amplified region, such as the FGF-related oncogenes INT-2 and HST-1, are very rarely expressed in these tumors. Here we show that another candidate oncogene, designated D11S287, implicated in the pathogenesis of parathyroid adenomas, is also amplified in breast cancers. Significantly, it is consistently co-amplified with INT-2 and HST-1 in 36 out of 202 primary tumors, including one case in which the amplified unit did not encompass the translocation breakpoint marker BCL-1. This implies that D11S287 is on the same side of the breakpoint as INT-2, and pulsed-field gel electrophoresis indicates that D11S287 is less than 250 kb from the BCL-1 marker. Since D11S287 RNA was present at elevated levels in a group of tumors and cell lines in which the 11q13 region is amplified, it may be the key oncogene on this amplified unit, and could also be activated by BCL-1 translocations.	ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND LABS,DOMINION HOUSE,59 BARTHOLOMEW CLOSE,LONDON EC1A 7BE,ENGLAND; NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Cancer Research UK; University of London; Queen Mary University London; Netherlands Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								ADELAIDE J, 1988, ONCOGENE, V2, P413; ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1989, ONCOGENE, V4, P89; ARNOLD A, 1989, J CLIN ENDOCR METAB, V69, P496, DOI 10.1210/jcem-69-3-496; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BALE AE, 1990, AM J HUMAN GENET S1, V47; BALE SJ, 1989, GENOMICS, V4, P320, DOI 10.1016/0888-7543(89)90336-4; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BYSTROM C, 1990, P NATL ACAD SCI USA, V87, P1968, DOI 10.1073/pnas.87.5.1968; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; EHRICH E, 1987, GENE, V57, P229, DOI 10.1016/0378-1119(87)90126-0; ERIKSON J, 1984, P NATL ACAD SCI-BIOL, V81, P4144, DOI 10.1073/pnas.81.13.4144; FANTL V, 1989, CANCER CEL, V7, P283; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FRIEDMAN E, 1990, J CLIN ENDOCR METAB, V71, P293, DOI 10.1210/jcem-71-2-293; GOLDFARB M, 1991, ONCOGENE, V6, P65; GUERIN M, 1988, ONCOGENE RES, V3, P21; HATADA I, 1988, ONCOGENE, V3, P537; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HUEBNER K, 1988, ONCOGENE RES, V3, P263; KODURU PRK, 1989, ONCOGENE, V4, P929; LACROIX H, 1989, ONCOGENE, V4, P145; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LISCIA DS, 1989, ONCOGENE, V4, P1219; MACHOTKA SV, 1989, CLIN CHIM ACTA, V184, P207, DOI 10.1016/0009-8981(89)90053-3; Maniatis T., 1982, MOL CLONING; NGUYEN C, 1988, ONCOGENE, V3, P703; PARKES HC, 1990, BRIT J CANCER, V61, P39, DOI 10.1038/bjc.1990.9; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; RABBITTS PH, 1988, ONCOGENE, V3, P99; ROSENBERG CL, 1991, ONCOGENE, V6, P449; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SOMERS KD, 1990, ONCOGENE, V5, P915; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THAKKER RV, 1989, NEW ENGL J MED, V321, P218, DOI 10.1056/NEJM198907273210403; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1989, ONCOGENE, V4, P915; TSUDA T, 1988, JPN J CANCER RES, V79, P584, DOI 10.1111/j.1349-7006.1988.tb00026.x; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VARLEY JM, 1988, ONCOGENE, V3, P87; WADA A, 1988, BIOCHEM BIOPH RES CO, V157, P828, DOI 10.1016/S0006-291X(88)80324-3; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHOU DJ, 1988, ONCOGENE, V2, P279	52	475	484	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					439	444						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011398				2022-12-25	WOS:A1991FT34400013
J	CHOI, EJ; TOSCANO, DG; RYAN, JA; RIEDEL, N; TOSCANO, WA				CHOI, EJ; TOSCANO, DG; RYAN, JA; RIEDEL, N; TOSCANO, WA			DIOXIN INDUCES TRANSFORMING GROWTH FACTOR-ALPHA IN HUMAN KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL KERATINOCYTES; SQUAMOUS-CELL CARCINOMAS; FACTOR-RECEPTOR; SIGNAL TRANSDUCTION; TERMINAL DIFFERENTIATION; FACTOR BINDING; TGF-ALPHA; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; TCDD; INDUCTION	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a widespread environmental toxicant, is a tumor promoter that induces hyperplasia in epithelia cells. Exposure of cultured human keratinocytes to TCDD, resulted in a time-dependent dioxin-specific Ah receptor-mediated release of transforming growth factor-alpha (TGF-alpha) into the culture medium. Cultures exposed to TCDD showed a rate of TGF-alpha secretion into the medium of about 30 fmol/ml/day, as well as a 3- to 6-fold increase in TGF-alpha mRNA expression. Increased production of TGF-alpha in human keratinocytes exposed to TCDD demonstrates a modulation of autocrine regulation in those cells. These results suggest that induction of TGF-alpha could be an important part of the mechanism of dioxin-mediated toxicity and tumor promotion.	UNIV MINNESOTA, DIV ENVIRONM & OCCUPAT HLTH, ENVIRONM TOXICOL PROGRAM, BOX 197, MINNEAPOLIS, MN 55455 USA; MASSACHUSETTS GEN HOSP, DIABET UNIT, BOSTON, MA 02114 USA; BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA	University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Massachusetts General Hospital; Boston University					NIEHS NIH HHS [ES-02866] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002866] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABERNETHY DJ, 1985, CARCINOGENESIS, V6, P651, DOI 10.1093/carcin/6.4.651; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BENVENISTE M, 1988, J CELL BIOL, V106, P1903, DOI 10.1083/jcb.106.6.1903; BOMBICK DW, 1988, P NATL ACAD SCI USA, V85, P4128, DOI 10.1073/pnas.85.12.4128; BOMBICK DW, 1987, LIFE SCI, V41, P429, DOI 10.1016/0024-3205(87)90218-9; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; CARPENTER G, 1986, ONCOGENES GROWTH CON, P65; CHOI EJ, 1988, J BIOL CHEM, V263, P17167; COFFEY RJ, 1988, CANCER RES, V48, P1596; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COHEN S, 1963, J INVEST DERMATOL, V40, P1; COHEN S, 1980, J BIOL CHEM, V255, P4834; COHEN S, 1962, J BIOL CHEM, V237, P1555; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DIGIOVANNI J, 1988, PROG CANCER RES THER, V34, P51; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FISHER JM, 1989, MOL CARCINOGEN, V1, P216, DOI 10.1002/mc.2940010403; Green H, 1980, Harvey Lect, V74, P101; GREENLEE WF, 1987, REV BIOCHEM TOXICOL, V8, P1; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HIRSCH V, 1986, P NATL ACAD SCI USA, V83, P9754, DOI 10.1073/pnas.83.24.9754; HUDSON LG, 1986, TOXICOL APPL PHARM, V82, P481, DOI 10.1016/0041-008X(86)90283-8; HUDSON LG, 1985, TOXICOL APPL PHARM, V77, P251, DOI 10.1016/0041-008X(85)90324-2; KNUTSON JC, 1980, CELL, V22, P27, DOI 10.1016/0092-8674(80)90151-8; KOCIBA RJ, 1976, TOXICOL APPL PHARM, V35, P553, DOI 10.1016/0041-008X(76)90078-8; KORC M, 1985, J CELL PHYSIOL, V124, P344, DOI 10.1002/jcp.1041240226; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LS, 1979, P NATL ACAD SCI USA, V76, P5168, DOI 10.1073/pnas.76.10.5168; LEE LS, 1982, CARCINOGENESIS, P471; MADHUKAR BV, 1984, P NATL ACAD SCI-BIOL, V81, P7407, DOI 10.1073/pnas.81.23.7407; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; Maniatis T, 1989, MOL CLONING; MILSTONE LM, 1984, J INVEST DERMATOL, V82, P532, DOI 10.1111/1523-1747.ep12261149; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OKEEFE E, 1982, J INVEST DERMATOL, V78, P482, DOI 10.1111/1523-1747.ep12510246; OSBORNE R, 1985, TOXICOL APPL PHARM, V77, P434, DOI 10.1016/0041-008X(85)90183-8; OSBORNE R, 1988, PROGR CANCER RES THE, V34, P407; PARTRIDGE M, 1989, BRIT J CANCER, V60, P542, DOI 10.1038/bjc.1989.310; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PITOT HC, 1980, BIOCHIM BIOPHYS ACTA, V605, P191, DOI 10.1016/0304-419X(80)90004-9; PITOT HC, 1980, CANCER RES, V40, P3616; PITTELKOW MR, 1988, ANN NY ACAD SCI, V548, P211, DOI 10.1111/j.1749-6632.1988.tb18809.x; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1982, NATURE, V300, P271, DOI 10.1038/300271a0; POLAND A, 1977, MOL PHARMACOL, V13, P924; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1975, CELL, V6, P317, DOI 10.1016/0092-8674(75)90183-X; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; ROSE SP, 1976, EXPERIENTIA, V32, P913, DOI 10.1007/BF02003764; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1986, ONCOGENES GROWTH CON, P77; SMITH JM, 1985, NATURE, V315, P515, DOI 10.1038/315515a0; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; VOS JG, 1971, TOXICOL APPL PHARM, V19, P617, DOI 10.1016/0041-008X(71)90294-8; WATTENBERG EV, 1989, J BIOL CHEM, V264, P213; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINSTEIN IB, 1988, MUTAT RES, V202, P413; WEINSTEIN IB, 1990, ADV SEC MESS PHOSPH, V24, P307; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	68	114	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9591	9597						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033054				2022-12-25	WOS:A1991FM45900041
J	PROSSNITZ, E				PROSSNITZ, E			DETERMINATION OF A REGION OF THE HISJ BINDING-PROTEIN INVOLVED IN THE RECOGNITION OF THE MEMBRANE COMPLEX OF THE HISTIDINE TRANSPORT-SYSTEM OF SALMONELLA-TYPHIMURIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPONENTS; POLYMERASE; PERMEASE; SEQUENCE; OPERON; SITES; GENE; DNA	Site-directed mutagenesis has been utilized to examine the nature of the interaction of the histidine-binding protein (HisJ) with the membrane-bound components of the histidine transport system. In order to examine a region of the HisJ protein involved in the interaction with the membrane components, a number of charged amino acids in the vicinity of the genetically isolated interaction mutant hisJ5625 (R176C) were mutated. It was found that residues Asp171, Arg176, and Asp178 could be independently altered without affecting the histidine-binding affinity of the HisJ protein. However, the alteration of residues Asp171 and Arg176 greatly reduced the interaction of the HisJ protein with the membrane protein complex, whereas altering residue Asp178 had no effect on this interaction. Simultaneously, altering residues Asp183 and Glu184 resulted in a completely defective protein. The ability of a hisJ5625 suppressor HisP protein (HisP(T205A)) to suppress the newly created site-directed mutants was also examined. This suppressor demonstrated specificity toward the amino acid present at position 176 and was also able the suppress the mutation created at position 171.	UNIV CALIF BERKELEY, DEPT BIOCHEM, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302				ADAMS MD, 1989, J BIOL CHEM, V264, P15739; ALVARADOURBINA G, 1981, SCIENCE, V214, P270, DOI 10.1126/science.6169150; AMES GF, 1984, J BACTERIOL, V160, P1181, DOI 10.1128/JB.160.3.1181-1183.1984; AMES GFL, 1970, P NATL ACAD SCI USA, V66, P1096, DOI 10.1073/pnas.66.4.1096; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVER JE, 1972, ANAL BIOCHEM, V50, P73, DOI 10.1016/0003-2697(72)90487-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAO B, 1982, J BIOL CHEM, V257, P1131; PAYNE GM, 1985, MOL GEN GENET, V200, P493, DOI 10.1007/BF00425737; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHYAMALA V, 1989, J BACTERIOL, V171, P1602, DOI 10.1128/jb.171.3.1602-1608.1989; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8	22	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9673	9677						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033059				2022-12-25	WOS:A1991FM45900053
J	RICE, MS; DAHLQUIST, FW				RICE, MS; DAHLQUIST, FW			SITES OF DEAMIDATION AND METHYLATION IN TSR, A BACTERIAL CHEMOTAXIS SENSORY TRANSDUCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MULTIPLE METHYLATION; PROTEIN-PHOSPHORYLATION; COVALENT MODIFICATION; GENE-PRODUCT; IDENTIFICATION; CHEB; ACID; TRG; ADAPTATION	The sensory transducer proteins in bacterial chemotaxis undergo two covalent modifications, deamidation and reversible methylation, in response to attractants and repellents. Oligonucleotide-directed mutagenesis was used to alter putative methylation and deamidation sites in one of the transducers to further define these sites and their role in chemotaxis. The mutations, in combination with peptide maps and Edman analysis, have clarified the sites of covalent modification in Tsr. Tsr contains six specific glutamates and glutamines that serve as methyl-accepting sites. An arginine-containing tryptic peptide (R1) has two sites, one at glutamate 493 and a newly located site at gluatmate 502. A lysine-containing peptide (K1) has four methyl-accepting sites. Two of the lysine peptide sites are glutamates and can accept methyl groups without deamidation. The other two sites are glutamines and two methyl-accepting sites are created by two distinct deamidations. Both deamidations can occur on the same polypeptide chain. Single glutamate mutants have shown that one deamidation (at glutamine 311) proceeds rapidly, while the other deamidation (at glutamine 297) has a half-life of approximately 60 min under our experimental conditions.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon					NIGMS NIH HHS [GM33677] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033677, R37GM033677] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; BOYD A, 1980, J BACTERIOL, V143, P809, DOI 10.1128/JB.143.2.809-815.1980; CALLAHAN AM, 1987, J BACTERIOL, V169, P1246, DOI 10.1128/jb.169.3.1246-1253.1987; CHELSKY D, 1981, BIOCHEMISTRY-US, V20, P977, DOI 10.1021/bi00507a051; CHELSKY D, 1980, P NATL ACAD SCI-BIOL, V77, P2434, DOI 10.1073/pnas.77.5.2434; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; DEFRANCO AL, 1979, J BACTERIOL, V139, P107, DOI 10.1128/JB.139.1.107-114.1979; DEFRANCO AL, 1980, P NATL ACAD SCI-BIOL, V77, P2429, DOI 10.1073/pnas.77.5.2429; ENGSTROM P, 1983, J BACTERIOL, V156, P1268; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; HAYASHI H, 1979, J BIOCHEM-TOKYO, V85, P1213; HAZELBAUER GL, 1989, P NATL ACAD SCI USA, V86, P1448, DOI 10.1073/pnas.86.5.1448; HAZELBAUER GL, 1988, CAN J MICROBIOL, V34, P466, DOI 10.1139/m88-080; HEDBLOM ML, 1983, J BACTERIOL, V155, P1463, DOI 10.1128/JB.155.3.1463-1466.1983; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; IMAE Y, 1987, J BACTERIOL, V169, P371, DOI 10.1128/jb.169.1.371-379.1987; KEHRY MR, 1982, CELL, V29, P761, DOI 10.1016/0092-8674(82)90438-X; KEHRY MR, 1983, J BIOL CHEM, V258, P5050; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; KEHRY MR, 1982, J BIOL CHEM, V257, P378; KEHRY MR, 1983, MOBILITY RECOGNITION, P533; KIHARA M, 1981, J BACTERIOL, V145, P1209, DOI 10.1128/JB.145.3.1209-1221.1981; KLEENE SJ, 1979, P NATL ACAD SCI USA, V76, P6309, DOI 10.1073/pnas.76.12.6309; KLEENE SJ, 1977, J BIOL CHEM, V252, P3214; KONDOH H, 1979, P N ATL ACAD SCI US, V76, P11; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEE L, 1988, J BACTERIOL, V170, P4769, DOI 10.1128/jb.170.10.4769-4774.1988; Maniatis T., 1982, MOL CLONING; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NOWLIN DM, 1988, PROTEINS, V3, P102, DOI 10.1002/prot.340030205; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; Osborn M J, 1974, Methods Enzymol, V31, P642; RIDGWAY HF, 1977, J BACTERIOL, V132, P657, DOI 10.1128/JB.132.2.657-665.1977; ROLLINS C, 1981, CELL, V25, P333, DOI 10.1016/0092-8674(81)90051-9; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SHERRIS D, 1981, P NATL ACAD SCI-BIOL, V78, P6051, DOI 10.1073/pnas.78.10.6051; SILVERMAN M, 1977, P NATL ACAD SCI USA, V74, P3317, DOI 10.1073/pnas.74.8.3317; SPRINGER MS, 1977, P NATL ACAD SCI USA, V74, P3312, DOI 10.1073/pnas.74.8.3312; SPRINGER MS, 1982, J BIOL CHEM, V257, P6861; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STEWART RC, 1988, J BACTERIOL, V170, P5728, DOI 10.1128/jb.170.12.5728-5738.1988; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STOCK JB, 1981, J BIOL CHEM, V256, P826; TERWILLIGER TC, 1986, J BIOL CHEM, V261, P814; VANDERWERF P, 1977, J BIOL CHEM, V252, P2793; WEIS RM, 1988, P NATL ACAD SCI USA, V85, P83, DOI 10.1073/pnas.85.1.83	51	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9746	9753						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033064				2022-12-25	WOS:A1991FM45900064
J	LEONG, DA; THORNER, MO				LEONG, DA; THORNER, MO			A POTENTIAL CODE OF LUTEINIZING-HORMONE-RELEASING HORMONE-INDUCED CALCIUM-ION RESPONSES IN THE REGULATION OF LUTEINIZING-HORMONE SECRETION AMONG INDIVIDUAL GONADOTROPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ESTROUS-CYCLE; HEMOLYTIC PLAQUE-ASSAY; ANTERIOR-PITUITARY-CELLS; CYTOPLASMIC FREE CALCIUM; PAROTID ACINAR-CELLS; PROTEIN KINASE-C; CYTOSOLIC CALCIUM; INTRACELLULAR CALCIUM; INOSITOL PHOSPHATES; MESSENGER-RNA	Luteinizing hormone-releasing hormone (LHRH) induces two Ca2+ responses in single gonadotropes: a Ca2+ spike/plateau or oscillation. Similar receptor-mediated Ca2+ signals have been reported in many cell types but their functional significance is obscure. Accordingly, we have determined the concentration-response properties of LHRH-induced luteinizing hormone (LH) release at the single cell level. We demonstrate a critical single cell LHRH threshold for LH release. Each gonadotrope had a particular LHRH threshold value and a range of different single cell thresholds was distributed in the gonadotrope population. The physiological significance of the threshold was demonstrated by a striking reduction (DELTA-ED50 = 153 nM) of the LHRH threshold immediately before the preovulatory surge of LH release. The metestrous phenotype of secretion resembled a quantal process in contrast with the graded process of the proestrous phenotype. That is, the quantity of hormone secreted per metestrous gonadotrope was independent of LHRH concentration and more all-or-none than graded. The LHRH threshold and the quantal secretion process of metestrous gonadotropes was further studied by measuring cytosolic Ca2+ using fura-2 and digital imaging microscopy. We provide evidence suggesting that the Ca2+ spike/plateau and oscillation are the respective responses to subthreshold and suprathreshold concentrations of LHRH. It is proposed therefore that the Ca2+ oscillation and spike/plateau response form a binary intracellular signaling code that functions as an on-off switch. It is further proposed that this potential code unraveled here for the regulation of hormone secretion may also regulate other gonadotrope functions. Thus, while the Ca2+ spike/plateau response is strongly associated with LH release, it may be associated with reduced levels of LH-beta-mRNA, and reduced numbers of LHRH receptors. Conversely, while the Ca2+ oscillation appears to be unrelated to LH release, it may be associated with increased levels of LH-beta mRNA, and increased numbers of LHRH receptors. This model may explain in molecular terms the long-standing observation that an invariant, albeit pulsatile, pattern of LHRH release is sufficient to support the preovulatory surge of LH release.	UNIV VIRGINIA, HLTH SCI CTR, DEPT NEUROSCI, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia	LEONG, DA (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT MED, CHARLOTTESVILLE, VA 22908 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013197] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-13197] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALEXANDER SE, 1990, AM J OBSTET GYNECOL, V162, P446, DOI 10.1016/0002-9378(90)90403-T; ALLAERTS W, 1988, J THEOR BIOL, V131, P441, DOI 10.1016/S0022-5193(88)80040-7; ANDREWS WV, 1986, ENDOCRINOLOGY, V118, P1148, DOI 10.1210/endo-118-3-1148; ANDREWS WV, 1988, J BIOL CHEM, V263, P13755; ATTARDI B, 1989, MOL ENDOCRINOL, V3, P1236, DOI 10.1210/mend-3-8-1236; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CATT KJ, 1985, J STEROID BIOCHEM, V23, P677, DOI 10.1016/S0022-4731(85)80003-0; CHANG JP, 1988, ENDOCRINOLOGY, V123, P87, DOI 10.1210/endo-123-1-87; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; CLARKE IJ, 1987, NEUROENDOCRINOLOGY, V46, P82, DOI 10.1159/000124800; CLAYTON RN, 1985, J STEROID BIOCHEM, V23, P691, DOI 10.1016/S0022-4731(85)80004-2; CLAYTON RN, 1980, ENDOCRINOLOGY, V107, P699, DOI 10.1210/endo-107-3-699; Crowley W F Jr, 1985, Recent Prog Horm Res, V41, P473; FOX SR, 1985, ENDOCRINOLOGY, V116, P1485, DOI 10.1210/endo-116-4-1485; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; HOLL RW, 1988, J BIOL CHEM, V263, P9682; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KIM KT, 1989, P NATL ACAD SCI USA, V86, P9881, DOI 10.1073/pnas.86.24.9881; Knobil E, 1980, Recent Prog Horm Res, V36, P53; LEONG DA, 1985, ENDOCRINOLOGY, V116, P1371, DOI 10.1210/endo-116-4-1371; LEONG DA, 1989, METHOD ENZYMOL, V168, P263; LLINAS R R, 1977, Neurosciences Research Program Bulletin, V15, P565; LOUMAYE E, 1982, SCIENCE, V215, P983, DOI 10.1126/science.6296998; MARIAN J, 1981, MOL PHARMACOL, V19, P399; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NAOR Z, 1989, P NATL ACAD SCI USA, V86, P4501, DOI 10.1073/pnas.86.12.4501; NAOR Z, 1986, J BIOL CHEM, V261, P2506; NAOR Z, 1981, J BIOL CHEM, V256, P2226; NAOR Z, 1988, MOL ENDOCRINOL, V2, P512, DOI 10.1210/mend-2-6-512; NAOR ZV, 1988, MOL ENDOCRINOL, V1, P512; NEHER E, 1986, EMBO J, V5, P51, DOI 10.1002/j.1460-2075.1986.tb04176.x; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NEILL JD, 1983, ENDOCRINOLOGY, V112, P1135, DOI 10.1210/endo-112-3-1135; PARK OK, 1989, NEUROENDOCRINOLOGY, V50, P66, DOI 10.1159/000125203; PENNER R, 1988, J EXP BIOL, V139, P329; PICKERING AJMC, 1979, J ENDOCRINOL, V83, P53, DOI 10.1677/joe.0.0830053; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; RAPP PE, 1981, J EXP BIOL, V93, P119; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SAKTIB SRL, 1988, MOL ENDOCRINOL, V2, P1033; SARKAR DK, 1976, NATURE, V264, P461, DOI 10.1038/264461a0; SAVOYMOORE RT, 1980, SCIENCE, V209, P942, DOI 10.1126/science.6250218; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SMITH PF, 1984, ENDOCRINOLOGY, V115, P2484, DOI 10.1210/endo-115-6-2484; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; WEISS J, 1990, MOL ENDOCRINOL, V4, P557, DOI 10.1210/mend-4-4-557; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8; ZMEILI SM, 1986, ENDOCRINOLOGY, V119, P1867, DOI 10.1210/endo-119-4-1867	58	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9016	9022						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026609				2022-12-25	WOS:A1991FM03800056
J	SEI, Y; MCINTYRE, T; FRIDE, E; YOSHIMOTO, K; SKOLNICK, P; ARORA, PK				SEI, Y; MCINTYRE, T; FRIDE, E; YOSHIMOTO, K; SKOLNICK, P; ARORA, PK			INHIBITION OF CALCIUM MOBILIZATION IS AN EARLY EVENT IN OPIATE-INDUCED IMMUNOSUPPRESSION	FASEB JOURNAL			English	Article						OPIATES; OPIATE, RECEPTORS; CENTRAL NERVOUS SYSTEM; CALCIUM MOBILIZATION; T-CELLS; B-CELLS; IMMUNOSUPPRESSION	FLUORESCENT INDICATORS; BETA-ENDORPHIN; MORPHINE; MICE; IMMUNOMODULATION; LYMPHOCYTES; CELLS	Morphine administered as a subcutaneous implant inhibits the initial increase in cytoplasmic free-calcium [Ca2+]i induced by mitogens in mouse splenocytes. This effect was not reproduced by incubation of splenocytes with morphine (10(-8)-10(-4) M). Analysis of splenocyte subpopulations demonstrates that this effect was manifest in both B and T cells. However, within T cell subpopulations, CD4+ but not CD8+ cells were affected. Adrenalectomy abolished this effect of morphine in CD4+ T but not CD4-, CD8- spleen cells (most likely Thy 1.2- B cells). Moreover, simultaneous administration of the opiate antagonist naltrexone blocked the effect of morphine in CD4-, CD8- spleen cells, but not in CD4+ T cells. These data indicate that the effects of morphine on mitogen-stimulated increase in [Ca2+]i may be mediated through distinct glucocorticoid-dependent and -independent mechanisms. The morphine-induced inhibition of an increase in [Ca2+]i in immune cells reported here may be an early event mediating opiate-induced immunosuppression.	NIDDKD, NEUROSCI LAB, BLDG 8, ROOM 111, BETHESDA, MD 20892 USA; NIMH, CEREBRAL METAB LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ARORA PK, 1990, CELL IMMUNOL, V126, P343, DOI 10.1016/0008-8749(90)90326-M; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BRIGGS JH, 1967, LANCET, V2, P1227; BRYANT HU, 1988, J PHARMACOL EXP THER, V245, P913; BRYANT HU, 1987, LIFE SCI, V41, P1731, DOI 10.1016/0024-3205(87)90601-1; BRYANT HU, 1990, J PHARMACOL EXP THER, V255, P410; CARR DJJ, 1988, CELL IMMUNOL, V116, P44, DOI 10.1016/0008-8749(88)90208-0; CHERUBIN CE, 1971, ARCH INTERN MED, V128, P309, DOI 10.1001/archinte.1971.00310200145021; DELITALA G, 1984, OPIOID MODULATION EN, P65; GELFAND EW, 1987, IMMUNOL REV, V95, P59, DOI 10.1111/j.1600-065X.1987.tb00500.x; GEORGE R, 1955, BRIT J PHARM CHEMOTH, V10, P260, DOI 10.1111/j.1476-5381.1955.tb00092.x; GIBSON A, 1979, BRIT J PHARMACOL, V65, P139, DOI 10.1111/j.1476-5381.1979.tb17342.x; Gibson R D, 1970, J Pharm Sci, V59, P426, DOI 10.1002/jps.2600590338; HARACZ JL, 1981, NEUROENDOCRINOLOGY, V33, P170, DOI 10.1159/000123224; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KREEK MJ, 1983, LIFE SCI, V33, P409, DOI 10.1016/0024-3205(83)90529-5; LINCH DC, 1987, IMMUNOL REV, V95, P137, DOI 10.1111/j.1600-065X.1987.tb00503.x; LOURIA DB, 1967, ANN INTERN MED, V67, P1, DOI 10.7326/0003-4819-67-1-1; LUCKHOFF A, 1986, CELL CALCIUM, V7, P233, DOI 10.1016/0143-4160(86)90003-5; MINTA A, 1989, J BIOL CHEM, V264, P8171; SEI Y, 1991, J IMMUNOL, V146, P194; SEI Y, 1991, IN PRESS J IMMUNOL M; SIBINGA NES, 1988, ANNU REV IMMUNOL, V6, P219; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; TUBARO E, 1983, J INFECT DIS, V148, P656, DOI 10.1093/infdis/148.4.656; Weber R J, 1987, NIDA Res Monogr, V76, P341; WEBER RJ, 1989, SCIENCE, V245, P188, DOI 10.1126/science.2749256; YAHYA MD, 1987, LIFE SCI, V41, P2503	28	34	34	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2194	2199		10.1096/fasebj.5.8.2022315	http://dx.doi.org/10.1096/fasebj.5.8.2022315			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	2022315				2022-12-25	WOS:A1991FK11100012
J	OLSON, ST; BJORK, I				OLSON, ST; BJORK, I			PREDOMINANT CONTRIBUTION OF SURFACE APPROXIMATION TO THE MECHANISM OF HEPARIN ACCELERATION OF THE ANTITHROMBIN-THROMBIN REACTION - ELUCIDATION FROM SALT CONCENTRATION EFFECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY HEPARIN; CATALYZED PROTEASE INACTIVATION; MOLECULAR WEIGHT HEPARIN; ANTI-THROMBIN; FACTOR-XA; TRANSIENT KINETICS; NUCLEIC-ACIDS; BINDING SEQUENCE; PENTASACCHARIDE; INHIBITION	Heparin has been shown to accelerate the inactivation of alpha-thrombin by antithrombin III (AT) by promoting the initial encounter of proteinase and inhibitor in a ternary thrombin-AT-heparin complex. The aim of the present work was to evaluate the relative contributions of an AT conformational change induced by heparin and of a thrombin-heparin interaction to the promotion by heparin of the thrombin-AT interaction in this ternary complex. This was achieved by comparing the ionic and nonionic contributions to the binary and ternary complex interactions involved in ternary complex assembly at pH 7.4, 25-degrees-C, and 0.1-0.35 M NaCl. Equilibrium binding and kinetic studies of the binary complex interactions as a function of salt concentration indicated a similar large ionic component for thrombin-heparin and AT-heparin interactions, but a predominantly nonionic contribution to the thrombin-AT interaction. Stopped-flow kinetic studies of ternary complex formation under conditions where heparin was always saturated with AT demonstrated that the ternary complex was assembled primarily from free thrombin and AT-heparin binary complex at all salt concentrations. Moreover, the ternary complex interaction of thrombin with AT bound to heparin exhibited a substantial ionic component similar to that of the thrombin-heparin binary complex interaction. Comparison of the ionic and nonionic components of thrombin binary and ternary complex interactions indicated that: 1) additive contributions of ionic thrombin-heparin and nonionic thrombin-AT binary complex interactions completely accounted for the binding energy of the thrombin ternary complex interaction, and 2) the heparin-induced AT conformational change made a relatively insignificant contribution to this binding energy. The results thus suggest that heparin promotes the encounter of thrombin and AT primarily by approximating the proteinase and inhibitor on the polysaccharide surface. Evidence was further obtained for alternative modes of thrombin binding to the AT-heparin complex, either with or without the active site of the enzyme complexed with AT. This finding is consistent with the ternary complex encounter of thrombin and AT being mediated by thrombin binding to nonspecific heparin sites, followed by diffusion along the heparin surface to a unique site adjacent to the bound inhibitor.	SWEDISH UNIV AGR SCI, CTR BIOMED, DEPT VET MED CHEM, S-75123 UPPSALA, SWEDEN	Swedish University of Agricultural Sciences	OLSON, ST (corresponding author), HENRY FORD HOSP, DIV BIOCHEM RES, EDUC & RES BLDG, RM 3126, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.				NHLBI NIH HHS [HL-39888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888, R29HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERESFORD CH, 1990, INT J BIOCHEM, V22, P121, DOI 10.1016/0020-711X(90)90172-Y; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; Carrell R. W., 1987, THROMB DIATH HAEMO, P1; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; EVANS SA, 1982, J BIOL CHEM, V257, P3014; GETTINS P, 1989, CARBOHYD RES, V185, P69, DOI 10.1016/0008-6215(89)84022-4; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; JORDAN R, 1979, J BIOL CHEM, V254, P2902; JORDAN RE, 1980, J BIOL CHEM, V255, P81; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3522, DOI 10.1021/bi00556a017; MACHOVICH R, 1978, EUR J BIOCHEM, V83, P473, DOI 10.1111/j.1432-1033.1978.tb12113.x; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MARESGUIA M, 1965, J BIOL CHEM, V240, P1579; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; NORDENMAN B, 1981, BIOCHIM BIOPHYS ACTA, V672, P227, DOI 10.1016/0304-4165(81)90289-0; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1989, THROMB HAEMOSTASIS, V62, P326; OLSON ST, 1987, THROMB HAEMOSTASIS, V58, P8; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; POMERANTZ MW, 1978, BIOCHIM BIOPHYS ACTA, V535, P66, DOI 10.1016/0005-2795(78)90033-8; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030	42	213	224	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6353	6364						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007588				2022-12-25	WOS:A1991FE37300054
J	SAVAGE, B; RUGGERI, ZM				SAVAGE, B; RUGGERI, ZM			SELECTIVE RECOGNITION OF ADHESIVE SITES IN SURFACE-BOUND FIBRINOGEN BY GLYCOPROTEIN-IIB-IIIA ON NONACTIVATED PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; AMINO-ACID SEQUENCE; FACTOR-VIII; ARTERY SUBENDOTHELIUM; THROMBUS FORMATION; IIB/IIIA COMPLEX; ALPHA-CHAIN; GAMMA-CHAIN; PROTEIN; RECEPTOR	We demonstrate that unstimulated platelets attach to immobilized fibrinogen in a selective process mediated by the membrane glycoprotein (GP) complex IIb-IIIa (alpha-IIb-beta-3). The initial attachment, independent of platelet activation, is followed by spreading and irreversible adhesion even in the presence of activation inhibitors. Using fibrinogen fragments derived from plasmin digestion, we found that unstimulated platelets do not attach to immobilized fragment E, which contains an Arg-Gly-Asp sequence at A-alpha-95-97, and adhere to fragments X and D, both containing the gamma-400-411 dodecapeptide adhesion sequence, less efficiently than to intact fibrinogen. Thus, the carboxyl terminus of the A-alpha chain, missing in the "early" fragment X used in these studies, appears to be involved in the interaction of fibrinogen with unstimulated platelets. In contrast, activated platelets adhere to immobilized fibrinogen and fragments X, D, and E in a time-dependent and equivalent manner. Although activated platelets adhere to immobilized vitronectin, fibronectin, and von Willebrand factor through GP IIb-IIIa, unstimulated platelets fail to adhere to vitronectin and have only a limited capacity to adhere to fibronectin and von Willebrand factor. These results demonstrate that GP IIb-IIIa on unstimulated platelets displays a recognition specificity for attachment to immobilized adhesive proteins that is distinct from that seen following platelet activation. Thus, unstimulated platelets selectively interact with fibrinogen, and the initial attachment is followed by spreading and irreversible adhesion in the absence of exogenous agonists. This process may be regulated by plasmin cleavage of the fibrinogen A-alpha chain and may play an important role during normal hemostasis and during the pathological development of thrombotic vascular occlusions.	Scripps Res Inst, RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	SAVAGE, B (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [HL-31950] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCH E, 1990, J CLIN INVEST, V85, P1372, DOI 10.1172/JCI114581; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERLINER S, 1988, J BIOL CHEM, V263, P7500; BUDZYNSK.AZ, 1974, J BIOL CHEM, V249, P2294; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COLLER BS, 1980, BLOOD, V55, P169; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; HANDA M, 1986, J BIOL CHEM, V261, P2579; HAVERSTICK DM, 1985, BLOOD, V66, P946; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LAHIRI B, 1972, BIOCHIM BIOPHYS ACTA, V303, P161; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LOMBARDO VT, 1985, J CLIN INVEST, V76, P1950, DOI 10.1172/JCI112193; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MOSESSON MW, 1974, J BIOL CHEM, V249, P4656; MOSESSON MW, 1972, J BIOL CHEM, V247, P5210; NEWMAN J, 1971, BRIT J HAEMATOL, V21, P1, DOI 10.1111/j.1365-2141.1971.tb03413.x; NIIYA K, 1987, BLOOD, V70, P475; PACKHAM MA, 1969, J LAB CLIN MED, V73, P686; PATSCHEKE H, 1978, THROMB RES, V12, P485, DOI 10.1016/0049-3848(78)90319-5; PHILLIPS DR, 1988, BLOOD, V71, P831; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PLOW EF, 1985, BLOOD, V66, P724; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; SIXMA JJ, 1977, SEMIN HEMATOL, V14, P265; STRICKLAND DK, 1982, BIOCHEMISTRY-US, V21, P721, DOI 10.1021/bi00533a021; SWITZER ME, 1976, J CLIN INVEST, V57, P925, DOI 10.1172/JCI108369; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; TURITTO VT, 1985, BLOOD, V65, P823; VROMAN L, 1977, ANN NY ACAD SCI, V283, P65, DOI 10.1111/j.1749-6632.1977.tb41753.x; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1986, BLOOD, V67, P322; WEISS HJ, 1978, BLOOD, V51, P267	50	264	266	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11227	11233						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040630				2022-12-25	WOS:A1991FQ77400081
J	UMEZAWA, T; DAVIN, LB; LEWIS, NG				UMEZAWA, T; DAVIN, LB; LEWIS, NG			FORMATION OF LIGNANS (-)-SECOISOLARICIRESINOL AND (-)-MATAIRESINOL WITH FORSYTHIA-INTERMEDIA CELL-FREE-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS	In vivo labeling experiments of Forsythia intermedia plant tissue with [8-C-14]- and [9,9-H-2(2), OC2H-3]coniferyl alcohols revealed that the lignans, (-)-secoisolariciresinol and (-)-matairesinol, were derived from two coniferyl alcohol molecules; no evidence for the formation of the corresponding (+)-enantiomers was found. Administration of (+/-)-[Ar-H-3]secoisolariciresinols to excised shoots of F. intermedia resulted in a significant conversion into (-)-matairesinol; again, the (+)-antipode was not detected. Experiments using cell-free extracts of F. intermedia confirmed and extended these findings. In the presence of NAD(P)H and H2O2, the cell-free extracts catalyzed the formation of (-)-secoisolariciresinol, with either [8-C-14]- or [9,9-H-2(2),OCH-2(3)]coniferyl alcohols as substrates. The (+)-enantiomer was not formed. Finally, when either (-)-[Ar-H-3] or (+/-)-[Ar-H-2]secoisolariciresinols were used as substrates, in the presence of NAD(P), only (-)- and not (+)-matairesinol formation occurred. The other antipode, (+)-secoisolariciresinol, did not serve as a substrate for the formation of either (+)- or (-)-matairesinol. Thus, in F. intermedia, the formation of the lignan, (-)-secoisolariciresinol,occurs under strict stereochemical control, in a reaction or reactions requiring NAD(P)H and H2O2 as cofactors. This stereo-selectivity is retained in the subsequent conversion into (-)-matairesinol, since (+)-secoisolariciresinol is not a substrate. These are the first two enzymes to be discovered in lignan formation.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164; VIRGINIA POLYTECH INST & STATE UNIV,COMMONWEALTH CTR WOOD SCI,BLACKSBURG,VA 24061; VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM,BLACKSBURG,VA 24061	Washington State University; Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University				Davin, Laurence/0000-0002-3248-6485; Lewis, Norman/0000-0001-5742-032X				BENDER RA, 1979, CANCER CHEMOTHERAPY, P100; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN E, 1987, HETEROCYCLES, V26, P1169, DOI 10.3987/R-1987-05-1169; CHEN CL, 1977, P AM PHYTOPATH SOC, V4, P135; CHIBA M, 1978, Shoyakugaku Zasshi, V32, P194; CHIBA M, 1979, Shoyakugaku Zasshi, V33, P150; FREUDENBERG K, 1952, CHEM BER-RECL, V85, P1181, DOI 10.1002/cber.19520851213; GARDNER JAF, 1959, CAN J CHEM, V37, P1703, DOI 10.1139/v59-246; INAGAKI I, 1972, CHEM PHARM BULL, V20, P2710; ISHII H, 1983, YAKUGAKU ZASSHI, V103, P279, DOI 10.1248/yakushi1947.103.3_279; KRAHMER RL, 1970, WOOD SCI TECHNOL, V4, P122, DOI 10.1007/BF00365298; LEWIS NG, 1989, J CHROMATOGR, V479, P345, DOI 10.1016/S0021-9673(01)83349-5; MACRAE WD, 1984, PHYTOCHEMISTRY, V23, P1207, DOI 10.1016/S0031-9422(00)80428-8; MIKI K, 1980, PHYTOCHEMISTRY, V19, P449, DOI 10.1016/0031-9422(80)83199-2; MIKI K, 1979, TETRAHEDRON LETT, V9, P799; NEWMAN J, 1986, HOLZFORSCHUNG, V40, P369, DOI 10.1515/hfsg.1986.40.6.369; RAHMAN MMA, 1990, PHYTOCHEMISTRY, V729, P1841; RAO CBS, 1978, CHEM LIGNANS, P377; SAKAKIBARA A, 1987, HOLZFORSCHUNG, V41, P1, DOI 10.1515/hfsg.1987.41.1.1; STOCKIGT J, 1977, HOLZFORSCHUNG, V31, P41, DOI 10.1515/hfsg.1977.31.2.41; STRUBE RE, 1963, ORG SYNTH, V4, P417; SUBRAMANIAN R, 1975, J CHROMATOGR, V107, P230, DOI 10.1016/S0021-9673(00)82772-7; UMEZAWA T, 1990, BIOCHEM BIOPH RES CO, V171, P1008, DOI 10.1016/0006-291X(90)90784-K; UMEZAWA T, 1990, J CHEM SOC CHEM COMM, P1405, DOI 10.1039/c39900001405; WHITING DA, 1985, NAT PROD REP, V2, P191, DOI 10.1039/np9850200191	25	105	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10210	10217						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037574				2022-12-25	WOS:A1991FP08600035
J	CLEMENTZ, T; RAETZ, CRH				CLEMENTZ, T; RAETZ, CRH			A GENE CODING FOR 3-DEOXY-D-MANNO-OCTULOSONIC-ACID TRANSFERASE IN ESCHERICHIA-COLI - IDENTIFICATION, MAPPING, CLONING, AND SEQUENCING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; MEMBRANE LIPID-SYNTHESIS; ACID-DEFICIENT MUTANT; SALMONELLA-TYPHIMURIUM; CTP-CMP-3-DEOXY-D-MANNO-OCTULOSONATE CYTIDYLYLTRANSFERASE; 3-DEOXY-D-MANNOOCTULOSONATE-8-PHOSPHATE SYNTHETASE; EXOGENOUS 3-DEOXY-D-MANNO-OCTULOSONATE; LIPOPOLYSACCHARIDE BIOSYNTHESIS; 8-PHOSPHATE SYNTHETASE; NUCLEOTIDE-SEQUENCE	An autoradiographic assay applicable to colonies immobilized on filter paper was developed for obtaining temperature-sensitive mutants of Escherichia coli defective in the transfer of 3-deoxy-D-manno-octulosonic acid (KDO) from CMP-KDO to a tetraacyldisaccharide 1,4'-bisphosphate precursor of lipid A, designated lipid IV(A). Cell-free extracts from two mutants found in a population of 30,000 mutagen-treated cells showed normal KDO transferase activity when assayed at 30-degrees-C, but almost no activity at 42-degrees-C. The mutation was mapped by mating one of the mutants with different Hfr strains and analyzing genetic linkage of KDO transferase activity to selectable markers. The lesion was located to a position between 80 and 84 min on the E. coli chromosome. A plasmid from the Clarke and Carbon collection (Clarke, L., and Carbon, J. (1976) Cell 9, 91-99), pLC17-24, known to contain genes from the rfa region (81 min), was shown to overexpress KDO transferase activity 4-5 times and to correct the mutation when the plasmid was conjugated into the mutant strains. The KDO transferase gene, designated kdtA, was subcloned from pLC17-24 into a multicopy vector. The resulting plasmid, pCL3, overproduced transferase activity approximately 100-fold. The kdtA gene was shown to code for a 43-kDa polypeptide, as judged by radiolabeling of minicells. Its DNA sequence was determined. The results demonstrate that overexpression of this single gene product greatly stimulates the incorporation of two stereochemically distinct KDO residues during lipopolysaccharide biosynthesis in extracts of E. coli.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,POB 2000,RAHWAY,NJ 07065	Merck & Company					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019551] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19551] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bachmann B. J., 1987, ESCHERICHIA COLI SAL, V2, P807; BHATTACHARJEE AK, 1978, BIOCHEMISTRY-US, V17, P645, DOI 10.1021/bi00597a013; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BULAWA CE, 1981, J BACTERIOL, V148, P391, DOI 10.1128/JB.148.1.391-393.1981; CAPOBIANCO JO, 1987, J BACTERIOL, V169, P4030, DOI 10.1128/jb.169.9.4030-4035.1987; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; COLEMAN WG, 1985, J BACTERIOL, V161, P1209, DOI 10.1128/JB.161.3.1209-1214.1985; CREEGER ES, 1979, J BIOL CHEM, V254, P804; Davis R., 1980, ADV BACTERIAL GENETI; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GHALAMBOR MA, 1966, J BIOL CHEM, V241, P3207; GHALAMBOR MA, 1963, BIOCHEM BIOPH RES CO, V10, P346, DOI 10.1016/0006-291X(63)90536-9; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; GOLDMAN RC, 1987, J BACTERIOL, V169, P5060, DOI 10.1128/jb.169.11.5060-5065.1987; GOLDMAN RC, 1988, J BACTERIOL, V170, P2185, DOI 10.1128/jb.170.5.2185-2191.1988; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; GOLDMAN RC, 1985, J BACTERIOL, V163, P256, DOI 10.1128/JB.163.1.256-261.1985; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HANCOCK REW, 1976, J BACTERIOL, V127, P98, DOI 10.1128/JB.127.1.98-108.1976; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; KADAM SK, 1985, J BACTERIOL, V161, P277, DOI 10.1128/JB.161.1.277-284.1985; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOHLBRENNER WE, 1987, J BIOL CHEM, V262, P4534; KOHLBRENNER WE, 1985, J BIOL CHEM, V260, P4695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1981, MOL GEN GENET, V184, P218, DOI 10.1007/BF00272908; LEHMANN V, 1977, EUR J BIOCHEM, V81, P443, DOI 10.1111/j.1432-1033.1977.tb11969.x; LEVY SB, 1977, TOPICS INFECTIOUS DI, V2, P181; Miller J.H., 1972, EXPT MOL GENETICS; MUNSON RS, 1978, J BIOL CHEM, V253, P1503; NAKAMURA K, 1979, J BACTERIOL, V137, P595, DOI 10.1128/JB.137.1.595-604.1979; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POULSEN P, 1983, EUR J BIOCHEM, V135, P223, DOI 10.1111/j.1432-1033.1983.tb07641.x; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1977, P NATL ACAD SCI USA, V74, P1412, DOI 10.1073/pnas.74.4.1412; RAETZ CRH, 1975, P NATL ACAD SCI USA, V72, P2274, DOI 10.1073/pnas.72.6.2274; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAY BL, 1987, J BIOL CHEM, V262, P1122; RAY PH, 1982, METHOD ENZYMOL, V83, P525; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1972, P NATL ACAD SCI USA, V69, P3756, DOI 10.1073/pnas.69.12.3756; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; Rietschel E. T., 1984, HDB ENDOTOXIN CHEM E, VI; SANDERSON KE, 1972, J BACTERIOL, V112, P58, DOI 10.1128/JB.112.1.58-63.1972; SANDERSON KE, 1987, ESCHERICHIA COLI SAL, V2, P877; SCHMIDT MA, 1983, EUR J BIOCHEM, V131, P509, DOI 10.1111/j.1432-1033.1983.tb07291.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOKER NG, 1984, TRANSCRIPTION TRANSL, P153; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; SUTCLIFFE J, 1985, FED PROC, V44, P652; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; ULLMANN A, 1970, LACTOSE OPERON, P143; Unger F. M., 1981, ADV CARBOHYD CHEM BI, V38, P324; WOISETSCHLAGER M, 1986, J BACTERIOL, V168, P437, DOI 10.1128/jb.168.1.437-439.1986	60	108	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9687	9696						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033061				2022-12-25	WOS:A1991FM45900055
J	GOTTSCHALK, WK				GOTTSCHALK, WK			THE PATHWAY MEDIATING INSULINS EFFECTS ON PYRUVATE-DEHYDROGENASE BYPASSES THE INSULIN-RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; MONOCLONAL-ANTIBODY; PHOSPHORYLATION; CELLS; REPLACEMENT; MECHANISM; PROTEINS	The effect of insulin on pyruvate dehydrogenase activity was examined in two different cell types that over expressed either normal or defective human insulin receptors, RAT 1 embryonic fibroblasts and Chinese hamster ovary (CHO) cells. Insulin stimulated pyruvate dehydrogenase activity in cells that expressed normal insulin receptors (RAT 1 HIRc, and CHO-WT and CHO-T cells), or receptors in which lysine 1018 in the ATP-binding site of the tyrosine kinase domain was exchanged for alanine (RAT 1 A/K1018 and CHO-mut cells). For both rat and hamster cell lines, the insulin dose-response curves from cells that expressed the mutant receptors were identical to those from the appropriate controls that over expressed the normal insulin receptors. Insulin failed to stimulate pyruvate dehydrogenase activity in CHO-DELTA-cells, which expressed a mutant human insulin receptor that was truncated by 112 amino acids at the carboxyl terminal of the beta-chain. Control studies verified that all the cells used in this study exhibited the expected phenotypes with respect to the number of insulin receptors which they expressed, insulin-stimulated tyrosine kinase activity, and the biological consequences of inactivating the insulin receptor tyrosine kinase. These findings show that the insulin receptor tyrosine kinase does not play an obligatory role in the insulin signaling pathway that stimulates pyruvate dehydrogenase activity.			GOTTSCHALK, WK (corresponding author), UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163, USA.			Gottschalk, William/0000-0001-6760-2338				CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELLIS L, 1986, COLD SPRING HARB SYM, V51, P773, DOI 10.1101/SQB.1986.051.01.090; GIUGNI TD, 1988, J BIOL CHEM, V263, P18988; GOTTSCHALK WK, 1988, ARCH BIOCHEM BIOPHYS, V261, P175, DOI 10.1016/0003-9861(88)90116-6; HOFMANN C, 1980, DIABETES, V29, P865, DOI 10.2337/diabetes.29.11.865; HUGHES WA, 1980, BIOCHEM J, V192, P469, DOI 10.1042/bj1920469; JACOBS S, 1983, J BIOL CHEM, V258, P9581; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; LELOIR LF, 1959, ARCH BIOCHEM BIOPHYS, V81, P508, DOI 10.1016/0003-9861(59)90232-2; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MARSHALL S, 1985, J BIOL CHEM, V260, P4128; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1989, INSULIN ACTION, P53; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MORGAN DO, 1986, P NATL ACAD SCI USA, V83, P328, DOI 10.1073/pnas.83.2.328; MUKHERJEE C, 1975, BIOCHEM J, V148, P229, DOI 10.1042/bj1480229; PANG DT, 1985, J BIOL CHEM, V260, P7131; PIKE LJ, 1984, J BIOL CHEM, V259, P9913; PIKE LJ, 1987, METHOD ENZYMOL, V146, P353; RECHLER MM, 1980, ENDOCRINOLOGY, V107, P1451, DOI 10.1210/endo-107-5-1451; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; ROMERO G, 1988, SCIENCE, V240, P509, DOI 10.1126/science.3282305; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUTTER WJ, 1987, INSULIN ACTION DIABE, P1; SALTIEL AR, 1988, AM J PHYSIOL, V255, pC1, DOI 10.1152/ajpcell.1988.255.1.C1; SALTIEL AR, 1987, ENDOCRINOLOGY, V120, P967, DOI 10.1210/endo-120-3-967; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; WALKER DH, 1987, BIOCHEMISTRY-US, V26, P1428, DOI 10.1021/bi00379a033; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WIELAND O, 1969, H-S Z PHYSIOL CHEM, V350, P329, DOI 10.1515/bchm2.1969.350.1.329; WIELAND OH, 1971, ARCH BIOCHEM BIOPHYS, V43, P593	35	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8814	8819						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026596				2022-12-25	WOS:A1991FM03800031
J	LI, CX; STIFANI, S; SCHNEIDER, WJ; POZNANSKY, MJ				LI, CX; STIFANI, S; SCHNEIDER, WJ; POZNANSKY, MJ			LOW-DENSITY-LIPOPROTEIN RECEPTORS ON EPITHELIAL-CELL (MADIN-DARBY CANINE KIDNEY) MONOLAYERS - ASYMMETRIC DISTRIBUTION CORRELATES WITH FUNCTIONAL DIFFERENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDCK CELLS; TRANSCYTOSIS; ENDOCYTOSIS; TRANSPORT; GLYCOPROTEIN; MEMBRANE; BINDING; SITE	Low density lipoprotein (LDL) receptors are present on both the apical and basal surfaces of confluent monolayers of Madin-Darby canine kidney (MDCK) epithelial cells grown on gelatin-coated polycarbonate filters. Although there is only a single species of receptor protein present, as shown by immunoblotting, the receptors on the two surfaces were found to behave differently. LDL receptors on the basal surface show all of the characteristics of the LDL receptor described in fibroblasts in that their number is dependent upon the sterol (or LDL) content of the medium; however, regulation is only affected by LDL in the medium in contact with the basal side. In contrast, the apical surface LDL receptors are not regulated by the presence of LDL in the media on either the apical or basal surface. LDL particles can be transported across the monolayer in a temperature-dependent and -specific manner from the apical to the basal sides of the cell, but not in the opposite direction. The binding of I-125-LDL to both surfaces can be effectively inhibited not only by unlabeled LDL and very low density lipoprotein, but also by an antibody directed against the LDL receptor. The data suggest that the LDL receptors on the two aspects of the cell surface are biochemically identical, but differ in function. Thus, the basal surface receptor is involved in the control of cell cholesterol homeostasis, while that on the apical surface is responsible for the transport of LDL to the basal side.	UNIV ALBERTA, DEPT PHYSIOL, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV ALBERTA, LIPID & LIPOPROT RES GRP, EDMONTON T6G 2H7, ALBERTA, CANADA	University of Alberta; University of Alberta; University of Alberta				Stifani, Stefano/0000-0002-2376-7701				ABRAHAMSON DR, 1981, J CELL BIOL, V91, P270, DOI 10.1083/jcb.91.1.270; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HERZOG V, 1983, J CELL BIOL, V97, P607, DOI 10.1083/jcb.97.3.607; LAMB JF, 1981, BIOCHIM BIOPHYS ACTA, V644, P333, DOI 10.1016/0005-2736(81)90391-6; LILLEHOJ EP, 1986, EXP PATHOL-JENA, V29, P1; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PESONEN M, 1984, J CELL BIOL, V99, P796, DOI 10.1083/jcb.99.3.796; PESONEN M, 1983, J CELL BIOL, V97, P638, DOI 10.1083/jcb.97.3.638; ROUDRIGUEZBOULA.E, 1989, SCIENCE, V245, P243; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SIMONS K, 1985, ANN REV CELL BIOL, V1, P234; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; TAYLOR Z, 1982, J CLIN INVEST, V69, P1136; VANLENTEN BJ, 1983, J BIOL CHEM, V258, P5151; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x; WALL DA, 1985, AM J PHYSIOL, V248, pC12, DOI 10.1152/ajpcell.1985.248.1.C12; WINDLER EET, 1980, J BIOL CHEM, V255, P464	27	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9263	9270						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026624				2022-12-25	WOS:A1991FM03800090
J	YUAN, J; SIMOS, G; BLOBEL, G; GEORGATOS, SD				YUAN, J; SIMOS, G; BLOBEL, G; GEORGATOS, SD			BINDING OF LAMIN-A TO POLYNUCLEOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; NUCLEAR-ENVELOPE; ATTACHMENT SITES; CHROMATIN; ORGANIZATION; ERYTHROCYTES; ASSOCIATION; CHROMOSOMES; EXPRESSION	Morphological observations suggest a close association between heterochromatin and the nuclear lamina. To investigate the molecular aspects of this association, we have established a simple sedimentation assay employing purified lamin proteins, or their I-125-labeled derivatives, and polynucleosomal particles isolated from avian erythrocytes. We report here that purified, unlabeled lamin A and I-125-lamin A, but not I-125-lamin B or I-125-bovine serum albumin, bind to polynucleosomes in a saturable and specific fashion. The specific binding of I-125-lamin A is of high affinity (K(d) = approximately 1 x 10(-9) M) and is distinctly temperature-dependent. This interaction is not affected by exogenous polyionic agents such as polylysine and DNA, but it can be abolished by protease digestion of the polynucleosomes. These data suggest that nuclear lamin A maintains a direct association with a proteinaceous constituent of interphase chromatin.	EUROPEAN MOLEC BIOL LAB,PROGRAMME CELL BIOL,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	YUAN, J (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.		Simos, George/AAH-2596-2021	Georgatos, Spyros/0000-0002-2078-7467; Simos, George/0000-0001-5453-3185	NIGMS NIH HHS [GM07982-09] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BENAVENTE R, 1986, J CELL BIOL, V103, P1847, DOI 10.1083/jcb.103.5.1847; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BURKE B, 1990, EXP CELL RES, V186, P169, DOI 10.1016/0014-4827(90)90223-W; COMINGS DE, 1968, AM J HUM GENET, V20, P440; DAVIES HG, 1968, NATURE, V217, P1122, DOI 10.1038/2171122a0; DJABALI K, 1991, CELL, V64, P109, DOI 10.1016/0092-8674(91)90213-I; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FAWCETT DW, 1966, AM J ANAT, V119, P129, DOI 10.1002/aja.1001190108; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRANKE WW, 1981, J CELL BIOL, V91, P39; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; Gerace L, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P967; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; GUO XW, 1989, J BIOL CHEM, V264, P11653; KROHNE G, 1989, J CELL BIOL, V109, P2003, DOI 10.1083/jcb.109.5.2003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTAU VC, 1964, P NATL ACAD SCI USA, V52, P93, DOI 10.1073/pnas.52.1.93; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MCKEON FD, 1984, CELL, V36, P83, DOI 10.1016/0092-8674(84)90076-X; MURRAY AB, 1979, J CELL SCI, V35, P59; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; PETER M, 1989, J MOL BIOL, V208, P393, DOI 10.1016/0022-2836(89)90504-4; ROBER RA, 1989, DEVELOPMENT, V105, P365; STICK R, 1985, CELL, V41, P191, DOI 10.1016/0092-8674(85)90073-X; VANHOLDE KE, 1989, CHROMATIN, P282; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; WORMAN HJ, 1988, J BIOL CHEM, V263, P12135; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; ZENTGRAF H, 1984, J CELL BIOL, V99, P272, DOI 10.1083/jcb.99.1.272	34	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9211	9215						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026620				2022-12-25	WOS:A1991FM03800083
J	SHAMOO, Y; WEBSTER, KR; WILLIAMS, KR; KONIGSBERG, WH				SHAMOO, Y; WEBSTER, KR; WILLIAMS, KR; KONIGSBERG, WH			A RETROVIRUS-LIKE ZINC DOMAIN IS ESSENTIAL FOR TRANSLATIONAL REPRESSION OF BACTERIOPHAGE-T4 GENE-32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CAULIFLOWER MOSAIC-VIRUS; NUCLEOTIDE-SEQUENCE; LEUKEMIA-VIRUS; MESSENGER-RNA; PROTEIN; GAG; DNA; POL; EXPRESSION; REGION	Gene 32 protein (gp32), a single-stranded DNA-binding protein from bacteriophage T4, contains a zinc-binding subdomain with sequence homologies to the 3-cysteine/1-histidine zinc-binding motif found in a variety of retroviruses and plant viruses. In vitro studies suggest that autoregulation of gp32 occurs at the level of translation by gp32 specifically binding gene 32 mRNA at an unusual stem-loop structure that can be modeled as an RNA pseudoknot. Nucleation of gp32 binding via this pseudoknot is thought to be needed to facilitate cooperative binding of gp32 through a largely unstructured region that overlaps the ribosome binding site (McPheeters, D. S., Stormo, G. D., and Gold, L. (1988) J. Mol. Biol. 201, 517-535). Removal of Zn(II) from gp32 results in a protein that retains the ability to bind single-stranded RNA with high affinity but is unable to specifically autoregulate itself at the level of translation. Deletion of the pseudoknot sequences from the gene 32 autoregulatory region results in an mRNA that cannot be repressed by gp32. These results suggest that the zinc-binding subdomain of gp32 plays an essential role in autoregulation by providing a critical element necessary for nucleating cooperative binding at the gene 32 mRNA pseudoknot.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	SHAMOO, Y (corresponding author), YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		; Williams, Kenneth/B-5986-2016	Shamoo, Yousif/0000-0001-9241-8962; Williams, Kenneth/0000-0001-7792-9588				ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BERG JM, 1990, J BIOL CHEM, V265, P6513; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; DUMAS P, 1987, J BIOMOL STRUCT DYN, V4, P707, DOI 10.1080/07391102.1987.10507674; FUETTERER J, 1987, TRENDS BIOCHEM SCI, V12, P92, DOI 10.1016/0968-0004(87)90044-2; GIEDROC DP, 1987, BIOCHEMISTRY-US, V26, P5251, DOI 10.1021/bi00391a007; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; HAENNI AL, 1980, TRANSFER RNA BIOL AS, P539; HULL R, 1986, EMBO J, V5, P3083, DOI 10.1002/j.1460-2075.1986.tb04614.x; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KAWAKAMI T, 1987, VIROLOGY, V158, P300, DOI 10.1016/0042-6822(87)90202-9; KEATING KM, 1988, BIOCHEMISTRY-US, V27, P5240, DOI 10.1021/bi00414a044; LAPREVOTTE I, 1984, J VIROL, V50, P884, DOI 10.1128/JVI.50.3.884-894.1984; MACFARLANE SA, 1989, NUCLEIC ACIDS RES, V17, P2245, DOI 10.1093/nar/17.6.2245; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; MILLER K, 1989, NUCLEIC ACIDS RES, V17, P2134, DOI 10.1093/nar/17.5.2134; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; NADLER SG, 1990, J BIOL CHEM, V265, P10389; ONO M, 1985, J VIROL, V55, P387, DOI 10.1128/JVI.55.2.387-394.1985; PARRAGA G, 1988, SCIENCE, V241, P635; RICE NR, 1985, VIROLOGY, V142, P357, DOI 10.1016/0042-6822(85)90344-7; RICHINS RD, 1987, NUCLEIC ACIDS RES, V15, P8451, DOI 10.1093/nar/15.20.8451; RUSSEL M, 1976, J BIOL CHEM, V251, P7263; SHAMOO Y, 1988, PROTEINS, V4, P1, DOI 10.1002/prot.340040103; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; SONIGO P, 1985, CELL, V42, P369, DOI 10.1016/S0092-8674(85)80132-X; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TAMURA TA, 1983, J VIROL, V47, P137, DOI 10.1128/JVI.47.1.137-145.1983; VANBELKUM A, 1987, NUCLEIC ACIDS RES, V15, P2837, DOI 10.1093/nar/15.7.2837; VONHIPPEL PH, 1982, J MOL BIOL, V162, P795, DOI 10.1016/0022-2836(82)90548-4; WERNER T, 1990, VIROLOGY, V174, P225, DOI 10.1016/0042-6822(90)90071-X	31	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					7967	7970						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022625				2022-12-25	WOS:A1991FK44100002
J	EDGEWORTH, J; GORMAN, M; BENNETT, R; FREEMONT, P; HOGG, N				EDGEWORTH, J; GORMAN, M; BENNETT, R; FREEMONT, P; HOGG, N			IDENTIFICATION OF P8,14 AS A HIGHLY ABUNDANT HETERODIMERIC CALCIUM-BINDING PROTEIN COMPLEX OF MYELOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS ANTIGEN; BRAIN S-100 PROTEIN; BOVINE BRAIN; SUBCELLULAR-LOCALIZATION; 2-DIMENSIONAL ANALYSIS; POLYACRYLAMIDE GELS; SUBUNIT COMPOSITION; NEURITE EXTENSION; TISSUE PROTEINS; SEQUENCE	In this report we describe the biochemical characterization of neutrophil and monocyte p8 and p14. Together the two proteins comprise approximately 45% of cytosolic protein in neutrophils and approximately 40-fold less in monocytes. They fractionated together in several chromatographic procedures and were found to exist as a noncovalently associated complex with a stoichiometry of 1:1, named p8,14. Cross-linking experiments showed p8,14 to form heterodimers under conditions simulating the cytosol. An apparent molecular mass of 35,000 daltons was obtained for the p8,14 complex in molecular sizing experiments which suggests the presence of modifications or distinctive structural features. Two major forms of p14 can be identified by two-dimensional gel electrophoresis, both of which form heterodimers with p8. The lower molecular weight variant of p14 lacks Cys-3 (Met-Thr-Cys-Lys-Met...) suggesting that differing translational start sites account for these two forms of p14. A protocol has been devised for the rapid purification of milligram quantities of p8 and p14 from neutrophil cytosol using fast-protein liquid chromatography.	IMPERIAL CANC RES FUND,PROT STRUCT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	EDGEWORTH, J (corresponding author), IMPERIAL CANC RES FUND,MACROPHAGE LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ANDERSON NG, 1978, ANAL BIOCHEM, V85, P331, DOI 10.1016/0003-2697(78)90229-4; ANDERSON NL, 1978, ANAL BIOCHEM, V85, P341, DOI 10.1016/0003-2697(78)90230-0; ANDERSSON KB, 1988, SCAND J IMMUNOL, V28, P241, DOI 10.1111/j.1365-3083.1988.tb02437.x; BAKOUCHE O, 1987, J IMMUNOL, V138, P4249; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRANDTZAEG P, 1987, AM J CLIN PATHOL, V87, P700, DOI 10.1093/ajcp/87.6.700; BRUGGEN J, 1988, NATURE, V331, P570, DOI 10.1038/331570a0; BURMEISTER G, 1986, IMMUNOBIOLOGY, V171, P461, DOI 10.1016/S0171-2985(86)80077-8; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P380; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DALE I, 1983, EUR J BIOCHEM, V134, P1, DOI 10.1111/j.1432-1033.1983.tb07522.x; DANNIES PS, 1971, J BIOL CHEM, V246, P6276; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOOLEY DC, 1982, EXP HEMATOL, V10, P591; DORIN JR, 1987, NATURE, V326, P614, DOI 10.1038/326614a0; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EDGEWORTH J, 1989, NATURE, V342, P189, DOI 10.1038/342189a0; FREEMONT P, 1989, NATURE, V339, P516, DOI 10.1038/339516b0; HOGG N, 1989, EUR J IMMUNOL, V19, P1053, DOI 10.1002/eji.1830190615; HOGG N, 1985, IMMUNOLOGY, V56, P673; ISOBE T, 1981, EUR J BIOCHEM, V115, P469; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; MCNAMARA MP, 1988, LANCET, V2, P1163; MURAO S, 1989, J BIOL CHEM, V264, P8356; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; ROGERS J, 1989, NATURE, V339, P661, DOI 10.1038/339661a0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SOHNLE PG, 1989, CLIN RES, V37, P11; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; STEWART JA, 1972, BIOCHEM BIOPH RES CO, V46, P1405, DOI 10.1016/S0006-291X(72)80132-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATT KWK, 1983, IMMUNOLOGY, V48, P79; WILKINSON MM, 1988, J CELL SCI, V91, P221; WILSON GB, 1973, CLIN CHIM ACTA, V49, P79, DOI 10.1016/0009-8981(73)90346-X; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; ZWALDO G, 1988, CLIN EXP IMMUNOL, V72, P510	40	351	360	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7706	7713						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019594				2022-12-25	WOS:A1991FJ34200062
J	ADAMS, MD; MAGUIRE, DJ; OXENDER, DL				ADAMS, MD; MAGUIRE, DJ; OXENDER, DL			ALTERING THE BINDING-ACTIVITY AND SPECIFICITY OF THE LEUCINE BINDING-PROTEINS OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; TRANSPORT-SYSTEMS; EXPRESSION; GENES	Two leucine-binding proteins with overlapping specificities for the branched-chain amino acids are present in Escherichia coli. In order to study the basis of specificity for the very similar hydrophobic ligands, we have constructed a series of site-directed mutants of both proteins based on inspection of the leucine-isoleucine-valine-binding protein crystal structure reported by Sack et al. (Sack, J. S., Saper, M. A., and Quiocho, F. A. (1989) J. Mol. Biol. 206, 171-191). Each of the mutant proteins was overexpressed and purified, and their binding activity for a wide variety of potential ligands was measured. By introducing a common restriction endonuclease cleavage site in the two proteins, two hybrid binding proteins consisting of the amino-terminal third of one binding protein fused to the carboxyl-terminal two-thirds of the other were created. The results of these studies indicated that the binding site of the leucine-isoleucine-valine binding protein can accommodate a branch at the beta-carbon of the ligand and that hydrophilic groups on the ligand can be accommodated only in certain orientations. None of the single amino acid substitutions resulted in complete switches in specificity between the two proteins, suggesting that additional residues are involved in leucine binding and discrimination among the branched-chain amino acid substrates.	UNIV MICHIGAN, DEPT BIOL CHEM, 1301 E CATHERINE ST, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011024] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM11024] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1990, J BIOL CHEM, V265, P11436; ANDERSON JJ, 1977, J BACTERIOL, V130, P384, DOI 10.1128/JB.130.1.384-392.1977; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1510; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; GRADDIS TUJ, 1990, THESIS U MICHIGAN AN; HARRISON LI, 1975, J BACTERIOL, V122, P957, DOI 10.1128/JB.122.3.957-965.1975; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDICK R, 1985, ENZYMES BIOL MEMBR, V3, P577; LANDICK RC, 1983, THESIS U MICHIGAN AN; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; NEU HC, 1965, J BIOL CHEM, V240, P3685; OXENDER DL, 1980, P NATL ACAD SCI-BIOL, V77, P2005, DOI 10.1073/pnas.77.4.2005; PENROSE WR, 1968, J BIOL CHEM, V243, P5921; PIPERNO JR, 1968, J BIOL CHEM, V243, P5914; RAHMANIAN M, 1973, J BACTERIOL, V116, P1258, DOI 10.1128/JB.116.3.1258-1266.1973; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SU TZ, 1988, GENE, V69, P81, DOI 10.1016/0378-1119(88)90380-0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	23	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6209	6214						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007577				2022-12-25	WOS:A1991FE37300034
J	FLORINECASTEEL, K; LEMASTERS, JJ; HERMAN, B				FLORINECASTEEL, K; LEMASTERS, JJ; HERMAN, B			LIPID ORDER IN HEPATOCYTE PLASMA-MEMBRANE BLEBS DURING ATP DEPLETION MEASURED BY DIGITIZED VIDEO FLUORESCENCE POLARIZATION MICROSCOPY	FASEB JOURNAL			English	Note						FLUORESCENCE POLARIZATION; DIGITIZED VIDEO MICROSCOPY; MEMBRANE FLUIDITY; TRIMETHYLAMMONIUMDIPHENYLHEXATRIENE; HYPOXIA	ACCELERATED PHOSPHOLIPID DEGRADATION; RAT-LIVER; CELL-DEATH; FLUIDITY; INJURY; PEROXIDATION; PREVENTION; ISCHEMIA; INCREASE; BILAYERS	Low-light digitized video fluorescence polarization microscopy was used to measure lipid order parameters in plasma membrane blebs of single, cultured rat hepatocytes during ATP depletion with the metabolic inhibitors cyanide and iodoacetic acid. Hepatocytes were labeled on the microscope stage with the plasma membrane probe trimethylammoniumdiphenylhexatriene at successive stages of cell injury. A pair of fluorescence polarization ratio images was obtained from a series of four fluorescence images recorded with a polarizer in the emission path oriented first parallel and then perpendicular to each of two orthogonal excitation light polarization directions. From the polarization ratio images, the lipid order parameter S was determined in individual plasma membrane blebs. Results indicate that the plasma membrane becomes uniformly rigid within a few minutes of the addition of metabolic inhibitors when small surface blebs have formed and ATP levels have fallen by > 95%. The measured order parameter of S almost-equal-to 0.95 in plasma membrane blebs, compared with S almost-equal-to 0.75 in normoxic cell plasma membranes, remained unchanged throughout the course of bleb development and ultimate cell death. These findings demonstrate that significant alteration in hepatocyte plasma membrane structure occurs early in hypoxic cell injury.	UNIV N CAROLINA, DEPT CELL BIOL & ANAT, CB 7090, 232 TAYLOR HALL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULM TOXICOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER CANC RES CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NIA NIH HHS [AG07218] Funding Source: Medline; NIEHS NIH HHS [ES07126] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007218, R01AG007218] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLOCK ER, 1989, AM J PHYSIOL, V257, pC223, DOI 10.1152/ajpcell.1989.257.2.C223; CHIEN KR, 1978, J BIOL CHEM, V253, P4809; EICHENBERGER K, 1982, FEBS LETT, V142, P59, DOI 10.1016/0014-5793(82)80219-6; FARBER JL, 1978, AM J PATHOL, V92, P713; FARBER JL, 1981, AM J PATHOL, V102, P271; FARBER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312, DOI 10.1016/0003-9861(81)90459-8; FLORINECASTEEL K, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P559; FLORINECASTEEL K, 1990, BIOPHYS J, V57, P1199, DOI 10.1016/S0006-3495(90)82639-4; FREDERIKS WM, 1984, VIRCHOWS ARCH B, V46, P269, DOI 10.1007/BF02890316; GORES GJ, 1989, AM J PHYSIOL, V257, pC347, DOI 10.1152/ajpcell.1989.257.2.C347; GORES GJ, 1988, AM J PHYSIOL, V255, pC315, DOI 10.1152/ajpcell.1988.255.3.C315; HERMAN B, 1988, FASEB J, V2, P146, DOI 10.1096/fasebj.2.2.3342967; HERMAN B, 1991, IN PRESS CRC CRITICA; HEYN MP, 1979, FEBS LETT, V108, P359, DOI 10.1016/0014-5793(79)80564-5; JONES RL, 1989, AM J PATHOL, V135, P541; KUHRY JG, 1983, CELL BIOPHYS, V5, P129, DOI 10.1007/BF02796139; LEMASTERS JJ, 1983, J CELL BIOL, V97, P778, DOI 10.1083/jcb.97.3.778; NACHBAUR J, 1972, BIOCHIM BIOPHYS ACTA, V274, P426, DOI 10.1016/0005-2736(72)90189-7; NEWKIRK JD, 1973, BIOCHIM BIOPHYS ACTA, V298, P562, DOI 10.1016/0005-2736(73)90074-6; NIEMINEN AL, 1988, CELL CALCIUM, V9, P237, DOI 10.1016/0143-4160(88)90004-8; OHYASHIKI T, 1986, BIOCHIM BIOPHYS ACTA, V861, P311, DOI 10.1016/0005-2736(86)90433-5; OKAYASU T, 1984, AM J PATHOL, V117, P163; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; RICEEVANS C, 1981, BIOCHEM BIOPH RES CO, V100, P1537, DOI 10.1016/0006-291X(81)90693-8; STORCH J, 1985, BIOCHIM BIOPHYS ACTA, V812, P473, DOI 10.1016/0005-2736(85)90322-0; STUBBS CD, 1981, BIOCHEMISTRY-US, V20, P4257, DOI 10.1021/bi00518a004; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; VICTORIA EJ, 1971, BIOCHIM BIOPHYS ACTA, V239, P443, DOI 10.1016/0005-2760(71)90036-1	28	33	33	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1991	5	7					2078	2084		10.1096/fasebj.5.7.2010060	http://dx.doi.org/10.1096/fasebj.5.7.2010060			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	2010060				2022-12-25	WOS:A1991FF44200010
J	BENNETT, VD; PALLANTE, KM; ADAMS, SL				BENNETT, VD; PALLANTE, KM; ADAMS, SL			THE SPLICING PATTERN OF FIBRONECTIN MESSENGER-RNA CHANGES DURING CHONDROGENESIS RESULTING IN AN UNUSUAL FORM OF THE MESSENGER-RNA IN CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; CHICK-EMBRYO CHONDROCYTES; HUMAN-PLASMA FIBRONECTIN; III CONNECTING SEGMENT; CELL-SURFACE PROTEIN; GENE-EXPRESSION; RETINOIC ACID; VIRAL TRANSFORMATION; LIMB-BUD; COLLAGEN	Chondrogenesis, the differentiation of mesenchyme into cartilage, results in a change in composition of the extracellular matrix. The cartilage matrix contains several unique components, including type II collagen and chondroitin sulfate proteoglycan; it also contains fibronectin, a glycoprotein that mediates the interaction of cells with their matrix. We show that chick cartilage fibronectin mRNA contains an unusual pattern of alternatively spliced exons. Specifically, it contains exon IIIB but does not contain exon IIIA whereas fibronectin mRNA from mesenchyme contains both exons IIIB and IIIA. Thus the splicing pattern of the fibronectin mRNA must change from B+A+ to B+A- during chondrogenesis. Most fibronectin mRNA in other mesenchymal tissues contains exon IIIA but little exon IIIB (B-A+). Culturing of chondrocytes (cartilage-producing cells) results in loss of exon IIIB from fibronectin mRNA (B-A-). Manipulation of culture conditions to produce more adhesive chondrocytes (treatment with hyaluronidase, transformation with Rous sarcoma virus, and treatment with retinoic acid) increases the amount of fibronectin mRNA containing exon IIIA. These results suggest that exon IIIB may mediate the interactions of chondrocytes with the unique components of the cartilage matrix and exon IIIA may play a role in chondrocyte adhesion.			BENNETT, VD (corresponding author), UNIV PENN, SCH DENT MED, DEPT ANAT & HISTOL, PHILADELPHIA, PA 19104 USA.							ADAMS SL, 1987, J CELL BIOL, V105, P483, DOI 10.1083/jcb.105.1.483; ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; ALLEBACH ES, 1985, MOL CELL BIOL, V5, P1002, DOI 10.1128/MCB.5.5.1002; AMRANI DL, 1985, EXP CELL RES, V160, P171, DOI 10.1016/0014-4827(85)90246-0; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; BURNETT W, 1979, BIOCHEM BIOPH RES CO, V86, P478, DOI 10.1016/0006-291X(79)91739-X; BURTONWURSTER N, 1988, BIOCHEM BIOPH RES CO, V154, P1088, DOI 10.1016/0006-291X(88)90252-5; CHACKO S, 1969, J EXP MED, V130, P417, DOI 10.1084/jem.130.2.417; DESSAU W, 1980, J EMBRYOL EXP MORPH, V57, P51; DESSAU W, 1981, J CELL BIOL, V90, P78, DOI 10.1083/jcb.90.1.78; DESSAU W, 1978, BIOCHEM J, V169, P55, DOI 10.1042/bj1690055; DESSAU W, 1978, J CELL BIOL, V79, P342, DOI 10.1083/jcb.79.2.342; FFRENCHCONSTANT C, 1989, DEVELOPMENT, V106, P375; FOCHT RJ, 1984, MOL CELL BIOL, V4, P1843, DOI 10.1128/MCB.4.9.1843; GIONTI E, 1983, J BIOL CHEM, V258, P7190; GLANT TT, 1985, HISTOCHEMISTRY, V82, P149, DOI 10.1007/BF00708199; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HASELGROVE JC, 1985, ANAL BIOCHEM, V150, P449, DOI 10.1016/0003-2697(85)90534-2; HAUSCHKA S, 1983, LIMB DEV REGENERAT B, P303; HINCHLIFFE JR, 1980, DEV VERTEBRATE LIMB, P107; HOLUND B, 1982, HISTOCHEMISTRY, V76, P517, DOI 10.1007/BF00489906; HORTON W, 1986, DEV BIOL, V115, P392, DOI 10.1016/0012-1606(86)90258-7; HORTON WE, 1987, DEV BIOL, V123, P508, DOI 10.1016/0012-1606(87)90409-X; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1988, J CELL BIOL, V106, P1289, DOI 10.1083/jcb.106.4.1289; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; KINGSTON RE, 1990, CURRENT PROTOCOLS MO, V1; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; KOSHER RA, 1982, CELL DIFFER DEV, V11, P217, DOI 10.1016/0045-6039(82)90069-0; KOSHER RA, 1983, CARTILAGE, V1, P59; LEBOY PS, 1988, J BIOL CHEM, V263, P8515; MELNICK M, 1981, J EMBRYOL EXP MORPH, V63, P193; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEVO Z, 1972, DEV BIOL, V28, P219, DOI 10.1016/0012-1606(72)90139-X; NEWMAN SA, 1979, SCIENCE, V205, P662, DOI 10.1126/science.462174; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; OETTINGER HF, 1985, DEV BIOL, V109, P63, DOI 10.1016/0012-1606(85)90346-X; OKAYAMA M, 1976, P NATL ACAD SCI USA, V73, P3224, DOI 10.1073/pnas.73.9.3224; PACIFICI M, 1977, CELL, V11, P891, DOI 10.1016/0092-8674(77)90300-2; PAUL JI, 1986, J BIOL CHEM, V261, P2258; PENNYPACKER JP, 1979, EXP CELL RES, V121, P411, DOI 10.1016/0014-4827(79)90022-3; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SHAPIRO SS, 1976, ARCH BIOCHEM BIOPHYS, V174, P74, DOI 10.1016/0003-9861(76)90325-8; SOLURSH M, 1973, CALC TISS RES, V13, P131, DOI 10.1007/BF02015403; STROHMAN RC, 1977, CELL, V10, P265, DOI 10.1016/0092-8674(77)90220-3; TAMKUN JW, 1983, J BIOL CHEM, V258, P4641; TOMASEK JJ, 1982, DEV BIOL, V90, P118, DOI 10.1016/0012-1606(82)90217-2; VASAN NS, 1975, CALC TISS RES, V19, P99, DOI 10.1007/BF02563995; VIBEPEDERSEN K, 1984, EMBO J, V3, P2511, DOI 10.1002/j.1460-2075.1984.tb02165.x; von der Mark K, 1980, Curr Top Dev Biol, V14, P199; WEST CM, 1979, CELL, V17, P491; WURSTER NB, 1982, BIOCHEM BIOPH RES CO, V109, P1094, DOI 10.1016/0006-291X(82)91889-7; WYKE JA, 1973, VIROLOGY, V52, P587, DOI 10.1016/0042-6822(73)90357-7; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553	64	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5918	5924						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005128				2022-12-25	WOS:A1991FD37000087
J	SCARIA, PV; SHAFER, RH				SCARIA, PV; SHAFER, RH			BINDING OF ETHIDIUM-BROMIDE TO A DNA TRIPLE HELIX - EVIDENCE FOR INTERCALATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYNUCLEOTIDES; COMPLEXES; ACID; POLY(DA).POLY(DT); EQUILIBRIUM; SEQUENCES; PLASMIDS; CLEAVAGE; LIGANDS; LATTICE	The interaction of ethidium, a DNA intercalator, with the poly(dA).poly(dT) duplex and the poly(dA).2poly(dT) triplex has been investigated by a variety of spectrophotometric and hydrodynamic techniques. The fluorescence of ethidium is increased when either the duplex or triplex form is present. Binding constants, determined from absorbance measurements, indicate that binding to the triple helical form is substantially stronger than to the duplex, with a larger binding site size (2.8 base triplets compared to 2.4 base pairs). Furthermore, while binding to poly(dA).poly(dT) shows strong positive cooperativity, binding to the triplex is noncooperative. Thermal denaturation experiments demonstrate that ethidium stabilizes the triple helix. Binding to either form induces a weak circular dichroism band in the visible wavelength region, while in the region around 310 nm, there is a band that is strongly dependent on the degree of saturation of the duplex, and which is positive for the duplex but negative for the triplex. Both fluorescence energy transfer and quenching studies provide evidence of intercalation of ethidium in both duplex and triplex complexes. Binding of ethidium leads to an initial decrease in viscosity for both the duplex and triplex structures, followed by an increase, which is greater for the duplex. Taken together, these results strongly suggest that ethidium binds to the poly(dA).2poly(dT) triple helix via an intercalative mechanism.			SCARIA, PV (corresponding author), UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143, USA.				NATIONAL CANCER INSTITUTE [R01CA027343] Funding Source: NIH RePORTER; NCI NIH HHS [CA27343] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKTIPIS S, 1973, BIOCHEMISTRY-US, V12, P1213, DOI 10.1021/bi00730a031; AKTIPIS S, 1970, BIOCHEM BIOPH RES CO, V39, P307, DOI 10.1016/0006-291X(70)90577-2; ARNOTT S, 1974, J MOL BIOL, V88, P523, DOI 10.1016/0022-2836(74)90499-9; ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; ARNOTT S, 1976, NUCLEIC ACIDS RES, V3, P2459, DOI 10.1093/nar/3.10.2459; BARTON JK, 1986, J AM CHEM SOC, V108, P2081, DOI 10.1021/ja00268a057; Bloomfield V. A., 1974, PHYSICAL CHEM NUCLEI, P442; BRESLOFF JL, 1981, BIOCHEMISTRY-US, V20, P3547, DOI 10.1021/bi00515a038; BROITMAN SL, 1987, P NATL ACAD SCI USA, V84, P5120, DOI 10.1073/pnas.84.15.5120; CHAIRES JB, 1983, BIOCHEMISTRY-US, V22, P4204, DOI 10.1021/bi00287a007; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DOUTHART RJ, 1973, BIOCHEMISTRY-US, V12, P214, DOI 10.1021/bi00726a006; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; GRISWOLD BL, 1951, ANAL CHEM, V23, P192, DOI 10.1021/ac60049a041; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; JONES RL, 1986, BIOCHEMISTRY-US, V25, P7431, DOI 10.1021/bi00371a027; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; Le Pecq J B, 1971, Methods Biochem Anal, V20, P41, DOI 10.1002/9780470110393.ch2; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3073, DOI 10.1093/nar/6.9.3073; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LEHRMAN EA, 1977, NUCLEIC ACIDS RES, V4, P1381, DOI 10.1093/nar/4.5.1381; LEPECQ J, 1965, CR HEBD ACAD SCI, V260, P7033; LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MARKY LA, 1990, BIOCHEMISTRY-US, V29, P4805, DOI 10.1021/bi00472a009; MCGHEE JD, 1976, J MOL BIOL, V103, P679; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PERROUAULT L, 1990, NATURE, V344, P358, DOI 10.1038/344358a0; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; REINHARDT CG, 1982, BIOCHEM BIOPH RES CO, V104, P1376, DOI 10.1016/0006-291X(82)91402-4; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; SANTOS CDL, 1989, BIOCHEMISTRY-US, V28, P7282; SARI MA, 1990, BIOCHEMISTRY-US, V29, P4205, DOI 10.1021/bi00469a025; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STURM J, 1982, BIOPOLYMERS, V21, P1189, DOI 10.1002/bip.360210613; UMEMOTO K, 1990, J AM CHEM SOC, V112, P4539, DOI 10.1021/ja00167a063; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; Waring J. M., 1974, BIOCHEM J, V143, P483; WILSON WD, 1985, BIOCHEMISTRY-US, V24, P3991, DOI 10.1021/bi00336a029; WINKLE SA, 1982, NUCLEIC ACIDS RES, V10, P8211, DOI 10.1093/nar/10.24.8211	48	239	244	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5417	5423						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005088				2022-12-25	WOS:A1991FD37000013
J	BOYD, JM; SIMMONS, DT				BOYD, JM; SIMMONS, DT			EVIDENCE THAT SV40 SURFACE TUMOR-ANTIGEN ORIGINATES FROM THE NUCLEUS AND CYTOPLASM	ONCOGENE			English	Article							LARGE-T-ANTIGEN; TRANSPORT-DEFECTIVE MUTANT; SIMIAN VIRUS-40; PLASMA-MEMBRANE; CELL-SURFACE; HYBRID VIRUSES; WILD-TYPE; ASSOCIATION; BINDING; PHOSPHORYLATION	Simian virus 40 large T antigen exposed at the cell surface is oligomerized and phosphorylated in a mature fashion. NP40-soluble surface T antigen, prepared from infected cells, sediments mainly as a tetramer and has a nuclear phosphorylation pattern. Since these are modifications that occur over several hours, surface T appears to be a population of older molecules. This is in apparent contradiction to kinetic studies showing that T antigen arrives at the surface in 20 min. We present a model to account for this apparent discrepancy. It postulates that both newly-synthesized and older, mature molecules are transported to the surface. The newly-synthesized molecules are highly unstable and lost rapidly from the surface whereas the mature molecules are stable and accumulate over time. This stability may be due to oligomerization and/or phosphorylation or to an interaction with other surface molecules that act as anchors. Our model further proposes that most of the T antigen in transit to the surface is newly-synthesized protein from the cytoplasm, while the majority of the T antigen at the surface is mature protein from the nucleus.			BOYD, JM (corresponding author), UNIV DELAWARE,SCH LIFE & HLTH SCI,NEWARK,DE 19716, USA.				NATIONAL CANCER INSTITUTE [R01CA036118] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; DEPPERT W, 1982, VIROLOGY, V122, P56, DOI 10.1016/0042-6822(82)90377-4; FANNING E, 1981, J VIROL, V37, P92, DOI 10.1128/JVI.37.1.92-102.1981; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GREENSPAN DS, 1981, P NATL ACAD SCI-BIOL, V78, P105, DOI 10.1073/pnas.78.1.105; HENNING R, 1983, NATURE, V305, P736, DOI 10.1038/305736a0; JARVIS DL, 1984, VIROLOGY, V134, P168, DOI 10.1016/0042-6822(84)90282-4; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KLOCKMANN U, 1985, J VIROL, V56, P541, DOI 10.1128/JVI.56.2.541-548.1985; KLOCKMANN U, 1983, EMBO J, V2, P1151, DOI 10.1002/j.1460-2075.1983.tb01560.x; KLOCKMANN U, 1983, VIROLOGY, V126, P717, DOI 10.1016/S0042-6822(83)80029-4; LANFORD RE, 1980, VIROLOGY, V105, P314, DOI 10.1016/0042-6822(80)90033-1; LANFORD RE, 1980, VIROLOGY, V105, P303, DOI 10.1016/0042-6822(80)90032-X; LANFORD RE, 1982, VIROLOGY, V119, P169, DOI 10.1016/0042-6822(82)90074-5; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEVITSKY K, 1983, INT J CANCER, V32, P597, DOI 10.1002/ijc.2910320513; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; RINKE Y, 1989, VIROLOGY, V170, P424, DOI 10.1016/0042-6822(89)90433-9; SANTOS M, 1984, J VIROL, V51, P376, DOI 10.1128/JVI.51.2.376-383.1984; SANTOS M, 1984, J VIROL, V49, P50, DOI 10.1128/JVI.49.1.50-56.1984; SANTOS M, 1982, VIROLOGY, V120, P1, DOI 10.1016/0042-6822(82)90002-2; SCHEIDTMANN KH, 1986, VIROLOGY, V150, P85, DOI 10.1016/0042-6822(86)90268-0; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1984, J VIROL, V50, P636, DOI 10.1128/JVI.50.2.636-640.1984; SCHICKEDANZ J, 1986, VIROLOGY, V148, P47, DOI 10.1016/0042-6822(86)90402-2; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHMIEG FI, 1984, J VIROL, V52, P350, DOI 10.1128/JVI.52.2.350-355.1984; SIMMONS D, 1980, VIROLOGY, V34, P650; SIMMONS DT, 1984, J BIOL CHEM, V259, P8633; SIMMONS DT, 1990, J VIROL, V64, P1973, DOI 10.1128/JVI.64.5.1973-1983.1990; SIMMONS DT, 1977, J VIROL, V24, P319, DOI 10.1128/JVI.24.1.319-325.1977; SOULE HR, 1982, INT J CANCER, V29, P337, DOI 10.1002/ijc.2910290318; WALSER A, 1989, J VIROL, V63, P3926, DOI 10.1128/JVI.63.9.3926-3933.1989; WALSER A, 1989, ONCOGENE, V4, P249	36	0	0	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					379	387						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011395				2022-12-25	WOS:A1991FT34400005
J	BANSAL, N; HOULE, A; MELNYKOVYCH, G				BANSAL, N; HOULE, A; MELNYKOVYCH, G			APOPTOSIS - MODE OF CELL-DEATH INDUCED IN T-CELL LEUKEMIA LINES BY DEXAMETHASONE AND OTHER AGENTS	FASEB JOURNAL			English	Article						APOPTOSIS; DEXAMETHASONE; CEM CELLS; ENDONUCLEASE; DNA FRAGMENTATION; RU 486	DNA FRAGMENTATION; GLUCOCORTICOIDS; ENDONUCLEASE; THYMOCYTES; ACTIVATION; INDUCTION; CLEAVAGE; NUCLEASE; RECEPTOR; LEADS	Glucocorticoids can mediate the destruction of thymocytes and T cell-derived leukemia cells through a mechanism known as apoptosis. The characteristic feature of apoptosis is fragmentation of DNA at internucleosomal linkers through the activity of a specific endonuclease. In this study, an attempt was made to compare dexamethasone-induced apoptosis in two T cell-derived human leukemia lines (CEM-C1 and CEM-C7) to the cell killing brought about by selected cytotoxic agents. In the CEM-C7 cell line (dexamethasone-sensitive), apoptosis was induced not only by dexamethasone but by actinomycin D, cycloheximide, and 25-OH cholesterol. In the CEM-C1 cell line (dexamethasone-resistant) cycloheximide, 25-OH cholesterol, or cell starvation could induce apoptosis. It appears that in leukemic cells apoptosis may be induced by a variety of unrelated toxic agents and is not limited to glucocorticoids.	VET AFFAIRS MED CTR,RES SERV 151,4801 LINWOOD BLVD,KANSAS CITY,MO 64128; UNIV KANSAS,MED CTR,DEPT MICROBIOL MOLEC GENET & IMMUNOL,KANSAS CITY,KS 66103	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas; University of Kansas Medical Center								ALNEMRI ES, 1989, J BIOL CHEM, V264, P4104; BANSAL N, 1990, J CELL PHYSIOL, V143, P105, DOI 10.1002/jcp.1041430114; BANSAL N, 1989, LEUKEMIA RES, V13, P875, DOI 10.1016/0145-2126(89)90040-4; BAXTER GD, 1989, BIOCHEM BIOPH RES CO, V162, P30, DOI 10.1016/0006-291X(89)91957-8; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; COHEN JJ, 1984, J IMMUNOL, V132, P38; COMPTON MM, 1986, ENDOCRINOLOGY, V118, P38, DOI 10.1210/endo-118-1-38; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDEN EA, 1986, CANCER RES, V46, P617; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; SELLINS KS, 1987, J IMMUNOL, V139, P3199; THOMPSON EB, 1985, KLIN WOCHENSCHR, V63, P689, DOI 10.1007/BF01733111; VANDENBOGERT C, 1989, J STEROID BIOCHEM, V33, P955, DOI 10.1016/0022-4731(89)90246-X; VEDECKIS WV, 1983, MOL CELL ENDOCRINOL, V30, P215, DOI 10.1016/0303-7207(83)90049-7; WIRA CR, 1974, J BIOL CHEM, V249, P5328; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZAWYDIWSKI R, 1983, CANCER RES, V43, P3865	24	131	134	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					211	216		10.1096/fasebj.5.2.2004665	http://dx.doi.org/10.1096/fasebj.5.2.2004665			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	2004665				2022-12-25	WOS:A1991EZ00200011
J	NAKASHIMA, K; KANAMARU, K; AIBA, H; MIZUNO, T				NAKASHIMA, K; KANAMARU, K; AIBA, H; MIZUNO, T			SIGNAL TRANSDUCTION AND OSMOREGULATION IN ESCHERICHIA-COLI - A NOVEL TYPE OF MUTATION IN THE PHOSPHORYLATION DOMAIN OF THE ACTIVATOR PROTEIN, OMPR, RESULTS IN A DEFECT IN ITS PHOSPHORYLATION-DEPENDENT DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 REGULATORY COMPONENTS; EXHIBITING DIFFERENT PHENOTYPES; OUTER-MEMBRANE PROTEINS; POSITIVE REGULATOR; WILD-TYPE; GENES; ENVZ; EXPRESSION; KINASE; PHOSPHOTRANSFER	The transcriptional factors, OmpR and EnvZ, are crucially involved in the osmotic regulation of ompF and ompC expression in Escherichia coli. The DNA binding ability of the positive regulator, OmpR, is modulated through its phosphorylation and dephosphorylation mediated by EnvZ in response to the medium osmolarity. In this study, two examples of a novel type of mutant ompR allele, ompR96A and ompR115S, whose phenotype is OmpF- OmpC- irrespective of the medium osmolarity, were characterized. These mutations result in amino acid conversions, Glu96 to Ala and Arg115 to Ser, respectively, within the phosphorylation domain of OmpR. Nevertheless, these mutant proteins were capable of undergoing phosphorylation and dephosphorylation normally, just like wild-type OmpR. However, the phosphorylation-dependent enhancement of their in vitro DNA binding ability was found to be severely affected. It was thus revealed that these mutant OmpR represent a novel type in terms of the mechanism of phosphorylation-dependent activation of the function of OmpR, i.e. those are normally phosphorylated but not activated to bind to the cognate promoter DNAs. In this respect, it was further suggested that OmpR oligomerization may be involved in the mechanism underlying the phosphorylation-dependent enhancement of the DNA binding ability of OmpR. The mutant proteins characterized in this study seem to be defective in this particular oligomerization process observed in vitro.	NAGOYA UNIV,SCH AGR,MICROBIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Nagoya University			Kanamaru, Kengo/GNP-8187-2022	Kanamaru, Kengo/0000-0002-6844-0841; Kanamaru, Kyoko/0000-0003-3964-7891				AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; AIBA H, 1990, FEBS LETT, V261, P19, DOI 10.1016/0014-5793(90)80626-T; CHOI DS, 1987, J BIOCHEM, V102, P975, DOI 10.1093/oxfordjournals.jbchem.a122174; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; GARRETT S, 1985, J BACTERIOL, V162, P840, DOI 10.1128/JB.162.2.840-844.1985; HALL MN, 1981, ANNU REV GENET, V15, P91, DOI 10.1146/annurev.ge.15.120181.000515; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; JO YL, 1986, J BIOL CHEM, V261, P5252; KANAMARU K, 1990, J BIOCHEM-TOKYO, V108, P483, DOI 10.1093/oxfordjournals.jbchem.a123225; KANAMARU K, 1989, J BIOL CHEM, V264, P21633; KATO M, 1989, FEBS LETT, V249, P168, DOI 10.1016/0014-5793(89)80617-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUYAMA SI, 1986, J BACTERIOL, V168, P1309, DOI 10.1128/jb.168.3.1309-1314.1986; MIZUNO T, 1988, J BIOL CHEM, V263, P1008; MIZUNO T, 1987, J BIOCHEM-TOKYO, V101, P387, DOI 10.1093/oxfordjournals.jbchem.a121923; MIZUNO T, 1990, MOL MICROBIOL, V4, P1077, DOI 10.1111/j.1365-2958.1990.tb00681.x; NARA F, 1986, MOL GEN GENET, V205, P51; NARA F, 1986, MOL GEN GENET, V202, P194, DOI 10.1007/BF00331636; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLAUCH JM, 1988, J BACTERIOL, V170, P439, DOI 10.1128/jb.170.1.439-441.1988; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TATE S, 1988, FEBS LETT, V242, P27, DOI 10.1016/0014-5793(88)80978-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANDERSMAN C, 1980, J BACTERIOL, V143, P1374, DOI 10.1128/JB.143.3.1374-1383.1980	28	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10775	10780						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040597				2022-12-25	WOS:A1991FQ77400014
J	PAN, H; CLARY, D; SADOWSKI, PD				PAN, H; CLARY, D; SADOWSKI, PD			IDENTIFICATION OF THE DNA-BINDING DOMAIN OF THE FLP RECOMBINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; 2-MU CIRCLE; REGIONAL SIMILARITIES; FUNCTIONAL DISSECTION; ESCHERICHIA-COLI; TARGET SEQUENCE; YEAST PLASMID; PROTEIN; GENE; PURIFICATION	We have subjected the FLP protein of the 2-mu-M plasmid to partial proteolysis by proteinase K and have found that FLP can be digested into two major proteinase K-resistant peptides of 21 and 13 kDa, respectively. The 21-kDa peptide contains a site-specific DNA-binding domain that binds to the FLP recognition target (FRT) site with an affinity similar to that observed for the native FLP protein. This peptide can induce DNA bending upon binding to a DNA fragment containing the FRT site, but the angle of the bend (approximately 24-degrees) is smaller in magnitude than that induced by the native FLP protein (60-degrees). The additional DNA bending induced by the interaction between two native FLP molecules bound to the FRT site is not observed with the 21-kDa DNA-binding peptide. Amino-terminal sequencing has been used to map this peptide to an internal region of FLP that begins at residue Leu-148. It is likely that the DNA-binding peptide includes the catalytic site of the FLP protein.	UNIV TORONTO,DEPT MED GENET,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto								ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; AMIN AA, 1989, MOL CELL BIOL, V9, P1987, DOI 10.1128/MCB.9.5.1987; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BABINEAU D, 1985, J BIOL CHEM, V260, P2313; BEATTY LG, 1988, J MOL BIOL, V204, P283, DOI 10.1016/0022-2836(88)90576-1; BOULANGER PA, 1989, NUCLEIC ACIDS RES, V17, P7761, DOI 10.1093/nar/17.19.7761; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; HENRY YAL, 1990, NUCLEIC ACIDS RES, V18, P2617, DOI 10.1093/nar/18.9.2617; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOZUMI N, 1981, P NATL ACAD SCI-BIOL, V78, P7019, DOI 10.1073/pnas.78.11.7019; HUET J, 1987, P NATL ACAD SCI USA, V84, P3648, DOI 10.1073/pnas.84.11.3648; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOOS M, 1988, J BIOL CHEM, V263, P6005; MOSKALUK C, 1988, P NATL ACAD SCI USA, V85, P1826, DOI 10.1073/pnas.85.6.1826; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; QIAN XH, 1990, J BIOL CHEM, V265, P21779; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; Sambrook J., 1989, MOL CLONING LABORATO, P31; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; UTATSU I, 1987, J BACTERIOL, V169, P5537, DOI 10.1128/jb.169.12.5537-5545.1987	36	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11347	11354						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040639				2022-12-25	WOS:A1991FQ77400098
J	MOSER, B; SCHUMACHER, C; VONTSCHARNER, V; CLARKLEWIS, I; BAGGIOLINI, M				MOSER, B; SCHUMACHER, C; VONTSCHARNER, V; CLARKLEWIS, I; BAGGIOLINI, M			NEUTROPHIL-ACTIVATING PEPTIDE-2 AND GRO MELANOMA GROWTH-STIMULATORY ACTIVITY INTERACT WITH NEUTROPHIL-ACTIVATING PEPTIDE-1/INTERLEUKIN-8 RECEPTORS ON HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN DERMAL FIBROBLASTS; AMINO-ACID-SEQUENCE; GENE-EXPRESSION; HUMAN-MONOCYTES; INTERLEUKIN-8; CELLS; LEUKOCYTES; PROTEINS; IDENTIFICATION	Neutrophil-activating peptide 1/interleukin 8 (NAP-1/IL-8), neutrophil-activating peptide 2 (NAP-2), and gro/melanoma growth-stimulatory activity (gro/MGSA) are potent inflammatory cytokines with homologous structure and similar neutrophil-activating properties. Receptors on human neutrophils that interact with these peptides were studied. Analysis of I-125-NAP-1/IL-8 binding at 0-4-degrees-C revealed 64,500 +/- 14,000 receptors/cell with an apparent K(d) of 0.18 +/- 0.07 nM (mean +/- S.D. of six independent experiments). Unlabeled NAP-1/IL-8, NAP-2, and gro/MGSA competed with I-125-NAP-1/IL-8 for binding to human neutrophils. Competition with increasing concentrations of unlabeled NAP-2 and gro/MGSA resolved two classes of NAP-1/IL-8 binding sites: about 70% of them bound NAP-2 and gro/MGSA with high affinity (K(d): 0.34 +/- 0.2 and 0.14 +/- 0.02), while 30% were of low affinity (K(d): 100 +/- 20 and 130 +/- 10 nM). Different binding sites, however, were not apparent upon competition with unlabeled NAP-1/IL-8, suggesting that both classes of receptors have similar affinities for NAP-1/IL-8. The existence of two receptors was also suggested by ligand cross-linking and cross-desensitization experiments. Two neutrophil membrane proteins with apparent M(r) of 66,000-74,000 and 42,000-46,000 became cross-linked to I-125-NAP-1/IL-8, and the labeling was decreased when excess NAP-1/IL-8, NAP-2, or gro/MGSA was present. Stimulation of neutrophils with NAP-1/IL-8 resulted in desensitization toward a subsequent challenge with NAP-2 or gro/MGSA as shown by the rise in cytosolic free calcium. By contrast, following primary stimulation with NAP-2 or gro/MGSA, responses to NAP-1/IL-8 were only moderately attenuated, supporting the existence of NAP-1/IL-8 receptors which bind NAP-2 or gro/MGSA with low affinity. In conclusion, our results demonstrate that NAP-2 and gro/MGSA act upon human neutrophils by directly interacting with two classes of receptors for NAP-1/IL-8.	UNIV BERN,THEODOR KOCH INST,CH-3000 BERN,SWITZERLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1W5,BC,CANADA	University of Bern; University of British Columbia				Moser, Bernhard/0000-0002-4354-4572				AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BESEMER J, 1989, J BIOL CHEM, V264, P17409; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; COLDITZ I, 1989, AM J PATHOL, V134, P755; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; FOUNTOULAKIS M, 1989, J IMMUNOL, V143, P3266; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; GROB PM, 1990, J BIOL CHEM, V265, P8311; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; KUNKEL SL, 1990, RESPIRATORY DISTRESS, P204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN CG, 1989, BIOCHEM BIOPH RES CO, V160, P1403, DOI 10.1016/S0006-291X(89)80160-3; LARSEN CG, 1989, IMMUNOLOGY, V68, P31; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; LOETSCHER H, 1990, CELL, V61, P251; MANNERVIK B, 1982, METHOD ENZYMOL, V87, P370; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MUNSON P, 1990, USERS GUIDE LIGAND; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; SYLVESTER I, 1990, AM REV RESPIR DIS, V141, P683, DOI 10.1164/ajrccm/141.3.683; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WALZ A, 1991, CHEMOTACTIC CYTOKINE, V2; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; WESTWICK J, 1989, IMMUNOL TODAY, V10, P146, DOI 10.1016/0167-5699(89)90164-3; YOSHIMURA T, 1987, J IMMUNOL, V139, P788; ZIELER K, 1989, TRENDS BIOCHEM SCI, V14, P314	43	229	234	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10666	10671						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037605				2022-12-25	WOS:A1991FP08600099
J	VANBLITTERSWIJK, WJ; HILKMANN, H; DEWIDT, J; VANDERBEND, RL				VANBLITTERSWIJK, WJ; HILKMANN, H; DEWIDT, J; VANDERBEND, RL			PHOSPHOLIPID-METABOLISM IN BRADYKININ-STIMULATED HUMAN FIBROBLASTS .2. PHOSPHATIDYLCHOLINE BREAKDOWN BY PHOSPHOLIPASE-C AND PHOSPHOLIPASE-D - INVOLVEMENT OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; HUMAN NEUTROPHIL; PHORBOL ESTER; D ACTIVATION; PHOSPHOINOSITIDE HYDROLYSIS; HL-60 GRANULOCYTES; ENDOTHELIAL-CELLS; DIACYLGLYCEROL; MECHANISM; GENERATION	Bradykinin (BK) and phorbol 12-myristate 13-acetate (PMA) both stimulate the hydrolysis of phosphatidylcholine (PC) in human fibroblasts, resulting in the formation of phosphatidic acid (PA) and diacylglycerol (DG) (Van Blitterswijk, W. J., Hilkmann, H., de Widt, J., and Van der Bend, R. L. (1990) J. Biol. Chem. 266, 10337-10343). Stimulation with BK resulted in the rapid and synchronous formation of [H-3]choline and [H-3]myristoyl-PA from the correspondingly prelabeled PC, indicative of phospholipase D (PLD) activity. In the presence of ethanol or n-butanol, transphosphatidylation by PLD resulted in the formation of [H-3]phosphatidylethanol or - butanol, respectively, at the cost of PA and DG formation. This suggests that PC-derived DG is generated via a PLD/PA phosphohydrolase pathway. A more pronounced but delayed formation of these products was observed by PMA stimulation. The Ca2+ ionophore ionomycin also activated PLD and accelerated (synergized) the response to PMA. Both [H-3]choline and [H-3]phosphocholine were released into the extracellular medium in a time- and stimulus-dependent fashion, without apparent changes in the high intracellular levels of [H-3]phosphocholine. The protein kinase C (PKC) inhibitors staurosporin and 1-O-hexadecyl-2-O-methylglycerol inhibited BK- and PMA-induced activation of PLD. Down-regulation of PKC by long-term pretreatment of cells with phorbol ester caused a dramatic drop in background [H-3]choline levels, while subsequent stimulation with BK, ionomycin, or PMA failed to increase these levels and failed to induce transphosphatidylation. From these results we conclude that PLD activation is entirely mediated by (downstream of) PKC. Unexpectedly, however, BK stimulation of these PKC-depleted cells caused a marked generation of DG from PC within 15 s, which was not seen in BK-stimulated control cells, suggesting PC breakdown by a phospholipase C (PLC(c)). We conclude that cells stimulated with BK generate DG via both the PLC(c) and the PLD/PA hydrolase pathway, whereas PMA stimulates mainly the latter pathway. BK stimulation of normal cells leads to activation of PKC and, by consequence, to attenuation of the level of PLC(c)-generated DG and to stimulation of the PLD pathway, whereas the reverse occurs in PKC-down-regulated cells.			VANBLITTERSWIJK, WJ (corresponding author), NETHERLANDS CANC INST,ANTONI VAN LEEUWENHOEK HUIS,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.							BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DIAZMECO MT, 1989, BIOCHEM J, V263, P115, DOI 10.1042/bj2630115; EXTON JH, 1990, J BIOL CHEM, V265, P1; FOLCH J, 1957, J BIOL CHEM, V226, P497; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; KRAMER IM, 1989, J BIOL CHEM, V264, P5876; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; MARTIN TW, 1989, BIOCHEM BIOPH RES CO, V165, P319, DOI 10.1016/0006-291X(89)91072-3; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; PAI JK, 1988, J BIOL CHEM, V263, P12472; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SLIVKA SR, 1988, J BIOL CHEM, V263, P12242; SMITH GA, 1978, LIPIDS, V13, P92, DOI 10.1007/BF02533373; STASSEN FL, 1989, J BIOL CHEM, V264, P4916; SUNDLER R, 1972, BIOCHIM BIOPHYS ACTA, V280, P559, DOI 10.1016/0005-2760(72)90136-1; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; TING AE, 1990, J BIOL CHEM, V265, P5337; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANBLITTERSWIJK WJ, 1987, LIPIDS, V22, P842, DOI 10.1007/BF02535541; VANBLITTERSWIJK WJ, 1990, J BIOL CHEM, V266, P10337; VANCE DE, 1980, J BIOL CHEM, V255, P1064; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	39	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10344	10350						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037586				2022-12-25	WOS:A1991FP08600056
J	CASTAGNOLA, P; BET, P; QUARTO, R; GENNARI, M; CANCEDDA, R				CASTAGNOLA, P; BET, P; QUARTO, R; GENNARI, M; CANCEDDA, R			CDNA CLONING AND GENE-EXPRESSION OF CHICKEN OSTEOPONTIN - EXPRESSION OF OSTEOPONTIN MESSENGER-RNA IN CHONDROCYTES IS ENHANCED BY TRYPSIN TREATMENT OF CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEO-SARCOMA CELLS; MAJOR 66-KDA PHOSPHOPROTEIN; TRANSFORMING GROWTH-FACTOR; X COLLAGEN-SYNTHESIS; BONE SIALOPROTEIN; EMBRYONIC CHICK; ULTRASTRUCTURAL IMMUNOLOCALIZATION; HYPERTROPHIC CHONDROCYTES; DEVELOPMENTAL EXPRESSION; EXTRACELLULAR-MATRIX	A cDNA clone, pCP15, specific for the chicken 66-kDa major bone phosphoprotein (osteopontin), was isolated from a subtracted library enriched in DNAs coding for mRNAs expressed in chicken differentiating chondrocytes. Northern blot analysis of RNAs extracted from several chick embryo tissues and organs, confirm and extend the observation that osteopontin mRNA expression is not restricted to tissues involved in phosphate metabolism. Osteopontin mRNA was detected in sternal resting chondrocytes at higher levels than in hypertrophic chondrocytes; therefore osteopontin gene transcription occurs in chondrocytes at many stages of differentiation. The steady state level of osteopontin mRNA was enhanced by trypsin treatment of cultured cells. An increased level of osteopontin mRNA in quail chondrocytes constitutively expressing v-myc oncogene is also shown.			CASTAGNOLA, P (corresponding author), IST NAZL RIC CANC, DIFFERENZIAMENTO CELLULARE LAB, VIALE BENEDETTO XV 10, I-16132 GENOA, ITALY.		Quarto, Rodolfo/AAB-2182-2019; Castagnola, Patrizio/H-2029-2012	Castagnola, Patrizio/0000-0003-2008-9199; Quarto, Rodolfo/0000-0002-1146-894X				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ANDREWS ATB, 1967, BIOCHEM J, V104, P705, DOI 10.1042/bj1040705; BONATTI S, 1982, J VIROL, V42, P64, DOI 10.1128/JVI.42.1.64-70.1982; BRUDER S, 1990, IN PRESS CALCIF TISS; CANCEDDA FD, 1988, J CELL BIOL, V107, P2455, DOI 10.1083/jcb.107.6.2455; CANCEDDA FD, 1990, J BIOL CHEM, V265, P19060; CANCEDDA R, 1985, J CELL BIOCHEM, V28, P7, DOI 10.1002/jcb.240280103; CASTAGNOLA P, 1986, J CELL BIOL, V102, P2310, DOI 10.1083/jcb.102.6.2310; CASTAGNOLA P, 1988, J CELL BIOL, V106, P461, DOI 10.1083/jcb.106.2.461; CASTAGNOLA P, 1987, DEV BIOL, V123, P332, DOI 10.1016/0012-1606(87)90391-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; Doty S B, 1976, Prog Histochem Cytochem, V8, P1; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; FRANZEN A, 1989, MATRIX, V9, P261, DOI 10.1016/S0934-8832(89)80001-0; GERSTENFELD LC, 1990, ANAT RECORD, V228, P93, DOI 10.1002/ar.1092280113; GIBSON GJ, 1984, J CELL BIOL, V99, P208, DOI 10.1083/jcb.99.1.208; GIONTI E, 1985, P NATL ACAD SCI USA, V82, P2756, DOI 10.1073/pnas.82.9.2756; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; HALL BK, 1968, J EXP ZOOL, V168, P283, DOI 10.1002/jez.1401680302; HALL BK, 1972, ANAT REC, V173, P391; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANAOKA H, 1976, J BONE JOINT SURG AM, V58, P226, DOI 10.2106/00004623-197658020-00011; HOLTROP ME, 1972, CALC TISS RES, V9, P140, DOI 10.1007/BF02061952; KAHN AJ, 1975, NATURE, V258, P325, DOI 10.1038/258325a0; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KISS I, 1987, P NATL ACAD SCI USA, V84, P6399, DOI 10.1073/pnas.84.18.6399; KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MAYNE R, 1983, CARTILAGE, V1, P200; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; NODA M, 1988, J BIOL CHEM, V263, P13916; NODA M, 1987, J CELL PHYSIOL, V133, P426, DOI 10.1002/jcp.1041330303; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OLDBERG A, 1989, J CELL BIOL, V109, P3183, DOI 10.1083/jcb.109.6.3183; PRINCE CW, 1987, COLLAGEN REL RES, V7, P305; QUARTO R, 1990, J CELL BIOL, V110, P1379, DOI 10.1083/jcb.110.4.1379; RODAN SB, 1989, J BIOL CHEM, V264, P19934; SENGER DR, 1988, CANCER RES, V48, P5770; SHIMOMURA Y, 1984, CLIN ORTHOP RELAT R, P93; SOLURSH M, 1975, CELL DIFFER DEV, V4, P131, DOI 10.1016/0045-6039(75)90034-2; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; SWANSON GJ, 1989, HEARING RES, V41, P169, DOI 10.1016/0378-5955(89)90008-7; TACCHETTI C, 1989, DEV BIOL, V132, P442, DOI 10.1016/0012-1606(89)90240-6; TACCHETTI C, 1987, J CELL BIOL, V105, P999, DOI 10.1083/jcb.105.2.999; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; WRANA LL, 1990, NUCLEIC ACIDS RES, V17, P10119; YOON K, 1987, BIOCHEM BIOPH RES CO, V148, P1129, DOI 10.1016/S0006-291X(87)80250-4; YOUNG MF, 1984, NUCLEIC ACIDS RES, V12, P4207, DOI 10.1093/nar/12.10.4207; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115; ZHANG R, 1990, J BIOL CHEM, V265, P15375; [No title captured]	58	43	44	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9944	9949						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033080				2022-12-25	WOS:A1991FM45900090
J	KURATA, S; HATA, R				KURATA, S; HATA, R			EPIDERMAL GROWTH-FACTOR INHIBITS TRANSCRIPTION OF TYPE-I COLLAGEN GENES AND PRODUCTION OF TYPE-I COLLAGEN IN CULTURED HUMAN SKIN FIBROBLASTS IN THE PRESENCE AND ABSENCE OF L-ASCORBIC-ACID 2-PHOSPHATE, A LONG-ACTING VITAMIN-C DERIVATIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN MESSENGER-RNAS; NUCLEAR FACTOR-I; FACTOR-BETA; 1ST INTRON; EXTRACELLULAR-MATRIX; POLYACRYLAMIDE GELS; REGULATORY ELEMENTS; RAT-LIVER; PROMOTER; CELLS	Recombinant human epidermal growth factor (EGF, 2-10 ng/ml) stimulated growth and production of noncollagenous proteins, but inhibited production of collagen by 60% in cultured human skin fibroblasts. Type analysis of the collagen produced indicated that inhibition of the collagen production observed was mainly a reflection of a reduction in type I collagen. The accumulation of pro-alpha-1(I) and pro-alpha-2(I) mRNAs and the transcriptional activity of these genes were determined in human skin fibroblasts in order to investigate site(s) of regulation of type I collagen production by human EGF in the absence and presence of L-ascorbic acid 2-phosphate (Asc 2-P), a long-acting vitamin C derivative. Human EGF (10 ng/ml) used alone reduced the steady state levels of mRNAs for pro-alpha-1(I) and pro-alpha-2(I) chains and transcriptional activity of these genes in vitro by 45%. Asc 2-P (0.2 mM) alone, on the other hand raised production of type I collagen and the steady state levels of mRNAs for pro-alpha-1(I) and pro-alpha-2(I) collagen chains as well as stimulated transcriptional activity of these genes. Human EGF attenuated these stimulative effects of Asc 2-P. These results indicate that human EGF regulates type I collagen synthesis at the transcriptional level in cultured fibroblasts in the presence and absence of Asc 2-P. The possibility that human EGF plays a role as a regulator of type I collagen genes in vivo was discussed.	TOKYO MED & DENT UNIV,MED RES INST,DEPT BIOCHEM GENET,CHIYODA KU,TOKYO 101,JAPAN; TOKYO MED & DENT UNIV,MED RES INST,DEPT TISSUE PHYSIOL,CHIYODA KU,TOKYO 101,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BORNSTEIN P, 1980, METABOLIC CONTROL DI, P1089; BRENNER DA, 1987, J BIOL CHEM, V262, P17690; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; COCKAYNE D, 1986, BIOCHEMISTRY-US, V25, P3202, DOI 10.1021/bi00359a018; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HAMALAINEN L, 1985, J BIOL CHEM, V260, P720; HARBERS K, 1984, P NATL ACAD SCI-BIOL, V81, P1504, DOI 10.1073/pnas.81.5.1504; HATA R, 1988, EUR J BIOCHEM, V174, P231, DOI 10.1111/j.1432-1033.1988.tb14087.x; HATA R, 1988, EUR J BIOCHEM, V173, P261, DOI 10.1111/j.1432-1033.1988.tb13993.x; HATA R, 1990, CELL BIOL INT REP, V74, P509; HATA R, 1990, BIOSCIENCES BIOTECHN, P165; HATA RI, 1980, BIOCHEMISTRY-US, V19, P169, DOI 10.1021/bi00542a026; HATA RI, 1984, ENDOCRINOLOGY, V115, P867, DOI 10.1210/endo-115-3-867; HATA RI, 1989, J CELL PHYSIOL, V138, P8, DOI 10.1002/jcp.1041380103; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IMAI Y, 1967, JPN J PHARMACOL, V17, P317, DOI 10.1254/jjp.17.317; KISSANE JM, 1958, J BIOL CHEM, V233, P184; KIVIRIKKO KI, 1984, EXTRACELLULAR MATRIX, P83; KRANE SM, 1984, EXTRACELLULAR MATRIX, P413; KRATOCHWIL K, 1989, CELL, V57, P807, DOI 10.1016/0092-8674(89)90795-2; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; LYONS BL, 1984, NUCLEIC ACIDS RES, V12, P2569, DOI 10.1093/nar/12.5.2569; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MYERS JC, 1981, P NATL ACAD SCI-BIOL, V78, P3516, DOI 10.1073/pnas.78.6.3516; NINOMIYA Y, 1982, BIOMED RES-TOKYO, V3, P70, DOI 10.2220/biomedres.3.70; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; OKA Y, 1983, J CLIN INVEST, V72, P249, DOI 10.1172/JCI110964; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; RAGHOW R, 1986, J BIOL CHEM, V261, P4677; RAGHOW R, 1984, J BIOL CHEM, V259, P2718; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; SCHWARTZ E, 1982, J CELL BIOL, V92, P462, DOI 10.1083/jcb.92.2.462; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; TAJIMA S, 1982, BIOCHEM BIOPH RES CO, V106, P632, DOI 10.1016/0006-291X(82)91157-3; WANG XF, 1985, CELL, V43, P659, DOI 10.1016/0092-8674(85)90238-7	45	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9997	10003						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033086				2022-12-25	WOS:A1991FM45900098
J	LECLERC, S; XIE, BX; ROY, R; GOVINDAN, MV				LECLERC, S; XIE, BX; ROY, R; GOVINDAN, MV			PURIFICATION OF A HUMAN GLUCOCORTICOID RECEPTOR GENE PROMOTER-BINDING PROTEIN - PRODUCTION OF POLYCLONAL ANTIBODIES AGAINST THE PURIFIED FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; HUMAN ANDROGEN RECEPTOR; DOWN-REGULATION; AFFINITY-CHROMATOGRAPHY; GEL-ELECTROPHORESIS; NUCLEAR-PROTEIN; MESSENGER-RNA; DNA; TRANSCRIPTION; SEQUENCE	The glucocorticoid receptor (GR) is an essential protein involved in mediating glucocorticoid-regulated gene transcription. The cellular GR concentration is modulated by a number of factors including glucocorticoids, which are capable of down-regulating their own receptor concentration. To further study this phenomenon, the human GR (hGR) gene promoter was isolated and was shown to contain the seqquences essential for glucocorticoid-dependent down-regulation in CV-1 cells by gene transfer. Further transfections performed with the hGR gene demonstrated that the nucleotide sequence between -250 and -750 is implicated in the down-regulation of the hGR by hormone. The promoter region of human GR is extremely rich in G + C sequences which are known to be involved in the regulation of many housekeeping genes such as GR, as well as a number of cellular oncogenes. Using a combination of partial purification of DNA-binding proteins, DNA-protein interaction by gel shift analysis and preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis, we have identified a protein factor (GRF-1) of 95 kDa which interacts with the human GR gene fragment implicated in homologous down-regulation. Polyclonal antibodies were then raised against the protein following purification. This method of purification and identification may be universally applied to purify and characterize unknown factors which may be involved in the regulation of genes such as hGR gene.	UNIV LAVAL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA	Laval University	LECLERC, S (corresponding author), CHU LAVAL,RES CTR,MRC,MOLEC ENDOCRINOL GRP,2705 LAURIER BLVD,QUEBEC CITY G1V 4G2,QUEBEC,CANADA.							ANSORGE W, 1982, P ELECTROPHORESIS, P235; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; COHEN RB, 1986, MOL CELL BIOL, V6, P821, DOI 10.1128/MCB.6.3.821; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABER PW, 1989, MOL CELL ENDOCRINOL, V61, P257, DOI 10.1016/0303-7207(89)90137-8; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOVINDAN MV, 1990, MOL ENDOCRINOL, V4, P417, DOI 10.1210/mend-4-3-417; GOVINDAN MV, 1980, EXP CELL RES, V127, P293, DOI 10.1016/0014-4827(80)90435-8; GOVINDAN MV, 1984, J BIOL CHEM, V259, P2915; GOVINDAN MV, 1985, NUCLEIC ACIDS RES, V13, P8293, DOI 10.1093/nar/13.23.8293; GOVINDAN MV, 1990, IN PRESS J STEROID B; GRONEMEYER H, 1985, J BIOL CHEM, V60, P6916; GVINDAN MV, 1982, P NATL ACAD SCI USA, V79, P5157; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HUCKABY CS, 1987, P NATL ACAD SCI USA, V84, P8380, DOI 10.1073/pnas.84.23.8380; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADANOGA JT, 1986, P NATL ACAD SCI USA, V83, P5889; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KALINYAK JE, 1987, J BIOL CHEM, V262, P10441; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OKRET S, 1986, P NATL ACAD SCI USA, V83, P5899, DOI 10.1073/pnas.83.16.5899; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; Sambrook J, 1989, MOL CLONING LABORATO; SAPOLSKY RM, 1984, ENDOCRINOLOGY, V114, P287, DOI 10.1210/endo-114-1-287; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZENKE M, 1986, EMBO J, V5, P378	47	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8711	8719						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026589				2022-12-25	WOS:A1991FM03800015
J	PELECH, SL; SAMIEI, M; CHAREST, DL; HOWARD, SL; SALARI, H				PELECH, SL; SAMIEI, M; CHAREST, DL; HOWARD, SL; SALARI, H			CHARACTERIZATION OF CALCIUM-INDEPENDENT FORMS OF PROTEIN KINASE-C-BETA IN PHORBOL ESTER-TREATED RABBIT PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL DOWN-REGULATION; REGENERATING RAT-LIVER; PROTEOLYTIC ACTIVATION; MEMBRANE-ASSOCIATION; THYMOMA CELLS; ISOZYMES; BINDING; TRANSLOCATION; DEGRADATION; BRAIN	The subcellular distribution, size, and activation state of protein kinase C (PKC) were studied after short term exposure of rabbit platelets to a saturating dose of 12-O-tetradecanoylphorbol 13-acetate (TPA). Cytosolic and Nonidet P-40-solubilized particulate extracts prepared from TPA-treated platelets were subjected to analytical column chromatography on Mono Q, hydroxylapatite, and Superose 6/12. PKC activity was assayed according to the ability of the enzyme to phosphorylate (i) histone H1 in the presence of the activators calcium, diacylglycerol, and phosphatidylserine; (ii) histone H1 after proteolytic activation of PKC with trypsin; and (iii) protamine in the absence of calcium and lipid. Within 1 min of TPA treatment of platelets, greater than 95% of the PKC activity was particulate associated, as assessed by all three methods. The particulate PKC activity from 1-min TPA-treated cells eluted from Mono Q with almost-equal-to 0.35 M NaCl (peak I), and it was highly dependent upon Ca2+ and lipid for optimal histone H1 phosphorylation. With longer exposure times of platelets to TPA, the disappearance of the Mono Q peak I form of PKC was correlated with the production of new PKC species that were released from Mono Q with almost-equal-to 0.4 M NaCl (peak II), almost-equal-to 0.5 M NaCl (peak III), and almost-equal-to 0.6 M NaCl (peak IV). These last forms of PKC were still lipid activated but exhibited little Ca2+ dependence. The Mono Q peak III form displayed a particularly high level of histone H1 phosphorylating activity in the absence of lipid and Ca2+. All of these forms behaved as almost-equal-to 65-kDa proteins on Superose 6/12, but on sodium dodecyl sulfate-polyacrylamide gels, Western blotting with anti-PKC-beta-antibodies revealed immunoreactive polypeptides of almost-equal-to 79 kDa (Mono Q peaks I, II, and IV) and almost-equal-to 100-kDa (Mono Q peak III). Hydroxylapatite column chromatography permitted partial resolution of the Mono Q peaks I and II forms, which were eluted within a concentration range of potassium phosphate (100-150 mM) which was typical of the beta-isozyme of PKC. Treatment of the Mono Q peak III and IV PKC forms with alkaline phosphatase resulted in the production of the peak I form, which implicated protein phosphorylation in the interconversion of the various PKC forms.	UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 123,BC,CANADA	University of British Columbia	PELECH, SL (corresponding author), UNIV BRITISH COLUMBIA,BIOMED RES CTR,2222 HLTH SCI MALL,VANCOUVER V6T 123,BC,CANADA.							ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; AVISSAR S, 1986, EXP CELL RES, V165, P353, DOI 10.1016/0014-4827(86)90589-6; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BAZZI MD, 1987, BIOCHEM BIOPH RES CO, V147, P248, DOI 10.1016/S0006-291X(87)80113-4; BEH I, 1989, FEBS LETT, V249, P264, DOI 10.1016/0014-5793(89)80637-4; BORNER C, 1989, J BIOL CHEM, V264, P13902; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHILBA K, 1986, J BIOL CHEM, V261, P13013; COCHET C, 1986, BIOCHEM BIOPH RES CO, V134, P1031; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; DEVRIES G, 1988, BIOCH CELL BIOL, V67, P260; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; FLOTOW H, 1990, J BIOL CHEM, V262, P14042; FOURNIER A, 1989, BIOCHEM BIOPH RES CO, V161, P556, DOI 10.1016/0006-291X(89)92635-1; FU T, 1989, BIOCHEM BIOPH RES CO, V162, P1279, DOI 10.1016/0006-291X(89)90812-7; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; GUY GR, 1986, BIOCHEM BIOPH RES CO, V135, P146, DOI 10.1016/0006-291X(86)90954-X; HAGIWARA M, 1990, ARCH BIOCHEM BIOPHYS, V280, P201, DOI 10.1016/0003-9861(90)90536-8; HASHIMOTO E, 1986, FEBS LETT, V200, P63, DOI 10.1016/0014-5793(86)80511-7; HOUWELING M, 1989, FEBS LETT, V247, P487, DOI 10.1016/0014-5793(89)81397-3; HUANG FL, 1988, ARCH BIOCHEM BIOPHYS, V267, P503, DOI 10.1016/0003-9861(88)90057-4; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; HUANG KP, 1986, J BIOL CHEM, V261, P4781; INOUE M, 1977, J BIOL CHEM, V252, P7610; ISHIZUKA T, 1990, BIOCHEM BIOPH RES CO, V169, P966, DOI 10.1016/0006-291X(90)91988-5; ITO M, 1988, BIOCHEM BIOPH RES CO, V153, P648, DOI 10.1016/S0006-291X(88)81144-6; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRUG E, 1987, J BIOL CHEM, V262, P11852; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG U, 1987, J BIOL CHEM, V262, P8047; LEACH KL, 1985, CANCER RES, V45, P1958; LEE MH, 1986, J BIOL CHEM, V261, P4867; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MCDONALD JR, 1987, BIOCHEM J, V242, P695, DOI 10.1042/bj2420695; MEGGIO F, 1988, FEBS LETT, V237, P225, DOI 10.1016/0014-5793(88)80206-0; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; MELLONI E, 1985, P NATL ACAD SCI USA, V82, P6435, DOI 10.1073/pnas.82.19.6435; MELLONI E, 1986, J BIOL CHEM, V261, P4101; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MIZUTA K, 1987, BIOCHEM BIOPH RES CO, V146, P239, DOI 10.1016/0006-291X(87)90716-9; MURRAY AW, 1987, TRENDS BIOCHEM SCI, V12, P53, DOI 10.1016/0968-0004(87)90026-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; PONTREMOLI S, 1986, BIOCHEM BIOPH RES CO, V136, P228, DOI 10.1016/0006-291X(86)90898-3; SAKANOUE Y, 1987, EUR J BIOCHEM, V168, P669, DOI 10.1111/j.1432-1033.1987.tb13468.x; SCHWANTKE N, 1984, FEBS LETT, V177, P36, DOI 10.1016/0014-5793(84)80976-X; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; TAPLEY PM, 1984, BIOCHEM BIOPH RES CO, V122, P158, DOI 10.1016/0006-291X(84)90453-4; TAPLEY PM, 1985, EUR J BIOCHEM, V151, P419, DOI 10.1111/j.1432-1033.1985.tb09118.x; TAPLEY PM, 1984, BIOCHEM BIOPH RES CO, V118, P835, DOI 10.1016/0006-291X(84)91470-0; TOPER R, 1986, BIOCHEM BIOPH RES CO, V141, P605, DOI 10.1016/S0006-291X(86)80216-9; TSUKUDA M, 1988, BIOCHEM BIOPH RES CO, V155, P1387, DOI 10.1016/S0006-291X(88)81295-6; VILA J, 1989, FEBS LETT, V255, P205, DOI 10.1016/0014-5793(89)81092-0; VIRGILIO FD, 1984, NATURE, V310, P691; VONRUECKER AA, 1988, BIOCHEM BIOPH RES CO, V151, P997, DOI 10.1016/S0006-291X(88)80464-9; WATANABE M, 1988, BIOCHEM BIOPH RES CO, V152, P642, DOI 10.1016/S0006-291X(88)80087-1; WHEELERJONES CPD, 1989, BIOCHEM J, V263, P969, DOI 10.1042/bj2630969; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	64	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8696	8705						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026587				2022-12-25	WOS:A1991FM03800013
J	PENNING, TM; ABRAMS, WR; PAWLOWSKI, JE				PENNING, TM; ABRAMS, WR; PAWLOWSKI, JE			AFFINITY LABELING OF 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE WITH 3-ALPHA-BROMOACETOXYANDROSTERONE AND 11-ALPHA-BROMOACETOXYPROGESTERONE - ISOLATION AND SEQUENCE OF ACTIVE-SITE PEPTIDES CONTAINING REACTIVE CYSTEINES - SEQUENCE CONFIRMATION USING NUCLEOTIDE-SEQUENCE FROM A CDNA CLONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOSOL; STEROID BINDING-SITES; PLACENTAL ESTRADIOL 17-BETA-DEHYDROGENASE; ANTI-INFLAMMATORY DRUG; AMINO-ACID SEQUENCE; HYDROXYSTEROID DEHYDROGENASE; INHIBITION; IDENTIFICATION; PURIFICATION; PROTEIN	Homogeneous 3-alpha-hydroxysteroid dehydrogenase (3-alpha-HSD, EC 1.1.1.50) of rat liver cytosol is potently inhibited at its active site by nonsteroidal anti-inflammatory drugs (NSAIDs). Using 3-alpha-bromoacetoxy-5-alpha-androstan-17-one (BrAnd, a substrate analog) and 11-alpha-bromoacetoxyprogesterone (Br11P, a glucocorticoid analog) as affinity-labeling agents, kinetic evidence was obtained that these agents alkylate this site. Inactivation of 3-alpha-HSD with either [C-14]BrAnd or [C-14] Br11P led to the incorporation of 1 mol of affinity-labeling agent per enzyme monomer. Complete acid hydrolysis of 3-alpha-HSD radiolabeled with either agent followed by amino acid analysis led to the identification of [C-14]carboxymethylcysteine indicating that [C-14]BrAnd and [C-14]Br11P covalently tag discrete reactive cysteine(s) at the enzyme active site. Trypsin digestion of [C-14]BrAnd-inactivated 3-alpha-HSD followed by peptide mapping led to the purification of a single radiolabeled peptide (3A1) which gave the following sequence: H2N-Ser-Ile-Gly-Val-Ser-Asn-Phe-Asn-X-Arg-CO2H. Identical experiments on [C-14]Br11P-inactivated 3-alpha-HSD led to the purification of three radiolabeled peptides (11P1-11P3). The major radiolabeled peptide (11P1) had an identical sequence to 3A1 which was tagged with [C-14]BrAnd. The minor radiolabeled peptides had the following sequences: H2N-Ser-Lys-Asp-Ile-Ile-Leu-Val-Ser-Tyr-X-Thr-Leu-Gly-Ser-Ser-Arg-CO2H (11P2) and H2N-Ser-Pro-Val-Leu-Leu-Asp-Asp-Pro-Val-Leu-X-Ala-Ile-Ala-Lys-CO2H (11P3). In each peptide group X was identified as carboxymethylcysteine. Alignment of the peptide sequences with the primary structure of 3-alpha-HSD, deduced from its cDNA clone, assigned peptide 11P1 to residues 162-171, peptide 11P2 to residues 208-223, and peptide 11P3 to residues 232-246 of the amino acid sequence. The reactive cysteines correspond to Cys170, Cys217, and Cys242. We propose that Cys170 labeled by BrAnd may lie within the catalytic pocket of the enzyme. By contrast the 11-alpha-bromoacetoxy group in Br11P labeled several reactive cysteines which may be involved in the binding of glucocorticoids and NSAIDs.	UNIV PENN,SCH DENT MED,DEPT ANAT & HISTOL,PHILADELPHIA,PA 19104	University of Pennsylvania	PENNING, TM (corresponding author), UNIV PENN,SCH MED,DEPT PHARMACOL,37TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.		Abrams, William R/A-5782-2008	Penning, Trevor/0000-0002-3937-1066	NCI NIH HHS [CA01335] Funding Source: Medline; NIGMS NIH HHS [GM33464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ARIAS F, 1973, J BIOL CHEM, V248, P5641; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CHIN CC, 1982, BIOCHEMISTRY-US, V21, P3322, DOI 10.1021/bi00257a012; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; GLAZER AN, 1987, LAB TECH BIOCH MOL B, P13; KAHN MS, 1990, J BIOL CHEM, V265, P8431; KITZ R, 1962, J BIOL CHEM, V237, P3245; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MURDOCK GL, 1983, J BIOL CHEM, V258, P1460; OLSEN KW, 1976, J MOL BIOL, V107, P577, DOI 10.1016/S0022-2836(76)80084-8; OLSEN KW, 1976, J MOL BIOL, V107, P571, DOI 10.1016/S0022-2836(76)80083-6; PAPPIN DJC, 1990, CURRENT RES PROTEIN, P191; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; PELTOKETO H, 1988, FEBS LETT, V239, P73, DOI 10.1016/0014-5793(88)80548-9; PENNING TM, 1985, J PHARM SCI, V74, P651, DOI 10.1002/jps.2600740614; PENNING TM, 1987, BIOCHEM BIOPH RES CO, V148, P646, DOI 10.1016/0006-291X(87)90925-9; PENNING TM, 1986, STEROIDS, V47, P221; PENNING TM, 1984, BIOCHEM J, V222, P601, DOI 10.1042/bj2220601; PENNING TM, 1987, BIOCHEM J, V245, P269, DOI 10.1042/bj2450269; PENNING TM, 1983, P NATL ACAD SCI-BIOL, V80, P4504, DOI 10.1073/pnas.80.14.4504; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SIEGEL IH, 1974, ENZYME KINETICS, P109; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; STRICKLER RC, 1975, J BIOL CHEM, V250, P7656; SWEET F, 1972, J BIOL CHEM, V247, P3424; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; THE VL, 1989, MOL ENDOCRINOL, V3, P1301, DOI 10.1210/mend-3-8-1301; VOGEL K, 1980, J BIOL CHEM, V255, P9621	29	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8826	8834						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026597				2022-12-25	WOS:A1991FM03800033
J	SKRIVER, K; WIKOFF, WR; PATSTON, PA; TAUSK, F; SCHAPIRA, M; KAPLAN, AP; BOCK, SC				SKRIVER, K; WIKOFF, WR; PATSTON, PA; TAUSK, F; SCHAPIRA, M; KAPLAN, AP; BOCK, SC			SUBSTRATE PROPERTIES OF C1BAR INHIBITOR MA (ALANINE 434-]GLUTAMIC ACID) - GENETIC AND STRUCTURAL EVIDENCE SUGGESTING THAT THE P12-REGION CONTAINS CRITICAL DETERMINANTS OF SERINE PROTEASE INHIBITOR INHIBITOR SUBSTRATE STATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY ANGIONEUROTIC-EDEMA; ANTITHROMBIN-III; C1 INHIBITOR; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; REACTIVE CENTER; ALPHA-1-PROTEINASE INHIBITOR; PROTEINASE-INHIBITORS; MONOCLONAL-ANTIBODY; PLASMA KALLIKREIN	The serine protease inhibitor (serpin) C1BAR inhibitor inactivates enzymes involved in the regulation of vascular permeability. A patient from the Ma family with the genetic disorder hereditary angioedema inherited a dysfunctional C1BAR inhibitor allele. Relative to normal plasma, the patient's plasma contained an additional C1BAR inhibitor immunoreactive band, which comigrated with normal C1BAR inhibitor cleaved by plasma kallikrein, C1BARs, or factor XIIa. C1BAR inhibitor Ma did not react with a monoclonal antibody to a neoepitope that is present in complexed and cleaved normal C1BAR inhibitor, suggesting conformational differences between cleaved normal C1BAR inhibitor and cleaved C1BAR inhibitor Ma. Molecular cloning and sequencing of exon 8 of the C1BAR inhibitor Ma allele revealed a single C to A mutation, changing alanine 434 to glutamic acid. Ala 434 of C1BAR inhibitor aligns with the P12 residue of the prototypical serpin alpha-1-antitrypsin. The P12 amino acid of all inhibitory serpins is alanine, and it is present in a highly conserved region on the amino-terminal side of the serpin-reactive center loop. Whereas normal C1BAR inhibitor expressed by transfected COS-1 cells formed complexes with and was cleaved by kallikrein, fXIIa, and C1BARs, COS-1-expressed Ala434 --> Glu C1BAR inhibitor was cleaved by these enzymes but did not form complexes with them. These results, together with evidence from other studies, suggest that serpin protease inhibitor activity is the result of a protein conformational change that occurs when the P12 region of a serpin moves from a surface location, on the reactive site loop of the native molecule, to an internal location within sheet A of the complexed inhibitor.	TEMPLE UNIV, HLTH SCI CTR,SCH MED,DEPT MICROBIOL IMMUNOL, 3400 N BROAD ST, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, THROMBOSIS RES CTR, PHILADELPHIA, PA 19140 USA; VANDERBILT UNIV, MED CTR, SCH MED, DIV HEMATOL, NASHVILLE, TN 37232 USA; SUNY STONY BROOK, DEPT MED, STONY BROOK, NY 11794 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Vanderbilt University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Skriver, Karen/K-9860-2014	Skriver, Karen/0000-0003-2225-4012	FOGARTY INTERNATIONAL CENTER [F05TW004025] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040875] Funding Source: NIH RePORTER; FIC NIH HHS [TW-04025] Funding Source: Medline; NHLBI NIH HHS [HL-40875] Funding Source: Medline; NIAID NIH HHS [AI-16377] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIACH M, 1988, THROMB HAEMOSTASIS, V60, P94; AIACH M, 1985, THROMB RES, V39, P559, DOI 10.1016/0049-3848(85)90236-1; ASAKURA S, 1990, J BIOL CHEM, V265, P5135; ASAKURA S, 1989, J BIOL CHEM, V264, P13736; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; BOCK SC, 1982, NUCLEIC ACIDS RES, V10, P8113, DOI 10.1093/nar/10.24.8113; BOCK SC, 1990, PROTEIN ENG, V4, P107, DOI 10.1093/protein/4.2.107; BOCK SC, 1991, RECOMBINANT TECHNOLOGY IN HEMOSTASIS AND THROMBOSIS, P25; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BURGER D, 1986, J BIOL CHEM, V261, P324; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CARRELL RW, 1989, MOL BIOL MED, V6, P35; CASO R, 1991, BRIT J HAEMATOL, V77, P87, DOI 10.1111/j.1365-2141.1991.tb07953.x; CUGNO M, 1990, J CLIN INVEST, V85, P1215, DOI 10.1172/JCI114555; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DEAGOSTINI A, 1988, J CLIN INVEST, V82, P700, DOI 10.1172/JCI113650; DEAGOSTINI A, 1984, J CLIN INVEST, V73, P1542, DOI 10.1172/JCI111360; DEAGOSTINI A, 1985, P NATL ACAD SCI USA, V82, P5190; DEVRAJKIZUK R, 1988, BLOOD, V72, P1518; ELDERING E, 1988, J BIOL CHEM, V263, P11776; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GETTINS P, 1989, J BIOL CHEM, V264, P3781; HARIS PI, 1990, BIOCHEMISTRY-US, V29, P1377, DOI 10.1021/bi00458a005; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LEVY NJ, 1990, P NATL ACAD SCI USA, V87, P265, DOI 10.1073/pnas.87.1.265; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MEDICUS RG, 1980, J IMMUNOL, V125, P390; MOLHOSABATIER P, 1989, J CLIN INVEST, V84, P1236, DOI 10.1172/JCI114290; PATSTON P, 1989, THROMB HAEMOSTASIS, V62, pA66; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; PERRY DJ, 1989, FEBS LETT, V254, P174, DOI 10.1016/0014-5793(89)81033-6; SAMAMA JP, 1989, J MOL BIOL, V210, P877, DOI 10.1016/0022-2836(89)90116-2; SKRIVER K, 1989, J BIOL CHEM, V264, P3066; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WRIGHT HT, 1990, J MOL BIOL, V213, P513	38	145	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9216	9221						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026621				2022-12-25	WOS:A1991FM03800084
J	KATAOKA, J; HABUKA, N; FURUNO, M; MIYANO, M; TAKANAMI, Y; KOIWAI, A				KATAOKA, J; HABUKA, N; FURUNO, M; MIYANO, M; TAKANAMI, Y; KOIWAI, A			DNA-SEQUENCE OF MIRABILIS ANTIVIRAL PROTEIN (MAP), A RIBOSOME-INACTIVATING PROTEIN WITH AN ANTIVIRAL PROPERTY, FROM MIRABILIS-JALAPA L AND ITS EXPRESSION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSIDASE ACTIVITY; MAJOR SOLUBLE-PROTEIN; POTATO TUBEROUS ROOTS; RICIN A-CHAIN; NUCLEOTIDE-SEQUENCE; SWEET-POTATO; EUKARYOTIC RIBOSOMES; PHYTOLACCA-AMERICANA; RIBONUCLEIC-ACID; RNA-POLYMERASE	We cloned a cDNA for Mirabilis antiviral protein (MAP), a ribosome-inactivating protein (RIP), which inhibits the mechanical transmission of plant virus and the in vitro protein synthesis of both prokaryotes and eukaryotes. The cDNA consisted of 1066 nucleotides and could encode 278 amino acids. The major part of the amino acid sequence (from Ala29 to Ser278) was identical with the sequence of native MAP as determined by protein sequencing. An NH2-terminal extra-peptide (28 amino acid residues) of MAP was comparable with the signal peptides of plant proteins accumulating in the vacuole. A stable hairpin structure was predicted in the 3'-noncoding region of the cDNA. Tandem repeated sequences were found downstream from the hairpin structure. They were composed of triple complete repeats of a heptanucleotide with preceding and following hexa-nucleotide repeats. The cDNA was expressed in Escherichia coli based on the T7 expression system. The product encoded by the cDNA was confirmed to be MAP precursor by Western blotting followed by immunological analysis. The growth of the transformants was inhibited by the expression of the gene. MAP precursor also seemed to inhibit the protein synthesis of E. coli just as native MAP has been observed to do.			KATAOKA, J (corresponding author), JAPAN TOBACCO INC,LIFE SCI RES LAB,6-2 UMEGAOKA,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN.		Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175				ALBERTS B, 1989, MOL BIOL CELL, P433; BARBIERI L, 1982, CANCER SURV, V1, P489; BENATTI L, 1989, EUR J BIOCHEM, V183, P465, DOI 10.1111/j.1432-1033.1989.tb14951.x; CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; CHAN YL, 1983, J BIOL CHEM, V258, P2768; CHOW TP, 1990, J BIOL CHEM, V265, P8670; COLEMAN WH, 1981, BIOCHIM BIOPHYS ACTA, V654, P57, DOI 10.1016/0005-2787(81)90136-2; ENDO Y, 1988, J BIOL CHEM, V263, P8735; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Endo Y, 1988, IMMUNOTOXINS, P75; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRAHAM JS, 1985, J BIOL CHEM, V260, P6555; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HABUKA N, 1990, J BIOL CHEM, V265, P10988; HABUKA N, 1989, J BIOL CHEM, V264, P6629; HARLEY SM, 1982, P NATL ACAD SCI-BIOL, V79, P5935, DOI 10.1073/pnas.79.19.5935; HATTORI T, 1983, BIOCHEM BIOPH RES CO, V113, P235, DOI 10.1016/0006-291X(83)90456-4; HATTORI T, 1985, PLANT MOL BIOL, V5, P313, DOI 10.1007/BF00020629; HATTORI T, 1987, EUR J BIOCHEM, V166, P533, DOI 10.1111/j.1432-1033.1987.tb13546.x; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IKEDA T, 1987, PLANT CELL REP, V6, P216, DOI 10.1007/BF00268483; IRVIN JD, 1975, ARCH BIOCHEM BIOPHYS, V169, P522, DOI 10.1016/0003-9861(75)90195-2; JANSEN FK, 1988, IMMUNOTOXINS, P97; KUBO S, 1990, Annals of the Phytopathological Society of Japan, V56, P481, DOI 10.3186/jjphytopath.56.481; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LEWIN BM, 1985, GENES, P206; MURAKAMI S, 1986, PLANT MOL BIOL, V7, P343, DOI 10.1007/BF00032564; NAKAMURA K, 1986, FEBS LETT, V198, P16, DOI 10.1016/0014-5793(86)81175-9; NEWBURY SF, 1987, CELL, V48, P297, DOI 10.1016/0092-8674(87)90433-8; Olsnes S., 1982, MOL ACTION TOXINS VI, P51; OWENS RA, 1973, VIROLOGY, V56, P390, DOI 10.1016/0042-6822(73)90319-X; RAGETLI HWJ, 1962, VIROLOGY, V18, P241, DOI 10.1016/0042-6822(62)90010-7; ROBERTS WK, 1979, BIOCHEMISTRY-US, V18, P2615, DOI 10.1021/bi00579a028; ROSE GD, 1980, P NATL ACAD SCI-BIOL, V77, P4643, DOI 10.1073/pnas.77.8.4643; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMOOKLER MM, 1971, ANN APPL BIOL, V69, P157, DOI 10.1111/j.1744-7348.1971.tb04668.x; SPENA A, 1985, EMBO J, V4, P2153, DOI 10.1002/j.1460-2075.1985.tb03909.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKANAMI Y, 1990, Annals of the Phytopathological Society of Japan, V56, P488, DOI 10.3186/jjphytopath.56.488; VERMA HN, 1979, CAN J BOT, V57, P1214, DOI 10.1139/b79-146; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; WOLF SF, 1987, NUCLEIC ACIDS RES, V15, P2911, DOI 10.1093/nar/15.7.2911; WYATT SD, 1969, PHYTOPATHOLOGY, V59, P1787; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	48	54	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8426	8430						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022657				2022-12-25	WOS:A1991FK44100071
J	RAO, GN; CORSON, MA; BERK, BC				RAO, GN; CORSON, MA; BERK, BC			URIC-ACID STIMULATES VASCULAR SMOOTH-MUSCLE CELL-PROLIFERATION BY INCREASING PLATELET-DERIVED GROWTH-FACTOR A-CHAIN EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLASTS; SEQUENCE; RECEPTOR; DISEASE; PDGF	Recent data suggest that uric acid is generated locally in the vessel wall by the action of xanthine oxidase. This enzyme, activated during ischemia/reperfusion by proteolytic conversion of xanthine dehydrogenase, catalyzes the oxidation of xanthine, thereby generating free radicals and uric acid. Because of the potential role of ischemia/reperfusion in vascular disease, we studied the effects of uric acid on rat aortic vascular smooth muscle cell (VSMC) growth. Uric acid stimulated VSMC DNA synthesis, as measured by [H-3]thymidine incorporation, in a concentration-dependent manner with half-maximal activity at 150-mu-M. Maximal induction of DNA synthesis by uric acid (250-mu-M) was approximately 70% of 10% calf serum and equal to 10 ng/ml platelet-derived growth factor (PDGF) AB or 20 ng/ml fibroblast growth factor. Neither uric acid precursors (xanthine and hypoxanthine) nor antioxidants (ascorbic acid, glutathione, and alpha-tocopherol) were mitogenic for VSMC. Uric acid was mitogenic for VSMC but not for fibroblasts or renal epithelial cells. The time course for uric acid stimulation of VSMC growth was slower than serum, suggesting induction of an autocrine growth mechanism. Exposure of quiescent VSMC to uric acid stimulated accumulation of PDGF A-chain mRNA (>5-fold at 8 h) and secretion of PDGF-like material in conditioned medium (> 10-fold at 24 h). Uric acid-induced [H-3]thymidine incorporation was markedly inhibited by incubation with anti-PDGF A-chain polyclonal antibodies. Thus uric acid stimulates VSMC growth via an autocrine mechanism involving PDGF A-chain. These findings suggest that generation of uric acid during ischemia/reperfusion contributes to atherogenesis and intimal proliferation following arterial injury.			RAO, GN (corresponding author), EMORY UNIV, SCH MED, DEPT MED, DIV CARDIOL, ATLANTA, GA 30322 USA.			Berk, Bradford/0000-0002-2767-4115				AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK MG, 1990, BIOCHEM J, V266, P765, DOI 10.1042/bj2660765; DZAU VJ, 1987, AM J CARDIOL, V60, pI99; FESSEL WJ, 1980, AM J MED, V68, P401, DOI 10.1016/0002-9343(80)90111-4; FRIEDL HP, 1989, FASEB J, V3, P2512, DOI 10.1096/fasebj.3.13.2806779; HALL ARTHUR P., 1965, ARTHRITIS RHEUM, V8, P846, DOI 10.1002/art.1780080449; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; IDSTROM JP, 1990, AM J PHYSIOL, V258, pH1668, DOI 10.1152/ajpheart.1990.258.6.H1668; LASSEN UV, 1961, BIOCHIM BIOPHYS ACTA, V53, P557, DOI 10.1016/0006-3002(61)90215-3; MOHRMAN DE, 1990, AM J PHYSIOL, V259, pH772, DOI 10.1152/ajpheart.1990.259.3.H772; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; PEDEN DB, 1990, P NATL ACAD SCI USA, V87, P7638, DOI 10.1073/pnas.87.19.7638; PERSKY VW, 1979, CIRCULATION, V59, P969, DOI 10.1161/01.CIR.59.5.969; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAO GN, 1988, DNA-J MOLEC CELL BIO, V7, P423, DOI 10.1089/dna.1.1988.7.423; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P5007, DOI 10.1093/nar/13.14.5007; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH815, DOI 10.1152/ajpheart.1986.250.5.H815; SMITH JK, 1989, AM J PHYSIOL, V257, pH1782, DOI 10.1152/ajpheart.1989.257.6.H1782; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201	25	327	344	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8604	8608						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022672				2022-12-25	WOS:A1991FK44100096
J	TAYLOR, MG; MASSEY, V				TAYLOR, MG; MASSEY, V			KINETIC AND ISOTOPIC STUDIES OF THE OXIDATIVE HALF-REACTION OF PHENOL HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; UNACTIVATED ARYL HALIDES; FLAVIN; OXYGEN; MECHANISMS; FLAVOPROTEINS; DERIVATIVES; SUBSTRATE; COMPLEX; ENZYME	Phenol hydroxylase, an FAD-containing monooxygenase, catalyzes the conversion of substituted phenols to the corresponding catechol. Use of metapyrocatechase, capable of dioxygenation of several catechols to give highly absorbing products, permitted determination of the time course of product release from phenol hydroxylase. Product dissociated prior to complete reoxidation of the enzyme, most likely concomitant with formation of the 4a-hydroxyflavin species (intermediate III). Deuterated phenol and thiophenol exhibited no kinetic isotope effect during the oxidative half-reaction. Isotope effects of 1.7 to 3.7 were found with resorcinol for the conversion of the second intermediate to intermediate III. These effects limited the possible models for phenol hydroxylation. An attempt was made to distinguish whether the spectrum of intermediate II is due entirely to that of the flavin moiety of phenol hydroxylase or whether some radical intermediate form involved in the formation of catechol makes a significant visible contribution. Reduced native and 6-hydroxy-FAD phenol hydroxylase were reacted with oxygen and resorcinol in order to provide evidence for the identity of intermediate II.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM-11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RF, 1987, J BIOL CHEM, V262, P17475; ANDERSON RF, 1990, J BIOL CHEM, V265, P1952; Ballou D. P., 1982, FLAVINS FLAVOPROTEIN, P301; BEATY NB, 1981, J BIOL CHEM, V256, P4611; BRUICE TC, 1983, J CHEM SOC CHEM COMM, P14, DOI 10.1039/c39830000014; BRUICE TC, 1980, ACCOUNTS CHEM RES, V13, P256, DOI 10.1021/ar50152a002; COGOLLI P, 1979, J ORG CHEM, V44, P2642, DOI 10.1021/jo01329a011; DETMER K, 1984, Journal of Biological Chemistry, V259, P1532; DETMER K, 1985, J BIOL CHEM, V260, P5998; DETMER K, 1982, FALVINS FLAVOPROTEIN, P334; DETMER KM, 1984, THESIS U MICHIGAN; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENTSCH B, 1976, J BIOL CHEM, V251, P7367; ENTSCH B, 1987, J BIOL CHEM, V262, P6060; ENTSCH B, 1974, BIOCHEM BIOPH RES CO, V57, P1018, DOI 10.1016/0006-291X(74)90798-0; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; GHISLA S, 1977, EUR J BIOCHEM, V76, P139, DOI 10.1111/j.1432-1033.1977.tb11579.x; JONES KC, 1986, J BIOL CHEM, V261, P2553; KOJIMA Y, 1961, J BIOL CHEM, V236, P2223; MANSTEIN DJ, 1986, J BIOL CHEM, V261, P6169; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1986, BIOCHEMISTRY-US, V25, P8103, DOI 10.1021/bi00372a046; MAYER EJ, 1981, ANAL BIOCHEM, V116, P227, DOI 10.1016/0003-2697(81)90348-1; MURRAY K, 1972, EUR J BIOCHEM, V28, P301, DOI 10.1111/j.1432-1033.1972.tb01914.x; NEUJAHR HY, 1973, EUR J BIOCHEM, V35, P386, DOI 10.1111/j.1432-1033.1973.tb02851.x; NOZAKI M, 1963, BIOCHEM Z, V338, P582; POULSEN LL, 1974, BIOCHEM PHARMACOL, V23, P3431, DOI 10.1016/0006-2952(74)90346-3; POWLOWSKI J, 1990, J BIOL CHEM, V265, P4969; SCHOPFER LM, 1980, J BIOL CHEM, V255, P5355; SPECTOR T, 1972, J BIOL CHEM, V247, P7123; TAYLOR MG, 1990, J BIOL CHEM, V265, P13687; TAYLOR MG, 1991, J BIOL CHEM, V266, P8281; TESTAFERRI L, 1980, TETRAHEDRON LETT, V21, P3099, DOI 10.1016/S0040-4039(00)77418-1; VERVOORT J, 1986, BIOCHEMISTRY-US, V25, P8062, DOI 10.1021/bi00372a040; WESSIAK A, 1984, J BIOL CHEM, V259, P2547; WESSIAK A, 1983, J AM CHEM SOC, V105, P4809, DOI 10.1021/ja00352a045; ZIEGLER DM, 1971, FLAVINS FLAVOPROTEIN, P507	37	7	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8291	8301						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022646				2022-12-25	WOS:A1991FK44100054
J	VANCE, JE; AASMAN, EJ; SZARKA, R				VANCE, JE; AASMAN, EJ; SZARKA, R			BREFELDIN-A DOES NOT INHIBIT THE MOVEMENT OF PHOSPHATIDYLETHANOLAMINE FROM ITS SITES OF SYNTHESIS TO THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; LIPOPROTEIN SECRETION; GOLGI PROTEINS; PHOSPHOLIPIDS; LIVER; PHOSPHATIDYLSERINE; BIOSYNTHESIS	Brefeldin A, a fungal metabolite which interrupts trafficking of proteins via the Golgi by causing disassembly of the Golgi stacks, has been used to investigate the mechanism of movement of phosphatidylethanolamine (PtdEtn) from its sites of synthesis to the cell surface. PtdEtn is made in hepatocytes by two major pathways, (a) from CDP-ethanolamine on the endoplasmic reticulum and (b) by decarboxylation of phosphatidylserine in mitochondria. Monolayer cultures of rat hepatocytes were incubated with radiolabeled precursors of PtdEtn ([H-3]ethanolamine or [H-3]serine) in the presence or absence of brefeldin A. The movement of newly made PtdEtn to the plasma membrane was studied by treatment of intact cells with trinitrobenzene sulfonate which reacted only with PtdEtn on the outside surface of the cells to produce N-trinitrophenyl-PtdEtn; PtdEtn in intracellular membranes remained underivatized by this reagent. Using this method, the incorporation of radioactivity into cell surface and intracellular PtdEtn could be differentiated. The studies showed that PtdEtn made by the two different biosynthetic routes was rapidly transported to the outside leaflet of the plasma membrane. However, the kinetics and the extent of labeling of the cell surface PtdEtn, relative to that of the intracellular PtdEtn pool, were different from each labeled precursor. The incorporation of [H-3]ethanolamine into PtdEtn on the cell surface gradually increased to a constant level of 1.8% of the label of intracellular PtdEtn after 3 h. In contrast, after 0.5-1 h, cell surface PtdEtn labeled from [H-3]serine comprised 4% of the intracellular PtdEtn pool; the extent of labeling gradually declined to a constant level of approximately 2.4% by 3 h. Brefeldin A did not interrupt the movement of PtdEtn, derived from either biosynthetic origin, to the cell surface even though protein secretion was greatly reduced. Thus, apparently PtdEtn and proteins are independently transported to the cell surface of hepatocytes.	UNIV ALBERTA,DEPT MED,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta	VANCE, JE (corresponding author), UNIV ALBERTA,LIPID & LIPOPROT GRP,EDMONTON T6G 2S2,ALBERTA,CANADA.							BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; BJERVE KS, 1973, BIOCHIM BIOPHYS ACTA, V296, P549, DOI 10.1016/0005-2760(73)90115-X; BJERVE KS, 1985, BIOCHIM BIOPHYS ACTA, V833, P396, DOI 10.1016/0005-2760(85)90096-7; BRETSCHER MS, 1976, NATURE, V260, P21, DOI 10.1038/260021a0; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DENNIS EA, 1972, J LIPID RES, V13, P263; DESILVA NS, 1981, J BIOL CHEM, V256, P5845; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; JONES AL, 1966, J HISTOCHEM CYTOCHEM, V14, P215, DOI 10.1177/14.3.215; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN K S, 1983, Cell, V34, P233; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; SALERNO DM, 1973, BIOCHIM BIOPHYS ACTA, V326, P325, DOI 10.1016/0005-2760(73)90134-3; SCOW RO, 1985, PROG LIPID RES, V24, P197, DOI 10.1016/0163-7827(85)90002-5; SLEIGHT RG, 1983, J BIOL CHEM, V258, P9050; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; URBANI L, 1990, J BIOL CHEM, V265, P1919; VALTERSSON C, 1982, J LIPID RES, V23, P868; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANCE JE, 1989, BIOCHIM BIOPHYS ACTA, V1006, P59, DOI 10.1016/0005-2760(89)90323-8; VANCE JE, 1986, J BIOL CHEM, V261, P4486; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANCE JE, 1988, BIOCHIM BIOPHYS ACTA, V263, P5898; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WEIGEL PH, 1981, J BIOL CHEM, V256, P2615; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	42	110	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8241	8247						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022641				2022-12-25	WOS:A1991FK44100047
J	SHIRABE, K; YUBISUI, T; NISHINO, T; TAKESHITA, M				SHIRABE, K; YUBISUI, T; NISHINO, T; TAKESHITA, M			ROLE OF CYSTEINE RESIDUES IN HUMAN NADH-CYTOCHROME-B5 REDUCTASE STUDIED BY SITE-DIRECTED MUTAGENESIS - CYS-273 AND CYS-283 ARE LOCATED CLOSE TO THE NADH-BINDING SITE BUT ARE NOT CATALYTICALLY ESSENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RAT-LIVER MICROSOMES; HUMAN-ERYTHROCYTES; CYTOCHROME B5; NITRATE REDUCTASE; IDENTIFICATION; PARTICIPATION; DEHYDROGENASE; PROTEINS; DOMAINS	Human NADH-cytochrome b5 reductase (EC 1.6.2.2) contains 4 cyteine residues (Cys-203, -273, -283, and -297). Cys-283 was previously proposed to be involved in NADH binding by chemical modification (Hackett, C. S., Novoa, W. B., Ozols, J., and Strittmatter, P. (1986) J. Biol. Chem. 261, 9854-9857). In the present study the role of cysteines in the enzyme was probed by replacing these residues by Ser, Ala, or Gly employing site-directed mutagenesis and chemical modification. Four mutants, in which 1 of the 4 Cys residues was replaced by Ser, retained comparable k(cat) and K(m) values to those of the wild type. All of these mutants were as sensitive as the wild type to treatment with SH modifiers, while a double mutant, C273S/C283S was resistant. Since inhibition by SH modifiers was protected by NADH, Cys-273 and Cys-283 were implicated to be close to the NADH-binding site. C273A and C273A/C283A mutants showed approximately one-fifth of the enzyme-FAD reduction rate of the wild type as revealed by steady-state kinetics and by stopped-flow analysis. Anaerobic titration has shown that reduction and re-oxidation processes including formation of the red semiquinone of these mutants were not significantly altered from those of the wild type. From these results it was concluded that none of the Cys residues of the enzyme are essential in the catalytic reaction, but Cys-273 conserved among the enzymes homologous to NADH-cytochrome b5 reductase plays role(s) in facilitating the reaction. A difference spectrum with a peak at 317 nm, which was formerly considered to be derived from the interaction between NAD+ and Cys-283 of the reduced enzyme, appeared upon binding of NAD+ not only to the reduced wild type enzyme but also to the C273A/C283A mutant in which both of the Cys residues close to the NADH-binding site were replaced.	MED COLL OITA, DEPT BIOCHEM, HAZAMA CHO, OITA 87956, JAPAN; YOKOHAMA CITY UNIV, SCH MED, DEPT BIOCHEM, YOKOHAMA 236, JAPAN	Oita University; Yokohama City University								BARBER MJ, 1986, J BIOL CHEM, V261, P4562; BOYER PD, 1954, J AM CHEM SOC, V76, P4331, DOI 10.1021/ja01646a025; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DEV IK, 1988, P NATL ACAD SCI USA, V85, P1472, DOI 10.1073/pnas.85.5.1472; HACKETT CS, 1986, J BIOL CHEM, V261, P9854; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HULTQUIST DE, 1971, NATURE-NEW BIOL, V229, P252, DOI 10.1038/newbio229252a0; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; IYANAGI T, 1984, BIOCHEMISTRY-US, V23, P1418, DOI 10.1021/bi00302a013; IYANAGI T, 1977, BIOCHEMISTRY-US, V16, P2725, DOI 10.1021/bi00631a021; KEYES SR, 1980, J BIOL CHEM, V255, P1357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOUGIN A, 1988, PROTEIN ENG, V2, P45, DOI 10.1093/protein/2.1.45; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OZOLS J, 1985, J BIOL CHEM, V260, P1953; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRABE K, 1989, BIOCHIM BIOPHYS ACTA, V1008, P189, DOI 10.1016/0167-4781(80)90007-X; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; STRITTMATTER P, 1959, J BIOL CHEM, V234, P2661; STRITTMATTER P, 1958, J BIOL CHEM, V233, P748; STRITTMATTER P, 1959, J BIOL CHEM, V234, P2665; STRITTMATTER P, 1965, J BIOL CHEM, V240, P4481; STRITTMATTER P, 1957, J BIOL CHEM, V228, P785; TAKANO T, 1987, J MOL BIOL, V195, P749, DOI 10.1016/0022-2836(87)90195-1; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; Williams C H Jr, 1979, Methods Enzymol, V62, P185; YUBISUI T, 1984, J BIOCHEM-TOKYO, V96, P579, DOI 10.1093/oxfordjournals.jbchem.a134871; YUBISUI T, 1980, J BIOL CHEM, V255, P2454; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1986, J BIOCHEM-TOKYO, V99, P407, DOI 10.1093/oxfordjournals.jbchem.a135495; YUBISUI T, 1991, J BIOL CHEM, V266, P66; YUBISUI T, 1989, RED CELL, P107	37	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7531	7536						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019583				2022-12-25	WOS:A1991FJ34200035
J	BURDON, T; SANKARAN, L; WALL, RJ; SPENCER, M; HENNIGHAUSEN, L				BURDON, T; SANKARAN, L; WALL, RJ; SPENCER, M; HENNIGHAUSEN, L			EXPRESSION OF A WHEY ACIDIC PROTEIN TRANSGENE DURING MAMMARY DEVELOPMENT - EVIDENCE FOR DIFFERENT MECHANISMS OF REGULATION DURING PREGNANCY AND LACTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; BETA-CASEIN GENE; HORMONAL-REGULATION; MICE; PROMOTER; MILK; RAT; DIRECTS; GLAND; MOUSE	Expression of the mouse whey acidic protein (WAP) gene is specific to the mammary gland, is induced several thousand-fold during pregnancy, and is under the control of steroid and peptide hormones. To study developmental regulation of the mouse WAP gene, a 7.2-kilobase (kb) WAP transgene, including 2.6 kb of 5'- and 1.6 kb of 3'-flanking sequences, was introduced into mice. Of the 13 lines of mice examined, 6 expressed the transgenes during lactation at levels between 3 and 54% of the endogenous gene. Although expression was dependent on the site of integration, the transgenes within a given locus were expressed in a copy number-dependent manner and were coordinately regulated. The WAP transgenes were expressed specifically in the mammary gland, but showed a deregulated pattern of expression during mammary development. In all six lines of mice, induction of the WAP transgenes during pregnancy preceded that of the endogenous gene. During lactation, expression in two lines increased coordinately with the endogenous gene, and in three other lines of mice, transgene expression decreased to a basal level. These data indicate that the 7.2-kb gene contains some but not all of the elements necessary for correct developmental regulation. At a functional level it appears as if a repressor element, which inactivates the endogenous gene until late pregnancy, and an element necessary for induction during lactation are absent from the transgene. Complementary results from developmental and hormone induction studies suggest that WAP gene expression during pregnancy and lactation is mediated by different mechanisms.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892; NIDDKD,DIABET BRANCH,BETHESDA,MD 20892; USDA ARS,BELTSVILLE AGR RES CTR,BELTSVILLE,MD 20705	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Agriculture (USDA)				Hennighausen, Lothar/0000-0001-8319-9841				ALSHAWI R, 1990, MOL CELL BIOL, V10, P1192, DOI 10.1128/MCB.10.3.1192; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; CHEN L, 1990, CELL REG, V1, P45; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVINOY E, 1988, REPROD NUTR DEV, V28, P1145, DOI 10.1051/rnd:19880711; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; EISENSTEIN RS, 1988, MOL CELL BIOL, V8, P3183, DOI 10.1128/MCB.8.8.3183; GUNZBURG WH, 1991, IN PRESS MOL ENDOCRI; HAMMER RE, 1987, MOL CELL BIOL, V7, P2956, DOI 10.1128/MCB.7.8.2956; HENNIGHAUSEN L, 1990, TRANSGENIC ANIMALS, P65; HENNIGHAUSEN LG, 1982, EUR J BIOCHEM, V125, P131, DOI 10.1111/j.1432-1033.1982.tb06660.x; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; IDZERDA RL, 1989, MOL CELL BIOL, V9, P5154, DOI 10.1128/MCB.9.11.5154; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; LEE KF, 1989, MOL ENDOCRINOL, V3, P447, DOI 10.1210/mend-3-3-447; LEE KF, 1988, NUCLEIC ACIDS RES, V16, P1027, DOI 10.1093/nar/16.3.1027; Maniatis T., 1982, MOL CLONING; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; SCHOENENBERGER CA, 1990, DEV BIOL, V139, P327, DOI 10.1016/0012-1606(90)90302-Y; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SIMONS JP, 1987, NATURE, V328, P530, DOI 10.1038/328530a0; SINGER PA, 1986, J BIOL CHEM, V261, P538; THORADSON G, 1984, MAMMARY GLAND DEV RE, P459; TOMASETTO C, 1989, MOL ENDOCRINOL, V3, P1579, DOI 10.1210/mend-3-10-1579; VILOTTE JL, 1989, EUR J BIOCHEM, V186, P43, DOI 10.1111/j.1432-1033.1989.tb15175.x	29	128	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6909	6914						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016304				2022-12-25	WOS:A1991FG72700044
J	DEHERREROS, AG; DOMINGUEZ, I; DIAZMECO, MT; GRAZIANI, G; CORNET, ME; GUDDAL, PH; JOHANSEN, T; MOSCAT, J				DEHERREROS, AG; DOMINGUEZ, I; DIAZMECO, MT; GRAZIANI, G; CORNET, ME; GUDDAL, PH; JOHANSEN, T; MOSCAT, J			REQUIREMENT OF PHOSPHOLIPASE C-CATALYZED HYDROLYSIS OF PHOSPHATIDYLCHOLINE FOR MATURATION OF XENOPUS-LAEVIS OOCYTES IN RESPONSE TO INSULIN AND RAS P21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS; DIACYLGLYCEROL; STIMULATION; PROTEINS; TRANSFORMATION; MICROINJECTION; DIGLYCERIDE; ACTIVATION; RELEASE; CELLS	Recent studies have demonstrated the activation of phospholipase C-mediated hydrolysis of phosphatidylcholine both by growth factors and by the product of ras oncogene, ras p21. Also, evidence has been presented indicating that the stimulation of this phospholipid-degradative pathway is sufficient to activate mitogenesis in fibroblasts. In Xenopus laevis oocytes, microinjection of transforming ras p21 is a potent inducer of maturation, whereas microinjection of a neutralizing anti-ras p21 antibody specifically inhibits maturation induced by insulin but not by progesterone. The results presented here demonstrate that microinjection of phosphatidylcholine-hydrolyzing phospholipase C is sufficient to induce maturation of Xenopus laevis oocytes. Furthermore, microinjection of a neutralizing anti-phosphatidylcholine-hydrolyzing phospholipase C specifically blocks the maturation program induced by ras p21/insulin but not by progesterone.	HOSP GEN GREGORIO MARANON,DR ESQUERDO 46,E-28007 MADRID,SPAIN; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV TROMSO,INST MED BIOL,N-9001 TROMSO,NORWAY	General University Gregorio Maranon Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); UiT The Arctic University of Tromso			Graziani, Grazia/G-5747-2012; Johansen, Terje/AAY-1753-2021; Moscat, Jorge/A-7011-2009; de Herreros, A Garcia/H-3104-2014; Johansen, Terje/N-2971-2015	Graziani, Grazia/0000-0002-0221-768X; Johansen, Terje/0000-0003-1451-9578; de Herreros, A Garcia/0000-0001-5270-0808; Johansen, Terje/0000-0003-1451-9578; Diaz-Meco, Maria/0000-0003-0147-0998; /0000-0001-9617-4141				BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CLARK MA, 1986, BIOCHEM BIOPH RES CO, V140, P114, DOI 10.1016/0006-291X(86)91065-X; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DIAZMECO MT, 1989, BIOCHEM J, V263, P115, DOI 10.1042/bj2630115; EXTON JH, 1990, J BIOL CHEM, V265, P1; GLASS DB, 1978, ANAL BIOCHEM, V87, P5704; HERRERO C, 1988, BIOCHEM J, V255, P807, DOI 10.1042/bj2550807; JOHANSEN T, 1988, GENE, V65, P293, DOI 10.1016/0378-1119(88)90466-0; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1987, NATURE, V330, P267; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LITTLE C, 1988, BIOCHEM SOC T, V17, P271; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MOSCAT J, 1987, BIOCHEM J, V242, P441, DOI 10.1042/bj2420441; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MYRNES BJ, 1980, ACTA CHEM SCAND B, V32, P375; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QUIAN Z, 1989, J BIOL CHEM, V264, P21720; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; WASSERMAN WJ, 1984, DEV BIOL, V105, P315, DOI 10.1016/0012-1606(84)90288-4	32	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6825	6829						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016297				2022-12-25	WOS:A1991FG72700030
J	FOYT, HL; LEROITH, D; ROBERTS, CT				FOYT, HL; LEROITH, D; ROBERTS, CT			DIFFERENTIAL ASSOCIATION OF INSULIN-LIKE GROWTH FACTOR-I MESSENGER-RNA VARIANTS WITH POLYSOMES INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; RIBONUCLEIC-ACIDS; 5'-UNTRANSLATED REGIONS; MOLECULAR-CLONING; SCANNING MODEL; PROTO-ONCOGENE; RAT-LIVER; SEQUENCE; GENE; EXPRESSION	Expression of the rat insulin-like growth factor I (IGF-I) gene results in a number of mature mRNA species that differ in size primarily at the 3' end due to differential polyadenylation site usage. Additionally, alternate splicing in both 5' and 3' regions produces RNAs which have the capacity to encode different IGF-I precursor peptides. We have analyzed total and polysomal RNAs using Northern blot analyses and solution hybridization/RNase protection assays to assess the in vivo translatability of these various IGF-I mRNA species. The results suggest that all of the known splicing variants are found on polysomes and may, therefore, be translated into a number of IGF-I precursors in vivo. One particular 5'-untranslated (UTR) variant is relatively enriched in polysomal RNA, a finding which suggests that removal of some of the 5'-UTR sequences encoded by exon 1 may enhance translatability. Of the IGF-I mRNAs with different lengths of 3'-UTR, only the shorter species were found on polysomes, suggesting that some aspect of the long 3'-UTR may prevent translation. Thus, differential processing of the primary transcript of the IGF-I gene may serve to generate IGF-I mRNA species which specify different precursors as well as to control their relative translatability.	NIDDKD,DIABET BRANCH,MOLEC & CELLULAR PHYSIOL SECT,BLDG 10,RM 8S-243,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				ADAMO M, 1989, ENDOCRINOLOGY, V124, P2737, DOI 10.1210/endo-124-6-2737; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P7873, DOI 10.1093/nar/14.20.7873; BERGER SL, 1987, METHOD ENZYMOL, V152, P227; BINDER R, 1989, J BIOL CHEM, V264, P16910; BUCCI C, 1989, NUCLEIC ACIDS RES, V17, P3596, DOI 10.1093/nar/17.9.3596; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CLEMMONS DR, 1986, J BIOL CHEM, V261, P293; CONOVER CA, 1989, J CLIN ENDOCR METAB, V69, P25, DOI 10.1210/jcem-69-1-25; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; FAWCETT DH, 1990, J MOL ENDOCRINOL, V4, P201, DOI 10.1677/jme.0.0040201; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; GOLDSTEIN BJ, 1989, BIOCHEM BIOPH RES CO, V159, P664, DOI 10.1016/0006-291X(89)90046-6; HEPLER JE, 1990, ENDOCRINOLOGY, V127, P1550, DOI 10.1210/endo-127-3-1550; HOYT EC, 1988, MOL ENDOCRINOL, V2, P1077, DOI 10.1210/mend-2-11-1077; KOZAK M, 1980, CELL, V22, P7, DOI 10.1016/0092-8674(80)90148-8; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS JP, 1982, P NATL ACAD SCI-BIOL, V79, P4015, DOI 10.1073/pnas.79.13.4015; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAJARA R, 1989, AM J PHYSIOL, V257, P252; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; LOWE WL, 1988, MOL ENDOCRINOL, V2, P528, DOI 10.1210/mend-2-6-528; LUND PK, 1986, J BIOL CHEM, V261, P4539; LUND PK, 1989, MOL ENDOCRINOL, V3, P2054, DOI 10.1210/mend-3-12-2054; MAGNUSON MA, 1983, J BIOL CHEM, V258, P2712; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MULLER M, 1990, NUCLEIC ACIDS RES, V18, P364, DOI 10.1093/nar/18.2.364; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PROBST F, 1987, MOL CELL BIOL, V7, P1629; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RAYMOND V, 1989, ONCOGENE RES, V5, P1; ROBERTS CT, 1987, MOL ENDOCRINOL, V1, P243, DOI 10.1210/mend-1-3-243; ROBERTS CT, 1987, BIOCHEM BIOPH RES CO, V146, P1154, DOI 10.1016/0006-291X(87)90768-6; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; ROTWEIN P, 1986, P NATL ACAD SCI USA, V83, P77, DOI 10.1073/pnas.83.1.77; SHIMATSU A, 1987, NUCLEIC ACIDS RES, V15, P7196, DOI 10.1093/nar/15.17.7196; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SWIDERSKI RE, 1979, NUCLEIC ACIDS RES, V6, P3685, DOI 10.1093/nar/6.11.3685; TONOUCHI N, 1989, BIOCHEM BIOPH RES CO, V163, P1056, DOI 10.1016/0006-291X(89)92328-0; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; WONG EA, 1989, DNA-J MOLEC CELL BIO, V8, P649, DOI 10.1089/dna.1.1989.8.649	44	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7300	7305						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016330				2022-12-25	WOS:A1991FG72700101
J	PAS, HH; MEYER, GH; KRUIZINGA, WH; TAMMINGA, KS; VANWEEGHEL, RP; ROBILLARD, GT				PAS, HH; MEYER, GH; KRUIZINGA, WH; TAMMINGA, KS; VANWEEGHEL, RP; ROBILLARD, GT			31PHOSPHO-NMR DEMONSTRATION OF PHOSPHOCYSTEINE AS A CATALYTIC INTERMEDIATE ON THE ESCHERICHIA-COLI PHOSPHOTRANSFERASE SYSTEM EIIMTL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHOCARRIER PROTEIN; SUGAR-TRANSPORT; BACTERIAL PHOSPHOENOLPYRUVATE; STAPHYLOCOCCUS-AUREUS; MANNITOL PERMEASE; MANNOSE PERMEASE; PHOSPHORYLATION; BINDING; GLUCOSE; CYSTEINE	The mannitol-specific phosphotransferase system transport protein, Enzyme II(Mtl), contains two catalytically important phosphorylated amino acid residues, both present on the cytoplasmic part of the enzyme. Recently, this portion has been subcloned, purified, and shown to be an enzymatically active domain. The N-terminal half has also been subcloned and shown to be the mannitol-binding domain. When combined the two domains catalyze mannitol phosphorylation at the expense of phospho-HPr (van Weeghel, R. P., Meyer, G. H., Pas, H. H., Keck, W. H., and Robillard, G. T., Biochemistry in press). The phospho-NMR spectrum of the purified phosphorylated cytoplasmic domain, taken at pH 8.0, shows two signals, one at -6.9 ppm compared with inorganic phosphate resulting from phosphohistidine and one at +11.9 ppm originating from phosphocysteine. Addition of mannitol plus membranes containing the N-terminal mannitol-binding domain results in the formation of mannitol 1-phosphate and the disappearance of the two signals at -6.9 and +11.9 ppm.	DEPT CHEM, NYENBORGH 16, 9747 AG GRONINGEN, NETHERLANDS; BIOSON INST, 9747 AG GRONINGEN, NETHERLANDS				Pas, Hendri H/G-9749-2011	Pas, Hendri H/0000-0001-8823-2591				AKERFELDT S, 1959, ACTA CHEM SCAND, V13, P1479, DOI 10.3891/acta.chem.scand.13-1479; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DOOIJEWAARD G, 1979, BIOCHEMISTRY-US, V18, P2996, DOI 10.1021/bi00581a014; ERNI B, 1989, J BIOL CHEM, V264, P18733; ERNI B, 1987, J BIOL CHEM, V262, P5238; GASSNER M, 1977, EUR J BIOCHEM, V75, P287, DOI 10.1111/j.1432-1033.1977.tb11528.x; GRENIER FC, 1985, BIOCHEMISTRY-US, V24, P4872, DOI 10.1021/bi00339a022; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; HAYS JB, 1973, J BIOL CHEM, V248, P941; LENGELER JW, 1990, BIOCHIM BIOPHYS ACTA, V1018, P155, DOI 10.1016/0005-2728(90)90238-Y; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10659, DOI 10.1021/bi00499a012; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MUELLER EG, 1990, BIOCHEMISTRY-US, V29, P6892, DOI 10.1021/bi00481a019; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5515, DOI 10.1021/bi00415a019; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5520, DOI 10.1021/bi00415a020; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROBILLARD GT, 1979, BIOCHEMISTRY-US, V18, P2984, DOI 10.1021/bi00581a012; SAIER MH, 1985, J CELL BIOCHEM, V27, P43, DOI 10.1002/jcb.240270106; SCHNETZ K, 1990, J BIOL CHEM, V265, P13464; STEPHAN MM, 1989, BIOCHEMISTRY-US, V28, P7941, DOI 10.1021/bi00445a058; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANWEEGHEL, 1991, IN PRESS BIOCHEMISTR; VANWEEGHEL RP, IN PRESS BIOCHEMISTR; VOGEL HJ, 1989, METHOD ENZYMOL, V177, P263; WHITE DW, 1990, J BACTERIOL, V172, P1509, DOI 10.1128/jb.172.3.1509-1515.1990	27	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6690	6692						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016284				2022-12-25	WOS:A1991FG72700009
J	TRIGGIANI, M; DSOUZA, DM; CHILTON, FH				TRIGGIANI, M; DSOUZA, DM; CHILTON, FH			METABOLISM OF 1-ACYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE IN THE HUMAN NEUTROPHIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING FACTOR; FACTOR 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; CALCIUM IONOPHORE; RABBIT; RAT; 1-O-ALKYL-2-ARACHIDONOYL-SN-GLYCERO-3-PHOSPHOCHOLINE; ARACHIDONATE; MACROPHAGES; ACYLATION; ANALOGS	The biosynthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine (1-acyl-2-acetyl-GPC) together with that of 1-alkyl-2-acetyl-GPC (platelet-activating factor) has been demonstrated in a variety of inflammatory cells and tissues. It has been hypothesized that the relative proportion of these phospholipids produced upon cell activation may be influenced by their rates of catabolism. We studied the catabolism of 1-acyl-2-acetyl-GPC in resting and activated human neutrophils and compared it to that of 1-alkyl-2-acetyl-GPC. Neutrophils rapidly catabolize both 1-alkyl-2-acetyl-GPC and 1-acyl-2-acetyl-GPC; however, the rate of catabolism of 1-acyl-2-acetyl-GPC is approximately 2-fold higher than that of 1-alkyl-2-acetyl-GPC. In addition, most of 1-acyl-2-acetyl-GPC is catabolized through a pathway different from that of 1-alkyl-2-acetyl-GPC. The main step in the catabolism of 1-acyl-2-acetyl-GPC is the removal of the long chain at the sn-1 position; the long chain residue is subsequently incorporated either into triglycerides or into phosphatidylcholine. The 1-lyso-2-acetyl-GPC formed in this reaction is then further degraded to glycerophosphocholine, choline, or phosphocholine. 1-Acyl-2-acetyl-GPC is also catabolized, to a lesser extent, through deacetylation at the sn-2 position and reacylation with a long chain fatty acid. Stimulation of neutrophils by A23187 results in a higher rate of catabolism of 1-acyl-2-acetyl-GPC by increasing both the removal of the long chain at the sn-1 position and the deacetylation-reacylation at the sn-2 position. In a broken cell preparation, the cytosolic fraction of the neutrophil was shown to contain an enzyme activity which cleaved the sn-1 position of 1-acyl-2-acetyl-GPC and 1-acyl-2-lyso-GPC but not of 1,2-diacyl-GPC. Taken together, these data demonstrate that the human neutrophil is able to catabolize 1-acyl-2-acetyl-GPC in a manner both quantitatively and qualitatively different from that of platelet-activating factor. The differential catabolism may regulate the relative proportion of these two bioactive phospholipids in the neutrophil.	JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine			Triggiani, Massimo/K-8271-2016	Triggiani, Massimo/0000-0001-7318-2093	NIAID NIH HHS [AI 26771, AI 24985] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024985, R01AI026771, R29AI024985] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENVENISTE J, 1977, NATURE, V269, P170, DOI 10.1038/269170a0; BLANK ML, 1982, RES COMMUN CHEM PATH, V38, P3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CHILTON FH, 1983, J BIOL CHEM, V258, P7268; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; KRAMER RM, 1984, J BIOL CHEM, V259, P3316; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; MUELLER HW, 1984, J BIOL CHEM, V259, P4554; NAKAYAMA R, 1989, J BIOCHEM-TOKYO, V105, P494, DOI 10.1093/oxfordjournals.jbchem.a122693; OFLAHERTY JT, 1983, RES COMMUN CHEM PATH, V39, P291; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; SATOUCHI K, 1985, BIOCHEM BIOPH RES CO, V128, P1409, DOI 10.1016/0006-291X(85)91097-6; STURK A, 1989, BIOCHIM BIOPHYS ACTA, V993, P148, DOI 10.1016/0304-4165(89)90157-8; TESSNER TG, 1987, J BIOL CHEM, V262, P12660; TOKUMURA A, 1989, J LIPID RES, V30, P219; TRIGGIANI M, 1989, BIOCHIM BIOPHYS ACTA, V1006, P41, DOI 10.1016/0005-2760(89)90321-4; TRIGGIANI M, 1990, J IMMUNOL, V144, P4773; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; WAKU K, 1974, J BIOCHEM-TOKYO, V75, P1307, DOI 10.1093/oxfordjournals.jbchem.a130515; WEY HE, 1989, J CELL BIOCHEM, V39, P305, DOI 10.1002/jcb.240390310; YASUDA K, 1988, BIOMED ENVIRON MASS, V16, P137, DOI 10.1002/bms.1200160124	24	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6928	6935						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016306				2022-12-25	WOS:A1991FG72700047
J	XU, TS; BOWMAN, EP; GLASS, DB; LAMBETH, JD				XU, TS; BOWMAN, EP; GLASS, DB; LAMBETH, JD			STIMULATION OF ADRENAL MITOCHONDRIAL CHOLESTEROL SIDE-CHAIN CLEAVAGE BY GTP, STEROIDOGENESIS ACTIVATOR POLYPEPTIDE (SAP), AND STEROL CARRIER PROTEIN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENOCORTICOTROPIC HORMONE; CORTICOSTERONE SYNTHESIS; RAT; CELLS; CORTEX; CYTOCHROME-P-450; CYCLOHEXIMIDE; PURIFICATION; ACTH; SITE	Several factors are known to stimulate cholesterol side-chain cleavage in isolated adrenal mitochondria, including steroidogenesis activator polypeptide (SAP), GTP, and sterol carrier protein2 (SCP2). All of these reportedly function at the level of the translocation of cholesterol to the inner membrane wherein side-chain cleavage to form pregnenolone occurs. We have investigated the activating effects of these factors alone and in combination. Under conditions where exogenous cholesterol is provided and multiple turnovers of a transport system are required, GTP stimulated steroidogenesis in isolated mitochrondria and in adrenal homogenates, and this effect was enhanced by a GTP regenerating system. SAP alone had little effect under these conditions, but synergized with GTP to stimulate cholesterol metabolism. A truncated SAP analog and a variant from the C terminus of the minor heat-shock protein GRP78 had similar effects, but an unrelated peptide had no effect. GTP stimulated side-chain cleavage with the same EC50 in both resting mitochondria (from dexamethasone-treated rats) and in activated mitochondria (from ether-treated rats), but SAP effects were most apparent in resting mitochondria. In contrast, SCP2 stimulation was additive with other factors, suggesting an independent mechanism of action. While the data are consistent with biological roles for these factors, the relatively small magnitude of the in vitro effects may indicate that cell disruption and mitochondrial isolation disrupt important structural or other features which are necessary for the full expression of the steroidogenic response.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ROLLINS BLDG,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322	Emory University; Emory University					NIDDK NIH HHS [DK27373] Funding Source: Medline; NIGMS NIH HHS [GM08367] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTHUR JR, 1976, BIOCHEM J, V158, P47, DOI 10.1042/bj1580047; BECKETT GJ, 1977, EUR J BIOCHEM, V72, P223, DOI 10.1111/j.1432-1033.1977.tb11243.x; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; BOYD GS, 1973, ANN NY ACAD SCI, V212, P361, DOI 10.1111/j.1749-6632.1973.tb47607.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRALL RJ, 1972, ARCH BIOCHEM BIOPHYS, V148, P70; CRAIN RC, 1980, BIOCHEMISTRY-US, V19, P1433, DOI 10.1021/bi00548a026; CRIVELLO JF, 1978, BIOCHIM BIOPHYS ACTA, V542, P315, DOI 10.1016/0304-4165(78)90027-2; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; FERGUSON JJ, 1963, J BIOL CHEM, V238, P2754; GARREN LD, 1965, P NATL ACAD SCI USA, V53, P1443, DOI 10.1073/pnas.53.6.1443; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1991, IN PRESS ENDOCRINE R; HALL PF, 1984, CAN J BIOCHEM CELL B, V62, P653, DOI 10.1139/o84-087; HALL PF, 1979, J BIOL CHEM, V254, P9080; HEGGENESS MH, 1978, P NATL ACAD SCI USA, V75, P3863, DOI 10.1073/pnas.75.8.3863; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; JEFCOATE CR, 1974, EUR J BIOCHEM, V42, P539, DOI 10.1111/j.1432-1033.1974.tb03369.x; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; LAMBETH JD, 1985, ENDOCR RES, V10, P283; LAMBETH JD, 1987, J BIOL CHEM, V262, P9181; LAMBETH JD, 1984, PHOSPHOLIPIDS CELLUL, P189; LI X, 1989, MOL ENDOCRINOL, V3, P1944, DOI 10.1210/mend-3-12-1944; MASON JI, 1978, BIOCHEM J, V173, P1045; MATSUYAMA H, 1971, ENDOCRINOLOGY, V88, P692, DOI 10.1210/endo-88-3-692; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MERTZ LM, 1989, ENDOCR RES, V15, P101, DOI 10.1080/07435808909039091; MERTZ LM, 1989, J BIOL CHEM, V264, P15274; PARVIN R, 1969, METHOD ENZYMOL, V8, P17; PEDERSEN RC, 1987, SCIENCE, V236, P188, DOI 10.1126/science.3563495; PEDERSEN RC, 1983, P NATL ACAD SCI-BIOL, V80, P1882, DOI 10.1073/pnas.80.7.1882; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; PRIVALLE CT, 1987, MOL CELL ENDOCRINOL, V53, P87, DOI 10.1016/0303-7207(87)90195-X; SALA GB, 1979, J BIOL CHEM, V254, P3861; SIMPSON ER, 1978, J BIOL CHEM, V253, P3135; SIMPSON ER, 1972, EUR J BIOCHEM, V28, P442, DOI 10.1111/j.1432-1033.1972.tb01931.x; STEVENS VL, 1985, ARCH BIOCHEM BIOPHYS, V242, P324, DOI 10.1016/0003-9861(85)90508-9; STEVENS VL, 1984, J BIOL CHEM, V259, P1174; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; VAHOUNY G V, 1984, Endocrine Research, V10, P473; VAHOUNY GV, 1983, J BIOL CHEM, V258, P1731; XU XX, 1989, J BIOL CHEM, V264, P17674; YANAGIBASHI K, 1988, ENDOCRINOLOGY, V123, P2075, DOI 10.1210/endo-123-4-2075	43	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6801	6807						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016295				2022-12-25	WOS:A1991FG72700027
J	ALLEN, TD; WICK, KL; MATTHEWS, KS				ALLEN, TD; WICK, KL; MATTHEWS, KS			IDENTIFICATION OF AMINO-ACIDS IN LAC REPRESSOR PROTEIN CROSS-LINKED TO OPERATOR DNA SPECIFICALLY SUBSTITUTED WITH BROMODEOXYURIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; TRYPSIN-RESISTANT CORE; ESCHERICHIA-COLI; LACTOSE REPRESSOR; RECOGNITION HELIX; BINDING ACTIVITY; SEQUENCE; REGION; HEADPIECE; DIGESTION	Amino acids in lac repressor protein which form cross-links to lac operator DNA specifically substituted with bromodeoxyuridine (BrdU) have been identified. Five sites of cross-linking in BrdU-substituted operator DNA were found at positions +3, +4, +14, +18, and +19 relative to the initiation site for transcription (Wick, K. L., and Matthews, K. S. (1991) J. Biol. Chem. 266, 6106-6112). Irradiation of complexes of repressor and each of these five singly substituted operator DNAs was executed under large scale conditions to generate sufficient complex for proteolysis, separation of the peptide-DNA, and peptide sequencing. The DNAs substituted with BrdU for thymidine at positions +3, +18, and +19 yielded cross-links to the peptide spanning residues 23-33, with the cross-link identified at His-29. Substitution at position +14 resulted in a cross-link to Tyr-17 within the peptide containing amino acids 13-22. These results are consistent with the structure determined by NMR and molecular dynamics calculations of the NH2-terminal headpiece-symmetric operator complex (Lamerichs, R. M. J. N., Boelens, R., van der Marel, G. A., van Boom, J. H., Kaptein, R., Buck, F., Fera, B., and Ruterjans, H. (1989) Biochemistry 28, 2895-2991; de Vlieg, J., Berendsen, H. J. C., and van Gunsteren, W. F. (1989) Proteins 6, 104-127). This structure indicates proximity of His-29 in the major groove to thymidines at positions +3 and +4. Since base pairs at positions +18 and +19 occupy symmetrical positions to +3 and +4 in the promoter distal region of the operator, it would be anticipated that cross-links similar to the +3 and +4 positions would form at these sites; this prediction is not borne out by the behavior at +4/+18, as no peptide could be identified cross-linked to DNA substituted at +4. Molecular dynamics simulations and the NMR data indicate that Tyr-17 interacts with the thymine at position +8, which is symmetrically related to position +14. Although BrdU-associated strand scission at +8 is protected, this site does not cross-link with bound lac repressor; inversely, DNA substituted with BrdU at +14 cross-links to repressor, but is not protected from strand scission by the presence of the protein. These differences at symmetrically related nucleotide positions (+4 versus +18, +8 versus +14) reflect the inherent asymmetry in the interaction. The identification of amino acids in proximity to specifically substituted sites confirms that positions of several amino acids in the intact protein-operator complex correspond to those in the structure of the NH2-terminal headpiece-operator DNA complex.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University					NIGMS NIH HHS [GM 22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER K, 1972, NATURE, V237, P322, DOI 10.1038/237322a0; ARNDT K, 1982, J MOL BIOL, V161, P439, DOI 10.1016/0022-2836(82)90248-0; BARBIER B, 1984, BIOCHEMISTRY-US, V23, P2933, DOI 10.1021/bi00308a013; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BEYREUTHER K, 1978, NATURE, V274, P767, DOI 10.1038/274767a0; BEYREUTHER K, 1975, EUR J BIOCHEM, V59, P491, DOI 10.1111/j.1432-1033.1975.tb02477.x; BOELENS R, 1987, J MOL BIOL, V193, P213, DOI 10.1016/0022-2836(87)90638-3; BUTLER AP, 1977, BIOCHEMISTRY-US, V16, P4757, DOI 10.1021/bi00641a001; CULARD F, 1981, NUCLEIC ACIDS RES, V9, P5175, DOI 10.1093/nar/9.19.5175; DEVLIEG J, 1989, PROTEINS, V6, P104, DOI 10.1002/prot.340060203; DEVOLIEG J, 1988, PROTEINS, V3, P209; EBRIGHT RH, 1986, P NATL ACAD SCI USA, V83, P303, DOI 10.1073/pnas.83.2.303; EVANS RK, 1986, P NATL ACAD SCI USA, V83, P5382, DOI 10.1073/pnas.83.15.5382; FANNING TG, 1975, BIOCHEMISTRY-US, V14, P2512, DOI 10.1021/bi00682a034; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FILES JG, 1976, J BIOL CHEM, V251, P3386; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GILBERT W, 1975, PROTEIN LIGAND INTER, P193; HSIEH WT, 1981, J BIOL CHEM, V256, P4856; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; MANLY SP, 1984, J MOL BIOL, V179, P335, DOI 10.1016/0022-2836(84)90069-X; MATTHEWS BW, 1982, P NATL ACAD SCI-BIOL, V79, P1428, DOI 10.1073/pnas.79.5.1428; MERRILL BM, 1984, J BIOL CHEM, V259, P850; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PARADISO PR, 1979, J BIOL CHEM, V254, P4739; PFAHL M, 1974, GENETICS, V76, P669; PLATT T, 1973, J BIOL CHEM, V248, P110; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROSENBERG JM, 1977, NUCLEIC ACIDS RES, V4, P567, DOI 10.1093/nar/4.3.567; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; SAMS CF, 1988, BIOCHEMISTRY-US, V27, P2277, DOI 10.1021/bi00407a005; SARTORIUS J, 1989, EMBO J, V8, P1265, DOI 10.1002/j.1460-2075.1989.tb03500.x; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SHALLOWAY D, 1980, CELL, V20, P411, DOI 10.1016/0092-8674(80)90627-3; SHAMOO Y, 1988, PROTEINS, V4, P1, DOI 10.1002/prot.340040103; SIMONS A, 1984, P NATL ACAD SCI-BIOL, V81, P1624, DOI 10.1073/pnas.81.6.1624; SMITH TF, 1971, J MOL BIOL, V59, P273, DOI 10.1016/0022-2836(71)90051-9; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3845, DOI 10.1021/bi00361a016; WICK KL, 1991, J BIOL CHEM, V266, P6106; ZUIDERWEG ERP, 1985, BIOPOLYMERS, V24, P2257, DOI 10.1002/bip.360241208	54	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6113	6119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007569				2022-12-25	WOS:A1991FE37300020
J	FISCHER, RT; TRZASKOS, JM; MAGOLDA, RL; KO, SS; BROSZ, CS; LARSEN, B				FISCHER, RT; TRZASKOS, JM; MAGOLDA, RL; KO, SS; BROSZ, CS; LARSEN, B			LANOSTEROL 14-ALPHA-METHYL DEMETHYLASE - ISOLATION AND CHARACTERIZATION OF THE 3RD METABOLICALLY GENERATED OXIDATIVE DEMETHYLATION INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL-BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; C-32 DEMETHYLATION; CYTOCHROME-P-450; 14-ALPHA-DEMETHYLATION; MICROSOMES; YEAST; PURIFICATION; ACCUMULATION; MECHANISMS	Conditions have been identified which permit metabolic formation of the third oxidized intermediate in the lanosterol 14-alpha-methyl demethylase reaction cascade. Metabolism of either the immediate precursor substrate 3-beta-hydroxylanost-8-en-32-al or lanost-8-ene-3-beta,32-diol under mixed function oxidase conditions affords formation of the intermediate. It must be emphasized that the intermediate can only be detected if saponification procedures are omitted during sterol isolation. Comparative chemical and biochemical studies of the isolated metabolite with 3-beta,15-alpha-dihydroxylanost-8-en-32-al reveal that the metabolite is not the 15-alpha-hydroxylanosterol aldehyde, a putative demethylase intermediate. The metabolite is efficiently converted to the demethylated DELTA-8,14-diene sterol in the absence of molecular oxygen or NADPH, thus supporting its identity as the final oxidized intermediate in the lanosterol 14-alpha-methyl demethylase cascade. H-1 NMR analysis shows a proton resonance at 7.86 ppm consistent with a formyloxy proton. Mass spectral and infrared analysis of the metabolite clearly establish oxygen insertion into the immediate precursor substrate, 3-beta-hydroxylanost-8-en-32-al. Collectively, the biochemical and chemical characteristics of the metabolite support a structural assignment for the metabolite as 14-alpha-formyloxy-lanost-8-en-3-beta-ol.	DUPONT CO,DEPT MED PROD,EXPTL STN,POB 80400,WILMINGTON,DE 19880; DUPONT CO,DEPT CENT RES & DEV,WILMINGTON,DE 19880	DuPont; DuPont								AKHTAR M, 1969, BIOCHEM J, V111, P757, DOI 10.1042/bj1110757; AKHTAR M, 1977, BIOORG CHEM, V6, P473, DOI 10.1016/0045-2068(77)90046-3; AKHTAR M, 1978, BIOCHEM J, V169, P449, DOI 10.1042/bj1690449b; AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; ALEXANDE.K, 1972, J CHEM SOC CHEM COMM, P383, DOI 10.1039/c39720000383; AOYAMA Y, 1984, J BIOL CHEM, V259, P1661; AOYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V1001, P196; AOYAMA Y, 1987, J BIOL CHEM, V262, P1239; COLE PA, 1988, J AM CHEM SOC, V110, P1284, DOI 10.1021/ja00212a043; FISCHER RT, 1989, J LIPID RES, V30, P1621; FISCHER RT, 1988, FASEB J, V2, pA580; GALLIKIENLE M, 1980, EUR J BIOCHEM, V110, P93, DOI 10.1111/j.1432-1033.1980.tb04844.x; GIBBONS GF, 1976, BIOCHEM BIOPH RES CO, V69, P781, DOI 10.1016/0006-291X(76)90943-8; GUENGERICH FP, 1987, J BIOL CHEM, V262, P8459; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; KALB VF, 1986, GENE, V45, P237, DOI 10.1016/0378-1119(86)90021-1; MIYAIRI S, 1985, J BIOL CHEM, V260, P320; O'Keefe DP, 1987, RECENT ADV PHYTOCHEM, V21, P151; PASCAL RA, 1980, J AM CHEM SOC, V102, P6599, DOI 10.1021/ja00541a055; SHAFIEE A, 1986, J LIPID RES, V27, P1; SLIGAR SG, 1980, P NATL ACAD SCI USA, V77, P1240, DOI 10.1073/pnas.77.3.1240; STEVENSON DE, 1988, J CHEM SOC PERK T 1, P2043, DOI 10.1039/p19880002043; TABUSHI I, 1985, J AM CHEM SOC, V107, P4466, DOI 10.1021/ja00301a016; TRZASKOS J, 1986, J BIOL CHEM, V261, P4651; TRZASKOS JM, 1986, J BIOL CHEM, V261, P6937; TRZASKOS JM, 1984, J BIOL CHEM, V259, P3402; TRZASKOS JM, 1985, ENZYMES BIOL MEMBR, V2, P177; WOODWARD RB, 1957, J CHEM SOC, V1, P1131; YOSHIDA Y, 1984, J BIOL CHEM, V259, P1655	29	100	100	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6124	6132						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007571				2022-12-25	WOS:A1991FE37300022
J	MOCK, WL; ZHANG, JZ				MOCK, WL; ZHANG, JZ			MECHANISTICALLY SIGNIFICANT DIASTEREOSELECTION IN THE SULFOXIMINE INHIBITION OF CARBOXYPEPTIDASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KETONIC SUBSTRATE-ANALOG; ACTIVE-SITE; COBALT CARBOXYPEPTIDASE; PEPTIDE HYDROLYSIS; CRYSTAL-STRUCTURE; CATALYSIS; THERMOLYSIN; ENZYME; PH; MECHANISMS	The diastereomers of L-alpha-[[S-(2-phenylethyl)sulfonimidoyl]methyl]benzenepropanoic acid bind differentially to carboxypeptidase A. These putative transition state-analogue inhibitors show unique and interpretationally significant pH dependences for K(i), as well as for the visible absorption spectra of their E.I complexes in the case of the cobalt-substituted enzyme. From the geometry of the enzymically preferred isomer, it may be concluded that the mechanism of peptide scission by the enzyme entails addition of a nucleophile to the si face of the bound-substrate prochiral carboxamide linkage. New interpretational constraints on the mode of action of the enzyme are thereby imposed.			MOCK, WL (corresponding author), UNIV ILLINOIS,DEPT CHEM,CHICAGO,IL 60680, USA.							ARNETT EM, 1963, PROG PHYS ORG CHEM, V1, P223, DOI 10.1002/9780470171806.ch5; AULD DS, 1974, BIOCHEMISTRY-US, V13, P4355, DOI 10.1021/bi00718a018; BOND MD, 1986, J INORG BIOCHEM, V28, P97, DOI 10.1016/0162-0134(86)80074-5; BURGI HB, 1973, J AM CHEM SOC, V95, P5065, DOI 10.1021/ja00796a058; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CHRISTIANSON DW, 1988, J AM CHEM SOC, V110, P5560, DOI 10.1021/ja00224a047; CHRISTIANSON DW, 1987, P NATL ACAD SCI USA, V84, P1512, DOI 10.1073/pnas.84.6.1512; CHRISTIANSON DW, 1985, J AM CHEM SOC, V107, P8281, DOI 10.1021/ja00312a089; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; DZIKLINSKA H, 1989, B SOC CHIM BELG, V98, P277; FERSHT A, 1985, ENZYME STRUCTURE MEC, P53; GALARDY RE, 1985, BIOCHEMISTRY-US, V24, P7607, DOI 10.1021/bi00347a016; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; GELB MH, 1985, BIOCHEMISTRY-US, V24, P1813, DOI 10.1021/bi00329a001; GROBELNY D, 1985, BIOCHEM J, V232, P15, DOI 10.1042/bj2320015; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; HANSON JE, 1989, BIOCHEMISTRY-US, V28, P6294, DOI 10.1021/bi00441a022; JACOBSEN NE, 1981, ACS SYM SER, V171, P221; KAM CM, 1979, BIOCHEMISTRY-US, V18, P3032, DOI 10.1021/bi00581a019; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; KIRBY AJ, 1980, ADV PHYS ORG CHEM, V17, P173; KOJRO E, 1987, FEBS LETT, V212, P83, DOI 10.1016/0014-5793(87)81561-2; KUNUGI S, 1982, EUR J BIOCHEM, V124, P157, DOI 10.1111/j.1432-1033.1982.tb05919.x; LATT SA, 1971, BIOCHEMISTRY-US, V10, P4263, DOI 10.1021/bi00799a017; MOCK WL, 1986, BIOCHEMISTRY-US, V25, P2920, DOI 10.1021/bi00358a028; MOCK WL, 1980, ARCH BIOCHEM BIOPHYS, V203, P542, DOI 10.1016/0003-9861(80)90211-8; MOCK WL, 1988, J BIOL CHEM, V263, P8635; MOCK WL, 1989, J AM CHEM SOC, V111, P4467, DOI 10.1021/ja00194a049; MOCK WL, 1990, J ORG CHEM, V55, P5791, DOI 10.1021/jo00309a025; MOCK WL, 1981, BIOCHEM BIOPH RES CO, V102, P389, DOI 10.1016/0006-291X(81)91533-3; PAUPTIT RA, 1988, J MOL BIOL, V199, P525, DOI 10.1016/0022-2836(88)90623-7; Quiocho F A, 1971, Adv Protein Chem, V25, P1, DOI 10.1016/S0065-3233(08)60278-8; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; RIORDAN JF, 1984, METHOD ENZYMAT AN, V5, P44; SAYRE LM, 1986, J AM CHEM SOC, V108, P1632, DOI 10.1021/ja00267a037; SPRATT TE, 1983, J AM CHEM SOC, V105, P3679, DOI 10.1021/ja00349a055; WOOLLEY P, 1975, NATURE, V258, P677, DOI 10.1038/258677a0; YAGIL G, 1967, J PHYS CHEM-US, V71, P1034, DOI 10.1021/j100863a040	40	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6393	6400						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007591				2022-12-25	WOS:A1991FE37300060
J	WANKE, IE; WONG, NCW				WANKE, IE; WONG, NCW			DIABETES-MELLITUS DECREASES THE ACTIVITY OF THE ALBUMIN PROMOTER INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYKINASE GENE-TRANSCRIPTION; RAT HEPATOMA-CELLS; MESSENGER-RNA; MULTIHORMONAL REGULATION; PRIMARY CULTURES; DOMINANT ROLE; INSULIN; LIVER; HEPATOCYTES; EXPRESSION	Diabetes mellitus (DM) has been shown previously to decrease hepatic synthesis of both albumin and albumin mRNA. These findings prompted us to ask whether decreased albumin expression is due to changes in the rate of gene transcription. A cell-free in vitro transcription assay demonstrated that activity of the albumin promoter in hepatonuclear extracts was diminished 3- to 4-fold in diabetic compared with control animals. This decrease was abolished in extracts prepared from diabetic animals treated with insulin. The potential mechanisms for diminished activity were examined by mixing extracts from normal and diabetic animals prior to incubation with DNA templates. In the presence of limited amounts of albumin promoter DNA, addition of diabetic to control extract caused a reduction in promoter activity, suggesting that an inhibitor or inhibitors of albumin promoter activity is/are present in the liver of diabetic rats.	UNIV CALGARY, DEPT MED, CALGARY T2N 4N1, ALBERTA, CANADA; UNIV CALGARY, DEPT MED BIOCHEM, CALGARY T2N 4N1, ALBERTA, CANADA	University of Calgary; University of Calgary								BRETHERTONWATT D, 1989, DIABETOLOGIA, V32, P881, DOI 10.1007/BF00297454; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHU DTW, 1988, J BIOL CHEM, V263, P13007; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; DAVIS BB, 1988, BIOCHEM BIOPH RES CO, V154, P1081, DOI 10.1016/0006-291X(88)90251-3; FLAIM KE, 1985, AM J PHYSIOL, V249, pE447, DOI 10.1152/ajpendo.1985.249.5.E447; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; GOODRIDGE AG, 1986, ANN NY ACAD SCI, V478, P46, DOI 10.1111/j.1749-6632.1986.tb15520.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANNER DK, 1986, ANN NY ACAD SCI, V478, P175, DOI 10.1111/j.1749-6632.1986.tb15530.x; JEFFERSON LS, 1983, J BIOL CHEM, V258, P1369; JUNOD A, 1967, P SOC EXP BIOL MED, V126, P201; KAHN CR, 1985, ANNU REV MED, V36, P429; KELLER SA, 1990, 1990 ANN M END SOC A, P88; LEDOUX SP, 1988, DIABETES, V37, P1015, DOI 10.2337/diabetes.37.8.1015; LEE KL, 1986, ARCH BIOCHEM BIOPHYS, V248, P597, DOI 10.1016/0003-9861(86)90513-8; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIKE AA, 1982, DIABETES, V31, P7, DOI 10.2337/diab.31.1.S7; LLOYD CE, 1987, AM J PHYSIOL, V252, pC205, DOI 10.1152/ajpcell.1987.252.2.C205; LONN U, 1988, BIOCHEM PHARMACOL, V37, P3441, DOI 10.1016/0006-2952(88)90694-6; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; Maniatis T., 1982, MOL CLONING; MARIASH CN, 1982, ANAL BIOCHEM, V121, P388, DOI 10.1016/0003-2697(82)90498-5; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; MIRA E, 1989, J BIOL CHEM, V264, P18209; OBRIEN RM, 1990, DIABETES CARE, V13, P327, DOI 10.2337/diacare.13.3.327; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PEAVY DE, 1978, P NATL ACAD SCI USA, V75, P5879, DOI 10.1073/pnas.75.12.5879; PEAVY DE, 1985, AM J PHYSIOL, V248, pE656, DOI 10.1152/ajpendo.1985.248.6.E656; PLANT PW, 1983, J BIOL CHEM, V258, P5355; Porte DJR, 1981, TXB ENDOCRINOLOGY, P715; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; SASAKI K, 1984, J BIOL CHEM, V259, P5242; STRAUS DS, 1987, J BIOL CHEM, V262, P1955; WHITE JD, 1990, ENDOCRINOLOGY, V126, P765, DOI 10.1210/endo-126-2-765; WONG NCW, 1990, J BIOL CHEM, V265, P8775	38	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6068	6072						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007564				2022-12-25	WOS:A1991FE37300013
J	ALTIN, JG; KUJUBU, DA; RAFFIONI, S; EVELETH, DD; HERSCHMAN, HR; BRADSHAW, RA				ALTIN, JG; KUJUBU, DA; RAFFIONI, S; EVELETH, DD; HERSCHMAN, HR; BRADSHAW, RA			DIFFERENTIAL INDUCTION OF PRIMARY-RESPONSE (TIS) GENES IN PC12 PHEOCHROMOCYTOMA CELLS AND THE UNRESPONSIVE VARIANT PC12NNR5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; TETRADECANOYL PHORBOL ACETATE; SWISS 3T3 CELLS; RAT PHEOCHROMOCYTOMA; NEURITE OUTGROWTH; NEURONAL DIFFERENTIATION; TYROSINE PHOSPHORYLATION; FACTORS ENCODES; TUMOR PROMOTER	As a measure of the transmembrane signals that they transduce, two neurotrophic agents, nerve growth factor (NGF) and basic fibroblast growth factor (bFGF), and the muscarinic agonist carbachol were compared for their ability to induce TIS (tetradecanoyl phorbol acetate-inducible sequences) transcripts, representing a family of immediate early response genes, in the rat pheochromocytoma cell line PC12 and the morphologically unresponsive variant PC12nnr5. Three genes, TIS1 (also designated NGFIB), TIS8 (also designated NGFIA), and TIS21, induced in these cells by NGF (Kujubu, D. A., Lim, R. W., Varnum, B. C., and Herschman, H. R. (1987) Oncogene 1, 257-262, 1987), are also induced by bFGF and carbachol. In native PC12 cells the level of expression of TIS8 and TIS21 is similar for all three stimuli, as well as for tetradecanoyl phorbol acetate (TPA). In contrast, the induction of TIS1 by NGF and TPA is slight and is only just detectable after stimulation by bFGF, but is strong for carbachol. Thus, although all of these agents can stimulate protein kinase (PK-C), at least one TIS gene can apparently be differentially regulated by these ligands, suggesting that alternative signaling pathways must also exist. In keeping with this view, bFGF, and to a lesser degree NGF, can elicit a TIS gene response in PC12 cells in which PK-C has been down-regulated with TPA. The response to carbachol (and TPA) is effectively blocked under these conditions. Since both NGF and bFGF stimulate neurite outgrowth in such cells, PK-C is apparently not essential, i.e. does not represent the sole mechanism, for signal transduction leading to modulation of gene expression for these factors. Consistent with this model, putative protein kinase inhibitors, K252a and sphingosine, did not inhibit the TIS gene responses to bFGF. However, these agents also failed to block TIS gene responses to carbachol and TPA indicating that they were ineffective as PK-C inhibitors under these conditions. The NGF-induced response was, however, blocked by K252a indicating a unique step in the mechanism of this factor not shared by the other ligands. Sphingosine did not block TIS induction with NGF. The mutant cell line PC12 nnr5 does not respond morphologically to either NGF or bFGF. However, TIS gene responses to bFGF are unaffected, whereas those to NGF are completely abolished. The response to TPA is altered quantitatively but not qualitatively; the induction by carbachol is largely eliminated, apparently as a result of a 90% reduction in muscarinic receptors. Thus, TIS gene inductions may be necessary but are not sufficient to permit neurite outgrowth in PC12 cells and, with NGF and bFGF, can occur by PK-C-independent as well as a PK-C-dependent mechanisms.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Altin, Joseph G/C-9935-2009; Bradshaw, Ralph A/K-1515-2013		NIDDK NIH HHS [DK1815] Funding Source: Medline; NIGMS NIH HHS [GM 24797] Funding Source: Medline; NINDS NIH HHS [NS19964] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019964] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BURSTEIN DE, 1982, BRAIN RES, V247, P115, DOI 10.1016/0006-8993(82)91033-2; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; CREMINS J, 1986, J CELL BIOL, V103, P887, DOI 10.1083/jcb.103.3.887; CROSS AJ, 1984, BIOCHEM BIOPH RES CO, V119, P163, DOI 10.1016/0006-291X(84)91633-4; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; EVELETH DD, 1989, J NEUROSCI RES, V24, P67, DOI 10.1002/jnr.490240110; FOX GM, 1988, J BIOL CHEM, V263, P18452; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HALL FL, 1988, J BIOL CHEM, V263, P4460; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KUJUBU DA, 1987, ONCOGENE, V1, P257; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; MAHER PA, 1989, J NEUROSCI RES, V24, P29, DOI 10.1002/jnr.490240106; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MATTHIES HJG, 1987, J NEUROSCI, V7, P1198; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MUTOH T, 1988, J BIOL CHEM, V263, P15853; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REINHOLD DS, 1989, J BIOL CHEM, V264, P3538; ROWLAND EA, 1987, J BIOL CHEM, V262, P7504; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SIGMUND O, 1990, J BIOL CHEM, V265, P2257; SMITH DS, 1989, J NEUROCHEM, V53, P800, DOI 10.1111/j.1471-4159.1989.tb11776.x; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; TOGARI A, 1985, J NEUROSCI, V5, P307; TRAYNOR AE, 1984, DEV BRAIN RES, V14, P205; TROTTA RJ, 1990, J CELL PHYSIOL, V143, P68, DOI 10.1002/jcp.1041430109; VARNUM BC, 1989, ONCOGENE, V4, P119; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WU BY, 1989, J BIOL CHEM, V264, P9000	59	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5401	5406						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005087				2022-12-25	WOS:A1991FD37000010
J	BAUERLE, C; DORL, J; KEEGSTRA, K				BAUERLE, C; DORL, J; KEEGSTRA, K			KINETIC-ANALYSIS OF THE TRANSPORT OF THYLAKOID LUMENAL PROTEINS IN EXPERIMENTS USING INTACT CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; TRANSIT PEPTIDE; PLASTOCYANIN; PRECURSOR; GENE; PEA; TRANSLOCATION; MATURATION; MEMBRANES; SEQUENCE	The transport of the lumenal protein plastocyanin has been proposed to occur in two steps: 1) transport across the chloroplastic envelope to the stroma and 2) transport across the thylakoid membrane to the lumen where proteolytic maturation occurs. A partially processed stromal form of plastocyanin has been tentatively identified as a pathway intermediate and as the substrate for the second translocation step (Smeekens, S., Bauerle, C., Hageman, J., Keegstra, K., and Weisbeek, P. (1986) Cell 46, 365-375). In this study, we have examined the transport kinetics of several lumenal proteins under various incubation conditions. Soluble intermediate sized forms were observed in import reactions with plastocyanin precursors from three higher plant species and with the precursor of the 33-kDa polypeptide of the oxygen-evolving enhancer complex. The accumulation patterns observed for these soluble intermediate sized forms depended on incubation conditions and could not be consistently explained by a simple model where the intermediate sized form is the substrate for the second step. Thus, it has not been possible to clearly identify the substrate for thylakoid translocation in organello.	UNIV WISCONSIN, DEPT BOT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison								ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; BAUERLE C, 1991, J BIOL CHEM, V266, P5876; FLUGGE UI, 1986, EUR J BIOCHEM, V160, P563, DOI 10.1111/j.1432-1033.1986.tb10075.x; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KEEGSTRA K, 1988, BIOESSAYS, V9, P15, DOI 10.1002/bies.950090105; KIRWIN PM, 1987, J BIOL CHEM, V262, P16386; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAST DI, 1989, PLANT MOL BIOL, V12, P655, DOI 10.1007/BF00044156; MEADOWS JW, 1989, FEBS LETT, V253, P244, DOI 10.1016/0014-5793(89)80968-8; NIELSEN PS, 1987, FEBS LETT, V225, P159, DOI 10.1016/0014-5793(87)81149-3; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1985, NATURE, V317, P456, DOI 10.1038/317456a0; THEG SM, 1989, J BIOL CHEM, V264, P6730; VORST O, 1988, GENE, V65, P59, DOI 10.1016/0378-1119(88)90417-9; WALES R, 1989, PLANT MOL BIOL, V12, P439, DOI 10.1007/BF00017583; WEISBEEK P, 1989, J CELL SCI, P199	20	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5884	5890						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005124				2022-12-25	WOS:A1991FD37000082
J	CARPENTER, CD; INGRAHAM, HA; COCHET, C; WALTON, GM; LAZAR, CS; SOWADSKI, JM; ROSENFELD, MG; GILL, GN				CARPENTER, CD; INGRAHAM, HA; COCHET, C; WALTON, GM; LAZAR, CS; SOWADSKI, JM; ROSENFELD, MG; GILL, GN			STRUCTURAL-ANALYSIS OF THE TRANSMEMBRANE DOMAIN OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE KINASE; YEAST HEXOKINASE-A; EGF RECEPTOR; POINT MUTATION; NEU ONCOGENE; RESOLUTION; ACTIVATION; CELLS; EXPRESSION; MEMBRANE	The ligand-binding domain of the epidermal growth factor (EGF) receptor is separated from the cytoplasmic protein tyrosine kinase domain by a predicted single transmembrane segment. Antipeptide antibodies prepared against the outer portion of the predicted transmembrane segment confirmed this area was exposed only when cells were treated with permeabilizing agents. To investigate structural requirements for signal transduction by the transmembrane domain, three types of mutant EGF receptor were prepared. The first type was designed to shorten the transmembrane domain, the second to place proline substitutions within this domain, and the third to make amino acid substitutions analogous to those present in the transforming c-erbB2/neu oncoprotein. Mutant human receptors were expressed in null recipient mouse B82L and Chinese hamster ovary cells. All receptors bound EGF and exhibited EGF-stimulated protein tyrosine kinase activity in vivo as assayed using a I-125-labeled monoclonal anti-phosphotyrosine antibody. EGF stimulated growth of cells expressing each mutant receptor with similar dose-response characteristics. In contrast to other growth factor receptors, the transmembrane domain of the EGF receptor is tolerant to a variety of changes which neither mimic EGF action by constitutive activation nor interfere with ligand-induced signal transduction.	CEN,DEPT RECH FONDAMENTALE,INSERM,U244,REGULAT ENDOCRINES LAB,F-38041 GRENOBLE,FRANCE; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego				Cochet, Claude/0000-0002-1772-4270	NIDDK NIH HHS [DK07044] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007044] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COCHET C, 1988, J BIOL CHEM, V263, P3290; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FOX RO, 1982, NATURE, V300, P325, DOI 10.1038/300325a0; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEIFER D, 1983, J MOL BIOL, V163, P451, DOI 10.1016/0022-2836(83)90068-2; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; TANFORD C, 1978, SCIENCE, V200, P1012, DOI 10.1126/science.653353; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; [No title captured]	36	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5750	5755						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005111				2022-12-25	WOS:A1991FD37000061
J	CLARK, BJ; WATERMAN, MR				CLARK, BJ; WATERMAN, MR			THE HYDROPHOBIC AMINO-TERMINAL SEQUENCE OF BOVINE 17-ALPHA-HYDROXYLASE IS REQUIRED FOR THE EXPRESSION OF A FUNCTIONAL HEMOPROTEIN IN COS 1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHESIZING SECRETORY PROTEIN; ENDOPLASMIC-RETICULUM; MICROSOMAL-MEMBRANES; CYTOCHROME-P-450; SIGNAL; TRANSLOCATION; INSERTION; TOPOLOGY; ENZYME; CDNA	The endoplasmic reticulum is a major site of localization for eukaryotic cytochrome P-450 mixed-function oxidase complexes. Previous studies have shown that the microsomal forms of P-450 insert into the membrane via their hydrophobic amino terminus through the signal recognition particle-dependent pathway. We have examined the insertion of bovine 17-alpha-hydroxylase (P45017-alpha) into the endoplasmic reticulum of COS 1 cells to evaluate the functional role of its hydrophobic amino-terminal sequence and membrane insertion. An NH2-terminal truncated protein, P450-DELTA-2-17, which lacked amino acids 2-17 was expressed in COS 1 cells, subcellular fractions were isolated, and P450-DELTA-2-17 was localized by immunoblot analysis. Compared to the full-length P45017-alpha, the NH2-terminal truncation resulted in a 2.5-fold decrease in P45017-alpha protein recovered with the microsomal fraction, 50% of which was an integral membrane protein as defined by resistance to Na2CO3 extraction. Despite correct membrane localization. P450-DELTA-2-17 was not a functional enzyme in COS 1 cells. A CO difference spectrum of microsomes containing P450-DELTA-2-17 did not give a typical 450 nm absorbance. We conclude that the hydrophobic amino terminus is required for the expression of a functionally competent P45017-alpha in COS 1 cells and suggest that the insertion of the amino terminus into the membrane is necessary for the folding of this protein into its correct structural form.	UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	CLARK, BJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Clark, Barbara/0000-0003-1558-1904	NIGMS NIH HHS [GM 37429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM037429] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARNUN S, 1980, P NATL ACAD SCI-BIOL, V77, P965, DOI 10.1073/pnas.77.2.965; BERG P, 1983, MOL CELL BIOL, V3, P280; CHIOU SH, 1990, J BIOL CHEM, V265, P3549; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FELDMAN RA, 1982, CANCER CELL ORGANELL, V11, P263; FRANKE WW, 1981, EXP CELL RES, V134, P345, DOI 10.1016/0014-4827(81)90435-3; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HOWELL KE, 1989, TRENDS BIOCHEM SCI, V14, P44, DOI 10.1016/0968-0004(89)90040-6; King T.E., 1967, METHODS ENZYMOL, P216, DOI DOI 10.1016/0076-6879(67)10043-8; Masters B, 1967, METHOD ENZYMOL, V10, P565; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NEBERT DW, 1987, DNA-J MOLEC CELL BIO, V6, P1, DOI 10.1089/dna.1987.6.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SAKAKI T, 1989, DNA-J MOLEC CELL BIO, V8, P409, DOI 10.1089/dna.1.1989.8.409; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	32	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5898	5904						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005126				2022-12-25	WOS:A1991FD37000084
J	NICKELL, C; ANDERSON, WF; LLOYD, RS				NICKELL, C; ANDERSON, WF; LLOYD, RS			SUBSTITUTION OF BASIC-AMINO-ACIDS WITHIN ENDONUCLEASE-V ENHANCES NONTARGET DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR-OPERATOR INTERACTION; DIFFUSION-DRIVEN MECHANISMS; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; PROTEIN TRANSLOCATION; ECORI ENDONUCLEASE; NUCLEIC-ACIDS; DENV-GENE; EQUILIBRIUM MEASUREMENTS	Several DNA-interactive proteins, including the DNA repair enzyme T4 endonuclease V, have been shown to locate their target recognition sites utilizing an electrostatically mediated facilitated diffusion mechanism. Previous work indicates that a decrease in the affinity of endonuclease V for nontarget DNA results in an increased nontarget dissociation rate. This study was designed to investigate the effect of an increase in the affinity of endonuclease V for nontarget DNA. Using a working structural model of the enzyme as a guide, the electrostatic character of endonuclease V was altered. Substitution of Thr-7 with Lys-7 resulted in an enzyme with wild type in vitro characteristics. Mutations which increased the positive charge along a proposed solvent-exposed alpha-helical face had significant effects. The mutants Ala-30, Val-31 --> Lys-30, Leu-31 and Asn-37 --> Lys-37 displayed wild type in vitro apurinic-specific and dimer-specific nicking activities. Although the processive dimer-specific nicking rate of the Lys-37 mutant resembled that of wild type, the rate of the Lys-30, Leu-31 mutant was reduced by 60%. In addition, the salt concentration range over which these mutants processively nick dimer-containing DNA has been greatly expanded. Both mutants are shown to have an increased affinity for nontarget DNA.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University				Lloyd, R. Stephen/0000-0001-7273-372X	NCI NIH HHS [CA 09582] Funding Source: Medline; NIEHS NIH HHS [ES 00267, ES 04091] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES004091] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON WF, 1985, BIOSYSTEMS, V18, P3, DOI 10.1016/0303-2647(85)90056-5; ANDERSON WF, 1982, J MOL BIOL, V159, P745, DOI 10.1016/0022-2836(82)90111-5; BACON DJ, 1986, J MOL BIOL, V191, P153, DOI 10.1016/0022-2836(86)90252-4; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3833, DOI 10.1021/bi00516a026; BELINTSEV BN, 1980, NUCLEIC ACIDS RES, V8, P1391, DOI 10.1093/nar/8.6.1391; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERG OG, 1982, TRENDS BIOCHEM SCI, V7, P52, DOI 10.1016/0968-0004(82)90075-5; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BLOOMER AC, 1978, NATURE, V276, P362, DOI 10.1038/276362a0; BRUNGER AT, 1988, XPLOR VERSION 15 MAN; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; DOWD DR, 1990, J BIOL CHEM, V265, P3424; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; EHBRECHT HJ, 1985, J BIOL CHEM, V260, P6160; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GRUSKIN EA, 1988, J BIOL CHEM, V263, P12728; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HAMILTON RW, 1989, J BIOL CHEM, V265, P17422; HANNON R, 1980, EMBO J, V5, P3313; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; KAWASHIMA H, 1984, MOL GEN GENET, V193, P288, DOI 10.1007/BF00330682; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGOWSKI J, 1983, NUCLEIC ACIDS RES, V11, P501, DOI 10.1093/nar/11.2.501; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; LLOYD RS, 1978, CANCER RES, V38, P3191; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; MAZUR SJ, 1989, BIOPOLYMERS, V28, P929, DOI 10.1002/bip.360280503; MCMILLAN S, 1981, J VIROL, V40, P211, DOI 10.1128/JVI.40.1.211-223.1981; MORIKAWA K, 1988, J MOL BIOL, V202, P683, DOI 10.1016/0022-2836(88)90298-7; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; NARDONE G, 1986, J BIOL CHEM, V261, P2128; PARK CS, 1982, J BIOL CHEM, V257, P6950; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RADANY EH, 1984, J VIROL, V52, P846, DOI 10.1128/JVI.52.3.846-856.1984; RECINOS A, 1986, BIOCHEM BIOPH RES CO, V138, P945, DOI 10.1016/S0006-291X(86)80587-3; RECINOS A, 1986, J BACTERIOL, V168, P1014, DOI 10.1128/jb.168.2.1014-1018.1986; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4721, DOI 10.1021/bi00339a002; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SEAWELL PC, 1980, J VIROL, V35, P790, DOI 10.1128/JVI.35.3.790-796.1980; SINGER P, 1987, J BIOL CHEM, V262, P14178; SINGER PT, 1988, J BIOL CHEM, V263, P4208; STGEITZ TA, 1981, P NATL ACAD SCI USA, V79, P3097; STUBBS G, 1977, NATURE, V267, P215; SUNG MT, 1970, P NATL ACAD SCI USA, V67, P1616, DOI 10.1073/pnas.67.3.1616; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; VALERIE K, 1984, NUCLEIC ACIDS RES, V12, P8085, DOI 10.1093/nar/12.21.8085; VERSHON A K, 1986, Proteins Structure Function and Genetics, V1, P302, DOI 10.1002/prot.340010404; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WARNER HR, 1981, J VIROL, V40, P204, DOI 10.1128/JVI.40.1.204-210.1981; WHEELER AR, 1987, BIOCHEMISTRY-US, V26, P3322, DOI 10.1021/bi00386a012; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	64	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5634	5642						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005104				2022-12-25	WOS:A1991FD37000044
J	OZAKI, H; SATO, T; KUBOTA, H; HATA, Y; KATSUBE, Y; SHIMONISHI, Y				OZAKI, H; SATO, T; KUBOTA, H; HATA, Y; KATSUBE, Y; SHIMONISHI, Y			MOLECULAR-STRUCTURE OF THE TOXIC DOMAIN OF HEAT-STABLE ENTEROTOXIN PRODUCED BY A PATHOGENIC STRAIN OF ESCHERICHIA-COLI - A PUTATIVE BINDING-SITE FOR A BINDING-PROTEIN ON RAT INTESTINAL EPITHELIAL-CELL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BRUSH-BORDER MEMBRANES; ANALOG; RECEPTOR; DESIGN; STH	Heat-stable enterotoxins are a family of toxic peptides that are produced by enterotoxigenic Escherichia coli and consist of 18 and 19 amino acid residues (Aimoto, S., Takao, T., Shimonishi, Y., Hara, S., Takeda, T., Takeda, Y., and Miwatani, T. (1982) Eur. J. Biochem. 129, 257-263). A synthetic fully toxic analog of the enterotoxin, Mpr5-ST(p)(5-17), where Mpr is beta-mercaptopropionic acid and which consists of 13 amino acid residues from Cys5 to Cys17 in a heat-stable enterotoxin but is deaminated at its N terminus (Kubota, H., Hidaka, Y., Ozaki, H., Ito, H., Hirayama, T., Takeda, Y., and Shimonishi, Y. (1989) Biochem. Biophys. Res. Commun. 161, 229-235), has been crystallized from water, and its crystal structure has been solved by a direct method and refined by least square procedures to give an R factor of 0.089. The crystal belongs to the orthorhombic space group P2(1)2(1)2(1) with unit cell constants a = 21.010 (2) angstrom, b = 27.621 (4) angstrom, and c = 12.781 (1) angstrom. The asymmetric unit of the crystals contains one peptide molecule with 13 water molecules. A right-hand spiral peptide backbone extends throughout the molecule. Three beta-turns are located along this spiral and fixed tightly by three intramolecular disulfide linkages. The actual structure predicts the binding region on the enterotoxin to the receptor protein on the membrane of rat intestinal epithelial cells.	OSAKA UNIV, INST PROT RES, YAMADA OKA 3-2, SUITA, OSAKA 565, JAPAN	Osaka University								AIMOTO S, 1983, BIOCHEM BIOPH RES CO, V112, P320, DOI 10.1016/0006-291X(83)91833-8; AIMOTO S, 1982, EUR J BIOCHEM, V129, P257, DOI 10.1111/j.1432-1033.1982.tb07047.x; ASHIDA T, 1979, UNIVERSAL CRYSTALLOG, P53; FRANTZ JC, 1984, INFECT IMMUN, V43, P622, DOI 10.1128/IAI.43.2.622-630.1984; GARIEPY J, 1986, BIOCHEMISTRY-US, V25, P7854, DOI 10.1021/bi00372a011; GARIEPY J, 1986, P NATL ACAD SCI USA, V83, P483, DOI 10.1073/pnas.83.2.483; HIDAKA Y, 1988, PEPTIDE CHEM 1987, P159; HIRAYAMA T, 1990, ADV CHOLERA RELATED, V7, P105; IKEMURA H, 1984, B CHEM SOC JPN, V57, P2550, DOI 10.1246/bcsj.57.2550; JOHNSON CK, 1976, ORTEP II FORTRAN THE; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KUBOTA H, 1989, BIOCHEM BIOPH RES CO, V161, P229, DOI 10.1016/0006-291X(89)91585-4; KUNO T, 1986, J BIOL CHEM, V261, P1470; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OHKUBO T, 1986, BIOPOLYMERS, V25, pS123; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSENFIELD RE, 1975, ACTA CRYSTALLOGR B, V31, P462, DOI 10.1107/S0567740875003020; Sheldrick G.M, 1986, SHELXS86 PROGRAM CRY; SHIMONISHI Y, 1987, FEBS LETT, V215, P165, DOI 10.1016/0014-5793(87)80134-5; SMITH HW, 1970, J MED MICROBIOL, V3, P387, DOI 10.1099/00222615-3-3-387; TAKAO T, 1984, J BIOL CHEM, V259, P6105; TAKAO T, 1985, FEBS LETT, V193, P250, DOI 10.1016/0014-5793(85)80163-0; TAKAO T, 1983, FEBS LETT, V152, P1, DOI 10.1016/0014-5793(83)80469-4; TAKAO T, 1984, BIOCHEM BIOPH RES CO, V125, P845, DOI 10.1016/0006-291X(84)91360-3; THOMPSON MR, 1985, INFECT IMMUN, V47, P834, DOI 10.1128/IAI.47.3.834-836.1985; YAMASAKI S, 1990, B CHEM SOC JPN, V63, P2063, DOI 10.1246/bcsj.63.2063; YOSHIMURA S, 1985, FEBS LETT, V181, P138, DOI 10.1016/0014-5793(85)81129-7; ZANOTTI G, 1989, INT J PEPT PROT RES, V34, P222	28	91	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5934	5941						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005130				2022-12-25	WOS:A1991FD37000090
J	XIAO, H; KALMAN, M; IKEHARA, K; ZEMEL, S; GLASER, G; CASHEL, M				XIAO, H; KALMAN, M; IKEHARA, K; ZEMEL, S; GLASER, G; CASHEL, M			RESIDUAL GUANOSINE 3',5'-BISPYROPHOSPHATE SYNTHETIC ACTIVITY OF RELA NULL MUTANTS CAN BE ELIMINATED BY SPOT NULL MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; 5'-DIPHOSPHATE 3'-DIPHOSPHATE; GENE-PRODUCT; HISTIDINE OPERON; SALMONELLA-TYPHIMURIUM; STRINGENT RESPONSE; PROTEIN-SYNTHESIS; PPGPP; TETRAPHOSPHATE	It was known previously that 1) the relA gene of Escherichia coli encodes an enzyme capable of guanosine 3',5'-bispyrophosphate (ppGpp) synthesis, 2) an uncharacterized source of ppGpp synthesis exists in relA null strains, and 3) cellular degradation of ppGpp is mainly due to a manganese-dependent ppGpp 3'-pyrophosphohydrolase encoded by the spoT gene. Here, the effects of spoT gene insertions and deletions are compared with analogous alterations in neighboring genes in the spo operon and found to be lethal in relA+ strains as well as slower growing in relAl backgrounds than DELTA-relA hosts. Cells with null alleles in both the relA and spoT genes are found no longer to accumulate ppGpp after glucose exhaustion or after chelation of manganese ions by picolinic acid addition; the inability to form ppGpp is reversed by a minimal spoT gene on a multicopy plasmid. Strains apparently lacking ppGpp show a complex phenotype including auxotrophy for several amino acids and morphological alterations. We propose that the SpoT protein can either catalyze or control the alternative pathway of ppGpp synthesis in addition to its known role as a (p)ppGpp 3'-pyrophosphohydrolase. We favor the possibility that the SpoT protein is a bifunctional enzyme capable of catalyzing either ppGpp synthesis or degradation.	NICHHD,MOLEC REGULAT SECT,MOLEC GENET LAB,BLDG 6,RM 333,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)					PHS HHS [25286] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AN G, 1979, J BACTERIOL, V137, P1100, DOI 10.1128/JB.137.3.1100-1110.1979; ATHERLY AG, 1979, J BACTERIOL, V138, P530, DOI 10.1128/JB.138.2.530-534.1979; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; Belitskii B R, 1982, Mol Biol (Mosk), V16, P857; BRODA P, 1968, J BACTERIOL, V96, P1877; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; CHIARAMELLO AE, 1990, J BACTERIOL, V172, P2013, DOI 10.1128/jb.172.4.2013-2019.1990; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ENGEL JA, 1979, REGULATION MACROMOLE, P25; FEHR S, 1981, J BACTERIOL, V145, P68, DOI 10.1128/JB.145.1.68-73.1981; FREUNDLICH M, 1977, CELL, V12, P1121, DOI 10.1016/0092-8674(77)90174-X; FRIESEN JD, 1975, J BIOL CHEM, V250, P304; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GALLANT J, 1972, J BIOL CHEM, V247, P6055; GENTRY DR, 1986, GENE, V48, P33, DOI 10.1016/0378-1119(86)90349-5; GENTRY DR, 1988, J BACTERIOL, V171, P1271; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HASELTINE WA, 1973, P NATL ACAD SCI USA, V70, P1564, DOI 10.1073/pnas.70.5.1564; HEINEMEYER EA, 1977, FEBS LETT, V84, P357, DOI 10.1016/0014-5793(77)80724-2; HEINEMEYER EA, 1978, P NATL ACAD SCI USA, V75, P4180, DOI 10.1073/pnas.75.9.4180; HEINEMEYER EA, 1978, EUR J BIOCHEM, V89, P125, DOI 10.1111/j.1432-1033.1978.tb20904.x; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; IGARASHI K, 1989, NUCLEIC ACIDS RES, V17, P8755, DOI 10.1093/nar/17.21.8755; JOHNSON GS, 1979, J BIOL CHEM, V254, P5483; JUSTESEN J, 1986, BIOCHIMIE, V68, P715, DOI 10.1016/S0300-9084(86)80165-1; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LAFFLER T, 1974, CELL, V1, P27, DOI 10.1016/0092-8674(74)90151-2; LAGOSKY PA, 1980, J BACTERIOL, V144, P499, DOI 10.1128/JB.144.2.499-508.1980; LAGOSKY PA, 1981, J BIOL CHEM, V256, P1651; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; MATZURA H, 1968, J BACTERIOL, V96, P1877, DOI 10.1128/JB.96.5.1877-1879.1968; METZGER S, 1989, J BIOL CHEM, V264, P21146; METZGER S, 1989, J BIOL CHEM, V264, P9122; METZGER S, 1988, J BIOL CHEM, V263, P15699; Miller J.H, 1972, EXPT MOL GENETICS, P1; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PAO CC, 1978, MOL GEN GENET, V158, P271, DOI 10.1007/BF00267198; PEDERSEN FS, 1977, EUR J BIOCHEM, V76, P91, DOI 10.1111/j.1432-1033.1977.tb11573.x; QUAY SC, 1979, J BACTERIOL, V137, P1059, DOI 10.1128/JB.137.2.1059-1062.1979; RHEE SG, 1978, P NATL ACAD SCI USA, V75, P3138, DOI 10.1073/pnas.75.7.3138; RICHTER D, 1979, RIBOSOMES STRUCTURE, P743; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; RUDD KE, 1985, J BACTERIOL, V163, P534, DOI 10.1128/JB.163.2.534-542.1985; SARUBBI E, 1989, J BIOL CHEM, V264, P15074; SARUBBI R, 1988, MOL GEN GENET, V213, P214; SHAND RF, 1989, J BACTERIOL, V171, P737, DOI 10.1128/jb.171.2.737-743.1989; SOMERVILLE CR, 1979, J MOL BIOL, V111, P77; STAMMINGER G, 1974, CELL, V1, P85, DOI 10.1016/0092-8674(74)90066-X; STAUFFER GV, 1987, ESCHERICHIA COLI SAL, V1, P412; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; SY J, 1976, BIOCHEMISTRY-US, V15, P606, DOI 10.1021/bi00648a024; SY J, 1973, P NATL ACAD SCI USA, V70, P306, DOI 10.1073/pnas.70.2.306; SY J, 1980, J BIOL CHEM, V255, P56; SY J, 1977, P NATL ACAD SCI USA, V74, P5529, DOI 10.1073/pnas.74.12.5529; UZAN M, 1978, MOL GEN GENET, V165, P21, DOI 10.1007/BF00270372; UZAN M, 1976, BIOCHEM BIOPH RES CO, V69, P751, DOI 10.1016/0006-291X(76)90939-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; ZACHARIAS M, 1989, EMBO J, V8, P3357, DOI 10.1002/j.1460-2075.1989.tb08498.x	61	596	622	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5980	5990						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005134				2022-12-25	WOS:A1991FD37000096
J	RAWSON, C; SHIRAHATA, S; COLLODI, P; NATSUNO, T; BARNES, D				RAWSON, C; SHIRAHATA, S; COLLODI, P; NATSUNO, T; BARNES, D			ONCOGENE TRANSFORMATION FREQUENCY OF NONSENESCENT SFME CELLS IS INCREASED BY C-MYC	ONCOGENE			English	Note							MOUSE EMBRYO CELLS; RAS ONCOGENES; CULTURE; SERUM; GENE; FIBROBLASTS; INHIBITION	Immortalized, postcrisis mouse embryo cell cultures derived in serum-containing medium display genomic abnormalities and an altered, preneoplastic phenotype. These lines can be transformed with single oncogenes, such as Ha-ras, while efficient transformation of precrisis, genomically unaltered rodent embryo cultures require cooperating oncogenes, such as Ha-ras and the mouse c-myc gene constitutively expressed. Serum-free mouse embryo (SFME) cells, cultured under conditions in which serum is replaced by growth factors and other supplements, are 'immortalized' in the genomically unaltered state. SFME cells do not exhibit growth crisis or gross chromosomal aberration, and are dependent on epidermal growth factor for survival, growth inhibited by serum, and are nontumorigenic. Transformation of SFME cells can be achieved with ras alone, but the introduction of c-myc increased the transfection frequency upon subsequent transfection with ras by as much as twenty fold. Similar results were obtained with mutationally activated neu oncogene and with genomic human tumor DNA. Constitutive expression of c-myc alone did not alter the properties of the SFME cells. These results demonstrate that c-myc alters cellular responses to oncogenes in a culture system in which oncogene-induced immortalization is not a factor, indicating that the effects of myc may extend beyond an 'immortalization' function in these cells.	OREGON STATE UNIV,ENVIRONM HLTH SCI CTR,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University					NCPDCID CDC HHS [NCI-01226] Funding Source: Medline	NCPDCID CDC HHS		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; CORSARO CM, 1981, SOMAT CELL GENET, V7, P603, DOI 10.1007/BF01549662; GOSPODAROWICZ D, 1984, METHODS MOL CELL BIO, V1, P69; Ham R G, 1979, Methods Enzymol, V58, P44; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOO D, 1990, J CELL PHYSIOL, V142, P210, DOI 10.1002/jcp.1041420126; LOO D, 1989, J CELL PHYSIOL, V139, P484, DOI 10.1002/jcp.1041390306; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; LOO DT, 1989, CELL GROWTH CELL DIV, P17; Maniatis T., 1982, MOL CLONING; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; RAWSON C, 1990, EXP CELL RES, V186, P177, DOI 10.1016/0014-4827(90)90224-X; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SHIRAHATA S, 1990, J CELL PHYSIOL, V144, P69, DOI 10.1002/jcp.1041440110; SORRENTINO V, 1987, P NATL ACAD SCI USA, V84, P4131, DOI 10.1073/pnas.84.12.4131; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299	22	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					487	489						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011405				2022-12-25	WOS:A1991FT34400022
J	CAIRNS, W; CAIRNS, C; PONGRATZ, I; POELLINGER, L; OKRET, S				CAIRNS, W; CAIRNS, C; PONGRATZ, I; POELLINGER, L; OKRET, S			ASSEMBLY OF A GLUCOCORTICOID RECEPTOR COMPLEX PRIOR TO DNA-BINDING ENHANCES ITS SPECIFIC INTERACTION WITH A GLUCOCORTICOID RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR; TRANSCRIPTION FACTOR; GENE-REGULATION; PROTEIN; DIMER; ACID; EXPRESSION; HOMODIMER; SEQUENCE; DOMAIN	Gel retardation analysis with full- and half-palindromic sequences using partially purified glucocorticoid receptor (GR) resulted in GR-glucocorticoid response element (GRE) species of identical mobilities, suggesting that formation of the dimeric GR protein complex is not catalyzed by DNA binding. These results are in contrast to the behavior of the isolated DNA binding domain of the glucocorticoid receptor where dimerization occurred on the GRE. Density gradient centrifugation of cytosolic GR resulted in two forms, a 4 S peak characteristic of the monomeric GR and a fraction which sediments at 6 S which is consistent with the observed size of the dimeric GR. These two forms were found to differ in their ability to bind to specific DNA sequences with the 6 S species having a higher affinity for a GRE. Taken together our results are consistent with a two-step model for hormone-induced transformation of GR: dissociation of the multimeric untransformed complex and dimerization of the GR to yield a high affinity DNA binding species.			CAIRNS, W (corresponding author), KAROLINSKA INST,HUDDINGE UNIV HOSP F60,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN.							BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; DAHLMAN K, 1989, J BIOL CHEM, V264, P804; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DENIS M, 1987, J BIOL CHEM, V262, P11803; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELLSE, 1989, CELL, V60, P953; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GODOWSKI PJ, 1989, BIOCHEM PHARMACOL, V38, P3135, DOI 10.1016/0006-2952(89)90605-9; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; OKRET S, 1985, BIOCHEMISTRY-US, V24, P6581, DOI 10.1021/bi00344a041; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RODRIGUEZ R, 1990, MOL ENDOCRINOL, V4, P1782, DOI 10.1210/mend-4-12-1782; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHEIDEREIT C, 1986, DNA-J MOLEC CELL BIO, V5, P383, DOI 10.1089/dna.1986.5.383; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UNGER AL, 1988, MOL ENDOCRINOL, V2, P952, DOI 10.1210/mend-2-10-952; WRANGE O, 1989, J BIOL CHEM, V264, P5253; WRANGE O, 1986, J BIOL CHEM, V261, P1770	29	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11221	11226						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040629				2022-12-25	WOS:A1991FQ77400080
J	LOETSCHER, P; PRATT, G; RECHSTEINER, M				LOETSCHER, P; PRATT, G; RECHSTEINER, M			THE C-TERMINUS OF MOUSE ORNITHINE DECARBOXYLASE CONFERS RAPID DEGRADATION ON DIHYDROFOLATE-REDUCTASE - SUPPORT FOR THE PEST HYPOTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELA-CELLS; INTRACELLULAR DEGRADATION; SACCHAROMYCES-CEREVISIAE; ERYTHROLEUKEMIA-CELLS; RETICULOCYTE LYSATE; MEMBRANE-PROTEINS; ENZYME; ATP; SEQUENCES; GENE	Several years ago, we proposed that polypeptide regions rich in proline (P), glutamic acid (E), serine (S), and threonine (T) (PEST) target intracellular proteins for destruction (Rogers, S., Wells, R., and Rechsteiner, M. (1986) Science 234, 364-368). To test the PEST hypothesis, we have produced chimeric proteins in which the N or C terminus of mouse dihydrofolate reductase is extended by the PEST-containing C terminus of mouse ornithine decarboxylase. Oligonucleotides encoding the 37 C-terminal residues of mouse ornithine decarboxylase (mODC) or equivalent lengths of dissimilar amino acids were inserted at appropriate sites in a dihydrofolate reductase (DHFR) expression vector. The various fusion proteins were expressed in Escherichia coli and purified to homogeneity by enzyme affinity chromatography. All purified fusion proteins exhibited similar abilities to convert dihydrofolate to tetrahydrofolate, thereby demonstrating that the attachment of peptide extensions to either terminus did not prevent the proper folding of DHFR. Metabolic stabilities of the radioiodinated fusion proteins were assayed in rabbit reticulocyte lysate or Xenopus egg extract. Proteolysis was found to be energy-dependent with mODC-DHFR fusion proteins being degraded from 2 to almost 40-fold faster than the parental DHFR molecule or DHFR fusion proteins bearing non-PEST extensions. Deletion of most of the PEST region from the mODC extension resulted in a significantly more stable fusion protein. Rapid proteolysis of DHFR proteins containing intact mODC extensions provides support for the PEST hypothesis.	UNIV UTAH, SCH MED, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah								BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPECCHI MR, 1974, P NATL ACAD SCI USA, V71, P4732, DOI 10.1073/pnas.71.12.4732; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CLARKE S, 1983, TRENDS BIOCHEM SCI, V8, P391, DOI 10.1016/0968-0004(83)90300-6; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DIRCKS L, 1986, J CELL PHYSIOL, V126, P371, DOI 10.1002/jcp.1041260307; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FLAMIGNI F, 1989, BIOCHEM BIOPH RES CO, V163, P1217, DOI 10.1016/0006-291X(89)91107-8; FLAMIGNI F, 1990, BIOCHEM BIOPH RES CO, V172, P939, DOI 10.1016/0006-291X(90)90766-G; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1990, J BIOL CHEM, V265, P11823; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; GUPTA SV, 1977, BIOCHEMISTRY-US, V16, P3073, DOI 10.1021/bi00633a005; HENDIL KB, 1976, J CELL PHYSIOL, V87, P289, DOI 10.1002/jcp.1040870304; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; KAUFMAN BT, 1971, BIOCHEM BIOPH RES CO, V44, P608, DOI 10.1016/S0006-291X(71)80126-2; KNOWLES SE, 1976, BIOCHEM J, V156, P609, DOI 10.1042/bj1560609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGRELL JB, 1972, METHOD MOL BIOL, V2, P251; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MCILHINNEY A, 1974, BIOCHIM BIOPHYS ACTA, V372, P366, DOI 10.1016/0304-4165(74)90198-6; MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1987, NATURE, V326, P542, DOI 10.1038/326542a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; PROUTY WF, 1976, J CELL PHYSIOL, V89, P65, DOI 10.1002/jcp.1040890107; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; RECHSTEINER M, 1991, IN PRESS SEMIN CELL; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROGERS SW, 1988, J BIOL CHEM, V263, P19833; ROGERS SW, 1988, J BIOL CHEM, V263, P19850; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; ROTE K, 1989, J BIOL CHEM, V264, P9772; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW WV, 1987, BIOCHEM J, V246, P1; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STONE D, 1979, J BIOL CHEM, V254, P480; TSURU D, 1988, J BIOCHEM, V104, P580, DOI 10.1093/oxfordjournals.jbchem.a122514; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671	52	89	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11213	11220						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040628				2022-12-25	WOS:A1991FQ77400079
J	REESE, JC; KATZENELLENBOGEN, BS				REESE, JC; KATZENELLENBOGEN, BS			MUTAGENESIS OF CYSTEINES IN THE HORMONE BINDING DOMAIN OF THE HUMAN ESTROGEN-RECEPTOR - ALTERATIONS IN BINDING AND TRANSCRIPTIONAL ACTIVATION BY COVALENTLY AND REVERSIBLY ATTACHING LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; GLUCOCORTICOID RECEPTORS; KETONONESTROL AZIRIDINE; ANTIESTROGEN BINDING; TAMOXIFEN AZIRIDINE; STEROID-BINDING; MAMMALIAN-CELLS; DNA-BINDING; IDENTIFICATION; PROTEIN	We have carried out experiments to determine the role of the cysteines in the hormone-binding domain (HBD) of the human estrogen receptor (ER) in receptor function. In each mutant receptor, 1 of the 4 cysteines in the HBD (cysteines 381, 417, 447, and 530) was changed by in vitro mutagenesis of the ER cDNA (containing Gly400) from cysteine to alanine; Cys530 was also mutated to a serine. The mutant and wild-type receptor cDNAs were expressed in Chinese hamster ovary cells using an expression vector containing the Rous sarcoma virus promoter. The mutant and wildtype receptors were assayed for hormone binding and for their ability to activate estrogen-responsive reporter plasmids. All ER mutants bound estradiol (E2) with affinity similar to wild-type ER, displaying a K(d) between 0.3 and 0.8 nM (wild-type ER K(d) = 0.45 +/- 0.10 nM). All were capable of covalent labeling by the affinity ligands ketononestrol aziridine, an estrogen agonist, and tamoxifen aziridine, an antagonist. Since in previous work we identified Cys530 as the site of covalent attachment of these ligands (Harlow, K. W., Smith, D. N., Katzenellenbogen, J. A., Greene, G. L., and Katzenellenbogen, B. S. (1989) J. Biol. Chem. 264, 17476-17485) it appears that an alternate residue(s) can be labeled in the absence of a cysteine at position 530; studies with methyl methanethiosulfonate, a cysteine-specific reagent, suggest that this residue is probably another cysteine in the HBD. The C381A, C417A, C530A and C530S ERs showed E2-Stimulated transcriptional activation profiles similar to wild-type ER whereas the dose response for E2 for the C447A mutant was shifted to the right, requiring 50 x higher E2 concentrations to achieve half-maximal response. Tamoxifen aziridine inhibited E2-stimulated transcription, and ketononestrol aziridine stimulated transcription by wild-type, C530A, and C530S ER, but the effectiveness of these covalently attaching ligands was altered in the C530A and C530S mutants. Thus, these two mutant receptors are altered in their transactivation response to agonist and antagonist affinity labeling ligands but are unaltered in their response to reversibly binding estrogens and antiestrogens. In addition, we show that a mutant ER (C447A) can have an affinity for E2 similar to that of wild-type ER but differs in its ability to activate transcription in response to E2, indicating a decoupling of the hormone binding and transcriptional activation functions in this receptor.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,407 S GOODWIN AVE,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign				reese, joseph/0000-0003-3578-4266				BEATO M, 1989, CELL, V56, P6335; CHANG TC, 1990, J BIOL CHEM, V265, P8176; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; ELLISTON JF, 1987, ENDOCRINOLOGY, V121, P667, DOI 10.1210/endo-121-2-667; FAWELL SE, 1989, MOL ENDOCRINOL, V3, P1002, DOI 10.1210/mend-3-6-1002; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GILMOUR DS, 1985, MOL CELL BIOL, V5, P2009, DOI 10.1128/MCB.5.8.2009; GOLDING TS, 1988, P NATL ACAD SCI USA, V85, P69, DOI 10.1073/pnas.85.1.69; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; KATZENELLENBOGEN BS, 1987, BIOCHEMISTRY-US, V26, P2364, DOI 10.1021/bi00382a043; KATZENELLENBOGEN BS, 1985, BREAST CANCER RES TR, V5, P231, DOI 10.1007/BF01806018; KATZENELLENBOGEN BS, 1983, J STEROID BIOCHEM, V19, P59, DOI 10.1016/S0022-4731(83)80007-7; KATZENELLENBOGEN BS, 1981, J BIOL CHEM, V256, P2908; KATZENELLENBOGEN JA, 1983, J BIOL CHEM, V258, P3487; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MESHINCHI S, 1990, J BIOL CHEM, V264, P11643; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MILLER MA, 1984, CANCER RES, V44, P5038; MILLER NR, 1988, J BIOL CHEM, V263; MONUZ A, 1988, EMBO J, V7, P151; POULIN R, 1989, BREAST CANCER RES TR, V14, P65, DOI 10.1007/BF01805977; REESE JC, 1990, ENDOCRINOLOGY S, V126, P96; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SILVA CM, 1989, J BIOL CHEM, V264, P6638; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; THOMPSON EW, 1989, CANCER RES, V49, P6929; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WAKELING AE, 1987, J ENDOCRINOL, V112, pR7, DOI 10.1677/joe.0.112R007; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647	40	110	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10880	10887						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040605				2022-12-25	WOS:A1991FQ77400030
J	AIZAWA, H; EMORI, Y; MORI, A; MUROFUSHI, H; SAKAI, H; SUZUKI, K				AIZAWA, H; EMORI, Y; MORI, A; MUROFUSHI, H; SAKAI, H; SUZUKI, K			FUNCTIONAL ANALYSES OF THE DOMAIN-STRUCTURE OF MICROTUBULE-ASSOCIATED PROTEIN-4 (MAP-U)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-CORTEX; BINDING DOMAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; RAT CEREBELLUM; TAU PROTEINS; HELA-CELLS; BRAIN; PURIFICATION; CDNA; TUBULIN	Bovine microtubule-associated protein-4 (MAP-4), which was previously named MAP-U, consists of an amino-terminal projection domain (N-domain) and a carboxyl-terminal microtubule-binding domain (C-domain) (Aizawa, H., Emori, Y., Murofushi, H., Kawasaki, H., Sakai, H., and Suzuki, K. (1990) J. Biol. Chem. 265, 13849-13855). The C-domain contains a region rich in proline (Pro-rich region) and a region containing four assembly-promoting sequences (AP sequence region) which is shared by MAP-2 and tau. We purified a series of truncated fragments of MAP-4 expressed in Escherichia coli. An N-domain fragment did not bind to microtubules, while a C-domain fragment promoted microtubule assembly. Both of the fragments corresponding to the Pro-rich region (P fragment) and the AP sequence region (A4 fragment) promoted tubulin polymerization, although the A4 fragment had lower activity than intact MAP-4 and P fragment. A4 fragment produced morphologically normal microtubules whereas P fragment produced abnormal microtubules such as duplex microtubules and tight bundles of microtubules with diverse diameters. We concluded that both Pro-rich and AP sequence regions take part in the promotion of tubulin polymerization, and that the former is important for the MAP to bind to microtubules with high efficiency and the latter is essential for the formation of microtubules with normal morphology.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; Tokyo Metropolitan Institute of Medical Science								AIZAWA H, 1988, J BIOL CHEM, V263, P7703; AIZAWA H, 1990, J BIOL CHEM, V265, P13849; AIZAWA H, 1989, J BIOL CHEM, V264, P5885; BERNHARDT R, 1985, J NEUROSCI, V5, P977; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BULINSKI JC, 1980, J BIOL CHEM, V255, P1570; CACERES A, 1983, P NATL ACAD SCI-BIOL, V80, P1738, DOI 10.1073/pnas.80.6.1738; CHAPIN S J, 1990, Journal of Cell Biology, V111, p389A; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; Dustin P., 1984, MICROTUBULES; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOTTLIEB RA, 1985, J CELL BIOL, V101, P1782, DOI 10.1083/jcb.101.5.1782; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HUBER G, 1984, J NEUROSCI, V4, P151; HUBER G, 1984, J CELL BIOL, V98, P777, DOI 10.1083/jcb.98.2.777; IZANT JG, 1980, P NATL ACAD SCI-BIOL, V77, P4741, DOI 10.1073/pnas.77.8.4741; JACOBS M, 1975, NATURE, V257, P707, DOI 10.1038/257707a0; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KOTANI S, 1988, J BIOL CHEM, V263, P5385; KUZNETSOV SA, 1981, FEBS LETT, V135, P237, DOI 10.1016/0014-5793(81)80790-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LEWIS SA, 1986, J CELL BIOL, V102, P2106, DOI 10.1083/jcb.102.6.2106; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; LEWIS SA, 1986, J CELL BIOL, V102, P2098, DOI 10.1083/jcb.102.6.2098; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MATUS A, 1981, P NATL ACAD SCI-BIOL, V78, P3010, DOI 10.1073/pnas.78.5.3010; MUROFUSHI H, 1987, J BIOCHEM-TOKYO, V102, P1101, DOI 10.1093/oxfordjournals.jbchem.a122148; MUROFUSHI H, 1986, J CELL BIOL, V103, P1911, DOI 10.1083/jcb.103.5.1911; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; PARYSEK LM, 1984, J CELL BIOL, V99, P1309, DOI 10.1083/jcb.99.4.1309; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; VOTOR WA, 1982, J ULTRASTRUCT RES, V80, P374; WEATHERBEE JA, 1980, BIOCHEMISTRY-US, V19, P4116, DOI 10.1021/bi00558a033; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	42	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9841	9846						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033072				2022-12-25	WOS:A1991FM45900076
J	GRZESKOWIAK, K; YANAGI, K; PRIVE, GG; DICKERSON, RE				GRZESKOWIAK, K; YANAGI, K; PRIVE, GG; DICKERSON, RE			THE STRUCTURE OF B-HELICAL C-G-A-T-C-G-A-T-C-G AND COMPARISON WITH C-C-A-A-C-G-T-T-G-G - THE EFFECT OF BASE PAIR REVERSALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATIONAL ENHANCER ACTIVITY; DNA DODECAMER; CRYSTAL-STRUCTURE; CONFORMATION; COMPLEX; TRACT; FLEXIBILITY; REFINEMENT; DYNAMICS; GEOMETRY	The crystal structure of the DNA decamer C-G-A-T-C-G-A-T-C-G has been solved to a resolution of 1.5 angstrom, with a final R-factor of 16.1% for 5,107 two-sigma reflections. Crystals are orthorhombic space group P2(1)2(1)2(1), with cell dimensions a = 38.93 angstrom, b = 39.63 angstrom, c = 33.30 angstrom, and 10 base pairs/asymmetric unit. The final structure contains 404 DNA atoms, 142 water molecules treated as oxygen atoms, and two Mg(H2O)6(2+) complexes. Decamers stack atop one another to simulate continuous helical columns through the crystal, as with three previously solved monoclinic decamers, but the lateral contacts between columns are quite different in the orthorhombic and monoclinic cells. Narrow and wide regions of the minor groove exhibit a single spine or two ribbons of hydration, respectively, and the minor groove is widest when B(II) phosphate conformations are opposed diagonally across the groove. Phosphate conformation, in turn, appears to have a base sequence dependence. Twist, rise, cup, and roll are linked as has been observed in the three monoclinic decamers and can be characterized by high or low twist profiles. In all five known decamer crystal structures and eight representative dodecamers, a high twist profile is observed with G-C and G-A steps whereas all other R-R steps are low twist profiles (R = purine). A-T and A-C steps are intermediate in character whereas C-A and C-G exhibit behavior that is strongly influenced by the profiles of the preceding and following steps. When sufficient data are in hand, sequence/structure relationships for all helix parameters probably should be considered in a 4-base pair context. At this stage of limited information the problem is compounded because there are 136 unique 4-base steps x-A-B-y in a double helix as compared with only 10 2-base steps A-B.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Privé, Gilbert G/A-3039-2008	Prive, Gilbert/0000-0002-0712-4319	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031299] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31299] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; BRENNAN RG, 1986, J BIOMOL STRUCT DYN, V3, P649, DOI 10.1080/07391102.1986.10508453; BRENNAN RG, 1985, J MOL BIOL, V181, P561, DOI 10.1016/0022-2836(85)90429-2; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chandrasekaran R., 1989, LANDOLTBORNSTEIN B, V1/II, P31; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; COLL M, 1989, BIOCHEMISTRY-US, V28, P310, DOI 10.1021/bi00427a042; CRUSE WBT, 1986, J MOL BIOL, V192, P891, DOI 10.1016/0022-2836(86)90035-5; Dickerson R.E., 1990, STRUCTURE METHODS, V3, P1; DICKERSON RE, 1987, J BIOMOL STRUCT DYN, V5, P557, DOI 10.1080/07391102.1987.10506413; DICKERSON RE, 1989, J BIOMOL STRUCT DYN, V6, P627, DOI 10.1080/07391102.1989.10507726; DICKERSON RE, 1989, NUCLEIC ACIDS RES, V17, P1797, DOI 10.1093/nar/17.5.1797; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; DICKERSON RE, 1990, IN PRESS NUCLEOSIDES; Dickerson RE, 1989, EMBO J, V8, P1; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; HEINEMANN U, 1989, J MOL BIOL, V210, P369, DOI 10.1016/0022-2836(89)90337-9; HEINEMANN U, 1991, IN PRESS EMBO J; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HUBNER P, 1989, J MOL BIOL, V205, P493, DOI 10.1016/0022-2836(89)90220-9; JOHNSON RC, 1987, NATURE, V329, P462, DOI 10.1038/329462a0; KOPKA ML, 1983, J MOL BIOL, V163, P129, DOI 10.1016/0022-2836(83)90033-5; LARSEN TL, 1990, THESIS UCLA; LEVITT M, 1978, J AM CHEM SOC, V100, P2607, DOI 10.1021/ja00477a004; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OLSON WK, 1982, NUCLEIC ACIDS RES, V10, P777, DOI 10.1093/nar/10.3.777; Prive G. G., 1988, STRUCTURE EXPRESSION, V2, P27; PRIVE GG, 1987, SCIENCE, V238, P498, DOI 10.1126/science.3310237; PRIVE GG, 1991, J MOL BIOL, V217, P177, DOI 10.1016/0022-2836(91)90619-H; ROBERTS RJ, 1987, NUCLEIC ACIDS RES, V15, pR189, DOI 10.1093/nar/15.suppl.r189; Rossmann M. G., 1972, MOL REPLACEMENT METH; Saenger W., 1989, J MOL BIOL, V205, P787; WESTHOF E, 1987, J BIOMOL STRUCT DYN, V5, P581, DOI 10.1080/07391102.1987.10506414; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0; YANAGI K, 1991, J MOL BIOL, V217, P201, DOI 10.1016/0022-2836(91)90620-L; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332	41	171	174	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8861	8883						23	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026600				2022-12-25	WOS:A1991FM03800036
J	TAKATA, Y; WEBSTER, NJG; OLEFSKY, JM				TAKATA, Y; WEBSTER, NJG; OLEFSKY, JM			MUTATION OF THE 2 CARBOXYL-TERMINAL TYROSINES RESULTS IN AN INSULIN-RECEPTOR WITH NORMAL METABOLIC SIGNALING BUT ENHANCED MITOGENIC SIGNALING PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERED AUTOPHOSPHORYLATION SITES; PROTEIN KINASE-C; GROWTH FACTOR-I; CELL-CYCLE; PHOSPHORYLATION; BINDING; ENDOCYTOSIS; REPLACEMENT; ACTIVATION; MUTANTS	Our previous studies have shown that the deletion of the insulin receptor carboxyl terminus impairs metabolic, but augments mitogenic, signaling (McClain, D. A., Maegawa, H., Levy, J., Huecksteadt, T., Dull, T. J., Lee, J., Ullrich, A., and Olefsky, J. M. (1988) J. Biol. Chem. 263, 8904-8911; Thies, R. S., Ullrich, A., and McClain, D. A. (1989) J. Biol. Chem. 264, 12820-12825). To explore further the regulatory role of the insulin receptor carboxyl terminus, a mutant insulin receptor was constructed in which the two tyrosines (Y1316 and Y1322) on the carboxyl terminus were replaced with phenylalanines. Rat 1 fibroblasts expressing high levels of this mutant receptor (Y/F2 cells) exhibited normal insulin binding and normal insulin internalization. The absence of the two tyrosines in the carboxyl terminus did not affect the phosphotransferase activity of the beta-subunit and insulin-stimulated glucose transport. However, the Y/F2 cells showed markedly enhanced sensitivity for insulin-stimulated DNA synthesis. Dose-response curves for both insulin-stimulated thymidine uptake and 5-bromo-2-deoxyuridine incorporation in the Y/F2 cell lines were shifted to the left (4-10-fold) compared with those observed in the cells expressing similar numbers of wild type receptors. Thus, the two tyrosines of the insulin receptor carboxyl terminus do not modulate the kinase function of the insulin receptor, although they are autophosphorylated in native receptors. Moreover, these tyrosines are not necessary for stimulation of glucose transport. On the other hand, these results suggest that the two carboxyl-terminal tyrosine residues exert an inhibitory effect on mitogenic signaling in native insulin receptors.	UNIV CALIF SAN DIEGO,DEPT MED V111G,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,RES SERV,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Webster, Nick/AAI-8410-2021		PHS HHS [33651] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; CAWOOD AH, 1983, CELL TISSUE KINET, V16, P51; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GAWLER D, 1988, BIOCHEM J, V249, P537, DOI 10.1042/bj2490537; GOREN HJ, 1987, BIOCHEMISTRY-US, V26, P2374, DOI 10.1021/bi00382a044; GRUNBERGER G, 1984, SCIENCE, V223, P932, DOI 10.1126/science.6141638; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KARASIK A, 1990, J BIOL CHEM, V265, P10226; KAZILAUSKAS A, 1990, SCIENCE, V247, P1578; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LEVY JR, 1988, J BIOL CHEM, V263, P6101; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1990, J BIOL CHEM, V265, P947; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; THIES RS, 1989, J BIOL CHEM, V264, P12820; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; ZAPF J, 1986, HORM RES, V24, P121, DOI 10.1159/000180551	35	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9135	9139						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026614				2022-12-25	WOS:A1991FM03800072
J	STAATZ, WD; FOK, KF; ZUTTER, MM; ADAMS, SP; RODRIGUEZ, BA; SANTORO, SA				STAATZ, WD; FOK, KF; ZUTTER, MM; ADAMS, SP; RODRIGUEZ, BA; SANTORO, SA			IDENTIFICATION OF A TETRAPEPTIDE RECOGNITION SEQUENCE FOR THE ALPHA-2-BETA-1-INTEGRIN IN COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX RECEPTORS; ADHESIVE PROTEINS; CELL-ADHESION; DEPENDENT ADHESION; PLATELET-ADHESION; LAMININ RECEPTOR; FIBRONECTIN; BINDING; COMPLEX; FAMILY	The alpha-2-beta-1 integrin serves as either a specific cell surface receptor for collagen or as both a collagen and laminin receptor depending upon the cell type. Recently we established that the alpha-2-beta-1 integrin binds to a site within the alpha-1(I)-CB3 fragment of type I collagen (Staatz, W. D., Walsh, J. J., Pexton, T., and Santoro, S. A. (1990) J. Biol. Chem. 265, 4778-4781). To define the alpha-2-beta-1 recognition sequence further we have prepared an overlapping set of synthetic peptides which completely spans the 148-amino acid alpha-1(I)-CB3 fragment and tested the peptides for ability to inhibit cell adhesion to collagen and laminin substrates. The minimal active recognition sequence defined by these experiments is a tetrapeptide of the sequence Asp-Gly-Glu-Ala (DGEA) corresponding to residues 435-438 of the type I collagen sequence. The DGEA-containing peptides effectively inhibited alpha-2-beta-1-mediated Mg2+-dependent adhesion of platelets, which use the alpha-2-beta-1 integrin as a collagen-specific receptor, to collagen but had no effect on alpha-5-beta-1-mediated platelet adhesion to fibronectin or alpha-6-beta-1-mediated platelet adhesion to laminin. In contrast, with T47D breast adenocarcinoma cells, which use alpha-2-beta-1 as a collagen/laminin receptor, adhesion to both collagen and laminin was inhibited by DGEA-containing peptides. Deletion of the alanine residue or substitution of alanine for either the glutamic or aspartic acid residues in DGEA-containing peptides resulted in marked loss of inhibitory activity. These results indicate that the amino acid sequence DGEA serves as a recognition site for the alpha-2-beta-1 integrin complex on platelets and other cells.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,BOX 8118,ST LOUIS,MO 63110; MONSANTO CO,ST LOUIS,MO 63198; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Monsanto; Washington University (WUSTL)					NHLBI NIH HHS [HL 40506] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040506] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORNSTEI.P, 1966, BIOCHEMISTRY-US, V5, P3460, DOI 10.1021/bi00875a012; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHELBERG MK, 1990, J CELL BIOL, V111, P262; CHIANG TM, 1975, J BIOL CHEM, V250, P6916; COLLER BS, 1989, BLOOD, V74, P182; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FAUVEL F, 1978, THROMB RES, V12, P273, DOI 10.1016/0049-3848(78)90298-0; FAUVEL F, 1980, THROMB RES, V12, P841; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAVERSTICK DM, 1985, BLOOD, V66, P946; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEGRAND YJ, 1980, BIOCHEM BIOPH RES CO, V96, P1579, DOI 10.1016/0006-291X(80)91354-6; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; MOULD AP, 1990, J BIOL CHEM, V265, P4020; PISCHEL KD, 1988, J CLIN INVEST, V81, P505, DOI 10.1172/JCI113348; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WILKE MS, 1990, J INVEST DERMATOL, V95, P264, DOI 10.1111/1523-1747.ep12484883	35	363	398	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7363	7367						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019571				2022-12-25	WOS:A1991FJ34200011
J	YOO, SH; ALBANESI, JP				YOO, SH; ALBANESI, JP			HIGH-CAPACITY, LOW AFFINITY CA2+ BINDING OF CHROMOGRANIN-A - RELATIONSHIP BETWEEN THE PH-INDUCED CONFORMATIONAL CHANGE AND CA2+ BINDING PROPERTY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; RABBIT SKELETAL-MUSCLE; PURIFIED RYANODINE RECEPTOR; CALCIUM-RELEASE CHANNEL; AMINO-ACID SEQUENCE; ENDOPLASMIC-RETICULUM; TERMINAL CISTERNAE; MOLECULAR-CLONING; NERVOUS-TISSUE; MESSENGER-RNA	Chromogranin A, the major intravesicular protein of adrenal chromaffin granules, bound Ca2+ in a pH-dependent manner. Both the maximal binding and affinity of chromogranin A for Ca2+ were dependent on pH. Chromogranin A bound 670 nmol of Ca2+/mg (32 mol/mol) and 1150 nmol of Ca2+/mg (55 mol/mol) at pH 7.5 and 5.5, respectively, with dissociation constants (K(d)) of 2.7 and 4 mM. This pH dependence probably reflects different conformations of the protein at the two pH values. Conformational differences of chromogranin A at two different pH values were demonstrated by limited tryptic digestion patterns confirming previous results obtained by circular dichroism spectroscopy (Yoo, S. H., and Albanesi, J. P. (1990) J. biol. Chem. 265, 14414-14421). Sedimentation equilibrium studies revealed the native molecular mass of chromogranin A to be 100 kDa at pH 7.5 ad 192 kDa at pH 5.5, indicating dimeric and tetrameric states of the protein at the two pH levels. we postulate that the pH- and Ca2+-induced conformational changes of chromogranin A may have a role both in the regulation of Ca2+ release of chromaffin granules and in the early stages of secretory vesicle biogenesis.	UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038567] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM38567] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BLASCHKO H, 1967, NATURE, V215, P58, DOI 10.1038/215058a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; CALA SE, 1983, J BIOL CHEM, V258, P1932; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; COZENS B, 1984, J BIOL CHEM, V259, P6248; FISCHERCOLBRIE R, 1987, ANN NY ACAD SCI, V493, P120, DOI 10.1111/j.1749-6632.1987.tb27189.x; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FLIEGEL L, 1989, BIOCHIM BIOPHYS ACTA, V982, P1, DOI 10.1016/0005-2736(89)90166-1; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; GREELEY GH, 1989, ENDOCRINOLOGY, V124, P1235, DOI 10.1210/endo-124-3-1235; HELLE KB, 1966, MOL PHARMACOL, V2, P298; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; HUTTNER WB, 1987, ANN NY ACAD SCI, V493, P397, DOI 10.1111/j.1749-6632.1987.tb27223.x; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IKEMOTO N, 1974, J BIOL CHEM, V249, P2357; IKEMOTO N, 1972, J BIOL CHEM, V247, P7835; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; KOCH GLE, 1989, BIOCHEM SOC T, V17, P328, DOI 10.1042/bst0170328; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LONGANO SC, 1988, ARCH BIOCHEM BIOPHYS, V263, P410, DOI 10.1016/0003-9861(88)90653-4; MACER DRJ, 1988, J CELL SCI, V91, P61; MACLENNAN DH, 1973, COLD SPRING HARB SYM, V37, P469, DOI 10.1101/SQB.1973.037.01.058; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MAURER A, 1985, P NATL ACAD SCI USA, V82, P4036, DOI 10.1073/pnas.82.12.4036; MICHALAK M, 1980, J BIOL CHEM, V255, P1317; MINTON AP, 1990, ANAL BIOCHEM, V190, P1, DOI 10.1016/0003-2697(90)90125-S; OCONNOR DT, 1984, J BIOL CHEM, V259, P3237; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; OSTWALD TJ, 1974, J BIOL CHEM, V249, P5867; REIFFEN FU, 1986, BIOCHEMISTRY-US, V25, P4402, DOI 10.1021/bi00363a034; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; REITHMEIER RAF, 1987, CALCIUM BINDING PROT, P62; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SIETZEN M, 1987, NEUROSCIENCE, V22, P131, DOI 10.1016/0306-4522(87)90203-X; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V262, P1; SMITH AD, 1967, BIOCHEM J, V103, P483, DOI 10.1042/bj1030483; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SMITH WJ, 1967, MOL PHARMACOL, V3, P52; TAKEMOTO K, 1986, NATURE, V324, P476; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; VAN PN, 1989, J BIOL CHEM, V264, P17494; WAISMAN DM, 1985, J BIOL CHEM, V260, P1652; WEILER R, 1990, FEBS LETT, V265, P27, DOI 10.1016/0014-5793(90)80875-J; WILLIAMS RW, 1986, J BIOL CHEM, V261, P2408; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; YOO SH, 1990, BIOCHIM BIOPHYS ACTA, V1040, P66, DOI 10.1016/0167-4838(90)90146-7; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1990, J BIOL CHEM, V265, P13446	63	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7740	7745						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019597				2022-12-25	WOS:A1991FJ34200067
J	MAGNUSSON, I; SCHUMANN, WC; BARTSCH, GE; CHANDRAMOULI, V; KUMARAN, K; WAHREN, J; LANDAU, BR				MAGNUSSON, I; SCHUMANN, WC; BARTSCH, GE; CHANDRAMOULI, V; KUMARAN, K; WAHREN, J; LANDAU, BR			NONINVASIVE TRACING OF KREBS CYCLE METABOLISM IN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC GLYCOGEN FORMATION; QUANTITATIVE-ANALYSIS; RAT-LIVER; GLUCONEOGENESIS INVIVO; GLUCOSE-LOAD; PATHWAYS; COMPARTMENTATION; CARBON; ATOMS; C-14	To quantify intrahepatic Krebs cycle metabolism, phenyl acetate, excreted in urine as a glutamine conjugate, was given to healthy subjects infused with [3-C-14]lactate. They were studied after 60 h of fasting and when given glucose after an overnight fast. Distributions of C-14 in glutamate from urinary phenylacetylglutamine and blood glucose were determined. Corrections to the distributions because of the fixation of (CO2)-C-14 formed from the [3-C-14]lactate were determined by administering [C-14]bicarbonate. Comparisons of distributions in glucose and glutamate support the assumption that the glutamate distributions reflect those in hepatic alpha-ketoglutarate. From the distributions in glutamate, the extent of exchange of labeled with unlabeled carbons and relative flow rates in the cycle in liver were estimated. Dilution of C-14 by C-12 in the cycle was found in the fasted but not the fed state. In the fasted state, pyruvate carboxylation was estimated to be at least twice the rate of Krebs cycle flux and the rate of pyruvate's decarboxylation < 1/25 the rate of its carboxylation. In the fed state, the rate of decarboxylation was estimated to be between one-sixth and one-half the rate of carboxylation. The rate of conversion of oxalacetate to fumarate in both states appeared to be > 6 times the rate of Krebs cycle flux.	UNIV HOSP CLEVELAND,DEPT MED,2074 ABINGTON RD,CLEVELAND,OH 44106; KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN PHYSIOL,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,DEPT CLIN PHYSIOL,S-10401 STOCKHOLM 60,SWEDEN; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; UNIV MINNESOTA,DIV BIOMETRY,MINNEAPOLIS,MN 55414	University Hospitals of Cleveland; Karolinska Institutet; Karolinska Institutet; Case Western Reserve University; Case Western Reserve University; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014507, R37DK014507] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-14507] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ambrose AM, 1933, J BIOL CHEM, V101, P669; BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; BARTELS H, 1987, FEBS LETT, V221, P277, DOI 10.1016/0014-5793(87)80940-7; BERNSTEIN IA, 1957, METHOD ENZYMOL, V4, P561, DOI 10.1016/0076-6879(57)04071-9; Bernt E., 1974, METHODS ENZYMATIC AN, P1704, DOI DOI 10.1016/B978-0-12-091304-6.50017-3; BRIN M, 1952, ARCH BIOCHEM BIOPHYS, V39, P214, DOI 10.1016/0003-9861(52)90275-0; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; CRABTREE B, 1990, BIOCHEM J, V270, P219, DOI 10.1042/bj2700219; EKLOF R, 1983, SCAND J GASTROENTERO, V18, P9; EXTON JH, 1967, J BIOL CHEM, V242, P2622; GOEBEL R, 1982, FED PROC, V41, P96; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HEMS R, 1984, FEBS LETT, V177, P138, DOI 10.1016/0014-5793(84)80998-9; HEMS R, 1983, FEBS LETT, V153, P438, DOI 10.1016/0014-5793(83)80659-0; HETENYI G, 1982, FED PROC, V41, P104; HETENYI G, 1982, CAN J PHYSIOL PHARM, V60, P1603, DOI 10.1139/y82-237; HILL RJ, 1958, J BIOL CHEM, V230, P169; HOSTETLER KY, 1969, J BIOL CHEM, V244, P2075; JAMES MO, 1972, P R SOC LONDON B, V182, P5; KADISH AH, 1968, CLIN CHEM, V14, P116; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KATZ J, 1989, J BIOL CHEM, V264, P12994; KATZ J, 1987, FEBS LETT, V220, P257, DOI 10.1016/0014-5793(87)80916-X; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; KOEPPE RE, 1955, J BIOL CHEM, V216, P813; KOEPPE RE, 1966, CAN J BIOCHEM CELL B, V44, P1289, DOI 10.1139/o66-147; LANDAU BR, 1985, METHOD ENZYMOL, V110, P100; LANDAU BR, 1988, FASEB J, V2, P2368, DOI 10.1096/fasebj.2.8.3282961; LEMIEUX G, 1976, AM J PHYSIOL, V231, P1068, DOI 10.1152/ajplegacy.1976.231.4.1068; MAGNUSSON I, 1987, J CLIN INVEST, V80, P1748, DOI 10.1172/JCI113267; MAGNUSSON I, 1989, METABOLISM, V38, P583, DOI 10.1016/0026-0495(89)90221-7; MAGNUSSON I, 1988, P NATL ACAD SCI USA, V86, P4682; MARSOLAIS C, 1989, J BIOL CHEM, V264, P19761; MARSOLAIS C, 1987, J BIOL CHEM, V262, P2604; MOLDAVE K, 1957, J BIOL CHEM, V229, P463; MOSBACH EH, 1951, ARCH BIOCHEM BIOPHYS, V33, P179, DOI 10.1016/0003-9861(51)90095-1; NORSTEN C, 1990, BIOCHEM J, V265, P569, DOI 10.1042/bj2650569; RADZIUK J, 1989, AM J PHYSIOL, V257, pE158, DOI 10.1152/ajpendo.1989.257.2.E158; ROSE IA, 1962, J BIOL CHEM, V237, P3325; RUDERMAN NB, 1975, ANNU REV MED, V26, P245, DOI 10.1146/annurev.me.26.020175.001333; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; SHULMAN G, 1986, DIABETES, V35, pA38; SHULMAN GI, 1987, J CLIN INVEST, V80, P387, DOI 10.1172/JCI113084; SIMELL O, 1986, PEDIATR RES, V20, P1117, DOI 10.1203/00006450-198611000-00011; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; SWIM HE, 1954, J BACTERIOL, V67, P419, DOI 10.1128/JB.67.4.419-425.1954; Van SLYKE DONALD D., 1940, JOUR BIOL CHEM, V136, P509; WALS PA, 1988, J BIOL CHEM, V263, P4876; WEINMAN EO, 1957, PHYSIOL REV, V37, P252, DOI 10.1152/physrev.1957.37.2.252; WILLIAMS CM, 1969, BIOCHEM MED METAB B, V3, P164, DOI 10.1016/0006-2944(69)90008-8; WOLFE RR, 1988, AM J PHYSIOL, V254, pE532, DOI 10.1152/ajpendo.1988.254.4.E532; 1959, INT COMMISSION RADIO, V2	53	164	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6975	6984						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016309				2022-12-25	WOS:A1991FG72700054
J	LI, ZL; PAULIN, D				LI, ZL; PAULIN, D			HIGH-LEVEL DESMIN EXPRESSION DEPENDS ON A MUSCLE-SPECIFIC ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE GENE; ALPHA-SUBUNIT GENE; TROPONIN-I GENE; ACETYLCHOLINE-RECEPTOR; REGULATORY ELEMENTS; HAMSTER DESMIN; ACTIN GENE; DEVELOPMENTAL REGULATION; INTERMEDIATE FILAMENTS; FUNCTIONAL-ANALYSIS	Expression of the desmin gene is increased several-fold during myogenesis. To identify the DNA sequences involved in this regulation, a 16-kilobase fragment containing a 4.5-kilobase 5'-flanking region and the complete sequence of the human desmin gene has been isolated. The transcription initiation sites were determined by S1 nuclease mapping and primer extension analysis. A series of constructs have been made by fusing different lengths of human desmin 5'-flanking fragments to the bacterial chloramphenicol acetyl transferase (CAT) gene, these constructs were introduced either into mouse myogenic cells or into nonmyogenic cells. Comparison of the transient expression of CAT between myogenic and nonmyogenic cells demonstrated that the sequence including 228 base pairs upstream of the transcription initiation site is sufficient to confer low level, muscle-specific expression of the desmin gene. A negative region was located between -693 and -228 base pairs relative to the desmin mRNA start site. High level expression of the gene depends on a 280-base pair muscle-specific enhancer located between -693 and -973 base pairs upstream of the transcription initiation site. This enhancer can activate either the desmin promoter or heterologous promoters about 20-70-fold in myogenic cells. The enhancer, which also acts in myoblast, is discussed in the context of early expression of the desmin during skeletal myogenesis in the mammalian embryo.	INST PASTEUR,PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LI, ZL (corresponding author), UNIV PARIS 07,BIOL MOLEC & DIFFERENTIAT CELLULAIRE LAB,25 RUE DR ROUX,PARIS 15,FRANCE.		Li, Zhenlin/E-3937-2016	LI, Zhenlin/0000-0002-3706-4505				BABAI F, 1990, DIFFERENTIATION, V44, P132, DOI 10.1111/j.1432-0436.1990.tb00546.x; BALDWIN TJ, 1989, NATURE, V341, P716, DOI 10.1038/341716a0; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BOLMONT C, 1990, J SUBMICR CYTOL PATH, V22, P117; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUCKINGHAM ME, 1989, BRIT MED BULL, V45, P608, DOI 10.1093/oxfordjournals.bmb.a072348; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CAPETANAKI YG, 1984, P NATL ACAD SCI-BIOL, V81, P6909, DOI 10.1073/pnas.81.22.6909; CARAVATTI M, 1982, J MOL BIOL, V160, P59, DOI 10.1016/0022-2836(82)90131-0; DAUBAS P, 1988, NUCLEIC ACIDS RES, V16, P1251, DOI 10.1093/nar/16.4.1251; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRICHNIK JM, 1986, NUCLEIC ACIDS RES, V14, P2956; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HILL CS, 1986, J CELL BIOL, V103, P2185, DOI 10.1083/jcb.103.6.2185; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JIANG CK, 1990, NUCLEIC ACIDS RES, V18, P247, DOI 10.1093/nar/18.2.247; JORCANO JL, 1984, J MOL BIOL, V176, P21, DOI 10.1016/0022-2836(84)90380-2; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; KAUFMAN SJ, 1989, CELLULAR MOL BIOL MU, P47; KLARSFELD A, 1987, MOL CELL BIOL, V7, P951, DOI 10.1128/MCB.7.2.951; KONIECZNY SF, 1987, MOL CELL BIOL, V7, P3065, DOI 10.1128/MCB.7.9.3065; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEONARD GD, 1986, BASIC METHOD MOL BIO; LI ZL, 1989, GENE, V78, P243; LILIENBAUM A, 1986, EMBO J, V5, P2809, DOI 10.1002/j.1460-2075.1986.tb04572.x; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LILIENBAUM A, 1988, CELL MOL BIOL, V34, P663; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MINTY A, 1986, MOL CELL BIOL, V6, P2137, DOI 10.1128/MCB.6.6.2137; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; OLSON EN, 1989, ONCOGENE, V4, P907; PIEPER FR, 1987, EMBO J, V6, P3611, DOI 10.1002/j.1460-2075.1987.tb02692.x; PIEPER FR, 1988, MOL BIOL REP, V13, P59, DOI 10.1007/BF00805640; PIETTE J, 1989, EMBO J, V8, P687, DOI 10.1002/j.1460-2075.1989.tb03427.x; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; QUAX W, 1985, CELL, V43, P327, DOI 10.1016/0092-8674(85)90038-8; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAX CM, 1988, NUCLEIC ACIDS RES, V16, P8058; SEILERTUYNS A, 1984, P NATL ACAD SCI-BIOL, V81, P2980, DOI 10.1073/pnas.81.10.2980; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TRASK RV, 1988, J BIOL CHEM, V263, P17142; WANG XM, 1990, EMBO J, V9, P783, DOI 10.1002/j.1460-2075.1990.tb08174.x; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	70	65	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6562	6570						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007603				2022-12-25	WOS:A1991FE37300083
J	LADINE, JR; CARLOW, D; LEE, WT; CROSS, RL; FLYNN, TG; LEVY, HR				LADINE, JR; CARLOW, D; LEE, WT; CROSS, RL; FLYNN, TG; LEVY, HR			INTERACTION OF LEUCONOSTOC-MESENTEROIDES GLUCOSE-6-PHOSPHATE-DEHYDROGENASE WITH PYRIDOXAL 5'-DIPHOSPHO-5'-ADENOSINE - AFFINITY LABELING OF LYS-21 AND LYS-343	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; REACTIVE LYSINE RESIDUE; ACTIVE-SITE; LYSYL RESIDUES; SEQUENCE; 5'-PHOSPHATE; PHOSPHATE; PEPTIDE; KINASES; PROTEIN	Pyridoxal 5'-diphospho-5'-adenosine (PLP-AMP) inhibits glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides competitively with respect to glucose 6-phosphate and noncompetitively with respect to NAD+ or NADP+, with K(i) = 40-mu-M in the NADP-linked and 34-mu-M in the NAD-linked reaction. Incubation of glucose-6-phosphate dehydrogenase with [H-3]PLP-AMP followed by borohydride reduction shows that incorporation of 0.85 mol of PLP-AMP per mol of enzyme subunit is required for complete inactivation. Both glucose 6-phosphate and NAD+ protect against this covalent modification. The proteolysis of the modified enzyme and isolation and sequencing of the labeled peptides revealed that Lys-21 and Lys-343 are the sites of PLP-AMP interaction and that glucose 6-phosphate and NAD+ protect both lysyl residues against modification. Pyridoxal 5'-phosphate (PLP) also modifies Lys-21 and probably Lys-343. Lys-21 is part of a highly conserved region that is present in all glucose-6-phosphate dehydrogenases that have been sequenced. Lys-343 corresponds to an arginyl residue in other glucose-6-phosphate dehydrogenases and is in a region that is less homologous with those enzymes. PLP-AMP and PLP are believed to interact with L. mesenteroides glucose-6-phosphate dehydrogenase at the glucose 6-phosphate binding site. Simultaneous binding of NAD+ induces conformational changes (Kurlandsky, S. B., Hilburger, A. C., and Levy, H. R. (1988) Arch. Biochem. Biophys. 264, 93-102) that are postulated to interfere with Schiff's-base formation with PLP or PLP-AMP. One or both of the lysyl residues covalently modified by PLP or PLP-AMP may be located in regions of the enzyme undergoing the NAD+-induced conformational changes.	SYRACUSE UNIV,DEPT BIOL,BIOL RES LABS,130 COLL PL,SYRACUSE,NY 13244; SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,SYRACUSE,NY 13210; QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA	Syracuse University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Queens University - Canada					NCRR NIH HHS [SO7 RR07068-22] Funding Source: Medline; NIGMS NIH HHS [GM 41085, GM 23152] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023152, R37GM023152, R01GM041085] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MJ, 1983, J BIOL CHEM, V258, P5867; BHADBHADE MM, 1987, FEBS LETT, V211, P243, DOI 10.1016/0014-5793(87)81445-X; CARMADELLA L, 1988, EUR J BIOCHEM, V171, P485; CARMADELLA L, 1981, BIOCHEM BIOPH RES CO, V103, P1384; Cleland W W, 1979, Methods Enzymol, V63, P103; COLOMBO G, 1974, BIOCHEMISTRY-US, V13, P3085, DOI 10.1021/bi00712a014; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; DEMOSS RD, 1953, J BACTERIOL, V66, P10, DOI 10.1128/JB.66.1.10-16.1953; FOUTS D, 1988, GENE, V63, P261, DOI 10.1016/0378-1119(88)90530-6; GRONENBORN AM, 1984, EUR J BIOCHEM, V145, P365, DOI 10.1111/j.1432-1033.1984.tb08563.x; HAGHIGHI B, 1982, BIOCHEMISTRY-US, V21, P6415, DOI 10.1021/bi00268a015; HAGHIGHI B, 1982, BIOCHEMISTRY-US, V21, P6421, DOI 10.1021/bi00268a016; HO YS, 1988, NUCLEIC ACIDS RES, V16, P7746, DOI 10.1093/nar/16.15.7746; JEFFERY J, 1989, BIOCHEM BIOPH RES CO, V160, P1290, DOI 10.1016/S0006-291X(89)80143-3; JEFFERY J, 1989, EUR J BIOCHEM, V186, P551, DOI 10.1111/j.1432-1033.1989.tb15242.x; JEFFERY J, 1985, BIOCHEMISTRY-US, V24, P666, DOI 10.1021/bi00324a019; JOHANSSON S, 1974, J BIOL CHEM, V249, P6040; KASLOW D C, 1987, Genomics, V1, P19, DOI 10.1016/0888-7543(87)90100-5; KEMP RG, 1964, J BIOL CHEM, V239, P2998; KURLANDSKY SB, 1988, ARCH BIOCHEM BIOPHYS, V264, P93, DOI 10.1016/0003-9861(88)90574-7; LADINE JR, 1991, IN PRESS J BIOL CHEM, V266; LEVY HR, 1983, ARCH BIOCHEM BIOPHYS, V222, P473, DOI 10.1016/0003-9861(83)90546-5; LEVY HR, 1989, BIOCHEM SOC T, V17, P313, DOI 10.1042/bst0170313; MILHAUSEN M, 1975, EUR J BIOCHEM, V50, P453, DOI 10.1111/j.1432-1033.1975.tb09823.x; MORJANA NA, 1989, J BIOL CHEM, V264, P2912; OLIVE C, 1971, J BIOL CHEM, V246, P2047; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P2511, DOI 10.1093/nar/14.6.2511; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P7822; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; TAGAYA M, 1986, BIOCHEMISTRY-US, V25, P2958, DOI 10.1021/bi00358a034; TAKIZAWA T, 1986, P NATL ACAD SCI USA, V83, P4157, DOI 10.1073/pnas.83.12.4157; TAMURA JK, 1986, J BIOL CHEM, V261, P4126; TAMURA JK, 1988, J BIOL CHEM, V263, P7907; TAMURA JK, 1985, FED PROC, V44, P1619	35	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5558	5562						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005097				2022-12-25	WOS:A1991FD37000033
J	MOLLEMAN, A; HOITING, B; DUIN, M; VANDENAKKER, J; NELEMANS, A; DENHERTOG, A				MOLLEMAN, A; HOITING, B; DUIN, M; VANDENAKKER, J; NELEMANS, A; DENHERTOG, A			POTASSIUM CHANNELS REGULATED BY INOSITOL 1,3,4,5-TETRAKISPHOSPHATE AND INTERNAL CALCIUM IN DDT1 MF-2 SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG TAENIA CECI; 1,4,5-TRISPHOSPHATE KINASE-ACTIVITY; ADRENOCEPTOR STIMULATION; BINDING-PROTEIN; HISTAMINE; CA-2+; TRISPHOSPHATE; RECEPTOR; PHOSPHATES; ACTIVATION	This study was carried out to determine the intracellular components responsible for the transmembrane current evoked by stimulation of H-1-histaminergic receptors in DDT1 MF-2 smooth muscle cells. Histamine elicited an outward current that was reversed below the K+ equilibrium potential and passed voltage-independent K+ channels. A histamine concentration-dependent rise in outward current and in cytoplasmic-free Ca2+ with similar time courses was observed. The histamine-induced current was not found after depletion of internal Ca2+ stores, suggesting a coupling between internal Ca2+ and K+ current. The time course of the initial increase in inositol (1,4,5)-trisphosphate (Ins (1,4,5)P3) caused by histamine differs from that of the internal Ca2+ response. However, a significant concentration-dependent increase in inositol (1,3,4,5)-tetrakisphosphate (Ins (1,3,4,5)P4) was seen during the whole stimulating period. The role of internal Ca2+, Ins (1,4,5)P3, and Ins (1,3,4,5)P4 on the outward current was also examined by the addition of these substances directly to the cytoplasm. Internal application of Ca2+ increased the amplitude and duration of the histamine-induced current whereas internal EGTA suppressed the outward current. Internal Ins (1,4,5)P3 did not affect the histamine-induced K+ current, Ins (1,3,4,5)P4 inhibited the outward current, and the combination of Ins (1,3,4,5)P4 and Ca2+ abolished this response. The noradrenaline response evoked under normal conditions is not reflected by a change in transmembrane current or a change in Ins (1,3,4,5)P4 but is associated with an increase in Ins (1,4,5)P3 and internal Ca2+. Stimulation of alpha-1-adrenoceptors, however, also evoked an outward current after the addition of Ins (1,3,4,5)P4 intracellularly. It is concluded that K+ channels, carrying the histamine outward current, are activated from the combined action of internal Ca2+ and Ins (1,3,4,5)P4.			MOLLEMAN, A (corresponding author), UNIV GRONINGEN, DEPT PHARMACOL & CLIN PHARMACOL, BLOEMSINGEL 1, 9713 BZ GRONINGEN, NETHERLANDS.							AMBLER SK, 1989, MOL PHARMACOL, V35, P369; BENHAM CD, 1985, NATURE, V316, P345, DOI 10.1038/316345a0; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BIDEN TJ, 1988, BIOCHEM J, V256, P697, DOI 10.1042/bj2560697; BIELKIEWICZVOLLRATH B, 1987, MOL PHARMACOL, V31, P513; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; CHILVERS ER, 1989, EUR J PHARMACOL, V164, P587, DOI 10.1016/0014-2999(89)90269-0; CHIU AT, 1987, J PHARMACOL EXP THER, V240, P123; DENHERTOG A, 1982, J PHYSIOL-LONDON, V325, P423, DOI 10.1113/jphysiol.1982.sp014160; DENHERTOG A, 1981, J PHYSIOL-LONDON, V316, P109; DONALDSON J, 1985, BRIT J PHARMACOL, V85, P499, DOI 10.1111/j.1476-5381.1985.tb08887.x; DONIE F, 1989, FEBS LETT, V254, P155, DOI 10.1016/0014-5793(89)81029-4; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HALL IP, 1988, BRIT J PHARMACOL, V95, P1204, DOI 10.1111/j.1476-5381.1988.tb11757.x; HANSEN CA, 1986, J BIOL CHEM, V261, P8100; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HESCHELER J, 1987, BIOMED BIOCHIM ACTA, V46, pS677; HESKETH TR, 1983, J BIOL CHEM, V258, P4876; HOITING B, 1990, EUR J PHARM-MOLEC PH, V189, P31, DOI 10.1016/0922-4106(90)90227-O; IMBODEN JB, 1987, J CLIN INVEST, V79, P1538, DOI 10.1172/JCI112986; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOHANSON RA, 1988, J BIOL CHEM, V263, P7465; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MATSUMOTO T, 1989, AM J PHYSIOL, V257, pH563, DOI 10.1152/ajpheart.1989.257.2.H563; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MITSUHASHI M, 1989, MOL PHARMACOL, V35, P751; MITSUHASHI M, 1988, J CELL PHYSIOL, V134, P367, DOI 10.1002/jcp.1041340307; MOLLEMAN A, 1989, EUR J PHARMACOL, V169, P167, DOI 10.1016/0014-2999(89)90829-7; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; MURRAY RK, 1989, AM J PHYSIOL, V257, pL209, DOI 10.1152/ajplung.1989.257.4.L209; NELEMANS A, 1987, EUR J PHARMACOL, V133, P215, DOI 10.1016/0014-2999(87)90153-1; NELEMANS A, 1987, EUR J PHARMACOL, V140, P39, DOI 10.1016/0014-2999(87)90631-5; NELEMANS A, 1990, EUR J PHARM-MOLEC PH, V189, P41, DOI 10.1016/0922-4106(90)90228-P; NORRIS JS, 1974, NATURE, V248, P422, DOI 10.1038/248422a0; OKABE K, 1987, PFLUG ARCH EUR J PHY, V409, P561, DOI 10.1007/BF00584654; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; REMBOLD CM, 1989, AM J PHYSIOL, V257, pC122, DOI 10.1152/ajpcell.1989.257.1.C122; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SHEARS SB, 1989, CELL SIGNAL, V1, P125, DOI 10.1016/0898-6568(89)90001-6; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; VILLALOBOSMOLINA R, 1983, EUR J PHARMACOL, V90, P457, DOI 10.1016/0014-2999(83)90573-3; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091	46	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5658	5663						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005105				2022-12-25	WOS:A1991FD37000047
J	AGELLON, LB; WALSH, A; HAYEK, T; MOULIN, P; JIANG, XC; SHELANSKI, SA; BRESLOW, JL; TALL, AR				AGELLON, LB; WALSH, A; HAYEK, T; MOULIN, P; JIANG, XC; SHELANSKI, SA; BRESLOW, JL; TALL, AR			REDUCED HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL IN HUMAN CHOLESTERYL ESTER TRANSFER PROTEIN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER PROTEIN; HUMAN-PLASMA; MONOCLONAL-ANTIBODY; APOLIPOPROTEIN-E; GENE; INHIBITION; ATHEROSCLEROSIS; SUSCEPTIBILITY; TRIGLYCERIDE; ACCUMULATION	The human cholesteryl ester transfer protein (CETP) facilitates the exchange of neutral lipids among lipoproteins. In order to evaluate the effects of increased plasma CETP on lipoprotein levels, a human CETP minigene was placed under the control of the mouse metallothionein-I promoter and used to develop transgenic mice. Integration of the human CETP transgene into the mouse genome resulted in the production of active plasma CETP. Zinc induction of CETP transgene expression caused depression of serum cholesterol due to a significant reduction of high density lipoprotein cholesterol. There was no change in total cholesterol content in very low and low density lipoproteins. However, there was a decrease in the free cholesterol/ cholesteryl ester ratio in plasma and in all lipoprotein fractions of transgenic mouse plasma, suggesting stimulation of plasma cholesterol esterification. The results suggest that high levels of plasma CETP activity may be a cause of reduced high density lipoproteins in humans.	ROCKEFELLER UNIV, BIOCHEM GENET & METAB LAB, NEW YORK, NY 10021 USA	Rockefeller University	AGELLON, LB (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV MOLEC MED, 630 W 168TH ST, NEW YORK, NY 10032 USA.		Breslow, Jan L/B-7544-2008; Tall, Alan/AAT-8528-2021		NHLBI NIH HHS [HL32435, HL43165, HL22682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL043165, R01HL032435, R01HL022682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; BISGAIER CL, 1991, J LIPID RES, V32, P21; BRECKENRIDGE WC, 1985, ARTERIOSCLEROSIS, V5, P256, DOI 10.1161/01.ATV.5.3.256; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; CHAJEK T, 1980, BIOCHEMISTRY-US, V19, P3673, DOI 10.1021/bi00557a006; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HA YC, 1985, BIOCHIM BIOPHYS ACTA, V833, P203, DOI 10.1016/0005-2760(85)90191-2; HA YC, 1986, COMP BIOCHEM PHYS B, V83, P463; Hatch F T, 1968, Adv Lipid Res, V6, P1; HESLER CB, 1988, J BIOL CHEM, V263, P5020; HESLER CB, 1987, J BIOL CHEM, V262, P2275; HOFMANN SL, 1988, SCIENCE, V239, P1277, DOI 10.1126/science.3344433; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JARNAGIN AS, 1987, P NATL ACAD SCI USA, V84, P1854, DOI 10.1073/pnas.84.7.1854; JIANG XC, 1991, J BIOL CHEM, V266, P4631; LEBOEUF RC, 1990, J LIPID RES, V31, P91; MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397; MCPHERSON R, 1991, IN PRESS ARTERIOSCLE; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORTON RE, 1981, J BIOL CHEM, V256, P1992; NEWNHAM HH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P57, DOI 10.1016/0005-2760(90)90218-M; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SMITH JD, 1990, J BIOL CHEM, V265, P14709; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; TALL A, 1987, J CLIN INVEST, V79, P1217, DOI 10.1172/JCI112940; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; WALSH A, 1989, J BIOL CHEM, V264, P6488; WEISGRABER KH, 1983, CRC HDB ELECTROPHORE, P103; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112	38	268	278	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10796	10801						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040599				2022-12-25	WOS:A1991FQ77400017
J	CARONI, P; ROTHENFLUH, A; MCGLYNN, E; SCHNEIDER, C				CARONI, P; ROTHENFLUH, A; MCGLYNN, E; SCHNEIDER, C			S-CYCLOPHILIN - NEW MEMBER OF THE CYCLOPHILIN FAMILY ASSOCIATED WITH THE SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							A-BINDING-PROTEIN; CIS-TRANS-ISOMERASE; PEPTIDYL-PROLYL ISOMERASE; NEUROSPORA-CRASSA; CYCLOSPORINE-A; SACCHAROMYCES-CEREVISIAE; IMMUNOSUPPRESSANT FK506; FK506-BINDING PROTEIN; SEQUENCE-ANALYSIS; GENE	Cyclophilin is an abundant and ubiquitous cytosolic protein that is conserved throughout evolution from man to bacteria. It is the target of the immunosuppressive drug cyclosporin A. Cyclophilin has peptidyl-prolyl cis/trans-isomerase activity, and it accelerates protein folding in vitro, suggesting that it might be involved in the folding of cytosolic proteins. We describe a novel cyclophilin-like protein, S-cyclophilin, in the chick. Analysis of S-cyclophilin cDNA revealed the presence of a signal sequence followed by an open reading frame coding for a protein very similar to cytosolic cyclophilin, except for the presence of unique additional short amino acid segments at the N and C termini of the protein. S-Cyclophilin mRNA was abundant and present in all embryonic chick tissues tested. Cyclophilin and S-cyclophilin are coded by separate genes in the chick genome. Recombinant S-cyclophilin was expressed in insect cells by means of the baculovirus system. Pulse-chase experiments revealed that a significant fraction of newly synthesized recombinant S-cyclophilin was rapidly secreted into the culture medium. Our findings indicate that cyclophilins are associated with most if not all intra- and extracellular compartments and suggest that enzyme-assisted conformational conversions in proteins might also take place in post-endoplasmic reticulum compartments, possibly including the extracellular space.	CIBA GEIGY AG,DEPT ONCOL,CH-4002 BASEL,SWITZERLAND	Novartis	CARONI, P (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.			Rothenfluh, Adrian/0000-0002-3813-5723				CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHRMANN U, 1986, DEV BIOL, V118, P209, DOI 10.1016/0012-1606(86)90089-8; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; Maniatis T., 1982, MOL CLONING; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SPIK G, 1991, J BIOL CHEM, V266, P10735; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SUMMERS MD, 1988, TEXAS A M B TEXAS AG, V1555; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	31	109	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10739	10742						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040593				2022-12-25	WOS:A1991FQ77400008
J	LEONARD, JL; EKENBARGER, DM; FRANK, SJ; FARWELL, AP; KOEHRLE, J				LEONARD, JL; EKENBARGER, DM; FRANK, SJ; FARWELL, AP; KOEHRLE, J			LOCALIZATION OF TYPE-I IODOTHYRONINE 5'-DEIODINASE TO THE BASOLATERAL PLASMA-MEMBRANE IN RENAL CORTICAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE ISOMERASE; RAT-LIVER; SUBCELLULAR-LOCALIZATION; REVERSE TRIIODOTHYRONINE; TRI-IODOTHYRONINE; THYROID-HORMONES; PROXIMAL TUBULE; KIDNEY; THYROXINE; BINDING	Type I iodothyronine 5'-deiodinase is an integral membrane protein catalyzing the phenolic ring deiodination of thyroxine. We recently showed that the substrate binding subunit of this approximately 50-kDa protein is selectively labeled with N-bromoacetyl-L-thyroxine, allowing ready identification of the type I enzyme without the need to maintain catalytic activity. In this study, we used both affinity labeling and catalytic activity to determine the regional distribution of this enzyme in rat kidney and to localize the enzyme to specific plasma membrane domain(s) of renal epithelial cells. The type I enzyme was present exclusively in tubular epithelial cells of the outer renal cortex and co-purified with basolateral plasma membranes; the renal medulla lacked activity. LLC-PK, cells, derived from the proximal convoluted tubule, have abundant type I 5'-deiodinating activity. We used this homogenous cell line to verify that the type I enzyme was localized to the cytosolic surface of the basolateral membrane. Digitonin permeabilization increased affinity labeling of the enzyme 4-fold, and approximately 75% of the affinity label was incorporated into the 27-kDa substrate binding subunit. Affinity labeling of the type I enzyme in LLC-PK1 cells mimicked the affinity labeling of the substrate binding subunit of type I 5'-deiodinase in rat kidney (Kohrle, J., Rasmussen, U. B., Ekenbarger, D. M., Alex, S., Rokos, H., Hesch, R. D., and Leonard, J. L. (1990) J. Biol. Chem. 265, 6155-6163). Subcellular fractionation of LLC-PK1 cell homogenates showed that both affinity labeled and catalytically active type I enzyme were present on the cytosolic surface of the basolateral region of the renal cell membrane.			LEONARD, JL (corresponding author), UNIV MASSACHUSETTS,SCH MED,MOLEC ENDOCRINOL LAB,WORCESTER,MA 01655, USA.		Köhrle, Josef/AAH-6438-2020	Köhrle, Josef/0000-0002-9187-9078; Farwell, Alan/0000-0001-7716-2719	NIDDK NIH HHS [DK38772, T32 DK07302] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007302, R01DK038772] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFDEMBRINKE D, 1979, BIOCHEM J, V180, P273, DOI 10.1042/bj1800273; BENVENGA S, 1988, J CLIN ENDOCR METAB, V67, P6, DOI 10.1210/jcem-67-1-6; BENVENGA S, 1989, ENDOCRINOLOGY, V124, P1265, DOI 10.1210/endo-124-3-1265; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BOADO RJ, 1988, ENDOCRINOLOGY, V123, P1264, DOI 10.1210/endo-123-3-1264; BOADO RJ, 1988, BIOCHEM BIOPH RES CO, V155, P1297, DOI 10.1016/S0006-291X(88)81282-8; Booth A G, 1974, Biochem J, V142, P575; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG SY, 1980, P NATL ACAD SCI-BIOL, V77, P3425, DOI 10.1073/pnas.77.6.3425; EMERY AEH, 1967, BIOCHEM J, V105, P599, DOI 10.1042/bj1050599; EVANS WH, 1978, PREPARATION CHARACTE, P93; FEKKES D, 1979, BIOCHIM BIOPHYS ACTA, V587, P12, DOI 10.1016/0304-4165(79)90215-0; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; HEIDRICH H, 1972, J CELL BIOL, V54, P232, DOI 10.1083/jcb.54.2.232; HENNEMANN G, 1986, ENDOCRINOLOGY, V119, P1870, DOI 10.1210/endo-119-4-1870; HESCH RD, 1975, CLIN CHIM ACTA, V59, P209, DOI 10.1016/0009-8981(75)90031-5; HEYMA P, 1978, CLIN SCI MOL MED, V55, P567, DOI 10.1042/cs0550567; HORIUCHI R, 1981, J BIOL CHEM, V257, P3139; INOUE M, 1983, J BIOL CHEM, V258, P5183; KINNESAF.E, 1974, J MEMBRANE BIOL, V17, P263, DOI 10.1007/BF01870187; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87; LEONARD JL, 1981, BIOCHIM BIOPHYS ACTA, V659, P205, DOI 10.1016/0005-2744(81)90285-0; LEONARD JL, 1980, ENDOCRINOLOGY, V107, P1376, DOI 10.1210/endo-107-5-1376; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P274, DOI 10.1210/endo-103-1-274; LEONARD JL, 1986, FRONTIERS THYROIDOLO, V1, P437; Leonard JL, 1986, THYROID HORMONE META, P189; MACIEL RMB, 1979, ENDOCRINOLOGY, V104, P365, DOI 10.1210/endo-104-2-365; MCELLIGOTT MA, 1985, J BIOL CHEM, V260, P1986; Meister A, 1976, ENZYMES BIOL MEMBR, Vv3, P315; MOL JA, 1986, J BIOL CHEM, V261, P7640; MOL JA, 1984, BIOCHEM BIOPH RES CO, V124, P475, DOI 10.1016/0006-291X(84)91578-X; MOORE DJ, 1971, METHOD ENZYMOL, V22, P130; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RAO ML, 1982, BIOCHEM J, V206, P19, DOI 10.1042/bj2060019; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SAFRAN M, 1990, ENDOCRINOLOGY, V126, P826, DOI 10.1210/endo-126-2-826; SCHOENMAKERS CHH, 1989, BIOCHEM BIOPH RES CO, V162, P857, DOI 10.1016/0006-291X(89)92389-9; SIMONS K, 1987, EMBO J, V6, P2241, DOI 10.1002/j.1460-2075.1987.tb02496.x; SPIRO RG, 1967, J BIOL CHEM, V242, P1915; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trouet A, 1974, Methods Enzymol, V31, P323; TSAO B, 1980, J BIOL CHEM, V255, P7708; WEEKE J, 1973, SCAND J CLIN LAB INV, V32, P357, DOI 10.3109/00365517309084359	45	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11262	11269						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040632				2022-12-25	WOS:A1991FQ77400086
J	STREMLER, KE; STAFFORINI, DM; PRESCOTT, SM; MCINTYRE, TM				STREMLER, KE; STAFFORINI, DM; PRESCOTT, SM; MCINTYRE, TM			HUMAN PLASMA PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE - OXIDATIVELY FRAGMENTED PHOSPHOLIPIDS AS SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; BOVINE BRAIN; PAF; PHOSPHATIDYLCHOLINE; DIFFERENTIATION; LIPOPROTEIN; DEGRADATION; HYDROLYSIS; PROTECTION	Human plasma platelet-activating factor (PAF) acetylhydrolase hydrolyzes the sn-2 acetyl residue of PAF, but not phospholipids with long chain sn-2 residues. It is associated with low density lipoprotein (LDL) particles, and is the LDL-associated phospholipase A2 activity that specifically degrades oxidatively damaged phospholipids (Stremler, K. E., Stafforini, D. M., Prescott, S. M., Zimmerman, G. A., and McIntyre, T. M. (1989) J. Biol. Chem. 264, 5331-5334). To identify potential substrates, we synthesized phosphatidylcholines with sn-2 residues from two to nine carbon atoms long, and found the V/k ratio decreased as the sn-2 residue was lengthened: the C5 homolog was 50%, the C6 20%, while the C-9 homolog was only 2% as efficient as PAF. However, the presence of an omega-oxo function radically affected hydrolysis: the half-life of the sn-2 9-aldehydic homolog was identical to that of PAF. We oxidized [2-arachidonoyl]phosphatidylcholine and isolated a number of more polar phosphatidylcholines. We treated these with phospholipase C, derivatized the resulting diglycerides for gas chromatographic/ mass spectroscopic analysis, and found a number of diglycerides where the m/z ratio was consistent with a series of short to medium length sn-2 residues. We treated the polar phosphatidylcholines with acetylhydrolase and derivatized the products for analysis by gas chromatography/mass spectroscopy. The liberated residues were more polar than straight chain standards and had m/z ratios from 129 to 296, consistent with short to medium chain residues. Therefore, oxidation fragments the sn-2 residue of phospholipids, and the acetylhydrolase specifically degrades such oxidatively fragmented phospholipids.	UNIV UTAH, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INS, BLDG 500, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT INTERNAL MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828, R01HL034127] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09602] Funding Source: Medline; NHLBI NIH HHS [HL34127, HL35828] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; COREY EJ, 1972, J AM CHEM SOC, V94, P6190, DOI 10.1021/ja00772a043; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; GOETZL EJ, 1980, BIOCHEM BIOPH RES CO, V94, P881, DOI 10.1016/0006-291X(80)91317-0; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HANDLEY DA, 1987, THROMB HAEMOSTASIS, V57, P187; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V963, P192, DOI 10.1016/0005-2760(88)90280-9; Kates M., 1972, LABORATORY TECHNIQUE, V3, P393; MUELLER HW, 1983, J BIOL CHEM, V258, P6213; NIJSSEN JG, 1986, BIOCHIM BIOPHYS ACTA, V876, P611, DOI 10.1016/0005-2760(86)90050-0; RUBIN DB, 1988, RADIAT RES, V116, P364, DOI 10.2307/3577473; SHEN TY, 1987, PLATELET ACTIVATING, P153; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; STAFFORINI DM, 1991, METHOD ENZYMOL, V197, P411; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; TAN KH, 1984, BIOCHEM J, V220, P243, DOI 10.1042/bj2200243; TERASHITA Z, 1983, LIFE SCI, V32, P1975, DOI 10.1016/0024-3205(83)90049-8; TOKUMURA A, 1985, J BIOL CHEM, V260, P2710; TOKUMURA A, 1988, BIOCHEM BIOPH RES CO, V155, P863, DOI 10.1016/S0006-291X(88)80575-8; TOUQUI L, 1985, BIOCHEM J, V229, P811, DOI 10.1042/bj2290811; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WARDLOW ML, 1986, J IMMUNOL, V136, P3441; YASUDA M, 1977, JPN J PHARMACOL, V27, P429, DOI 10.1254/jjp.27.429; YOSHIDA JI, 1986, J PHARM PHARMACOL, V38, P878, DOI 10.1111/j.2042-7158.1986.tb03375.x; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1987, AM REV RESPIR DIS, V136, P204, DOI 10.1164/ajrccm/136.1.204	35	276	282	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11095	11103						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040620				2022-12-25	WOS:A1991FQ77400061
J	HILL, KE; LLOYD, RS; YANG, JG; READ, R; BURK, RF				HILL, KE; LLOYD, RS; YANG, JG; READ, R; BURK, RF			THE CDNA FOR RAT SELENOPROTEIN-P CONTAINS 10 TGA CODONS IN THE OPEN READING FRAME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN GLUTATHIONE-PEROXIDASE; AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; MESSENGER-RNA; ACTIVE-SITE; SELENIUM; SELENOCYSTEINE; PURIFICATION; EXPRESSION	Selenoprotein P is a plasma protein recently purified and characterized as containing 7.5 +/- 1.0 selenium atoms/molecule as selenocysteine. In rats maintained on a defined diet containing nutritionally adequate amounts of selenate as the sole selenium source, over half the selenium in plasma is accounted for by selenoprotein P. Its cDNA has been cloned from a rat liver library and sequenced. The sequence is highly unusual, containing 10 TGA codons in its open reading frame prior to the TAA termination codon. TGA designates selenocysteine in other selenoproteins, and limited peptide sequencing that included the amino acids encoded by two of the TGA codons verified that they correspond to selenocysteine. The deduced 366-amino acid sequence is histidine- and cysteine-rich and contains 9 of its selenocysteines in the terminal 122 amino acids. Comparison of the deduced amino acid sequence of selenoprotein P with those of other selenoproteins reveals no significant similarities. Selenoprotein P represents a new class of selenoproteins and is the first protein described with more than 1 selenocysteine in a single polypeptide chain. The primary structure of selenoprotein P suggests that it might be responsible for some of the antioxidant properties of selenium.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University	HILL, KE (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV GASTROENTEROL,C-2104,MCN,NASHVILLE,TN 37232, USA.			Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES 00267, ES 02497] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R37ES002497, R01ES002497] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BURK RF, 1983, ANNU REV NUTR, V3, P53, DOI 10.1146/annurev.nu.03.070183.000413; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; BURK RF, 1991, IN PRESS AM J PHYSL; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; DUNN DK, 1989, NUCLEIC ACIDS RES, V17, P6390, DOI 10.1093/nar/17.15.6390; GUNZLER WA, 1984, H-S Z PHYSIOL CHEM, V365, P195, DOI 10.1515/bchm2.1984.365.1.195; HO YS, 1988, NUCLEIC ACIDS RES, V16, P5207, DOI 10.1093/nar/16.11.5207; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; MENON NK, 1987, J BACTERIOL, V169, P5401, DOI 10.1128/jb.169.12.5401-5407.1987; MENON NK, 1988, J BACTERIOL, V170, P4429; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; READ R, 1990, J BIOL CHEM, V265, P17899; SLIWKOWSKI MX, 1988, P NATL ACAD SCI USA, V85, P368, DOI 10.1073/pnas.85.2.368; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7178, DOI 10.1093/nar/15.17.7178; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; YANG JG, 1987, J BIOL CHEM, V262, P13372; YANG JG, 1989, J NUTR, V119, P1010, DOI 10.1093/jn/119.7.1010; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	27	216	226	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10050	10053						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037562				2022-12-25	WOS:A1991FP08600009
J	TODD, MJ; HAUSINGER, RP				TODD, MJ; HAUSINGER, RP			REACTIVITY OF THE ESSENTIAL THIOL OF KLEBSIELLA-AEROGENES UREASE - EFFECT OF PH AND LIGANDS ON THIOL MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JACK BEAN UREASE; 2,2'-DIPYRIDYL DISULFIDE; ACTIVE-SITE; PURIFICATION; PAPAIN; SEQUENCE; ANIONS; PROBE	The kinetics of Klebsiella aerogenes urease inactivation by disulfide and alkylating agents was examined and found to follow pseudo-first-order kinetics. Reactivity of the essential thiol is affected by the presence of substrate and competitive inhibitors, consistent with a cysteine located proximal to the active site. In contrast to the results observed with other reagents, the rate of activity loss in the presence of 5,5'-dithiobis(2-nitrobenzoic acid)(DTNB) saturated at high reagent concentrations, indicating that DTNB must first bind to urease before inactivation can occur. The pH dependence for the rate of urease inactivation by both disulfide and alkylating agents was consistent with an interaction between the thiol and a second ionizing group. The resulting macroscopic pK(a) values for the 2 residues are <5 and 12. Spectrophotometric studies at pH 7.75 demonstrated that 2,2'-dithiodipyridine (DTDP) modified 8.5 +/- 0.2 mol of thiol/mol of enzyme or 4.2 mol of thiol/mol of catalytic unit. With the slow tight binding competitive inhibitor phenylphosphorodiamidate (PPD) bound to urease, 1.1 +/- 0.1 mol of thiol/mol of catalytic unit were protected from modification. PPD-bound DTDP-modified urease could be reactivated by dialysis, consistent with the presence of one thiol per active site. Analogous studies at pH 6.1, using the competitive inhibitor phosphate, confirmed the presence of one protected thiol per catalytic unit. Under denaturing conditions, 25.5 +/- 0.3 mol of thiol/mol of enzyme (M(r) = 211,800) were modified by DTDP.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824	Michigan State University; Michigan State University				Hausinger, Robert/0000-0002-3643-2054	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022387] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22387] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS A T D B, 1970, Archives of Biochemistry and Biophysics, V141, P538, DOI 10.1016/0003-9861(70)90172-4; Andrews R. K., 1988, BIOINORGANIC CHEM NI, P141; BEDNAR RA, 1990, BIOCHEMISTRY-US, V29, P3684, DOI 10.1021/bi00467a014; BROCKLEHURST K, 1979, BIOCHEM J, V183, P233, DOI 10.1042/bj1830233; CARDEMIL E, 1987, CHEM MODIFICATIONS E, P23; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P1335, DOI 10.1139/o80-181; GORIN G, 1965, BIOCHIM BIOPHYS ACTA, V99, P418, DOI 10.1016/S0926-6593(65)80196-5; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KITZ R, 1962, J BIOL CHEM, V237, P3245; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHADEVAN S, 1977, BIOCHEM J, V163, P495, DOI 10.1042/bj1630495; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; MULROONEY SB, 1989, J GEN MICROBIOL, V135, P1769; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; NAKANO H, 1984, AGR BIOL CHEM TOKYO, V48, P1495, DOI 10.1080/00021369.1984.10866339; NORRIS R, 1976, BIOCHEM J, V159, P245, DOI 10.1042/bj1590245; RIDDLES PW, 1983, BIOCHIM BIOPHYS ACTA, V743, P115, DOI 10.1016/0167-4838(83)90424-7; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SAADA AB, 1988, ZBL BAKT-INT J MED M, V269, P160; SCHREINER W, 1985, PC TECH J, V5, P170; TAKISHIMA K, 1988, EUR J BIOCHEM, V175, P151, DOI 10.1111/j.1432-1033.1988.tb14177.x; TODD MJ, 1989, J BIOL CHEM, V264, P15835; TODD MJ, 1987, J BIOL CHEM, V262, P5963; TSOU C, 1962, SCI SINICA, V11, P1535; WEATHERBURN MW, 1967, ANAL CHEM, V39, P971, DOI 10.1021/ac60252a045; WINKLER RG, 1988, TRENDS BIOCHEM SCI, V13, P97, DOI 10.1016/0968-0004(88)90049-7	29	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10260	10267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037578				2022-12-25	WOS:A1991FP08600043
J	HUANG, Y; HUI, DY				HUANG, Y; HUI, DY			CHOLESTEROL ESTERASE BIOSYNTHESIS IN RAT PANCREATIC AR42J CELLS - POSTTRANSCRIPTIONAL ACTIVATION BY GASTRIC HORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; UNTRANSLATED REGION; EXPRESSION; PROTEINS; LIPASE; GENE; IRON	This study used the rat pancreatoma AR42J as a model system to investigate the possible regulation of cholesterol esterase biosynthesis in pancreas. Initial experiments were performed to verify the synthesis of pancreatic cholesterol esterase by the AR42J cells. Results indicated that this pancreatoma cell line synthesized two forms of cholesterol esterase (M(r) = 71,000 and 74,000). The 74-kDa protein is most likely the precursor protein, and the 71-kDa protein is the matured enzyme secreted by the AR42J cells. The synthesis and secretion of cholesterol esterase were stimulated 2-5-fold by incubating the cells with 0.5-4 nM of cholecystokinin or 0.5-2 nM of secretin. Analysis of the RNA isolated from the hormone-stimulated cells revealed that stimulation of cholesterol esterase biosynthesis was not due to an increase in cholesterol esterase mRNA. Furthermore, inhibition of transcription with actinomycin D has no effect on the hormone-induced cholesterol esterase biosynthesis. Therefore, the mechanism of hormone stimulation was not dependent on de novo RNA synthesis. In vitro translation studies showed that the cholesterol esterase mRNA isolated from stimulated AR42J cells were translated more efficiently than those from control cells. Thus, the increased cholesterol esterase biosynthesis induced by gastric hormones was most likely mediated by post-transcriptional modification of the cholesterol esterase mRNA.	UNIV CINCINNATI,DEPT PATHOL & LAB MED,CINCINNATI,OH 45267	University of Cincinnati					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040917] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAKKA N, 1990, BIOCHEM J, V268, P471, DOI 10.1042/bj2680471; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; Grossman MI, 1944, AM J PHYSIOL, V141, P0038, DOI 10.1152/ajplegacy.1944.141.1.38; Grossman MI, 1943, AM J PHYSIOL, V138, P0676, DOI 10.1152/ajplegacy.1943.138.4.676; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; JACOBSON PW, 1990, J BIOL CHEM, V265, P515; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIDDLE RA, 1986, AM J PHYSIOL, V251, pG243, DOI 10.1152/ajpgi.1986.251.2.G243; Maniatis T., 1982, MOL CLONING; Pavlov I. P., 1910, WORK DIGESTIVE GLAND; ROTHMAN SS, 1989, HDB PHYSL 6, V3, P465; Rudd E.A., 1984, P185; SABB JE, 1986, J NUTR, V116, P892, DOI 10.1093/jn/116.5.892; Schaffalitzky de Muckadell O B, 1986, Pancreas, V1, P536, DOI 10.1097/00006676-198611000-00012; SCHEELE G, 1986, EXOCRINE PANCREAS BI, P55; SCHEELE GA, 1989, HDB PHYSL, V3, P477; SCHICK J, 1984, J CELL BIOL, V99, P1569, DOI 10.1083/jcb.99.5.1569; STEINHILBER W, 1988, P NATL ACAD SCI USA, V85, P6597, DOI 10.1073/pnas.85.18.6597; TSUJITA T, 1987, BIOCHEMISTRY-US, V26, P8423, DOI 10.1021/bi00399a059; WICKER C, 1984, EUR J BIOCHEM, V139, P381, DOI 10.1111/j.1432-1033.1984.tb08017.x; WICKER C, 1985, EUR J BIOCHEM, V151, P461, DOI 10.1111/j.1432-1033.1985.tb09124.x; WILLIAMS JA, 1980, AM J PHYSIOL, V238, pG269, DOI 10.1152/ajpgi.1980.238.4.G269; Williams JA, 1989, HDB PHYSL GASTROIN 6, VIII, P419; WILSON SB, 1986, J BIOL CHEM, V261, P5179	31	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6720	6725						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016288				2022-12-25	WOS:A1991FG72700014
J	MOR, A; DELFOUR, A; NICOLAS, P				MOR, A; DELFOUR, A; NICOLAS, P			IDENTIFICATION OF A D-ALANINE-CONTAINING POLYPEPTIDE PRECURSOR FOR THE PEPTIDE OPIOID, DERMORPHIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID RESIDUE; RAT-BRAIN; HIGH-AFFINITY; AMPHIBIAN SKIN; BINDING-SITES; RECEPTOR-BINDING; BETA-ENDORPHIN; SELECTIVITY; DERMENKEPHALIN; SEQUENCE	The naturally occurring amphibian skin peptides dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) and dermenkephalin (Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2) are highly potent and selective agonists at the mu- and the DELTA-opioid receptors, respectively. For peptides synthesized by animal cells, they have a rather peculiar structural feature of containing a D-amino acid residue in their sequence which imparts biological activity on them. The cloned cDNA encoding the prodermorphin precursor contains the usual alanine and methionine codons at positions where D-alanine and D-methionine are present in the mature products. In this study, dermorphin precursor was characterized in extracts from amphibian skin by antisera recognizing distinct epitopes within the predicted structure of prodermorphin. Proteolytic digestion of purified endogenous pro-dermorphin generated a peptide containing a D-alanine in position 2, identified as prepro-dermorphin-(80-89), i.e. Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-Gly-Glu-Ala. In addition, analysis of skin extracts by enzyme immunoassays coupled to high performance liquid chromatography separations revealed the presence of, besides dermenkephalin, novel dermenkephalin-related peptides, i.e. [L-Met2]dermenkephalin, dermenkephalin-OH, and [Met(O)6]dermenkephalin. [L-Met2]dermenkephalin was present in frog skin in a concentration of about 100 times that of dermenkephalin. These observations confirm that, despite the presence of D-amino acid residues, dermorphin and dermenkephalin are genuine products of post-translational processing of a ribosomally made precursor. They suggest that D-Ala and D-Met develop from a dehydrogenation/hydrogenation stereoinversion of their corresponding L isomers incorporated into prodermorphin, a process that occurs with low efficiency at an early stage of biosynthesis.			MOR, A (corresponding author), UNIV PARIS 07,INST JACQUES MONOD,BIOACTIVAT PEPTIDES LAB,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE.		Nicolas, Pierre/C-7908-2009					ABRAHAM GE, 1974, ACTA ENDOCR-COP S183, V75, P1; AKIYAMA K, 1985, P NATL ACAD SCI USA, V82, P2543, DOI 10.1073/pnas.82.8.2543; AMICHE M, 1987, BIOCHEM BIOPH RES CO, V148, P1432, DOI 10.1016/S0006-291X(87)80292-9; AMICHE M, 1989, MOL PHARMACOL, V35, P774; AMICHE M, 1988, INT J PEPT PROT RES, V32, P28; AMICHE M, 1988, INT J PEPT PROT RES, V32, P506; AMICHE M, 1990, EUR J BIOCHEM, V189, P625, DOI 10.1111/j.1432-1033.1990.tb15531.x; BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BROCCARDO M, 1981, BRIT J PHARMACOL, V73, P625, DOI 10.1111/j.1476-5381.1981.tb16797.x; BUFFA R, 1982, HISTOCHEMISTRY, V76, P273, DOI 10.1007/BF00501929; BULANT M, 1988, J BIOL CHEM, V263, P17189; BYCROFT BW, 1969, NATURE, V224, P595, DOI 10.1038/224595a0; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; DELAYGOYET P, 1988, J BIOL CHEM, V263, P4124; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; KAMATANI Y, 1989, BIOCHEM BIOPH RES CO, V160, P1015, DOI 10.1016/S0006-291X(89)80103-2; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KREIL G, 1989, EUR J PHARMACOL, V162, P123, DOI 10.1016/0014-2999(89)90611-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARUS LH, 1989, J BIOL CHEM, V264, P3047; LAZARUS LH, 1989, J BIOL CHEM, V264, P354; LAZARUS LH, 1990, MOL PHARMACOL, V37, P886; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOR A, 1989, NEUROPEPTIDES, V13, P51, DOI 10.1016/0143-4179(89)90021-8; MOR A, 1989, FEBS LETT, V255, P269, DOI 10.1016/0014-5793(89)81104-4; MOR A, 1990, BIOCHEM BIOPH RES CO, V170, P30, DOI 10.1016/0006-291X(90)91236-L; MOSBERG HI, 1983, P NATL ACAD SCI-BIOL, V80, P5871, DOI 10.1073/pnas.80.19.5871; NEGRI L, 1981, PEPTIDES, V2, P45, DOI 10.1016/0196-9781(81)90009-7; NICOLAS P, 1986, BIOCHEM BIOPH RES CO, V140, P565, DOI 10.1016/0006-291X(86)90769-2; NICOLAS P, 1988, BIOCHIMIE, V70, P177, DOI 10.1016/0300-9084(88)90058-2; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; SAGAN S, 1989, J BIOL CHEM, V264, P17100; SAGAN S, 1989, BIOCHEM BIOPH RES CO, V163, P726, DOI 10.1016/0006-291X(89)92283-3; TSOU K, 1985, NEUROPEPTIDES, V5, P449, DOI 10.1016/0143-4179(85)90051-4; YAMASHIRO D, 1983, INT J PEPT PROT RES, V21, P219	35	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6264	6270						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007579				2022-12-25	WOS:A1991FE37300042
J	STEIN, J; RETTENMIER, CW				STEIN, J; RETTENMIER, CW			PROTEOLYTIC PROCESSING OF A PLASMA MEMBRANE-BOUND PRECURSOR TO HUMAN MACROPHAGE COLONY-STIMULATING FACTOR (CSF-1) IS ACCELERATED BY PHORBOL ESTER	ONCOGENE			English	Article							FACTOR-I RECEPTOR; HUMAN-MONOCYTES; GROWTH-FACTOR; INDEPENDENT MECHANISMS; MOLECULAR-CLONING; EXPRESSION; CELLS; BINDING; PROTEIN; GENE	A transmembrane precursor to human macrophage colony-stimulating factor (M-CSF, CSF-1) is stably expressed at the cell surface where it is slowly and inefficiently cleaved to yield a soluble form of the growth factor. Incubation in the presence of phorbol ester resulted in rapid cleavage of the plasma membrane-bound precursor and release of soluble CSF-1. Within 60 min after phorbol treatment the quantity of growth factor recovered in the medium was more than 30-fold greater than that observed in the absence of the agent. The growth factor released in the presence of phorbol was biologically active and exhibited the same electrophoretic mobility as that obtained in the absence of the drug. Phorbol ester-accelerated processing of the cell surface CSF-1 precursor was abrogated by long-term exposure to phorbol, but was not inhibited by pretreatment with cycloheximide or incubation in serum-free medium. These results suggest that the enhanced post-translational processing of the CSF-1 precursor resulted from activation of a pre-existing cellular protease via a mechanism involving phorbol ester-mediated stimulation of protein kinase C.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040603] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [HL40603] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEN BDM, 1983, J CELL PHYSIOL, V116, P207, DOI 10.1002/jcp.1041160212; COCHET C, 1984, J BIOL CHEM, V259, P2553; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; ERNST TJ, 1989, J BIOL CHEM, V264, P5700; GUILBERT LJ, 1983, J CELL PHYSIOL, V115, P276, DOI 10.1002/jcp.1041150310; HALENBECK R, 1988, J BIOTECHNOL, V8, P45, DOI 10.1016/0168-1656(88)90067-3; HEARD JM, 1987, ONCOGENE RES, V1, P423; HORIGUCHI J, 1986, BIOCHEM BIOPH RES CO, V141, P924, DOI 10.1016/S0006-291X(86)80131-0; HORIGUCHI J, 1987, BLOOD, V69, P1259; HORIGUCHI J, 1988, MOL CELL BIOL, V8, P3951, DOI 10.1128/MCB.8.9.3951; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MANOS MM, 1988, MOL CELL BIOL, V8, P5035, DOI 10.1128/MCB.8.11.5035; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; OSTER W, 1987, BLOOD, V70, P1700; RALPH P, 1986, BLOOD, V68, P633; RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413; RAMBALDI A, 1987, BLOOD, V69, P1409; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RETTENMIER CW, 1989, HEMATOL ONCOL CLIN N, V3, P479, DOI 10.1016/S0889-8588(18)30543-4; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SHADLE PJ, 1989, J CELL BIOCHEM, V40, P91, DOI 10.1002/jcb.240400110; SHERR CJ, 1990, HDB EXPT PHARM, V95, P667; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STANLEY ER, 1986, METHOD ENZYMOL, V116, P563; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529	32	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					601	605						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030912				2022-12-25	WOS:A1991FR93900015
J	SHENG, Z; FRANCOIS, JM; HITCHCOCKDEGREGORI, SE; POTTER, JD				SHENG, Z; FRANCOIS, JM; HITCHCOCKDEGREGORI, SE; POTTER, JD			EFFECTS OF MUTATIONS IN THE CENTRAL HELIX OF TROPONIN-C ON ITS BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; CHICKEN SKELETAL-MUSCLE; PROTEOLYTIC FRAGMENTS; MAGNETIC-RESONANCE; BINDING-SITES; CONTRACTION; CALMODULIN; TROPOMYOSIN; RESOLUTION; CALCIUM	To investigate the role of the central helix of skeletal muscle troponin C (TnC), five deletion mutants (Dobrowolski, Z., Xu, G. Q., and Hitchcock-DeGregori, S. E. (1991) J. Biol. Chem. 266, 5703-5710) of chicken TnC in the D/E linker region (K87EDAKGKSEEE97), dEDA, dKG, dKGK, dSEEE, and dKED-AKGK, were assayed for their ability to regulate muscle contraction by testing their effectiveness in restoring force and Ca2+ regulation to TnC-depleted rabbit skinned skeletal muscle fibers. By comparison with rabbit skeletal TnC, wild-type TnC, and chicken TnC, all mutants except dKG equally restored force development and Ca2+ regulation to TnC-depleted skinned muscle fibers. In contrast, approximately 4 times more dKG than rabbit skeletal TnC was required to reach 50% force restoration. Also, the pCa50 for dKG activation of force was significantly decreased. Thus, most of the TnC mutants that we studied did not have significantly altered biological activity in the skinned fiber assay. However, the 2-residue deletion in the central helix (dKG) significantly affected TnC activity. This deletion would be expected to produce a 160-degrees rotation in the alpha-helix versus 60-degrees for dKGK and dEDA, 40-degrees in dSEEE, and 20-degrees in dKEDAKGK. Therefore, the change in orientation of the two Ca2+-binding domains appears to be a major parameter affecting TnC activity. The shift in the Ca2+ dependence in force activation may result from the inability of the Ca2+-specific domain to properly interact with its binding site on troponin I, an interaction which is known to increase the affinity of TnC for Ca2+ (Potter, J. D., and Gergely, J. (1975) J. Biol. Chem. 250, 4628-4633). In addition, the length of the central helix of TnC, Gly92, and the negatively charged cluster, EEE, appear not to be crucial for TnC activity.	UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,POB 016189,MIAMI,FL 33101; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT NEUROSCI & CELL BIOL,PISCATAWAY,NJ 08854	University of Miami; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036326] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BRANDT PW, 1984, J MOL BIOL, V180, P379, DOI 10.1016/S0022-2836(84)80010-8; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; DOBROWOLSKI Z, 1990, BIOPHYS J, V57, P144; EBASHI S, 1966, J BIOCHEM-TOKYO, V60, P733, DOI 10.1093/oxfordjournals.jbchem.a128504; Ebashi S, 1974, Essays Biochem, V10, P1; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GUTH K, 1987, J BIOL CHEM, V262, P13627; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; HITCHCOCK SE, 1981, J MOL BIOL, V147, P153, DOI 10.1016/0022-2836(81)90083-8; KERRICK WGL, 1985, J BIOL CHEM, V260, P5687; KERRICK WGL, 1975, J APPL PHYSIOL, V39, P1052, DOI 10.1152/jappl.1975.39.6.1052; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; REINACH FC, 1988, J BIOL CHEM, V263, P2371; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SUNDARALINGAM M, 1985, P NATL ACAD SCI USA, V82, P7944, DOI 10.1073/pnas.82.23.7944; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; WANG CLA, 1987, J BIOL CHEM, V262, P9636; XU GQ, 1988, J BIOL CHEM, V263, P13962; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT HG, 1982, J BIOL CHEM, V257, P7678	38	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5711	5715						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005108				2022-12-25	WOS:A1991FD37000055
J	ROSE, T; BRUNE, M; WITTINGHOFER, A; LEBLAY, K; SUREWICZ, WK; MANTSCH, HH; BARZU, O; GILLES, AM				ROSE, T; BRUNE, M; WITTINGHOFER, A; LEBLAY, K; SUREWICZ, WK; MANTSCH, HH; BARZU, O; GILLES, AM			STRUCTURAL AND CATALYTIC PROPERTIES OF A DELETION DERIVATIVE (DELTA-133-157) OF ESCHERICHIA-COLI ADENYLATE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; INHIBITOR P1,P5-DI(ADENOSINE-5'-)PENTAPHOSPHATE; COMPLEX; RESOLUTION; PROTEINS	Escherichia coli adenylate kinase (AKe) as well as the enzyme from yeast and mitochondria differs from the muscle cytosolic variant (AK1) by an insertion of 25 amino acid residues that are missing in AK1. The extra sequence, highly homologous in "large" size variants, is situated between residues 133 and 157 in AKe. Removal of 25 codons in the corresponding adk gene resulted in expression of a modified form of adenylate kinase (DELTA-133-157 AKe) which still conserved 7% of the maximal activity of the wild-type protein. The apparent K(m) for nucleotide substrates was increased by a factor of 4.6 (ADP), 23 (ATP) or 43 (AMP) in DELTA-133-157 AKe when compared with the wild-type enzyme. The secondary structure of DELTA-133-157 AKe, as well as its thermal stability were very similar to the parent protein. However, the deleted protein was much more sensitive than the wild-type enzyme to inactivation by trypsin. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of trypsin digested DELTA-133-157 AKe revealed accumulation of several well defined fragments which were not observed in the case of wild-type enzyme. We conclude that the additional sequence, although necessary for expression of full activity in AKe, is not critical for catalysis. It is perhaps responsible for interaction of enzyme with other cellular components although a different mechanism of water shielding for large and small size variants of AK can be also envisaged.	INST PASTEUR,UNITE BIOCHIM REGULAT CELLULAIRES,F-75724 PARIS 15,FRANCE; MAX PLANCK INST MED RES,BIOPHYS ABT,W-6900 HEIDELBERG 1,GERMANY; NATL RES COUNCIL CANADA,STEACIE INST MOLEC SCI,OTTAWA K1A 0R6,ONTARIO,CANADA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Max Planck Society; National Research Council Canada				ROSE, Thierry/0000-0001-8863-0207				Boyer P.D, 1973, ENZYMES, P279; BRUNE M, 1985, NUCLEIC ACIDS RES, V13, P7139, DOI 10.1093/nar/13.19.7139; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; DIEDERICHS K, 1990, BIOCHEMISTRY-US, V29, P8138, DOI 10.1021/bi00487a022; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; ESMON BE, 1980, J BACTERIOL, V141, P405, DOI 10.1128/JB.141.1.405-408.1980; GILLES AM, 1986, P NATL ACAD SCI USA, V83, P5798, DOI 10.1073/pnas.83.16.5798; GOELZ SE, 1982, BIOCHEMISTRY-US, V21, P189, DOI 10.1021/bi00530a032; HAASE GHW, 1989, J MOL BIOL, V207, P151, DOI 10.1016/0022-2836(89)90446-4; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; JENKS WP, 1975, ADV ENZYMOL, V43, P219; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; MANIATIS T, 1982, MOL CLONING LABORATO, pA3; MONNOT M, 1987, J BIOL CHEM, V262, P2502; MULLER CW, 1988, J MOL BIOL, V202, P909, DOI 10.1016/0022-2836(88)90567-0; RAY BD, 1988, BIOCHEMISTRY-US, V27, P8669, DOI 10.1021/bi00423a024; REINSTEIN J, 1989, J BIOL CHEM, V264, P8107; SAINTGIRONS I, 1987, J BIOL CHEM, V262, P622; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VETTER I, 1991, IN PRESS BIOCHEMISTR; VETTER IR, 1990, BIOCHEMISTRY-US, V29, P7459, DOI 10.1021/bi00484a015; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YANG PW, 1987, BIOCHEMISTRY-US, V26, P2706, DOI 10.1021/bi00384a009	27	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10781	10786						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040598				2022-12-25	WOS:A1991FQ77400015
J	LU, S; CIARDELLI, T; REYES, VE; HUMPHREYS, RE				LU, S; CIARDELLI, T; REYES, VE; HUMPHREYS, RE			NUMBER AND PLACEMENT OF HYDROPHOBIC RESIDUES IN A LONGITUDINAL STRIP GOVERNS HELIX FORMATION OF PEPTIDES IN THE PRESENCE OF LIPID VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CIRCULAR-DICHROISM; CYTOCHROME-C; SECONDARY-STRUCTURE; GLOBULAR PROTEINS; PREDICTION; ALGORITHM; ANTIGENS; CONFORMATION; INTERMEDIATE; SELECTION	Alpha-helix formation of a peptidyl sequence is stabilized by hydrophobic residues recurring at positions which create a longitudinal hydrophobic strip upon folding of the sequence as a helix against a hydrophobic surface. To test that hypothesis, we measured by circular dichroism the helical coiling on lipid vesicles of nine analogs of a prototypic helix peptide PH-1.0, Leu-Tyr-Gln-Glu-Leu-Gln-Lys-Leu-Thr-Gln-Thr-Leu-Lys. In these analogs, Thr was substituted for 1 or 2 Leu residues in the longitudinal hydrophobic strip Leu1...Leu5..Leu8...Leu12 which forms in the alpha-helical configuration. We found that coiling of analogs of Leu-Tyr-Gln-Glu-Leu-Gln-Lys-Leu-Tyr-Gln-Thr-Leu-Lys on lipid vesicles depends upon the strength and structure of its longitudinal hydrophobic strip.	UNIV MASSACHUSETTS,SCH MED,DEPT PHARMACOL,55 LAKE AVE N,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,DEPT MED,WORCESTER,MA 01655; DARTMOUTH COLL,DEPT PHARMACOL,HANOVER,NH 03755	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Dartmouth College					NATIONAL CANCER INSTITUTE [R01CA037645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007272] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37645] Funding Source: Medline; NIAID NIH HHS [T32-AI-07272] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERZOFSKY JA, 1987, IMMUNOL REV, V98, P9, DOI 10.1111/j.1600-065X.1987.tb00518.x; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLAWN JF, 1989, MOL IMMUNOL, V26, P1069, DOI 10.1016/0161-5890(89)90071-0; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ELLIOTT WL, 1987, J IMMUNOL, V138, P2949; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; LARK L R, 1989, Peptide Research, V2, P314; LIM VI, 1974, J MOL BIOL, V88, P873, DOI 10.1016/0022-2836(74)90405-7; LU S, 1990, J IMMUNOL, V145, P899; LUESCHER IF, 1990, J BIOL CHEM, V265, P11177; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PERUTZ MF, 1965, J MOL BIOL, V13, P669, DOI 10.1016/S0022-2836(65)80134-6; REYES VE, 1988, MOL IMMUNOL, V25, P867, DOI 10.1016/0161-5890(88)90123-X; REYES VE, 1989, J BIOL CHEM, V264, P12854; REYES VE, 1990, MOL IMMUNOL, V27, P1021, DOI 10.1016/0161-5890(90)90125-J; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SHIFFER M, 1967, BIOPHYS J, V7, P121; STILLE CJ, 1987, MOL IMMUNOL, V24, P1021, DOI 10.1016/0161-5890(87)90068-X; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; TORGERSON RR, 1991, J BIOL CHEM, V266, P5521; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VITA C, 1990, MOL IMMUNOL, V27, P291, DOI 10.1016/0161-5890(90)90142-M; VOGEL H, 1987, BIOCHEMISTRY-US, V26, P4562, DOI 10.1021/bi00388a060; YANG JT, 1986, METHOD ENZYMOL, V130, P208	33	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10054	10057						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037563				2022-12-25	WOS:A1991FP08600010
J	PARKER, AE; WHEELER, GN; ARNEMANN, J; PIDSLEY, SC; ATALIOTIS, P; THOMAS, CL; REES, DA; MAGEE, AI; BUXTON, RS				PARKER, AE; WHEELER, GN; ARNEMANN, J; PIDSLEY, SC; ATALIOTIS, P; THOMAS, CL; REES, DA; MAGEE, AI; BUXTON, RS			DESMOSOMAL GLYCOPROTEIN-II AND GLYCOPROTEIN-III - CADHERIN-LIKE JUNCTIONAL MOLECULES GENERATED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; EPITHELIAL-CELLS; IDENTIFICATION; UVOMORULIN; SEQUENCE; CALCIUM; DESMOCOLLINS; COMPONENTS; PROTEIN; GENE	We have cloned the human genes coding for desmosomal glycoproteins DGII and DGIII, found in desmosomal cell junctions, and sequencing shows that they are related to the cadherin family of cell adhesion molecules. Thus a new super family of cadherin-like molecules exists which also includes the other major desmosomal glycoprotein, DGI (Wheeler, G. N., Parker, A. E., Thomas, C. L., Ataliotis, P., Poynter, D., Arnemann, J., Rutman, A. J., Pidsley, S. C., Watt, F. M., Rees, D. A., Buxton, R. S., and Magee, A. I. (1991) Proc. Natl. Acad. Sci. U. S. A., in press). DGIII differs from DGII by the addition of a 46-base pair exon containing an in-frame stop codon resulting in mature protein molecular weights of 84,633 for DGII and 78,447 for DGIII. The unique carboxyl-terminal region of DGII contains a potential serine phosphorylation site explaining why only DGII is phosphorylated on serine. The cadherin cell adhesion recognition sequence (His-Ala-Val) is replaced by Phe-Ala-Thr, suggesting that DGII/III may be adhesive molecules using a different mechanism.	NATL INST MED RES, EUKARYOT MOLEC GENET LAB, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research			Wheeler, Grant N/D-3023-2009; Magee, Anthony/V-8345-2019	Wheeler, Grant N/0000-0002-4335-8577; Ataliotis, Paris/0000-0002-9741-6410				ARNEMANN J, 1991, IN PRESS GENOMICS; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BLASCHUK OW, 1990, J MOL BIOL, V211, P679, DOI 10.1016/0022-2836(90)90065-T; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN SM, 1983, J BIOL CHEM, V258, P2621; COWIN P, 1984, J CELL SCI, V70, P41; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANKE WW, 1987, CIBA F SYMP, V125, P26; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; GREER W, 1985, MGS REFERENCE MANUAL; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HOLTON JL, 1990, J CELL SCI, V97, P239; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAPPRELL HP, 1985, EUR J CELL BIOL, V36, P217; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; MATTEY DL, 1987, CIBA F SYMP, V125, P49; MATTEY DL, 1985, J CELL SCI, V75, P377; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MOTT RF, 1989, COMPUT APPL BIOSCI, V5, P123; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARRISH EP, 1990, J CELL SCI, V96, P239; PENN EJ, 1987, J CELL BIOL, V105, P2327, DOI 10.1083/jcb.105.5.2327; PENN EJ, 1987, J CELL BIOL, V105, P57, DOI 10.1083/jcb.105.1.57; PEYRIERAS N, 1983, P NATL ACAD SCI-BIOL, V80, P6274, DOI 10.1073/pnas.80.20.6274; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; STEINBERG MS, 1987, CIBA F SYMP, V125, P3; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; VAUX DJT, 1988, NATURE, V336, P36, DOI 10.1038/336036a0; VOLK T, 1986, J CELL BIOL, V103, P1441, DOI 10.1083/jcb.103.4.1441; WALSH FS, 1990, J NEUROCHEM, V55, P805, DOI 10.1111/j.1471-4159.1990.tb04563.x; WHEELER GN, 1991, IN PRESS P NATL ACAD; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305	41	116	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10438	10445						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037591				2022-12-25	WOS:A1991FP08600068
J	VANBLITTERSWIJK, WJ; HILKMANN, H; DEWIDT, J; VANDERBEND, RL				VANBLITTERSWIJK, WJ; HILKMANN, H; DEWIDT, J; VANDERBEND, RL			PHOSPHOLIPID-METABOLISM IN BRADYKININ-STIMULATED HUMAN FIBROBLASTS .1. BIPHASIC FORMATION OF DIACYLGLYCEROL FROM PHOSPHATIDYLINOSITOL AND PHOSPHATIDYLCHOLINE, CONTROLLED BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE HYDROLYSIS; ARACHIDONIC-ACID; PHORBOL ESTER; INOSITOL PHOSPHATES; ENDOTHELIAL-CELLS; HUMAN-NEUTROPHILS; PLASMA-MEMBRANES; 3T3 FIBROBLASTS; ACTIVATION; PATHWAYS	Stimulation of human fibroblasts with bradykinin (BK) results in the generation of diacylglycerol (DG) and phosphatidic acid (PA). Prelabeling of the cells with [H-3]arachidonic acid and [C-14]palmitic acid allowed us to quantitate these lipid second messengers and to determine their origin, i.e. DG(i) and PA(i) from H-3-enriched inositol phospholipids, and DG(c) and PA(c) from C-14-enriched phosphatidylcholine, respectively. BK elicited a biphasic DG response: a first peak at 10-15 s, containing DG(i), followed by a second peak at 10-30 min, which is mainly DG(c). The latter did not result from de novo lipid biosynthesis. BK also generated free [H-3]arachidonate and, to a lesser extent, mono[H-3]arachidonoylglycerol. BK stimulation rapidly increased PA(i), much more so than PA(c), suggesting that DG(i), rather than DG(c), is the preferred substrate for the enzyme DG kinase. Short pretreatment of the cells with phorbol 12-myristate 13-acetate (PMA) abolished the BK-induced breakdown of phosphoinositides, but did not affect the second-phase DG(c) level. PMA alone also elicited DG(c) formation, but more slowly, suggesting a different mechanism. Down-regulation of protein kinase C (PKC) by long term treatment with phorbol ester, prior to BK stimulation, resulted in (i) enhanced DG(i) and decreased PA(i) formation, suggesting that DG kinase activity is positively controlled by PKC; (ii) the unexpected manifestation of rapidly formed DG(c); (iii) no change in the DG(c) levels obtained after 30-min BK stimulation, but complete suppression of PMA-induced DG(c) formation. In contrast, two inhibitors of PKC, staurosporin and 1-O-hexadecyl-2-O-methylglycerol, inhibited both BK- and PMA-induced DG(c) formation at 30 min, leaving the rapid response towards BK unaffected. The results suggest that the BK-induced rapid and later-phase DG formation and the PMA-induced DG formation are differentially controlled by PKC via mechanisms that differ in the susceptibility to down-regulation or inhibition of PKC.			VANBLITTERSWIJK, WJ (corresponding author), NETHERLANDS CANC INST,ANTONI VAN LEEUWENHOEK HUIS,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.							BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BROEKMAN MJ, 1981, J BIOL CHEM, V256, P8271; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; EXTON JH, 1990, J BIOL CHEM, V265, P1; FAROOQUI AA, 1990, BIOCHEM BIOPH RES CO, V166, P1001, DOI 10.1016/0006-291X(90)90910-F; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAMMON CM, 1989, J NEUROCHEM, V53, P95, DOI 10.1111/j.1471-4159.1989.tb07299.x; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; HONG SL, 1982, J BIOL CHEM, V257, P7151; HUANG FL, 1989, J BIOL CHEM, V264, P4238; INNIS RB, 1981, P NATL ACAD SCI-BIOL, V78, P2630, DOI 10.1073/pnas.78.4.2630; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JACKSON TR, 1987, EMBO J, V6, P49, DOI 10.1002/j.1460-2075.1987.tb04717.x; KANOH H, 1989, BIOCHEM J, V258, P455, DOI 10.1042/bj2580455; KAYA H, 1989, J BIOL CHEM, V264, P4972; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KRAMER IM, 1989, J BIOL CHEM, V264, P5876; LEMAITRE RN, 1990, BIOCHEM J, V260, P291; MACDONALD JIS, 1989, BIOCHIM BIOPHYS ACTA, V1004, P151, DOI 10.1016/0005-2760(89)90263-4; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MILLER RJ, 1987, TRENDS NEUROSCI, V10, P226, DOI 10.1016/0166-2236(87)90161-5; MORRISON WR, 1964, ANAL BIOCHEM, V7, P218, DOI 10.1016/0003-2697(64)90231-3; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; RAGABTHOMAS JMF, 1987, BIOCHIM BIOPHYS ACTA, V917, P388, DOI 10.1016/0005-2760(87)90117-2; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SLIVKA SR, 1988, J BIOL CHEM, V263, P12242; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; STASSEN FL, 1989, J BIOL CHEM, V264, P4916; TAKUWA N, 1987, BIOCHEM J, V243, P647, DOI 10.1042/bj2430647; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129; VANBLITTERSWIJK WJ, 1982, BIOCHIM BIOPHYS ACTA, V688, P495, DOI 10.1016/0005-2736(82)90361-3; VANBLITTERSWIJK WJ, 1987, LIPIDS, V22, P842, DOI 10.1007/BF02535541; VANBLITTERSWIJK WJ, 1990, J BIOL CHEM, V266, P10344; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; WATSON SP, 1984, BIOCHEM BIOPH RES CO, V121, P386, DOI 10.1016/0006-291X(84)90734-4	46	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10337	10343						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037585				2022-12-25	WOS:A1991FP08600055
J	ROSENWALD, AG; PAGANO, RE; RAVIV, Y				ROSENWALD, AG; PAGANO, RE; RAVIV, Y			ACTIVATION OF 5-[I-125] IODONAPHTHYL-1-AZIDE VIA EXCITATION OF FLUORESCENT (N-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)) LIPID ANALOGS IN LIVING CELLS - A POTENTIAL TOOL FOR IDENTIFICATION OF COMPARTMENT-SPECIFIC PROTEINS AND PROTEINS INVOLVED IN INTRACELLULAR-TRANSPORT AND METABOLISM OF LIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANE; CULTURED FIBROBLASTS; PLASMA-MEMBRANE; GOLGI-APPARATUS; BINDING PROTEINS; CERAMIDE ANALOG; ANIMAL-CELLS; SPHINGOMYELIN; BIOSYNTHESIS; PHOSPHATIDYLCHOLINE	We describe a new technique for analysis of proteins located near fluorescent lipid analogs in intact living cells using the membrane-permeant, photoactivatable probe, 5-[I-125]iodonaphthyl-1-azide ([I-125]INA). [I-125]INA can be activated directly with UV light or indirectly through excitation of adjacent fluorophores (photosensitizers) with visible light to modify nearby proteins covalently with I-125. In this report we demonstrate that fluorescent phospholipids and sphingolipids containing N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-6-aminocaproic acid serve as appropriate photosensitizers for [I-125]INA. Using Chinese hamster ovary fibroblasts, we optimized the labeling conditions with respect to lipid concentration and time of irradiation and then examined the profiles of cellular proteins that were labeled when fluorescent analogs of ceramide, sphingomyelin, and phosphatidic acid were used as photosensitizers in living cells. The use of different fluorescent lipids, which label different subcellular compartments of cells as determined by fluorescence microscopy, derivatized different sets of cellular proteins with I-125. The labeled proteins were subsets of the total set of proteins available for derivatization as determined by direct activation of [I-125]INA. Most proteins labeled by this procedure were pelleted by centrifugation of cell lysates at high speed (260,000 x g), but several soluble proteins were also labeled under these conditions. The implications of using this technique for identification of compartment-specific proteins and proteins involved in lipid metabolism and transport are discussed.	CARNEGIE INST WASHINGTON,DEPT EMBRYOL,115 W UNIV PKWY,BALTIMORE,MD 21210; NIDDKD,CELL BIOL & GENET LAB,BETHESDA,MD 20892	Carnegie Institution for Science; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NIGMS NIH HHS [R37 GM22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYLEY H, 1980, BIOCHEMISTRY-US, V19, P3883, DOI 10.1021/bi00558a001; BERCOVICI T, 1978, BIOCHEMISTRY-US, V17, P1484, DOI 10.1021/bi00601a020; BISHOP WR, 1988, ONCOGENE RES, V2, P205; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; DAWIDOWICZ EA, 1987, ANNU REV BIOCHEM, V56, P43, DOI 10.1146/annurev.bi.56.070187.000355; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Gitler C, 1980, Ann N Y Acad Sci, V346, P199, DOI 10.1111/j.1749-6632.1980.tb22100.x; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KISHIMOTO Y, 1983, ENZYMES, V16, P357; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P344; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; NICHOLS JW, 1981, BIOCHEMISTRY-US, V20, P2783, DOI 10.1021/bi00513a012; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PAGANO RE, 1985, TRENDS BIOCHEM SCI, V10, P421, DOI 10.1016/0968-0004(85)90022-2; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PAGANO RE, 1981, J CELL BIOL, V91, P872, DOI 10.1083/jcb.91.3.872; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; RAVIV Y, 1989, BIOCHEMISTRY-US, V28, P1313, DOI 10.1021/bi00429a055; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RAVIV Y, 1987, P NATL ACAD SCI USA, V84, P6103, DOI 10.1073/pnas.84.17.6103; SCHROIT AJ, 1987, BIOCHEMISTRY-US, V26, P1812, DOI 10.1021/bi00381a004; SCHROIT AJ, 1990, BIOCHEMISTRY-US, V29, P10303, DOI 10.1021/bi00497a003; SLEIGHT RG, 1987, ANNU REV PHYSIOL, V49, P193; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; ZACHOWSKI A, 1987, FEBS LETT, V223, P315, DOI 10.1016/0014-5793(87)80311-3	41	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9814	9821						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033068				2022-12-25	WOS:A1991FM45900072
J	INOSTROZA, J; FLORES, O; REINBERG, D				INOSTROZA, J; FLORES, O; REINBERG, D			FACTORS INVOLVED IN SPECIFIC TRANSCRIPTION BY MAMMALIAN RNA POLYMERASE-II - PURIFICATION AND FUNCTIONAL-ANALYSIS OF GENERAL TRANSCRIPTION FACTOR-IIE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR; ACCURATE TRANSCRIPTION; DNA; ACTIVATION; PROTEINS; COMPLEXES; PROMOTERS; SEQUENCES; SUBUNIT; DOMAIN	Mammalian RNA polymerase II transcription factor IIE (TFIIE) was purified to apparent homogeneity. The activity copurified with polypeptides of 34 and 56 kDa. The 56-kDa subunit was sufficient for low levels of transcription activity in a transcription system reconstituted in vitro with highly purified general transcription factors and RNA polymerase II. The 34-kDa polypeptide was found to be stimulatory. The native molecular mass of TFIIE, as determined by gel filtration, was estimated to be approximately 200 kDa, suggesting that TFIIE exists in solution as a tetramer composed of two 56-kDa and two 34-kDa polypeptides. Consistent with previous studies demonstrating an interaction of TFIIE with RNA polymerase II, we found that the entry of TFIIE into the transcription cycle was subsequent to the entry of RNA polymerase II.			INOSTROZA, J (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.			Reinberg, Danny/0000-0003-4288-2016	NIGMS NIH HHS [GM 37110] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037110] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DARBY MK, 1985, J BIOL CHEM, V260, P4501; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KAWAGUCHI T, 1990, P NATL ACAD SCI USA, V87, P6619, DOI 10.1073/pnas.87.17.6619; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0	30	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9304	9308						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026628				2022-12-25	WOS:A1991FM03800096
J	KLOC, M; REDDY, B; CRAWFORD, S; ETKIN, LD				KLOC, M; REDDY, B; CRAWFORD, S; ETKIN, LD			A NOVEL 110-KDA MATERNAL CAAX BOX-CONTAINING PROTEIN FROM XENOPUS IS PALMITOYLATED AND ISOPRENYLATED WHEN EXPRESSED IN BACULOVIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-RELATED GENE; FUSHI-TARAZU PROTEIN; SACCHAROMYCES-CEREVISIAE; MEVALONIC ACID; A-FACTOR; COMPETITIVE INHIBITOR; STEROL BIOSYNTHESIS; PLASMA-MEMBRANE; CDNA CLONE; TGF-BETA	We describe a unique 110-kDa protein, xlcaax-1, that is a member of a group of membrane-associated proteins such as the ras and ras-related proteins and nuclear lamins. Many of these proteins are involved in signal transduction or cell signaling, possess a C-terminal CAAX box, and undergo fatty acid acylation (Glomset, J. A., Gelb, M. H., and Farnsworth, C. C. (1990) Trends Biochem. Sci. 15, 139-142). The ras and ras-related proteins bind GTP and in most cases are both isoprenylated and palmitoylated. The xlcaax-1 protein possesses a C-terminal CAAX sequence that is identical to the N-ras protein. In addition to the CAAX box, xlcaax-1 contains a series of basic amino acids upstream of the CAAX sequence similar to several nonpalmitoylated forms of the ras-related proteins. When the xlcaax-1 cDNA is expressed in a baculovirus expression system, the product undergoes isoprenylation and palmitoylation utilizing a mechanism similar to that of the ras proteins. In addition, the xlcaax-1 protein is isoprenylated, and a minor fraction is palmitoylated in Xenopus XTC tissue culture cells. We have also demonstrated that the protein is associated with membrane fractions in full-grown Xenopus oocytes and in Xenopus XTC tissue culture cells and that membrane association is isoprenylation-dependent. The presence of maternal molecules possessing signal transduction potential is an attractive mechanism for modulating the effects of growth factors and other signal molecules during development.	BAYLOR UNIV,DEPT MOLEC VIROL,HOUSTON,TX 77030	Baylor University	KLOC, M (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030, USA.		Kloc, Malgorzata/AAF-6982-2020					ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CARROLL SB, 1985, CELL, V43, P47, DOI 10.1016/0092-8674(85)90011-X; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JAMES G, 1989, J BIOL CHEM, V264, P20998; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLOC M, 1989, DEVELOPMENT, V107, P899; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; KROHNE G, 1987, EMBO J, V6, P3801, DOI 10.1002/j.1460-2075.1987.tb02716.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWY DR, 1989, NATURE, V341, P384, DOI 10.1038/341384a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MAGEE T, 1988, NATURE, V335, P114, DOI 10.1038/335114a0; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; OLLO R, 1987, P NATL ACAD SCI USA, V84, P5700, DOI 10.1073/pnas.84.16.5700; PIZON V, 1988, ONCOGENE, V3, P201; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; PUDNEY M, 1973, EXPERIENTIA, V29, P466, DOI 10.1007/BF01926785; SADLER SE, 1981, J BIOL CHEM, V256, P6368; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SCHROEPFER GJ, 1981, ANNU REV BIOCHEM, V50, P585, DOI 10.1146/annurev.bi.50.070181.003101; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; SUMMERS MD, 1988, MANUAL METHODS BACUL; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WILCOX CA, 1987, BIOCHEMISTRY-US, V26, P1029, DOI 10.1021/bi00378a008; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	51	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8206	8212						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022638				2022-12-25	WOS:A1991FK44100041
J	SORKIN, A; WATERS, C; OVERHOLSER, KA; CARPENTER, G				SORKIN, A; WATERS, C; OVERHOLSER, KA; CARPENTER, G			MULTIPLE AUTOPHOSPHORYLATION SITE MUTATIONS OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR - ANALYSIS OF KINASE-ACTIVITY AND ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE KINASE; FACTOR EGF RECEPTOR; MEDIATED ENDOCYTOSIS; DIRECT VISUALIZATION; HUMAN-FIBROBLASTS; A-431 CELLS; A431 CELLS; INTERNALIZATION; PHOSPHORYLATION; DEGRADATION	We have utilized site-directed mutants to study the role of autophosphorylation of the epidermal growth factor (EGF) receptor in the regulation of receptor kinase activity and ligand-induced endocytosis. A single mutation of the major autophosphorylation site, Y1173, and a double mutation of two autophosphorylation sites, Y1173 and Y1148, did not inhibit kinase activity in vivo, using PLC-gamma-1 as a specific substrate for the EGF receptor kinase. The simultaneous mutation of three major autophosphorylation sites (Y1173, Y1148, Y1068), however, caused more than a 50% decrease in EGF-induced tyrosine phosphorylation of PLC-gamma-1. The triple mutation also resulted in a substantial inhibition of the EGF-receptor endocytic system. We have used three types of experiments to analyze internalization, recycling, and degradation of EGF in cells with these mutants or the wild-type receptor. Using a simple mathematical model we have shown that the internalization rate constant is 2-fold lower in cells expressing the triple mutation receptor (F3 cells) than in cells expressing wild-type EGF receptor (wild-type cells). However, the rate constant for recycling was similar in both cell types. The EGF degradation rate constant was also lower in F3 cells. EGF-induced EGF receptor degradation was slower in F3 cells (t1/2 = 4 h) than in wild-type cells (t1/2 = 1 h). Therefore, our results suggest that multiple autophosphorylations of the carboxyl terminus of the EGF receptor are required for EGF receptor kinase activation, and for the internalization and intracellular processing of the EGF.receptor complex.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOMED ENGN,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University	SORKIN, A (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.		Waters, Christopher/V-2759-2019	Sorkin, Alexander/0000-0002-4446-1920	NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER; NCI NIH HHS [CA24071] Funding Source: Medline; NHLBI NIH HHS [HL07411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COHEN S, 1985, J BIOL CHEM, V260, P2351; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GLAUDHAUG IP, 1987, EUR J BIOCHEM, V164, P265; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HELIN K, 1991, IN PRESS ONCOGENE; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONNEGER A, 1989, EMBO J, V7, P3055; HONNEGER AM, 1987, CELL, V51, P199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LUND KA, 1990, J BIOL CHEM, V265, P15713; MAGNI M, 1991, IN PRESS BIOCH J; MAGROLIS B, 1989, CELL, V57, P1101; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MCKANNA JA, 1979, P NATL ACAD SCI USA, V76, P5689, DOI 10.1073/pnas.76.11.5689; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; NESTEROV A, 1990, MOL CELL BIOL, V10, P5011, DOI 10.1128/MCB.10.9.5011; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; OPRESKO LK, 1987, J BIOL CHEM, V262, P4109; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STOSCHECK CM, 1983, ARCH BIOCHEM BIOPHYS, V227, P457, DOI 10.1016/0003-9861(83)90476-9; VANZOELEN EJJ, 1989, BIOCHEM J, V262, P549, DOI 10.1042/bj2620549; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WATERS CM, 1990, BIOCHEMISTRY-US, V29, P3563, DOI 10.1021/bi00466a020; [No title captured]	41	105	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8355	8362						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022651				2022-12-25	WOS:A1991FK44100062
J	TANG, WJ; KRUPINSKI, J; GILMAN, AG				TANG, WJ; KRUPINSKI, J; GILMAN, AG			EXPRESSION AND CHARACTERIZATION OF CALMODULIN-ACTIVATED (TYPE-I) ADENYLYCYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; BINDING REGULATORY PROTEINS; SITE-DIRECTED MUTAGENESIS; BETA-GAMMA-SUBUNITS; BORDETELLA-PERTUSSIS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CATALYTIC UNIT; GENE; PURIFICATION	A complementary DNA that encodes a bovine brain, calmodulin-sensitive (type I) adenylylcyclase has been inserted into the baculovirus genome under the control of the strong polyhedron promoter. Expression of the recombinant adenylycyclase in Sf9 cells using recombinant baculovirus increases adenylycyclase activity in cell membranes to 10-20 nmol.min-1.mg-1 (approximately 0.1% of membrane protein). The catalytic activity of the recombinant adenylylcyclase can be stimulated by G(S-alpha), calmodulin, or forskolin, and it can be inhibited by adenosine analogs and by G protein beta-gamma subunits. The specific activity of the purified recombinant protein approximates 5-mu-mol.min-1.mg-1. This is similar to that of the enzyme purified from bovine brain. Type I adenylycyclase has a quasiduplicated structure. There are two membrane-spanning domains, each with six putative transmembrane helices, and there are two presumed nucleotide-binding domains that are about 55% similar to each other. No catalytic activity is detectable when each half of the adenylylcyclase molecule is expressed by itself. However, coexpression of the two halves results in considerable enzymatic activity. Interaction between the two halves of adenylylcyclase may be necessary for catalysis.			TANG, WJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.			Tang, Wei-Jen/0000-0002-8267-8995	NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1984, NUCLEIC ACIDS RES, V12, P9427, DOI 10.1093/nar/12.24.9427; AU DC, 1989, BIOCHEMISTRY-US, V28, P2772, DOI 10.1021/bi00433a005; BENDER JL, 1983, J BIOL CHEM, V258, P2432; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; ESCUYER V, 1988, GENE, V71, P293, DOI 10.1016/0378-1119(88)90045-5; GARBERS D L, 1990, New Biologist, V2, P499; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GROSS MK, 1987, J BIOL CHEM, V262, P8672; GUO LH, 1982, NUCLEIC ACIDS RES, V10, P2065, DOI 10.1093/nar/10.6.2065; HARRISON JK, 1989, J BIOL CHEM, V264, P15880; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LACHMANN PJ, 1986, CIBA F SYMP, V119, P25; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOGOTHETIS DE, 1987, NATURE, V327, P21; LONDOS C, 1979, PHYSL REGULATORY FUN, P271; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LYNCH TJ, 1976, BIOCHEM BIOPH RES CO, V68, P6116; MAIORELLA B, 1988, BIO-TECHNOL, V6, P1406, DOI 10.1038/nbt1288-1406; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MILLER LK, 1989, BIOESSAYS, V11, P91, DOI 10.1002/bies.950110404; MINOCHERHOMJEE AM, 1988, CALMODULIN, P249; MOLLNER S, 1988, EUR J BIOCHEM, V171, P265, DOI 10.1111/j.1432-1033.1988.tb13785.x; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NEER EJ, 1978, J BIOL CHEM, V253, P5808; PEN J, 1989, NUCLEIC ACIDS RES, V17, P451, DOI 10.1093/nar/17.1.451; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; ROBERTSON DL, 1988, GENE, V73, P363, DOI 10.1016/0378-1119(88)90501-X; ROSENBERG GB, 1987, J BIOL CHEM, V262, P7623; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SUMMERS MD, 1987, TEX AGR EXP STN B, V55, P1; van der Eb A J, 1980, Methods Enzymol, V65, P826; WANG JYJ, 1981, P NATL ACAD SCI-BIOL, V78, P4684, DOI 10.1073/pnas.78.8.4684; XIA ZG, 1990, J BIOL CHEM, V265, P6517; YEAGER RE, 1985, BIOCHEMISTRY-US, V24, P3776, DOI 10.1021/bi00335a054; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	50	379	387	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8595	8603						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022671				2022-12-25	WOS:A1991FK44100095
J	BATEMAN, A; SINGH, A; SHUSTIK, C; MARS, WM; SOLOMON, S				BATEMAN, A; SINGH, A; SHUSTIK, C; MARS, WM; SOLOMON, S			THE ISOLATION AND IDENTIFICATION OF MULTIPLE FORMS OF THE NEUTROPHIL GRANULE PEPTIDES FROM HUMAN LEUKEMIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-ACTH; DIFFERENTIATION; PURIFICATION; ANTIBIOTICS; EXPRESSION; DEFENSINS; SEQUENCE; ALPHA; LUNG; CDNA	HP-1 is a 30-residue cysteine- and arginine-rich peptide of the human neutrophil primary granule and is the most abundant human representative of the family of peptides variously called defensins and corticostatins. Peptides belonging to this family have many biological activities including the non-oxidative destruction of ingested microorganisms, the inhibition of adrenocorticotropin-stimulated synthesis of glucocorticoids, monocyte chemotaxis, the non-cytolytic inhibition of [H-3]thymidine incorporation in HL-60 promyelocyte-like cells and the stimulation of nifedipine-sensitive calcium channels. Using a combination of reversed-phase and size-exclusion high performance liquid chromatography and an HP-1 radio-immunoassay, three immunoreactive peptides were detected and isolated from the promyelocyte-like cell line, HL-60, and from leukocytes of patients with chronic myelogenous and chronic lymphocytic leukemias. One of these peptides was HP-1 itself. A second was identified by gas-phase Edman microsequencing as an amino-terminally extended fragment of the HP-1 precursor which we call HP1-56. The third is likely to arise from enzymatic cleavage of the precursor at a dibasic site. Of the leukemic cells the greates amount of HP1-56 relative to HP-1 was found in cells from a patients in myeloblastic crisis but overall the richest source of HP1-56 relative to HP-1 was found to be in fetal lung tissue. HP1-56 is difficult to detect in normal peripheral neutrophils and its presence in cells that are actively biosynthesizing primary granule components such as HL-60 may make it useful for studying the biosynthesis of granule polypeptides, their ontogeny, and possibly as a marker protein for leukemic diseases.	MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,DIV HEMATOL,MONTREAL H3A 1A1,QUEBEC,CANADA; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM,HOUSTON,TX 77030	McGill University; Royal Victoria Hospital; University of Texas System; UTMD Anderson Cancer Center	BATEMAN, A (corresponding author), MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED OBSTET & GYNECOL,ENDOCRINE LAB,MONTREAL H3A 1A1,QUEBEC,CANADA.			Bateman, Andrew/0000-0003-0597-769X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD004365] Funding Source: NIH RePORTER; NICHD NIH HHS [3 RO1 HDO4365] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BATEMAN A, 1985, Journal of Applied Biochemistry, V7, P126; BATEMAN A, 1989, ENDOCR REV, V10, P92, DOI 10.1210/edrv-10-1-92; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BENNETT HPJ, 1984, BIOCHEMISTRY-US, V126, P39; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; COHEN P, 1987, BIOCHIMIE, V69, P87, DOI 10.1016/0300-9084(87)90239-2; COLLINS SJ, 1987, BLOOD, V70, P1233; DAHER KA, 1988, P NATL ACAD SCI USA, V85, P7327, DOI 10.1073/pnas.85.19.7327; EIPPER BA, 1983, J BIOL CHEM, V258, P7292; ESCH F, 1984, ANAL BIOCHEM, V126, P39; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LICHTENSTEIN A, 1986, BLOOD, V69, P1607; MACLEOD RJ, 1991, P NATL ACAD SCI USA, V88, P552, DOI 10.1073/pnas.88.2.552; MARS WM, 1988, BLOOD, V71, P1713; MARS WM, 1985, BLOOD, V65, P1218; MOORE HP, 1983, NATURE, V302, P434, DOI 10.1038/302434a0; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; SELSTED ME, 1983, J BIOL CHEM, V258, P4485; SINGH A, 1988, BIOCHEM BIOPH RES CO, V155, P524, DOI 10.1016/S0006-291X(88)81118-5; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WIEDEMANN LM, 1989, LEUKEMIA, V3, P227; ZHU Q, 1989, ENDOCR RES, V15, P129, DOI 10.1080/07435808909039093; ZHU QH, 1988, P NATL ACAD SCI USA, V85, P592, DOI 10.1073/pnas.85.2.592; ZHU QZ, 1987, J STEROID BIOCHEM, V27, P1017	28	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7524	7530						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019582				2022-12-25	WOS:A1991FJ34200034
J	MCCRACKEN, AA; KRUSE, KB; VALENTINE, J; ROBERTS, C; YOHANNES, TZ; BROWN, JL				MCCRACKEN, AA; KRUSE, KB; VALENTINE, J; ROBERTS, C; YOHANNES, TZ; BROWN, JL			CONSTRUCTION AND EXPRESSION OF ALPHA-1-PROTEINASE INHIBITOR MUTANTS AND THE EFFECTS OF THESE MUTATIONS ON SECRETION OF THE VARIANT INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-ANTITRYPSIN; SALT BRIDGE; PROTEINS; DEFICIENCY; DISRUPTION; DEFECT; LIVER; GENE	Human-alpha-1-proteinase inhibitor (A1Pi) deficiency, associated with the Z variant A1Pi gene, results from defective secretion of the inhibitor from the liver and appears to be a direct consequence of replacement of Glu342 with Lys. To investigate the effect of the amino acid occupying position 342 on secretion of A1Pi, we have used oligonucleotide-directed mutagenesis of A1Pi cDNA to randomly change the codon specifying this amino acid. Since replacement of Glu342 by Lys leads to a change in the predicted secondary structure for this protein, we also tested the possibility that defective secretion of A1PiZ is the result of this type of alteration. For this purpose, site-directed mutagenesis was used to produce sequences encoding A1Pi retaining Glu342 but predicted to have A1PiZ type secondary structure. The effects of 10 different amino acids occupying position 342 on the secretion of A1Pi were determined by pulse-chase experiments and by enzyme-linked immunosorbent assay of medium from transiently transfected COS cells. Results of these studies show that secretion of A1Pi is most efficient when position 342 is occupied by a negatively charged amino acid, efficient but somewhat less so when occupied by a neutral amino acid, and least efficient when a positively charged residue is present. The mutation designed to alter secondary structure had no effect on the secretion of A1Pi. As indicated by immunofluorescence microscopy and mobility of intracellular A1Pi on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, lowered secretion is accompanied by accumulation of A1Pi in the endoplasmic reticulum of the transfected cells. These results are compatible with the ideas that secretion of A1Pi is directly influenced by the amino acid occupying position 342, that a positively charged amino acid in this position is especially detrimental to secretion of this protein, and that the rate-limiting step in the secretion of the altered forms is transport from endoplasmic reticulum to Golgi.	UNIV NEVADA,DEPT BIOL,RENO,NV 89557; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [HL37128] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037128] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATHURST IC, 1983, FEBS LETT, V153, P270, DOI 10.1016/0014-5793(83)80622-X; BATHURST IC, 1984, FEBS LETT, V177, P179, DOI 10.1016/0014-5793(84)81279-X; BRANTLY M, 1988, SCIENCE, V242, P1700, DOI 10.1126/science.2904702; CARRELL RW, 1982, NATURE, V298, P320; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Fagerhol M K, 1981, Adv Hum Genet, V11, P1; FOREMAN RC, 1987, FEBS LETT, V216, P79, DOI 10.1016/0014-5793(87)80760-3; Gadek J., 1982, METABOLIC BASIS INHE, P1450; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; KIDD VJ, 1983, NATURE, V304, P230, DOI 10.1038/304230a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LE A, 1990, J BIOL CHEM, V265, P14001; LEVITT M, 1976, J MOL BIOL, V104, P59, DOI 10.1016/0022-2836(76)90004-8; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MCCRACKEN AA, 1989, MOL CELL BIOL, V9, P1406, DOI 10.1128/MCB.9.4.1406; MILLER RR, 1976, J BIOL CHEM, V251, P4751; NUKIWA T, 1987, BIOCHEMISTRY-US, V26, P5259, DOI 10.1021/bi00391a008; OGUSHI F, 1987, J CLIN INVEST, V80, P1366, DOI 10.1172/JCI113214; PRAKASH V, 1985, METHOD ENZYMOL, V117, P53; SHARP HL, 1969, J LAB CLIN MED, V73, P934; SIFERS RN, 1987, NUCLEIC ACIDS RES, V15, P1459, DOI 10.1093/nar/15.4.1459; SIFERS RN, 1989, J BIOL CHEM, V264, P2997; VERBANAC KM, 1986, J BIOL CHEM, V261, P9979	27	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7578	7582						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019587				2022-12-25	WOS:A1991FJ34200042
J	NINFA, AJ; BENNETT, RL				NINFA, AJ; BENNETT, RL			IDENTIFICATION OF THE SITE OF AUTOPHOSPHORYLATION OF THE BACTERIAL PROTEIN-KINASE PHOSPHATASE NRII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; GLNALG OPERON; ENVIRONMENTAL SENSOR; PHOSPHORYL GROUP; OMPC GENES; CHEMOTAXIS; TRANSCRIPTION; PHOSPHOTRANSFER; EXPRESSION	Previous studies have established that the Escherichia coli protein kinase/phosphatase nitrogen regulator II (NR(II) also known as NtrB) becomes autophosphorylated on a histidine residue when incubated with ATP. We show that the major site at which NR(II) was autophosphorylated was contained within a peptide consisting of amino acid residues 136-142 of NR(II), and thus probably corresponds to His-139. A minor site of phosphorylation, accounting for about 2% of the phosphate in NR(II)-P, was found in a peptide that corresponds to residues 158-169.			NINFA, AJ (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,540 E CANFIELD AVE,DETROIT,MI 48201, USA.			Bennett, Richard/0000-0002-0243-2443				AIBA H, 1989, J BIOL CHEM, V264, P8563; AIBA H, 1990, FEBS LETT, V261, P19, DOI 10.1016/0014-5793(90)80626-T; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; BUENO R, 1985, J BACTERIOL, V164, P816, DOI 10.1128/JB.164.2.816-822.1985; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; HUANG Y, 1990, J BACTERIOL, V172, P1142, DOI 10.1128/jb.172.2.1142-1144.1990; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; JIN SG, 1990, J BACTERIOL, V172, P4945, DOI 10.1128/jb.172.9.4945-4950.1990; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; MAGASANIK B, 1987, ESCHERICHIA COLI SAL, P1318; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; MIRANDARIOS J, 1987, NUCLEIC ACIDS RES, V15, P2757; NINFA AJ, 1986, J BACTERIOL, V168, P1002, DOI 10.1128/jb.168.2.1002-1004.1986; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; OLMEDO G, 1990, IN PRESS J MOL BIOL, V215; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; STOCK AM, 1988, COLD SPRING HARB SYM, V53, P49, DOI 10.1101/SQB.1988.053.01.009; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6	32	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6888	6893						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016302				2022-12-25	WOS:A1991FG72700041
J	OKAJIMA, T; TANIZAWA, K; YONEYA, T; FUKUI, T				OKAJIMA, T; TANIZAWA, K; YONEYA, T; FUKUI, T			ROLE OF LEUCINE-66 IN THE ASYMMETRIC RECOGNITION OF SUBSTRATES IN CHICKEN MUSCLE ADENYLATE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; GLYCINE-RICH REGION; ATP-BINDING SITE; INHIBITOR P1,P5-DI(ADENOSINE-5'-)PENTAPHOSPHATE; ADENOSINE DIPHOSPHOPYRIDOXAL; ESCHERICHIA-COLI; INDUCED-FIT; MECHANISM; COMPLEX; AMP	Adenylate kinase has two distinct binding sites for nucleotide substrates, MgATP and AMP. To identify the location of the site that specifically interacts with the adenine ring of AMP, we have substituted Ala, Gly, Val, Gln, and Trp for Leu66 of the recombinant chicken muscle enzyme by site-directed mutagenesis. All the purified Leu66 mutant enzymes exhibited an essentially identical circular dichroism spectrum and had thermal stabilities similar to the wild-type enzyme. Steady state kinetic analysis showed that the LeU66 mutant enzymes have significantly decreased V(max) values and markedly large K(m) values only for AMP. These results show that the binding site for the adenine ring of AMP in adenylate kinase is presumably located close to Leu66, which is invariant in all the enzymes so far sequenced. Significant inhibition of activities of the mutant enzymes and quenching of the Trp66 fluorescence by substrates suggest that in some Leu66 mutant enzymes, MgATP also binds to the AMP-binding site. Thus, Leu66 of adenylate kinase might play a role in the asymmetric recognition of the adenine ring of AMP from that of MgATP. Furthermore, the hydrophobicity of the residue at position 66 appears to be important for the positive cooperativity of substrate binding.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University				Okajima, Toshihide/0000-0003-1733-9580				Boyer P.D, 1973, ENZYMES, P279; DIEDERICHS K, 1990, BIOCHEMISTRY-US, V29, P8138, DOI 10.1021/bi00487a022; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; FLORINI JR, 1957, BIOCHIM BIOPHYS ACTA, V25, P575, DOI 10.1016/0006-3002(57)90529-2; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; FRY DC, 1987, BIOCHEMISTRY-US, V26, P1645, DOI 10.1021/bi00380a024; HAMADA M, 1978, ARCH BIOCHEM BIOPHYS, V190, P772, DOI 10.1016/0003-9861(78)90338-7; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MULLER CW, 1988, J MOL BIOL, V202, P909, DOI 10.1016/0022-2836(88)90567-0; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; SACHSENHEIMER W, 1977, J MOL BIOL, V114, P23, DOI 10.1016/0022-2836(77)90280-7; SANDERS CR, 1989, BIOCHEMISTRY-US, V28, P9028, DOI 10.1021/bi00449a011; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; TAGAYA M, 1987, J BIOL CHEM, V262, P8257; TAGAYA M, 1989, J BIOL CHEM, V264, P990; TANIZAWA Y, 1987, J BIOCHEM-TOKYO, V101, P1289, DOI 10.1093/oxfordjournals.jbchem.a121993; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; Westphal U., 1969, METHOD ENZYMOL, V15, P761; YAGAMI T, 1988, FEBS LETT, V229, P261, DOI 10.1016/0014-5793(88)81137-2; YONEYA T, 1989, J BIOCHEM-TOKYO, V105, P158, DOI 10.1093/oxfordjournals.jbchem.a122631; YONEYA T, 1990, J BIOL CHEM, V265, P21488	27	19	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11442	11447						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050660				2022-12-25	WOS:A1991FT76200010
J	HELLERSTEIN, MK				HELLERSTEIN, MK			APPENDIX - RELATIONSHIP BETWEEN PRECURSOR ENRICHMENT AND RATIO OF EXCESS M2/EXCESS M1 ISOTOPOMER FREQUENCIES IN A SECRETED POLYMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT MED,DIV ENDOCRINOL & METAB,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	HELLERSTEIN, MK (corresponding author), UNIV CALIF BERKELEY,DEPT NUTR SCI,BERKELEY,CA 94720, USA.								0	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10920	10924						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040609				2022-12-25	WOS:A1991FQ77400036
J	REISS, Y; SEABRA, MC; ARMSTRONG, SA; SLAUGHTER, CA; GOLDSTEIN, JL; BROWN, MS				REISS, Y; SEABRA, MC; ARMSTRONG, SA; SLAUGHTER, CA; GOLDSTEIN, JL; BROWN, MS			NONIDENTICAL SUBUNITS OF P21H-RAS FARNESYLTRANSFERASE - PEPTIDE BINDING AND FARNESYL PYROPHOSPHATE CARRIER FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY LIPOPROTEIN RECEPTOR; PROTEIN TRANSFERASE; GAMMA-SUBUNIT; RAS PROTEINS; CYSTEINE; CONTAIN; P21RAS; CELLS	The protein farnesyltransferase purified from rat brain contains two nonidentical subunits, alpha and beta. The holoenzyme forms a stable complex with [H-3]farnesyl pyrophosphate(FPP) that can be isolated by gel filtration. The [H-3]FPP is not covalently bound to the enzyme; it is released unaltered when the enzyme is denatured. When incubated with an acceptor such as p21H-ras, the complex transfers [H-3]farnesyl from the bound [H-3]FPP to the ras protein. This transfer is not sensitive to dilution by unbound FPP, suggesting that the [H-3]FPP is bound at a site that leads to direct transfer to the p21H-ras acceptor. Cross-linking studies show that the p21H-ras binds to the lower molecular weight subunit (beta-subunit), raising the possibility that the [H-3]FPP binds to the alpha-subunit. If this suggestion can be confirmed, it would invoke a reaction mechanism in which the alpha-subunit acts as a prenyl pyrophosphate carrier that delivers FPP to p21H-ras which is bound to the beta-subunit.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	REISS, Y (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Seabra, Miguel/AAC-3099-2019; Seabra, Miguel C/M-3280-2013	Seabra, Miguel C/0000-0002-6404-4892	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARLOW E, 1988, ANTIBODIES LABORATOR, P82; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; REISS Y, 1990, Methods (Orlando), V1, P241, DOI 10.1016/S1046-2023(05)80323-8; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; ROBISHAW JD, 1989, J BIOL CHEM, V264; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	23	187	193	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10672	10677						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037606				2022-12-25	WOS:A1991FP08600100
J	DENSLOW, ND; ANDERS, JC; OBRIEN, TW				DENSLOW, ND; ANDERS, JC; OBRIEN, TW			BOVINE MITOCHONDRIAL RIBOSOMES POSSESS A HIGH-AFFINITY BINDING-SITE FOR GUANINE-NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIAL CHARACTERIZATION; MAMMALIAN MITOCHONDRIA; LIVER-MITOCHONDRIA; ELONGATION-FACTORS; ESCHERICHIA-COLI; MESSENGER-RNA; PROTEIN; IDENTIFICATION; TRANSLOCATION; COMPLEX	Mammalian mitochondrial ribosomes possess a binding site for guanine nucleotides. GTP binds in unit stoichiometry and with high affinity (K(d) = 15.3 +/- 2.8 nM) to the small subunit of bovine mitochondrial ribosomes. This binding activity survives high salt washes, indicating that the nucleotide binds to an integral site within this subunit. GDP also binds to the small subunit with high affinity (K(d) = 17 +/- 5.8 nm) and in unit stoichiometry. The GTP binding activity can be competed with GDP but not appreciably by other nucleotides, indicating that both GTP and GDP bind specifically and to the same site. The non-hydrolyzable analogs of GTP, guanylyl-5'-imidophosphate, and guanylyl-(beta-gamma-methylene)-diphosphonate also bind to the small subunit, but with reduced affinity. These results indicate that mammalian mitochondrial ribosomes, unlike other ribosomes, are able to interact directly with guanosine triphosphate, suggesting that the bound GTP may be involved in a novel regulatory mechanism in mitochondrial protein synthesis.	WALTER REED ARMY MED CTR,DEPT IMMUNOL,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	DENSLOW, ND (corresponding author), UNIV FLORIDA,J HILLIS MILLER HLTH CTR,COLL MED,DEPT BIOCHEM & MOLEC BIOL,BOX J-245,GAINESVILLE,FL 32610, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015438] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15438] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLENDE JE, 1988, FASEB J, V2, P2356, DOI 10.1096/fasebj.2.8.2452111; BARRELL BG, 1979, NATURE, V282, P189, DOI 10.1038/282189a0; BODLEY JW, 1970, J BIOL CHEM, V245, P5656; CANTOR RC, 1980, BIOPHYSICAL CHEM 3, P943; CHUNG HKJ, 1990, J BIOL CHEM, V265, P21000; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DEBRUIJN MHL, 1983, EMBO J, V2, P1309, DOI 10.1002/j.1460-2075.1983.tb01586.x; DENSLOW ND, 1989, J BIOL CHEM, V264, P8328; DENSLOW ND, 1978, EUR J BIOCHEM, V91, P441, DOI 10.1111/j.1432-1033.1978.tb12696.x; DENSLOW ND, 1979, BIOCHEM BIOPH RES CO, V90, P1257, DOI 10.1016/0006-291X(79)91172-0; DENSLOW ND, 1988, BIOCHEMISTRY-US, V27, P3521, DOI 10.1021/bi00409a059; EBERLY SL, 1985, J BIOL CHEM, V260, P8721; HAMILTON MG, 1974, BIOCHEMISTRY-US, V13, P5400, DOI 10.1021/bi00723a024; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LIAO HX, 1990, J BIOL CHEM, V265, P11761; LIAO HX, 1990, J BIOL CHEM, V265, P13618; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; OBRIEN TW, 1990, BIOCHIM BIOPHYS ACTA, V1050, P174, DOI 10.1016/0167-4781(90)90162-U; OBRIEN TW, 1977, INT CELL BIOL, P245; OBRIEN TW, 1976, HDB GENETICS, V5, P535; OHASHI A, 1980, J BIOL CHEM, V255, P7740; SACCHI A, 1973, BIOCHIM BIOPHYS ACTA, V308, P390, DOI 10.1016/0005-2787(73)90332-8; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; SPREMULLI L, 1987, BIOCHEM BIOPH RES CO, V147, P1077, DOI 10.1016/S0006-291X(87)80180-8; ULBRICH B, 1980, EUR J BIOCHEM, V2108, P337; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009	26	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9586	9590						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033053				2022-12-25	WOS:A1991FM45900040
J	UNGER, E; PETTERSSON, I; ERIKSSON, UJ; LINDAHL, U; KJELLEN, L				UNGER, E; PETTERSSON, I; ERIKSSON, UJ; LINDAHL, U; KJELLEN, L			DECREASED ACTIVITY OF THE HEPARAN SULFATE-MODIFYING ENZYME GLUCOSAMINYL N-DEACETYLASE IN HEPATOCYTES FROM STREPTOZOTOCIN-DIABETIC RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLOMERULAR BASEMENT-MEMBRANE; IV COLLAGEN; LIVER; COMPLICATIONS; ASSAY	N-Deacetylation is the initial polymer modification step in heparan sulfate biosynthesis and a prerequisite to subsequent N- and O-sulfation. It has previously been shown that the sulfation of liver heparan sulfate is lowered in diabetes (Kjellen, L., Bielefeld, D., and Hook, M. (1983) Diabetes 32, 337-342). To investigate whether the reduced sulfation is the result of a lowered N-deacetylase activity, we have assayed this enzyme in hepatocytes from streptozotocin-diabetic rats. In addition, the activity of the glucuronosyl C5-epimerase, which catalyzes a modification reaction subsequent to N-sulfation, was measured. The deacetylase activity, expressed per microgram of cell protein, was about 40% lower in diabetic hepatocytes as compared with control cells, whereas the epimerase activity was unaffected. Recently, a approximately 110-kDa glycoprotein that carries N-sulfotransferase activity was identified as one of at least two protein components required for N-deacetylation in mouse mastocytoma tissue (Petterson, I., Kusche, M., Unger, E., Wlad, H., Nylund, L., Lindahl, U., and Kjellen, L. (1991) J. Biol. Chem. 266, 8044-8049). We therefore investigated if the lowered N-deacetylase activity in diabetes could be ascribed to a deficiency in either one of the corresponding rat components. The results indicated that (i) the glycoprotein component is present in limiting amounts in both control and diabetic cells, (ii) diabetes results in a lowered activity of this component, and (iii) excess amounts of the additional protein(s) needed for N-deacetylase activity are present in both control and diabetic cells.	UNIV UPPSALA,DEPT MED CELL BIOL,S-75123 UPPSALA,SWEDEN; UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN	Uppsala University; Uppsala University	UNGER, E (corresponding author), SWEDISH UNIV AGR SCI,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN.		Kjellen, Lena/F-1362-2011					BRANDAN E, 1988, J BIOL CHEM, V263, P2417; CAMPBELL P, 1983, ANAL BIOCHEM, V131, P146, DOI 10.1016/0003-2697(83)90146-X; COHEN MP, 1988, DIABETES, V37, P1324, DOI 10.2337/diabetes.37.10.1324; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; ERIKSSON UJ, 1988, TERATOLOGY, V37, P365, DOI 10.1002/tera.1420370410; FURTH J, 1957, P SOC EXP BIOL MED, V95, P824; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; JEFFERSON LS, 1983, J BIOL CHEM, V258, P1369; KANWAR YS, 1983, P NATL ACAD SCI-BIOL, V80, P2272, DOI 10.1073/pnas.80.8.2272; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; KENNEDY L, 1984, DIABETOLOGIA, V26, P93; KJELLEN L, 1983, DIABETES, V32, P337, DOI 10.2337/diabetes.32.4.337; KJELLEN L, 1991, ANN REV BIOCH, V60, P43; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; Lindahl U., 1989, HEPARIN, P159; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; NAVIA JL, 1983, ANAL BIOCHEM, V135, P134, DOI 10.1016/0003-2697(83)90741-8; OBRINK B, 1982, METHOD ENZYMOL, V82, P513; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; SEGLEN PO, 1972, EXP CELL RES, V74, P450, DOI 10.1016/0014-4827(72)90400-4; TARSIO JF, 1987, BIOCHEMISTRY-US, V26, P1014, DOI 10.1021/bi00378a006; TARSIO JF, 1988, DIABETES, V37, P532, DOI 10.2337/diabetes.37.5.532	22	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8671	8674						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026583				2022-12-25	WOS:A1991FM03800007
J	HEPBURN, PA; MARGISON, GP; TISDALE, MJ				HEPBURN, PA; MARGISON, GP; TISDALE, MJ			ENZYMATIC METHYLATION OF CYTOSINE IN DNA IS PREVENTED BY ADJACENT O6-METHYLGUANINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							N-NITROSOUREA; CARCINOGENESIS; HYPOMETHYLATION; MAINTENANCE; ALKYLATION; DENOVO; CELLS; SITES	The effect of O6-alkylation of guanine residues on the enzymic methylation of cytosine has been studied using synthetic oligonucleotides in which all guanines in cytosine-guanine sequences at potentially methylatable sites are replaced by O6-methylguanine. In contrast with the unmodified forms, which showed high acceptance activity for methyl-H-3-labeled groups from S-adenosyl-L-[methyl-H-3]methionine in the presence of DNA methylase, the modified oligonucleotides were not substrates for the enzyme either in the single-stranded or annealed forms. In view of the importance of cytosine methylation in the down-regulation of certain genes, the potential to affect gene expression by this mechanism may be a contributory factor in the toxic and carcinogenic effects of chemical methylating agents.	UNIV ASTON,INST PHARMACEUT SCI,CANC RES CAMPAIGN EXPTL CHEMOTHERAPY GRP,BIRMINGHAM B4 7ET,W MIDLANDS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND	Aston University; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research			Margison, Geoff/E-4146-2019					ATKINSON T, 1985, OLIGONUCLEOTIDE SYNT, P35; BABICH MA, 1987, MUTAT RES, V184, P245, DOI 10.1016/0167-8817(87)90023-X; BIRD AP, 1984, NATURE, V307, P503, DOI 10.1038/307503a0; BOEHM TLJ, 1981, CARCINOGENESIS, V2, P39, DOI 10.1093/carcin/2.1.39; BOLDEN A, 1984, J BIOL CHEM, V259, P2437; BOLDEN AH, 1986, MOL CELL BIOL, V6, P1135, DOI 10.1128/MCB.6.4.1135; BOLDEN AH, 1985, NUCLEIC ACIDS RES, V13, P3479, DOI 10.1093/nar/13.10.3479; BOROWYBOROWSKI H, 1987, BIOCHEMISTRY-US, V26, P2465, DOI 10.1021/bi00383a010; BRISCOE WT, 1984, CHEM-BIOL INTERACT, V52, P103, DOI 10.1016/0009-2797(84)90086-3; BULL VL, 1987, BIOCHEM PHARMACOL, V36, P3215, DOI 10.1016/0006-2952(87)90636-8; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; HOLLIDAY R, 1979, BRIT J CANCER, V40, P513, DOI 10.1038/bjc.1979.216; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; KARRAN P, 1982, NATURE, V296, P770, DOI 10.1038/296770a0; MARGISON GP, 1989, CHEM CARCINOGENESIS, P547; MATHES WB, 1988, CARCINOGENESIS, V9, P2065; MEDCALF ASC, 1983, CARCINOGENESIS, V4, P115, DOI 10.1093/carcin/4.1.115; NEWBOLD RF, 1980, NATURE, V283, P596, DOI 10.1038/283596a0; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; TURNBULL JF, 1976, NUCLEIC ACIDS RES, V3, P677, DOI 10.1093/nar/3.3.677; VOIGT JM, 1990, BIOCHEMISTRY-US, V29, P1632, DOI 10.1021/bi00458a039; YAROSH DB, 1985, MUTAT RES, V145, P1, DOI 10.1016/0167-8817(85)90034-3; YAROSH DB, 1983, CARCINOGENESIS, V4, P199, DOI 10.1093/carcin/4.2.199	23	49	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					7985	7987						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022628				2022-12-25	WOS:A1991FK44100007
J	HOCHBERG, A; SIBLEY, C; PIXLEY, M; SADOVSKY, Y; STRAUSS, B; BOIME, I				HOCHBERG, A; SIBLEY, C; PIXLEY, M; SADOVSKY, Y; STRAUSS, B; BOIME, I			CHORIOCARCINOMA CELLS INCREASE THE NUMBER OF DIFFERENTIATING HUMAN CYTOTROPHOBLASTS THROUGH AN INVITRO INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; PLACENTAL-LACTOGEN; ALPHA-SUBUNIT; TROPHOBLAST; SECRETION	The human placenta arises from the zygote through single cell intermediates called cytotrophoblasts that in turn give rise to a syncytium. In culture, mononucleated cytotrophoblasts exhibit little, if any, cell division but are converted to multinucleated cells. Choriocarcinoma, the malignant tumor of placenta trophoblast, comprises a mixed population of dividing cellular intermediates that resemble cytotrophoblasts but are less differentiated. Because the choriocarcinoma intermediates arise from dividing cells, the tumor may contain one or more cell types in abundance not present in the population of isolated placental cells. To study placental differentiation through cell-cell interaction, choriocarcinoma cell lines were co-cultured with placenta-derived cytotrophoblasts, and placental hormone biosynthesis, as a marker of differentiation was examined. We reasoned that intermediates formed by the tumor might interact with and complement those intermediates in the placenta-derived cytotrophoblast population. Co-culturing either the JAr or JEG choriocarcinoma cell lines with cytotrophoblasts elevated the synthesis of the chorionic gonadotropin alpha and beta-subunits 10-20 fold, and human placental lactogen 5-fold. The effect was specific for these trophoblast-derived cells, since comparable quantities of Chinese hamster ovary or HeLa cells did not affect the placental cytotrophoblast culture. Further experiments suggested that the source of enhanced synthesis was the cytotrophoblasts. We propose that an interaction between cytotrophoblasts and choriocarcinoma cells occurs, which results in an increased number of differentiating cytotrophoblasts. Such co-cultures may represent a model system for examining choriocarcinoma cell interaction with normal cells, a process known to occur in vivo. The data are also consistent with the hypothesis that the regulated chorionic gonadotropin production in the placenta is determined by interaction among trophoblast cells at different stages of differentiation.	WASHINGTON UNIV, SCH MED, DEPT OBSTET & GYNECOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	HOCHBERG, A (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PHARMACOL, ST LOUIS, MO 63110 USA.							BAGSHAWE KD, 1969, CHORIOCARCINOMA CLIN, P72; BOYD JD, 1970, HUMAN PLACENTA, P140; CHOU JY, 1977, NATURE, V268, P543, DOI 10.1038/268543a0; CORLESS CL, 1987, J BIOL CHEM, V262, P14197; DANIELSMCQUEEN S, 1987, TROPHOBLAST RES, V2, P423; ENDERS AC, 1965, OBSTET GYNECOL, V25, P378; GASPARD UJ, 1980, PLACENTA, V1, P135, DOI 10.1016/S0143-4004(80)80022-1; GILEADI O, 1988, INT CONGR SER, V798, P251; HERTZ R, 1978, CHORIOCARCINOMA RELA, P23; HOSHINA M, 1983, J CELL BIOL, V97, P1200, DOI 10.1083/jcb.97.4.1200; HOSHINA M, 1985, PLACENTA, V6, P163, DOI 10.1016/S0143-4004(85)80066-7; HUSSA RO, 1977, IN VITRO CELL DEV B, V13, P443, DOI 10.1007/BF02615105; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; MAZUR M, 1987, GESTATIONAL TROPHOBL; OTANI F, 1989, BIOCHEM BIOPH RES CO, V160, P6, DOI 10.1016/0006-291X(89)91612-4; OTANI T, 1988, J BIOL CHEM, V263, P7322; PATTILLO RA, 1974, HORMONES CANCERS, P363; PIERCE GB, 1963, AM J PATHOL, V43, P153; RUDDON RW, 1980, CANCER RES, V40, P4519; WYNN R, 1972, AM J OBSTET GYNECOL, V14, P339	20	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8517	8522						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022665				2022-12-25	WOS:A1991FK44100084
J	ALLES, A; ALLEY, K; BARRETT, JC; BUTTYAN, R; COLUMBANO, A; COPE, FO; COPELAN, EA; DUKE, RC; FAREL, PB; GERSHENSON, LE; GOLDGABER, D; GREEN, DR; HONN, KV; HULLY, J; ISAACS, JT; KERR, JFR; KRAMMER, PH; LOCKSHIN, RA; MARTIN, DP; MCCONKEY, DJ; MICHAELSON, J; SCHULTEHERMANN, R; SERVER, AC; SZENDE, B; TOMEI, LD; TRITTON, TR; UMANSKY, SR; VALERIE, K; WARNER, HR				ALLES, A; ALLEY, K; BARRETT, JC; BUTTYAN, R; COLUMBANO, A; COPE, FO; COPELAN, EA; DUKE, RC; FAREL, PB; GERSHENSON, LE; GOLDGABER, D; GREEN, DR; HONN, KV; HULLY, J; ISAACS, JT; KERR, JFR; KRAMMER, PH; LOCKSHIN, RA; MARTIN, DP; MCCONKEY, DJ; MICHAELSON, J; SCHULTEHERMANN, R; SERVER, AC; SZENDE, B; TOMEI, LD; TRITTON, TR; UMANSKY, SR; VALERIE, K; WARNER, HR			APOPTOSIS - A GENERAL COMMENT	FASEB JOURNAL			English	Article							DEATH				ALLES, A (corresponding author), OHIO STATE UNIV, ARTHUR G JAMES CANC HOSP & RES INST, COLUMBUS, OH 43210 USA.		Valerie, Kristoffer/AAL-8299-2021	Columbano, Amedeo/0000-0002-6956-9030				GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GROMKOWSKI SH, 1988, J IMMUNOL, V141, P774; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	7	83	83	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2127	2128		10.1096/fasebj.5.8.2022310	http://dx.doi.org/10.1096/fasebj.5.8.2022310			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	2022310				2022-12-25	WOS:A1991FK11100002
J	COGNET, M; BERGOT, MO; KAHN, A				COGNET, M; BERGOT, MO; KAHN, A			CIS-ACTING DNA ELEMENTS REGULATING EXPRESSION OF THE LIVER PYRUVATE-KINASE GENE IN HEPATOCYTES AND HEPATOMA-CELLS - EVIDENCE FOR TISSUE-SPECIFIC ACTIVATORS AND EXTINGUISHER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; ADULT-RAT HEPATOCYTES; TRANSCRIPTION FACTOR; ALBUMIN GENE; CHLORAMPHENICOL ACETYLTRANSFERASE; 5'-FLANKING REGION; ENHANCER ELEMENTS; UPSTREAM ELEMENT; NEGATIVE CONTROL; MAMMALIAN-CELLS	To identify the DNA sequences that cis-regulate the expression of the rat liver pyruvate kinase (L-PK) genes, a series of constructs in which the chloramphenicol acetyltransferase reporter gene is driven by various deleted fragments of the 3200 base pairs (bp) upstream of the L-PK gene cap site have been assayed for transient expression after introduction into hepatoma HepG2 cells, rat hepatocytes in primary culture, fibroblast LTK- cells, myogenic C2C12 cells, and CHO cells. Four distinct regulatory domains have been characterized. A proximal promoter region containing a binding site for the hepatocyte nuclear factor 1 (HNF1) which is sufficient to confer liver specificity, even in the presence of a ubiquitous enhancer. A distal promoter region (-96 to -283 bp) containing binding sites for the liver-specific factor A1 (LFA1), the ubiquitous nuclear factor 1 (NF1), the major late transcriptional factor (MLTF), and so far unidentified proteins binding to the L5-PK region which is essential to maximally activate expression of the construct in HepG2 cells. An extinguisher region, located between positions -2082 and -1170 bp, which decreases efficiency of the L-PK promoter in HepG2 cells, but not in hepatocytes in primary culture. Finally, a far upstream region (-2900 to -2500 bp) which seems to correspond to a liver-specific DNase I hypersensitive site and which behaves in HepG2 cells as an activating sequence efficient in the absence of the extinguisher.			COGNET, M (corresponding author), CHU COCHIN,INSERM,U129,INST COCHIN GENET MOLEC,RECH GENET & PATHOL MOLEC LAB,F-75014 PARIS,FRANCE.		Vasseur, Mireille/L-6958-2017	Vasseur, Mireille/0000-0001-6963-4114				BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BRIATA P, 1989, BIOCHEM BIOPH RES CO, V160, P1415, DOI 10.1016/S0006-291X(89)80162-7; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHANG HK, 1989, MOL CELL BIOL, V9, P5189, DOI 10.1128/MCB.9.11.5189; CHODOSH L, 1987, SCIENCE, V239, P684; COGNET M, 1987, J MOL BIOL, V196, P11, DOI 10.1016/0022-2836(87)90507-9; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; COSTA RH, 1986, MOL CELL BIOL, V6, P4697, DOI 10.1128/MCB.6.12.4697; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DESIMONE V, 1989, NUCLEIC ACIDS RES, V17, P9407, DOI 10.1093/nar/17.22.9407; DEVLIN BH, 1989, J BIOL CHEM, V264, P13896; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; FRASLIN JM, 1985, EMBO J, V4, P2487, DOI 10.1002/j.1460-2075.1985.tb03960.x; GINOT F, 1989, EUR J BIOCHEM, V180, P289, DOI 10.1111/j.1432-1033.1989.tb14646.x; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HIGUCHI K, 1988, J BIOL CHEM, V263, P18530; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LAMAS E, 1987, J HISTOCHEM CYTOCHEM, V35, P559, DOI 10.1177/35.5.3104450; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; LEFF T, 1989, J BIOL CHEM, V264, P16132; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; REUE K, 1988, J BIOL CHEM, V263, P6857; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHAEFFER E, 1989, J BIOL CHEM, V264, P7153; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SEGLEN PO, 1973, EXP CELL RES, V76, P25, DOI 10.1016/0014-4827(73)90414-X; SWIFT FV, 1987, EMBO J, V6, P1339, DOI 10.1002/j.1460-2075.1987.tb02373.x; TREMP GL, 1989, J BIOL CHEM, V264, P19904; TSUTSUMI KI, 1989, MOL CELL BIOL, V11, P4923; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; WASYLYK B, 1984, NUCLEIC ACIDS RES, V12, P5589, DOI 10.1093/nar/12.14.5589; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMADA K, 1990, J BIOL CHEM, V265, P19885; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	59	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7368	7375						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019572				2022-12-25	WOS:A1991FJ34200012
J	KATAGIRI, H; ASANO, T; SHIBASAKI, Y; LIN, JL; TSUKUDA, K; ISHIHARA, H; AKANUMA, Y; TAKAKU, F; OKA, Y				KATAGIRI, H; ASANO, T; SHIBASAKI, Y; LIN, JL; TSUKUDA, K; ISHIHARA, H; AKANUMA, Y; TAKAKU, F; OKA, Y			SUBSTITUTION OF LEUCINE FOR TRYPTOPHAN-412 DOES NOT ABOLISH CYTOCHALASIN-B LABELING BUT MARKEDLY DECREASES THE INTRINSIC ACTIVITY OF GLUT1 GLUCOSE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESPONSIVE TISSUES; HUMAN-ERYTHROCYTE; MESSENGER-RNA; HEXOSE TRANSPORTER; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; RAT-BRAIN; PROTEIN; CLONING; SEQUENCE	GLUT1 glucose transporter cDNA was modified to introduce a single amino acid substitution of leucine for tryptophan 412, a putative cytochalasin B photo-affinity labeling site. Although the mutated transporter was expressed into plasma membranes of Chinese hamster ovary cells, glucose transport activity of the mutated transporter was observed to be only 15-30% of that of the wild-type GLUT1 when glucose transport activity was assessed by 2-deoxyglucose uptake at 0.1-10 mM concentrations. Analysis of glucose uptake kinetics depict that a mutation induced a 3-fold decrease in turnover number and a 2.5-fold increase in K(m) compared with the wild-type GLUT1. Importantly, cytochalasin B labeling was not abolished but decreased by 40%, and cytochalasin B binding was also decreased. In addition, the results obtained with side-specific glucose analogs suggested that the outer glucose binding site of the mutant appeared intact but the inner binding site was modulated. These results indicate 1) tryptophan 412 is not a cytochalasin B labeling site(s), although this residue is located in or close to the inner glucose binding site of the GLUT1 glucose transporter, 2) substitution of leucine for tryptophan 412 decreases the intrinsic activity of GLUT1 glucose transporter, which is definable as the turnover number/K(m), to approximately 15% of that of the wild-type.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,TOKYO 100,JAPAN	University of Tokyo; Asahi Life Foundation								ASANO T, 1989, J BIOL CHEM, V264, P3416; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BAKER GF, 1973, J PHYSIOL-LONDON, V231, P143, DOI 10.1113/jphysiol.1973.sp010225; BALDWIN JM, 1980, BIOCHIM BIOPHYS ACTA, V599, P699, DOI 10.1016/0005-2736(80)90211-4; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CARTERSU C, 1982, J BIOL CHEM, V257, P5419; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; DEZIEL M, 1984, BIOCHIM BIOPHYS ACTA, V772, P403, DOI 10.1016/0005-2736(84)90157-3; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KRUPKA TM, 1971, BIOCHEMISTRY-US, V10, P1143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; PESSIN JE, 1982, P NATL ACAD SCI-BIOL, V79, P2286, DOI 10.1073/pnas.79.7.2286; PILCH PF, 1990, ENDOCRINOLOGY, V126, P3, DOI 10.1210/endo-126-1-3; SHANAHAN MF, 1982, BIOCHEM BIOPH RES CO, V107, P38, DOI 10.1016/0006-291X(82)91666-7; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7	32	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7769	7773						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019601				2022-12-25	WOS:A1991FJ34200072
J	SANGHERA, JS; PADDON, HB; PELECH, SL				SANGHERA, JS; PADDON, HB; PELECH, SL			ROLE OF PROTEIN-PHOSPHORYLATION IN THE MATURATION-INDUCED ACTIVATION OF A MYELIN BASIC-PROTEIN KINASE FROM SEA STAR OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; EARLY MITOTIC EVENTS; CONTROL GENE CDC2+; CELL-CYCLE; PROMOTING FACTOR; M-PHASE; XENOPUS OOCYTES; PERIODIC ACTIVATION; POSSIBLE MECHANISM; HISTONE-H1 KINASE	We have previously described the purification of a myelin basic protein (MBP) kinase from maturing sea star oocytes (Sanghera, J. S., Paddon, H. B., Bader, S. A., and Pelech, S. L. (1990) J. Biol. Chem. 265, 52-57). The ability of the purified 44-kDa protein to bind azido-ATP and undergo autophosphorylation on the serine residue implied that it is a protein kinase. Furthermore, partial amino acid sequence data has revealed that it is a novel protein kinase, which we have provisionally designated p44mpk. Autophosphorylation of p44mpk to 0.7 mol of phosphate/mol of enzyme was correlated with a modest (approximately 17%) increase in the MBP-phosphorylating activity of the kinase. Rabbit polyclonal antibody raised against purified p44mpk recognized on immunoblots the protein in highly purified preparations as well as crude oocyte extracts. The affinity-purified anti-p44mpk antibody could immunoprecipitate active kinase, but a subpopulation of the antibody also appeared to be inhibitory. Using this antibody, we have demonstrated that the up to 12-fold stimulation of the cytosolic MBP-phosphorylating activity of this kinase that occurs during sea star oocyte maturation is not due to an increase in the amount of enzyme protein, either from a redistribution within the oocyte or protein synthesis. A slight retardation of the migration of the activated p44mpk on sodium dodecyl sulfate-polyacrylamide gels and its tighter interaction with a MonoQ column is consistent with phosphorylation of the kinase during maturation. p44mpk underwent enhanced phosphorylation when oocytes prelabeled with [P-32]orthophosphate were induced to mature with 1-methyladenine. The stimulated MBP-phosphorylating activity of p44mpk in cytosols from maturing oocytes was partly stabilized by the presence of the phosphatase inhibitor beta-glycerol phosphate. Furthermore, treatment of purified p44mpk with protein phosphatase 2A and alkaline phosphatase resulted in 56 and 86% decreases, respectively, in the activity of the kinase. Together, these findings strongly implicate a role for phosphorylation of p44mpk in its activation during sea star oocyte maturation.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1W5, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1W5, BC, CANADA	University of British Columbia; University of British Columbia								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; CICIRELLI MF, 1988, FEBS LETT, V241, P195, DOI 10.1016/0014-5793(88)81060-3; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DABAUVALLE MC, 1988, CELL, V52, P525, DOI 10.1016/0092-8674(88)90465-5; Deibler G E, 1984, Prog Clin Biol Res, V146, P249; DOREE M, 1983, DEV BIOL, V99, P489, DOI 10.1016/0012-1606(83)90298-1; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ERICKSON E, 1988, 2ND MESSENGERS PHOSP, V12, P135; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; ERIKSON E, 1989, J BIOL CHEM, V264, P19577; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GUERRIER P, 1977, MOL CELL ENDOCRINOL, V7, P137, DOI 10.1016/0303-7207(77)90063-6; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LABBE JC, 1988, DEV BIOL, V127, P157, DOI 10.1016/0012-1606(88)90197-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MEIJER L, 1987, BIOCHEMISTRY-US, V26, P7968, DOI 10.1021/bi00398a063; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1984, INT REV CYTOL, V86, P129, DOI 10.1016/S0074-7696(08)60179-5; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; PICARD A, 1987, DEV GROWTH DIFFER, V29, P93; PICKETTGIES CA, 1985, J BIOL CHEM, V260, P2046; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SANO K, 1985, DEV GROWTH DIFFER, V27, P263; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0	51	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6700	6707						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016285				2022-12-25	WOS:A1991FG72700011
J	SMITH, BL; AGRE, P				SMITH, BL; AGRE, P			ERYTHROCYTE MR-28,000 TRANSMEMBRANE PROTEIN EXISTS AS A MULTISUBUNIT OLIGOMER SIMILAR TO CHANNEL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION PROTEIN; RED-CELL MEMBRANE; PLASMA-MEMBRANE; EYE LENS; POLYPEPTIDE; LIVER; RAT; SPECTRIN; CLONING; PURIFICATION	A novel M(r) 28,000 erythrocyte transmembrane protein was recently purified and found to exist in two forms, "28kDa" and "gly28kDa," the latter containing N-linked carbohydrate (Denker, B. M., Smith, B. L., Kuhajda, F. P., and Agre, P. (1988) J. Biol. Chem. 263, 15634-15642). Although 28kDa protein resembles the Rh polypeptides biochemically, structural homologies were not identified by immunoblot or two-dimensional iodopeptide maps. The NH2-terminal amino acid sequence for the first 35 residues of purified 28kDa protein is 37% identical to the 26-kDa major intrinsic protein of lens (Gorin, M. B., Yancey, S. B., Cline, J., Revel, J.-P., and Horwitz, J. Cell 39, 49-59). Antisera to a synthetic peptide corresponding to the NH2-terminus of 28kDa protein gave a single reaction of molecular mass 28kDa on immunoblots of erythrocyte membranes. Selective digestions of intact erythrocytes and inside-out membrane vesicles with carboxypeptidase Y indicated the existence of a 5-kDa COOH-terminal cytoplasmic domain. Multiple studies indicated that 28kDa and gly28kDa proteins exist together as a multisubunit oligomer: 1) similar partial solubilizations in Triton X-100; 2) co-purification during ion exchange and lectin affinity chromatography; 3) cross-linking in low concentrations of glutaraldehyde; and 4) physical analyses of purified proteins and solubilized membranes in 1% (v/v) Triton X-100 showed 28kDa and gly28kDa proteins behave as a large single unit with Stokes radius of 61 angstrom and sedimentation coefficient of 5.7 S. These studies indicate that the 28kDa and gly28kDa proteins are distinct from the Rh polypeptides and exist as a multisubunit oligomer. The 28kDa protein has NH2-terminal amino acid sequence homology and membrane organization similar to major intrinsic protein and other members of a newly recognized family of transmembrane channel proteins.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,103 HUNTARIAN,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL ANAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33991] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1987, J BIOL CHEM, V262, P17497; ALLEN DP, 1987, BIOCHEM BIOPH RES CO, V149, P266, DOI 10.1016/0006-291X(87)91634-2; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BAKER ME, 1990, CELL, V60, P185, DOI 10.1016/0092-8674(90)90731-S; BENEDETTI EL, 1976, BIOCHIM BIOPHYS ACTA, V457, P353, DOI 10.1016/0304-4157(76)90004-6; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BLANCHARD D, 1988, BLOOD, V72, P1424; BOK D, 1982, J CELL BIOL, V92, P213, DOI 10.1083/jcb.92.1.213; BROEKHUYSE RM, 1976, EXP EYE RES, V28, P365; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; DAVIS J, 1982, J BIOL CHEM, V257, P5816; DENKER BM, 1988, J BIOL CHEM, V263, P15634; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; ELDER JH, 1977, J BIOL CHEM, V252, P6510; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; GAHMBERG CG, 1983, EMBO J, V2, P223, DOI 10.1002/j.1460-2075.1983.tb01409.x; GAHMBERG CG, 1984, J IMMUNOL, V133, P334; GOODEN M, 1985, BIOCHEM BIOPH RES CO, V128, P993, DOI 10.1016/0006-291X(85)90145-7; GOODENOUGH DA, 1979, INVEST OPHTH VIS SCI, V18, P1104; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; GRUIJTERS WTM, 1987, J CELL BIOL, V104, P565, DOI 10.1083/jcb.104.3.565; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HELENIUS A, 1972, J BIOL CHEM, V247, P3656; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KISTLER J, 1988, NATURE, V331, P721, DOI 10.1038/331721a0; KUMAR NM, 1986, J CELL BIOL, V103, P767, DOI 10.1083/jcb.103.3.767; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLLISON PL, 1987, BLOOD TRANSFUSION CL; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P4378; NICHOLSON BJ, 1983, CELL, V32, P967, DOI 10.1016/0092-8674(83)90081-8; PAUL DL, 1983, J CELL BIOL, V96, P625, DOI 10.1083/jcb.96.3.625; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PERACCHIA C, 1985, CURR EYE RES, V4, P431, DOI 10.3109/02713688509025157; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467; RIDGWELL K, 1984, FEBS LETT, V174, P7, DOI 10.1016/0014-5793(84)81066-2; ROSSE WF, 1989, RED BLOOD CELL MEMBR, P299; SABOORI AM, 1989, J CLIN INVEST, V83, P187, DOI 10.1172/JCI113857; SABOORI AM, 1988, P NATL ACAD SCI USA, V85, P4042, DOI 10.1073/pnas.85.11.4042; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SAS DF, 1985, J CELL BIOL, V100, P216, DOI 10.1083/jcb.100.1.216; Steck T. L., 1989, CELL SHAPE DETERMINA, P205; Steele J C Jr, 1978, Methods Enzymol, V48, P11; SUYAMA K, 1990, BLOOD, V75, P255; Tanford C, 1961, PHYS CHEM MACROMOLEC, P364; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZAMPIGHI GA, 1985, P NATL ACAD SCI USA, V82, P8468, DOI 10.1073/pnas.82.24.8468	53	329	339	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6407	6415						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007592				2022-12-25	WOS:A1991FE37300062
J	JORCYK, CL; WATSON, DK; MAVROTHALASSITIS, GJ; PAPAS, TS				JORCYK, CL; WATSON, DK; MAVROTHALASSITIS, GJ; PAPAS, TS			THE HUMAN ETS1 GENE - GENOMIC STRUCTURE, PROMOTER CHARACTERIZATION AND ALTERNATIVE SPLICING	ONCOGENE			English	Article							LONG TERMINAL REPEAT; ONCOGENE C-ETS; PROTO-ONCOGENE; TRANSCRIPTION FACTOR; FUNCTIONAL-CHARACTERIZATION; TRANSFORMING GENE; NUCLEAR PROTEINS; LEUKEMIA VIRUSES; E26 RETROVIRUS; SARCOMA-VIRUS	Genomic clones encompassing the human ETS1 gene were isolated and utilized to define its molecular organization. This gene consists of eight exons spanning over 60 kb. The 5' end of the human ETS1 gene was subcloned and characterized. S1 nuclease, primer extension and RNAase protection analyses of human mRNAs showed multiple transcription initiation sites. DNA sequence analysis indicated a high G + C content in the promoter region and the absence of either a 'TATA' box or a 'CAAT' box. Six consensus recognition sequences for the transcription factor SP1, two AP1 consensus sequences and one consensus AP2 recognition sequence were identified, as well as two GC elements with dyad symmetry. A palindromic region similar to the serum response element of the c-fos gene and two octamer consensus recognition sequences were located upstream of the promoter region. A series of promoter deletion constructs positioned upstream from the bacterial chloramphenicol acetyl transferase gene were transfected into HeLa cells and their functional promoter activity assayed. The deletion constructs identified the 5' boundary for maximum promoter activity at 486 bp upstream of the first initiation site and suggest possible positive and negative regulatory regions. Polymerase chain reaction analysis of ETS1 cDNA identified several amplified products, indicating alternative splicing. In addition to the presence of mRNA products lacking exon VII, products lacking exon IV, as well as ones lacking both exons IV and VII, were found.			JORCYK, CL (corresponding author), NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA.							ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BERG PE, 1989, NUCLEIC ACIDS RES, V17, P8833, DOI 10.1093/nar/17.21.8833; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHEN JH, 1988, ONCOGENE RES, V2, P371; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESIMONE V, 1989, NUCLEIC ACIDS RES, V17, P9407, DOI 10.1093/nar/17.22.9407; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FIELD LJ, 1985, P NATL ACAD SCI USA, V82, P6196, DOI 10.1073/pnas.82.18.6196; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAMPE A, 1989, ONCOGENE RES, V4, P9; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KEOHAVONG P, 1982, NUCLEIC ACIDS RES, V10, P1215, DOI 10.1093/nar/10.4.1215; KIM SJ, 1989, J BIOL CHEM, V264, P402; KOIZUMI S, 1990, ONCOGENE, V5, P675; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; Maniatis T., 1982, MOL CLONING; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; ROVIGATTI U, 1986, SCIENCE, V232, P398, DOI 10.1126/science.3457468; SACCHI N, 1988, LEUKEMIA, V2, P12; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SETH A, 1991, IN PRESS ONCOGENE; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	64	102	102	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					523	532						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030910				2022-12-25	WOS:A1991FR93900005
J	CASEY, ML; WORD, RA; MACDONALD, PC				CASEY, ML; WORD, RA; MACDONALD, PC			ENDOTHELIN-1 GENE-EXPRESSION AND REGULATION OF ENDOTHELIN MESSENGER-RNA AND PROTEIN-BIOSYNTHESIS IN AVASCULAR HUMAN AMNION - POTENTIAL SOURCE OF AMNIOTIC-FLUID ENDOTHELIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; VASOCONSTRICTOR PEPTIDE; SEQUENCE; IDENTIFICATION; CRITERIA; BINDING; CULTURE; TISSUE; PLASMA	We demonstrated previously that preproendothelin mRNA is present in avascular human amnion tissue and in human amnion cells maintained in primary monolayer culture. In this investigation we sought to identify the specific endothelin (ET) gene that is expressed in amnion and to determine whether endothelin is produced by amnion. Using oligonucleotides specific for ET-1, ET-2, and ET-3 mRNA, we identified preproET-1 mRNA in human amnion tissue. By radioimmunoassay of ET we found that human amnion tissue explants and amnion cells in culture secrete immunoreactive ET into the medium. PreproET mRNA levels and immunoreactive ET production by human amnion cells in monolayer culture are increased in response to treatment with agents that are known to be present in human amniotic fluid, i.e. epidermal growth factor, interleukin-1, and tumor necrosis factor-alpha. We found that the level of preproET mRNA in amnion cells was low compared with that in human umbilical endothelial cells; treatment with cycloheximide together with a stimulus of ET-1 gene transcription led to a striking increase in the level of preproET mRNA in amnion cells compared with a much weaker response in endothelial cells. These findings suggest that protein synthesis-dependent mechanisms may be of great importance in maintaining low levels of preproET mRNA in amnion tissue and in regulating the amount of preproET mRNA in amnion exposed to stimuli of ET-1 transcription. In addition, we demonstrated that immunoreactive ET is present in human amniotic fluid at the midtrimester of pregnancy and at term. Thus, it is likely that the avascular fetal amnion is one tissue site of origin of ET in amniotic fluid during human pregnancy.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	CASEY, ML (corresponding author), UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235, USA.				NICHD NIH HHS [5-P50-HD11149, 1-T32-HD07190] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011149, T32HD007190] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALEY PA, 1990, J CLIN INVEST, V85, P1320, DOI 10.1172/JCI114570; CALVO JJ, 1990, ENDOCRINOLOGY, V126, P2288, DOI 10.1210/endo-126-5-2288; CASEY ML, 1989, J CLIN INVEST, V83, P430, DOI 10.1172/JCI113901; CASEY ML, 1988, J BIOL CHEM, V263, P7846; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLOZEL M, 1989, J CARDIOVASC PHAR S5, V13, P229; COX SM, 1989, P SOC GYNECOL INVEST, V289; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; DSOUZA SW, 1985, LANCET, V2, P272; FUKUDA Y, 1988, BIOCHEM BIOPH RES CO, V155, P167, DOI 10.1016/S0006-291X(88)81064-7; HIRATA Y, 1988, FEBS LETT, V239, P13, DOI 10.1016/0014-5793(88)80536-2; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; ITOH Y, 1988, FEBS LETT, V231, P440, DOI 10.1016/0014-5793(88)80867-6; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KOHNO M, 1990, AM J MED, V88, P614, DOI 10.1016/0002-9343(90)90527-K; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOZUKA M, 1989, BIOCHEM BIOPH RES CO, V159, P317, DOI 10.1016/0006-291X(89)92440-6; KURIHARA H, 1989, J CARDIOVASC PHAR S5, V13, P132; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; OHTA K, 1990, BIOCHEM BIOPH RES CO, V169, P578, DOI 10.1016/0006-291X(90)90370-3; OKITA JR, 1983, IN VITRO CELL DEV B, V19, P117; ORLANDO C, 1990, ENDOCRINOLOGY, V126, P1780, DOI 10.1210/endo-126-3-1780; PERNOW J, 1989, BIOCHEM BIOPH RES CO, V161, P647, DOI 10.1016/0006-291X(89)92648-X; POHL U, 1989, J CARDIOVASC PHAR S5, V13, P188; RAO CV, 1984, J CLIN ENDOCR METAB, V58, P1034, DOI 10.1210/jcem-58-6-1034; RESINK TJ, 1989, BIOCHEM BIOPH RES CO, V158, P279, DOI 10.1016/S0006-291X(89)80209-8; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ AL, 1976, AM J OBSTET GYNECOL, V127, P470; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIGENO T, 1989, J CARDIOVASC PHARM, V13, P174; SUGIURA M, 1989, BIOCHEM BIOPH RES CO, V162, P1396, DOI 10.1016/0006-291X(89)90829-2; SUNNERGREN KP, 1990, MOL CELL ENDOCRINOL, V68, pR7, DOI 10.1016/0303-7207(90)90174-7; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; UCHIDA Y, 1988, EUR J PHARMACOL, V154, P227, DOI 10.1016/0014-2999(88)90106-9; WIKLUND NP, 1988, ACTA PHYSIOL SCAND, V134, P311, DOI 10.1111/j.1748-1716.1988.tb08495.x; WONG PYD, 1989, BRIT J PHARMACOL, V98, P1191, DOI 10.1111/j.1476-5381.1989.tb12664.x; WORD RA, 1990, AM J OBSTET GYNECOL, V162, P1103; YANAGISAWA M, 1989, BIOCHEM PHARMACOL, V38, P1877; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1989, J CARDIOVASC PHAR S5, V13, P13; YOSHIZAWA T, 1990, SCIENCE, V247, P462, DOI 10.1126/science.2405487; YOSHIZUMI M, 1990, BIOCHEM BIOPH RES CO, V166, P324, DOI 10.1016/0006-291X(90)91948-R	44	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5762	5768						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005113				2022-12-25	WOS:A1991FD37000063
J	ZIMMERMAN, WB; BYUN, E; MCKINNEY, TD; SOKOL, PP				ZIMMERMAN, WB; BYUN, E; MCKINNEY, TD; SOKOL, PP			SULFHYDRYL-GROUPS ARE ESSENTIAL FOR ORGANIC CATION-EXCHANGE IN RABBIT RENAL BASOLATERAL MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; ANION-EXCHANGE; TRANSPORT; TETRAETHYLAMMONIUM; DISULFIDE; REAGENTS; CARRIER	The effect of N-ethylmaleimide (NEM), an irreversible sulfhydryl modifying reagent, on the transport of organic cations in the renal basolateral membrane was examined. The studies were conducted examining the exchange of [H-3]tetraethylammonium (TEA) for unlabeled TEA in basolateral membrane vesicles isolated from the outer cortex of rabbit kidneys. NEM inactivated TEA transport in a dose-dependent fashion with an IC50 value of 260-mu-M. The rate of TEA transport inactivation followed apparent pseudo-first-order reaction kinetics. A replot of the data gave a linear relationship between the apparent rate constants and the NEM concentration with a slope of 4.0. The data imply that inactivation involves the binding of at least four molecules of NEM per active transport unit. This is most consistent with the presence of four sulfhydryl groups at this site. The substrate TEA displayed a dose-dependent enhancement of NEM inactivation, with 50% enhancement occurring at 365-mu-M TEA. Another organic cation, N1-methylnicotinamide, known to share a common transport mechanism with the TEA/TEA exchanger is also capable of increasing the reactivity of sulfhydryl groups to NEM. These results demonstrate that there are essential sulfhydryl groups for organic cation transport in the basolateral membrane. In addition, the capability of organic cations to alter the susceptibility to sulfhydryl modification suggests that these groups may have a dynamic role in the transport process.	INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT PHARMACOL & TOXICOL, INDIANAPOLIS, IN 46202 USA; RICHARD L ROUDEBUSH VET ADM MED CTR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	ZIMMERMAN, WB (corresponding author), BALL STATE UNIV, CTR MED EDUC, MARIA BINGHAM HALL, MUNCIE, IN 47306 USA.				NCRR NIH HHS [5 S07 RR5371] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005371] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BOUMENDILPODEVIN EF, 1977, BIOCHIM BIOPHYS ACTA, V467, P364, DOI 10.1016/0005-2736(77)90314-5; BRATER DC, 1991, KIDNEY, pCH105; GLAZER AN, 1970, ANNU REV BIOCHEM, V39, P101, DOI 10.1146/annurev.bi.39.070170.000533; HOLOHAN PD, 1980, J PHARMACOL EXP THER, V215, P191; HORI R, 1989, J BIOL CHEM, V264, P12232; HORI R, 1987, J PHARMACOL EXP THER, V241, P1010; KABACK HR, 1989, HARVEY LECT, V83, P77; KINSELLA JL, 1979, J PHARMACOL EXP THER, V209, P443; KNAUF PA, 1971, J GEN PHYSIOL, V58, P190, DOI 10.1085/jgp.58.2.190; KRUPKA RM, 1985, J MEMBRANE BIOL, V84, P35, DOI 10.1007/BF01871646; LEHIR M, 1990, RENAL PHYSIOL BIOCH, V13, P154; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LIPKOWITZ MS, 1989, AM J PHYSIOL, V256, pF18, DOI 10.1152/ajprenal.1989.256.1.F18; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKINNEY TD, 1985, AM J PHYSIOL, V249, pF532, DOI 10.1152/ajprenal.1985.249.4.F532; MONTROSERAFIZADEH C, 1989, AM J PHYSIOL, V257, pF243, DOI 10.1152/ajprenal.1989.257.2.F243; ROBILLARD GT, 1982, EUR J BIOCHEM, V127, P597; ROSS CR, 1983, ANNU REV PHARMACOL, V23, P65, DOI 10.1146/annurev.pa.23.040183.000433; SOKOL PP, 1987, J PHARMACOL EXP THER, V243, P455; SOKOL PP, 1987, J PHARMACOL EXP THER, V242, P152; SOKOL PP, 1988, J BIOL CHEM, V263, P7118; SOKOL PP, 1990, AM J PHYSIOL, V258, pF1599; SOKOL PP, 1986, BIOCHIM BIOPHYS ACTA, V862, P335, DOI 10.1016/0005-2736(86)90236-1; SOKOL PP, 1985, J PHARMACOL EXP THER, V233, P694; SOKOL PP, 1986, J BIOL CHEM, V261, P3282; WEBB LH, 1966, ENZYMES METABOL INH, V2, P721	26	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5459	5463						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005090				2022-12-25	WOS:A1991FD37000019
J	CURRIN, RT; GORES, GJ; THURMAN, RG; LEMASTERS, JJ				CURRIN, RT; GORES, GJ; THURMAN, RG; LEMASTERS, JJ			PROTECTION BY ACIDOTIC PH AGAINST ANOXIC CELL KILLING IN PERFUSED-RAT-LIVER - EVIDENCE FOR A PH PARADOX	FASEB JOURNAL			English	Article						ANOXIA; ISCHEMIA; LACTATE DEHYDROGENASE; REOXYGENATION; REPERFUSION	LIPID-PEROXIDATION; REPERFUSION INJURY; CHEMICAL HYPOXIA; HEPATOCYTES; ACIDOSIS; DEATH; HEPATOTOXICITY; PRESERVATION; VIABILITY; STORAGE	Reperfusion of ischemic tissues causes a paradoxical injury. Here, we measured lactate dehydrogenase (LDH) release as an indicator of tissue damage in perfused rat livers during anoxia and reoxygenation. During anoxia, LDH release was substantially reduced at acidotic pH (pH 6.1-6.9). Using anoxia at pH 6.1 followed by reoxygenation at pH 7.3 to model ischemia and reperfusion, an abrupt release of LDH occurred after reperfusion. A similar release of LDH occurred when pH of anoxic livers was increased to 7.3 without reoxygenation, but LDH release did not occur after reoxygenation at pH 6.1. Thus, a rapid increase of pH rather than reoxygenation accounted for tissue injury after reperfusion of ischemic liver.	UNIV N CAROLINA, SCH MED,DEPT CELL BIOL & ANAT,CELL BIOL LABS, CAMPUS BOX 7090,236 TAYLOR HALL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, HEPATOBIOL & TOXICOL LAB, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NIDDK NIH HHS [DK30874] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; ADKISON D, 1986, ACTA PHYSIOL SCAND, V126, P101; BADR MZ, 1986, J PHARMACOL EXP THER, V238, P1138; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; BING OHL, 1973, SCIENCE, V180, P1297, DOI 10.1126/science.180.4092.1297; BONVENTRE JV, 1985, AM J PHYSIOL, V249, pC149, DOI 10.1152/ajpcell.1985.249.1.C149; BRADFORD BU, 1986, J PHARMACOL EXP THER, V236, P263; CALDWELLKENKEL JC, 1989, HEPATOLOGY, V10, P292, DOI 10.1002/hep.1840100307; CASINI AF, 1987, BIOCHEM PHARMACOL, V36, P3689, DOI 10.1016/0006-2952(87)90021-9; CHIEN KR, 1981, CIRC RES, V48, P711, DOI 10.1161/01.RES.48.5.711; GORES GJ, 1989, J CLIN INVEST, V83, P386, DOI 10.1172/JCI113896; GORES GJ, 1989, AM J PHYSIOL, V257, pC347, DOI 10.1152/ajpcell.1989.257.2.C347; GORES GJ, 1988, AM J PHYSIOL, V255, pC315, DOI 10.1152/ajpcell.1988.255.3.C315; HEARSE DJ, 1978, J MOL CELL CARDIOL, V10, P641, DOI 10.1016/S0022-2828(78)80004-2; KALLERHOFF M, 1985, TRANSPLANTATION, V39, P485, DOI 10.1097/00007890-198505000-00005; KLONER RA, 1974, AM J PATHOL, V74, P399; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; NIEMINEN AL, 1990, BIOCHEM BIOPH RES CO, V167, P600, DOI 10.1016/0006-291X(90)92067-A; PENTTILA A, 1974, SCIENCE, V185, P277, DOI 10.1126/science.185.4147.277; ROUSLIN W, 1986, J MOL CELL CARDIOL, V18, P1187, DOI 10.1016/S0022-2828(86)80044-X; SIEGERS CP, 1979, TOXICOLOGY, V15, P55, DOI 10.1016/0300-483X(79)90019-2; STARKE PE, 1986, J BIOL CHEM, V261, P3006; THOMAS CE, 1988, J PHARMACOL EXP THER, V245, P493; THURMAN RG, 1988, TRANSPLANTATION, V46, P502, DOI 10.1097/00007890-198810000-00006	25	146	150	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1991	5	2					207	210		10.1096/fasebj.5.2.2004664	http://dx.doi.org/10.1096/fasebj.5.2.2004664			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	2004664				2022-12-25	WOS:A1991EZ00200010
J	LEE, BS; GUNN, RB; KOPITO, RR				LEE, BS; GUNN, RB; KOPITO, RR			FUNCTIONAL DIFFERENCES AMONG NONERYTHROID ANION-EXCHANGERS EXPRESSED IN A TRANSFECTED HUMAN CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; HUMAN CYTOMEGALO-VIRUS; RED-BLOOD-CELLS; INTRACELLULAR PH; CHLORIDE TRANSPORT; HUMAN ERYTHROCYTES; BAND-3 GENE; PROTEIN; MEMBRANE; CLONING	A new transient expression system has been developed to investigate the function of anion exchangers in vivo. Human 293 cells were cotransfected with AE2 or AE3 cDNA together with a plasmid encoding a cell surface marker protein. Staining of the cells with antibody directed against a cell surface epitope present in the marker protein permitted the detection of cells expressing functional anion exchangers. Intracellular pH (pH(i)) recording in individual transfectants loaded with the fluorescent pHi indicator, 2',7'-bis(carboxyethyl)-5, 6-carboxyfluorescein, was used to determine the flux of HCO3- as a measure of Cl-/HCO3- exchange activity. Cells expressing either anion exchanger displayed significantly enhanced Cl-/HCO3- exchange activity compared with controls expressing only the marker. Transfection with either anion exchanger or with control plasmid resulted in altered intrinsic buffering capacity profiles compared with untransfected controls. Expression of either AE2 or AE3 did not result in changes in resting pH(i). The activities of both AE2 and AE3 were stimulated at alkaline pH(i), suggesting that an internal protonation site in AE2 and AE3 may regulate their activities. Both exchangers were inhibited reversibly and irreversibly by the anion 4,4'-diisothiocyanostilbene-2,2'-disulfonate with IC50 values of 142 and 0.430-mu-m for AE2 and AE3, respectively. These data indicate that structural differences in these highly conserved anion exchangers give rise to differences in affinities at the external anion binding site.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; EMORY UNIV,SCH MED,DEPT PHYSIOL,ATLANTA,GA 30322	Stanford University; Emory University			Lee, Beth S/E-9578-2010	Lee, Beth S/0000-0002-1468-6387				ALPER SL, 1988, J BIOL CHEM, V263, P17092; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BARTEL D, 1989, EMBO J, V8, P3601, DOI 10.1002/j.1460-2075.1989.tb08533.x; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; FUNDER J, 1978, J GEN PHYSIOL, V71, P721, DOI 10.1085/jgp.71.6.721; FUNDER J, 1976, J PHYSIOL-LONDON, V262, P679, DOI 10.1113/jphysiol.1976.sp011615; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRINSTEIN S, 1984, J CELL PHYSIOL, V121, P87, DOI 10.1002/jcp.1041210112; GUAN JL, 1988, J BIOL CHEM, V263, P5306; GUNN RB, 1973, J GEN PHYSIOL, V61, P185, DOI 10.1085/jgp.61.2.185; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JENNINGS ML, 1976, J MEMBRANE BIOL, V28, P187, DOI 10.1007/BF01869697; JESSEN F, 1986, J MEMBRANE BIOL, V92, P195, DOI 10.1007/BF01869388; JONAS AJ, 1990, J BIOL CHEM, V265, P17545; KNAUF PA, 1984, J GEN PHYSIOL, V83, P683, DOI 10.1085/jgp.83.5.683; KNAUF PA, 1986, PHYSL MEMBRANE DISOR, P191; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LAMBERT A, 1978, J PHYSIOL-LONDON, V275, P51, DOI 10.1113/jphysiol.1978.sp012177; LAW FY, 1983, AM J PHYSIOL, V244, pC68, DOI 10.1152/ajpcell.1983.244.1.C68; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MILANICK MA, 1986, AM J PHYSIOL, V250, pC955, DOI 10.1152/ajpcell.1986.250.6.C955; MUALLEM S, 1985, J BIOL CHEM, V260, P6641; OLSNES S, 1987, BIOCHEMISTRY-US, V26, P2778, DOI 10.1021/bi00384a019; OLSNES S, 1986, J CELL BIOL, V102, P967, DOI 10.1083/jcb.102.3.967; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; THOMAS RC, 1984, J PHYSIOL-LONDON, V354, pP3; VAUGHANJONES RD, 1979, J PHYSIOL-LONDON, V295, P111, DOI 10.1113/jphysiol.1979.sp012957; WENZL E, 1989, AM J PHYSIOL, V257, pG741, DOI 10.1152/ajpgi.1989.257.5.G741	42	182	182	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11448	11454						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050661				2022-12-25	WOS:A1991FT76200011
J	ROCHE, P; LEROUGE, P; PONTHUS, C; PROME, JC				ROCHE, P; LEROUGE, P; PONTHUS, C; PROME, JC			STRUCTURAL DETERMINATION OF BACTERIAL NODULATION FACTORS INVOLVED IN THE RHIZOBIUM-MELILOTI-ALFALFA SYMBIOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEA STEM SEGMENTS; HOST-SPECIFICITY; C-13-NMR ASSIGNMENTS; NUCLEOTIDE-SEQUENCE; GENES; OLIGOSACCHARIDE; LEGUMINOSARUM; H-1-NMR; EXPRESSION; INHIBITION	Extracellular signals produced by Rhizobium meliloti are able to induce root hair deformations and nodule organogenesis on alfalfa. The production of these signals is controlled by bacterial nod genes. To enable their isolation in significant amounts, an overproducing strain was constructed. These Nod factors were first extracted by butanol from the culture medium and further purified by reverse-phase high performance liquid chromatography, ion-exchange, and Sephadex LH-20 chromatographies. The structure of the major signal, called NodRm-1, was determined by mass spectrometry, nuclear magnetic resonance, S-35 labeling, chemical analysis, and enzymatic degradation, and was shown to be a sulfated and acylated tetramer of glucosamine namely, beta-D-GlcpN(2,9-hexadecadienoyl) - (1 --> 4) - beta - D - Glc p NAc - (1 --> 4) - beta - D - Glc p NAc - (1 --> 4) - D - GlcpNAc-6-SO3H. Another Nod factor (called Ac-NodRm-1) was copurified and identified as NodRm-1 acetylated on the C-6 of the nonreducing end sugar. NodRm-1 elicits root hair deformation specifically on alfalfa at a concentration less than 10(-10) M but has no effect on vetch (a heterologous host plant).	CNRS, CTR RECH BIOCHIM & GENET CELLULAIRES, 118 ROUTE NARBONNE, F-31062 TOULOUSE, FRANCE; SANOFI RECH, F-31036 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Sanofi-Aventis; Sanofi France								BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BLUMBERG K, 1982, ANAL BIOCHEM, V119, P407, DOI 10.1016/0003-2697(82)90605-4; BOYD J, 1985, CARBOHYD RES, V139, P35; DARVILL AG, 1984, ANNU REV PLANT PHYS, V35, P243, DOI 10.1146/annurev.pp.35.060184.001331; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DEBELLE F, 1986, J BACTERIOL, V168, P1075, DOI 10.1128/jb.168.3.1075-1086.1986; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DELL A, 1988, CARBOHYD RES, V179, P7, DOI 10.1016/0008-6215(88)84105-3; DEMARY M, 1978, NOUV J CHIM, V2, P373; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; FAUCHER C, 1988, J BACTERIOL, V170, P5489, DOI 10.1128/jb.170.12.5489-5499.1988; FAUCHER C, 1989, MOL PLANT MICROBE IN, V2, P291, DOI 10.1094/MPMI-2-291; FAUCHER C, 1989, SIGNAL MOL PLANT MIC, P379; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; GOLLIN DJ, 1984, BIOL CELL, V51, P275; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HIRANO S, 1987, PROGR BIOTECHNOLOGY, V3, P163; HOUNSELL EF, 1986, EUR J BIOCHEM, V157, P375, DOI 10.1111/j.1432-1033.1986.tb09679.x; KARLSSON KA, 1971, J MEMBRANE BIOL, V5, P169, DOI 10.1007/BF02107722; LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; LONG SR, 1982, NATURE, V298, P485, DOI 10.1038/298485a0; MCDOUGALL GJ, 1988, PLANTA, V175, P412, DOI 10.1007/BF00396348; MULLIGAN JT, 1989, GENETICS, V122, P7; PETERS NK, 1986, SCIENCE, V233, P977, DOI 10.1126/science.3738520; PROME JC, 1987, RAPID COMMUN MASS SP, V1, P50; ROCHE P, 1991, ADV MOL GENETICS PLA, V1, P119; SHARP JK, 1984, J BIOL CHEM, V259, P1312; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STRECKER G, 1989, CARBOHYD RES, V185, P1, DOI 10.1016/0008-6215(89)84016-9; TORRI G, 1985, BIOCHEM BIOPH RES CO, V128, P134, DOI 10.1016/0006-291X(85)91655-9; TRUCHET G, 1985, J BACTERIOL, V164, P1200, DOI 10.1128/JB.164.3.1200-1210.1985; URBANIKSYPNIEWSKA T, 1989, ARCH MICROBIOL, V152, P527, DOI 10.1007/BF00425481; VAN KTT, 1985, NATURE, V314, P615, DOI 10.1038/314615a0; Vincent JM, 1970, IBP HDB; YORK WS, 1984, PLANT PHYSIOL, V75, P295, DOI 10.1104/pp.75.2.295; ZAAT SAJ, 1987, J BACTERIOL, V169, P3388, DOI 10.1128/jb.169.7.3388-3391.1987	38	139	140	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10933	10940						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040610				2022-12-25	WOS:A1991FQ77400038
J	ALKSNIS, M; BARKHEM, T; STROMSTEDT, PE; AHOLA, H; KUTOH, E; GUSTAFSSON, JA; POELLINGER, L; NILSSON, S				ALKSNIS, M; BARKHEM, T; STROMSTEDT, PE; AHOLA, H; KUTOH, E; GUSTAFSSON, JA; POELLINGER, L; NILSSON, S			HIGH-LEVEL EXPRESSION OF FUNCTIONAL FULL LENGTH AND TRUNCATED GLUCOCORTICOID RECEPTOR IN CHINESE-HAMSTER OVARY CELLS - DEMONSTRATION OF LIGAND-INDUCED DOWN-REGULATION OF EXPRESSED RECEPTOR MESSENGER-RNA AND PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; HEAT-SHOCK PROTEIN; RAT-LIVER CYTOSOL; WILD-TYPE; MONOCLONAL-ANTIBODIES; HORMONE; SEQUENCES; GENE; CDNA; MECHANISMS	Full length human glucocorticoid receptor and truncated receptor derivatives lacking the major amino-terminal trans-activating domain were expressed in stably transfected Chinese hamster ovary (CHO) cells. The receptors were co-expressed together with human metallothionein IIa, and the expression levels were amplified in the presence of increasing concentrations of metal. In amplified cells, both synthesized receptor forms showed the expected molecular weights, as assayed by affinity labeling and immunoblotting. They were expressed at concentrations of about 350,000-520,000 molecules/cell which corresponds to a 10-fold increase in receptor levels as compared to rat liver cells. The hormone (agonist or antagonist) binding properties of the expressed proteins were very similar to those characteristic of authentic glucocorticoid receptors in tissues or cultured cells. Moreover, the expressed proteins specifically recognized a glucocorticoid-response element sequence motif in in vitro protein-DNA binding experiments. The activation of a glucocorticoid-responsive reporter gene by the expressed full length receptor was dramatic (about 75-fold) and strictly ligand-dependent. In contrast, the expressed amino-terminal deletion mutant exhibited considerably weaker functional activity but showed normal hormone-binding properties. Upon exposure to dexamethasone in vivo, the expressed receptor mRNAs and proteins were down-regulated about 2- to 6-fold, indicating that regulatory signals important for autoregulation may be contained within structures corresponding to the ligand and DNA-binding domains. Transcription from the expression vector was not negatively regulated from the hormone, strongly arguing that receptor down-regulation was due to a post-transcriptional mechanism. In conclusion, this expression system should be a useful tool for further structural and functional studies of the receptor, including the biochemistry of its activation from a cryptic to a functional species, and its ligand-dependent autoregulation.	KARO BIO AB,BOX 4032,S-14104 HUDDINGE,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet								BEATO M, 1972, J BIOL CHEM, V247, P7890; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; DAHLMAN K, 1989, J BIOL CHEM, V264, P804; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DONG Y, 1988, MOL ENDOCRINOL, V2, P1256, DOI 10.1210/mend-2-12-1256; DONG Y, 1989, J BIOL CHEM, V264, P13679; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIEDMAN JS, 1989, BIO-TECHNOL, V7, P359, DOI 10.1038/nbt0489-359; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; MIESFELD R, 1984, NATURE, V312, P779, DOI 10.1038/312779a0; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; OKRET S, 1986, P NATL ACAD SCI USA, V83, P5899, DOI 10.1073/pnas.83.16.5899; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; ROUSSEAU GG, 1975, J STEROID BIOCHEM, V6, P75, DOI 10.1016/0022-4731(75)90032-1; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; TIZARD R, 1990, P NATL ACAD SCI USA, V87, P4514, DOI 10.1073/pnas.87.12.4514; WEBER F, 1984, CELL, V36, P983, DOI 10.1016/0092-8674(84)90048-5; WESTPHAL HM, 1984, EMBO J, V3, P1493, DOI 10.1002/j.1460-2075.1984.tb02001.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WRANGE O, 1984, J BIOL CHEM, V259, P4534; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P205	40	102	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10078	10085						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037566				2022-12-25	WOS:A1991FP08600016
J	EGAWA, T; OGURA, T; MAKINO, R; ISHIMURA, Y; KITAGAWA, T				EGAWA, T; OGURA, T; MAKINO, R; ISHIMURA, Y; KITAGAWA, T			OBSERVATION OF THE O-O STRETCHING RAMAN BAND FOR CYTOCHROME-P-450CAM UNDER CATALYTIC CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-IV=O; HORSERADISH-PEROXIDASE; COMPOUND-II; RESONANCE; IRON; PORPHYRIN; VIBRATION; P-450CAM; SPECTRA; HEME	Dioxygen stretching (nu-OO) Raman band was observed for the oxy form of Pseudomonas putida cytochrome P-450 (P-450cam) generated at room temperature under catalytic conditions, that is, in the presence of D-camphor, beta-NADH, putidaredoxin, and putidaredoxin reductase, by using the mixed flow transient Raman apparatus. At the same time the visible absorption spectra were monitored for the transient species. It was found that the nu-OO frequency is little altered by binding of putidaredoxin to P-450cam, although the reduction rate of the oxy form becomes faster. Another intermediate with an oxygen isotope-sensitive band was not found in a time region until 2 s after mixing of the reduced enzyme with oxygen.	INST MOLEC SCI, OKAZAKI NATL RES INST, OKAZAKI, AICHI 444, JAPAN; KEIO UNIV, SCH MED, DEPT BIOCHEM, SHINJUKU KU, TOKYO 160, JAPAN	National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB); Keio University								ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; BANGCHAROENPAURPONG O, 1986, J BIOL CHEM, V261, P8089; CHAMPION PM, 1978, J AM CHEM SOC, V100, P3743, DOI 10.1021/ja00480a015; CHAMPION PM, 1989, J AM CHEM SOC, V111, P3433, DOI 10.1021/ja00191a053; CHOTTARD G, 1984, INORG CHEM, V23, P4557, DOI 10.1021/ic00194a030; DAWSON JH, 1978, FEBS LETT, V88, P127, DOI 10.1016/0014-5793(78)80623-1; EISENSTEIN L, 1977, BIOCHEM BIOPH RES CO, V77, P1377, DOI 10.1016/S0006-291X(77)80131-9; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HASHIMOTO S, 1984, P JPN ACAD B-PHYS, V60, P345, DOI 10.2183/pjab.60.345; HASHIMOTO S, 1987, J AM CHEM SOC, V109, P8096, DOI 10.1021/ja00260a030; HASHIMOTO S, 1991, IN PRESS J AM CHEM S; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; HINTZ MJ, 1982, J BIOL CHEM, V257, P4324; ISHIMURA Y, 1971, BIOCHEM BIOPH RES CO, V42, P140, DOI 10.1016/0006-291X(71)90373-1; MCCANDLISH E, 1980, J AM CHEM SOC, V102, P4268, DOI 10.1021/ja00532a053; MIZUTANI Y, 1990, J AM CHEM SOC, V112, P6809, DOI 10.1021/ja00175a011; NISHIMURA Y, 1990, 12TH P INT C RAM SPE, P702; OGURA T, 1985, BIOCHIM BIOPHYS ACTA, V832, P220, DOI 10.1016/0167-4838(85)90335-8; OGURA T, 1988, REV SCI INSTRUM, V59, P1316, DOI 10.1063/1.1139716; OGURA T, 1990, J BIOL CHEM, V265, P14721; PEDERSON TC, 1976, MICROSOMES DRUG OXID, P275; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; RECZEK CM, 1989, J MOL STRUCT, V214, P27, DOI 10.1016/0022-2860(89)80004-3; SATO R, 1973, DRUG METAB DISPOS, V1, P6; SHARROCK M, 1976, BIOCHIM BIOPHYS ACTA, V420, P8, DOI 10.1016/0005-2795(76)90340-8; SITTER AJ, 1985, BIOCHIM BIOPHYS ACTA, V828, P229, DOI 10.1016/0167-4838(85)90301-2; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; Spiro T. G., 1987, BIOL APPL RAMAN SPEC, P39; TERNER J, 1985, BIOCHIM BIOPHYS ACTA, V828, P73, DOI 10.1016/0167-4838(85)90011-1; TSUBAKI M, 1981, P NATL ACAD SCI-BIOL, V78, P3581, DOI 10.1073/pnas.78.6.3581; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; YU CA, 1974, J BIOL CHEM, V249, P102	34	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10246	10248						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037577				2022-12-25	WOS:A1991FP08600040
J	BLUM, M; CUNNINGHAM, A; PANG, H; HOFMANN, T				BLUM, M; CUNNINGHAM, A; PANG, H; HOFMANN, T			MECHANISM AND PATHWAY OF PENICILLOPEPSIN-CATALYZED TRANSPEPTIDATION AND EVIDENCE FOR NONCOVALENT TRAPPING OF AMINO-ACID AND PEPTIDE INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; SUBSTRATE-BINDING; SECONDARY BINDING; PIG PEPSIN; PROTEINASES; RESOLUTION; ACYL; PEPSTATIN; INHIBITOR; COMPLEX	Penicillopepsin acting on Nph-Ala2-amide (where Nph = p-nitrophenylalanyl) catalyzes a transpeptidation reaction which leads to the formation of Nph2-Ala2-amide, which arises from condensation of the substrate with enzyme-bound Nph, as the first product released from the enzyme. This is followed by a stage during which Nph3 and Ala2-amide are the major products. A small amount of Nph4 is also formed during this time. Nph and Nph2, formed during the reactions, are tightly, but probably not covalently, bount to the enzyme. They appear as free products only as a result of the cleavage of Nph3 and Nph4 and after most of the substrate Nph-Ala2-amide has been used up. They act as acceptors for the substrate and for Nph2-Ala2-amide. Nph3-Ala2-amide, formed by condensation of Nph-Ala2-amide or of Nph2-Ala2-amide with enzyme-bound Nph2 or Nph, respectively, is also released but is cleaved rapidly to give Nph3 and Ala2-amide. Incorporation of O-18 from [O-18]water into the carbonyl oxygens of the products is extensive and shows that release of the intermediates is slower than peptide bond cleavage and peptide bond formation. Hence the rate-limiting step in these reactions is product release. No O-18 is incorporated into the initial substrate. We propose that Nph and Nph2 as intermediates are held in the active site by hydrogen bonds and by two strong electostatic interactions.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto								ALBER T, 1989, PREDICTION PROTEIN S, P161; ALLEN B, 1990, J BIOL CHEM, V265, P5060; ANTONOV VK, 1981, EUR J BIOCHEM, V117, P195; ANTONOV VK, 1978, FEBS LETT, V88, P87, DOI 10.1016/0014-5793(78)80613-9; ATHERTON E, 1978, J CHEM SOC CHEM COMM, P537, DOI 10.1039/c39780000537; BERGEL F, 1954, J CHEM SOC, P2409, DOI 10.1039/jr9540002409; BLUM M, 1985, BIOCHEM SOC T, V13, P1044, DOI 10.1042/bst0131044; BOTT R, 1982, BIOCHEMISTRY-US, V21, P6956, DOI 10.1021/bi00269a052; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; FISCHER G, 1987, ENZYME MECHANISMS, P229; HOFMANN T, 1982, BIOCHEM J, V203, P603, DOI 10.1042/bj2030603; Hofmann T, 1976, Methods Enzymol, V45, P434; HOFMANN T, 1988, BIOCHEMISTRY-US, V27, P1140, DOI 10.1021/bi00404a010; HOFMANN T, 1984, BIOCHEMISTRY-US, V23, P5253; JAMES MNG, 1982, P NATL ACAD SCI-BIOL, V79, P6137, DOI 10.1073/pnas.79.20.6137; JAMES MNG, 1983, J MOL BIOL, V163, P299, DOI 10.1016/0022-2836(83)90008-6; LUTEK MK, 1988, J BIOL CHEM, V263, P8011; POLGAR L, 1987, FEBS LETT, V219, P1, DOI 10.1016/0014-5793(87)81179-1; SALI A, 1989, EMBO J, V8, P2179, DOI 10.1002/j.1460-2075.1989.tb08340.x; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHMIDT PG, 1985, BIOCHEM BIOPH RES CO, V129, P597, DOI 10.1016/0006-291X(85)90193-7; SILVER MS, 1983, BIOCHIM BIOPHYS ACTA, V743, P13, DOI 10.1016/0167-4838(83)90412-0; SOMAYAJI V, 1988, J AM CHEM SOC, V110, P2625, DOI 10.1021/ja00216a042; SPECTOR LB, 1982, COVALENT CATALYSIS E, P137; TAKAHASHI M, 1974, BIOCHEM BIOPH RES CO, V57, P39, DOI 10.1016/S0006-291X(74)80354-2; TAKAHASHI M, 1975, BIOCHEM J, V147, P549, DOI 10.1042/bj1470549; WANG TT, 1976, BIOCHEM J, V153, P701, DOI 10.1042/bj1530701; WANG TT, 1974, BIOCHEM BIOPH RES CO, V57, P865, DOI 10.1016/0006-291X(74)90626-3; WANG TT, 1976, BIOCHEM J, V153, P691, DOI 10.1042/bj1530691	29	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9501	9507						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033049				2022-12-25	WOS:A1991FM45900029
J	MANGEL, WF; LIN, B; RAMAKRISHNAN, V				MANGEL, WF; LIN, B; RAMAKRISHNAN, V			CONFORMATION OF ONE-CHAIN AND 2-CHAIN HIGH-MOLECULAR-WEIGHT UROKINASE ANALYZED BY SMALL-ANGLE NEUTRON-SCATTERING AND VACUUM ULTRAVIOLET CIRCULAR-DICHROISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PLASMINOGEN-ACTIVATOR; ESCHERICHIA-COLI; MASS UROKINASE; SECONDARY STRUCTURE; BINDING-SITES; PRO-UROKINASE; HIGH-AFFINITY; HUMAN-URINE; RECEPTOR	The structures of one- and two-chain high molecular weight human urokinase were analyzed by small-angle neutron scattering and vacuum ultraviolet circular dichroism. Both one- and two-chain high molecular weight urokinases exhibited a radius of gyration of 31 angstrom and a maximum dimension of 90 angstrom. Neither parameter was affected by the presence of lysine sufficient to saturate all the lysine-binding sites in human plasminogen. These physical parameters are consistent with the sedimentation coefficient of high molecular weight urokinase and indicate that both proteins are highly asymmetric. Neither protein contained much alpha-helix or parallel beta-sheet. Most of the secondary structure was in the form of antiparallel beta-sheet and beta-turns, very similar to the secondary structure of plasminogen. The macroscopic kinetic constants, K(m) and k(cat), for the hydrolysis of (< Glu-Gly-Arg-NH)2-rhodamine by two-chain high molecular weight urokinase and low molecular weight urokinase which lacks the epidermal growth factor and kringle domains were similar. These structural and kinetic data are consistent with the domains in both forms of urokinase being independent structural and functional units.			MANGEL, WF (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.			Ramakrishnan, V/0000-0002-4699-2194				APPELLA E, 1987, J BIOL CHEM, V262, P4437; Barlow G H, 1976, Methods Enzymol, V45, P239; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BOGUSKY MJ, 1989, BIOCHEMISTRY-US, V28, P6728, DOI 10.1021/bi00442a028; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; EATON DL, 1984, J BIOL CHEM, V259, P6241; Guinier A., 1955, SMALL ANGLE SCATTERI, P5; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P133, DOI 10.1515/bchm2.1982.363.1.133; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; HOLLEMAN WH, 1975, THROMB RES, V7, P683, DOI 10.1016/0049-3848(75)90194-2; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; KASAI S, 1985, J BIOL CHEM, V260, P2377; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; KUMOSINSKI TF, 1982, ARCH BIOCHEM BIOPHYS, V219, P89, DOI 10.1016/0003-9861(82)90137-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCAS MA, 1983, J BIOL CHEM, V258, P2171; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MAGNUSSON S, 1976, PROTEOLYSIS PHYSL RE, P203; MANGEL WF, 1990, NATURE, V344, P488, DOI 10.1038/344488a0; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; OSWALD RE, 1989, NATURE, V337, P579, DOI 10.1038/337579a0; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PELTZ SW, 1982, BIOCHEMISTRY-US, V21, P2798, DOI 10.1021/bi00540a035; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETERSEN LC, 1986, BIOCHIM BIOPHYS ACTA, V883, P313, DOI 10.1016/0304-4165(86)90324-7; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; RAMAKRISHNAN V, 1991, IN PRESS BIOCHEMISTR; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SCHNEIDER D, 1984, NEUTRONS BIOL, P119; SIEGEL JB, 1980, ANAL BIOCHEM, V104, P160, DOI 10.1016/0003-2697(80)90292-4; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STRASSBURGER W, 1983, FEBS LETT, V157, P219, DOI 10.1016/0014-5793(83)80551-1; SUENSON E, 1981, BIOCHEM J, V197, P619, DOI 10.1042/bj1970619; SUTHERLAND JC, 1982, NUCL INSTRUM METHODS, V195, P375, DOI 10.1016/0029-554X(82)90803-5; SUTHERLAND JC, 1980, NUCL INSTRUM METHODS, V172, P195, DOI 10.1016/0029-554X(80)90634-5; THORSEN S, 1988, EUR J BIOCHEM, V175, P22; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V251, P363; TREXLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2457, DOI 10.1073/pnas.80.9.2457; URANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P222, DOI 10.1016/0003-9861(88)90588-7; VALI Z, 1982, J BIOL CHEM, V257, P2104; VARDI A, 1981, BIOCHEM BIOPH RES CO, V103, P97; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WINKLER ME, 1986, BIOCHEMISTRY-US, V25, P4041, DOI 10.1021/bi00362a008; WINKLER ME, 1985, BIO-TECHNOL, V3, P990, DOI 10.1038/nbt1185-990; WUN TC, 1982, J BIOL CHEM, V257, P7262	57	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9408	9412						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033041				2022-12-25	WOS:A1991FM45900014
J	TANSEY, WP; CATANZARO, DF				TANSEY, WP; CATANZARO, DF			SP1 AND THYROID-HORMONE RECEPTOR DIFFERENTIALLY ACTIVATE EXPRESSION OF HUMAN GROWTH-HORMONE AND CHORIONIC SOMATOMAMMOTROPIN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GHF-1; PLACENTAL-LACTOGEN GENES; PITUITARY-TUMOR-CELLS; TRANS-ACTING FACTOR; BINDING-SITE; CHLORAMPHENICOL ACETYLTRANSFERASE; STIMULATE TRANSCRIPTION; GLUCOCORTICOID RECEPTOR; REGULATED EXPRESSION; RESPONSE ELEMENTS	Activation of hGH-1 expression is mediated by the pituitary-specific transcription factor GHF-I/Pit-I which binds the 5'-flanking DNA at two sites: I (-96/-70) and II (-134/-106). Although the factor(s) which direct the placental-specific expression of hCS-1 are not known, hCS-1 sequences are transcriptionally active in pituitary cells. In the present study we examined the effects of sequence differences between hGH-1 and hCS-1 5'-flanking DNAs in determining their basal and thyroid hormone-regulated promoter activities. We showed that Sp1 is a major determinant of both hGH-1 and hCS-1 promoter activities and that in hGH-1, binding and activation by Sp1 are modulated by interference from GHF-I/Pit-1 binding at the adjacent site II sequence. A single base which differed in site II of hCS-1 greatly reduced GHF-1/Pit-1 binding and thus faciltated binding and activation by Sp1. Further differences in promoter activity of hGH-1 and hCS-1 sequences were accounted for by a thyroid hormone-responsive element between -62/-48 in the hCS-1 gene. However, induction by T3 was independent of either Sp1 or GHF-1/Pit-1 binding in the site II region. These data demonstrate that a small number of base changes between hGH and hCS promoter sequences subserve a number of mechanisms which may differentially modulate the expression of hGH and hCS genes.	UNIV SYDNEY, SCH BIOL SCI, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney								APRILETTI JW, 1988, J BIOL CHEM, V263, P9409; BARLOW JW, 1986, P NATL ACAD SCI USA, V83, P9021, DOI 10.1073/pnas.83.23.9021; BARSH GS, 1983, NUCLEIC ACIDS RES, V11, P3939, DOI 10.1093/nar/11.12.3939; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BRENT GA, 1988, MOL ENDOCRINOL, V2, P792, DOI 10.1210/mend-2-9-792; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CATANZARO DF, 1987, MOL ENDOCRINOL, V1, P90, DOI 10.1210/mend-1-1-90; CATTINI PA, 1986, J BIOL CHEM, V261, P3367; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; EBERHARDT NL, 1990, SERONO SYM, V67, P221; FLUG F, 1987, J BIOL CHEM, V262, P6373; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIRT H, 1987, DNA-J MOLEC CELL BIO, V6, P59, DOI 10.1089/dna.1987.6.59; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; INGRAHAM HA, 1990, ANNU REV PHYSIOL, V52, P773; JANSON L, 1987, NUCLEIC ACIDS RES, V15, P4997, DOI 10.1093/nar/15.13.4997; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LEMAIGRE FP, 1989, DNA-J MOLEC CELL BIO, V8, P149, DOI 10.1089/dna.1.1989.8.149; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4237; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NICKEL BE, 1990, BIOCHEM J, V267, P653, DOI 10.1042/bj2670653; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x	54	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9805	9813						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033067				2022-12-25	WOS:A1991FM45900071
J	KANOFSKY, JR; SIMA, P				KANOFSKY, JR; SIMA, P			SINGLET OXYGEN PRODUCTION FROM THE REACTIONS OF OZONE WITH BIOLOGICAL MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; AQUEOUS-SOLUTIONS; LINOLEATE ESTERS; OZONATION; LUMINESCENCE; LACTOPEROXIDASE; DECOMPOSITION; ERYTHROCYTES; PROTECTION; GENERATION	The reaction of ozone with a number of biological molecules was found to produce singlet oxygen in high yield. At pH 7.0, the reaction of ozone with an equimolar amount of biological molecule produced the following singlet oxygen yields (mole of singlet oxygen/mole of ozone): cysteine, 0.49 +/- 0.02; methionine, 1.13 +/- 0.11; reduced glutathione, 0.33 +/- 0.02; albumin, 1.00 +/- 0.05; uric acid, 0.64 +/- 0.09; ascorbic acid, 0.96 +/- 0.007; NADPH, 1.07 +/- 0.07; NADH, 0.95 +/- 0.01. Thus, singlet oxygen may be an important intermediate in the biochemical damage caused by ozone.	EDWARD HINES JR DEPT VET AFFAIRS HOSP,MED SERV,HINES,IL 60141; EDWARD HINES JR DEPT VET AFFAIRS HOSP,RES SERV,HINES,IL 60141; LOYOLA UNIV,STRITCH SCH MED,DEPT MED,MAYWOOD,IL 60153; LOYOLA UNIV,STRITCH SCH MED,DEPT MOLEC & CELLULAR BIOCHEM,MAYWOOD,IL 60153	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago; Loyola University Chicago					NIGMS NIH HHS [GM32974] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032974] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG DA, 1978, PHOTOCHEM PHOTOBIOL, V28, P743, DOI 10.1111/j.1751-1097.1978.tb07011.x; BARTON JP, 1973, J CHEM SOC PERK T 2, P1547, DOI 10.1039/p29730001547; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; EISENBERG WC, 1985, J AM CHEM SOC, V107, P8299, DOI 10.1021/ja00312a101; FIREY PA, 1988, PHOTOCHEM PHOTOBIOL, V48, P357, DOI 10.1111/j.1751-1097.1988.tb02834.x; FORNI L, 1982, J PHYS CHEM-US, V86, P255, DOI 10.1021/j100391a025; FREEMAN BA, 1981, ARCH BIOCHEM BIOPHYS, V208, P212, DOI 10.1016/0003-9861(81)90142-9; GIAMALVA D, 1985, BIOCHEM BIOPH RES CO, V133, P773, DOI 10.1016/0006-291X(85)90971-4; GIAMALVA DH, 1986, J AM CHEM SOC, V108, P6646, DOI 10.1021/ja00281a033; HART EJ, 1983, ANAL CHEM, V55, P46, DOI 10.1021/ac00252a015; HEWITT CN, 1990, NATURE, V344, P56, DOI 10.1038/344056a0; HOIGNE J, 1976, WATER RES, V10, P377, DOI 10.1016/0043-1354(76)90055-5; KANOFSKY JR, 1984, J PHOTOCHEM, V25, P105, DOI 10.1016/0047-2670(84)87014-8; KANOFSKY JR, 1989, CHEM-BIOL INTERACT, V70, P1, DOI 10.1016/0009-2797(89)90059-8; KANOFSKY JR, 1983, J BIOL CHEM, V258, P5991; KANOFSKY JR, 1990, PHOTOCHEM PHOTOBIOL, V51, P299, DOI 10.1111/j.1751-1097.1990.tb01714.x; KANOFSKY JR, 1991, PHOTOCHEM PHOTOBIOL, V53, P93, DOI 10.1111/j.1751-1097.1991.tb08472.x; KANOFSKY JR, 1984, J BIOL CHEM, V259, P5596; KHAN AU, 1983, P NATL ACAD SCI-BIOL, V80, P5195, DOI 10.1073/pnas.80.17.5195; MADDEN MC, 1987, PROSTAGLANDINS, V34, P445, DOI 10.1016/0090-6980(87)90089-X; MEADOWS J, 1987, ENVIRON RES, V43, P410, DOI 10.1016/S0013-9351(87)80041-5; MEADOWS J, 1986, ARCH BIOCHEM BIOPHYS, V246, P838, DOI 10.1016/0003-9861(86)90340-1; MEHLMAN MA, 1987, ENVIRON RES, V42, P36, DOI 10.1016/S0013-9351(87)80005-1; MEINERS BA, 1977, ENVIRON RES, V14, P99, DOI 10.1016/0013-9351(77)90072-X; MORGAN DL, 1985, TOXICOLOGY, V36, P243, DOI 10.1016/0300-483X(85)90057-5; MUDD JB, 1974, ARCH BIOCHEM BIOPHYS, V161, P408, DOI 10.1016/0003-9861(74)90322-1; MUDD JB, 1969, ATMOS ENVIRON, V3, P669, DOI 10.1016/0004-6981(69)90024-9; MURRAY RW, 1970, ANN NY ACAD SCI, V171, P121, DOI 10.1111/j.1749-6632.1970.tb39311.x; MURRAY RW, 1968, J AM CHEM SOC, V90, P537, DOI 10.1021/ja01004a085; PATTERSON MS, 1990, J PHOTOCH PHOTOBIO B, V5, P69, DOI 10.1016/1011-1344(90)85006-I; PRYOR WA, 1984, J AM CHEM SOC, V106, P7094, DOI 10.1021/ja00335a038; PRYOR WA, 1983, ADV MOD ENV TOXICOL, P7; Putnam E., 1975, 3 SERUM ALBUMIN, VSecond, P133, DOI [10.1016/B978-0-12-568401-9.50010-4, DOI 10.1016/B978-0-12-568401-9.50010-4]; RODGERS MAJ, 1982, J AM CHEM SOC, V104, P5541, DOI 10.1021/ja00384a070; SALOMAA P, 1964, J AM CHEM SOC, V86, P1, DOI 10.1021/ja01055a001; STARY FE, 1976, J AM CHEM SOC, V98, P1880, DOI 10.1021/ja00423a039; WARREN DL, 1988, TOXICOLOGY, V53, P113, DOI 10.1016/0300-483X(88)90241-7; Weiss J, 1935, T FARADAY SOC, V31, P0668, DOI 10.1039/tf9353100668; WHITESIDE C, 1988, FREE RADICAL BIO MED, V5, P305, DOI 10.1016/0891-5849(88)90101-3	39	121	130	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9039	9042						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026612				2022-12-25	WOS:A1991FM03800059
J	HATZOGLOU, M; BOSCH, F; PARK, EA; HANSON, RW				HATZOGLOU, M; BOSCH, F; PARK, EA; HANSON, RW			HORMONAL-CONTROL OF INTERACTING PROMOTERS INTRODUCED INTO CELLS BY RETROVIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; HEMATOPOIETIC STEM-CELLS; LONG TERMINAL REPEAT; I-HYPERSENSITIVE SITES; MEDIATED GENE-TRANSFER; MURINE LEUKEMIA-VIRUS; MAMMARY-TUMOR VIRUS; BETA-GLOBIN GENE; REGULATORY REGION	The interaction of promoters contained in a Moloney murine leukemia virus (MoMLV)-based retroviral vector was studied after infection of FTO-2B rat hepatoma and NIH 3T3 mouse fibroblast cells. Segments of the phosphoenolpyruvate carboxykinase (PEPCK) promoter-regulatory region, which are known from previous studies to confer responsiveness to hormones, were linked to the structural genes for bovine growth hormone, amino-3'-glycosyl phosphotransferase (neo), and herpes-virus thymidine kinase and inserted into a MoMLV-based retroviral vector. In vectors in which PEPCK was the only internal promoter, it was the major site of gene transcription. This dominant effect was independent of the orientation of the PEPCK promoter relative to the 5' long terminal repeat of the provirus and was noted with as little as -174 base pairs of the 5'-flanking sequence. NIH 3T3 cells, which do not express the endogenous PEPCK gene, transcribed the transduced PEPCK-chimeric genes at the same high levels as was observed in hepatoma cells. When two promoters were present in the provirus, the expression of chimeric structural genes depended on the relative position and orientation of these genes as well as the type of cell infected by the retrovirus. Differential responses of proviral promoters in infected cells were also observed in the presence of hormones. Dibutyryl cyclic AMP increased the expression of genes linked to the PEPCK promoter in FTO-2B and NIH 3T3 cells, whereas glucocorticoids stimulated transcription from both the PEPCK promoter and the long terminal repeat in FTO-2B cells. The effect of these hormones on transcription of proviral promoters depended on their position relative to the 5' long terminal repeat. In contrast, insulin uniformly inhibited transcription from the PEPCK promoter in a position-independent manner but only in hepatoma cells and not in fibroblasts. In clonally isolated FTO-2B cells infected with a retrovirus, the site of proviral integration was also a major factor determining the expression and hormonal regulation from the internal promoters. The data suggest that the hormonal regulation of the expression of genes contained in retroviral vectors depends on the type and position of the regulatory elements present in the provirus and the lineage of the infected cell.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University	HATZOGLOU, M (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,PEW CTR MOLEC NUTR,CLEVELAND,OH 44106, USA.			BOSCH, FATIMA/0000-0002-7705-5515				ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; BARKLIS E, 1986, CELL, V47, P391, DOI 10.1016/0092-8674(86)90596-9; BENDER MA, 1989, MOL CELL BIOL, V9, P1426, DOI 10.1128/MCB.9.4.1426; BOWTELL DDL, 1988, J VIROL, V62, P2464, DOI 10.1128/JVI.62.7.2464-2473.1988; CHANG SMW, 1987, MOL CELL BIOL, V7, P854, DOI 10.1128/MCB.7.2.854; CONE RD, 1987, MOL CELL BIOL, V7, P887, DOI 10.1128/MCB.7.2.887; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; EGLITIS MA, 1985, SCIENCE, V230, P1395, DOI 10.1126/science.2999985; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; EMERMAN M, 1986, MOL CELL BIOL, V6, P792, DOI 10.1128/MCB.6.3.792; EMERMAN M, 1986, NUCLEIC ACIDS RES, V15, P23; EPISKOPOU V, 1984, P NATL ACAD SCI-BIOL, V81, P4657, DOI 10.1073/pnas.81.15.4657; FEINSTEIN SC, 1982, J MOL BIOL, V156, P549, DOI 10.1016/0022-2836(82)90266-2; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GARVER RI, 1987, P NATL ACAD SCI USA, V84, P1050, DOI 10.1073/pnas.84.4.1050; HANSON RW, 1973, AM J CLIN NUTR, V26, P55, DOI 10.1093/ajcn/26.1.55; HANTZOPOULOS PA, 1989, P NATL ACAD SCI USA, V86, P3519, DOI 10.1073/pnas.86.10.3519; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HILBERG F, 1987, P NATL ACAD SCI USA, V84, P5232, DOI 10.1073/pnas.84.15.5232; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; JOLLY DJ, 1986, MOL CELL BIOL, V6, P1141, DOI 10.1128/MCB.6.4.1141; JOYNER A, 1983, NATURE, V305, P556, DOI 10.1038/305556a0; KILLARY AM, 1984, BIOCHEM GENET, V22, P201, DOI 10.1007/BF00484224; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LEDLEY FD, 1987, P NATL ACAD SCI USA, V84, P5335, DOI 10.1073/pnas.84.15.5335; LINNEY E, 1987, J VIROL, V61, P3248, DOI 10.1128/JVI.61.10.3248-3253.1987; LOH TP, 1987, MOL CELL BIOL, V7, P3775, DOI 10.1128/MCB.7.10.3775; LOUIS SD, 1988, P NATL ACAD SCI USA, V85, P3150; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MCIVOR RS, 1987, MOL CELL BIOL, V7, P838, DOI 10.1128/MCB.7.2.838; MILLER AD, 1984, SCIENCE, V225, P993, DOI 10.1126/science.6089340; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MIYANOHARA A, 1988, P NATL ACAD SCI USA, V85, P6538, DOI 10.1073/pnas.85.17.6538; OVERHAUSER J, 1985, J VIROL, V54, P133, DOI 10.1128/JVI.54.1.133-144.1985; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARKMAN R, 1986, SCIENCE, V232, P1373, DOI 10.1126/science.3520819; PENG H, 1988, P NATL ACAD SCI USA, V85, P8146, DOI 10.1073/pnas.85.21.8146; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SCHERER G, 1982, P NATL ACAD SCI-BIOL, V79, P7205, DOI 10.1073/pnas.79.23.7205; SELDEN RF, 1987, SCIENCE, V236, P714, DOI 10.1126/science.3472348; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SORGE J, 1984, P NATL ACAD SCI-BIOL, V81, P6627, DOI 10.1073/pnas.81.21.6627; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; STEWART CL, 1987, EMBO J, V6, P383, DOI 10.1002/j.1460-2075.1987.tb04766.x; THAYER MJ, 1990, MOL CELL BIOL, V10, P2660, DOI 10.1128/MCB.10.6.2660; TREMP GL, 1989, J BIOL CHEM, V264, P19904; TSUKIYAMA T, 1989, MOL CELL BIOL, V9, P4670, DOI 10.1128/MCB.9.11.4670; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; WAGNER EF, 1985, EMBO J, V4, P663, DOI 10.1002/j.1460-2075.1985.tb03680.x; WEIHER H, 1987, J VIROL, V61, P2742, DOI 10.1128/JVI.61.9.2742-2746.1987; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P3014, DOI 10.1073/pnas.85.9.3014; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WOLFF JA, 1987, P NATL ACAD SCI USA, V84, P3344, DOI 10.1073/pnas.84.10.3344; WOYCHIK RP, 1982, NUCLEIC ACIDS RES, V10, P7197, DOI 10.1093/nar/10.22.7197; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; YEE JK, 1987, P NATL ACAD SCI USA, V84, P5197, DOI 10.1073/pnas.84.15.5197; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194	72	20	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8416	8425						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022656				2022-12-25	WOS:A1991FK44100070
J	HAYAKAWA, Y				HAYAKAWA, Y			STRUCTURE OF A GROWTH-BLOCKING PEPTIDE PRESENT IN PARASITIZED INSECT HEMOLYMPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							JUVENILE-HORMONE; MANDUCA-SEXTA; PROTHORACICOTROPIC HORMONE; PSEUDALETIA-SEPARATA; HELIOTHIS-VIRESCENS; TOBACCO HORNWORM; HOST; PUPATION; RELEASE; CALYX	Last instar larvae of the insect armyworm, Pseudaletia separata, parasitized with the parasitoid wasp, Apanteles kariyai, do not initiate metamorphosis and, ultimately, the wasp larvae emerge from the host larvae about 10 days after parasitization (Tanaka, T., Agui, N., and Hiruma, K. (1987) Gen. Comp. Endocrinol. 67, 364-374). It is necessary for the parasitoid wasp to perturb the armyworm's endocrinological processes that control normal metamorphosis from larvae to pupae. This endocrinological perturbation allows the parasitoid to complete its larval growth before emerging from the host larvae. It is obligatory for the parasitoid larvae to emerge while the host is still in a larval stage because the sclerotized pupal cuticle is impenetrable for the parasitoid larvae. A growth-blocking peptide with repressive activity against juvenile hormone esterase has been proven to exist in the parasitized host larval plasma (Hayakawa, Y. (1990) J. Biol. Chem. 265, 10813-10816). Here, I describe the detailed structure of this peptide and also the corresponding synthetic peptide to confirm this structure.			HAYAKAWA, Y (corresponding author), HOKKAIDO UNIV,INST LOW TEMP SCI,BIOCHEM LAB,SAPPORO,HOKKAIDO 060,JAPAN.							BECKAGE NE, 1982, GEN COMP ENDOCR, V47, P308, DOI 10.1016/0016-6480(82)90238-6; BECKAGE NE, 1985, ANNU REV ENTOMOL, V30, P317; DAHLMAN DL, 1990, ARCH INSECT BIOCHEM, V13, P29, DOI 10.1002/arch.940130104; DOVER BA, 1987, J INSECT PHYSIOL, V33, P333, DOI 10.1016/0022-1910(87)90121-1; HAMMOCK BD, 1990, NATURE, V344, P458, DOI 10.1038/344458a0; HAMMOCK BD, 1985, METHOD ENZYMOL, V111, P487; HAMMOCK BD, 1985, COMPREHENSIVE INSECT, V7, P431; HANGLIK TN, 1989, J BIOL CHEM, V264, P12419; HAYAKAWA Y, 1990, J BIOL CHEM, V265, P10813; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIRUMA K, 1985, GEN COMP ENDOCR, V63, P201; JONES D, 1986, J INSECT PHYSIOL, V32, P315, DOI 10.1016/0022-1910(86)90044-2; NIJHOUT HF, 1974, J EXP BIOL, V61, P493; RAABE M, 1989, RECENT DEV INSECT NE, P69; ROUNTREE DB, 1986, J EXP BIOL, V120, P41; STEEL CGH, 1985, COMPREHENSIVE INSECT, V8, P1; STRAND MR, 1990, ARCH INSECT BIOCHEM, V13, P41, DOI 10.1002/arch.940130105; TANAKA T, 1987, GEN COMP ENDOCR, V67, P364, DOI 10.1016/0016-6480(87)90191-2; TANAKA T, 1987, ANN ENTOMOL SOC AM, V80, P530, DOI 10.1093/aesa/80.4.530; VINSON SB, 1980, Q REV BIOL, V55, P143, DOI 10.1086/411731; WATSON RD, 1987, INSECT BIOCHEM, V17, P955, DOI 10.1016/0020-1790(87)90102-8; WEBB BA, 1986, J INSECT PHYSIOL, V32, P339, DOI 10.1016/0022-1910(86)90046-6; WROBLEWSKI VJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P461, DOI 10.1016/0003-9861(90)90285-7	23	91	99	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					7982	7984						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022627				2022-12-25	WOS:A1991FK44100006
J	PETTERSSON, I; KUSCHE, M; UNGER, E; WLAD, H; NYLUND, L; LINDAHL, U; KJELLEN, L				PETTERSSON, I; KUSCHE, M; UNGER, E; WLAD, H; NYLUND, L; LINDAHL, U; KJELLEN, L			BIOSYNTHESIS OF HEPARIN - PURIFICATION OF A 110-KDA MOUSE MASTOCYTOMA PROTEIN REQUIRED FOR BOTH GLUCOSAMINYL N-DEACETYLATION AND N-SULFATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SULFOTRANSFERASE; CELLS	The polymer modification process in the biosynthesis of heparin/heparan sulfate is initiated by N-deacetylation, followed by N-sulfation, of N-acetylglucosamine units. Chromatography of a detergent extract from mouse mastocytoma on wheat germ agglutinin-Sepharose yielded a protein fraction, eluted with 0.3 M N-acetylglucosamine, that expressed N-deacetylase activity, but only after recombination with proteins that did not bind to the lectin column. In subsequent purification of the active lectin-bound component, all assays were performed following addition of the unbound protein fraction. After two additional chromatography steps, on blue Sepharose and 3', 5'-ADP-agarose, the lectin-binding N-deacetylase component had been purified about 4300-fold with an 11% yield and showed essentially a single band, corresponding to an apparent molecular weight of approximately 110,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Analysis of the purified 110-kDa protein showed that it contained, in addition to the N-deacetylase, N-sulfotransferase activity; however, the expression of N-sulfotransferase activity was independent of additional proteins. Backtracking the N-sulfotransferase through the purification scheme previously applied to the N-deacetylase showed the two enzyme activities to be cofractionated in each separation step. It is proposed that the expression of glucosaminyl N-deacetylase activity depends on the concerted action of (at least) two protein components, one of which also possesses glucosaminyl N-sulfotransferase activity.	SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT VET MED CHEM,BOX 575,S-75123 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences			Kjellen, Lena/F-1362-2011					BALASUBR.AS, 1967, ANAL BIOCHEM, V21, P22, DOI 10.1016/0003-2697(67)90078-4; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; FURTH J, 1957, P SOC EXP BIOL MED, V95, P824; GOHLER D, 1984, EUR J BIOCHEM, V138, P301, DOI 10.1111/j.1432-1033.1984.tb07915.x; HOOK M, 1975, J BIOL CHEM, V250, P6065; JACOBSSON KG, 1985, J BIOL CHEM, V260, P2154; JANSSON L, 1975, BIOCHEM J, V149, P49, DOI 10.1042/bj1490049; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; LEVY L, 1962, P SOC EXP BIOL MED, V190, P901; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; Lindahl U., 1989, HEPARIN, P159; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; MALMSTROM A, 1980, J BIOL CHEM, V255, P3878; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAVIA JL, 1983, ANAL BIOCHEM, V135, P134, DOI 10.1016/0003-2697(83)90741-8; RENOSTO F, 1977, ARCH BIOCHEM BIOPHYS, V180, P416, DOI 10.1016/0003-9861(77)90056-X; RIESENFELD J, 1982, J BIOL CHEM, V257, P421; RIESENFELD J, 1982, J BIOL CHEM, V257, P7050; ROBBINS PW, 1962, METHOD ENZYMOL, V5, P964, DOI 10.1016/S0076-6879(62)05343-4; SILBERT JE, 1963, J BIOL CHEM, V238, P3542; SILBERT JE, 1967, J BIOL CHEM, V242, P5153; SILBERT JE, 1967, J BIOL CHEM, V242, P5146	28	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8044	8049						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022632				2022-12-25	WOS:A1991FK44100016
J	SANDY, JD; BOYNTON, RE; FLANNERY, CR				SANDY, JD; BOYNTON, RE; FLANNERY, CR			ANALYSIS OF THE CATABOLISM OF AGGRECAN IN CARTILAGE EXPLANTS BY QUANTITATION OF PEPTIDES FROM THE 3 GLOBULAR DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; CORE PROTEIN; PROTEOGLYCAN; INTERLEUKIN-1; RELEASE; BIOSYNTHESIS; CULTURES	A method has been developed for the production, isolation, and quantitation of 15 marker peptides from the three globular domains (G1, G2, and G3) and the interglobular domain of bovine aggrecan (aggregating cartilage proteoglycan). Three of the peptides are from G1, two are from the interglobular domain, four are from G2, and six are from G3. The method involves separation of tryptic peptides by sequential anion-exchange, cation-exchange, and reversed-phase high performance liquid chromatography and quantitation by absorbance at 220 nm. The values obtained (peak area per microgram of core protein) were a function of the molar yield and also the size and aromatic residue content of individual peptides. This procedure has been applied to aggrecan purified from fresh calf articular cartilage and to aggrecan isolated from the medium and tissue compartments of cartilage explant cultures, maintained in basal medium for 15 days without and with interleukin-1-alpha. These analyses indicate that aggrecan which is released into explant medium has a reduced content of the G1 domain, but has a normal content of the G2 domain, the COOH-terminal region of the interglobular domain, and also the G3 domain. On the other hand, aggrecan which is retained by the cartilage during 15 days of culture has a normal content of G1, interglobular domain, and G2 domains but, in the presence of interleukin-1-alpha, it has a reduced content of the G3 domain. The percentage of medium molecules which retained the G1 domain was higher in control cultures (about 35%) than in interleukin cultures (about 20%), and this was consistent with the relative aggregability of these samples. Taken together these results suggest that catabolism of aggrecan in articular cartilage involves a specific proteolysis of the core protein at a site which is within the interglobular domain and NH2-terminal to the sequence LPGG. This process occurs in control cultures but is accelerated by the addition of interleukin-1-alpha. Degraded molecules which lack the G1 domain are released preferentially into the medium; however, these molecules carry both the G2 and G3 domains, indicating that these domains do not confer strong matrix binding properties on aggrecan. The method described here for the isolation of peptides from bovine aggrecan should have wide application to structural and biosynthetic studies on this molecule in species such as human and rat, since many of the marker peptides are from highly conserved regions of the aggrecan core protein.	UNIV S FLORIDA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612	State University System of Florida; University of South Florida	SANDY, JD (corresponding author), SHRINERS HOSP CRIPPLED CHILDREN,TAMPA UNIT,TAMPA,FL 33612, USA.				NIAMS NIH HHS [AR 38580] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038580] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE K, 1990, BIOCHEM SOC T, V18, P200, DOI 10.1042/bst0180200; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; HASCALL VC, 1983, ARCH BIOCHEM BIOPHYS, V224, P206, DOI 10.1016/0003-9861(83)90205-9; MORALES TI, 1984, J BIOL CHEM, V259, P6720; MURPHY G, 1986, COLLAGEN REL RES, V6, P351; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; RATCLIFFE A, 1986, BIOCHEM J, V238, P571, DOI 10.1042/bj2380571; SANDY JD, 1987, BIOCHIM BIOPHYS ACTA, V931, P255, DOI 10.1016/0167-4889(87)90214-X; SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304-4165(78)90308-2; SANDY JD, 1986, J ORTHOPAED RES, V4, P263, DOI 10.1002/jor.1100040302; SANDY JD, 1990, J BIOL CHEM, V265, P21108; SUEYOSHI T, 1985, J BIOCHEM-TOKYO, V97, P1811, DOI 10.1093/oxfordjournals.jbchem.a135241; TYLER JA, 1985, BIOCHEM J, V227, P869, DOI 10.1042/bj2270869	18	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8198	8205						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022637				2022-12-25	WOS:A1991FK44100040
J	TRILIVAS, I; MCDONOUGH, PM; BROWN, JH				TRILIVAS, I; MCDONOUGH, PM; BROWN, JH			DISSOCIATION OF PROTEIN-KINASE-C REDISTRIBUTION FROM THE PHOSPHORYLATION OF ITS SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; THYROTROPIN-RELEASING-HORMONE; 1321N1 ASTROCYTOMA-CELLS; PHORBOL ESTERS; INDUCED TRANSLOCATION; MUSCARINIC AGONISTS; CELLULAR SUBSTRATE; PLASMA-MEMBRANE; RAT-BRAIN; 3T3 CELLS	Increases in cytoplasmic [Ca2+] caused by receptor activation are thought to stimulate the redistribution of loosely associated protein kinase C (PKC) to a tightly membrane-bound form that is activated by diacylglycerol. The precise role of Ca2+-dependent redistribution of PKC in the activation of this enzyme has not been critically assessed. We examined the relationship between PKC redistribution and substrate phosphorylation by comparing the kinetics and the Ca2+ dependence of the two events. Using immunoblotting with specific PKC antibodies, we find that 1321N1 cells express the alpha-form of PKC, approximately 10-20% of which is membrane-associated in unstimulated cells. This fraction is increased to 60% in response to muscarinic receptor stimulation. Agonist-induced redistribution of PKC is rapid and transient, peaking at 30 s and returning to control levels by 2-5 min. Stimulation of muscarinic receptors also rapidly increases phosphorylation of both an endogenous 80-kDa protein and the peptide substrate, VRKRTLRRL. However, unlike the time course of PKC redistribution, PKC-mediated phosphorylation of these substrates is sustained for up to 30 min. To compare the Ca2+ dependence of PKC redistribution and substrate phosphorylation, we buffered muscarinic receptor-induced increases in cytoplasmic [Ca2+] with the divalent cation chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid. Under these conditions, redistribution of PKC and phosphorylation of the exogenous peptide substrate are inhibited by about 80%. In contrast, muscarinic receptor-stimulated phosphorylation of the 80-kDa protein occurs even when increases in cytoplasmic [Ca2+] are prevented. Taken together, these data demonstrate that the redistribution of PKC does not correlate in extent or duration with phosphorylation of PKC substrates.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,0636,9500 GILMAN DR,LA JOLLA,CA 92093	University of California System; University of California San Diego					NIGMS NIH HHS [GM 36927] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM036927, R01GM036927] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; BLENIS J, 1985, P NATL ACAD SCI USA, V82, P7621, DOI 10.1073/pnas.82.22.7621; BROWN MR, 1989, AM J PHYSIOL, V257, pH99; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; COCHET C, 1984, J BIOL CHEM, V259, P2553; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DIAZGUERRA MJM, 1990, BIOCHEM J, V269, P163, DOI 10.1042/bj2690163; DRUST DS, 1985, BIOCHEM BIOPH RES CO, V128, P531, DOI 10.1016/0006-291X(85)90079-8; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; FEARON CW, 1987, J BIOL CHEM, V262, P9515; FU T, 1989, BIOCHEM BIOPH RES CO, V162, P1279, DOI 10.1016/0006-291X(89)90812-7; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GODSON C, 1990, J BIOL CHEM, V265, P8369; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HIRASAWA K, 1985, ANNU REV PHARMACOL, V25, P147, DOI 10.1146/annurev.pharmtox.25.1.147; HOUSE C, 1987, SCIENCE, V238, P1727; HUANG KP, 1989, ACTA ENDOCRINOL-COP, V121, P307, DOI 10.1530/acta.0.1210307; INOUE M, 1977, J BIOL CHEM, V252, P7610; ISACKE CM, 1986, EMBO J, V5, P2889, DOI 10.1002/j.1460-2075.1986.tb04584.x; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MASLIAH E, 1990, J NEUROSCI, V10, P2113; MASTERS SB, 1984, MOL PHARMACOL, V26, P149; MAY WS, 1985, NATURE, V317, P549, DOI 10.1038/317549a0; MCDONOUGH PM, 1988, BIOCHEM J, V249, P135, DOI 10.1042/bj2490135; MELLONI E, 1986, J BIOL CHEM, V261, P4101; MESSING RO, 1989, J NEUROSCI, V9, P507; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P9146; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PELECH SL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P100, DOI 10.1016/0167-4889(90)90179-H; RODRIGUEZPENA A, 1986, BIOCHEM BIOPH RES CO, V140, P379, DOI 10.1016/0006-291X(86)91101-0; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SHIMOHAMA S, 1990, J CHEM NEUROANAT, V3, P367; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; WITTERS LA, 1987, METHOD ENZYMOL, V141, P412; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0; WOODGETT JR, 1987, CELL MEMBRANES METHO, V3, P215	64	92	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8431	8438						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022658				2022-12-25	WOS:A1991FK44100072
J	BARKALOW, FJB; SCHWARZBAUER, JE				BARKALOW, FJB; SCHWARZBAUER, JE			LOCALIZATION OF THE MAJOR HEPARIN-BINDING SITE IN FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PLASMA FIBRONECTIN; HUMAN-LUNG FIBROBLASTS; SULFATE PROTEOGLYCANS; CELL-BINDING; ADHESION; DOMAIN; IDENTIFICATION; FRAGMENTS; RECEPTOR; SEGMENT	We have identified the major site required for the interaction of fibronectin (FN) with heparin. Affinity chromatography was used to test the binding ability of a library of truncated, monomeric forms of fibronectin (deminectins) containing deletions or two point mutations in the heparin-binding domain. This domain consists of type III repeats 12, 13, and 14. Deletions of individual repeats showed that both III13 and III14 are required for complete binding. Small deletions within these repeats localized a major site of heparin interaction to the amino-terminal half of III13. Site-directed mutagenesis of adjacent arginines within this sequence to uncharged residues reduced heparin binding by 98%, identifying these positively charged amino acids as essential for the interaction. A significant role for the flanking alternatively spliced regions and for repeat III12 was not found. We conclude that, while both repeats III13 and III14 participate in heparin binding, there is a major site of interaction in repeat III13 that accounts for nearly all of the activity. The significance of multiple heparin-binding sites within this domain is discussed and a model is proposed to account for how these sites may function in vivo.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University				Schwarzbauer, Jean/0000-0003-1012-7593	NATIONAL CANCER INSTITUTE [R01CA044627] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DAVID G, 1989, J CELL BIOL, V108, P1165, DOI 10.1083/jcb.108.3.1165; GARCIAPARDO A, 1987, BIOCHEM J, V241, P923, DOI 10.1042/bj2410923; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAYASHI M, 1980, J BIOL CHEM, V255, P17; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Hynes RO, 1990, FIBRONECTINS; ICHIHARATANAKA K, 1990, J BIOL CHEM, V265, P401; IZZARD CS, 1986, EXP CELL RES, V165, P320, DOI 10.1016/0014-4827(86)90586-0; KATO M, 1989, J CELL BIOL, V109, P320; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LORIES V, 1989, J BIOL CHEM, V264, P7009; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; Mosher DF, 1989, FIBRONECTIN; MOULD AP, 1990, J BIOL CHEM, V265, P4020; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SCHWARZBAUER JE, 1987, P NATL ACAD SCI USA, V84, P754, DOI 10.1073/pnas.84.3.754; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V154, P15, DOI 10.1111/j.1432-1033.1986.tb09353.x; TATUNASHVILI LV, 1990, J MOL BIOL, V211, P161, DOI 10.1016/0022-2836(90)90018-H; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1988, EXP CELL RES, V177, P272, DOI 10.1016/0014-4827(88)90461-2; WOODS A, 1985, J BIOL CHEM, V260, P872; YAMADA KM, 1980, J BIOL CHEM, V255, P6055	36	127	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7812	7818						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019604				2022-12-25	WOS:A1991FJ34200078
J	HILDERMAN, RH; MARTIN, M; ZIMMERMAN, JK; PIVORUN, EB				HILDERMAN, RH; MARTIN, M; ZIMMERMAN, JK; PIVORUN, EB			IDENTIFICATION OF A UNIQUE MEMBRANE-RECEPTOR FOR ADENOSINE 5',5'''-P1,P4-TETRAPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; DIADENOSINE 5',5'''-P1,P4-TETRAPHOSPHATE; ADENYLYLATED NUCLEOTIDES; PLATELET-AGGREGATION; BINDING ACTIVITIES; VASOMOTOR ACTIVITY; HEAT-SHOCK; AP4A; ADENOSINE(5')TETRAPHOSPHO(5')ADENOSINE; TETRAPHOSPHATE	Adenosine 5',5'''-P1,P4-tetraphosphate (Ap4A) has been implicated as a modulator of cell stress. We have performed binding studies which indicate that membranes from all tissues tested bind tritium-labeled Ap4A. The characteristics of Ap4A binding were determined on brain membrane homogenates after development of an optimized in vitro filter-binding assay. Ap4A binding is specific for adenylated dinucleotides and for the length of the phosphate bridge. A K(d) of 0.71-mu-M for Ap4A was determined.			HILDERMAN, RH (corresponding author), CLEMSON UNIV,DEPT BIOL SCI,CLEMSON,SC 29634, USA.							BOCHNER BR, 1984, CELL, V37, P225, DOI 10.1016/0092-8674(84)90318-0; BOETTCHER BR, 1980, J BIOL CHEM, V255, P7129; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BUSSE R, 1988, AM J PHYSIOL, V254, pH828, DOI 10.1152/ajpheart.1988.254.5.H828; COLACINO J, 1988, FASEB J, V2, P332; DENISENKO ON, 1984, FEBS LETT, V178, P149, DOI 10.1016/0014-5793(84)81259-4; FERNANDEZ A, 1984, BIOCHEM BIOPH RES CO, V121, P155, DOI 10.1016/0006-291X(84)90700-9; FLODGAARD H, 1982, BIOCHEM J, V208, P737, DOI 10.1042/bj2080737; GAHAN LJ, 1990, FASEB J, V4, P1704; GILSON G, 1988, EXP CELL RES, V177, P143, DOI 10.1016/0014-4827(88)90032-8; GRAU VP, 1982, J BIOL CHEM, V257, P1848; HARRISON MJ, 1975, FEBS LETT, V54, P57, DOI 10.1016/0014-5793(75)81067-2; HILDERMAN RH, 1983, BIOCHEMISTRY-US, V22, P4353, DOI 10.1021/bi00288a001; JUST G, 1987, BIOCHEM J, V246, P681, DOI 10.1042/bj2460681; KOBAYASHI Y, 1989, BIOCHEM BIOPH RES CO, V160, P1379, DOI 10.1016/S0006-291X(89)80156-1; KOSOWER EM, 1969, NATURE, V224, P117, DOI 10.1038/224117a0; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; LEE PC, 1983, J BIOL CHEM, V258, P6827; LOUIE S, 1988, THROMB RES, V49, P557, DOI 10.1016/0049-3848(88)90253-8; LUTHJE J, 1983, BIOCHEM BIOPH RES CO, V115, P253, DOI 10.1016/0006-291X(83)90997-X; LUTHJE J, 1984, BIOCHEM BIOPH RES CO, V118, P704, DOI 10.1016/0006-291X(84)91451-7; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORFANOUDAKIS G, 1990, BIOCHIMIE, V72, P271, DOI 10.1016/0300-9084(90)90083-S; POHL U, 1987, BIOL CHEM H-S, V368, P1094; PRESCOTT M, 1990, ANAL BIOCHEM, V184, P330, DOI 10.1016/0003-2697(90)90690-B; RAPAPORT E, 1981, P NATL ACAD SCI-BIOL, V78, P838, DOI 10.1073/pnas.78.2.838; TANAKA Y, 1981, J BIOCHEM-TOKYO, V90, P1131, DOI 10.1093/oxfordjournals.jbchem.a133565; VARSHAVSKY A, 1983, CELL, V34, P711, DOI 10.1016/0092-8674(83)90526-3; WEINMANNDORSCH C, 1984, EUR J BIOCHEM, V138, P179, DOI 10.1111/j.1432-1033.1984.tb07897.x; ZOURGUI L, 1986, BIOCHIM BIOPHYS ACTA, V846, P2222	30	99	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6915	6918						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016305				2022-12-25	WOS:A1991FG72700045
J	FORCHHAMMER, K; LEINFELDER, W; BOESMILLER, K; VEPREK, B; BOCK, A				FORCHHAMMER, K; LEINFELDER, W; BOESMILLER, K; VEPREK, B; BOCK, A			SELENOCYSTEINE SYNTHASE FROM ESCHERICHIA-COLI - NUCLEOTIDE-SEQUENCE OF THE GENE (SELA) AND PURIFICATION OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; EXPRESSION; CLEAVAGE; SERINE; DNA	The nucleotide sequence of the selA gene from Escherichia coli whose product is involved in the conversion of seryl-tRNA(UCA)Sec into selenocysteyl-tRNA(UCA)Sec was determined. selA codes for a polypeptide of a calculated M(r) of 50,667; a protein of appropriate size was synthesized in vivo in a T7 promoter/polymerase system. An assay for SELA activity was devised which is based on the seryl-tRNA(UCA)Sec-dependent incorporation of [Se-75] selenium into acid-insoluble material. It was used to follow SELA purification from cells that overproduced the protein from a phage T7 promoter plasmid. Purified native SELA protein migrates in gel filtration experiments with a native M(r) of about 600,000. SELA contains 1 mol of bound pyridoxal 5-phosphate/mol of 50-kDa subunit. Evidence is presented that the overall conversion of seryl-tRNA(UCA)Sec to selenocysteyl-tRNA(UCA)Sec occurs at the SELA protein. SELA, therefore, has the function of a selenocysteine synthase.	UNIV MUNICH, LEHRSTUHL MIKROBIOL, MARIA WARD STR 1A, W-8000 MUNICH 19, GERMANY	University of Munich								Bock A, 1988, Biofactors, V1, P245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DREISEIKELMANN B, 1979, BIOCHIM BIOPHYS ACTA, V562, P418, DOI 10.1016/0005-2787(79)90105-9; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; FORCHHAMMER K, 1990, J BIOL CHEM, V265, P9346; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; Garabedian PA Der, 1986, EUR J BIOCHEM, V156, P589, DOI [10.1111/j.1432-1033.1986.tb09618.x, DOI 10.1111/J.1432-1033.1986.TB09618.X]; GRAY CP, 1978, P NATL ACAD SCI USA, V75, P50, DOI 10.1073/pnas.75.1.50; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HOLBROOK EL, 1990, BIOCHEMISTRY-US, V29, P435, DOI 10.1021/bi00454a019; LABROW R, 1966, J BIOL CHEM, V241, P1239; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; LEINFELDER W, 1989, THESIS L MAXIMILIANS; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; Maurer H., 1971, DISK ELECTROPHORESIS; Maxam A M, 1980, Methods Enzymol, V65, P499; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SCHON A, 1989, NUCLEIC ACIDS RES, V17, P7159, DOI 10.1093/nar/17.18.7159; SODA K, 1969, BIOCHEM J, V114, P629, DOI 10.1042/bj1140629; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TORCHINSKY YM, 1990, ANN NY ACAD SCI, V585, P68, DOI 10.1111/j.1749-6632.1990.tb28042.x; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	28	92	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6318	6323						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007584				2022-12-25	WOS:A1991FE37300049
J	KESTI, T; SYVAOJA, JE				KESTI, T; SYVAOJA, JE			IDENTIFICATION AND TRYPTIC CLEAVAGE OF THE CATALYTIC CORE OF HELA AND CALF THYMUS DNA-POLYMERASE EPSILON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYACRYLAMIDE GELS; REPLICATION INVITRO; AUXILIARY PROTEIN; DELTA; ALPHA; PURIFICATION; DISTINCT; FORMS; PCNA	DNA polymerase-epsilon, formerly known as a proliferating cell nuclear antigen-independent form of DNA polymerase-delta, has been shown elsewhere to be catalytically and structurally distinct from DNA polymerase-delta. The catalytic activity of HeLa DNA polymerase-epsilon, an enzyme consisting of > 200- and 55-kDa polypeptides, was assigned to the larger polypeptide by polymerase trap reaction. This catalytic polypeptide was cleaved by incubation with trypsin into two polypeptide fragments with molecular masses of 122 and 136 kDa, the former of which was relatively resistant to further proteolysis and possessed the polymerase activity. The cleavage increased the polymerase and exonuclease activities of the enzyme some 2-3-fold. DNA polymerase-epsilon was also purified in a smaller 140-kDa form from calf thymus. The digestion of this form of the enzyme by trypsin also generated a 122-kDa polypeptide. These results suggest that the catalytic core of DNA polymerase-epsilon is a 258-kDa polypeptide that is composed of two segments linked with a protease-sensitive area. One of the segments harbors both DNA polymerase and 3' --> 5' exonuclease activities. In spite of the different polypeptide structures, the catalytic properties of the HeLa enzyme, its trypsin-digested form, and the calf thymus enzyme remained essentially the same.	UNIV OULU, DEPT BIOCHEM, LINNANMAA, SF-90570 OULU, FINLAND	Finland National Institute for Health & Welfare; University of Oulu								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDD ME, 1989, J BIOL CHEM, V264, P6557; Burgers P M, 1989, Prog Nucleic Acid Res Mol Biol, V37, P235; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; BYRNES JJ, 1978, BIOCHEMISTRY-US, V17, P4226, DOI 10.1021/bi00613a018; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CRUTE JJ, 1986, BIOCHEMISTRY-US, V25, P26, DOI 10.1021/bi00349a005; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; DOWNEY KM, 1988, CANCER CELLS EUKARYO, V6, P403; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; FOCHER F, 1988, NUCLEIC ACIDS RES, V16, P6279, DOI 10.1093/nar/16.14.6279; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1987, BIOCHEMISTRY-US, V26, P1076, DOI 10.1021/bi00378a014; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2998, DOI 10.1021/bi00408a050; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; SYVAOJA JE, 1990, BIOESSAYS, V12, P533, DOI 10.1002/bies.950121106; TAN CK, 1986, J BIOL CHEM, V261, P2310; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; WAHL AF, 1986, BIOCHEMISTRY-US, V25, P7821, DOI 10.1021/bi00372a006; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; WONG SW, 1989, J BIOL CHEM, V264, P5924; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	35	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6336	6341						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007586				2022-12-25	WOS:A1991FE37300052
J	ARORA, KK; FILBURN, CR; PEDERSEN, PL				ARORA, KK; FILBURN, CR; PEDERSEN, PL			GLUCOSE PHOSPHORYLATION - SITE-DIRECTED MUTATIONS WHICH IMPAIR THE CATALYTIC FUNCTION OF HEXOKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-BRAIN HEXOKINASE; AMINO-ACID SEQUENCE; MITOCHONDRIAL BOUND HEXOKINASE; YEAST HEXOKINASE; BINDING-SITE; TERMINAL HALVES; CLONED CDNA; TUMOR; METABOLISM; RESOLUTION	Recent studies from this and other laboratories have resulted in the cloning and sequencing of hexokinases from a variety of tissues including yeast, human kidney, rat brain, rat liver, and mouse hepatoma. Significantly, studies on the hepatoma enzyme conducted in this laboratory (Arora, K. K., Fanciulli, M., and Pedersen, P. L. (1990) J. Biol. Chem. 265, 6481-6488) resulted also in its overexpression in Escherichia coli in active form. We have now used site-directed mutagenesis for the first time in studies of hexokinase to evaluate the role of amino acid residues predicted to interact with either glucose or ATP. Four amino acid residues (Ser-603, Asp-657, Glu-708, and Glu-742) believed to interact with glucose were mutated to alanine or glycine, whereas a lysine residue (Lys-558) thought to be directly involved in binding ATP was mutated to either methionine or arginine. Of all the mutations in residues believed to interact with glucose, the Asp-657 --> Ala mutation is the most profound, reducing the hexokinase activity to a level < 1% of the wild type. The relative V(max) values for Ser-603 --> Ala, Glu-708 --> Ala, and Glu-742 --> Ala enzymes are 6, 10, and 6.5%, respectively, of the wild-type enzyme. Glu-708 and Glu-742 mutations increase the apparent K(m) for glucose 50- and 14-fold, respectively, while the Ser-603 --> Ala mutation decreases the apparent K(m) for glucose 5-fold. At the putative ATP binding site, the relative V(max) for Lys-558 --> Arg and Lys-558 --> Met enzymes are 70 and 29%, respectively, of the wild-type enzyme with no changes in apparent K(m) for glucose. No changes were observed in the apparent K(m) for ATP with any mutation. These results support the view that all 4 residues predicted to interact with glucose from earlier x-ray studies may play a role in binding and/or catalysis. The Asp-657 and Ser-603 residues may be involved in both, while Glu-708 and Glu-742 clearly contribute to binding but are not essential for catalysis. In contrast, Lys-558 appears to be essential neither for binding nor catalysis.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,MOLEC & CELLULAR BIOENERGET LAB,BALTIMORE,MD 21205; NIA,GERONTOL RES CTR,BIOL CHEM LAB,BALTIMORE,MD 21224	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)					NCI NIH HHS [CA 32742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ANDERSON CM, 1978, J MOL BIOL, V123, P15, DOI 10.1016/0022-2836(78)90374-1; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ARORA KK, 1990, J BIOL CHEM, V265, P6481; ARORA KK, 1990, J BIOL CHEM, V265, P5324; ARORA KK, 1988, J BIOL CHEM, V263, P17422; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; HALDANE JBS, 1932, ALLGEMEINE CHEM ENZY, P119; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA H, 1989, MOL CELL BIOL, V9, P5630, DOI 10.1128/MCB.9.12.5630; NAKASHIMA RA, 1988, CANCER RES, V48, P913; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; PARRY DM, 1983, J BIOL CHEM, V258, P904; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5643; SCHIRCH DM, 1987, ARCH BIOCHEM BIOPHYS, V257, P1, DOI 10.1016/0003-9861(87)90536-4; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; STEITZ TA, 1977, J BIOL CHEM, V252, P4494; STEITZ TA, 1981, PHILOS T ROY SOC B, V293, P43, DOI 10.1098/rstb.1981.0058; TAMURA JK, 1988, J BIOL CHEM, V263, P7907; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WHITE TK, 1987, ARCH BIOCHEM BIOPHYS, V259, P402, DOI 10.1016/0003-9861(87)90506-6; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	25	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5359	5362						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005085				2022-12-25	WOS:A1991FD37000002
J	TORGERSON, RR; LEW, RA; REYES, VE; HARDY, L; HUMPHREYS, RE				TORGERSON, RR; LEW, RA; REYES, VE; HARDY, L; HUMPHREYS, RE			HIGHLY RESTRICTED DISTRIBUTIONS OF HYDROPHOBIC AND CHARGED AMINO-ACIDS IN LONGITUDINAL QUADRANTS OF ALPHA-HELICES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN	Helix formation in folding proteins is stabilized by binding of recurrent hydrophobic side chains in one longitudinal quadrant against the locally most hydrophobic region of the protein. To test this hypothesis, we fitted sequences of 247 alpha-helices of 55 proteins to the circular (infinite) template square circle triangle circle square circle circle square circle triangle circle square circle circle square circle triangle circle to maximize the strip-of-helix hydrophobicity index (the mean hydrophobicity of residues in square positions). These template-predicted configurations closely matched crystallographic structures in 87% of four- or five-turn helices compared. We determined the longitudinal quadrant distributions of amino acids in the template-fitted, sheet projections of alpha-helices with respect to the best longitudinal, hydrophobic strip on each helix and to the N and C termini, interiors, and entire helices. Amino acids Leu, Ile, Val, and Phe were concentrated in one longitudinal quadrant (p < 0.001). Lys, Arg, Asp, and Glu were not in the quadrant of Leu, Ile, Val, and Phe (p < 0.001). Significant quadrant distributions for other amino acids and for termini of the helices were also found.	UNIV MASSACHUSETTS,MED CTR,SCH MED,DEPT PHARMACOL,55 LAKE AVE N,WORCESTER,MA 01655; UNIV MASSACHUSETTS,MED CTR,DEPT MED,WORCESTER,MA 01655; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NIAID NIH HHS [T32 AI-07272] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007272] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; GOLDSCHMIDT TG, 1991, IN PRESS VACCINES; KAISER ET, 1987, METHOD ENZYMOL, V154, P473; KENDALL M, 1961, ADV THEORY STAT, V3, P224; LU S, 1990, J IMMUNOL, V145, P899; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; PERUTZ MF, 1965, J MOL BIOL, V13, P669, DOI 10.1016/S0022-2836(65)80134-6; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; REYES VE, 1989, J BIOL CHEM, V264, P12854; REYES VE, 1990, MOL IMMUNOL, V27, P1021, DOI 10.1016/0161-5890(90)90125-J; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2	14	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5521	5524						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005094				2022-12-25	WOS:A1991FD37000027
J	MAKOVER, D; CUDDY, M; YUM, S; BRADLEY, K; ALPERS, J; SUKHATME, V; REED, JC				MAKOVER, D; CUDDY, M; YUM, S; BRADLEY, K; ALPERS, J; SUKHATME, V; REED, JC			PHORBOL ESTER-MEDIATED INHIBITION OF GROWTH AND REGULATION OF PROTOONCOGENE EXPRESSION IN THE HUMAN T-CELL LEUKEMIA LINE JURKAT	ONCOGENE			English	Article							C-MYC; FOLLICULAR LYMPHOMA; MOLECULAR-CLONING; SARCOMA VIRUS; CDNA CLONE; GENE; DIFFERENTIATION; ENCODES; FOS; SEQUENCE	The expression and function of several proto-oncogenes were examined in a human acute T cell leukemia line, JURKAT, during phorbol ester-induced terminal differentiation. Treating JURKAT cells with the phorbol ester tetradecanoyl phorbol acetate (TPA) inhibited their proliferation and induced expression of the gene for the interleukin 2 receptor alpha chain (IL2R-alpha), consistent with previous reports. In unstimulated proliferating JURKAT cells, high levels of C-MYC, N-RAS, and BCL2 mRNAs were found that diminished rapidly following TPA-induced cessation of growth. In contrast, accumulation of mRNAs for the C-FOS, C-JUN, and EGR-1 genes increased markedly in TPA-treated cells and preceded the induction of IL2R-alpha mRNA. Expression of the C-MYB, C-RAF-1, C-LCK, C-FYN, and C-FGR proto-oncogenes was relatively unchanged. To explore directly the function of two of these proto-oncogenes in regulating the growth of JURKAT T cells, we stably transferred C-MYC and BCL2 expression plasmids into these cells. Despite sustained expression of C-MYC, BCL2, or the combination of these proto-oncogenes, TPA continued to inhibit JURKAT cell growth and to induce IL2R expression. Thus, although C-MYC and BCL2 proto-oncogene expression correlated with proliferation in TPA-treated JURKAT cells, continuous over-expression of even the combination of these oncogenes was insufficient for abrogating the effects of TPA in these leukemic T cells. Because human lymphoid malignancies frequently contain chromosomal translocations that deregulate the expression of C-MYC and BCL2, our findings could have relevance for attempts to induce terminal differentiation of leukemic cells by in vitro exposure of patients' bone marrow cells to phorbol esters.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Pennsylvania; University of Pennsylvania; University of Chicago			Sukhatme, Vikas/W-2776-2019		NCI NIH HHS [CA47956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047956] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHM JL, 1986, CANCER RES, V46, P3711; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BOHNMANN D, 1987, SCIENCE, V238, P1386; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P155; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCHINI G, 1983, P  NATL ACAD SCI US, V80, P7380; GAUWERKY CE, 1988, ONCOGENE, V2, P431; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GREENE WC, 1984, J IMMUNOL, V133, P1042; GROSSO LE, 1985, CANCER RES, V45, P847; INOUE K, 1987, ONCOGENE, V1, P301; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LEE WMF, 1989, ONCOGENES, P37; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEONARD WJ, 1984, NATURE, V311, P636; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PEGORARO L, 1980, BLOOD, V55, P859; PERLMUTTER RM, 1989, SCIENCE, V245, P344, DOI 10.1126/science.2787933; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; RAPP UR, 1988, HDB ONCOGENES, P213; REED J, 1990, IN PRESS P INT S CHI; REED J, 1988, INTERLEUKIN, V2, P367; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REED JC, 1985, MOL CELL BIOL, V5, P3361, DOI 10.1128/MCB.5.12.3361; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REED JC, 1987, DEV RECOGNITION TRAN, P39; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	52	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					455	460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011401				2022-12-25	WOS:A1991FT34400016
J	MENOZZI, D; VINAYEK, R; JENSEN, RT; GARDNER, JD				MENOZZI, D; VINAYEK, R; JENSEN, RT; GARDNER, JD			DOWN-REGULATION AND RECYCLING OF HIGH-AFFINITY CHOLECYSTOKININ RECEPTORS ON PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; INSULIN-RECEPTORS; ENZYME-SECRETION; AMYLASE RELEASE; MONENSIN; BINDING; INTERNALIZATION; LIGAND; PINOCYTOSIS; FIBROBLASTS	First incubating dispersed acini from rat pancreas with monensin, a cation ionophore that can inhibit recycling of receptors, inhibited binding of I-125-cholecystokin 8 (I-125-CCK-8) measured during a second incubation by as much as 50%. A maximal effect of monensin required 90 min of first incubation. Detectable inhibition of binding of I-125-CCK-8 occurred with 300 nM monensin, and inhibition increased progressively with concentrations of monensin up to 25-mu-M. Pancreatic acini possess two classes of receptors that bind I-125-CCK-8. One class has a high affinity (K(d) = 461 pM) and a low capacity for CCK (512 fmol/mg DNA); the other class has a low affinity (K(d) = 47 nM) and a high capacity for CCK (18 pmol/mg DNA). First incubating acini with monensin caused an 84% decrease in the number of high affinity CCK receptors with no change in the number of low affinity CCK receptors or the values of K(d) for either class of receptors indicating that there is recycling of high affinity CCK receptors but not low affinity CCK receptors. First incubating acini with monensin did not alter CCK-stimulated amylase secretion indicating that in contrast to previous conclusions, occupation of low affinity CCK receptors mediates CCK-stimulated enzyme secretion. Moreover, the biphasic dose-response curve for CCK-stimulated enzyme secretion from monensin-treated acini suggests that pancreatic acini also possess a third, previously unrecognized class of very low affinity CCK receptors.	NIDDKD,DIGEST DIS BRANCH,BLDG 10,ROOM 9C-103,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BOTTARO DP, 1989, J BIOL CHEM, V264, P5916; Burton K., 1968, METHODS ENZYMOLOGY B, V12B, P163; CARPENTIER JL, 1984, J BIOL CHEM, V259, P4190; CESKA M, 1969, CLIN CHIM ACTA, V26, P445, DOI 10.1016/0009-8981(69)90072-2; CESKA M, 1969, CLIN CHIM ACTA, V26, P437, DOI 10.1016/0009-8981(69)90071-0; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; CHANG RSL, 1985, SCIENCE, V230, P177, DOI 10.1126/science.2994227; CHANG RSL, 1986, MOL PHARMACOL, V30, P212; CHANG RSL, 1988, NEUROL NEUROBIOL, V47, P13; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; DELISLE RC, 1987, AM J PHYSIOL, V253, pG711, DOI 10.1152/ajpgi.1987.253.6.G711; FEHLMANN M, 1982, P NATL ACAD SCI-BIOL, V79, P5921, DOI 10.1073/pnas.79.19.5921; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GARDNER JD, 1977, J PHYSIOL-LONDON, V270, P439, DOI 10.1113/jphysiol.1977.sp011961; GARDNER JD, 1987, PHYSL GASTROINTESTIN, P1109; GLADHAUG IP, 1988, J BIOL CHEM, V263, P12199; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; HONDA T, 1987, AM J PHYSIOL, V252, pG77, DOI 10.1152/ajpgi.1987.252.1.G77; HUANG SC, 1989, AM J PHYSIOL, V257, pG169, DOI 10.1152/ajpgi.1989.257.1.G169; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; MULLER WA, 1980, J CELL BIOL, V86, P304, DOI 10.1083/jcb.86.1.304; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEIKIN SR, 1978, AM J PHYSIOL-ENDOC M, V235, P743; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; SANKARAN H, 1982, AM J PHYSIOL, V242, pG250, DOI 10.1152/ajpgi.1982.242.3.G250; SANKARAN H, 1980, J BIOL CHEM, V255, P1849; SATO S, 1989, AM J PHYSIOL, V257, pG202, DOI 10.1152/ajpgi.1989.257.2.G202; SCHVARTZ I, 1987, J BIOL CHEM, V262, P17046; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7; STEER CJ, 1980, J BIOL CHEM, V255, P3008; STEIN BS, 1984, J BIOL CHEM, V259, P4762; VANLEUVEN F, 1980, CELL, V20, P37, DOI 10.1016/0092-8674(80)90232-9; WANK SA, 1988, AM J PHYSIOL, V255, pG106, DOI 10.1152/ajpgi.1988.255.1.G106; WEISSMAN AM, 1986, P NATL ACAD SCI USA, V83, P1463, DOI 10.1073/pnas.83.5.1463; WHITTAKER J, 1986, BIOCHEM J, V234, P463, DOI 10.1042/bj2340463; WILEMAN T, 1984, BIOCHEM J, V220, P665, DOI 10.1042/bj2200665; WILLIAMS JA, 1988, AM J PHYSIOL, V254, pG513, DOI 10.1152/ajpgi.1988.254.4.G513	40	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10385	10391						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037588				2022-12-25	WOS:A1991FP08600061
J	PERCIVAL, MD				PERCIVAL, MD			HUMAN 5-LIPOXYGENASE CONTAINS AN ESSENTIAL IRON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID SEQUENCE; SOYBEAN LIPOXYGENASE-1; MOLECULAR-CLONING; ARACHIDONATE 12-LIPOXYGENASE; RETICULOCYTE LIPOXYGENASE; MAMMALIAN LIPOXYGENASES; PORCINE LEUKOCYTES; LEUKOTRIENES; BIOSYNTHESIS; CDNA	The iron content of human 5-lipoxygenase has been determined by a colorimetric assay using the chromogenic ligand FerroZine. The highly active enzyme was obtained from a baculovirus expression system and purified using an ATP-agarose chromatography column (Denis, D., Falgueyret, J.-P., Riendeau, D., and Abramovitz, M. (1991) J. Biol. Chem. 266, 5072-5079). A linear correlation was observed between the enzyme's specific activity and iron content in six different preparations. Enzyme with the highest specific activity (24-mu-mol of 5-hydroperoxyeicosatetraenoic acid/mg of protein) contained 1.1 mol of iron/mol of enzyme, whereas inactive enzyme contained no detectable iron. The iron is tightly bound to the enzyme and could only be released after inactivation of the enzyme by exposure to oxygen.			PERCIVAL, MD (corresponding author), MERCK FROSST CTR THERAPEUT RES, DEPT BIOCHEM, POINTE CLAIRE H9R 4P8, QUEBEC, CANADA.							BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BRAIN SD, 1990, PHARMACOL THERAPEUT, V46, P57, DOI 10.1016/0163-7258(90)90035-Z; CARTER GW, 1989, NEW TREND L, V3, P50; CLAPP CH, 1985, BIOCHEMISTRY-US, V24, P1826, DOI 10.1021/bi00329a004; COREY EJ, 1989, J AM CHEM SOC, V111, P1452, DOI 10.1021/ja00186a046; DEGROOT JJM, 1975, BIOCHIM BIOPHYS ACTA, V377, P71, DOI 10.1016/0005-2744(75)90287-9; DENIS D, 1991, J BIOL CHEM, V266, P5072; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DUNHAM WR, 1990, EUR J BIOCHEM, V190, P611, DOI 10.1111/j.1432-1033.1990.tb15616.x; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; FORDHUTCHINSON AW, 1989, LEUKOTRIENES LIPOXYG, V2, P406; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2592, DOI 10.1073/pnas.86.8.2592; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK MO, 1990, J AM CHEM SOC, V112, P5375, DOI 10.1021/ja00169a069; GARSSEN GJ, 1971, BIOCHEM J, V122, P327, DOI 10.1042/bj1220327; GIBIAN MJ, 1987, ANAL BIOCHEM, V163, P343, DOI 10.1016/0003-2697(87)90234-X; JACKSON WP, 1988, J MED CHEM, V31, P499, DOI 10.1021/jm00398a001; KEMAL C, 1987, BIOCHEMISTRY-US, V26, P7064, DOI 10.1021/bi00396a031; KONIG W, 1990, EICOSANOIDS, V3, P1; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; NAVARATNAM S, 1988, BIOCHIM BIOPHYS ACTA, V956, P70, DOI 10.1016/0167-4838(88)90299-3; NELSON MJ, 1988, J AM CHEM SOC, V110, P2985, DOI 10.1021/ja00217a056; PISTORIUS EK, 1974, J BIOL CHEM, V249, P3183; RAPOPORT S, 1984, EUR J BIOCHEM, V139, P573, DOI 10.1111/j.1432-1033.1984.tb08043.x; RIENDEAU D, 1991, BIOCHEM J, V274, P287, DOI 10.1042/bj2740287; ROUZER CA, 1990, METHOD ENZYMOL, V187, P312; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; STRASSER M, 1988, HELV CHIM ACTA, V71, P1156, DOI 10.1002/hlca.19880710528; SUMMERS JB, 1987, J MED CHEM, V30, P574, DOI 10.1021/jm00386a022; Vliegenthart J. F. G., 1982, FREE RADICAL BIO MED, P29; WIESNER R, 1983, BIOMED BIOCHIM ACTA, V42, P431; YAMAMOTO S, 1989, PROSTAG LEUKOTR ESS, V35, P219, DOI 10.1016/0952-3278(89)90005-7; YAMAMOTO S, 1988, ANN NY ACAD SCI, V524, P12; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142	45	117	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10058	10061						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037564				2022-12-25	WOS:A1991FP08600011
J	FUKAI, F; SUZUKI, H; SUZUKI, K; TSUGITA, A; KATAYAMA, T				FUKAI, F; SUZUKI, H; SUZUKI, K; TSUGITA, A; KATAYAMA, T			RAT PLASMA FIBRONECTIN CONTAINS 2 DISTINCT CHEMOTACTIC DOMAINS FOR FIBROBLASTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD MONOCYTES; METASTATIC MELANOMA-CELLS; BINDING FRAGMENT; PARTICULATE ACTIVATORS; ADHESIVE FUNCTION; PHAGOCYTOSIS; IDENTIFICATION; LOCALIZATION; MIGRATION; COLLAGEN	Mechanism of fibronectin (FN)-induced chemotaxis of fibroblastic cells has not been fully understood. The present study was performed to establish a molecular nature of the chemotactic region of rat plasma FN. The chemotactic dose-response pattern of intact FN for mouse embryo fibroblastic cells, NIH-L13 cells, which was represented as a "bell-shape" curve with a maximum activity at around 50 nM, changed to a "biphasic" mode through a proteolysis with thermolysin. Two distinct chemotactic components were isolated from the thermolytic fragments. One component, a fragment with a molecular mass of 110-150 kDa, was estimated to contain the central cell-binding domain and the carboxyl-terminal heparin-binding domain of the intact FN molecule. Cell migration stimulated by the 110-150-kDa fragment increased successively in a dose-dependent manner, and the capability to promote the migration was much higher than that of the intact FN (over 2-fold). The second chemotactic component, a fragment with a molecular mass of 21 kDa, was shown to reside in the carboxyl-terminal fibrin-binding domain. The 21-kDa fragment produced a bell-shape dose-response pattern, being consistent with the intact FN, whereas a maximum response occurred at a 100-fold lower concentration (0.5 nM) than that of the intact FN molecule. At higher concentrations, this fragment revealed an inhibitory activity for the cell migration in response to the 110-150-kDa fragment. No significant molecular interaction between these two active components was observed by polyacrylamide gel electrophoresis under nondenaturing conditions, suggesting that the 21-kDa fragment may act directly on the cell to inhibit the cell migration. These results suggest that rat plasma FN contains at least two chemotactically active components that regulate cooperatively chemotactic migration of fibroblastic cells.	SCI UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PATHOPHYSIOL,TOKYO 162,JAPAN; SCI UNIV TOKYO,BIOSCI RES INST,NODA,CHIBA 278,JAPAN	Tokyo University of Science; Tokyo University of Science								ALBINI A, 1983, FEBS LETT, V156, P222, DOI 10.1016/0014-5793(83)80500-6; ALBINI A, 1987, J CELL BIOL, V105, P1867, DOI 10.1083/jcb.105.4.1867; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; BOWERSOX JC, 1980, J CELL BIOL, V87, pA64; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; CZOP JK, 1982, J IMMUNOL, V129, P163; CZOP JK, 1982, J IMMUNOL, V129, P2678; CZOP JK, 1985, J IMMUNOL, V134, P1844; CZOP JK, 1981, P NATL ACAD SCI-BIOL, V78, P3649, DOI 10.1073/pnas.78.6.3649; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DONALDSON DJ, 1985, J CELL BIOL, V101, P73, DOI 10.1083/jcb.101.1.73; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FEHR J, 1979, J CLIN INVEST, V64, P8, DOI 10.1172/JCI109466; GAUSSMULLER V, 1980, J LAB CLIN MED, V96, P1071; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; KELLER HU, 1981, CELL BIOL INT REP, V5, P3, DOI 10.1016/0309-1651(81)90151-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKABE T, 1990, J BIOL CHEM, V265, P14270; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; MENSING H, 1983, EUR J CELL BIOL, V29, P268; Mosher, 1989, FIBRONECTIN, P1; Mosher D F, 1980, Prog Hemost Thromb, V5, P111; NAGAI T, 1988, BIOCHIM BIOPHYS ACTA, V967, P176; NAGATA K, 1985, J CELL BIOL, V101, P386, DOI 10.1083/jcb.101.2.386; NORRIS DA, 1982, J IMMUNOL, V129, P1612; OBARA M, 1987, FEBS LETT, V213, P261, DOI 10.1016/0014-5793(87)81502-8; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; POSTLETHWAITE AE, 1976, J EXP MED, V143, P1299, DOI 10.1084/jem.143.6.1299; POSTLETHWAITE AE, 1981, J EXP MED, V153, P494, DOI 10.1084/jem.153.2.494; RENNARD SI, 1981, P NATL ACAD SCI-BIOL, V78, P7147, DOI 10.1073/pnas.78.11.7147; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P3967; SEKIGUCHI K, 1981, J BIOL CHEM, V256, P6452; SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926; SEPPA HEJ, 1981, CELL BIOL INT REP, V5, P813, DOI 10.1016/0309-1651(81)90253-8; STRAUS AH, 1989, EXP CELL RES, V183, P126, DOI 10.1016/0014-4827(89)90423-0; TSUKAMOTO Y, 1981, J IMMUNOL, V127, P673; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; YAMAGUCHI K, 1988, ANAL BIOCHEM, V172, P104, DOI 10.1016/0003-2697(88)90417-4; YANO H, 1989, Protein Sequences and Data Analysis, V2, P385; YONEMASU K, 1983, MICROBIOL IMMUNOL, V27, P283, DOI 10.1111/j.1348-0421.1983.tb03590.x	48	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8807	8813						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026595				2022-12-25	WOS:A1991FM03800030
J	DHAWAN, J; LICHTLER, AC; ROWE, DW; FARMER, SR				DHAWAN, J; LICHTLER, AC; ROWE, DW; FARMER, SR			CELL-ADHESION REGULATES PRO-ALPHA-1(I) COLLAGEN MESSENGER-RNA STABILITY AND TRANSCRIPTION IN MOUSE FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GENE-EXPRESSION; RAT-BRAIN; C-FOS; 1,25-DIHYDROXYVITAMIN-D; TRANSLATION; DEGRADATION; TUBULIN; REGION	Adhesive interactions are important modulators of cellular phenotype. Previously, we demonstrated that quiescent, suspension-arrested cells are not equivalent to density-arrested cells in their patterns of gene expression (Dhawan, J., and Farmer, S. R. (1990) J. Biol. Chem. 265, 9015-9021). In particular, pro-alpha-1(I) collagen expression depended strongly on the extent of cell adhesion. In this paper, we demonstrate that the adhesion-induced rise in collagen gene expression is due to regulation at multiple levels. Steady state levels of pro-alpha-1(I) collagen mRNA increased up to 10-fold by 6 h after replating suspended cells, and this rise is blocked by inhibition of protein synthesis. Transcription of the pro-alpha-1(I) collagen gene was measured by run-on assay as well as by activation of a rat alpha-1(I) promoter-chloramphenicol acetyltransferase reporter gene construct. Both assays reveal a 5-fold depression of pro-alpha-1(I) collagen gene transcription in suspended cells. Reattachment of suspended cells resulted in the activation of alpha-1(I) gene transcription by 2-h postreplating, reaching a 3-5-fold level of induction by 18 h. The pro-alpha-1(I) collagen mRNA was substantially more labile in suspended cells than in adherent cells (t1/2 values of approximately 2 h in nonadherent cells and > 8 h in exponentially growing or density-arrested cells). Furthermore, reattachment of suspended cells for 18 h resulted in a stabilization of collagen mRNA. We conclude that cell adhesion regulates pro-alpha-1(I) collagen gene expression selectively and at transcriptional and posttranscriptional sites.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV CONNECTICUT,MED CTR,DEPT PEDIAT,FARMINGTON,CT 06032	Boston University; University of Connecticut				Farmer, Stephen/0000-0003-2483-2795				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; BENECKE BJ, 1980, J CELL PHYSIOL, V103, P247, DOI 10.1002/jcp.1041030209; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BOND JF, 1984, MOL CELL BIOL, V4, P1313, DOI 10.1128/MCB.4.7.1313; BOND JF, 1983, MOL CELL BIOL, V3, P1333, DOI 10.1128/MCB.3.8.1333; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BURRIDGE K, 1986, Cancer Reviews, V4, P18; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; DHAWAN J, 1990, J BIOL CHEM, V265, P9015; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DOZIN B, 1990, J BIOL CHEM, V265, P7216; FARMER SR, 1989, CELL SHAPE DETERMINA, P173; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAMALAINE L, 1985, J BIOL CHEM, V260, P3773; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; KINDY MS, 1988, J BIOL CHEM, V263, P11426; LIAU G, 1989, J BIOL CHEM, V264, P10315; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; LIMIAL M, 1985, SCIENCE, V230, P1126; OLASHAW NE, 1985, MEDIATORS CELL GROWT, P31; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; PETTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SVOBODA KKH, 1987, DEV BIOL, V123, P455, DOI 10.1016/0012-1606(87)90403-9; TAMM I, 1977, P NATL ACAD SCI USA, V74, P5011, DOI 10.1073/pnas.74.11.5011; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WU R, 1985, NUCLEIC ACIDS RES, V13, P2485	36	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8470	8475						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022661				2022-12-25	WOS:A1991FK44100077
J	VANDEVIJVER, MJ; KUMAR, R; MENDELSOHN, J				VANDEVIJVER, MJ; KUMAR, R; MENDELSOHN, J			LIGAND-INDUCED ACTIVATION OF A431 CELL EPIDERMAL GROWTH-FACTOR RECEPTORS OCCURS PRIMARILY BY AN AUTOCRINE PATHWAY THAT ACTS UPON RECEPTORS ON THE SURFACE RATHER THAN INTRACELLULARLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-RECEPTOR; FACTOR-ALPHA; TGF-ALPHA; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; CARCINOMA-CELLS; KINASE-ACTIVITY; BINDING; ANTIBODIES; PROTEIN	A431 cells express high numbers of epidermal growth factor (EGF) receptors and produce a ligand for these receptors, transforming growth factor-alpha (TGF-alpha). We have obtained evidence that the EGF receptors on these cells may be activated through an "autocrine" pathway by ligand and have investigated whether activation of phosphorylation of the receptor by the endogenously produced TGF-alpha occurs intracellularly or at the cell surface. When A431 cells were cultured under serum-free conditions, in the absence of exogenous ligand, EGF receptors were found to have a basal level of phosphorylation. When cells were labeled by culturing with P-32(i) in the continuous presence of monoclonal antibodies that block binding of TGF-alpha to the EGF receptor, phosphorylation decreased to 30 +/- 10% of the basal level. This reduction could not be accounted for by the decrease in receptor content attributable to down-regulation and catabolism of EGF receptors that resulted from the binding of anti-receptor monoclonal antibodies. The reduction in receptor phosphorylation mediated by antibody was accompanied by the accumulation of increased levels of secreted TGF-alpha species in the culture medium. We also pulse-labeled A431 cells for 15 min with [S-35]cysteine and immunoprecipitated the cell lysate with anti-phosphotyrosine antibody after various chase periods. Tyrosine-phosphorylated EGF receptor became detectable after 40 min of chase and reached a maximum after 4-6 h; these times are in agreement with the intervals required for EGF receptors to reach the cell surface after synthesis and then to achieve maximal expression. In addition, only the 170-kDa, mature EGF receptor species, and not the 160-kDa intracellular precursor, was immunoprecipitated with the anti-phosphotyrosine antibody. The results of these pulse-chase experiments and the finding that anti-receptor monoclonal antibody can block receptor phosphorylation suggest that activation of EGF receptors can result from the binding of an endogenous ligand (presumably TGF-alpha), which occurs at the cell surface and not during receptor biosynthesis and intracellular processing.	MEM SLOAN KETTERING CANC CTR,RECEPTOR BIOL LAB,1275 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University				van de Vijver, Marc/0000-0002-0385-4787	NCI NIH HHS [CA-42060, CA-37641] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042060, U01CA037641, U19CA037641, R37CA042060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DICKSON RB, 1986, CANCER RES, V46, P1707; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIMARCO E, 1989, ONCOGENE, V4, P831; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; GILL GN, 1984, J BIOL CHEM, V259, P7755; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; KUMAR R, 1990, J BIOL CHEM, V265, P4578; KUMAR R, 1989, CANCER RES, V49, P5180; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LENSLEY PS, 1985, P NATL ACAD SCI USA, V82, P356; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MASUI H, 1984, CANCER RES, V44, P1002; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; Sato J D, 1983, Mol Biol Med, V1, P511; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; SODERQUIST AM, 1986, J MEMBRANE BIOL, V90, P97, DOI 10.1007/BF01869927; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STROMBERG K, 1986, J CELL BIOCHEM, V32, P247, DOI 10.1002/jcb.240320402; SUNADA H, 1985, ANAL BIOCHEM, V149, P438, DOI 10.1016/0003-2697(85)90595-0; SUNADA H, 1990, J CELL PHYSIOL, V142, P284, DOI 10.1002/jcp.1041420210; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	45	118	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7503	7508						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019581				2022-12-25	WOS:A1991FJ34200031
J	GRUSS, A; MORETTO, V; EHRLICH, SD; DUWAT, P; DABERT, P				GRUSS, A; MORETTO, V; EHRLICH, SD; DUWAT, P; DABERT, P			GC-RICH DNA-SEQUENCES BLOCK HOMOLOGOUS RECOMBINATION INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLI RECA PROTEIN; DEPENDENT ATPASE ACTIVITY; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; DUPLEX DNA; NUCLEOTIDE-SEQUENCE; SSB PROTEIN; BINDING; REPLICATION; MECHANISM	The capacity of the RecA protein of Escherichia coli to promote an essential step in homologous recombination, strand transfer, was tested on DNA substrates varying in percentage GC. GC content was determined by a novel method using the polymerase chain reaction. Strand transfer activity is greatly reduced as a function of increasing GC content of the DNA. Some reduction is observed with substrates having a GC percentage similar to that of E. coli. The transfer reaction between sequences adjacent, but not distal, to GC-rich sequences is similarly decreased, suggesting that the structure of RecA-DNA complexes may differ with the GC content of DNA. Our results implicate an important role of DNA sequence in homologous recombination and suggest that many sequences are excluded due to their GC content.			GRUSS, A (corresponding author), INRA,INST BIOTECHNOL,GENET MICROBIENNE LAB,DOMAINE VILVERT,F-78350 JOUY EN JOSAS,FRANCE.		Ehrlich, S./Y-2423-2019; DABERT, Patrick/I-7830-2018	Ehrlich, S./0000-0002-7563-4046; Gruss, Alexandra/0000-0001-7426-5229; Dabert, Patrick/0000-0002-6124-2316				BLAHO JA, 1987, J BIOL CHEM, V262, P6082; CHOW SA, 1986, J BIOL CHEM, V261, P6961; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; De Ley J, 1970, J BACTERIOL, V101, P738, DOI 10.1128/JB.101.3.738-754.1970; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; INNIS MA, 1990, PCR PROTOCOLS, P54; JULIN DA, 1986, J BIOL CHEM, V261, P1025; KIM JI, 1989, J BIOL CHEM, V264, P21848; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LONG CM, 1987, J BACTERIOL, V169, P5745, DOI 10.1128/jb.169.12.5745-5754.1987; MCKENZIE T, 1986, PLASMID, V15, P93, DOI 10.1016/0147-619X(86)90046-6; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; RIELE HT, 1986, EMBO J, V5, P631, DOI 10.1002/j.1460-2075.1986.tb04257.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEST SC, 1980, P NATL ACAD SCI-BIOL, V77, P2569, DOI 10.1073/pnas.77.5.2569	22	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6667	6669						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016280				2022-12-25	WOS:A1991FG72700003
J	THORNBURG, T; MILLER, C; THUREN, T; KING, L; WAITE, M				THORNBURG, T; MILLER, C; THUREN, T; KING, L; WAITE, M			GLYCEROL REORIENTATION DURING THE CONVERSION OF PHOSPHATIDYLGLYCEROL TO BIS(MONOACYLGLYCEROL)PHOSPHATE IN MACROPHAGE-LIKE RAW-264.7 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID CLASS DISTRIBUTION; CULTURED BHK-CELLS; LYSOBISPHOSPHATIDIC ACID; ALVEOLAR MACROPHAGES; RAT-LIVER; LYSO(BIS)PHOSPHATIDIC ACID; STEREOCHEMICAL CONFIGURATION; STEREO-CONFIGURATION; SPECIES VARIATIONS; ARACHIDONIC-ACID	Bis(monoacylglycero)phosphate (BMP) has the unique stereoconfiguration of 3-acyl-sn-glycero-1-phosphoryl-1'-sn-[3'-acylglycerol] (Brotherus, J., Renkonen, O., Herrmann, J., and Fischer, W. (1974) Chem. Phys. Lipids 13, 178-182) which differs from other known mammalian phospholipids that have the sn-glycero-3-phosphoryl configuration. This stereo-chemistry may contribute to its physiologic function. Here we describe studies using the macrophage-like cell line RAW 264.7 designed to determine how this unique stereoconfiguration occurs. These studies show that the stereoconfiguration of BMP produced from exogenous phosphatidylglycerol (PG) by RAW 264.7 cells has the expected stereoconfiguration of 3-acyl-sn-glycero-1-phosphoryl-1'-sn-[3'-acylglycerol]. Experiments using diacyl-sn-[2-H-3]glycero-3-phosphoryl-sn-1'-[2-H-3]glycerol demonstrate that this unique stereoconfiguration is not produced due to an oxidation/reduction mechanism involving the sn-2-glycerol carbon. When dioleoyl-sn-[1-C-14]glycero-3-phosphoryl-rac-glycerol was converted to C-14-labeled BMP, the C-14 label was found esterified to the phosphate moiety. These results suggest that a stereospecific enzyme is capable of reorienting the radiolabeled glycerol backbone of this PG substrate, effectively changing the stereochemistry of the lipid. We also show that this enzyme is stereoselective with regard to the base glycerol moiety of the substrate PG used. Finally, we propsoe a new pathway for the synthesis of BMP from PG.			THORNBURG, T (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,300 S HAWTHORNE RD,WINSTON SALEM,NC 27103, USA.				NCI NIH HHS [CA-12197] Funding Source: Medline; NHLBI NIH HHS [HL-31338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRANOFF BW, 1971, P NATL ACAD SCI USA, V68, P411, DOI 10.1073/pnas.68.2.411; BAER E, 1950, J BIOL CHEM, V185, P615; BAXTER CF, 1969, LIPIDS, V4, P243, DOI 10.1007/BF02532640; BLEISTEIN J, 1980, H-S Z PHYSIOL CHEM, V361, P1445; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BODY D. R., 1967, CHEM PHYS LIPIDS, V1, P254, DOI 10.1016/0009-3084(67)90032-1; BROCKERHOFF H, 1979, LIPIDS, V14, P88, DOI 10.1007/BF02533575; BROTHERUS J, 1974, CHEM PHYS LIPIDS, V13, P178, DOI 10.1016/0009-3084(74)90034-6; BROTHERUS J, 1977, J LIPID RES, V18, P191; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COCHRAN FR, 1987, J IMMUNOL, V138, P1877; COCHRAN FR, 1985, BIOCHEM BIOPH RES CO, V130, P800, DOI 10.1016/0006-291X(85)90487-5; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; DAVIDSON FM, 1958, BIOCHEM J, V69, P458, DOI 10.1042/bj0690458; DONNER L, 1976, HOPPESEYLERS Z PHYSL, V357, P811; FISCHER W, 1973, BIOCHIM BIOPHYS ACTA, V296, P527, DOI 10.1016/0005-2760(73)90113-6; FRENTZENBERTRAMS M, 1981, H-S Z PHYSIOL CHEM, V362, P1229, DOI 10.1515/bchm2.1981.362.2.1229; HUTERER S, 1979, J LIPID RES, V20, P966; HUTERER SJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P68, DOI 10.1016/0005-2760(89)90308-1; HUTERER SJ, 1985, BIOCHIM BIOPHYS ACTA, V876, P318; JOUTTI A, 1979, BIOCHIM BIOPHYS ACTA, V575, P10, DOI 10.1016/0005-2760(79)90125-5; JOUTTI A, 1976, BIOCHIM BIOPHYS ACTA, V450, P206, DOI 10.1016/0005-2760(76)90092-8; JOUTTI A, 1979, J LIPID RES, V20, P840; JOUTTI A, 1979, J LIPID RES, V20, P230; KAHMA K, 1976, LIPIDS, V11, P539, DOI 10.1007/BF02532899; LONG C, 1953, BIOCHEM J, V54, P612, DOI 10.1042/bj0540612; MASON RJ, 1972, J CLIN INVEST, V51, P2399, DOI 10.1172/JCI107052; MATSUZAWA Y, 1978, J BIOL CHEM, V253, P6650; MATSUZAWA Y, 1980, J LIPID RES, V21, P202; POORTHUIS BJHM, 1976, J BIOL CHEM, V251, P4596; POORTHUIS BJHM, 1978, J LIPID RES, V19, P309; POORTHUIS BJHM, 1975, J BIOL CHEM, V250, P3297; ROUSER G, 1969, LIPIDS, V4, P599, DOI 10.1007/BF02531047; ROUSER G, 1968, LIPIDS, V3, P287, DOI 10.1007/BF02531203; SENG PN, 1971, H-S Z PHYSIOL CHEM, V352, P280, DOI 10.1515/bchm2.1971.352.1.280; SIAKOTOS AN, 1969, LIPIDS, V4, P234, DOI 10.1007/BF02532638; SIMON G, 1969, LIPIDS, V4, P607, DOI 10.1007/BF02531048; SOMERHARJU P, 1977, BIOCHIM BIOPHYS ACTA, V487, P154, DOI 10.1016/0005-2760(77)90052-2; SOMERHARJU P, 1980, BIOCHIM BIOPHYS ACTA, V618, P407, DOI 10.1016/0005-2760(80)90259-3; SOMERHARJU P, 1979, THESIS U HELSINKI HE, P18; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAITE M, 1990, J BIOL CHEM, V265, P21720; WAITE M, 1987, FASEB J, V1, P318, DOI 10.1096/fasebj.1.4.3653583; WALSH C, 1979, ENZYMATIC REACTION M, P347; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114; WHERRETT JR, 1973, LIPIDS, V8, P531, DOI 10.1007/BF02531989; Wittig G., 1960, ORG SYNTH, V40, P66; YAMAMOTO A, 1970, LIPIDS, V5, P566, DOI 10.1007/BF02532747; Yoe JH, 1941, IND ENG CHEM, V13, P0238, DOI 10.1021/i560092a014	50	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6834	6840						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016299				2022-12-25	WOS:A1991FG72700032
J	CHEN, TA; SMITH, MM; LE, S; STERNGLANZ, R; ALLFREY, VG				CHEN, TA; SMITH, MM; LE, S; STERNGLANZ, R; ALLFREY, VG			NUCLEOSOME FRACTIONATION BY MERCURY AFFINITY-CHROMATOGRAPHY - CONTRASTING DISTRIBUTION OF TRANSCRIPTIONALLY ACTIVE DNA-SEQUENCES AND ACETYLATED HISTONES IN NUCLEOSOME FRACTIONS OF WILD-TYPE YEAST-CELLS AND CELLS EXPRESSING A HISTONE-H3 GENE ALTERED TO ENCODE A CYSTEINE-110 RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; REVERSIBLE CHANGES; CORE PARTICLE; S-CEREVISIAE; CHROMATIN; ACID; H-3; ORGANIZATION; CONFORMATION; PURIFICATION	A technique for the separation of transcriptionally active and inactive nucleosomes by mercury affinity chromatography has been applied to study the nucleosomal distribution of DNA sequences from the GAL1, ACT1, HIS4, MAT-alpha, and HMRa genes of yeast. In mammalian cells, the method has been shown to separate active from inactive nucleosomes and to fractionate the active nucleosomes into two classes, one retained on the mercury column because of salt-labile associations with certain thiol-reactive non-histone proteins, and the other bound by covalent linkage of the cysteine 110 thiol groups of histone H3 molecules to the mercurated support. The first class of nucleosomes is elutable in 0.5 M NaCl; the second is displaced by 10 mM dithiothreitol (DTT) (Walker, J., Chen, T. A., Sterner, R., Berger, M., Winston, F., and Allfrey, V. G. (1990) J. Biol. Chem. 265, 5736-5746). We show that, in wild-type yeast cells, in which histone H3 lacks cysteinyl residues, very little DNA and a negligible complement of nucleosomes appear in the DTT-eluate, confirming the requirement for the H3-thiols in the mercury-binding reaction. Moreover, the DTT-eluted fraction is seriously deficient in the actively transcribed GAL1, ACT1, HIS4, and MAT-alpha DNA sequences. Site-directed mutagenesis was employed to create an H3 gene containing a cysteine codon in place of the alanine codon at position 110 of the yeast H3 amino acid sequence. A strain was constructed containing the mutant histone H3 gene instead of the normal H3 gene. Subsequent fractionations of the mutant nucleosomes by mercury-affinity chromatography revealed a characteristic nucleosome peak in the DTT-eluted fraction. Its content of transcribed GAL1, ACT1, and HIS4 DNA sequences was 20- to 500-fold higher than that of the corresponding DTT-eluted fraction of wild-type yeast. Although this result is in accord with the finding that, in mammalian cells, the thiol groups of histone H-3 become accessible when nucleosomes "unfold" during transcription, we find that nucleosomes containing the GAL1 DNA sequences of the yeast H-3-mutant also bind to the mercury column when the gene is not being expressed. We conclude that many yeast nucleosomes are maintained in a "primed," potentially active state, possibly due to the very high constitutive levels of acetylation of the core histones. However, the nucleosomes of the HMRa gene, which is not expressed in a MAT-alpha yeast strain, are virtually absent from the DTT-eluted nucleosome fractions of the H-3-mutant cells, indicating that prolonged silencing of the gene is accompanied by compaction and loss of H-3-thiol reactivity of its nucleosomes.	ROCKEFELLER UNIV,CELL BIOL LAB,NEW YORK,NY 10021; UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794	Rockefeller University; University of Virginia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA14908] Funding Source: Medline; NIGMS NIH HHS [GM28220, GM17383] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028220, R56GM028220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFAGEME CR, 1974, J BIOL CHEM, V249, P3729; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ALLFREY VG, 1980, CELL BIOL, V3, P347; BODE J, 1980, EUR J BIOCHEM, V110, P143, DOI 10.1111/j.1432-1033.1980.tb04849.x; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRANDT WF, 1982, EUR J BIOCHEM, V121, P501, DOI 10.1111/j.1432-1033.1982.tb05815.x; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; BURLINGAME RW, 1985, SCIENCE, V228, P546, DOI 10.1126/science.3983639; CAMERINIOTERO RD, 1977, P NATL ACAD SCI USA, V74, P5519, DOI 10.1073/pnas.74.12.5519; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHAN S, 1988, J BIOL CHEM, V263, P15643; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; DELANGE RJ, 1973, J BIOL CHEM, V248, P3261; ESHAGHPOUR H, 1980, BIOCHEMISTRY-US, V19, P1797, DOI 10.1021/bi00550a011; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HEREFORD LM, 1977, CELL, V10, P453, DOI 10.1016/0092-8674(77)90032-0; JEROME JF, 1986, MOL CELL BIOL, V6, P1633, DOI 10.1128/MCB.6.5.1633; JOHNSON EM, 1987, J BIOL CHEM, V262, P6943; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHR D, 1979, P NATL ACAD SCI USA, V76, P4285, DOI 10.1073/pnas.76.9.4285; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; Maniatis T, 1989, DECONTAMINATION DILU; MARDIAN JKW, 1978, BIOCHEMISTRY-US, V18, P3825; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MIRZABEKOV AD, 1978, P NATL ACAD SCI USA, V75, P4184, DOI 10.1073/pnas.75.9.4184; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NELSON DA, 1982, J BIOL CHEM, V257, P1565; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PANYIM S, 1971, BIOCHEMISTRY-US, V10, P3911, DOI 10.1021/bi00797a018; PEREZORTIN JE, 1989, YEAST, V5, P219, DOI 10.1002/yea.320050404; POGO BGT, 1966, P NATL ACAD SCI USA, V55, P805, DOI 10.1073/pnas.55.4.805; PRIOR CP, 1980, CELL, V20, P597, DOI 10.1016/0092-8674(80)90306-2; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RUIZCARR.A, 1973, ARCH BIOCHEM BIOPHYS, V154, P185, DOI 10.1016/0003-9861(73)90047-7; SCHULTZ LD, 1978, BIOCHEMISTRY-US, V17, P750, DOI 10.1021/bi00597a031; SMITH MM, 1983, J MOL BIOL, V169, P641, DOI 10.1016/S0022-2836(83)80163-6; SMITH MM, 1988, J CELL BIOL, V106, P557, DOI 10.1083/jcb.106.3.557; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERNER R, 1987, NUCLEIC ACIDS RES, V15, P4375, DOI 10.1093/nar/15.11.4375; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; VIDALI G, 1978, P NATL ACAD SCI USA, V75, P2239, DOI 10.1073/pnas.75.5.2239; WALKER J, 1990, J BIOL CHEM, V265, P5736; WINSTON F, 1984, CELL, V39, P675, DOI 10.1016/0092-8674(84)90474-4; ZAMA M, 1978, BIOCHEM BIOPH RES CO, V85, P1446, DOI 10.1016/0006-291X(78)91165-8	50	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6489	6498						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007598				2022-12-25	WOS:A1991FE37300074
J	SANDMANN, J; PERALTA, EG; WURTMAN, RJ				SANDMANN, J; PERALTA, EG; WURTMAN, RJ			COUPLING OF TRANSFECTED MUSCARINIC ACETYLCHOLINE-RECEPTOR SUBTYPES TO PHOSPHOLIPASE-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-BRAIN; HYDROLYSIS; EXPRESSION; PHOSPHATIDYLETHANOL; DIACYLGLYCEROL; HETEROGENEITY; ACTIVATION; METABOLISM; CLONING; GENES	Muscarinic receptor-induced changes in the activities of phospholipase D (PLD) and of phosphoinositide-phospholipase C (PI-PLC) were investigated in human embryonic kidney (HEK) cells transfected with, and stably expressing, the human m1, m2, m3, and m4 mAChR subtypes, respectively. PLD and PI-PLC activities in these four transfected cell lines as well as in nontransfected cells were measured by the formation of [H-3]phosphatidylethanol ([H-3]PEt) and [H-3]inositol phosphates ([H-3]IP) after labeling cellular phospholipids with [H-3]oleic acid and [H-3]inositol. The muscarinic receptor agonist carbachol had no significant effects on [H-3]PEt and [H-3]IP formation in nontransfected HEK cells. In cells expressing the m1 or m3 receptors carbachol (1 mM; in the presence of 400 mM ethanol and 10 mM lithium chloride) caused the formation of [H-3]PEt of about 12,000 cpm/mg protein (basal PEt formation was not measurable) and increased [H-3]IP formation by 20,000-30,000 cpm/mg (a 7-10-fold increase over basal levels). The EC50 values (0.3-1.5-mu-M) were similar for both effects and both mAChR subtypes. In contrast, in cells expressing m2 or m4 receptor subtypes the magnitude of [H-3]PEt (about 4,000 cpm/mg protein) or [H-3]IP (3,000-4,000 cpm/mg) formation was much smaller and the EC50 values (20-40-mu-M) much higher than for the m1 and m3 receptors. Neomycin (1 mM) inhibited the m1 and m3 receptor-mediated production of IP by 50%, whereas the PEt formation was attenuated by 20% in the same cells. We conclude that activation of all of the four mAChR subtypes, although with different efficiencies, can stimulate PLD. The m1 and m3 receptor-mediated stimulation of the PLD may be at least partially independent of the PI-PLC stimulation.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University	SANDMANN, J (corresponding author), MIT, DEPT BRAIN & COGNIT SCI, BLDG E25-604, CAMBRIDGE, MA 02139 USA.							ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; ASHKENAZI A, 1988, COLD SPRING HARB SYM, V53, P263, DOI 10.1101/SQB.1988.053.01.033; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CONCLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698; DOODS HN, 1987, J PHARMACOL EXP THER, V242, P257; EXTON JH, 1990, J BIOL CHEM, V265, P1; GUSTAVSSON L, 1987, BIOCHEM BIOPH RES CO, V142, P958, DOI 10.1016/0006-291X(87)91507-5; HAMMER R, 1986, LIFE SCI, V38, P1653, DOI 10.1016/0024-3205(86)90409-1; HORWITZ J, 1991, J NEUROCHEM, V56, P509, DOI 10.1111/j.1471-4159.1991.tb08179.x; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LINDMAR R, 1988, BIOCHEM PHARMACOL, V37, P4689, DOI 10.1016/0006-2952(88)90339-5; LIPSKY JJ, 1982, J PHARMACOL EXP THER, V220, P287; LOEFFELHOLZ K, 1989, Biochemical Pharmacology, V38, P1543; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MEI L, 1989, LIFE SCI, V45, P1831, DOI 10.1016/0024-3205(89)90537-7; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAI JK, 1988, J BIOL CHEM, V263, P12472; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; QIAN Z, 1990, J BIOL CHEM, V265, P3607; QIAN Z, 1989, J BIOL CHEM, V264, P21720; SANDMANN J, 1990, ADV SEC MESS PHOSPH, V24, P176; SANDMANN J, 1991, IN PRESS J NEUROCHEM, V56; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; 1989, TRENDS PHARM SCI S, pR7	33	103	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6031	6034						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007563				2022-12-25	WOS:A1991FE37300007
J	WRIGHT, PA; WILLIAMS, ED; LEMOINE, NR; WYNFORDTHOMAS, D				WRIGHT, PA; WILLIAMS, ED; LEMOINE, NR; WYNFORDTHOMAS, D			RADIATION-ASSOCIATED AND SPONTANEOUS HUMAN THYROID CARCINOMAS SHOW A DIFFERENT PATTERN OF RAS ONCOGENE MUTATION	ONCOGENE			English	Note							ENZYMATIC AMPLIFICATION; ACTIVATION; TUMORS	Activated ras oncogenes in experimentally induced rodent tumours have been demonstrated to show specific patterns of oncogene activation which depend on the inducing agent, with H-ras activation in nitrosomethylurea (NMU) induced tumours, and K-ras activation in tumours induced by ionising radiation. We report a study of 12 radiation-associated human thyroid tumours, using polymerase chain reaction (PCR) amplification of paraffin-embedded material and allele-specific hybridisation with mutant-specific probes for the 3 ras oncogenes. Compared to 68 'spontaneous' human thyroid tumours, the radiation-associated cases show the same overall prevalence of ras mutation. However there is a significantly higher rate of K-ras mutation in radiation-associated follicular carcinomas than in 'spontaneous' follicular carcinomas (60% compared to 6%, P < 0.05), suggesting that radiation may preferentially activate k-ras in human as well as rodent tumours.			WRIGHT, PA (corresponding author), UNIV COLL CARDIFF,DEPT PATHOL,THYROID TUMOUR BIOL RES GRP,CANC RES CAMPAIGN,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							DONIACH I, 1958, BRIT MED BULL, V14, P181, DOI 10.1093/oxfordjournals.bmb.a069666; DUFFY BJ, 1950, J CLIN ENDOCRINOL, V10, P1296, DOI 10.1210/jcem-10-10-1296; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; LEMOINE NR, 1988, ONCOGENE, V3, P541; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAWEY MJ, 1987, MOL CELL BIOL, V7, P932, DOI 10.1128/MCB.7.2.932	8	75	76	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					471	473						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011403				2022-12-25	WOS:A1991FT34400019
J	CHEN, Z; KOELSCH, G; HAN, HP; WANG, XJ; LIN, XL; HARTSUCK, JA; TANG, J				CHEN, Z; KOELSCH, G; HAN, HP; WANG, XJ; LIN, XL; HARTSUCK, JA; TANG, J			RECOMBINANT RHIZOPUSPEPSINOGEN - EXPRESSION, PURIFICATION, AND ACTIVATION PROPERTIES OF RECOMBINANT RHIZOPUSPEPSINOGENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROBIAL ACID PROTEINASES; ASPARTIC PROTEINASE; RHIZOPUS-CHINENSIS; PORCINE PEPSINOGEN; INTRAMOLECULAR ACTIVATION; COMPARATIVE SPECIFICITY; SYNTHETIC PEPTIDES; CRYSTAL-STRUCTURE; ACTIVE-SITE; PROTEASE	A cDNA clone, which contained the complete rhizopuspepsin structure and the putative proregion, was placed in three different Escherichia coli expression vectors for the synthesis of rhizopuspepsinogen (Rpg). Recombinant Rpgs which were expressed in the cytosol of E. coli as inclusion bodies (cRpg and tRpg) were not active. After solubilization in 6 m urea and refolding by rapid dilution, both of these Rpgs were purified to homogeneity. The third zymogen, pRpg, which was secreted to the periplasmic space of E. coli with an omp leader, was fully active and also was purified. The expression level of pRpg was higher (over 40 mg/liter culture) than that of cRpg (about 1.5 mg/liter culture). Amino-terminal sequence analysis of the zymogens revealed that cRpg and pRpg contain 40 and 51 residues of prosequence, respectively. tRpg, which was expressed under the control of T7 promoter, was synthesized at 500 mg/liter culture and was purified at 50 mg/liter culture. This zymogen contained, in addition to 51 residues of proregion, 16 residues inherited from the expression vector construction. All of these Rpgs spontaneously converted to rhizopuspepsin in solutions of pH less than 5. Each of the conversions was associated with a change of molecular weight as monitored in sodium dodecyl sulfate-polyacrylamide electrophoresis. At least one intermediate of conversion was observed in the pH range of 2 to 3 for both the cRpg and pRpg zymogens. For pRpg and tRpg, kinetic data demonstrated that the Rpg to rhizopuspepsin conversion was accomplished by a first order, unimolecular reaction at pH 2. The first order kinetic constants in this pH at 15-degrees-C were 1.1 and 2.4 min-1 for pRpg and tRpg, respectively. The activation rate decreased as pH was raised above pH 2. At pH greater than 3.0, rhizopus-pepsin-catalyzed, second-order activation also takes place. Consequently, the recombinant Rpgs are activated by either of two cleavage mechanisms as is the case for pepsinogen. These results also support the hypothesis that Rpg is synthesized in Rhizopus chinensis as a zymogen. Rpg in the host fungus is probably activated by an acid environment of pH less than 5 in the secretory granules to become rhizopuspepsin before secretion.	OKLAHOMA MED RES FDN,PROT STUDIES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center					NIADDK NIH HHS [AM-01107] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALJANABI J, 1972, J BIOL CHEM, V247, P4628; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; BUSTIN M, 1971, J BIOL CHEM, V246, P615; DELANEY R, 1987, J BIOL CHEM, V262, P1461; ESUMI H, 1978, FEBS LETT, V86, P33, DOI 10.1016/0014-5793(78)80092-1; GRAY GL, 1986, GENE, V48, P41, DOI 10.1016/0378-1119(86)90350-1; HARTSUCK JA, 1988, 18TH LIND LANG C ELS; HEINRIKSON RL, 1989, AM J HYPERTENS, V2, P367, DOI 10.1093/ajh/2.5.367; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN XL, 1989, J BIOL CHEM, V264, P4482; Maniatis T., 1982, MOL CLONING; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7095; MCPHIE P, 1972, J BIOL CHEM, V247, P4277; MCPHIE P, 1976, ANAL BIOCHEM, V73, P258, DOI 10.1016/0003-2697(76)90166-4; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; OKA T, 1974, ARCH BIOCHEM BIOPHYS, V165, P65, DOI 10.1016/0003-9861(74)90142-8; OKA T, 1973, ARCH BIOCHEM BIOPHYS, V156, P543, DOI 10.1016/0003-9861(73)90303-2; OTSURU M, 1982, INT J BIOCHEM, V14, P925; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; SODEK J, 1970, CAN J BIOCHEM CELL B, V48, P1014, DOI 10.1139/o70-158; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUBRAMANIAN E, 1977, P NATL ACAD SCI USA, V74, P556, DOI 10.1073/pnas.74.2.556; SUGUNA K, 1987, J MOL BIOL, V196, P877, DOI 10.1016/0022-2836(87)90411-6; TAKAHASHI K, 1987, J BIOL CHEM, V262, P1468; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TONOUCHI N, 1986, NUCLEIC ACIDS RES, V14, P7557, DOI 10.1093/nar/14.19.7557; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; 1985, SAS USERS GUIDE STAT; [No title captured]	34	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11718	11725						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050673				2022-12-25	WOS:A1991FT76200048
J	ANAND, R; CONROY, WG; SCHOEPFER, R; WHITING, P; LINDSTROM, J				ANAND, R; CONROY, WG; SCHOEPFER, R; WHITING, P; LINDSTROM, J			NEURONAL NICOTINIC ACETYLCHOLINE-RECEPTORS EXPRESSED IN XENOPUS OOCYTES HAVE A PENTAMERIC QUATERNARY STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIN IMMUNOGENIC REGION; TORPEDO-CALIFORNICA; ALPHA-SUBUNIT; GENE FAMILY; FUNCTIONAL EXPRESSION; MONOCLONAL-ANTIBODIES; BRAIN; CDNA; CLONING; PURIFICATION	We have determined the subunit stoichiometry of chicken neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes by quantitation of the amount of radioactivity in individual subunits of [S-35] methionine-labeled receptors. The chicken neuronal nicotinic acetylcholine receptor appears to be a pentamer of two alpha-4 acetylcholine-binding subunits and three beta-2 structural subunits. We also show that these expressed receptors bind L-[H-3]nicotine with high affinity, are transported to the surface of the oocyte outer membrane, and cosediment on sucrose gradients with acetylcholine receptors isolated from chicken brain. Using this unique and generally applicable method of determining subunit stoichiometry of receptors expressed in oocytes, we obtained the expected (alpha-1)2-beta-1-gamma-delta stoichiometry for muscle-type acetylcholine receptors assembled from coexpression of either Torpedo alpha-1 or human alpha-1 subunits, with Torpedo beta-1, gamma, and delta-subunits.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	Salk Institute				Whiting, Paul/0000-0002-4121-1379	NINDS NIH HHS [NS11323] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011323] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANAND R, 1990, NUCLEIC ACIDS RES, V18, P4272, DOI 10.1093/nar/18.14.4272; BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BERTRAND D, 1988, NATO ASI SERIES H, V25; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; BOULTER J, 1990, J BIOL CHEM, V265, P4472; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CONROY WG, 1990, J BIOL CHEM, V265, P21642; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; DAS MK, 1989, BIOCHEM BIOPH RES CO, V165, P865, DOI 10.1016/S0006-291X(89)80046-4; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; FORNASARI D, 1990, NEUROSCI LETT, V111, P351, DOI 10.1016/0304-3940(90)90287-J; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; KARLIN A, 1983, J BIOL CHEM, V258, P6678; KUBALEK E, 1987, J CELL BIOL, V105, P9, DOI 10.1083/jcb.105.1.9; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LINDSTROM J, 1979, BIOCHEMISTRY-US, V18, P4465, DOI 10.1021/bi00588a003; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; NOMOTO H, 1986, EUR J BIOCHEM, V157, P233, DOI 10.1111/j.1432-1033.1986.tb09661.x; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; PEDERSEN SE, 1990, J BIOL CHEM, V265, P569; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SAEDI MS, 1990, FEBS LETT, V267, P55, DOI 10.1016/0014-5793(90)80286-R; SCHOEPFER R, 1988, FEBS LETT, V226, P235, DOI 10.1016/0014-5793(88)81430-3; SCHOEPFER R, 1988, NEURON, V1, P241, DOI 10.1016/0896-6273(88)90145-6; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WHITING P, 1986, J NEUROSCI, V6, P3061; WHITING P, 1987, FEBS LETT, V219, P459, DOI 10.1016/0014-5793(87)80272-7; WHITING P, 1987, FEBS LETT, V213, P55, DOI 10.1016/0014-5793(87)81464-3; WHITING P, 1987, P NATL ACAD SCI USA, V84, P595, DOI 10.1073/pnas.84.2.595; WHITING P, 1989, 19TH SOC NEUR ANN 1, V15, P496; WHITING PJ, 1991, MOL BRAIN RES, V10, P61, DOI 10.1016/0169-328X(91)90057-5; WHITING PJ, 1986, BIOCHEMISTRY-US, V25, P2082, DOI 10.1021/bi00356a037; WHITING PJ, 1988, J NEUROSCI, V8, P3395; WHITING PJ, 1987, J NEUROSCI, V7, P4005; WHITING PJ, 1987, NATURE, V327, P515, DOI 10.1038/327515a0	46	307	311	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11192	11198						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040627				2022-12-25	WOS:A1991FQ77400076
J	MILLER, RT; COUNILLON, L; PAGES, G; LIFTON, RP; SARDET, C; POUYSSEGUR, J				MILLER, RT; COUNILLON, L; PAGES, G; LIFTON, RP; SARDET, C; POUYSSEGUR, J			STRUCTURE OF THE 5'-FLANKING REGULATORY REGION AND GENE FOR THE HUMAN GROWTH FACTOR-ACTIVATABLE NA/H EXCHANGER NHE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+ ANTIPORTER GENE; H+ EXCHANGE; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; METABOLIC-ACIDOSIS; MEMBRANE-VESICLES; CLONING; CELLS; PROTEIN; DNA	The amiloride-sensitive, growth factor-activatable Na/H exchanger (NHE-1) is a ubiquitous mammalian protein that is involved in the regulation of intracellular pH and cell volume. We have determined the intron/exon boundaries and the transcription initiation sites and have characterized a portion of the 5'-flanking regulatory region of the human NHE-1 gene. The Na/H exchanger gene spans approximately 70 kilobases. The coding region is divided into 12 exons and 11 introns, one of which is 41.5 kilobases in length. The first exon contains the entire 5'-noncoding region, which is 786 bases long, and 352 bases of the coding sequence. Primer extension identified two discrete start sites for RNA polymerase. 1377 bases of the 5'-regulatory region were sequenced. The promoter/enhancer region is characterized by a TATA box, four GC boxes, two CAAT boxes, five CACCC boxes, three Ap-1 sites, a cyclic AMP response element, and four partial glucocorticoid response elements. Promoter activities of a 313- and a 1441-base pair fragment containing the TATA box were demonstrated by their ability to direct chloramphenicol acetyltransferase expression when transiently expressed in fibroblasts.	BRIGHAM & WOMENS HOSP,DEPT ENDOCRINE HYPERTENS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV NICE,CNRS,CTR BIOCHIM,F-06034 NICE,FRANCE	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	MILLER, RT (corresponding author), UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Pages, Gilles/N-7135-2017		NIDDK NIH HHS [2 R01 DK39298-04A1, 5 R29 DK41726-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041726, R01DK039298] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ARONSON PS, 1986, NA H EXCHANGE INTRAC; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERGER SL, 1987, METHOD ENZYMOL, V152, P44; BIDET M, 1987, AM J PHYSIOL, V253, pF945, DOI 10.1152/ajprenal.1987.253.5.F945; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DUDLEY C, 1990, KIDNEY INT, V37, P384; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GRINSTEIN S, 1988, NAH EXCHANGE; HARRIS RC, 1984, J CLIN INVEST, V74, P1979, DOI 10.1172/JCI111619; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HILDEBRANDT F, 1990, KIDNEY INT, V37, P539; HORIE S, 1990, P NATL ACAD SCI USA, V87, P4742, DOI 10.1073/pnas.87.12.4742; IGARASHI P, 1990, J AM SOC NEPHROL, V1, P721; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KINSELLA J, 1984, P NATL ACAD SCI-BIOL, V81, P630, DOI 10.1073/pnas.81.2.630; KINSELLA J, 1985, P NATL ACAD SCI USA, V82, P3606, DOI 10.1073/pnas.82.11.3606; KINSELLA JL, 1985, AM J PHYSIOL, V248, pF233, DOI 10.1152/ajprenal.1985.248.2.F233; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAPF R, 1991, J CLIN INVEST, V87, P747, DOI 10.1172/JCI115057; LEWIN B, 1990, GENES, V4; LIFTON RP, 1991, HYPERTENSION, V17, P8, DOI 10.1161/01.HYP.17.1.8; LIFTON RP, 1990, GENOMICS, V7, P131, DOI 10.1016/0888-7543(90)90530-8; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATTEI MG, 1988, CYTOGENET CELL GENET, V48, P6, DOI 10.1159/000132575; MILLER RT, 1987, J BIOL CHEM, V262, P9115; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOE O, 1990, J AM SOC NEPHROL, V1, P655; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; PEARCE D, 1990, KIDNEY INT, V37, P233; POUYSSEGUR J, 1990, GASTROENTEROLOGY, V99, P565; PREISIG PA, 1988, J CLIN INVEST, V82, P1445, DOI 10.1172/JCI113750; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAIBAUD O, 1990, NATURE, V344, P204, DOI 10.1038/344204a0; RAO GN, 1990, J BIOL CHEM, V265, P19393; REILLY RF, 1990, J AM SOC NEPHROL, V1, P743; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J, 1989, MOL CLONING LABORATO; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; STROUD RM, 1985, ANNU REV CELL BIOL, V1, P317, DOI 10.1146/annurev.cb.01.110185.001533; TAKAICHI K, 1990, J AM SOC NEPHROL, V1, P745; TSE C M, 1990, Gastroenterology, V98, pA208; WAKABAYASHI S, 1991, J CELL BIOCHEM, V15, P174; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879	52	77	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10813	10819						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040601				2022-12-25	WOS:A1991FQ77400020
J	TOKUI, T; INAGAKI, M; NISHIZAWA, K; YATANI, R; KUSAGAWA, M; AJIRO, K; NISHIMOTO, Y; DATE, T; MATSUKAGE, A				TOKUI, T; INAGAKI, M; NISHIZAWA, K; YATANI, R; KUSAGAWA, M; AJIRO, K; NISHIMOTO, Y; DATE, T; MATSUKAGE, A			INACTIVATION OF DNA-POLYMERASE BETA BY INVITRO PHOSPHORYLATION WITH PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; IMMUNOCHEMICAL CHARACTERIZATION; GENE; EXPRESSION; BINDING; REQUIREMENTS; INVOLVEMENT; RECOGNITION; ACTIVATION; PROMOTER	The M(r) = 38,300 polypeptide of the purified recombinant rat DNA polymerase-beta served as an excellent substrate for protein kinase C (PKC) in vitro but not for the catalytic subunit of cAMP-dependent protein kinase. The phosphorylation by PKC resulted in inactivation of DNA polymerase beta-activity, and recovery was achieved by dephosphorylation with alkaline phosphatase. Since the phosphorylated DNA polymerase-beta was retained with use of a single-stranded DNA-cellulose column, inactivation might occur at a site different from that for the DNA binding. Amino acid sequence analysis of the phosphopeptides revealed that the phosphorylated sites were 2 serine residues at positions 44 and 55 from the NH2 terminus, either or both of which might be involved in the catalytic activity of DNA polymerase-beta. Thus, the inactivation of the DNA repair enzyme, DNA polymerase-beta, by PKC may be an important process in the modification of DNA metabolism in the nucleus through signal transduction processes.	AICHI CANC CTR,RES INST,EXPTL RADIOL LABS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; KANAZAWA MED UNIV,INST MED SCI,KAHOKU,ISHIKAWA 92002,JAPAN; MIE UNIV,SCH MED,DEPT PATHOL,TSU,MIE 514,JAPAN; MIE UNIV,SCH MED,DEPT THORAC & CARDIOVASC SURG,TSU,MIE 514,JAPAN	Aichi Cancer Center; Kanazawa Medical University; Mie University; Mie University			Inagaki, Masaki/B-9920-2016					Beavo J A, 1974, Methods Enzymol, V38, P299; CAPITANI S, 1987, BIOCHEM BIOPH RES CO, V142, P367, DOI 10.1016/0006-291X(87)90283-X; DATE T, 1990, BIOCHEMISTRY-US, V29, P5027, DOI 10.1021/bi00473a005; DATE T, 1988, BIOCHEMISTRY-US, V27, P2983, DOI 10.1021/bi00408a048; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; FRY M, 1983, ENZYMES NUCLEIC ACID, P39; GIRARD PR, 1985, P NATL ACAD SCI USA, V82, P3030, DOI 10.1073/pnas.82.9.3030; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; INAGAKI M, 1987, ARCH BIOCHEM BIOPHYS, V254, P136, DOI 10.1016/0003-9861(87)90089-0; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KRAFT AS, 1987, BIOCHEM BIOPH RES CO, V144, P393, DOI 10.1016/S0006-291X(87)80523-5; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MISRA UK, 1987, BIOCHEM BIOPH RES CO, V145, P760, DOI 10.1016/0006-291X(87)91030-8; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; POMMIER Y, 1990, J BIOL CHEM, V265, P9418; SPANOS A, 1981, NUCLEIC ACIDS RES, V9, P1825, DOI 10.1093/nar/9.8.1825; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YAMAGUCHI M, 1987, MOL CELL BIOL, V7, P2012, DOI 10.1128/MCB.7.5.2012; YAMAGUCHI M, 1989, J CELL PHYSIOL, V141, P431, DOI 10.1002/jcp.1041410225; YAMAGUCHI M, 1982, J BIOL CHEM, V257, P3932; YAMAGUCHI M, 1989, J BIOCHEM-TOKYO, V105, P79, DOI 10.1093/oxfordjournals.jbchem.a122623; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773	31	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10820	10824						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040602				2022-12-25	WOS:A1991FQ77400021
J	LANZA, F; WOLF, D; FOX, CF; KIEFFER, N; SEYER, JM; FRIED, VA; COUGHLIN, SR; PHILLIPS, DR; JENNINGS, LK				LANZA, F; WOLF, D; FOX, CF; KIEFFER, N; SEYER, JM; FRIED, VA; COUGHLIN, SR; PHILLIPS, DR; JENNINGS, LK			CDNA CLONING AND EXPRESSION OF PLATELET P24/CD9 - EVIDENCE FOR A NEW FAMILY OF MULTIPLE MEMBRANE-SPANNING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY BA-2; TUMOR-ASSOCIATED ANTIGEN; TRITON X-114; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR-CLONING; PHASE-SEPARATION; FIXED TISSUE; CD9 ANTIGEN; RECEPTOR; P24	This study was designed to clone, sequence, and express the full-length cDNA for the human platelet p24/CD9 antigen. A 1.3-kilobase cDNA clone was identified that has an open reading frame encoding a mature protein of 228 amino acids (approximately 25,400 Da) containing 10 cysteine residues and four putative transmembrane domains. The identity of the clone was confirmed by: (i) its predicted size, (ii) identity to four peptide sequences from the isolated protein including the NH2 terminus, and (iii) expression of the isolated clone in Xenopus oocytes and Chinese hamster ovary cells. p24/CD9 has sequence identity (24-34%) to four other cell-surface proteins: ME491, a melanoma antigen; CO-029, a carcinoma antigen; CD37, a leukocyte antigen; and SM23, an antigen of the parasitic helminth Schistosoma mansoni. The five proteins have a similar number of amino acids and are characterized by the presence of four putative transmembrane domains. These data indicate the presence of a new family of surface antigens that may function in cellular activation and differentiation.	UNIV TENNESSEE, CTR HLTH SCI, MEMPHIS, TN 38163 USA; VET ADM MED CTR, MEMPHIS, TN 38104 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; St Jude Children's Research Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LANZA, F (corresponding author), COR THERAPEUT INC, S SAN FRANCISCO, CA 94080 USA.		Lanza, Francois/H-9252-2016	Lanza, Francois/0000-0002-5802-4748	NHLBI NIH HHS [HL 28947, HL 32254, HL 38171] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028947, R29HL038171, R37HL028947, R01HL032254] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINSON B, 1984, CANCER RES, V44, P2577; ATKINSON B, 1985, HYBRIDOMA, V4, P243, DOI 10.1089/hyb.1985.4.243; AZZARONE B, 1985, J CELL PHYSIOL, V125, P420, DOI 10.1002/jcp.1041250309; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOUCHEIX C, 1983, FEBS LETT, V161, P289, DOI 10.1016/0014-5793(83)81027-8; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BOUCHEIX C, 1988, NOUV REV FR HEMATOL, V30, P201; BOUCHEIX C, 1987, LEUCOCYTE TYPING, V3, P780; BRUZZONE R, 1990, J CELL BIOL, V111, P154; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; CLEMETSON KJ, 1984, BIOCHIM BIOPHYS ACTA, V778, P463, DOI 10.1016/0005-2736(84)90395-X; COLEMAN A, 1984, TRANSCRIPTION TRANSL, P271; ENOUF J, 1985, FEBS LETT, V183, P403, DOI 10.1016/0014-5793(85)80819-X; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GORMAN DJ, 1985, NOUV REV FR HEMATOL, V27, P255; GREAVES MF, 1980, BLOOD, V56, P1141; HATO T, 1990, BLOOD, V75, P1087; HERCEND T, 1981, CELL IMMUNOL, V64, P192, DOI 10.1016/0008-8749(81)90470-6; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGASHIHARA M, 1985, BLOOD, V65, P382; HOTTA H, 1988, CANCER RES, V48, P2955; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; JENNINGS LK, 1985, BLOOD, V65, P1112; JENNINGS LK, 1989, BLOOD, V74, P169; JONES NH, 1982, LEUKEMIA RES, V6, P449, DOI 10.1016/0145-2126(82)90002-9; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KERSEY JH, 1981, J EXP MED, V153, P726, DOI 10.1084/jem.153.3.726; KHANDURI U, 1986, THROMB HAEMOSTASIS, V55, P98; KOMADA Y, 1983, LEUKEMIA RES, V7, P487, DOI 10.1016/0145-2126(83)90044-9; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEBIEN T, 1982, LEUKEMIA RES, V6, P299, DOI 10.1016/0145-2126(82)90091-1; LEBIEN TW, 1985, MOL IMMUNOL, V22, P1185; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLER JL, 1986, BLOOD, V68, P743; NEWMAN PJ, 1982, THROMB RES, V27, P221, DOI 10.1016/0049-3848(82)90202-X; NEWMAN RA, 1982, BIOCHIM BIOPHYS ACTA, V701, P318, DOI 10.1016/0167-4838(82)90234-5; PHILLIPS DR, 1972, BIOCHEMISTRY-US, V11, P4582, DOI 10.1021/bi00774a025; RENDU F, 1987, BIOCHEM BIOPH RES CO, V146, P1397, DOI 10.1016/0006-291X(87)90805-9; ROSS AH, 1985, ARCH BIOCHEM BIOPHYS, V242, P540, DOI 10.1016/0003-9861(85)90241-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEHAFER J, 1984, INT J CANCER, V34, P821, DOI 10.1002/ijc.2910340613; SEEHAFER JG, 1988, BIOCHIM BIOPHYS ACTA, V952, P92, DOI 10.1016/0167-4838(88)90105-7; SEEHAFER JG, 1988, BIOCHIM BIOPHYS ACTA, V957, P399, DOI 10.1016/0167-4838(88)90231-2; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WORTHINGTON RE, 1990, BRIT J HAEMATOL, V74, P216, DOI 10.1111/j.1365-2141.1990.tb02568.x; WRIGHT MD, 1990, J IMMUNOL, V144, P3195; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZOLA H, 1984, DIS MARKERS, V2, P399	60	96	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10638	10645						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037603				2022-12-25	WOS:A1991FP08600095
J	ABE, S; ARAKI, S; SATAKE, M; FUJIWARA, N; KON, K; ANDO, S				ABE, S; ARAKI, S; SATAKE, M; FUJIWARA, N; KON, K; ANDO, S			STRUCTURE OF TRIPHOSPHONOGLYCOSPHINGOLIPID CONTAINING N-ACETYLGALACTOSAMINE 6-O-2-AMINOETHYLPHOSPHONATE IN THE NERVOUS-SYSTEM OF APLYSIA-KURODAI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA HARE; PHOSPHONOGLYCOSPHINGOLIPIDS; GLYCOSPHINGOLIPIDS; LOCALIZATION; SKIN	A phosphonoglycosphingolipid, named F-21, was found in the nervous system of Aplysia kurodai by two-dimensional thin-layer chromatography (Abe, S., Araki, S., and Satake, M. (1986) Biomed. Res. (Tokyo)7, 47-51). F-21 was isolated from the nervous tissue of Aplysia in this study, and its chemical structure was characterized as follows, where 2-AEP is 2-amino-ethylphosphonate. [GRAPHICS] The major aliphatic components of the ceramide portion were palmitic acid (75%), stearic acid (22%), octadeca-4-sphingenine (43%), and anteisononadeca-4-sphingenine (54%). Some information on the steric interactions in the sugar moiety was obtained by NMR spectroscopy. The ring protons of the internal galactose, H1, H3, and H4 and H3 of the side chain galactose were shifted, as compared to the corresponding protons of dephosphonylated F-21. This may indicate the interactions between the 2-AEP residue of N-acetylgalactosamine and the internal galactose and between the N-acetyl group of N-acetylgalactosamine and the side chain galactose, implying a sterically restricted and unique structure that may relate to some biological functions of F-21.	NIIGATA UNIV,SCH MED,DEPT ANESTHESIOL,NIIGATA 951,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT MEMBRANE BIOCHEM,TOKYO 173,JAPAN	Niigata University; Tokyo Metropolitan Institute of Gerontology	ABE, S (corresponding author), NIIGATA UNIV,BRAIN RES INST,DEPT NEUROCHEM,ASAHIMACHI 1,NIIGATA 951,JAPAN.		ANDO, Shinji/D-6280-2011	ANDO, Shinji/0000-0002-3508-035X				ABE S, 1986, BIOMED RES-TOKYO, V7, P47, DOI 10.2220/biomedres.7.47; ABE S, 1988, J BIOCHEM-TOKYO, V104, P220, DOI 10.1093/oxfordjournals.jbchem.a122446; ABE S, 1985, BRAIN RES, V327, P259, DOI 10.1016/0006-8993(85)91519-7; ARAKI S, 1989, J BIOL CHEM, V264, P19922; ARAKI S, 1986, J BIOL CHEM, V261, P5138; ARAKI S, 1987, J BIOL CHEM, V262, P14141; ARAKI S, 1987, J BIOCHEM-TOKYO, V101, P145, DOI 10.1093/oxfordjournals.jbchem.a121885; CARTER HE, 1967, J LIPID RES, V8, P391; DITTMER JC, 1964, J LIPID RES, V5, P126; GARDELL S, 1953, ACTA CHEM SCAND, V7, P207, DOI 10.3891/acta.chem.scand.07-0207; GASA S, 1983, J LIPID RES, V24, P174; King EJ, 1932, BIOCHEM J, V26, P292, DOI 10.1042/bj0260292; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; PARKKINEN J, 1985, J BIOL CHEM, V260, P971; ROE JH, 1955, J BIOL CHEM, V212, P335; STILLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464; SUGITA M, 1989, J BIOL CHEM, V264, P15028; TAI T, 1975, J BIOCHEM-TOKYO, V78, P679, DOI 10.1093/oxfordjournals.jbchem.a130955; WATANABE Y, 1989, J BIOCHEM-TOKYO, V106, P972, DOI 10.1093/oxfordjournals.jbchem.a122984	19	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9939	9943						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033079				2022-12-25	WOS:A1991FM45900089
J	OGAMI, K; KARDASSIS, D; CLADARAS, C; ZANNIS, VI				OGAMI, K; KARDASSIS, D; CLADARAS, C; ZANNIS, VI			PURIFICATION AND CHARACTERIZATION OF A HEAT-STABLE NUCLEAR FACTOR CIIIB1 INVOLVED IN THE REGULATION OF THE HUMAN APOC-III GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; DNA-BINDING PROTEINS; IMMUNOGLOBULIN PROMOTER INVITRO; LOW-DENSITY LIPOPROTEINS; MESSENGER-RNA; INTESTINAL TRANSCRIPTION; ACTIVATES TRANSCRIPTION; ALANINE APOLIPOPROTEIN; HUMAN PLASMA; B GENE	The apoC-III promoter region -86 to -74 is recognized by two nuclear factors designated CIIIB1 and CIIIB2 (NF-BA1) which are both activators of apoC-III gene transcription (Ogami, K., Hadzopoulou-Cladaras, M., Cladaras, C., and Zannis, V. I. (1990) J. Biol. Chem. 265, 9808-9815). In this communication we report the purification of factor CIIIB1 from rat liver nuclear extracts. The purification procedure included anion- and cation-exchange chromatography, DNA sequence-specific affinity chromatography, and heat treatment at 85-degrees-C for 5 min. The ligand used for affinity chromatography was a mutated apoC-III -90 to -73 promoter sequence which binds only the CIIIB1 factor. The purified protein was identified as a polypeptide of M(r) 41,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and photoaffinity cross-linking. The binding site of CIIIB1, defined by DNase I footprinting and methylation interference assays, contains the octameric motif CAGGTGAC. Nucleotide substitutions within this sequence abolished the binding of the purified factor. DNase I footprinting analysis showed that purified CIIIB1 protein protects the apoA-II promoter region -65 to -48 which contains an identical octameric CAGGTGAC motif in the antisense strand suggesting that CIIIB1 may also play a role in apoA-II gene regulation.	BOSTON UNIV,MED CTR,HOUSMAN MED RES CTR,INST CARDIOVASC,DEPT BIOCHEM,MOLEC GENET SECT,BOSTON,MA 02118	Boston University	OGAMI, K (corresponding author), BOSTON UNIV,MED CTR,HOUSMAN MED RES CTR,INST CARDIOVASC,DEPT MED,MOLEC GENET SECT,BOSTON,MA 02118, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043909, R01HL033952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43909, HL33952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BREWER HB, 1974, J BIOL CHEM, V249, P4975; BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; CHAMBAZ J, 1991, IN PRESS J BIOL CHEM; CHEUNG P, 1984, P NATL ACAD SCI-BIOL, V81, P508, DOI 10.1073/pnas.81.2.508; CILIBERTO G, 1985, CELL, V41, P531, DOI 10.1016/S0092-8674(85)80026-X; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Herbert P. N., 1982, METABOLIC BASIS INHE, P589; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KARATHANASIS SK, 1985, J LIPID RES, V26, P451; KARDASSIS D, 1990, J BIOL CHEM, V265, P21733; KARDASSIS D, 1990, MOL CELL BIOL, V10, P2653, DOI 10.1128/MCB.10.6.2653; KRAUSS RM, 1973, CIRC RES, V33, P403, DOI 10.1161/01.RES.33.4.403; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LEFF T, 1989, J BIOL CHEM, V264, P16132; LENICH C, 1988, J LIPID RES, V29, P755; LUCERO MA, 1989, NUCLEIC ACIDS RES, V17, P2283, DOI 10.1093/nar/17.6.2283; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; OGAMI K, 1990, J BIOL CHEM, V265, P9808; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PROTTER AA, 1984, DNA-J MOLEC CELL BIO, V3, P449, DOI 10.1089/dna.1.1984.3.449; QUARFORDT SH, 1982, J BIOL CHEM, V257, P4642; REUE K, 1988, J BIOL CHEM, V263, P6857; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SHARPE CR, 1984, NUCLEIC ACIDS RES, V12, P3917, DOI 10.1093/nar/12.9.3917; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; SHULMAN RS, 1974, J BIOL CHEM, V249, P4969; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; WINDLER E, 1980, J BIOL CHEM, V255, P5475; WU AL, 1979, J BIOL CHEM, V254, P7316; ZANNIS VI, 1980, J BIOL CHEM, V255, P1759; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	48	28	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9640	9646						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033057				2022-12-25	WOS:A1991FM45900048
J	POLOSA, PL; ATTARDI, G				POLOSA, PL; ATTARDI, G			DISTINCTIVE PATTERN AND TRANSLATIONAL CONTROL OF MITOCHONDRIAL PROTEIN-SYNTHESIS IN RAT-BRAIN SYNAPTIC ENDINGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH DEHYDROGENASE; HELA-CELLS; DENATURING CONDITIONS; GENOME; RNAS; DNA; ELECTROPHORESIS; SYNAPTOGENESIS; SEQUENCE; PRODUCTS	Mitochondrial gene expression has been investigated in synaptic endings from rat cerebral cortex isolated at various stages during the postnatal development and maturation of the animal. The pattern of the mitochondrial translation products labeled in vitro in rat brain synaptosomes revealed some distinctive features when compared with the pattern observed in a rat fibroblast cell line, the most remarkable being the apparent absence of labeling of the ND5 product. This absence contrasted with the presence in synaptosomes of an amount of ND5 mRNA comparable with that found in the rat fibroblast cell line. The rate of mitochondrial protein synthesis per unit amount of mtDNA inbrain synaptosomes showed a characteristic reproducible burst at 10-13 days after birth, thereafter declining sharply in the 3rd week to reach a level that remained constant over a 2-year period. The postnatal burst of mitochondrial protein synthesis coincided with a sharp increase in cytochrome c oxidase activity, pointing to a phase of rapid assembly of respiratory complexes. A comparison of the levels of mitochondrial mRNAs with the corresponding rates of protein synthesis during the animal development and maturation showed a lack of correlation. These observations, together with the apparent lack of translation of the ND5 mRNA, indicate that translational control plays a major role in the regulation of gene expression in rat brain synaptic mitochondria.			POLOSA, PL (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.		Loguercio Polosa, Paola/I-5633-2012		NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMALRIC F, 1978, J MOL BIOL, V118, P1, DOI 10.1016/0022-2836(78)90241-3; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1986, BIOESSAYS, V5, P34, DOI 10.1002/bies.950050111; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; ATTARDI G, 1989, ADV MYOCHEM, V2, P55; BLOOM FE, 1972, STRUCTURE FUNCTION S, P101; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTATORE P, 1984, BIOCHEM BIOPH RES CO, V118, P284, DOI 10.1016/0006-291X(84)91098-2; CANTATORE P, 1987, GENE, V53, P41, DOI 10.1016/0378-1119(87)90091-6; CANTATORE P, 1987, FEBS LETT, V213, P144, DOI 10.1016/0014-5793(87)81480-1; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; CHOMYN A, 1988, J BIOL CHEM, V263, P16395; CHOMYN A, 1987, CYTOCHROME SYSTEMS M, P145; CHOMYN A, 1990, STRUCTURE FUNCTION B, P179; CLEETER MWJ, 1985, BIOCHEM J, V230, P739, DOI 10.1042/bj2300739; COSTANTINO P, 1977, J BIOL CHEM, V252, P1702; ENGLAND JM, 1976, J NEUROCHEM, V27, P895, DOI 10.1111/j.1471-4159.1976.tb05152.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOX TD, 1986, TRENDS GENET, V2, P97, DOI 10.1016/0168-9525(86)90192-7; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; JONES DG, 1979, EXP NEUROL, V64, P245, DOI 10.1016/0014-4886(79)90266-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERMAN M, 1970, BIOCHEM BIOPH RES CO, V40, P1492, DOI 10.1016/0006-291X(70)90037-9; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MASON TL, 1973, J BIOL CHEM, V248, P1346; MILSTEIN JM, 1968, J NEUROCHEM, V15, P411, DOI 10.1111/j.1471-4159.1968.tb11627.x; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; RENIS M, 1989, J NEUROCHEM, V52, P750, DOI 10.1111/j.1471-4159.1989.tb02518.x; STEWARD O, 1986, J NEUROSCI, V6, P412; WEBER ED, 1980, BRAIN RES, V185, P17, DOI 10.1016/0006-8993(80)90667-8	34	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					10011	10017						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033035				2022-12-25	WOS:A1991FM45900100
J	KALLESTAD, JC; SHOYAB, M; LINSLEY, PS				KALLESTAD, JC; SHOYAB, M; LINSLEY, PS			DISULFIDE BOND ASSIGNMENT AND IDENTIFICATION OF REGIONS REQUIRED FOR FUNCTIONAL-ACTIVITY OF ONCOSTATIN-M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-REGULATOR; 3-DIMENSIONAL STRUCTURE; LEUKOCYTE INTERFERON; SECONDARY STRUCTURE; RECEPTOR; INTERLEUKIN-2; RESOLUTION; CYTOKINES; CLEAVAGE; PROTEINS	Oncostatin M is a polypeptide cytokine having unique structure and diverse biological activities, including the ability to inhibit growth of certain cultured tumor cells. Here we have determined the disulfide bonding pattern of recombinant oncostatin M and have used site-directed mutagenesis to identify regions of this molecule necessary for receptor binding and growth inhibitory activities. Two intramolecular disulfide bonds, C6-C127 and C49-C167, were identified in recombinant oncostatin M. Analysis of mutations at each of the five cysteines in oncostatin M indicated that mutants C49S and C167S were inactive (< 1/10 wild type activity) in growth inhibitory assays and radioreceptor assays. Carboxyl-terminal deletion mutations terminating at S185 and beyond were active, but further shortening abolished activity in both assays. Two deletion mutants proximal to C49 (DELTA-22-36 and DELTA-44-47) and insertion mutant GAG77 also were inactive. One deletion mutant, DELTA-87-90, had significantly (approximately 3-fold) increased activities in both growth inhibitory assays and radioreceptor assays. A potential amphiphilic domain was identified beginning at C167 and extending toward the carboxyl terminus. Two mutants having altered hydrophobic residues within this domain (F176G and F184G) were inactive, suggesting that these residues are required for proper conformation of the receptor binding site. Taken together, these results indicate that biological activity of oncostatin M requires discontinuous regions of the molecule, including residues near the essential disulfide bond, C49-C167, and within a putative amphiphilic helix at the carboxyl terminus. Oncostatin M thus belongs to a growing family of cytokines whose interactions with their respective receptors are mediated in part by known or predicted carboxyl-terminal amphiphilic helices.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DIV ONCOGEN, SEATTLE, WA 98121 USA	Bristol-Myers Squibb								BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BROWN TJ, 1990, UCLA SYM BI, V131, P195; BROWN TJ, 1987, J IMMUNOL, V139, P2977; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEMAEYER E, 1988, INTERFERONS OTHER RE, P14; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDGRAF B, 1989, J BIOL CHEM, V264, P816; LINSLEY PS, 1990, MOL CELL BIOL, V10, P1882, DOI 10.1128/MCB.10.5.1882; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; WETZEL R, 1981, NATURE, V289, P606, DOI 10.1038/289606a0; WETZEL R, 1983, BIOL INTERFERON SYST, P101; WILLIAMS RW, 1985, J BIOL CHEM, V260, P3937; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	25	32	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8940	8945						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026606				2022-12-25	WOS:A1991FM03800045
J	MARGULIS, BA; WELSH, M				MARGULIS, BA; WELSH, M			ANALYSIS OF PROTEIN-BINDING TO HEAT-SHOCK PROTEIN-70 IN PANCREATIC-ISLET CELLS EXPOSED TO ELEVATED-TEMPERATURES OR INTERLEUKIN-1-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOATING ATPASE; PURIFICATION; CALMODULIN; FAMILY; HSP70; ACID	To elucidate a role for heat shock proteins in islet function, isolated pancreatic islets were labeled with [S-35]methionine after control, heat shock, or interleukin 1-beta (IL-1-beta) treatment, extracted in the presence of detergent, and then passed over affinity columns with antibodies against heat shock protein 70 (hsp 70), hsp 70 itself, or ATP conjugated to the columns. In control or IL-1-beta-treated islets, the antibody column efficiently absorbed hsp 70 together with two other proteins of molecular masses 46 and 53 kDa. In extracts from heat-shocked cells, the binding of cellularly synthesized hsp 70 to the antibody column was inefficient but improved by the addition of unlabeled partially purified hsp 70 to the extracts. When assessing the binding of proteins in the extracts to the hsp 70 column, hsp 70 and the 46- and 53-kDa proteins among others all bound to the column. No differences in the patterns of binding to the hsp 70 column between extracts from the different islet exposures were noticed. The 46-kDa protein was identified as actin by immunoblot analysis. ATP-agarose column chromatography revealed a pattern of binding similar to that of the hsp 70 column. It is concluded that hsp 70 contains at least two functional domains, one adjacent to the epitope recognized by the antibody and active in restoring cellular function after heat shock, whereas the other has the ability to bind the 46- and 53-kDa and possibly other proteins. Furthermore, the stress induced by heat shock differs significantly from that after IL-1-beta treatment with respect to the functional behavior of hsp 70.	UNIV UPPSALA,CTR BIOMED,DEPT MED CELL BIOL,S-75123 UPPSALA,SWEDEN	Uppsala University				Welsh, Michael/0000-0002-5467-9755				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CLARK BD, 1986, BIOCHEM BIOPH RES CO, V139, P974, DOI 10.1016/S0006-291X(86)80273-X; EIZIRIK DL, 1990, ENDOCRINOLOGY, V127, P2290, DOI 10.1210/endo-127-5-2290; EIZIRIK DL, 1988, DIABETES, V37, P916, DOI 10.2337/diabetes.37.7.916; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GUERRIERO V, 1989, J CELL PHYSIOL, V140, P471, DOI 10.1002/jcp.1041400310; GUIDON PT, 1986, BIOCHEMISTRY-US, V25, P3231, DOI 10.1021/bi00359a023; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHANGUE NB, 1984, EMBO J, V3, P1871, DOI 10.1002/j.1460-2075.1984.tb02061.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MILARSKI KL, 1989, J CELL BIOL, V108, P413, DOI 10.1083/jcb.108.2.413; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELSH M, 1988, J MOL ENDOCRINOL, V1, P27, DOI 10.1677/jme.0.0010027	20	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9295	9298						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026626				2022-12-25	WOS:A1991FM03800094
J	ROTHENBERG, PL; LANE, WS; KARASIK, A; BACKER, J; WHITE, M; KAHN, CR				ROTHENBERG, PL; LANE, WS; KARASIK, A; BACKER, J; WHITE, M; KAHN, CR			PURIFICATION AND PARTIAL SEQUENCE-ANALYSIS OF PP185, THE MAJOR CELLULAR SUBSTRATE OF THE INSULIN-RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; SODIUM DODECYL-SULFATE; DIMENSIONAL GEL-ELECTROPHORESIS; POLYACRYLAMIDE GELS; PROTEIN-KINASE; RAT ADIPOCYTES; ENDOGENOUS SUBSTRATE; INTACT-CELLS; STIMULATES PHOSPHORYLATION; AFFINITY-CHROMATOGRAPHY	Insulin stimulates the tyrosine phosphorylation of a 185-kDa putative cytosolic substrate protein (pp185) in diverse cell types. After intravenous insulin infusion into the live intact rat, pp185 and the 95-kDa insulin receptor beta-subunit were the major proteins that tyrosine phosphorylated in liver, skeletal muscle, and adipose tissue. Both proteins were maximally phosphorylated within 30 s andboth increased in phosphotyrosine content in parallel with increasing insulin dose. However, pp185 tyrosine phosphorylation was transient, with almost complete dephosphorylation within 2-3 min despite continued insulin stimulation. To identify pp185 directly, we purified pp185 from insulin-stimulated rat liver, using a denaturation-based extraction procedure that blocks endogenous protein phosphatases and thus allows a high yield, single step isolation of phosphotyrosyl proteins by anti-phosphotyrosine antibody immunoaffinity absorption. From 50 rat livers, 50-100 pmol of pp185 was isolated. Edman degradation of seven internal tryptic peptide fragments of pp185 yielded novel amino acid sequences, indicating that pp185 is a new protein. Antipeptide antibodies were raised which specifically recognize a single, 185-kDa insulin-stimulated phosphotyrosyl protein in liver, skeletal muscle, adipose tissue, and several cultured cell lines. These results indicate that pp185 is expressed in a variety of insulin-responsive tissues is the major protein rapidly tyrosine phosphorylated under physiological conditions in the intact animal, and also provide a route for cloning the pp185 gene and elucidating the function of pp185 in insulin signal transduction.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIBET CTR,DIV RES,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,DEPT BIOL,PROT MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AVRUCH J, 1982, J BIOL CHEM, V257, P5162; BEGUINOT F, 1988, BIOCHEMISTRY-US, V27, P3222, DOI 10.1021/bi00409a015; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOSCHETTI E, 1985, AFFINITY CHROMATOGR, P11; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JL, 1976, J BIOL CHEM, V251, P1009; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLARKE S, 1981, BIOCHIM BIOPHYS ACTA, V670, P195, DOI 10.1016/0005-2795(81)90009-X; CONDORELLI G, 1989, J BIOL CHEM, V264, P12633; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CRETTAZ M, 1984, DIABETES, V33, P477, DOI 10.2337/diabetes.33.5.477; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P1277, DOI 10.1073/pnas.69.5.1277; DELVECCHIO RL, 1989, BIOCHIM BIOPHYS ACTA, V986, P41, DOI 10.1016/0005-2736(89)90270-8; DESCHATRETTE J, 1979, SOMAT CELL GENET, V5, P697, DOI 10.1007/BF01542636; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEHLMANN M, 1985, P NATL ACAD SCI USA, V82, P8634, DOI 10.1073/pnas.82.24.8634; FREYCHET P, 1971, P NATL ACAD SCI USA, V68, P1833, DOI 10.1073/pnas.68.8.1833; FRIEDENBERG GR, 1985, J BIOL CHEM, V260, P12444; GORDON J, 1958, J EXP MED, V108, P37, DOI 10.1084/jem.108.1.37; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HARLOW E, 1988, ANTIBODIES LABORATOR, P302; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HELMERHORST E, 1980, ANAL BIOCHEM, V104, P130, DOI 10.1016/0003-2697(80)90287-0; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HUNTER JB, 1987, ANAL BIOCHEM, V164, P430, DOI 10.1016/0003-2697(87)90515-X; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1974, J BIOL CHEM, V249, P2249; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, NATURE, V298, P67; KATHURIA S, 1986, P NATL ACAD SCI USA, V83, P8570, DOI 10.1073/pnas.83.22.8570; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KOWALSKI A, 1983, BIOCHEM BIOPH RES CO, V117, P885, DOI 10.1016/0006-291X(83)91679-0; LACKS SA, 1979, ANAL BIOCHEM, V100, P357, DOI 10.1016/0003-2697(79)90241-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; LI KW, 1989, ANAL BIOCHEM, V182, P44, DOI 10.1016/0003-2697(89)90715-X; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; Reichlin M, 1980, Methods Enzymol, V70, P159; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; ROTH RA, 1990, HDB EXPT PHARM INSUL, V92, P169; ROTHENBERG P, 1990, HDB EXPT PHARM INSUL, V92, P209; SCHIMKE RT, 1962, J BIOL CHEM, V237, P1921; SCHIMKE RT, 1963, J BIOL CHEM, V260, P12444; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; SUZUKI H, 1988, ANAL BIOCHEM, V172, P259, DOI 10.1016/0003-2697(88)90440-X; SWEET LJ, 1987, FASEB J, V1, P55, DOI 10.1096/fasebj.1.1.3038645; SZEWCZYK B, 1985, ANAL BIOCHEM, V150, P403, DOI 10.1016/0003-2697(85)90528-7; TAIRA M, 1989, SCIENCE, V245, P63, DOI 10.1126/science.2544997; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIDT DG, 1959, CIRC RES, V7, P759, DOI 10.1161/01.RES.7.5.759; Weber K., 1975, PROTEINS, VI, P179; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; ZAMAN Z, 1979, ANAL BIOCHEM, V100, P64, DOI 10.1016/0003-2697(79)90110-6	88	206	211	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8302	8311						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022647				2022-12-25	WOS:A1991FK44100055
J	ROBERTS, WL; DOCTOR, BP; FOSTER, JD; ROSENBERRY, TL				ROBERTS, WL; DOCTOR, BP; FOSTER, JD; ROSENBERRY, TL			BOVINE BRAIN ACETYLCHOLINESTERASE PRIMARY SEQUENCE INVOLVED IN INTERSUBUNIT DISULFIDE LINKAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; TORPEDO ELECTRIC ORGAN; STRUCTURAL CHARACTERIZATION; MOLECULAR-FORMS; CHOLINESTERASE; PROTEINS; IDENTIFICATION; DOMAIN; ANCHOR; BONDS	Three distinct classes of membrane-bound acetylcholinesterases (AChEs) have been identified. A12 AChE is composed of 12 catalytic subunits that are linked to noncatalytic collagen-like subunits through intersubunit disulfide bonds. G2 AChE is localized in membranes by a glycoinositol phospholipid covalently linked to the C-terminal amino acid. Brain G4 AChE involves two catalytic subunits linked by a direct intersubunit disulfide bond while the other two are disulfide-linked to a membrane-binding 20-kDa noncatalytic subunit. Molecular cloning studies have so far failed to find evidence of more than one AChE gene in any organism although alternative splicing of torpedo AChE mRNA results in different C-terminal sequences for the A12 and G2 AChE forms. Support for a single bovine AChE gene is provided in this report by amino acid sequencing of the N-terminal domains from the G2 erythrocyte, G4 fetal serum, and G4 brain AChE. Comparison of the 38-amino acid sequences reveals virtually complete identity among the three AChE forms. Additional extensive identity between the fetal serum and brain AChEs was demonstrated by sequencing several brain AChE peptides isolated by high performance liquid chromatography after trypsin digestion of nitro-cellulose blots of brain AChE catalytic subunits. Cysteines involved in intersubunit disulfide linkages in brain AChE were reduced selectively with dithiothreitol in the absence of denaturants and radioalkylated with iodoacetamide. The observed sequence of the major radiolabeled tryptic peptide was C*SDL, where C* was the radioalkylated cysteine residue. This sequence is precisely the same as that observed at the C terminus of fetal bovine serum AChE and shows close homology to the C-terminal sequence of torpedo A12 AChE. We conclude that the mammalian brain G4 AChEs utilize the same exon splicing pattern as the A12 AChEs and that factors other than the primary sequence of the AChE catalytic subunits dictate assembly with either the collagen-like or the 20-kDa noncatalytic subunits.	CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106; WALTER REED ARMY MED CTR,DIV BIOCHEM,WASHINGTON,DC 20307	Case Western Reserve University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center					NINDS NIH HHS [NS16577] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DELAHOZ D, 1986, LIFE SCI, V39, P195, DOI 10.1016/0024-3205(86)90530-8; DOCTOR BP, 1990, FEBS LETT, V266, P123, DOI 10.1016/0014-5793(90)81522-P; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; FOURNIER D, 1989, J MOL BIOL, V210, P15, DOI 10.1016/0022-2836(89)90287-8; FUTERMAN AH, 1985, BIOCHEM J, V226, P369, DOI 10.1042/bj2260369; GIBNEY G, 1988, J BIOL CHEM, V263, P1140; HAAS R, 1985, ANAL BIOCHEM, V148, P154, DOI 10.1016/0003-2697(85)90640-2; HAAS R, 1988, BIOCHEMISTRY-US, V27, P6453, DOI 10.1021/bi00417a038; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; LEE SL, 1982, J BIOL CHEM, V257, P2283; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P12945; MACPHEEQUIGLEY K, 1986, J BIOL CHEM, V261, P3565; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; Means G E, 1977, Methods Enzymol, V47, P469; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROBERTS WL, 1986, BIOCHEMISTRY-US, V25, P3091, DOI 10.1021/bi00359a004; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; ROSENBERRY TL, 1982, METHOD ENZYMOL, V82, P325; ROTUNDO RL, 1988, P NATL ACAD SCI USA, V85, P7805, DOI 10.1073/pnas.85.20.7805; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; TSIM KWK, 1988, P NATL ACAD SCI USA, V85, P1262, DOI 10.1073/pnas.85.4.1262	30	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7481	7487						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019579				2022-12-25	WOS:A1991FJ34200027
J	FREITAG, NE; MCENTEE, K				FREITAG, NE; MCENTEE, K			SITE-DIRECTED MUTAGENESIS OF THE RECA PROTEIN OF ESCHERICHIA-COLI - TYROSINE-264 IS REQUIRED FOR EFFICIENT ATP HYDROLYSIS AND STRAND EXCHANGE BUT NOT FOR LEXA REPRESSOR INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LABEL 8-AZIDOADENOSINE 5'-TRIPHOSPHATE; DNA; BINDING; CLEAVAGE; PURIFICATION; COMPLEXES; UMUD	The role of Tyr264 in nucleotide binding and hydrolysis catalyzed by the RecA protein of Escherichia coli was investigated by constructing Gly, Ser, and Phe substitution mutations using oligonucleotide-directed mutagenesis. The corresponding mutant recA genes neither restored resistance to killing by ultraviolet irradiation nor increased homologous recombination in a recA strain. The purified RecA (Gly264) protein was unable to bind nucleotide, hydrolyze ATP, or form stable ternary complexes with adenosine 5'-O-thiotriphosphate and DNA although the mutant protein bound DNA normally in the absence of nucleotide. The RecA(Phe264) and RecA(Ser264) proteins hydrolyzed. ATP poorly and the rates were reduced approximately 8- and 18-fold, respectively. Although capable of low levels of ATP hydrolysis, neither the RecA(Phe264) nor the RecA(Ser264) protein promoted DNA pairing or strand exchange reactions in vitro. Furthermore, these mutant RecA proteins were impaired in their ability to form salt-resistant ternary complexes with adenosine 5'-O-thiotriphosphate) and DNA as judged by filter binding. Nevertheless, nucleoprotein complexes formed with either RecA(Phe264) or RecA(Ser264) protein directed efficient cleavage of LexA repressor in vitro. These results demonstrate that Tyr264 is required for efficient ATP hydrolysis and for homologous pairing of DNA but does not participate in activating RecA protein for LexA repressor autodigestion.	UNIV CALIF LOS ANGELES,SCH MED,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIGMS NIH HHS [GM29558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYANT FR, 1985, J BIOL CHEM, V260, P1196; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1983, J BIOL CHEM, V258, P2586; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DASGUPTA C, 1980, CELL, V22, P437, DOI 10.1016/0092-8674(80)90354-2; EGELMAN EH, 1988, J MOL BIOL, V200, P329, DOI 10.1016/0022-2836(88)90245-8; FREITAG N, 1989, P NATL ACAD SCI USA, V86, P8363, DOI 10.1073/pnas.86.21.8363; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; KEENER SL, 1984, J BACTERIOL, V160, P153, DOI 10.1128/JB.160.1.153-160.1984; KNIGHT KL, 1985, J BIOL CHEM, V260, P867; KNIGHT KL, 1985, J BIOL CHEM, V260, P177; KNIGHT KL, 1985, J BIOL CHEM, V260, P185; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P5872, DOI 10.1021/bi00368a006; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; Maniatis T., 1982, MOL CLONING; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MCENTEE K, 1985, BIOCHEMISTRY-US, V24, P4345, DOI 10.1021/bi00337a014; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; Miller J.H., 1972, EXPT MOL GENETICS; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; ROBERTS JW, 1981, NATURE, V290, P422, DOI 10.1038/290422a0; ROBERTS JW, 1983, LAMBDA, V2, P123; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; TESSMAN ES, 1985, J BACTERIOL, V163, P688, DOI 10.1128/JB.163.2.688-695.1985; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8850; WEINSTOCK GM, 1981, P NATL ACAD SCI USA, V256, P8845; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220; ZHAO XJ, 1990, MOL GEN GENET, V222, P369, DOI 10.1007/BF00633842	38	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7058	7066						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016315				2022-12-25	WOS:A1991FG72700065
J	VEROSTEK, MF; ATKINSON, PH; TRIMBLE, RB				VEROSTEK, MF; ATKINSON, PH; TRIMBLE, RB			STRUCTURE OF SACCHAROMYCES-CEREVISIAE ALG3,SEC18 MUTANT OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-LINKED OLIGOSACCHARIDES; MAGNETIC-RESONANCE SPECTROSCOPY; HAMSTER OVARY CELLS; GLYCOPROTEIN CORE OLIGOSACCHARIDES; N-ACETYLGLUCOSAMINIDASE-H; YEAST EXTERNAL INVERTASE; PROTEIN GLYCOSYLATION; H-1-NMR SPECTROSCOPY; HIGH-RESOLUTION; 500 MHZ	Asparagine-linked oligosaccharides are synthesized by transfer of Glc3Man9GlcNAc2 from dolichol pyrophosphate to nascent polypeptides. Assembly of the precursor proceeds by highly ordered sequential addition of mannose and glucose to form Glc3Man9GlcNAc2-P-P-dolichol. Yeast mutants in asparagine-linked glycosylation (alg), generated by an H-3-Man suicide technique, were assigned to eight complementation groups which define steps in oligosaccharide-lipid synthesis (Huffaker, T.C., and Robbins, P.W. (1982) J. Biol. Chem. 257, 3203-3210). Alg3 invertase oligosaccharides are resistant to endo-beta-N-acetylglucosaminidase H, and the lipid-oligosaccharide pool yields Man5GlcNAc2, suggesting its structure may be that from mammalian cells lacking Man-P-dolichol (Chapman, A., et al. (1980) J. Biol. Chem. 255, 4441-4446). To test this supposition, the endoplasmic reticulum form of invertase derepressed in alg3,sec18 yeast at 37-degrees-C was isolated as a source of oligosaccharides whose processing beyond glucose and/or mannose trimming, if involved, would be prevented. Man8GlcNAc2 and Man5GlcNAc2 were released by peptide-N-glycosidase F from alg3, sec18 invertase in a 1:5 molar ratio. H-1 NMR spectroscopy revealed Man8GlcNAc2 to be the alpha-1,2-mannosidase-trimming product described earlier (Byrd, J. C., Tarentino, A. L., Maley, F., Atkinson, P. H., and Trimble, R. B. (1982) J. Biol. Chem. 257, 14657-14666), while Man5GlcNAc2 was Man-alpha-1, 2Man-alpha-1,2Man-alpha-1,3(Man-alpha-1,6)Man-beta-1,4GlcNAc-beta-1,4GlcNAc. This provides a structural proof for the lipid-linked Man5GlcNAc2 originally proposed from enzymatic and chemical analyses of the radiolabeled mammalian precursor. Experimental evidence indicates that, unlike the mammalian cell mutants which are unable to synthesize Man-P-dolichol, alg3 yeast accumulate Man5GlcNAc2-P-P-dolichol due to a defective alpha-1,3-mannosyltransferase required for the next step in oligosaccharide-lipid elongation.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, POB 509, ALBANY, NY 12201 USA; SUNY ALBANY, SCH PUBL HLTH, ALBANY, NY 12222 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [CA13402] Funding Source: Medline; NIGMS NIH HHS [GM23900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA013402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU L, 1986, P NATL ACAD SCI USA, V83, P3081, DOI 10.1073/pnas.83.10.3081; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BROCKHAUSEN I, 1988, GLYCOCONJUGATE J, V5, P419, DOI 10.1007/BF01049917; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARVER JP, 1981, BIOCHEMISTRY-US, V20, P6607, DOI 10.1021/bi00526a014; CECCARINI C, 1984, J MOL BIOL, V176, P161, DOI 10.1016/0022-2836(84)90387-5; CHAPMAN A, 1979, CELL, V17, P509, DOI 10.1016/0092-8674(79)90259-9; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; CHU FK, 1978, J BIOL CHEM, V253, P8691; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; CUMMING DA, 1989, BIOCHEMISTRY-US, V28, P6500, DOI 10.1021/bi00441a051; DORLAND L, 1981, J BIOL CHEM, V256, P7708; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ESMON B, 1984, J BIOL CHEM, V259, P322; Goldstein A, 1975, Methods Enzymol, V42, P504; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1979, J BIOL CHEM, V254, P2754; LI E, 1978, J BIOL CHEM, V253, P7762; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PHILLIPS LR, 1981, CARBOHYD RES, V90, P149, DOI 10.1016/S0008-6215(00)85623-2; PRAKASH C, 1982, BIOCHEMISTRY-US, V21, P4810, DOI 10.1021/bi00262a045; REARICK JI, 1981, J BIOL CHEM, V256, P3762; RUNGE KW, 1984, J BIOL CHEM, V259, P412; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STANLEY P, 1983, SOMAT CELL GENET, V9, P593, DOI 10.1007/BF01574260; STANLEY P, 1988, J BIOL CHEM, V263, P11374; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; TARENTINO AL, 1989, METHOD CELL BIOL, V32, P111; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TRIMBLE RB, 1978, J BIOL CHEM, V253, P4508; TRIMBLE RB, 1980, J BIOL CHEM, V255, P232; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; TROWBRIDGE IS, 1979, CELL, V17, P503, DOI 10.1016/0092-8674(79)90258-7; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; TSAI PK, 1984, P NATL ACAD SCI-BIOL, V81, P6340, DOI 10.1073/pnas.81.20.6340; TURCO SJ, 1977, P NATL ACAD SCI USA, V74, P4411, DOI 10.1073/pnas.74.10.4411; VANHALBEEK H, 1980, FEBS LETT, V121, P71; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; ZENG YC, 1990, J BIOL CHEM, V265, P2296	49	33	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5547	5551						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005096				2022-12-25	WOS:A1991FD37000031
J	WOOD, MJ; YAU, P; IMAI, BS; GOLDBERG, MW; LAMBERT, SJ; FOWLER, AG; BALDWIN, JP; GODFREY, JE; MOUDRIANAKIS, EN; KOCH, MHJ; IBEL, K; MAY, RP; BRADBURY, EM				WOOD, MJ; YAU, P; IMAI, BS; GOLDBERG, MW; LAMBERT, SJ; FOWLER, AG; BALDWIN, JP; GODFREY, JE; MOUDRIANAKIS, EN; KOCH, MHJ; IBEL, K; MAY, RP; BRADBURY, EM			NEUTRON AND X-RAY SCATTER STUDIES OF THE HISTONE OCTAMER AND AMINO AND CARBOXYL DOMAIN TRIMMED OCTAMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLES; PROTEOLYTIC DIGESTION; CRYSTALLOGRAPHIC STRUCTURE; BIOLOGICAL MACROMOLECULES; LIMIT PEPTIDES; CHROMATIN; RESOLUTION; IDENTIFICATION; DNA; REGIONS	The structure of the nucleosome has been under intense investigation using neutron crystallography, x-ray crystallography, and neutron solution scattering. However the dimension of the histone octamer inside the nucleosome is still a subject of controversy. The radius of gyration (R(g)) of the octamer obtained from solution neutron scattering of core particles at 63% (H2O)-H-2, 37% (H2O)-H-1 is 33 angstrom, and x-ray crystallography study of isolated histone octamer gives a R(g) of 32.5 angstrom, while the reported values using x-ray crystallography of core particles from two individual studies are 29.7 and 30.4 angstrom, respectively. We report here studies of isolated histone octamer and trypsin-limited digested octamer using both neutron solution scattering and small angle x-ray scattering. The R(g) of the octamer obtained is 33 angstrom, whereas that of the trimmed octamer is 29.8 angstrom, similar to the structure obtained from the crystals of the core particles. The N-terminal domains of the core histones in the octamer have been shown by high resolution nuclear magnetic resonance (Schroth, G. P., Yau, P., Imai, B. S., Gatewood, J. M., and Bradbury, E. M. (1990) FEBS Lett. 268, 117-120) to be mobile and flexible; it is likely that these regions are disordered and "not seen" by x-ray crystallography.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY; INST MAX VON LAUE PAUL LANGEVIN,F-38042 GRENOBLE,FRANCE; UNIV CALIF LOS ALAMOS SCI LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545	University of California System; University of California Davis; Johns Hopkins University; European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); United States Department of Energy (DOE); Los Alamos National Laboratory	WOOD, MJ (corresponding author), LIVERPOOL POLYTECH,SCH INFORMAT SCI & TECHNOL,DIV PHYS,BYROM ST,LIVERPOOL L3 3AF,ENGLAND.		Wood, Matthew/HDN-1469-2022	Yau, Peter/0000-0002-1984-185X; Goldberg, Martin/0000-0002-0610-4332; Imai, Brian/0000-0001-7865-9700	NIGMS NIH HHS [GM 33495] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BENTLEY GA, 1981, J MOL BIOL, V145, P771, DOI 10.1016/0022-2836(81)90314-4; BOHM L, 1981, EUR J BIOCHEM, V119, P67, DOI 10.1111/j.1432-1033.1981.tb05577.x; BOHM L, 1980, EUR J BIOCHEM, V106, P525, DOI 10.1111/j.1432-1033.1980.tb04599.x; BOHM L, 1982, EUR J BIOCHEM, V123, P299, DOI 10.1111/j.1432-1033.1982.tb19767.x; BRADBURY EM, 1986, SUPRAMOLECULAR STRUC; BRADDOCK GW, 1981, BIOPOLYMERS, V20, P327, DOI 10.1002/bip.1981.360200206; BURLINGAME RW, 1985, SCIENCE, V228, P546, DOI 10.1126/science.3983639; CARY PD, 1978, EUR J BIOCHEM, V89, P475, DOI 10.1111/j.1432-1033.1978.tb12551.x; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FINCH JT, 1977, NATURE, V269, P29, DOI 10.1038/269029a0; GODFREY JE, 1990, BIOCHEMISTRY-US, V29, P965, DOI 10.1021/bi00456a018; IBEL K, 1976, J APPL CRYSTALLOGR, V9, P296, DOI 10.1107/S0021889876011394; IMAI BS, 1986, J BIOL CHEM, V261, P8784; KLUG A, 1985, SCIENCE, V229, P1109, DOI 10.1126/science.4035352; KNEALE GG, 1977, Q REV BIOPHYS, V10, P485, DOI 10.1017/S0033583500003206; LILLEY DMJ, 1977, NUCLEIC ACIDS RES, V4, P2039, DOI 10.1093/nar/4.6.2039; Matthews HR, 1985, ENZYMOLOGY POSTTRANS, V2, P125; MAY RP, 1982, J APPL CRYSTALLOGR, V15, P15, DOI 10.1107/S0021889882011285; MOSS T, 1976, EUR J BIOCHEM, V71, P337, DOI 10.1111/j.1432-1033.1976.tb11120.x; MOSS T, 1976, BIOCHEMISTRY-US, V15, P2261, DOI 10.1021/bi00656a003; MOUDRIANAKIS EN, 1985, SCIENCE, V229, P1110, DOI 10.1126/science.229.4718.1110; MURRAY K, 1968, BIOCHEM J, V107, P207, DOI 10.1042/bj1070207; PARDON JF, 1977, NUCLEIC ACIDS RES, V4, P3199, DOI 10.1093/nar/4.9.3199; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SCHROTH GP, 1990, FEBS LETT, V268, P117, DOI 10.1016/0014-5793(90)80987-T; SIBBET GJ, 1983, EUR J BIOCHEM, V133, P393, DOI 10.1111/j.1432-1033.1983.tb07475.x; STEFANOVSKY VY, 1989, NUCLEIC ACIDS RES, V17, P10069, DOI 10.1093/nar/17.23.10069; STUHRMANN HB, 1974, J APPL CRYSTALLOGR, V7, P173, DOI 10.1107/S0021889874009071; SUAU P, 1977, NUCLEIC ACIDS RES, V4, P3769, DOI 10.1093/nar/4.11.3769; UBERBACHER EC, 1989, J BIOMOL STRUCT DYN, V7, P1; UBERBACHER EC, 1986, SCIENCE, V230, P1247; WHITLOCK JP, 1977, J BIOL CHEM, V252, P6516; WHITLOCK JP, 1978, J BIOL CHEM, V253, P3857; YAU P, 1982, EUR J BIOCHEM, V129, P281, DOI 10.1111/j.1432-1033.1982.tb07050.x	35	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5696	5702						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005107				2022-12-25	WOS:A1991FD37000053
J	NAKAGAWA, SH; TAGER, HS				NAKAGAWA, SH; TAGER, HS			IMPLICATIONS OF INVARIANT RESIDUE LEUB6 IN INSULIN-RECEPTOR INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN; HEXAMER; MONOMER; TRANSFORMATION; SEMISYNTHESIS; DYNAMICS; ANALOGS; FORMS	By the chemical synthesis of modified insulin B chains and the combination of the synthetic B chains with natural insulin A chains, we have prepared insulin analogs with natural and unnatural amino acid replacements of invariant residue Leu(B6). Analogs have been investigated by reference to their potencies for interaction with the insulin receptor (as assessed by competition for I-125-labeled binding to isolated canine hepatocytes) and to their abilities to undergo the structural transitions that are characteristic of insulin self-aggregation (as assessed by the spectroscopic analysis of analog complexes with cobalt). Our results identify that (a) replacement of Leu(B6) by glycine has nearly the equivalent effect as deletion of residues B1-B6 in decreasing receptor binding potency of the analog to only about 0.05% of that of insulin; (b) relative to the Gly(B6) derivative, replacements that increase the relative hydrophobicity of the residue B6 side chain also increase the relative receptor binding potencies of the resulting analogs; (c) negative steric effects resulting from substitutions by valine, phenylalanine, and gamma-ethylnorleucine limit the potential for enhancing potency as the result of increased hydrophobicity; and (d) two analogs with disparate potency for receptor interaction (those with alanine and gamma-ethylnorleucine at position B6, analogs exhibiting about 1 and 48% of the potency of insulin, respectively) undergo the T6 --> R6 structural transition in the presence of Co2+ and phenol which is typical of insulin but result in hexameric complexes with greatly reduced stability. We conclude that leucine provides a closely determined best fit at insulin position B6, and we discuss our findings in terms of insulin conformations that may apply to the receptor-bound state of the hormone.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago					NIDDK NIH HHS [DK 18347, DK 20595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018347, R01DK018347, P60DK020595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTSON NF, 1945, J AM CHEM SOC, V67, P308, DOI 10.1021/ja01218a046; ASSOIAN RK, 1982, P NATL ACAD SCI USA, V79, P5141; BAILEY JL, 1959, J BIOL CHEM, V234, P1733; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BENTLEY G, 1976, NATURE, V261, P166, DOI 10.1038/261166a0; Blundell T., 1972, ADV PROTEIN CHEM, V26, P279; BONNEVIENIELSEN V, 1982, P NATL ACAD SCI-BIOL, V79, P2167, DOI 10.1073/pnas.79.7.2167; BRANGE J, 1990, DIABETES CARE, V13, P923, DOI 10.2337/diacare.13.9.923; Chance R. E., 1981, PEPTIDES SYNTHESIS S, P721; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; GATTNER HG, 1980, H-S Z PHYSIOL CHEM, V361, P1135; GEIGER R, 1973, H-S Z PHYSIOL CHEM, V354, P1285, DOI 10.1515/bchm2.1973.354.2.1285; GEIGER R, 1977, MOL ENDOCRINOL, P27; GRAU U, 1985, DIABETES, V34, P1174, DOI 10.2337/diabetes.34.11.1174; Hansch C, 1979, SUBSTITUENT CONSTANT, P18; INOUYE K, 1981, BIOPOLYMERS, V20, P1845, DOI 10.1002/bip.1981.360200909; KAARSHOLM NC, 1989, BIOCHEMISTRY-US, V28, P4427, DOI 10.1021/bi00436a046; KATSOYAN.PG, 1967, BIOCHEMISTRY-US, V6, P2635, DOI 10.1021/bi00861a001; KRUGER P, 1987, EUR BIOPHYS J BIOPHY, V14, P449, DOI 10.1007/BF00293254; MIRMIRA RG, 1991, J BIOL CHEM, V266, P1428; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; MORODER L, 1976, H-S Z PHYSIOL CHEM, V357, P1651, DOI 10.1515/bchm2.1976.357.2.1651; NAKAGAWA SH, 1986, J BIOL CHEM, V261, P7332; NAKAGAWA SH, 1989, J BIOL CHEM, V264, P272; RENSCHEIDT H, 1984, EUR J BIOCHEM, V142, P7, DOI 10.1111/j.1432-1033.1984.tb08243.x; ROY M, 1989, J BIOL CHEM, V264, P19081; ROY M, 1990, J BIOL CHEM, V265, P5448; SCHARTMANN B, 1983, H-S Z PHYSIOL CHEM, V364, P179, DOI 10.1515/bchm2.1983.364.1.179; SCHROEDER WA, 1969, ARCH BIOCHEM BIOPHYS, V130, P551, DOI 10.1016/0003-9861(69)90069-1; SCHWARTZ G, 1978, BIOCHEMISTRY-US, V17, P4550, DOI 10.1021/bi00614a029; SCHWARTZ GP, 1989, P NATL ACAD SCI USA, V86, P458, DOI 10.1073/pnas.86.2.458; SMITH GD, 1984, P NATL ACAD SCI-BIOL, V81, P7093, DOI 10.1073/pnas.81.22.7093; TAGER H, 1980, P NATL ACAD SCI-BIOL, V77, P3181, DOI 10.1073/pnas.77.6.3181; TAGER HS, 1990, HDB EXPT PHARM, V92, P41; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; THOMAS B, 1989, BIOL CHEM H-S, V370, P1235, DOI 10.1515/bchm3.1989.370.2.1235; WEISS MA, 1989, BIOCHEMISTRY-US, V28, P9855, DOI 10.1021/bi00451a046; WODAK SJ, 1984, J MOL BIOL, V181, P317; WOLLMER A, 1987, BIOL CHEM H-S, V368, P903, DOI 10.1515/bchm3.1987.368.2.903	40	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11502	11509						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050662				2022-12-25	WOS:A1991FT76200017
J	NG, L; TAN, CK; DOWNEY, KM; FISHER, PA				NG, L; TAN, CK; DOWNEY, KM; FISHER, PA			ENZYMOLOGIC MECHANISM OF CALF THYMUS DNA POLYMERASE-DELTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE CDC2 GENE; CELL NUCLEAR ANTIGEN; AUXILIARY PROTEIN; SACCHAROMYCES-CEREVISIAE; REPLICATION INVITRO; ABASIC SITES; KB-CELLS; ALPHA; BINDING; RECOGNITION	The catalytic core protomer of calf thymus DNA polymerase-delta (pol-delta) was purified to apparent homogeneity by a modified procedure, and its enzymologic mechanism was investigated using a combination of steady-state kinetics and semiquantitative sedimentation binding analyses. Like DNA polymerase-alpha (pol-alpha), in the absence of a primer, pol-delta was able to bind single-stranded but not double-stranded DNA. This, in conjunction with the observation of induced substrate (dNTP) inhibition of pol-delta in the presence of a correctly base-paired 2',3'-dideoxyribonucleotide-terminated primer, suggests that pol-delta follows an ordered sequential ter-reactant mechanism of substrate recognition and binding similar to that elucidated for pol-alpha. Pol-delta binds template first followed by primer and then template-directed dNTP. With suitable substrates, addition to incubations of proliferating cell nuclear antigen, the pol-delta auxiliary factor, leads to a reduction in K(m) and increase in V(max). This suggests that proliferating cell nuclear antigen enhances the processivity of pol-delta by increasing both the residence time of pol-delta on the DNA template-primer and the rate at which individual nucleotides are incorporated.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHARMACOL SCI,STONY BROOK,NY 11794; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM,MIAMI,FL 33101	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Miami; University of Miami					NIDDK NIH HHS [DK-26206] Funding Source: Medline; NIEHS NIH HHS [ES-04068] Funding Source: Medline; NIGMS NIH HHS [GM-35943] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035943] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOW J, 1989, TRENDS GENET, V5, P134, DOI 10.1016/0168-9525(89)90050-4; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BUDD M, 1987, P NATL ACAD SCI USA, V84, P2838, DOI 10.1073/pnas.84.9.2838; Cleland W W, 1979, Methods Enzymol, V63, P500; Cleland W. W, 1970, ENZYMES, V2, P1; DOWNEY KM, 1988, CANCER CELLS EUKARYO, V6, P403; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; FISHER PA, 1979, J BIOL CHEM, V254, P1033; FISHER PA, 1979, J BIOL CHEM, V254, P6128; FISHER PA, 1981, J BIOL CHEM, V256, P133; JOHNSON LM, 1985, CELL, V43, P369, DOI 10.1016/0092-8674(85)90042-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NG L, 1989, J BIOL CHEM, V264, P13018; NGL, 1990, J BIOL CHEM, V265, P11948; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; RICHARD RE, 1989, J BIOL CHEM, V264, P4704; SITNEY KC, 1989, CELL, V56, P599, DOI 10.1016/0092-8674(89)90582-5; SO AG, 1988, BIOCHEMISTRY-US, V27, P4591, DOI 10.1021/bi00413a001; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TAN CK, 1986, J BIOL CHEM, V261, P2310; WONG SW, 1986, J BIOL CHEM, V261, P7958; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; WONG SW, 1989, J BIOL CHEM, V264, P5924; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	30	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11699	11704						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050671				2022-12-25	WOS:A1991FT76200045
J	STEWART, MJ; SHEAN, ML; PAEPER, BW; DUESTER, G				STEWART, MJ; SHEAN, ML; PAEPER, BW; DUESTER, G			THE ROLE OF CCAAT/ENHANCER-BINDING PROTEIN IN THE DIFFERENTIAL TRANSCRIPTIONAL REGULATION OF A FAMILY OF HUMAN LIVER ALCOHOL-DEHYDROGENASE GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA BOX; DEVELOPMENTAL REGULATION; NUCLEOTIDE-SEQUENCE; MOLECULAR ANALYSIS; HEPATOMA-CELLS; ALBUMIN GENE; ADH-1 GENE; MOUSE; C/EBP; DNA	The transcription factor CCAAT/enhancer-binding protein (C/EBP) was found to selectively trans-activate one member of the human class I alcohol dehydrogenase (ADH) gene family. A comparison of the promoters for the three human class I ADH genes ADH1, ADH2, and ADH3 indicated a very similar pattern of binding sites (sites A-F) for rat liver nuclear proteins located between -10 and -210 base pairs (bp). In all three promoters site A consisted of two binding sites for the transcription factor C/EBP closely flanking both sides of the TATA box, but C/EBP bound with much greater affinity to site A of ADH2. C/EBP also bound at two locations which coincide with site D (-120 bp) and site E (-160 bp) of all three promoters. Cotransfection studies of human hepatoma cells using ADH-cat fusions and a C/EBP expression plasmid indicated that the human ADH2 promoter responded well to C/EBP trans-activation whereas the human ADH1 and ADH3 promoters, which bind C/EBP weakly, responded poorly. Individual mutations in several ADH2 nuclear factor-binding sites allowed the identification of four functional C/EBP-binding sites, i.e. two in site A as well as one each in sites D and E. Also, the ADH2 TATA box was found to be dispensable for C/EBP induction. Compared to ADH2 and ADH3, site A in ADH1 contains four extra base pairs between the two C/EBP motifs, and deletion of these nucleotides increased the C/EBP responsiveness of ADH1 presumably by changing the spacing of the two C/EBP motifs. Thus, sequence divergence of human class I ADH gene family members has led to forms which vary in their responsiveness to C/EBP. We suggest that C/EBP contributes to liver-specific expression of the human class I ADH gene family by selectively inducing the ADH2 gene via a TATA-independent mechanism during liver development.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523	Colorado State University					NIAAA NIH HHS [AA07261, K02 AA00119] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007261, K02AA000119] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BALAK KJ, 1982, J BIOL CHEM, V257, P5000; BILANCHONE V, 1986, NUCLEIC ACIDS RES, V14, P3911, DOI 10.1093/nar/14.9.3911; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CECI JD, 1987, GENE, V59, P171, DOI 10.1016/0378-1119(87)90325-8; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DITLOW CC, 1984, BIOCHEMISTRY-US, V23, P6363, DOI 10.1021/bi00321a012; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DUESTER G, 1986, J BIOL CHEM, V261, P2027; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLMES RS, 1983, ISOZYMES-CURR T BIOL, V8, P155; IKUTA T, 1986, BIOCHEM BIOPH RES CO, V140, P1020, DOI 10.1016/0006-291X(86)90737-0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEO MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P241, DOI 10.1016/0003-9861(87)90492-9; li T K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P427; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MARDH G, 1985, P NATL ACAD SCI USA, V82, P4979, DOI 10.1073/pnas.82.15.4979; MARDH G, 1986, BIOCHEMISTRY-US, V25, P7279, DOI 10.1021/bi00371a005; Maxam A M, 1980, Methods Enzymol, V65, P499; MEZEY E, 1971, EXP MOL PATHOL, V15, P148, DOI 10.1016/0014-4800(71)90095-5; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MURRAY RF, 1971, SCIENCE, V171, P71, DOI 10.1126/science.171.3966.71; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OKUDA A, 1983, J BIOL CHEM, V258, P2899; PIKKARAINEN P, 1969, NATURE, V222, P563, DOI 10.1038/222563a0; PIKKARAINEN PH, 1967, PEDIATR RES, V1, P165, DOI 10.1203/00006450-196705000-00001; ROBERTS AB, 1984, RETINOIDS, V2, P209; Sambrook J, 1989, MOL CLONING LABORATO; SMITH M, 1973, ANN HUM GENET, V37, P49, DOI 10.1111/j.1469-1809.1973.tb01814.x; SMITH M, 1986, ADV HUM GENET, V15, P249; SMITH M, 1972, ANN HUM GENET, V35, P243, DOI 10.1111/j.1469-1809.1957.tb01398.x; SMITH M, 1971, ANN HUM GENET, V34, P251, DOI 10.1111/j.1469-1809.1971.tb00238.x; STEWART MJ, 1990, MOL CELL BIOL, V10, P5007, DOI 10.1128/MCB.10.9.5007; STEWART MJ, 1990, GENE, V90, P271, DOI 10.1016/0378-1119(90)90190-3; VONBAHRLINDSTROM H, 1986, BIOCHEMISTRY-US, V25, P2465; WAGNER FW, 1983, BIOCHEMISTRY-US, V22, P1857, DOI 10.1021/bi00277a018; ZACHMAN RD, 1961, J BIOL CHEM, V236, P2309; ZHANG K, 1987, GENE, V57, P27, DOI 10.1016/0378-1119(87)90173-9	47	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11594	11603						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050667				2022-12-25	WOS:A1991FT76200030
J	HUANG, JZ; SCHELL, MA				HUANG, JZ; SCHELL, MA			INVIVO INTERACTIONS OF THE NAHR TRANSCRIPTIONAL ACTIVATOR WITH ITS TARGET SEQUENCES - INDUCER-MEDIATED CHANGES RESULTING IN TRANSCRIPTION ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PSEUDOMONAS-PUTIDA; NUCLEOTIDE-SEQUENCES; POSITIVE REGULATOR; INDUCIBLE GENES; PROTEIN-BINDING; DNA; CLONING; EXPRESSION; PROMOTERS	The nahR gene from the NAH7 naphthalene degradation plasmid encodes a LysR-type transcriptional activator of the nah and sal promoters (P(nah) and P(sal), respectively) that responds to the inducer salicylate. In vivo methylation protection experiments with dimethyl sulfate showed that in the absence of inducer, NahR interacts in a similar manner with its target sites at P(sal) and P(nah). Both target sites also have very similar sequences comprised of a 4-base pair interrupted dyad containing two symmetrical guanines (-73 and -64 of P(nah); -71 and -62 of P(sal)), each located in adjacent major grooves on the same helical face, and both strongly protected by NahR. When inducer was present, several additional guanines Of P(nah) (-35, -45, and -58) and P(sal) (-42 and -40) became protected from methylation, while a guanine at -52 Of P(nah) became markedly enhanced for methylation, indicating that inducer and NahR-dependent interactions with these downstream sites of each promoter are quite different. Deletion of P(sal) sequences downstream of -30 did not affect its methylation patterns suggesting that NahR alone is responsible for the altered reactivities of these nucleotides. Similar in vivo methylation analyses with inducer-insensitive or inducer-independent NahR mutants also suggested that all alterations in methylation sensitivity are directly caused by NahR. It is more probable that the salicylate-induced reactivity changes result from direct NahR-guanine contacts which are required for, but not sufficient for transcription activation; however, they could also result from NahR-induced DNA contortions caused by upstream protein-DNA contacts.	UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602	University System of Georgia; University of Georgia					NIGMS NIH HHS [GM32255] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032255] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNETT MJ, 1990, J BACTERIOL, V172, P3695, DOI 10.1128/jb.172.7.3695-3700.1990; BURN J, 1987, GENE DEV, V1, P362; BURN JE, 1989, MOL MICROBIOL, V3, P1567, DOI 10.1111/j.1365-2958.1989.tb00142.x; CHANG M, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P292; CHANG M, 1990, NUCLEIC ACIDS RES, V18, P979, DOI 10.1093/nar/18.4.979; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; DITTA G, 1985, PLASMID, V13, P149, DOI 10.1016/0147-619X(85)90068-X; FISHER RF, 1989, J BACTERIOL, V171, P5492, DOI 10.1128/jb.171.10.5492-5502.1989; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; GRUND AD, 1983, J BACTERIOL, V156, P89, DOI 10.1128/JB.156.1.89-94.1983; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HONG GF, 1987, NUCLEIC ACIDS RES, V15, P9677, DOI 10.1093/nar/15.23.9677; LEE N, 1987, P NATL ACAD SCI USA, V62, P1100; LINDQUIST S, 1989, J BACTERIOL, V171, P3746, DOI 10.1128/jb.171.7.3746-3753.1989; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; McKenney K, 1981, Gene Amplif Anal, V2, P383; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; MEAGHER RB, 1977, CELL, V10, P521, DOI 10.1016/0092-8674(77)90039-3; MENON KP, 1990, P NATL ACAD SCI USA, V87, P3708, DOI 10.1073/pnas.87.10.3708; MILLER JF, 1986, P NATL ACAD SCI USA, V83, P1433, DOI 10.1073/pnas.83.5.1433; NIELSEN PE, 1989, BIOESSAYS, V11, P152, DOI 10.1002/bies.950110510; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; ROTHMEL RK, 1990, J BACTERIOL, V172, P922, DOI 10.1128/jb.172.2.922-931.1990; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHELL MA, 1985, GENE, V36, P301, DOI 10.1016/0378-1119(85)90185-4; SCHELL MA, 1986, P NATL ACAD SCI USA, V83, P369, DOI 10.1073/pnas.83.2.369; SCHELL MA, 1986, J BACTERIOL, V166, P9, DOI 10.1128/jb.166.1.9-14.1986; SCHELL MA, 1989, J BACTERIOL, V171, P1952, DOI 10.1128/jb.171.4.1952-1959.1989; SCHELL MA, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P165; SCHELL MA, 1989, J BACTERIOL, V171, P837, DOI 10.1128/jb.171.2.837-846.1989; SCHELL MA, 1987, RNA POLYM REGULATION, P455; SCHELL MA, 1990, J BIOL CHEM, V265, P11628; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SMITH S, 1990, THESIS U GEORGIA; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; WEK RC, 1988, J MOL BIOL, V203, P643, DOI 10.1016/0022-2836(88)90199-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YEN KM, 1985, J BACTERIOL, V162, P1008, DOI 10.1128/JB.162.3.1008-1013.1985	40	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10830	10838						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040603				2022-12-25	WOS:A1991FQ77400023
J	JUSZCZAK, RJ; TURCHIN, H; TRUNEH, A; CULP, J; KASSIS, S				JUSZCZAK, RJ; TURCHIN, H; TRUNEH, A; CULP, J; KASSIS, S			EFFECT OF HUMAN-IMMUNODEFICIENCY-VIRUS GP120 GLYCOPROTEIN ON THE ASSOCIATION OF THE PROTEIN TYROSINE KINASE P56LCK WITH CD4 IN HUMAN LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; LSTRA CELLS; RECEPTOR; BINDING; HIV; SITE; PHOSPHORYLATION; IDENTIFICATION; DISSOCIATION; EXPRESSION	The human immunodeficiency virus binds to CD4+ T lymphocytes through the interaction of its envelope glycoprotein (gp120) with the CD4 molecule. The src-related protein tyrosine kinase p56lck is physically associated with CD4 and is co-immunoprecipitated by CD4 monoclonal antibody (mAb). Activators of protein kinase C (PKC) cause the dissociation of p56lck from CD4. Here we report that gp120 mAb immunoprecipitated the p56lck.CD4.gpl20 complex after short term treatment (20 min) of human T lymphocytes with gp120. The p56lck that was associated with the CD4.gp120 complex was dissociated by activators of PKC. This effect was abolished by pretreatment of cells with PKC inhibitors. Thus the p56lck.CD4.gp120 immune complex immunoprecipitated by gp120 mAb behaves in a similar manner, with respect to PKC activation or inhibition, to the p56lck.CD4 complex immunoprecipitated by CD4 mAb. Short term treatment of cells with gp120, followed by gp120 mAb, resulted in an increase in the tyrosine kinase activity of p56lck associated with CD4. However, the amount of enzyme associated with CD4 remained unchanged. Long term treatment (20 h) of human T lymphocytes with gp120 resulted in the down-regulation of cell surface CD4 molecules. A parallel decrease in CD4-associated gp120 was also observed. In addition, gp120 caused the dissociation of p56lck and CD4. However, the dissociation of the p56lck from CD4 occurred at much faster rate than the down-regulation of surface CD4 molecules. Such mechanisms may account for the down-regulation of cell surface CD4 molecules and the depletion of functional CD4+ T lymphocytes which are characteristic of human immunodeficiency virus infections and acquired immune deficiency syndrome pathogenesis.	SMITHKLINE BEECHAM PHARMACEUT,DEPT CELL SCI,L-101,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline			Truneh, Alem/ABB-7891-2020					AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; CASNELLIE JE, 1987, J BIOL CHEM, V262, P9859; CHANH TC, 1987, P NATL ACAD SCI USA, V84, P3891, DOI 10.1073/pnas.84.11.3891; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; HILLMAN K, 1990, J IMMUNOL, V144, P2131; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; LYERLY HK, 1987, P NATL ACAD SCI USA, V84, P4601, DOI 10.1073/pnas.84.13.4601; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALMON P, 1988, J EXP MED, V168, P1953, DOI 10.1084/jem.168.6.1953; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TREVILLYAN JM, 1986, BIOCHEM BIOPH RES CO, V140, P392, DOI 10.1016/0006-291X(86)91103-4; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; ZORN NE, 1990, BIOCHEM BIOPH RES CO, V166, P1133, DOI 10.1016/0006-291X(90)90984-U	36	96	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11176	11183						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040625				2022-12-25	WOS:A1991FQ77400074
J	THOMAS, J; VANPATTEN, SM; HOWARD, P; DAY, KH; MITCHELL, RD; SOSNICK, T; TREWHELLA, J; WALSH, DA; MAURER, RA				THOMAS, J; VANPATTEN, SM; HOWARD, P; DAY, KH; MITCHELL, RD; SOSNICK, T; TREWHELLA, J; WALSH, DA; MAURER, RA			EXPRESSION IN ESCHERICHIA-COLI AND CHARACTERIZATION OF THE HEAT-STABLE INHIBITOR OF THE CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT CYTOCHEMICAL-LOCALIZATION; RABBIT SKELETAL-MUSCLE; H-35 HEPATOMA-CELLS; CATALYTIC SUBUNIT; REGULATORY SUBUNIT; SITE-A; PURIFICATION; BINDING; DELETION	Pure heat-stable inhibitor of the cAMP-dependent protein kinase (PKI) has been isolated in high yield by using a bacterial expression vector constructed to synthesize the complete sequence of the rabbit muscle protein kinase inhibitor, plus an amino-terminal initiator methionine and glycine. Bacterially expressed PKI has an inhibitory activity identical to that of the protein isolated from rabbit skeletal muscle and, by gel filtration and gel electrophoresis, has the same physicochemical characteristics as the native physiological form of PKI. Fourier transformed infrared spectroscopy and CD establish that PKI has unusually large amounts of random coil and turn structures, with significantly smaller amounts of alpha-helix and beta-structures.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA; UNIV CALIF LOS ALAMOS SCI LAB, DIV LIFE SCI, LOS ALAMOS, NM 87545 USA	University of Iowa; University of California System; University of California Davis; United States Department of Energy (DOE); Los Alamos National Laboratory			Freed, Karl F/J-7764-2018	Freed, Karl F/0000-0001-6240-2599; Trewhella, Jill/0000-0002-8555-6766	NHLBI NIH HHS [HL14388] Funding Source: Medline; NIADDK NIH HHS [AM25295, AM21019] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P30AM025295, R01AM021019] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHBY CD, 1973, J BIOL CHEM, V248, P1255; BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; BYUS CV, 1982, J CELL BIOL, V93, P727, DOI 10.1083/jcb.93.3.727; CHENG HC, 1986, J BIOL CHEM, V261, P989; DAY RN, 1989, J BIOL CHEM, V264, P431; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; FLETCHER WH, 1982, J CELL BIOL, V93, P719, DOI 10.1083/jcb.93.3.719; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1989, J BIOL CHEM, V264, P14579; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON JM, 1979, BIOCHEMISTRY-US, V18, P4835, DOI 10.1021/bi00589a011; PARRISH JR, 1972, BIOPOLYMERS, V11, P1001, DOI 10.1002/bip.1972.360110506; PRESS WH, 1986, NUMERICAL RECIPES AR, P495; REED J, 1989, BIOCHEM J, V264, P371, DOI 10.1042/bj2640371; RICHARDSON JM, 1990, J BIOL CHEM, V265, P13635; RINGHEIM GE, 1988, J BIOL CHEM, V263, P18247; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SLICE LW, 1989, J BIOL CHEM, V264, P20940; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TREWHELLA J, 1989, BIOCHEMISTRY-US, V28, P1294, DOI 10.1021/bi00429a052; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WEBER K, 1969, J BIOL CHEM, V244, P4406; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1982, J BIOL CHEM, V257, P6028; WHITEHOUSE S, 1983, METHOD ENZYMOL, V99, P80	38	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10906	10911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040607				2022-12-25	WOS:A1991FQ77400034
J	LANE, BG; BERNIER, F; DRATEWKAKOS, E; SHAFAI, R; KENNEDY, TD; PYNE, C; MUNRO, JR; VAUGHAN, T; WALTERS, D; ALTOMARE, F				LANE, BG; BERNIER, F; DRATEWKAKOS, E; SHAFAI, R; KENNEDY, TD; PYNE, C; MUNRO, JR; VAUGHAN, T; WALTERS, D; ALTOMARE, F			HOMOLOGIES BETWEEN MEMBERS OF THE GERMIN GENE FAMILY IN HEXAPLOID WHEAT AND SIMILARITIES BETWEEN THESE WHEAT GERMINS AND CERTAIN PHYSARUM SPHERULINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LABELED EM POLYPEPTIDE; BULK MESSENGER-RNA; ABSCISIC-ACID; MOLECULAR-CLONING; PROTEIN-SYNTHESIS; POLY(A)-RICH RNA; EMBRYOS; EXPRESSION; SEQUENCES; DRY	By screening approximately 10(6) plaques in a wheat DNA library with a "full-length" germin cDNA probe, two genomic clones were detected. When digested with EcoRI, one clone yielded a 2.8-kilobase pair fragment (gf-2.8) and the other yielded a 3.8-kilobase pair fragment (gf-3.8). By nucleotide sequencing, each of gf-2.8 and gf-3.8 was found to encode a complete sequence for germin and germin mRNA, and to contain appreciable amounts of 5'- and 3'-flanking sequences. The "cap" site in gf-2.8 was determined by primer extension and the corresponding site in gf-3.8 was deduced by analogy. The mRNA coding sequences in gf-2.8 and gf-3.8 are intronless and 87% homologous with one another. The 5'-flanking regions in gf-2.8 and gf-3.8 contain recognizable sites of what are probably cis-acting elements but there is otherwise little if any significant similarity between them. In addition to putative TATA and CAAT boxes in the 5'-flanking regions of gf-2.8 and gf-3.8, there are AT-rich inverted-repeats, GC boxes, long purine-rich sequences, two 19-base pair direct-repeat sequences in gf-2.8, and a remarkably long (200-base pair) inverted-repeat sequence (approximately 90% homology) in gf-3.8. An 8% difference between the mature-protein coding regions in gf-2.8 and gf-3.8 is reflected by a corresponding 7% difference between the corresponding 201-residue proteins. Most significantly, the same 8% difference between the mature-protein coding regions in gf-2.8 and gf-3.8 is allied with no change whatever in a central part (61-151) of the encoded polypeptide sequences. It seems likely that this central, strongly conserved core in the germins is of first importance in the biochemical involvements of the proteins. When an equivalence is assumed between like amino acids, the gf-2.8 and gf-3.8 germins show significant (approximately 44%) similarity to spherulins 1a and 1b of Physarum polycephalum, a similarity that increases to approximately 50% in the conserved core of germin. Near the middle (87-96) of the conserved core in the germins is a rare PH(I/T)HPRATEI decapeptide sequence which is shared by spherulins (1a and 1b) and germins (gf-2.8 and gf-3.8). These similarities are discussed in the context of evidence which can be interpreted to suggest that the biochemistry of germins and spherulins is involved with cellular, perhaps cell-wall responses to desiccation, hydration, and osmotic stress. Of special interest in this regard, the 5'-flanking region in the gf-2.8 gene contains two sequences which are characteristic of auxin-responsive genes.	UNIV LAVAL,FAC SCI & GENIE,DEPT BIOL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA	Laval University	LANE, BG (corresponding author), UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA.		Bernier, Francois/AAP-2174-2020; Bernier, Francois/V-7150-2018	Altomare, Filiberto/0000-0002-2589-6320				BAKER J, 1988, PLANT MOL BIOL, V11, P277, DOI 10.1007/BF00027385; BERNIER F, 1987, GENE, V59, P265, DOI 10.1016/0378-1119(87)90334-9; BERNIER F, 1986, BIOCHEM CELL BIOL, V64, P337, DOI 10.1139/o86-047; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Chandler P. M., 1988, J CELL BIOCHEM     S, V12, P143; CHET I, 1969, J BACTERIOL, V100, P674; CLOSE TJ, 1989, PLANT MOL BIOL, V13, P95, DOI 10.1007/BF00027338; CUMING AC, 1984, EUR J BIOCHEM, V145, P351, DOI 10.1111/j.1432-1033.1984.tb08561.x; CUMING AC, 1979, EUR J BIOCHEM, V99, P217, DOI 10.1111/j.1432-1033.1979.tb13248.x; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DRATEWKAKOS E, 1989, J BIOL CHEM, V264, P4896; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; FUTERS TS, 1990, THEOR APPL GENET, V80, P43, DOI 10.1007/BF00224014; GALAU GA, 1987, DEV BIOL, V123, P198, DOI 10.1016/0012-1606(87)90442-8; GOMEZ J, 1988, NATURE, V334, P262, DOI 10.1038/334262a0; Gorman J. A., 1980, GROWTH DIFFERENTIATI, P157; GRZELCZAK ZF, 1983, CAN J BIOCHEM CELL B, V61, P1233, DOI 10.1139/o83-159; GRZELCZAK ZF, 1985, CAN J BIOCHEM CELL B, V63, P1003, DOI 10.1139/o85-125; GRZELCZAK ZF, 1984, CAN J BIOCHEM CELL B, V62, P1351, DOI 10.1139/o84-172; GRZELCZAK ZF, 1982, CAN J BIOCHEM CELL B, V60, P389, DOI 10.1139/o82-046; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HAM J, 1989, NUCLEIC ACIDS RES, V17, P5781, DOI 10.1093/nar/17.14.5781; HANLEYBOWDOIN L, 1983, EUR J BIOCHEM, V135, P9, DOI 10.1111/j.1432-1033.1983.tb07611.x; HOFMANN T, 1984, CAN J BIOCHEM CELL B, V2, P908; HURKMAN W J, 1990, Plant Physiology (Rockville), V93, P108; Hurkman WJ, 1990, ENV INJURY PLANTS, P205; JAIKARAN ASI, 1990, J BIOL CHEM, V265, P12503; JOHNSTON FB, 1957, NATURE, V179, P160, DOI 10.1038/179160b0; JUMP JA, 1954, AM J BOT, V41, P561, DOI 10.2307/2438716; KENNEDY TD, 1979, CAN J BIOCHEM CELL B, V57, P927, DOI 10.1139/o79-112; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; LANE B, 1987, BIOCHEM CELL BIOL, V65, P1001, DOI 10.1139/o87-131; LANE B, 1987, BIOCHEM CELL BIOL, V65, P354, DOI 10.1139/o87-045; LANE BG, 1986, BIOCHEM CELL BIOL, V64, P1025, DOI 10.1139/o86-136; LANE BG, 1988, ROOTS OF MODERN BIOCHEMISTRY, P457; LANE BG, 1981, EUR J BIOCHEM, V114, P457, DOI 10.1111/j.1432-1033.1981.tb05167.x; LANE BG, 1981, CAN J BIOCHEM CELL B, V59, P868, DOI 10.1139/o81-120; LANE BG, 1985, LIPMANN S CELLULAR R, P311; Marcus A, 1969, Symp Soc Exp Biol, V23, P143; MCCLURE BA, 1989, PLANT CELL, V1, P229, DOI 10.1105/tpc.1.2.229; MCCUBBIN WD, 1985, CAN J BIOCHEM CELL B, V63, P803, DOI 10.1139/o85-102; Messing J., 1988, FOCUS, V10, P21; MORRIS PC, 1990, EUR J BIOCHEM, V190, P625, DOI 10.1111/j.1432-1033.1990.tb15618.x; MUNDY J, 1988, EMBO J, V7, P2279, DOI 10.1002/j.1460-2075.1988.tb03070.x; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; MURRAY MG, 1984, GENE, V30, P237, DOI 10.1016/0378-1119(84)90126-4; QU LH, 1983, NUCLEIC ACIDS RES, V11, P5903, DOI 10.1093/nar/11.17.5903; RAHMAN S, 1988, BIOCHEM CELL BIOL, V66, P100, DOI 10.1139/o88-013; Raub T. J., 1982, CELL BIOL PHYSARUM D, VII, P21; SEARS ER, 1974, HDB GENETICS, V2, P59; SHAFAI R, 1989, THESIS U TORONTO; SHELNESS GS, 1985, J BIOL CHEM, V260, P8637; SMITH JJ, 1989, PLANT MOL BIOL, V13, P601, DOI 10.1007/BF00027321; THOMPSON EW, 1980, J BIOL CHEM, V255, P5965; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940	59	104	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10461	10469						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037593				2022-12-25	WOS:A1991FP08600071
J	LOKKER, NA; MOVVA, NR; STRITTMATTER, U; FAGG, B; ZENKE, G				LOKKER, NA; MOVVA, NR; STRITTMATTER, U; FAGG, B; ZENKE, G			STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF HUMAN INTERLEUKIN-3 - IDENTIFICATION OF RESIDUES REQUIRED FOR BIOLOGICAL-ACTIVITY BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NEUTRALIZING MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; BINDING; RECEPTOR; PROTEINS; IL-3; DIFFERENTIATION; EXPRESSION; PREDICTION	Recombinant human interleukin-3 (rhuIL-3) variants were generated by site-directed mutagenesis and expression in Escherichia coli. Amino acid deletions and substitutions were made in the previously identified epitopes of two huIL-3-specific neutralizing monoclonal antibodies (mAbs). The rhuIL-3 variants were analyzed for their ability to bind to the IL-3 receptor and to induce the proliferation of the human IL-3-dependent cell line M-O7. Several deletion mutants spanning the epitopes of these neutralizing mAbs indicated the importance of residues Pro33 and Leu34 for biological activity. Further, substitution of Pro33 with Asn (Asn33) showed an enhanced proliferative activity (4-fold) and a moderate increase in receptor binding (2-fold) compared to wild-type (wt) rhuIL-3. The most remarkable change, however, was seen with variant Gly33, which showed a 14-fold increase in promoting the growth of M-O7 cells without a significant modification in its receptor binding capacity. In contrast, substitution of Leu34 with Gly (Gly34) yielded an IL-3 variant that had a 25-fold decreased receptor binding capacity and proliferative activity, while Glu34 had properties similar to wild-type rhuIL-3. Analysis of the binding of these variants to different rhuIL-3-specific monoclonal antibodies suggested that no major modification had occurred in their conformations. These results indicate that both residues, Pro33 and Leu34, play a critical role in modulating the activity of rhuIL-3.	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Novartis; Sandoz								ALTMAN A, 1984, P NATL ACAD SCI-BIOL, V81, P2176, DOI 10.1073/pnas.81.7.2176; ANTONI G, 1986, J IMMUNOL, V137, P3201; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BROWN CB, 1990, J IMMUNOL, V144, P2184; BUDEL LM, 1990, BLOOD, V75, P1439; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COHEN FE, 1986, SCIENCE, V234, P349, DOI 10.1126/science.3489989; COLLAWN JF, 1988, J BIOL CHEM, V263, P8625; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; GILLIO AP, 1990, J CLIN INVEST, V85, P1560, DOI 10.1172/JCI114605; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAUSHANSKY K, 1990, INT J CELL CLONING, V8, P26, DOI 10.1002/stem.5530080704; KOBAYASHI M, 1990, BLOOD, V75, P2143; KUO LM, 1986, J IMMUNOL, V137, P1538; KURIMOTO Y, 1989, J EXP MED, V170, P467, DOI 10.1084/jem.170.2.467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDGRAF B, 1989, J BIOL CHEM, V264, P816; LILLQUIST JS, 1988, J IMMUNOL, V141, P1975; LOKKER NA, 1991, J IMMUNOL, V146, P893; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; Maniatis T., 1982, MOL CLONING; MARINUS MG, 1973, J BACTERIOL, V114, P1143, DOI 10.1128/JB.114.3.1143-1150.1973; MATTEUCCI MD, 1981, J AM CHEM SOC, V103, P3185, DOI 10.1021/ja00401a041; MAYER P, 1989, BLOOD, V74, P613; MOORE MAS, 1988, LYMPHOKINES, V15, P219; MORRIS CF, 1990, COLONY STIMULATING F, V49, P177; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OKABE M, 1990, BLOOD, V75, P1788; PARK LS, 1989, J BIOL CHEM, V264, P5420; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; ROBB RJ, 1988, P NATL ACAD SCI USA, V85, P5654, DOI 10.1073/pnas.85.15.5654; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMON D, 1987, PLASMID, V17, P46, DOI 10.1016/0147-619X(87)90007-2; Smith K A, 1990, Eur Cytokine Netw, V1, P7; TADMORI W, 1989, J IMMUNOL, V142, P1950; URDAL DL, 1989, ANN NY ACAD SCI, V554, P167, DOI 10.1111/j.1749-6632.1989.tb22418.x; YANG YC, 1990, INT J CELL CLONING, V8, P121, DOI 10.1002/stem.5530080711; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	45	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10624	10631						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037601				2022-12-25	WOS:A1991FP08600093
J	BELGRADER, P; DEY, R; BEREZNEY, R				BELGRADER, P; DEY, R; BEREZNEY, R			MOLECULAR-CLONING OF MATRIN-3 - A 125-KILODALTON PROTEIN OF THE NUCLEAR MATRIX CONTAINS AN EXTENSIVE ACIDIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; LAMIN-B; INTERCHROMATIN GRANULES; MONOCLONAL-ANTIBODIES; C SHARE; SEQUENCE; ORGANIZATION; CDNA; IDENTIFICATION; LIVER	We report here the cloning and sequencing of matrin 3, an acidic internal matrix protein, from a rat insuloma cDNA library. The nucleotide sequence has a single open reading frame encoding a polypeptide of 845 amino acids. The Genbank and National Biomedical Research Foundation databases did not contain any sequences similar to that of matrin 3. The primary structure consists of 33% charged residues and is generally hydrophilic. The amino-terminal region (residues 1-120) is positively charged and contains a large number of amino acids with free hydroxyl groups (26 of the first 100 residues) as in the lamins and several non-lamin intermediate filament proteins. A highly acidic domain (approximately 170 amino acids) near the carboxyl terminus, in which 32% of the amino acid residues are acidic (Glu or Asp), is a characteristic found in other nuclear proteins (Earnshaw, W. C. (1987) J. Cell Biol. 105, 1479-1482). A putative nuclear targeting signal sequence (Ser-Lys-Lys-Lys-Leu-Lys-Lys-Val-Glu) is located in the middle of the highly acidic domain. The corresponding human deduced partial amino acid sequence is 96% identical to the rat sequence, indicating that matrin 3 is a highly conserved protein.	SUNY BUFFALO, DEPT BIOL SCI, BUFFALO, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023922] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-23922] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUTTER PS, 1980, J CELL SCI, V44, P395; AGUTTER PS, 1985, NUCLEAR ENVELOPE STR, P539; ALLEN SL, 1977, BIOCHEM BIOPH RES CO, V75, P111, DOI 10.1016/0006-291X(77)91296-7; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P119; Berezney R, 1979, CELL NUCLEUS, V7, P413; BODNAR JW, 1988, J THEOR BIOL, V132, P479, DOI 10.1016/S0022-5193(88)80086-9; BOUTEILLE M, 1983, INT REV CYTOL, V83, P135, DOI 10.1016/S0074-7696(08)61687-3; CHALY N, 1984, J CELL BIOL, V99, P661, DOI 10.1083/jcb.99.2.661; CLEVENGER CV, 1984, EXP CELL RES, V151, P194, DOI 10.1016/0014-4827(84)90368-9; COMINGS DE, 1981, CELL NUCLEUS, V9, P89; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; FAIFERMAN I, 1975, BIOCHEMISTRY-US, V14, P3808, DOI 10.1021/bi00688a013; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FIELDS AP, 1986, EXP CELL RES, V164, P139, DOI 10.1016/0014-4827(86)90461-1; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HANCOCK R, 1982, BIOL CELL, V46, P105; HERMAN R, 1978, J CELL BIOL, V78, P663, DOI 10.1083/jcb.78.3.663; HOGER TH, 1988, EUR J CELL BIOL, V47, P283; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; JACKSON DA, 1984, J CELL SCI, P59; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAUFMANN SH, 1989, J BIOL CHEM, V264, P13946; KROHNE G, 1987, EMBO J, V6, P3801, DOI 10.1002/j.1460-2075.1987.tb02716.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEBEL S, 1987, EXP CELL RES, V169, P560, DOI 10.1016/0014-4827(87)90216-3; LEHNER CF, 1986, EXP CELL RES, V162, P205, DOI 10.1016/0014-4827(86)90439-8; LEHNER CF, 1986, J BIOL CHEM, V261, P3293; MANIATIS T, 1982, MOL CLONING LABORATO, P326; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MILLER TE, 1978, J CELL BIOL, V76, P675, DOI 10.1083/jcb.76.3.675; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; NICKERSON JA, 1990, P NATL ACAD SCI USA, V87, P2259, DOI 10.1073/pnas.87.6.2259; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; OSBORN M, 1987, EXP CELL RES, V170, P195, DOI 10.1016/0014-4827(87)90129-7; PETERS KE, 1980, J CELL BIOL, V86, P135, DOI 10.1083/jcb.86.1.135; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUSTELL J, 1982, NUCLEIC ACIDS RES, V10, P51, DOI 10.1093/nar/10.1.51; RAZIN SV, 1987, BIOESSAYS, V6, P19, DOI 10.1002/bies.950060106; RIEDEL W, 1989, BIOCHIM BIOPHYS ACTA, V1008, P119, DOI 10.1016/0167-4781(89)90179-6; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shaper J H, 1978, Adv Enzyme Regul, V17, P213; SHELTON KR, 1980, J BIOL CHEM, V255, P978; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH HC, 1985, J CELL BIOL, V101, P560, DOI 10.1083/jcb.101.2.560; STUURMAN N, 1990, J BIOL CHEM, V265, P5460; TURNER BM, 1987, J CELL SCI, V87, P269; VERHEIJEN R, 1988, J CELL SCI, V90, P11; VERHEIJEN R, 1986, J CELL SCI, V80, P103; WALKER JM, 1980, FEBS LETT, V122, P264, DOI 10.1016/0014-5793(80)80453-4	63	125	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9893	9899						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033075				2022-12-25	WOS:A1991FM45900082
J	GUPTA, SD; DOWHAN, W; WU, HC				GUPTA, SD; DOWHAN, W; WU, HC			PHOSPHATIDYLETHANOLAMINE IS NOT ESSENTIAL FOR THE N-ACYLATION OF APOLIPOPROTEIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID VESICLE FUSION; MUREIN-LIPOPROTEIN; OUTER-MEMBRANE; SALMONELLA-TYPHIMURIUM; ACYL MOIETIES; INTACT-CELLS; FATTY-ACIDS; BIOSYNTHESIS; PROLIPOPROTEIN; DIGLYCERIDE	It has been postulated that the N-acyl fatty acid attached to the amino terminus of the major Escherichia coli lipoprotein is derived from the fatty acid at the 1-position of phosphatidylethanolamine (PtdEtn) (Jackowski, S., and Rock, C. O. (1986) J. Biol. Chem. 261, 11328-11333). To ascertain the role of PtdEtn in the conversion of apolipoprotein to the mature lipoprotein the lipoprotein from E. coli strain AH930 (pss::kan) containing a null mutation in the phosphatidylserine synthase gene (pss) was studied. Pulse labeling with [S-35]methionine for 30 s or 5 min revealed the formation of mature lipoprotein in both wild-type (W3110) and mutant (AH930) cells. [H-3]Palmitate-labeled lipoproteins from both the mutant and wild-type cells were found to contain nearly identical amounts of alkali-resistant (amide-linked, 41-42%) and alkali-labile (ester-linked, 58-59%) fatty acids. Edman degradation and dansylation of the immunoaffinity-purified [S-35]cysteine-labeled lipoprotein showed that the NH2 terminus of the lipoprotein in the mutant was blocked as in the wild type. In vitro assay of apolipoprotein N-acyltransferase using membranes either from the mutant or the wild-type strain as the source of both the enzyme and the acyl donor revealed that both membranes were equally active in the conversion of [S-35]methionine-labeled apolipoprotein to lipoprotein. These data strongly suggest that PtdEtn is not essential for the N-acylation of apolipoprotein to form lipoprotein, and other major phospholipids such as phosphatidylglycerol and cardiolipin can serve as the donor of fatty acid in the N-acylation of apolipoprotein.	UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL,4301 JONES BRIDGE RD,BETHESDA,MD 20814; UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	Uniformed Services University of the Health Sciences - USA; University of Texas System					NIGMS NIH HHS [GM20487, GM28810] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028810] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTSCH LL, 1969, J BACTERIOL, V98, P75, DOI 10.1128/JB.98.1.75-81.1969; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAUN V, 1969, EUR J BIOCHEM, V10, P426, DOI 10.1111/j.1432-1033.1969.tb00707.x; BRAUN V, 1970, EUR J BIOCHEM, V13, P336, DOI 10.1111/j.1432-1033.1970.tb00936.x; BRIDGEN J, 1975, INSTRUMENTATION AMIN, P118; CHATTOPADHYAY PK, 1977, P NATL ACAD SCI USA, V74, P5318, DOI 10.1073/pnas.74.12.5318; CHATTOPADHYAY PK, 1979, J BACTERIOL, V137, P309, DOI 10.1128/JB.137.1.309-312.1979; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DEV IK, 1984, J BIOL CHEM, V259, P1114; GUPTA SD, 1991, FEMS MICROBIOL LETT, V78, P37; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; Harris E L, 1988, Methods Mol Biol, V3, P33, DOI 10.1385/0-89603-126-8:33; HARTLEY BS, 1970, BIOCHEM J, V119, P805, DOI 10.1042/bj1190805f; HUSSAIN M, 1982, J BIOL CHEM, V257, P5177; JACKOWSKI S, 1986, J BIOL CHEM, V261, P1328; KANEGASAKI S, 1979, EUR J BIOCHEM, V95, P287, DOI 10.1111/j.1432-1033.1979.tb12964.x; LAI JS, 1980, J BACTERIOL, V144, P451, DOI 10.1128/JB.144.1.451-453.1980; LAI JS, 1980, J BIOL CHEM, V255, P5384; LIN JJC, 1976, J BACTERIOL, V125, P892, DOI 10.1128/JB.125.3.892-904.1976; NISHIJIMA S, 1988, J BACTERIOL, V170, P775, DOI 10.1128/jb.170.2.775-780.1988; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TOKUNAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P2255, DOI 10.1073/pnas.79.7.2255; TOKUNAGA M, 1984, J BIOL CHEM, V259, P3825	23	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9983	9986						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033085				2022-12-25	WOS:A1991FM45900096
J	MAY, LT; SANTHANAM, U; SEHGAL, PB				MAY, LT; SANTHANAM, U; SEHGAL, PB			ON THE MULTIMERIC NATURE OF NATURAL HUMAN INTERLEUKIN-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTOR; BETA-2 INTERFERON; MULTIPLE FORMS; GROWTH-FACTOR; FACTOR-II; RECEPTOR; EXPRESSION; CELLS; INFECTION; MONOCYTES	Natural human interleukin-6 (IL-6) characterized under completely denaturing conditions consists of a set of differentially modified phosphoglycoproteins of molecular mass in the range from 23 to 30 kDa ("25-kDa" O-glycosylated species and "30-kDa" O- and N-glycosylated species). The 25-kDa O-glycosylated IL-6 (which contains only Ser- or Thr-GalNAc-Gal-NeuNAc and thus should not bind wheat germ or lentil lectins) bound to and was eluted from a wheat germ lectin affinity column by GlcNAc and from a lentil lectin affinity column by methyl-alpha-D-Man suggesting that the 25-kDa IL-6 species formed heteromeric complexes with the N-glycosylated 30-kDa IL-6. In nondenaturing gels (0.2% Nonidet P-40-polyacrylamide gel electrophoresis (PAGE)), even under reducing conditions (15 mM dithiothreitol or 1 M beta-mercaptoethanol and heating), fibroblast-derived IL-6 migrated as a predominant complex of mass approximately 85 kDa and additional minor 45-65-kDa complexes. Little IL-6 was detected in the size range 23-30 kDa. Elution of the major 85-kDa complex and re-electrophoresis through sodium dodecyl sulfate-PAGE revealed that it represented a heteromeric aggregate of the 25- and 30-kDa IL-6 species the 45-65-kDa complexes were largely composed of the 25-kDa protein. The bulk of fibroblast-derived IL-6 eluted in the size range 45-85 kDa from a Sephadex G-200 gel filtration column further indicating that fibroblast-derived IL-6 was largely multimeric even in dilute solutions. Functionally the high molecular mass IL-6 fractions from the G-200 column were less active in the B9 hybridoma growth factor assay than the lower molecular mass fractions but appeared to be equally active in the Hep3B hepatocyte-stimulating factor assay. Taken together, the data indicate that natural human IL-6 exists as a multimeric aggregate with varying biological activity.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016262] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16262] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1989, Ann N Y Acad Sci, V557, P1; BARRY MR, 1985, P NATL ACAD SCI USA, V82, P1443; BAUER J, 1988, BLOOD, V72, P1134; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BHARDWAJ N, 1989, J IMMUNOL, V143, P2153; BOWCOCK A M, 1988, Genomics, V3, P8, DOI 10.1016/0888-7543(88)90152-8; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1987, J IMMUNOL, V139, P4116; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; COULIE PG, 1987, EUR J IMMUNOL, V17, P1435, DOI 10.1002/eji.1830171008; FERGUSON-SMITH A C, 1988, Genomics, V2, P203, DOI 10.1016/0888-7543(88)90003-1; FONG YM, 1989, J IMMUNOL, V142, P2321; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P19758; FULLER GM, 1985, J CELL BIOL, V101, P1481, DOI 10.1083/jcb.101.4.1481; HELFGOTT DC, 1989, J IMMUNOL, V142, P948; JABLONS DM, 1989, J IMMUNOL, V142, P1542; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; MAY LT, 1988, J BIOL CHEM, V263, P7760; MAY LT, 1988, BIOCHEM BIOPH RES CO, V152, P1144, DOI 10.1016/S0006-291X(88)80404-2; MOOS M, 1988, J BIOL CHEM, V263, P6005; PESTKA S, 1983, J BIOL CHEM, V258, P9706; ROMERO R, 1990, J CLIN INVEST, V85, P1392, DOI 10.1172/JCI114583; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; SANTHANAM U, 1989, ARCH BIOCHEM BIOPHYS, V274, P161, DOI 10.1016/0003-9861(89)90427-X; SCHIEL X, 1990, EUR J IMMUNOL, V20, P883, DOI 10.1002/eji.1830200425; SEHGAL PB, 1987, SCIENCE, V235, P731, DOI 10.1126/science.3492764; SEHGAL PB, 1990, MOL BIOL MED, V7, P117; SEHGAL PB, 1986, P NATL ACAD SCI USA, V83, P5219, DOI 10.1073/pnas.83.14.5219; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; URBANSKI A, 1990, J INVEST DERMATOL, V94, P808, DOI 10.1111/1523-1747.ep12874666; VANOERS MHJ, 1988, CLIN EXP IMMUNOL, V71, P314; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	38	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9950	9955						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033081				2022-12-25	WOS:A1991FM45900091
J	OKA, S; ARITA, H				OKA, S; ARITA, H			INFLAMMATORY FACTORS STIMULATE EXPRESSION OF GROUP-II PHOSPHOLIPASE-A2 IN RAT CULTURED ASTROCYTES - 2 DISTINCT PATHWAYS OF THE GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MESSENGER-RNA SYNTHESIS; ARACHIDONIC-ACID; PROSTAGLANDIN-E; CEREBROSPINAL-FLUID; BRAIN; GLUCOCORTICOIDS; INTERLEUKIN-1; PURIFICATION; METABOLISM	Inflammatory factors such as tumor necrosis factor (TNF), interleukin 1 (IL-1), and lipopolysaccharide (LPS) greatly enhance the expression of group II phospholipase A2 (PLA2-II) mRNA, leading to increased secretion of PLA2-II enzyme from rat-cultured astrocytes. The potent antiinflammatory agent dexamethasome suppressed the PLA2-II expression induced by LPS. In vivo studies also demonstrated that the level of PLA2-II mRNA in the brain increased with intravenous injection of LPS. These results suggest that PLA2-II in the brain plays important roles in the inflammatory response. Agents which increase intracellular cAMP concentration did not stimulate PLA2-II expression by themselves but selectively enhanced TNF-induced PLA2-II expression about 5-fold. Phorbol ester, a well known protein kinase C activator, increased the PLA2-II expression. H-7, a protein kinase C inhibitor, inhibited the LPS-induced PLA2-II expression, but did not inhibit the TNF-induced one. Therefore, we conclude that the TNF-activated pathway differs from the LPS-activated one: the former is enhanced by cAMP and the latter involves protein kinase C.	SHIONOGI & CO LTD,SHIONOGI RES LAB,5-12-4 SAGISU,FUKUSHIMA KU,OSAKA 553,JAPAN	Shionogi & Company Limited								BERNHEIM HA, 1980, J PHYSIOL-LONDON, V301, P69, DOI 10.1113/jphysiol.1980.sp013189; BOLTON C, 1984, INT J IMMUNOPHARMACO, V6, P155, DOI 10.1016/0192-0561(84)90011-0; BOSISIO E, 1976, PROSTAGLANDINS, V11, P773, DOI 10.1016/0090-6980(76)90186-6; CHANG HW, 1987, J BIOCHEM, V102, P147, DOI 10.1093/oxfordjournals.jbchem.a122026; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; FONTANA A, 1984, J IMMUNOL, V133, P1696; FORST S, 1986, BIOCHEMISTRY-US, V25, P8381, DOI 10.1021/bi00374a008; GAUDET RJ, 1980, J NEUROCHEM, V35, P653, DOI 10.1111/j.1471-4159.1980.tb03704.x; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HARA S, 1988, J BIOCHEM-TOKYO, V104, P326, DOI 10.1093/oxfordjournals.jbchem.a122467; HARTUNG HP, 1987, BRAIN RES, V417, P347, DOI 10.1016/0006-8993(87)90461-6; HAYAKAWA M, 1987, J BIOCHEM-TOKYO, V101, P1311, DOI 10.1093/oxfordjournals.jbchem.a121996; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; IWASAKI N, 1984, J MED SOC TOHO U, V30, P692; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; Maniatis T, 1982, MOL CLONING LABORATO; MARKI F, 1986, BIOCHIM BIOPHYS ACTA, V879, P149, DOI 10.1016/0005-2760(86)90097-4; MERRILL JE, 1983, J NEUROIMMUNOL, V4, P223, DOI 10.1016/0165-5728(83)90037-1; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; YAMAMOTO K, 1988, BIOCHEM BIOPH RES CO, V156, P882, DOI 10.1016/S0006-291X(88)80926-4	28	279	283	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9956	9960						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033082				2022-12-25	WOS:A1991FM45900092
J	PRYZDIAL, ELG; MANN, KG				PRYZDIAL, ELG; MANN, KG			THE ASSOCIATION OF COAGULATION FACTOR-XA AND FACTOR-VA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BOVINE FACTOR-X; CALCIUM-BINDING PROPERTIES; ACTIVATED PROTEIN-C; PROTHROMBINASE COMPLEX; PHOSPHOLIPID-VESICLES; CATALYZED ACTIVATION; ISOLATED SUBUNITS; ENZYME; MECHANISM	The binding of factor Xa to factor Va in the presence of Ca2+ ions and phospholipid is fundamental for the activation of prothrombin to thrombin. Nevertheless, the biochemistry of the intrinsic association between factors Xa and Va is poorly understood. In the present study we have measured the formation of the protein-protein complex in the absence of phospholipid by using analytical ultracentrifugation. Factor Xa or factor Va were respectively modified with a chromophore-peptidyl-chloromethyl ketone or a thiol-specific chromophore, which permitted selective evaluation of the sedimentation of either component by virtue of its unique absorbance properties. Regardless of which protein was labeled, a factor Xa-Va complex (s20,w = 9.8) was formed. The interaction is specific and reversible. In 2 mM Ca2+ and at 20-degrees-C, the dissociation constant for the binding of factor Xa to factor Va is 0.8-mu-M with a 1:1 stoichiometry. The association has multiphasic Ca2+ dependence. At concentrations of Ca2+ below 1 mM or above 2 mM, a weaker protein-protein equilibrium is maintained.	UNIV VERMONT, DEPT BIOCHEM, BURLINGTON, VT 05404 USA	University of Vermont					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL035058] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35058] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNAMALAI AE, 1987, BLOOD, V70, P139; BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BERG OG, 1985, BIOPHYS J, V47, P1, DOI 10.1016/S0006-3495(85)83870-4; BLOOM JW, 1978, BIOCHEMISTRY-US, V17, P4430, DOI 10.1021/bi00614a012; BOHLEN P, 1983, METHOD ENZYMOL, V91, P17; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P531; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; ESMON CT, 1979, J BIOL CHEM, V254, P964; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1982, J BIOL CHEM, V257, P38; HALEY PE, 1989, J BIOL CHEM, V264, P16303; HAUGLAND RP, 1989, MOL PROBES HDB, P35; HENDERSON PJ, 1973, BIOCHEM J, V135, P101, DOI 10.1042/bj1350101; HENRIKSEN RA, 1975, ARCH BIOCHEM BIOPHYS, V170, P149, DOI 10.1016/0003-9861(75)90106-X; HIBBARD LS, 1980, J BIOL CHEM, V255, P638; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4506, DOI 10.1021/bi00852a047; JACKSON CM, 1984, PROG HEMOST THROMB, V7, P55; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JOHNSTON JP, 1946, T FARADAY SOC, V42, P789, DOI 10.1039/tf9464200789; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4893, DOI 10.1021/bi00667a022; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LINDHOUT MJ, 1978, BIOCHIM BIOPHYS ACTA, V533, P318, DOI 10.1016/0005-2795(78)90378-1; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5494, DOI 10.1021/bi00265a018; MAMMEN EF, 1983, SEMIN THROMB HEMOST, V9, pU1; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1980, HDB CLIN LABORATORY, P15; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORRIS S, 1978, J BIOL CHEM, V253, P4604; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; Oncley J. L., 1941, ANN NY ACAD SCI, V41, P121; OWREN PA, 1947, LANCET, V252, P446; RADCLIFFE RD, 1972, J BIOL CHEM, V247, P7735; RADCLIFFE RD, 1973, ARCH BIOCHEM BIOPHYS, V155, P381, DOI 10.1016/0003-9861(73)90127-6; ROSING J, 1980, J BIOL CHEM, V255, P274; SEGAL IH, 1975, ENZYME KINETICS BEHA, P72; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; SUGO T, 1984, J BIOL CHEM, V259, P5705; TANFORD C, 1961, PHYSICAL CHEM MACROM, P194; TRACY PB, 1983, J BIOL CHEM, V258, P662; TRACY PB, 1987, HUM PATHOL, V18, P162, DOI 10.1016/S0046-8177(87)80334-9; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TUCKER MM, 1983, J BIOL CHEM, V258, P1210; TUCKER MM, 1983, BIOCHEMISTRY-US, V22, P4540, DOI 10.1021/bi00288a029; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; YUE RH, 1978, THROMB HAEMOSTASIS, V40, P350	66	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8969	8977						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026608				2022-12-25	WOS:A1991FM03800050
J	THOMPSON, KS; TOWLE, HC				THOMPSON, KS; TOWLE, HC			LOCALIZATION OF THE CARBOHYDRATE RESPONSE ELEMENT OF THE RAT L-TYPE PYRUVATE-KINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POST-TRANSCRIPTIONAL REGULATION; THYROID-HORMONE; MESSENGER-RNAS; LIVER; EXPRESSION; GLUCOSE; FRUCTOSE; S14; TRIIODOTHYRONINE; HEPATOCYTES	Pyruvate kinase is a major regulatory enzyme of glycolysis. Transcription of the L-type pyruvate kinase (L-PK) gene in rat liver is induced by feeding a carbohydrate-rich diet. To investigate the regulatory DNA sequences required for this response, primary hepatocytes were transfected with plasmids containing the 5'-flanking sequence of the rat L-PK gene fused to the chloramphenicol acetyltransferase (CAT) gene. Sequences from -4300 to +12 of the L-PK gene directed an increase in CAT activity when hepatocytes were switched from media containing 10 mM lactate to 25 mM glucose. Average induction was 17-fold (n = 13; S.E. = 2.9). Addition of fructose to the media also induced CAT activity. Carbohydrate regulation of the L-PK promoter was retained with 5'-deletions to -197, but constructs deleted to -96 were completely unresponsive. The 101-base pair fragment from -197 to -96 of the L-PK gene can confer carbohydrate regulation when fused in either orientation to the heterologous thymidine kinase promoter, thus defining a carbohydrate response element in this region. Expression of the transfected gene was regulated by insulin and glucagon in a pattern similar to that seen for the endogenous L-PK gene, suggesting that control of L-PK promoter activity was responsible for carbohydrate-mediated changes in L-PK mRNA production.	UNIV MINNESOTA,DEPT BIOCHEM,4-225 MILLARD HALL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007323] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26919] Funding Source: Medline; NIGMS NIH HHS [5T32-GM07323] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACK DW, 1986, J BIOL CHEM, V261, P4190; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; CARR FE, 1984, P NATL ACAD SCI-BIOL, V81, P974, DOI 10.1073/pnas.81.3.974; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGNET M, 1987, J MOL BIOL, V196, P11, DOI 10.1016/0022-2836(87)90507-9; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANNER D, 1990, J BIOL CHEM, V265, P10173; INOUE H, 1984, J BIOCHEM-TOKYO, V96, P1457, DOI 10.1093/oxfordjournals.jbchem.a134974; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JUMP DB, 1990, J BIOL CHEM, V265, P3474; KINLAW WB, 1986, J CLIN INVEST, V78, P1091, DOI 10.1172/JCI112665; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; MARIASH CN, 1982, ANAL BIOCHEM, V121, P388, DOI 10.1016/0003-2697(82)90498-5; MARIASH CN, 1981, J CLIN INVEST, V68, P1485, DOI 10.1172/JCI110401; MUNNICH A, 1987, J BIOL CHEM, V262, P17065; MUNNICH A, 1984, J BIOL CHEM, V259, P228; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; STROBL W, 1989, J BIOL CHEM, V264, P1190; TREMP GL, 1989, J BIOL CHEM, V264, P19904; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; YAMADA K, 1990, J BIOL CHEM, V265, P19885; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	28	136	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8679	8682						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026584				2022-12-25	WOS:A1991FM03800009
J	ORGAMBIDE, G; MONTROZIER, H; SERVIN, P; ROUSSEL, J; TRIGALETDEMERY, D; TRIGALET, A				ORGAMBIDE, G; MONTROZIER, H; SERVIN, P; ROUSSEL, J; TRIGALETDEMERY, D; TRIGALET, A			HIGH HETEROGENEITY OF THE EXOPOLYSACCHARIDES OF PSEUDOMONAS-SOLANACEARUM STRAIN GMI 1000 AND THE COMPLETE STRUCTURE OF THE MAJOR POLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATIC ANTIGENS; EXTRACELLULAR POLYSACCHARIDE; METHYLATION ANALYSIS; AVIRULENT MUTANTS; VIRULENT-STRAIN; NMR-SPECTRA; AERUGINOSA; LIPOPOLYSACCHARIDES; SPECTROSCOPY; DERIVATIVES	The exopolysaccharide of Pseudomonas solanacearum, which is believed to play an important role in bacterial virulence, was considered by most authors as a homogeneous entity essentially composed of N-acetylgalactosamine. The present work demonstrates the high degree of heterogeneity of this exopolysaccharidic material, which consists of a high molecular weight acidic polysaccharide and a mainly noncarbohydrate structure as major subfractions. Rhamnose-rich polyoside and glucan fractions are also present as minor components. We report the complete structure of the acidic heteropolymer involving, in addition to N-acetylgalactosamine, equimolar ratios of two rare amino sugars, 2-N-acetyl-2-deoxy-L-galacturonic acid and 2-N-acetyl-4-N-(3-hydroxybutanoyl)-2,4,6-trideoxy-D-glucose. The structure of this acidic exopolysaccharide provides the first precise basis for the analysis of the correlation exopolysaccharide structure with pathogenicity in P. solanacearum.	CNRS,CTR RECH BIOCHIM & GENET CELLULAIRES,118 ROUTE NARBONNE,F-31062 TOULOUSE,FRANCE; CNRS,RMN HAUT CHAMP,INTERACT MOLEC & REACTIV CHIM & PHOTOCHIM LAB,F-31062 TOULOUSE,FRANCE; INRA,BIOL MOLEC RELAT PLANTES MICROORGANISMES LAB,F-31326 CASTANET TOLOSAN,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS)								AKIYAMA Y, 1986, AGR BIOL CHEM TOKYO, V50, P747, DOI 10.1080/00021369.1986.10867455; AVIGAD GAD, 1965, METHOD CARBOHYDCHEM, V5, P161; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOCK K, 1974, J CHEM SOC PERK T 2, P293, DOI 10.1039/p29740000293; BOUCHER CA, 1985, J GEN MICROBIOL, V131, P2449; Buddenhagen I., 1986, ACIAR P, P126; BUDDENHAGEN IVAN, 1964, ANN REV PHYTOPATHOL, V2, P203, DOI 10.1146/annurev.py.02.090164.001223; CHEETHAM NWH, 1983, CARBOHYD RES, V112, P1, DOI 10.1016/0008-6215(83)88261-5; CODUTI PL, 1977, ANAL BIOCHEM, V78, P21, DOI 10.1016/0003-2697(77)90004-5; COPLIN DL, 1990, MOL PLANT MICROBE IN, V3, P271, DOI 10.1094/MPMI-3-271; Denny T. P., 1988, Molecular Plant-Microbe Interactions, V1, P215, DOI 10.1094/MPMI-1-215; DEREVITSKAYA VA, 1981, BIOORG KHIM+, V7, P410; DISCHE Z, 1962, METHODS CARBOHYDR CH, V1, P481; DODDRELL DM, 1982, J MAGN RESON, V48, P323, DOI 10.1016/0022-2364(82)90286-4; DOUGHERTY RC, 1973, ORG MASS SPECTROM, V7, P805, DOI 10.1002/oms.1210070706; DRIGUES P, 1985, J BACTERIOL, V162, P504, DOI 10.1128/JB.162.2.504-509.1985; DUDMAN WF, 1959, NATURE, V184, P1969, DOI 10.1038/1841969a0; GAGNAIRE D, 1978, ORG MAGN RESONANCE, V11, P344, DOI 10.1002/mrc.1270110706; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GLAZEBROOK J, 1990, INT J BIOL MACROMOL, V12, P67, DOI 10.1016/0141-8130(90)90055-F; GODWA SS, 1980, PHYTOPATHOL Z, V98, P68; GRAY JX, 1990, MOL MICROBIOL, V4, P1425, DOI 10.1111/j.1365-2958.1990.tb02052.x; HAVERKAMP J, 1982, EUR J BIOCHEM, V122, P305, DOI 10.1111/j.1432-1033.1982.tb05881.x; HNDRICK C, 1984, APPL ENVIRON MICROB, V8, P94; HOLLINGSWORTH RI, 1984, CARBOHYD RES, V134, pC7, DOI 10.1016/0008-6215(84)85035-1; HUSAIN A, 1958, PHYTOPATHOLOGY, V48, P155; JANDA J, 1971, FEBS LETT, V16, P343, DOI 10.1016/0014-5793(71)80386-1; KARKKAINEN J, 1969, CARBOHYD RES, V10, P113, DOI 10.1016/S0008-6215(00)81093-9; KELMAN A, 1954, PHYTOPATHOLOGY, V44, P693; KNIREL YA, 1982, EUR J BIOCHEM, V125, P221, DOI 10.1111/j.1432-1033.1982.tb06672.x; KNIREL YA, 1985, EUR J BIOCHEM, V150, P541, DOI 10.1111/j.1432-1033.1985.tb09055.x; KNIREL YA, 1986, EUR J BIOCHEM, V155, P659, DOI 10.1111/j.1432-1033.1986.tb09537.x; KNIREL YA, 1984, CARBOHYD RES, V133, pC8; Kochetkov N K, 1966, Adv Carbohydr Chem Biochem, V21, P39; KOERNER TAW, 1987, METHOD ENZYMOL, V138, P38; LIPKIND GM, 1988, CARBOHYD RES, V175, P59, DOI 10.1016/0008-6215(88)80156-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PHILIPHOLLINGSWORTH S, 1989, J BIOL CHEM, V264, P5710; SHARON N, 1960, J BIOL CHEM, V235, P1; SHASHKOV AS, 1979, CARBOHYD RES, V72, P215, DOI 10.1016/S0008-6215(00)83938-5; SHERBROCKCOX V, 1984, CARBOHYD RES, V135, P147, DOI 10.1016/0008-6215(84)85012-0; Taylor R. L., 1976, METHODS CARBOHYDRATE, V7, P149; TRIGALETDEMERY D, 1989, NATO ASI SER H, V28, P219; VANDERVEEN M, 1963, J ORG CHEM, V28, P564; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5; WALLIS FM, 1978, PHYSIOL PLANT PATHOL, V13, P307, DOI 10.1016/0048-4059(78)90047-4; WHATLEY MH, 1980, PLANT PHYSIOL, V65, P557, DOI 10.1104/pp.65.3.557; XU PL, 1988, J BACTERIOL, V170, P617, DOI 10.1128/jb.170.2.617-622.1988; YOKOTA S, 1988, J BIOCHEM-TOKYO, V104, P671, DOI 10.1093/oxfordjournals.jbchem.a122530; ZEHAVI S, 1973, J BIOCH, V248, P433; ZEHAVI U, 1973, J BIOL CHEM, V248, P433	53	64	70	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8312	8321						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022648				2022-12-25	WOS:A1991FK44100056
J	JONES, JC; ZHEN, WP; REED, E; PARKER, RJ; SANCAR, A; BOHR, VA				JONES, JC; ZHEN, WP; REED, E; PARKER, RJ; SANCAR, A; BOHR, VA			GENE-SPECIFIC FORMATION AND REPAIR OF CISPLATIN INTRASTRAND ADDUCTS AND INTERSTRAND CROSS-LINKS IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE GENE; PREFERENTIAL DNA-REPAIR; UVRABC EXCISION NUCLEASE; STRAND SPECIFICITY; 6-4 PHOTOPRODUCTS; N-METHYLPURINES; ACTIVE GENE; DHFR GENE; CIS-DIAMMINEDICHLOROPLATINUM(II); MECHANISM	We have used three methods to study the formation and repair of intrastrand adducts and interstrand cross-links in the DNA of Chinese hamster ovary cells induced by the anticancer drug cis-diamminedichloroplatinum II (cisplatin). Using atomic absorption spectroscopy, we found that 21% of the total genomic cisplatin adducts were removed at 8 h and 42% at 24 h. We use ABC excinuclease digestion, coupled with our previously reported methodology to quantify DNA strand breaks, to detect cisplatin intrastrand adducts in specific genomic regions. These adducts were removed faster in the transcribed dihydrofolate reductase and c-myc genes compared to a noncoding fragment, a region containing the little or nontranscribed c-fos oncogene, and to the overall genome. Interstrand cross-links in specific sequences were quantified by Southern hybridization of denatured-renatured DNA separated on a neutral gel. We found that cross-links were removed more efficiently from the gene regions than intrastrand adducts and, at high levels of cross-linking, removal was similar from transcribed and from nontranscribed regions.	NCI,MOLEC PHARMACOL LAB,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,MED BRANCH,BETHESDA,MD 20892; UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Bohr, Vilhelm/AAP-5931-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK DJ, 1985, NUCLEIC ACIDS RES, V13, P7395, DOI 10.1093/nar/13.20.7395; BOHR VA, 1990, J CANCER RES CLIN, V116, P384, DOI 10.1007/BF01612922; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1987, CANCER RES, V47, P6426; BOHR VA, 1989, LAB INVEST, V61, P143; BOHR VA, 1986, J BIOL CHEM, V261, P6666; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; CHU G, 1987, MOL BIOL MED, V4, P277; EASTMAN A, 1982, BIOCHEM BIOPH RES CO, V105, P869, DOI 10.1016/0006-291X(82)91050-6; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FLAMM WG, 1969, SUBCELLULAR COMPONEN, P129; FRAVAL HNA, 1979, CANCER RES, V39, P1793; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HARRIS LJ, 1983, NUCLEIC ACIDS RES, V11, P8303, DOI 10.1093/nar/11.23.8303; HOLLANDER MC, 1989, CANCER RES, V49, P1687; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; HUSAIN I, 1985, J BACTERIOL, V163, P817, DOI 10.1128/JB.163.3.817-823.1985; KAUFMAN RJ, 1981, MOL CELL BIOL, V1, P1069, DOI 10.1128/MCB.1.12.1069; LEDOUX SP, 1990, J BIOL CHEM, V265, P14875; MASUDA H, 1988, CANCER RES, V48, P5713; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MILLER AD, 1984, CELL, V36, P51; PAGE JD, 1990, BIOCHEMISTRY-US, V29, P1016, DOI 10.1021/bi00456a026; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; REED E, 1990, CANCER RES, V50, P2256; REED E, 1987, P NATL ACAD SCI USA, V84, P5024, DOI 10.1073/pnas.84.14.5024; REED E, 1988, ATOM SPECTROSC, V9, P93; REED E, 1988, CLIN RES, V36, pA499; Reed E., 1990, CANCER CHEMOTHERAPY, P465; Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0; ROBERTS JJ, 1981, BIOCHIM BIOPHYS ACTA, V655, P146, DOI 10.1016/0005-2787(81)90004-6; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR A, 1988, DNA REPAIR LABORATOR, V3, P479; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; TANG MS, 1989, J BIOL CHEM, V264, P14455; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VOS JMH, 1987, CELL, V50, P789, DOI 10.1016/0092-8674(87)90337-0; WASSERMANN K, 1990, J BIOL CHEM, V265, P13906; ZHEN WP, 1986, PHOTOCHEM PHOTOBIOL, V44, P47, DOI 10.1111/j.1751-1097.1986.tb03562.x; ZOLAN ME, 1984, BIOCHEMISTRY-US, V23, P63, DOI 10.1021/bi00296a010	45	172	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7101	7107						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016318				2022-12-25	WOS:A1991FG72700072
J	NEMER, M; THORNTON, RD; STUEBING, EW; HARLOW, P				NEMER, M; THORNTON, RD; STUEBING, EW; HARLOW, P			STRUCTURE, SPATIAL, AND TEMPORAL EXPRESSION OF 2 SEA-URCHIN METALLOTHIONEIN GENES, SPMTB1 AND SPMTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRONGYLOCENTROTUS-PURPURATUS; DIFFERENTIAL EXPRESSION; GEL-ELECTROPHORESIS; BINDING-PROTEIN; MESSENGER-RNAS; ACTIN GENES; CELL-TYPE; I GENE; EMBRYO; SEQUENCES	The metallothionein-B genes of the sea urchin Strongylocentrotus purpuratus encode a metallothionein (MT) isoform distinguishable from the MTA isoform. The MTB subfamily consists of at least two genes, MTB1 and MTB2, and possibly two to three others. The unique MTB1 and MTA genes have a high degree of identity but diverge in structural detail and expression. Transcripts of the MTA, MTB1, troponin C Spec 1, and CyIIIa actin genes begin simultaneously to accumulate at an early blastula stage. MTB1 mRNA becomes localized in the embryonic gut and oral ectoderm, whereas MTA, Spec 1, and CyIIIa actin mRNAs are spatially restricted to the aboral ectoderm. Several DNA elements are localized at the same positions in the MTB1 and MTA genes: these include respective CATA and TATA boxes, two metal response elements, and three distinct upstream DNA elements that are also present, and in the same order, in the Spec 1 gene promoter. A heptameric sequence, element A, is present at two sites each in the Spec 1 and CyIIIa actin genes, five sites in MTA, but only one site in MTB1. Most strikingly, the first intron of MTA contains elements not found in the MTB1 introns, including a consensus metal response element, an element A, and the P3A site demonstrated in the CyIIIa actin gene to be linked to the regulation of spatial expression.			NEMER, M (corresponding author), FOX CHASE CANC INST,INST CANC RES,PHILADELPHIA,PA 19111, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD004367] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NICHD NIH HHS [HD-04367] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKASAKA K, 1990, DEV GROWTH DIFFER, V32, P9; ANGERER LM, 1986, DEV BIOL, V116, P543, DOI 10.1016/0012-1606(86)90156-9; BONHAM K, 1987, DNA-J MOLEC CELL BIO, V6, P519, DOI 10.1089/dna.1987.6.519; BRITTEN RJ, 1978, CELL, V15, P1175, DOI 10.1016/0092-8674(78)90044-2; BRUSKIN AM, 1981, DEV BIOL, V87, P308, DOI 10.1016/0012-1606(81)90154-8; BUCHERP, 1986, NUCLEIC ACIDS RES, V24, P10009; CALZONE FJ, 1988, GENE DEV, V2, P1074, DOI 10.1101/gad.2.9.1074; CARD JP, 1988, CELL TISSUE RES, V252, P307; COHEN LH, 1981, J CELL BIOL, V91, pA69; COMPERE SJ, 1981, CELL, V25, P233, DOI 10.1016/0092-8674(81)90248-8; COX KH, 1986, J MOL BIOL, V188, P159, DOI 10.1016/0022-2836(86)90301-3; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FUREY WF, 1986, SCIENCE, V231, P704, DOI 10.1126/science.3945804; Gedamu L, 1987, Experientia Suppl, V52, P361; GRAY DM, 1981, BIOPOLYMERS, V20, P1337, DOI 10.1002/bip.1981.360200702; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HARDIN PE, 1988, J MOL BIOL, V202, P417, DOI 10.1016/0022-2836(88)90275-6; HARDIN SH, 1985, J MOL BIOL, V186, P243, DOI 10.1016/0022-2836(85)90101-9; HARLOW P, 1989, MOL CELL BIOL, V9, P5445, DOI 10.1128/MCB.9.12.5445; HEGUY A, 1986, MOL CELL BIOL, V6, P2149, DOI 10.1128/MCB.6.6.2149; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; Karin M, 1987, Experientia Suppl, V52, P401; LEE JJ, 1986, J MOL BIOL, V188, P173, DOI 10.1016/0022-2836(86)90302-5; LEE JJ, 1984, J MOL BIOL, V172, P149, DOI 10.1016/S0022-2836(84)80035-2; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LYNN DA, 1983, P NATL ACAD SCI-BIOL, V80, P2656, DOI 10.1073/pnas.80.9.2656; MCCLAY DR, 1978, DEV BIOL, V63, P179, DOI 10.1016/0012-1606(78)90123-9; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; NEMER M, 1984, DEV BIOL, V102, P471, DOI 10.1016/0012-1606(84)90212-4; NEMER M, 1986, DEV BIOL, V114, P214, DOI 10.1016/0012-1606(86)90397-0; NEMER M, 1985, P NATL ACAD SCI USA, V82, P4992, DOI 10.1073/pnas.82.15.4992; RICHARDS RI, 1984, CELL, V37, P263, DOI 10.1016/0092-8674(84)90322-2; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; Searle P F, 1987, Experientia Suppl, V52, P407; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SERFLING E, 1985, EMBO J, V4, P3851, DOI 10.1002/j.1460-2075.1985.tb04157.x; Sharp P A, 1980, Methods Enzymol, V65, P750; SHOTT RJ, 1984, DEV BIOL, V101, P295, DOI 10.1016/0012-1606(84)90143-X; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; THEZE N, 1990, MOL REPROD DEV, V25, P110, DOI 10.1002/mrd.1080250203; TOMLINSON CR, 1990, MOL REPROD DEV, V25, P328, DOI 10.1002/mrd.1080250404; VARSHNEY U, 1986, MOL CELL BIOL, V6, P26, DOI 10.1128/MCB.6.1.26; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, MOL CELL BIOL, V7, P48, DOI 10.1128/MCB.7.1.48; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; YANG Q, 1989, DEV BIOL, V135, P53, DOI 10.1016/0012-1606(89)90157-7	54	51	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6586	6593						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007604				2022-12-25	WOS:A1991FE37300086
J	SARTOR, O; SAMESHIMA, JH; ROBBINS, KC				SARTOR, O; SAMESHIMA, JH; ROBBINS, KC			DIFFERENTIAL ASSOCIATION OF CELLULAR PROTEINS WITH FAMILY PROTEIN-TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRUS SHUTTLE VECTOR; EXPRESS HIGH-LEVELS; MONOCLONAL-ANTIBODIES; PHOSPHOLIPASE-C; SARCOMA-VIRUS; GENE-PRODUCT; SRC GENE; PP60C-SRC; PHOSPHOTYROSINE; PHOSPHORYLATION	We have sought to identify candidate substrates for src family protein-tyrosine kinases potentially important for transformation. Transfected NIH/3T3 cells, each overexpressing a normal or activated version of the fyn, fgr, or src translational product, were examined using antibody to phosphotyrosine as a probe. Expression of each cDNA induced similar but distinct patterns of tyrosine phosphorylated cellular proteins, with the extent of phosphorylation being greatest in cells expressing an activated kinase. A 70-kDa tyrosine-phosphorylated protein was found to associate with the activated fyn gene product. A protein designated p130, tyrosine phosphorylated in vitro, and in vivo, was found to physically associate with the activated product of each src family gene examined. Physical interaction of three different highly transforming tyrosine kinases with a common cellular protein suggests that p130 may play an important role in transformation induced by src family kinases.	NIDR,CELLULAR DEV & ONCOL LAB,BLDG 30,RM 211,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HORAK ID, 1990, ONCOGENE, V5, P597; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KAWAKAMI Y, 1989, ONCOGENE, V4, P389; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAU AF, 1986, VIROLOGY, V151, P86, DOI 10.1016/0042-6822(86)90106-6; LAU AF, 1989, ONCOGENE RES, V1, P185; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PIWNICAWORMS H, 1986, MOL CELL BIOL, V6, P2033, DOI 10.1128/MCB.6.6.2033; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SUJITA K, 1989, J VIROL, V63, P1715; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	43	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6462	6466						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007595				2022-12-25	WOS:A1991FE37300069
J	SUGUMARAN, M; SEMENSI, V				SUGUMARAN, M; SEMENSI, V			QUINONE METHIDE AS A NEW INTERMEDIATE IN EUMELANIN BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPACHROME CONVERSION; INSECT CUTICLE; METAL-IONS; ENZYME; OXIDOREDUCTASE; SCLEROTIZATION; MECHANISM; PATHWAY	The conversion of dopachrome to dihydroxyindole(s), a key reaction in eumelanin biosynthetic pathway, has been shown to be under the control of dopachrome conversion factor. Dopachrome conversion factor isolated from the hemolymph of Manduca sexta larvae, which is devoid of any tyrosinase activity, exhibits a narrow substrate specificity and readily bleaches the iminochromes derived from the oxidation of L-dopa, L-dopa methyl ester, and alpha-methyl-L-dopa, but failed to attack the corresponding D-isomers. The product formed in the case of L-dopachrome was identified to be 5,6-dihydroxyindole. Therefore, aromatization of dopachrome seems to accompany its decarboxylation as well. However, the enzyme also converts L-dopachrome methyl ester to an indole derivative indicating that it can deprotonate the alpha-hydrogen when the carboxyl group is blocked. These results are accounted for by the transient formation and further transformation of a reactive quinone methide intermediate during the dopachrome conversion factor-catalyzed reaction. The fact that the enzyme-catalyzed conversion of alpha-methyl dopachrome methyl ester (where both decarboxylation and deprotonation are blocked) resulted in the generation of a stable quinone methide in the reaction mixture confirms this contention and supports our recent proposal that quinone methide and not indolenine is the key transient intermediate in the conversion of dopachrome to dihydroxyindole observed during melanogenesis (Sugumaran, M., Dali, H., and Semensi, B. (1990) Bioorg. Chem. 18, 144-153).			SUGUMARAN, M (corresponding author), UNIV MASSACHUSETTS,DEPT BIOL,HARBOR CAMPUS,BOSTON,MA 02125, USA.				PHS HHS [R01-A1-14753] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANGLE SR, 1990, J AM CHEM SOC, V112, P3698, DOI 10.1021/ja00165a087; ASO Y, 1989, INSECT BIOCHEM, V19, P401, DOI 10.1016/0020-1790(89)90045-0; BARBER JI, 1984, J INVEST DERMATOL, V83, P145, DOI 10.1111/1523-1747.ep12263381; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BOWERS WS, 1982, SCIENCE, V217, P647, DOI 10.1126/science.217.4560.647; GAUDIANO G, 1989, J ORG CHEM, V54, P5090, DOI 10.1021/jo00282a024; HEMMINGWAY RW, 1983, J CHEM SOC CHEM COMM, P1035; ITO S, 1989, Journal of Investigative Dermatology, V92, p261S, DOI 10.1111/1523-1747.ep13076587; KORNER AM, 1980, J INVEST DERMATOL, V75, P192, DOI 10.1111/1523-1747.ep12522650; KORNER AM, 1985, J INVEST DERMATOL, V85, P229, DOI 10.1111/1523-1747.ep12276688; LEARY GJ, 1980, WOOD SCI TECHNOL, V14, P21, DOI 10.1007/BF00353460; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; Lipke H., 1983, Advances in Insect Physiology, V17, P1, DOI 10.1016/S0065-2806(08)60216-7; MASON HS, 1948, J BIOL CHEM, V172, P83; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; PROTA G, 1988, MED RES REV, V8, P525, DOI 10.1002/med.2610080405; Raper HS, 1928, PHYSIOL REV, V8, P245, DOI 10.1152/physrev.1928.8.2.245; SAUL SJ, 1989, FEBS LETT, V255, P340, DOI 10.1016/0014-5793(89)81117-2; SAUL SJ, 1990, J BIOL CHEM, V265, P16992; SENOH S, 1959, J AM CHEM SOC, V81, P6222, DOI 10.1021/ja01532a028; SENOH S, 1959, J AM CHEM SOC, V81, P626; Sugumaran M., 1988, Advances in Insect Physiology, V21, P179, DOI 10.1016/S0065-2806(08)60124-1; SUGUMARAN M, 1987, BIOORG CHEM, V15, P194, DOI 10.1016/0045-2068(87)90019-8; SUGUMARAN M, 1990, ARCH INSECT BIOCHEM, V14, P93, DOI 10.1002/arch.940140205; SUGUMARAN M, 1990, BIOORG CHEM, V18, P144, DOI 10.1016/0045-2068(90)90036-5; SUGUMARAN M, 1990, BIOL OXIDATION SYSTE, V1, P347; THOMPSON DC, 1989, CHEM-BIOL INTERACT, V72, P157, DOI 10.1016/0009-2797(89)90025-2; WALSH C, 1982, TETRAHEDRON, V38, P871, DOI 10.1016/0040-4020(82)85068-0	28	88	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6073	6078						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007565				2022-12-25	WOS:A1991FE37300014
J	BLAKE, TJ; SHAPIRO, M; MORSE, HC; LANGDON, WY				BLAKE, TJ; SHAPIRO, M; MORSE, HC; LANGDON, WY			THE SEQUENCES OF THE HUMAN AND MOUSE C-CBL PROTOONCOGENES SHOW V-CBL WAS GENERATED BY A LARGE TRUNCATION ENCOMPASSING A PROLINE-RICH DOMAIN AND A LEUCINE ZIPPER-LIKE MOTIF	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; LYMPHOMAS	The murine Cas NS-1 retrovirus carries the v-cbl oncogene and induces pre-B cell lymphomas and myeloid leukemias. The cellular homolog of v-cbl has been identified in mouse and human DNA, and was recently mapped to mouse chromosome 9 and human chromosome 11q23. To determine the coding sequences of the human and mouse c-cbl proto-oncogenes cDNA clones were isolated from libraries prepared from the human T cell leukemia lines CCRF-CEM and HUT 78, and the mouse pre-B cell line 70Z/3. DNA sequencing revealed an open reading frame encoding 906 amino acids in the human cDNAs and 896 amino acids in 70Z/3. The sequence showed that v-cbl is a markedly truncated form of murine c-cbl containing 355 N-terminal amino acids. The nucleotide sequence of v-cbl is identical to murine c-cbl in this region, and the human sequence has only five amino acid changes in the v-cbl portion. The most notable features of the sequence which was lost in the generation of v-cbl is a C-terminal leucine zipper and a stretch of 208 amino acids containing 23% proline and 19% serine/threonine residues. This proline-rich sequence has similarities to the transcriptional activation domains of some transcription factors, and v-cbl's transforming potential may be due to the loss of this region and the leucine zipper.	INST MED & VET SCI,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA; NIAID,IMMUNOPATHOL LAB,BETHESDA,MD 20892	Institute Medical & Veterinary Science Australia; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Morse, Herbert/0000-0002-9331-3705				BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; GAZDAR AF, 1980, BLOOD, V55, P409; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; PAIGE CJ, 1978, J IMMUNOL, V121, P641; REGNIER DC, 1989, J VIROL, V63, P3678, DOI 10.1128/JVI.63.9.3678-3682.1989; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE PD, 1990, IN PRESS CANCEER GEN; YUNIS JJ, 1986, CLIN HAEMATOL, V15, P597	17	259	266	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					653	657						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030914				2022-12-25	WOS:A1991FR93900022
J	CHABBERT, M; LAMI, H; TAKAHASHI, M				CHABBERT, M; LAMI, H; TAKAHASHI, M			COFACTOR-INDUCED ORIENTATION OF THE DNA BASES IN SINGLE-STRANDED-DNA COMPLEXED WITH RECA PROTEIN - A FLUORESCENCE ANISOTROPY AND TIME-DECAY STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LINEAR DICHROISM; BINDING; POLYNUCLEOTIDES; TRYPTOPHAN; FILAMENTS; 1,N6-ETHENOADENINE; RECOMBINATION; STOICHIOMETRY; SPECTROSCOPY	The structure of the RecA-single-stranded DNA complex was investigated by studying the fluorescence emission of poly(deoxy-1,N6-ethenoadenylic acid (poly(d-epsilon-A)), a fluorescent derivative of poly(dA), under various viscosity conditions. The fluorescence intensity and average lifetime of poly(d-epsilon-A) are much smaller than those of nonpolymerized monoethenonucleotides (1,N6-ethenoadenosine 5'-triphosphate and 1,N6-ethenoadenine deoxyribose 5'-monophosphate) at low viscosity and reflect intramolecular base-base collisions in the polymer. They considerably increased upon RecA binding, both in the presence and absence of cofactor ATP or adenosine 5'-O-(3-thiotriphosphate). This increase, as well as the increase in fluorescence anisotropy upon RecA binding, was very similar to that which resulted from sucrose addition to free poly(d-epsilon-A). These observations point to a decrease in the mobility of DNA bases upon RecA binding. In the presence of cofactor, the fluorescence features became independent of viscosity. This strongly suggests the absence of base motion of significant amplitude on the time scale of the fluorescence lifetime (about 10 ns). In the absence of cofactor, however, these features remained sensitive to viscosity, implying residual local motions of the bases. Such cofactor-dependent rigid attachment of DNA bases to stiff phosphate backbone could facilitate the search for homology between two DNA molecules during recombination.	CNRS,INST BIOL MOLEC & CELLULAIRE,CARCEROGENESE & MUTAGENESE MOLEC GRP,15 RUE RENE DESCARTES,F-67084 STRASBOURG,FRANCE; UNIV STRASBOURG 1,F-67084 STRASBOURG,FRANCE; UNIV LOUIS PASTEUR,FAC PHARM,F-67400 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Chabbert, Marie/K-1245-2015					ALCALA JR, 1987, BIOPHYS J, V51, P587, DOI 10.1016/S0006-3495(87)83383-0; BARKER BM, 1978, BIOPOLYMERS, V17, P1361; BEVINGTON PR, 1986, DATA REDUCTION ERROR; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P454; CAZENAVE C, 1983, EMBO J, V2, P2247, DOI 10.1002/j.1460-2075.1983.tb01730.x; CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; DICAPUA E, 1987, NUCLEIC ACIDS MOL BI, V1, P174; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; GRUBER BA, 1975, P NATL ACAD SCI USA, V72, P3966, DOI 10.1073/pnas.72.10.3966; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; KINOSITA K, 1977, BIOPHYS J, V20, P289, DOI 10.1016/S0006-3495(77)85550-1; KOHWISHIGEMATSU T, 1978, P NATL ACAD SCI USA, V75, P4689, DOI 10.1073/pnas.75.10.4689; KUBISTA M, 1988, NUCLEOS NUCLEOT, V7, P783, DOI 10.1080/07328318808056330; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LEDNEVA RK, 1978, NUCLEIC ACIDS RES, V5, P4225, DOI 10.1093/nar/5.11.4225; LEONARD NJ, 1984, CRC CR REV BIOCH MOL, V15, P125, DOI 10.3109/10409238409102299; LIPARI G, 1980, BIOPHYS J, V30, P489, DOI 10.1016/S0006-3495(80)85109-5; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MEROLA F, 1989, BIOCHEMISTRY-US, V28, P3383, DOI 10.1021/bi00434a038; MONTORO T, 1988, J CHEM PHYS, V89, P2712, DOI 10.1063/1.455693; Norden B., 1988, NATO ADV SCI INST C, V242, P133; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; STEINER RF, 1973, BIOCHIM BIOPHYS ACTA, V294, P24, DOI 10.1016/0005-2787(73)90311-0; STUDIER FW, 1965, J MOL BIOL, V11, P373, DOI 10.1016/S0022-2836(65)80064-X; TAKAHASHI M, 1987, J BIOL CHEM, V262, P8109; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1986, J MOL BIOL, V189, P711, DOI 10.1016/0022-2836(86)90501-2; TAKAHASHI M, 1989, J BIOL CHEM, V264, P288; TAKAHASHI M, 1984, THESIS TOULOUSE; TOULME JJ, 1984, FOLIA BIOL-PRAGUE, V30, P119; VINCENT M, 1988, BIOCHEMISTRY-US, V27, P8752, DOI 10.1021/bi00424a010; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEAST RC, 1974, HDB CHEM PHYSICS, pD192; WEAVER AJ, 1989, BIOCHEMISTRY-US, V28, P8624, DOI 10.1021/bi00447a053; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9	45	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5395	5400						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005086				2022-12-25	WOS:A1991FD37000009
J	PANDIELLA, A; MASSAGUE, J				PANDIELLA, A; MASSAGUE, J			MULTIPLE SIGNALS ACTIVATE CLEAVAGE OF THE MEMBRANE TRANSFORMING GROWTH FACTOR-ALPHA PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; TRANSMEMBRANE PRECURSOR; PHORBOL ESTER; CELL LINE; RECEPTOR; SEQUENCE; CLONING; DOMAIN; CDNA	Cleavage of the membrane-anchored precursor for transforming growth factor-alpha (TGF-alpha), a rate-limiting step in the generation of soluble TGF-alpha, can be stimulated by phorbol esters acting via protein kinase C. In the present study, activators of other intracellular signaling pathways were tested for their ability to stimulate pro-TGF-alpha cleavage in Chinese hamster ovary cells transfected with a pro-TGF-alpha cDNA. Treatment with the Ca2+ ionophore, A23187, rapidly increased the rate of pro-TGF-alpha cleavage over 25-fold. This effect of A23187 on pro-TGF-alpha cleavage was dependent on the influx of extracellular calcium and was largely independent of protein kinase C activation. In contrast, phorbol 12-myristate 13-acetate stimulation of pro-TGF-alpha cleavage via activation of protein kinase C did not require extracellular calcium. Stimulation of pro-TGF-alpha cleavage by serum was largely independent of both protein kinase C and extracellular calcium influx, whereas activators of protein kinase A and protein kinase G did not stimulate pro-TGF-alpha cleavage. These results suggest that regulation of pro-TGF-alpha cleavage is a complex process that can be controlled by extracellular agents via at least three distinct signal transduction pathways.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,1275 YORK AVE,BOX 116,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Pandiella, Atanasio/O-5180-2014	Pandiella, Atanasio/0000-0002-4704-8971; Massague, Joan/0000-0001-9324-8408				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CHIDA K, 1986, J BIOL CHEM, V261, P3013; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HOVIS JG, 1986, J BIOL CHEM, V261, P380; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; INAGAKI M, 1986, MOL PHARMACOL, V29, P577; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; KAO JPY, 1990, J CELL BIOL, V111, P193; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LETELLIER M, 1990, J EXP MED, V172, P693, DOI 10.1084/jem.172.3.693; LODISH HF, 1990, J BIOL CHEM, V265, P10893; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MOND JJ, 1987, P NATL ACAD SCI USA, V84, P8588, DOI 10.1073/pnas.84.23.8588; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSTOV KE, 1982, J BIOL CHEM, V257, P1816; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SACHS DH, 1980, J IMMUNOL, V124, P2130; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P17307; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	50	117	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5769	5773						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005114				2022-12-25	WOS:A1991FD37000064
J	WU, JJ; LARK, MW; CHUN, LE; EYRE, DR				WU, JJ; LARK, MW; CHUN, LE; EYRE, DR			SITES OF STROMELYSIN CLEAVAGE IN COLLAGEN TYPE-II, TYPE-IX, TYPE-X, AND TYPE-XI OF CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-3; SYNOVIAL FIBROBLASTS; ENDOGENOUS ACTIVATOR; ARTICULAR-CARTILAGE; PURIFICATION; PROTEOGLYCAN; TISSUE; PROCOLLAGENASE; PROTEINS; GENE	Human recombinant stromelysin-1 was shown to cleave four types of collagen (types II, IX, X, and XI) prepared from bovine and rat cartilages at specific sites. Stromelysin-1 cleaved salt-soluble native molecules of type IX collagen into two main triple-helical fragments, COL1 and COL2,3. Protein microsequencing identified the exact cleavage sites in the NC2 domain of all three chains, alpha-1(IX), alpha-2(IX), and alpha-3(IX). Stromelysin-1 also acted as a "telopeptidase," in that it efficiently clipped intact molecules of types II and XI collagens at sites just inside their terminal cross-linking hydroxylysine residues. Native molecules of type X collagen were cleaved by stromelysin-1 within their triple helical domains at a COOH-terminal site that reduced the alpha-1(X) chain size by 10 kDa. These findings suggest an important role for stromelysin in the turnover and remodeling of the collagenous matrix of cartilage both normally and in degenerative joint disease.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM & MOLEC PATHOL,RAHWAY,NJ 07065; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	Merck & Company; University of Washington; University of Washington Seattle	WU, JJ (corresponding author), UNIV WASHINGTON,DEPT ORTHOPAED,SEATTLE,WA 98195, USA.				NIAMS NIH HHS [R37 AR037318, R01 AR036794, AR36794, AR37318] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037318, R37AR037318, R01AR036794, R37AR036794] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; CHIN JR, 1985, J BIOL CHEM, V260, P2367; Eyre D, 1987, STRUCTURE FUNCTION C, P261; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; EYRE DR, 1987, J RHEUMATOL, V14, P25; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; GUNJASMITH Z, 1989, BIOCHEM J, V258, P115, DOI 10.1042/bj2580115; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; KIMURA T, 1989, EUR J BIOCHEM, V179, P71, DOI 10.1111/j.1432-1033.1989.tb14522.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NGUYEN Q, 1989, BIOCHEM J, V259, P61, DOI 10.1042/bj2590061; NINOMIYA Y, 1985, BIOCHEMISTRY-US, V24, P4223, DOI 10.1021/bi00336a061; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OKADA Y, 1989, FEBS LETT, V244, P473, DOI 10.1016/0014-5793(89)80586-1; PODELL DN, 1978, BIOCHEM BIOPH RES CO, V81, P176, DOI 10.1016/0006-291X(78)91646-7; SAUS J, 1988, J BIOL CHEM, V263, P6742; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VATER CA, 1983, J BIOL CHEM, V258, P9374; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423	30	227	235	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5625	5628						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005102				2022-12-25	WOS:A1991FD37000042
J	DECHAVIGNY, A; HEACOCK, PN; DOWHAN, W				DECHAVIGNY, A; HEACOCK, PN; DOWHAN, W			SEQUENCE AND INACTIVATION OF THE PSS GENE OF ESCHERICHIA-COLI - PHOSPHATIDYLETHANOLAMINE MAY NOT BE ESSENTIAL FOR CELL VIABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-DERIVED OLIGOSACCHARIDES; POLYMORPHIC PHASE-BEHAVIOR; FREEZE-FRACTURE TECHNIQUES; PHOSPHATIDYLSERINE SYNTHETASE; PHOSPHOLIPID-COMPOSITION; CYTIDINE "5'-DIPHOSPHO-1,2-DIACYL-SN-GLYCEROL; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; P-31 NMR; SYNTHASE	Phosphatidylethanolamine is the only zwitterionic phospholipid in Escherichia coli and accounts for 70-80% of the total glycerophospholipids of this organism. To investigate the function of phosphatidylethanolamine in E. coli, we constructed an inactivated allele (pss93::kan) of the gene encoding the phosphatidylserine synthase which catalyzes the committed step to the synthesis of phosphatidylethanolamine. Growth of this mutant was dependent on a plasmid-borne copy of the wild type gene. After curing the mutant of the wild type gene, growth stopped when the content of phosphatidylethanolamine reached 30% of the total phospholipid. Divalent metal ions at millimolar concentrations suppressed the growth phenotype of the mutant in the following order of efficiency: Ca2+ > Mg2+ > Sr2+. Although phosphatidylserine synthase activity was not detectable, phosphatidylethanolamine was still present at 0.007% of the total phospholipid after growth for many generations in rich medium containing 20 mM Mg2+. The remainder of the phospholipid was primarily phosphatidylglycerol and cardiolipin with no other unique phosphate-containing chloroform-soluble material present. The phospholipid to protein ratio and the fatty acid composition were very similar to the parental strain. The broad divalent metal ion auxotrophy brought about by the lack of phosphatidylethanolamine suggests a primarily structural role for this phospholipid in E. coli.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,POB 20708,HOUSTON,TX 77225	University of Texas System					NIGMS NIH HHS [GM 20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAELEE MS, 1984, J BIOL CHEM, V259, P857; Battey, 1986, BASIC METHODS MOL BI; BOHIN JP, 1984, J BACTERIOL, V157, P956, DOI 10.1128/JB.157.3.956-957.1984; BREY RN, 1979, J BACTERIOL, V139, P824, DOI 10.1128/JB.139.3.824-834.1979; CABELLO F, 1976, NATURE, V259, P4846; CHANG CF, 1986, J BACTERIOL, V167, P935, DOI 10.1128/jb.167.3.935-939.1986; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P11, DOI 10.1016/0005-2736(78)90107-4; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; FINE JB, 1982, J LIPID RES, V23, P660; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; GANGOLA P, 1987, J BIOL CHEM, V262, P12570; GOPALAKRISHNAN AS, 1986, J BIOL CHEM, V261, P1329; GREENER A, 1980, J BACTERIOL, V144, P312, DOI 10.1128/JB.144.1.312-321.1980; HASIN M, 1982, J BIOL CHEM, V257, P2475; HAWROT E, 1978, J BIOL CHEM, V253, P8213; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; HIRABAYASHI T, 1976, BIOCHEMISTRY-US, V15, P5205, DOI 10.1021/bi00669a002; JACKOWSKI S, 1986, J BIOL CHEM, V261, P1328; JACKSON BJ, 1983, J BIOL CHEM, V258, P2394; KENNEDY EP, 1988, J BACTERIOL, V170, P2457, DOI 10.1128/jb.170.6.2457-2461.1988; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P5212, DOI 10.1021/bi00669a003; LI QX, 1988, J BIOL CHEM, V263, P11516; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LOUIE K, 1986, J BACTERIOL, V165, P805, DOI 10.1128/jb.165.3.805-812.1986; LOUIE K, 1980, J BIOL CHEM, V255, P1124; LUSK JE, 1969, J BIOL CHEM, V244, P1653; Maniatis T., 1982, MOL CLONING; MCINTYRE TM, 1977, J BIOL CHEM, V255, P4487; Miller J.H., 1972, EXPT MOL GENETICS; MILLER KJ, 1987, J BACTERIOL, V169, P682, DOI 10.1128/jb.169.2.682-686.1987; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V1, P4; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; NISHIJIMA S, 1988, J BACTERIOL, V170, P775, DOI 10.1128/jb.170.2.775-780.1988; OHTA A, 1977, J BACTERIOL, V132, P434, DOI 10.1128/JB.132.2.434-443.1977; OHTA A, 1981, J BIOL CHEM, V256, P2219; RAETZ CRH, 1979, J BACTERIOL, V139, P544, DOI 10.1128/JB.139.2.544-551.1979; RAETZ CRH, 1976, J BIOL CHEM, V251, P3242; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1987, BIOCHEMISTRY-US, V26, P4022, DOI 10.1021/bi00387a042; RAETZ CRH, 1977, J BIOL CHEM, V252, P5911; RANDO RR, 1988, FASEB J, V2, P2348, DOI 10.1096/fasebj.2.8.3282960; Rilfors L, 1984, MEMBRANE FLUIDITY, P205; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER M, 1979, BIOCHEMISTRY-US, V18, P4425, DOI 10.1021/bi00587a024; SHARMA S, 1982, NUCLEIC ACIDS RES, V10, P5209, DOI 10.1093/nar/10.17.5209; SHIBUYA I, 1985, J BACTERIOL, V161, P1086, DOI 10.1128/JB.161.3.1086-1092.1985; SILBERT DF, 1968, J BACTERIOL, V95, P1658, DOI 10.1128/JB.95.5.1658-1665.1968; SNYDER F, 1987, PLATELET ACTIVATING; TAKASE I, 1987, J BACTERIOL, V169, P5692, DOI 10.1128/jb.169.12.5692-5699.1987; VASILENKO I, 1982, BIOCHIM BIOPHYS ACTA, V684, P282, DOI 10.1016/0005-2736(82)90018-9; WU HC, 1987, BACTERIAL OUTER MEMB, P37; YU F, 1986, J BIOL CHEM, V261, P2284; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	60	199	208	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5323	5332						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	2002065				2022-12-25	WOS:A1991FC21700094
J	HASHIMOTO, T; TAKAHASHI, R; YANDELL, DW; XU, HJ; HU, SX; GUNNELL, S; BENEDICT, WF				HASHIMOTO, T; TAKAHASHI, R; YANDELL, DW; XU, HJ; HU, SX; GUNNELL, S; BENEDICT, WF			CHARACTERIZATION OF INTRAGENIC DELETIONS IN 2 SPORADIC GERMINAL MUTATION CASES OF RETINOBLASTOMA RESULTING IN ABNORMAL GENE-EXPRESSION	ONCOGENE			English	Note							SUSCEPTIBILITY GENE; CELL-CYCLE; GENOMIC ORGANIZATION; PRODUCT; PHOSPHORYLATION; SEQUENCES; PROTEIN; MITOSIS; CANCER	Two gross intragenic deletions of the retinoblastoma (RB) gene from patients with sporadic hereditary disease were analysed in detail. This study was undertaken to determine whether there were common mechanisms for these deletions and whether changes found in the tumors were identical to those found in the constitutional cells. Short repeats at the deletion breakpoints were found in both tumors, one resulting in a 2.0 kb deletion including exons 21 and 22, and the other producing a 3.7 kb deletion including exons 14-17. In addition, the identical sequence changes documented in genomic DNAs and transcripts of these tumors were also observed in the constitutional cells. Both deletions were in-frame and resulted in a truncated transcript and protein identical to the expected size based on the exons deleted. These studies provide further documentation of the events which represent the actual 'two hits' originally hypothesized to be responsible for retinoblastoma development.	BAYLOR UNIV,CTR BIOTECHNOL,4000 RES FOREST DR,THE WOODLANDS,TX 77381; MASSACHUSETTS EYE & EAR HOSP,DEPT OPHTHALMOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Baylor College of Medicine; Baylor University; Harvard University; Harvard Medical School					NATIONAL EYE INSTITUTE [R01EY002715] Funding Source: NIH RePORTER; NEI NIH HHS [EY02715, EY06195] Funding Source: Medline; DRS NIH HHS [BRSG 790G16254] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); DRS NIH HHS		BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; BOOKSTEIN R, 1989, MOL CELL BIOL, V9, P1628, DOI 10.1128/MCB.9.4.1628; BRUNIER D, 1989, EMBO J, V8, P3127, DOI 10.1002/j.1460-2075.1989.tb08465.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SMITH CL, 1989, J VIROL, V63, P1569, DOI 10.1128/JVI.63.4.1569-1577.1989; TANG A, 1989, ONCOGENE, V4, P401; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; XU HJ, 1989, ONCOGENE, V4, P807; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	27	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					463	469						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011402				2022-12-25	WOS:A1991FT34400018
J	KARIYA, K; KARNS, LR; SIMPSON, PC				KARIYA, K; KARNS, LR; SIMPSON, PC			EXPRESSION OF A CONSTITUTIVELY ACTIVATED MUTANT OF THE BETA-ISOZYME OF PROTEIN-KINASE-C IN CARDIAC MYOCYTES STIMULATES THE PROMOTER OF THE BETA-MYOSIN HEAVY-CHAIN ISOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; RAT-HEART MYOCYTES; ALPHA-1-ADRENERGIC RECEPTOR; PHORBOL ESTER; REGULATORY DOMAIN; MAMMALIAN-CELLS; MOLECULAR-BASIS; GROWTH-FACTORS; ALPHA; GENE	Cultured neonatal rat cardiac myocytes express at least three isozymes of protein kinase C (PKC), and two PKC isozymes are translocated to different intracellular sites on activation with alpha-1-adrenergic agonists or phorbol myristate acetate. Differential intracellular localization upon activation was compatible with differential function, and we therefore asked whether PKC isozymes had distinct roles in regulating transcription of the cardiac myosin heavy chain (MHC) genes. Cardiac myocytes were transfected with chloramphenicol acetyltransferase reporter plasmids containing the promoters of the beta-MHC or alpha-MHC isogenes. An alpha-1-adrenergic agonist stimulated the beta-MHC promoter by 3-fold but had no effect on the alpha-MHC promoter. This pattern of MHC promoter regulation by an alpha-1 agonist was the same as that found previously for the endogenous MHC mRNAs in this model system. Myocytes were then co-transfected with the beta- or alpha-MHC-chloramphenicol acetyltransferase plasmids and expression plasmids encoding wild-type or constitutively activated mutants of the alpha- and beta-isozymes of PKC. Co-transfection with wild-type alpha-PKC or wild-type beta-PKC did not stimulate the beta-MHC promoter, and none of the expressed PKCs affected the alpha-MHC promoter. However, the constitutively activated mutant of beta-PKC stimulated the beta-MHC promoter by 8-fold, whereas stimulation by the activated alpha-PKC mutant was only 40% as great (3-fold). In contrast, the constitutively activated alpha-PKC and beta-PKC mutants were equally potent in stimulating a reporter plasmid containing AP-1 recognition sequences. All transfected PKCs were expressed equally in the myocytes, as judged by immunofluorescence. These data indicate that transcription of the beta-MHC isogene is stimulated preferentially by beta-PKC in cardiac myocytes and provide direct evidence for differential functions of alpha-PKC and beta-PKC in transcriptional regulation.	VET AFFAIRS MED CTR,DIV CARDIOL,4150 CLEMENT ST,SAN FRANCISCO,CA 94121; VET AFFAIRS MED CTR,RES SERV,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031113, R01HL042150] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42150, HL31113, R01 HL031113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GODSON C, 1990, J BIOL CHEM, V265, P8369; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MAHDAVI V, 1989, UCLA S MOL CELL BIOL, V93, P369; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	29	160	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10023	10026						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037558				2022-12-25	WOS:A1991FP08600002
J	KESAVAN, P; MUKHOPADHAYAY, S; MURPHY, S; RENGARAJU, M; LAZAR, MA; DAS, M				KESAVAN, P; MUKHOPADHAYAY, S; MURPHY, S; RENGARAJU, M; LAZAR, MA; DAS, M			THYROID-HORMONE DECREASES THE EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ERBA; MESSENGER-RNA; TGF-ALPHA; GLUCOCORTICOID RECEPTOR; TRANSGENIC MICE; PROTO-ONCOGENE; RETINOIC ACID; EGF-RECEPTOR; TRANSCRIPTIONAL REGULATION; SIGNAL TRANSDUCTION	The receptors for epidermal growth factor (EGF) and thyroid hormone (T3) are prototypes, respectively, of transmembrane signaling proteins and nuclear transcription regulatory proteins. Oncogenic homologs of these two receptor genes, v-erbB and v-erbA, cooperate with each other in cellular transformation and blockage of erythrocytic differentiation. As a first step toward investigating this cooperation, we have studied the relationship between the normal homologs of these two receptors in A431 cells. Treatment of these cells with T3 has no significant effect on EGF receptor gene transcription but leads to a drastic decrease in the steady-state level of receptor mRNA. The down-regulatory effect is visible by 2 h and persists up to 8 h, but EGF receptor mRNA returns to normal (sometimes higher than normal) level by 48-72 h. The T3-induced decrease in EGF receptor mRNA (found during 2-8 h of T3 treatment) is due to a specific destabilization of EGF receptor mRNA. The 5.6-kb mRNA that encodes the full-length transmembrane EGF receptor is preferentially degraded. The half-life of the 2.6-kb mRNA that encodes the aberrant C-terminally truncated receptor is unaffected by T3. In other studies we found that T3 decreases the rate of synthesis of the full-length EGF receptor protein and reduces its steady-state amount. Overall the results demonstrate a negative regulatory effect of T3 in post-transcriptional control of EGF receptor expression, and raise interesting questions regarding the mechanism of this down-regulation, and the possible roles of T3 receptors in the control of EGF receptor function.	UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	KESAVAN, P (corresponding author), UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104, USA.		Lazar, Mitchell A/AAF-3738-2019		NCI NIH HHS [CA-43787, CA-15822] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043787, P01CA015822] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; COHEN S, 1962, J BIOL CHEM, V237, P1555; CONNEELY OM, 1986, SCIENCE, V233, P767, DOI 10.1126/science.2426779; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEPALO L, 1988, CANCER RES, V48, P1105; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FERNANDEZPOL JA, 1989, J BIOL CHEM, V264, P4151; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOATH SB, 1985, PEDIATR RES, V19, P277, DOI 10.1203/00006450-198503000-00004; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KESAVAN P, 1990, ONCOGENE, V5, P483; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P479, DOI 10.1210/mend-2-6-479; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MUKKU VR, 1984, J BIOL CHEM, V259, P6543; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; MURTHY U, 1986, J CELL BIOL, V103, P333, DOI 10.1083/jcb.103.2.333; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1976, P NATL ACAD SCI USA, V73, P3877, DOI 10.1073/pnas.73.11.3877; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAMUELS HH, 1983, MOL BASIS THYROID HO, P35; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANTOS A, 1987, J BIOL CHEM, V262, P16880; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; THOMPSON KL, 1989, J BIOL CHEM, V264, P3230; VONDERHAAR BK, 1986, ENDOCRINOLOGY, V119, P580, DOI 10.1210/endo-119-2-580; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	65	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10282	10286						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037580				2022-12-25	WOS:A1991FP08600046
J	VIEL, A; LEMAIRE, M; PHILIPPE, H; MORALES, J; MAZABRAUD, A; DENIS, H				VIEL, A; LEMAIRE, M; PHILIPPE, H; MORALES, J; MAZABRAUD, A; DENIS, H			STRUCTURAL AND FUNCTIONAL-PROPERTIES OF THESAURIN A (42SP50), THE MAJOR PROTEIN OF THE 42-S PARTICLES PRESENT IN XENOPUS-LAEVIS PREVITELLOGENIC OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; FACTOR 1-ALPHA EF-1-ALPHA; AMINOACYL TRANSFER-RNA; SEA-URCHIN EGGS; BIOCHEMICAL-RESEARCH; 5S RNA; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION FACTOR; STORAGE PARTICLES; SACCHAROMYCES-CEREVISIAE	Thesaurin a is one of two protein components of a 42 S ribonucleoprotein particle that is very abundant in previtellogenic oocytes of Xenopus laevis. The primary function of the 42 S particle is the long-term storage of 5 S RNA and aminoacyl-tRNA. Thesaurin a is homologous to eukaryotic elongation factor 1-alpha (EF-1-alpha) and to prokaryotic elongation factor Tu (EF-Tu). Sequence comparison with EF-1-alpha and EF-Tu of different species indicates that thesaurin a is rather distantly related to all eukaryotic elongation factors. In spite of this, the secondary structure of thesaurin a, deduced from hydrophobic cluster analysis, is remarkably similar to that of EF-1-alpha and EF-Tu. The binding and catalytic properties of thesaurin a are also similar but not identical to those of EF-1-alpha. Like EF-1-alpha, purified thesaurin a binds tRNA, GDP, and GTP. Unlike EF-1-alpha, thesaurin a binds discharged tRNA more tightly than charged tRNA, and GTP more tightly than GDP. Thesaurin a also hydrolyzes GTP and catalyzes the mRNA-dependent binding of aminoacyl-tRNA to 80 S ribosomes. The functional properties of the 42 S particle are in general agreement with those of purified thesaurin a. In particular, the 42 S particle contains GTP and efficiently transfers aminoacyl-tRNA to 80 S ribosomes without addition of exogenous elongation factor.	UNIV PIERRE & MARIE CURIE, CNRS, LAB PROPER, CTR GENET MOLEC, F-91198 GIF SUR YVETTE, FRANCE; UNIV PARIS 11, BIOL CELLULAIRE LAB 4, CNRS, UA 1134, F-91405 ORSAY, FRANCE; UNIV PARIS 06, PHYSIOL REPROD LAB, CNRS, UA 555, INRA, F-75252 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Sorbonne Universite				Morales, Julia/0000-0003-1632-5419				BALDACCI G, 1990, NUCLEIC ACIDS RES, V18, P507, DOI 10.1093/nar/18.3.507; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; Dayhoff MO, 1978, ATLAS PROTEIN SEQUEN, V5; DENIS H, 1985, EUR J BIOCHEM, V149, P549, DOI 10.1111/j.1432-1033.1985.tb08960.x; DENIS H, 1987, BIOCHIMIE, V69, P495, DOI 10.1016/0300-9084(87)90087-3; DENIS H, 1972, EUR J BIOCHEM, V25, P524, DOI 10.1111/j.1432-1033.1972.tb01724.x; Denis H, 1983, Subcell Biochem, V9, P263; DENIS H, 1980, DEV BIOL, V77, P218, DOI 10.1016/0012-1606(80)90468-6; DEVER TE, 1989, J BIOL CHEM, V264, P20518; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FORD PJ, 1971, NATURE, V233, P561, DOI 10.1038/233561a0; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; INAMINE JM, 1989, NUCLEIC ACIDS RES, V17, P10126, DOI 10.1093/nar/17.23.10126; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KLOETZEL PM, 1981, NUCLEIC ACIDS RES, V9, P605, DOI 10.1093/nar/9.3.605; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KURIYAMA R, 1990, J CELL SCI, V95, P231; KUSHIRO A, 1987, EUR J BIOCHEM, V170, P93, DOI 10.1111/j.1432-1033.1987.tb13671.x; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LECHNER K, 1987, MOL GEN GENET, V208, P523, DOI 10.1007/BF00328150; LEMAIRE M, 1987, J BIOL CHEM, V262, P654; LINZ JE, 1986, J BIOL CHEM, V261, P5022; LOECHEL S, 1989, NUCLEIC ACIDS RES, V17, P10127, DOI 10.1093/nar/17.23.10127; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; MAIRY M, 1972, EUR J BIOCHEM, V25, P535, DOI 10.1111/j.1432-1033.1972.tb01725.x; MAIRY M, 1971, DEV BIOL, V24, P143, DOI 10.1016/0012-1606(71)90092-3; Maniatis T., 1982, MOL CLONING; MATTAJ IW, 1987, EMBO J, V6, P2409, DOI 10.1002/j.1460-2075.1987.tb02519.x; MATTAJ IW, 1983, J CELL BIOL, V97, P1261, DOI 10.1083/jcb.97.4.1261; MIYAZAKI M, 1988, J BIOCHEM-TOKYO, V103, P508, DOI 10.1093/oxfordjournals.jbchem.a122301; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MONTANDON PE, 1983, NUCLEIC ACIDS RES, V11, P5877, DOI 10.1093/nar/11.17.5877; MONTANDON PE, 1990, NUCLEIC ACIDS RES, V18, P75, DOI 10.1093/nar/18.1.75; MULNERLORILLON O, 1989, FEBS LETT, V251, P219, DOI 10.1016/0014-5793(89)81458-9; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; NAGATA S, 1983, P NATL ACAD SCI-BIOL, V80, P6192, DOI 10.1073/pnas.80.20.6192; OHTA K, 1990, J BIOL CHEM, V265, P3240; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PETIT C, 1976, GENETIQUE POPULATION; PICARD B, 1980, EUR J BIOCHEM, V109, P359, DOI 10.1111/j.1432-1033.1980.tb04802.x; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; ROOBOL K, 1978, EUR J BIOCHEM, V90, P471, DOI 10.1111/j.1432-1033.1978.tb12626.x; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; Swofford D.L., 1985, PAUP PHYLOGENETIC AN; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VANDENEYNDE H, 1989, DEVELOPMENT, V106, P11; VANHEMERT FJ, 1984, EMBO J, V3, P1109, DOI 10.1002/j.1460-2075.1984.tb01937.x; VIEL A, 1987, FEBS LETT, V223, P232, DOI 10.1016/0014-5793(87)80295-8; VIEL A, 1990, DEV BIOL, V141, P270, DOI 10.1016/0012-1606(90)90383-T; WEGNEZ M, 1979, EUR J BIOCHEM, V98, P67, DOI 10.1111/j.1432-1033.1979.tb13161.x	67	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10392	10399						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037589				2022-12-25	WOS:A1991FP08600062
J	DUCKWORTH, PF; VLAHCEVIC, ZR; STUDER, EJ; GURLEY, EC; HEUMAN, DM; BEG, ZH; HYLEMON, PB				DUCKWORTH, PF; VLAHCEVIC, ZR; STUDER, EJ; GURLEY, EC; HEUMAN, DM; BEG, ZH; HYLEMON, PB			EFFECT OF HYDROPHOBIC BILE-ACIDS ON 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE-ACTIVITY AND MESSENGER-RNA LEVELS IN THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; DENSITY LIPOPROTEIN RECEPTOR; MEVALONATE-DERIVED PRODUCT; STEROL REGULATORY ELEMENT; DEPENDENT PROTEIN-KINASE; ENZYMIC ACTIVITY; TRANSCRIPTIONAL REGULATION; LIVER; CHOLESTEROL; MODULATION	We have previously reported that relatively hydrophobic bile acids, decreased hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase (reductase) activity whereas, hydrophilic bile acids had little effect on the enzyme. The purpose of the present study was to determine in more detail the mechanism of down-regulation of hepatic reductase activity by hydrophobic bile salts. Groups of rats were fed bile acids of differing hydrophobicity: ursodeoxycholic, cholic (CA), chenodeoxycholic (CDCA), deoxycholic (DCA), or cholesterol for 14 days. Reductase specific activities and concentrations of reductase protein were determined in hepatic microsomes. Quantitation of "steady state" levels of reductase mRNA was performed using Northern and dot blot hybridization. Reductase gene transcriptional activity (nuclear "run-on") was determined in nuclei isolated from livers of animals fed different bile acids. Hydrophobic bile acids and cholesterol significantly decreased reductase activity: CA (57%), CDCA (77%), DCA (73%), cholesterol (89%), and reductase protein levels as measured by an enzyme-linked immunosorbent assay method were also decreased; CA (27%), CDCA (31%), DCA (42%), and cholesterol (35%). Reductase mRNA levels were also decreased after feeding hydrophobic bile acid: CA (43%), CDCA (47%), DCA (54%), and cholesterol (53%). Ursodeoxycholic, a hydrophilic bile acid, caused a much smaller decrease in reductase activity (18%), protein mass (16%), and mRNA levels (10%). Decreased transcriptional activities were observed in CA- and cholesterol-fed rats. Surprisingly, CDCA- and DCA-fed animals showed transcriptional activities similar to control animals even though steady state mRNA levels were low in CDCA- and DCA-fed animals. We hypothesize a post-transcriptional regulation of reductase mRNA by hydrophobic bile acids.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,BOX 678 MCV STN,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298; NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892	Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NIDDK NIH HHS [P01 DK38030] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038030] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AREBALO RE, 1980, P NATL ACAD SCI-BIOL, V77, P6429, DOI 10.1073/pnas.77.11.6429; AREBALO RE, 1982, P NATL ACAD SCI-BIOL, V79, P51, DOI 10.1073/pnas.79.1.51; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BEG ZH, 1982, BIOCHEM BIOPH RES CO, V108, P559, DOI 10.1016/0006-291X(82)90865-8; BEG ZH, 1987, J BIOL CHEM, V262, P13228; BEG ZH, 1985, J BIOL CHEM, V260, P1682; BEG ZH, 1987, METABOLISM, V36, P900, DOI 10.1016/0026-0495(87)90101-6; BEG ZH, 1980, J BIOL CHEM, V255, P8541; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BROWN MS, 1980, J LIPID RES, V21, P515; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE CF, 1985, J BIOL CHEM, V260, P4363; COHEN BI, 1977, J LIPID RES, V18, P223; DANIELSSON H, 1967, EUR J BIOCHEM, V2, P44, DOI 10.1111/j.1432-1033.1967.tb00103.x; DAVIS PJ, 1987, P NATL ACAD SCI USA, V84, P118, DOI 10.1073/pnas.84.1.118; DAWSON PA, 1989, J BIOL CHEM, V264, P9046; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; ERICKSON SK, 1980, BIOCHIM BIOPHYS ACTA, V620, P70, DOI 10.1016/0005-2760(80)90186-1; GREENBERG ME, 1990, CURRENT PROTOCOLS MO; HAMPRECHT B, 1971, EUR J BIOCHEM, V18, P15, DOI 10.1111/j.1432-1033.1971.tb01208.x; HEUMAN DM, 1988, HEPATOLOGY, V8, P358, DOI 10.1002/hep.1840080228; HEUMAN DM, 1989, J LIPID RES, V30, P1161; HEUMAN DM, 1989, J LIPID RES, V30, P719; HEUMAN DM, 1988, HEPATOLOGY, V8, P892, DOI 10.1002/hep.1840080431; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; RAICHT RF, 1974, GASTROENTEROLOGY, V67, P1155; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SAUCIER SE, 1987, J BIOL CHEM, V262, P14056; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; SIMONET WS, 1989, J BIOL CHEM, V264, P569; SPADY DK, 1986, P NATL ACAD SCI USA, V83, P1916, DOI 10.1073/pnas.83.6.1916; SWELL L, 1953, P SOC EXP BIOL MED, V84, P428, DOI 10.3181/00379727-84-20669; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VAHOUNY GV, 1959, P SOC EXP BIOL MED, V101, P538, DOI 10.3181/00379727-101-25008; WATT SM, 1984, J LIPID RES, V25, P448; WHITEHEAD TR, 1984, ARCH BIOCHEM BIOPHYS, V230, P483, DOI 10.1016/0003-9861(84)90428-4	42	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9413	9418						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033042				2022-12-25	WOS:A1991FM45900015
J	EISENREICH, W; SCHWARZKOPF, B; BACHER, A				EISENREICH, W; SCHWARZKOPF, B; BACHER, A			BIOSYNTHESIS OF NUCLEOTIDES, FLAVINS, AND DEAZAFLAVINS IN METHANOBACTERIUM-THERMOAUTOTROPHICUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ACETIC-ACID; C-13-LABELED PRECURSORS; METHANOSARCINA-BARKERI; METHANOGENIC BACTERIA; AUTOTROPHIC SYNTHESIS; 4-CARBON PRECURSOR; NMR-SPECTROSCOPY; ESCHERICHIA-COLI; XYLENE RING; 2 CO2	The biosynthesis of deazaflavins, flavins, ribonucleotides, and selected amino acids was studied in Methanobacterium thermoautotrophicum by incorporation of C-13-labeled acetate and pyruvate. C-13 enrichments were monitored by C-13 and H-1 NMR spectroscopy. The biosynthesis of ribonucleotides follows the standard pathway. The xylene ring of riboflavin is formed from two pentose moieties in agreement with studies in yeasts and eubacteria. The pyrimidine ring and the ribityl side chain of the deazaflavin chromophore of coenzyme F420 are derived from the purine nucleotide pool. The phenolic ring and C-5 of the deazaflavin system are supplied by the shikimate pathway. A hypothetical mechanism for the assembly of the deazaflavin chromophore from 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione and 4-hydroxyphenyl-pyruvate is proposed.			EISENREICH, W (corresponding author), TECH UNIV MUNICH,LEHRSTUHL ORGAN CHEM & BIOCHEM,LICHTENBERGSTR 4,W-8046 GARCHING,GERMANY.		Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				BACHER A, 1983, J BIOL CHEM, V258, P3431; BACHER A, 1985, J AM CHEM SOC, V107, P6380, DOI 10.1021/ja00308a037; BACHER A, 1990, CHEM BIOCH FLAVOENZY, P215; BAKHIET N, 1984, CURR MICROBIOL, V10, P195, DOI 10.1007/BF01627254; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BURROWS RB, 1978, J BACTERIOL, V136, P657, DOI 10.1128/JB.136.2.657-667.1978; CHEESEMAN P, 1972, J BACTERIOL, V112, P527, DOI 10.1128/JB.112.1.527-531.1972; CRESSWELL RM, 1960, J CHEM SOC, P4776, DOI 10.1039/jr9600004776; DANIELS L, 1985, SYST APPL MICROBIOL, V6, P12, DOI 10.1016/S0723-2020(85)80004-7; DOY CH, 1960, NATURE, V186, P529, DOI 10.1038/186529a0; EIKMANNS B, 1983, ARCH MICROBIOL, V136, P111, DOI 10.1007/BF00404783; EIRICH LD, 1978, BIOCHEMISTRY-US, V17, P4583, DOI 10.1021/bi00615a002; EKER APM, 1981, PHOTOCHEM PHOTOBIOL, V33, P65, DOI 10.1111/j.1751-1097.1981.tb04298.x; EKIEL I, 1984, BIOCHEMISTRY-US, V23, P1683, DOI 10.1021/bi00303a016; EKIEL I, 1983, J BACTERIOL, V156, P316, DOI 10.1128/JB.156.1.316-326.1983; FOOR F, 1975, J BIOL CHEM, V250, P3545; FUCHS G, 1980, ARCH MICROBIOL, V127, P267, DOI 10.1007/BF00427203; FUCHS G, 1978, ARCH MICROBIOL, V117, P61, DOI 10.1007/BF00689352; FUCHS G, 1978, ARCH MICROBIOL, V118, P121, DOI 10.1007/BF00406084; HUSTER R, 1983, FEMS MICROBIOL LETT, V19, P207; JACOBSON F, 1984, BIOCHEMISTRY-US, V23, P979, DOI 10.1021/bi00300a028; JAENCHEN R, 1984, ARCH MICROBIOL, V137, P362, DOI 10.1007/BF00410735; KENEALY WR, 1982, J BACTERIOL, V150, P1357, DOI 10.1128/JB.150.3.1357-1365.1982; KOZLUK T, 1987, J AM CHEM SOC, V109, P4698, DOI 10.1021/ja00249a036; LEVAN Q, 1985, J BACTERIOL, V162, P1280, DOI 10.1128/JB.162.3.1280-1284.1985; MCCORMICK JRD, 1982, J AM CHEM SOC, V104, P4014, DOI 10.1021/ja00378a044; NEUBERGER G, 1985, BIOCHEM BIOPH RES CO, V127, P175, DOI 10.1016/S0006-291X(85)80141-8; NIELSEN P, 1981, BIOCHIM BIOPHYS ACTA, V662, P312, DOI 10.1016/0005-2744(81)90044-9; Plaut G.W, 1960, J BIOL CHEM, V235, P41; PLAUT GWE, 1963, J BIOL CHEM, V238, P2225; SCHERER P, 1984, ARCH MICROBIOL, V138, P354, DOI 10.1007/BF00410903; SCHWARZKOPF B, 1990, ARCH MICROBIOL, V153, P259, DOI 10.1007/BF00249078; STUPPERICH E, 1984, ARCH MICROBIOL, V139, P14, DOI 10.1007/BF00692705; STUPPERICH E, 1984, ARCH MICROBIOL, V139, P8, DOI 10.1007/BF00692704; TAYLOR GT, 1977, ARCH MICROBIOL, V113, P17, DOI 10.1007/BF00428574; VOLK R, 1990, J BIOL CHEM, V265, P19479; VOLK R, 1988, J AM CHEM SOC, V110, P3651, DOI 10.1021/ja00219a047; WOLFE RS, 1985, TRENDS BIOCHEM SCI, V10, P396, DOI 10.1016/0968-0004(85)90068-4; YOUNG DW, 1986, NAT PROD REP, V3, P395, DOI 10.1039/np9860300395; ZEIKUS JG, 1977, J BACTERIOL, V132, P604, DOI 10.1128/JB.132.2.604-613.1977	43	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9622	9631						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033055				2022-12-25	WOS:A1991FM45900046
J	FAUST, JR; DICE, JF				FAUST, JR; DICE, JF			EVIDENCE FOR ISOPENTENYLADENINE MODIFICATION ON A CELL CYCLE-REGULATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POST-TRANSLATIONAL MODIFICATION; MEVALONIC ACID; TRANSFER-RNA; POSTTRANSLATIONAL MODIFICATION; ISOPRENOID SYNTHESIS; CYSTEINE RESIDUE; DNA-REPLICATION; GROWTH-FACTOR; LAMIN-B; BIOSYNTHESIS	We have prepared antibodies that recognize isopentenyladenosine (i6A), a modified nucleoside derived from mevalonic acid (MVA). In immunoblot assays, affinity-purified anti-i6A antibodies specifically bound to a 26-kDa protein (i6A26) in Chinese hamster ovary cells. Anti-i6A recognition of i6A26 was blocked with i6A but not adenosine or isopentenol. Employing immunoblot analysis we have quantitated the level of i6A26 in cells expressing various rates of DNA synthesis. The cellular content of i6A26 was reduced 4-fold in quiescent cells cultured in the absence of serum. When serum-deprived cells were stimulated to enter the cell cycle the amount of i6A26 increased in the cells during the G1 phase. However, when synchronized cells were stimulated with serum-containing medium in the presence of mevinolin (an inhibitor of cellular MVA synthesis), we observed impaired G1 expression of i6A26 and delayed onset of S phase DNA synthesis. Mevinolin addition to asynchronously growing cells resulted in low rates of cellular DNA synthesis and suppressed levels of i6A26 which were reversed by coincubation with MVA. The ability of MVA to restore DNA synthesis and the cellular content of i6A26 in mevinolin-treated cells showed similar MVA concentration and time dependences. Regenerating liver tissue also exhibited elevated levels of i6A26. Thus, the expression of i6A26 correlates with cellular proliferation and growth. We speculate that i6A26 contains isopentenyladenine moieties and mediates isoprenoid regulation of DNA synthesis. Isopentenyladenylated proteins may also function in cytokinin regulation of proliferation and differentiation in plants.			FAUST, JR (corresponding author), TUFTS UNIV,SCH MED,DEPT PHYSIOL,136 HARRISON AVE,BOSTON,MA 02111, USA.				NIADDK NIH HHS [AM 39428] Funding Source: Medline; NIDDK NIH HHS [DK 07542] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE H, 1976, Tetrahedron Letters, V42, P3807; AKIYOSHI DE, 1984, P NATL ACAD SCI-BIOL, V81, P5994, DOI 10.1073/pnas.81.19.5994; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; BREUNGER E, 1986, BIOCH BIPHYS RES COM, V139, P209; BROWN MS, 1980, J LIPID RES, V21, P505; BUCHER NLR, 1978, ADV ENZYME REGUL, V16, P205; BUCK M, 1984, CELL, V36, P523, DOI 10.1016/0092-8674(84)90245-9; BUCK M, 1981, NUCLEIC ACIDS RES, V9, P401, DOI 10.1093/nar/9.2.401; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DOYLE JW, 1988, J CELL PHYSIOL, V137, P133, DOI 10.1002/jcp.1041370116; ERLANGER BF, 1964, P NATL ACAD SCI USA, V52, P68, DOI 10.1073/pnas.52.1.68; FAIRBANKS KP, 1984, J BIOL CHEM, V259, P1546; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FAUST J, 1987, J BIOL CHEM, V262, P1996; GALLO RC, 1969, SCIENCE, V165, P400, DOI 10.1126/science.165.3891.400; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HABENICHT AJR, 1980, J BIOL CHEM, V255, P5134; HALL RH, 1973, ANNU REV PLANT PHYS, V24, P415, DOI 10.1146/annurev.pp.24.060173.002215; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HUMAYUN MZ, 1974, BIOCHIM BIOPHYS ACTA, V349, P84, DOI 10.1016/0005-2787(74)90011-2; HUNEEUS VQ, 1980, P NATL ACAD SCI-BIOL, V77, P5842, DOI 10.1073/pnas.77.10.5842; IHARA M, 1980, EXP CELL RES, V126, P273, DOI 10.1016/0014-4827(80)90265-7; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TJ, 1987, J NEUROCHEM, V49, P513, DOI 10.1111/j.1471-4159.1987.tb02894.x; LARSON RA, 1982, P NATL ACAD SCI-BIOL, V79, P3028, DOI 10.1073/pnas.79.9.3028; LATEN HM, 1985, P NATL ACAD SCI USA, V82, P1113, DOI 10.1073/pnas.82.4.1113; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LETHAM DS, 1983, ANNU REV PLANT PHYS, V34, P163, DOI 10.1146/annurev.pp.34.060183.001115; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MATESE WA, 1990, J BIOL CHEM, V265, P17883; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PERKINS SL, 1982, BIOCHIM BIOPHYS ACTA, V711, P83, DOI 10.1016/0005-2760(82)90012-1; QUESNEYHUNEEUS V, 1983, J BIOL CHEM, V258, P378; REPKO EM, 1989, J BIOL CHEM, V264, P9945; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEPPLORENZINO L, 1989, FEBS LETT, V245, P110, DOI 10.1016/0014-5793(89)80202-9; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; SKOOG F, 1970, ANN REV PLANT PHYSIO, V21, P359, DOI 10.1146/annurev.pp.21.060170.002043; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WEILER EW, 1987, TRENDS BIOCHEM SCI, V12, P271, DOI 10.1016/0968-0004(87)90133-2; WOLD F, 1981, ANNU REV BIOCHEM, V50, P783, DOI 10.1146/annurev.bi.50.070181.004031; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; ZHANG R, 1987, PLANT PHYSIOL, V83, P334, DOI 10.1104/pp.83.2.334	55	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9961	9970						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033083				2022-12-25	WOS:A1991FM45900093
J	SIPE, DM; MURPHY, RF				SIPE, DM; MURPHY, RF			BINDING TO CELLULAR RECEPTORS RESULTS IN INCREASED IRON RELEASE FROM TRANSFERRIN AT MILDLY ACIDIC PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE ERYTHROID-CELLS; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; FUNCTIONAL EQUIVALENCE; RABBIT RETICULOCYTES; CHELATING AGENTS; KINETICS; MUTANT; SITES; ACIDIFICATION	In order to better understand the cellular delivery of iron from serum transferrin (Tf), we compared iron release from receptor-bound and free Tf. While free Tf did not release all iron until below pH 4.6, receptor-bound Tf released significantly more iron at mildly acidic pH, with essentially all iron released between pH 5.6 and 6.0. Since Tf is acidified to a minimum pH of 5.4 in K562 cells, this result accounts for the nearly complete extraction of iron from Tf by these cells. Comparison of fluorescence from Tf conjugated with lissamine rhodamine sulfonyl chloride (LRSC-Tf) free in solution and bound to receptor provides further evidence that the Tf receptor modulates low pH-mediated conformational changes in Tf. As pH was decreased from neutrality, the fluorescence of free LRSC-Tf began to increase below pH 6.2; the fluorescence of LRSC-Tf bound to human receptors did not increase until below pH 5.6. Binding to the Tf receptor, while facilitating iron release from Tf, appears to partially inhibit a conformational change that causes the increase in LRSC-Tf fluorescence at low pH. The fluorescence of human LRSC-Tf bound to murine receptors increases at a higher pH, 6.0, indicating that there are differences in conformational stabilization of Tf by receptors of different species. The results suggest that the Tf receptor, in addition to providing a means by which cells may internalize Tf, functions to increase the release of iron from Tf in the endosome.	CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, CTR FLUORESCENCE RES BIOMED SCI, PITTSBURGH, PA 15213 USA	Carnegie Mellon University; Carnegie Mellon University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08067, GM32508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AISEN P, 1978, TRANSPORT PROTEINS, P277; ANKEL E, 1980, BIOCHEM PHARMACOL, V29, P1833, DOI 10.1016/0006-2952(80)90146-X; ARMSTRONG NJ, 1983, BIOCHIM BIOPHYS ACTA, V762, P175, DOI 10.1016/0167-4889(83)90069-1; BAKKEREN DL, 1988, INT J BIOCHEM, V20, P837; BAKKEREN DL, 1987, INT J BIOCHEM, V19, P179, DOI 10.1016/0020-711X(87)90329-6; BALDWIN DA, 1986, S AFR J CHEM, V39, P197; BALDWIN DA, 1982, BIOCHIM BIOPHYS ACTA, V719, P140, DOI 10.1016/0304-4165(82)90317-8; BATES GW, 1973, J BIOL CHEM, V248, P3228; BOMFORD A, 1985, BIOCHEMISTRY-US, V24, P3472, DOI 10.1021/bi00335a013; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; FOLEY AA, 1988, BIOCHIM BIOPHYS ACTA, V965, P154, DOI 10.1016/0304-4165(88)90051-7; FORD S, 1988, EUR J BIOCHEM, V178, P477, DOI 10.1111/j.1432-1033.1988.tb14473.x; GABER BP, 1970, BIOCHIM BIOPHYS ACTA, V221, P228, DOI 10.1016/0005-2795(70)90262-X; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; HARRIS DC, 1977, BIOCHIM BIOPHYS ACTA, V496, P563, DOI 10.1016/0304-4165(77)90338-5; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; IACOPETTA BJ, 1983, J BIOL CHEM, V258, P9108; KARIN M, 1981, J BIOL CHEM, V256, P3245; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KOJIMA N, 1979, J BIOL CHEM, V254, P8847; MAKEY DG, 1976, BIOCHIM BIOPHYS ACTA, V453, P250, DOI 10.1016/0005-2795(76)90270-1; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MARNELL MH, 1984, J CELL BIOL, V99, P1907, DOI 10.1083/jcb.99.6.1907; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MORGAN EH, 1971, BIOCHIM BIOPHYS ACTA, V244, P103, DOI 10.1016/0304-4165(71)90125-5; MORGAN EH, 1979, BIOCHIM BIOPHYS ACTA, V580, P312, DOI 10.1016/0005-2795(79)90144-2; MORGAN EH, 1981, BIOCHIM BIOPHYS ACTA, V642, P119, DOI 10.1016/0005-2736(81)90143-7; MORGAN EH, 1988, ANN NY ACAD SCI, V526, P65, DOI 10.1111/j.1749-6632.1988.tb55493.x; MORGAN EH, 1983, BIOCHIM BIOPHYS ACTA, V733, P39, DOI 10.1016/0005-2736(83)90089-5; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; NUNEZ MT, 1983, J BIOL CHEM, V258, P1146; PATERSON S, 1984, J CELL PHYSIOL, V120, P225, DOI 10.1002/jcp.1041200217; PRINCIOTTO JV, 1975, NATURE, V255, P87, DOI 10.1038/255087a0; RAO K, 1983, FEBS LETT, V160, P213, DOI 10.1016/0014-5793(83)80969-7; SIPE DM, 1991, J BIOL CHEM, V266, P3469; SIPE DM, 1987, P NATL ACAD SCI USA, V84, P7119, DOI 10.1073/pnas.84.20.7119; SIPE DM, 1988, J CELL BIOL, V107, P119; SIPE DM, 1987, J CELL BIOL, V105, P248; SUN IL, 1987, J BIOL CHEM, V262, P15915; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; WILSON RB, 1989, METHOD CELL BIOL, V31, P293; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505; YOUNG SP, 1982, BIOCHIM BIOPHYS ACTA, V718, P35, DOI 10.1016/0304-4165(82)90006-X	52	111	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8002	8007						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022630				2022-12-25	WOS:A1991FK44100010
J	UEMURA, Y; LEE, TC; SNYDER, F				UEMURA, Y; LEE, TC; SNYDER, F			A COENZYME A-INDEPENDENT TRANSACYLASE IS LINKED TO THE FORMATION OF PLATELET-ACTIVATING-FACTOR (PAF) BY GENERATING THE LYSO-PAF INTERMEDIATE IN THE REMODELING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; ARACHIDONIC-ACID; LYSOPHOSPHOLIPIDS; PHOSPHOLIPIDS; BIOSYNTHESIS; NEUTROPHILS	The remodeling pathway for the biosynthesis of platelet-activating factor (PAF) consists of the following reaction sequence: alkylacylglycerophosphocholine --> lyso-PAF --> PAF. Results presented in this article describe a novel transacylase activity that generates the lyso-PAF intermediate, which can then be acetylated to form PAF. Ethanolamine-containing lysoplasmalogens, 1-acyl-2-lyso-sn-glycero-3-phosphoethanolamine, alkyllysophosphoethanolamine, unlabeled lyso-PAF, 1-acyl-2-lyso-GPC, where GPC is sn-glycero-3-phosphocholine, and choline-containing lysoplasmalogens were all able to stimulate the formation of [H-3]lyso-PAF from a [H-3]alkylacyl-GPC precursor pool associated with HL-60 cell (granulocytic type) membranes. Other glycerolipids containing free hydroxyl groups (3-alkyl-2-lyso-sn-glycero-1-phosphocholine, lysophosphatidylserine, lysophosphatidylinositol, diacylglycerols, alkylglycerols, and monoacylglycerols), cholesterol, phosphatidylcholine, and phosphatidylethanolamine had no stimulatory effect on the release of [H-3]lyso-PAF from the prelabled membranes under identical incubation conditions. The observed transacylase reaction is directly coupled to PAF production, since the addition of a lysoethanolamine plasmalogen preparation to HL-60 membranes in the presence of [C-14]acetyl-CoA stimulated PAF formation; under these conditions the lysoethanolamine plasmalogen was acylated. The transacylase responsible for the release of lyso-PAF from the membrane-associated alkylacyl-GPC was not affected by Ca2+, EGTA, or a known phospholipase A2 inhibitor, p-bromophenacyl bromide. The fact that the unnatural analog of lyso-PAF, lysophosphatidylserine, and lysophosphatidylinositol did not influence transacylase activity, whereas detergents such as deoxycholate and Triton X-100 inhibited the activity, demonstrated the observed stimulatory effects of the choline- and ethanolamine-containing lysophospholipids on the formation of [H-3]lyso-PAF from [H-3]alkylacyl-GPC were not due to any detergent property of these lysophospholipids. Thus, we conclude a CoA-independent transacylase (possessing phospholipase A2/acyltransferase activities) can be responsible for the formation of the lyso-PAF intermediate in the remodeling route of PAF biosynthesis.	OAK RIDGE ASSOCIATED UNIV,DIV MED SCI,POB 117,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory					PHS HHS [27109-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BILLAH MM, 1985, J BIOL CHEM, V260, P6899; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DOEBBER TW, 1987, P NATL ACAD SCI USA, V84, P7557, DOI 10.1073/pnas.84.21.7557; HAYAISHI O, 1955, METHOD ENZYMOL, V1, P660, DOI 10.1016/0076-6879(55)01115-4; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; LEE TC, 1985, PHOSPHOLIPIDS CELLUL, V2, P1; LEE TC, 1987, PLATELET ACTIVATING, P115; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SNYDER F, 1989, P SOC EXP BIOL MED, V190, P125; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SUGA K, 1990, J BIOL CHEM, V265, P12363; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SUGIURA T, 1990, BIOCHIM BIOPHYS ACTA, V1047, P223, DOI 10.1016/0005-2760(90)90520-8; VANHEUSDEN GPH, 1980, J BIOL CHEM, V255, P9312; YANG SF, 1967, J BIOL CHEM, V242, P477	21	121	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8268	8272						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022643				2022-12-25	WOS:A1991FK44100051
J	KAVANAUGH, MP; VARNUM, MD; OSBORNE, PB; CHRISTIE, MJ; BUSCH, AE; ADELMAN, JP; NORTH, RA				KAVANAUGH, MP; VARNUM, MD; OSBORNE, PB; CHRISTIE, MJ; BUSCH, AE; ADELMAN, JP; NORTH, RA			INTERACTION BETWEEN TETRAETHYLAMMONIUM AND AMINO-ACID-RESIDUES IN THE PORE OF CLONED VOLTAGE-DEPENDENT POTASSIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELAYED RECTIFIER PROPERTIES; RAT-BRAIN; K+ CHANNEL; CHARYBDOTOXIN; EXPRESSION; DIVERSITY; CDNA; IONS	Extracellular tetraethylammonium (TEA) inhibits currents in Xenopus oocytes that have been injected with mRNAs encoding voltage-dependent potassium channels. Concentration-response curves were used to measure the affinity of TEA; this differed up to 700-fold among channels RBK1 (K(D) 0.3 mM), RGK5 (K(D) 11 mM), and RBK2 (K(D) > 200 mM). Studies in which chimeric channels were expressed localized TEA binding to the putative extracellular loop between transmembrane domains S5 and S6. Site-directed mutagenesis of residues in this region identified the residue Tyr379 of RBK1 as a crucial determinant of TEA sensitivity; substitution of Tyr in the equivalent positions of RBK2 (Val381) and RGK5 (His401) made these channels as sensitive to TEA as RBK1. Nonionic forces are involved in TEA binding because (i) substitution of the Phe for Tyr379 in RBK1 increased itsaffinity, (ii) protonation of His401 in RGK5 selectively reduced its affinity, and (iii) the affinity of TEA was unaffected by changes in ionic strength. The results suggest an explanation for the marked differences in TEA sensitivity that have been observed among naturally occurring and cloned potassium channels and indicate that the amino acid corresponding to residue 379 in RBK1 lies within the external mouth of the ion channel.			KAVANAUGH, MP (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.		Osborne, Peregrine/C-5907-2008; North, Richard/GQA-6156-2022	Osborne, Peregrine/0000-0002-8458-4159; Christie, MacDonald/0000-0002-0622-609X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003161, R01DA003160, R37DA003160] Funding Source: NIH RePORTER; NIDA NIH HHS [DA03161, DA03160] Funding Source: Medline; NIDDK NIH HHS [DK32979] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CHRISTIE MJ, 1990, NEURON, V2, P405; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HILLE B, 1967, J GEN PHYSIOL, V50, P1287, DOI 10.1085/jgp.50.5.1287; Hille B, 1984, IONIC CHANNELS EXCIT; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MASSEFSKI W, 1990, SCIENCE, V249, P521, DOI 10.1126/science.1696395; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MILLER C, 1988, NEURON, V1, P1003, DOI 10.1016/0896-6273(88)90157-2; MONTAL M, 1990, FASEB J, V4, P2623, DOI 10.1096/fasebj.4.9.1693348; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; STANFIELD PR, 1983, REV PHYSIOL BIOCH P, V97, P1, DOI 10.1007/BFb0035345; STUHMER W, 1988, FEBS LETT, V242, P199, DOI 10.1016/0014-5793(88)81015-9; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TASAKI I, 1957, J GEN PHYSIOL, V40, P859, DOI 10.1085/jgp.40.6.859; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; VERGARA C, 1984, BIOPHYS J, V45, P73, DOI 10.1016/S0006-3495(84)84114-4; VILLARROEL A, 1988, PFLUG ARCH EUR J PHY, V413, P118, DOI 10.1007/BF00582521; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	33	139	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7583	7587						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019588				2022-12-25	WOS:A1991FJ34200043
J	TAGLE, DA; SLIGHTOM, JL; JONES, RT; GOODMAN, M				TAGLE, DA; SLIGHTOM, JL; JONES, RT; GOODMAN, M			CONCERTED EVOLUTION LED TO HIGH EXPRESSION OF A PROSIMIAN PRIMATE DELTA-GLOBIN GENE LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; COMPLETE NUCLEOTIDE-SEQUENCE; AMINO-ACID-SEQUENCES; OLD-WORLD MONKEY; GAMMA-GLOBIN; GALAGO-CRASSICAUDATUS; DNA-SEQUENCES; PLASMID DNA; RECOMBINATION; PSEUDOGENE	The delta-globin gene in simian primates is either weakly expressed (in hominoids and New World monkeys) or silent (in Old World monkeys). In prosimian primates, however, an unequal homologous crossover between the psi-eta and delta-loci of lemurs produced a hybrid psi-eta-delta-pseudogene locus, whereas in tarsier the delta-locus encodes a beta-type chain found in 18% of adult tarsier hemoglobin molecules. In the present study, the nucleotide and amino acid sequences of the galago-delta and beta-globin genes and their encoded peptides were determined, and evidence is provided showing that the galago-delta-locus encodes a beta-type chain (beta-2) found in 40% of the galago fetal and postnatal hemoglobin molecules, whereas the beta-locus encodes the remaining 60% of the beta-type chain (beta-1). Galago beta-1 and beta-2 chains differ from each other by only one amino acid residue. The homology between the galago delta and beta-loci extends from 800 base pairs 5' of the proximal CCAAT element to near the end of exon 3 as a result of a recombination event in which beta-sequence replaced delta-sequence. After this initial recombination event, concerted evolution between the loci continued over their conserved coding, intron 1, and promoter regions but failed to occur between the two loci in their intron 2 and distal 5'-flanking sequences where the two loci have now diverged by 20%. Calculations based on this divergence value and on a rate of noncoding sequence evolution of 4.2 x 10(-9) to 5.5 x 10(-9) substitutions/site/year for the lorisform lineage to galago yielded a date of 18-24 million years ago for the initial recombination event. The fact that the promoter sequences of the galago delta-locus are the same as that of the galago beta-locus may account for the high level of expression of the galago delta-gene.	WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT ANAT & CELL BIOL,DETROIT,MI 48201; UPJOHN CO,MOLEC BIOL UNIT 7242,KALAMAZOO,MI 49001; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201	Wayne State University; Wayne State University; Pfizer; Oregon Health & Science University					NATIONAL CENTER FOR RESEARCH RESOURCES [S06RR008167] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033940] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-08167] Funding Source: Medline; NHLBI NIH HHS [HL-33940] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONIOU M, 1988, EMBO J, V7, P377, DOI 10.1002/j.1460-2075.1988.tb02824.x; BAILEY WJ, 1991, MOL BIOL EVOL, V8, P155; BARNICOT NA, 1972, PROSIMIAN BIOL, P891; BARRIE PA, 1981, J MOL BIOL, V149, P319, DOI 10.1016/0022-2836(81)90476-9; BEARD KC, 1988, NATURE, V331, P712, DOI 10.1038/331712a0; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOYER SH, 1971, BIOCHEM GENET, V5, P405, DOI 10.1007/BF00487132; CLEARY ML, 1981, CELL, V26, P181, DOI 10.1016/0092-8674(81)90301-9; CZELUSNIAK J, 1982, NATURE, V298, P297, DOI 10.1038/298297a0; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; DANIELS GR, 1983, NUCLEIC ACIDS RES, V11, P7595, DOI 10.1093/nar/11.21.7595; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DRESSLER D, 1982, ANNU REV BIOCHEM, V51, P727, DOI 10.1146/annurev.bi.51.070182.003455; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; GINGERICH PD, 1984, YEARB PHYS ANTHROPOL, V27, P57; GOODMAN M, 1987, COLD SPRING HARB SYM, V52, P875, DOI 10.1101/SQB.1987.052.01.096; GOODMAN M, 1984, J MOL BIOL, V180, P803, DOI 10.1016/0022-2836(84)90258-4; HARDIES SC, 1984, J BIOL CHEM, V259, P3748; HARDISON RC, 1984, MOL BIOL EVOL, V1, P302; HARDISON RC, 1984, MOL BIOL EVOL, V1, P390; HARRIS S, 1984, J MOL BIOL, V180, P785, DOI 10.1016/0022-2836(84)90257-2; HILL A, 1984, J BIOL CHEM, V259, P3739; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JEFFREYS AJ, 1982, J MOL BIOL, V156, P487, DOI 10.1016/0022-2836(82)90262-5; JONES RT, 1964, COLD SPRING HARB SYM, V29, P297, DOI 10.1101/SQB.1964.029.01.032; JUKES T H, 1969, P21; KIMURA A, 1983, NUCLEIC ACIDS RES, V11, P2541, DOI 10.1093/nar/11.9.2541; KOOP BF, 1988, P NATL ACAD SCI USA, V85, P3893, DOI 10.1073/pnas.85.11.3893; KOOP BF, 1989, J BIOL CHEM, V264, P68; KOOP BF, 1989, MOL BIOL EVOL, V6, P580; KOSCHE KA, 1985, NUCLEIC ACIDS RES, V13, P7781, DOI 10.1093/nar/13.21.7781; LACY E, 1980, CELL, V21, P545, DOI 10.1016/0092-8674(80)90492-4; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; Maniatis T., 1982, MOL CLONING; MARGOT JB, 1989, J MOL BIOL, V205, P15, DOI 10.1016/0022-2836(89)90362-8; MARTIN RD, 1988, NATURE, V331, P660, DOI 10.1038/331660a0; MARTIN SL, 1983, J MOL BIOL, V164, P513, DOI 10.1016/0022-2836(83)90048-7; MARTIN SL, 1980, P NATL ACAD SCI-BIOL, V77, P3563, DOI 10.1073/pnas.77.6.3563; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MORRISON WT, 1981, HEMOGLOBIN, V5, P403; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEI M, 1986, MOL BIOL EVOL, V3, P418; PAUPLIN Y, 1987, NUCLEIC ACIDS RES, V15, P5899, DOI 10.1093/nar/15.14.5899; PONCZ M, 1983, J BIOL CHEM, V258, P1599; RADDING CM, 1982, ANNU REV GENET, V16, P405, DOI 10.1146/annurev.ge.16.120182.002201; RADDING CM, 1978, ANNU REV BIOCHEM, V47, P847, DOI 10.1146/annurev.bi.47.070178.004215; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVATIER P, 1987, J MOL EVOL, V24, P297, DOI 10.1007/BF02134128; SAVATIER P, 1985, J MOL BIOL, V182, P21, DOI 10.1016/0022-2836(85)90024-5; SAVATIER P, 1987, J MOL EVOL, V24, P309, DOI 10.1007/BF02134129; SCHON EA, 1981, CELL, V27, P359, DOI 10.1016/0092-8674(81)90419-0; SCHROEDER WA, 1968, PRIMARY STRUCTURE PR, P108; SHELTON JB, 1985, HEMOGLOBIN, V9, P325, DOI 10.3109/03630268508997008; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SPRITZ RA, 1988, MOL BIOL EVOL, V5, P21; SPRITZ RA, 1980, CELL, V21, P639, DOI 10.1016/0092-8674(80)90427-4; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; TAGLE DA, 1990, THESIS WAYNE STATE U; VINCENT KA, 1989, J MOL BIOL, V207, P465, DOI 10.1016/0022-2836(89)90457-9; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WATANABE B, 1985, BIOL CHEM H-S, V366, P265, DOI 10.1515/bchm3.1985.366.1.265; WILSON JB, 1979, J CHROMATOGR, V179, P271, DOI 10.1016/S0021-9673(00)83830-3; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; ZWEIG SE, 1984, NUCLEIC ACIDS RES, V12, P767, DOI 10.1093/nar/12.1Part2.767	66	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7469	7480						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019578				2022-12-25	WOS:A1991FJ34200026
J	ISHIMI, Y; KIKUCHI, A				ISHIMI, Y; KIKUCHI, A			IDENTIFICATION AND MOLECULAR-CLONING OF YEAST HOMOLOG OF NUCLEOSOME ASSEMBLY PROTEIN-I WHICH FACILITATES NUCLEOSOME ASSEMBLY INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; CHROMATIN STRUCTURE; NUCLEOLAR PROTEIN; MAMMALIAN-CELLS; HISTONE-BINDING; ACIDIC PROTEIN; AP-I; DNA; REPLICATION; SEQUENCE	Yeast DNA coding for nucleosome assembly protein I (NAP-I), which facilitates nucleosome assembly in vitro at physiological ionic conditions, was cloned and its gene product was characterized. A monoclonal antibody against NAP-I (58 kDa) from human HeLa cells was used to screen a genomic library of Saccharomyces cerevisiae constructed into lambda-gt11. A 60-kDa protein was detected by immunoblotting in the extracts of Escherichia coli lysogenized with a positive clone. The 60-kDa protein purified from the extracts had an activity equivalent to that of NAP-I from mouse and human cells. The amino acid sequence deduced from the gene coding for the yeast NAP-I defines a polypeptide of molecular mass 47,848 Da with three negatively charged regions. While the two regions contain 8 and 10 acidic amino acids out of 13 amino acid residues, the longest stretch has 15 glutamic and 13 aspartic acids out of 38 residues. These regions are probably involved in the interaction with histones. Proteins recognized by the anti-NAP-I antibody were also present in Xenopus oocytes and Drosophila cultured cells. Possible roles of NAP-I are discussed in relation to other nucleosome assembly proteins.			ISHIMI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BUGLER B, 1987, J BIOL CHEM, V262, P10922; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FOTEDAR R, 1989, P NATL ACAD SCI USA, V86, P6459, DOI 10.1073/pnas.86.17.6459; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; ISHIMI Y, 1985, CELL STRUCT FUNCT, V10, P373, DOI 10.1247/csf.10.373; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1983, J BIOCHEM-TOKYO, V94, P735, DOI 10.1093/oxfordjournals.jbchem.a134414; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KROHNE G, 1980, EXP CELL RES, V129, P167, DOI 10.1016/0014-4827(80)90341-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; OTTER R, 1983, METHOD ENZYMOL, V100, P171; PEREZORTIN JE, 1989, YEAST, V5, P219, DOI 10.1002/yea.320050404; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPP M, 1990, J BIOL CHEM, V265, P9357; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; WEINTRAUB H, 1979, NUCLEIC ACIDS RES, V7, P781, DOI 10.1093/nar/7.3.781; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	37	161	163	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7025	7029						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016313				2022-12-25	WOS:A1991FG72700060
J	THOM, JR; MORRIS, NP				THOM, JR; MORRIS, NP			BIOSYNTHESIS AND PROTEOLYTIC PROCESSING OF TYPE-XI COLLAGEN IN EMBRYONIC CHICK STERNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL EXTENSIONS; PROCOLLAGEN N-PROTEINASE; CARTILAGE COLLAGENS; V COLLAGEN; BLOOD-VESSELS; I PROCOLLAGEN; PC-COLLAGEN; TISSUE FORM; HUMAN-SKIN; CLEAVAGE	The biosynthesis and proteolytic processing of type XI procollagen was examined using pulse-chase labeling of 17-day embryonic chick sterna in organ culture with [H-3]proline. Products of biosynthesis were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis with and without prior reduction of disulfide bonds. Pro-alpha chains, intermediates, and matrix forms were identified by cyanogen bromide or Staphylococcus aureus V8 protease digestion. The results show that type XI pro-alpha chains assemble into trimeric molecules with interchain disulfide bonds. Proteolytic processing begins at least 40 min after the start of labeling which is later than that of type II procollagen (25 min). This first processing step involves the loss of the domain containing the interchain disulfide bonds which most likely is the carboxyl propeptide. In the case of the pro-alpha-3 chain, this generates the matrix form, m-alpha-3, which retains its amino propeptide. For the pro-alpha-1 and pro-alpha-2 chains, this step generates intermediate forms, p-alpha-1 and p-alpha-2, which undergo a second proteolytic conversion to m-alpha-1 and m-alpha-2, and yet retain a pepsin-labile domain. The conversion of p-alpha-2 to m-alpha-2 is largely complete 2 h after labeling. p-alpha-1 is converted to m-alpha-1 very slowly and is 50% complete after 18 h of chase in organ culture. The apparent proteolytic processing within the amino propeptide, and the differential rate of processing between two chains in the same molecule are unusual and distinguish type XI from collagen types I, II, and III. It is possible that the extremely slow processing of p-alpha-1 affects the formation of the heterotypic cartilage collagen fibrils and may be related to the function of type XI collagen.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University	THOM, JR (corresponding author), OREGON HLTH SCI UNIV,SHRINERS HOSP CRIPPLED CHILDREN,RES UNIT,PORTLAND,OR 97201, USA.			Oxford, Julia/0000-0002-4850-3569	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039862] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39862] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHINGER HP, 1982, J BIOL CHEM, V257, P4590; BERGER J, 1985, BIOCHEMISTRY-US, V24, P600, DOI 10.1021/bi00324a009; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BROEK DL, 1985, J BIOL CHEM, V260, P555; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BURGESON RE, 1976, P NATL ACAD SCI USA, V73, P2579, DOI 10.1073/pnas.73.8.2579; BURGESON RE, 1982, J BIOL CHEM, V257, P7852; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; CLARK CC, 1988, BIOCHEM J, V250, P65, DOI 10.1042/bj2500065; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; Eyre D, 1987, STRUCTURE FUNCTION C, P261; EYRE DR, 1984, BIOCHEM BIOPH RES CO, V118, P724, DOI 10.1016/0006-291X(84)91454-2; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FESSLER LI, 1981, J BIOL CHEM, V256, P9640; FESSLER LI, 1979, J BIOL CHEM, V254, P233; FESSLER LI, 1981, J BIOL CHEM, V256, P9646; FLEISCHMAJER R, 1985, ANN NY ACAD SCI, V460, P246, DOI 10.1111/j.1749-6632.1985.tb51172.x; FLEISCHMAJER R, 1987, CELL TISSUE RES, V247, P105, DOI 10.1007/BF00216552; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; FURUTO DK, 1983, ARCH BIOCHEM BIOPHYS, V226, P604, DOI 10.1016/0003-9861(83)90329-6; GADHER SJ, 1988, EUR J BIOCHEM, V175, P1, DOI 10.1111/j.1432-1033.1988.tb14158.x; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KEENE DR, 1987, J CELL BIOL, V105, P2393, DOI 10.1083/jcb.105.5.2393; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KUHN K, 1987, STRUCTURE FUNCTION C, P1; KUMAMOTO CA, 1980, P NATL ACAD SCI-BIOL, V77, P6434, DOI 10.1073/pnas.77.11.6434; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MORRIS NP, 1990, J BIOL CHEM, V265, P10081; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; PELTONEN L, 1980, P NATL ACAD SCI-BIOL, V77, P162, DOI 10.1073/pnas.77.1.162; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SMITH GN, 1987, COLLAGEN REL RES, V7, P17; SMITH GN, 1987, COLLAGEN REL RES, V7, P315; SOKOLOV BP, 1989, ANAL BIOCHEM, V176, P365, DOI 10.1016/0003-2697(89)90324-2; SUSSMAN M D, 1984, Journal of Orthopaedic Research, V2, P134, DOI 10.1002/jor.1100020204; TIMPL R, 1981, CLIN ORTHOP RELAT R, V158, P224; UITTO J, 1977, BIOCHEMISTRY-US, V16, P3421, DOI 10.1021/bi00634a020; UITTO J, 1979, EUR J BIOCHEM, V99, P97, DOI 10.1111/j.1432-1033.1979.tb13236.x; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WIRTZ MK, 1990, J BIOL CHEM, V265, P6312; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; WOTTON SF, 1988, FEBS LETT, V234, P79, DOI 10.1016/0014-5793(88)81307-3; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423	51	67	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7262	7269						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016327				2022-12-25	WOS:A1991FG72700096
J	MAYORGA, LS; BERTINI, F; STAHL, PD				MAYORGA, LS; BERTINI, F; STAHL, PD			FUSION OF NEWLY FORMED PHAGOSOMES WITH ENDOSOMES IN INTACT-CELLS AND IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; GTP-BINDING PROTEIN; GOLGI-APPARATUS; ENDOPLASMIC-RETICULUM; INVITRO FUSION; TRANSPORT; RECONSTITUTION; INVOLVEMENT; MACROPHAGES; MEMBRANE	Phagosomes are membrane-bound vesicles, formed by the receptor-mediated internalization of particulate ligands, which exchange soluble and membrane proteins with other endocytic compartments as a part of their maturation process. This exchange of material is undoubtedly mediated by fusion of phagosomes with other membrane-bound compartments of the endocytic pathway. By using a particulate probe (fixed Staphylococcus aureus coated with mouse anti-dinitrophenol monoclonal antibody) localized in phagosomes and a soluble probe (dinitrophenol-derivatized beta-glucuronidase) internalized by receptor-mediated endocytosis, we have studied phagosome-endosome and phagosome-lysosome fusion in intact cells and in a cell-free system. Vesicle fusion was assessed by measuring beta-glucuronidase activity associated with S. aureus particles after lysis of the membranes. In intact macrophages, newly formed phagosomes fused with early endosomes and with lysosomes. Fusion with lysosomes was observed to commence after a short lag period of about 5 min. In broken-cell preparations, phagosomes were able to fuse with early endosomes. It was not possible to reconstitute phagosome-lysosome fusion in vitro. In vitro phagosome-endosome fusion required energy and cytosolic- and membrane-associated proteins. A nonhydrolyzable analog of GTP stimulated fusion at low cytosol concentrations and inhibited fusion at high cytosol concentrations. These observations indicate that the mechanisms mediating phagosome-endosome fusion are similar to those described for endosome-endosome fusion. Our results suggest that exchange of material with endosomes is an important step in the process of phagosome maturation.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID AVE,ST LOUIS,MO 63110; NATL UNIV CUYO,CONSEJO NACL INVEST CIENT & TECN,INST HISTOL EMBRIOL,RA-5500 MENDOZA,ARGENTINA	Washington University (WUSTL); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza			Stahl, Philip/D-6315-2012	Mayorga, Luis S/0000-0002-5995-0671	NCI NIH HHS [CA 12858] Funding Source: Medline; NIAID NIH HHS [AI 20015] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA012858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020015, R37AI020015] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EJ, 1987, J IMMUNOL, V139, P3777; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, J BIOL CHEM, V264, P13171; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; GRESHAM HD, 1987, J IMMUNOL, V139, P4159; GRUENBERG J, 1987, P NATL ACAD SCI USA, V84, P5758, DOI 10.1073/pnas.84.16.5758; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; KELLER RK, 1975, J BIOL CHEM, V250, P4765; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG T, 1988, EUR J CELL BIOL, V46, P39; MAYORGA LS, 1989, J BIOL CHEM, V264, P5392; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; MULLER WA, 1980, J CELL BIOL, V86, P304, DOI 10.1083/jcb.86.1.304; MULLOCK BM, 1989, J CELL BIOL, V108, P2093, DOI 10.1083/jcb.108.6.2093; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OATES PJ, 1980, J CELL BIOL, V85, P804, DOI 10.1083/jcb.85.3.804; ROEDERER M, 1990, EUR J CELL BIOL, V51, P229; ROTH J, 1983, TECHNIQUES IMMUNOCYT, V2, P217; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SHEPHERD V, 1988, LIFE CHEM REPORTS, V6, P317; Silverstein S. C., 1989, FUNDAMENTAL IMMUNOLO; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; WARD DM, 1990, J CELL BIOL, V110, P1013, DOI 10.1083/jcb.110.4.1013; WILEMAN T, 1985, BIOCHEM J, V232, P1; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	38	124	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6511	6517						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007600				2022-12-25	WOS:A1991FE37300076
J	NISHIMOTO, M; GOTOH, O; OKUDA, K; NOSHIRO, M				NISHIMOTO, M; GOTOH, O; OKUDA, K; NOSHIRO, M			STRUCTURAL-ANALYSIS OF THE GENE ENCODING RAT CHOLESTEROL ALPHA-HYDROXYLASE, THE KEY ENZYME FOR BILE-ACID BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL-INDUCIBLE CYTOCHROME-P-450; STEROID 21-HYDROXYLASE GENES; LIVER MICROSOMES; TESTOSTERONE 16-ALPHA-HYDROXYLASE; GEL-ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; CLONING; DNA; CDNA	The gene encoding cholesterol 7-alpha-hydroxylase (P450VIIA) was isolated from rat genomic DNA. The gene spanned about 11 kilobases and contained six exons. Blotting analysis of genomic DNA and complete matching of restriction maps of several isolated genomic clones indicated that there appeared to be only one gene in the rat genome. The putative transcription initiation site was present 61 base pairs upstream from the ATG codon. The typical TATA sequence and CCAAT promoter element were found at 24 and 47 base pairs upstream from the transcription initiation site, respectively. Alignment of several P450 proteins showed that the cholesterol 7-alpha-hydroxylase gene shared location of introns with none of the other P450 genes except for intron 5, which was in the same position as intron 10 of the gene encoding P450IVA1. The alignment also indicated that the distal helix of cholesterol 7-alpha-hydroxylase contained an asparagine in place of the well conserved threonine that is postulated to be involved in the O2 binding site. Unusual residues, Asn-126 and Thr-442, were also found at the sites where all other P450s have positively charged amino acids, which are considered to be involved in interaction with heme propionate. These replacements may be related to the unique function and unusual lability of the hydroxylase. Analysis of evolutionary distance between the cholesterol 7-alpha-hydroxylase gene and other known P450 genes indicated that yeast P450LIA is most closely related to P450VIIA. This finding suggests that the cholesterol 7-alpha-hydroxylase gene is an evolutionarily old P450 gene.	HIROSHIMA UNIV,SCH DENT,DEPT BIOCHEM,KASUMI 1-2-3,MINAMI KU,HIROSHIMA 734,JAPAN; SAITAMA CANC CTR,DEPT BIOCHEM,INA,SAITAMA 362,JAPAN	Hiroshima University								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALASUBRAMANIAM S, 1975, ADV BILE ACID RES, V3, P61; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BJORKHEM I, 1974, BIOCHEM BIOPH RES CO, V61, P934, DOI 10.1016/0006-291X(74)90245-9; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BOZAK KR, 1990, P NATL ACAD SCI USA, V87, P3904, DOI 10.1073/pnas.87.10.3904; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; GOTOH O, 1990, B MATH BIOL, V52, P359, DOI 10.1016/S0092-8240(05)80216-2; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; HASHIMOTO T, 1989, J BIOCHEM-TOKYO, V105, P676, DOI 10.1093/oxfordjournals.jbchem.a122725; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P503, DOI 10.1089/dna.1.1989.8.503; KWOK CT, 1981, J LIPID RES, V22, P570; LABBE D, 1908, DNA, V7, P253; LI YC, 1990, J BIOL CHEM, V265, P12012; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MATSUNAGA T, 1988, J BIOL CHEM, V263, P17995; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MYANT NB, 1977, J LIPID RES, V18, P135; NEBERT DW, 1989, DNA-J MOLEC CELL BIO, V8, P1, DOI 10.1089/dna.1.1989.8.1; NISHIRO M, 1990, J BIOL CHEM, V265, P10036; NOSHIRO M, 1989, FEBS LETT, V257, P97, DOI 10.1016/0014-5793(89)81795-8; NOSHIRO M, 1990, FEBS LETT, V268, P137, DOI 10.1016/0014-5793(90)80992-R; OGISHIMA T, 1987, J BIOL CHEM, V262, P7646; PICADOLEONARD J, 1987, DNA-J MOLEC CELL BIO, V6, P439, DOI 10.1089/dna.1987.6.439; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCALLEN TJ, 1983, P NATL ACAD SCI-BIOL, V80, P2477, DOI 10.1073/pnas.80.9.2477; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; SOGAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P5066, DOI 10.1073/pnas.81.16.5066; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUWA Y, 1985, J BIOL CHEM, V260, P7980; WADA F, 1968, J BIOCHEM-TOKYO, V64, P415, DOI 10.1093/oxfordjournals.jbchem.a128911; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; WONG G, 1987, BIOCHEMISTRY-US, V26, P8683, DOI 10.1021/bi00400a029	46	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6467	6471						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007596				2022-12-25	WOS:A1991FE37300070
J	CADEPOND, F; SCHWEIZERGROYER, G; SEGARDMAUREL, I; JIBARD, N; HOLLENBERG, SM; GIGUERE, V; EVANS, RM; BAULIEU, EE				CADEPOND, F; SCHWEIZERGROYER, G; SEGARDMAUREL, I; JIBARD, N; HOLLENBERG, SM; GIGUERE, V; EVANS, RM; BAULIEU, EE			HEAT-SHOCK PROTEIN-90 AS A CRITICAL FACTOR IN MAINTAINING GLUCOCORTICOSTEROID RECEPTOR IN A NONFUNCTIONAL STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-BINDING DOMAIN; MR = 90,000; DNA-BINDING; PROGESTERONE-RECEPTOR; DEOXYRIBONUCLEIC-ACID; NUCLEAR-LOCALIZATION; FUNCTIONAL DOMAINS; PLASMID DNA; RAT-LIVER; HORMONE	Previous work demonstrated that the ligand binding domain (LBD) was required to determine the formation of the cytosolic, untransformed, inactive, 8 S, heterooligomeric form of the human glucocorticosteroid receptor (hGR) which includes the 90-kDa heat shock protein (hsp90) (Pratt, W. B., Jolly, D. J., Pratt, D. V., Hollenberg, S. M., Giguere, V., Cadepond, F. M., Schweizer-Groyer, G., Catelli, M. G., Evans, R. M., and Baulieu, E. E. (1988) J. Biol. Chem. 263, 267-273). Truncations of hGR deleting all or almost all of the LBD give GR derivatives in the non-hsp90-interacting 4 S form able to stimulate transcription in a hormone-independent manner. To identify the LBD subregion(s) involved in 8 S formation, we analyzed the sedimentation behavior of hGR mutants with various LBD internal deletions and/or truncations transiently expressed in cells that contain hsp90 but very low levels of endogenous GR, and we correlated the results with their transcriptional activity. LBD has been divided into three subregions: two of them, LBD1 (between amino acids 551 and 626) and LBD2 (between amino acids 627 and 696), include amino acid sequences highly conserved in the steroid receptor superfamily, and LBD3 consists of the carboxyl-terminal part of the molecule (amino acids 697-777). Each of these subregions can be deleted without impeding 8 S heterooligomer formation, and the corresponding receptors do not have transcriptional activity in the absence as well as in the presence of hormone. When linked to hGR mutants truncated after amino acids 532 or 550, each subregion does separately promote 8 S heterooligomeric complex formation and repress the intrinsic constitutive transcriptional activity of the truncated receptors. These 8 S complexes contain hsp90. In a control experiment, the linkage of 1,017 amino acids of beta-galactosidase to the carboxyl-terminal of 1-532 hGR gave a hybrid receptor still constitutively transcriptionally active which did not bind hsp90. These results provide evidence that there is a strong correlation between the association with hsp90 and the loss of GR functional properties and that hsp90 may play a critical role in maintaining the receptor in a nonfunctional state.	UNIV PARIS SUD,INSERM,U33,HORMONES LAB,F-94275 LE KREMLIN BICETR,FRANCE; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,SAN DIEGO,CA 92138	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Howard Hughes Medical Institute; Salk Institute				Evans, Ronald/0000-0002-9986-5965; Giguere, Vincent/0000-0001-9567-3694				BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; Baulieu EE, 1989, STEROID THYROID HORM, P301; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BUCHOU T, 1983, BIOCHEM BIOPH RES CO, V114, P479, DOI 10.1016/0006-291X(83)90805-7; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DENIS M, 1988, J STEROID BIOCHEM, V30, P271, DOI 10.1016/0022-4731(88)90105-7; DENIS M, 1988, J BIOL CHEM, V263, P18520; DENIS M, 1989, J BIOL CHEM, V264, P6005; DENIS M, 1989, CANCER RES, V49, pS2275; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GARGER SJ, 1983, BIOCHEM BIOPH RES CO, V117, P835, DOI 10.1016/0006-291X(83)91672-8; GEHRING U, 1985, FEBS LETT, V179, P138, DOI 10.1016/0014-5793(85)80208-8; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLBROOK NJ, 1983, J BIOL CHEM, V258, P6477; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1989, CANCER RES, V49, pS2292; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOUSLEY PR, 1990, J BIOL CHEM, V265, P12778; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; LEFEBVRE P, 1988, BIOCHEMISTRY-US, V27, P9186, DOI 10.1021/bi00426a017; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; OKRET S, 1985, BIOCHEMISTRY-US, V24, P6581, DOI 10.1021/bi00344a041; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1988, J BIOL CHEM, V263, P267; RAAKA BM, 1989, MOL ENDOCRINOL, V3, P332, DOI 10.1210/mend-3-2-332; RADANYI C, 1989, J BIOL CHEM, V264, P2568; REXIN M, 1988, BIOCHEMISTRY-US, V27, P5593, DOI 10.1021/bi00415a030; RINGOLD GM, 1985, ANNU REV PHARMACOL, V25, P529, DOI 10.1146/annurev.pa.25.040185.002525; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SEGNITZ B, 1990, J BIOL CHEM, V265, P2789; SHERMAN MR, 1983, J BIOL CHEM, V258, P366; SHERMAN MR, 1984, ANNU REV PHYSIOL, V46, P83; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; URDA LA, 1989, MOL ENDOCRINOL, V3, P251, DOI 10.1210/mend-3-2-251; VEDECKIS WV, 1983, BIOCHEMISTRY-US, V22, P1983, DOI 10.1021/bi00277a038; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	59	144	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5834	5841						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005120				2022-12-25	WOS:A1991FD37000075
J	EISENSTEIN, E				EISENSTEIN, E			CLONING, EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF BIOSYNTHETIC THREONINE DEAMINASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; ASPARTATE TRANSCARBAMOYLASE; MONOVALENT CATIONS; TRYPTOPHANASE; BINDING; ENZYMES; OPERON; K-12; SITE; BETA	Feedback inhibition of the regulatory enzyme threonine deaminase by isoleucine provides an important level of enzymic control over branched chain amino acid biosynthesis in Escherichia coli. Cloning ilvA, the structural gene for threonine deaminase, under control of the trc promoter results in expression of active enzyme upon induction by isopropyl 1-thio-beta-D-galactoside to levels of approximately 20% of the soluble protein in cell extracts. High level expression of threonine deaminase has facilitated the development of a rapid and efficient protocol for the purification of gram quantities of enzyme with a specific activity 3-fold greater than previous preparations. The catalytic activity of threonine deaminase is absolutely dependent on the presence of pyridoxal phosphate, and the tetrameric molecule is isolated containing 1 mol of cofactor/56,000-Da chain. Wild-type threonine deaminase demonstrates a sigmoidal dependence of initial velocity on threonine concentration in the absence of isoleucine, consistent with a substrate-promoted conversion of the enzyme from a low activity to a high activity conformation. The enzymic dehydration of threonine to alpha-ketobutyrate measured by steady-state kinetics, performed at 20-degrees-C in 0.05 M potassium phosphate, pH 7.5, is described by a Hill coefficient, n(H), of 2.3 and a K0.5 of 8.0 mM. The negative allosteric effector L-isoleucine strongly inhibits the enzyme, yielding a value for n(H) of 3.9 and K0.5 of 74 mM whereas enzyme activity is greatly increased by L-valine, which yields nearly hyperbolic kinetics characterized by a value for n(H) of 1.0 and a K0.5 of 5.7 mM. Thus, these effectors promote dramatic and opposing effects on the transition from the low activity to the high activity conformation of the tetrameric enzyme.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,CATONSVILLE,MD 21228		EISENSTEIN, E (corresponding author), UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,9600 GUDELSKY DR,ROCKVILLE,MD 20850, USA.							AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS O, 1971, METHODS ENZYMOL B, V17, P555; BURNS RO, 1968, J BIOL CHEM, V243, P178; CALHOUN DH, 1973, J BIOL CHEM, V248, P3511; CHANGEUX JEAN-PIERRE, 1962, JOUR MOLECULAR BIOL, V4, P220; CHANGEUX JP, 1963, COLD SPRING HARB SYM, V28, P497, DOI 10.1101/SQB.1963.028.01.066; CHANGEUX JP, 1961, COLD SPRING HARB SYM, V26, P313, DOI 10.1101/SQB.1961.026.01.037; COX JL, 1987, GENE, V56, P185, DOI 10.1016/0378-1119(87)90136-3; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DAVIS L, 1965, ANAL BIOCHEM, V12, P36, DOI 10.1016/0003-2697(65)90139-9; EISENSTEIN E, 1990, FASEB J, V4, pA2124; FELDBERG RS, 1971, EUR J BIOCHEM, V21, P438, DOI 10.1111/j.1432-1033.1971.tb01490.x; FOOTE J, 1985, J MOL BIOL, V186, P175, DOI 10.1016/0022-2836(85)90267-0; FREUNDLICH M, 1963, COLD SPRING HARB SYM, V28, P505, DOI 10.1101/SQB.1963.028.01.067; GERHART JC, 1963, COLD SPRING HARB SYM, V28, P491, DOI 10.1101/SQB.1963.028.01.065; HATANAKA M, 1962, ARCH BIOCHEM BIOPHYS, V97, P596, DOI 10.1016/0003-9861(62)90129-7; HATFIELD GW, 1970, J BIOL CHEM, V245, P787; HATFIELD GW, 1971, BIOCHEM BIOPH RES CO, V44, P464, DOI 10.1016/0006-291X(71)90624-3; HATFIELD GW, 1968, BIOCHEM BIOPH RES CO, V33, P397, DOI 10.1016/0006-291X(68)90584-6; HENSLEY P, 1981, J MOL BIOL, V152, P131, DOI 10.1016/0022-2836(81)90098-X; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KOERNER K, 1975, BIOCHIM BIOPHYS ACTA, V397, P220, DOI 10.1016/0005-2744(75)90195-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAWTHER RP, 1978, MOL GEN GENET, V167, P227, DOI 10.1007/BF00266916; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; MILES EW, 1975, BIOCHEM BIOPH RES CO, V66, P94, DOI 10.1016/S0006-291X(75)80299-3; Miller J.H., 1972, EXPT MOL GENETICS; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; SNELL EE, 1975, ADV ENZYMOL RAMB, V42, P287; STRUHL K, 1985, Biotechniques, V3, P452; Stryer L., 1988, BIOCHEMISTRY-US; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; SZENTIRMAI A, 1968, J BACTERIOL, V95, P1672, DOI 10.1128/JB.95.5.1672-1679.1968; TORAYA T, 1976, EUR J BIOCHEM, V69, P411, DOI 10.1111/j.1432-1033.1976.tb10925.x; UMBARGER HE, 1973, ADV ENZYMOL RAMB, V37, P349; UMBARGER HE, 1956, SCIENCE, V123, P848, DOI 10.1126/science.123.3202.848; UMBARGER HE, 1957, J BACTERIOL, V73, P105, DOI 10.1128/JB.73.1.105-112.1957; UMBARGER HE, 1956, J BACTERIOL, V71, P443, DOI 10.1128/JB.71.4.443-449.1956; UMBARGER HE, 1957, J BIOL CHEM, V233, P415; Umbarger HE, 1987, ESCHERICHIA COLI SAL, P352; VIEIRA J, 1987, METHOD ENZYMOL, V153, P1; WADA H, 1961, J BIOL CHEM, V236, P2089; WATANABE T, 1972, P NATL ACAD SCI USA, V69, P1086, DOI 10.1073/pnas.69.5.1086; WEK RC, 1986, J BIOL CHEM, V261, P2441; YUNIS AA, 1960, J BIOL CHEM, V235, P3163	49	51	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5801	5807						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005118				2022-12-25	WOS:A1991FD37000070
J	LIU, JW; LACY, J; SUKHATME, VP; COLEMAN, DL				LIU, JW; LACY, J; SUKHATME, VP; COLEMAN, DL			GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR INDUCES TRANSCRIPTIONAL ACTIVATION OF EGR-1 IN MURINE PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM GROWTH-FACTORS; PROTEIN-KINASE-C; ADENYLATE-CYCLASE ACTIVITY; REGULATORY FACTOR; GENE-EXPRESSION; FACTORS ENCODES; MESSENGER-RNA; CELLS; FOS; JUN	Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic hematopoietic growth factor that induces both growth and differentiation of tissue macrophages. The subcellular mechanism of action of GM-CSF is unknown. We have examined the effect of GM-CSF on the immediate early response gene, Egr-1, in murine peritoneal macrophages. Our data demonstrate that recombinant GM-CSF (25 units/ml) produces a 12-fold increase in Egr-1 mRNA within 30 min. Pretreatment with cycloheximide (10-mu-g/ml) had no effect on the ability of GM-CSF to increase Egr-1 mRNA. In nuclear runoff studies, GM-CSF increased the transcription rate of Egr-1 by 10-fold at 10 min. The maximal effect on Egr-1 transcription occurred at 25 min (13-fold) and decreased by 45 min. The half-life of Egr-1 mRNA in GM-CSF-treated macrophages is 13-21 min. We were unable to calculate the half-life in control cells, however, because of the short half-life and low level of constitutive expression of Egr-1 mRNA. Endogenous protein kinase C activity in macrophages was depleted by treatment with 12-O-tetradecanoylphorbol-13-acetate for 24 h. GM-CSF increased Egr-1 mRNA in protein kinase C-depleted macrophages, whereas the stimulatory effect of 12-O-tetradecanoylphorbol-13-acetate on Egr-1 was blocked. These data show that GM-CSF rapidly increases transcription of Egr-1 mRNA. The effect of GM-CSF on Egr-1 mRNA does not require de novo protein synthesis or protein kinase C. These findings provide a basis for investigating the molecular mechanism of action of GM-CSF in tissue macrophages.	VET AFFAIRS MED CTR, MED SERV 111I, 950 CAMPBELL AVE, West Haven, CT 06516 USA; YALE UNIV, SCH MED, DEPT INTERNAL MED, West Haven, CT 06516 USA; YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06510 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University; Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago			Sukhatme, Vikas/W-2776-2019					ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERG JM, 1990, J BIOL CHEM, V265, P6513; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHODAKEWITZ JA, 1988, J IMMUNOL, V140, P832; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COFFEY RG, 1988, J IMMUNOL, V140, P2695; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLEMAN DL, 1989, J IMMUNOL, V143, P4134; COLEMAN DL, 1988, BLOOD, V72, P573; CURRAN T, 1988, ONCOGENE HDB, V1, P307; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HAMILTON TA, 1985, J BIOL CHEM, V260, P1378; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; JAMIESON GA, 1989, J CELL PHYSIOL, V139, P262, DOI 10.1002/jcp.1041390207; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; LACY J, 1989, EMBO J, V8, P1973, DOI 10.1002/j.1460-2075.1989.tb03603.x; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; METCALF D, 1986, BLOOD, V67, P257; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOND JJ, 1987, P NATL ACAD SCI USA, V84, P8588, DOI 10.1073/pnas.84.23.8588; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRIS JG, 1974, BIOL PHYSICAL CHEM, P257; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; RUEF C, 1990, REV INFECT DIS, V12, P41; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	47	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5929	5933						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005129				2022-12-25	WOS:A1991FD37000089
J	SAFER, B; REINBERG, D; JACOB, WF; MALDONADO, E; CARCAMO, J; GARFINKEL, S; COHEN, R				SAFER, B; REINBERG, D; JACOB, WF; MALDONADO, E; CARCAMO, J; GARFINKEL, S; COHEN, R			INTERACTION OF CAP SEQUENCE SITE BINDING-FACTOR AND TRANSCRIPTION FACTOR IID PRECEDING AND FOLLOWING BINDING TO THE ADENOVIRUS-2 MAJOR LATE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA-BOX; DNA-BINDING; ACCURATE TRANSCRIPTION; ACTIVATION DOMAIN; INITIATION SITE; PROTEIN; GENE; IDENTIFICATION; SPECIFICITY	Interaction of cloned yeast, drosophila, and human transcription factor IID (yTFIID, dTFIID, and hTFIID, respectively) with the adenovirus 2 major late promoter (Ad2 MLP) confers a more limited pattern of DNase I protection than that obtained using highly purified native hTFIID (Hahn, S., Buratowski, S., Sharp, P. A. and Guarente, L. (1989) EMBO J. 8, 3379-3382; Van Dyke, M. W., and Sawadogo, M. (1990) Mol. Cell. Biol. 10, 3415-3420; Horikoshi, M., Wang, C. K., Fujii, H., Cromlish, J. A., Weil, P. A., and Roeder, R. G. (1989) Nature 341, 299-303; Peterson, M. G., Tanese, N., Pugh, B. F., and Tjian, R. (1990) Science 248, 1625-1630; Hoey, T., Dynlacht, B. D., Peterson, M. G., Pugh, B. F., and Tjian, R. (1990) Cell 61, 1179-1186). Since the mass of the cloned TFIIDs is considerably less than that of native hTFIID (27-38 kDa versus 120-140 kDa), it is considered likely that native hTFIID exists as a mixed heterodimer. We have recently identified, purified, and characterized a novel transcription factor that binds to the CAP site region (+l to +23) of the Ad2 MLP. This CAP site binding factor, designated CBF, is required for optimal transcriptional activity. We now show that when bound to the Ad2 MLP, yTFIID and CBF interact to generate the extended pattern of DNase I protection conferred by native hTFIID. In addition, bound yTFIID and CBF interact such that the stability of the complex exceeds that of each factor bound alone. We also demonstrate the existence in nuclear extracts of a hTFIID and CBF heterodimer by the electrophoretic mobility shift analysis. CBF, therefore, may represent the first identified member of a large family of gene-specific TFIID-associated factors that are required for the regulated gene-specific expression of TFIID activity.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	SAFER, B (corresponding author), NHLBI,PROT & RNA BIOSYNTH SECT,MOLEC HEMATOL LAB,BLDG 10,RM 7D18,BETHESDA,MD 20892, USA.			Reinberg, Danny/0000-0003-4288-2016				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIRE A, 1984, J BIOL CHEM, V259, P2509; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KELEHER RJ, 1990, CELL, V61, P1209; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; VANDYKE MW, 1990, MOL CELL BIOL, V10, P3415, DOI 10.1128/MCB.10.7.3415; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	28	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10989	10994						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040615				2022-12-25	WOS:A1991FQ77400046
J	GENGE, BR; WU, LNY; ADKISSON, HD; WUTHIER, RE				GENGE, BR; WU, LNY; ADKISSON, HD; WUTHIER, RE			MATRIX VESICLE ANNEXINS EXHIBIT PROTEOLIPID-LIKE PROPERTIES - SELECTIVE PARTITIONING INTO LIPOPHILIC SOLVENTS UNDER ACIDIC CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS SHARE HOMOLOGY; FACTOR RECEPTOR-KINASE; 5 DISTINCT CALCIUM; EPIPHYSEAL CARTILAGE; BINDING-PROTEINS; LIPOCORTIN-I; PHOSPHOLIPASE-A2 ACTIVITY; CA-2+-BINDING PROTEINS; ALKALINE-PHOSPHATASE; TYROSINE KINASE	Calcifiable proteolipids present in mineralizing tissues have been postulated to enhance apatite deposition by structuring membrane phosphatidylserine molecules into a conformation conducive to mineralformation. To examine whether proteolipid-like molecules are present in mineralizable matrix vesicles (MV), the vesicles were first extracted with chloroform/methanol (2:1, v/v), and then with chloroform/methanol/HCl (200:100:1, v/v) and the organic-soluble proteins subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. Protein fractions were analyzed by Coomassie Blue staining and by immunoblot analysis of electrophoretically transferred MV protein with antisera to the 33- and 36-kDa annexins. We found that several MV proteins selectively partitioned into the lipophilic milieu under acidic conditions; however, very little protein did so at neutral pH. The principal organic-soluble MV proteins had molecular masses of 14,33, and 36 kDa, with lesser bands at 28, 30, and 68 kDa. Immunological analyses revealed that the 33- and 36-kDa proteins were the MV annexins; the 14-kDa protein appeared to be hemoglobin, based on NH2-terminal sequencing. Our findings indicate that under acidic conditions the 33-and 36-kDa MV annexins undergo a conformational change which imparts a marked increase in the hydrophobicity of the proteins. While these observations reveal that the annexins possess proteolipid-like properties, radiolabeling and immunoprecipitation studies using [H-3]myristic acid in chondrocyte cultures indicate that the MV annexins are not myristylated. Amino-terminal sequence analysis of the peptides generated by site-specific cleavage of the 33- and the 36-kDa MV annexins at tryptophan residues indicate that the 33 kDa is highly homologous to anchorin CII, a protein known to bind type II collagen, while the 36-kDa protein shares close homology with endonexin II, a tyrosine kinase substrate.	UNIV S CAROLINA, DEPT CHEM, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018983] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR18983] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADKISSON HD, 1989, CONNECT TISSUE RES, V22, P175; ALI SY, 1970, P NATL ACAD SCI USA, V67, P1513, DOI 10.1073/pnas.67.3.1513; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BERNARD GW, 1972, J ULTRA MOL STRUCT R, V41, P1, DOI 10.1016/S0022-5320(72)90034-2; BERNARD GW, 1969, AM J ANAT, V125, P271, DOI 10.1002/aja.1001250303; BOGGS JM, 1977, BIOCHEMISTRY-US, V16, P2325, DOI 10.1021/bi00630a003; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; BOYAN BD, 1989, ANAT REC, V224, P211, DOI 10.1002/ar.1092240210; BOYANSALYERS BD, 1980, CALCIFIED TISSUE INT, V30, P167, DOI 10.1007/BF02408622; ENNEVER J, 1977, J DENT RES, V56, P967, DOI 10.1177/00220345770560082301; ENNEVER J, 1978, J DENT RES, V57, P637, DOI 10.1177/00220345780570041901; ENNEVER J, 1980, ATHEROSCLEROSIS, V35, P209, DOI 10.1016/0021-9150(80)90085-4; FOLCH J, 1952, PHOSPHORUS METABOL, V2, P186; FOLCHPI J, 1972, ANN NY ACAD SCI, V195, P86, DOI 10.1111/j.1749-6632.1972.tb54788.x; GEISOW MJ, 1986, TRENDS BIOCHEM SCI, V11, P420, DOI 10.1016/0968-0004(86)90176-3; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GUERIN M, 1978, BIOCHEMISTRY-US, V17, P2510, DOI 10.1021/bi00606a009; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HALE JE, 1987, J BIOL CHEM, V262, P1916; HOSOKAWA R, 1988, J BIOL CHEM, V263, P10045; HSU HHT, 1986, INT J BIOCHEM, V18, P1141, DOI 10.1016/0020-711X(86)90089-3; HUANG HV, 1983, METHOD ENZYMOL, V91, P318; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; KATSURA N, 1986, BONE, V7, P137, DOI 10.1016/8756-3282(86)90686-1; KESSLER RJ, 1984, J BIOL CHEM, V259, P9059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landis WJ, 1985, CHEM BIOL MINERALIZE, P360; MCLEAN FM, 1987, J BIOL CHEM, V262, P10481; MEERS P, 1990, BIOCHEMISTRY-US, V29, P3325, DOI 10.1021/bi00465a025; MOLLENHAUER J, 1983, EMBO J, V2, P45, DOI 10.1002/j.1460-2075.1983.tb01378.x; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; REGISTER TC, 1986, J BIOL CHEM, V261, P9354; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SAUER GR, 1988, J BIOL CHEM, V263, P13718; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V122, P2191, DOI 10.1210/endo-122-5-2191; SEATON BA, 1990, J BIOL CHEM, V265, P4567; SHADLE PJ, 1985, J BIOL CHEM, V260, P6354; SISCA RF, 1972, CALC TISS RES, V9, P1, DOI 10.1007/BF02061941; SUDHOF TC, 1984, BIOCHEM BIOPH RES CO, V123, P100, DOI 10.1016/0006-291X(84)90385-1; SWAIN LD, 1988, J DENT RES, V67, P526, DOI 10.1177/00220345880670030101; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALHMU WB, 1990, BONE MINER, V8, P195, DOI 10.1016/0169-6009(90)90105-O; WEBER K, 1969, J BIOL CHEM, V244, P4406; WU LNY, 1989, J BIOL CHEM, V264, P21346; WU LNY, 1991, J BIOL CHEM, V266, P1195; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1977, CALC TISS RES, V23, P125, DOI 10.1007/BF02012777; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311	54	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10678	10685						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037607				2022-12-25	WOS:A1991FP08600101
J	LEE, RM; RAPP, UR; BLACKSHEAR, PJ				LEE, RM; RAPP, UR; BLACKSHEAR, PJ			EVIDENCE FOR ONE OR MORE RAF-1 KINASE KINASE(S) ACTIVATED BY INSULIN AND POLYPEPTIDE GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; SERINE THREONINE KINASE; DIMENSIONAL GEL-ELECTROPHORESIS; PDGF BETA-RECEPTOR; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; RAPID STIMULATION; CELLS; ONCOGENE	The protein product of the Raf-1 proto-oncogene is a protein serine/threonine kinase that is activated after stimulation of cells with insulin and other mitogens. To investigate the mechanism of this activation, we used purified Raf-1 expressed in E. coli as a substrate for a putative Raf-1 protein kinase kinase. In three different insulin-sensitive cell types, insulin activated Raf-1 kinase kinase activity in crude cytosolic cellular fractions. The insulin stimulation of this activity was evident as early as 2 min after exposure to insulin, maximal at 5-8 min, and inapparent at 15 min. Phosphoamino acid analysis of phosphorylated Raf-1 revealed that serine was the primary phosphate acceptor for the insulin-activated kinase or kinases; small amounts of phosphothreonine were also detected. The insulin effect occurred in cells depleted of protein kinase C, and in extracts depleted of endogenous Raf-1 kinase by immunodepletion; these data argue against protein kinase C or Raf-1 kinase itself being the insulin-stimulated activity. The insulin-activated kinase or kinases phosphorylated the Raf-1 protein on multiple sites in vitro, as evidenced by tryptic mapping; at least some of these appeared to overlap with sites phosphorylated in response to serum in intact cells. Several other mitogens and growth factors stimulated Raf-1 kinase kinase activity, including epidermal growth factor, platelet-derived growth factor, fibroblast growth factor, serum, and phorbol 12-myristate 13-acetate. This insulin- and mitogen-stimulated Raf-1 kinase kinase activity may play a role in mediating the phosphorylation and possibly the activation of the Raf-1 kinase by insulin and other growth factors.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, BOX 3897, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIABET & METAB SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DIV ENDOCRINOL METAB & GENET, DURHAM, NC 27710 USA; NCI, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21701 USA	Duke University; Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AVRUCH J, 1982, J BIOL CHEM, V257, P5162; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; FROST SC, 1987, J BIOL CHEM, V262, P9872; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISHIKAWA F, 1986, JPN J CANCER RES, V77, P1183; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KOHNO T, 1990, METHOD ENZYMOL, V185, P187; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAI WS, 1990, J BIOL CHEM, V265, P16556; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; LOBAUGH LA, 1990, J BIOL CHEM, V265, P18393; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; MCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1987, ONCOGENE HDB, P213; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SMITH CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2641, DOI 10.1073/pnas.77.5.2641; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU KT, 1987, J BIOL CHEM, V262, P16677	38	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10351	10357						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037587				2022-12-25	WOS:A1991FP08600057
J	GRINNELL, BW; WALLS, JD; GERLITZ, B				GRINNELL, BW; WALLS, JD; GERLITZ, B			GLYCOSYLATION OF HUMAN PROTEIN-C AFFECTS ITS SECRETION, PROCESSING, FUNCTIONAL ACTIVITIES, AND ACTIVATION BY THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; MAMMALIAN-CELLS; CA-2+ BINDING; EXPRESSION; THROMBOMODULIN; MECHANISM; SEQUENCE; CLEAVAGE; SITE; PRECURSOR	Human protein C (HPC) is an antithrombotic serine protease that circulates in the plasma as several glycoforms. To examine the role of glycosylation in the function of this protein, we singly eliminated each of the four potential N-linked glycosylation sites by site-directed mutagenesis of Asn to Gln at amino acid positions 97, 248, and 313 (HPC derivatives Q097, Q248, and Q313) or at the unusual consensus sequence Asn-X-Cys at 329 (HPC derivative Q329). The cDNAs for wild type and each derivative were inserted into expression vectors and expressed both transiently and stably in human 293 and hamster AV12-664 cells. We demonstrate that N-linked glycosylation at position 97 in the light chain of HPC is critical for efficient secretion and affects the degree of core glycosylation at Asn-329. Glycosylation at position 248 affects the intracellular processing of the internal Lys-Arg (KR) KR cleavage site, and partial glycosylation at the sequence Asn-329-X-Cys is responsible for the natural alpha-glycoform. Altering the glycosylation pattern of the protein had no significant effect on the level of fully gamma-carboxylated HPC secreted from the 293 cell line. However, elimination of glycosylation sites in the heavy chain resulted in a 2- to 3-fold increase in anticoagulant activity. Utilizing synthetic substrate, both the K(m) and k(cat) were affected, depending on the specific glycosylation site eliminated. However, there were no significant differences in the inhibition kinetics by alpha-1-antitrypsin (association rate constants of 10-11 M-1S-1 and t 1/2 of 27-29 min at 40-mu-M alpha-1-antitrypsin) or t 1/2 in human plasma (17-18 min). A comparison of the rate of activation of each derivative by thrombin alone or in complex with thrombomodulin revealed that Q313 was activated approximately 2.5-fold faster than wt HPC, independent of calcium concentration. This increase in rate was due to an enhanced affinity of thrombin-thrombomodulin for Q313, as indicated by a 3-fold reduction in K(m). Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein. Furthermore, we demonstrate the ability to improve the catalytic efficiency of this enzyme through carbohydrate modifications.			GRINNELL, BW (corresponding author), ELI LILLY & CO, LILLY RES LAB, DEPT CARDIOVASC RES, 0424, INDIANAPOLIS, IN 46285 USA.							BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; BERG DT, 1989, MOL CELL BIOL, V9, P5248, DOI 10.1128/MCB.9.11.5248; BERG DT, 1988, NUCLEIC ACIDS RES, V16, P9057, DOI 10.1093/nar/16.18.9057; CHAVIN SI, 1984, J BIOL CHEM, V259, P3387; CLOUSE LH, 1986, NEW ENGL J MED, V314, P1298, DOI 10.1056/NEJM198605153142006; COMP PC, 1981, J CLIN INVEST, V68, P1221, DOI 10.1172/JCI110368; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; EHRLICH HJ, 1989, J BIOL CHEM, V264, P14298; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1989, PROG HEMOST THROMB, V9, P29; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FOSTER DC, 1990, BIOCHEMISTRY-US, V29, P347, DOI 10.1021/bi00454a007; GARDINER JE, 1983, PROG HEMATOL, V13, P265; GOOCHEE CF, 1990, BIO-TECHNOL, V8, P421, DOI 10.1038/nbt0590-421; GRINNELL BW, 1987, BIO-TECHNOL, V5, P1189, DOI 10.1038/nbt1187-1189; GRINNELL BW, 1989, GENETICS MOL BIOL IN, P226; GRINNELL BW, 1990, PROTEIN C RELATED AN, P13; HAU L, 1988, THROMB HAEMOSTASIS, V60, P267; HEEB MJ, 1990, J BIOL CHEM, V265, P2365; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KISIEL W, 1981, METHOD ENZYMOL, V80, P320; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARLAR RA, 1982, BLOOD, V59, P1067; MARTINEZ J, 1983, BLOOD, V61, P1196; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; OPPENHEIMER C, 1988, CURRENT ADV VITAMIN, P165; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; Pfleiderer G, 1970, METHOD ENZYMOL, V19, P514; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SAIRAM MR, 1989, FASEB J, V3, P1915, DOI 10.1096/fasebj.3.8.2542111; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STENFLO J, 1982, J BIOL CHEM, V257, P2180; SUTTIE JW, 1986, THROMB RES, V44, P129, DOI 10.1016/0049-3848(86)90189-1; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; WALLS JD, 1989, GENE, V81, P139, DOI 10.1016/0378-1119(89)90344-2; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; ZOLTON R P, 1973, Thrombosis Research, V3, P23, DOI 10.1016/0049-3848(73)90123-0	49	118	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9778	9785						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033065				2022-12-25	WOS:A1991FM45900068
J	KIM, HJ; LIU, TC; PATEL, MS				KIM, HJ; LIU, TC; PATEL, MS			EXPRESSION OF CDNA SEQUENCES ENCODING MATURE AND PRECURSOR FORMS OF HUMAN DIHYDROLIPOAMIDE DEHYDROGENASE IN ESCHERICHIA-COLI - DIFFERENCES IN KINETIC MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-REDUCTASE; LIPOAMIDE DEHYDROGENASE; DISULFIDE OXIDOREDUCTASES; MUTAGENESIS; MITOCHONDRIA; COMPLEXES; SITE	The cDNA sequences encoding mature and precursor forms of human dihydrolipoamide dehydrogenase (E3) were expressed in Escherichia coli using a lambda-P(L) promoter-driven prokaryotic expression vector. The expressed proteins in total cell extracts were identified by Western blot analysis using anti-pig heart E3 antibody and also by measurement of E3 activity. Most of the expressed human E3 polypeptides (five bands) were found in the insoluble pellet while primarily full-length mature E3 was found in the soluble fraction. About 2% of the total soluble protein was mature human E3 when expressed in wild type E. coli AR120. Since wild type E. coli has its own endogenous E3 activity, the expression of human E3 was performed in a pyruvate dehydrogenase complex-deficient strain of E. coli, JRG1342. The expressed recombinant human E3s in JRG1342 were purified to near homogeneity. The amino-terminal amino acid sequence analysis revealed that the recombinant mature E3 had an expected sequence while the recombinant precursor E3 lost 19 amino acid residues of its 35-amino acid leader sequence presumably due to a proteolytic cleavage. The recombinant mature E3 displayed comparable kinetic properties to those reported for highly purified mammalian E3s. The truncated precursor E3 showed about half of the mature E3 activity. The double-reciprocal plot for the mature E3 in the direction of NAD+ reduction showed parallel lines (ping-pong mechanism) while that for the truncated precursor E3 displayed intersecting lines (sequential mechanism). In the direction of NADH oxidation,the kinetic mechanisms of both E3s were apparently a ping-pong mechanism. These kinetic results showed that the partial 16-amino acid extension in the leader sequence changed the kinetic mechanism of human E3 so that it resembled that of glutathione reductase.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, 2109 ABINGTON RD, CLEVELAND, OH 44106 USA	Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478, R01DK042885] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42885, DK20478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON N, 1988, BIOCHEM J, V256, P741, DOI 10.1042/bj2560741; BERRY A, 1989, BIOCHEMISTRY-US, V28, P1264, DOI 10.1021/bi00429a047; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; CHIEN SM, 1986, BIOCHEM BIOPH RES CO, V141, P313, DOI 10.1016/S0006-291X(86)80370-9; ICEN AL, 1971, FEBS LETT, V16, P29, DOI 10.1016/0014-5793(71)80676-2; IDE S, 1967, J BIOL CHEM, V242, P54; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTY CJ, 1963, J BIOL CHEM, V238, P3443; Maniatis T., 1982, MOL CLONING; MANNERVIK B, 1973, BIOCHEM BIOPH RES CO, V53, P1151, DOI 10.1016/0006-291X(73)90585-8; MASSEY V, 1960, BIOCHEM J, V77, P341, DOI 10.1042/bj0770341; OTULAKOWSKI G, 1987, J BIOL CHEM, V262, P17313; PAI EF, 1983, J BIOL CHEM, V258, P1752; PONS G, 1988, P NATL ACAD SCI USA, V85, P1422, DOI 10.1073/pnas.85.5.1422; REED JK, 1973, J BIOL CHEM, V248, P4834; REED LJ, 1958, J BIOL CHEM, V232, P143; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1982, J MOL BIOL, V160, P287, DOI 10.1016/0022-2836(82)90177-2; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; STAAL GEJ, 1969, BIOCHIM BIOPHYS ACTA, V185, P49, DOI 10.1016/0005-2744(69)90281-2; THEKKUMKARA TJ, 1989, ANN NY ACAD SCI, V573, P113, DOI 10.1111/j.1749-6632.1989.tb14990.x; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; WALKER JL, 1986, J BIOL CHEM, V261, P2214; Williams CH., 1976, ENZYMES, P89	29	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9367	9373						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033038				2022-12-25	WOS:A1991FM45900008
J	RAO, NV; WEHNER, NG; MARSHALL, BC; GRAY, WR; GRAY, BH; HOIDAL, JR				RAO, NV; WEHNER, NG; MARSHALL, BC; GRAY, WR; GRAY, BH; HOIDAL, JR			CHARACTERIZATION OF PROTEINASE-3 (PR-3), A NEUTROPHIL SERINE PROTEINASE - STRUCTURAL AND FUNCTIONAL-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; TOXIC LYMPHOCYTE-T; PERFORMANCE LIQUID-CHROMATOGRAPHY; GLOMERULAR BASEMENT-MEMBRANE; PORCINE PANCREATIC ELASTASE; SECRETORY-CELL METAPLASIA; OXIDIZED-B-CHAIN; CATHEPSIN-G; POLYMORPHONUCLEAR-LEUKOCYTE; HUMAN-PLASMA	Proteinase 3 (PR-3) is a human polymorphonuclear leukocyte (PMNL) serine proteinase that degrades elastin in vitro and causes emphysema when administered by tracheal insufflation to hamsters (Kao, R. C., Wehner, N. G., Skubitz, K. M., Gray, B. H., and Hoidal, J. R. (1988) J. Clin. Invest. 82, 1963-1973). We have determined the primary structure of several PR-3 peptides and have analyzed catalytic properties of the enzyme. The enzyme has considerable amino acid sequence homology with two other well characterized PMNL neutral serine proteinases, elastase and cathepsin G. Furthermore, the NH2-terminal amino acid sequence of PR-3 is identical to that of the target antigen of the anti-neutrophil cytoplasmic autoantibodies associated with Wegener's granulomatosis. PR-3 degrades a variety of matrix proteins including fibronectin, laminin, vitronectin, and collagen type IV. It shows no or minimal activity against interstitial collagens types I and III, respectively. The analysis of peptides generated by PR-3 digestion of insulin chains and the activity profile against a panel of chromogenic synthetic peptide substrates show that PR-3 prefers small aliphatic amino acids (alanine, serine, and valine) at the P1 site. The elastase-like specificity of PR-3 is consistent with its striking sequence homology to elastase at substrate binding sites. PR-3 is inhibited by alpha-1-proteinase inhibitor (k(a) = 8.1 x 10(6) M-1 s-1; delay time = 25 ms) and alpha-2-macroglobulin (k(a) = 1.1 x 10(7) M-1 s-1; delay time = 114 ms) but not by alpha-1-anti-chymotrypsin. In contrast to elastase and cathepsin G, PR-3 is not inhibited by secretory leukoprotease inhibitor and is weakly inhibited by eglin c. Thus, PR-3 is distinct from the other PMNL proteinases.	UNIV UTAH, MED CTR,DEPT PULM MED,DIV PULM,RM 4R240, 50 N MED DR, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, MED CTR, DEPT BIOL, SALT LAKE CITY, UT 84132 USA; UNIV MINNESOTA, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Minnesota System; University of Minnesota Twin Cities			Gray, Bruce/AAW-1221-2020	Gray, Bruce/0000-0002-7321-5403	NHLBI NIH HHS [HL-37615, 1K08 HL 02370, HL 07636] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002370, R01HL037615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1978, AGENTS ACTIONS, V8, P3, DOI 10.1007/BF01972395; BAICI A, 1981, BIOCHEM PHARMACOL, V30, P703, DOI 10.1016/0006-2952(81)90154-4; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BLOW AMJ, 1977, BIOCHEM J, V161, P13, DOI 10.1042/bj1610013; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BRAUN NJ, 1987, BIOL CHEM H-S, V368, P299, DOI 10.1515/bchm3.1987.368.1.299; CAMPANELLI D, 1990, J CLIN INVEST, V85, P904, DOI 10.1172/JCI114518; CARRELL RW, 1988, NATURE, V331, P478, DOI 10.1038/331478a0; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; COHEN AB, 1983, AM REV RESPIR DIS, V127, pS2; DAVIES M, 1978, CLIN SCI MOL MED, V54, P233, DOI 10.1042/cs0540233; DEJONG C, 1982, J CHROMATOGR, V241, P345, DOI 10.1016/S0021-9673(00)81759-8; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERIKSSON S, 1978, ACTA MED SCAND, V203, P449; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; GRAY WR, 1981, J BIOL CHEM, V256, P4734; GROSS WL, 1986, LANCET, V1, P806; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HECK LW, 1990, AM J PATHOL, V136, P1267; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; JANOFF A, 1985, ANNU REV MED, V36, P207; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JENNE D, 1988, J IMMUNOL, V140, P318; JENNE DE, 1990, NATURE, V346, P520, DOI 10.1038/346520a0; JENNETTE JC, 1990, BLOOD, V75, P2263; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; KEZDY FJ, 1970, METHOD ENZYMOL, V19, P3; KITZ R, 1962, J BIOL CHEM, V237, P3245; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LEHRER RI, 1975, INFECT IMMUN, V11, P1226, DOI 10.1128/IAI.11.6.1226-1234.1975; LEVY H, 1979, BIOCHIM BIOPHYS ACTA, V567, P35, DOI 10.1016/0005-2744(79)90169-4; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; MAINARDI CL, 1980, J BIOL CHEM, V255, P5435; MCDONALD JA, 1980, J BIOL CHEM, V255, P8848; MENNINGER H, 1980, Z RHEUMATOL, V39, P145; MERRITT TA, 1983, J CLIN INVEST, V72, P656, DOI 10.1172/JCI111015; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NARAYANAN AS, 1969, BIOCHEM J, V114, P11, DOI 10.1042/bj1140011; NILES JL, 1989, BLOOD, V74, P1888; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; ODEBERG H, 1975, J CLIN INVEST, V56, P1118, DOI 10.1172/JCI108186; ORAY B, 1983, J CHROMATOGR, V270, P253, DOI 10.1016/S0021-9673(01)96371-X; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; PIPOLY DJ, 1987, BIOCHEMISTRY-US, V26, P5748, DOI 10.1021/bi00392a025; POWERS JC, 1977, BIOCHIM BIOPHYS ACTA, V485, P156, DOI 10.1016/0005-2744(77)90203-0; SAKLATVALA J, 1980, BIOCHIM BIOPHYS ACTA, V615, P167, DOI 10.1016/0005-2744(80)90020-0; SALVESEN G, 1983, ANN NY ACAD SCI, V421, P316, DOI 10.1111/j.1749-6632.1983.tb18120.x; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SAVAGE COS, 1987, LANCET, V1, P1389; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHMID J, 1987, J IMMUNOL, V139, P250; SEGAL DM, 1972, BIOCHEMISTRY-US, V11, P349, DOI 10.1021/bi00753a007; SIBILLE Y, 1986, AM REV RESPIR DIS, V134, P134; SINHA S, 1987, P NATL ACAD SCI USA, V84, P2228, DOI 10.1073/pnas.84.8.2228; SMITH CE, 1985, BIOCHEM J, V225, P463, DOI 10.1042/bj2250463; SNIDER GL, 1984, AM REV RESPIR DIS, V129, P155; SNIDER GL, 1985, AM REV RESPIR DIS, V132, P1155; TAPUHI Y, 1981, J CHROMATOGR, V205, P325, DOI 10.1016/S0021-9673(00)82660-6; TARR GE, 1978, ANAL BIOCHEM, V84, P622, DOI 10.1016/0003-2697(78)90086-6; THOMAS JM, 1981, ANAL BIOCHEM, V118, P194, DOI 10.1016/0003-2697(81)90178-0; THOMPSON RC, 1973, BIOCHEMISTRY-US, V12, P51, DOI 10.1021/bi00725a010; THOMPSON RC, 1973, BIOCHEMISTRY-US, V12, P57, DOI 10.1021/bi00725a011; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5647, DOI 10.1021/bi00619a010; TRAVIS J, 1965, J BIOL CHEM, V240, P1962; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; TURINO GM, 1981, CONNECTIVE TISSUE AR, P247; VANDERWOUDE FJ, 1985, LANCET, V1, P425; VINCENT JP, 1972, BIOCHEMISTRY-US, V11, P2967, DOI 10.1021/bi00766a007; VIRCA GD, 1984, J BIOL CHEM, V259, P8870; VISSER L, 1972, BIOCHIM BIOPHYS ACTA, V268, P257, DOI 10.1016/0005-2744(72)90223-9; VISSERS MCM, 1984, BIOCHIM BIOPHYS ACTA, V804, P154, DOI 10.1016/0167-4889(84)90144-7; Wilcox P. E., 1970, METHODS ENZYMOLOGY, P64, DOI [10.1016/0076-6879(70)19007-0, DOI 10.1016/0076-6879(70)19007-0]; WILDE CG, 1990, J BIOL CHEM, V265, P2038; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P811, DOI 10.1021/bi00598a010; YAMAMOTO M, 1967, J BIOCHEM-TOKYO, V62, P141, DOI 10.1093/oxfordjournals.jbchem.a128642; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	88	272	276	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9540	9548						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033050				2022-12-25	WOS:A1991FM45900034
J	SCOTT, JP; MONTGOMERY, RR; RETZINGER, GS				SCOTT, JP; MONTGOMERY, RR; RETZINGER, GS			DIMERIC RISTOCETIN FLOCCULATES PROTEINS, BINDS TO PLATELETS, AND MEDIATES VONWILLEBRAND FACTOR-DEPENDENT AGGLUTINATION OF PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IB; ACID SEQUENCE; AGGREGATION; PEPTIDES; DISEASE; DOMAIN; PLASMA	Ristocetin in aqueous solution dimerizes with an equilibrium dissociation constant of 5.0 x 10(-4) M, i.e. approximately 1.1 mg ml-1 (Waltho, J. P., and Williams, D. H. (1989) J. Am. Chem. Soc. 111, 2475-2480). At concentrations of about 1.0 mg ml-1 ristocetin flocculates many proteins, lyses platelets and, in the presence of von Willebrand factor, agglutinates both fresh and formalin-fixed platelets. Because ristocetin exists as both monomeric and dimeric species, we sought to determine which of these forms flocculates proteins and agglutinates platelets. We found that: 1) the initial rate of flocculation of certain proteins, 2) the initial rate of agglutination of formalin-fixed platelets, and 3) the binding of ristocetin to formalin-fixed platelets are higher order solely with respect to the concentration of ristocetin dimers. As to the operative mechanism, it appears that bifunctional dimers cross-link proteins that possess multiple copies of a common recognition site. Preliminary evidence indicates that a recognition site is a beta-turn of the form X-P-G-X'.	MED COLL WISCONSIN,DEPT PATHOL,MILWAUKEE,WI 53226; BLOOD CTR SE WISCONSIN INC,MILWAUKEE,WI 53233	Medical College of Wisconsin; Versiti Blood Center of Wisconsin	SCOTT, JP (corresponding author), MED COLL WISCONSIN,DEPT PEDIAT,MILWAUKEE,WI 53226, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033721] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL33721-06] Funding Source: Medline; PHS HHS [P01-H244612-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMSON AW, 1976, PHYSICAL CHEM SURFAC, P68; BRINKHOUS KM, 1978, THROMB RES, V13, P591, DOI 10.1016/0049-3848(78)90148-2; BRINKHOUS KM, 1975, THROMB RES, V6, P267, DOI 10.1016/0049-3848(75)90074-2; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; EEISS HJ, 1973, J CLIN INVEST, V52, P2708; ESCOLAR G, 1988, BRIT J HAEMATOL, V69, P379, DOI 10.1111/j.1365-2141.1988.tb02377.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GAINES GL, 1966, INSOLUBLE MONOLAYERS, P173; GANGAROSA EJ, 1958, NEW ENGL J MED, V259, P156, DOI 10.1056/NEJM195807242590402; GANGAROSA EJ, 1960, ARCH INTERN MED, V105, P107; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LENTNER C, 1984, GEIGY SCI TABLES, V3, P212; MIHALYI E, 1968, BIOCHEMISTRY-US, V7, P208, DOI 10.1021/bi00841a026; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; NIETO M, 1971, BIOCHEM J, V124, P845, DOI 10.1042/bj1240845; Philip J.E., 1957, ANTIBIOT ANN, P699; RETZINGER GS, 1985, ANAL BIOCHEM, V150, P131, DOI 10.1016/0003-2697(85)90451-8; RODMAN NF, 1966, LAB INVEST, V15, P641; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SCHULLEK J, 1984, J CLIN INVEST, V73, P421, DOI 10.1172/JCI111228; SEAMAN GVH, 1986, AM CLIN PROD REV, V5, P25; SEGEL IH, 1976, BIOCH CALCULATIONS, P309; SENOGLES SE, 1983, J BIOL CHEM, V258, P2327; STIBBE J, 1976, THROMB RES, V8, P151, DOI 10.1016/0049-3848(76)90258-9; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TSAO CH, 1975, BLOOD, V45, P621; VCICENTE V, 1989, BLOOD, V74, pA170; VICENTE V, 1988, J BIOL CHEM, V263, P18473; WALTHO JP, 1989, J AM CHEM SOC, V111, P2475, DOI 10.1021/ja00189a017; WHITE JG, 1987, HEMOSTASIS THROMBOSI, P537; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879	36	128	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8149	8155						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022635				2022-12-25	WOS:A1991FK44100033
J	GAVINI, N; DAVIDSON, BE				GAVINI, N; DAVIDSON, BE			REGULATION OF PHEA EXPRESSION BY THE PHER PRODUCT IN ESCHERICHIA-COLI IS MEDIATED THROUGH ATTENUATION OF TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID VECTORS; OPERON; PROMOTERS; RNA; CLONING; REGION; K-12; GENE	In Escherichia coli, the expression of the phenylalanine biosynthetic enzyme chorismate mutase/prephenate dehydratase, encoded by pheA, is elevated in strains carrying pheR mutants. By constructing a series of pheA' 'cat' lacZ fusions with different endpoints for deletions of the pheA regulatory DNA, the site of action of the pheR product on pheA expression was determined to be the pheA attenuator. Southern blot analysis of chromosomal DNA from a pheR374 strain showed it to carry a deletion of pheR and the flanking DNA on each side. This deletion resulted in a decrease of approximately 30% in the intracellular concentration of tRNA(Phe), the pheR product. The expression of the pheST operon, which encodes the two subunits of phenylalanyl-tRNA synthetase and which is also regulated by attenuation control involving phenylalanyl-tRNA(Phe), was increased 5-fold by the pheR374 allele. No effect of pheR on pheST expression was seen in a pheST(att-) strain. It was concluded that the elevated expression of pheA and pheST in pheR mutants is a consequence of a lower frequency of transcription termination in the attenuator caused by lower levels of phenylalanyl-tRNA(Phe).	UNIV MELBOURNE,RUSSELL GRIMWADE SCH BIOCHEM,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne								AIBA H, 1981, J BIOL CHEM, V256, P1905; AKSOY S, 1984, J BACTERIOL, V157, P363, DOI 10.1128/JB.157.2.363-367.1984; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; CAILLET J, 1985, NUCLEIC ACIDS RES, V13, P3699, DOI 10.1093/nar/13.10.3699; DAVIDSON BE, 1972, J BIOL CHEM, V247, P4441; DEREUSE H, 1986, FEMS MICROBIOL LETT, V37, P193, DOI 10.1016/0378-1097(86)90403-9; DILLELA AG, 1985, FOCUS, V7, P1; GAVINI N, 1990, J BIOL CHEM, V265, P21527; GAVINI N, 1990, J BIOL CHEM, V265, P21532; GOWRISHANKAR J, 1982, J BACTERIOL, V152, P1; GOWRISHANKAR J, 1982, J BACTERIOL, V150, P1122, DOI 10.1128/JB.150.3.1122-1129.1982; GOWRISHANKAR J, 1982, J BACTERIOL, V150, P1130, DOI 10.1128/JB.150.3.1130-1137.1982; HUDSON GS, 1984, J MOL BIOL, V180, P1023, DOI 10.1016/0022-2836(84)90269-9; JOHNSTON HM, 1980, P NATL ACAD SCI-BIOL, V77, P508, DOI 10.1073/pnas.77.1.508; KOLTER R, 1982, ANNU REV GENET, V16, P113, DOI 10.1146/annurev.ge.16.120182.000553; LANDICK R, 1987, ESCHERICHIA SALMONEL, V1, P1453; Maniatis T., 1982, MOL CLONING; MAYAUX JF, 1985, J MOL BIOL, V184, P31, DOI 10.1016/0022-2836(85)90041-5; Miller JH., 1972, EXPT MOL GENETICS; MONOD J, 1951, BIOCHIM BIOPHYS ACTA, V7, P585, DOI 10.1016/0006-3002(51)90072-8; Pittard AJ, 1987, ESCHERICHIA COLI SAL, P368; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPRINGER M, 1985, J MOL BIOL, V181, P467, DOI 10.1016/0022-2836(85)90420-6; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Winkler M.E., 1987, ESCHERICHIA COLI SAL, P395; ZURAWSKI G, 1978, P NATL ACAD SCI USA, V75, P4271, DOI 10.1073/pnas.75.9.4271	26	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7750	7753						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019599				2022-12-25	WOS:A1991FJ34200069
J	PAHUJA, SL; ZIELINSKI, JE; GIORDANO, G; MCMURRAY, WJ; HOCHBERG, RB				PAHUJA, SL; ZIELINSKI, JE; GIORDANO, G; MCMURRAY, WJ; HOCHBERG, RB			THE BIOSYNTHESIS OF D-RING FATTY-ACID ESTERS OF ESTRIOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOIDAL DERIVATIVES; ESTRADIOL; ESTROGEN; PREGNENOLONE; RECEPTOR; CELLS; RAT; MICROSOMES; TISSUES; TUMORS	Biological esterification with fatty acids is a feature that is now known to be common to most steroids. The esterification of estradiol in the D-ring at the 17-beta-hydroxyl leads to a family of extremely active estrogens. Similarly, esterification of the weaker estrogen, estriol (E3), has an even greater impact on its hormonal potency. We have recently shown that synthetic long chain esters of E3 at either 16-alpha- or 17-beta- are highly potent estrogens. The estrogenic activity of the synthetic E3 esters led us to determine whether E3 is biologically esterified, and if so, to characterize the resulting esters. Incubation of E3 with rat lung, a tissue which is highly active in esterifying estradiol, produces a nonpolar metabolite which upon saponification is converted back into E3. There was no evidence for the formation of a diester. Purification by high performance liquid chromatography separates the nonpolar metabolite into two peaks, one the C-16-alpha- (approximately 60%) and the other the C-17-beta-ester (approximately 40%). The two fractions were further purified and characterized; each is a mixture of fatty acid esters of E3. The composition of the C-16-alpha- and the C-17-beta-fatty acid esters of E3 is identical. The predominant fatty acids are arachidonate, 34%, palmitate, 26%, followed by oleate 14%, linoleate 13%, stearate 8%, and palmitoleate 5%. The similarity of the esters at C-16 and C-17 may indicate that the fatty acid precursor for the acyltransferase is the same for both hydroxyl groups. It may also suggest that the same enzyme esterifies both positions in the D-ring. Since synthetic estriol fatty acid esters are extremely potent and long-lived estrogens, the enzymatic esterification of estriol produces powerful estrogens with considerable physiological potential.	YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,MASS SPECT FACIL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR COMPREHENS CANC,NEW HAVEN,CT 06510	Yale University; Yale University					NATIONAL CANCER INSTITUTE [R01CA029591] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29591] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABULHAJJ YJ, 1982, STEROIDS, V40, P149, DOI 10.1016/0039-128X(82)90029-0; ADAMS JB, 1986, J STEROID BIOCHEM, V24, P1159, DOI 10.1016/0022-4731(86)90377-8; CLARK JH, 1977, ENDOCRINOLOGY, V100, P91, DOI 10.1210/endo-100-1-91; CLARK JH, 1984, J STEROID BIOCHEM, V20, P1005, DOI 10.1016/0022-4731(84)90011-6; DEGHENGHI R, 1979, BURGERS MED CHEM, P917; EMMENS CW, 1962, METHOD HORMONE RES, P59; HOCHBERG R, 1979, J STEROID BIOCHEM, V11, P1333, DOI 10.1016/0022-4731(79)90103-1; HOCHBERG RB, 1977, P NATL ACAD SCI USA, V74, P941, DOI 10.1073/pnas.74.3.941; HOCHBERG RB, 1990, ANN NY ACAD SCI, V595, P74, DOI 10.1111/j.1749-6632.1990.tb34284.x; HUGGINS C, 1955, J EXP MED, V102, P335, DOI 10.1084/jem.102.3.335; JANOCKO L, 1984, ENDOCRINOLOGY, V114, P1180, DOI 10.1210/endo-114-4-1180; KATZ J, 1987, J STEROID BIOCHEM, V26, P687, DOI 10.1016/0022-4731(87)91040-5; LARNER JM, 1985, ENDOCRINOLOGY, V117, P1209, DOI 10.1210/endo-117-3-1209; LARNER JM, 1985, J STEROID BIOCHEM, V22, P407, DOI 10.1016/0022-4731(85)90446-7; LARNER JM, 1985, J STEROID BIOCHEM, V23, P637, DOI 10.1016/0022-4731(85)90015-9; LEE FT, 1988, BIOCHIM BIOPHYS ACTA, V963, P258, DOI 10.1016/0005-2760(88)90289-5; Levitz M, 1977, Vitam Horm, V35, P109; MACLUSKY NJ, 1989, ENDOCRINOLOGY, V124, P318, DOI 10.1210/endo-124-1-318; MARTYN P, 1988, MOL CELL ENDOCRINOL, V60, P7, DOI 10.1016/0303-7207(88)90114-1; MAWHINNEY TP, 1982, J ORG CHEM, V47, P3336, DOI 10.1021/jo00138a032; MELLONNUSSBAUM S, 1980, J BIOL CHEM, V255, P5566; MELLONNUSSBAUM S, 1979, J BIOL CHEM, V254, P2500; MELLONNUSSBAUM SH, 1982, J BIOL CHEM, V257, P5678; PAHUJA SL, 1989, J BIOL CHEM, V264, P3216; PARIS A, 1989, J STEROID BIOCHEM, V33, P465, DOI 10.1016/0022-4731(89)90338-5; POULIN R, 1990, J STEROID BIOCHEM, V35, P237, DOI 10.1016/0022-4731(90)90280-6; SCHATZ F, 1981, ENDOCRINOLOGY, V109, P697; VALLETSTROUVE C, 1986, MECH AGEING DEV, V35, P233, DOI 10.1016/0047-6374(86)90126-0; ZIELINSKI JE, 1991, IN PRESS J STEROID B	29	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7410	7416						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019576				2022-12-25	WOS:A1991FJ34200018
J	JAMES, P; COHEN, P; CARAFOLI, E				JAMES, P; COHEN, P; CARAFOLI, E			IDENTIFICATION AND PRIMARY STRUCTURE OF CALMODULIN BINDING DOMAINS IN THE PHOSPHORYLASE-KINASE HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; MOLECULAR-BASIS; ALPHA-SUBUNIT; BETA-SUBUNITS; CDNA CLONING; ACTIVATION; DEFICIENCY; TROPONIN	Fast twitch skeletal muscle phosphorylase kinase was isolated and incubated with a radioactive, bifunctional, photoactivable, and cleavable cross-linker conjugated to calmodulin. Incubation of the holoenzyme only resulted in the labeling of the alpha-subunit in the presence of Ca2+. After cleavage with CNBr (and subdigestion with Asp-N protease), a sequence was identified (residues 1069-1087) in the alpha-subunit which had the predominant basic character and the propensity to form an amphiphilic helix like other calmodulin binding domains. If cross-linked calmodulin was incubated with the isolated subunits of phosphorylase kinase, radioactivity was recovered in seven CNBr peptides: three came from the alpha-subunits, one of them corresponding to the sequence labeled in the holoenzyme. Three came from the beta-subunit, and one came from the gamma-subunit. The latter contained the two adjacent calmodulin binding domains recently identified in the gamma-subunit (Dasgupta, M., Honeycutt, T., and Blumenthal, D. K. (1988) J. Biol. Chem. 264, 17156-17163).	SWISS FED INST TECHNOL,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	ETH Zurich; University of Dundee			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				BENDER PK, 1989, P NATL ACAD SCI USA, V86, P9996, DOI 10.1073/pnas.86.24.9996; BURCHELL A, 1976, FEBS LETT, V67, P17, DOI 10.1016/0014-5793(76)80861-7; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; CHAN KFJ, 1982, J BIOL CHEM, V257, P5956; COHEN P, 1979, FEBS LETT, V104, P25, DOI 10.1016/0014-5793(79)81078-9; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COHEN P, 1980, EUR J BIOCHEM, V111, P563, DOI 10.1111/j.1432-1033.1980.tb04972.x; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; COHEN P, 1988, MOL ASPECTS CELL REG, V5, P123; COHEN PTW, 1981, EUR J BIOCHEM, V115, P619; COHEN PTW, 1976, EUR J BIOCHEM, V66, P347, DOI 10.1111/j.1432-1033.1976.tb10524.x; CRABB JW, 1990, ELECTROPHORESIS, V11, P133, DOI 10.1002/elps.1150110206; CRABB JW, 1984, J BIOL CHEM, V259, P6346; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DENNY JB, 1984, P NATL ACAD SCI-BIOL, V81, P5286, DOI 10.1073/pnas.81.17.5286; DEPAOLIROACH AA, 1979, FEBS LETT, V105, P321, DOI 10.1016/0014-5793(79)80639-0; GRAND RJA, 1981, EUR J BIOCHEM, V113, P359, DOI 10.1111/j.1432-1033.1981.tb05074.x; GUERINI D, 1986, THESIS SWISS FEDRAL; JAFFE CL, 1980, BIOCHEMISTRY-US, V19, P4423, DOI 10.1021/bi00560a007; JAMES P, 1988, J BIOL CHEM, V263, P2905; JENNISSNE HP, 1975, FEBS LETT, V42, P77; KEE SM, 1986, J BIOL CHEM, V261, P4732; KILIMANN MW, 1988, P NATL ACAD SCI USA, V85, P9381, DOI 10.1073/pnas.85.24.9381; LANDANT D, 1988, J BIOL CHEM, V263, P2612; MEYER HE, 1990, EUR J BIOCHEM, V188, P367, DOI 10.1111/j.1432-1033.1990.tb15413.x; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; PICKETTGIES CA, 1986, ENZYMES, V17, P396; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; PICTON C, 1983, METHOD ENZYMOL, V102, P219; SHARMA RK, 1980, J BIOL CHEM, V255, P1102; SHENOLIKAR S, 1979, EUR J BIOCHEM, V100, P329, DOI 10.1111/j.1432-1033.1979.tb04175.x; SKUSTER JR, 1980, J BIOL CHEM, V255, P2203; VANAMAN TC, 1987, METHOD ENZYMOL, V139, P417; ZANDER NF, 1988, P NATL ACAD SCI USA, V85, P2929, DOI 10.1073/pnas.85.9.2929	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7087	7091						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016317				2022-12-25	WOS:A1991FG72700069
J	POULIN, R; WECHTER, RS; PEGG, AE				POULIN, R; WECHTER, RS; PEGG, AE			AN EARLY ENLARGEMENT OF THE PUTRESCINE POOL IS REQUIRED FOR GROWTH IN L1210 MOUSE LEUKEMIA-CELLS UNDER HYPOOSMOTIC STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; POLYAMINE TRANSPORT-SYSTEM; ORNITHINE DECARBOXYLASE; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; ALPHA-DIFLUOROMETHYLORNITHINE; EXTERNAL OSMOLALITY; VOLUME REGULATION; ANISOTONIC MEDIA; MAMMALIAN-CELLS	Hypoosmotic stress is a potent inducer of ornithine decarboxylase (ODC) activity in a variety of mammalian cells, but the physiological relevance of this response has not been determined. To test whether an increased putrescine content confers a growth advantage at lower osmolarities, we compared the ability of L1210 mouse leukemia cells and of ODC-overproducing variants obtained from this cell line (D-R cells) to proliferate after a hypotonic shock (325 --> 130 mosmol/kg). The growth rate of D-R cells at 130 mosmol/kg was greater-than-or-equal-to 5-fold higher than in L1210 cells; and unlike the ODC-overproducing strain, L1210 cells underwent up to a 90% loss of viability over time as seen after restoration of normosmotic growth conditions and by trypan blue exclusion tests. The addition of putrescine or L-ornithine stimulated the proliferation of both cell sublines up to 5-fold in a concentration-dependent manner, with a maximal effect observed at about 10 and 100-mu-M, respectively. Putrescine restored virtually normal growth rates in both sublines at osmolarities as low as 190 mosmol/kg. No other alpha,omega-diamine was active in that respect whereas spermidine was markedly inhibitory. Furthermore, D-R cells incubated at 130 mosmol/kg showed a marked growth inhibition by 1-aminooxy-3-aminopropane (potent ODC inhibitor to which they are resistant in isotonic media) as a result of putrescine but not spermidine depletion. Whereas ODC was strongly and rapidly induced by hypotonic shock there was a precipitous decline in S-adenosylmethionine decarboxylase activity. Putrescine synthesis and accumulation were nevertheless reduced in D-R cells incubated at 130 mosmol/kg because of a decreased availability of L-ornithine. When either putrescine or L-ornithine was added to hypotonic media, D-R cells accumulated putrescine massively for extended periods together with a reduction in spermidine and spermine contents. Putrescine transport patterns were altered by hypotonic shock, net excretion of the diamine being reduced by about 80%, with a concurrent enlargement of the intracellular pool. Finally, parental L1210 cells incubated with an irreversible inhibitor of S-adenosylmethionine decarboxylase for 24 h until hypotonic shock and supplemented with putrescine in the presence of the drug thereafter exhibited a greatly exaggerated growth stimulation by the diamine. These results demonstrate an essential role for an early increase in putrescine content in the growth adaptation of a mammalian cell line to a lower osmolarity.	PENN STATE UNIV, MILTON S HERSHEY MED CTR,COLL MED, DEPT CELLULAR & MOLEC PHYSIOL,POB 850, HERSHEY, PA 17033 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DEPT PHARMACOL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NCI NIH HHS [CA 18138, CA 37606] Funding Source: Medline; NIGMS NIH HHS [GM 26290] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA018138, R01CA018138, U01CA037606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERS TL, 1989, AM J PHYSIOL, V257, pC545, DOI 10.1152/ajpcell.1989.257.3.C545; BYERS TL, 1990, J CELL PHYSIOL, V143, P460, DOI 10.1002/jcp.1041430309; CASARA P, 1989, J AM CHEM SOC, V111, P9111, DOI 10.1021/ja00207a024; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; DEZEURE F, 1989, INT J BIOCHEM, V21, P889, DOI 10.1016/0020-711X(89)90288-7; DIRCKS L, 1986, J CELL PHYSIOL, V126, P371, DOI 10.1002/jcp.1041260307; FRIEDMAN Y, 1977, BIOCHEM BIOPH RES CO, V77, P57, DOI 10.1016/S0006-291X(77)80164-2; GAWELTHOMPSON KJ, 1989, J CELL PHYSIOL, V140, P359, DOI 10.1002/jcp.1041400222; GEERING K, 1986, CURR TOP MEMBR TRANS, V27, P221; GORDONSMITH RH, 1983, BIOCHEM PHARMACOL, V32, P3701, DOI 10.1016/0006-2952(83)90138-7; GRENS A, 1990, J BIOL CHEM, V265, P11810; HIRVONEN A, 1989, BIOCHEM J, V258, P709, DOI 10.1042/bj2580709; HOFFMANN EK, 1987, CURR TOP MEMBR TRANS, V30, P125; HUDSON RL, 1988, P NATL ACAD SCI USA, V85, P279, DOI 10.1073/pnas.85.1.279; KAHANA C, 1985, J BIOL CHEM, V260, P5390; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; KANAMOTO R, 1987, J BIOL CHEM, V262, P14801; KAPYAHO K, 1982, BIOCHIM BIOPHYS ACTA, V714, P93, DOI 10.1016/0304-4165(82)90130-1; KHOMUTOV RM, 1985, BIOCHEM BIOPH RES CO, V130, P596, DOI 10.1016/0006-291X(85)90458-9; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KRISTENSEN LO, 1984, BIOCHEM J, V221, P265, DOI 10.1042/bj2210265; LERUDULIER D, 1984, SCIENCE, V224, P1064, DOI 10.1126/science.224.4653.1064; MAGER J, 1955, NATURE, V176, P933, DOI 10.1038/176933a0; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MATSUI Y, 1989, BIOCHEM INT, V18, P825; MCCORMACK SA, 1989, AM J PHYSIOL, V256, pG868, DOI 10.1152/ajpgi.1989.256.5.G868; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; MUNRO GF, 1975, BIOCHIM BIOPHYS ACTA, V411, P263, DOI 10.1016/0304-4165(75)90306-2; MUNRO GF, 1973, J BACTERIOL, V115, P469, DOI 10.1128/JB.115.2.469-475.1973; OGASAWARA T, 1989, J BIOCHEM-TOKYO, V105, P164, DOI 10.1093/oxfordjournals.jbchem.a122633; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1988, ADV ENZYME REGUL, V27, P43; PEGG AE, 1979, BIOCHIM BIOPHYS ACTA, V568, P416, DOI 10.1016/0005-2744(79)90310-3; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1984, BIOCHEM J, V224, P29, DOI 10.1042/bj2240029; PEGG AE, 1988, BIOCHEMISTRY-US, V27, P1408, DOI 10.1021/bi00405a003; PEGG AE, 1988, CANCER RES, V48, P2678; PERRY JW, 1980, BIOCHIM BIOPHYS ACTA, V629, P24, DOI 10.1016/0304-4165(80)90261-5; PERSSON L, 1988, J BIOL CHEM, V263, P3528; POHJANPELTO P, 1976, J CELL BIOL, V68, P512, DOI 10.1083/jcb.68.3.512; PORTER CW, 1984, CANCER RES, V44, P126; POULIN R, 1990, J BIOL CHEM, V265, P4025; POULIN R, 1989, BIOCHEM J, V263, P215, DOI 10.1042/bj2630215; RINEHART CA, 1984, J BIOL CHEM, V259, P4750; RINEHART CA, 1985, P NATL ACAD SCI USA, V82, P4365, DOI 10.1073/pnas.82.13.4365; ROTIROTI LW, 1973, EXP CELL RES, V79, P295, DOI 10.1016/0014-4827(73)90448-5; ROTIROTI LW, 1973, EXP CELL RES, V79, P311, DOI 10.1016/0014-4827(73)90449-7; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SEELY JE, 1982, J BIOL CHEM, V257, P7549; SEILER N, 1990, INT J BIOCHEM, V22, P211, DOI 10.1016/0020-711X(90)90332-W; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SHINOHARA T, 1977, NATURE, V270, P406, DOI 10.1038/270406a0; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; VICEPSMADORE D, 1982, BIOCHIM BIOPHYS ACTA, V717, P305, DOI 10.1016/0304-4165(82)90184-2; YAMAMOTO S, 1986, CHEM PHARM BULL, V34, P3038; YAMAMOTO S, 1989, MICROBIOL IMMUNOL, V33, P11, DOI 10.1111/j.1348-0421.1989.tb01493.x	61	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6142	6151						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007573				2022-12-25	WOS:A1991FE37300025
J	BAUERLE, C; KEEGSTRA, K				BAUERLE, C; KEEGSTRA, K			FULL-LENGTH PLASTOCYANIN PRECURSOR IS TRANSLOCATED ACROSS ISOLATED THYLAKOID MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; PROTEINS; GENE; CHLOROPLASTS; POLYPEPTIDE; SEQUENCE; BINDING; ATP; LOCALIZATION; CHLOROPHYLL	In higher plants, the chloroplastic protein plastocyanin is synthesized as a transit peptide-containing precursor by cytosolic ribosomes and posttranslationally transported to the thylakoid lumen. En route to the lumen, a plastocyanin precursor is first imported into chloroplasts and then further directed across the thylakoid membrane by a second distinct transport event. A partially processed form of plastocyanin is observed in the stroma during import experiments using intact chloroplasts and has been proposed to be the translocation substrate for the second step (Smeekens, S., Bauerle, C., Hageman, J., Keegstra, K., and Weisbeek, P. (1986) Cell 46, 365-375). To further characterize this second step, we have reconstituted thylakoid transport in a system containing in vitro-synthesized precursor proteins and isolated thylakoid membranes. This system was specific for lumenal proteins since stromal proteins lacking the appropriate targeting information did not accumulate in the thylakoid lumen. Plastocyanin precursor was taken up by isolated thylakoids, proteolytically processed to mature size, and converted to holo form. Translocation was temperature-dependent and was stimulated by millimolar levels of ATP but did not strictly require the addition of stromal factors. We have examined the substrate requirements of thylakoid translocation by testing the ability of different processed forms of plastocyanin to transport in the in vitro system. Interestingly, only the full-length plastocyanin precursor, not the partially processed intermediate form, was competent for transport in this in vitro system.	UNIV WISCONSIN, DEPT BOT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison								BAUERLE C, 1991, J BIOL CHEM, V266, P5884; BOULTER D, 1977, INT REV BIOCHEM, V13, P3; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CASHMORE AR, 1983, GENETIC ENG PLANTS A, P29; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1986, J BIOL CHEM, V261, P4804; DOBRES MS, 1987, PLANT MOL BIOL, V8, P53, DOI 10.1007/BF00016434; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HARINGTON A, 1982, J MOL EVOL, V18, P287, DOI 10.1007/BF01733893; KEEGSTRA K, 1988, BIOESSAYS, V9, P15, DOI 10.1002/bies.950090105; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; LAST DI, 1989, PLANT MOL BIOL, V12, P655, DOI 10.1007/BF00044156; LAUTNER A, 1988, J BIOL CHEM, V263, P10077; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MEYER DI, 1988, TRENDS BIOCHEM SCI, V13, P471, DOI 10.1016/0968-0004(88)90233-2; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; THEG SM, 1989, J BIOL CHEM, V264, P6730; VANDERPLAS J, 1989, MOL MICROBIOL, V3, P275; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VORST O, 1988, GENE, V65, P59, DOI 10.1016/0378-1119(88)90417-9; WEBBER AN, 1989, FEBS LETT, V242, P435, DOI 10.1016/0014-5793(89)80517-4; WEISBEEK P, 1989, J CELL SCI, P199; WILLEY DL, 1983, MOL GEN GENET, V189, P85, DOI 10.1007/BF00326059	29	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5876	5883						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005123				2022-12-25	WOS:A1991FD37000081
J	STOORVOGEL, W; SCHWARTZ, AL; STROUS, GJ; FALLON, RJ				STOORVOGEL, W; SCHWARTZ, AL; STROUS, GJ; FALLON, RJ			A POOL OF INTRACELLULAR PHOSPHORYLATED ASIALOGLYCOPROTEIN RECEPTORS WHICH IS NOT INVOLVED IN ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOMA-CELLS; MANNOSE 6-PHOSPHATE RECEPTOR; PROTEIN KINASE-C; TRANSFERRIN RECEPTOR; MEDIATED ENDOCYTOSIS; CYTOPLASMIC DOMAIN; PHORBOL ESTERS; GOLGI-COMPLEX; IMMUNOELECTRON MICROSCOPY; LYSOSOMAL-ENZYME	One proposed function of the asialoglycoprotein receptor in hepatocytes is to mediate the endocytosis of galactose and N-acetylgalactosamine-exposing glycoproteins. Recently we defined a pool of intracellular H1 subunits of the asialoglycoprotein receptor (ASGPR) in the human hepatoma cell line HepG2 which appeared not to be involved in endocytosis (Stoorvogel, W., Geuze, H. J., Griffith, J. M., Schwartz, A. L., and Strous, G. J. (1989) J. Cell Biol. 108, 2137-2148). In addition, a pool of stably phosphorylated intracellular ASGPR has been detected (Fallon, R. J., and Schwartz, A. L. (1988) J. Biol. Chem. 263, 13159-13166). In the current study we integrate these findings and provide evidence for the existence of two types of intracellular nonexchangeable compartments containing ASGPR. A transiently phosphorylated pool of ASGPR shuttles between the plasma membrane and endosomes, via a pathway identical to that of the transferrin receptor. The second pool comprises 20% of the total intracellular ASGPR, is stably phosphorylated at a serine residue, and is located in intracellular compartments devoid of recycling transferrin receptor. We refer to this ASGPR pool as the "silent pool." We furthermore show that the two receptor pools are confined to compartments exhibiting different buoyant densities on sucrose density gradients. ASGPR in the "silent pool" is fully glycosylated, suggesting a post-Golgi sorting mechanism for trafficking to this compartment. Possible functions of the "silent" ASGPR pool are discussed.	STATE UNIV UTRECHT,SCH MED,DEPT CELL BIOL,3584 CX UTRECHT,NETHERLANDS; WASHINGTON UNIV,ST LOUIS CHILDRENS HOSP,SCH MED,EDWARD MALLINKRODT DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,ST LOUIS CHILDRENS HOSP,SCH MED,DEPT PAEDIAT,ST LOUIS,MO 63110	Utrecht University; St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)								ABDULLAH M, 1987, Journal of Cell Biology, V105, p167A; AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BUYS SS, 1984, CELL, V38, P569, DOI 10.1016/0092-8674(84)90511-7; CARLIN BE, 1986, PROTEIN COMPARTMENTA, P71; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FALLON RJ, 1988, J BIOL CHEM, V263, P13159; FALLON RJ, 1986, J BIOL CHEM, V261, P5081; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GEUZE HJ, 1983, EUR J CELL BIOL, V32, P38; GEUZE HJ, 1984, EMBO J, V3, P2677, DOI 10.1002/j.1460-2075.1984.tb02193.x; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MAY WS, 1985, J BIOL CHEM, V260, P9419; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SCHWARTZ AL, 1984, BIOCHEM J, V223, P481, DOI 10.1042/bj2230481; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1985, J BIOL CHEM, V260, P1979; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; STOORVOGEL W, 1990, TARGETED DIAGNOSIS T; VANDENBOSCH RA, 1986, EXP CELL RES, V162, P231, DOI 10.1016/0014-4827(86)90441-6; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; WARD DM, 1989, J BIOL CHEM, V264, P8164; WILLINGHAM MC, 1980, CELL, V21, P67, DOI 10.1016/0092-8674(80)90115-4; WILLINGHAM MC, 1981, P NATL ACAD SCI-BIOL, V78, P6967, DOI 10.1073/pnas.78.11.6967; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x; ZIJDERHANDBLEEKEMOLEN JE, 1987, J CELL BIOL, V104, P1647, DOI 10.1083/jcb.104.6.1647	46	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5438	5444						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005089				2022-12-25	WOS:A1991FD37000016
J	TAKAGI, J; FUJISAWA, T; SEKIYA, F; SAITO, Y				TAKAGI, J; FUJISAWA, T; SEKIYA, F; SAITO, Y			COLLAGEN-BINDING DOMAIN WITHIN BOVINE PROPOLYPEPTIDE OF VONWILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; GLYCOPROTEIN-IIB-IIIA; AMINO-ACID RESIDUES; ANTIGEN-II; RECOGNITION SITE; PLATELETS; FIBRONECTIN; IDENTIFICATION; LOCALIZATION; FRAGMENTS	Two reduced/alkylated fragments of bovine propolypeptide of von Willebrand factor (pp-vWF) that inhibit pp-vWF binding to collagen were isolated. One is a tryptic fragment of molecular mass of about 30 kDa and inhibits the binding at a molar concentration about 20 times higher than the intact pp-vWF. Amino acid sequence of this fragment was determined almost completely, and it was revealed that this fragment corresponded to the carboxyl-terminal region of pp-vWF molecule beginning with Phe557. The other active fragment was obtained by lysyl endopeptidase digestion. This migrated as a 21.5/21-kDa doublet in sodium dodecyl sulfate-polyacrylamide gel electrophoresis, but deglycosylation of this doublet resulted in production of single species of 19 kDa. The difference between the doublet constituents, therefore, was of carbohydrate composition. The extent of inhibition of collagen-binding by this 21.5/21-kDa fragment was comparable to that of the 30-kDa fragment, and furthermore, location of this fragment in the molecule was established to be between Phe570 and Lys682. These were the only fragments among those obtained by proteolytic digestions that had significant competitive effect on the binding of intact pp-vWF to collagen. These results strongly suggest that at least one collagen-binding site should be present in the carboxyl-terminal region of bovine pp-vWF extending from residue 570 to 682.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT BIOL SCI,MEGURO KU,TOKYO 152,JAPAN	Tokyo Institute of Technology								BERLINER S, 1988, J BIOL CHEM, V263, P7500; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; COLLER BS, 1983, BLOOD, V61, P99; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; FRETTO LJ, 1986, J BIOL CHEM, V261, P5679; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; INGHAM KC, 1989, J BIOL CHEM, V264, P16977; KESSLER CM, 1984, BLOOD, V63, P1291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MASCELLI MA, 1986, BIOCHEMISTRY-US, V25, P6325, DOI 10.1021/bi00368a074; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; NYMAN D, 1977, THROMB RES, V11, P433, DOI 10.1016/0049-3848(77)90196-7; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PARETI FI, 1986, J BIOL CHEM, V261, P15310; PARKER RI, 1986, BLOOD, V68, P732; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; SCOTT JP, 1981, BLOOD, V58, P1075; SEKIGUCHI K, 1980, BIOCHEM BIOPH RES CO, V97, P709, DOI 10.1016/0006-291X(80)90322-8; TAKAGI J, 1989, J BIOL CHEM, V264, P10425; TAKAGI J, 1989, J BIOL CHEM, V264, P6017; TUDDENHAM EGD, 1982, BRIT J HAEMATOL, V52, P259, DOI 10.1111/j.1365-2141.1982.tb03888.x; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553; YAMADA KM, 1980, J BIOL CHEM, V255, P6055	32	28	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5575	5579						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005098				2022-12-25	WOS:A1991FD37000035
J	VILLANI, A; CIRINO, NM; BALDI, E; KESTER, M; MCFADDEN, ER; PANUSKA, JR				VILLANI, A; CIRINO, NM; BALDI, E; KESTER, M; MCFADDEN, ER; PANUSKA, JR			RESPIRATORY SYNCYTIAL VIRUS-INFECTION OF HUMAN MONONUCLEAR PHAGOCYTES STIMULATES SYNTHESIS OF PLATELET-ACTIVATING-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PROTEIN KINASE-C; PAF-ACETHER; CELL-LINE; ALVEOLAR MACROPHAGES; HUMAN-NEUTROPHILS; ARACHIDONIC-ACID; U937 CELLS; BIOCHEMICAL CHARACTERISTICS; INDUCED-DIFFERENTIATION	Production of platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF), a potent mediator of inflammation, by mononuclear phagocytes varies with their stage of cellular differentiation and the nature of the eliciting stimulus. The human monocytic cell line U937 can be induced to differentiate to a macrophage-like cell following phorbol myristate acetate exposure, and after differentiation, these cells efficiently support replication of respiratory syncytial virus (RSV). U937 cells induced to differentiate with phorbol myristate acetate demonstrated a time-dependent decrease in PAF synthesis. RSV infection of these differentiated U937 cells caused a sustained stimulation of PAF synthesis that paralleled viral replication and was dependent on infectious virus. Virus increased the activity of lyso-PAF:acetyl-CoA acetyltransferase (PAF acetyltransferase) in cell lysates, thus enhancing the anabolic pathway of PAF synthesis without altering the activity of PAF acetylhydrolase, which regulates PAF catabolism. RSV infection of human monocytes also caused a marked increase in [H-3] PAF production compared to uninfected monocytes. Thus, virus infection serves as a novel stimulus to induce PAF synthesis in human mononuclear phagocytes and suggests that increased PAF production may have a critical role in the inflammatory response to RSV.	UNIV HOSP CLEVELAND,CTR AIRWAY DIS,2074 ABINGTON RD,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,DEPT MED,DIV NEPHROL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106	University Hospitals of Cleveland; University Hospitals of Cleveland; Case Western Reserve University			baldi, elisabetta/AAA-6629-2019	Baldi, Elisabetta/0000-0003-1808-3097	NCRR NIH HHS [M01 RR0080] Funding Source: Medline; NHLBI NIH HHS [HL 37117] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERT DH, 1984, BIOCHIM BIOPHYS ACTA, V796, P92, DOI 10.1016/0005-2760(84)90242-X; ALLRED JB, 1969, ANAL BIOCHEM, V29, P293, DOI 10.1016/0003-2697(69)90312-1; BILLAH MM, 1985, J BIOL CHEM, V260, P6899; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOMALASKI JS, 1987, BIOCHEM J, V244, P497, DOI 10.1042/bj2440497; BRAQUET P, 1986, TRANSPLANT P, V18, P10; BRAQUET P, 1986, TRENDS PHARMACOL SCI, V7, P397, DOI 10.1016/0165-6147(86)90401-3; BRASS EP, 1988, BIOCHEM J, V250, P819, DOI 10.1042/bj2500819; CAMUSSI G, 1989, EUR J BIOCHEM, V182, P661, DOI 10.1111/j.1432-1033.1989.tb14876.x; CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980; COBB MA, 1983, J RETICULOENDOTH SOC, V33, P197; CUSS FM, 1986, LANCET, V2, P189; DOEBBER TW, 1987, P NATL ACAD SCI USA, V84, P7557, DOI 10.1073/pnas.84.21.7557; DUBOIS C, 1989, J IMMUNOL, V143, P964; DULIOUST A, 1989, BIOCHEM J, V263, P165, DOI 10.1042/bj2630165; DUVAL D, 1986, BIOCHIM BIOPHYS ACTA, V887, P204, DOI 10.1016/0167-4889(86)90056-X; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; GIMENEZ HB, 1989, J GEN VIROL, V70, P89, DOI 10.1099/0022-1317-70-1-89; GOLDFELD AE, 1989, P NATL ACAD SCI USA, V86, P1490, DOI 10.1073/pnas.86.5.1490; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; GUINEA R, 1989, J BIOL CHEM, V264, P21923; HAMASAKI Y, 1984, AM REV RESPIR DIS, V129, P742, DOI 10.1164/arrd.1984.129.5.742; HANAHAN DJ, 1987, PROG LIPID RES, V26, P1, DOI 10.1016/0163-7827(87)90006-3; HATTORI T, 1983, J CLIN INVEST, V72, P237, DOI 10.1172/JCI110962; HOBER D, 1989, CLIN EXP IMMUNOL, V78, P329; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KRILOV LR, 1987, J GEN VIROL, V68, P1749, DOI 10.1099/0022-1317-68-6-1749; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; LEONELLI FM, 1989, CLIN SCI, V77, P561, DOI 10.1042/cs0770561; MARTINMONDIERE C, 1987, PROSTAGLANDINS, V34, P163, DOI 10.1016/0090-6980(87)90206-1; McIntosh K., 1985, VIROLOGY, P1285; MIDULLA F, 1989, AM REV RESPIR DIS, V140, P771, DOI 10.1164/ajrccm/140.3.771; MIZEL SB, 1978, J IMMUNOL, V120, P1497; MYERS RF, 1984, BIOCHEM BIOPH RES CO, V118, P217, DOI 10.1016/0006-291X(84)91089-1; NAKAGAWA Y, 1989, PROG LIPID RES, V28, P205, DOI 10.1016/0163-7827(89)90013-1; NIETO ML, 1988, J BIOL CHEM, V263, P2217; NOLFO R, 1990, PROSTAGLANDINS, V39, P157, DOI 10.1016/0090-6980(90)90072-4; PANUSKA JR, 1988, BIOCHEM J, V249, P501, DOI 10.1042/bj2490501; PANUSKA JR, 1990, J CLIN INVEST, V86, P113, DOI 10.1172/JCI114672; PANUSKA JR, 1990, AM J PHYSIOL, V259, pL396, DOI 10.1152/ajplung.1990.259.6.L396; PARKS DR, 1979, P NATL ACAD SCI USA, V76, P1962, DOI 10.1073/pnas.76.4.1962; PONPIPOM MM, 1988, BIOCHEM BIOPH RES CO, V150, P1213, DOI 10.1016/0006-291X(88)90758-9; PREVOST MC, 1988, BIOCHIM BIOPHYS ACTA, V962, P354, DOI 10.1016/0005-2760(88)90265-2; Pringle C. R., 1987, Molecular basis of virus disease, P51; ROBERTS NJ, 1986, J EXP MED, V163, P511, DOI 10.1084/jem.163.3.511; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROLAPLESZCZYNSK.M, 1988, NEW TRENDS LIPID MED, V2, P89; ROLAPLESZCZYNSKI M, 1987, BIOCHEM BIOPH RES CO, V142, P754, DOI 10.1016/0006-291X(87)91478-1; ROUXLOMBARD P, 1986, CELL IMMUNOL, V97, P286, DOI 10.1016/0008-8749(86)90399-0; RUBIN AHE, 1987, AM REV RESPIR DIS, V136, P1145, DOI 10.1164/ajrccm/136.5.1145; SCHENKEIN HA, 1986, CELL IMMUNOL, V102, P307, DOI 10.1016/0008-8749(86)90424-7; SHAW JO, 1981, J IMMUNOL, V127, P1250; SHEN TY, 1987, PLATELET ACTIVATING, P153; SISSON JH, 1987, J IMMUNOL, V138, P3918; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SYNDER F, 1985, MED RES REV, V5, P107; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAYLOR RR, 1989, CLIN SCI, V76, P195, DOI 10.1042/cs0760195; TENNEY DJ, 1987, J IMMUNOL, V139, P3076; UHING RJ, 1989, J BIOL CHEM, V264, P9224; VOLOVITZ B, 1988, PEDIATR RES, V24, P504, DOI 10.1203/00006450-198810000-00018; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WIEDERHOLD MD, 1988, BIOCHIM BIOPHYS ACTA, V959, P296, DOI 10.1016/0005-2760(88)90203-2	65	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5472	5479						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005091				2022-12-25	WOS:A1991FD37000021
J	GRANT, SG; CHAPMAN, VM				GRANT, SG; CHAPMAN, VM			DETAILED GENETIC-MAPPING OF THE A-RAF PROTOONCOGENE ON THE MOUSE X-CHROMOSOME	ONCOGENE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; GLYCEROL KINASE-DEFICIENCY; CHRONIC GRANULOMATOUS-DISEASE; ELECTROPHORETIC VARIATION; TRANSFORMING SEQUENCE; CARRYING RETROVIRUS; ADRENAL HYPOPLASIA; SYNOVIAL SARCOMA; FAMILY; EXPRESSION	The transcribed murine A-raf proto-oncogene has been localized to the proximal region of the mouse X chromosome, within the context of four other active genes in this region which together constitute a conserved linkage group between mouse and man. This localization has been accomplished using species-specific restriction fragment length variation and DNAs from a previously defined informative subset of progeny representative of a set of 100 progeny from an interspecific backcross between inbred C57BL/6JRos and wild-derived Mus spretus. This new data regionally orders the mouse A-raf locus relative to the 24 X-linked markers previously examined in this backcross. We find that A-raf co-localizes with two other active genes, tissue inhibitor of metalloproteinases (Timp) and synapsin (Syn-1), 4.0 +/- 2.0 cM distal to the Otc gene at the proximal end of the mouse X chromosome, for a partial gene order in this region of: centromere-Cybb-Otc-Timp/A-raf/Syn-1-Xlr-1-Hprt.	NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA	Roswell Park Cancer Institute			Grant, Stephen G/D-6984-2014	Grant, Stephen G/0000-0002-9236-0913	NIGMS NIH HHS [GM24125, GM33160] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024125, R01GM033160] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVNER P, 1987, SOMAT CELL MOLEC GEN, V13, P267, DOI 10.1007/BF01535208; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; BARTLEY JA, 1986, J PEDIATR-US, V108, P189, DOI 10.1016/S0022-3476(86)80980-5; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BROWN SDM, 1985, TRENDS GENET, V1, P219, DOI 10.1016/0168-9525(85)90086-1; BURMEISTER M, 1988, Genomics, V2, P189, DOI 10.1016/0888-7543(88)90002-X; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CHAMBERLAIN JS, 1987, SOMAT CELL MOLEC GEN, V13, P671, DOI 10.1007/BF01534487; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; CHAPMAN VM, 1983, GENETICS, V103, P785; CHELLY J, 1988, HUM GENET, V78, P222, DOI 10.1007/BF00291665; DAVIES KE, 1987, CYTOGENET CELL GENET, V46, P277, DOI 10.1159/000132481; DAVISSON M T, 1987, Genomics, V1, P213, DOI 10.1016/0888-7543(87)90047-4; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DEWALD GW, 1989, CANCER GENET CYTOGEN, V42, P173, DOI 10.1016/0165-4608(89)90085-X; DISTECHE CM, 1989, GENOMICS, V5, P177, DOI 10.1016/0888-7543(89)90044-X; ELLIOTT RW, 1990, GENOMICS, V6, P635, DOI 10.1016/0888-7543(90)90498-J; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FRANCKE U, 1985, AM J HUM GENET, V37, P250; FRANCKE U, 1984, CYTOGENET CELL GENET, V38, P298, DOI 10.1159/000132078; FROHMAN MA, 1989, CELL, V56, P145, DOI 10.1016/0092-8674(89)90887-8; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; GILGENKRANTZ S, 1989, CYTOGENET CELL GENET, V51, P1004; GRANT SG, 1990, IN PRESS CYTOGENET C; GUENET JL, 1986, CURR TOP MICROBIOL, V127, P109; HAMMOND J, 1985, LANCET, V1, P54; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KENWRICK S, 1987, CELL, V48, P351, DOI 10.1016/0092-8674(87)90438-7; KILIMANN MW, 1985, EMBO J, V4, P1997, DOI 10.1002/j.1460-2075.1985.tb03883.x; KISS Z, 1988, FEBS LETT, V240, P221, DOI 10.1016/0014-5793(88)80372-7; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LAFRENIERE RG, 1989, CYTOGENET CELL GENET, V51, P1028; LALLEY PA, 1989, CYTOGENET CELL GENET, V51, P503, DOI 10.1159/000132806; LYON MF, 1988, AM J HUM GENET, V42, P8; MCCABE ERB, 1989, J CLIN INVEST, V83, P95, DOI 10.1172/JCI113890; MIYOSHI J, 1984, NUCLEIC ACIDS RES, V12, P1821, DOI 10.1093/nar/12.4.1821; MORTON CC, 1989, GENOMICS, V4, P367, DOI 10.1016/0888-7543(89)90344-3; MULLINS LJ, 1988, GENOMICS, V3, P187, DOI 10.1016/0888-7543(88)90078-X; MULLINS LJ, 1990, GENOMICS, V7, P19, DOI 10.1016/0888-7543(90)90514-U; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NIELSEN JT, 1977, GENETICS, V87, P319; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; NOGUCHI T, 1988, ONCOGENE, V3, P709; OBRIEN SJ, 1983, NATURE, V302, P839, DOI 10.1038/302839a0; OBRIEN SJ, 1988, ANNU REV GENET, V22, P323, DOI 10.1146/annurev.ge.22.120188.001543; OHNO S, 1969, ANNU REV GENET, V3, P495, DOI 10.1146/annurev.ge.03.120169.002431; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; REEVES BR, 1989, ONCOGENE, V4, P373; SEARLE AG, 1989, ANN HUM GENET, V53, P89, DOI 10.1111/j.1469-1809.1989.tb01777.x; STEPHENSON DA, 1988, NUCLEIC ACIDS RES, V16, P1642, DOI 10.1093/nar/16.4.1642; STEPHENSON DA, 1988, CURR TOP MICROBIOL, V137, P18; STEPHENSON DA, 1991, IN PRESS MAMMALIAN G; STORM SM, 1990, ONCOGENE, V5, P345; SZPIRER J, 1985, SOMAT CELL MOLEC GEN, V11, P93, DOI 10.1007/BF01534739; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TRONICK SR, 1989, GENOMICS, V5, P546, DOI 10.1016/0888-7543(89)90022-0; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; VANOMMEN GJB, 1986, CELL, V47, P499, DOI 10.1016/0092-8674(86)90614-8; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247	72	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					397	402						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011396				2022-12-25	WOS:A1991FT34400007
J	STEWART, LC; KLINMAN, JP				STEWART, LC; KLINMAN, JP			COOPERATIVITY IN THE DOPAMINE BETA-MONOOXYGENASE REACTION - EVIDENCE FOR ASCORBATE REGULATION OF ENZYME-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN GRANULES; MEMBRANE-BOUND FORM; NOREPINEPHRINE BIOSYNTHESIS; SUBUNIT DISSOCIATION; INSITU KINETICS; HYDROXYLASE; ACID; CELLS; PH; MECHANISM	The steady-state kinetic behavior of dopamine beta-monooxygenase (D-beta-M) has been examined over a 1000-fold range of ascorbate concentrations. Kinetic plots exhibit extreme curvature indicative of apparent negative cooperativity in the interaction of D-beta-M with ascorbate, with a calculated Hill coefficient of 0.15-0.30. The observed cooperativity is found to be independent of enzyme concentration and tyramine and oxygen concentrations, as well as the pH employed for the assay. Similar kinetic data have been obtained with both soluble and purified membrane-derived forms of enzyme. An investigation of the effect of the anion activator fumarate upon the observed kinetic patterns has demonstrated a conversion to a less cooperative kinetic pattern at low pH and high concentrations of fumarate. This phenomenon is attributed to an inhibitory binding of the structurally similar monoanionic species of fumarate to the ascorbate reductant site. A simple model has been used to assess the change in apparent V(max) and K(m) parameters with increased ascorbate concentrations. At all pH values examined, there is a dramatic decrease in the affinity of D-beta-M for ascorbate from a K(m) of approximately 0.05-0.10 mM (ascorbate concentration < 1 mM) to K(m) > 10 mM at limiting ascorbate; at the same time there is a 3- to 4-fold increase in the limiting V(max) value. Several models have been considered to explain the observed activation of D-beta-M by high levels of ascorbic acid.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NIGMS NIH HHS [GM 25765] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025765, R37GM025765] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN N, 1983, BIOCHEMISTRY-US, V22, P3096, DOI 10.1021/bi00282a012; AHN NG, 1989, J BIOL CHEM, V264, P12259; AHN NG, 1987, J BIOL CHEM, V262, P1485; ALBERTY RA, 1954, J AM CHEM SOC, V76, P2485, DOI 10.1021/ja01638a053; ANDREWS GC, 1982, ASCORBIC ACID CHEM M; BEERS MF, 1986, J BIOL CHEM, V261, P2529; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4656, DOI 10.1021/bi00437a022; CARTY SE, 1985, ENZYMES BIOL MEMBR, V2, P449; COLOMBO G, 1987, ARCH BIOCHEM BIOPHYS, V252, P71, DOI 10.1016/0003-9861(87)90009-9; CORCORAN JJ, 1984, J BIOL CHEM, V259, P6208; DHARIWAL KR, 1989, J BIOL CHEM, V264, P15404; DHAWAN S, 1986, J BIOL CHEM, V261, P7680; FITZPATRICK PF, 1986, ARCH BIOCHEM BIOPHYS, V249, P70, DOI 10.1016/0003-9861(86)90561-8; FRIEDEN C, 1979, ANNU REV BIOCHEM, V48, P471, DOI 10.1146/annurev.bi.48.070179.002351; GOLDSTEIN M, 1968, BIOCHEMISTRY-US, V7, P2724, DOI 10.1021/bi00848a005; GROUSELLE M, 1982, BIOCHEM J, V202, P759, DOI 10.1042/bj2020759; HUYGHE BG, 1991, J BIOL CHEM, V266, P11544; INGEBRETSEN OC, 1980, BIOCHIM BIOPHYS ACTA, V628, P182, DOI 10.1016/0304-4165(80)90365-7; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; KATO K, 1988, J MED CHEM, V31, P793, DOI 10.1021/jm00399a019; KAUFMAN S, 1965, PHARMACOL REV, V17, P71; KISTIAKOWSKY GB, 1952, J AM CHEM SOC, V74, P5020, DOI 10.1021/ja01140a009; KLINMAN JP, 1984, J BIOL CHEM, V259, P3399; KLINMAN JP, 1982, BIOCHEMISTRY-US, V21, P67, DOI 10.1021/bi00530a013; LEVINE M, 1985, J BIOL CHEM, V260, P5598; LEVINE M, 1986, J BIOL CHEM, V261, P7347; LEVINE MA, 1983, FEBS LETT, V158, P134, DOI 10.1016/0014-5793(83)80693-0; LJONES T, 1984, COPPER PROTEINS COPP, V2, P131; MENNITI FS, 1987, J BIOL CHEM, V262, P7651; MENNITI FS, 1986, J BIOL CHEM, V261, P6901; MILLER SM, 1985, BIOCHEMISTRY-US, V24, P2114, DOI 10.1021/bi00330a004; Neet K E, 1980, Methods Enzymol, V64, P192; PATZAK A, 1986, J CELL BIOL, V102, P510, DOI 10.1083/jcb.102.2.510; PHILLIPS JH, 1987, ANN NY ACAD SCI, V493, P27, DOI 10.1111/j.1749-6632.1987.tb27178.x; Rottenberg H, 1979, Methods Enzymol, V55, P547; SALAMA G, 1980, J GEN PHYSIOL, V75, P109, DOI 10.1085/jgp.75.2.109; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SAXENA A, 1985, J BIOL CHEM, V260, P3386; SEGEL IH, 1975, ENZYMIC KINETICS, P67; SKOTLAND T, 1979, INORG PERSPECT BIOL, V2, P151; STEWART LC, 1988, J BIOL CHEM, V263, P12183; STEWART LC, 1987, BIOCHEMISTRY-US, V26, P5302, DOI 10.1021/bi00391a013; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STEWART LC, 1989, THESIS U CALIFORNIA; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TERLAND O, 1975, FEBS LETT, V59, P52, DOI 10.1016/0014-5793(75)80339-5; TINOCO I, 1985, PHYSICAL CHEM PRINCI; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WINKLER H, 1976, NEUROSCIENCE, V1, P65, DOI 10.1016/0306-4522(76)90001-4; WINKLER H, 1987, ANN NY ACAD SCI, V493, P3, DOI 10.1111/j.1749-6632.1987.tb27176.x; Winkler H, 1982, SECRETORY GRANULE, P3	54	26	27	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11537	11543						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050664				2022-12-25	WOS:A1991FT76200022
J	SHOUN, H; TANIMOTO, T				SHOUN, H; TANIMOTO, T			DENITRIFICATION BY THE FUNGUS FUSARIUM-OXYSPORUM AND INVOLVEMENT OF CYTOCHROME-P-450 IN THE RESPIRATORY NITRITE REDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEM	From conditions for production in Fusarium oxysporum of the unique nitrate/nitrite-inducible cytochrome P-450, tentatively called P-450dNIR, it was expected that the fungus is capable of metabolizing nitrate dissimilatively. Here we report that F. oxysporum exhibits a distinct denitrifying ability which results in the anaerobic evolution of nitrous oxide (N2O) from nitrate or nitrite. Comparison of the cell growth during denitrification indicated that the dissimilatory reduction of nitrate to nitrite is an energetically favorable process in F. oxysporum; however, further reduction of nitrite to N2O might be energy-exhausting and may function as a detoxification mechanism. A potent nitrite reductase activity to form N2O could be reconstituted by combination of the cell-free extract prepared from the denitrifying cells and an NADH-phenadinemethosulfate-dependent reducing system. The activity was strongly inhibited by carbon monoxide, cyanide, oxygen (O2), and the antibody against P-450dNIR. The results, along with those concerning inducing conditions of P-450dNIR, were highly indicative that the cytochrome is involved in the denitrifying nitrite reduction. This work has thus presented not only the first demonstration that a eukaryote exhibits a marked denitrifying ability, but also the first instance of a cytochrome P-450 that is involved in a reducing reaction with a distinct physiological significance against a hydrophilic, inorganic substrate.			SHOUN, H (corresponding author), UNIV TSUKUBA,INST APPL BIOCHEM,SAKURA,IBARAKI 305,JAPAN.							ALLISON C, 1989, APPL ENVIRON MICROB, V55, P2899, DOI 10.1128/AEM.55.11.2899-2903.1989; BLEAKLEY BH, 1982, APPL ENVIRON MICROB, V44, P1342, DOI 10.1128/AEM.44.6.1342-1348.1982; CASTRO CE, 1985, BIOCHEMISTRY-US, V24, P204, DOI 10.1021/bi00322a029; COYNE MS, 1989, APPL ENVIRON MICROB, V55, P2924, DOI 10.1128/AEM.55.11.2924-2931.1989; FERGUSON SJ, 1987, TRENDS BIOCHEM SCI, V12, P354, DOI 10.1016/0968-0004(87)90164-2; Garrett R H, 1978, Adv Microb Physiol, V18, P1; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GOTOH O, 1989, FRONTIERS BIOTRANSFO, V1, P196; GUENGERICH FP, 1988, J BIOL CHEM, V263, P8168; JANES HW, 1982, PLANT PHYSIOL, V70, P853, DOI 10.1104/pp.70.3.853; KNOWLES R, 1982, MICROBIOL REV, V46, P43, DOI 10.1128/MMBR.46.1.43-70.1982; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEVERT DW, 1991, DNA CELL BIOL, V10, P1; NICHOLAS DJ, 1964, BIOCHIM BIOPHYS ACTA, V86, P466, DOI 10.1016/0304-4165(64)90086-8; OMER CA, 1990, J BACTERIOL, V172, P3335, DOI 10.1128/jb.172.6.3335-3345.1990; OMURA T, 1964, J BIOL CHEM, V239, P2370; Russell JA, 1944, J BIOL CHEM, V156, P457; SATO R, 1956, S INORGANIC NITROGEN, P163; SATOH T, 1976, AGR BIOL CHEM TOKYO, V40, P953, DOI 10.1080/00021369.1976.10862149; SHOUN H, 1983, J BIOCHEM, V94, P1219, DOI 10.1093/oxfordjournals.jbchem.a134467; SHOUN H, 1989, FEBS LETT, V244, P11, DOI 10.1016/0014-5793(89)81151-2; SHOUN H, 1989, AGR BIOL CHEM TOKYO, V53, P2153, DOI 10.1080/00021369.1989.10869624; SHOUN H, 1985, J BIOCHEM, V97, P755, DOI 10.1093/oxfordjournals.jbchem.a135115; SHOUN H, 1991, AGR BIOL CHEM TOKYO, V55, P593, DOI 10.1080/00021369.1991.10870623	24	217	229	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11078	11082						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040619				2022-12-25	WOS:A1991FQ77400059
J	BAME, KJ; LIDHOLT, K; LINDAHL, U; ESKO, JD				BAME, KJ; LIDHOLT, K; LINDAHL, U; ESKO, JD			BIOSYNTHESIS OF HEPARAN-SULFATE - COORDINATION OF POLYMER-MODIFICATION REACTIONS IN A CHINESE-HAMSTER OVARY CELL MUTANT DEFECTIVE IN N-SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE; CONCERTED ACTION; ACID RESIDUES; O-SULFATION; ANTITHROMBIN; GLYCOSAMINOGLYCANS; DEPOLYMERIZATION; DESULFATION; METHANOL; WATER	A previous study identified a Chinese hamster ovary cell mutant, pgsE-606, which is defective in the N-sulfotransferase that catalyzes one of the initial polymer-modification reactions in the biosynthesis of heparan sulfate (Bame, K. J., and Esko, J. D. (1989) J. Biol. Chem. 264, 8059-8065). The structure of heparan sulfate generated by these cells reflects a 3-5-fold reduction in enzyme activity. The mutant produces heparan sulfate with half the content of N-sulfated glucosamine residues of that produced by wild-type cells and a more sparse distribution of N-sulfated residues. The present study demonstrates corresponding reductions in the proportion of 6-O-sulfated glucosamine residues (41% reduction) and the content of L-iduronic acid (51% reduction). The amount of 2-O-sulfated L-iduronic acid declines more dramatically (from 25% of total L-iduronic acid in the wild type to 8.4% in the mutant). Enzymatic assay of mixed O-sulfotransferases showed that the mutant has more activity than the wild type. Previous studies on the biosynthesis of heparin/heparan sulfate in cell-free systems point to a pivotal role of N-sulfation in determining the extent of the subsequent polymer-modification reactions. The present study shows that this concept also applies to heparan sulfate biosynthesis in the intact cell.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294; SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN; UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN	University of Alabama System; University of Alabama Birmingham; Swedish University of Agricultural Sciences; Uppsala University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R01GM033063] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33063] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1991, IN PRESS J BIOL CHEM, V266; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; GALLAGHER JT, 1989, HEPARIN, P135; HOOK M, 1974, BIOCHEM J, V137, P33; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; JACOBSSON I, 1979, BIOCHEM J, V179, P77, DOI 10.1042/bj1790077; JACOBSSON KG, 1985, J BIOL CHEM, V260, P2154; JANSSON L, 1975, BIOCHEM J, V149, P49, DOI 10.1042/bj1490049; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; Lindahl U., 1989, HEPARIN, P159; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RIESENFELD J, 1982, J BIOL CHEM, V257, P421; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005	29	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10287	10293						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037581				2022-12-25	WOS:A1991FP08600047
J	JARAMILLO, M; PELLETIER, J; EDERY, I; NIELSEN, PJ; SONENBERG, N				JARAMILLO, M; PELLETIER, J; EDERY, I; NIELSEN, PJ; SONENBERG, N			MULTIPLE MESSENGER-RNAS ENCODE THE MURINE TRANSLATION INITIATION-FACTOR EIF-4E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; GENE-EXPRESSION; STIMULATION; SUBUNIT; COMPLEX; TISSUES; CELLS	All eukaryotic cellular mRNAs (except organellar) possess at their 5' end the structure m7GpppX (where X is any nucleotide) termed the "cap." The cap structure facilitates the melting of mRNA 5' secondary structure through the action of initiation factor-4F (eIF-4F) in conjunction with eIF-4B. eIF-4F consists of three subunits of which one, eIF-4E (eIF-4E has recently been designated eIF-4-alpha according to the Nomenclature Committee of the International Union of Biochemistry (NC-IUB) (Safer, B. (1989) Eur. J. Biochem. 186, 1-3)), contains the cap binding site. Several lines of evidence suggest that eIF-4E regulates the rate of translation initiation. Consequently, changes in cellular eIF-4E levels could control growth and differentiation. To investigate the possibility that eIF-4E expression is regulated, we studied the pattern of eIF-4E expression in several cell lines. Here, we show the existence of multiple mRNAs for eIF-4E that are generated by differential polyadenylation. In addition, we show tissue-specific differences in eIF-4E mRNA expression and utilization of polyadenylation sites.	MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,QUEBEC,CANADA; MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY	McGill University; McGill University; Max Planck Society								ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; Battey, 1986, BASIC METHODS MOL BI; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; CONROY SC, 1990, ARCH BIOCHEM BIOPHYS, V282, P363, DOI 10.1016/0003-9861(90)90130-Q; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1983, J BIOL CHEM, V258, P1398; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HUYNH TV, 1975, DNA CLONING PRACTICA, V1; HYMAN R, 1972, J NATL CANCER I, V48, P173; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P1598, DOI 10.1128/MCB.3.9.1598; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; Maniatis T., 1982, MOL CLONING; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RAY BK, 1983, P NATL ACAD SCI-BIOL, V80, P663, DOI 10.1073/pnas.80.3.663; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; SAFER B, 1989, EUR J BIOCHEM, V186, P1, DOI 10.1111/j.1432-1033.1989.tb15169.x; SARKAR G, 1984, BIOCHIM BIOPHYS ACTA, V783, P122, DOI 10.1016/0167-4781(84)90003-4; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; SMITH M R, 1990, New Biologist, V2, P648; SONENBERG N, 1980, NATURE, V285, P331, DOI 10.1038/285331a0; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	32	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10446	10451						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037592				2022-12-25	WOS:A1991FP08600069
J	MINAMI, Y; KAWASAKI, H; MIYATA, Y; SUZUKI, K; YAHARA, I				MINAMI, Y; KAWASAKI, H; MIYATA, Y; SUZUKI, K; YAHARA, I			ANALYSIS OF NATIVE FORMS AND ISOFORM COMPOSITIONS OF THE MOUSE 90-KDA HEAT-SHOCK PROTEIN, HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TRANSFORMING PROTEIN; 2 CELLULAR PROTEINS; GLUCOCORTICOID RECEPTOR; ACTIN-FILAMENTS; MR 90,000; BINDING; SEQUENCE; COMPLEX; INVITRO; KINASE	The 90-kDa heat shock protein, HSP90, of the mouse has two isoforms, alpha and beta, which are electrophoretically separable. We have investigated the native forms of HSP90 molecules under physiological conditions and determined their isoform compositions. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that HSP90 purified from mouse lymphoma L5178Y cells consists of approximately 40% alpha and 60% beta-isoforms. Analysis by nondenaturing polyacrylamide gel electrophoresis showed that the purified HSP90 exists predominantly as a dimer, but a considerable amount of monomer was also detected. Western blotting using polyclonal anti-mouse HSP90 antibodies revealed that the native forms of HSP90 in the crude L5178Y cell lysates are also dimer and monomer. The nondenaturing polyacrylamide gel electrophoresis resolved the dimeric forms into two separate bands that were identified as alpha/alpha and beta/beta homodimers by two methods: sodium dodecyl sulfate-polyacrylamide gel electrophoresis and peptide mapping. In addition, the results showed that the monomeric form consists mainly of the beta-isoform. Both the alpha and beta-isoforms were shown to bind equally to actin filaments.	TOKYO METROPOLITAN INST MED SCI,DEPT CELL BIOL,HONKOMAGOME 3-18-22,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science			Kawasaki, Hiroshi/C-3048-2011; Miyata, Y/X-7111-2019	Kawasaki, Hiroshi/0000-0002-2517-159X; 				ADKINS B, 1982, J VIROL, V43, P448, DOI 10.1128/JVI.43.2.448-455.1982; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BARNIER JV, 1987, EXP CELL RES, V170, P186, DOI 10.1016/0014-4827(87)90128-5; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; IANNOTTI AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P54, DOI 10.1016/0003-9861(88)90569-3; KELLEY PM, 1982, MOL CELL BIOL, V2, P267, DOI 10.1128/MCB.2.3.267; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKS KW, 1989, J CELL PHYSIOL, V140, P601, DOI 10.1002/jcp.1041400327; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MOORE SK, 1987, GENE, V56, P29, DOI 10.1016/0378-1119(87)90155-7; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; OPPERMANN H, 1982, VIROLOGY, V113, P736; PARDEW GH, 1988, J BIOL CHEM, V263, P13802; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; RATAJCZAK T, 1988, BIOCHEM BIOPH RES CO, V151, P1156, DOI 10.1016/S0006-291X(88)80487-X; RENOIR JM, 1990, J BIOL CHEM, V265, P14402; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; ROSE DW, 1989, J BIOL CHEM, V264, P6239; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; SCHUH S, 1985, J BIOL CHEM, V260, P4292; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; YAHARA I, 1986, CELL STRUCT FUNCT, V11, P65, DOI 10.1247/csf.11.65; YONEZAWA N, 1988, EUR J BIOCHEM, V177, P1, DOI 10.1111/j.1432-1033.1988.tb14337.x	41	94	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10099	10103						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037568				2022-12-25	WOS:A1991FP08600019
J	SZYF, M; BOZOVIC, V; TANIGAWA, G				SZYF, M; BOZOVIC, V; TANIGAWA, G			GROWTH-REGULATION OF MOUSE DNA METHYLTRANSFERASE GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THYMIDINE KINASE GENE; CELL-CYCLE; MESSENGER-RNA; DAM METHYLTRANSFERASE; METHYLATION PATTERNS; DENOVO METHYLATION; ESCHERICHIA-COLI; C-MYC; REPLICATION; PROMOTER	The steady state level of DNA methyltransferase mRNA is markedly increased as growth-arrested Balb/c 3T3 cells progress into the S phase of the cell cycle. mRNA abundance is reduced to the basal level before termination of DNA synthesis activity. Maintenance DNA methylation activity in nuclear extracts follows a similar pattern with two exceptions. (a) A small peak of DNA methylation activity is detected in early G1 phase. (b) The extinction of DNA methylation activity lags behind the termination of DNA synthesis. Nuclear runon experiments demonstrate that the gene is transcribed in growth-arrested cells, and expression of the gene is post-transcriptionally regulated. We suggest that this mode of regulation of the DNA methyltransferase gene might play an important role in determining and maintaining DNA methylation patterns.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	SZYF, M (corresponding author), MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA.							ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; HOLTHUIS J, 1990, SCIENCE, V247, P1454, DOI 10.1126/science.2321007; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; LATHAM KE, 1989, MOL CELL BIOL, V9, P3203, DOI 10.1128/MCB.9.8.3203; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; RAZIN A, 1985, BIOCH BIOL DNA METHY, P239; SCHMIDT M, 1990, P NATL ACAD SCI USA, V87, P3685, DOI 10.1073/pnas.87.10.3685; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1984, P NATL ACAD SCI-BIOL, V81, P3278, DOI 10.1073/pnas.81.11.3278; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; SZYF M, 1990, P NATL ACAD SCI USA, V86, P6853; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WALKER W, 1989, CELL GROWTH DIVISION, P139; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; YISRAELI J, 1985, DNA METHYLATION BIOC, P353	37	139	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10027	10030						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037559				2022-12-25	WOS:A1991FP08600003
J	ARDAIL, D; LERME, F; LOUISOT, P				ARDAIL, D; LERME, F; LOUISOT, P			INVOLVEMENT OF CONTACT SITES IN PHOSPHATIDYLSERINE IMPORT INTO LIVER-MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSLOCATION; MEMBRANES; CELLS	The synthesis, translocation, and decarboxylation of phosphatidylserine can occur in a cell-free system (Voelker, D. R. (1989) J. Biol. Chem. 264, 8019-8025). We made use of the spatial separation of the site of biosynthesis and the site of decarboxylation of phosphatidylserine to demonstrate that mitochondrial contact sites are intimately involved in the translocation of phosphatidylserine prior to decarboxylation. In that sense, the inhibition of phosphatidylserine decarboxylase leads to an accumulation of this phospholipid in the contact site-enriched fractions without mixing the inner membrane phospholipid pool. On the other hand, newly synthesized phosphatidylethanolamine can be exported very rapidly to the mitochondrial surface in the same way, i.e. via contact sites. These data provide further evidence for the existence of a structural and functional microcompartmentation at the inner mitochondrial membrane surface.	UNIV LYON 1,DEPT BIOCHEM,F-69365 LYONS 2,FRANCE; CNRS,U189,INSERM,F-69921 OULLINS,FRANCE	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)								ARDAIL D, 1990, J BIOL CHEM, V265, P18797; ARDAIL D, 1989, BIOCHEM BIOPH RES CO, V164, P1009, DOI 10.1016/0006-291X(89)91770-1; BARANSKA J, 1984, BIOCHIM BIOPHYS ACTA, V773, P23, DOI 10.1016/0005-2736(84)90546-7; BLOK MC, 1971, BIOCHIM BIOPHYS ACTA, V233, P281; DAWIDOWICZ EA, 1987, ANNU REV BIOCHEM, V56, P43, DOI 10.1146/annurev.bi.56.070187.000355; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; FOLCH J, 1957, J BIOL CHEM, V226, P497; KNOLL G, 1983, BIOCHIM BIOPHYS ACTA, V733, P102, DOI 10.1016/0005-2736(83)90095-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; SIMBENI R, 1990, J BIOL CHEM, V265, P281; TEWARI JP, 1972, CYTOBIOS, V5, P261; VANVENETIE R, 1982, BIOCHIM BIOPHYS ACTA, V692, P379; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; WRIGGLES.JM, 1970, BIOCHIM BIOPHYS ACTA, V205, P125, DOI 10.1016/0005-2728(70)90243-4	16	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					7978	7981						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022626				2022-12-25	WOS:A1991FK44100005
J	CALIGIURI, MG; BAUERLE, R				CALIGIURI, MG; BAUERLE, R			IDENTIFICATION OF AMINO-ACID-RESIDUES INVOLVED IN FEEDBACK-REGULATION OF THE ANTHRANILATE SYNTHASE COMPLEX FROM SALMONELLA-TYPHIMURIUM - EVIDENCE FOR AN AMINO-TERMINAL REGULATORY SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-PHOSPHORIBOSYLPYROPHOSPHATE PHOSPHORIBOSYLTRANSFERASE AGGREGATE; SYNTHETASE; BINDING; MUTAGENESIS; EXPRESSION; EVOLUTION; CLONING; OPERON; FORMS	The anthranilate synthase-phosphoribosyl transferase complex, a heterotetrameric enzyme made up of the TrpE and TrpD polypeptides, catalyzes three reactions comprising the first two steps of tryptophan biosynthesis in Salmonella typhimurium. All three activities of the complex are subject to feedback inhibition by tryptophan, which results from allosteric effects associated with the binding of one molecule of inhibitor to each of the TrpE subunits of the complex. Random in vitro chemical mutagenesis of the trpE gene was used to generate a collection of mutant forms of the complex which displayed varying degrees of resistance to feedback inhibition. Single amino acid substitutions, identified by DNA sequencing, were found at 14 different residues within the TrpE polypeptide. The residues were distributed throughout TrpE, but those that appeared to be most critical for regulation were found in two clusters, one at the extreme amino-terminal end, including residues Glu-39, Ser-40, and Ala-41, and the other in the middle of the polypeptide, including residues Asn-288, Pro-289, Met-293, Phe-294, and Gly-305. Kinetic and binding studies of the purified mutant complexes demonstrated that 9 of the 14 had a marked decrease in affinity for tryptophan with little or no change in substrate affinity or catalytic capacity. The remaining five enzymes exhibited more subtle changes, having small decreases in inhibitor affinity coupled with small increases in substrate affinity. Mutant enzymes that were not totally feedback-resistant had a decreased kinetic response to tryptophan binding. All enzymes exhibited alterations in tryptophan-induced conformational changes as monitored by dye-ligand chromatography.	UNIV VIRGINIA, DEPT BIOL, GILMER HALL, CHARLOTTESVILLE, VA 22901 USA; UNIV VIRGINIA, INST MOLEC BIOL, CHARLOTTESVILLE, VA 22901 USA	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035889] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35889, GM07082] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE R, 1987, METHOD ENZYMOL, V142, P366; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budowsky E I, 1976, Prog Nucleic Acid Res Mol Biol, V16, P125; CRAWFORD IP, 1989, ANNU REV MICROBIOL, V43, P567, DOI 10.1146/annurev.mi.43.100189.003031; DAVIS RW, 1980, ADV BACTERIAL GENET, P94; FREIFELDER D, 1982, PHYSICAL BIOCH, P655; Gibson F., 1970, METHODS ENZYMOL    A, V17, P362; GRIESHABER M, 1974, BIOCHEMISTRY-US, V13, P373, DOI 10.1021/bi00699a024; GRIESHABER M, 1972, NATURE-NEW BIOL, V236, P232, DOI 10.1038/newbio236232a0; HENDERSON EJ, 1970, J BIOL CHEM, V245, P1424; HENDERSON EJ, 1970, J BIOL CHEM, V245, P1416; HENDERSON EJ, 1971, J BIOL CHEM, V246, P6891; Hill AV, 1910, J PHYSIOL-LONDON, V40, P190; HONG SC, 1987, THESIS U VIRGINIA CH; ITO J, 1969, NATURE, V223, P57, DOI 10.1038/223057a0; MATSUI K, 1987, J BACTERIOL, V169, P5330, DOI 10.1128/jb.169.11.5330-5332.1987; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NAGANO H, 1970, J BIOL CHEM, V245, P3097; PABST MJ, 1973, J BIOL CHEM, V248, P901; PATTERSON T, 1984, PLASMID, V12, P149, DOI 10.1016/0147-619X(84)90039-8; Pittard AJ, 1987, ESCHERICHIA COLI SAL, P368; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segel I.H., 1975, ENZYME KINETICS, P108; SOBERON X, 1980, GENE, V9, P287, DOI 10.1016/0378-1119(90)90328-O; SOMERVILLE RL, 1965, J MOL BIOL, V11, P747, DOI 10.1016/S0022-2836(65)80032-8; SOPHIANOPOULOS AJ, 1985, METHOD ENZYMOL, V117, P354; SUBRAMANIAN S, 1984, CRC CR REV BIOCH MOL, V16, P169, DOI 10.3109/10409238409102302; WARBURTON N, 1983, NUCLEIC ACIDS RES, V11, P5837, DOI 10.1093/nar/11.17.5837; YANOFSKY C, 1982, J MOL BIOL, V155, P235, DOI 10.1016/0022-2836(82)90003-1; ZALKIN H, 1973, ADV ENZYMOL RAMB, V38, P1; ZALKIN H, 1968, BIOCHEMISTRY-US, V7, P3566, DOI 10.1021/bi00850a034; ZALKIN H, 1972, J BIOL CHEM, V247, P5996	34	82	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8328	8335						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022650				2022-12-25	WOS:A1991FK44100058
J	HAYLETT, T; THILO, L				HAYLETT, T; THILO, L			ENDOSOME-LYSOSOME FUSION AT LOW-TEMPERATURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; ISOLATED RAT HEPATOCYTES; EPIDERMAL GROWTH-FACTOR; LOW-DENSITY LIPOPROTEIN; PLASMA-MEMBRANE; ASIALOGLYCOPROTEIN RECEPTOR; SECONDARY LYSOSOMES; PINOCYTIC VESICLES; CELLS; DEGRADATION	Based on an initial study (Dunn, W. A., Hubbard, A. L., and Aronson, Jr., N. N. (1980) J. Biol. Chem. 255, 5971-5978), low temperature is often used to selectively inhibit fusion between endosomes and lysosomes. Here we have tried to characterize the nature of this inhibition. In addition to endocytic contents markers, we have used a covalent membrane marker to measure the interaction between endosomes and lysosomes over extended periods of time at low temperature. Mouse macrophage cells (P388D1) and human skin fibroblasts were enzymatically labeled with radioactive galactose to provide a covalent marker for plasma-membrane glycoconjugates. Subsequent endocytic membrane traffic for 24 h at 16-degrees-C resulted in a significant transfer of membrane marker, as well as of endocytic contents marker, to high density lysosomes, as observed by subcellular fractionation. The kinetics of this transfer have been analyzed for macrophages using the membrane marker, horseradish peroxidase as fluid-phase, and iodinated acetyl low density lipoprotein as receptor-mediated endocytic contents marker. Transfer to lysosomes occurred only about 6 h after application of the respective marker at 16-degrees-C. When transfer to lysosomes was initiated by 15 min preincubation at 37-degrees-C, subsequent cooling to 16-degrees-C did not inhibit ongoing transfer which continued with the same kinetics as when observed after the lag phase. These results show that low temperature delays an unidentified pre-fusion step, but does not inhibit endosome-lysosome fusion as such.	UNIV CAPE TOWN, SCH MED, CAPE TOWN 7925, SOUTH AFRICA	University of Cape Town								BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BURGERT HG, 1983, EXP CELL RES, V144, P127, DOI 10.1016/0014-4827(83)90447-0; BURNSIDE J, 1982, BIOCHEM J, V204, P525, DOI 10.1042/bj2040525; DECHASTELLIER C, 1987, EUR J CELL BIOL, V44, P112; DRAYE JP, 1988, J CELL BIOL, V107, P2109, DOI 10.1083/jcb.107.6.2109; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; DUNN WA, 1980, J BIOL CHEM, V255, P5971; ENGLAND IG, 1986, BIOCHEM PHARMACOL, V35, P201, DOI 10.1016/0006-2952(86)90514-9; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; GABEL CA, 1987, J CELL BIOL, V105, P1561, DOI 10.1083/jcb.105.4.1561; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Hall C W, 1978, Methods Enzymol, V50, P439; HARE JF, 1988, J BIOL CHEM, V263, P8759; HAYLETT T, 1986, J CELL BIOL, V103, P1249, DOI 10.1083/jcb.103.4.1249; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; KAPLAN J, 1979, J BIOL CHEM, V254, P7329; KOREN HS, 1975, J IMMUNOL, V114, P894; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MCCLOSKEY M, 1984, INT REV CYTOL, V87, P19, DOI 10.1016/S0074-7696(08)62439-0; MELLMAN IS, 1980, J CELL BIOL, V86, P712, DOI 10.1083/jcb.86.3.712; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; OKA JA, 1983, J BIOL CHEM, V258, P253; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; SCHWARTZ AL, 1986, J BIOL CHEM, V261, P5225; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; STEINMAN RM, 1974, J CELL BIOL, V63, P949, DOI 10.1083/jcb.63.3.949; SULLIVAN PC, 1987, J CELL PHYSIOL, V131, P58, DOI 10.1002/jcp.1041310110; THILO L, 1983, METHOD ENZYMOL, V98, P415; TOMODA H, 1989, J BIOL CHEM, V264, P15445; TYCKO B, 1983, J CELL BIOL, V97, P1762, DOI 10.1083/jcb.97.6.1762; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1981, J BIOL CHEM, V256, P2615; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; YOUNG MR, 1986, EXP CELL RES, V164, P199, DOI 10.1016/0014-4827(86)90467-2; ZIOMEK CA, 1980, J CELL BIOL, V86, P849, DOI 10.1083/jcb.86.3.849	38	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8322	8327						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022649				2022-12-25	WOS:A1991FK44100057
J	MUELLER, GM; MCKOWN, RL; COROTTO, LV; HAGUE, C; WARREN, GJ				MUELLER, GM; MCKOWN, RL; COROTTO, LV; HAGUE, C; WARREN, GJ			INHIBITION OF RECRYSTALLIZATION IN ICE BY CHIMERIC PROTEINS CONTAINING ANTIFREEZE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FUSION VECTORS; WINTER FLOUNDER; ESCHERICHIA-COLI; POLYPEPTIDES; DNA; PRECURSOR; SEQUENCE; GLYCOPROTEINS; BIOSYNTHESIS; ADSORPTION	Using synthetic DNA, we assembled a gene encoding a protein identical in sequence to one of the antifreeze proteins produced by the fish Pseudopleuronectes americanus (winter flounder). To address the relationship between structure and function, we also assembled genes encoding proteins varying in sequence and length. The synthetic genes were cloned into a bacterial expression vector to generate translational fusions to the 3' end of a truncated staphylococcal protein A gene; the chimeric proteins encoded by these fusions, varying only in their antifreeze domains, were isolated from Escherichia coli. The antifreeze domains conferred the ability to inhibit ice recrystallization, which is characteristic of naturally occurring antifreeze proteins, on the chimeric proteins. The chimeric proteins varied in their effectiveness of inhibiting ice recrystallization according to the number of 11-amino acid repeats present in the antifreeze moiety. A protein with only two repeats lacked activity, while the inhibitory activity increased progressively for proteins containing three, four, and five repeats. Some activity was lost upon removal of either the salt bridge or the carboxyl-terminal arginine, but surprisingly, not when both features were absent together.	DNA PLANT TECHNOL CORP,6701 SAN PABLO AVE,OAKLAND,CA 94608									ABRAHMSEN L, 1988, THESIS ROYAL I TECHN; BROWN RA, 1985, BIOPOLYMERS, V24, P1265, DOI 10.1002/bip.360240713; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11307; DAVIES PL, 1982, P NATL ACAD SCI-BIOL, V79, P335, DOI 10.1073/pnas.79.2.335; DEVRIES AL, 1983, ANNU REV PHYSIOL, V45, P245, DOI 10.1146/annurev.ph.45.030183.001333; DEVRIES AL, 1977, BIOCHIM BIOPHYS ACTA, V495, P385; DUMAN J, 1983, ANNU REV PHYSIOL, V45, P261, DOI 10.1146/annurev.ph.45.030183.001401; FOURNEY RM, 1984, CAN J ZOOL, V62, P28, DOI 10.1139/z84-006; GOURLIE B, 1984, J BIOL CHEM, V259, P4960; GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; GREEN RL, 1988, MOL GEN GENET, V215, P165, DOI 10.1007/BF00331320; HEW CL, 1986, EUR J BIOCHEM, V160, P267, DOI 10.1111/j.1432-1033.1986.tb09966.x; HEW CL, 1984, J CHROMATOGR, V296, P213, DOI 10.1016/S0021-9673(01)96414-3; HEW CL, 1987, INTEGRATION CONTROL, P299; KERR WL, 1985, CRYO-LETT, V6, P371; KNIGHT CA, 1986, CRYOBIOLOGY, V23, P256, DOI 10.1016/0011-2240(86)90051-9; KNIGHT CA, 1988, CRYOBIOLOGY, V25, P55, DOI 10.1016/0011-2240(88)90020-X; KNIGHT CA, 1984, NATURE, V308, P295, DOI 10.1038/308295a0; LIN Y, 1981, P NATL ACAD SCI-BIOL, V78, P2825, DOI 10.1073/pnas.78.5.2825; MCKOWN RL, 1991, IN PRESS CRYOBIOLOGY; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; OSUGA DT, 1978, J BIOL CHEM, V253, P6669; PETERS ID, 1989, PROTEIN ENG, V3, P145, DOI 10.1093/protein/3.2.145; PICKETT M, 1984, EUR J BIOCHEM, V143, P35, DOI 10.1111/j.1432-1033.1984.tb08335.x; RANCOURT DE, 1990, BIO-TECHNOL, V8, P453, DOI 10.1038/nbt0590-453; RAYMOND JA, 1989, P NATL ACAD SCI USA, V86, P881, DOI 10.1073/pnas.86.3.881; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UHLEN M, 1984, J BIOL CHEM, V259, P1695; UHLEN M, 1983, GENE, V23, P369, DOI 10.1016/0378-1119(83)90025-2; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILLIS DK, 1981, MOL GEN GENET, V183, P497, DOI 10.1007/BF00268771; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	36	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7339	7344						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019569				2022-12-25	WOS:A1991FJ34200007
J	TSUJI, Y; MILLER, LL; MILLER, SC; TORTI, SV; TORTI, FM				TSUJI, Y; MILLER, LL; MILLER, SC; TORTI, SV; TORTI, FM			TUMOR-NECROSIS-FACTOR-ALPHA AND INTERLEUKIN-1-ALPHA REGULATE TRANSFERRIN RECEPTOR IN HUMAN-DIPLOID FIBROBLASTS - RELATIONSHIP TO THE INDUCTION OF FERRITIN HEAVY-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; CELL-SURFACE GLYCOPROTEIN; SUBUNIT MESSENGER-RNAS; UNTRANSLATED REGION; CHELATABLE IRON; GROWTH-FACTORS; CDNA SEQUENCE; DNA-SYNTHESIS; PROLIFERATION; PROTEIN	We have studied transferrin receptor expression in MRC5 human fibroblasts in response to tumor necrosis factor-alpha (TNF, cachectin) or interleukin 1-alpha (IL-1). Treatment of exponentially growing MRC5 cells with these cytokines led to a 3-4-fold increase in transferrin receptor mRNA and a coordinate increase in transferrin receptor protein by 24 h. Under these conditions, stimulation of [H-3]thymidine incorporation was minimal, suggesting that the induction of transferrin receptor by TNF and IL-1 is mediated by a growth-independent regulatory mechanism. A study of the time course of this response showed that cytokine-mediated increases in transferrin receptor mRNA and protein proceeded after a lag of 12-24 h. A simultaneous analysis of the effects of TNF and IL-1 on ferritin in MRC5 cells was also performed. Ferritin L mRNA levels were unchanged. However, induction of ferritin H mRNA was seen within 4 h, preceding the induction of the transferrin receptor. The synthesis of ferritin H (but not ferritin L) protein peaked at 8 h after TNF or IL-1 treatment, followed by a rapid decrease in both ferritin H and L protein synthesis. As ferritin H synthesis declined, levels of transferrin receptor protein increased, reaching a maximum by 24 h. These results suggest that the cytokine-dependent induction of ferritin H and subsequent increase in the transferrin receptor are related and possibly interdependent events. This study demonstrates that the complex role of TNF and IL-1 in iron homeostasis includes modulation of the transferrin receptor.	VET ADM MED CTR,3801 MIRANDA AVE,154-N,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042412, R01DK042412] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42412] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROSIO P, 1978, J BIOL CHEM, V253, P4451; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER BA, 1985, J IMMUNOL, V135, P3969; BOYD D, 1985, J BIOL CHEM, V260, P1755; CAIRO G, 1985, BIOCHEM BIOPH RES CO, V133, P314, DOI 10.1016/0006-291X(85)91877-7; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIDSBURY JR, 1986, J BIOL CHEM, V261, P949; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HORI T, 1988, CELL STRUCT FUNCT, V13, P425, DOI 10.1247/csf.13.425; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1979, J SUPRAMOL STR CELL, V11, P579, DOI 10.1002/jss.400110415; LE JM, 1987, LAB INVEST, V56, P234; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVI S, 1988, J BIOL CHEM, V263, P18086; LIN JX, 1987, J BIOL CHEM, V262, P11908; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; MAY WS, 1985, J MEMBRANE BIOL, V88, P205, DOI 10.1007/BF01871086; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MUSGROVE E, 1984, J CELL PHYSIOL, V118, P6, DOI 10.1002/jcp.1041180103; NECKERS LM, 1983, P NATL ACAD SCI-BIOL, V80, P3494, DOI 10.1073/pnas.80.11.3494; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PALOMBELLA VJ, 1987, J BIOL CHEM, V262, P1950; RAO KK, 1985, MOL CELL BIOL, V5, P595, DOI 10.1128/MCB.5.4.595; ROESER HP, 1980, IRON BIOCH MED, V2; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROUAULT T, 1985, J BIOL CHEM, V260, P4862; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SUTHERLAND R, 1981, P NATL ACAD SCI-BIOL, V78, P4515, DOI 10.1073/pnas.78.7.4515; TAETLE R, 1988, BLOOD, V71, P1590; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TSUJI Y, 1984, MECH AGEING DEV, V27, P219, DOI 10.1016/0047-6374(84)90047-2; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; WHITE K, 1988, J BIOL CHEM, V263, P8938	46	105	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7257	7261						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016326				2022-12-25	WOS:A1991FG72700095
J	VANHEUGTEN, HAA; KASPERAITIS, MAM; THOMAS, AAM; VOORMA, HO				VANHEUGTEN, HAA; KASPERAITIS, MAM; THOMAS, AAM; VOORMA, HO			EVIDENCE THAT EUKARYOTIC INITIATION-FACTOR (EIF) 2 IS A CAP-BINDING PROTEIN THAT STIMULATES CAP RECOGNITION BY EIF-4B AND EIF-4F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; REOVIRUS MESSENGER-RNA; FACTOR-II; CROSS-LINKING; TRANSLATIONAL CONTROL; SECONDARY STRUCTURE; RIBONUCLEIC-ACIDS; RIBOSOME BINDING; MAMMALIAN-CELLS; 5'-TERMINAL CAP	We studied the mRNA-binding properties of eukaryotic initiation factor (eIF) 2. This Met-tRNA-binding factor interacts with the cap structure of reoviral mRNA in an ATP-independent manner. Both the beta- and gamma-subunit of eIF-2 are involved in the UV-induced cross-linking of eIF-2 to the cap. The interaction of eIF-2 with a messenger is sensitive to the cap analogue 7-methyl-guanosine 5'-triphosphate as measured by cross-linking and by mRNA retention on nitrocellulose filters. The cap-binding property of eIF-2 does not conflict with the current mRNA-binding model of initiation factors eIF-4A, -4B, and -4F: cross-linking of eIF-4E and of eIF-4B is stimulated by eIF-2. The eIF-2-mediated increase of eIF-4E interaction results in a decrease of the cross-linking of the beta- and gamma-subunits of eIF-2. The presence of GTP in the cross-linking assay interferes with the interaction of eIF-2 with the cap structure but does not inhibit the eIF-2 stimulated eIF-4E and -4B cross-linking. These observations indicate a role for eIF-2 in the mRNA recognition.			VANHEUGTEN, HAA (corresponding author), STATE UNIV UTRECHT,DEPT MOLEC CELL BIOL,PADUALAAN 8,3584 CH UTRECHT,NETHERLANDS.							ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; AMESZ H, 1979, EUR J BIOCHEM, V98, P513, DOI 10.1111/j.1432-1033.1979.tb13212.x; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BARRIEUX A, 1977, J BIOL CHEM, V252, P392; BOMMER UA, 1989, FEBS LETT, V244, P323, DOI 10.1016/0014-5793(89)80555-1; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; DASSO MC, 1990, EUR J BIOCHEM, V187, P361, DOI 10.1111/j.1432-1033.1990.tb15313.x; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DISEGNI G, 1979, BIOCHEMISTRY-US, V18, P2847, DOI 10.1021/bi00580a027; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; EDERY I, 1983, J BIOL CHEM, V258, P1398; FURUICHI Y, 1976, P NATL ACAD SCI USA, V73, P3448, DOI 10.1073/pnas.73.10.3448; GONSKY R, 1990, J BIOL CHEM, V265, P9083; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HERMAN RC, 1989, TRENDS BIOCHEM SCI, V14, P219, DOI 10.1016/0968-0004(89)90030-3; ITAMAR D, 1984, EUR J BIOCHEM, V145, P373, DOI 10.1111/j.1432-1033.1984.tb08564.x; KAEMPFER R, 1979, EUR J BIOCHEM, V94, P591, DOI 10.1111/j.1432-1033.1979.tb12929.x; KAEMPFER R, 1983, EUR J BIOCHEM, V131, P545, DOI 10.1111/j.1432-1033.1983.tb07296.x; KAEMPFER R, 1981, P NATL ACAD SCI-BIOL, V78, P1542, DOI 10.1073/pnas.78.3.1542; KAEMPFER R, 1978, P NATL ACAD SCI USA, V75, P650, DOI 10.1073/pnas.75.2.650; KAEMPFER R, 1978, P NATL ACAD SCI USA, V75, P209, DOI 10.1073/pnas.75.1.209; KONINGS DAM, 1987, J THEOR BIOL, V127, P63, DOI 10.1016/S0022-5193(87)80161-3; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; LEE KAW, 1983, J BIOL CHEM, V258, P707; LEE KAW, 1982, P NATL ACAD SCI-BIOL, V79, P3447, DOI 10.1073/pnas.79.11.3447; LLOYD MA, 1980, J BIOL CHEM, V255, P1189; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; NYGARD O, 1980, FEBS LETT, V113, P125, DOI 10.1016/0014-5793(80)80510-2; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PANNIERS R, 1988, J BIOL CHEM, V263, P5519; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; PELLETIER J, 1985, MOL CELL BIOL, V5, P3222, DOI 10.1128/MCB.5.11.3222; PEREZBERCOFF R, 1982, J VIROL, V41, P30, DOI 10.1128/JVI.41.1.30-41.1982; RAY BK, 1985, J BIOL CHEM, V260, P7651; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSEN H, 1979, BIOCHEM BIOPH RES CO, V91, P449, DOI 10.1016/0006-291X(79)91542-0; ROSEN H, 1982, J BIOL CHEM, V257, P946; ROSEN H, 1981, BIOCHEMISTRY-US, V20, P3011, DOI 10.1021/bi00514a004; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SAFER B, 1989, EUR J BIOCHEM, V186, P1, DOI 10.1111/j.1432-1033.1989.tb15169.x; SEAL SN, 1989, J BIOL CHEM, V264, P7363; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; SONENBERG N, 1989, BIOESSAYS, V11, P128, DOI 10.1002/bies.950110504; SONENBERG N, 1977, P NATL ACAD SCI USA, V74, P4288, DOI 10.1073/pnas.74.10.4288; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1979, NUCLEIC ACIDS RES, V7, P15, DOI 10.1093/nar/7.1.15; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SONENBERG N, 1981, CELL, V27, P563, DOI 10.1016/0092-8674(81)90398-6; SONENBERG N, 1981, NUCLEIC ACIDS RES, V9, P1643, DOI 10.1093/nar/9.7.1643; Voorma H O, 1979, Methods Enzymol, V60, P124, DOI 10.1016/S0076-6879(79)60012-5; WALTON GM, 1975, BIOCHIM BIOPHYS ACTA, V390, P231, DOI 10.1016/0005-2787(75)90344-5; WESTERMANN P, 1981, NUCLEIC ACIDS RES, V9, P2387, DOI 10.1093/nar/9.10.2387; WESTERMANN P, 1986, FEBS LETT, V205, P171, DOI 10.1016/0014-5793(86)80891-2; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515	65	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7279	7284						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016328				2022-12-25	WOS:A1991FG72700098
J	CRAWFORD, AW; BECKERLE, MC				CRAWFORD, AW; BECKERLE, MC			PURIFICATION AND CHARACTERIZATION OF ZYXIN, AN 82,000-DALTON COMPONENT OF ADHERENS JUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; TYROSINE KINASE SUBSTRATE; SMOOTH-MUSCLE; ALPHA-ACTININ; CELL-ADHESION; PROTEINS; FIBROBLASTS; VINCULIN; LOCALIZATION; SITES	We describe here the purification and characterization of a recently identified adherens junction protein that has an apparent molecular mass of 82 kDa on sodium dodecyl sulfate-polyacrylamide gels (Beckerle, M. C. (1986) J. Cell Biol. 103, 1679-1687). The 82-kDa protein was isolated from avian smooth muscle by a low ionic strength alkaline pH extraction followed by ammonium sulfate fractionation. Sequential chromatographic separation using DEAE-cellulose, phenyl-Sepharose CL-4B, and hydroxylapatite resins results in a purified 82-kDa protein. The 82-kDa protein has a Stokes radius of 5.6 nm and a relative sedimentation coefficient of 3.0 S. The calculated native molecular mass of the protein based on its hydrodynamic properties is 69 kDa, and the derived frictional ratio (f/f0) is 2.1. The protein does not focus discretely by isoelectric-focusing-sodium dodecyl sulfate-polyacrylamide gel electrophoresis; there are numerous isoelectric point variants in the range of 6.4-7.2, with the average isoelectric point being 6.9. The 82-kDa protein is phosphorylated in vivo and appears to be a cytoplasmic component of adherens junctions. The properties of the 82-kDa protein distinguish it from other known adherens junction proteins of this molecular mass. In fibroblasts, the 82-kDa protein is found in adhesion plaques as well as along actin-containing stress fibers near where they terminate at sites of cell-substratum adhesion. It is also found in the cell-cell adherens junctions of pigmented retinal epithelial cells and the dense plaques of smooth muscle cells. Since the 82-kDa protein is found at both cell-substratum and cell-cell adherens junctions, we propose to call it zyxin, meaning a joining, to indicate that it is found at regions where extracellular ligands are structurally and functionally joined to the cytoskeleton.			CRAWFORD, AW (corresponding author), UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112, USA.							BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BECKERLE MC, 1986, J CELL BIOCHEM, V30, P259, DOI 10.1002/jcb.240300307; BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN WT, 1985, J HISTOCHEM CYTOCHEM, V33, P576, DOI 10.1177/33.6.3889142; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CRAWFORD AW, 1990, CYTOPLASMIC ORG SYST, P405; CURTIS ASG, 1964, J CELL BIOL, V20, P199, DOI 10.1083/jcb.20.2.199; DAMSKY CH, 1985, J CELL BIOL, V100, P1528, DOI 10.1083/jcb.100.5.1528; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HATHAWAY DR, 1982, J BIOL CHEM, V257, P9072; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IZZARD CS, 1976, J CELL SCI, V21, P129; JAEGER EC, 1955, SOURCE BOOK BIOL NAM; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; PAKKANEN R, 1989, J CELL BIOCHEM, V41, P1, DOI 10.1002/jcb.240410102; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; SENECAL JL, 1987, J CLIN INVEST, V80, P778, DOI 10.1172/JCI113134; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SINGER II, 1979, CELL, V16, P675, DOI 10.1016/0092-8674(79)90040-0; SOBER HA, 1968, CRC HDB BIOCH, pC3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X	42	135	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5847	5853						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005121				2022-12-25	WOS:A1991FD37000077
J	SHI, E; KAN, M; XU, JM; MCKEEHAN, WL				SHI, E; KAN, M; XU, JM; MCKEEHAN, WL			16-KILODALTON HEPARIN BINDING (FIBROBLAST) GROWTH-FACTOR TYPE ONE APPEARS IN A STABLE 40-KILODALTON COMPLEX AFTER RECEPTOR-DEPENDENT INTERNALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTORS; FACTOR-I; ENDOTHELIAL-CELLS; STIMULATION; PROTEINS; THROMBIN	Incubation of 16-kDa I-125-labeled heparin binding (acidic fibroblast) growth factor type one (HBGF-1) with human hepatoma cells and normal rat hepatocytes resulted in the appearance of a stable I-125-labeled complex with an apparent molecular mass of 40 kDa. The complex could be isolated with specific antibodies against HBGF-1. In contrast to membrane receptor-bound I-125-HBGF-1, the complex was resistant to dissociation by detergents, acid, heat, and reducing or denaturing agents. Formation of a stable complex did not require treatment with cross-linking agents. Appearance of the 40-kDa complex was dependent on time, temperature, and enriched culture medium. Conditions that enhanced or reduced display of specific HBGF-1 membrane receptor sites enhanced or reduced the appearance of the 40-kDa complex. Dansylcadaverine, chloroquine, and staurosporine blocked the appearance of the 40-kDa complex concurrent with the blockage of internalization of the receptor-bound HBGF-1. Two-dimensional gel electrophoretic analysis, metabolic labeling with L-[S-35]cysteine, and recovery of 16-kDa HBGF-1 from the 40-kDa complex after base treatment suggest involvement of a 24-kDa cellular protein in the complex formation. These results suggest a potentially novel receptor-dependent pathway for metabolism of HBGF-1.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946						NATIONAL CANCER INSTITUTE [P01CA037589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310, R01DK040739] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37589] Funding Source: Medline; NIDDK NIH HHS [DK 35310, DK 40739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER JB, 1979, NATURE, V278, P743, DOI 10.1038/278743a0; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COMENS PG, 1982, J BIOL CHEM, V257, P42; FRIESEL R, 1988, BIOCHEM BIOPH RES CO, V151, P957, DOI 10.1016/S0006-291X(88)80459-5; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HOSHI H, 1988, FASEB J, V2, P2797, DOI 10.1096/fasebj.2.12.2457532; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAN M, 1988, J BIOL CHEM, V263, P11306; MANSSON PE, 1989, CANCER RES, V49, P2485; MCKEEHAN WL, 1987, ANAL BIOCHEM, V164, P563, DOI 10.1016/0003-2697(87)90534-3; MIYAZAKI M, 1989, EXP CELL RES, V182, P415, DOI 10.1016/0014-4827(89)90246-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SAVIOLAKIS GA, 1981, J BIOL CHEM, V256, P4924; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2	18	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5774	5779						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005115				2022-12-25	WOS:A1991FD37000065
J	ODONNELL, ME				ODONNELL, ME			ENDOTHELIAL-CELL SODIUM-POTASSIUM-CHLORIDE COTRANSPORT - EVIDENCE OF REGULATION BY CA2+ AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; FERRET RED-CELLS; PHORBOL ESTER; ANGIOTENSIN-II; INOSITOL TRISPHOSPHATE; CYTOSOLIC CALCIUM; HUMAN-FIBROBLASTS; VASOPRESSIN; STIMULATION; BRADYKININ	Previous studies have shown that vascular endothelial cells exhibit a highly active Na-K-Cl cotransport system that is regulated by a variety of vasoactive hormones and neurotransmitters, suggesting that the cotransporter may play an important role in endothelial cell function. In this study, the regulation of endothelial cell Na-K-Cl cotransport was further investigated by probing the stimulus-transfer pathway by which vasoactive agents stimulate the cotransporter. Specifically, three peptides previously shown to stimulate cotransport activity (angiotensin II, vasopressin, and bradykinin) were evaluated. Na-K-Cl cotransport was assessed in cultured bovine aortic endothelial cells as bumetanide-sensitive K+ influx. Stimulation of Na-K-Cl cotransport by angiotensin II, vasopressin, or bradykinin was found to be reduced either by removal of extracellular Ca2+ or by treatment of the cells with 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid. In addition, the calmodulin antagonist W-7 was found to prevent stimulation of endothelial cell Na-K-Cl cotransport by the three peptides. These findings suggest that regulation of endothelial cell cotransport by these vasoactive peptides may be both Ca2+- and calmodulin-dependent. Angiotensin II, vasopressin, and bradykinin were also found to elevate phosphatidylinositol hydrolysis in the cultured endothelial cells. Thus, the possibility that regulation of endothelial Na-K-Cl cotransport by these vasoactive peptides also involves diacylglycerol activation of protein kinase C was investigated. A 10-min exposure of the endothelial cells to low doses of phorbol 12-myristate 13-acetate was found to reduce Na-K-Cl cotransport whether in the presence or absence of angiotensin II, vasopressin, or bradykinin. However, down-regulation of protein kinase C by a 40-h exposure to higher doses of the phorbol ester was found to elevate Na-K-Cl cotransport activity under both control and agonist-stimulated conditions, indicating that activation of protein kinase C results in inhibition of endothelial cell Na-K-Cl cotransport. Thus, protein kinase C activation may serve as negative feedback in the stimulus-transfer pathway by which these agonists regulate endothelial cell Na-K-Cl cotransport.			ODONNELL, ME (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT HUMAN PHYSIOL,DAVIS,CA 95616, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031959, R23HL031959] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31959] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIYAR N, 1986, LIFE SCI, V39, P37, DOI 10.1016/0024-3205(86)90435-2; AIYAR N, 1987, MOL PHARMACOL, V31, P180; ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P234; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BERGMEYER HU, 1974, METHODS ENZYMATIC AN, V1; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BLUMBERG PM, 1984, BIOCHEM PHARMACOL, V33, P933, DOI 10.1016/0006-2952(84)90448-9; BROCK TA, 1985, J BIOL CHEM, V260, P4158; BROCK TA, 1986, AM J PHYSIOL, V250, pC888, DOI 10.1152/ajpcell.1986.250.6.C888; CHIOU CY, 1975, BRIT J PHARMACOL, V53, P279, DOI 10.1111/j.1476-5381.1975.tb07359.x; CHIPPERFIELD AR, 1986, CLIN SCI, V71, P465, DOI 10.1042/cs0710465; COLDENSTANFIELD M, 1987, CIRC RES, V61, P632, DOI 10.1161/01.RES.61.5.632; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; FLATMAN PW, 1988, J PHYSIOL-LONDON, V397, P471, DOI 10.1113/jphysiol.1988.sp017013; FLATMAN PW, 1987, J PHYSIOL-LONDON, V386, P407, DOI 10.1113/jphysiol.1987.sp016541; GORDON JL, 1983, BRIT J PHARMACOL, V79, P531, DOI 10.1111/j.1476-5381.1983.tb11028.x; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; JOHNS A, 1987, TISSUE CELL, V19, P733, DOI 10.1016/0040-8166(87)90015-2; LAMBERT TL, 1986, J BIOL CHEM, V261, P5288; MORGANBOYD R, 1987, AM J PHYSIOL, V253, pC588, DOI 10.1152/ajpcell.1987.253.4.C588; NABIKA T, 1985, J BIOL CHEM, V260, P4661; O'DONNELL M E, 1989, Journal of Cell Biology, V109, p314A; ODONNELL ME, 1989, J BIOL CHEM, V264, P20326; ODONNELL ME, 1989, AM J PHYSIOL, V257, pC36, DOI 10.1152/ajpcell.1989.257.1.C36; OWEN NE, 1982, P NATL ACAD SCI-BIOL, V79, P3537, DOI 10.1073/pnas.79.11.3537; OWEN NE, 1986, J CELL BIOL, V103, P2053, DOI 10.1083/jcb.103.5.2053; OWEN NE, 1985, J BIOL CHEM, V260, P1445; PALFREY HC, 1982, P NATL ACAD SCI-BIOL, V79, P3780, DOI 10.1073/pnas.79.12.3780; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SAKATA A, 1987, BIOCHEM BIOPH RES CO, V148, P112, DOI 10.1016/0006-291X(87)91083-7; SCHILLING WP, 1988, AM J PHYSIOL, V255, pH219, DOI 10.1152/ajpheart.1988.255.2.H219; SMITH JB, 1984, P NATL ACAD SCI-BIOL, V81, P7812, DOI 10.1073/pnas.81.24.7812; SMITH JB, 1987, J BIOL CHEM, V262, P17455; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WALLNOFER A, 1987, BIOCHEM BIOPH RES CO, V148, P273, DOI 10.1016/0006-291X(87)91106-5	38	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11559	11566						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050666				2022-12-25	WOS:A1991FT76200025
J	CHAUHAN, J; DAKSHINAMURTI, K				CHAUHAN, J; DAKSHINAMURTI, K			TRANSCRIPTIONAL REGULATION OF THE GLUCOKINASE GENE BY BIOTIN IN STARVED RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PANCREATIC BETA-CELL; GLUCOSE SENSOR; LIVER GLUCOKINASE; MESSENGER-RNA; INSULIN; HEPATOCYTES; CDNA	The purpose of this work was to investigate whether biotin, a water-soluble vitamin, regulates the glucokinase gene. Biotin was administered intraperitoneally to starved rats, and the time course of glucokinase induction was followed over a time period of 12 h. The glucokinase mRNA was increased 19.6-fold during the first 1 h after biotin administration, afterwards rapidly decayed, and was hardly detectable by 4 h. The amount of glucokinase activity as determined by conventional enzyme activity assay increased in a time-dependent fashion, reaching 4-fold by 2 h of biotin administration. The transcriptional activity of the gene as measured by a nuclear run-on assay was increased about 6.7-fold within 45 min of biotin administration. These findings indicate that biotin can regulate the glucokinase gene at the transcriptional stage in the starved rat.	UNIV MANITOBA, DEPT BIOCHEM & MOLEC BIOL, WINNIPEG R3E 0W3, MANITOBA, CANADA	University of Manitoba								ANDREONE TL, 1989, J BIOL CHEM, V264, P363; [Anonymous], [No title captured]; BEDOYA FJ, 1986, DIABETES, V35, P61, DOI 10.2337/diabetes.35.1.61; BHULLAR RP, 1985, J CELL PHYSL, V238, P294; BOECKX RL, 1975, BIOCHIM BIOPHYS ACTA, V383, P282, DOI 10.1016/0005-2787(75)90057-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAKSHINA.K, 1970, J BIOL CHEM, V245, P5600; DAKSHINAMURTI K, 1970, CAN J BIOCHEM CELL B, V48, P493, DOI 10.1139/o70-079; DAKSHINAMURTI K, 1968, ARCH BIOCHEM BIOPHYS, V127, P17, DOI 10.1016/0003-9861(68)90195-1; DAKSHINAMURTI K, 1988, ANNU REV NUTR, V8, P211, DOI 10.1146/annurev.nu.08.070188.001235; DAKSHINAMURTI K, 1968, CAN J BIOCHEM CELL B, V46, P75, DOI 10.1139/o68-012; DAKSHINAMURTI K, 1981, J CELL PHYSIOL, V107, P427, DOI 10.1002/jcp.1041070314; DAKSHINAMURTI K, 1969, ENZYMOL BIOL CLIN, V11, P423; HOPPNER W, 1989, J BIOL CHEM, V264, P20643; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; MEGLASSON MD, 1986, DIABETES, V35, P1163, DOI 10.2337/diabetes.35.10.1163; SINGH IN, 1988, MOL CELL BIOCHEM, V79, P47, DOI 10.1007/BF00229397; SPENCE JT, 1984, J BIOL CHEM, V259, P6393; SPENCE JT, 1983, J BIOL CHEM, V258, P9143; SPENCE JT, 1981, J BIOL CHEM, V256, P1598; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1	29	113	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10035	10038						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037560				2022-12-25	WOS:A1991FP08600005
J	KERPPOLA, RE; SHYAMALA, VK; KLEBBA, P; AMES, GFL				KERPPOLA, RE; SHYAMALA, VK; KLEBBA, P; AMES, GFL			THE MEMBRANE-BOUND PROTEINS OF PERIPLASMIC PERMEASES FORM A COMPLEX - IDENTIFICATION OF THE HISTIDINE PERMEASE HISQMP COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; MALTOSE TRANSPORT-SYSTEM; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; BINDING-PROTEIN; CROSS-LINKING; MULTIDRUG RESISTANCE; BACTERIAL TRANSPORT; NUCLEOTIDE-BINDING; OUTER MEMBRANE	The membrane-bound proteins of periplasmic transport systems have been hypothesized to form a complex with relatively little experimental support. Here we present experimental evidence that HisQ, HisM, and HisP, the membrane-bound proteins of the periplasmic histidine transport system of Salmonella typhimurium, form such a complex. We have developed antibodies specific to each of these proteins to aid in their characterization. Extractions with urea, alkaline pH, or Triton X-114 show that HisQ and HisM are integral membrane proteins. By these tests HisP displays an unusual behavior, being associated with the membrane whether or not HisQ and HisM are present and despite its hydrophilic sequence. However, the nature of HisPs interaction with the membrane is shown to vary depending on the presence of HisQ and HisM. In their absence, HisP is somewhat peripherally associated with the membrane, while in their presence it binds much more tightly, indicating that it forms a complex in association with HisQ and HisM. This is demonstrated by the coimmunoprecipitation of all three proteins by antibodies directed against any one of them. Chemical cross-linking allowed the characterization of the subunit stoichiometry of the complex as two HisPs to one HisQ and one HisM. Within this complex all three proteins probably contact each other and the two HisPs form a dimer. We hypothesize that HisQ and HisM with their multiple membrane-spanning segments form a "channel" within which the HisP subunits are located.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA; MED COLL WISCONSIN, DEPT MICROBIOL, MILWAUKEE, WI 53226 USA	University of California System; University of California Berkeley; Medical College of Wisconsin					NIDDK NIH HHS [DK1212] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES GF, 1986, CELL, V47, P323, DOI 10.1016/0092-8674(86)90585-4; AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GF, 1990, RES MICROBIOL, V141, P341; AMES GF, 1985, BIOCHIMIE, V67, P149, DOI 10.1016/S0300-9084(85)80242-X; AMES GFL, 1978, P NATL ACAD SCI USA, V75, P5447, DOI 10.1073/pnas.75.11.5447; AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; AMES GFL, 1974, J BIOL CHEM, V249, P634; AMES GFL, 1985, CURR TOP MEMBR TRANS, V23, P103; AMES GFL, 1984, MICROBIOLOGY 1984, P13; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRENNER MB, 1985, CELL, V40, P183, DOI 10.1016/0092-8674(85)90321-6; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DEAN DA, 1989, J BACTERIOL, V171, P503, DOI 10.1128/jb.171.1.503-510.1989; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GALLAGHER MP, 1989, EUR J BIOCHEM, V180, P133, DOI 10.1111/j.1432-1033.1989.tb14623.x; GILSON E, 1982, J BIOL CHEM, V257, P9915; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KANG CH, 1989, J MOL BIOL, V207, P643, DOI 10.1016/0022-2836(89)90475-0; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KLEBBA PE, 1990, J BIOL CHEM, V265, P6800; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miller JH., 1972, EXPT MOL GENETICS; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; OI VT, 1977, SELECTED METHODS CEL, P357; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; PROSSNITZ E, 1989, THESIS U CALIFORNIA; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; SMIT J, 1975, J BACTERIOL, V124, P942, DOI 10.1128/JB.124.2.942-958.1975; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STERN MJ, 1988, MOL MICROBIOL, V2, P141, DOI 10.1111/j.1365-2958.1988.tb00015.x; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988	50	110	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9857	9865						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033074				2022-12-25	WOS:A1991FM45900078
J	JUTGLAR, L; BORRELL, JI; AUSIO, J				JUTGLAR, L; BORRELL, JI; AUSIO, J			PRIMARY, SECONDARY, AND TERTIARY STRUCTURE OF THE CORE OF A HISTONE H1-LIKE PROTEIN FROM THE SPERM OF MYTILUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEAR MAGNETIC-RESONANCE; GLOBULAR DOMAIN; CHROMOSOMAL PROTEIN; H-1 HISTONES; CHROMATIN; CONFORMATION; SPERMATOZOA; NUCLEOSOME; HOMOLOGY	We have analyzed the structure of the trypsin-resistant core of the protein PL-II* of the sperm from Mytilus californianus. The peptide has a molecular mass of 8436 Da and its primary sequence is ATGGAKKPSTLSMIVAAIQAMKNRKGSSVQAIRKYILANNKGINTSRLGSAMKLAFAKGLKSGVLVRPKTSAGASGATGSFRVG. This sequence bears an enormous homology and fulfills the constraints of the consensus sequence of the trypsin-resistant peptides of the proteins of the histone H1 family. Secondary structure analysis using Fourier-transform infared spectroscopy as well as predictive methods indicate the presence of 20-30% beta-structure and approximately 25% alpha-helix for this peptide. As in the case of histone H1 proteins, the protein PL-II* core exhibits a compact globular structure as deduced from hydrodynamic measurements. The presence of a histone H1 protein with protamine-like features, seems to be thus, a common general feature of the chromatin composition in the sperm of the bivalve molluscs.	UNIV VICTORIA, DEPT BIOCHEM & MICROBIOL, VICTORIA V8W 3P6, BC, CANADA; ESCOLA TECN SUPER ENGINYERS IND, UNIDAD QUIM MACROMOLEC, E-08028 BARCELONA, SPAIN; CSIC, CTR ENSENANZA TECN SUPER, INST QUIM SARRIA, DEPT QUIM ORGAN, E-08017 BARCELONA, SPAIN	University of Victoria; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Ramon Llull; Institut Quimic de Sarria			Borrell, Jose I./M-1646-2013	Borrell, Jose I./0000-0001-9409-2919				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; AUSIO J, 1987, BIOCHEMISTRY-US, V26, P975, DOI 10.1021/bi00378a001; AUSIO J, 1988, J BIOL CHEM, V263, P10141; AUSIO J, 1982, EXP CELL RES, V141, P39, DOI 10.1016/0014-4827(82)90065-9; AUSIO J, 1986, COMP BIOCHEM PHYS B, V85, P439, DOI 10.1016/0305-0491(86)90025-8; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1981, DOI 10.1021/bi00356a022; BRADBURY EM, 1975, EUR J BIOCHEM, V52, P605, DOI 10.1111/j.1432-1033.1975.tb04032.x; BRIAND G, 1980, FEBS LETT, V112, P147, DOI 10.1016/0014-5793(80)80167-0; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHAN DCF, 1984, J BIOMOL STRUCT DYN, V2, P319, DOI 10.1080/07391102.1984.10507570; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLORE GM, 1987, EMBO J, V6, P1833, DOI 10.1002/j.1460-2075.1987.tb02438.x; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; CRANEROBINSON C, 1989, PROTEIN ENG, V2, P577, DOI 10.1093/protein/2.8.577; CRIMMINS DL, 1989, ANAL BIOCHEM, V176, P255, DOI 10.1016/0003-2697(89)90305-9; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DOWNING MR, 1976, ANAL BIOCHEM, V74, P298, DOI 10.1016/0003-2697(76)90211-6; EISENBERG H, 1981, Q REV BIOPHYS, V14, P142, DOI 10.1017/S0033583500002237; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIANCOTTI V, 1983, EUR J BIOCHEM, V136, P509, DOI 10.1111/j.1432-1033.1983.tb07770.x; HAYASHI T, 1987, J BIOCHEM-TOKYO, V102, P369, DOI 10.1093/oxfordjournals.jbchem.a122063; HOLLOWAY PW, 1989, BIOCHEMISTRY-US, V28, P931, DOI 10.1021/bi00429a002; HURLEY CK, 1977, ANAL BIOCHEM, V80, P624, DOI 10.1016/0003-2697(77)90687-X; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; KMIECIK D, 1985, EUR J BIOCHEM, V150, P359, DOI 10.1111/j.1432-1033.1985.tb09028.x; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIAO LW, 1981, J BIOL CHEM, V256, P3024; LOSA R, 1984, J MOL BIOL, V175, P529, DOI 10.1016/0022-2836(84)90183-9; MANNERMAA RM, 1990, BIOCHEM BIOPH RES CO, V168, P254, DOI 10.1016/0006-291X(90)91701-S; MANTSCH HH, 1986, SPECTROSCOPY BIOL SY, P1; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PORTER DC, 1988, J BIOL CHEM, V263, P2750; STRICKLAND WN, 1980, EUR J BIOCHEM, V104, P567, DOI 10.1111/j.1432-1033.1980.tb04460.x; SUBIRANA JA, 1973, BIOCHIM BIOPHYS ACTA, V317, P364, DOI 10.1016/0005-2795(73)90231-6; Tanford C., 1961, PHYSICAL CHEM MACROM, P317; TURNELL WG, 1988, FEBS LETT, V232, P263, DOI 10.1016/0014-5793(88)80750-6; USCHEWA A, 1985, CELL BIOL INT REP, V9, P253, DOI 10.1016/0309-1651(85)90042-6; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WALKER JM, 1979, FEBS LETT, V100, P394, DOI 10.1016/0014-5793(79)80378-6; WALKER JM, 1977, EUR J BIOCHEM, V76, P461, DOI 10.1111/j.1432-1033.1977.tb11616.x; WASACZ FM, 1987, BIOCHEMISTRY-US, V26, P1464, DOI 10.1021/bi00379a038; YAGUCHI M, 1979, BIOCHEM BIOPH RES CO, V90, P1400, DOI 10.1016/0006-291X(79)91191-4; ZARBOCK J, 1986, P NATL ACAD SCI USA, V83, P7628, DOI 10.1073/pnas.83.20.7628	46	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8184	8191						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022636				2022-12-25	WOS:A1991FK44100038
J	KRIEGER, TJ; HOOK, VYH				KRIEGER, TJ; HOOK, VYH			PURIFICATION AND CHARACTERIZATION OF A NOVEL THIOL PROTEASE INVOLVED IN PROCESSING THE ENKEPHALIN PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDULLARY CHROMAFFIN GRANULES; ISLET SECRETORY GRANULES; BOVINE ADRENAL-MEDULLA; CONVERTING ENZYME; CARBOXYPEPTIDASE-H; RAT PITUITARY; MESSENGER-RNA; SUBSTANCE-P; PROENKEPHALIN; PROINSULIN	Proteolytic processing enzymes are required to convert the enkephalin precursor to active opioid peptides. In this study, a novel 33-kDa thiol protease that cleaves complete precursor in the form of [S-35]methionine preproenkephalin was purified from bovine adrenal medullary chromaffin granules. Chromatography on concanavalin A-Sepharose and Sephacryl S-200, chromatofocusing, and chromatography on thiopropyl-Sepharose resulted in an 88,000-fold purification with a recovery of 35% of enzyme activity. The thiol protease is a glycoprotein with a pI of 6.0. It cleaves [S-35]methionine preproenkephalin with a pH optimum of 5.5, indicating that it is functional at the intragranular pH of 5.5-6.0. Interestingly, production of trichloroacetic acid-soluble products was optimal at pH 4.0, suggesting that processing of initial precursor and intermediates may require slightly different pH conditions. The protease requires dithiothreitol for activity and is inhibited by the thiol protease inhibitors iodoacetate, p-hydroxymercuribenzoate, mercuric chloride, and cystatin. These properties distinguish it from other thiol proteases (cathepsins B, H, L, N, and S), indicating that a unique thiol protease has been identified. The enzyme converted [S-35]cysteine preproenkephalin (possessing [S-35]cysteine residues specifically within the precursor's NH2-terminal segment) to 22.1-, 21.6-, 17.7-, 17.3-, and 15.0-kDa intermediates that contain the precursor's NH2-terminal segment; proenkephalin in vivo is converted to similar intermediates. The enzyme cleaves peptide F at Lys-Arg and Lys-Lys dibasic amino acid sites to generate methionine enkephalin and intermediates. The appropriate vesicular localization, pH optimum, proteolytic products, and cleavage site specificity suggest that this thiol protease may be involved in enkephalin precursor processing. Most interestingly, [S-35]methionine beta-preprotachykinin, a precursor of substrance P, is minimally cleaved, suggesting that the thiol protease may possess some selectivity for the enkephalin precursor.			KRIEGER, TJ (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814, USA.							BARRETT AJ, 1980, MAMMALIAN PROTEASES, P267; BIRCH NP, 1987, J BIOL CHEM, V262, P3382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DOCHERTY K, 1982, P NATL ACAD SCI-BIOL, V79, P4613, DOI 10.1073/pnas.79.15.4613; DOCHERTY K, 1982, ANN REV PHYSL, V44, P626; EVANGELISTA R, 1982, BIOCHEM BIOPH RES CO, V106, P895, DOI 10.1016/0006-291X(82)91795-8; FLETCHER DJ, 1980, DIABETES, V29, P593, DOI 10.2337/diab.29.8.593; FLETCHER DJ, 1981, J CELL BIOL, V90, P312, DOI 10.1083/jcb.90.2.312; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; HARMAR AJ, 1986, FEBS LETT, V208, P67, DOI 10.1016/0014-5793(86)81534-4; HOOK VYH, 1990, BIOCHEM BIOPH RES CO, V167, P722, DOI 10.1016/0006-291X(90)92085-E; HOOK VYH, 1984, FEBS LETT, V172, P212, DOI 10.1016/0014-5793(84)81128-X; HOOK VYH, 1987, J BIOL CHEM, V262, P12583; HOOK VYH, 1984, P NATL ACAD SCI-BIOL, V81, P2776, DOI 10.1073/pnas.81.9.2776; HOOK VYH, 1985, J BIOL CHEM, V260, P5991; JONES BN, 1980, ARCH BIOCHEM BIOPHYS, V204, P392, DOI 10.1016/0003-9861(80)90048-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG I, 1982, BIOCHEM BIOPH RES CO, V106, P186, DOI 10.1016/0006-291X(82)92076-9; LINDBERG I, 1990, ENDOCRINOLOGY, V126, P480, DOI 10.1210/endo-126-1-480; LISTON DR, 1983, NATURE, V302, P62, DOI 10.1038/302062a0; LOH YP, 1982, P NATL ACAD SCI-BIOL, V79, P108, DOI 10.1073/pnas.79.1.108; LOH YP, 1985, J BIOL CHEM, V260, P7194; MIZUNO K, 1982, BIOCHEM BIOPH RES CO, V108, P1235, DOI 10.1016/0006-291X(82)92132-5; MIZUNO K, 1980, BIOCHEM BIOPH RES CO, V97, P1283, DOI 10.1016/S0006-291X(80)80005-2; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PARISH DC, 1986, J BIOL CHEM, V261, P4392; PATEY G, 1984, FEBS LETT, V172, P303, DOI 10.1016/0014-5793(84)81146-1; POLLARD HB, 1979, J BIOL CHEM, V254, P1170; RODRIGUEZ C, 1989, J BIOL CHEM, V264, P5988; SARIA A, 1980, NEUROSCI LETT, V20, P195, DOI 10.1016/0304-3940(80)90145-7; SHEN FS, 1989, J BIOL CHEM, V264, P15600; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; UNGAR A, 1983, PHYSIOL REV, V63, P787, DOI 10.1152/physrev.1983.63.3.787; WEBB EC, 1986, EUR J BIOCHEM, V157, P16; YOSHIKAWA K, 1984, J BIOL CHEM, V259, P4301	39	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8376	8383						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022653				2022-12-25	WOS:A1991FK44100065
J	GIBSON, MA; SANDBERG, LB; GROSSO, LE; CLEARY, EG				GIBSON, MA; SANDBERG, LB; GROSSO, LE; CLEARY, EG			COMPLEMENTARY-DNA CLONING ESTABLISHES MICROFIBRIL-ASSOCIATED GLYCOPROTEIN (MAGP) TO BE A DISCRETE COMPONENT OF THE ELASTIN-ASSOCIATED MICROFIBRILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; FIBRILLIN; TISSUES; ANTIGEN	Affinity-purified antibodies to microfibril-associated glycoprotein (MAGP) were used to screen a random-primed, bovine nuchal ligament cDNA library in lambda-gt11. A 303-base pair clone, cM5, was isolated which encoded an amino acid sequence homologous with that determined directly from a Lys-C peptide of MAGP. A 936-base pair cDNA clone, cM32, was identified in an oligo(dT)-primed cDNA library using plaque hybridization with clone cM5. Clone cM32 encoded amino acid sequences corresponding to sequences obtained from three Lys-C peptides of MAGP, indicating that the clone was an authentic cDNA for the glycoprotein. The cDNA coded for the entire MAGP polypeptide (21 kDa) of 183 amino acids including a putative signal peptide of 17-19 amino acids. This was confirmed by in vitro translation of synthetic mRNAs transcribed from cM32. The amino acid composition of the encoded protein was virtually identical to that previously published for MAGP. DNA sequence analysis of cM32 indicated that MAGP contains two structurally dissimilar regions, an amino-terminal domain containing high levels of glutamine, proline, and acidic amino acids and a carboxyl-terminal domain containing all 13 of the cysteine residues and most of the basic amino acids. Northern blot hybridization of poly(A+) RNA from fetal nuchal ligament with clone cM32 identified a single mRNA species for MAGP of approximately 1.1 kilobases. The evidence indicates that MAGP is a distinct component of 12-nm microfibrils and that it is not derived from a larger microfibrillar glycopolypeptide.	JERRY L PETTIS MEM VET ADM MED CTR,LOMA LINDA,CA 92367; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT PATHOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL)	GIBSON, MA (corresponding author), UNIV ADELAIDE,DEPT PATHOL,ADELAIDE,SA 5000,AUSTRALIA.				NHLBI NIH HHS [HL26499] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026499] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battey, 1986, BASIC METHODS MOL BI; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cleary E.G., 1987, CONNECTIVE TISSUE DI, V12, P55; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; CLEARY EG, 1988, ELASTIN ELASTASES, P31; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1987, IMMUNOL CELL BIOL, V65, P345, DOI 10.1038/icb.1987.39; GIBSON MA, 1985, J BIOL CHEM, V260, P1149; GUBLER U, 1987, GUIDE MOL TECHNIQUES, P330; HELMS C, 1987, METHOD ENZYMOL, V153, P69; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HYNES RO, 1987, METHOD ENZYMOL, V144, P447; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; KUMARATILAKE JS, 1989, EUR J CELL BIOL, V50, P117; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sambrook J, 1989, MOL CLONING LABORATO; STREETEN BW, 1988, CURR EYE RES, V7, P139, DOI 10.3109/02713688808995743; VIERA J, 1987, METHOD ENZYMOL, V153, P3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	22	114	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7596	7601						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019589				2022-12-25	WOS:A1991FJ34200045
J	HASEMANN, CA; CAPRA, JD				HASEMANN, CA; CAPRA, JD			MUTATIONAL ANALYSIS OF ARSONATE BINDING BY A CRIA+ ANTIBODY - VH AND VL JUNCTIONAL DIVERSITY ARE ESSENTIAL FOR BINDING-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-AZOPHENYLARSONATE ANTIBODIES; CROSS-REACTIVE IDIOTYPE; AMINO-ACID-SEQUENCE; CHAIN VARIABLE REGIONS; ARS-A ANTIBODIES; DIRECTED MUTAGENESIS; HEAVY-CHAIN; STRAIN; MOUSE; AFFINITY	To assess the impact of various heavy and light chain mutations on p-azophenylarsonate binding, murine antibodies have been produced in insect cells (SF9) utilizing a baculovirus expression system. When expressed in this system, an antibody composed of a canonical CRI(A+) heavy and light chain can bind antigen and express idiotype indistinguishably from analogous hybridoma-derived antibodies. Antibodies comprised of either light chains mutant at the V-J junction or heavy chains mutant at the V-D junction were found to be incapable of binding arsonate. In addition, substitutions in the first and second complementarity determining regions of the heavy chain were shown to play a role in arsonate binding, most likely related to affinity maturation targeted at the carrier protein. These results confirm the obligatory role that junctional diversity plays in the generation of arsonate-specific antibodies, as well as extend our understanding of the role of other variable region amino acids in arsonate binding.	UNIV TEXAS,SW MED CTR,PROGRAM IMMUNOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	HASEMANN, CA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235, USA.				NATIONAL CANCER INSTITUTE [T32CA009082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012127, R37AI012127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031689] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09082] Funding Source: Medline; NIAID NIH HHS [AI-12127] Funding Source: Medline; NIGMS NIH HHS [GM-31689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; JESKE DJ, 1984, J IMMUNOL, V133, P1090; KUETTNER MG, 1972, J EXP MED, V135, P579, DOI 10.1084/jem.135.3.579; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDOLFI NF, 1986, J IMMUNOL, V137, P362; LEO O, 1985, J IMMUNOL, V134, P1734; MANSER T, 1987, J EXP MED, V166, P1456, DOI 10.1084/jem.166.5.1456; MILNER ECB, 1986, IMMUNOL TODAY, V7, P36, DOI 10.1016/0167-5699(86)90121-0; MILNER ECB, 1982, J IMMUNOL, V129, P193; PARHAMISEREN B, 1989, J IMMUNOL, V143, P4090; PAWLAK LL, 1973, J EXP MED, V137, P22, DOI 10.1084/jem.137.1.22; ROSE DR, 1990, P NATL ACAD SCI USA, V87, P338, DOI 10.1073/pnas.87.1.338; ROTHSTEIN TL, 1983, MOL IMMUNOL, V20, P161, DOI 10.1016/0161-5890(83)90127-X; SANZ I, 1987, P NATL ACAD SCI USA, V84, P1085, DOI 10.1073/pnas.84.4.1085; SHARON J, 1989, J IMMUNOL, V142, P596; SHARON J, 1990, P NATL ACAD SCI USA, V87, P4814, DOI 10.1073/pnas.87.12.4814; SHARON J, 1986, P NATL ACAD SCI USA, V83, P2628, DOI 10.1073/pnas.83.8.2628; SIEGELMAN M, 1981, P NATL ACAD SCI-BIOL, V78, P7679, DOI 10.1073/pnas.78.12.7679; SIEKEVITZ M, 1983, EUR J IMMUNOL, V13, P123, DOI 10.1002/eji.1830130207; SIMS J, 1982, SCIENCE, V216, P309, DOI 10.1126/science.6801765; SLAUGHTER CA, 1984, J IMMUNOL, V132, P3164; SLAUGHTER CA, 1983, J EXP MED, V158, P1615, DOI 10.1084/jem.158.5.1615; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH JA, 1987, BIOCHEMISTRY-US, V26, P604, DOI 10.1021/bi00376a036; Summers MD, 1987, TEXAS AGR EXPT STATI; WANG AL, 1973, J IMMUNOL, V110, P1646; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	28	25	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7626	7632						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019590				2022-12-25	WOS:A1991FJ34200049
J	BROWN, KL; BROOKS, HB; BEHNKE, D; JACOBSEN, DW				BROWN, KL; BROOKS, HB; BEHNKE, D; JACOBSEN, DW			STABILIZATION OF THERMALLY LABILE ALKYLCOBALAMINS BY A HAPTOCORRIN FROM CHICKEN SERUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALT-CARBON BOND; CO-C BOND; HUMAN INTRINSIC FACTOR; VITAMIN B12 BINDING; DISSOCIATION ENERGY; ADENOSYLCOBALAMIN; ORGANOCOBALAMINS; THERMOLYSIS; COBALAMINS; CHEMISTRY	Binding of neopentylcobalamin and benzylcobalamin to the apoprotein of a haptocorrin from chicken serum has been demonstrated spectrophotometrically. The spectra of the protein-bound cobalamins strongly resemble those of base-on alkylcobalamins and show that when unbound these sterically hindered alkylcobalamins are only approximately 75% (benzyl) and 40% (neopentyl) base-on, at neutral pH and at 5-degrees-C. The haptocorrin was found to stabilize the spontaneous thermal decomposition of the neutral species of benzylcobalamin and neopentylcobalamin by 470-fold (3.6 kcal) and 166-fold (3.0 kcal), respectively, relative to the protein-free species. After correction of the activation parameters for the thermal decomposition of the protein-free, neutral alkylcobalamins for the relative proportions of base-on and base-off species, the haptocorrin was found to stabilize the base-on species of both alkylcobalamins by 275- to 1400-fold (approximately 3.3 to 4.3 kcal). From the temperature dependence of the decomposition reactions, the enthalpies of activation are found to be essentially identical for the protein-free and protein-bound species of either cobalamin. Thus, stabilization of the thermal decomposition of these sterically hindered alkylcobalamins by haptocorrin is entirely due to entropic factors.	UNIV CINCINNATI,COLL MED,DEPT BIOL SCI,CINCINNATI,OH 45267; CLEVELAND CLIN EDUC FDN,RES INST,DEPT BRAIN & VASC RES,CLEVELAND,OH 44106; CLEVELAND CLIN EDUC FDN,RES INST,DEPT LAB HEMATOL,CLEVELAND,OH 44106	University of Cincinnati; Cleveland Clinic Foundation; Cleveland Clinic Foundation	BROWN, KL (corresponding author), MISSISSIPPI STATE UNIV,DEPT CHEM,BOX CH,MISSISSIPPI STATE,MS 39762, USA.				NIDDK NIH HHS [DK35265, DK40212] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R15DK040212, R01DK035265] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER JJ, 1973, BIOCHEMISTRY-US, V12, P1054, DOI 10.1021/bi00730a006; BARKER HA, 1960, J BIOL CHEM, V235, P480; BLAU RJ, 1985, J AM CHEM SOC, V107, P3530, DOI 10.1021/ja00298a021; BRESCIANIPAHOR N, 1985, COORDIN CHEM REV, V63, P1, DOI 10.1016/0010-8545(85)80021-7; BRODIE JD, 1969, P NATL ACAD SCI USA, V62, P461, DOI 10.1073/pnas.62.2.461; BROWN KL, 1984, INORG CHEM, V23, P1463, DOI 10.1021/ic00178a032; BROWN KL, 1988, J BIOL CHEM, V263, P1872; BROWN KL, 1988, INORG CHEM, V27, P3548, DOI 10.1021/ic00293a023; CHEMALY SM, 1980, J CHEM SOC DALTON, P2259, DOI 10.1039/dt9800002259; CHEMALY SM, 1980, J CHEM SOC DALTON, P2274, DOI 10.1039/dt9800002274; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FINKE RG, 1984, INORG CHEM, V23, P3041, DOI 10.1021/ic00188a002; FIRTH, 1967, BIOCHEM, V6, P2178; GRATE JH, 1979, J AM CHEM SOC, V101, P4601, DOI 10.1021/ja00510a027; HALPERN J, 1984, J AM CHEM SOC, V106, P8317, DOI 10.1021/ja00338a065; HAY BP, 1987, J AM CHEM SOC, V109, P8012, DOI 10.1021/ja00260a011; HAY BP, 1986, J AM CHEM SOC, V108, P4820, DOI 10.1021/ja00276a020; HIPPE E, 1971, BIOCHIM BIOPHYS ACTA, V243, P75, DOI 10.1016/0005-2795(71)90038-9; HIPPE E, 1971, BIOCHIM BIOPHYS ACTA, V243, P83, DOI 10.1016/0005-2795(71)90039-0; JACOBSEN DW, 1986, METHOD ENZYMOL, V123, P28; JACOBSEN DW, 1986, METHOD ENZYMOL, V123, P14; JACOBSEN DW, 1981, ANAL BIOCHEM, V113, P3120; KAPLAN BH, 1968, J BIOL CHEM, V243, P1787; KIM SH, 1988, J AM CHEM SOC, V110, P3120, DOI 10.1021/ja00218a021; KRAUTLER B, 1989, J AM CHEM SOC, V111, P8936; LENHERT PG, 1968, PROC R SOC LON SER-A, V303, P45, DOI 10.1098/rspa.1968.0039; MAILLARD B, 1983, J AM CHEM SOC, V105, P5095, DOI 10.1021/ja00353a039; MARQUES HM, 1988, J BIOL CHEM, V263, P12378; MORLEY CGD, 1968, BIOCHEMISTRY-US, V7, P1231, DOI 10.1021/bi00843a046; NEXO E, 1982, B12, V2, P57; NOME F, 1987, CAN J CHEM, V65, P2095, DOI 10.1139/v87-347; REENSTRA WW, 1979, J AM CHEM SOC, V101, P5780, DOI 10.1021/ja00513a052; Retey J., 1982, B12, VII, P357; SCHRAUZER GN, 1981, J AM CHEM SOC, V103, P541, DOI 10.1021/ja00393a009; SCHRAUZER GN, 1970, J AM CHEM SOC, V92, P2997, DOI 10.1021/ja00713a012; TOOHEY JI, 1969, J BIOL CHEM, V236, P2119; TORAYA T, 1975, BIOCHEMISTRY-US, V14, P3949, DOI 10.1021/bi00689a004; TORAYA T, 1988, BIOCHEMISTRY-US, V27, P7677, DOI 10.1021/bi00420a016; TORAYA T, 1979, BIOCHEMISTRY-US, V18, P417, DOI 10.1021/bi00570a005; YAKUSHEVA MI, 1977, BIOCHIM BIOPHYS ACTA, V484, P216, DOI 10.1016/0005-2744(77)90127-9	40	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6737	6741						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016289				2022-12-25	WOS:A1991FG72700017
J	HOHL, D; MEHREL, T; LICHTI, U; TURNER, ML; ROOP, DR; STEINERT, PM				HOHL, D; MEHREL, T; LICHTI, U; TURNER, ML; ROOP, DR; STEINERT, PM			CHARACTERIZATION OF HUMAN LORICRIN - STRUCTURE AND FUNCTION OF A NEW CLASS OF EPIDERMAL-CELL ENVELOPE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED ENVELOPE; INTERMEDIATE FILAMENT SUBUNITS; CORNIFIED ENVELOPE; MOUSE EPIDERMIS; ALPHA-KERATIN; KERATOHYALIN GRANULES; SECONDARY STRUCTURE; GLOBULAR-PROTEINS; MESSENGER-RNA; TRANSGLUTAMINASE	We have isolated and characterized a full-length cDNA clone encoding human loricrin. Curiously, this protein displays major differences from the recently described mouse loricrin (Mehrel, T., Hohl, D., Nakazawa, H., Rothnagel, J. A., Longley, M. A., Bundman, D., Cheng, C. K., Lichti, U., Bisher, M. E., Steven, A. C., Steinert, P. M., Yuspa, S. H., and Roop, D. R. (1990) Cell 61, 1103-1112). Although both proteins are glycine-serine-cysteine-rich, the sequences have not been conserved. However, analysis of the sequences reveals a common motif of quasi-peptide repeats of an aliphatic or aromatic amino acid residue followed by several glycine and/or serine and cysteine residues. These sequences are interspersed and flanked by short glutamine- or glutamine/lysine-rich peptides. Thus loricrins consist of a family of cell envelope proteins of highly variable sequences that nevertheless retain common structural elements. We show that unlike all other putative protein components of the cell envelope, loricrins are highly insoluble, due at least in part to cross-linking by disulfide bonds. Furthermore, we have isolated four peptides from purified human cell envelopes that contain recognizable loricrin sequences and which are cross-linked by the N-epsilon-(gamma-glutamyl)lysine isodipeptide bond. The presence of such bonds thus affords an explanation for the extraordinary insolubility of loricrin by cross-linking to the cell envelope and can also explain the low steady-state levels of monomeric loricrin in cytoskeletal extracts of epidermis. This study represents the first report of this isodipeptide cross-link in a protein component of the cornified cell envelope. We propose a model for the structure of loricrin in which (i) the unusual glycine-serine-rich sequences adopt a flexible loop conformation, indexed on the recurrent aliphatic residues; (ii) inter- or intramolecular isodipeptide and disulfide cross-links induce or stabilize folding of loricrin so as to form a more compact rosette-like structure; and (iii) the presence of the flexible glycine-rich loops necessarily will impart a flexible character to the cell envelope and entire epithelium.	NCI,DERMATOL BRANCH,BETHESDA,MD 20892; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BADEN HP, 1987, J INVEST DERMATOL, V89, P454, DOI 10.1111/1523-1747.ep12460759; BALMAIN A, 1979, DEV BIOL, V73, P338, DOI 10.1016/0012-1606(79)90071-X; BISHER ME, 1990, 12TH P INT C EL MICR, P940; BRAMHALL S, 1969, ANAL BIOCHEM, V31, P146, DOI 10.1016/0003-2697(69)90251-6; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURLEY SK, 1989, TRENDS BIOTECHNOL, V7, P354, DOI 10.1016/0167-7799(89)90036-X; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; CONDIT CM, 1986, NATURE, V323, P178, DOI 10.1038/323178a0; CONWAY JF, 1989, BIOL WOOL HAIR, P127; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; FARBMANN AI, 1966, ANAT REC, V156, P269, DOI 10.1002/ar.1091560304; FISHER C, 1987, J INVEST DERMATOL, V88, P661, DOI 10.1111/1523-1747.ep12470281; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLDSMITH L. A., 1983, BIOCH PHYSL SKIN, P184; HANIGAN H, 1978, BIOCHIM BIOPHYS ACTA, V522, P589, DOI 10.1016/0005-2744(78)90090-6; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; HENNINGS H, 1981, BIOCHEM BIOPH RES CO, V102, P739, DOI 10.1016/S0006-291X(81)80194-5; HOHL D, 1989, J INVEST DERMATOL, V92, P445; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; JESSEN H, 1986, J INVEST DERMATOL, V87, P737, DOI 10.1111/1523-1747.ep12456866; JESSEN H, 1974, J CELL SCI, V15, P359; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LOBITZ CJ, 1982, J INVEST DERMATOL, V78, P150, DOI 10.1111/1523-1747.ep12506301; MA ASP, 1986, J CELL BIOL, V103, P41, DOI 10.1083/jcb.103.1.41; MACK JW, 1988, BIOCHEMISTRY-US, V27, P5418, DOI 10.1021/bi00415a006; MANIATIS T, 1982, MOL CLONING LABORATO, P320; MARRS JM, 1971, J INVEST DERMATOL, V56, P174, DOI 10.1111/1523-1747.ep12260779; MARTINET N, 1990, BIOCHEM J, V271, P305, DOI 10.1042/bj2710305; MATOLTSY AG, 1970, J CELL BIOL, V47, P593, DOI 10.1083/jcb.47.3.593; MATOLTSY AG, 1966, J INVEST DERMATOL, V46, P127, DOI 10.1038/jid.1966.19; Matoltsy AG, 1967, ULTRASTRUCTURE NORMA, P76; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MICHEL S, 1987, J INVEST DERMATOL, V88, P301, DOI 10.1111/1523-1747.ep12466177; PARRY DAD, 1985, BIOCHEM BIOPH RES CO, V127, P1012, DOI 10.1016/S0006-291X(85)80045-0; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; RESING KA, 1984, J CELL BIOL, V99, P1372, DOI 10.1083/jcb.99.4.1372; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROOP DR, 1984, J BIOL CHEM, V259, P8037; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shivers B D, 1986, Methods Enzymol, V124, P497; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; STEINERT PM, 1982, BIOCHEMISTRY-US, V21, P177, DOI 10.1021/bi00530a030; STEINERT PM, 1979, BIOCHEMISTRY-US, V18, P5664, DOI 10.1021/bi00592a022; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; Steven AC, 1989, CYTOSKELETAL EXTRACE, P15; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; Sun TT, 1984, CANCER CELLS, V1, P169; TARR GE, 1982, METHODS PROTEIN SEQU, P223; TAUTZ D, 1986, NATURE, V322, P652, DOI 10.1038/322652a0; TEZUKA T, 1987, J INVEST DERMATOL, V88, P47, DOI 10.1111/1523-1747.ep12464862; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; YUSPA SH, 1982, J BIOL CHEM, V257, P9906; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	71	279	282	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6626	6636						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007607				2022-12-25	WOS:A1991FE37300092
J	MCGRATH, ME; HINES, WM; SAKANARI, JA; FLETTERICK, RJ; CRAIK, CS				MCGRATH, ME; HINES, WM; SAKANARI, JA; FLETTERICK, RJ; CRAIK, CS			THE SEQUENCE AND REACTIVE SITE OF ECOTIN - A GENERAL INHIBITOR OF PANCREATIC SERINE PROTEASES FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SUBTILISIN INHIBITOR; EXTRAGENIC PALINDROMIC SEQUENCES; IONIZATION MASS-SPECTROMETRY; MESSENGER-RNA; PROTEIN INHIBITORS; REP SEQUENCES; SPECIFICITY; CONSENSUS; PROMOTERS; EVOLUTION	Ecotin, a serine protease inhibitor found in the periplasm of Escherichia coli, is unusual in its ability to inhibit chymotrypsin, trypsin, and elastase. To address the structural basis of its broad specificity, the gene for ecotin has been cloned and its sequence determined. A promoter of the 17-base pair spacing class was identified, and the probable transcriptional start site lies 18 base pairs upstream from a ribosome binding locus. The gene is followed by a series of conserved repetitive extragenic palindromic sequences. Ecotin has a signal peptide of 20 amino acids which confirms its periplasmic localization. Sequence analyses by Edman degradation and mass spectrometry confirmed 71% of the deduced protein sequence of calculated monomeric molecular mass 16,096 Da. Comparisons of the primary structure for the 142-amino acid protein with the major classes of serine protease inhibitors suggest that ecotin is a novel inhibitor. The reactive site of ecotin was determined to be Met84 for its complexes with chymotrypsin, trypsin, and elastase. The scissile Met84-Met85 bond lies within a disulfide-bonded protein segment similar to other classes of inhibitors.	UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	MCGRATH, ME (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NIDDK NIH HHS [DK 39304] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039304] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARDELT W, 1985, BIOCHEMISTRY-US, V24, P5313, DOI 10.1021/bi00341a007; BECERRIL B, 1985, GENE, V37, P53, DOI 10.1016/0378-1119(85)90257-4; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; CHUNG CH, 1983, J BIOL CHEM, V258, P1032; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FALICK AM, 1986, ANAL CHEM, V58, P1308, DOI 10.1021/ac00298a009; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; HIGGINS CF, 1988, GENE, V72, P3, DOI 10.1016/0378-1119(88)90122-9; HOCHSTRASSER K, 1975, Z PHYS CHEM, V356, P1859; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; IKENAKA T, 1974, J BIOCHEM-TOKYO, V76, P1191, DOI 10.1093/oxfordjournals.jbchem.a130672; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; KARAS M, 1989, BIOMED ENVIRON MASS, V18, P841, DOI 10.1002/bms.1200180931; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; LASKOWSKI M, 1987, COLD SPRING HARB SYM, V52, P545, DOI 10.1101/SQB.1987.052.01.062; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASKOWSKI M, 1978, P INT S PROTEINS VER; Maniatis T., 1982, MOL CLONING; MITSUI Y, 1979, NATURE, V277, P447, DOI 10.1038/277447a0; NEU HC, 1965, J BIOL CHEM, V240, P3685; NEWBURY SF, 1987, CELL, V48, P297, DOI 10.1016/0092-8674(87)90433-8; ONEILL MC, 1989, J MOL BIOL, V207, P301, DOI 10.1016/0022-2836(89)90256-8; ONEILL MC, 1989, J BIOL CHEM, V264, P5522; OZAWA K, 1966, J BIOL CHEM, V241, P3955; PAPAMOKOS E, 1982, J MOL BIOL, V158, P515, DOI 10.1016/0022-2836(82)90212-1; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKANARI JA, 1989, P NATL ACAD SCI USA, V86, P4863, DOI 10.1073/pnas.86.13.4863; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TASHIRO M, 1983, FED PROC, V42, P1953; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YANG Y, 1988, P NATL ACAD SCI USA, V85, P8850, DOI 10.1073/pnas.85.23.8850; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	38	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6620	6625						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007606				2022-12-25	WOS:A1991FE37300091
J	CHATTERTON, JE; PHILLIPS, ML; CURTISS, LK; MILNE, RW; MARCEL, YL; SCHUMAKER, VN				CHATTERTON, JE; PHILLIPS, ML; CURTISS, LK; MILNE, RW; MARCEL, YL; SCHUMAKER, VN			MAPPING APOLIPOPROTEIN-B ON THE LOW-DENSITY-LIPOPROTEIN SURFACE BY IMMUNOELECTRON MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAIN; MONOCLONAL-ANTIBODIES; SERUM-LIPOPROTEINS; STRUCTURAL DOMAINS; APOPROTEIN-B; HETEROGENEITY; SEQUENCE; PROTEIN; IDENTIFICATION; CHOLESTEROL	Apolipoprotein B (apoB) was mapped using electron microscopy to visualize pairs of monoclonal antibodies binding to the low density lipoprotein (LDL) surface. The sites at which these monoclonals bind the apoB polypeptide sequence had already been established. The angular distances between all possible pairs of binding sites except one allowed the relative placement of six epitopes on the LDL sphere. We conclude that apoB extends over at least a hemisphere of the LDL surface since four epitopes are located in the Northern Hemisphere at sites arbitrarily designated as the North Pole, the Aleutian Islands, Bogota, and in the Atlantic Ocean, while two are found in the Southern Hemisphere at Buenos Aires and at Madagascar. ApoB appears to possess a restricted flexibility, since these relative epitope locations show a substantial standard deviation in latitude and longitude. Mapping of additional epitopes may provide an answer to the question of whether apoB circumnavigates the LDL sphere.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA; Scripps Res Inst, RES INST, LA JOLLA, CA 92037 USA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, QUEBEC, CANADA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; Scripps Research Institute; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of California System; University of California Los Angeles					NHLBI NIH HHS [HL 14197] Funding Source: Medline; NIGMS NIH HHS [GM 13914, GM 07185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185, R01GM013914] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADLEY W A, 1978, P111; BROWN MS, 1984, SCI AM, V251, P58, DOI 10.1038/scientificamerican1184-58; CARDIN AD, 1984, J BIOL CHEM, V259, P8522; CHEN GC, 1989, J BIOL CHEM, V264, P14369; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; FISHER WR, 1971, BIOCHEMISTRY-US, V10, P1622, DOI 10.1021/bi00785a019; Forte T, 1972, Adv Lipid Res, V10, P1; GINSBURG GS, 1984, J BIOL CHEM, V259, P6667; GONIAS SL, 1988, J BIOL CHEM, V263, P10903; GULIKKRZYWICKI T, 1979, J MOL BIOL, V131, P475, DOI 10.1016/0022-2836(79)90003-2; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGGNER P, 1978, Q REV BIOPHYS, V11, P371, DOI 10.1017/S0033583500002304; LAKE JA, 1985, ANNU REV BIOCHEM, V54, P507, DOI 10.1146/annurev.biochem.54.1.507; LEE DM, 1987, BIOCHEM BIOPH RES CO, V144, P210, DOI 10.1016/S0006-291X(87)80497-7; LEE P, 1976, CAN J BIOCHEM CELL B, V54, P42, DOI 10.1139/o76-007; LESLIE RB, 1969, CHEM PHYS LIPIDS, V3, P152, DOI 10.1016/0009-3084(69)90006-1; LUZZATI V, 1979, J MOL BIOL, V131, P435, DOI 10.1016/0022-2836(79)90002-0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILNE R, 1989, J BIOL CHEM, V264, P19754; MILNE RW, 1987, MOL IMMUNOL, V24, P435, DOI 10.1016/0161-5890(87)90017-4; PEASE RJ, 1990, J BIOL CHEM, V265, P553; PHILLIPS ML, 1989, J LIPID RES, V30, P415; POLLARD H, 1969, P NATL ACAD SCI USA, V64, P304, DOI 10.1073/pnas.64.1.304; ROUX KH, 1982, J IMMUNOL, V129, P2548; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SCHUMAKER VN, 1973, ACCOUNTS CHEM RES, V6, P398, DOI 10.1021/ar50072a002; SEEGAN GW, 1979, P NATL ACAD SCI USA, V76, P907, DOI 10.1073/pnas.76.2.907; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SHEN MMS, 1981, J LIPID RES, V22, P236; SWAMINATHAN N, 1976, BIOCHEMISTRY-US, V15, P1516, DOI 10.1021/bi00652a024; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; WRIGLEY NG, 1983, J MOL BIOL, V169, P771, DOI 10.1016/S0022-2836(83)80170-3; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1989, J LIPID RES, V30, P443	40	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5955	5962						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005131				2022-12-25	WOS:A1991FD37000093
J	YONEZAWA, N; NISHIDA, E; IIDA, K; KUMAGAI, H; YAHARA, I; SAKAI, H				YONEZAWA, N; NISHIDA, E; IIDA, K; KUMAGAI, H; YAHARA, I; SAKAI, H			INHIBITION OF ACTIN POLYMERIZATION BY A SYNTHETIC DODECAPEPTIDE PATTERNED ON THE SEQUENCE AROUND THE ACTIN-BINDING SITE OF COFILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPOLYMERIZING FACTOR; PORCINE BRAIN; F-ACTIN; STARFISH OOCYTES; SKELETAL-MUSCLE; CROSS-LINKING; CHICK BRAIN; PROTEIN; DEPACTIN; PURIFICATION	Cofilin is an F-actin side-binding and -depolymerizing protein with an apparent molecular mass of 21 kDa. By means of the end label fingerprinting method, the amino acid residue on cofilin sequence cross-linked to actin by zero length cross-linker, 1-ethyl-3-(3-dimethylamino propyl)carbodiimide, was identified as Lys112 and/or Lys114. A synthetic dodecapeptide patterned on the sequence around the actin-cross-linking site of cofilin (Trp104-Met115) inhibited the binding of cofilin to actin. Moreover, the dodecapeptide was found to be a potent inhibitor of actin polymerization. Thus, we conclude that the dodecapeptide sequence constitutes the region essential for the actin-binding and -depolymerizing activity of cofilin. A sequence similar to the dodecapeptide is found in other actin-depolymerizing proteins, destrin, actin-depolymerizing factor, and depactin. Therefore, the dodecapeptide sequence may be a consensus sequence essential for actin-binding and -depolymerizing activity in actin-depolymerizing proteins.	UNIV TOKYO,FAC SCI,DEPT BIOCHEM & BIOPHYS,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT CELL BIOL,TOKYO 113,JAPAN; ASAHI GLASS CO LTD,RES CTR,YOKOHAMA 221,JAPAN	University of Tokyo; Tokyo Metropolitan Institute of Medical Science; AGC Inc			Yonezawa, Naoto/F-8300-2011					ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; ANDRE E, 1988, J BIOL CHEM, V263, P722; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRENNER SL, 1983, J BIOL CHEM, V258, P5013; BRESNICK AR, 1990, J BIOL CHEM, V265, P9236; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COOPER JA, 1986, J BIOL CHEM, V261, P477; GIULIANO KA, 1988, BIOCHEMISTRY-US, V27, P8931, DOI 10.1021/bi00425a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE C, 1988, EMBO J, V7, P4157, DOI 10.1002/j.1460-2075.1988.tb03311.x; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; MORIYAMA K, 1990, J BIOL CHEM, V265, P5771; MUNEYUKI F, 1985, J BIOCHEM-TOKYO, V97, P563, DOI 10.1093/oxfordjournals.jbchem.a135091; NISHIDA E, 1984, J BIOCHEM-TOKYO, V95, P387, DOI 10.1093/oxfordjournals.jbchem.a134619; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTOH K, 1984, BIOCHEMISTRY-US, V23, P6757, DOI 10.1021/bi00321a073; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P6186, DOI 10.1021/bi00368a053; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P5269, DOI 10.1021/bi00438a052; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P435, DOI 10.1021/bi00350a024; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; TAKAGI T, 1988, J BIOL CHEM, V263, P3097; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YONEZAWA N, 1987, CELL STRUCT FUNCT, V12, P443, DOI 10.1247/csf.12.443; YONEZAWA N, 1988, BIOCHEM J, V251, P121, DOI 10.1042/bj2510121	37	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10485	10489						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037594				2022-12-25	WOS:A1991FP08600074
J	KELM, RJ; MANN, KG				KELM, RJ; MANN, KG			THE COLLAGEN BINDING-SPECIFICITY OF BONE AND PLATELET OSTEONECTIN IS RELATED TO DIFFERENCES IN GLYCOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE TUMOR; PROTEIN BM-40; SUGAR CHAINS; SPARC; CARBOHYDRATE; OLIGOSACCHARIDES; PURIFICATION; GLYCOPROTEIN; LOCALIZATION; HYDROXYAPATITE	In this study we report that bone and platelet osteonectin are structurally and functionally heterogeneous in terms of glycosylation and collagen binding capacity. The relative sensitivity of bone and platelet osteonectin to specific glycosidases was used to evaluate potential differences in glycosylation. Although native bone and platelet osteonectin are electrophoretically nonidentical, N-glycanase treatment yielded products with the same apparent molecular weight. Bone osteonectin was also susceptible to cleavage by endo H but not to neuraminidase, while platelet osteonectin was susceptible to neuraminidase but not to endo H. In lectin blotting experiments of bone and platelet osteonectin, concanavalin A bound specifically to bone osteonectin but not to platelet osteonectin. However, Lens culinaris agglutinin bound to platelet osteonectin but not to bone osteonectin. These data suggest that bone and platelet osteonectin differ in their oligosaccharide side chain structures, with bone osteonectin possessing a high mannose-type and platelet osteonectin, a complex-type structure. Solid-phase binding techniques were used to functionally evaluate bone and platelet osteonectin in terms of collagen binding. Although bone ostenectin bound specifically to types I, III, and V collagen, platelet osteonectin had no apparent affinity for these collagen types suggesting that the two proteins are also functionally distinct.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont								ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BOLANDER ME, 1988, P NATL ACAD SCI USA, V85, P2919, DOI 10.1073/pnas.85.9.2919; CLEZARDIN P, 1988, EUR J BIOCHEM, V175, P275, DOI 10.1111/j.1432-1033.1988.tb14194.x; DENNIS JW, 1984, J CELL BIOL, V99, P1416, DOI 10.1083/jcb.99.4.1416; DOMENICUCCI C, 1988, BIOCHEM J, V253, P139, DOI 10.1042/bj2530139; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; FINDLAY DM, 1988, BIOCHEMISTRY-US, V27, P1483, DOI 10.1021/bi00405a013; FISHER LW, 1987, J BIOL CHEM, V262, P9702; GEHRONROBEY P, 1989, J CELL BIOL, V108, P719; HAIR GA, 1990, BLOOD, V76, pA1822; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HUGHES RC, 1987, EUR J BIOCHEM, V163, P57, DOI 10.1111/j.1432-1033.1987.tb10736.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KELM RJ, 1990, BLOOD, V75, P1105; KIYOHARA T, 1974, ARCH BIOCHEM BIOPHYS, V164, P575, DOI 10.1016/0003-9861(74)90069-1; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KUWATA F, 1985, J BIOL CHEM, V260, P6993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKATBUTTGEREIT B, 1988, FEBS LETT, V236, P352, DOI 10.1016/0014-5793(88)80054-1; MANN K, 1987, FEBS LETT, V218, P167, DOI 10.1016/0014-5793(87)81040-2; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MCVEY JH, 1988, J BIOL CHEM, V263, P11111; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MIZOUCHI T, 1981, J BIOCHEM-TOKYO, V90, P1023; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; ROMBERG RW, 1986, BIOCHEMISTRY-US, V25, P1176, DOI 10.1021/bi00353a035; ROMBERG RW, 1985, J BIOL CHEM, V260, P2728; SAGE H, 1986, J CELL PHYSIOL, V127, P373, DOI 10.1002/jcp.1041270305; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SAGE H, 1984, J BIOL CHEM, V259, P3993; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SPIRO RG, 1984, J BIOL CHEM, V259, P9858; STENNER DD, 1984, P NATL ACAD SCI-BIOL, V81, P2868, DOI 10.1073/pnas.81.9.2868; STENNER DD, 1986, P NATL ACAD SCI USA, V83, P6892, DOI 10.1073/pnas.83.18.6892; Swaroop A, 1988, GENOMICS, V2, P37, DOI 10.1016/0888-7543(88)90107-3; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TRACY RP, 1988, INT J BIOCHEM, V20, P653, DOI 10.1016/0020-711X(88)90159-0; TRACY RP, 1987, CALCIUM REGULATION B, V9, P401; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; VILLARREAL XC, 1989, BIOCHEMISTRY-US, V28, P6483, DOI 10.1021/bi00441a049; WASI S, 1984, CAN J BIOCHEM CELL B, V62, P470, DOI 10.1139/o84-064; YAMASHITA K, 1983, ARCH BIOCHEM BIOPHYS, V225, P993, DOI 10.1016/0003-9861(83)90116-9; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; ZHU BCR, 1984, J BIOL CHEM, V259, P3962	47	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9632	9639						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033056				2022-12-25	WOS:A1991FM45900047
J	SOLEIMANI, M; LESOINE, GA; BERGMAN, JA; ARONSON, PS				SOLEIMANI, M; LESOINE, GA; BERGMAN, JA; ARONSON, PS			CATION SPECIFICITY AND MODES OF THE NA+-CO23--HCO3- COTRANSPORTER IN RENAL BASOLATERAL MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-BICARBONATE COTRANSPORT; PROXIMAL CONVOLUTED TUBULE; KIDNEY EPITHELIAL-CELLS; NA+-HCO3 COTRANSPORT; KINETIC-PROPERTIES; INTRACELLULAR PH; STRAIGHT TUBULE; TRANSPORT; CORTEX; MECHANISM	The cation specificity and possible exchange modes of the Na+:CO3(2-):HCO3- cotransporter were evaluated by use of basolateral membrane vesicles isolated from rabbit renal cortex. External Li+ inhibited HCO3- gradient-stimulated Na-22 uptake, indicating that Li+ interacts with the Na+:CO3(2-):HCO3- cotransporter. No interaction with K+, choline, Rb+, Cs+, or NH4+ could be similarly detected. Imposing an outward Li+ gradient caused quenching of acridine orange fluorescence in the presence but not in the absence of HCO3-, suggesting that Li+:base cotransport takes place via the Na+:CO3(2-):HCO3- cotransporter. Imposing an outward gradient of unlabeled Na+ stimulated the initial rate of Na-22 uptake and induced its transient uphill accumulation, indicating Na+-Na+ exchange. Na+-Na+ exchange was observed in the presence but not in the absence of HCO3- and was inhibited by 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), suggesting that it occurs via the Na+:CO3(2-):HCO3- cotransporter. Similarly, an outward Li+ gradient stimulated uphill Na-22 accumulation, indicating Na+-Li+ exchange. Na+-Li+ exchange was observed in the presence but not in the absence of HCO3-, and was inhibited by DIDS, suggesting that it also occurs via the Na+:CO3(2-):HCO3- cotransporter. Both Na+-Na+ and Li+-Na+ exchange modes were sensitive to inhibition by harmaline but not by amiloride. We conclude that Li+ is an alternative substrate for the renal Na+:CO3(2-):HCO3- cotransporter. Transport modes of the system include cation:base cotransport and HCO3-dependent cation-cation exchange.	RICHARD L ROUDEBUSH VET ADM MED CTR,INDIANAPOLIS,IN 46202; YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Yale University; Yale University	SOLEIMANI, M (corresponding author), INDIANA UNIV,SCH MED,DEPT MED,NEPHROL SECT,FH 108,1120 S DR,INDIANAPOLIS,IN 46202, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM033793, P01AM017433] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-17433, AM-33793] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIBA T, 1986, J CLIN INVEST, V78, P1472, DOI 10.1172/JCI112738; ALPERN RJ, 1986, J CLIN INVEST, V78, P502, DOI 10.1172/JCI112602; ALPERN RJ, 1985, J GEN PHYSIOL, V86, P613, DOI 10.1085/jgp.86.5.613; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIAGI BA, 1985, J MEMBRANE BIOL, V88, P25, DOI 10.1007/BF01871210; BIAGI BA, 1986, AM J PHYSIOL, V250, pF267, DOI 10.1152/ajprenal.1986.250.2.F267; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; GRASSL SM, 1986, J BIOL CHEM, V261, P8778; GRASSL SM, 1987, J BIOL CHEM, V262, P2682; JENTSCH TJ, 1986, J BIOL CHEM, V261, P673; JENTSCH TJ, 1985, J BIOL CHEM, V260, P5554; JENTSCH TJ, 1984, J MEMBRANE BIOL, V81, P189, DOI 10.1007/BF01868713; KRAPF R, 1987, J GEN PHYSIOL, V90, P833, DOI 10.1085/jgp.90.6.833; PREISIG P A, 1989, American Journal of Physiology, V256, pF751; SASAKI S, 1985, AM J PHYSIOL, V249, pF417, DOI 10.1152/ajprenal.1985.249.3.F417; SOLEIMANI M, 1989, J BIOL CHEM, V264, P18302; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; SOLEIMANI M, 1989, J CLIN INVEST, V83, P945, DOI 10.1172/JCI113980; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, P360, DOI 10.1007/BF00595689	19	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8706	8710						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026588				2022-12-25	WOS:A1991FM03800014
J	SCHIMMEL, P				SCHIMMEL, P			RNA MINIHELICES AND THE DECODING OF GENETIC INFORMATION	FASEB JOURNAL			English	Review						AMINOACYL TRANSFER RNA SYNTHETASE; GENETIC CODE; TRANSFER RNAS; RNA RECOGNITION; AMINOACYLATION	PHENYLALANINE TRANSFER-RNA; ESCHERICHIA-COLI; MOLECULAR RECOGNITION; MAJOR DETERMINANT; BINDING-SITE; IDENTITY; SYNTHETASE; AMINOACYLATION; PARAMETERS; ANTICODON	The rules of the genetic code are determined by the specific aminoacylation of transfer RNAs by aminoacyl transfer RNA synthetases. A straightforward analysis shows that a system of synthetase-tRNA interactions that relies on anticodons for specificity could, in principle, enable most synthetases to distinguish their cognate tRNA isoacceptors from all others. Although the anticodons of some tRNAs are recognition sites for the cognate aminoacyl tRNA synthetases, for other synthetases the anticodon is dispensable for specific aminoacylation. In particular, alanine and histidine tRNA synthetases aminoacylate small RNA minihelices that reconstruct the part of their cognate tRNAs that is proximate to the amino acid attachment site. Helices with as few as six base pairs can be efficiently aminoacylated. The specificity of aminoacylation is determined by a few nucleotides and can be converted from one amino acid to another by the change of only a few nucleotides. These findings suggest that, for a subgroup of the synthetases, there is a distinct code in the acceptor helix of transfer RNAs that determines aminoacylation specificity.			SCHIMMEL, P (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.				NIGMS NIH HHS [GM 15539, GM 23562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R37GM015539, R01GM023562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; COOLEY L, 1982, P NATL ACAD SCI-BIOL, V79, P6475, DOI 10.1073/pnas.79.21.6475; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DEDUVE C, 1988, NATURE, V333, P117, DOI 10.1038/333117a0; DEDUVE C, 1991, BLUEPRINT CELL NATUR, pCH8; EIGEN M, 1989, SCIENCE, V244, P673, DOI 10.1126/science.2497522; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; HARADA F, 1972, FEBS LETT, V19, P352, DOI 10.1016/0014-5793(72)80078-4; HILL K, 1989, BIOCHEMISTRY-US, V28, P2577, DOI 10.1021/bi00432a035; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HOU YM, 1989, BIOCHEMISTRY-US, V28, P4942, DOI 10.1021/bi00438a005; HOU YM, 1989, TRENDS BIOCHEM SCI, V14, P233, DOI 10.1016/0968-0004(89)90033-9; HOU YM, 1989, BIOCHEMISTRY-US, V28, P6800, DOI 10.1021/bi00443a003; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; HOUNTONDJI C, 1985, BIOCHEMISTRY-US, V24, P1175, DOI 10.1021/bi00326a018; HOUNTONDJI C, 1986, BIOCHEMISTRY-US, V25, P16, DOI 10.1021/bi00349a003; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P2635, DOI 10.1021/bi00224a011; MOLLER W, 1990, BIOCHIMIE, V72, P361, DOI 10.1016/0300-9084(90)90033-D; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MURAMATSU T, 1988, J BIOL CHEM, V263, P9261; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PARK SJ, 1988, J BIOL CHEM, V263, P16527; PARK SJ, 1989, BIOCHEMISTRY-US, V28, P2740, DOI 10.1021/bi00432a056; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; RENAUD M, 1982, EUR J BIOCHEM, V123, P267, DOI 10.1111/j.1432-1033.1982.tb19763.x; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAMPSON JR, 1989, SCIENCE, V243, P1363; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SCHIMMEL P, 1991, TRENDS BIOCHEM SCI, V16, P1, DOI 10.1016/0968-0004(91)90002-D; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHIMMEL P, 1990, NUCLEIC ACIDS MOL BI, V4, P274; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SHI JP, 1991, J BIOL CHEM, V266, P2705; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042	51	19	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2180	2187		10.1096/fasebj.5.8.2022314	http://dx.doi.org/10.1096/fasebj.5.8.2022314			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	2022314				2022-12-25	WOS:A1991FK11100010
J	MELONI, FJ; SCHMAIER, AH				MELONI, FJ; SCHMAIER, AH			LOW-MOLECULAR-WEIGHT KININOGEN BINDS TO PLATELETS TO MODULATE THROMBIN-INDUCED PLATELET ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; ALPHA-THROMBIN; FACTOR-XII; AFFINITY-CHROMATOGRAPHY; ENDOTHELIAL-CELLS; BLOOD-PLATELETS; GEL FILTRATION; HAGEMAN-FACTOR; HEAVY-CHAIN; LIGHT CHAIN	The kininogens, high molecular weight kininogen (HK) and low molecular weight kininogen (LK), are multifunctional, single-gene products that contain bradykinin and identical amino-terminal heavy chains. Studies were performed to determine if LK would bind directly to platelets. I-125-LK specifically bound to gel-filtered platelets inthe presence of 50-mu-M Zn2+. HK effectively competed with I-125-LK for the same binding site (K(i) = 27 +/- 9 nM, n = 5). Similarly, the K(i) for LK inhibition of I-125-LK binding was 12 +/- 1 nM (n = 3). Albumin, fibrinogen, factor XIII, and kallikrein did not inhibit I-125-LK binding to unstimulated platelets. I-125-LK (66 kDa) was not cleaved upon binding to platelets. The binding of I-125-LK to unstimulated platelets was found to be fully reversible by the addition of a 50 molar excess of unlabeled LK at both 10 and 20 min. LK binding to platelets was saturable with an apparent K(d) of 27 +/- 2 nM (mean +/- S.E., n = 9) and 647 +/- 147 binding sites/platelet. Both LK and HK at plasma concentrations inhibited thrombin-induced platelet aggregation. LK and HK at about 5% of plasma concentration also inhibited thrombin-induced secretion of both stirred and unstirred platelets. Both kininogens were found to be noncompetitive inhibitors of proteolytically active thrombin binding to platelets. The kininogens did not inhibit D-phenylalanyl-prolyl-arginine chloromethyl ketone-treated thrombin from binding to platelets. These studies indicated that both kininogens have a region on their heavy chain which allows them to bind to platelets. Further,kininogen binding by its heavy chain modulates thrombin activation of platelets since it prevents proteolytically active thrombin from binding to its receptor.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,THROMBOSIS RES CTR,3400 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MED,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Schmaier, Alvin/AAM-1063-2020	Schmaier, Alvin/0000-0002-3884-6234	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035553, K04HL001615] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL01615, HL35553, HL07878] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; BAUGHMAN DJ, 1970, METHOD ENZYMOL, V19, P145; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRASS LF, 1982, J BIOL CHEM, V257, P4000; CANELLAS PF, 1981, J IMMUNOL METHODS, V47, P375, DOI 10.1016/0022-1759(81)90294-5; CHA S, 1976, BIOCHEM PHARMACOL, V25, P2695, DOI 10.1016/0006-2952(76)90259-8; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; DEFREITAS FM, 1964, CIRCULATION, V29, P66, DOI 10.1161/01.CIR.29.1.66; ENJOYJI K, 1988, J BIOL CHEM, V263, P973; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOUNARIS AD, 1984, BIOCHEM J, V221, P445, DOI 10.1042/bj2210445; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; GRIFFIN JH, 1977, P NATL ACAD SCI USA, V74, P4636; GUSTAFSON EG, 1986, CLIN RES, V34, P459; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HARMON JT, 1988, BIOCHEMISTRY-US, V27, P2151, DOI 10.1021/bi00406a050; HAYASHI I, 1985, J BIOL CHEM, V260, P6115; ISHIGURO H, 1987, BIOCHEMISTRY-US, V26, P2863, DOI 10.1021/bi00384a030; JACOBSEN S, 1966, NATURE, V210, P98, DOI 10.1038/210098a0; JOHNSON DA, 1987, THROMB RES, V48, P187, DOI 10.1016/0049-3848(87)90415-4; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; KOMIYA M, 1974, J BIOCHEM-TOKYO, V76, P833; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA H, 1983, INT J BIOL MACROMOL, V5, P159, DOI 10.1016/0141-8130(83)90031-4; MAIER M, 1983, P NATL ACAD SCI-BIOL, V80, P3928, DOI 10.1073/pnas.80.13.3928; MAIER M, 1983, ANAL BIOCHEM, V134, P336, DOI 10.1016/0003-2697(83)90307-X; MANCINI GA, 1964, IMMUNOCHEMISTRY, V22, P235; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MARCEAU F, 1983, GEN PHARMACOL, V14, P209, DOI 10.1016/0306-3623(83)90001-0; MULLER R, 1983, METHOD ENZYMOL, V92, P589; MULLERESTERL W, 1982, BIOCHIM BIOPHYS ACTA, V706, P145, DOI 10.1016/0167-4838(82)90480-0; NAWA H, 1983, P NATL ACAD SCI-BIOL, V80, P90, DOI 10.1073/pnas.80.1.90; ODEGARD OR, 1975, THROMB RES, V6, P287, DOI 10.1016/0049-3848(75)90078-X; OKUBUKO L, 1984, BIOCHEMISTRY-US, V23, P3891; PIXLEY RA, 1986, THROMB RES, V41, P89, DOI 10.1016/0049-3848(86)90282-3; PURI RN, 1987, T ASS AM PHYS C, P232; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMAIER AH, 1986, BLOOD, V67, P119; SCHMAIER AH, 1986, J CLIN INVEST, V77, P1565, DOI 10.1172/JCI112472; SCHMAIER AH, 1980, BLOOD, V56, P1013; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCHMAIER AH, 1983, THROMB RES, V33, P51; SCOTT CF, 1979, EUR J BIOCHEM, V100, P77, DOI 10.1111/j.1432-1033.1979.tb02035.x; SCOTT CF, 1980, J CLIN INVEST, V65, P413, DOI 10.1172/JCI109684; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SCULLY RF, 1982, BIOCHIM BIOPHYS ACTA, V700, P130; Segel IH, 1976, BIOCH CALCULATIONS; SHIMADA T, 1987, J BIOCHEM-TOKYO, V102, P913, DOI 10.1093/oxfordjournals.jbchem.a122132; SHORE JD, 1987, BIOCHEMISTRY-US, V26, P2250, DOI 10.1021/bi00382a027; SUEYOSHI T, 1985, FEBS LETT, V182, P193, DOI 10.1016/0014-5793(85)81182-0; SUEYOSHI T, 1987, J BIOL CHEM, V262, P2768; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; TANGEN O, 1971, THROMB DIATH HAEMOST, V25, P268; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; THOMPSON RE, 1978, J EXP MED, V147, P488, DOI 10.1084/jem.147.2.488; TIMMONS S, 1978, THROMB RES, V12, P297, DOI 10.1016/0049-3848(78)90300-6; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WICKLMAYR M, 1979, FEBS LETT, V98, P61, DOI 10.1016/0014-5793(79)80152-0; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WORKMAN EF, 1977, J BIOL CHEM, V252, P7118; ZOGEL CR, 1988, J SUBMICRO CYTOL PAT, V20, P269	70	93	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6786	6794						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016293				2022-12-25	WOS:A1991FG72700025
J	YANG, M; GELI, V; OPPLIGER, W; SUDA, K; JAMES, P; SCHATZ, G				YANG, M; GELI, V; OPPLIGER, W; SUDA, K; JAMES, P; SCHATZ, G			THE MAS-ENCODED PROCESSING PROTEASE OF YEAST MITOCHONDRIA - INTERACTION OF THE PURIFIED ENZYME WITH SIGNAL PEPTIDES AND A PURIFIED PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-ORNITHINE TRANSCARBAMYLASE; SODIUM DODECYL SULFATE; CYTOCHROME-C OXIDASE; DIHYDROFOLATE-REDUCTASE; PROTEOLYTIC CLEAVAGE; POLYACRYLAMIDE GEL; TARGETING FUNCTION; IMPORT; MATRIX; SUBUNIT	The matrix of yeast mitochondria contains a chelator-sensitive protease that removes matrix-targeting signals from most precursor proteins transported into this compartment. The enzyme consists of two nonidentical subunits that are encoded by the nuclear genes MAS1 and MAS2. With the aid of these cloned genes, we have now overexpressed the active holoenzyme in yeast, purified it in milligram amounts, and studied its biochemical and physical properties. Atomic absorption analysis shows that the purified enzyme lacks significant amounts of zinc, manganese, or cobalt; if none of these metal ions is added during the assay, the enzyme is catalytically inactive but can still cleave substoichiometric amounts of substrate. The amino-terminal sequences of the two mature subunits were determined; comparison with the deduced amino acid sequences of the corresponding precursors revealed that the MAS1 and MAS2 subunits are synthesized with prepeptides composed of 19 and 13 residues, respectively, which have similar sequences. The enzyme is inhibited competitively by chemically synthesized matrix-targeting peptides; the degree of inhibition correlates with the peptides' targeting efficacy. Matrix-targeting peptides containing the cleavage site of the corresponding authentic precursor protein are cleaved correctly by the purified enzyme. A purified artificial precursor protein bound to the holoenzyme can be photocross-linked to the MAS2 subunit.	UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND; SWISS FED INST TECHNOL,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND	University of Basel; Swiss Federal Institutes of Technology Domain; ETH Zurich					NIGMS NIH HHS [2 R01 GM 37803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKER A, 1987, P NATL ACAD SCI USA, V84, P317; BOHNI P, 1980, ORG EXPRESSION MITOC, P423; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CERLETTI N, 1983, J BIOL CHEM, V258, P4944; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EPAND RM, 1986, J BIOL CHEM, V261, P17; GELI V, 1990, J BIOL CHEM, V265, P19216; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HURT EC, 1987, J BIOL CHEM, V262, P1420; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KUMAMOTO T, 1986, J BIOCHEM-TOKYO, V100, P247, DOI 10.1093/oxfordjournals.jbchem.a121700; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; MAARSE AC, 1984, EMBO J, V3, P2831, DOI 10.1002/j.1460-2075.1984.tb02216.x; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MCADA PC, 1982, J BIOL CHEM, V257, P3177; MIURA S, 1982, EUR J BIOCHEM, V122, P641; NGUYEN M, 1987, J CELL BIOL, V104, P1193, DOI 10.1083/jcb.104.5.1193; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WELZ B, 1983, ATOMABSOPRTIONSSPEKT; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YAFFE MP, 1985, EMBO J, V4, P2069, DOI 10.1002/j.1460-2075.1985.tb03893.x; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	46	63	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6416	6423						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007593				2022-12-25	WOS:A1991FE37300063
J	YANO, T; KURAMITSU, S; TANASE, S; MORINO, Y; HIROMI, K; KAGAMIYAMA, H				YANO, T; KURAMITSU, S; TANASE, S; MORINO, Y; HIROMI, K; KAGAMIYAMA, H			THE ROLE OF HIS143 IN THE CATALYTIC MECHANISM OF ESCHERICHIA-COLI ASPARTATE-AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; PIG-HEART; RESIDUE; GENE	In aspartate aminotransferase (AspAT), His143 is located within a hydrogen-bonding distance to Asp222 that forms a strong ion pair with the ring nitrogen of the coenzyme, pyridoxal 5'-phosphate (PLP) or pyridoxamine 5'-phosphate (PMP). His143 of Escherichia coli AspAT was replaced by Ala or Asn. The mutant enzyme H143A showed a slight increase in the maximum velocity of the overall transamination reaction between aspartate and 2-oxoglutarate, while H143N AspAT showed a decrease to 60% in the maximum rate of the overall reactions in both directions. In all of the half-transamination reactions with four substrates, aspartate, glutamate, oxalacetate, and 2-oxoglutarate, the catalytic competence as defined by k(max)/K(d) decreased by 3-18-fold upon replacing His143 by either Ala or Asn. The extent of the decrease varied from one substrate to another; it was largely contributed to by the decrease in affinities for all substrates. The equilibrium constants, [PMP-form][keto acid]/{[PLP-form][amino acid]}, decreased by over 10-fold upon the mutations at position 143. Both H143A and H143N AspATs exhibited a considerably decreased affinity for 2-methylaspartate, an external-aldimine-forming substrate analogue, yet without appreciable alteration in the affinity for succinate and glutarate, which are non-aldimine-forming analogues. All these findings suggest that, although His143 is not essential for catalysis, it might assist the formation of enzyme-substrate complex.	OSAKA MED COLL, DEPT MED CHEM, TAKATSUKI, OSAKA 569, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT BIOCHEM, KUMAMOTO 860, JAPAN; FUKUYAMA UNIV, FAC ENGN, DEPT FOOD SCI & TECHNOL, FUKUYAMA, HIROSHIMA 72902, JAPAN	Osaka Medical College; Kumamoto University; Fukuyama University								ARNONE A, 1985, TRANSAMINASES, P326; Arnone A, 1985, TRANSAMINASES, P138; BORISOV VV, 1985, TRANSAMINASES, P155; CSONKA LN, 1979, GENETICS, V93, P321; FASELLA P, 1966, BIOCHEMISTRY-US, V5, P197, DOI 10.1021/bi00865a026; FONDA ML, 1970, J BIOL CHEM, V245, P2709; GEHRING H, 1985, TRANSAMINASES, P317; HARUTYUNYAN EG, 1985, TRANSAMINASES, P164; INOUE Y, 1989, J BIOL CHEM, V264, P9673; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JANSONIUS JN, 1985, TRANSAMINASES, P110; JENKINS WT, 1966, BIOCHEM BIOPH RES CO, V22, P376, DOI 10.1016/0006-291X(66)90656-5; JENKINS WT, 1957, J AM CHEM SOC, V79, P2655, DOI 10.1021/ja01567a086; JENKINS WT, 1985, TRANSAMINASES, P215; KALLEN RG, 1985, TRANSAMINASES, P37; KAMITORI S, 1987, J BIOCHEM, V101, P813, DOI 10.1093/jb/101.3.813; KAMITORI S, 1990, J BIOCHEM-TOKYO, V108, P175, DOI 10.1093/oxfordjournals.jbchem.a123178; KAMITORI S, 1988, J BIOCHEM-TOKYO, V104, P317, DOI 10.1093/oxfordjournals.jbchem.a122464; KARMEN A, 1955, J CLIN INVEST, V34, P126, DOI 10.1172/JCI103055; KIICK DM, 1983, BIOCHEMISTRY-US, V22, P375, DOI 10.1021/bi00271a022; KONDO K, 1987, J BIOL CHEM, V262, P8648; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; KURAMITSU S, 1985, J BIOCHEM, V97, P1259, DOI 10.1093/oxfordjournals.jbchem.a135173; KURAMITSU S, 1985, BIOCHEM BIOPH RES CO, V133, P134, DOI 10.1016/0006-291X(85)91851-0; MARTINEZCARRION M, 1967, J BIOL CHEM, V242, P1426; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORINO Y, 1980, FRONTIERS PROTEIN CH, P515; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OVCHINNIKOV YA, 1973, FEBS LETT, V29, P31, DOI 10.1016/0014-5793(73)80008-0; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; VELICK SF, 1962, J BIOL CHEM, V237, P2109; YAMASAKI M, 1975, BIOCHEM BIOPH RES CO, V65, P652, DOI 10.1016/S0006-291X(75)80196-3	33	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6079	6085						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007566				2022-12-25	WOS:A1991FE37300015
J	COLEMAN, MB; STEINBERG, MH; ADAMS, JG				COLEMAN, MB; STEINBERG, MH; ADAMS, JG			HEMOGLOBIN TERRE HAUTE ARGININE-BETA-106 - A POSTHUMOUS CORRECTION TO THE ORIGINAL STRUCTURE OF HEMOGLOBIN INDIANAPOLIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BODY BETA-THALASSEMIA; G8 LEU->PRO; CHAIN; MUTATION; DNA; POLYMERASE; PHENOTYPE; ARGININE; FAMILY	The initial report of Hb Indianapolis described two affected individuals with the phenotype of severe beta-thalassemia that was dominantly inherited. The structure of this variant could not be deduced by standard techniques because of its extreme instability. Because of this limitation, the structure was ascertained by analysis of the abnormal globin chain, which had been radioactively labeled. These studies strongly suggested that the structure of this variant was cysteine beta-112 to arginine. Subsequent to this report, two additional families with Hb Indianapolis were found. The carriers were minimally affected and the abnormal hemoglobin was only mildly unstable. This major difference in phenotypic expression suggested that further investigation of the original family should be carried out. Unfortunately, both of the original carriers of the variant succumbed to their severe anemia prior to the subsequent reports. However, by the use of the polymerase chain reaction, enough DNA was obtained to sequence the third exon of the beta-globin gene in the original family from the DNA scraped off a 10-year-old bone marrow microscope slide. These studies revealed a substitution of leucine to arginine at position 106 of the beta-globin chain. The polymerase chain reaction results may be consistent with the original protein structural data, if incomplete tryptic cleavage of this arginine residue occurred in the original sample. We have renamed this variant Hb Terre Haute in an attempt to avoid confusion with the Cys-beta-112 --> Arg substitution.	UNIV MISSISSIPPI,MED CTR,SCH MED,DEPT MED,JACKSON,MS 39216	University of Mississippi; University of Mississippi Medical Center	COLEMAN, MB (corresponding author), UNIV MISSISSIPPI,MED CTR,SCH MED,VET AFFAIRS MED CTR,JACKSON,MS 39216, USA.			Steinberg, Martin/0000-0001-8800-8020				ADAMS JG, 1979, J BIOL CHEM, V254, P3479; ADAMS JG, 1990, BRIT J HAEMATOL, V75, P561, DOI 10.1111/j.1365-2141.1990.tb07799.x; ADAMS JG, 1990, SEMIN HEMATOL, V27, P229; ADAMS JG, 1979, J CLIN INVEST, V63, P931, DOI 10.1172/JCI109393; ADAMS JG, 1981, RED CELL, P81; BAIGET M, 1986, HEMOGLOBIN, V10, P483, DOI 10.3109/03630268609014133; BERIS P, 1988, BLOOD, V72, P801; DEBIASI R, 1988, HEMOGLOBIN, V12, P323, DOI 10.3109/03630268808998033; FEI YJ, 1989, BLOOD, V73, P1075; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HYDE RD, 1972, LANCET, V2, P1170; KAZAZIAN H H JR, 1989, American Journal of Human Genetics, V45, pA242; KAZAZIAN HH, 1986, AM J HUM GENET, V38, P860; KLEIHAUER E, 1971, KLIN WOCHENSCHR, V48, P651; KOBAYASHI Y, 1987, BLOOD, V70, P1688; KOHNE E, 1976, FEBS LETT, V64, P443, DOI 10.1016/0014-5793(76)80346-8; KOLER RD, 1973, AM J MED, V55, P549, DOI 10.1016/0002-9343(73)90213-1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THEIN SL, 1990, P NATL ACAD SCI USA, V87, P3924, DOI 10.1073/pnas.87.10.3924; WAJCMAN H, 1975, BIOCHEMISTRY-US, V14, P5017, DOI 10.1021/bi00693a036	21	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5798	5800						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005117				2022-12-25	WOS:A1991FD37000069
J	JAMES, P; WHELEN, S; HALL, BD				JAMES, P; WHELEN, S; HALL, BD			THE RET1 GENE OF YEAST ENCODES THE 2ND-LARGEST SUBUNIT OF RNA POLYMERASE-III - STRUCTURAL-ANALYSIS OF THE WILD-TYPE AND RET1-1 MUTANT ALLELES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BETA-SUBUNIT; NUCLEOTIDE-SEQUENCE; DNA-SEQUENCE; GEL-ELECTROPHORESIS; CHLOROPLAST DNA; CORE SUBUNITS; RPOB GENE; TRANSFORMATION	We have previously reported on the isolation of the ret1-1 mutation in yeast, which reduces the efficiency of transcription termination by RNA polymerase III. We have cloned the RET1 gene by complementation of an ochre suppression phenotype in ret1-1 cells. The RET1 gene was mapped to near the HIS3 gene on the right arm of chromosome 15 by using hybridization to OFAGE gels. Sequencing of the RET1 gene has identified its product as the second-largest subunit of RNA polymerase III. We have carried out an extensive sequence alignment with other RNA polymerase second-largest subunits and discuss the conservation of several functional domains. The RET1 gene was used to recover the ret1-1 mutant allele from genomic DNA using an integration/excision technique. Plasmid-based fine mapping and fragment swapping were used to localize the ret1-1 mutation for sequencing. We discuss the ret1-1 sequence lesion with regard to possible roles in transcription. In particular, the recessive nature of the ret1-1 mutation may have major implications for our understanding of the transcription process.	UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011895, T32GM007735] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07735, GM62-0379, GM11895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1965, EMBO, V4, P2657; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BELL GI, 1977, J BIOL CHEM, V252, P3082; BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; FUKADA R, 1974, J MOL BIOL, V87, P523; GLASS RE, 1986, MOL GEN GENET, V203, P487, DOI 10.1007/BF00422074; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; GUDENUS R, 1988, GENETICS, V119, P517; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIMMELFARB HJ, 1987, MOL CELL BIOL, V7, P2155, DOI 10.1128/MCB.7.6.2155; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; HUET J, 1982, J BIOL CHEM, V257, P2613; HUET J, 1987, P NATL ACAD SCI USA, V84, P3648, DOI 10.1073/pnas.84.11.3648; JAMES P, 1990, GENETICS, V125, P293; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KONTERMANN R, 1989, MOL GEN GENET, V219, P373, DOI 10.1007/BF00259609; KUNES S, 1987, GENETICS, V115, P73; KURJAN J, 1980, CELL, V20, P701, DOI 10.1016/0092-8674(80)90316-5; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; LISITSYN NA, 1988, EUR J BIOCHEM, V177, P262; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; OHME M, 1986, FEBS LETT, V200, P87, DOI 10.1016/0014-5793(86)80516-6; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; PANKA D, 1985, J BIOL CHEM, V260, P1427; PATEL DD, 1989, J VIROL, V63, P1076, DOI 10.1128/JVI.63.3.1076-1086.1989; PUHLER G, 1989, NUCLEIC ACIDS RES, V17, P4517, DOI 10.1093/nar/17.12.4517; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; RIVA M, 1987, J BIOL CHEM, V262, P14377; ROEDER GS, 1980, CELL, V21, P239, DOI 10.1016/0092-8674(80)90131-2; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCAFE C, 1990, MOL CELL BIOL, V10, P1270, DOI 10.1128/MCB.10.3.1270; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; Sherman F., 1983, METHODS YEAST GENETI; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; WALKER SS, 1989, MOL CELL BIOL, V9, P2914, DOI 10.1128/MCB.9.7.2914; WANDZILAK TM, 1978, BIOCHEMISTRY-US, V17, P426, DOI 10.1021/bi00596a007; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WITTEKIND M, 1988, MOL CELL BIOL, V8, P3997, DOI 10.1128/MCB.8.10.3997; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	65	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5616	5624						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005101				2022-12-25	WOS:A1991FD37000041
J	FUSHITANI, K; RIGGS, AF				FUSHITANI, K; RIGGS, AF			THE EXTRACELLULAR HEMOGLOBIN OF THE EARTHWORM, LUMBRICUS-TERRESTRIS - OXYGENATION PROPERTIES OF ISOLATED CHAINS, TRIMER, AND A REASSOCIATED PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT; ERYTHROCRUORIN; DISSOCIATION; BINDING; PROTEIN; PH	The extracellular hemoglobin of the earthworm Lumbricus terrestris has a two-tiered hexagonal structure that can be dissociated into 1/12 subunits. The Hb contains four major kinds of oxygen-binding chains, a, b, c, and d, of which a-c form a disulfide-linked trimer. Additional non-heme chains are necessary for the assembly of the intact 3800-kDa molecule of approximately 200 subunits. Oxygen equilibria have been measured for chains c and d, the abc trimer, the partially reassembled product of addition of chain d to the trimer, and the intact molecule. The results show that oxygenation of the trimer but not the isolated c or d subunits is modulated by both pH and Ca2+ ions. Cooperativity of oxygen binding by the trimer is low (Hill coefficient almost-equal-to 1.3). However, addition of chain d results in a substantial decrease in oxygen affinity and a large increase in cooperativity so that the oxygen equilibrium becomes indistinguishable from that of the intact native molecule at pH 6.8. Light-scattering data show that the smallest observed trimeric abc unit is the dimer (abc)2 at pH 6.8. Analysis of the major sedimentation velocity boundary of the product of the abc unit and chain d in the CO form in the absence of calcium surprisingly can be accounted for entirely in terms of a nondissociating dimer, (abc)2 and chain d. The data for the CO form in the presence of calcium are best fitted in terms of (abc)2.d. Although both subunits c and d also form dimers, oxygen binding by subunit c, but not d, is highly cooperative. These observations, taken together, suggest that the two dimers (abc)2 and d2 are likely to be the major participants in forming the primary functional unit, (abcd)2, which at pH 7.4 is partially dissociated when in the CO form. Subunit d is clearly necessary for the formation of a cooperative unit. The hypothesis that (abcd)2 is a primary functional unit is consistent with a stoichiometry of 2 (abcd)2 units per 1/12 subunit or 24 such units in each molecule of Hb which would contain, in all, 192 heme-containing chains.	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin					NIGMS NIH HHS [GM 35847, GM 28410] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847, R01GM028410] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1987, ANNU REV BIOPHYS BIO, V16, P583; ANTONINI E, 1977, ANNU REV BIOPHYS BIO, V6, P239, DOI 10.1146/annurev.bb.06.060177.001323; ATHA DH, 1979, J BIOL CHEM, V254, P3393; CHIANCONE E, 1972, J MOL BIOL, V70, P73, DOI 10.1016/0022-2836(72)90164-7; Cox D. J, 1978, METHOD ENZYMOL, V48F, P212; DALES RP, 1970, Z ZELLFORSCH MIK ANA, V109, P20, DOI 10.1007/BF00364928; DOLMAN D, 1978, ANAL BIOCHEM, V87, P127, DOI 10.1016/0003-2697(78)90576-6; Fushitani K., 1986, P77; FUSHITANI K, 1986, J BIOL CHEM, V261, P8414; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; FUSHITANI K, 1988, P NATL ACAD SCI USA, V85, P9461, DOI 10.1073/pnas.85.24.9461; FUSHITANI K, 1990, IN PRESS STRUCTURE F; GOSS DJ, 1975, BIOCHEMISTRY-US, V14, P5461, DOI 10.1021/bi00696a012; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; KAPP OH, 1988, BIOPHYS J, V53, pA280; KAPP OH, 1987, P NATL ACAD SCI USA, V84, P7532, DOI 10.1073/pnas.84.21.7532; KAPP OH, 1981, BIOCHEM BIOPH RES CO, V101, P509, DOI 10.1016/0006-291X(81)91289-4; KEGELES G, 1979, FEBS LETT, V103, P5, DOI 10.1016/0014-5793(79)81238-7; Lapennas G N, 1981, Methods Enzymol, V76, P449; PILZ I, 1980, INT J BIOL MACROMOL, V2, P279, DOI 10.1016/0141-8130(80)90045-8; RKOSZ MJ, 1982, BIOCHIM BIOPHYS ACTA, V707, P291; ROSSIFANELLI MR, 1970, ARCH BIOCHEM BIOPHYS, V141, P278; ROYER WE, 1988, J BIOL CHEM, V263, P13762; SANTUCCI R, 1984, J MOL BIOL, V179, P713, DOI 10.1016/0022-2836(84)90163-3; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; SUZUKI T, 1990, J BIOL CHEM, V265, P12168; VINOGRADOV SN, 1977, BIOCHIM BIOPHYS ACTA, V492, P136, DOI 10.1016/0005-2795(77)90221-5; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	29	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10275	10281						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037579				2022-12-25	WOS:A1991FP08600045
J	JENAL, U; RECHSTEINER, T; TAN, PY; BUHLMANN, E; MEILE, L; LEISINGER, T				JENAL, U; RECHSTEINER, T; TAN, PY; BUHLMANN, E; MEILE, L; LEISINGER, T			ISOLEUCYL-TRANSFER RNA-SYNTHETASE OF METHANOBACTERIUM-THERMOAUTOTROPHICUM MARBURG - CLONING OF THE GENE, NUCLEOTIDE-SEQUENCE, AND LOCALIZATION OF A BASE CHANGE CONFERRING RESISTANCE TO PSEUDOMONIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYL-TRANSFER-RNA; SITE-DIRECTED MUTAGENESIS; ILES-LSP OPERON; ESCHERICHIA-COLI; METHANOCOCCUS-VANNIELII; 3-DIMENSIONAL STRUCTURE; RIBOSOMAL-PROTEINS; BINDING-SITE; IDENTIFICATION; CONSTRUCTION	The ileS gene encoding the isoleucyl-tRNA synthetase of the thermophilic archaebacterium Methanobacterium thermoautotrophicum Marburg was isolated and sequenced. ileS was closely flanked by an unknown open reading frame and by purL and thus is arranged differently from the organizations observed in several eubacteria or in Saccharomyces cerevisiae. The deduced amino acid sequence of isoleucyl-tRNA synthetase was compared with primary sequences of isoleucyl-, valyl-, leucyl-, and methionyl-tRNA synthetases from eubacteria and yeast. The archaebacterial enzyme fitted well into this group of enzymes. It contained the two short consensus sequences observed in class I aminoacyl-tRNA synthetases as well as regions of homology with enzymes of the isoleucine family. Comparison between the isoleucyl-tRNA synthetases of M. thermoautotrophicum yielded 36% amino acid identity with the yeast enzyme and 32% identity with the corresponding enzyme from Escherichia coli. The ileS gene of the pseudomonic acid-resistant M. thermoautotrophicum mutant MBT10 was also sequenced. The mutant enzyme had undergone a glycine to aspartic acid transition at position 590, in a conserved region comprising the KMSKS consensus sequence. The inhibition constants of pseudomonic acid, K(i)Ile and K(i)ATP, for the mutant enzyme were 10-fold higher than those determined for the wild-type enzyme. Both the mutant and the wild-type ileS gene were expressed in E. coli, and their products displayed the expected difference in sensitivity toward pseudomonic acid.	SWISS FED INST TECHNOL,INST MIKROBIOL,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Meile, Leo/B-3716-2016					AUER J, 1989, CAN J MICROBIOL, V35, P200, DOI 10.1139/m89-031; BEDOUELLE H, 1986, NATURE, V320, P371, DOI 10.1038/320371a0; BEDOUELLE H, 1990, J BACTERIOL, V172, P3940, DOI 10.1128/jb.172.7.3940-3945.1990; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P2480, DOI 10.1021/bi00383a012; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BROWN JW, 1989, CRIT REV MICROBIOL, V16, P287, DOI 10.3109/10408418909105479; BRUNIE S, 1987, J MOL GRAPHICS, V5, P18, DOI 10.1016/0263-7855(87)80039-5; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHATTON B, 1987, J BIOL CHEM, V262, P15094; CLARKE ND, 1988, SCIENCE, V240, P521, DOI 10.1126/science.3282306; Cleland W. W, 1970, ENZYMES, V2, P1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FEINBERG AP, 1987, ANAL BIOCHEM, V132, P6; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FUCHS G, 1978, ARCH MICROBIOL, V117, P61, DOI 10.1007/BF00689352; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HECK JD, 1988, J BIOL CHEM, V263, P868; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOUNTONDJI C, 1985, BIOCHEMISTRY-US, V24, P1175, DOI 10.1021/bi00326a018; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; HOUNTONDJI C, 1990, BIOCHEMISTRY-US, V29, P8190, DOI 10.1021/bi00487a029; HOUNTONDJI C, 1986, BIOCHEMISTRY-US, V25, P16, DOI 10.1021/bi00349a003; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISAKI L, 1990, J BACTERIOL, V172, P469, DOI 10.1128/JB.172.1.469-472.1990; ISAKI L, 1990, J BACTERIOL, V172, P6512, DOI 10.1128/jb.172.11.6512-6517.1990; KAMIO Y, 1985, J BIOL CHEM, V260, P5616; KIENER A, 1987, J BACTERIOL, V169, P1010, DOI 10.1128/jb.169.3.1010-1016.1987; KIENER A, 1986, FEMS MICROBIOL LETT, V33, P15; KLEIN A, 1988, MOL GEN GENET, V213, P409, DOI 10.1007/BF00339610; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; KOPKE AKE, 1989, CAN J MICROBIOL, V35, P11; LECHNER K, 1987, MOL GEN GENET, V208, P523, DOI 10.1007/BF00328150; LECHNER K, 1988, NUCLEIC ACIDS RES, V16, P7817, DOI 10.1093/nar/16.16.7817; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MARTINDALE DW, 1989, CURR GENET, V15, P99, DOI 10.1007/BF00435455; MAYAUX JF, 1981, BIOCHEMISTRY-US, V20, P4647, DOI 10.1021/bi00519a020; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILLER KW, 1987, J BIOL CHEM, V262, P7391; MYERS AM, 1985, J BIOL CHEM, V260, P5371; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OSTERGAARD L, 1987, SYST APPL MICROBIOL, V9, P199; POLISKY B, 1975, P NATL ACAD SCI USA, V72, P3310, DOI 10.1073/pnas.72.9.3310; POSORSKE LH, 1979, BIOCHIM BIOPHYS ACTA, V576, P128, DOI 10.1016/0005-2795(79)90491-4; RECHSTEINER T, 1989, EUR J BIOCHEM, V181, P41, DOI 10.1111/j.1432-1033.1989.tb14691.x; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santi D V, 1974, Methods Enzymol, V29, P620; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHLEIF RF, 1981, PRACTICAL METHODS MO, P201; SCHONHEIT P, 1980, ARCH MICROBIOL, V127, P59, DOI 10.1007/BF00414356; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; THOMM M, 1989, CAN J MICROBIOL, V35, P30, DOI 10.1139/m89-005; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZILLIG W, 1989, CAN J MICROBIOL, V35, P73, DOI 10.1139/m89-011	71	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10570	10577						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037598				2022-12-25	WOS:A1991FP08600085
J	REHEMTULLA, A; RUF, W; EDGINGTON, TS				REHEMTULLA, A; RUF, W; EDGINGTON, TS			THE INTEGRITY OF THE CYSTEINE-186-CYSTEINE-209 BOND OF THE 2ND DISULFIDE LOOP OF TISSUE FACTOR IS REQUIRED FOR BINDING OF FACTOR-VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; FACTOR-X; PHOSPHOLIPID-VESICLES; MONOCLONAL-ANTIBODY; CELLULAR RECEPTOR; MEMBRANE-PROTEIN; GROWTH-FACTOR; COAGULATION; ACTIVATION; CDNA	The structural basis of function of tissue factor (TF), the cell surface receptor and cofactor for the serine protease factor VIIa, cannot be inferred from the primary sequence. The functional significance of the two disulfide bonded loops in the surface domain of TF has been analyzed using site-directed mutagenesis to selectively preclude covalent stabilization of these loops by pairwise substitution of serine residues for cysteines. Mutant TF lacking either the amino (TF(S49S57)) or carboxyl (TF(S186S209)) disulfide bond were expressed on the surface of cells consistent with proper processing. Each reacted with a panel of monoclonal antibodies further suggesting proper global folding of the mutant proteins. TF(S186S209) exhibited a selective decrease in reactivity with an antibody directed against one epitope locus in the carboxyl aspect of the surface domain of TF. Whereas TF(S49S57) was functionally comparable to the wild type protein, TF(S186S209) was functionally 30-40-fold less effective, and the affinity of factor VIIa binding to this mutant was indirectly estimated to be diminished 20-fold. These data suggest that the Cys186-Cys209 disulfide bond is required to maintain conformation and implicate the disulfide loop or adjacent structures in the carboxyl half of the surface domain of TF in receptor function.	DEPT IMMUNOL,VASC CELL & MOLEC BIOL PROGRAM,LA JOLLA,CA 92037						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS BS, 1991, GENE, V98, P264; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BACH R, 1981, J BIOL CHEM, V256, P8324; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; BURRI BJ, 1987, BIOCHIM BIOPHYS ACTA, V923, P176, DOI 10.1016/0304-4165(87)90002-X; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; FAIR DS, 1983, BLOOD, V62, P784; FAIR DS, 1987, J BIOL CHEM, V262, P11692; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HURLE MR, 1990, BIOCHEMISTRY-US, V29, P4410, DOI 10.1021/bi00470a021; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NARACHI MA, 1987, J BIOL CHEM, V262, P13107; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PANTOLIANO MW, 1987, BIOCHEMISTRY-US, V26, P2077, DOI 10.1021/bi00382a002; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; PLOPLIS VA, 1987, J BIOL CHEM, V262, P9503; REHEMTULLA A, 1991, IN PRESS THROMB HAEM; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1989, THROMB HAEMOSTASIS, V62, P69; SAUER MK, 1988, MOL CELL BIOL, V8, P1011, DOI 10.1128/MCB.8.3.1011; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TAYLOR FB, 1991, IN PRESS CIRC SHOCK; WEISS HJ, 1988, BLOOD, V71, P629; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; ZHANG RM, 1989, J BIOL CHEM, V264, P18472	43	82	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10294	10299						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037582				2022-12-25	WOS:A1991FP08600048
J	SEIGNEURET, M; NEUMANN, JM; RIGAUD, JL				SEIGNEURET, M; NEUMANN, JM; RIGAUD, JL			DETERGENT DELIPIDATION AND SOLUBILIZATION STRATEGIES FOR HIGH-RESOLUTION NMR OF THE MEMBRANE-PROTEIN BACTERIORHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEAR-MAGNETIC-RESONANCE; BETA-D-THIOGLUCOSIDE; TWO-DIMENSIONAL NMR; M13 COAT PROTEIN; PURPLE MEMBRANE; TRITON X-100; DODECYLPHOSPHOCHOLINE MICELLES; MONOMERIC BACTERIORHODOPSIN; NONIONIC DETERGENT; MODEL	High-resolution NMR studies of bacteriorhodopsin require the availability of the detergent-solubilized protein with both high concentration and small rotational correlation time. A procedure is described for the optimized preparation of such samples. Bacteriorhodopsin was first delipidated by detergent treatment of purple membrane under nonsolubilizing conditions for the protein. The delipidated aggregated protein could then be solubilized into monomers at concentration close to millimolar by selected detergents. The solubilizing detergent had an important effect on the rotational correlation time of the protein as shown by measuring in each case the temperature-dependent stability of the protein, the size of the detergent-protein complex, and the detergent viscosity. Consistently, a strong influence of the detergent was also found on spectral resolution in C-13 NMR spectra of solubilized bacteriorhodopsin labeled with [1-C-13]phenylalanine. Best resolution was obtained using n-dodecylmaltoside as detergent, with which relatively narrow well resolved C-13 NMR resonances were observed at 50-degrees-C. It is suggested that high-resolution NMR studies performed with this detergent may contribute to the structural resolution of bacteriorhodopsin.			SEIGNEURET, M (corresponding author), CENS, DEPT BIOL CELLULAIRE & MOLEC, CNRS, URA 1290, F-91191 GIF SUR YVETTE, FRANCE.							ABRAGAM A, 1961, PRINCIPLES NUCLEAR M; BAX A, 1989, ANNU REV BIOCHEM, V58, P223; BAYLEY H, 1981, P NATL ACAD SCI-BIOL, V78, P2225, DOI 10.1073/pnas.78.4.2225; BOWERS JL, 1988, BIOCHEMISTRY-US, V27, P5156, DOI 10.1021/bi00414a031; BROUILLETTE CG, 1989, PROTEINS, V5, P38, DOI 10.1002/prot.340050106; BROWN LR, 1981, BIOCHIM BIOPHYS ACTA, V647, P95, DOI 10.1016/0005-2736(81)90298-4; BROWN LR, 1982, BIOPHYS J, V37, P319, DOI 10.1016/S0006-3495(82)84680-8; CASADIO R, 1980, BIOCHIM BIOPHYS ACTA, V590, P13, DOI 10.1016/0005-2728(80)90142-5; DENCHER NA, 1982, METHOD ENZYMOL, V88, P5; HAPPE M, 1976, BIOCHEM BIOPH RES CO, V72, P1504, DOI 10.1016/S0006-291X(76)80184-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENRY GD, 1987, BIOCHEMISTRY-US, V26, P3619, DOI 10.1021/bi00386a055; HENRY GD, 1990, J MOL BIOL, V212, P11, DOI 10.1016/0022-2836(90)90299-2; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; HWANG SB, 1977, J MEMBRANE BIOL, V33, P325, DOI 10.1007/BF01869523; INAGAKI F, 1989, BIOCHEMISTRY-US, V28, P5985, DOI 10.1021/bi00440a040; Kouyama T, 1988, Adv Biophys, V24, P123, DOI 10.1016/0065-227X(88)90006-8; KUHLBRANDT W, 1988, Q REV BIOPHYS, V21, P429, DOI 10.1017/S0033583500004625; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; MARKLEY JL, 1989, METHOD ENZYMOL, V176, P12; MIERCKE LJW, 1989, J BIOL CHEM, V264, P7531; Moller J. V., 1986, PROGR PROTEIN LIPID, P147; Oesterhelt D, 1974, Methods Enzymol, V31, P667; ONISHI H, 1965, CAN J MICROBIOL, V11, P365, DOI 10.1139/m65-044; OSBORNE HB, 1974, EUR J BIOCHEM, V44, P383, DOI 10.1111/j.1432-1033.1974.tb03495.x; POPOT JL, 1989, J MOL BIOL, V210, P829, DOI 10.1016/0022-2836(89)90111-3; REYNOLDS JA, 1977, P NATL ACAD SCI USA, V74, P2803, DOI 10.1073/pnas.74.7.2803; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHIKSNIS RA, 1987, BIOCHEMISTRY-US, V26, P1373, DOI 10.1021/bi00379a025; SHIMAMOTO T, 1985, J BIOCHEM-TOKYO, V97, P1807, DOI 10.1093/oxfordjournals.jbchem.a135240; SZUNDI I, 1987, P NATL ACAD SCI USA, V84, P3681, DOI 10.1073/pnas.84.11.3681; Tanford C., 1961, PHYS CHEM MACROMOLEC; TIMMINS PA, 1988, FEBS LETT, V238, P361, DOI 10.1016/0014-5793(88)80513-1; TSUCHIYA T, 1984, J BIOCHEM-TOKYO, V96, P1593, DOI 10.1093/oxfordjournals.jbchem.a134989	35	45	45	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10066	10069						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037565				2022-12-25	WOS:A1991FP08600013
J	SIMBENI, R; PON, L; ZINSER, E; PALTAUF, F; DAUM, G				SIMBENI, R; PON, L; ZINSER, E; PALTAUF, F; DAUM, G			MITOCHONDRIAL-MEMBRANE CONTACT SITES OF YEAST - CHARACTERIZATION OF LIPID COMPONENTS AND POSSIBLE INVOLVEMENT IN INTRAMITOCHONDRIAL TRANSLOCATION OF PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; OUTER	Submitochondrial membrane fractions from yeast that are enriched in inner and outer membrane contact sites were analyzed with respect to their lipid composition. Characteristic features were the significantly reduced content of phosphatidylinositol, the decreased amount of phosphatidylcholine, and the enrichment in phosphatidylethanolamine and cardiolipin. Coisolation of phosphatidylserine synthase with the outer membrane portion and enrichment of phosphatidylserine decarboxylase in the inner membrane portion of isolated contact sites provided the basis for a metabolic assay to study phosphatidylserine transfer from the outer to the inner mitochondrial membrane via contact sites. The efficient conversion to [H-3]phosphatidylethanolamine of [H-3]phosphatidylserine synthesized from [H-3]serine in situ supports the notion that mitochondrial membrane contact sites are zones of intramitochondrial translocation of phosphatidylserine.	GRAZ TECH UNIV,INST BIOCHEM & LEBENSMITTLECHEM,PETERGASSE 12-II,A-8010 GRAZ,AUSTRIA; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND	Graz University of Technology; University of Basel					NIGMS NIH HHS [5 F32 GM11799-03 BI-3] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011799] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDAIL D, 1990, J BIOL CHEM, V265, P18797; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; BURGER KNJ, 1990, EXPERIENTIA, V46, P631, DOI 10.1007/BF01939702; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1989, J BIOL CHEM, V264, P2945; FOLCH J, 1957, J BIOL CHEM, V226, P497; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHLENDIECK K, 1986, BIOCHIM BIOPHYS ACTA, V860, P672, DOI 10.1016/0005-2736(86)90567-5; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SIMBENI R, 1990, J BIOL CHEM, V265, P281; SPERKAGOTTLIEB CDM, 1988, BIOCHIM BIOPHYS ACTA, V946, P227, DOI 10.1016/0005-2736(88)90397-5; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	22	122	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10047	10049						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037561				2022-12-25	WOS:A1991FP08600008
J	TAL, S; CHUN, TW; GAVINI, N; BURGESS, BK				TAL, S; CHUN, TW; GAVINI, N; BURGESS, BK			THE DELTA-NIFB (OR DELTA-NIFE) FEMO COFACTOR-DEFICIENT MOFE PROTEIN IS DIFFERENT FROM THE DELTA-NIFH PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; KLEBSIELLA-PNEUMONIAE; AZOTOBACTER-VINELANDII; NITROGEN-FIXATION; ELECTRON-TRANSFER; PURIFICATION; BIOSYNTHESIS; REDUCTASE; PRODUCTS; ABSENCE	We have examined three strains of Azotobacter vinelandii, which contain defined deletions within the nifH, nifB, or nifE genes. All three strains accumulate inactive FeMo cofactor-deficient forms of the MoFe protein of nitrogenase. These forms can be activated in vitro by addition of isolated FeMo cofactor in N-methylformamide. Although the phenotypes of these strains are superficially the same, our characterizations demonstrate that the FeMo cofactor-deficient MoFe protein synthesized by the DELTA-nifH strain is quite different from that synthesized by either the DELTA-nifB or DELTA-nifE strains. These differences include the following: 1) the activation of the DELTA-nifH protein requires MgATP, whereas the activation of the DELTA-nifB and DELTA-nifE proteins does not; 2) the DELTA-nifH extracts can be activated with FeMo cofactor to wild-type levels of activity, whereas DELTA-nifB and DELTA-nifE extracts cannot; 3) the DELTA-nifH protein is markedly less heat stable than the DELTA-nifB and DELTA-nifE proteins; and 4) the migration of the DELTA-nifH protein on native gels is very different when compared with DELTA-nifB and DELTA-nifE, which look like each other. These data can be explained if the nifB and nifE gene products are only involved in FeMo cofactor biosynthesis, whereas the nifH gene product is involved in both the initial synthesis of FeMo cofactor and in the insertion of preformed FeMo cofactor into the MoFe protein. A model is presented that suggests that the FeMo cofactor-deficient MoFe protein synthesized by the DELTA-nifH strain is the one that normally participates in MoFe protein assembly in wild-type cells.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Chun, Tae-Wook/W-9187-2019	Chun, Tae-Wook/0000-0001-5153-7340	NIGMS NIH HHS [R01 GM43144] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1981, CURRENT PERSPECTIVES, P71; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EADY RR, 1978, FEBS LETT, V95, P211, DOI 10.1016/0014-5793(78)80995-8; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HOOVER T R, 1988, Biofactors, V1, P199; LJONES T, 1978, BIOCHEM BIOPH RES CO, V80, P22, DOI 10.1016/0006-291X(78)91098-7; Merrick M. J., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P293; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBERTS GP, 1978, J BACTERIOL, V136, P267, DOI 10.1128/JB.136.1.267-279.1978; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBINSON AE, 1984, BIOCHEM J, V219, P495, DOI 10.1042/bj2190495; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; Smith B. E., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P91; STEPHENS PJ, 1985, MOLYBDENUM ENZYMES, P117; STIEFEL EI, 1985, MOLYBDENUM ENZYMES, P89; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; YANG SS, 1982, J BIOL CHEM, V257, P8042	26	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10654	10657						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037604				2022-12-25	WOS:A1991FP08600097
J	XIANG, MQ; GE, T; TOMLINSON, CR; KLEIN, WH				XIANG, MQ; GE, T; TOMLINSON, CR; KLEIN, WH			STRUCTURE AND PROMOTER ACTIVITY OF THE LPS1 GENES OF LYTECHINUS-PICTUS - DUPLICATED EXONS ACCOUNT FOR LPS1 PROTEINS WITH 8 CALCIUM-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EMBRYOS; TROPONIN-C SUPERFAMILY; MESSENGER-RNAS; STRONGYLOCENTROTUS-PURPURATUS; TRANSCRIPTION FACTOR; ACTIN GENE; ECTODERM; DNA; EMBRYOGENESIS; EXPRESSION	The LpS1 genes of the sea urchin Lytechinus pictus are activated early in development in aboral ectoderm cells. They therefore have ontogenic properties similar to their counterparts in Stronglyocentrotus purpuratus, the Spec genes. Both gene families encode proteins belonging to the calmodulin superfamily as evidenced by the presence of distinct EF-hand (helix-loop-helix) domains. The presence of eight EF-hand domains in LpS1 proteins suggests that the LpS1 genes arose from a duplication of an ancestral Spec-like gene. The LpS1 genes were further analyzed to increase our understanding of the mechanisms underlying their evolution and activation in aboral ectoderm cells. Genomic DNA blot analysis showed two LpS1 genes, LpS1-alpha and LpS1-beta, which did not appear to be closely linked. LpS1 genomic clones were isolated by screening an L. pictus genomic library with an LpS1 cDNA clone, and partial gene structures for both LpS1-alpha and LpS1-beta were constructed. These revealed internal duplication of the LpS1 genes that accounted for the eight EF-hand domains in the LpS1 proteins. Duplication of exon 1 in both genes suggested four different LpS1 proteins could be derived from the LpS1 genes. Primer extension to map the transcriptional initiation sites of the LpS1 genes and sequencing analysis showed there was little in common among the 5'-flanking regions of the LpS1 and Spec genes except for the presence of a binding site for the transcription factor USF. A sea urchin gene-transfer expression system showed that 762 base pairs (bp) of 5'-flanking DNA and 17 bp of 5'-untranslated leader sequence of the LpS1-beta gene were sufficient for correct temporal and spatial expression of reporter chloramphenicol acetyltransferase and lacZ genes in sea urchin embryos. Deletions at the 5' end to either 511 or 368 bp resulted in a 3-4 fold decrease in chloramphenicol acetyltransferase activity and disrupted the exclusive activation of the lacZ gene in aboral ectodermal cells. Based on a lineage analysis among the LpS1 and Spec gene families and other related genes, we propose a model in which LpS1 genes evolved from a series of duplications of an ancestral Spec-like gene.	UNIV HOUSTON, DEPT BIOL, HOUSTON, TX 77204 USA	University of Houston System; University of Houston	XIANG, MQ (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA.		Tomlinson, Craig/F-1319-2017	Tomlinson, Craig/0000-0003-0923-1449	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022619] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22619] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRUSKIN AM, 1982, DEV BIOL, V91, P317, DOI 10.1016/0012-1606(82)90038-0; CARPENTER CD, 1984, CELL, V36, P663, DOI 10.1016/0092-8674(84)90346-5; DEMAILLE JG, 1982, CALCIUM CELL FUNCTIO, V2, P111; FLYTZANIS CN, 1987, P NATL ACAD SCI USA, V84, P151, DOI 10.1073/pnas.84.1.151; GAN L, 1990, DEV BIOL, V142, P346, DOI 10.1016/0012-1606(90)90355-M; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARDIN PE, 1988, J MOL BIOL, V202, P417, DOI 10.1016/0022-2836(88)90275-6; HARDIN PE, 1987, J MOL EVOL, V25, P126, DOI 10.1007/BF02101754; HARDIN SH, 1985, J MOL BIOL, V186, P243, DOI 10.1016/0022-2836(85)90101-9; HARDIN SH, 1987, BIOCHEMISTRY-US, V26, P3518, DOI 10.1021/bi00386a040; HOUGHEVANS BR, 1988, DEV BIOL, V129, P198, DOI 10.1016/0012-1606(88)90174-1; HOUGHEVANS BR, 1990, DEVELOPMENT, V110, P41; KLEIN W H, 1990, P123; KLEIN WH, 1991, NOVEL CALCIUM BINDIN; LEE JJ, 1984, J MOL BIOL, V172, P149, DOI 10.1016/S0022-2836(84)80035-2; LIN G, 1990, DEV BIOL, V139, P186, DOI 10.1016/0012-1606(90)90287-S; LYNN DA, 1983, P NATL ACAD SCI-BIOL, V80, P2656, DOI 10.1073/pnas.80.9.2656; MCMAHON AP, 1985, DEV BIOL, V108, P420, DOI 10.1016/0012-1606(85)90045-4; Moncrief N.D., 1988, CALCIUM CHANNEL STRU, P16; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Norman AW, 1987, CALCIUM BINDING PROT; PERRET C, 1988, J MOL EVOL, V27, P351, DOI 10.1007/BF02101198; Sambrook J, 1989, MOL CLONING LAB MANU, P650; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; THIEBAUD P, 1990, GENE DEV, V4, P1999, DOI 10.1101/gad.4.11.1999; TOMLINSON CR, 1990, MOL REPROD DEV, V25, P328, DOI 10.1002/mrd.1080250404; TOMLINSON CR, 1990, DEVELOPMENT, V110, P259; XIANG MQ, 1988, J BIOL CHEM, V263, P17173	29	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10524	10533						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037596				2022-12-25	WOS:A1991FP08600080
J	METZLER, CM; VISWANATH, R; METZLER, DE				METZLER, CM; VISWANATH, R; METZLER, DE			EQUILIBRIA AND ABSORPTION-SPECTRA OF TRYPTOPHANASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHENOL-LYASE; BAND-SHAPE ANALYSIS; CARBON CARBON LYASES; MONO-VALENT CATIONS; ESCHERICHIA-COLI; PYRIDOXAL-PHOSPHATE; INDOLE-LYASE; ACTIVE-SITE; ASPARTATE-AMINOTRANSFERASE; MECHANISTIC DEDUCTIONS	Tryptophanase (tryptophan: indole-lyase) from Escherichia coli has been isolated in the holoenzyme form and its absorption spectra and acid-base chemistry have been reevaluated. Apoenzyme has been prepared by dialysis against sodium phosphate and L-alanine and molar absorptivities of the coenzyme bands have been estimated by readdition of pyridoxal 5'-phosphate. The spectrophotometric titration curve, whose midpoint is at pH 7.6 in 0.1 M potassium phosphate buffers, indicates some degree of cooperativity in dissociation of a pair of protons. Resolution of the computed spectra of individual ionic forms of the enzyme with lognormal distribution curves shows that band shapes are similar to those of model Schiff bases and of aspartate aminotransferase. Using molar areas from the latter we estimated amounts of individual tautomeric species. In addition to ketoenamine and enolimine or covalent adduct the high pH form also appears to contain approximately 18% of a species with a dipolar ionic ring (protonated on the ring nitrogen and with phenolate -O-). We suggest that this may be the catalytically active form of the coenzyme in tryptophanase. The equilibrium between tryptophanase and L-alanine has also been reevaluated.			METZLER, CM (corresponding author), IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK001549] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01549] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNONE A, 1985, TRANSAMINASES, P307; BEHBAHANINEJAD I, 1987, METHOD ENZYMOL, V142, P414; DEELEY MC, 1981, J BACTERIOL, V147, P787, DOI 10.1128/JB.147.3.787-796.1981; DEMIDKINA TV, 1989, BIOCHIMIE, V71, P565, DOI 10.1016/0300-9084(89)90188-0; DEMIDKINA TV, 1987, EUR J BIOCHEM, V170, P311, DOI 10.1111/j.1432-1033.1987.tb13701.x; DEMIDKINA TV, 1989, BIOKHIMIYA, V5, P745; GOPINATHAN KP, 1968, BIOCHEMISTRY-US, V7, P1685, DOI 10.1021/bi00845a010; HARRIS CM, 1976, BIOCHIM BIOPHYS ACTA, V421, P181, DOI 10.1016/0304-4165(76)90284-1; HOCH JA, 1966, BIOCHEMISTRY-US, V5, P2229, DOI 10.1021/bi00871a011; HOGBERGRAIBAUD A, 1975, J BIOL CHEM, V250, P3352; HONDA T, 1986, J BIOCHEM-TOKYO, V100, P679, DOI 10.1093/oxfordjournals.jbchem.a121760; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JUNE DS, 1981, BIOCHEMISTRY-US, V20, P2707, DOI 10.1021/bi00513a001; JUNE DS, 1981, BIOCHEMISTRY-US, V20, P2714, DOI 10.1021/bi00513a002; KAGAMIYAMA H, 1972, J BIOL CHEM, V247, P1576; KALLEN RG, 1985, TRANSAMINASES, P37; KAZARINOFF MN, 1980, J BIOL CHEM, V255, P6228; KIICK DM, 1988, BIOCHEMISTRY-US, V27, P7333, DOI 10.1021/bi00419a023; KIICK DM, 1988, BIOCHEMISTRY-US, V27, P7339, DOI 10.1021/bi00419a024; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; METZLER CM, 1988, BIOCHEMISTRY-US, V27, P4923, DOI 10.1021/bi00413a050; METZLER CM, 1980, J AM CHEM SOC, V102, P6075, DOI 10.1021/ja00539a017; METZLER CM, 1987, ANAL BIOCHEM, V166, P313, DOI 10.1016/0003-2697(87)90580-X; METZLER CM, 1985, APPL SPECTROSC, V39, P333, DOI 10.1366/0003702854249042; METZLER DE, 1986, TRENDS BIOCHEM SCI, V11, P157, DOI 10.1016/0968-0004(86)90131-3; METZLER DE, 1973, BIOCHEMISTRY-US, V12, P5377, DOI 10.1021/bi00750a022; METZLER DE, 1972, BIOCHEM BIOPH RES CO, V46, P1588, DOI 10.1016/0006-291X(72)90790-5; METZLER DE, 1977, BIOCH CHEM REACTIONS, P193; MILES EW, 1986, VITAMIN B6 PYRIDOXAL, P253; MITRA J, 1988, BIOCHIM BIOPHYS ACTA, V965, P93, DOI 10.1016/0304-4165(88)90156-0; MORINO Y, 1967, J BIOL CHEM, V242, P2800; NAGANO K, 1967, J AM CHEM SOC, V89, P2891, DOI 10.1021/ja00988a016; NEWTON WA, 1964, P NATL ACAD SCI USA, V51, P382, DOI 10.1073/pnas.51.3.382; NIHIRA T, 1985, EUR J BIOCHEM, V149, P129, DOI 10.1111/j.1432-1033.1985.tb08902.x; PHILLIPS RS, 1987, ARCH BIOCHEM BIOPHYS, V256, P302, DOI 10.1016/0003-9861(87)90450-4; PHILLIPS RS, 1989, J BIOL CHEM, V264, P10627; PHILLIPS RS, 1989, J AM CHEM SOC, V111, P727, DOI 10.1021/ja00184a051; RAIBAUD O, 1976, J BIOL CHEM, V251, P2814; SCHNACKERZ KD, 1983, J BIOL CHEM, V258, P4839; SCHNACKERZ KD, 1986, VITAMIN B6 PYRIDOX A, P245; SIANO DB, 1969, J CHEM PHYS, V51, P1856, DOI 10.1063/1.1672270; SNELL EE, 1975, ADV ENZYMOL RAMB, V42, P287; Suelter C H, 1979, Methods Enzymol, V62, P561; SUELTER CH, 1976, ANAL BIOCHEM, V76, P221, DOI 10.1016/0003-2697(76)90280-3; SUELTER CH, 1977, J BIOL CHEM, V252, P1852; TANI S, 1990, BIOTECHNOL APPL BIOC, V12, P28; TISELIUS A, 1956, ARCH BIOCHEM BIOPHYS, V65, P132, DOI 10.1016/0003-9861(56)90183-7; TOKUSHIGE M, 1989, BIOCHIMIE, V71, P711, DOI 10.1016/0300-9084(89)90087-4; TORCHINSKY YM, 1987, BIOCH VITAMIN B6, P233; VEDERAS JC, 1978, J BIOL CHEM, V253, P5350; WATANABE T, 1977, J BIOCHEM, V82, P733, DOI 10.1093/oxfordjournals.jbchem.a131750; Yang B I, 1979, Methods Enzymol, V62, P528; YANG IY, 1975, J BIOL CHEM, V250, P2947; ZAKOMIRDINA LN, 1989, BIOCHIMIE, V71, P545, DOI 10.1016/0300-9084(89)90185-5; ZAKOMYRDINA LN, 1988, MOL BIOL+, V22, P159	55	57	57	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9374	9381						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033039				2022-12-25	WOS:A1991FM45900009
J	ONEILL, MA; DARVILL, AG; ALBERSHEIM, P				ONEILL, MA; DARVILL, AG; ALBERSHEIM, P			THE DEGREE OF ESTERIFICATION AND POINTS OF SUBSTITUTION BY O-ACETYL AND O-(3-HYDROXYBUTANOYL) GROUPS IN THE ACIDIC EXTRACELLULAR POLYSACCHARIDES SECRETED BY RHIZOBIUM-LEGUMINOSARUM BIOVARS VICIAE, TRIFOLII, AND PHASEOLI ARE NOT RELATED TO HOST RANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYM PLASMID PRL1JI; NODULATION GENES; SYMBIONT INTERACTIONS; AGROBACTERIUM-TUMEFACIENS; STRUCTURAL FEATURES; LECTIN; SPECIFICITY; BINDING; EXPRESSION; DETERMINANT	Rhizobium leguminosarum biovars viciae, trifolii, and phaseoli have been grown in the presence and absence of 4', 5,7-trihydroxyflavanone (naringenin) or 4',5,7-trihydroxyflavone (apigenin), which induce the expression of nodulation genes of the bacteria. The acidic polysaccharides secreted by the Rhizobium were isolated from the culture media and purified. The polysaccharides were cleaved with a bacteriophage enzyme and the octasaccharide repeating units formed were isolated. The glycosyl sequence and type of non-glycosyl substituents of the repeating units derived from a number of these Rhizobium biovars were shown by fast atom bombardment-mass spectroscopy and proton nuclear magnetic resonance spectroscopy (H-1 NMR) to be identical. Minor variations in the degree of esterification of the repeating units by O-acetyl and O-(3-hydroxybutanoyl) substituents were observed when the Rhizobium were grown in the presence or absence of the flavonoids. The variation in content and the points of attachment of the O-acetyl and O-(3-hydroxybutanoyl) substituents were as great within each Rhizobium biovar as between different Rhizobium biovars and, contrary to two recent reports (Philip-Hollingsworth, S., Hollingsworth, R. I., and Dazzo, F. B. (1989) J. Biol. Chem. 264, 1461-1466; Philip-Hollingsworth, S., Hollingsworth, R. I., Dazzo, F. B., Djordjevic, M.A., and Rolfe, B. G. (1989) J. Biol. Chem. 264, 5710-5714), the O-acylation patterns were not correlated with the host specificity of the bacteria.	UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia								ABE M, 1984, J BACTERIOL, V160, P517, DOI 10.1128/JB.160.2.517-520.1984; AMAN P, 1982, CARBOHYD RES, V103, P77, DOI 10.1016/S0008-6215(82)80009-8; BORHTAKUR D, 1986, MOL GEN GENET, V203, P320; CREMERS HCJ, 1991, IN PRESS J BIOL CHEM; DAZZO FB, 1984, BIOL CELL, V51, P267; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; DIEBOLD R, 1989, IN PRESS J BACTERIOL; DJORDJEVIC MA, 1987, ANNU REV PHYTOPATHOL, V25, P145, DOI 10.1146/annurev.py.25.090187.001045; FIRMIN JL, 1986, NATURE, V324, P90, DOI 10.1038/324090a0; HIGASHI S, 1978, J GEN APPL MICROBIOL, V24, P143, DOI 10.2323/jgam.24.143; HOLLINGSWORTH RI, 1988, CARBOHYD RES, V172, P97, DOI 10.1016/S0008-6215(00)90845-0; HOLLINGSWORTH RI, 1984, J BACTERIOL, V160, P510, DOI 10.1128/JB.160.2.510-516.1984; HOOYKAAS PJJ, 1981, NATURE, V291, P351, DOI 10.1038/291351a0; HOOYKAAS PJJ, 1982, PLASMID, V8, P73, DOI 10.1016/0147-619X(82)90042-7; INNES RW, 1985, MOL GEN GENET, V201, P421; JOHNSTON AWB, 1978, NATURE, V276, P634, DOI 10.1038/276634a0; KIJNE JW, 1986, LECTINS, V5, P3; Krieg, 1984, BERGEYS MANUAL SYSTE, V1, P234; KUO MS, 1986, CARBOHYD RES, V145, P247, DOI 10.1016/S0008-6215(00)90433-6; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; MCNEIL M, 1986, CARBOHYD RES, V146, P307, DOI 10.1016/0008-6215(86)85048-0; Miller JH., 1972, EXPT MOL GENETICS; MORT AJ, 1980, PLANT PHYSIOL, V66, P158, DOI 10.1104/pp.66.1.158; PETERS NK, 1986, SCIENCE, V233, P977, DOI 10.1126/science.3738520; PHILIPHOLLINGSWORTH S, 1989, J BIOL CHEM, V264, P1461; PHILIPHOLLINGSWORTH S, 1989, J BIOL CHEM, V264, P5710; REDMOND JW, 1986, NATURE, V323, P632, DOI 10.1038/323632a0; ROBERTSEN BK, 1981, PLANT PHYSIOL, V67, P389, DOI 10.1104/pp.67.3.389; ROLFE BG, 1988, ANNU REV PLANT PHYS, V39, P297, DOI 10.1146/annurev.pp.39.060188.001501; SCOTT J. E., 1965, METHOD CARBOHYD CHEM, V5, P38; SPAINK HP, 1989, EMBO J, V8, P2811, DOI 10.1002/j.1460-2075.1989.tb08427.x; SPAINK HP, 1987, NATURE, V328, P337, DOI 10.1038/328337a0; SPAINK HP, 1987, PLANT MOL BIOL, V9, P29; WIJFFELMAN CA, 1985, ARCH MICROBIOL, V143, P225, DOI 10.1007/BF00411240; ZAAT SAJ, 1987, J BACTERIOL, V169, P198, DOI 10.1128/jb.169.1.198-204.1987	35	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9549	9555						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033051				2022-12-25	WOS:A1991FM45900035
J	ERVASTI, JM; KAHL, SD; CAMPBELL, KP				ERVASTI, JM; KAHL, SD; CAMPBELL, KP			PURIFICATION OF DYSTROPHIN FROM SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; ERYTHROCYTE BAND 4.2; 1,4-DIHYDROPYRIDINE RECEPTOR; SARCOPLASMIC-RETICULUM; CYTOPLASMIC DOMAIN; MEMBRANE; PROTEIN; SUBUNIT; GLYCOPROTEIN; BINDING	Dystrophin was purified from rabbit skeletal muscle by alkaline dissociation of dystrophin-glycoprotein complex which was first prepared by derivatized lectin chromatography. Dystrophin-glycoprotein complex was isolated from digitonin-solubilized rabbit skeletal muscle membranes by a novel two-step method involving succinylated wheat germ agglutinin (sWGA) chromatography and DEAE-cellulose ion exchange chromatography. Proteins co-purifying with dystrophin were a protein triplet of M(r) 59,000 and four glycoproteins of M(r) 156,000, 50,000, 43,000, and 35,000, all previously identified as components of the dystrophin-glycoprotein complex. Alkaline treatment of sWGA/DEAE-purified dystrophin-glycoprotein complex resulted in complete dissociation of the dystrophin-glycoprotein complex. In order to separate dystrophin from its associated proteins, alkaline-dissociated dystrophin-glycoprotein complex was sedimented by sucrose gradient centrifugation. The residual glycoproteins which contaminated peak dystrophin-containing gradient fractions were then removed by WGA-Sepharose adsorption. The resulting protein appeared as a single band with an apparent M(r) of 400,000 on over-loaded Coomassie Blue-stained gels. The absence of WGA-peroxidase staining on nitrocellulose transfers of the pure protein indicated that the pure protein was devoid of contaminating glycoproteins. Antisera raised against the carboxyl terminus of human skeletal muscle dystrophin (which does not cross-react with the carboxyl terminus of the chromosome 6-encoded dystrophin-related protein) recognized the pure protein as did antisera specific for the amino terminus of human dystrophin. These data indicate that the protein isolated is indeed the intact, predominant skeletal muscle isoform product of the Duchenne muscular dystrophy gene.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa			Ervasti, James/AAZ-4786-2020	Kahl, Steven/0000-0001-7085-9556; Campbell, Kevin/0000-0003-2066-5889				ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CHANG HW, 1989, J BIOL CHEM, V264, P20831; COHEN SA, 1981, BIOCHIM BIOPHYS ACTA, V645, P253, DOI 10.1016/0005-2736(81)90196-6; COOPER BJ, 1988, NATURE, V334, P154, DOI 10.1038/334154a0; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HOLDEN KG, 1971, BIOCHEMISTRY-US, V10, P3105, DOI 10.1021/bi00792a019; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KORSGREN C, 1986, J BIOL CHEM, V261, P5536; KORSGREN C, 1988, J BIOL CHEM, V263, P10212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG AT, 1988, J BIOL CHEM, V263, P994; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; MURAYAMA T, 1989, P JPN ACAD B-PHYS, V65, P207, DOI 10.2183/pjab.65.207; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PONS F, 1990, P NATL ACAD SCI USA, V87, P7851, DOI 10.1073/pnas.87.20.7851; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SHARP AH, 1989, J BIOL CHEM, V264, P2816; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V66, P96; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	34	166	169	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9161	9165						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026615				2022-12-25	WOS:A1991FM03800076
J	GIBBS, CS; ZOLLER, MJ				GIBBS, CS; ZOLLER, MJ			RATIONAL SCANNING MUTAGENESIS OF A PROTEIN-KINASE IDENTIFIES FUNCTIONAL REGIONS INVOLVED IN CATALYSIS AND SUBSTRATE INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; KINETIC MECHANISM; NUCLEOTIDE-BINDING; AFFINITY LABELS; S-CEREVISIAE; SUBUNIT; ADENOSINE; SEQUENCE; RESIDUES	A systematic mutagenesis strategy was used to identify the functional regions and residues of a protein kinase. Clusters of the charged amino acids in the catalytic subunit of Saccharomyces cerevisiae cAMP-dependent protein kinase, were systematically mutated to alanine, producing a set of mutations that encompassed the entire molecule. Residues indispensable for enzyme activity were identified by testing the ability of the mutants to function in vivo. Active mutants were assayed in vitro, and mutants with reduced specific activity were subsequently analyzed by steady-state kinetics to determine the effects of the mutation on k(cat) and on K(m) for MgATP and for a peptide substrate. Specific residues and regions of the enzyme were identified that are likely to be important in catalysis and in binding of MgATP, functions that are common to all protein kinases. Additional regions were identified that are likely to be important in binding a peptide substrate, the recognition of which is likely to be specific to the serine/threonine protein kinases that have a requirement for basic residues around the target hydroxyamino acid. The properties of mutants defective in substrate recognition were consistent with an ordered sequential reaction mechanism. This represents the first comprehensive analysis of a protein kinase by a rational mutagenesis strategy.			GIBBS, CS (corresponding author), GENENTECH INC, DEPT PROT ENGN, SAN FRANCISCO, CA 94080 USA.							BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMSON HN, 1982, J BIOL CHEM, V257, P575; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P3018, DOI 10.1021/bi00433a042; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; FERSHT A, 1977, ENZYME STRUCTURE MEC, pCH3; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harlow E., 1988, ANTIBODIES LAB MANUA, P553; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; MANIATIS T, 1982, MOL CLONING LABORATO, P55; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; MOBASHERY S, 1988, BIOCHEMISTRY-US, V27, P3691, DOI 10.1021/bi00410a025; OHNO S, 1990, J BIOL CHEM, V265, P6296; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PINNA LA, 1979, BIOCHEM BIOPH RES CO, V87, P114, DOI 10.1016/0006-291X(79)91654-1; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1982, METHODS YEAST GENETI, P61; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SONDEK J, 1990, PROTEINS, V7, P299, DOI 10.1002/prot.340070402; SOWADSKI JM, 1985, J MOL BIOL, V182, P617, DOI 10.1016/0022-2836(85)90249-9; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P1219, DOI 10.1073/pnas.84.5.1219; WETZEL R, 1988, PROTEIN ENG, V2, P1, DOI 10.1093/protein/2.1.1; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZOLLER MJ, 1988, J BIOL CHEM, V263, P9142; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837; ZOLLER MJ, 1991, IN PRESS METHODS ENZ	53	306	313	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8923	8931						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026604				2022-12-25	WOS:A1991FM03800043
J	HANNIGAN, GE; WILLIAMS, BRG				HANNIGAN, GE; WILLIAMS, BRG			INDUCED FACTOR BINDING TO THE INTERFERON-STIMULATED RESPONSE ELEMENT - INTERFERON-ALPHA AND PLATELET-DERIVED GROWTH-FACTOR UTILIZE DISTINCT SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED NUCLEAR FACTORS; PROTEIN-KINASE-C; SYNTHETASE GENE; REGULATORY ELEMENTS; PROMOTER ELEMENT; 2-5A SYNTHETASE; DNA-BINDING; EXPRESSION; ACTIVATION	Interferon-alpha (IFN-alpha) and platelet-derived growth factor (PDGF) each rapidly stimulate binding of nuclear factors from Balb/c 3T3 fibroblasts, to a 29-base pair regulatory sequence derived from the 5' upstream region of the murine 2-5A synthetase gene. This regulatory sequence contains a functional interferon-stimulated response element (ISRE) and also functions as a PDGF-responsive sequence. We show that IFN-alpha induces binding of a protein of molecular mass 65 kDa to the ISRE. Constitutively expressed ISRE-binding proteins of 98 and 150 kDa are also demonstrated. Binding of inducible factors to the ISRE increases significantly within 15 min of IFN-alpha or PDGF treatment. PDGF-induced binding is not mediated by IFN-beta. The protein kinase inhibitors, staurosporine and K252a, block PDGF-induced ISRE binding and 2-5A synthetase gene expression. IFN-alpha-induced ISRE binding and gene activation are not blocked by these inhibitors. Treatment of cells with 12-O-tetradecanoyl-13-acetate or dibutyryl cyclic AMP does not activate ISRE binding factors or 2-5A synthetase gene expression. PDGF responsiveness of the ISRE in vivo is also sensitive to staurosporine, indicating that inhibition of a protein kinase activity blocks the PDGF-specific transcriptional signal. Our data indicate the signal transduction pathway for IFN-alpha-induced, ISRE-dependent transcription is distinct from the PDGF-induced ISRE response and is likely independent of cyclic AMP-dependent protein kinase and protein kinase C activities.	HOSP SICK CHILDREN, RES INST, 555 UNIV AVE, TORONTO M5G 1X8, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Williams, Bryan R. G./A-5021-2009; Hannigan, Greg/A-5092-2009	Williams, Bryan R. G./0000-0002-4969-1151; 				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCKWORTHRYSIEC.G, 1989, J INTERFERON RES, V9, P649; FALTYNEK CR, 1989, J BIOL CHEM, V264, P14304; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; GARCIABLANCO MA, 1989, MOL CELL BIOL, V9, P1060, DOI 10.1128/MCB.9.3.1060; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; KASE H, 1986, J ANTIBIOT, V39, P1059, DOI 10.7164/antibiotics.39.1059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LIN S, 1982, LIFE SCI, V32, P1479; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PINE R, 1989, MOL CELL BIOL, V9, P3533, DOI 10.1128/MCB.9.8.3533; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SAARMA M, 1986, EXP CELL RES, V166, P229, DOI 10.1016/0014-4827(86)90522-7; SAUNDERS M, 1985, 2 5A SYSTEM MOL CLIN, P163; SAUNDERS ME, 1985, EMBO J, V4, P1761, DOI 10.1002/j.1460-2075.1985.tb03848.x; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMEKENSETIENNE M, 1983, EUR J BIOCHEM, V130, P269, DOI 10.1111/j.1432-1033.1983.tb07146.x; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WAN YJY, 1988, J INTERFERON RES, V8, P105, DOI 10.1089/jir.1988.8.105; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WILLIAMS BRG, 1988, INTERFERON TREATMENT, P43; YAP WH, 1986, SCIENCE, V234, P355, DOI 10.1126/science.2429366; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	42	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8765	8770						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026593				2022-12-25	WOS:A1991FM03800023
J	CHALBOS, D; GALTIER, F; EMILIANI, S; ROCHEFORT, H				CHALBOS, D; GALTIER, F; EMILIANI, S; ROCHEFORT, H			THE ANTIPROGESTIN RU486 STABILIZES THE PROGESTIN-INDUCED FATTY-ACID SYNTHETASE MESSENGER-RNA BUT DOES NOT STIMULATE ITS TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; GENE-EXPRESSION; RECEPTOR; ESTROGEN; PROTEIN; BINDS; DNA; LOCALIZATION; COMPLEXES; ELEMENTS	Progestins induce fatty acid synthetase (FAS) in breast cancer cell lines, both increasing its gene transcription and mRNA stabilization (Joyeux, C., Rochefort, H., and Chalbos, D. (1989) Mol. Endocrinol. 4, 681-686). In vitro run-on transcription assays show that RU486, in contrast to progestin, inhibits FAS transcription by 40-50%. Moreover and surprisingly, anti-progestin RU486 also stabilizes FAS mRNA 3- to 4-fold in MCF7 cells as measured by chase experiments in the presence of actinomycin D or cordycepin or after short cell labeling with [H-3]uridine. Dexamethasone is inefficient in increasing the half-life of FAS mRNA in MCF7 cells. RU486 had no effect on MDA-MB 231 cells which contain glucocorticoid but no progesterone receptors, indicating that the progesterone receptor is implicated in this regulation. RU486-induced mRNA stabilization allows delayed accumulation of FAS mRNA. These results indicate that the progesterone receptor can be activated separately to stimulate gene transcription or stabilize mRNA.			CHALBOS, D (corresponding author), INSERM,U148,UNIT HORMONES & CANC,60 RUE NAVACELLES,F-34090 MONTPELLIER,FRANCE.		Emiliani, Stéphane/O-2454-2017	Emiliani, Stéphane/0000-0001-7344-8429				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BACK DW, 1986, J BIOL CHEM, V261, P4190; BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CAILLEAU R, 1974, J NATL CANCER I, V53, P647; CHALBOS D, 1987, J BIOL CHEM, V262, P9923; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CHONG MT, 1982, J BIOL CHEM, V257, P2996; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEAVERS IM, 1989, J BIOL CHEM, V264, P9114; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HORWITZ KB, 1978, CANCER RES, V38, P2434; JOYEUX C, 1989, MOL ENDOCRINOL, V4, P681; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LIAO S, 1980, J BIOL CHEM, V255, P5545; LOOSFELT H, 1981, J BIOL CHEM, V256, P3465; MAHMOUDI M, 1989, BIOTECHNIQUES, V7, P331; Maniatis T., 1982, MOL CLONING; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MOGUILEWSKI M, 1984, ANTIPROGESTIN STEROI, P87; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1978, COLD SPRING HARB SYM, V42, P639; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PERROTAPPLANAT M, 1986, J CELL BIOL, V102, P1191, DOI 10.1083/jcb.102.4.1191; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PRESS MF, 1988, ENDOCRINOLOGY, V122, P1165, DOI 10.1210/endo-122-3-1165; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; SHERIDAN PL, 1988, MOL ENDOCRINOL, V2, P1329, DOI 10.1210/mend-2-12-1329; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TZUKERMAN M, 1990, New Biologist, V2, P613	39	18	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8220	8224						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022639				2022-12-25	WOS:A1991FK44100043
J	BEDALE, WA; INMAN, RB; COX, MM				BEDALE, WA; INMAN, RB; COX, MM			RECA PROTEIN-FACILITATED DNA STRAND BREAKS - A MECHANISM FOR BYPASSING DNA STRUCTURAL BARRIERS DURING STRAND EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BRANCH MIGRATION; PARTIAL DENATURATION; M13 VECTORS; PURIFICATION; COMPLEXES; RECOMBINATION; VISUALIZATION; INSERTIONS; EXPRESSION	RecA protein promotes an unexpectedly efficient DNA strand exchange between circular single-stranded DNA and duplex DNAs containing short (50-400-base pair) heterologous sequences at the 5' (initiating) end. The major mechanism by which this topological barrier is bypassed involves DNA strand breakage. Breakage is both strand and position specific, occurring almost exclusively in the displaced (+) strand of the duplex within a 15-base pair region of the heterology/homology junction. Breakage also requires recA protein, ATP hydrolysis, and homologous sequences 3' to the heterology. Although the location of the breaks and the observed requirements clearly indicate a major role for recA protein in this phenomenon, the molecular mechanism is not yet clear. The breakage may reflect a DNA structure and/or some form of structural stress within the DNA during recA protein-mediated DNA pairing which either exposes the DNA at this precise position to the action of a contaminating nuclease or induces a direct mechanical break. We also find that when heterology is located at the 3' end of the linear duplex, strand exchange is halted (without DNA breakage) about 500 base pairs from the homology/heterology junction.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison				Bedale, Wendy/0000-0002-0122-4255	NIGMS NIH HHS [T32-GM07215, GM14711, GM32335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM032335, R01GM032335, T32GM007215, R01GM014711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BIANCHI M, 1985, EMBO J, V4, P3025, DOI 10.1002/j.1460-2075.1985.tb04039.x; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1983, J BIOL CHEM, V258, P2586; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; Davis R., 1980, ADV BACTERIAL GENETI; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HAHN TR, 1988, J BIOL CHEM, V263, P7431; HSIEH P, 1986, CELL, V44, P885, DOI 10.1016/0092-8674(86)90011-5; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; LICHTEN M, 1984, P NATL ACAD SCI-BIOL, V81, P7180, DOI 10.1073/pnas.81.22.7180; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LIVNEH Z, 1982, P NATL ACAD SCI-BIOL, V79, P3171, DOI 10.1073/pnas.79.10.3171; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; RAO BJ, 1990, UCLA SYM BI, V127, P387; REGISTER JC, 1987, J BIOL CHEM, V262, P12812; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sambrook J, 1989, MOL CLONING LABORATO; SENECOFF JF, 1985, P NATL ACAD SCI USA, V82, P7270, DOI 10.1073/pnas.82.21.7270; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; STASIAK A, 1984, COLD SPRING HARB SYM, V49, P561, DOI 10.1101/SQB.1984.049.01.063; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149	39	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6499	6510						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007599				2022-12-25	WOS:A1991FE37300075
J	MARINO, LR; TAKEUCHI, T; DICKINSON, CJ; YAMADA, T				MARINO, LR; TAKEUCHI, T; DICKINSON, CJ; YAMADA, T			EXPRESSION AND POSTTRANSLATIONAL PROCESSING OF GASTRIN IN HETEROLOGOUS ENDOCRINE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; ANTERIOR-PITUITARY; GENE; SECRETION; TRANSCRIPTION	The biosynthesis of gastrin involves a complex series of post-translational processing reactions that result in the formation of a biologically active secretory product. To study the mechanisms for two specific reactions in gastrin processing, namely dibasic cleavage and amidation, we infected AtT-20, GH3, and Rin5-f cells with the retroviral expression vector, pZip-NeoSV(X), containing human gastrin cDNA. We detected gastrin and its glycine extended post-translational processing intermediates (G-gly) in the media and cell extracts of successfully infected cells. Characterization of the molecular forms of gastrin in these cell lines revealed that GH3 and Rin5-f processed gastrin in a manner similar to antral G-cells but the cleavage of the Lys74-Lys75 bond that converts G34 to G17 appeared to be suppressed in AtT-20 cells. Even after conversion of this site to Arg74-Arg75 via site-directed mutagenesis, the At-20 cells synthesized G34 predominantly. All of the infected cells amidated gastrin but the gastrin/G-gly ratio, a reflection of amidation within the cells, was enhanced in GH3 and Rin5-f cells but diminished in AtT-20 cells upon treatment with dexamethasone (10(-4) M) for 3 days. The dibasic cleavage of gastrin was uneffected by dexamethasone. Our data suggest that the activities of post-translational processing reactions responsible for the synthesis of biologically active gastrin exhibit considerable tissue and substrate specificity.	UNIV MICHIGAN,MED CTR,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NICHD NIH HHS [K08 HD00760] Funding Source: Medline; NIDDK NIH HHS [P30 DK34933, R01 DK34306] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD000760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK034306] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER GK, 1988, J BIOL CHEM, V263, P5846; BIRNBERG NC, 1983, P NATL ACAD SCI-BIOL, V80, P6982, DOI 10.1073/pnas.80.22.6982; BOEL E, 1983, P NATL ACAD SCI-BIOL, V80, P2866, DOI 10.1073/pnas.80.10.2866; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHARRON J, 1986, P NATL ACAD SCI USA, V83, P8903, DOI 10.1073/pnas.83.23.8903; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAUGHERTY D, 1989, PHYSIOL REV, V69, P482, DOI 10.1152/physrev.1989.69.2.482; DAUGHERTY D, 1990, GASTROINTEST ENDOSC, P137; DICKINSON C, 1989, NEUROENDOCRINOLOGY G, V2, P63; DICKINSON CJ, 1990, AM J PHYSIOL, V258, pG810, DOI 10.1152/ajpgi.1990.258.5.G810; GLEMBOTSKI CC, 1984, J BIOL CHEM, V259, P6385; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS CB, 1982, GASTROENTEROLOGY, V83, P233; LARSSON LI, 1976, NATURE, V262, P609, DOI 10.1038/262609a0; MAINS RE, 1984, ENDOCRINOLOGY, V114, P1522, DOI 10.1210/endo-114-5-1522; MAINS RE, 1984, ENDOCRINOLOGY, V115, P1683, DOI 10.1210/endo-115-5-1683; MARINO LR, 1988, AM J PHYSIOL, V254, pG87, DOI 10.1152/ajpgi.1988.254.1.G87; MAY V, 1988, J BIOL CHEM, V263, P7550; REHFELD JF, 1986, J BIOL CHEM, V261, P5841; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN TG, 1986, J NEUROSCI, V6, P1685; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; SUGANO K, 1985, BIOCHEM BIOPH RES CO, V126, P72, DOI 10.1016/0006-291X(85)90572-8	24	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6133	6136						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007572				2022-12-25	WOS:A1991FE37300023
J	CHANG, JY				CHANG, JY			STABILITY OF HIRUDIN, A THROMBIN-SPECIFIC INHIBITOR - THE STRUCTURE OF ALKALINE-INACTIVATED HIRUDIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACHROMOBACTER-LYTICUS M497-1; HUMAN ALPHA-THROMBIN; RECOMBINANT HIRUDIN; PROTEOLYTIC-ENZYME; DISULFIDE BONDS; PROTEASE-I; PROTEINS; BINDING; DOMAIN; RESIDUES	Hirudin is a 65-amino acid polypeptide with three disulfide linkages. It is stable under extreme pH (1.47-12.9), high temperature (95-degrees-C), and in the presence of denaturants (6 M guanidinium chloride or 8 M urea). The thrombin inhibitory activity of hirudin remains unaffected even after cleavage of an internal peptide bond (Lys36-Asn37). One condition which effectively and irreversibly inactivates hirudin is the combination of elevated temperature and alkaline pH. Structural analysis reveals that inactivation is a consequence of base-catalyzed beta-elimination of the disulfide bonds. The reaction leads to the conversion of hirudin to a mixture of highly heterogeneous polymers (from monomer to heptamer) which are intra- and intermolecularly cross-linked by cystine (20%), lanthionine (50%), and lysinoalanine (30%).			CHANG, JY (corresponding author), CIBA GEIGY AG,PHARMACEUT RES LABS,CH-4002 BASEL,SWITZERLAND.							BADGY D, 1976, METHOD ENZYMOL, V45, P669; BOHAK Z, 1964, J BIOL CHEM, V239, P2878; CHANG JY, 1983, METHOD ENZYMOL, V91, P455; CHANG JY, 1988, ANAL BIOCHEM, V170, P542, DOI 10.1016/0003-2697(88)90670-7; CHANG JY, 1990, FEBS LETT, V260, P209, DOI 10.1016/0014-5793(90)80105-R; CHANG JY, 1990, J BIOL CHEM, V265, P22159; CHANG JY, 1989, J BIOL CHEM, V264, P7141; CHANG JY, 1983, FEBS LETT, V164, P307, DOI 10.1016/0014-5793(83)80307-X; CHANG JY, 1983, METHOD ENZYMOL, V91, P41, DOI 10.1016/S0076-6879(83)91009-1; DENNIS S, 1990, EUR J BIOCHEM, V188, P61, DOI 10.1111/j.1432-1033.1990.tb15371.x; DODT J, 1988, FEBS LETT, V229, P87, DOI 10.1016/0014-5793(88)80803-2; DODT J, 1990, J BIOL CHEM, V265, P713; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; FLORENCE TM, 1980, BIOCHEM J, V189, P507, DOI 10.1042/bj1890507; FOLKERS PJM, 1989, BIOCHEMISTRY-US, V28, P2601, DOI 10.1021/bi00432a038; GRUETTER M, 1990, EMBO J, V9, P2361; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; KRSTENANSKY JL, 1987, FEBS LETT, V211, P10, DOI 10.1016/0014-5793(87)81264-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARKWARDT F, 1958, H-S Z PHYSIOL CHEM, V312, P85, DOI 10.1515/bchm2.1958.312.1.85; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MASAKI T, 1978, AGR BIOL CHEM TOKYO, V42, P1443, DOI 10.1080/00021369.1978.10863183; NASHEF AS, 1977, J AGR FOOD CHEM, V25, P245, DOI 10.1021/jf60210a020; NI F, 1990, BIOCHEMISTRY-US, V29, P4479, DOI 10.1021/bi00470a030; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SAUER RT, 1986, BIOCHEMISTRY-US, V25, P5992, DOI 10.1021/bi00368a024; STERNBERG M, 1975, SCIENCE, V190, P992, DOI 10.1126/science.242077; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TSUNASAWA S, 1989, J BIOL CHEM, V264, P3832; TSUNASAWA S, 1987, J BIOCHEM-TOKYO, V101, P112; VILLAFRANCA JE, 1983, SCIENCE, V222, P782, DOI 10.1126/science.6356360; Volkin D.B., 1989, PROTEIN FUNCTION PRA, P1; VOLKIN DB, 1987, J BIOL CHEM, V262, P2945; WALLACE A, 1989, BIOCHEMISTRY-US, V28, P10079, DOI 10.1021/bi00452a030; WELLS JA, 1986, J BIOL CHEM, V261, P6564; WETZEL R, 1987, TRENDS BIOCHEM SCI, V12, P478, DOI 10.1016/0968-0004(87)90234-9; WHITAKER JR, 1983, CRC CR REV FOOD SCI, V19, P173, DOI 10.1080/10408398309527375; ZIEGLER K, 1967, NATURE, V214, P404, DOI 10.1038/214404a0	44	34	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10839	10843						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040604				2022-12-25	WOS:A1991FQ77400024
J	HAKES, DJ; BEREZNEY, R				HAKES, DJ; BEREZNEY, R			DNA-BINDING PROPERTIES OF THE NUCLEAR MATRIX AND INDIVIDUAL NUCLEAR MATRIX PROTEINS - EVIDENCE FOR SALT-RESISTANT DNA-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPLETED METAPHASE CHROMOSOMES; RAT ALPHA-2-MACROGLOBULIN GENE; SINGLE-STRANDED REGIONS; DROSOPHILA-MELANOGASTER; DEOXYRIBONUCLEIC-ACID; INTERPHASE NUCLEI; ATTACHMENT SITES; SUPERCOILED DNA; CHINESE-HAMSTER; ASSOCIATION REGIONS	The DNA binding characteristics of the rat nuclear matrix were investigated. A saturable and temperature-dependent, salt-resistant DNA binding to the nuclear matrix was discovered, with 70-80% of total bound DNA resistant to extraction with high concentrations of salt at 37-degrees-C, compared to < 5% at 0-degrees-C. The initial binding of DNA to nuclear matrix is sensitive to salt concentration, indicating a transition to a salt-resistant binding state. The nuclear matrix shows a preference for single-stranded DNA, both in saturation and competition assays, with little binding of RNA or double-stranded DNA. Further competition studies show a preference for matrix-attached DNA probably involving predominantly AT-rich sequences, while a specific sequence defined previously as a matrix-attached region (MAR; Cockerill, P. N., and Garrard, W. T. (1986) Cell 46, 273-282) only showed preference for a limited number of the total matrix binding sites. These results and estimates from saturation data of approximately 150,000 single-stranded DNA binding sites per matrix lead us to propose that the nuclear matrix contains different classes of DNA binding sites, each with a separate sequence specificity. Binding of DNA to individual matrix polypeptides separated on sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose blots was also temperature-dependent, salt-resistant, and showed a preference for binding DNA over RNA and nuclear matrix DNA over total genomic DNA. Subnuclear fractionation experiments further demonstrated that the nuclear matrix is enriched in the subset of higher molecular weight (> 50,000) DNA binding proteins of isolated nuclei and correspondingly depleted of the lower molecular weight ones. Of the approximately 12 major proteins separated on nonequilibrium two-dimensional gels, 7 were identified as specific DNA binding proteins including lamins A and C (but not B), and the internal nuclear matrix proteins, matrins D, E, F, G, and 4.	SUNY BUFFALO, DEPT BIOL SCI, BUFFALO, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIGMS NIH HHS [GM-23922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023922] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUTTER PS, 1980, J CELL SCI, V44, P395; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BASLER J, 1981, BIOCHEMISTRY-US, V20, P6921, DOI 10.1021/bi00527a027; BEREZNEY R, 1981, EXP CELL RES, V132, P1, DOI 10.1016/0014-4827(81)90076-8; BEREZNEY R, 1981, BIOCHEMISTRY-US, V20, P4995, DOI 10.1021/bi00520a028; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BEREZNEY R, 1982, NUCLEAR ENVELOPE NUC, P183; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P119; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BRACK C, 1975, J MOL BIOL, V96, P693, DOI 10.1016/0022-2836(75)90146-1; BUTTYAN R, 1986, BIOCHEM BIOPH RES CO, V138, P1334, DOI 10.1016/S0006-291X(86)80429-6; CHIMERA JA, 1985, J BIOL CHEM, V260, P9373; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COMINGS DE, 1978, J CELL SCI, V34, P233; COOK PR, 1980, NUCLEIC ACIDS RES, V8, P2895, DOI 10.1093/nar/8.13.2895; DALTON S, 1986, NUCLEIC ACIDS RES, V14, P6507, DOI 10.1093/nar/14.16.6507; DIJKWEL PA, 1979, NUCLEIC ACIDS RES, V6, P219, DOI 10.1093/nar/6.1.219; ELLIS GC, 1988, BIOCHEM BIOPH RES CO, V157, P500, DOI 10.1016/S0006-291X(88)80277-8; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HANCOCK R, 1982, BIOL CELL, V44, P201; HARRIS SG, 1988, BIOCHEM BIOPH RES CO, V152, P1383, DOI 10.1016/S0006-291X(88)80438-8; HENSON P, 1978, J MOL BIOL, V119, P487, DOI 10.1016/0022-2836(78)90198-5; HERMAN R, 1978, J CELL BIOL, V78, P663, DOI 10.1083/jcb.78.3.663; HOZIER JC, 1975, J MOL BIOL, V93, P181, DOI 10.1016/0022-2836(75)90127-8; HSIEH T, 1979, P NATL ACAD SCI USA, V76, P726, DOI 10.1073/pnas.76.2.726; HUNT BF, 1981, NUCLEIC ACIDS RES, V9, P349, DOI 10.1093/nar/9.2.349; IDE T, 1975, NATURE, V258, P445, DOI 10.1038/258445a0; ITO T, 1987, BIOCHEM BIOPH RES CO, V149, P449, DOI 10.1016/0006-291X(87)90388-3; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; JACKSON DA, 1986, EMBO J, V5, P1403, DOI 10.1002/j.1460-2075.1986.tb04374.x; JACKSON DA, 1981, NATURE, V292, P552, DOI 10.1038/292552a0; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; JEPPESEN PGN, 1979, NUCLEIC ACIDS RES, V7, P49, DOI 10.1093/nar/7.1.49; KAS E, 1987, J MOL BIOL, V198, P677, DOI 10.1016/0022-2836(87)90209-9; KUO MT, 1982, J CELL BIOL, V93, P278, DOI 10.1083/jcb.93.2.278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P309, DOI 10.1016/0022-2836(82)90331-X; LEVINGER LF, 1985, J BIOL CHEM, V260, P4311; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOTO LH, 1981, NATURE, V294, P481, DOI 10.1038/294481a0; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MIRKOVITCH J, 1986, J MOL BIOL, V190, P255, DOI 10.1016/0022-2836(86)90296-2; MOREAU J, 1981, P NATL ACAD SCI-BIOL, V78, P1341, DOI 10.1073/pnas.78.3.1341; MULLENDERS LHF, 1982, BIOCHIM BIOPHYS ACTA, V698, P70, DOI 10.1016/0167-4781(82)90186-5; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PARDOLL DM, 1980, EXP CELL RES, V128, P466, DOI 10.1016/0014-4827(80)90083-X; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; PETERS KE, 1980, J CELL BIOL, V86, P135, DOI 10.1083/jcb.86.1.135; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; POGO AO, 1981, CELL NUCLEUS, V8, P331; PROBST H, 1985, EUR J BIOCHEM, V146, P167, DOI 10.1111/j.1432-1033.1985.tb08634.x; RAZIN SV, 1986, NUCLEIC ACIDS RES, V14, P8189, DOI 10.1093/nar/14.20.8189; RAZIN SV, 1978, NUCLEIC ACIDS RES, V5, P4737, DOI 10.1093/nar/5.12.4737; RAZIN SV, 1979, NUCLEIC ACIDS RES, V7, P1713, DOI 10.1093/nar/7.6.1713; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBINSON SI, 1983, NUCLEIC ACIDS RES, V11, P5113, DOI 10.1093/nar/11.15.5113; Shaper J H, 1978, Adv Enzyme Regul, V17, P213; SHOEMAN RL, 1990, J BIOL CHEM, V265, P9055; SMALL D, 1985, NUCLEIC ACIDS RES, V13, P2413, DOI 10.1093/nar/13.7.2413; SMALL D, 1982, P NATL ACAD SCI-BIOL, V79, P5911, DOI 10.1073/pnas.79.19.5911; SMITH HC, 1984, J CELL BIOL, V99, P1794, DOI 10.1083/jcb.99.5.1794; THORBURN A, 1988, NUCLEIC ACIDS RES, V16, P7183, DOI 10.1093/nar/16.14.7183; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUTSUI K, 1988, J BIOL CHEM, V263, P7235; VANEEKELEN CAG, 1981, J CELL BIOL, V88, P554, DOI 10.1083/jcb.88.3.554; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3; ZEITLIN S, 1987, MOL CELL BIOL, V7, P111, DOI 10.1128/MCB.7.1.111; ZHANG JT, 1986, J CELL BIOL, V103, pA49	76	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11131	11140						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040622				2022-12-25	WOS:A1991FQ77400067
J	MARSHALL, S; BACOTE, V; TRAXINGER, RR				MARSHALL, S; BACOTE, V; TRAXINGER, RR			COMPLETE INHIBITION OF GLUCOSE-INDUCED DESENSITIZATION OF THE GLUCOSE-TRANSPORT SYSTEM BY INHIBITORS OF MESSENGER-RNA SYNTHESIS - EVIDENCE FOR RAPID TURNOVER OF GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; INSULIN-RECEPTOR; GROWTH-FACTOR; CYCLIC-AMP; PREMATURE TERMINATION; PROTEIN-KINASE; HELA-CELLS; TRANSCRIPTION; GENE; 5,6-DICHLORO-1-BETA-D-RIBOFURANOSYLBENZIMIDAZOLE	Glutamine:fructose-6-phosphate amidotransferase (GFAT) plays a key role in desensitizing the insulin-responsive glucose transport system (GTS), and recent studies have revealed that loss of GFAT activity accompanies desensitization. To gain insights into the mechanisms underlying loss of enzyme activity, we have used primary cultured adipocytes and two well established inhibitors of mRNA synthesis to estimate GFAT turnover. Both actinomycin D and 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) caused a rapid and extensive loss in GFAT activity (> 70% loss, t1/2 of 45 min) indicating that GFAT has a relatively short half-life. Since induction of insulin resistance requires GFAT, we next examined the ability of mRNA inhibitors to block glucose-induced desensitization. When adipocyteswere cultured for 18 h with 20 mM glucose, amino acids, and 25 ng/ml insulin, maximal insulin responsiveness of the GTS was reduced by > 70%. Both actinomycin D and DRB rapidly and completely prevented desensitization in a dose-dependent manner (ED50 of 16 nM and 15-mu-M, respectively). These findings are the predicted functional consequence of diminished GFAT activity. Evidence that actinomycin D acts selectively on GFAT without influencing other steps within the desensitization pathway was obtained using glucosamine, an agent that enters the hexosamine biosynthesis pathway at a point distal to the action of GFAT. Actinomycin D inhibited glucose-induced desensitization but failed to block glucosamine-induced desensitization. From these studies we conclude that 1) glucose-induced desensitization of the GTS can be completely prevented by actinomycin D and DRB, two potent and diverse inhibitors of mRNA synthesis; 2) the functional integrity of the desensitization pathway is maintained by a short-lived protein; and 3) the identity of this short-lived protein is most likely GFAT, the first and rate-limiting enzyme of the hexosamine biosynthesis pathway.			MARSHALL, S (corresponding author), UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,800 MADISON AVE,MEMPHIS,TN 38163, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038754, F32DK008206] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05-5423] Funding Source: Medline; NIDDK NIH HHS [DK08206, DK38754] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1985, MOL BASIS INSULIN AC, P263; BEKESI JG, 1969, J BIOL CHEM, V244, P5663; CAMPEN CA, 1986, ENDOCRINOLOGY, V119, P1454, DOI 10.1210/endo-119-4-1454; CZECH MP, 1988, J BIOL CHEM, V263, P11017; CZECH MP, 1984, BIOCHEM ACTION HORM, P93; DELGIACCO R, 1964, J BIOL CHEM, V239, P2400; DOLECKI GJ, 1979, DEV BIOL, V690, P219; FRASER NW, 1978, NATURE, V272, P590, DOI 10.1038/272590a0; GOLDBERG IH, 1964, FED PROC, V23, P958; GOODRIDGE AG, 1990, FASEB J, V4, P3099, DOI 10.1096/fasebj.4.13.2210156; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HOD Y, 1988, J BIOL CHEM, V263, P7747; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENNEY FT, 1967, SCIENCE, V156, P525, DOI 10.1126/science.156.3774.525; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; KNUTSON VP, 1985, J BIOL CHEM, V260, P4180; KORNFELD S, 1966, EXP CELL RES, V41, P592, DOI 10.1016/S0014-4827(66)80109-X; KOUSSIS D, 1978, J BIOL CHEM, V253, P4327; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAUB O, 1980, P NATL ACAD SCI-BIOL, V77, P3297, DOI 10.1073/pnas.77.6.3297; MAHER F, 1989, MOL ENDOCRINOL, V3, P2128, DOI 10.1210/mend-3-12-2128; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MEDDIO F, 1990, EUR J BIOCHEM, V187, P89; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MESSINA JL, 1990, HDB EXPT PHARM INSUL, P399; MILLER RE, 1985, CURR TOP CELL REGUL, V26, P65; MOLNAR J, 1964, J BIOL CHEM, V239, P3157; MOORE PS, 1989, MOL ENDOCRINOL, V3, P1724, DOI 10.1210/mend-3-11-1724; NELSON K, 1980, J BIOL CHEM, V255, P8509; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SHOELSON SE, 1989, MOL CELLULAR BIOL DI, P23; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; STIMAC E, 1984, MOL CELL BIOL, V4, P2082, DOI 10.1128/MCB.4.10.2082; TAMM I, 1979, P NATL ACAD SCI USA, V76, P5750, DOI 10.1073/pnas.76.11.5750; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; TILGHMAN S M, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1304, DOI 10.1073/pnas.71.4.1304; TRAXINGER RR, 1989, J BIOL CHEM, V264, P8156; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; WATZELE G, 1989, J BIOL CHEM, V264, P8753; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	44	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10155	10161						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037572				2022-12-25	WOS:A1991FP08600027
J	SCHWEERS, LA; SANDERS, MM				SCHWEERS, LA; SANDERS, MM			A PROTEIN WITH A BINDING-SPECIFICITY SIMILAR TO NF-KAPPA-B BINDS TO A STEROID-DEPENDENT REGULATORY ELEMENT IN THE OVALBUMIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-INTERFERON GENE; IMMUNOGLOBULIN ENHANCER; TRANSCRIPTIONAL REGULATION; INDUCIBLE ENHANCER; RESPONSE ELEMENT; CHICK OVIDUCT; PROMOTER; SEQUENCES; HORMONES; ESTROGEN	The chicken ovalbumin gene is regulated at the level of transcription by four classes of steroid hormones. A steroid-dependent regulatory element (SDRE) found from -900 to -732 is required for this steroid-mediated induction. To define more precisely sequences of the SDRE required for steroidal induction, a series of exonuclease III deletions were made in the 3' end of the SDRE. Fusion genes containing the mutant ovalbumin 5'-flanking sequences linked to the chloramphenicol acetyltransferase structural gene (CAT) were transfected into steroid-responsive primary oviduct cells. These functional studies defined a region of the SDRE from -793 to -759 that is essential for induction by steroids. Analysis of protein interactions in this 34-base pair region by copper-phenanthroline footprinting and methylation interference assays defined nucleotides required for protein binding. Footprinting showed protection of residues extending from -784 to -765, an area that included nucleotides that, when methylated, interfered with protein binding. In addition, this footprinted region contained 10 nucleotides that were identical to sequences contained in the beta-interferon gene regulatory element. An oligomer synthesized to this region of homology produced two DNA-protein complexes with oviduct nuclear proteins. Although this region of the interferon gene regulatory element binds the transcription factor NF-kappa-B, an oligomer from the immunoglobulin kappa-light chain gene known to bind NF-kappa-B did not compete with the SDRE oligomer for binding to oviduct nuclear proteins. Surprisingly, this same NF-kappa-B oligomer was able to restore steroid responsiveness to an SDRE mutant, while an oligomer from the immunoglobulin heavy chain gene inserted in the same position did not affect induction by steroids. These data suggest that a protein binding to sequences in the SDRE that are similar to an NF-kappa-B-binding site participates in the steroid-mediated increase in transcription of the chicken ovalbumin gene.	UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NIDDK NIH HHS [1-R29DK40082-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040082] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1987, J CELL BIOCHEM, V35, P293, DOI 10.1002/jcb.240350404; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; EVANS MI, 1984, ENDOCRINOLOGY, V115, P368, DOI 10.1210/endo-115-1-368; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FEAVERS IM, 1987, P NATL ACAD SCI USA, V84, P7453, DOI 10.1073/pnas.84.21.7453; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; GAUB MP, 1987, EMBO J, V6, P2313, DOI 10.1002/j.1460-2075.1987.tb02506.x; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GOODBOURNE S, 1986, CELL, P601; GRAVALLESE EM, 1989, MOL CELL BIOL, V9, P3184, DOI 10.1128/MCB.9.8.3184; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; JUMP DB, 1987, J BIOL CHEM, V262, P778; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT G, 1976, PROGR DIFFERENTIATIO, P437; MCKNIGHT GS, 1980, CELL, V22, P469; MCKNIGHT GS, 1978, CELL, V14, P403; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NELMS K, 1990, NUCLEIC ACIDS RES, V18, P1037; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; REUE K, 1988, J BIOL CHEM, V263, P6857; SANDERS MM, 1988, BIOCHEMISTRY-US, V27, P6550, DOI 10.1021/bi00417a053; SANDERS MM, 1985, ENDOCRINOLOGY, V116, P398, DOI 10.1210/endo-116-1-398; SANDERS MM, 1986, MOL GENETICS MAMMALI, P183; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEERS LA, 1990, J BIOL CHEM, V265, P7590; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; ZABEL U, 1991, J BIOL CHEM, V266, P252	47	14	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10490	10497						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037595				2022-12-25	WOS:A1991FP08600075
J	GHOSH, SS; WU, YQ; MOBASHERY, S				GHOSH, SS; WU, YQ; MOBASHERY, S			PEPTIDIC MECHANISM-BASED INACTIVATORS FOR CARBOXYPEPTIDASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-L-PHENYLALANINE; CATALYZED ENOLIZATION; KETONE SUBSTRATE; BETA-LACTAMASES; AGAMMA-LEU; INHIBITION; ANALOG; POTENT; DESIGN; ENZYME	N-(Cyanoacetyl)-L-phenylalanine (compound 1) and N-(3-chloropropionyl)-L-phenylalanine (compound 2) were studied as the first peptidic mechanism-based inactivators (suicide substrates) for the zinc protease carboxypeptidase A (CPA). A crucial deprotonation on the methylene-alpha to the amide carbonyl of 1 and 2 has been suggested to lead to the transient formation of a ketenimine and an alpha, beta-unsaturated amide, respectively. Subsequently, it is proposed that these key intermediates trap an active site nucleophile, resulting in covalent modification of the protein. In competition with the inactivation process, the enzyme hydrolyzes the amide bonds in these molecules. Partition ratios of 1180 +/- 40 and 1680 +/- 60 were determined for 1 and 2, respectively. N-Acroyl-L-phenylalanine (compound 4), the putative intermediate from 2, was independently studied to test the validity of the mechanistic scheme and was observed to be an active site-directed inactivator of CPA. A solvent deuterium isotope effect of 1.39 +/- 0.02 was noted for inactivation by 2 and one of 1.31 +/- 0.01 for its hydrolysis, in keeping with a proposed promoted water hydrolytic pathway for peptide hydrolysis by CPA (Christanson, D. W., and Lipscomb, W. N. (1989) Acc. Chem. Res. 22, 62-69). Details of the kinetic analysis and design concepts are discussed.	WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202; SALK INST BIOTECHNOL,IND ASSOCIATES INC,LA JOLLA,CA 92138	Wayne State University; Salk Institute					PHS HHS [7051] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BYERS LD, 1973, BIOCHEMISTRY-US, V12, P2070, DOI 10.1021/bi00735a008; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CHRISTIANSON DW, 1986, P NATL ACAD SCI USA, V83, P7568, DOI 10.1073/pnas.83.20.7568; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; GALARDY RE, 1984, BIOCHEMISTRY-US, V23, P2083, DOI 10.1021/bi00304a032; GARDELL SJ, 1985, NATURE, V317, P551, DOI 10.1038/317551a0; GELB MH, 1985, BIOCHEMISTRY-US, V24, P1813, DOI 10.1021/bi00329a001; HANSON JE, 1989, BIOCHEMISTRY-US, V28, P6294, DOI 10.1021/bi00441a022; HASS GM, 1971, BIOCHEMISTRY-US, V10, P3541; HASS GM, 1971, BIOCHEMISTRY-US, V10, P3535; JACOBSEN NE, 1981, J AM CHEM SOC, V103, P654, DOI 10.1021/ja00393a026; KAISER BL, 1969, P NATL ACAD SCI USA, V64, P36, DOI 10.1073/pnas.64.1.36; KOPPLE KD, 1966, AMINO ACIDS PEPTIDES; LABIA R, 1980, BIOCHIM BIOPHYS ACTA, V611, P351, DOI 10.1016/0005-2744(80)90071-6; LUMRY R, 1951, J AM CHEM SOC, V73, P4330, DOI 10.1021/ja01153a090; LUMRY R, 1955, DISCUSS FARADAY SOC, V20, P105; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MAYCOCK AL, 1975, J AM CHEM SOC, V97, P5613, DOI 10.1021/ja00852a066; MEZES PSF, 1982, FEBS LETT, V143, P265, DOI 10.1016/0014-5793(82)80113-0; MILES EW, 1975, BIOCHEM BIOPH RES CO, V64, P248, DOI 10.1016/0006-291X(75)90245-4; MOBASHERY S, 1990, P NATL ACAD SCI USA, V87, P578, DOI 10.1073/pnas.87.2.578; ONDETTI MA, 1979, BIOCHEMISTRY-US, V18, P1427, DOI 10.1021/bi00575a006; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; PENNING TM, 1985, BIOCHEM J, V226, P469, DOI 10.1042/bj2260469; SILVERMAN R, 1988, MECHANISM BASED ENZY, P22; SIMPSON RT, 1963, BIOCHEMISTRY-US, V2, P616, DOI 10.1021/bi00903a039; STEIN WH, 1948, J BIOL CHEM, V176, P367; SUGIMOTO T, 1979, J AM CHEM SOC, V101, P3946, DOI 10.1021/ja00508a038; SUGIMOTO T, 1978, J AM CHEM SOC, V100, P7750, DOI 10.1021/ja00492a064; SUH J, 1976, J AM CHEM SOC, V98, P1940, DOI 10.1021/ja00423a048; TANG SS, 1983, J BIOL CHEM, V258, P4331; UENO H, 1984, BIOCHEM BIOPH RES CO, V122, P485, DOI 10.1016/S0006-291X(84)80059-5	32	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8759	8764						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026592				2022-12-25	WOS:A1991FM03800022
J	GOLL, DE; DAYTON, WR; SINGH, I; ROBSON, RM				GOLL, DE; DAYTON, WR; SINGH, I; ROBSON, RM			STUDIES OF THE ALPHA-ACTININ ACTIN INTERACTION IN THE Z-DISK BY USING CALPAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; MYOFIBRILLAR PROTEIN TURNOVER; ACTIVATED NEUTRAL PROTEINASE; HUMAN-ERYTHROCYTE MEMBRANE; Z-LINE; STRIATED-MUSCLE; CAPPING PROTEIN; SMOOTH-MUSCLE; IMMUNOELECTRON MICROSCOPY; DICTYOSTELIUM-DISCOIDEUM	Both mu- and m-calpain (the micro- and millimolar Ca2+-requiring Ca2+-dependent proteinases) can completely remove Z-disks from skeletal muscle myofibrils and leave a space devoid of filaments in the Z-disk area. Alpha-actinin, a principal protein component of Z-disks, is removed from myofibrils by the calpains, and a 100-kDa polypeptide that comigrates in sodium dodecyl sulfate-polyacrylamide gel electrophoresis with the alpha-actinin subunit is released into the supernatant. Purified calpain does not degrade purified actin or purified alpha-actinin as indicated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and by N- and C-terminal amino acid analysis of calpain-treated and untreated alpha-actinin and actin. The 100-kDa polypeptide released from myofibrils by calpain elutes identically with native alpha-actinin off DEAE-cellulose and hydroxyapatite columns and, after purification, binds to pure F-actin in the same manner that untreated, native alpha-actinin binds. Calpain-released alpha-actinin also accelerates the rate of superprecipitation of reconstituted actomyosin, a sensitive property characteristic of native alpha-actinin. Consequently, the calpains release alpha-actinin from the Z-disk of myofibrils without degrading it or without altering its ability to bind to actin. These results indicate that alpha-actinin does not simply cross-link thin filaments across the Z-disk but that at least one additional protein (or perhaps an altered actin or alpha-actinin) is involved in the alpha-actinin/actin interaction in Z-disks.	IOWA STATE UNIV SCI & TECHNOL, DEPT ANIM SCI, MUSCLE BIOL GRP, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA	Iowa State University; Iowa State University	GOLL, DE (corresponding author), UNIV ARIZONA, MUSCLE BIOL GRP, TUCSON, AZ 85721 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20984] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKAWA N, 1970, Biochimica et Biophysica Acta, V200, P284, DOI 10.1016/0005-2795(70)90172-8; ARIMURA C, 1988, EUR J BIOCHEM, V177, P649, DOI 10.1111/j.1432-1033.1988.tb14419.x; AZANZA JL, 1981, BIOCHIMIE, V63, P729, DOI 10.1016/S0300-9084(81)80222-2; AZANZA JL, 1979, BIOCHEM J, V183, P339, DOI 10.1042/bj1830339; BARON MD, 1987, J BIOL CHEM, V262, P17623; BECHTEL PJ, 1979, J BIOL CHEM, V254, P1755; BENNETT JP, 1984, BIOCHEMISTRY-US, V23, P5081, DOI 10.1021/bi00316a039; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BRANTON D, 1981, CELL, V24, P24, DOI 10.1016/0092-8674(81)90497-9; BRIER J, 1983, J CELL BIOL, V97, P178, DOI 10.1083/jcb.97.1.178; BULLARD B, 1981, J PHYSIOL-LONDON, V317, pP19; BULLARD B, 1990, J MUSCLE RES CELL M, V11, P271, DOI 10.1007/BF01843580; BUSCH WA, 1972, J CELL BIOL, V52, P367, DOI 10.1083/jcb.52.2.367; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; CASELLA JF, 1989, P NATL ACAD SCI USA, V86, P5800, DOI 10.1073/pnas.86.15.5800; CASELLA JF, 1987, BIOCHEM BIOPH RES CO, V145, P625, DOI 10.1016/0006-291X(87)91366-0; CHEN WYJ, 1986, J MUSCLE RES CELL M, V7, P517, DOI 10.1007/BF01753568; CHENG NQ, 1989, J CELL BIOL, V108, P1761, DOI 10.1083/jcb.108.5.1761; CHOWRASHI PK, 1982, J CELL BIOL, V94, P565, DOI 10.1083/jcb.94.3.565; COLLEY NJ, 1990, J CELL SCI, V95, P11; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; DAVISON MD, 1989, INT J BIOL MACROMOL, V11, P81, DOI 10.1016/0141-8130(89)90047-0; DAYTON WR, 1979, BIOCHIM BIOPHYS ACTA, V584, P216, DOI 10.1016/0304-4165(79)90266-6; DAYTON WR, 1976, BIOCHEMISTRY-US, V15, P2159, DOI 10.1021/bi00655a020; DAYTON WR, 1976, BIOCHEMISTRY-US, V15, P2150, DOI 10.1021/bi00655a019; DAYTON WR, 1975, COLD SPRING HARBOR C, V2, P551; DRABIKOWSKI W, 1968, EUR J BIOCHEM, V5, P209, DOI 10.1111/j.1432-1033.1968.tb00359.x; DUHAIMAN AS, 1984, BIOCHEMISTRY-US, V23, P1600, DOI 10.1021/bi00303a003; EDMUNDS T, 1991, IN PRESS BIOCH BIOPH; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FRANZINI-ARMSTRONG C, 1970, Tissue and Cell, V2, P327, DOI 10.1016/S0040-8166(70)80023-4; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; FYRBERG E, 1990, J CELL BIOL, V110, P1999, DOI 10.1083/jcb.110.6.1999; GOLDSTEIN MA, 1986, J MUSCLE RES CELL M, V7, P527, DOI 10.1007/BF01753569; GOLL DE, 1972, J MOL BIOL, V67, P469, DOI 10.1016/0022-2836(72)90464-0; GOLL DE, 1964, J FOOD SCI, V29, P608, DOI 10.1111/j.1365-2621.1964.tb00418.x; Goll DE, 1990, INTRACELLULAR CALCIU, P3; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRANGER BL, 1978, CELL, V15, P1253, DOI 10.1016/0092-8674(78)90051-X; GRANGER BL, 1979, CELL, V18, P1053, DOI 10.1016/0092-8674(79)90218-6; GRANGER BL, 1980, CELL, V22, P727, DOI 10.1016/0092-8674(80)90549-8; HOLMES GR, 1976, BIOCHIM BIOPHYS ACTA, V446, P445, DOI 10.1016/0005-2795(76)90010-6; IMAMURA M, 1988, J BIOL CHEM, V263, P7800; ISOBE Y, 1988, P NATL ACAD SCI USA, V85, P6758, DOI 10.1073/pnas.85.18.6758; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; KUO SC, 1973, ANAL BIOCHEM, V55, P1, DOI 10.1016/0003-2697(73)90284-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; LANE BP, 1977, J HISTOCHEM CYTOCHEM, V25, P69, DOI 10.1177/25.1.833423; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; LING E, 1988, J BIOL CHEM, V263, P2209; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSBY ML, 1983, J FOOD SCI, V48, P1787, DOI 10.1111/j.1365-2621.1983.tb05085.x; MAHER PA, 1985, J CELL BIOL, V101, P1871, DOI 10.1083/jcb.101.5.1871; MARCHESI VT, 1985, ANNU REV CELL BIOL, V1, P531, DOI 10.1146/annurev.cellbio.1.1.531; MARUYAMA K, 1989, J MUSCLE RES CELL M, V10, P350, DOI 10.1007/BF01758431; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; MURACHI T, 1989, BIOCHEM INT, V18, P263; NAVE R, 1990, FEBS LETT, V269, P163, DOI 10.1016/0014-5793(90)81144-D; NELSON WJ, 1983, P NATL ACAD SCI-BIOL, V80, P363, DOI 10.1073/pnas.80.2.363; NELSON WJ, 1984, P NATL ACAD SCI-BIOL, V81, P3292, DOI 10.1073/pnas.81.11.3292; OHTAKI T, 1985, EUR J BIOCHEM, V153, P609, DOI 10.1111/j.1432-1033.1985.tb09344.x; PHILLIPS DR, 1977, J BIOL CHEM, V252, P5602; POLLARD TD, 1986, CELL MOTIL CYTOSKEL, V6, P649, DOI 10.1002/cm.970060613; RICHARDSON FL, 1981, EUR J CELL BIOL, V26, P91; ROBSON R M, 1970, Biochimica et Biophysica Acta, V200, P296, DOI 10.1016/0005-2795(70)90173-X; ROBSON RM, 1968, ANAL BIOCHEM, V24, P339, DOI 10.1016/0003-2697(68)90188-7; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P3961; SAIDE JD, 1989, J CELL BIOL, V109, P2157, DOI 10.1083/jcb.109.5.2157; SAINSBURY GM, 1980, BIOCHEM J, V191, P333, DOI 10.1042/bj1910333; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SATO M, 1987, NATURE, V325, P828, DOI 10.1038/325828a0; SCHACHAT FH, 1985, J CELL BIOL, V101, P1001, DOI 10.1083/jcb.101.3.1001; SCHOLLMEYER JE, 1973, J CELL BIOL, V59, pA306; SERAYDARIAN K, 1967, BIOCHIM BIOPHYS ACTA, V133, P399, DOI 10.1016/0005-2795(67)90544-2; SINGH I, 1977, BIOCHIM BIOPHYS ACTA, V491, P29, DOI 10.1016/0005-2795(77)90038-1; STROMER MH, 1972, J MOL BIOL, V67, P489, DOI 10.1016/0022-2836(72)90465-2; STROMER MH, 1969, J CELL BIOL, V40, P167, DOI 10.1083/jcb.40.1.167; SUZUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P537, DOI 10.1080/00021369.1985.10866759; SUZUKI A, 1981, AGR BIOL CHEM TOKYO, V45, P2535, DOI 10.1080/00021369.1981.10864916; SUZUKI A, 1976, J BIOL CHEM, V251, P6860; SUZUKI A, 1977, AGR BIOL CHEM TOKYO, V41, P1095, DOI 10.1080/00021369.1977.10862635; TAKAHASHI K, 1989, J BIOCHEM, V105, P529, DOI 10.1093/oxfordjournals.jbchem.a122701; TOYOOKA T, 1979, J MOL CELL CARDIOL, V11, P769, DOI 10.1016/0022-2828(79)90402-4; TSUNEKAWA S, 1989, FEBS LETT, V250, P493, DOI 10.1016/0014-5793(89)80783-5; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V14, P123, DOI 10.1111/j.1432-0436.1979.tb01021.x; WALLRAFF E, 1986, EMBO J, V5, P61, DOI 10.1002/j.1460-2075.1986.tb04178.x; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; WANG S-M, 1990, Journal of Cell Biology, V111, p426A; WEBER K, 1969, J BIOL CHEM, V244, P4406; WOODS KR, 1967, BIOCHIM BIOPHYS ACTA, V133, P369, DOI 10.1016/0005-2795(67)90078-5; YAMAGUCHI M, 1985, J MOL BIOL, V184, P621, DOI 10.1016/0022-2836(85)90308-0; YAMAGUCHI M, 1983, J CELL BIOL, V96, P435, DOI 10.1083/jcb.96.2.435; ZEECE MG, 1979, BIOCHIM BIOPHYS ACTA, V581, P365, DOI 10.1016/0005-2795(79)90258-7; ZIMMER DB, 1987, J ELECTRON MICR TECH, V6, P357, DOI 10.1002/jemt.1060060406; [No title captured]	99	156	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8501	8510						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022664				2022-12-25	WOS:A1991FK44100082
J	MOSER, D; TENDLER, M; GRIFFITHS, G; KLINKERT, MQ				MOSER, D; TENDLER, M; GRIFFITHS, G; KLINKERT, MQ			A 14-KDA SCHISTOSOMA-MANSONI POLYPEPTIDE IS HOMOLOGOUS TO A GENE FAMILY OF FATTY-ACID BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; METAL CHELATE ADSORBENT; DEVELOPMENTAL REGULATION; ESCHERICHIA-COLI; RAT-LIVER; MYELIN-P2 PROTEIN; MESSENGER-RNAS; CLONED CDNA; HEART; PURIFICATION	The complete nucleotide sequence encoding a Schistosoma mansoni protein termed Sm14 was determined from cDNA clones propagated in bacteriophage lambda-gt11 in Escherichia coli. The 14.8-kDa protein bears significant homologies with a family of related polypeptides which bind hydrophobic ligands. Members of this group of cytosolic proteins were originally identified based on their affinity for long chain fatty acids. The purified recombinant protein exhibited an affinity to fatty acids, in contrast to a mutant lacking 16 N-terminal amino acids. Immunofluorescence experiments show that tubercles, which are structures located on the dorsal surface of adult male schistosome and known to contain lipids, are stained using antibodies raised to the beta-galactosidase fusion protein. A regular staining pattern is also evident in the muscle layers as well as in the body of the parasite. As the schistosome cannot synthesize fatty acids de novo and is dependent on the uptake of lipids from serum, the available data support a role for Sm14 in the transport of fatty acids.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL HEIDELBERG,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY; OSWALDO CRUZ INST,DEPT HELMINTHOL,RIO DE JANEIRO,BRAZIL; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Fundacao Oswaldo Cruz; European Molecular Biology Laboratory (EMBL)			Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1985, J BIOL CHEM, V260, P1432; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BOHMER FD, 1988, J CELL BIOCHEM, V38, P199, DOI 10.1002/jcb.240380307; BUJARD H, 1987, METHOD ENZYMOL, V155, P265; CHAN L, 1985, J BIOL CHEM, V260, P2629; CHIANG CP, 1989, AM J PATHOL, V134, P1007; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DOBELI H, 1990, MOL BIOCHEM PARASIT, V41, P259, DOI 10.1016/0166-6851(90)90189-S; FELLEISEN R, 1988, MOL BIOCHEM PARASIT, V30, P19, DOI 10.1016/0166-6851(88)90128-4; FELLEISEN R, 1990, EMBO J, V9, P371, DOI 10.1002/j.1460-2075.1990.tb08120.x; FURLONG ST, 1989, EXP PARASITOL, V69, P65, DOI 10.1016/0014-4894(89)90172-0; GLATZ JFC, 1989, MOL CELL BIOCHEM, V88, P37, DOI 10.1007/BF00223421; GLATZ JFC, 1985, CHEM PHYS LIPIDS, V38, P115, DOI 10.1016/0009-3084(85)90061-1; GLATZ JFC, 1985, BIOCHIM BIOPHYS ACTA, V837, P57, DOI 10.1016/0005-2760(85)90085-2; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GORDON JI, 1985, CHEM PHYS LIPIDS, V38, P137, DOI 10.1016/0009-3084(85)90063-5; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JONES TA, 1988, EMBO J, V7, P1594; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KLINKERT MQ, 1987, MOL BIOCHEM PARASIT, V25, P247, DOI 10.1016/0166-6851(87)90088-0; KLINKERT MQ, 1989, MOL BIOCHEM PARASIT, V33, P113, DOI 10.1016/0166-6851(89)90025-X; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LOWE JB, 1985, J BIOL CHEM, V260, P3413; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LOWE JB, 1984, J BIOL CHEM, V259, P2696; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P1035; MEYER F, 1970, BIOCHIM BIOPHYS ACTA, V210, P256; NARAYANAN V, 1988, J BIOL CHEM, V263, P8332; OFFNER GD, 1986, J BIOL CHEM, V261, P5584; OFFNER GD, 1988, BIOCHEM J, V252, P191, DOI 10.1042/bj2520191; OSTERBURG G, 1982, NUCLEIC ACIDS RES, V10, P207, DOI 10.1093/nar/10.1.207; PEETERS RA, 1989, MOL CELL BIOCHEM, V88, P45; ROGERS MV, 1988, MOL BIOCHEM PARASIT, V29, P77, DOI 10.1016/0166-6851(88)90122-3; ROGERS MV, 1989, MOL BIOCHEM PARASIT, V35, P79, DOI 10.1016/0166-6851(89)90145-X; RUMJANEK FD, 1980, MOL BIOCHEM PARASIT, V1, P31, DOI 10.1016/0166-6851(80)90039-0; RUMJANEK FD, 1983, MOL BIOCHEM PARASIT, V9, P337, DOI 10.1016/0166-6851(83)90090-7; RUMJANEK FD, 1988, MOL BIOCHEM PARASIT, V28, P145, DOI 10.1016/0166-6851(88)90062-X; SAMUELSON JC, 1980, EXP PARASITOL, V50, P369, DOI 10.1016/0014-4894(80)90040-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH TM, 1969, PARASITOLOGY, V59, P293, DOI 10.1017/S0031182000082251; SPECTOR AA, 1975, J LIPID RES, V16, P165; STUBER D, 1900, IMMUNOLOGY METHODS; SUNDELIN J, 1985, J BIOL CHEM, V260, P6494; SUNDELIN J, 1985, J BIOL CHEM, V260, P6488; TENDLER M, 1986, INT J PARASITOL, V16, P347, DOI 10.1016/0020-7519(86)90113-X; WILSON RA, 1974, PARASITOLOGY, V68, P239, DOI 10.1017/S0031182000045765	56	144	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8447	8454						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022660				2022-12-25	WOS:A1991FK44100074
J	STOKES, DG; SAITTA, B; TIMPL, R; CHU, ML				STOKES, DG; SAITTA, B; TIMPL, R; CHU, ML			HUMAN ALPHA-3(VI) COLLAGEN GENE - CHARACTERIZATION OF EXONS CODING FOR THE AMINO-TERMINAL GLOBULAR DOMAIN AND ALTERNATIVE SPLICING IN NORMAL AND TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN VONWILLEBRAND-FACTOR; CARTILAGE MATRIX PROTEIN; TROPONIN-T ISOFORMS; PRE-MESSENGER-RNA; VI COLLAGEN; MOLECULAR-CLONING; SINGLE GENE; FACTOR-B; CHAINS; SEQUENCE	We recently reported the isolation and sequencing of human cDNA clones corresponding to the alpha-3 chain of type VI collagen (Chu, M.-L., Zhang, R.-Z., Pan, T.-c., Stokes, D., Conway, D., Kuo, H.-J., Glanville, R., Mayer, U., Mann, K., Deutzmann, R., and Timpl, R. (1990) EMBO J. 9, 385-393). The study indicates that the amino-terminal globular domain of the alpha-3(VI) chain consists of nine repetitive subdomains of approximately 200 amino acid residues (N1-N9) and the gene appeared to undergo alternative splicing since some clones lacked regions encoding the N9 and part of the N3 subdomains. In the present study, we report the exon structure for the region encoding the amino-terminal globular domain of the human alpha-3(VI) chain. The nine repetitive subdomains are encoded by 10 exons spanning 26 kilobase pairs of genomic DNA. Eight of the repetitive subdomains (N2-N9) were found to be encoded by separate exons of approximately 600 base pairs each. The only exception is the N1 subdomain which is encoded by two exons of 417 and 146 base pairs. Characterization of the exon/intron structure showed that the cDNA variants were the result of splicing out of exon 9 (encoding the N9 subdomain) and part of exon 3 (encoding the N3 subdomain). Nuclease S1 analysis and the polymerase chain reaction demonstrated that exon 7 (N7 subdomain) was also subject to alternative splicing in normal skin fibroblasts. Examination of these splicing events by nuclease S1 analysis in normal fibroblasts, three different human tumor cell lines, and several human tissues showed that splicing out of exon 9 is much more efficient in normal as compared to tumor cells.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,1020 LOCUST ST,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT DERMATOL,PHILADELPHIA,PA 19107; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Jefferson University; Jefferson University; Max Planck Society					NIAMS NIH HHS [AR-38912, AR-38188, AR-38923] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038912, P01AR038923, P01AR038188] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AYAD S, 1989, BIOCHEM J, V262, P753, DOI 10.1042/bj2620753; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BONALDO P, 1989, J BIOL CHEM, V264, P20235; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BROWN JWS, 1986, NUCLEIC ACIDS RES, V14, P9549, DOI 10.1093/nar/14.24.9549; BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393; BURNETT W, 1979, BIOCHEM BIOPH RES CO, V86, P478, DOI 10.1016/0006-291X(79)91739-X; CAMPBELL RD, 1983, P NATL ACAD SCI-BIOL, V80, P4464, DOI 10.1073/pnas.80.14.4464; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1987, EUR J BIOCHEM, V168, P309, DOI 10.1111/j.1432-1033.1987.tb13422.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; COLOMBATTI A, 1989, MATRIX, V9, P177, DOI 10.1016/S0934-8832(89)80048-4; CORBI AL, 1990, J BIOL CHEM, V265, P2782; DILLELA AG, 1985, FOCUS, V7, P1; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HUNG T, 1990, NUCLEIC ACIDS RES, V18, P4953, DOI 10.1093/nar/18.16.4953; JEFFREYS AJ, 1982, NATURE, V296, P9, DOI 10.1038/296009a0; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; KISS I, 1989, J BIOL CHEM, V264, P8126; KOLLER E, 1989, EMBO J, V8, P1073, DOI 10.1002/j.1460-2075.1989.tb03475.x; LEY TJ, 1982, P NATL ACAD SCI-BIOL, V79, P4775, DOI 10.1073/pnas.79.15.4775; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; Maniatis T, 1989, DECONTAMINATION DILU; MEDFORD RM, 1984, CELL, V38, P409, DOI 10.1016/0092-8674(84)90496-3; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; OYAMA F, 1989, BIOCHEMISTRY-US, V28, P1428, DOI 10.1021/bi00429a072; OYAMA F, 1989, J BIOL CHEM, V264, P10331; PARETI FI, 1986, J BIOL CHEM, V261, P15310; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SANGER F, 1977, P NATL ACAD SCI USA, V74, P4563; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; TITANI K, 1988, TRENDS BIOCHEM SCI, V13, P94, DOI 10.1016/0968-0004(88)90048-5; TRUEB B, 1989, J BIOL CHEM, V264, P136; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; WEIL D, 1988, AM J HUM GENET, V42, P435	50	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8626	8633						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022673				2022-12-25	WOS:A1991FK44100099
J	YORK, JD; LI, P; GARDELL, SJ				YORK, JD; LI, P; GARDELL, SJ			COMBINATORIAL MUTAGENESIS OF THE REACTIVE SITE REGION IN PLASMINOGEN-ACTIVATOR INHIBITOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; PROTEASE; PROTEINS; CLONING; SERPIN; FIBRIN; CHAIN	Plasminogen activator inhibitor (PAI-1) rapidly inactivates tissue plasminogen activator (t-PA) and urokinase (UK) with nearly identical association rate constants. The contributions of Ser344, Ala345, and Arg346 (P3, P2, and P1 residues, respectively) in PAI-1 to inhibition of UK and t-PA were evaluated using combinatorial mutagenesis of the human PAI-1 cDNA. A bacteriophage-lambda expression library potentially encoding the 8000 unique PAI-1 species were screened for inhibitory activity against UK using a fibrin indicator gel. 390 plaques demarcated by zones of retarded fibrinolysis were analyzed to determine the DNA sequences of their associated active PAI-1 species. We found 134 unique PAI-1 variants that retained inhibitory activity towards UK; they contained a variety of amino acids in their P3 and P2 positions but only Arg or, infrequently, Lys in their P1 position. Each of the unique active PAI-1 were assayed for inhibitory activity towards UK or t-PA; many substitutions differentially affected the ability of the inhibitor to inactivate UK and t-PA. For example, replacement of Ser344 and Ala345 with Val and Pro, respectively, yielded a PAI-1 variant exhibiting an association rate constant that was unchanged for t-PA but decreased 23-fold for UK, relative to native PAI-1. In general, the PAI-1 variants were more potent inhibitors of t-PA than UK. Hence, t-PA appears more tolerant than UK of structural diversity present in the P3 and P2 positions of the PAI-1 variants.	MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,W POINT,PA 19486	Merck & Company								CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; ERICKSON LA, 1984, ANAL BIOCHEM, V137, P454, DOI 10.1016/0003-2697(84)90113-1; GARDELL SJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P467, DOI 10.1016/0003-9861(90)90286-8; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; Maniatis T., 1982, MOL CLONING; MOSTELLER F, 1970, PROBABILITY STATISTI; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; READ RJ, 1986, PROTEINASE INHIBITOR, P301; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANZO MA, 1987, BIOCHEMISTRY-US, V26, P7443, DOI 10.1021/bi00397a037; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; VAUGHAN DE, 1989, J CLIN INVEST, V84, P586, DOI 10.1172/JCI114202; WHITE J, 1986, BIOCHEM SOC T, V14, P457, DOI 10.1042/bst0140457; Williams J W, 1979, Methods Enzymol, V63, P437	26	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8495	8500						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022663				2022-12-25	WOS:A1991FK44100081
J	CHOU, YH; NGAI, KL; GOLDMAN, R				CHOU, YH; NGAI, KL; GOLDMAN, R			THE REGULATION OF INTERMEDIATE FILAMENT REORGANIZATION IN MITOSIS - P34CDC2 PHOSPHORYLATES VIMENTIN AT A UNIQUE N-TERMINAL SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE; MITOTIC CELLS; HEAD DOMAIN; M-PHASE; INVITRO; SEQUENCE; DESMIN; GENE; KERATIN; IDENTIFICATION	The disassembly of vimentin-containing intermediate filament (IF) networks during mitosis in BHK-21 cells is accompanied by increased phosphorylation of vimentin (Chou, Y.-H., Rosevear, E., and Goldman, R. D. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1885-1889). We have recently identified p34cdc2 as the catalytic subunit of one of the two endogenous vimentin kinases in mitotic baby hamster kidney cells (Chou, Y.-H., Bischoff, J. R., Beach, D., and Goldman, R. D. (1990) Cell 62, 1063-1071). To begin to characterize the biochemical basis of the p34cdc2-mediated IF disassembly process, we have purified and sequenced the P-32-labeled tryptic peptides derived from in vitro-phosphorylated vimentin. The results demonstrate that Ser-55, in the N-terminal non-alpha-helical domain of vimentin, is the most favored phosphorylation site. This finding supports the idea that the N-terminal domain of type III IF protein plays a crucial role in regulating IF structure and supramolecular organization.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University	CHOU, YH (corresponding author), NORTHWESTERN UNIV,DEPT CELL MOLEC & STRUCT BIOL,CHICAGO,IL 60611, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036806, R01GM036806] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36806] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; AEBI U, 1988, PROTOPLASMA, V145, P73, DOI 10.1007/BF01349341; ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AUBIN JE, 1980, EXP CELL RES, V129, P149, DOI 10.1016/0014-4827(80)90340-7; BIRKENBERGER L, 1990, J CELL BIOL, V111, P2063, DOI 10.1083/jcb.111.5.2063; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; DESSEV GN, 1990, J BIOL CHEM, V265, P12636; EVANS RM, 1988, EUR J CELL BIOL, V46, P152; EVANS RM, 1989, J CELL BIOL, V108, P67, DOI 10.1083/jcb.108.1.67; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FISCHER S, 1986, BIOL CHEM H-S, V367, P1147, DOI 10.1515/bchm3.1986.367.2.1147; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; GARD DL, 1982, MOL CELL BIOL, V2, P1104, DOI 10.1128/MCB.2.9.1104; GARD DL, 1980, CELL, V19, P263, DOI 10.1016/0092-8674(80)90408-0; GEISLER N, 1989, EUR J BIOCHEM, V183, P441, DOI 10.1111/j.1432-1033.1989.tb14947.x; GEISLER N, 1983, FEBS LETT, V163, P22, DOI 10.1016/0014-5793(83)81153-3; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HERMANN H, 1989, DEVELOPMENT, V105, P279; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LANE EB, 1982, EMBO J, V1, P1365, DOI 10.1002/j.1460-2075.1982.tb01324.x; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR CM, 1981, CELL, V23, P135, DOI 10.1016/0092-8674(81)90278-6; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; QUAX W, 1983, CELL, V35, P215, DOI 10.1016/0092-8674(83)90224-6; QUINLAN RA, 1989, J CELL SCI, V93, P71; RAATS JMH, 1990, J CELL BIOL, V111, P1971, DOI 10.1083/jcb.111.5.1971; ROSEVEAR ER, 1990, CELL MOTIL CYTOSKEL, V17, P150, DOI 10.1002/cm.970170303; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STARGER JM, 1978, J CELL BIOL, V78, P93, DOI 10.1083/jcb.78.1.93; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TOLLE HG, 1987, EUR J CELL BIOL, V43, P35; TRAUB P, 1983, J CELL SCI, V63, P43; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; ZEHNER ZE, 1987, J BIOL CHEM, V262, P8112; ZIEVE GW, 1980, J CELL BIOL, V87, P160, DOI 10.1083/jcb.87.1.160	59	106	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7325	7328						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019567				2022-12-25	WOS:A1991FJ34200004
J	UCHIYAMA, H; NAGASAWA, K				UCHIYAMA, H; NAGASAWA, K			CHANGES IN THE STRUCTURE AND BIOLOGICAL PROPERTY OF N-]O SULFATE-TRANSFERRED, N-RESULFATED HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICOAGULANT ACTIVITY; NMR; DESULFATION; BINDING; BOVINE; SIZE	The N --> O sulfate transfer of heparin has been investigated as an approach to chemical 3-O-sulfation of the D-glucosamine residues in heparin. The pyridinium salt of porcine heparin was heated at 90-degrees-C in solid state for 90 min (in vacuo over P2O5) to effect the transfer of the N-sulfate groups to the HO groups in the polysaccharide, followed by N-resulfation. The product (N --> O sulfate-transferred, N-resulfated heparin (ST heparin)) was depolymerized with HONO to generate a mixture of di- and higher oligosaccharides. The borohydride-reduced oligosaccharides were separated on Bio-Gel P-4 and DEAE-Sephacel. The disaccharide trisulfate fraction (10.4% yield) was found to be a mixture of nearly equal amounts of IdoA(2-SO4)-AMan(R)(3,6-diSO4) and IdoA(2,3-diSO4)-AMan(R)(6-SO4), where IdoA represents L-iduronic acid and AMan(R) represents the alditol formed by reduction of 2,5-anhydro-D-mannose with NaBH4. Chemical and NMR spectroscopic analyses revealed that the N --> O sulfate transfer proceeded preferentially at HO-3 positions in both 6-O-sulfo-D-glucosamine and 2-O-sulfo-L-iduronic acid residues. Chromatography on antithrombin III-Sepharose gel indicated that the structural change involved in ST heparin resulted in an obvious increase in the ability to bind antithrombin III. Biological examination also indicated that this structural change resulted in moderate increases in all the activities (blood anti-clotting, anti-Factor IIa, and anti-Factor Xa) and in the strength of intrinsic fluorescence of antithrombin III.	KITASATO UNIV,SCH PHARMACEUT SCI,5-9-1 SHIROKANE,MINATO KU,TOKYO 108,JAPAN	Kitasato University								AYOTTE L, 1986, CARBOHYD RES, V145, P267, DOI 10.1016/S0008-6215(00)90434-8; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CASU B, 1983, ARZNEIMITTELFORSCH, V33-1, P135; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; Damus P S, 1976, Methods Enzymol, V45, P653; DODGSON KS, 1962, BIOCHEM J, V84, P106, DOI 10.1042/bj0840106; FERRO DR, 1986, J AM CHEM SOC, V108, P6773, DOI 10.1021/ja00281a052; GATTI G, 1979, MACROMOLECULES, V12, P1001, DOI 10.1021/ma60071a044; HORNER AA, 1988, BIOCHEM J, V251, P141, DOI 10.1042/bj2510141; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; INOUE Y, 1976, ANAL BIOCHEM, V71, P46, DOI 10.1016/0003-2697(76)90009-9; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; NAGASAVA K, 1980, METHODS CARBOHYDR CH, V8, P291; NAGASAWA K, 1974, CARBOHYD RES, V36, P265, DOI 10.1016/S0008-6215(00)83047-5; NAGASAWA K, 1972, CARBOHYD RES, V21, P420, DOI 10.1016/S0008-6215(00)84922-8; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OGAMO A, 1989, CARBOHYD RES, V193, P165, DOI 10.1016/0008-6215(89)85116-X; OGAMO A, 1990, J BIOCHEM-TOKYO, V108, P588, DOI 10.1093/oxfordjournals.jbchem.a123247; PETITOU M, 1989, HEPARIN CHEM BIOL PR, P65; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; TEIEN AN, 1977, THROMB RES, V11, P107, DOI 10.1016/0049-3848(77)90029-9; UCHIYAMA H, 1990, J BIOCHEM-TOKYO, V107, P377, DOI 10.1093/oxfordjournals.jbchem.a123053; YOSIZAWA Z, 1967, BIOCHIM BIOPHYS ACTA, V141, P358, DOI 10.1016/0304-4165(67)90110-9	27	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6756	6760						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016290				2022-12-25	WOS:A1991FG72700020
J	NOVAK, EK; BAUMANN, H; OVNIC, M; SWANK, RT				NOVAK, EK; BAUMANN, H; OVNIC, M; SWANK, RT			EXPRESSION OF EGASYN-ESTERASE IN MAMMALIAN-CELLS - SEQUESTRATION IN THE ENDOPLASMIC-RETICULUM AND COMPLEXATION WITH BETA-GLUCURONIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; COMPARTMENTALIZATION; INVOLVEMENT; SEQUENCE; ACID; DNA	Mouse egasyn cDNA was inserted into expression vector pCDpoly and transfected into mammalian cell lines. Transfected human HepG2 cells, monkey COS-1 cells, and mouse L cells expressed egasyn-esterase catalytic activity. Within COS-1 cells, egasyn was localized to the endoplasmic reticulum. Although individual cells produced large amounts of egasyn, no secretion was observed. No beta-glucuronidase-egasyn complexes were formed in transfected HepG2 or COS-1 cells. However, these complexes were readily detected in transfected L cells. Although the signal for retention of egasyn in the endoplasmic reticulum appears to be species independent, the signal for association with beta-glucuronidase is species restricted.	CHILDRENS HOSP RES FDN,DIV BASIC SCI RES,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	NOVAK, EK (corresponding author), ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036366] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31698] Funding Source: Medline; NIDDK NIH HHS [DK-14770] Funding Source: Medline; NIGMS NIH HHS [GM-36366] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDT E, 1980, BIOCHEM PHARMACOL, V29, P1927, DOI 10.1016/0006-2952(80)90105-7; BROWN J, 1987, J CELL BIOL, V105, P1571, DOI 10.1083/jcb.105.4.1571; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; KOMMA DJ, 1963, J HISTOCHEM CYTOCHEM, V11, P619, DOI 10.1177/11.5.619; KORZA G, 1988, J BIOL CHEM, V263, P3486; LI H, 1990, J BIOL CHEM, V265, P14732; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; LUSIS AJ, 1977, ISOZYMES, V2, P63; MEDDA S, 1986, BIOCHEM GENET, V24, P229, DOI 10.1007/BF00502791; MEDDA S, 1985, J BIOL CHEM, V260, P5802; MEDDA S, 1989, J BIOL CHEM, V264, P15824; MEDDA S, 1987, J BIOL CHEM, V262, P7248; MEDDA S, 1987, CELL, V50, P301, DOI 10.1016/0092-8674(87)90225-X; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PRUITT SC, 1988, GENE, V66, P121, DOI 10.1016/0378-1119(88)90230-2; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; SWANK RT, 1973, J MOL BIOL, V77, P371, DOI 10.1016/0022-2836(73)90445-2; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WHITING JF, 1990, HEPATOLOGY, V12, P893	24	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6377	6380						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007590				2022-12-25	WOS:A1991FE37300057
J	PIM, D; BANKS, L				PIM, D; BANKS, L			LOSS OF HPV-16 E7 DEPENDENCE IN CELLS TRANSFORMED BY HPV-16 E7 PLUS EJ-RAS CORRELATES WITH INCREASED C-MYC EXPRESSION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; CERVICAL-CARCINOMA; ADENOVIRUS E1A; ACTIVATED RAS; MOUSE CELLS; DNA; PROTEIN; ONCOGENE; SEQUENCES	We have previously shown that continued expression of the HPV-16 E7 gene was required to maintain the transformed phenotype of primary baby rat kidney cells transformed by HPV-16 E7 plus EJ-ras. In this study we aimed to investigate the possible mechanisms by which cells could overcome this continued requirement for E7 expression. Using an inducible system for expression of the E7 gene we were able to generate cell lines no longer dependent on continued E7 expression. All such lines were still fully transformed, maintained inducible E7 expression and showed increased proliferative activity in the presence of HPV-16 E7 gene product. Further analysis has demonstrated a marked increase in the presence of c-myc protein in these cell lines when compared with the parental cells, suggesting a possible mechanism by which E7 dependence can be overcome.	INT CTR GENET ENGN & BIOTECHNOL, PADRICIANO 99, I-34012 TRIESTE, ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB)								ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1988, VIROLOGY, V165, P326, DOI 10.1016/0042-6822(88)90695-2; BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CROOK T, 1989, P NATL ACAD SCI USA, V86, P5713, DOI 10.1073/pnas.86.15.5713; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1989, MOL CARCINOGEN, V2, P308, DOI 10.1002/mc.2940020605; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEES E, 1990, J GEN VIROL, V71, P183, DOI 10.1099/0022-1317-71-1-183; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MUNGER K, 1989, J VIROL, V63, P4417; OCADIZ R, 1987, CANCER RES, V47, P4173; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RIOU G, 1987, LANCET, V1, P761; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCE RP, 1988, CANCER RES, V48, P324; STOREY A, 1990, J GEN VIROL, V71, P965, DOI 10.1099/0022-1317-71-4-965; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	34	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					589	594						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030911				2022-12-25	WOS:A1991FR93900013
J	ALLAN, GF; ING, NH; TSAI, SY; SRINIVASAN, G; WEIGEL, NL; THOMPSON, EB; TSAI, MJ; OMALLEY, BW				ALLAN, GF; ING, NH; TSAI, SY; SRINIVASAN, G; WEIGEL, NL; THOMPSON, EB; TSAI, MJ; OMALLEY, BW			SYNERGISM BETWEEN STEROID-RESPONSE AND PROMOTER ELEMENTS DURING CELL-FREE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; RNA POLYMERASE-II; ESTROGEN-RECEPTOR; OVALBUMIN GENE; PROGESTERONE RECEPTORS; DEPENDENT INTERACTION; DISTAL PROMOTER; TATA BOX; UPSTREAM	We have analyzed quantitatively the influence of distal promoter elements on steroid-responsive gene expression in vitro. Functional synergism between enhancer and distal promoter elements was examined using two model promoters, one containing a natural promoter (mouse mammary tumor virus long terminal repeat) and one constructed artificially. Human glucocorticoid receptor (GR) expressed in baculovirus induces transcription from a mouse mammary tumor virus long terminal repeat-containing DNA template. Transcription is diminished by oligonucleotides containing a nuclear factor 1 (NF-1)-binding site or a glucocorticoid/progesterone response element. Quantitative analysis indicates that NF-1 and GR act synergistically during transcriptional activation. In contrast, efficient activation by GR or purified chick progesterone receptor of a glucocorticoid/progesterone response element-linked ovalbumin promoter does not require interaction with the chicken ovalbumin upstream promoter (COUP) element in the distal promoter. Lack of synergism is not related to enhancer strength, since the glucocorticoid/progesterone response elements can be moved further from the promoter or reduced to a single copy response element without increasing the dependence upon COUP. Strong synergism is restored following substitution of an NF-1 distal promoter element for the COUP element in this construct. Our results suggest that synergism between steroid response and distal promoter elements is dependent upon the identity of the promoter element rather than upon the inherent strength of the enhancer element.	BAYLOR UNIV, DEPT CELL BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77550 USA	Baylor University; University of Texas System; University of Texas Medical Branch Galveston			Ing, Nancy/AAC-9927-2020					ANKENBAUER W, 1988, P NATL ACAD SCI USA, V85, P7526, DOI 10.1073/pnas.85.20.7526; BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1990, J BIOL CHEM, V265, P5129; BAGCHI MK, 1987, MOL CELL BIOL, V7, P4151, DOI 10.1128/MCB.7.12.4151; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BRADSHAW MS, 1988, J BIOL CHEM, V263, P8485; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CATO ACB, 1989, MOL CELL BIOL, V9, P5324, DOI 10.1128/MCB.9.12.5324; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVERETT RD, 1983, NUCLEIC ACIDS RES, V11, P2447, DOI 10.1093/nar/11.8.2447; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KUHNEL B, 1986, J MOL BIOL, V190, P367, DOI 10.1016/0022-2836(86)90008-2; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; PARSLOW TG, 1987, SCIENCE, V235, P1498, DOI 10.1126/science.3029871; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TREISMAN R, 1985, NATURE, V315, P72, DOI 10.1038/315072a0; TSAI SY, 1990, J BIOL CHEM, V265, P17055; VONDERAHE D, 1985, NATURE, V313, P706, DOI 10.1038/313706a0; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X	50	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5905	5910						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005127				2022-12-25	WOS:A1991FD37000085
J	CHAZOTTE, B; HACKENBROCK, CR				CHAZOTTE, B; HACKENBROCK, CR			LATERAL DIFFUSION OF REDOX COMPONENTS IN THE MITOCHONDRIAL INNER MEMBRANE IS UNAFFECTED BY INNER MEMBRANE FOLDING AND MATRIX DENSITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID CYCLE ENZYMES; ELECTRON-TRANSPORT; CYTOCHROME-C; PHOTOBLEACHING RECOVERY; BIOLOGICAL-MEMBRANES; COMPLEX-I; ORGANIZATION; COLLISION; MOBILITY; FUSION	We report the first lateral diffusion measurements of redox components in normal-sized, matrix-containing, intact mitoplasts (inner membrane-matrix particles). The diffusion measurements were obtained by submicron beam fluorescence recovery after photo-bleaching measurements of individual, intact, rat liver mitoplasts bathed in different osmolarity media to control the matrix density and the extent of inner membrane folding. The data reveal that neither the extent of mitochondrial matrix density nor the complexity of the inner membrane folding have a significant effect on the mobility of inner membrane redox components. Diffusion coefficients for Complex I (NADH:ubiquinone oxidoreductase), Complex III (ubiquinol:cytochrome c oxidoreductase), Complex IV (cytochrome oxidase), ubiquinone, and phospholipid were found to be effectively invariant with the matrix density and/or membrane folding and essentially the same as values we reported previously for spherical, fused, ultralarge, matrix-free, inner membranes. Diffusion of proton-transporting Complex V (ATP synthase) appeared to be 2-3-fold slower at the greatest matrix density and degree of membrane folding. Consistent with a diffusion-coupled mechanism of electron transport, comparison of electron transport frequencies (productive collisions) with the theoretical, diffusion-controlled, collision frequencies (maximum collisions possible) revealed that there were consistently more calculated than productive collisions for all redox partners. Theoretical analyses of parameters for submicron fluorescence recovery after photobleaching measurements in intact mitoplasts support the finding of highly mobile redox components diffusing at the same rates as determined in conventional fluorescence recovery after photobleaching measurements in fused, ultra-large inner membranes. These findings support the Random Collision Model of Mitochondrial Electron Transport at the level of the intact mitoplast and suggest a similar conclusion for the intact mitochondrion.			CHAZOTTE, B (corresponding author), UNIV N CAROLINA, SCH MED, DEPT CELL BIOL & ANAT, CELL BIOL LABS, CHAPEL HILL, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM028704, R01GM028704] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28704] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIZENBUD BM, 1982, BIOPHYS J, V38, P287, DOI 10.1016/S0006-3495(82)84560-8; ANDREWS PM, 1975, EXP CELL RES, V90, P127, DOI 10.1016/0014-4827(75)90365-1; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; CHAZOTTE B, 1985, BIOCHIM BIOPHYS ACTA, V818, P87, DOI 10.1016/0005-2736(85)90142-7; CHAZOTTE B, 1989, J BIOL CHEM, V264, P4978; CHAZOTTE B, 1988, J BIOL CHEM, V263, P14359; DRAGSTEN P, 1979, P NATL ACAD SCI USA, V76, P5163, DOI 10.1073/pnas.76.10.5163; DSOUZA SF, 1983, BIOCHIM BIOPHYS ACTA, V724, P40, DOI 10.1016/0005-2728(83)90023-3; ELSON EL, 1989, METHOD CELL BIOL, V30, P307; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FUKUSHIMA T, 1989, J BIOL CHEM, V264, P16483; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GUPTE S, 1984, P NATL ACAD SCI-BIOL, V81, P2606, DOI 10.1073/pnas.81.9.2606; GUPTE SS, 1988, J BIOL CHEM, V263, P5241; GUPTE SS, 1988, J BIOL CHEM, V263, P5248; GUPTE SS, 1988, INTEGRATION MITOCHON, P95; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; Hackenbrock C R, 1979, Methods Enzymol, V56, P683; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; HACKENBROCK CR, 1972, J CELL BIOL, V53, P450, DOI 10.1083/jcb.53.2.450; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; HARDT SL, 1979, BIOPHYS CHEM, V10, P239, DOI 10.1016/0301-4622(79)85012-7; HOCHLI M, 1985, EUR J CELL BIOL, V38, P1; HOCHMAN J, 1985, BIOCHEMISTRY-US, V24, P2509, DOI 10.1021/bi00331a017; HOCHMAN J, 1985, P NATL ACAD SCI USA, V79, P6866; KAPITZA HG, 1985, TECHNIQUES ANAL MEMB, P345; KLINGENBERG M, 1967, BIOCH MITOCHONDRIA, P11; KOPPEL DE, 1983, BIOPHYS J, V43, P175, DOI 10.1016/S0006-3495(83)84338-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PETERSEN NO, 1981, J SUPRAMOL STR CELL, V17, P213, DOI 10.1002/jsscb.380170303; PIHL E, 1970, Experimental Cell Research, V63, P391, DOI 10.1016/0014-4827(70)90228-4; POWERSLEE SG, 1987, J BIOL CHEM, V262, P15683; ROBINSON JB, 1985, BIOCHEM MED METAB B, V33, P149, DOI 10.1016/0006-2944(85)90023-7; ROBINSON JB, 1987, J BIOL CHEM, V262, P1786; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SCHNEIDER H, 1980, J BIOL CHEM, V255, P3748; SCHNEIDER H, 1980, P NATL ACAD SCI-BIOL, V77, P442, DOI 10.1073/pnas.77.1.442; Srere P A, 1986, Adv Exp Med Biol, V194, P13; Srere P.A., 1988, INTEGRATION MITOCHON, P279; SRERE PA, 1982, TRENDS BIOCHEM SCI, V7, P375, DOI 10.1016/0968-0004(82)90119-0; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STONER CD, 1969, J CELL BIOL, V43, P521, DOI 10.1083/jcb.43.3.521; SUMEGI B, 1984, J BIOL CHEM, V259, P8748; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; VANDERKOOI JM, 1985, J CELL BIOL, V100, P435, DOI 10.1083/jcb.100.2.435; WILLIAMS JN, 1964, ARCH BIOCHEM BIOPHYS, V107, P537, DOI 10.1016/0003-9861(64)90313-3; WOLF DE, 1982, BIOPHYS J, V38, P295, DOI 10.1016/S0006-3495(82)84561-X; WU ES, 1977, BIOCHEMISTRY-US, V16, P3936, DOI 10.1021/bi00636a034	51	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5973	5979						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005133				2022-12-25	WOS:A1991FD37000095
J	JEFFERSON, JR; SLOTTE, JP; NEMECZ, G; PASTUSZYN, A; SCALLEN, TJ; SCHROEDER, F				JEFFERSON, JR; SLOTTE, JP; NEMECZ, G; PASTUSZYN, A; SCALLEN, TJ; SCHROEDER, F			INTRACELLULAR STEROL DISTRIBUTION IN TRANSFECTED MOUSE L-CELL FIBROBLASTS EXPRESSING RAT-LIVER FATTY ACID-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; PLASMA-MEMBRANE; CARRIER PROTEIN; ENDOPLASMIC-RETICULUM; CULTURED FIBROBLASTS; CHOLESTEROL POOLS; ESCHERICHIA-COLI; LIPID VESICLES; SPHINGOMYELIN; TRANSPORT	The potential role of liver fatty acid binding protein (L-FABP) in modulating cellular sterol distribution was examined in mouse L-cell fibroblasts transfected with cDNA encoding L-FABP. L-cells were chosen because they contain only a small amount of endogenous FABP which does not bind [H-3]cholesterol, does not enhance intermembrane sterol transfer, and whose content is unaltered by the expression of L-FABP. Transfected L-cells expressed 0.34% of cytosolic protein as L-FABP. Transfection alone with low expression of L-FABP (0.008% of cytosolic protein) had no effect on any of the parameters tested. Three aspects of cellular sterol transfer were examined. First, cellular sterol uptake, monitored by [H-3]cholesterol and the fluorescent sterol, DELTA-5,7,9(11),22-ergostatetraen-3-beta-ol, was increased 21.5 +/- 2.6% (p < 0.001) in L-cells expressing L-FABP. This increase was not accounted for by increased sterol esterification in the cells expressing L-FABP. Inhibition of both cholesterol transfer and esterification with 3-(decyldimethylsilyl)-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide from Sandoz abolished the L-FABP related enhancement of both [H-3]cholesterol uptake and esterification. Second, plasma membrane transbilayer distribution of sterol, determined by fluorescence methods indicated that the majority of sterol was in the inner leaflet of the plasma membrane. In transfected cells expressing L-FABP, twice as much sterol (28 +/- 4%) was present in the exofacial leaflet of the plasma membrane as compared to that of control cells (15 +/- 2%). Third, expression of L-FABP enhanced sterol transfer from the plasma membrane to microsomes in intact cells. Treatment of [H-3]cholesterol or [H-3]oleate-loaded cells with sphingomyelinase resulted in increased formation of radiolabeled cholesterol ester, consistent with enhanced microsomal esterification of plasma membrane derived cholesterol. Concomitantly, plasma membrane [H-3]cholesterol became less accessible to oxidation by cholesterol oxidase. Sphingomyelinase-stimulated cholesterol esterification was 21 +/- 3% greater in transfected cells. Concomitantly, accessibility of plasma membrane [H-3]cholesterol to cholesterol oxidase was decreased 18 +/- 3% in cells expressing L-FABP. These differences are consistent with the ability of L-FABP to influence sterol transport and plasma membrane transbilayer sterol distribution in intact cells.	UNIV CINCINNATI, MED CTR, DEPT PHARMACOL & CELL BIOPHYS, DIV PHARMACOL & MED CHEM, CINCINNATI, OH 45267 USA; UNIV NEW MEXICO, SCH MED, DEPT BIOCHEM, ALBUQUERQUE, NM 87131 USA	University System of Ohio; University of Cincinnati; University of New Mexico					NHLBI NIH HHS [HL07460] Funding Source: Medline; NIADDK NIH HHS [AM32309] Funding Source: Medline; NIDDK NIH HHS [DK41402] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM032309] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASS NM, 1984, BIOCHEMISTRY-US, V23, P6539, DOI 10.1021/bi00321a040; BELL FP, 1984, MEMBRANE FLUIDITY, P543; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASAEMLE DL, 1988, J LIPID RES, V29, P481; BUTKO P, 1990, BIOCHEMISTRY-US, V29, P4070, DOI 10.1021/bi00469a007; CALHOUN WI, 1979, BIOCHEMISTRY-US, V18, P1717, DOI 10.1021/bi00576a013; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9; DEMPSEY ME, 1984, CURR TOP CELL REGUL, V24, P63; FISCHER R T, 1985, Journal of Biological Physics, V13, P13, DOI 10.1007/BF01872877; FISCHER RT, 1984, CHEM PHYS LIPIDS, V36, P1, DOI 10.1016/0009-3084(84)90086-0; FISCHER RT, 1985, BIOCHEMISTRY-US, V24, P3322, DOI 10.1021/bi00334a037; FONTAINE RN, 1979, BIOCHIM BIOPHYS ACTA, V558, P1, DOI 10.1016/0005-2736(79)90310-9; GLATZ JFC, 1985, INT J BIOCHEM, V17, P13, DOI 10.1016/0020-711X(85)90080-1; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALE JE, 1982, EUR J BIOCHEM, V122, P649; JEFFERSON JR, 1990, J BIOL CHEM, V265, P11062; KANDUTSCH AA, 1977, P NATL ACAD SCI USA, V74, P2500, DOI 10.1073/pnas.74.6.2500; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LANGE Y, 1979, BIOCHIM BIOPHYS ACTA, V556, P388, DOI 10.1016/0005-2736(79)90127-5; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LOWE JB, 1984, J BIOL CHEM, V259, P2696; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEMECZ G, 1989, J CELL BIOL, V107, P640; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; OMALLEY JP, 1981, J LIPID RES, V22, P1214; PASTUSZYN A, 1987, J BIOL CHEM, V262, P13219; PAULUSSEN RJA, 1989, BIOCHIM BIOPHYS ACTA, V1001, P201, DOI 10.1016/0005-2760(89)90149-5; PEETERS RA, 1989, MOL CELL BIOCHEM, V88, P45; ROBERTSON DL, 1985, BIOCHEM J, V232, P553, DOI 10.1042/bj2320553; ROTHBLAT GH, 1978, J LIPID RES, V19, P350; RUSTOW B, 1982, ACTA BIOL MED GER, V41, P439; SCALLEN TJ, 1985, J BIOL CHEM, V260, P4733; SCHROEDER F, 1984, PROG LIPID RES, V23, P97, DOI 10.1016/0163-7827(84)90009-2; SCHROEDER F, 1990, J BIOL CHEM, V265, P151; SCHROEDER F, 1989, SER SYMP AD, V1, P29; SCHROEDER F, 1989, BIOCHEMISTRY-US, V28, P5992, DOI 10.1021/bi00440a041; SCHROEDER F, 1985, J BIOL CHEM, V260, P2904; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; SCHROEDER F, 1990, ARCH BIOCHEM BIOPHYS, V276, P55, DOI 10.1016/0003-9861(90)90009-N; SCHROEDER F, 1990, ADV CHOLESTEROL RES, P47; SCHROEDER F, 1991, IN PRESS P SOC EXP B; SLOTTE JP, 1984, BIOCHIM BIOPHYS ACTA, V793, P423, DOI 10.1016/0005-2760(84)90258-3; SLOTTE JP, 1984, BIOCHEM J, V222, P821, DOI 10.1042/bj2220821; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SLOTTE JP, 1987, BIOCHEM J, V248, P237, DOI 10.1042/bj2480237; SLOTTE JP, 1983, BIOCHIM BIOPHYS ACTA, V750, P434, DOI 10.1016/0005-2760(83)90182-0; SUN GY, 1988, ALCOHOL, V5, P153, DOI 10.1016/0741-8329(88)90013-4; SWEET WD, 1987, BIOCHEMISTRY-US, V26, P2828, DOI 10.1021/bi00384a026; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; TAN H, 1990, EUR J BIOCHEM, V190, P107, DOI 10.1111/j.1432-1033.1990.tb15552.x; THOMAS PD, 1988, BIOCHEM J, V251, P55, DOI 10.1042/bj2510055; THURNHOFER H, 1986, BIOCHIM BIOPHYS ACTA, V856, P174, DOI 10.1016/0005-2736(86)90024-6; UNTRACHT SH, 1977, J BIOL CHEM, V252, P4449; VAHOUNY GV, 1984, BIOCHEM BIOPH RES CO, V122, P509, DOI 10.1016/S0006-291X(84)80062-5; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VAN MEER G, 1987, TRENDS BIOCHEM SCI, V12, P375, DOI 10.1016/0968-0004(87)90173-3; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; VANHEUSDEN GPH, 1985, BIOCHIM BIOPHYS ACTA, V846, P21, DOI 10.1016/0167-4889(85)90105-3; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WEINSTEIN DB, 1969, J BIOL CHEM, V244, P4103	69	105	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5486	5496						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005092				2022-12-25	WOS:A1991FD37000023
J	WANG, AY; CHANG, YY; CRONAN, JE				WANG, AY; CHANG, YY; CRONAN, JE			ROLE OF THE TETRAMERIC STRUCTURE OF ESCHERICHIA-COLI PYRUVATE OXIDASE IN ENZYME ACTIVATION AND LIPID-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICALLY REQUIRES; MOLECULAR-CLONING; INVIVO FUNCTION; GENE POXB; SITE; TRANSFORMATION; VECTORS; DNA	Pyruvate oxidase of Escherichia coli, an enzyme greatly activated by phospholipids, is a tetramer of a M(r) 62,000 subunit. We have utilized the differing electrophoretic mobilities of several mutant oxidases on native polyacrylamide gels to study the role of the quaternary structure of the enzyme in the activation process. We found that when two poxB gene alleles coexisted in cells, heterotetrameric species were formed in addition to homotetramers. The concentration of each tetrameric species varied according to the concentration of the different subunits present, and the distribution seemed virtually identical to those expected from random mixing. We showed that the intrinsic activity of pyruvate oxidase was not affected by interactions among the four subunits. However, binding of the enzyme to lipids, a property required for function in vivo, required that a tetramer contain at least two subunits capable of lipid binding. Our data fit the model proposed previously (Grabau, C., Chang, Y.-Y., and Cronan, J. E., Jr. (1989) J. Biol. Chem. 264, 12510-12519) in which the carboxyl termini of two subunits interact to form a functional lipid-binding domain. We also have detected oxidase activity in a form of oxidase of unusually high electrophoretic mobility. This form seems to be either a monomeric or a dimeric form (more probably the former) of the oxidase subunit.			WANG, AY (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL & BIOCHEM,URBANA,IL 61801, USA.		Cronan, John/V-6626-2019	WANG, AI-YU/0000-0002-8485-602X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG YY, 1983, J BACTERIOL, V154, P756, DOI 10.1128/JB.154.2.756-762.1983; CHANG YY, 1986, J BACTERIOL, V167, P312, DOI 10.1128/jb.167.1.312-318.1986; CHANG YY, 1984, P NATL ACAD SCI-BIOL, V81, P4348, DOI 10.1073/pnas.81.14.4348; CHANG YY, 1982, J BACTERIOL, V151, P1279, DOI 10.1128/JB.151.3.1279-1289.1982; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; GRABAU C, 1989, J BIOL CHEM, V264, P12510; GRABAU C, 1986, BIOCHEMISTRY-US, V25, P3748, DOI 10.1021/bi00361a003; GRABAU C, 1984, J BACTERIOL, V160, P1088, DOI 10.1128/JB.160.3.1088-1092.1984; GRABAU C, 1986, NUCLEIC ACIDS RES, V14, P5449, DOI 10.1093/nar/14.13.5449; Hames B. D., 1981, GEL ELECTROPHORESIS; Maniatis T., 1982, MOL CLONING; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MESSING J, 1983, METHOD ENZYMOL, V101, P20; OBRIEN TA, 1976, BIOCHIM BIOPHYS ACTA, V452, P13, DOI 10.1016/0005-2744(76)90054-1; RECNY MA, 1982, J BIOL CHEM, V257, P2878; RECNY MA, 1983, J BIOL CHEM, V258, P5189; RUSSELL P, 1977, J BIOL CHEM, V252, P7883; RUSSELL P, 1977, J BIOL CHEM, V252, P7877; Sambrook J, 1989, MOL CLONING LABORATO; ZHANG TF, 1987, ARCH BIOCHEM BIOPHYS, V257, P485, DOI 10.1016/0003-9861(87)90595-9	21	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10959	10966						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040613				2022-12-25	WOS:A1991FQ77400042
J	KONFORTI, BB; DAVIS, RW				KONFORTI, BB; DAVIS, RW			DNA SUBSTRATE REQUIREMENTS FOR STABLE JOINT MOLECULE FORMATION BY THE RECA AND SINGLE-STRANDED DNA-BINDING PROTEINS OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED BRANCH MIGRATION; SUPERHELICAL DNA; HETERODUPLEX FORMATION; ELECTRON-MICROSCOPY; PLECTONEMIC JOINTS; EXONUCLEASE VII; ATP HYDROLYSIS; EXCHANGE; FRAGMENTS; COMPLEXES	In reactions between linear single-stranded DNAs (ssDNAs) and circular double-stranded DNAs (ds-DNAs), stable joint molecule formation promoted by the recA protein (RecA) requires negative superhelicity, a homologous end, and an RecA-ssDNA complex. Linear ssDNAs with 3'-end homology react more efficiently than linear ssDNAs with 5'-end homology. This 3'-end preference is explained by the finding that 3'-ends are more effectively coated by RecA than 5'-ends, as judged by exonuclease VII protection, and are thus more reactive. The ability of linear ssDNAs with 5'-end homology to react is improved by the presence of low concentrations of exonuclease VII. In reactions between ssDNAs and linear dsDNAs with end homology, stable joint molecule formation occurs more efficiently when the homology is at the 3'-end rather than at the 5'-end of the complementary strand. In addition, linear dsDNAs with homology at the 3'-end of the complementary strand react more efficiently with linear ssDNAs with 3'-end homology than with linear ssDNAs with 5'-end homology. The ability of linear ssDNAs with 5'-end homology to react, in the absence of single-stranded DNA-binding protein, is improved by adding 33-46 nucleotides of heterologous sequence to the 5'-end of the linear ssDNA. The poor reactivity of linear ssDNAs with 5'-end homology is explained by a lack of RecA at the 5'-ends of linear ssDNAs, which is a consequence of the polar association and dissociation of RecA.			KONFORTI, BB (corresponding author), STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R37HG000198] Funding Source: NIH RePORTER; NHGRI NIH HHS [R37 HGO0198-16] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BRYANT FR, 1985, J BIOL CHEM, V260, P1196; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHASE JW, 1974, J BIOL CHEM, V249, P4553; CHASE JW, 1974, J BIOL CHEM, V249, P4545; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CUNNINGHAM RP, 1981, CELL, V24, P213, DOI 10.1016/0092-8674(81)90517-1; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; DASGUPTA C, 1980, CELL, V22, P437, DOI 10.1016/0092-8674(80)90354-2; ENGELMAN EH, 1986, J MOL BIOL, V191, P677; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; KOWALCZYKOWSKI SC, 1987, TRENDS BIOCHEM SCI, V12, P141, DOI 10.1016/0968-0004(87)90070-3; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; Radding C.M., 1988, GENETIC RECOMBINATIO, P193; RADDING CM, 1977, J MOL BIOL, V116, P825, DOI 10.1016/0022-2836(77)90273-X; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; RIDDLES PW, 1985, J BIOL CHEM, V260, P170; RIDDLES PW, 1985, J BIOL CHEM, V260, P165; Sambrook J, 1989, MOL CLONING LABORATO; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1982, J BIOL CHEM, V257, P370; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451; WIEGAND RC, 1977, J MOL BIOL, V116, P805, DOI 10.1016/0022-2836(77)90272-8; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; WU AM, 1982, CELL, V30, P37, DOI 10.1016/0092-8674(82)90009-5	40	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10112	10121						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037569				2022-12-25	WOS:A1991FP08600021
J	PORCHER, C; PITIOT, G; PLUMB, M; LOWE, S; DEVERNEUIL, H; GRANDCHAMP, B				PORCHER, C; PITIOT, G; PLUMB, M; LOWE, S; DEVERNEUIL, H; GRANDCHAMP, B			CHARACTERIZATION OF HYPERSENSITIVE SITES, PROTEIN-BINDING MOTIFS, AND REGULATORY ELEMENTS IN BOTH PROMOTERS OF THE MOUSE PORPHOBILINOGEN DEAMINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; BETA-GLOBIN GENE; C-MYC GENE; TRANSCRIPTION FACTOR; ERYTHROID PROMOTER; DNA; SEQUENCE; CELLS; INDUCTION; SYNTHASE	Porphobilinogen deaminase, the third enzyme in the heme biosynthetic pathway, is encoded by a gene having two different promoters. Differential splicing of transcripts from the promoters yields two distinct mRNA species that are translated to give two isoforms of the protein. One isoform is ubiquitous, whereas the other is erythroid-specific. In this study, we have analyzed the gene regulatory elements that contribute to the tissue-specific promoter utilization of the mouse porphobilinogen deaminase gene. Six nuclear DNase I-hypersensitive sites were mapped in erythroid and nonerythroid cells, and four of these regions were further analyzed for in vitro nuclear protein-binding sites. The erythroid-specific promoter contains three erythroid nuclear factor GF-1-binding sites. The proximal GF-1-binding site, together with an adjacent duplicated CACCC motif, was sufficient to confer erythroid-specific expression in functional studies. Furthermore, as upstream gene sequences were shown to greatly increase promoter activity in erythroid cells, it suggests an upstream erythroid-specific enhancer may also be required for the up-regulation of the erythroid-specific promoter during erythropoiesis.	BEATSON INST CANC RES,GLASGOW G61 1BD,SCOTLAND	Beatson Institute	PORCHER, C (corresponding author), FACULTE X BICHAT,GENET MOLEC LAB,16 RUE H HUCHARD,F-75018 PARIS,FRANCE.		Porcher, Catherine/D-7026-2016					Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; EMERSON BM, 1987, P NATL ACAD SCI USA, V84, P4786, DOI 10.1073/pnas.84.14.4786; EMERSON BM, 1984, P NATL ACAD SCI-BIOL, V81, P95, DOI 10.1073/pnas.81.1.95; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GRANDCHAMP B, 1987, EUR J BIOCHEM, V162, P105, DOI 10.1111/j.1432-1033.1987.tb10548.x; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; MAGUIRE DJ, 1986, NUCLEIC ACIDS RES, V14, P1379, DOI 10.1093/nar/14.3.1379; Maxam A M, 1980, Methods Enzymol, V65, P499; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; PLUMB MA, 1985, NUCLEIC ACIDS RES, V13, P4047, DOI 10.1093/nar/13.11.4047; PLUMB MA, 1988, METHODS MOL BIOL, V4; ROMANA M, 1987, NUCLEIC ACIDS RES, V15, P7343, DOI 10.1093/nar/15.18.7343; SASSA S, 1978, J CLIN INVEST, V61, P499, DOI 10.1172/JCI108961; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SCHOENFELD N, 1987, EUR J BIOCHEM, V166, P663, DOI 10.1111/j.1432-1033.1987.tb13564.x; SEILERTUYNS A, 1986, NUCLEIC ACIDS RES, V14, P8755, DOI 10.1093/nar/14.22.8755; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3702, DOI 10.1073/pnas.82.11.3702; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON SH, 1989, BLOOD S1, V74, pA191	37	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10562	10569						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037597				2022-12-25	WOS:A1991FP08600084
J	PRINCE, MA; FRIEDMAN, B; GRUSKIN, EA; SCHROCK, RD; LLOYD, RS				PRINCE, MA; FRIEDMAN, B; GRUSKIN, EA; SCHROCK, RD; LLOYD, RS			SELECTIVE METAL-BINDING TO CYS-78 WITHIN ENDONUCLEASE-V CAUSES AN INHIBITION OF CATALYTIC ACTIVITIES WITHOUT ALTERING NONTARGET AND TARGET DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN-CONTAINING PEPTIDES; ULTRAVIOLET-IRRADIATED DNA; PROTON MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; DEOXYRIBONUCLEIC-ACID; ESCHERICHIA-COLI; NUCLEIC-ACIDS; DENV-GENE; POLY(ADENYLIC ACID); NACL CONCENTRATION	T4 endonuclease V is a pyrimidine dimer-specific DNA repair enzyme which has been previously shown not to require metal ions for either of its two catalytic activities or its DNA binding function by virtue of its ability to function in the presence of metal-chelating agents. However, we have investigated whether the single cysteine within the enzyme was able to bind metal salts and influence the various activities of this repair enzyme. A series of metals (Hg2+,Ag+, Cu+) were shown to inactivate both endonuclease Vs pyrimidine dimer-specific DNA glycosylase activity and the subsequent apurinic nicking activity. The binding of metal to endonuclease V did not interfere with nontarget DNA scanning or pyrimidine dimer-specific binding. The Cys-78 codon within the endonuclease V gene was changed by oligonucleotide site-directed mutagenesis to Thr-78 and Ser-78 in order to determine whether the native cysteine was directly involved in the enzyme's DNA catalytic activities and whether the cysteine was primarily responsible for the metal binding. The mutant enzymes were able to confer enhanced ultraviolet light (UV) resistance to DNA repair-deficient Escherichia coli at levels equal to that conferred by the wild type enzyme. The C78T mutant enzyme was purified to homogeneity and shown to be catalytically active on pyrimidine dimer-containing DNA. The catalytic activities of the C78T mutant enzyme were demonstrated to be unaffected by the addition of Hg2+ or Ag+ at concentrations 1000-fold greater than that required to inhibit the wild type enzyme. These data suggest that the cysteine is not required for enzyme activity but that the binding of certain metals to that amino acid block DNA incision by either preventing a conformational change in the enzyme after it has bound to a pyrimidine dimer or sterically interfering with the active site residue's accessibility to the pyrimidine dimer.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University				Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091, P30ES000267, T32ES007028] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 00267, ES 04091, ES 07028] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BONURA T, 1982, BIOCHIMIE, V64, P643, DOI 10.1016/S0300-9084(82)80104-1; COREY DR, 1989, J BIOL CHEM, V264, P3666; DIMICOLI JL, 1974, BIOCHEMISTRY-US, V13, P714, DOI 10.1021/bi00701a013; DIMICOLI JL, 1974, BIOCHEMISTRY-US, V13, P724, DOI 10.1021/bi00701a014; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; DOWD DR, 1990, J BIOL CHEM, V265, P3424; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; FRIEDBERG EC, 1971, J BACTERIOL, V106, P500, DOI 10.1128/JB.106.2.500-507.1971; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HIGGINS KM, 1987, MUTAT RES, V183, P117, DOI 10.1016/0167-8817(87)90053-8; ISHIDA M, 1990, BIOCHEMISTRY-US, V29, P3817, DOI 10.1021/bi00468a002; LLOYD R S, 1986, Biotechniques, V4, P8; LLOYD RS, 1987, MUTAT RES, V183, P109, DOI 10.1016/0167-8817(87)90052-6; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; LLOYD RS, 1989, PROTEINS, V6, P128, DOI 10.1002/prot.340060204; LLOYD RS, 1986, MUTAT RES, V165, P89; MCMILLAN S, 1981, J VIROL, V40, P211, DOI 10.1128/JVI.40.1.211-223.1981; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; RECINOS A, 1986, BIOCHEM BIOPH RES CO, V138, P945, DOI 10.1016/S0006-291X(86)80587-3; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; RECINOS A, 1986, J BACTERIOL, V168, P1014, DOI 10.1128/jb.168.2.1014-1018.1986; SCHALLER H, 1972, EUR J BIOCHEM, V26, P474, DOI 10.1111/j.1432-1033.1972.tb01789.x; SEAWELL PC, 1980, J VIROL, V35, P790, DOI 10.1128/JVI.35.3.790-796.1980; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; TOULME JJ, 1977, J BIOL CHEM, V252, P244; TOULME JJ, 1974, P NATL ACAD SCI USA, V71, P3185, DOI 10.1073/pnas.71.8.3185; VALERIE K, 1984, NUCLEIC ACIDS RES, V12, P8085, DOI 10.1093/nar/12.21.8085; VANMINDERHOUT L, 1974, MUTAT RES, V29, P333; WARNER HR, 1981, J VIROL, V40, P204, DOI 10.1128/JVI.40.1.204-210.1981; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648; YASUDA S, 1970, P NATL ACAD SCI USA, V67, P1839, DOI 10.1073/pnas.67.4.1839; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	36	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10686	10693						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037608				2022-12-25	WOS:A1991FP08600102
J	CRUZEN, ME; ARFIN, SM				CRUZEN, ME; ARFIN, SM			NUCLEOTIDE AND DEDUCED AMINO-ACID-SEQUENCE OF HUMAN THREONYL-TRANSFER RNA-SYNTHETASE REVEALS EXTENSIVE HOMOLOGY TO THE ESCHERICHIA-COLI AND YEAST ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYL-TRANSFER RNA; TRANSLATIONAL LEVEL; ISOLEUCYL-TRANSFER; GENE-REGULATION; EXPRESSION; RESISTANT; POLYPEPTIDES; CEREVISIAE; CLONING; 2ND	The nucleotide sequence of a cDNA coding human threonyl-tRNA synthetase has been determined. The predicted protein sequence is highly homologous to that of the yeast cytoplasmic, yeast mitochondria and Escherichia coli threonyl-tRNA synthetases. In particular, the three structural motifs recently shown to be common to class II aminoacyl-tRNA synthetases are present in the threonyl-tRNA synthetases from all sources. Primer extension and S1 nuclease analyses indicate that transcription initiates approximately 220-230 nucleotides upstream of the putative initiator methionine codon. This region contains a 10-nucleotide interrupted inverted repeat flanked by a 13-nucleotid interrupted direct repeat.			CRUZEN, ME (corresponding author), UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717, USA.							BRICK P, 1987, J MOL BIOL, V194, P287, DOI 10.1016/0022-2836(87)90376-7; BRUNIE S, 1987, J MOL GRAPHICS, V5, P18, DOI 10.1016/0263-7855(87)80039-5; CARLOCK LR, 1985, SOMAT CELL MOLEC GEN, V11, P267, DOI 10.1007/BF01534683; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DANG CV, 1988, FASEB J, V2, P2376, DOI 10.1096/fasebj.2.8.2452112; DEUTSCHER MP, 1984, J CELL BIOL, V99, P373, DOI 10.1083/jcb.99.2.373; DIGNAM JD, 1980, BIOCHEMISTRY-US, V19, P4978, DOI 10.1021/bi00563a007; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; GAMPEL A, 1989, P NATL ACAD SCI USA, V86, P6023, DOI 10.1073/pnas.86.16.6023; GANTT JS, 1981, P NATL ACAD SCI-BIOL, V78, P5367, DOI 10.1073/pnas.78.9.5367; GERKEN SC, 1984, J BIOL CHEM, V259, P9202; GRUNBERGMANAGO M, 1987, ESCHERICHIA COLI SAL, V2, P1386; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P10199, DOI 10.1093/nar/15.24.10199; HECK JD, 1988, J BIOL CHEM, V263, P868; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOUTONDJI C, 1986, BIOCHIMIE, V68, P1071; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; JONES MD, 1986, BIOCHEMISTRY-US, V25, P1887, DOI 10.1021/bi00356a008; JORDANA X, 1987, J BIOL CHEM, V262, P7189; KONTIS KJ, 1989, MOL CELL BIOL, V9, P1832, DOI 10.1128/MCB.9.5.1832; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LESTIENNE P, 1984, J BIOL CHEM, V259, P5232; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MAYAUX JF, 1983, P NATL ACAD SCI-BIOL, V80, P6152, DOI 10.1073/pnas.80.20.6152; MOINE H, 1988, P NATL ACAD SCI USA, V85, P7892, DOI 10.1073/pnas.85.21.7892; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; PAPE LK, 1985, J BIOL CHEM, V260, P5362; PAPE LK, 1985, NUCLEIC ACIDS RES, V13, P6171, DOI 10.1093/nar/13.17.6171; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; SPRINGER M, 1985, J MOL BIOL, V185, P93, DOI 10.1016/0022-2836(85)90185-8; THOMMES P, 1988, NUCLEIC ACIDS RES, V16, P5391, DOI 10.1093/nar/16.12.5391; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; TZAGOLOFF A, 1988, J BIOL CHEM, V263, P850; WEICKERT MJ, 1989, EDITORIAL COMMENTS, V16, P5; WEYGANDDURASEVIC I, 1987, NUCLEIC ACIDS RES, V15, P1887, DOI 10.1093/nar/15.5.1887; YANG DCH, 1985, CURR TOP CELL REGUL, V26, P325	42	22	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9919	9923						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033077				2022-12-25	WOS:A1991FM45900086
J	NAKAJIMA, M; DECHAVIGNY, A; JOHNSON, CE; HAMADA, J; STEIN, CA; NICOLSON, GL				NAKAJIMA, M; DECHAVIGNY, A; JOHNSON, CE; HAMADA, J; STEIN, CA; NICOLSON, GL			SURAMIN - A POTENT INHIBITOR OF MELANOMA HEPARANASE AND INVASION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-BINDING; COLON-CARCINOMA-CELLS; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; REVERSE-TRANSCRIPTASE; SULFATE DEGRADATION; BASEMENT-MEMBRANE; RAT; MUCOPOLYSACCHARIDOSIS; METASTASIS	Suramin, a polysulfonated naphthylurea, has anti-reverse transcriptase and anti-proliferative activities and inhibits the binding of various growth factors to their cell surface receptors. This drug is used in the treatment of acquired immunodeficiency syndrome and several types of cancers. Increased levels of circulating glycosaminoglycans have been observed in suramin-treated cancer patients, suggesting that it may inhibit glycosaminoglycan catabolism. Melanoma-derived heparanase, a heparan sulfate-specific endo-beta-D-glucuronidase that plays an important role in metastatic melanoma cell invasion through basement membranes, is inhibited by suramin in a dose-dependent manner: 100% inhibition was observed at a concentration of approximately 100-mu-M. Structurally related polysulfonated compounds, such as trypan blue and Evans blue, had lower heparanase inhibitory activities: the concentrations required for 50% heparanase inhibition (ID50) were 310-320-mu-M and six times higher than for suramin (ID50 = 46-mu-M). Oversulfated heparin tetrasaccharide, whose average molecular size is similar to suramin, had also much lower heparanase inhibitory activity than suramin. The inhibition constants (K(i)) for suramin and oversulfated heparin tetrasaccharide were 48 and 290-mu-M, respectively. Suramin had a remarkable inhibitory activity against B16 melanoma cell invasion through reconstituted basement membranes (ID50 < 10-mu-M). The inhibitory effects of suramin on melanoma heparanase and cell invasion appeared to be completely independent of its antiproliferative activity, because significant effects on melanoma cell growth were not observed at the concentrations of suramin used in this study. The results suggest that the antimetastatic effects of suramin may be due to its antiinvasive rather than antiproliferative activities.	NCI,CLIN ONCOL PROGRAM,MED BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	NAKAJIMA, M (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 108,HOUSTON,TX 77030, USA.		Hamada, Jun-ichi/D-7452-2012		NATIONAL CANCER INSTITUTE [R01CA041524, R35CA044352] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA41524, R35-CA44352] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMKOTTER J, 1983, BIOCHIM BIOPHYS ACTA, V761, P163, DOI 10.1016/0304-4165(83)90225-8; BECKER M, 1986, J NATL CANCER I, V77, P417; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; BRODER S, 1985, LANCET, V2, P627; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; CONSTANTOPOULOS G, 1980, P NATL ACAD SCI-BIOL, V77, P3700, DOI 10.1073/pnas.77.6.3700; CONSTANTOPOULOS G, 1983, AM J PATHOL, V113, P266; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; DECLERCQ E, 1979, CANCER LETT, V8, P9, DOI 10.1016/0304-3835(79)90017-X; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EISEN V, 1973, BRIT J PHARMACOL, V49, P678, DOI 10.1111/j.1476-5381.1973.tb08544.x; HORNE MK, 1988, BLOOD, V71, P273; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; IOZZO RV, 1987, J BIOL CHEM, V262, P1888; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; JENTSCH KD, 1987, J GEN VIROL, V68, P2183, DOI 10.1099/0022-1317-68-8-2183; JIN L, 1990, INT J CANCER, V45, P1088, DOI 10.1002/ijc.2910450618; KEREN Z, 1989, CANCER RES, V49, P295; KOPP R, 1990, CANCER RES, V50, P6490; KRAMER RH, 1982, J BIOL CHEM, V257, P2678; LAROCCA RV, 1990, P AN M AM SOC CLIN, V9, P268; LEVINE AM, 1986, ANN INTERN MED, V105, P32, DOI 10.7326/0003-4819-105-1-32; MITSUYA H, 1984, SCIENCE, V226, P172, DOI 10.1126/science.6091268; MYERS CE, 1990, P AN M AM SOC CLIN, V9, P133; NAKAJIMA M, 1989, CANCER RES, V49, P1698; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; RICOVERI W, 1986, CANCER RES, V46, P3855; ROLLO IM, 1975, PHARMACOL BASIS THER, P1081; SAIKI I, 1990, CANCER RES, V50, P3631; SPIGELMAN Z, 1987, CANCER RES, V47, P4694; STEIN CA, 1989, J CLIN ONCOL, V7, P499, DOI 10.1200/JCO.1989.7.4.499; VILLANUEVA GB, 1988, ANN NY ACAD SCI, V556, P496; VLODAVSKY I, 1982, EXP CELL RES, V140, P149, DOI 10.1016/0014-4827(82)90166-5; ZABRENETZKY VS, 1990, CANCER RES, V50, P5937	39	174	175	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9661	9666						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033058				2022-12-25	WOS:A1991FM45900051
J	KUROIWA, T; SAKAGUCHI, M; MIHARA, K; OMURA, T				KUROIWA, T; SAKAGUCHI, M; MIHARA, K; OMURA, T			SYSTEMATIC ANALYSIS OF STOP-TRANSFER SEQUENCE FOR MICROSOMAL MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; POSITIVELY CHARGED RESIDUES; PROTEIN TRANSLOCATION; ESCHERICHIA-COLI; ANCHOR DOMAIN; ORIENTATION; SIGNAL; CYTOCHROME-P-450; MECHANISMS; INSERTION	Co-translational protein translocation across the endoplasmic reticulum membrane is interrupted by particular amino acid sequences which are called stop-transfer sequences. Since the stop-transfer process should reflect the character of the protein translocation machinery, systematic examination on the structural requirements for stop-transfer sequences should give information about the translocation process. By the manipulation of the cDNA of interleukin 2, a typical secretory protein, the middle portion of the molecule was replaced with systematically constructed hydrophobic stretches, and two positively or negatively charged amino acid residues were introduced just behind the hydrophobic stretches. The modified proteins were synthesized with an in vitro transcription-translation system in the presence of dog pancreas rough microsomes, and their topologies in the membrane were examined with proteinase K digestion. The efficiency of stop-translocation depended on the hydrophobicity and the length of the inserted stretch. The segments followed by positively charged residues interrupted the translocation more efficiently than those with negatively charged residues. We observed that more than 19 alanine residues were required for efficient stop-translocation, whereas only 9 leucine residues were sufficient. We suggest that the positively charged residues following the hydrophobic stretches promote stop-translocation of the peptides through the channel.	KYUSHU UNIV, GRAD SCH MED SCI, DEPT MOLEC BIOL, HIGASHI KU, FUKUOKA 812, JAPAN	Kyushu University	KUROIWA, T (corresponding author), KYUSHU UNIV, FAC SCI, DEPT BIOL, HIGASHI KU, FUKUOKA 812, JAPAN.							BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; KASHIMA N, 1985, NATURE, V313, P402, DOI 10.1038/313402a0; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; VONHEIJNE G, 1985, CURR TOP MEMBR TRANS, V24, P151; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; YAMANE K, 1988, J BIOL CHEM, V263, P19690; YOST CS, 1983, CELL, V34, P759	28	97	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9251	9255						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026623				2022-12-25	WOS:A1991FM03800088
J	LINGNER, J; RADTKE, I; WAHLE, E; KELLER, W				LINGNER, J; RADTKE, I; WAHLE, E; KELLER, W			PURIFICATION AND CHARACTERIZATION OF POLY(A) POLYMERASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; 3' END; MULTIPLE FACTORS; BINDING-PROTEIN; YEAST; CLEAVAGE; POLYADENYLATION; INVITRO; TRANSCRIPTION; TRANSLATION	Poly(A) polymerase was purified 22,000-fold to homogeneity from a whole cell extract of Saccharomyces cerevisiae with a yield of 22%. The enzyme is a monomeric polypeptide with a denatured molecular weight of 63,000. Incorporation of labeled ATP into acid-precipitable material by the purified enzyme proceeds faster with manganese than with magnesium ions. Various RNA homopolymers as well as Escherichia coli tRNA or rRNA can serve as primers. An RNA that terminates at the natural poly(A) site of the CYC1 gene is not more efficiently elongated than several nonspecific substrates, indicating the requirement for additional factors to provide specificity. Elongation of the primer is distributive. Covering of a poly(A) primer with poly(A)-binding protein reduces the enzyme's activity more than 10-fold.			LINGNER, J (corresponding author), UNIV BASEL,BIOCTR,DEPT CELL BIOL,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Wahle, Elmar/0000-0003-2504-0677; Lingner, Joachim/0000-0002-2853-5803				BAER BW, 1983, J CELL BIOL, V96, P717, DOI 10.1083/jcb.96.3.717; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P846, DOI 10.1128/MCB.10.2.846; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; CORNISHBOWDEN A, 1978, BIOCHIM BIOPHYS ACTA, V523, P268, DOI 10.1016/0005-2744(78)90030-X; Edmonds M, 1976, Prog Nucleic Acid Res Mol Biol, V17, P149, DOI 10.1016/S0079-6603(08)60069-0; EDMONDS M, 1982, ENZYMES, V15, P217; EDMONDS M, 1990, METHOD ENZYMOL, V181, P160; FAHRNER K, 1980, NUCLEIC ACIDS RES, V8, P5725, DOI 10.1093/nar/8.23.5725; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; GRONER B, 1974, BIOCHEMISTRY-US, V13, P5378, DOI 10.1021/bi00723a020; HAFF LA, 1973, BIOCHEM BIOPH RES CO, V51, P704, DOI 10.1016/0006-291X(73)91372-7; HAFF LA, 1975, J BIOL CHEM, V250, P1838; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jacob ST, 1978, METHOD CANCER RES, V14, P191; KWAN SW, 1972, P NATL ACAD SCI USA, V69, P3247, DOI 10.1073/pnas.69.11.3247; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MCDEVITT MA, 1988, GENE DEV, V2, P588, DOI 10.1101/gad.2.5.588; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OSBORNE BI, 1988, GENE DEV, V2, P766, DOI 10.1101/gad.2.6.766; OSBORNE BI, 1989, P NATL ACAD SCI USA, V86, P4097, DOI 10.1073/pnas.86.11.4097; RUOHOLA H, 1988, P NATL ACAD SCI USA, V85, P5041, DOI 10.1073/pnas.85.14.5041; RUSSO P, 1989, P NATL ACAD SCI USA, V86, P8348, DOI 10.1073/pnas.86.21.8348; SACHS AB, 1985, MOL CELL BIOL, V5, P1993, DOI 10.1128/MCB.5.8.1993; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETYONO B, 1981, CELL, V24, P775, DOI 10.1016/0092-8674(81)90103-3; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	42	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8741	8746						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026590				2022-12-25	WOS:A1991FM03800019
J	DAINESE, P; BASSI, R				DAINESE, P; BASSI, R			SUBUNIT STOICHIOMETRY OF THE CHLOROPLAST PHOTOSYSTEM-II ANTENNA SYSTEM AND AGGREGATION STATE OF THE COMPONENT CHLOROPHYLL-A/B BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; SPINACH-CHLOROPLASTS; LHC-II; COMPLEX; POLYPEPTIDES; MEMBRANES; ELECTROPHORESIS; ORGANIZATION; QUANTITATION; LOCALIZATION	Photosystem (PS) II membranes, obtained by the method of Berthold et al. (Berthold, D. A., Babcock, G. T., and Yocum, C. F. (1981) FEBS Lett. 134, 231-234), have been fractionated by a sucrose gradient ultracentrifugation method which allows the quantitative separation of the three major chlorohyll binding complexes in these membranes: the chlorophyll (chl) a binding PSII reaction center core, the major light-harvesting complex II, and the minor chl a/b proteins called CP26, CP29, and CP24. Each fraction has been analyzed for its subunit stoichiometry by quantitative sodium dodecyl sulfate-polyacrylamide gel electrophoresis methods. The results show that 12 mol of light-harvesting complex II and 1.5 mol of each of the minor chl a/b proteins are present per mol of the PSII reaction center complex in PSII membranes. These data suggest a dimeric organization of PSII, in agreement with a recent crystallographic study (Bassi, R., Ghiretti Magaldi, A., Tognon, G., Giacometti, G. M., and Miller, K. (1989) Eur. J. Cell Biol. 50, 84-93) and imply that such a dimeric complex is served by antenna chl a/b proteins whose minimal aggregation state includes three polypeptides. This was confirmed by covalent cross-linking of purified antenna complexes.	UNIV PADUA,DIPARTIMENTO BIOL,VIA TRIESTE 75,I-35121 PADUA,ITALY	University of Padua				bassi, roberto/0000-0002-4140-8446				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ANDERSON JM, 1983, P NATL ACAD SCI-BIOL, V80, P745, DOI 10.1073/pnas.80.3.745; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BARBATO R, 1989, FEBS LETT, V251, P147, DOI 10.1016/0014-5793(89)81445-0; BASSI R, 1987, J BIOL CHEM, V262, P13333; BASSI R, 1989, EUR J CELL BIOL, V50, P84; BASSI R, 1990, PHOTOCHEM PHOTOBIOL, V52, P1187, DOI 10.1111/j.1751-1097.1990.tb08457.x; BASSI R, 1991, IN  PRESS J PHOTOCHE; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BRICKER TM, 1990, PHOTOSYNTH RES, V24, P1, DOI 10.1007/BF00032639; BRUCE BD, 1988, J BIOL CHEM, V263, P7302; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DEMMIN DS, 1989, J MOL EVOL, V29, P266, DOI 10.1007/BF02100210; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; DEVITRY C, 1984, BIOCHIM BIOPHYS ACTA, V767, P415, DOI 10.1016/0005-2728(84)90039-2; DEVITRY C, 1983, CR HEBD ACAD SCI, V279, P277; DIPAOLO ML, 1990, PLANTA, V181, P275, DOI 10.1007/BF00195877; DUNAHAY TG, 1984, BIOCHIM BIOPHYS ACTA, V764, P179, DOI 10.1016/0005-2728(84)90027-6; DUNSMUIR P, 1985, NUCLEIC ACIDS RES, V13, P2503, DOI 10.1093/nar/13.7.2503; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; HAYDEN DB, 1986, BIOCHIM BIOPHYS ACTA, V851, P86, DOI 10.1016/0005-2728(86)90251-3; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HINZ UG, 1987, CARLSBERG RES COMMUN, V52, P39, DOI 10.1007/BF02910426; HUBER R, 1990, EUR J BIOCHEM, V171, P203; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; Jaenicke R, 1986, Methods Enzymol, V131, P218; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P59, DOI 10.1016/0005-2728(87)90212-X; MATSUOKA M, 1987, NUCLEIC ACIDS RES, V15, P6302, DOI 10.1093/nar/15.15.6302; MCCAULEY SW, 1986, BIOCHIM BIOPHYS ACTA, V849, P175, DOI 10.1016/0005-2728(86)90023-X; MELIS A, 1983, BIOCHIM BIOPHYS ACTA, V724, P473, DOI 10.1016/0005-2728(83)90108-1; NAMBA O, 1987, P NATL ACAD SCI USA, V84, P109; Pichersky E., 1990, CURRENT RES PHOTOSYN, V3, P553; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; SATOH K, 1985, PHOTOCHEM PHOTOBIOL, V42, P845, DOI 10.1111/j.1751-1097.1985.tb01656.x; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SCHWARTZ E, 1990, PLANT MOL BIOL, V15, P157, DOI 10.1007/BF00017734; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUNDBY C, 1985, FEBS LETT, V191, P24, DOI 10.1016/0014-5793(85)80986-8; TRONRUD DE, 1986, J MOL BIOL, V188, P443, DOI 10.1016/0022-2836(86)90167-1; WELLBURN AR, 1983, ADV PHOTOSYNTHESIS R, V2, P10; WHITE MJ, 1987, EUR J BIOCHEM, V163, P545, DOI 10.1111/j.1432-1033.1987.tb10902.x; YOUVAN DC, 1984, CELL, V37, P949, DOI 10.1016/0092-8674(84)90429-X	43	140	140	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8136	8142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022634				2022-12-25	WOS:A1991FK44100031
J	SEPPALA, R; TIETZE, F; KRASNEWICH, D; WEISS, P; ASHWELL, G; BARSH, G; THOMAS, GH; PACKMAN, S; GAHL, WA				SEPPALA, R; TIETZE, F; KRASNEWICH, D; WEISS, P; ASHWELL, G; BARSH, G; THOMAS, GH; PACKMAN, S; GAHL, WA			SIALIC-ACID METABOLISM IN SIALURIA FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLNEURAMINIC ACID; LYSOSOMAL STORAGE DISORDER; SALLA DISEASE; CHROMATOGRAPHY; EGRESS	Sialuria is a rare inborn error of metabolism caused by excessive synthesis of sialic acid (N-acetylneuraminic acid, NeuAc). Fibroblasts cultured from the three known cases of sialuria contained 70-200-fold increases in soluble sialic acid, but normal concentrations of bound sialic acid. The sialic acid appeared in the cytosolic fraction of the cells on differential centrifugation, and was susceptible to borohydride reduction, suggesting that accumulated sialic acid was in the form of NeuAc and not CMP-NeuAc. In biochemical studies, CMP-NeuAc (50-mu-M) inhibited the UDP-N-acetylglucosamine (UDP-GlcNAc) 2-epimerase of normal fibroblasts by 84-100%, but inhibited the epimerase from sialuria cells by only 19-31%. Feeding sialuria cells up to 5mM D-glucosamine for 72 h increased free sialic acid content 20-60%, but normal cells were unaffected by this treatment. Cytidine feeding (5 mM, 72 h) reduced the NeuAc content of sialuria cells, initially 112, 104 and 266 nmol/mg protein, by 63-71 nmol/mg protein; CMP-NeuAc concentrations, initially 4,2, and 5 nmol/mg protein, increased by 14-33 nmol/mg protein. Consequently, the total cellular content of soluble sialic acid (NeuAc + CMP-NeuAc) was lowered 14-46% by cytidine feeding. The inheritance pattern of sialuria has not been determined. However, cells from both parents of one sialuria patient contained normal concentrations of free sialic acid, and the parental epimerase activity also responded normally to CMP-NeuAc. We conclude that the basic biochemical defect in all known cases of sialuria is a failure of CMP-NeuAc to feedback-inhibit UDP-GlcNAc 2-epimerase and cytidine feeding can lower the intracellular soluble sialic acid concentration of sialuria cells.	NIDDKD,MOLEC & CELL BIOL LAB,BETHESDA,MD 20892; NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,DIV MED GENET,SAN FRANCISCO,CA 94143; JOHNS HOPKINS UNIV,SCH MED,JOHN F KENNEDY INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	SEPPALA, R (corresponding author), NICHHD,HUMAN GENET BRANCH,HUMAN BIOCHEM GENET SECT,BETHESDA,MD 20892, USA.				PHS HHS [10981] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AULA P, 1979, ARCH NEUROL-CHICAGO, V36, P88, DOI 10.1001/archneur.1979.00500380058006; BEAUDET AL, 1989, METABOLIC BASIS INHE, P1603; Downs F, 1976, METHODS CARBOHYDRATE, VVII, P233; FONTAINE G, 1968, HELV PAEDIATR ACTA, V23, P1; GAHL WA, 1989, METABOLIC BASIS INHE, P2619; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; MANCINI GMS, 1986, HUM GENET, V73, P214, DOI 10.1007/BF00401229; MONTREUI.J, 1968, CLIN CHIM ACTA, V21, P61, DOI 10.1016/0009-8981(68)90011-9; PASCHKE E, 1987, J INHERIT METAB DIS, V10, P48, DOI 10.1007/BF01799487; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; RENLUND M, 1983, NEUROLOGY, V33, P57, DOI 10.1212/WNL.33.1.57; SILVER HKB, 1981, J CHROMATOGR, V224, P381, DOI 10.1016/S0378-4347(00)80210-8; SOMMAR KM, 1972, BIOCHIM BIOPHYS ACTA, V268, P581, DOI 10.1016/0005-2744(72)90355-5; STEVENSON RE, 1983, PEDIATRICS, V72, P441; THOMAS GH, 1985, PEDIATR RES, V19, P451, DOI 10.1203/00006450-198505000-00009; THOMAS GH, 1989, CLIN GENET, V36, P242; TIETZE F, 1989, J BIOL CHEM, V264, P15316; TONDEUR M, 1982, EUR J PEDIATR, V139, P142, DOI 10.1007/BF00441499; WARREN L, 1959, J BIOL CHEM, V234, P1971; WEISS P, 1989, J BIOL CHEM, V264, P17635; WILCKEN B, 1987, J INHERIT METAB DIS, V10, P97, DOI 10.1007/BF01800030	22	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7456	7461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019577				2022-12-25	WOS:A1991FJ34200024
J	SAKAGUCHI, K; APPELLA, E; OMICHINSKI, JG; CLORE, GM; GRONENBORN, AM				SAKAGUCHI, K; APPELLA, E; OMICHINSKI, JG; CLORE, GM; GRONENBORN, AM			SPECIFIC DNA-BINDING TO A MAJOR HISTOCOMPATIBILITY COMPLEX ENHANCER SEQUENCE BY A SYNTHETIC 57-RESIDUE DOUBLE ZINC FINGER PEPTIDE FROM A HUMAN ENHANCER BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; GEL-ELECTROPHORESIS; ESCHERICHIA-COLI; DOMAINS; RECOGNITION; MOTIF	Two 57-residue peptides containing one pair of "zinc fingers" from a human enhancer binding protein were prepared by solid-phase peptide synthesis. One peptide (MBP-DF) contained the native sequence, while the second peptide ([Abu11]MBP-DF) has an alpha-aminobutyric acid residue substituted for a nonconserved cysteine residue at position 11. The peptides were characterized by several chemical and physical methods, and their DNA binding properties were evaluated using gel retardation experiments. Spectroscopic studies demonstrated that addition of metal ions such as zinc and cobalt resulted in specific conformational changes in both peptides, indicating that cysteine-11 does not appear to be involved in metal chelation. One-dimensional H-1 NMR studies indicate that a stable folded structure is formed upon addition of zinc, and the chemical shift pattern is consistent with that previously observed for one constituent single finger (Omichinski, J., Clore, G. M., Appella, E., Sakaguchi, K., and Gronenborn, A. M. (1990) Biochemistry 29, 9324-9334). Gel retardation experiments demonstrate that the peptides are capable of interacting with a 15-mer oligonucleotide comprising a portion of the major histocompatibility complex enhancer sequence and that the interaction is zinc-dependent. The dissociation constant for the [Abu11]MBP-DF peptide is 1.4 x 10(-7) M with maximal binding occurring at a zinc-to-peptide ratio of 2 to 1. The binding specificity observed with respect to related enhancer sequences exhibits the same relative order as noted previously for the whole protein. Studies with point mutants of the major histocompatibility complex enhancer binding sequence indicate that the last GC base pair in a four-guanine stretch plays a pivotal role in the interaction between the peptide and DNA.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	SAKAGUCHI, K (corresponding author), NCI,HLTH EDUC LAB,BETHESDA,MD 20892, USA.		Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525; Sakaguchi, Kazuyasu/0000-0002-8434-4171				BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; Bertini I, 1984, Adv Inorg Biochem, V6, P71; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAN CM, 1990, GENE DEV, V4, P2119; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MAEKAWA T, 1989, J BIOL CHEM, V264, P14591; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAGAI K, 1988, NATURE, V332, P284, DOI 10.1038/332284a0; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014	26	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7306	7311						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016331				2022-12-25	WOS:A1991FG72700102
J	KUHNVELTEN, WN; BUNSE, T; FORSTER, MEC				KUHNVELTEN, WN; BUNSE, T; FORSTER, MEC			ENZYME KINETIC AND INHIBITION ANALYSES OF CYTOCHROME-P450XVII, A PROTEIN WITH A BIFUNCTIONAL CATALYTIC SITE - QUANTIFICATION OF EFFECTIVE SUBSTRATE CONCENTRATIONS AT THE ACTIVE-SITE AND THEIR SIGNIFICANCE FOR INTRINSIC CONTROL OF THE HYDROXYLASE LYASE REACTION SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTICULAR MICROSOMAL CYTOCHROME-P-450; SIDE-CHAIN CLEAVAGE; ISOLATED LEYDIG-CELLS; NEONATAL PIG TESTIS; TRYPTOPHAN SYNTHASE; RAT TESTIS; MULTIFUNCTIONAL PROTEINS; C-21 STEROIDS; BINDING; SYSTEM	An enzyme kinetic analysis of the cytochrome P450XVII-dependent testicular steroid-17-alpha-hydroxylase/17,20-lyase system was performed which catalyzes simultaneously, at one active site, the formation of androstenedione from progesterone (productive pathway, coordinated performance of both hydroxylase and lyase activities) and the formation of 17-alpha-hydroxyprogesterone as the intermediate (abortive pathway, isolated performance of hydroxylase activity only). Progesterone was used as the substrate and promegestone (17-alpha,21-dimethyl-4,9(10)-pregnadiene-3,20-dione) or estradiol as competitive inhibitors, and description of the data was based on the discrimination of those alternative routes of progesterone metabolism. The overall catalytic activity of P450XVII obeyed Michaelis-Menten kinetics (control incubations: V = 440 nM/min with 80 nM P450XVII, K(M) = 140 nM), and K(I) values amounted to 6.8-mu-M for promegestone and to 23.5-mu-M for estradiol. In contrast, analysis of the rates of both abortive and productive events yielded curvilinear Eadie-Hofstee plots. The former presented an apparent negative cooperative behavior with n(h) = 0.78 in the region of K(h), while the latter presented an apparent substrate inhibition behavior with the maximal rate occurring at that progesterone concentration where n(h) for the abortive path reached its minimum. Consequently, the ratio of productive versus abortive catalytic events decreased with increasing substrate supply, but did not reach zero. Effective substrate concentrations [S]eff with respect to either the productive or the abortive pathway were derived from Hill plots. Linearization of Eadie-Hofstee plots and parallel calculation methods using these [S]eff instead of [S] yielded V = 236 nM/min and [S]0.5eff = 131 nM for the abortive events and V = 217 nM/min and [S]0.5eff = 38 nM for the productive events. Both promegestone and estradiol were identified as competitive inhibitors of either reaction after consideration of effective progesterone concentrations. With the inhibitors, ratios of productive versus abortive events were constantly higher at a given substrate concentration than in control incubations, although neither promegestone nor estradiol affected progesterone or 17-alpha-hydroxyprogesterone accumulation in the endoplasmic reticulum membrane compartment. Rather, a linear correlation between ratios of productive versus abortive events and the overall catalytic rate as a measure of E.S complex concentration was obtained irrespective of the absence or presence of inhibitor. It was therefore concluded that promegestone and estradiol inhibit access or binding of progesterone to P450XVII, whereas the relative efficiency of androgen formation is solely dictated by the local substrate concentration being effective with respect to E.S formation. A model of P450XVII function is presented which proposes that excess substrate at the active site of the P450XVII enzyme protein hinders a certain fraction of a putative transient intermediate from being retained at the bifunctional catalytic site with the consequence that it cannot be further processed to androgen.	UNIV DUSSELDORF, INST PHYSIOL CHEM 2, W-4000 DUSSELDORF 1, GERMANY	Heinrich Heine University Dusseldorf	KUHNVELTEN, WN (corresponding author), UNIV ESSEN KLINIKUM, INST PHYSIOL CHEM, HUFELANDSTR 55, W-4300 ESSEN, GERMANY.							BELANGER A, 1980, BIOL REPROD, V22, P1094, DOI 10.1093/biolreprod/22.5.1094; CASCANTE M, 1990, EUR J BIOCHEM, V192, P369, DOI 10.1111/j.1432-1033.1990.tb19236.x; CHASALOW F, 1979, J BIOL CHEM, V254, P3000; CHEN QX, 1989, BIOCHEMISTRY-US, V28, P8856, DOI 10.1021/bi00448a026; CHUBB C, 1979, AM J PHYSIOL, V237, pE231, DOI 10.1152/ajpendo.1979.237.3.E231; CLELAND WW, 1990, BIOCHEMISTRY-US, V29, P3194, DOI 10.1021/bi00465a006; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; DHARIWAL MS, 1989, BIOCHEMISTRY-US, V28, P8397, DOI 10.1021/bi00447a019; EASTERBY JS, 1989, BIOCHEM J, V264, P605, DOI 10.1042/bj2640605; ECKSTEIN B, 1987, EUR J BIOCHEM, V166, P425, DOI 10.1111/j.1432-1033.1987.tb13533.x; ELLIS KJ, 1978, BIOCHEM J, V171, P513, DOI 10.1042/bj1710513d; ESTABROOK RW, 1975, J STEROID BIOCHEM, V6, P419, DOI 10.1016/0022-4731(75)90166-1; FORSTER MEC, 1989, CYTOCHROME P-450 : BIOCHEMISTRY AND BIOPHYSICS /, P391; HALL PF, 1986, STEROIDS, V48, P133; HARRISON RG, 1975, HDB PHYSL MALE REPRO, P219; HEYL BL, 1986, J BIOL CHEM, V261, P2743; HOCHBERG RB, 1975, J STEROID BIOCHEM, V6, P323, DOI 10.1016/0022-4731(75)90150-8; HUME R, 1984, EUR J BIOCHEM, V140, P583, DOI 10.1111/j.1432-1033.1984.tb08142.x; HYDE CC, 1988, J BIOL CHEM, V263, P17857; IKUSHIRO S, 1989, BIOCHIM BIOPHYS ACTA, V984, P50, DOI 10.1016/0005-2736(89)90341-6; IVANETICH KM, 1990, FASEB J, V4, P1591, DOI 10.1096/fasebj.4.6.2180768; KAWATO S, 1988, J BIOCHEM-TOKYO, V104, P188, DOI 10.1093/oxfordjournals.jbchem.a122439; KELLIS JT, 1987, J BIOL CHEM, V262, P8840; KIRSCHNER K, 1976, ANNU REV BIOCHEM, V45, P143, DOI 10.1146/annurev.bi.45.070176.001043; KOMINAMI S, 1989, BIOCHIM BIOPHYS ACTA, V985, P293, DOI 10.1016/0005-2736(89)90415-X; KUHNVELTEN N, 1984, ACTA ENDOCRINOL-COP, V105, P571, DOI 10.1530/acta.0.1050571; KUHNVELTEN N, 1989, J STEROID BIOCHEM, V33, P33, DOI 10.1016/0022-4731(89)90354-3; KUHNVELTEN N, 1988, BIOCHEM J, V256, P53; KUHNVELTEN N, 1989, BIOL CHEM H-S, V370, P925; KUHNVELTEN N, 1984, H-S Z PHYSIOL CHEM, V365, P773, DOI 10.1515/bchm2.1984.365.2.773; KUHNVELTEN N, 1982, DIABETOLOGIA, V23, P529; KUHNVELTEN N, 1984, J STEROID BIOCHEM, V21, P697, DOI 10.1016/0022-4731(84)90033-5; LARROQUE C, 1981, BIOCHEMISTRY-US, V20, P925, DOI 10.1021/bi00507a043; MAHAJAN DK, 1975, STEROIDS, V25, P217, DOI 10.1016/S0039-128X(75)90118-X; Markwell M A, 1981, Methods Enzymol, V72, P296; MATCHETT WH, 1974, J BIOL CHEM, V249, P4041; MCCARTHY JL, 1988, J STEROID BIOCHEM, V29, P307, DOI 10.1016/0022-4731(88)90031-3; MENARD RH, 1973, ARCH BIOCHEM BIOPHYS, V154, P8, DOI 10.1016/0003-9861(73)90029-5; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; NAKAJIN S, 1981, J BIOL CHEM, V256, P6134; NAKAJIN S, 1981, J BIOL CHEM, V256, P3871; NAKAJIN S, 1981, BIOCHEMISTRY-US, V20, P4037, DOI 10.1021/bi00517a014; NAKAJIN S, 1981, J STEROID BIOCHEM, V14, P1249, DOI 10.1016/0022-4731(81)90328-9; NAKAJIN S, 1983, J STEROID BIOCHEM, V19, P1345; NAMIKI M, 1988, BIOCHEM BIOPH RES CO, V157, P705, DOI 10.1016/S0006-291X(88)80307-3; NAYFEH SN, 1969, STEROIDS, V14, P269, DOI 10.1016/0039-128X(69)90015-4; NEBERT DW, 1989, DNA-J MOLEC CELL BIO, V8, P1, DOI 10.1089/dna.1.1989.8.1; OMURA T, 1964, J BIOL CHEM, V239, P2370; ONODA M, 1981, ENDOCRINOLOGY, V109, P763, DOI 10.1210/endo-109-3-763; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; OVADI J, 1989, BIOCHEM J, V257, P187, DOI 10.1042/bj2570187; PERRIN A, 1989, CYTOCHROME P-450 : BIOCHEMISTRY AND BIOPHYSICS /, P117; PUNJABI U, 1983, J STEROID BIOCHEM, V19, P1481, DOI 10.1016/0022-4731(83)91124-X; REILLY PEB, 1980, FEBS LETT, V119, P63, DOI 10.1016/0014-5793(80)80998-7; Rutey J., 1990, ANGEW CHEM, V102, P373, DOI DOI 10.1039/C4EE03271C; SAMUELS LT, 1975, J STEROID BIOCHEM, V6, P291, DOI 10.1016/0022-4731(75)90145-4; SAMUELS LT, 1974, ENDOCRINOLOGY, V94, P55, DOI 10.1210/endo-94-1-55; Segel I.H., 1975, ENZYME KINETICS; SHEETS JJ, 1985, BIOCHEMISTRY-US, V24, P6591, DOI 10.1021/bi00344a043; SONDERFAN AJ, 1987, ARCH BIOCHEM BIOPHYS, V255, P27, DOI 10.1016/0003-9861(87)90291-8; STANGE K, 1971, ANGEWANDTE STATISTIK, P121; SUHARA K, 1984, J BIOL CHEM, V259, P8729; SWINNEY DC, 1988, BIOCHEMISTRY-US, V27, P5461, DOI 10.1021/bi00415a012; VANDENBERG AP, 1979, BIOCHEM PHARMACOL, V28, P37, DOI 10.1016/0006-2952(79)90267-3; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WINTER JSD, 1989, J CLIN ENDOCR METAB, V68, P309, DOI 10.1210/jcem-68-2-309; YANASE T, 1989, J BIOL CHEM, V264, P18076	69	42	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6291	6301						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007581				2022-12-25	WOS:A1991FE37300045
J	JAIN, SK; DECANDIDO, S; KIELIAN, M				JAIN, SK; DECANDIDO, S; KIELIAN, M			PROCESSING OF THE P62 ENVELOPE PRECURSOR PROTEIN OF SEMLIKI FOREST VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SINDBIS VIRUS; PROTEOLYTIC CLEAVAGE; MEMBRANE-PROTEINS; GOLGI-COMPLEX; BREFELDIN-A; CELL-FUSION; BHK CELLS; LOW PH; GLYCOPROTEIN	The spike protein of Semliki Forest virus is composed of three subunits, E1, E2, and E3, which mediate the fusion of the virus membrane with that of the host cell. E2 and E3 are synthesized as a precursor, p62, which is cleaved post-translationally after an Arg-His-Arg-Arg sequence. In vitro mutagenesis of a cDNA clone of the spike proteins was used to specifically alter amino acids in this cleavage site. Cleavage of p62 was completely blocked by mutation of the proximal Arg residue to Phe, without affecting transport or surface expression of the spike protein. The cleavage mutation resulted in the loss of spike protein fusion activity within the physiological pH range. Fusion activity was restored by cleavage with exogenous chymotrypsin and showed the same low pH dependence as that of wild type. The cleavage sensitivity of newly synthesized p62 was investigated by pulse-chase analysis and chymotrypsin treatment in detergent solution. p62 was sensitive to cleavage immediately following its synthesis. Protein trapped in the rough endoplasmic reticulum or Golgi apparatus by carbonyl cyanide m-chlorophenylhydrazone, monensin, or Brefeldin A treatment was also fully sensitive to cleavage. These results suggest that p62 does not require an organelle-mediated conformational change for processing. Thus, in vivo, the site of p62 processing is probably controlled by the location or activity of the cleavage enzyme, rather than the sensitivity of the p62 substrate.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine				Kielian, Margaret/0000-0002-7395-4791	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038743] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA13330] Funding Source: Medline; NIGMS NIH HHS [GM-38743] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ASANO A, 1984, Tumor Research, V19, P1; BOGGS WM, 1989, VIROLOGY, V169, P485, DOI 10.1016/0042-6822(89)90178-5; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; FISHER JM, 1988, J BIOL CHEM, V263, P16515; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GAROFF H, 1980, NATURE, V288, P236, DOI 10.1038/288236a0; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; Harrison S. C., 1986, TOGAVIRIDAE FLAVIVIR, P21; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAWAOKA Y, 1988, P NATL ACAD SCI USA, V85, P324, DOI 10.1073/pnas.85.2.324; KIELIAN M, 1990, J VIROL, V64, P4614, DOI 10.1128/JVI.64.10.4614-4624.1990; KIELIAN M, 1990, MOL BIOL MED, V7, P17; KIELIAN M, 1985, J CELL BIOL, V101, P2284, DOI 10.1083/jcb.101.6.2284; Kielian M, 1986, TOGAVIRIDAE FLAVIVIR, P91; KIELIAN MC, 1984, J VIROL, V52, P281, DOI 10.1128/JVI.52.1.281-283.1984; KONDORKOCH C, 1983, J CELL BIOL, V97, P644, DOI 10.1083/jcb.97.3.644; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOBIGS M, 1990, J VIROL, V64, P1233, DOI 10.1128/JVI.64.3.1233-1240.1990; LOBIGS M, 1990, J VIROL, V64, P5214, DOI 10.1128/JVI.64.10.5214-5218.1990; MACKOW ER, 1988, P NATL ACAD SCI USA, V85, P645, DOI 10.1073/pnas.85.3.645; MANN E, 1983, J VIROL, V45, P1083, DOI 10.1128/JVI.45.3.1083-1089.1983; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MELANCON P, 1986, EMBO J, V5, P1551, DOI 10.1002/j.1460-2075.1986.tb04396.x; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; OMAR A, 1988, VIROLOGY, V166, P17, DOI 10.1016/0042-6822(88)90141-9; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PATERSON RG, 1989, J VIROL, V63, P1293, DOI 10.1128/JVI.63.3.1293-1301.1989; PEREZ LG, 1987, J VIROL, V61, P1609, DOI 10.1128/JVI.61.5.1609-1614.1987; PHALEN T, 1991, IN PRESS J CELL BIOL; PRESLEY JF, 1989, J VIROL, V63, P1975, DOI 10.1128/JVI.63.5.1975-1980.1989; RICE CM, 1985, J VIROL, V56, P227, DOI 10.1128/JVI.56.1.227-239.1985; RUSSELL DL, 1989, J VIROL, V63, P1619, DOI 10.1128/JVI.63.4.1619-1629.1989; Schlesinger S., 1986, TOGAVIRIDAE FLAVIVIR, P121, DOI [10.1007/978-1-4757-0785-4_5, DOI 10.1007/978-1-4757-0785-4_5]; SIMONS K, 1984, ADV PROTEIN CHEM, V36, P79, DOI 10.1016/S0065-3233(08)60296-X; WAHLBERG JM, 1989, J VIROL, V63, P4991, DOI 10.1128/JVI.63.12.4991-4997.1989; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WHITE J, 1980, P NATL ACAD SCI-BIOL, V77, P3273, DOI 10.1073/pnas.77.6.3273; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; ZIEMIECKI A, 1980, J GEN VIROL, V50, P111, DOI 10.1099/0022-1317-50-1-111	50	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5756	5761						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005112				2022-12-25	WOS:A1991FD37000062
J	KAARTINEN, V; WILLIAMS, JC; TOMICH, J; YATES, JR; HOOD, LE; MONONEN, I				KAARTINEN, V; WILLIAMS, JC; TOMICH, J; YATES, JR; HOOD, LE; MONONEN, I			GLYCOSAPARAGINASE FROM HUMAN-LEUKOCYTES - INACTIVATION AND COVALENT MODIFICATION WITH DIAZO-OXONORVALINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; GLUTAMINASE-ASPARAGINASE; ERWINIA-CHRYSANTHEMI; ESCHERICHIA-COLI; RAT-LIVER; GLYCOSYLASPARAGINASE; ACINETOBACTER; PURIFICATION; PROTEIN; SITE	The apparent active site of human leukocyte glycoasparaginase (N4-(beta-acetylglucosaminyl)-L-asparaginase EC 3.5.1.26) has been studied by labeling with an asparagine analogue, 5-diazo-4-oxo-L-norvaline. Glycoasparaginase was purified 4,600-fold from human leukocytes with an overall recovery of 12%. The purified enzyme has a K(m) of 110-mu-M, a V(max) of 34-mu-mol x l-1 x min-1, and a specific activity of 2.2 units/mg protein with N4-(beta-N-acetylglucosaminyl)-L-asparagine as substrate. The carbohydrate content of the enzyme is 15%, and it exhibits a broad pH maximum between 7 and 9. The 88-kDa native enzyme is composed of 19-kDa light (L) chains and 25-kDa heavy (H) chains and it has a heterotetrameric structure of L2H2-type. The glycoasparaginase activity decreases rapidly and irreversibly in the presence of 5-diazo-4-oxo-L-norvaline. At any one concentration of the compound, the inactivation of the enzyme is pseudo-first-order with time. The inhibitory constant, K(I), is 80-mu-M and the second-order rate constant 1.25 x 10(3) M-1 min-1 at pH 7.5. The enzyme activity is competitively protected against this inactivation by its natural substrate, aspartylglucosamine, indicating that this inhibitor binds to the active site or very close to it. The covalent incorporation of [5-C-14]diazo-4-oxo-L-norvaline paralleled the loss of the enzymatic activity and one inhibitor binding site was localized to each L-subunit of the heterotetrameric enzyme. Four peptides with the radioactive label were generated, purified by high performance liquid chromatography, and sequenced by Edman degradation. The sequences were overlapping and all contained the amino-terminal tripeptide of the L-chain. By mass spectrometry, the reacting group of 5-diazo-4-oxo-L-norvaline was characterized as 4-oxo-L-norvaline that was bound through an alpha-ketone ether linkage to the hydroxyl group of the amino-terminal amino acid threonine.	CHILDRENS HOSP LOS ANGELES,DIV MED GENET,LOS ANGELES,CA 90054; KUOPIO UNIV,CENT HOSP,DEPT CLIN CHEM,SF-70210 KUOPIO,FINLAND; CALTECH,DIV BIOL,PASADENA,CA 91125	Children's Hospital Los Angeles; Kuopio University Hospital; University of Eastern Finland; California Institute of Technology			Kaartinen, Vesa/AAU-5396-2021	Kaartinen, Vesa/0000-0002-9432-510X; TOMICH, JOHN/0000-0001-7848-8307				BAUMANN M, 1989, BIOCHEM J, V262, P189, DOI 10.1042/bj2620189; BEAUDET AL, 1989, METABOLIC BASIS INHE, P1603; Britton HTS, 1937, J CHEM SOC, P1848, DOI 10.1039/jr9370001848; COLEMAN JE, 1973, J BIOL CHEM, V248, P1741; DUGAL B, 1977, BIOCHEM J, V165, P497, DOI 10.1042/bj1650497; DUNLOP PC, 1978, J BIOL CHEM, V253, P1297; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; GRIFFIN PR, 1989, J BIOL CHEM, V264, P19066; HANDSCHUMACHER RE, 1968, SCIENCE, V161, P62, DOI 10.1126/science.161.3836.62; HEFTZ SA, 1989, TECHNIQUES PROTEIN C, P560; HOLCENBERG JS, 1978, BIOCHEMISTRY-US, V17, P411, DOI 10.1021/bi00596a005; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KAARTINEN V, 1990, ANAL BIOCHEM, V190, P98, DOI 10.1016/0003-2697(90)90140-5; KITZ R, 1962, J BIOL CHEM, V237, P3245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAITA T, 1974, J BIOCHEM-TOKYO, V76, P1351, DOI 10.1093/oxfordjournals.jbchem.a130690; March J., 1985, ADV ORG CHEM, P344; MCGOVERN MM, 1983, J BIOL CHEM, V258, P743; MINTON NP, 1986, GENE, V46, P25, DOI 10.1016/0378-1119(86)90163-0; MONONEN I, 1981, CARBOHYD RES, V88, P39, DOI 10.1016/S0008-6215(00)84599-1; PETERSON RG, 1977, J BIOL CHEM, V252, P2072; PLAPP BV, 1982, METHOD ENZYMOL, V87, P486; ROBERTS J, 1972, J BIOL CHEM, V247, P84; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; TANAKA S, 1988, J BIOL CHEM, V263, P8583; TARENTINO AL, 1969, ARCH BIOCHEM BIOPHYS, V130, P295, DOI 10.1016/0003-9861(69)90036-8; THOMAS DW, 1968, BIOCHEM BIOPH RES CO, V32, P519, DOI 10.1016/0006-291X(68)90693-1; TOLLERSRUD OK, 1989, BIOCHEM J, V260, P101, DOI 10.1042/bj2600101; TOLLERSRUD OK, 1988, BIOCHIM BIOPHYS ACTA, V953, P353, DOI 10.1016/0167-4838(88)90044-1; YAMASHINA I, 1972, GLYCOPROTEINS, P1187	30	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5860	5869						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005122				2022-12-25	WOS:A1991FD37000079
J	KIMURA, H; ODANI, S; NISHI, S; SATO, H; ARAKAWA, M; ONO, T				KIMURA, H; ODANI, S; NISHI, S; SATO, H; ARAKAWA, M; ONO, T			PRIMARY STRUCTURE AND CELLULAR-DISTRIBUTION OF 2 FATTY ACID-BINDING PROTEINS IN ADULT-RAT KIDNEYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; PERIPHERAL-NERVE MYELIN; LINKAGE RELATIONSHIPS; MOLECULAR-STRUCTURE; ALPHA-2U GLOBULIN; MEMBRANE DAMAGE; RENAL ISCHEMIA; MESSENGER-RNA; HEART; LIVER	Fatty acid-binding proteins (FABPs) were purified from the kidneys of female and male rats and characterized by primary structure and histological distribution in the kidney. Two FABPs (14 and 15.5 kDa) were found in male rat kidney cytosol whereas only 14-kDa FABP could be recognized in female rat kidneys throughout the purification steps. The amino acid sequence of the 14-kDa FABP was identical to that of rat heart FABP deduced from the cDNA sequence (Heuckeroth, R. O., Birkenmeier, E. H., Levin, M. S., and Gordon, J. I. (1987) J. Biol. Chem. 262, 9709-9717). Structural analysis of the male-specific 15.5-kDa FABP identified this second FABP as a proteolytically modified form of alpha-2u-globulin, an 18.7-kDa major urinary protein of adult male rats (Unterman, R. D., Lynch, K. R., Nakhasi, H. L., Dolan, K. P., Hamilton, J. W., Cohn, D. V., and Feigelson, P. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 3478-3482) which shares a common ancestry with a number of hydrophobic ligand-binding proteins such as serum retinol-binding proteins. Immunohistochemical investigation disclosed that heart-type FABP (14-kDa FABP) is localized in the cytoplasm of the epithelia of the distal tubules in both male and female rat kidneys whereas 15.5-kDa FABP immunostaining was observed predominantly in the endosomes or lysosomes of proximal tubules in male rat kidneys. These results suggest strongly the functional divergence of two FABPs in the rat kidney.	NIIGATA UNIV,SCH MED,DEPT MED 2,NIIGATA 951,JAPAN	Niigata University	KIMURA, H (corresponding author), NIIGATA UNIV,SCH MED,DEPT BIOCHEM,1-757 ASAHIMACHI DORI,NIIGATA 951,JAPAN.							ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; BARACNIETO M, 1971, NEPHRON, V8, P488, DOI 10.1159/000179952; BASS NM, 1986, BIOCHEM BIOPH RES CO, V137, P929, DOI 10.1016/0006-291X(86)90314-1; BILLICH S, 1988, EUR J BIOCHEM, V175, P549, DOI 10.1111/j.1432-1033.1988.tb14227.x; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; BREZIS M, 1984, KIDNEY INT, V26, P375, DOI 10.1038/ki.1984.185; CHAMBERLIN ME, 1986, AM J PHYSIOL, V251, pF758, DOI 10.1152/ajprenal.1986.251.4.F758; CLAFFEY KP, 1987, BIOCHEMISTRY-US, V26, P7900, DOI 10.1021/bi00398a054; CRISMAN TS, 1987, J MOL CELL CARDIOL, V19, P423, DOI 10.1016/S0022-2828(87)80394-2; FUJII S, 1988, J HYPERTENS, V6, P671, DOI 10.1097/00004872-198808000-00011; FUJII S, 1987, ARCH BIOCHEM BIOPHYS, V254, P552, DOI 10.1016/0003-9861(87)90137-8; GIBSON BW, 1988, J BIOL CHEM, V263, P4182; GLATZ JFC, 1984, J BIOL CHEM, V259, P4295; GLATZ JFC, 1985, INT J BIOCHEM, V17, P13, DOI 10.1016/0020-711X(85)90080-1; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; HELLFRITZSCH M, 1986, KIDNEY INT, V29, P983, DOI 10.1038/ki.1986.97; HENZEL WJ, 1988, J BIOL CHEM, V263, P16682; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HOHENLEI.F, 1961, AM J PHYSIOL, V200, P1095, DOI 10.1152/ajplegacy.1961.200.5.1095; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; KANDA T, 1989, EUR J BIOCHEM, V185, P27, DOI 10.1111/j.1432-1033.1989.tb15076.x; KIMURA H, 1989, BIOCHEM J, V260, P303, DOI 10.1042/bj2600303; KIMURA H, 1989, FEBS LETT, V246, P101, DOI 10.1016/0014-5793(89)80261-3; KURTZ DT, 1976, J BIOL CHEM, V251, P3594; LAM KT, 1988, J BIOL CHEM, V263, P15762; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACINNES JI, 1986, MOL CELL BIOL, V6, P3563, DOI 10.1128/MCB.6.10.3563; MATSUBARA H, 1969, BIOCHEM BIOPH RES CO, V35, P175, DOI 10.1016/0006-291X(69)90263-0; MATTHYS E, 1984, KIDNEY INT, V26, P153, DOI 10.1038/ki.1984.149; NEUHAUS OW, 1986, P SOC EXP BIOL MED, V182, P531; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PAULUSSEN RJA, 1988, ARCH BIOCHEM BIOPHYS, V264, P533, DOI 10.1016/0003-9861(88)90319-0; PAULUSSEN RJA, 1986, BIOCHIM BIOPHYS ACTA, V877, P342, DOI 10.1016/0005-2760(86)90198-0; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; ROY AK, 1966, BIOCHIM BIOPHYS ACTA, V127, P82, DOI 10.1016/0304-4165(66)90478-8; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; SAID B, 1984, J BIOL CHEM, V259, P1155; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUGIYAMA Y, 1980, BIOCHEM PHARMACOL, V29, P2063, DOI 10.1016/0006-2952(80)90492-X; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TAKAHASHI K, 1983, EUR J BIOCHEM, V136, P589, DOI 10.1111/j.1432-1033.1983.tb07781.x; TAKAHASHI K, 1982, BIOCHEM BIOPH RES CO, V106, P1099, DOI 10.1016/0006-291X(82)91225-6; UCHIDA T, 1988, J HISTOCHEM CYTOCHEM, V36, P693, DOI 10.1177/36.6.3367052; UNTERMAN RD, 1981, P NATL ACAD SCI-BIOL, V78, P3478, DOI 10.1073/pnas.78.6.3478; WALZ DA, 1988, J BIOL CHEM, V263, P14189; WEINBERG JM, 1985, AM J PHYSIOL, V248, pF876, DOI 10.1152/ajprenal.1985.248.6.F876	52	35	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5963	5972						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005132				2022-12-25	WOS:A1991FD37000094
J	POON, PH; SCHUMAKER, VN				POON, PH; SCHUMAKER, VN			MEASUREMENT OF MACROMOLECULAR INTERACTIONS BETWEEN COMPLEMENT SUBCOMPONENTS CLQ, CLRBAR, CLSBAR, AND IMMUNOGLOBULIN IGM BY SEDIMENTATION ANALYSIS USING THE ANALYTICAL ULTRACENTRIFUGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1ST COMPONENT; SEGMENTAL FLEXIBILITY; ACTIVATION; C1Q; COMPLEXES; PURIFICATION; ANTIBODY	The interactions between the complement components and with immunoglobulins are greatly enhanced by lowering the ionic strength and become readily measurable by physical techniques. Thus, the binding between C1q and IgM was previously shown to be appreciable (k = 1 x 10(6) M-1) at 0.084 M ionic strength (Poon, P. H., Phillips, M. L., and Schumaker, V. N. (1985) J. Biol. Chem. 260, 9357-9365). We have now found that, at 0.128 M ionic strength, the binding between human C1BAR (the activated first component of complement) and IgM was strong at physiological concentrations (k = 1 x 10(7) M-1), while under the same conditions binding between C1q and IgM was not observed. To explore the nature of the interactions responsible for this enhanced binding by C1BAR over C1q, mixtures of the various subcomponents of C1BAR were studied alone and with IgM. C1rBAR2 did not bind to C1q, even when the ionic strength was reduced to 0.098 M, nor did the presence of C1rBAR2 enhance the binding of C1q to IgM. In contrast, two C1sBAR2 independently bound to C1q (k = 1 x 10(6) M-1), and caused a marked increase in its association with IgM (k = 5 x 10(6) M-1) at 0.098 M ionic strength. No detectable interaction was found between C1sBAR2 and/or C1rBAR2 and IgM in the absence of C1q. Moreover, there was no detectable interaction between the C1BAR-like complex formed between C1rBAR2C1sBAR2 and the collagenous C1q stalks (pepsin-digested C1q) and IgM. These data suggest that the binding of C1sBAR2 to C1q, either alone or together with C1rBAR2, induces a conformational change in C1q which results in additional C1q heads binding to complementary sites on IgM.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013914] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13914] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSIMEH SN, 1974, J IMMUNOL, V113, P225; BORSOS T, 1981, MOL IMMUNOL, V18, P863, DOI 10.1016/0161-5890(81)90008-0; BORSOS T, 1965, SCIENCE, V150, P505, DOI 10.1126/science.150.3695.505; BUSBY TF, 1990, BIOCHEMISTRY-US, V29, P4613, DOI 10.1021/bi00471a016; BUSBY TF, 1988, BIOCHEMISTRY-US, V27, P6127, DOI 10.1021/bi00416a045; FEINSTEIN A, 1986, IMMUNOL TODAY, V7, P169, DOI 10.1016/0167-5699(86)90168-4; GOERS JW, 1977, J IMMUNOL, V118, P2182; HANSON DC, 1985, J BIOL CHEM, V260, P3576; HUGHESJONES NC, 1982, MOL IMMUNOL, V9, P1105; KILCHHERR E, 1982, MOL IMMUNOL, V19, P683, DOI 10.1016/0161-5890(82)90370-4; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; LAKATOS S, 1987, BIOCHEM BIOPH RES CO, V149, P378, DOI 10.1016/0006-291X(87)90377-9; MEDICUS RG, 1980, J IMMUNOL, V125, P390; MILLER F, 1965, J BIOL CHEM, V240, P3325; MILLER F, 1965, J BIOL CHEM, V240, P4740; POON PH, 1985, J BIOL CHEM, V260, P9357; POON PH, 1983, J MOL BIOL, V168, P563, DOI 10.1016/S0022-2836(83)80302-7; REID KBM, 1972, BIOCHEM J, V130, P749, DOI 10.1042/bj1300749; REID KBM, 1983, BIOCHEM SOC T, V11, P1; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P163; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; SCHUMAKER VN, 1957, BIOCHIM BIOPHYS ACTA, V23, P628, DOI 10.1016/0006-3002(57)90386-4; SIEGEL RC, 1981, J IMMUNOL, V127, P2447; SIEGEL RC, 1983, MOL IMMUNOL, V20, P53, DOI 10.1016/0161-5890(83)90105-0; SIM RB, 1981, METHOD ENZYMOL, V80, P26; TENNER AJ, 1981, J IMMUNOL, V127, P648; ZICCARDI RJ, 1984, J IMMUNOL, V132, P283; ZICCARDI RJ, 1985, MOL IMMUNOL, V22, P489, DOI 10.1016/0161-5890(85)90133-6; ZICCARDI RJ, 1985, J IMMUNOL, V134, P2559	29	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5723	5727						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005109				2022-12-25	WOS:A1991FD37000057
J	ROSENBERG, CL; KIM, HG; SHOWS, TB; KRONENBERG, HM; ARNOLD, A				ROSENBERG, CL; KIM, HG; SHOWS, TB; KRONENBERG, HM; ARNOLD, A			REARRANGEMENT AND OVEREXPRESSION OF D11S287E, A CANDIDATE ONCOGENE ON CHROMOSOME 11Q13 IN BENIGN PARATHYROID TUMORS	ONCOGENE			English	Article							ENDOCRINE NEOPLASIA TYPE-1; B-CELL LYMPHOMAS; HORMONE GENE; MOLECULAR-CLONING; DNA POLYMORPHISMS; PROTO-ONCOGENE; BREAST-CANCER; AMPLIFICATION; INT-2; ABNORMALITIES	We report the detailed molecular characterization of a human parathyroid adenoma with a clonal parathyroid hormone gene rearrangement. This rearrangement is similar to one we characterized recently in an independent adenoma. In these two, plus a third partially characterized adenoma, one allele of the PTH gene, on 11p15, is rearranged with DNA from the D11S287 region on 11q13. This region contains a transcribed sequence, D11S287E, distinct from known 11q13 oncogenes, that is expressed in all parathyroid tissues examined, but is overexpressed dramatically in all three tumors with PTH gene-D11S287 rearrangements. These findings suggest that overexpression of D11S287E, perhaps driven by the misplaced PTH gene's regulatory elements, contributed to the development of these benign tumors. D11S287E is a new candidate oncogene with potential importance in parathyroid adenomas and perhaps other tumors with 11q13 abnormalities.	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,HEMATOL ONCOL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Roswell Park Cancer Institute					NIDDK NIH HHS [DK11794, DK07028] Funding Source: Medline; NIGMS NIH HHS [GM20454] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028, P01DK011794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020454] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELAIDE J, 1988, ONCOGENE, V2, P413; ARNOLD A, 1989, J CLIN ENDOCR METAB, V69, P496, DOI 10.1210/jcem-69-3-496; ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; ARNOLD A, 1983, NEW ENGL J MED, V309, P1593, DOI 10.1056/NEJM198312293092601; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CROCE CM, 1985, BLOOD, V65, P1; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN E, 1990, J CLIN ENDOCR METAB, V71, P293, DOI 10.1210/jcem-71-2-293; FRIEDMAN E, 1989, NEW ENGL J MED, V321, P213, DOI 10.1056/NEJM198907273210402; FRIEND SH, 1988, NEW ENGL J MED, V318, P618; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; IGARASHI T, 1986, MOL CELL BIOL, V6, P1830, DOI 10.1128/MCB.6.5.1830; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KODURU PRK, 1989, ONCOGENE, V4, P929; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; NAKAI H, 1986, CYTOGENET CELL GENET, V43, P215, DOI 10.1159/000132324; NAYLOR SL, 1983, J EXP MED, V57, P1020; RABBITTS PH, 1988, ONCOGENE, V3, P99; Sambrook J, 1989, MOL CLONING LABORATO; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1982, ADV HUM GENET, V12, P341; THAKKER RV, 1989, NEW ENGL J MED, V321, P218, DOI 10.1056/NEJM198907273210403; THEILLET C, 1990, ONCOGENE, V5, P147; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VASICEK TJ, 1983, P NATL ACAD SCI-BIOL, V80, P2127, DOI 10.1073/pnas.80.8.2127; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZABEL BU, 1985, CYTOGENET CELL GENET, V39, P200, DOI 10.1159/000132135	41	240	241	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					449	453						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011400				2022-12-25	WOS:A1991FT34400015
J	VENTER, DJ; BEVAN, KL; LUDWIG, RL; RILEY, TEW; JAT, PS; THOMAS, DGT; NOBLE, MD				VENTER, DJ; BEVAN, KL; LUDWIG, RL; RILEY, TEW; JAT, PS; THOMAS, DGT; NOBLE, MD			RETINOBLASTOMA GENE DELETIONS IN HUMAN GLIOBLASTOMAS	ONCOGENE			English	Article							GENOMIC ORGANIZATION; SUSCEPTIBILITY GENE; OSTEO-SARCOMA; HUMAN DNA; NEOPLASMS; TUMORS; CANCER	The retinoblastoma susceptibility gene, RB, is the best characterised of the tumour suppressor genes, or 'anti-oncogenes'. Abnormal function of the RB protein is thought to result in loss of an inhibitory effect on cell growth, and thus contribute towards the development of certain human cancers. One group of human cancers of particular interest in relationship to retinoblastoma gene function are the gliomas, which are central nervous system tumours thought to originate from the neuroectoderm, the embryological tissue which also gives rise to retinoblastomas. We have therefore examined a group of benign and malignant gliomas for evidence of structural alterations of the RB gene. Four out of nine (44%) glioblastomas, the most malignant gliomas, showed loss of heterozygosity of a locus within this gene. In addition, one of these hemizygous tumours showed deletion of part of the RB protein-coding region, and this abnormality was also present in cells cultured from the tumour. These findings suggest that RB gene abnormalities may contribute to the development of glioblastomas.	LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON W1P 8BT,ENGLAND	Ludwig Institute for Cancer Research								ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; BIGNER SH, 1986, CANCER GENET CYTOGEN, V22, P121, DOI 10.1016/0165-4608(86)90172-X; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; CAVANEE WK, 1983, NATURE, V305, P779; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MIDDLETON PG, 1986, NUCLEIC ACIDS RES, V14, P1925, DOI 10.1093/nar/14.4.1925; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; REISSMANN PT, 1989, ONCOGENE, V4, P839; REY JA, 1987, CANCER GENET CYTOGEN, V29, P201, DOI 10.1016/0165-4608(87)90232-9; ROARTY JD, 1988, OPHTHALMOLOGY, V95, P1583; SEEMAYER TA, 1989, LAB INVEST, V60, P585; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	27	101	101	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					445	448						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011399				2022-12-25	WOS:A1991FT34400014
J	JONES, JG; BELLION, E				JONES, JG; BELLION, E			INVIVO C-13 AND N-15 NMR-STUDIES OF METHYLAMINE METABOLISM IN PSEUDOMONAS SPECIES MA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; GLUTAMATE-DEHYDROGENASE; NITROGEN ASSIMILATION; OXIDATION; BACTERIA; CARBON	Pseudomonas species MA was grown with methylamine as a sole source of carbon and nitrogen enabling the total flow of carbon and nitrogen into this organism to be simultaneously monitored in vivo using C-13 and N-15 NMR. [C-13]Methylamine was rapidly and extensively incorporated into the methyl group of N-methylglutamate during high oxygenation of the cell suspension, but when the oxygenation rate was lower, a significant portion was also found in the methyl group of gamma-glutamylmethylamide. At later times the carbon label was found in intermediates of the serine assimilation pathway, with glutamate derived from the tricarboxylic acid cycle being the most abundant product. Incorporation of [N-15]methylamine was only detected as N-methyl[N-15]glutamate, but when protein synthesis was inhibited, the label was also detected in the amino nitrogen of glutamate. When oxygenation rates were lower, the N-15-labeled methylamine was found in the methylamide group of gamma-glutamylmethylamide in addition to being incorporated into N-methylglutamate. Gamma-glutamylmethylamide formation was linked to the overall energy state of the cell and was not affected by inhibition of the carbon assimilation pathway. Neither 5-hydroxy-N-methylpyroglutamate nor N-methyl-alpha-ketoglutaramate were detected to any significant extent. A mechanism was proposed for the role of gamma-glutamylmethylamide in the regulation of endogenous nitrogen supplies in this organism.	UNIV TEXAS,DEPT CHEM,ARLINGTON,TX 76019	University of Texas System; University of Texas Arlington			Jones, John/A-8684-2010	Jones, John/0000-0002-3745-3885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038571] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38571] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony C., 1982, BIOCH METHYLOTROPHS; BELLION E, 1978, BIOCHIM BIOPHYS ACTA, V541, P425, DOI 10.1016/0304-4165(78)90152-6; BELLION E, 1975, J BACTERIOL, V122, P557, DOI 10.1128/JB.122.2.557-564.1975; BELLION E, 1984, J BACTERIOL, V157, P435, DOI 10.1128/JB.157.2.435-439.1984; BELLION E, 1972, ARCH BIOCHEM BIOPHYS, V153, P368, DOI 10.1016/0003-9861(72)90457-2; BELLION E, 1987, BIOCHEM J, V244, P565, DOI 10.1042/bj2440565; BELLION E, 1980, J BACTERIOL, V142, P786, DOI 10.1128/JB.142.3.786-790.1980; BELLION E, 1983, CURR MICROBIOL, V9, P37, DOI 10.1007/BF01567131; COOPER AJL, 1972, BIOCHEMISTRY-US, V11, P661; COOPER AJL, 1974, J BIOL CHEM, V249, P2554; CORNISH A, 1984, J GEN MICROBIOL, V130, P2565; DENHOLLANDER JA, 1981, P NATL ACAD SCI USA, V80, P5847; EADY RR, 1968, BIOCHEM J, V106, P245, DOI 10.1042/bj1060245; HARAN N, 1983, J BIOL CHEM, V258, P2929; HERSH LB, 1970, J BIOL CHEM, V245, P3526; HERSH LB, 1971, ARCH BIOCHEM BIOPHYS, V145, P115, DOI 10.1016/0003-9861(71)90016-6; HERSH LB, 1969, J BIOL CHEM, V244, P4677; KANAMORI K, 1982, J BIOL CHEM, V258, P14168; KLEIN GB, 1961, J ORG CHEM, V26, P1854; KUNG HF, 1969, J BIOL CHEM, V244, P4136; LAPIDOT A, 1979, BIOCHEMISTRY-US, V18, P704, DOI 10.1021/bi00571a024; MARTIN GJ, 1981, NMR BASIC PRINCIPLES, V0018; MUKUNDAN MA, 1968, NATURE, V217, P1013, DOI 10.1038/2171013a0; NEWAZ SS, 1975, J BACTERIOL, V124, P825, DOI 10.1128/JB.124.2.825-833.1975; SHAW WV, 1966, J BIOL CHEM, V241, P935; SHERRY AD, 1988, BIOCHEM J, V254, P593, DOI 10.1042/bj2540593; SIBIRNY AA, 1990, ARCH MICROBIOL, V154, P566; THOMAS GH, 1987, J BACTERIOL, V169, P359, DOI 10.1128/jb.169.1.359-366.1987; WALTER TE, 1982, J BIOL CHEM, V257, P1189	29	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11705	11713						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050672				2022-12-25	WOS:A1991FT76200046
J	KOZKA, IJ; CLARK, AE; HOLMAN, GD				KOZKA, IJ; CLARK, AE; HOLMAN, GD			CHRONIC TREATMENT WITH INSULIN SELECTIVELY DOWN-REGULATES CELL-SURFACE GLUT4 GLUCOSE TRANSPORTERS IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; DIFFERENTIAL REGULATION; HEXOSE-TRANSPORT; RESPONSIVENESS INVITRO; HORMONE RECEPTORS; DIABETES-MELLITUS; MESSENGER-RNA; PHORBOL ESTER; RESISTANCE; TRANSLOCATION	A new method for photoaffinity labeling of glucose transporters has been used to compare the effects of glucose-starvation, acute-insulin, and chronic-insulin treatments on the cell-surface glucose transporters in 3T3-L1 adipocytes. Starvation alone increased the cell-surface levels of GLUT1 and GLUT4 by almost-equal-to 4- and almost-equal-to 2-fold, respectively. As shown by Calderhead, D, M., Kitagawa, K., Tanner, L. T., Holman, G. D., and Lienhard, G. E. (1990) J. BioL Chem. 265, 13800-13808) acute-insulin treatment increased cell-surface GLUT1 and GLUT4 by almost-equal-to 5- and almost-equal-to l5-fold respectively. In contrast to this, chronic-insulin treatment gave a further 3-4-fold increase in both cell-surface and total cellular GLUT1, but availability of GLUT4 at the cell-surface was down-regulated to half the level found in the acute treatment but with no change in the total cellular level. This effect occurred in starved and non-starved cells and suggests that starvation, acute-insulin, and chronic-insulin treatments regulate glucose transporter availability through independent mechanisms. The down-regulation of GLUT4 reached a maximally reduced cell-surface level in 6 h while the rise in GLUT1 reached a maximum after 24-48 h. The rise in GLUT1 appeared to compensate for the decline in cell-surface GLUT4 as glucose transport activity was further increased during the long term treatment with insulin. The down-regulation of GLUT4 due to the chronic-insulin treatment is associated with a marked resistance of the cells to restimulate glucose transport and particularly to recruit further GLUT4 to the cell-surface following an additional insulin treatment. The defect appears to be in the signaling mechanism that is responsible for translocation.			KOZKA, IJ (corresponding author), UNIV BATH,DEPT BIOCHEM,CLAVERTON DOWN,BATH BA2 7AY,AVON,ENGLAND.			Holman, Geoffrey/0000-0001-7045-1358				BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DAVIES A, 1987, J BIOL CHEM, V262, P9347; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; FROST SC, 1985, J BIOL CHEM, V260, P2646; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GOULD GW, 1989, J BIOL CHEM, V264, P2180; HANIQUE B, 1990, J BIOL CHEM, V265, P7982; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JOOST HG, 1987, J BIOL CHEM, V262, P11261; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAHN CR, 1986, NEW ENGL J MED, V315, P252, DOI 10.1056/NEJM198607243150410; KARNIELI E, 1981, J CLIN INVEST, V68, P811, DOI 10.1172/JCI110318; KORANYI L, 1990, J CLIN INVEST, V85, P962, DOI 10.1172/JCI114526; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; OKA Y, 1988, J BIOL CHEM, V263, P13432; OLEFSKY JM, 1981, AM J MED, V70, P151, DOI 10.1016/0002-9343(81)90422-8; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SEINO S, 1990, DIABETES, V39, P129, DOI 10.2337/diabetes.39.2.129; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; SUSUKI K, 1980, P NATL ACAD SCI USA, V77, P2542; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TRAXINGER RR, 1989, J BIOL CHEM, V264, P8156; VANPUTTEN JPM, 1985, DIABETOLOGIA, V28, P51, DOI 10.1007/BF00277000; VANPUTTEN JPM, 1985, J BIOL CHEM, V260, P7996; WALKER PS, 1989, J BIOL CHEM, V264, P6587; ZORANO A, 1989, J BIOL CHEM, V264, P12358	38	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11726	11731						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050674				2022-12-25	WOS:A1991FT76200049
J	LAWSON, JH; MANN, KG				LAWSON, JH; MANN, KG			COOPERATIVE ACTIVATION OF HUMAN FACTOR-IX BY THE HUMAN EXTRINSIC PATHWAY OF BLOOD-COAGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-DEPENDENT ACTIVATION; BOVINE FACTOR-V; TISSUE FACTOR; FACTOR-X; FACTOR-VII; HUMAN-PROTHROMBIN; CHRISTMAS-FACTOR; PHOSPHOLIPID-VESICLES; FACTOR-XIA; PURIFICATION	The activation of human coagulation factor IX by human tissue factor.factor VIIa.PCPS.Ca2+ (TF.VIIa.PCPS.Ca2+) and factor Xa.PCPS.Ca2+ enzyme complexes was investigated. Reactions were performed in a highly purified system consisting of isolated human plasma proteins and recombinant human tissue factor with synthetic phospholipid vesicles (PCPS: 75% phosphatidylcholine (PC), 25% phosphatidylserine (PS)). Factor IX activation was evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, [H-3]factor IX activation peptide assay, colorimetric substrate thiobenzyl benzyloxycarbonyl-L-lysinate (Z-Lys-SBzl) hydrolysis, and specific incorporation of a fluorescent peptidyl chloromethyl ketone. Factor IX activation by the TF.VIIa.PCPS.Ca2+ enzyme complex was observed to proceed through the obligate non-enzymatic intermediate species factor IX-alpha. The simultaneous activation of human coagulation factors IX and X by the TF.VIIa.PCPS.Ca2+ enzyme complex were investigated. When factors IX and X were presented to the TF.VIIa complex, at equal concentrations, it was observed that the rate of factor IX activation remained unchanged while the rate of factor X activation slowed by 45%. When the proteolytic cleavage products of this reaction were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, it was observed that the intermediate species factor IX-alpha was generated more rapidly when factor X was present in the reaction mixture. When factor IX was treated with factor Xa.PCPS in the presence of Ca2+, it was observed that factor IX was rapidly converted to factor IX-alpha. The activation of factor IX-alpha by the TF.VIIa.PCPS.Ca2+ complex was evaluated, and it was observed that factor IX-alpha was activated more rapidly by the TF.VIIa.PCPS.Ca2+ complex than was factor IX itself. These data suggest that factors IX and X, when presented to the TF.VIIa.PCPS.Ca2+ enzyme complex, are both rapidly activated and that factor Xa, which is generated in the initial stages of the extrinsic pathway, participates in the first proteolytic step in the activation of factor IX, the generation of factor IX-alpha.	UNIV VERMONT, DEPT BIOCHEM, HLTH SCI COMPLEX, BURLINGTON, VT 05405 USA	University of Vermont					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL035058] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35058] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJAJ SP, 1983, BIOCHEMISTRY-US, V22, P4047, DOI 10.1021/bi00286a009; BAUER KA, 1990, BLOOD, V76, P731; Bevington PR, 1969, DATA REDUCTION ERROR; BROZE GJ, 1985, J BIOL CHEM, V260, P917; BROZE GJ, 1988, BLOOD, V71, P335; DAVIE EW, 1975, ANNU REV BIOCHEM, V44, P729, DOI 10.1146/annurev.bi.44.070175.004055; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JENNY R, 1986, PREP BIOCHEM, V16, P227, DOI 10.1080/00327488608062468; JESTY J, 1979, J BIOL CHEM, V254, P2337; KALOUSEK F, 1975, FEBS LETT, V50, P382, DOI 10.1016/0014-5793(75)80533-3; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; MORRISON SA, 1984, BLOOD, V63, P1338; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; SANDERS NL, 1985, BLOOD, V66, P204; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; ZUR M, 1980, J BIOL CHEM, V255, P5703	32	137	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11317	11327						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040636				2022-12-25	WOS:A1991FQ77400094
J	CLANCY, BM; HARRISON, SA; BUXTON, JM; CZECH, MP				CLANCY, BM; HARRISON, SA; BUXTON, JM; CZECH, MP			PROTEIN-SYNTHESIS INHIBITORS ACTIVATE GLUCOSE-TRANSPORT WITHOUT INCREASING PLASMA-MEMBRANE GLUCOSE TRANSPORTERS IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; INSULIN-STIMULATED TRANSLOCATION; FORSKOLIN PHOTOAFFINITY LABEL; HEXOSE-TRANSPORT; APPARENT TRANSLOCATION; POTENTIAL MECHANISM; GENE-TRANSCRIPTION; CYTOCHALASIN-B; FAT-CELLS; S6 KINASE	In this study, we tested the hypothesis that hexose transport regulation may involve proteins with relatively rapid turnover rates. 3T3-L1 adipocytes, which exhibit 10-fold increases in hexose transport rates within 30 min of the addition of 100 nM insulin, were utilized. Exposure of these cells to 300-mu-M anisomycin or 500-mu-M cycloheximide caused a maximal, 7-fold increase in 2-deoxyglucose transport rate after 4-8 h. The effects due to either insulin (0.5 h) or anisomycin (5 h) on the kinetics of zero-trans 3-O-methyl[C-14] glucose transport were similar, resulting in 2.5-3-fold increases in apparent V(max) values (control V(max) = 1.6 +/- 0.3 x 10(-7) mmol/s/10(6) cells) coupled with approximately 2-fold decreases in apparent K(m) values (control K(m) = 23 +/- 3.3 mM). Insulin elicited the expected increases in plasma membrane levels of HepG2/erythrocyte (GLUT1) and muscle/adipocyte (GLUT4) transporters (1.6- and 2.8-fold, respectively) as determined by protein immunoblotting. In contrast, neither total cellular contents nor plasma membrane levels of these two transporter isoforms were increased when 3T3-L1 adipocytes were treated with either anisomycin or cycloheximide. 3-[I-125]Iodo-4-azidophenethylamido-7-O-succinyldeacetylforskolin labeling of glucose transporters in plasma membrane fractions of similarly treated cells was also unaffected by these agents. Thus, a striking discrepancy was observed between the marked increase in cellular hexose transport rates due to these protein synthesis inhibitors and the unaltered amounts of glucose transporter proteins in the plasma membrane fraction. These data indicate that short-term protein synthesis inhibition in 3T3-L1 adipocytes leads to large increases in the intrinsic catalytic activity of one or both of the GLUT1 and GLUT4 transporter isoforms.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	CLANCY, BM (corresponding author), UNIV MASSACHUSETTS,MED CTR,MOLEC MED PROGRAM,WORCESTER,MA 01605, USA.				NIDDK NIH HHS [DK07302, DK30898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898, T32DK007302] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BALY DL, 1987, J BIOL CHEM, V262, P21; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BURGER M, 1988, EUR J BIOCHEM, V183, P255; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHRISTOPHER CW, 1976, P NATL ACAD SCI USA, V73, P2429, DOI 10.1073/pnas.73.7.2429; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DOOLITTLE RF, 1983, URFS ORFS, P85; FROST SC, 1985, J BIOL CHEM, V260, P2646; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GALE EF, 1972, MOL BASIS ANTIBIOTIC, P502; GOULD GW, 1989, J BIOL CHEM, V264, P2180; GREEN A, 1983, BIOCHEM J, V212, P189, DOI 10.1042/bj2120189; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JONES TLZ, 1989, J BIOL CHEM, V264, P7874; JOOST HG, 1986, J BIOL CHEM, V261, P33; JOOST HG, 1988, BIOCHEM J, V249, P155, DOI 10.1042/bj2490155; KARNIELI E, 1981, J CLIN INVEST, V68, P811, DOI 10.1172/JCI110318; KONO T, 1981, J BIOL CHEM, V256, P6400; KOZMA SC, 1989, EMBO J, V8, P4125, DOI 10.1002/j.1460-2075.1989.tb08597.x; KURODA M, 1987, J BIOL CHEM, V262, P245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE R, 1955, RECENT PROG HORM RES, V11, P343; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; MARTZ A, 1986, J BIOL CHEM, V261, P3606; MATTHAEI S, 1988, BIOCHEM J, V251, P491, DOI 10.1042/bj2510491; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; OKA Y, 1988, J BIOL CHEM, V263, P13432; OKA Y, 1984, J BIOL CHEM, V259, P8125; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SMITH U, 1984, J BIOL CHEM, V259, P8758; SUZUKI K, 1988, J BIOL CHEM, V263, P12247; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TOYODA N, 1987, J BIOL CHEM, V262, P2737; WADZINSKI BE, 1988, BIOCHEM J, V255, P983, DOI 10.1042/bj2550983; WADZINSKI BE, 1987, J BIOL CHEM, V262, P17683; WARDZALA LJ, 1981, J BIOL CHEM, V256, P7090; WARDZALA LJ, 1983, BIOCHIM BIOPHYS ACTA, V730, P49, DOI 10.1016/0005-2736(83)90315-2; WATANABE T, 1984, J BIOL CHEM, V259, P3117; YAMADA K, 1983, J BIOL CHEM, V258, P9786; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	48	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10122	10130						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037570				2022-12-25	WOS:A1991FP08600022
J	KAHARI, VM; LARJAVA, H; UITTO, J				KAHARI, VM; LARJAVA, H; UITTO, J			DIFFERENTIAL REGULATION OF EXTRACELLULAR-MATRIX PROTEOGLYCAN (PG) GENE-EXPRESSION - TRANSFORMING GROWTH FACTOR-BETA-1 UP-REGULATES BIGLYCAN (PGI), AND VERSICAN (LARGE FIBROBLAST PG) BUT DOWN-REGULATES DECORIN (PGII) MESSENGER-RNA LEVELS IN HUMAN FIBROBLASTS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; INCREASED COLLAGEN PRODUCTION; HUMAN DERMAL FIBROBLASTS; NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE CELLS; OSTEO-SARCOMA CELLS; FACTOR-BETA; I PROCOLLAGEN; CORE PROTEIN; INSITU HYBRIDIZATION	Proteoglycans (PGs) comprise a group of extracellular matrix macromolecules which play an important role in matrix biology. In this study, normal human skin and gingival fibroblast cultures were incubated with transforming growth factor-beta-1 (TGF-beta-1), and the expression of three PGs, viz. biglycan (PGI), decorin (PGII), and versican (a large fibroblast proteoglycan) was examined. The results indicate that TGF-beta-1 (5 ng/ml) markedly increased the expression of biglycan (up to 24-fold) and versican (up to 6-fold) mRNAs and the enhancement of biglycan expression was coordinate with elevated type I procollagen gene expression in the same cultures. In contrast, the expression of decorin mRNA was markedly (up to approximately 70%) inhibited by TGF-beta-1. The response to TGF-beta-1 was similar in both skin and gingival fibroblasts, although the gingival cells were clearly more responsive to stimulation by TGF-beta-1 with respect to biglycan gene expression. Analysis of S-35-labeled proteoglycans in the culture media of skin and gingival fibroblasts also revealed stimulation of biglycan and versican production, and reduction in decorin production. Quantitation of both [S-35]sulfate and [H-3]leucine-labeled decorin in cell culture media by immunoprecipitation revealed a 50% reduction in decorin production in cell cultures treated with TGF-beta-1. This TGF-beta-1-elicited reduction was accompanied by an apparent increase in the size of the decorin molecules, although the size of the core protein was not altered, as judged by Western immunoblotting following chondroitinase ABC digestion. Analysis of the proteoglycans in the matrix and membrane fractions also revealed increased amounts of versican in cultures treated with TGF-beta-1. These results indicate differential regulation of PG gene expression in fibroblasts by TGF-beta-1, and these observations emphasize the role of PGs in the extracellular matrix biology and pathology.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL,DEPT DERMATOL,1020 LOCUST ST, RM M-46 JAH, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON INST MOLEC MED, PHILADELPHIA, PA 19107 USA; UNIV ALABAMA, SCH DENT, DEPT PERIODONT, BIRMINGHAM, AL 35294 USA	Jefferson University; Jefferson University; Jefferson University; University of Alabama System; University of Alabama Birmingham			Kahari, Veli-Matti/T-4925-2019; Kähäri, Veli-Matti/E-5144-2011; Larjava, Hannu/GRO-4325-2022	Kahari, Veli-Matti/0000-0003-2421-9368; Kähäri, Veli-Matti/0000-0003-2421-9368; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035297, P01AR038923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028833] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38923, AR-35297] Funding Source: Medline; NIGMS NIH HHS [GM-28833] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHEN JK, 1987, P NATL ACAD SCI USA, V84, P5287, DOI 10.1073/pnas.84.15.5287; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1985, J BIOL CHEM, V260, P2315; DUNCAN MR, 1989, J INVEST DERMATOL, V92, P699, DOI 10.1111/1523-1747.ep12696891; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; ELIMA K, 1989, FEBS LETT, V258, P195, DOI 10.1016/0014-5793(89)81651-5; FALANGA V, 1987, J INVEST DERMATOL, V89, P100, DOI 10.1111/1523-1747.ep12580445; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GREVE H, 1990, BIOCHEM J, V269, P149, DOI 10.1042/bj2690149; HEINO J, 1988, BIOCHEM J, V252, P309, DOI 10.1042/bj2520309; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KAHARI VM, 1988, J INVEST DERMATOL, V90, P664, DOI 10.1111/1523-1747.ep12560826; KAHARI VM, 1990, ARCH DERMATOL, V126, P613, DOI 10.1001/archderm.126.5.613; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KVENG W, 1989, ANAL BIOCHEM, V182, P16; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LARJAVA H, 1989, J DENT RES, V68, P20, DOI 10.1177/00220345890680010301; LARJAVA H, 1988, BIOCHEM J, V256, P35, DOI 10.1042/bj2560035; LIAU G, 1989, J BIOL CHEM, V264, P10315; LONGAS MO, 1985, CONNECT TISSUE RES, V13, P117, DOI 10.3109/03008208509152390; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; NODA M, 1988, J BIOL CHEM, V263, P13916; NODA M, 1987, J CELL PHYSIOL, V133, P426, DOI 10.1002/jcp.1041330303; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PULKKINEN L, 1990, J BIOL CHEM, V265, P17780; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; Reddi A., 1984, EXTRACELLULAR MATRIX; ROTHE M, 1989, ARCH DERMATOL, V125, P1390, DOI 10.1001/archderm.125.10.1390; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAAMANEN AM, 1989, ARTHRITIS RHEUM-US, V32, P1282, DOI 10.1002/anr.1780321014; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Sambrook J, 1989, MOL CLONING LABORATO; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; TAKAGI M, 1990, J HISTOCHEM CYTOCHEM, V38, P319, DOI 10.1177/38.3.1689334; Uitto J, 1987, CONNECTIVE TISSUE DI; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	52	241	245	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10608	10615						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037600				2022-12-25	WOS:A1991FP08600091
J	KIZAWA, H; TOMURA, D; ODA, M; FUKAMIZU, A; HOSHINO, T; GOTOH, O; YASUI, T; SHOUN, H				KIZAWA, H; TOMURA, D; ODA, M; FUKAMIZU, A; HOSHINO, T; GOTOH, O; YASUI, T; SHOUN, H			NUCLEOTIDE-SEQUENCE OF THE UNIQUE NITRATE NITRITE-INDUCIBLE CYTOCHROME-P-450 CDNA FROM FUSARIUM-OXYSPORUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-CORTEX; AMINO-ACID-SEQUENCES; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; BACILLUS-MEGATERIUM; CODING NUCLEOTIDE; MOLECULAR-CLONING; ESCHERICHIA-COLI; GENE FAMILY; RAT-LIVER	A cDNA clone for the nitrate/nitrite-inducible cytochrome P-450 (P-450) of the fungus Fusarium oxysporum (tentatively termed P-450dNIR) was isolated by an immunoscreening method. Sequence determination revealed a polypeptide of 403 amino acid residues (M(r) = 44,371), which was shown to contain the full-length sequence of the fungal P-450. The amino terminus region of the predicted sequence contained neither the signal-like, hydrophobic domain that is commonly observed in microsomal P-450s nor the tagging prosequence that is essential for localization of mitochondrial P-450s. Further, the sequence exhibited higher homologies against those of soluble bacterial P-450s, in particular P-450s of Streptomyces, rather than those of eukaryotic P-450s including yeast and fungal P-450s. These results are highly indicative that P-450dNIR is the first soluble P-450 derived from eukaryotic organisms. The unique features might be related to the novel function of P-450dNIR, which is involved in a dissimilatory reduction of nitrite by the fungus. P-450dNIR was classified into a new family, P-450LV, and the corresponding gene of the fungus was named CYP55.	UNIV TSUKUBA,INST APPL BIOCHEM,SAKURA,IBARAKI 305,JAPAN; SAITAMA CANC CTR,INA,SAITAMA 362,JAPAN; AGCY IND SCI & TECHNOL,FERMENTAT RES INST,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST)			fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				ATTAR RM, 1989, NUCLEIC ACIDS RES, V17, P7535, DOI 10.1093/nar/17.18.7535; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLACK SD, 1986, CYTOCHROME P450 STRU, P161; BOZAK KR, 1990, P NATL ACAD SCI USA, V87, P3904, DOI 10.1073/pnas.87.10.3904; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; FEYEREISEN R, 1989, P NATL ACAD SCI USA, V86, P1465, DOI 10.1073/pnas.86.5.1465; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; GOTOH O, 1983, J BIOCHEM, V93, P807, DOI 10.1093/jb/93.3.807; GOTOH O, 1982, J MOL BIOL, V162, P705, DOI 10.1016/0022-2836(82)90398-9; GRAHAMLORENCE SE, 1989, CYTOCHROME P-450 : BIOCHEMISTRY AND BIOPHYSICS /, P652; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HANIU M, 1982, J BIOL CHEM, V257, P2657; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HE JS, 1989, BIOCHIM BIOPHYS ACTA, V1009, P301, DOI 10.1016/0167-4781(89)90120-6; HORII M, 1990, J BACTERIOL, V172, P3644, DOI 10.1128/jb.172.7.3644-3653.1990; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; KANEMOTO RH, 1989, J BACTERIOL, V171, P2506, DOI 10.1128/jb.171.5.2506-2512.1989; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lu A., 1980, PHARMACOL REV, V31, P227; MANIATIS T, 1982, MOL CLONING LABORATO, P365; MOROHASHI K, 1984, P NATL ACAD SCI-BIOL, V81, P4647, DOI 10.1073/pnas.81.15.4647; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OMER CA, 1990, J BACTERIOL, V172, P3335, DOI 10.1128/jb.172.6.3335-3345.1990; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGLARD D, 1989, GENE, V76, P121, DOI 10.1016/0378-1119(89)90014-0; SHOUN H, 1983, J BIOCHEM, V94, P1219, DOI 10.1093/oxfordjournals.jbchem.a134467; SHOUN H, 1989, FEBS LETT, V244, P11, DOI 10.1016/0014-5793(89)81151-2; SHOUN H, 1989, AGR BIOL CHEM TOKYO, V53, P2153, DOI 10.1080/00021369.1989.10869624; SHOUN H, 1985, J BIOCHEM, V97, P755, DOI 10.1093/oxfordjournals.jbchem.a135115; SOGAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P5066, DOI 10.1073/pnas.81.16.5066; UNGER BP, 1986, J BIOL CHEM, V261, P1158; VANGORCOM RFM, 1990, MOL GEN GENET, V223, P192, DOI 10.1007/BF00265053; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WEIGEL BJ, 1988, J BACTERIOL, V170, P3817, DOI 10.1128/jb.170.9.3817-3826.1988; YOSHIOKA H, 1986, J BIOL CHEM, V261, P4106; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	43	116	121	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10632	10637						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037602				2022-12-25	WOS:A1991FP08600094
J	BHATTACHARYYA, L; KOENIG, SH; BROWN, RD; BREWER, CF				BHATTACHARYYA, L; KOENIG, SH; BROWN, RD; BREWER, CF			INTERACTIONS OF ASPARAGINE-LINKED CARBOHYDRATES WITH CONCANAVALIN-A - NUCLEAR MAGNETIC-RELAXATION DISPERSION AND CIRCULAR-DICHROISM STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYBRID-TYPE GLYCOPEPTIDES; RESONANCE SPECTROSCOPY; ION BINDING; PROTON; OLIGOSACCHARIDES; GLYCOPROTEIN; TRANSITIONS; AGGLUTININ; MANGANESE; BIVALENCY	By using near-UV circular dichroism (CD) and solvent proton nuclear magnetic relaxation dispersion measurements, three different conformational states have been detected in Ca2+-Mn2+-concanavalin A upon binding a variety of asparagine-linked carbohydrates. Two of these transitions have been described previously, one for the binding of monosaccharides such as methyl alpha-D-mannopyranoside and oligosaccharides with terminal alpha-Glc or alpha-Man residues, and the second for the binding of oligomannose and complex type carbohydrates (Brewer, C. F., and Bhattacharyya, L. (1986) J. Biol. Chem. 261, 7306-7310). The third transition occurs upon binding a bisected biantennary complex type carbohydrate with terminal GlcNAc residues. Temperature-dependent nuclear magnetic relaxation dispersion and CD measurements have identified regions of the protein near the two metal ion binding sites that are associated with the conformation changes, and Tyr-12, which is part of the monosaccharide binding site, as responsible for the CD changes. The results support our previous conclusions that the rotamer conformation of the (alpha-1,6) arm of bisected complex type oligosaccharides binds to concanavalin A with dihedral angle-omega = -60-degrees whereas nonbisected complex type oligosacchardies bind with omega = 180-degrees (Bhattacharyya, L., Haraldsson, M., and Brewer, C. F. (1987) J. Biol. Chem. 262, 1294-1299). The present findings also explain the effects of increasing chain length of bisected complex type carbohydrates on their interactions with the lectin.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT IMMUNOL,BRONX,NY 10461; IBM CORP,THOMAS J WATSON RES CTR,YORKTOWN HTS,NY 10598	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; International Business Machines (IBM)					NATIONAL CANCER INSTITUTE [P30CA013330, R01CA016054] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002309] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA-13330, CA-16054] Funding Source: Medline; NCRR NIH HHS [I-S10-RR02309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGRAWAL BBL, 1965, BIOCHEM J, V96, pC23; ALHADEFF JA, 1989, CRIT REV ONCOL HEMAT, V9, P37, DOI 10.1016/S1040-8428(89)80014-9; ATKINSON PH, 1981, BIOCHEMISTRY-US, V20, P3979, DOI 10.1021/bi00517a006; BHATTACHARYYA L, 1989, EUR J BIOCHEM, V178, P721, DOI 10.1111/j.1432-1033.1989.tb14503.x; BHATTACHARYYA L, 1987, J BIOL CHEM, V262, P1288; BHATTACHARYYA L, 1987, J BIOL CHEM, V262, P1294; BRANDLEY BK, 1986, J LEUKOCYTE BIOL, V40, P97, DOI 10.1002/jlb.40.1.97; BREWER CF, 1986, J BIOL CHEM, V261, P7306; BREWER CF, 1979, BIOCHEMISTRY-US, V18, P2555, DOI 10.1021/bi00579a019; BREWER CF, 1983, BIOCHEMISTRY-US, V22, P3691, DOI 10.1021/bi00284a024; BREWER CF, 1983, J BIOMOL STRUCT DYN, V1, P961, DOI 10.1080/07391102.1983.10507497; BROWN RD, 1977, BIOCHEMISTRY-US, V16, P3883, DOI 10.1021/bi00636a026; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; Koenig S. H., 1987, NMR SPECTROSCOPY CEL, V2, P75; KOENIG SH, 1985, BIOCHEMISTRY-US, V24, P4980, DOI 10.1021/bi00340a003; KOENIG SH, 1973, P NATL ACAD SCI USA, V70, P475, DOI 10.1073/pnas.70.2.475; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIS H, 1978, J BIOL CHEM, V253, P3468; MEIROVITCH E, 1974, J AM CHEM SOC, V96, P7542, DOI 10.1021/ja00831a025; MONSIGNY M, 1984, Biology of the Cell (Paris), V51, P113; NARASIMHAN S, 1985, BIOCHEMISTRY-US, V24, P1694, DOI 10.1021/bi00328a019; PALMER AR, 1980, BIOCHEMISTRY-US, V19, P5063, DOI 10.1021/bi00563a020; PFLUMM MN, 1971, J BIOL CHEM, V246, P4369; REISFELD RA, 1987, ADV IMMUNOL, V40, P323, DOI 10.1016/S0065-2776(08)60242-4; RICHARDSON CE, 1976, J MOL BIOL, V102, P441, DOI 10.1016/0022-2836(76)90326-0; STROSBERG AD, 1986, LECTINS PROPERTIES F, P249; YARIV J, 1968, BIOCHIM BIOPHYS ACTA, V165, P303, DOI 10.1016/0304-4165(68)90063-9; YOUNG NM, 1982, BIOCHIM BIOPHYS ACTA, V701, P142, DOI 10.1016/0167-4838(82)90323-5	32	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9835	9840						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033071				2022-12-25	WOS:A1991FM45900075
J	KAMATH, AV; VAALER, GL; SNELL, EE				KAMATH, AV; VAALER, GL; SNELL, EE			PYRIDOXAL PHOSPHATE-DEPENDENT HISTIDINE DECARBOXYLASES - CLONING, SEQUENCING, AND EXPRESSION OF GENES FROM KLEBSIELLA-PLANTICOLA AND ENTEROBACTER-AEROGENES AND PROPERTIES OF THE OVEREXPRESSED ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PURIFICATION; PROTEINS; MEMBRANE	The hdc genes encoding the inducible pyridoxal-P-dependent histidine decarboxylase (HisDCase) of Klebsiella planticola and Enterobacter aerogenes were isolated, sequenced, and expressed in Escherichia coli under control of the lac promoter, and the overproduced enzymes were purified to homogeneity from the recombinant host. Formation of inclusion bodies during synthesis of the E. aerogenes enzyme was avoided by cooling the culture and inducing at 25-degrees-C. The cloned enzymes were produced in amounts three to four times those present in the fully induced native hosts and were identical in properties to those isolated earlier (Guirard, B. M., and Snell, E. E. (1987) J. Bacteriol. 169, 3963-3968). The two enzymes showed 85% sequence identity and also showed 80% sequence identity with the previously sequenced (Vaaler, G. L., Brasch, M. A., and Snell, E. E. (1986) J. Biol. Chem. 261, 11010-11014) HisDCase of Morganella morganii. Nevertheless, antibodies to the M. morganii HisDCase do not cross-react with these enzymes suggesting that the regions of amino acid variations are located on the outer surface of the proteins. All three HisDCases are the same length (377 amino acid residues); encoded N-terminal methionine was completely removed in each case. These closely related pyridoxal-P enzymes show no sequence homology with the pyruvoyl-dependent HisDCases of Gram-positive bacteria.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712; UNIV TEXAS,DEPT CHEM,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CARLSON J, 1984, J BIOTECHNOL, V1, P253, DOI 10.1016/0168-1656(84)90017-8; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GATTI R A, 1984, Biotechniques, V2, P148; GUIRARD BM, 1987, J BACTERIOL, V169, P3963, DOI 10.1128/jb.169.9.3963-3968.1987; JOSEPH DR, 1990, P NATL ACAD SCI USA, V87, P733, DOI 10.1073/pnas.87.2.733; Krieg NR, 1984, BERGEYS MANUAL SYSTE, V1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHMOOD R, 1990, J BIOL CHEM, V265, P4652; Maniatis T., 1982, MOL CLONING; MILL JH, 1972, EXPT MOL GENETICS; NAIK SM, 1990, P NATL ACAD SCI USA, V87, P2618, DOI 10.1073/pnas.87.7.2618; NAKAMURA K, 1979, J BACTERIOL, V137, P595, DOI 10.1128/JB.137.1.595-604.1979; TAGUCHI Y, 1984, J BIOL CHEM, V259, P5214; VAALER GL, 1986, J BIOL CHEM, V261, P1010; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; VANPOELJE PD, 1990, BIOCHEMISTRY-US, V29, P132, DOI 10.1021/bi00453a016; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WADA H, 1961, J BIOL CHEM, V236, P2089	22	41	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9432	9437						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033044				2022-12-25	WOS:A1991FM45900018
J	CARRAWAY, KL; CERIONE, RA				CARRAWAY, KL; CERIONE, RA			COMPARISON OF EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR-RECEPTOR INTERACTIONS IN INTACT A431 CELLS AND ISOLATED PLASMA-MEMBRANES - LARGE-SCALE RECEPTOR MICRO-AGGREGATION IS NOT DETECTED DURING EGF-STIMULATED EARLY EVENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; TYROSINE PROTEIN-KINASE; SIGNAL TRANSDUCTION; CROSS-LINKING; DIRECT VISUALIZATION; MOLECULAR-WEIGHT; CARCINOMA-CELLS; BINDING-SITE; ACTIVATION; PHOSPHORYLATION	We have used resonance energy transfer to monitor epidermal growth factor (EGF) receptor micro-aggregation at the surface of intact human epidermoid carcinoma (A431) cells. EGF molecules labeled with fluorescein isothiocyanate and eosin isothiocyanate were demonstrated to bind tightly to cellsurface receptors, to elicit immediate changes in cytosolic free [Ca2+], and to undergo endocytosis. Under conditions which maintain the integrity of the cell, we observed no energy transfer between the donor fluorescein isothiocyanate-labeled EGF molecules and the acceptor eosin isothiocyanate-labeled growth factors bound to receptors. However, after disruption of cells by Dounce homogenization, a significant degree of energy transfer was observed (approximately 10-20%) with membranes, indicative of receptor aggregation. These results suggest that EGF does not cause micro-aggregation of the majority of its receptors on the surface of intact A431 cells within the time period of the early events associated with growth factor action. Moreover, it appears that the A431 cells contain some component which imparts a constraint on the ability of EGF receptors to aggregate, and that some of this component is lost upon the disruption of cells.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University	CARRAWAY, KL (corresponding author), CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM40654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU M, 1986, J BIOL CHEM, V261, P2879; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; CARRAWAY KL, 1990, BIOCHEMISTRY-US, V29, P8741, DOI 10.1021/bi00489a034; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COCHET C, 1988, J BIOL CHEM, V263, P3290; FANGER BO, 1989, FASEB J, V3, P71, DOI 10.1096/fasebj.3.1.2783412; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P6414, DOI 10.1021/bi00369a011; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HART MJ, 1990, J BIOL CHEM, V265, P5990; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; KOLAND JG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P489, DOI 10.1016/0167-4889(90)90160-F; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NORTHWOOD IC, 1989, J BIOL CHEM, V264, P5746; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; ROTHENBERG P, 1983, J BIOL CHEM, V258, P2644; SAWYER ST, 1981, BIOCHEMISTRY-US, V20, P6280, DOI 10.1021/bi00524a057; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBELZEN N, 1988, J CELL PHYSIOL, V134, P413, DOI 10.1002/jcp.1041340312; WAHL M, 1988, J BIOL CHEM, V263, P7581; WHEELER LA, 1987, J BIOL CHEM, V262, P6531; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	33	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8899	8906						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026602				2022-12-25	WOS:A1991FM03800040
J	MIYATA, Y; YAHARA, I				MIYATA, Y; YAHARA, I			CYTOPLASMIC-8-S GLUCOCORTICOID RECEPTOR BINDS TO ACTIN-FILAMENTS THROUGH THE 90-KDA HEAT-SHOCK PROTEIN MOIETY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; REGULATED EIF-2-ALPHA KINASE; THYROID-HORMONE RECEPTOR; TRANSFORMING PROTEIN; PROGESTERONE-RECEPTOR; STEROID-RECEPTORS; NUCLEAR RECEPTORS; RETINOIC ACID; MR 90,000; MOLYBDATE	The glucocorticoid receptor exists in the cytoplasm of hormone-untreated cells as a complex with the 90-kDa heat shock protein (HSP90). Glucocorticoids induce dissociation of the glucocorticoid binding protein from HSP90 and translocation of the receptor to the nucleus. HSP90 binds to actin filaments, and calmodulin or tropomyosin inhibits the binding. We present here evidence that the HSP90-containing glucocorticoid receptor complexes (8 S receptor) bind to filamentous actin in vitro while the HSP90-free form of the receptor does not. The binding was detectable for both the crude cytosolic fractions and the partially purified 8 S glucocorticoid receptor. Purified HSP90 or tropomyosin completely abolished the binding. Calmodulin also inhibited the binding in a Ca2+-dependent manner. From these results, we conclude that the glucocorticoid receptor complex is able to bind actin filaments via the HSP90 moiety. The binding may provide an anchoring mechanism for the glucocorticoid receptor in the cytoplasm.	TOKYO METROPOLITAN INST MED SCI,DEPT CELL BIOL,3-18-22 HON KOMAGOME,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science			Miyata, Y/X-7111-2019					BRESNICK EH, 1989, J BIOL CHEM, V264, P492; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; DAHMER MK, 1984, ANNU REV PHYSIOL, V46, P67; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DENIS M, 1989, CANCER RES, V49, pS2275; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENIS M, 1987, J BIOL CHEM, V262, P11803; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HOLBROOK NJ, 1983, J BIOL CHEM, V258, P6477; HOUSLEY PR, 1985, J BIOL CHEM, V260, P3810; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; NISHIDA E, 1979, J BIOCHEM, V85, P1257; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; OKRET S, 1985, BIOCHEMISTRY-US, V24, P6581, DOI 10.1021/bi00344a041; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PASCUAL A, 1982, J BIOL CHEM, V257, P9640; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PICARD D, 1987, EMBO J, V6, P333; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1989, CANCER RES, V49, pS2222; RAFESTINOBLIN ME, 1989, J BIOL CHEM, V264, P9304; REDEUILH G, 1987, J BIOL CHEM, V262, P6969; RENOIR JM, 1990, J BIOL CHEM, V265, P14402; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRELOW FWE, 1967, ANAL CHEM, V39, P595, DOI 10.1021/ac60250a009; VEDECKIS WV, 1983, BIOCHEMISTRY-US, V22, P1983, DOI 10.1021/bi00277a038; WIKSTROM AC, 1987, ENDOCRINOLOGY, V120, P1232, DOI 10.1210/endo-120-4-1232; YAHARA I, 1986, CELL STRUCT FUNCT, V11, P65, DOI 10.1247/csf.11.65; YONEZAWA N, 1988, EUR J BIOCHEM, V177, P1, DOI 10.1111/j.1432-1033.1988.tb14337.x	44	96	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8779	8783						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026594				2022-12-25	WOS:A1991FM03800025
J	NOVELLI, A; BOULANGER, PA				NOVELLI, A; BOULANGER, PA			ASSEMBLY OF ADENOVIRUS TYPE-2 FIBER SYNTHESIZED IN CELL-FREE TRANSLATION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; TEMPERATURE-SENSITIVE MUTANT; HEAT-SHOCK PROTEINS; INTRACELLULAR-TRANSPORT; MOLECULAR CHAPERONES; STRUCTURAL PROTEINS; CAPSID PROTEINS; PENTON BASE; MORPHOGENESIS; TRIMERIZATION	Physicochemical and functional analyses of the translation products of fiber mRNA in rabbit reticulocyte lysate suggested that fiber polypeptide chains (monomers) were capable of self-assembling in vitro, forming trimeric fibers (trimers) without direct intervention of any other adenovirus-coded protein or cell nuclear matrix component. Kinetic studies showed that trimer formation occurred at a rate six times lower than that of fiber polypeptide synthesis. Fiber assembly was found to be relatively inefficient in vitro, with only 25-30% fiber polypeptides trimerized after 4-h translation reaction. The rate constant for fiber subunit assembly, extrapolated from the kinetic curves of trimer formation, was found to be in the order of magnitude of 10(5) M-1 s-1, with a t1/2 of 1.3 h at 30-degrees-C. A latence phase of approximately 40 min in the appearance of the first detectable trimers indicated that fiber assembly did not occur co-translationally, suggesting the existence of rate-limiting intermediate step(s) during assembly.	FAC MED MONTPELLIER,VIROL & PATHOGENESE MOLEC LAB,BLVD HENRI IV,F-34060 MONTPELLIER,FRANCE	Universite de Montpellier				Novelli Rousseau, Armelle/0000-0003-1407-3895				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOUDIN ML, 1983, EMBO J, V2, P1921, DOI 10.1002/j.1460-2075.1983.tb01680.x; BOUDIN ML, 1982, VIROLOGY, V116, P589, DOI 10.1016/0042-6822(82)90151-9; BOUDIN ML, 1979, VIROLOGY, V92, P125, DOI 10.1016/0042-6822(79)90219-8; BOULANGER P, 1983, BIOCHEM BIOPH RES CO, V110, P913, DOI 10.1016/0006-291X(83)91049-5; CAILLETBOUDIN ML, 1988, ANN INST PASTEUR VIR, V139, P141, DOI 10.1016/S0769-2617(88)80013-3; CAILLETBOUDIN ML, 1989, EUR J BIOCHEM, V184, P205, DOI 10.1111/j.1432-1033.1989.tb15008.x; CAILLETBOUDIN ML, 1991, J MOL BIOL, V217, P477, DOI 10.1016/0022-2836(91)90751-Q; CEPKO CL, 1982, CELL, V31, P407, DOI 10.1016/0092-8674(82)90134-9; CHATELLARD C, 1989, GENE, V81, P267, DOI 10.1016/0378-1119(89)90187-X; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; DEVAUX C, 1987, VIROLOGY, V161, P121, DOI 10.1016/0042-6822(87)90177-2; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; DHALLUIN JC, 1980, J VIROL, V33, P88, DOI 10.1128/JVI.33.1.88-99.1980; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; ISHIBASHI M, 1974, VIROLOGY, V58, P345, DOI 10.1016/0042-6822(74)90070-1; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAY P, 1980, ANN INST PASTEUR VIR, V131, P259, DOI 10.1016/S0769-2617(80)80001-3; MACEJAK DG, 1991, VIROLOGY, V180, P120, DOI 10.1016/0042-6822(91)90015-4; Maniatis T., 1982, MOL CLONING; MARTIN JC, 1978, J GEN VIROL, V41, P303; MORIN N, 1986, VIROLOGY, V152, P11, DOI 10.1016/0042-6822(86)90367-3; MORIN N, 1984, VIROLOGY, V136, P153, DOI 10.1016/0042-6822(84)90256-3; NERMUT MV, 1984, ADENOVIRUSES, P5; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PETTERSSON U, 1984, ADENOVIRUSES, P205; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SUNDQUIST B, 1973, VIROLOGY, V51, P252, DOI 10.1016/0042-6822(73)90389-9; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; VELICER LF, 1970, J VIROL, V5, P338, DOI 10.1128/JVI.5.3.338-352.1970; WEBER JM, 1989, VIROLOGY, V168, P180, DOI 10.1016/0042-6822(89)90419-4; WEBER JM, 1985, VIROLOGY, V140, P351, DOI 10.1016/0042-6822(85)90371-X; WILHELM JM, 1972, J VIROL, V9, P973, DOI 10.1128/JVI.9.6.973-980.1972; YEWDELL JW, 1988, CELL, V52, P843, DOI 10.1016/0092-8674(88)90426-6; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	43	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9299	9303						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026627				2022-12-25	WOS:A1991FM03800095
J	CHURCH, WR; OUELLETTE, LA; MESSIER, TL				CHURCH, WR; OUELLETTE, LA; MESSIER, TL			MODULATION OF HUMAN PROTHROMBIN ACTIVATION ON PHOSPHOLIPID-VESICLES AND PLATELETS USING MONOCLONAL-ANTIBODIES TO PROTHROMBIN FRAGMENT-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATION-SPECIFIC ANTIBODIES; CLOTTING FACTOR-V; BOVINE PROTHROMBIN; FACTOR-X; HUMAN-PLASMINOGEN; ALPHA-THROMBIN; BINDING SITE; HEAVY-CHAIN; PROTEIN-C; AFFINITY	Prothrombin contains two kringle domains that are removed during activation to the blood clotting enzyme alpha-thrombin. By analogy with other kringle-containing proteins the prothrombin kringles may play a role in the protein-protein interactions necessary for prothrombin activation. Four monoclonal antibodies to prothrombin kringle 2 have been produced against human prothrombin, and a fifth monoclonal antibody was produced against a synthetic peptide consisting of amino acid residues 216-231 of kringle 2. Each antibody was tested for its ability to block prothrombin activation by factor Xa. In the presence of phosphatidylcholine/phosphatidylserine vesicles and factor Va, two of the antibodies, alpha-HII-3 and alpha-HII-4, inhibited prothrombin activation at a 90 and 50% level, respectively. Two other monoclonal antibodies (alpha-HII-6 and alpha-HII-7) and the antipeptide antibody (alpha-HII-5) had no effect on prothrombin activation. When factor Xa was the catalyst alone, antibody alpha-HII-3 lost the ability to inhibit prothrombin activation whereas antibody alpha-HII-4 again partially inhibited the reaction. When human platelets were the reaction surface, the patterns of inhibition by the anti-fragment 2 antibodies were identical to that observed with phospholipid vesicles. These data suggest a role for prothrombin fragment 2 in activation, possibly by mediating the interaction of substrate prothrombin with factor Xa or factor Va on the phospholipid surface.			CHURCH, WR (corresponding author), UNIV VERMONT,DEPT BIOCHEM,BURLINGTON,VT 05405, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL035058, R29HL040467] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35058, HL-40467] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; BUTKOWSKI RJ, 1977, J BIOL CHEM, V252, P4942; CHURCH WR, 1985, THROMB RES, V38, P417, DOI 10.1016/0049-3848(85)90140-9; CHURCH WR, 1983, P NATL ACAD SCI-BIOL, V80, P255, DOI 10.1073/pnas.80.1.255; CHURCH WR, 1988, HYBRIDOMA, V7, P471, DOI 10.1089/hyb.1988.7.471; CHURCH WR, 1988, BLOOD, V72, P1911; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; CHURCH WR, 1988, J BIOL CHEM, V263, P6359; COX AC, 1970, BIOCHIM BIOPHYS ACTA, V207, P49; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1973, BIOCHIM BIOPHYS ACTA, V310, P289, DOI 10.1016/0005-2795(73)90034-2; EY PC, 1990, IMMUNOCHEMISTRY, V5, P429; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FURIE B, 1979, J BIOL CHEM, V254, P9766; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU HK, 1979, J BIOL CHEM, V254, P8751; LAU HKF, 1989, BIOCHIM BIOPHYS ACTA, V996, P95, DOI 10.1016/0167-4838(89)90100-3; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; Lundblad R L, 1976, Methods Enzymol, V45, P156; MADAR DA, 1980, J BIOL CHEM, V255, P8599; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1980, METAL ION PHOSPHOLIP, P3; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NESHEIM ME, 1988, J BIOL CHEM, V263, P1037; OWENS J, 1984, J BIOL CHEM, V259, P3800; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; RABIET MJ, 1986, J BIOL CHEM, V261, P3210; STENFLO J, 1973, BIOCHEM BIOPH RES CO, V50, P98, DOI 10.1016/0006-291X(73)91069-3; TAI MM, 1984, J BIOL CHEM, V259, P4162; TRACY PB, 1986, PLATELET RESPONSES M, P297; TUCKER MM, 1983, J BIOL CHEM, V258, P1210; VALI Z, 1984, J BIOL CHEM, V259, P3690	48	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8384	8391						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022654				2022-12-25	WOS:A1991FK44100066
J	YOON, SH; YU, HL; EBER, S; PRCHAL, JT				YOON, SH; YU, HL; EBER, S; PRCHAL, JT			MOLECULAR DEFECT OF TRUNCATED BETA-SPECTRIN ASSOCIATED WITH HEREDITARY ELLIPTOCYTOSIS - BETA-SPECTRIN GOTTINGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; MEMBRANE SKELETON; SPLICE JUNCTION; CHAIN; THALASSEMIA; VARIANT; RNA; MUTATION; CDNA	A large German family with autosomal dominantly inherited elliptocytosis, associated with truncated beta-spectrin missing the phosphorylated C-terminal peptide, has been described (Eber, S. W., Morris, S. A., Schroeter, W., and Gratzer, W. B. (1988) J. Clin. Invest. 81, 523-530). We have attempted to delineate the molecular defect of this abnormality at the gene level. Southern blot analyses revealed no evidence of a partial gene deletion or rearrangement. We used polymerase chain reaction (PCR) and amplified several relevant portions of the beta-spectrin gene, using genomic DNA from two different heterozygous patients. No abnormality was found in the last four exons of the beta-spectrin gene produced by PCR. Examination of the introns connecting the last four exons revealed a T to A substitution in the 5' splice site following the exon X in four of eight clones prepared from two affected individuals, but not from a normal subject of this family. To examine the effect of the T to A substitution in these patients, we made cDNA from the reticulocyte mRNA of the patient and examined its composition by PCR. Two distinct PCR fragments produced from the patient's beta-spectrin cDNA were found. One matched the predicted size for normal spectrin, while the other was 197 base pairs shorter. The mutant cDNA sequence revealed that the entire exon preceding the T to A substitution was spliced out, while the two terminal exons were preserved. The deletion of this exon resulted in a frameshift giving a different terminal amino acid (serine instead of leucine) as well as a new termination codon causing a deletion of 129 amino acids including potentially phosphorylated residues.	UNIV ALABAMA,DEPT OPHTHALMOL,DIV HEMATOL,1900 UNIV BLVD,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35294; UNIV GOTTINGEN,W-3400 GOTTINGEN,GERMANY	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Gottingen					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037462] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1990, NEW ENGL J MED, V323, P1530; BAIRD M, 1981, P NATL ACAD SCI-BIOL, V78, P4218, DOI 10.1073/pnas.78.7.4218; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BUSSLINGER M, 1981, CELL, V27, P289, DOI 10.1016/0092-8674(81)90412-8; COETZER T, 1982, BLOOD, V59, P900; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; DHERMY D, 1982, J CLIN INVEST, V70, P707, DOI 10.1172/JCI110666; EBER SW, 1988, J CLIN INVEST, V81, P523, DOI 10.1172/JCI113350; GALLAGHER P, 1990, CLIN RES, V38, pA266; GALLAGHER PG, 1990, BLOOD S, V76, pA8; HARRIS HW, 1980, J BIOL CHEM, V255, P1512; KISHIMOTO TK, 1989, J BIOL CHEM, V264, P3588; KNOWLES W, 1983, SEMIN HEMATOL, V20, P159; LIU SC, 1982, P NATL ACAD SCI-BIOL, V79, P2072, DOI 10.1073/pnas.79.6.2072; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; MARCHESI VT, 1983, BLOOD, V61, P1; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OHANIAN V, 1985, BRIT J HAEMATOL, V61, P31, DOI 10.1111/j.1365-2141.1985.tb04057.x; PALEK J, 1990, SEMIN HEMATOL, V27, P290; POTHIER B, 1987, BLOOD, V69, P1759; PRCHAL JT, 1987, P NATL ACAD SCI USA, V84, P7468, DOI 10.1073/pnas.84.21.7468; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SORGE J, 1990, J CLIN INVEST, V86, P1137, DOI 10.1172/JCI114818; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; VOGEL F, 1986, HUM GENET, P394; WEIL D, 1988, J BIOL CHEM, V263, P8561; WERNER D, 1984, ANAL BIOCHEM, V141, P329, DOI 10.1016/0003-2697(84)90050-2; WINKELMANN JC, 1988, BLOOD, V72, P328; YOON SH, 1990, GENE, V91, P297, DOI 10.1016/0378-1119(90)90104-Y; YU H, 1990, BLOOD S, V76, pA51; [No title captured]	33	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8490	8494						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022662				2022-12-25	WOS:A1991FK44100080
J	CONAWAY, JW; HANLEY, JP; GARRETT, KP; CONAWAY, RC				CONAWAY, JW; HANLEY, JP; GARRETT, KP; CONAWAY, RC			TRANSCRIPTION INITIATED BY RNA POLYMERASE-II AND TRANSCRIPTION FACTORS FROM LIVER - STRUCTURE AND ACTION OF TRANSCRIPTION FACTOR-EPSILON AND FACTOR-TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; TATA-BOX; BINDING-PROTEIN; ACCURATE TRANSCRIPTION; FUNCTIONAL-ANALYSIS; UPSTREAM ELEMENT; RAT-LIVER; GENE; PURIFICATION; COMPLEXES	We have fractionated rat liver and identified a set of transcription factors that are essential for accurate initiation by RNA polymerase II. These factors were resolved into five distinct enzyme fractions designated alpha, beta-gamma, delta, epsilon, and tau. Four of these fractions can now be replaced with purified proteins. Alpha and beta-gamma were previously purified to apparent homogeneity (Conaway, J. W., and Conaway, R. C. (1989) J. Biol. Chem. 264, 2357-2362). Here, we report purification to near homogeneity of transcription factor-epsilon. Epsilon has a native molecular mass of approximately 90 kDa and is composed of 34- and 58-kDa polypeptides. Both the 34- and 58-kDa polypeptides are required for runoff transcription. In addition, we show that transcription factor-tau is a rat liver homologue of the TATA factor (TFIID or BTF1) that can be efficiently replaced in transcription in vitro by recombinant yeast TFIID. Comparison of the two factors reveals, however, that they differ significantly in their abilities to direct the transcription system to discriminate between promoters of different sequences.			CONAWAY, JW (corresponding author), OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104, USA.			Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CARTHEW RW, 1988, J BIOL CHEM, V263, P17128; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHAMPOUX JJ, 1976, BIOCHEMISTRY-US, V15, P4638, DOI 10.1021/bi00666a014; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1990, J BIOL CHEM, V265, P5629; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KAWAGUCHI T, 1990, P NATL ACAD SCI USA, V87, P6619, DOI 10.1073/pnas.87.17.6619; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MATTOCCIA E, 1976, P NATL ACAD SCI USA, V73, P4551, DOI 10.1073/pnas.73.12.4551; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAPPAPORT J, 1987, J BIOL CHEM, V262, P17510; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	56	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7804	7811						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019603				2022-12-25	WOS:A1991FJ34200077
J	LEEBLUNDBERG, LMF; SONG, XH				LEEBLUNDBERG, LMF; SONG, XH			BRADYKININ AND BOMBESIN RAPIDLY STIMULATE TYROSINE PHOSPHORYLATION OF A 120-KDA GROUP OF PROTEINS IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; HUMAN-FIBROBLASTS; DNA-SYNTHESIS; KINASE-C; PHOSPHOLIPASE-C; 2ND MESSENGER; RECEPTOR; GROWTH; ACTIVATION; VASOPRESSIN	We have examined the effect of bradykinin (BK) and other peptide mediators with related cellular actions on tyrosine phosphorylation in confluent Swiss 3T3 fibroblast cells using an anti-phosphotyrosine antibody. Immunoblots of extracts from cells stimulated with BK showed a major heterogeneous band centered at M(r) 120,000. Three phosphorylated protein species were present within this band. The lower of these three phosphoproteins was occasionally present under basal conditions. The detection of this group of phosphoproteins by the antibody was prevented by coincubation with an excess of phosphotyrosine but not with an excess of phosphoserine or phosphothreonine. The BK-promoted increase in phosphorylation was rapid and transient with the peak response apparent following BK exposure for 1 min. The response was dose-dependent with half-maximal effect occurring at 10-30 nM BK. The antagonist Arg0, Hyp3, Thi5,8, D-Phe7-BK completely inhibited the response indicating that BK was acting via a B2 kinin receptor. Bombesin, at 0.1-mu-M, stimulated an increase in phosphorylation of the 120-kDa group of proteins with the same efficacy as 0.1-mu-M BK. On the other hand, 1-mu-M vasopressin was considerably less efficaceous than either of the former agonists. Short-term preexposure to 0.1-mu-M 12-O-tetradecanoyl-phorbol-13-acetate (1 min), a protein kinase C stimulator, or 30-mu-M H7 (15 min), a protein kinase C inhibitor, had no significant effect either on the basal or BK-promoted increase in tyrosine phosphorylation of these proteins. BK also stimulated inositol phosphate formation in these cells. Genistein, a tyrosine kinase inhibitor, inhibited BK stimulation of tyrosine phosphorylation. In addition, genistein partially inhibited BK stimulation of inositol phosphate formation. These results show that an increase in tyrosine phosphorylation of a 120-kDa group of proteins is an early protein kinase C-independent cellular signal elicited by both bradykinin and bombesin.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041659, R29GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CAHILL AL, 1989, NEUROSCIENCE, V30, P811, DOI 10.1016/0306-4522(89)90172-3; CIRILLO DM, 1986, MOL CELL BIOL, V6, P4641, DOI 10.1128/MCB.6.12.4641; DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P795, DOI 10.1016/S0006-291X(89)80036-1; DEMOLLE D, 1988, J BIOL CHEM, V263, P18459; DHAR A, 1990, MOL PHARMACOL, V37, P519; GOLDSTEIN RH, 1984, J BIOL CHEM, V259, P9263; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; HOUCHI H, 1990, MOL PHARMACOL, V37, P104; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ISACKE CM, 1986, EMBO J, V5, P2889, DOI 10.1002/j.1460-2075.1986.tb04584.x; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; JUNE CH, 1990, J IMMUNOL, V144, P1591; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1980, PHARMACOL REV, V32, P1; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROBERTS RA, 1989, J CELL SCI, V94, P527; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; VAVREK RJ, 1985, PEPTIDES, V6, P161, DOI 10.1016/0196-9781(85)90033-6; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	37	125	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7746	7749						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019598				2022-12-25	WOS:A1991FJ34200068
J	LUGEMWA, FN; ESKO, JD				LUGEMWA, FN; ESKO, JD			ESTRADIOL BETA-D-XYLOSIDE, AN EFFICIENT PRIMER FOR HEPARAN-SULFATE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EMBRYONIC-CHICKEN CARTILAGE; CHONDROITIN SULFATE; ENDOTHELIAL-CELLS; GLYCOSAMINOGLYCAN BIOSYNTHESIS; D-GALACTOSIDES; PROTEOGLYCAN; CULTURES; MUTANTS; STIMULATION; FIBROBLASTS	Animal cells utilize beta-D-xylosides as primers for glycosaminoglycan synthesis. However, most xylosides preferentially stimulate chondroitin sulfate synthesis and only weakly prime heparan sulfate synthesis. To test if the structure of the aglycone determines the type of glycosaminoglycan made, the priming activity of methyl, n-octyl, p-nitrophenyl, 4-methylumbelliferyl, trans,trans-farnesyl, cholesteryl, and estradiol beta-D-xylosides was compared. Their potency was tested in pgsA-745 cells, a Chinese hamster ovary cell mutant unable to initiate glycosaminoglycan synthesis due to a defect in xylosyltransferase. All of the xylosides stimulated chondroitin sulfate synthesis in the mutant, but only estradiol beta-D-xyloside primed heparan sulfate synthesis efficiently. When incubated with 30-mu-M estradiol beta-D-xyloside, mutant cells made about 3-fold more glycosaminoglycan than untreated wild-type cells and as much as 50% was heparan sulfate. Estradiol beta-D-xyloside also induced heparan sulfate synthesis in cycloheximide-treated wild-type Chinese hamster ovary cells, bovine aortic endothelial cells, baby hamster kidney cells, and Balb/c 3T3 fibroblasts. In addition to stimulating heparan sulfate synthesis, low concentrations of estradiol beta-D-xyloside inhibited the formation of endogenous heparan sulfate proteoglycans.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER; NCI NIH HHS [CA46464] Funding Source: Medline; NIGMS NIH HHS [GM33063] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAME KJ, 1989, J BIOL CHEM, V264, P8059; BARCZAIMARTOS M, 1950, NATURE, V165, P369, DOI 10.1038/165369a0; Dale JK, 1915, J AM CHEM SOC, V37, P2745, DOI 10.1021/ja02177a022; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FARACH MC, 1988, BIOL REPROD, V39, P443, DOI 10.1095/biolreprod39.2.443; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; GORDON PB, 1986, CARBOHYD RES, V151, P121, DOI 10.1016/S0008-6215(00)90334-3; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; HOPWOOD JJ, 1977, J BIOL CHEM, V252, P4777; IOZZO RV, 1989, ARCH BIOCHEM BIOPHYS, V269, P239, DOI 10.1016/0003-9861(89)90105-7; JOHNSTON LS, 1979, J BIOL CHEM, V254, P2575; KARLINSKY JB, 1989, J LAB CLIN MED, V114, P176; KJELLEN L, 1991, IN PRESS ANN REV BIO, V60; Koenigs W, 1901, BER DTSCH CHEM GES, V34, P957, DOI 10.1002/cber.190103401162; KOLSET SO, 1990, BIOCHEM J, V265, P637, DOI 10.1042/bj2650637; LEDBETTER SR, 1986, ARCH BIOCHEM BIOPHYS, V246, P403, DOI 10.1016/0003-9861(86)90486-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEVO Z, 1984, CONNECT TISSUE RES, V13, P45, DOI 10.3109/03008208409152142; NUWAYHID N, 1986, J BIOL CHEM, V261; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; PATTERSON MS, 1965, ANAL CHEM, V37, P854, DOI 10.1021/ac60226a017; PLATT JL, 1987, DEV BIOL, V123, P293, DOI 10.1016/0012-1606(87)90388-5; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROBINSON HC, 1981, BIOCHEM J, V194, P575, DOI 10.1042/bj1940575; ROBINSON J, 1984, J BIOL CHEM, V259, P3818; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; SHIMADA K, 1987, ARTERIOSCLEROSIS, V7, P627, DOI 10.1161/01.ATV.7.6.627; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; SPOONCER E, 1983, J CELL BIOL, V96, P510, DOI 10.1083/jcb.96.2.510; STEVENS RL, 1982, J BIOL CHEM, V257, P253; SUDHAKARAN PR, 1981, H-S Z PHYSIOL CHEM, V362, P39, DOI 10.1515/bchm2.1981.362.1.39; SUZUKI S, 1972, METHODS ENZYMOL    B, V28, P911	38	109	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6674	6677						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016281				2022-12-25	WOS:A1991FG72700005
J	SWACK, JA; MIER, JW; ROMAIN, PL; HULL, SR; RUDD, CE				SWACK, JA; MIER, JW; ROMAIN, PL; HULL, SR; RUDD, CE			BIOSYNTHESIS AND POSTTRANSLATIONAL MODIFICATION OF CD6, A T-CELL SIGNAL-TRANSDUCING MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-RECEPTOR COMPLEX; HUMAN LYMPHOCYTES-T; HUMAN INTERLEUKIN-2 RECEPTOR; RAT MAMMARY ADENOCARCINOMA; PROTEIN KINASE-C; MONOCLONAL-ANTIBODIES; MEMBRANE-PROTEINS; CROSS-LINKING; ACTIVATION; PHOSPHORYLATION	CD6 (T12) is a 130-kDa glycoprotein present on the surface of human T cells. Previously, we demonstrated that the anti-T12 and anti-2H1 monoclonal antibodies recognized different epitopes on CD6, and both were capable of transducing activation signals to T cells. Anti-T12 augmented suboptimal signaling via the TCR/CD3 complex and directly activated separated CD4+ but not CD8+ cells. Structural characterization of CD6 revealed that it contained intrachain disulfide bonds, was N-glycosylated, and in activated cells was phosphorylated on serine. Given the functional significance of CD6 and its involvement in signaling via CD3 and CD2 pathways, we examined in detail the biosynthesis, structural characteristics, and phosphorylation properties of this receptor-like molecule. These studies demonstrate that the nascent CD6 polypeptide on both T cells and thymocytes is 88 kDa, and the immature N-glycosylated form is 110 kDa. After maturation of N-linked glycan and addition of sulfated O-linked oligosaccharide, CD6 appears on the cell surface as a molecule of 130 kDa. CD6 is phosphorylated in resting cells and can be hyperphosphorylated when stimulated by phorbol 12-myristate 13-acetate, indicating that it may participate in the major common signaling pathway mediated through protein kinase C. Concanavalin A-activated cells are phosphorylated at an additional site(s) on the molecule and cannot be hyperphosphorylated with phorbol 12-myristate 13-acetate. These physical features reveal additional clues about the physiological role of CD6 and its mechanism of signal transduction and strongly suggest that CD6 represents a physiologically important membrane receptor involved in T cell activation.	NEW ENGLAND MED CTR HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111; UNIV MASSACHUSETTS,MED CTR,DIV RHEUMATOL & IMMUNOL,WORCESTER,MA 01655; UNIV MIAMI,SCH MED,DEPT ANAT & CELL BIOL,MIAMI,FL 33101; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHOL,DIV TUMOR IMMUNOL,BOSTON,MA 02115	Tufts Medical Center; Tufts University; University of Massachusetts System; University of Massachusetts Worcester; University of Miami; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022	Rudd, Christopher E/0000-0001-5295-9019	NCI NIH HHS [CA43590, CA08248] Funding Source: Medline; NIAMS NIH HHS [AR01590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; ANDERSON P, 1987, J IMMUNOL, V139, P678; BLUE ML, 1987, J IMMUNOL, V139, P3949; BREITMEYER JB, 1987, J IMMUNOL, V139, P2899; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; CHATILA TA, 1988, J IMMUNOL, V140, P4308; CLARK EA, 1986, IMMUNOL TODAY, V7, P267, DOI 10.1016/0167-5699(86)90008-3; COOPER JA, 1983, CURR TOP MICROBIOL, V107, P125; DO SI, 1990, J BIOL CHEM, V265, P114; DUTT A, 1990, J BIOL CHEM, V265, P430; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; FEUERSTEIN N, 1985, BIOCHEM BIOPH RES CO, V126, P206, DOI 10.1016/0006-291X(85)90592-3; FOX DA, 1985, J IMMUNOL, V134, P330; GANGEMI RMR, 1988, J IMMUNOL, V143, P2439; GILBERT CW, 1988, J IMMUNOL, V140, P2821; GREENE WC, 1986, ANNU REV IMMUNOL, V4, P69, DOI 10.1146/annurev.iy.04.040186.000441; HERCEND T, 1983, NATURE, V301, P158, DOI 10.1038/301158a0; HIYAMA K, 1975, J BIOL CHEM, V250, P1824; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; HUBBARD AL, 1976, BIOCH ANAL MEMBRANES, P427; HULL SR, 1989, J CELL BIOCHEM, V40, P67, DOI 10.1002/jcb.240400108; HULL SR, 1984, J BIOL CHEM, V259, P4866; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; JALKANEN S, 1988, J IMMUNOL, V141, P1615; KAMOUN M, 1981, J IMMUNOL, V127, P987; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KOZARSKY KF, 1988, MOL CELL BIOL, V8, P3357, DOI 10.1128/MCB.8.8.3357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; LEDERMAN S, 1989, J IMMUNOL, V143, P1149; LEONARD WJ, 1985, J BIOL CHEM, V260, P1872; Linker A., 1972, METHODS ENZYMOL, P902; LOUBE SR, 1983, BIOCHEM J, V210, P79, DOI 10.1042/bj2100079; MARTORELL J, 1987, EUR J IMMUNOL, V17, P1447, DOI 10.1002/eji.1830171010; MCMICHAEL AJ, 1987, LEUCOCYTE TYPING, V3, P31; MEUER S, 1986, MOL IMMUNOL, V23, P1157, DOI 10.1016/0161-5890(86)90146-X; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MORETTA A, 1985, J EXP MED, V162, P823, DOI 10.1084/jem.162.3.823; MORIMOTO C, 1988, J IMMUNOL, V140, P2165; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; REISFELD RA, 1982, P NATL ACAD SCI USA, V79, P1245; RUDD CE, 1987, J EXP MED, V166, P1758, DOI 10.1084/jem.166.6.1758; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SANT AJ, 1984, P NATL ACAD SCI-BIOL, V81, P1534, DOI 10.1073/pnas.81.5.1534; SANT AJ, 1988, J IMMUNOL, V140, P155; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SANT AJ, 1988, P NATL ACAD SCI USA, V140, P155; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCUDDER P, 1986, EUR J BIOCHEM, V157, P365, DOI 10.1111/j.1432-1033.1986.tb09678.x; SHACKELFORD DA, 1982, IMMUNOL REV, V66, P133, DOI 10.1111/j.1600-065X.1982.tb00437.x; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SWACK JA, 1989, MOL IMMUNOL, V26, P1037, DOI 10.1016/0161-5890(89)90068-0; SWACK JA, 1987, LEUKOCYTE TYPING, V3, P550; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P167; VANNOESEL C, 1988, NATURE, V333, P850, DOI 10.1038/333850a0; WANO Y, 1985, MICROBIOL IMMUNOL, V29, P451, DOI 10.1111/j.1348-0421.1985.tb00846.x; WEISS A, 1986, J IMMUNOL, V137, P819; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANG SY, 1986, J IMMUNOL, V137, P1097	66	38	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7137	7143						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016320				2022-12-25	WOS:A1991FG72700077
J	HIGGINS, EA; SIMINOVITCH, KA; ZHUANG, DL; BROCKHAUSEN, I; DENNIS, JW				HIGGINS, EA; SIMINOVITCH, KA; ZHUANG, DL; BROCKHAUSEN, I; DENNIS, JW			ABERRANT O-LINKED OLIGOSACCHARIDE BIOSYNTHESIS IN LYMPHOCYTES AND PLATELETS FROM PATIENTS WITH THE WISKOTT-ALDRICH SYNDROME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLGALACTOSAMINIDE ALPHA-2->6 SIALYLTRANSFERASE; PRESSURE LIQUID-CHROMATOGRAPHY; PORCINE SUBMAXILLARY-GLAND; FETAL CALF LIVER; ANEMIA TYPE-II; MUCIN SYNTHESIS; CELL-LINES; N-ACETYLGLUCOSAMINYLTRANSFERASE; SURFACE SIALOGLYCOPROTEIN; SIALIC ACIDS	The Wiskott-Aldrich syndrome (WAS) is an X-linked recessive immunodeficiency affecting B lymphocytes, T lymphocytes, and platelets. Previous studies on lymphocytes from WAS patients have revealed that leukosialin (CD43), a cell-surface glycoprotein bearing approximately 90 O-linked oligosaccharide chains, shows an aberrant electrophoretic mobility. To determine whether this finding reflects a different pattern of O-linked glycosylation in WAS cells, we have compared healthy individuals and WAS patients with respect to glycosyltransferase activities in T lymphocytes, platelets, and Epstein-Barr virus (EBV)-immortalized B cell lines. Stimulation of peripheral T cells from normal individuals in vitro with anti-CD3 antibodies and interleukin-2 was associated with a 3-fold increase in UDP-GlcNAc:Gal-beta-3GalNAc-R (GlcNAc to GalNAc) beta-6-N-acetylglucosaminyltransferase (core 2 GlcNAc-T) from 0.8 to 2.2 nmol/mg/h. In contrast, peripheral T lymphocytes from WAS patients showed an inversion of this phenotype with high core 2 GlcNAc-T activity in unstimulated cells (2.3 nmol/mg/h) and a 2-3-fold decrease in activity following stimulation. Core 2 GlcNAc-T activity was also three times higher in platelets from WAS patients than in normal platelets. Glycosyltransferase activities were measured in immortalized B cell lines established from WAS and normal subjects by infection with EBV. Core 2 GlcNAc-T was < 0.4 nmol/mg/h in WAS EBV-B cell lines compared to 2.4 nmol/mg/h in EBV-B cell lines from healthy individuals. In contrast, CMP-SA:SA-alpha-2-3Gal-beta-1-3GalNAc-R (where SA represents sialyl (sialic acid to GalNAc) alpha-6-sialyltransferase II activity was 2.0 nmol/mg/h in the WAS EBV-B cell and < 0.1 nmol/mg/h in EBV-B cell lines derived from normal subjects. Eleven other glycosyltransferase activities were measured and found to be similar in EBV-B cell lines from WAS and normal individuals. Polylactosamine sequences were much reduced in the O-linked oligosaccharides of CD43 from WAS EBV-B cells consistent with decreased core 2 GlcNAc-T activity and expression of core 1 oligosaccharides in the cells. In conclusion, B cells, T cells, and platelets in WAS patients show abnormal expression of two developmentally regulated glycosyltransferases, consistent with the idea that the WAS immunodeficiency is due to a failure of normal lymphocyte maturation.	UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	HIGGINS, EA (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO M5G 1X5,ONTARIO,CANADA.		Siminovitch, Katherine/K-1475-2013; Dennis, James/E-7268-2013					ALDRICH RA, 1954, PEDIATRICS, V13, P133; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; AXELSSON B, 1988, J IMMUNOL, V141, P2913; BERGH MLE, 1981, CARBOHYD RES, V94, P225, DOI 10.1016/S0008-6215(00)80720-X; BERGH MLE, 1983, EUR J BIOCHEM, V136, P113, DOI 10.1111/j.1432-1033.1983.tb07713.x; BERGH MLE, 1983, J BIOL CHEM, V258, P7430; BERGH MLE, 1982, BIOCHEM J, V201, P411, DOI 10.1042/bj2010411; BLAESE RM, 1968, LANCET, V1, P1056; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BROCKHAUSEN I, 1983, CAN J BIOCHEM CELL B, V61, P1322, DOI 10.1139/o83-169; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; BROCKHAUSEN I, 1983, CARBOHYD RES, V120, P3, DOI 10.1016/0008-6215(83)88002-1; CARLSON DM, 1973, J BIOL CHEM, V248, P5763; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; FUKUDA M N, 1990, Glycobiology, V1, P9, DOI 10.1093/glycob/1.1.9; FUKUDA MN, 1984, BRIT J HAEMATOL, V56, P55, DOI 10.1111/j.1365-2141.1984.tb01271.x; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; GAHMBERG CG, 1986, BLOOD, V67, P973; GOLDING B, 1984, J IMMUNOL, V133, P2966; GORDON J, 1986, IMMUNOLOGY, V58, P591; GREER WL, 1989, HUM GENET, V83, P227, DOI 10.1007/BF00285161; GREER WL, 1989, GENOMICS, V4, P60, DOI 10.1016/0888-7543(89)90315-7; GREER WL, 1989, BIOCHEM CELL BIOL, V67, P503, DOI 10.1139/o89-081; HUNTLEY CC, 1957, PEDIATRICS, V19, P351; KOZARSKY KF, 1988, MOL CELL BIOL, V8, P3357, DOI 10.1128/MCB.8.8.3357; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MCQUIRE EJ, 1967, J BIOL CHEM, V242, P3745; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; OCHS HD, 1980, BLOOD, V55, P243; OPPENHEIM JJ, 1970, J IMMUNOL, V104, P835; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PALLANT A, 1990, EUR J IMMUNOL, V20, P1423, DOI 10.1002/eji.1830200703; PARKMAN R, 1981, LANCET, V2, P1387; PERRY GS, 1980, J PEDIATR-US, V97, P72, DOI 10.1016/S0022-3476(80)80133-8; PILLER F, 1983, J BIOL CHEM, V258, P2293; PILLER F, 1988, J BIOL CHEM, V263, P15146; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SCHACHTER H, 1971, J BIOL CHEM, V246, P5321; SPITLER LE, 1975, CELL IMMUNOL, V19, P201, DOI 10.1016/0008-8749(75)90204-X; TORRES CR, 1984, J BIOL CHEM, V259, P3308; VANCHENKER W, 1985, J CLIN INVEST, V75, P541; VANHALBEEK H, 1981, FEBS LETT, V133, P45, DOI 10.1016/0014-5793(81)80467-X; VANHALBEEK H, 1980, BIOCHIM BIOPHYS ACTA, V623, P295, DOI 10.1016/0005-2795(80)90257-3; WILLIAMS D, 1980, J BIOL CHEM, V255, P1247; WILLIAMS D, 1990, J BIOL CHEM, V265, P11253; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	50	132	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6280	6290						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007580				2022-12-25	WOS:A1991FE37300044
J	MCCLOSKEY, DE; MCGUIRE, JJ; RUSSELL, CA; ROWAN, BG; BERTINO, JR; PIZZORNO, G; MINI, E				MCCLOSKEY, DE; MCGUIRE, JJ; RUSSELL, CA; ROWAN, BG; BERTINO, JR; PIZZORNO, G; MINI, E			DECREASED FOLYLPOLYGLUTAMATE SYNTHETASE-ACTIVITY AS A MECHANISM OF METHOTREXATE RESISTANCE IN CCRF-CEM HUMAN LEUKEMIA SUBLINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE; ENZYMATIC-SYNTHESIS; CELLS; INHIBITION; ANALOGS; POLYGLUTAMYLATION; POLYGLUTAMATES; INVITRO; GROWTH; DRUG	Determinants of methotrexate (MTX) resistance in cell lines resistant to short, but not continuous, MTX exposure were investigated since such lines may have relevance to clinical resistance. CCRF-CEM R30dm (R30dm), cloned from CCRF-CEM R30/6 (a MTX-resistant subline of the CCRF-CEM human leukemia cell line), had growth characteristics similar to CCRF-CEM. R30dm was resistant to a 24-h exposure to levels as high as 300-mu-M MTX but was as sensitive as CCRF-CEM to continuous MTX exposure. MTX resistance of R30dm was stable for > 68 weeks in the absence of selective pressure. Initial velocities of MTX transport were comparable for R30dm and CCRF-CEM, as were dihydrofolate reductase specific activity and MTX binding. A 2-fold thymidylate synthase activity decrease for R30dm from that of CCRF-CEM was not a significant factor in R30dm MTX resistance. Decreased MTX poly(gamma-glutamate) synthesis resulted in lower levels of drug accumulation by R30dm. Decreased polyglutamylation was attributable to folylpolyglutamate synthetase (FPGS) activity in R30dm extracts which was 1, 2, and less-than-or-equal-to 10% of CCRF-CEM extracts with the substrates MTX, aminopterin, and naturally occurring folates, respectively. Comparison of cell lines with varying levels of resistance to short term MTX exposure indicated that the extent of MTX resistance was proportional to the reduction of FPGS activity. The evidence supported decreased FPGS activity as the mechanism of resistance to short MTX exposure in the cell lines investigated.	NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, GRACE CANC DRUG CTR, 666 ELM ST, BUFFALO, NY 14263 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT MED, NEW HAVEN, CT 06510 USA; UNIV FIRENZE, CATTEDRA CHEMOTERAPIA, DIPARTIMENTO FARMACOL PRECLIN & CLIN, I-50100 FLORENCE, ITALY	Roswell Park Cancer Institute; Memorial Sloan Kettering Cancer Center; Yale University; Yale University; University of Florence			Mini, Enrico/AAA-5908-2019		NATIONAL CANCER INSTITUTE [P30CA024538, R01CA043500] Funding Source: NIH RePORTER; NCI NIH HHS [CA43500, CA24538, CA09072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERTINO JR, 1985, ADV ENZYME REGUL, V24, P3, DOI 10.1016/0065-2571(85)90066-4; BERTINO JR, 1981, CANCER CHEMOTHERAPY, V3, P359; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P91; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; COWAN KH, 1984, J BIOL CHEM, V259, P793; CURT GA, 1985, J CLIN INVEST, V76, P1323, DOI 10.1172/JCI112106; DIDDENS H, 1983, CANCER RES, V43, P5286; DOLNICK BJ, 1977, J BIOL CHEM, V252, P7697; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FREI E, 1984, P NATL ACAD SCI-BIOL, V81, P2873, DOI 10.1073/pnas.81.9.2873; FRY DW, 1982, J BIOL CHEM, V257, P1890; FRY DW, 1987, CANCER METAST REV, V5, P251, DOI 10.1007/BF00047000; JOLIVET J, 1983, NEW ENGL J MED, V309, P1094, DOI 10.1056/NEJM198311033091805; MCCLOSKEY D E, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P473; MCGUIRE JJ, 1980, J BIOL CHEM, V255, P5776; MCGUIRE JJ, 1985, CANCER RES, V45, P6395; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MCGUIRE JJ, 1986, BIOCHEM PHARMACOL, V35, P2607, DOI 10.1016/0006-2952(86)90060-2; MCGUIRE JJ, 1990, CANCER RES, V50, P1726; MCGUIRE JJ, 1989, CANCER RES, V49, P4517; MCGUIRE JJ, 1988, BIOCHEM PHARMACOL, V37, P3931, DOI 10.1016/0006-2952(88)90076-7; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MINI E, 1985, CANCER RES, V45, P317; NIMEC Z, 1983, ARCH BIOCHEM BIOPHYS, V226, P671, DOI 10.1016/0003-9861(83)90337-5; OSBORN MJ, 1958, J BIOL CHEM, V233, P969; PIZZORNO G, 1988, CANCER RES, V48, P2149; RODENHUIS S, 1986, CANCER RES, V46, P6513; ROMANINI A, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P595; ROSOWSKY A, 1986, J MED CHEM, V29, P655, DOI 10.1021/jm00155a012; ROSOWSKY A, 1980, BIOCHEM PHARMACOL, V29, P648, DOI 10.1016/0006-2952(80)90391-3; SHANE B, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P891; SOBRERO A, 1986, CANCER SURV, V5, P93; WASHTIEN WL, 1982, MOL PHARMACOL, V21, P723	34	186	187	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6181	6187						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007575				2022-12-25	WOS:A1991FE37300030
J	OLSON, ST; HALVORSON, HR; BJORK, I				OLSON, ST; HALVORSON, HR; BJORK, I			QUANTITATIVE CHARACTERIZATION OF THE THROMBIN-HEPARIN INTERACTION DISCRIMINATION BETWEEN SPECIFIC AND NONSPECIFIC-BINDING MODELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR WEIGHT HEPARIN; HIGH-AFFINITY HEPARIN; NUCLEIC-ACID INTERACTIONS; ANTI-COAGULANT ACTIVITY; NON-COOPERATIVE BINDING; ANTITHROMBIN-III; FACTOR-XA; ANTICOAGULANT ACTIVITY; PLATELET FACTOR-4; ALPHA-THROMBIN	Equilibrium binding of human alpha-thrombin to heparin was investigated at pH 7.4 as a function of thrombin and heparin concentrations, NaCl concentration, temperature, and heparin chain length with the extrinsic fluorescence probe, p-aminobenzamidine, or by quantitative affinity chromatography, in order to distinguish between sequence-specific and nonspecific electrostatic modes of binding. Analysis of binding data by a nonspecific binding model developed for protein-nucleic acid interactions, or by the discrete binding site model previously used to analyze the thrombin-heparin interaction, indicated that both models described the binding interaction equally well over the range of thrombin binding densities accessible to measurement. However, the strong dependence of the thrombin-heparin binding interaction on NaCl concentration, its minimal dependence on temperature, and the increase in apparent binding affinity with increasing heparin oligosaccharide chain length were best accounted for by a nonspecific electrostatic association of thrombin with 5 to 6 anionic residues contained in a 3-disaccharide binding site of heparin. This interaction was characterized by an intrinsic dissociation constant (K(D,obs)) of 6-10-mu-M at physiological ionic strength. Although the nonspecific binding model satisfactorily described the binding of thrombin to heparin chains ranging in size from 3 to approximately 13 disaccharides in terms of a single intrinsic K(D,obs), deviations from this model were apparent with longer heparin chains (approximately 22 to approximately 35 disaccharides) from a progressive decrease in the intrinsic K(D,obs) of up to 4-fold. Sedimentation equilibrium analyses of thrombin-heparin complexes suggested a second weaker binding site on thrombin for heparin, which accounted for these deviations as well as the observed insolubility of thrombin-heparin complexes at high thrombin binding densities.	SWEDISH UNIV AGR SCI, CTR BIOMED, DEPT VET MED CHEM, S-75123 UPPSALA, SWEDEN	Swedish University of Agricultural Sciences	OLSON, ST (corresponding author), HENRY FORD HOSP, DIV BIOCHEM RES, EDUC & RES BLDG, RM 3126, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039888, R01HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERESFORD CH, 1990, INT J BIOCHEM, V22, P121, DOI 10.1016/0020-711X(90)90172-Y; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BOCK PE, 1983, ANAL BIOCHEM, V135, P172, DOI 10.1016/0003-2697(83)90747-9; BRASWELL E, 1968, BIOCHIM BIOPHYS ACTA, V158, P103, DOI 10.1016/0304-4165(68)90077-9; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DIAKUN GP, 1978, MACROMOLECULES, V11, P1110, DOI 10.1021/ma60066a009; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; DUGGLEBY RG, 1977, BIOCHIM BIOPHYS ACTA, V481, P297, DOI 10.1016/0005-2744(77)90264-9; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; EVANS SA, 1982, J BIOL CHEM, V257, P3014; EVINGTON JRN, 1986, BIOCHIM BIOPHYS ACTA, V871, P85, DOI 10.1016/0167-4838(86)90136-6; EVINGTON JRN, 1986, BIOCHIM BIOPHYS ACTA, V870, P92, DOI 10.1016/0167-4838(86)90012-9; FENTON JW, 1989, ANN NY ACAD SCI, V556, P158; FENTON JW, 1977, J BIOL CHEM, V252, P3587; GETTINS P, 1989, CARBOHYD RES, V185, P69, DOI 10.1016/0008-6215(89)84022-4; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HOPWOOD J, 1976, FEBS LETT, V69, P51, DOI 10.1016/0014-5793(76)80651-5; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; JACQUES LB, 1977, METHOD BIOCHEM ANAL, V24, P203; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; JORDAN R, 1979, J BIOL CHEM, V254, P2902; JORDAN RE, 1982, J BIOL CHEM, V257, P400; JORDAN RE, 1980, J BIOL CHEM, V255, P81; JORDAN RE, 1980, J BIOL CHEM, V255, P73; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3522, DOI 10.1021/bi00556a017; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MACHOVICH R, 1978, EUR J BIOCHEM, V83, P473, DOI 10.1111/j.1432-1033.1978.tb12113.x; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MATTAI J, 1981, BIOCHIM BIOPHYS ACTA, V677, P303, DOI 10.1016/0304-4165(81)90100-8; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1980, THROMB RES, V19, P711, DOI 10.1016/0049-3848(80)90044-4; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1989, THROMB HAEMOSTASIS, V62, P326; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; PLETCHER CH, 1983, J BIOL CHEM, V258, P1086; POMERANTZ MW, 1978, BIOCHIM BIOPHYS ACTA, V535, P66, DOI 10.1016/0005-2795(78)90033-8; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1978, BIOPOLYMERS, V17, P159, DOI 10.1002/bip.1978.360170112; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; WILLIAMS JW, 1958, CHEM REV, V58, P715, DOI 10.1021/cr50022a005	63	226	228	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6342	6352						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007587				2022-12-25	WOS:A1991FE37300053
J	GORR, SU; HAMILTON, JW; COHN, DV				GORR, SU; HAMILTON, JW; COHN, DV			SULFATED SECRETED FORMS OF BOVINE AND PORCINE PARATHYROID CHROMOGRANIN-A (SECRETORY PROTEIN-I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS INSULIN-SECRETION; FLUOROGRAPHIC DETECTION; ADRENAL-MEDULLA; CELL-LINE; PANCREASTATIN; HORMONE; LOCALIZATION; VARIETY; RAT; PROTEOGLYCANS	Chromogranin A (secretory protein-I) is an acidic sulfated glycoprotein found in secretory granules of most endocrine and neuroendocrine cells. In the parathyroid it is co-stored and secreted with parathormone in response to hypocalcemia. Differences in post-translational modifications have been reported between chromogranin A from the bovine adrenal and porcine parathyroid glands. The former has been reported to be sulfated mainly on oligosaccharide residues and apparently includes a proteoglycan form, whereas the latter was previously reported to be tyrosine sulfated with little of the proteoglycan form present. Here we have directly compared (SO4)-S-35-labeled parathyroid chromogranin A from the pig and the cow to determine if these reported differences were tissue or species specific. We find that the chromogranin A secreted by the bovine gland contains a proteoglycan form, whereas that from the porcine gland does not. Moreover, chromogranin A of both species is primarily sulfated on oligosaccharide residues with little if any tyrosine sulfate detected. Differences were detected in the structure of sulfated O-linked oligosaccharides in bovine and porcine parathyroid chromogranin A.	UNIV LOUISVILLE, HLTH SCI CTR, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA; VET ADM MED CTR, CALCIUM ENDOCRINOL LAB, KANSAS CITY, MO 64128 USA; UNIV KANSAS, MED CTR, SCH MED, DEPT BIOCHEM, KANSAS CITY, KS 66103 USA	University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas; University of Kansas Medical Center	GORR, SU (corresponding author), UNIV LOUISVILLE, HLTH SCI CTR, DEPT ORAL HLTH, LOUISVILLE, KY 40292 USA.				NIDDK NIH HHS [DK38296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038296] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHREN B, 1988, DIABETES, V37, P281, DOI 10.2337/diabetes.37.3.281; ARPS H, 1987, BONE MINER, V2, P175; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BHARGAVA G, 1983, P NATL ACAD SCI-BIOL, V80, P878, DOI 10.1073/pnas.80.3.878; BOCHNER BR, 1983, ANAL BIOCHEM, V131, P510, DOI 10.1016/0003-2697(83)90206-3; BURGESS TL, 1984, J CELL BIOL, V99, P2223, DOI 10.1083/jcb.99.6.2223; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COHN DV, 1984, ENDOCRINOLOGY, V114, P1963, DOI 10.1210/endo-114-6-1963; COHN DV, 1982, P NATL ACAD SCI-BIOL, V79, P6056, DOI 10.1073/pnas.79.19.6056; COHN DV, 1982, ENDOCRINOLOGY, V110, P625, DOI 10.1210/endo-110-2-625; FALKENSAMMER G, 1985, J NEUROCHEM, V45, P1475, DOI 10.1111/j.1471-4159.1985.tb07215.x; FASCIOTTO BH, 1989, ENDOCRINOLOGY, V125, P1617, DOI 10.1210/endo-125-3-1617; FASCIOTTO BH, 1990, ENDOCRINOLOGY, V127, P1329, DOI 10.1210/endo-127-3-1329; FISCHERCOLBRIE R, 1987, ANN NY ACAD SCI, V493, P120, DOI 10.1111/j.1749-6632.1987.tb27189.x; FUNAKOSHI A, 1988, BIOCHEM BIOPH RES CO, V156, P1237, DOI 10.1016/S0006-291X(88)80765-4; GORR SU, 1988, J CELL BIOL, V106, P1937, DOI 10.1083/jcb.106.6.1937; GORR SU, 1988, BONE MINER, V4, P17; GORR SU, 1990, J BIOL CHEM, V265, P3012; GREELEY GH, 1989, ENDOCRINOLOGY, V124, P1235, DOI 10.1210/endo-124-3-1235; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; JEVONS FR, 1963, BIOCHEM J, V89, P621, DOI 10.1042/bj0890621; KIANG WL, 1982, J BIOL CHEM, V257, P1651; KUMARASAMY R, 1986, J BIOL CHEM, V261, P6473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJZOUB JA, 1982, J BIOL CHEM, V257, P3581; NGUYEN MH, 1987, J NEUROCHEM, V49, P38, DOI 10.1111/j.1471-4159.1987.tb03391.x; OCONNOR DT, 1983, REGUL PEPTIDES, V6, P263, DOI 10.1016/0167-0115(83)90145-3; RAVAZZOLA M, 1978, LANCET, V2, P371; REITZ HC, 1946, J AM CHEM SOC, V68, P1024, DOI 10.1021/ja01210a036; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; SCAMMELL JG, 1990, J HISTOCHEM CYTOCHEM, V38, P949, DOI 10.1177/38.7.2192000; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1645; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V262, P1; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; YANAGISHITA M, 1989, J BIOL CHEM, V264, P15714	39	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5780	5784						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005116				2022-12-25	WOS:A1991FD37000066
J	HOMAN, EC; JENSEN, DE; SANDO, JJ				HOMAN, EC; JENSEN, DE; SANDO, JJ			PROTEIN-KINASE-C ISOZYME EXPRESSION IN PHORBOL ESTER-SENSITIVE AND ESTER-RESISTANT EL4 THYMOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOCYTES-T; MESSENGER-RNA; RECEPTOR PROTEIN; RAT-BRAIN; MOLECULAR HETEROGENEITY; SUBSTRATE-SPECIFICITY; ADDITIONAL MEMBERS; MAMMALIAN-TISSUES; GENE-EXPRESSION; DOWN-REGULATION	To investigate whether differential protein kinase C isozyme expression in phorbol ester-sensitive and -resistant EL4 thymoma cells could account for the difference in phorbol ester responsiveness, we purified and characterized isozymes from the two cell lines. In both cell types, two peaks of protein kinase C activity were resolved on hydroxylapatite following DEAE-cellulose and phenyl-Superose chromatography. Western blot analysis showed that the first peak corresponded to protein kinase C-beta and the second to protein kinase C-alpha. Two-dimensional phosphotryptic mapping of the purified-alpha and beta-isozymes did not reveal any reproducible differences between sensitive and resistant EL4 cells. Nor were any differences between the cell types observed in the cytosolic versus membrane localization of alpha and beta-protein kinase C. Northern blot analysis showed the expression of mRNA for protein kinase C-alpha, -beta, -delta and -epsilon in both cell lines, and the absence of mRNA for gamma or zeta. Although no major differences in expression of alpha, beta, or delta-mRNA between sensitive and resistant EL4 cells were detectable, expression of protein kinase C-epsilon mRNA in resistant cells was only 20-25% of that in sensitive. Western blot analysis with anti-protein kinase C-epsilon antibodies showed the presence of the epsilon-isozyme in sensitive cells and the absence of detectable amounts in resistant cells. Although protein kinase C-epsilon constitutes only a small portion of the total protein kinase C in sensitive cells, the possibility is raised that decreased protein kinase C-epsilon expression may contribute to the failure of resistant EL4 cells to respond to phorbol esters.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,BOX 448,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,CTR CANC,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031184] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31184] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA Y, 1990, J BIOL CHEM, V265, P354; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEYERS AD, 1988, J IMMUNOL, V141, P3463; BIEMANN HPN, 1990, MOL CELL BIOL, V10, P2122, DOI 10.1128/MCB.10.5.2122; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GODSON C, 1990, J BIOL CHEM, V265, P8369; HAGIWARA M, 1990, BIOCHEM BIOPH RES CO, V168, P161, DOI 10.1016/0006-291X(90)91688-O; HARRISON JR, 1987, J BIOL CHEM, V262, P234; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HOMMA Y, 1988, CANCER RES, V48, P2744; HUANG FL, 1988, ARCH BIOCHEM BIOPHYS, V267, P503, DOI 10.1016/0003-9861(88)90057-4; INOUE M, 1977, J BIOL CHEM, V252, P7610; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KIKKAWA U, 1988, COLD SPRING HARB SYM, V53, P97, DOI 10.1101/SQB.1988.053.01.015; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; KORETZKY GA, 1989, J IMMUNOL, V143, P1692; KRAMER CM, 1986, CANCER RES, V46, P3040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PARKER PJ, 1984, EMBO J, V3, P953, DOI 10.1002/j.1460-2075.1984.tb01913.x; ROGUE P, 1990, J BIOL CHEM, V265, P4161; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; SANDO JJ, 1982, CANCER RES, V42, P1676; SANDO JJ, 1983, P NATL ACAD SCI-BIOL, V80, P2642, DOI 10.1073/pnas.80.9.2642; SANDO JJ, 1989, GENES SIGNAL TRANSDU, P279; SAWAMURA S, 1989, FEBS LETT, V247, P353, DOI 10.1016/0014-5793(89)81369-9; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SHEARMAN MS, 1988, FEBS LETT, V234, P387, DOI 10.1016/0014-5793(88)80122-4; SHOJI M, 1987, CANCER RES, V47, P6363; SMITH BM, 1988, J BIOL CHEM, V263, P6424; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; VILA J, 1989, FEBS LETT, V255, P205, DOI 10.1016/0014-5793(89)81092-0; WADA H, 1989, BIOCHEM BIOPH RES CO, V165, P533, DOI 10.1016/0006-291X(89)91102-9; WALKER JM, 1990, J BIOL CHEM, V265, P8016; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x	55	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5676	5681						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005106				2022-12-25	WOS:A1991FD37000050
J	DRESSLER, KA; KAN, CC; KOLESNICK, RN				DRESSLER, KA; KAN, CC; KOLESNICK, RN			SPHINGOMYELIN SYNTHESIS IS INVOLVED IN ADHERENCE DURING MACROPHAGE DIFFERENTIATION OF HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GH3 PITUITARY-CELLS; THYROTROPIN-RELEASING-HORMONE; PROTEIN KINASE-C; PHORBOL ESTERS; PHOSPHATIDYLCHOLINE METABOLISM; MONOCYTIC DIFFERENTIATION; LEUKEMIA-CELLS; FIBROBLASTS; CERAMIDE; EXPRESSION	Prior studies demonstrated that sphingomyelin degradation via a sphingomyelinase antagonized phorbol ester-mediated differentiation of HL-60 cells into macrophages (Kolesnick, R. N. (1989) J. Biol. Chem. 264, 7617-7623). The present studies show that phorbol esters induce early sphingomyelin synthesis in HL-60 cells and that this event may play a direct role in development of an adherent macrophage population. A maximally effective concentration of the potent phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA; 1 x 10(-7) M) stimulated an elevation in the sphingomyelin level at 24 h from 560 to 700 pmol/10(6) cells; a peak level of 1400 pmol/10(6) cells was achieved at 48 h. Phosphatidylcholine levels did not change significantly, indicating sphingomyelin synthesis was selective. The phosphatidylcholine:sphingomyelin ratio decreased from 10.3 to 7.9 at 24 h and to 5.3 at 48 h. Phorbol ester-induced sphingomyelin synthesis was biphasic. A burst of synthesis, detectable within 1 h and linear for 4 h, was followed by a prolonged phase at a slower rate. Ceramide synthesis was also biphasic. Ceramide levels decreased initially consistent with activation of the enzyme, phosphatidylcholine:ceramide cholinephosphotransferase and increased during the prolonged phase of sphingomyelin synthesis. During phorbol ester-induced differentiation, an adherent macrophage population was demonstrable by 14 h. This population contained the entire elevation of sphingomyelin levels. This demonstrates that early sphingomyelin synthesis defines a population of cells destined to become adherent macrophages. Studies were performed to directly manipulate sphingomyelin levels. Small unilamellar vesicles containing sphingomyelin did not directly induce macrophage differentiation but rather potentiated the effect of submaximal concentrations of phorbol ester. Sphingomyelin vesicles (2 x 10(-6) M) enhanced TPA (5 x 10(10) M)-induced adherence 2-fold from 12 to 24% of the total population. Sphingosylphosphorylcholine (5 x 10(-6) M), which may be acylated to sphingomyelin, was similarly effective. Further, exogenous sphingomyelinase, but not various phospholipases A2 and C, induced detachment of adherent macrophages. In sum, these studies demonstrate that phorbol esters induce early, selective synthesis of sphingomyelin in HL-60 cells. This event defines a population of cells destined to become adherent macrophages and may play a direct role in the adherence process.	CORNELL UNIV,MED CTR,COLL MED,MEMORIAL SLOAN KETTERING CANC CTR,DEPT MED,DIV ENDOCRINOL & METAB,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA042385, T32CA009512] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-42385, CA-09512-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADY RO, 1965, J BIOL CHEM, V240, P3693; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; FUJINO Y, 1968, BIOCHIM BIOPHYS ACTA, V152, P428, DOI 10.1016/0005-2760(68)90058-1; GATT S, 1980, J BIOL CHEM, V255, P3371; HICKSTEIN DD, 1987, J IMMUNOL, V138, P513; HUBSCHER G., 1960, JOUR LIPID RES, V1, P433; KISS Z, 1988, ARCH BIOCHEM BIOPHYS, V265, P38, DOI 10.1016/0003-9861(88)90368-2; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1989, J BIOL CHEM, V264, P11688; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LOCKNEY MW, 1984, BIOCHIM BIOPHYS ACTA, V796, P384, DOI 10.1016/0005-2760(84)90141-3; MAGEE WE, 1974, J CELL BIOL, V63, P492, DOI 10.1083/jcb.63.2.492; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MARGGRAF WD, 1982, BIOCHIM BIOPHYS ACTA, V710, P314, DOI 10.1016/0005-2760(82)90114-X; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MOMOI T, 1986, J BIOL CHEM, V261, P6270; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PREISS J, 1986, J BIOL CHEM, V261, P8597; REBECCHI MJ, 1983, J BIOL CHEM, V258, P227; SPENCE MW, 1990, BIOCHEM J, V268, P719, DOI 10.1042/bj2680719; STEVENS VL, 1989, CANCER RES, V49, P3229; SUGIYAMA E, 1990, BIOCHEM BIOPH RES CO, V169, P673, DOI 10.1016/0006-291X(90)90383-X; VOLKER DR, 1982, BIOCHEMISTRY-US, V21, P2753; WILSON E, 1988, J BIOL CHEM, V263, P9304; XIA XJ, 1989, J LIPID RES, V30, P181; YAM LT, 1971, AM J CLIN PATHOL, V21, P1	32	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11522	11527						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050663				2022-12-25	WOS:A1991FT76200020
J	MURRAY, IA; LEWENDON, A; SHAW, WV				MURRAY, IA; LEWENDON, A; SHAW, WV			STABILIZATION OF THE IMIDAZOLE RING OF HIS-195 AT THE ACTIVE-SITE OF CHLORAMPHENICOL ACETYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE ANALYSIS; MUTAGENESIS; RESOLUTION; MECHANISM; GENE	The imidazole of His-195 plays an essential role in the proposed general base mechanism of chloramphenicol acetyltransferase (CAT). The structure of the binary complex of CAT(III) and chloramphenicol suggests that two unusual interactions might determine the conformation of the side chain of His-195: (i) an intraresidue hydrogen bond between its main chain carbonyl and the protonated N-delta-1 of the imidazole ring and (ii) face-to-face van der Waals contact between the His-195 imidazole group and the aromatic side chain of Tyr-25. Tyr-25 also makes a hydrogen bond, via its phenolic hydroxyl, to the carbonyl oxygen of the substrate chloramphenicol. Replacement of Tyr-25 of CAT(III) by phenylalanine results in a modest increase in the K(m) for chloramphenicol (from 11.6 to 14.6-mu-m) and a 2-fold fall in k(cat) (599 to 258 s-1), indicative of a free energy contribution to transition state binding of 0.6 kcal mol-1 for the hydrogen bond between Tyr-25 and chloramphenicol. In contrast, substitution of Tyr-25 by alanine yields an enzyme that is dramatically impaired in its ability to bind chloramphenicol (K(m) = 173-mu-m). As k(cat) for Ala-25 CAT is also reduced (130 s-1), the loss of the aryl group results in a 69-fold decrease in k(cat)/k(m), corresponding to a free energy contribution to binding and catalysis of 2.5 kcal mol-1. In addition to the loss of the hydrogen bond between Tyr-25 and chloramphenicol, the loss of substrate affinity in Ala-25 CAT may be a direct consequence of reduced hydrophobicity of the chloramphenicol-binding site and/or the loss of critical constraints on the precise conformation of the catalytic imidazole. However, as with wild type CAT, inactivation of Ala-25 CAT by the affinity reagent 3-(bromoacetyl) chloramphenicol is accompanied by modification solely at N-epsilon-2 of His-195. Hence, the results demonstrate that tautomeric stabilization of the imidazole ring persists in the absence of van der Waals interactions with the side chain of Tyr-25, probably as a consequence of hydrogen bonding between the protonated N-delta-1 and the carbonyl oxygen of His-195.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,ENGLAND	University of Leicester								BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CHARLES IG, 1985, J BACTERIOL, V164, P123, DOI 10.1128/JB.164.1.123-129.1985; CULLIS PM, 1991, BIOCHEMISTRY-US, V30, P3758, DOI 10.1021/bi00229a024; DAY PJ, 1990, THESIS U LEICESTER L; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; GIBBS MR, 1990, BIOCHEMISTRY-US, V29, P11261, DOI 10.1021/bi00503a015; KLEANTHOUS C, 1985, BIOCHEMISTRY-US, V24, P5307, DOI 10.1021/bi00341a006; KLEANTHOUS C, 1984, BIOCHEM J, V223, P211, DOI 10.1042/bj2230211; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; LESLIE AGW, 1990, J MOL BIOL, V213, P167, DOI 10.1016/S0022-2836(05)80129-9; LEWENDON A, 1990, BIOCHEM J, V272, P499, DOI 10.1042/bj2720499; LEWENDON A, 1988, BIOCHEMISTRY-US, V27, P7385, DOI 10.1021/bi00419a032; LEWENDON A, 1990, BIOCHEMISTRY-US, V29, P2075, DOI 10.1021/bi00460a016; LOWE CR, 1984, METHOD ENZYMOL, V104, P97; MURRAY IA, 1991, BIOCHEMISTRY-US, V30, P3763, DOI 10.1021/bi00229a025; MURRAY IA, 1988, BIOCHEM J, V252, P173, DOI 10.1042/bj2520173; SHAW WV, 1967, J BIOL CHEM, V242, P687; SHAW WV, 1968, J BACTERIOL, V95, P1976, DOI 10.1128/JB.95.5.1976-1978.1968; SHAW WV, 1979, NATURE, V282, P870, DOI 10.1038/282870a0	20	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11695	11698						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050670				2022-12-25	WOS:A1991FT76200044
J	HOGG, PJ; STENFLO, J				HOGG, PJ; STENFLO, J			INTERACTION OF VITAMIN-K-DEPENDENT PROTEIN-Z WITH THROMBIN - CONSEQUENCES FOR THE AMIDOLYTIC ACTIVITY OF THROMBIN AND THE INTERACTION OF THROMBIN WITH PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; QUANTITATIVE AFFINITY-CHROMATOGRAPHY; BOVINE PLASMA; FACTOR-X; CHRISTMAS FACTOR; TERNARY COMPLEX; FIBRIN MONOMER; FACTOR-IX; PROTHROMBIN; ACTIVATION	Protein Z is a vitamin K-dependent protein of unknown function present in normal bovine plasma at a concentration of approximately 0.1-mu-M. Quantitative affinity chromatographic studies using diisopropyl-phosphoryl (DIP)-thrombin-Affi-Gel 10 as the affinity matrix and free DIP-thrombin as the competitor demonstrated that protein Z interacts with DIP-thrombin with a dissociation constant of 0.15 +/- 0.05-mu-M. Binding was independent of Ca2+. Protein C and factor IX, other vitamin K-dependent clotting proteins with the same domain structure as that of protein Z, did not interact with immobilized DIP-thrombin under these conditions; and factor X interacted with an affinity 20-fold lower than that for protein Z. The Michaelis constant, K(m), for hydrolysis of pyro-Glu-Pro-Arg-p-nitroanilide by thrombin was increased 1.8-fold, from 130 to 230-mu-M, as a result of the binding of protein Z and the K(m) for H-Val-Leu-Arg-p-nitroanilide 1.4-fold, from 390 to 560-mu-M. From these kinetic studies, a dissociation constant of 0.11 +/- 0.04-mu-M was calculated for the binding of protein Z to alpha-thrombin. Protein Z bound to large phospholipid vesicles (25% phosphatidylserine, 75% phosphatidylcholine) with a dissociation constant of 0.39 +/- 0.16-mu-M at a phospholipid to protein ratio of 82 mol of phospholipid/mol of protein Z at saturation. In the presence of protein Z thrombin associated with phospholipid vesicles, whereas thrombin did not interact with phospholipid vesicles in the absence of protein Z. These studies, therefore, demonstrate a physiologically relevant interaction between protein Z and thrombin. They also suggest a mechanism whereby thrombin is localized to an injury site by virtue of its interaction with protein Z bound to phospholipid surfaces.			HOGG, PJ (corresponding author), UNIV LUND, MALMO GEN HOSP, DEPT CHEMOTHERAPY, S-21401 MALMO, SWEDEN.			Hogg, Philip/0000-0001-6486-2863				BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FERNLUND P, 1982, J BIOL CHEM, V257, P2170; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; GITEL SN, 1973, P NATL ACAD SCI USA, V70, P1344, DOI 10.1073/pnas.70.5.1344; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HOGG PJ, 1984, ARCH BIOCHEM BIOPHYS, V234, P55, DOI 10.1016/0003-9861(84)90323-0; HOJRUP P, 1985, FEBS LETT, V184, P333, DOI 10.1016/0014-5793(85)80633-5; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4893, DOI 10.1021/bi00667a022; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LOTTENBERG R, 1982, THROMB RES, V28, P313, DOI 10.1016/0049-3848(82)90114-1; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORITA T, 1988, J BIOCHEM, V104, P368, DOI 10.1093/oxfordjournals.jbchem.a122475; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICHOL LW, 1981, BIOCHEMISTRY-US, V20, P4856, DOI 10.1021/bi00520a008; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; OWEN WG, 1974, J BIOL CHEM, V249, P594; PROWSE CV, 1977, BIOCHEM SOC T, V5, P255, DOI 10.1042/bst0050255; Segel I.H., 1975, ENZYME KINETICS BEHA, P161; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; STENFLO J, 1976, J BIOL CHEM, V251, P355; STENFLO J, 1982, J BIOL CHEM, V257, P2180; WOOD GM, 1988, CIRCULATION, V78, P513	34	48	48	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10953	10958						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040612				2022-12-25	WOS:A1991FQ77400041
J	ANTHONY, DD; MERRICK, WC				ANTHONY, DD; MERRICK, WC			EUKARYOTIC INITIATION-FACTOR (EIF)-4F - IMPLICATIONS FOR A ROLE IN INTERNAL INITIATION OF TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCEPHALOMYOCARDITIS VIRUS-RNA; BINDING PROTEIN COMPLEX; GLOBIN MESSENGER-RNA; UPSTREAM AUG CODONS; 5' NONTRANSLATED REGION; INFECTED HELA-CELLS; POLIOVIRUS RNA; 5'-TERMINAL CAP; RIBOSOMES; INVITRO	In order to study the eukaryotic translation initiation mechanisms of "internal initiation," "re-initiation," and/or "coupled internal initiation," a series of model mRNAs have been constructed which contain two nonoverlapping open reading frames(ORFs) that encode different lengths of rabbit-alpha-globin. These mRNAs, along with the bicistronic constructs TK/CAT and TK/P2CAT developed by Pelletier and Sonenberg (Pelletier, J., and Sonenberg, N. (1988) Nature 334, 320-325, 1988), were used to program an in vitro rabbit reticulocyte lysate translation system. Cap-dependent and cap-independent translation were distinguished by monitoring translation in the presence or absence of exogenously added cap analog (m7GTP). Messenger RNAs which translate both ORF1 and ORF2 by a cap-dependent mechanism, as well as mRNAs that translate ORF2 by a cap-independent mechanism while still translating ORF1 in a cap-dependent fashion have been obtained. These same alpha-globin mRNAs differ by no more than 45 nucleotides in intercistronic length. Initiation factor addition studies were performed in this same in vitro translation system. Both eukaryotic initiation factor (eIF)-4F and, to a lesser extent, eIF-4B can stimulate translation of an internally located ORF independent of upstream ORF translation and in a manner not dependent on mRNA cap recognition. This indicates that the cap-recognition initiation factor, eIF-4F, and eIF-4B facilitate cap-independent and internal initiation of an open reading frame.			ANTHONY, DD (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26796, T32-GM-07520] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; DUNCAN R, 1987, J BIOL CHEM, V262, P380; ETCHISON D, 1984, J VIROL, V51, P832, DOI 10.1128/JVI.51.3.832-837.1984; FLETCHER L, 1990, J BIOL CHEM, V265, P19582; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GEBALLE AP, 1988, J VIROL, V62, P3334, DOI 10.1128/JVI.62.9.3334-3340.1988; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HAHN J, 1982, MOL GEN GENET, V186, P204, DOI 10.1007/BF00331851; HINNEBUSCH AG, 1988, P NATL ACAD SCI USA, V85, P7279, DOI 10.1073/pnas.85.19.7279; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1988, J VIROL, V62, P4486, DOI 10.1128/JVI.62.12.4486-4492.1988; PELLETIER J, 1989, J VIROL, V63, P441, DOI 10.1128/JVI.63.1.441-444.1989; PETERSEN RB, 1985, J VIROL, V56, P683, DOI 10.1128/JVI.56.3.683-690.1985; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; RAY BK, 1985, J BIOL CHEM, V260, P7651; Rhoads R. E, 1985, PROGR MOL SUBCELLULA, V9, P104; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; WANG F, 1987, J VIROL, V61, P945, DOI 10.1128/JVI.61.4.945-954.1987; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	41	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10218	10226						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037575				2022-12-25	WOS:A1991FP08600036
J	BROOKE, RG; DUMAS, LB				BROOKE, RG; DUMAS, LB			RECONSTITUTION OF THE SACCHAROMYCES-CEREVISIAE DNA PRIMASE-DNA POLYMERASE PROTEIN COMPLEX INVITRO - THE 86-KDA SUBUNIT FACILITATES BUT IS NOT REQUIRED FOR COMPLEX-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; PURIFICATION; ALPHA	The immunoaffinity-purified subunits of the yeast DNA primase-DNA polymerase protein complex and subunit-specific monoclonal antibodies were used to explore the structural relationships of the subunits in the complex. The reconstituted four-subunit complex (180-, 86-, 58-, and 49-kDa polypeptides) behaved as a single species, exhibiting a Stokes radius of 80 angstrom and a sedimentation coefficient of 8.9 S. The calculated molecular weight of the reconstituted complex is 312,000. We infer that the stoichiometry of the complex is one of each subunit per complex. The complex has a prolate ellipsoid shape with an axial ratio of approximately 16. When the 180-kDa and DNA primase subunits were recombined in the absence of the 86-kDa subunit, a physical complex formed, as judged by immunoprecipitation of DNA primase activity and polypeptides with an anti-180-kDa monoclonal antibody. While the 86-kDa subunit readily forms a physical complex with the 180-kDa DNA polymerase catalytic subunit, we have not detected a complex containing 86-kDa and the DNA primase subcomplex (49- and 58-kDa subunits). The 86-kDa subunit was not required for DNA primase-DNA polymerase complex formation; the 180-kDa subunit and DNA primase heterodimer directly interact. However, the presence of the 86-kDa subunit increased the rate at which the DNA primase and 180-kDa polypeptides formed a complex and increased the total fraction of DNA primase activity that was associated with DNA polymerase activity. The observations demonstrate that the DNA primase p49.p58 heterodimer and the DNA polymerase p86.p180 heterodimer interact via the 180-kDa subunit. The four-subunit reconstituted complex was sufficient to catalyze the DNA chain extension coupled to RNA primer synthesis on a single-stranded DNA template, as previously observed in the conventionally purified complex isolated from wild type cells.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University					NIGMS NIH HHS [GM 23443] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKE RG, 1991, J BIOL CHEM, V266, P3005; BROOKS M, 1989, J BIOL CHEM, V264, P3602; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; GOULIAN M, 1989, J BIOL CHEM, V264, P19407; JOHNSON LM, 1985, CELL, V43, P369, DOI 10.1016/0092-8674(85)90042-X; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; PAUSCH MH, 1988, CANCER CELL, V6, P359; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; PLEVANI P, 1985, J BIOL CHEM, V260, P7102; SINGH H, 1984, J BIOL CHEM, V259, P7936; SINGH H, 1986, J BIOL CHEM, V261, P8564	11	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10093	10098						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037567				2022-12-25	WOS:A1991FP08600018
J	NILSSON, L; NYGARD, O				NILSSON, L; NYGARD, O			ALTERED SENSITIVITY OF EUKARYOTIC ELONGATION FACTOR-II FOR TRYPSIN AFTER PHOSPHORYLATION AND RIBOSOMAL-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; FACTOR-II; FACTOR EF-2; ADP-RIBOSYLATION; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; CROSS-LINKING; GTP-BINDING; FACTOR TU; ARTEMIA	We have used variations in the trypsin sensitivity of eukaryotic protein synthesis elongation factor 2 (eEF-2) to probe for structural alterations induced by phosphorylation, ribosomal binding, or guanosine nucleotides. We could not detect any nucleotide-related effect on the tryptic cleavage rate of Arg66. However, eEF-2 was protected from trypsin after ribosomal binding. Also, phosphorylation of eEF-2 led to a protection of Arg66. This indicates that phosphorylation leads to a structural rearrangement that could explain the reduced affinity of the phosphorylated factor for ribosomes (Carlberg, U., Nilsson, A., and Nygard, O. (1990) Eur. J. Biochem. 191, 639-645). Cleavage of Arg66 led to a complete loss of the ability of the factor to be phosphorylated. Furthermore, ribosome-bound eEF-2 was found to be inaccessible for phosphorylation. Based on these findings and previously published data, we suggest that the region around the sites of phosphorylation and trypsin cleavage is vitally important for the factor function and ribosomal binding.			NILSSON, L (corresponding author), UNIV STOCKHOLM,ARRHENIUS LABS E5,DEPT CELL BIOL,S-10691 STOCKHOLM,SWEDEN.							ARAI K, 1980, P NATL ACAD SCI-BIOL, V77, P1326, DOI 10.1073/pnas.77.3.1326; BOBUNENKO MG, 1990, BIOMED SCI, V1, P127; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; Colman R F, 1977, Methods Enzymol, V46, P240; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HUGHES SM, 1983, FEBS LETT, V164, P1, DOI 10.1016/0014-5793(83)80006-4; KAZIRO Y, 1989, NATO ADV SCI I A-LIF, V165, P291; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVERGNE JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P231, DOI 10.1016/0167-4781(90)90061-6; LOEWE PN, 1982, BIOORG CHEM, V11, P55; MIYAZAKI M, 1988, J BIOCHEM-TOKYO, V103, P508, DOI 10.1093/oxfordjournals.jbchem.a122301; MOLLER W, 1987, BIOCHIMIE, V69, P983, DOI 10.1016/0300-9084(87)90232-X; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NILSSON A, 1991, EUR J BIOCHEM, V195, P377, DOI 10.1111/j.1432-1033.1991.tb15716.x; NILSSON L, 1984, BIOCHIM BIOPHYS ACTA, V782, P49, DOI 10.1016/0167-4781(84)90105-2; NILSSON L, 1986, EUR J BIOCHEM, V161, P111, DOI 10.1111/j.1432-1033.1986.tb10130.x; NILSSON L, 1985, EUR J BIOCHEM, V148, P299, DOI 10.1111/j.1432-1033.1985.tb08839.x; NILSSON L, 1988, EUR J BIOCHEM, V171, P293, DOI 10.1111/j.1432-1033.1988.tb13789.x; NOLAN RD, 1975, EUR J BIOCHEM, V50, P391, DOI 10.1111/j.1432-1033.1975.tb09815.x; NYGARD O, 1987, BIOCHIM BIOPHYS ACTA, V908, P46, DOI 10.1016/0167-4781(87)90020-0; NYGARD O, 1987, BIOCHIM BIOPHYS ACTA, V910, P245; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; NYGARD O, 1989, EUR J BIOCHEM, V179, P603, DOI 10.1111/j.1432-1033.1989.tb14589.x; NYGARD O, 1984, EUR J BIOCHEM, V140, P93, DOI 10.1111/j.1432-1033.1984.tb08070.x; NYGARD O, 1985, BIOCHIM BIOPHYS ACTA, V824, P152, DOI 10.1016/0167-4781(85)90092-2; NYGARD O, 1990, J BIOL CHEM, V265, P6030; NYGARD O, 1985, EUR J BIOCHEM, V145, P345; PAL PK, 1978, J BIOL CHEM, V253, P6644; PETER ME, 1990, BIOCHEMISTRY-US, V29, P2876, DOI 10.1021/bi00463a033; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; VANHEMERT FJ, 1984, EMBO J, V3, P1109, DOI 10.1002/j.1460-2075.1984.tb01937.x; YONATH A, 1989, TRENDS BIOCHEM SCI, V14, P329, DOI 10.1016/0968-0004(89)90166-7; ZENGEL JM, 1984, NUCLEIC ACIDS RES, V12, P2181, DOI 10.1093/nar/12.4.2181	37	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10578	10582						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037599				2022-12-25	WOS:A1991FP08600086
J	TRAPNELL, BC; ZEITLIN, PL; CHU, CS; YOSHIMURA, K; NAKAMURA, H; GUGGINO, WB; BARGON, J; BANKS, TC; DALEMANS, W; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG				TRAPNELL, BC; ZEITLIN, PL; CHU, CS; YOSHIMURA, K; NAKAMURA, H; GUGGINO, WB; BARGON, J; BANKS, TC; DALEMANS, W; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG			DOWN-REGULATION OF CYSTIC-FIBROSIS GENE MESSENGER-RNA TRANSCRIPT LEVELS AND INDUCTION OF THE CYSTIC-FIBROSIS CHLORIDE SECRETORY PHENOTYPE IN EPITHELIAL-CELLS BY PHORBOL ESTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; TRANSMEMBRANE CONDUCTANCE REGULATOR; BETA-ADRENERGIC RESPONSE; APICAL-MEMBRANE; TRACHEAL EPITHELIUM; AIRWAY EPITHELIUM; CHANNELS; TRANSPORT; EXPRESSION; LINE	To evaluate the hypothesis that phorbol myristate acetate (PMA) might modulate the expression of the cystic fibrosis (CF) gene in epithelial cells, we examined the effect of PMA on CF mRNA levels and regulation of Cl- secretion. Strikingly, PMA down-regulated CF mRNA transcript numbers in a dose- and time-dependent manner. Importantly, in parallel with the reduction of CF mRNA levels, PMA-treated cells were unable to up-regulate Cl- secretion in a normal fashion in response to forskolin, an effect which was also dose- and time-dependent. Thus, PMA is capable of modulating expression of the CF gene and induces T84 cells to adopt the "CF phenotype" in regard to regulation of Cl- ion transport.	JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA; TRANSGENE SA, F-67082 STRASBOURG, FRANCE	Johns Hopkins University; Johns Hopkins University; Transgene SA	TRAPNELL, BC (corresponding author), NHLBI, PULM BRANCH, BLDG 10, RM 6D03, BETHESDA, MD 20892 USA.			Zeitlin, Pamela/0000-0002-2719-1834	NHLBI NIH HHS [R01HL40178, K08HL02188] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040178, K08HL002188] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARTHELSON RA, 1987, AM J PHYSIOL, V253, pC802, DOI 10.1152/ajpcell.1987.253.6.C802; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOAT TF, 1989, METABOLIC BASIS INHE, P269; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; DAVIES K, 1990, NATURE, V348, P110, DOI 10.1038/348110a0; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MANDEL KG, 1986, J BIOL CHEM, V261, P704; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; NAGAOKA I, 1990, J CLIN INVEST, V85, P2023, DOI 10.1172/JCI114669; REINLIB L, 1989, FASEB Journal, V3, pA862; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RINGE D, 1990, NATURE, V346, P312, DOI 10.1038/346312a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TRAPNELL BC, 1991, IN PRESS P NATL ACAD; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WEATHERALL DJ, 1981, PATHOPHYSIOLOGY BIOL; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1987, J CLIN INVEST, V80, P1523, DOI 10.1172/JCI113237; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; WIDDICOMBE JH, 1986, AM J PHYSIOL, V251, pR818, DOI 10.1152/ajpregu.1986.251.4.R818; WOOD LC, 1990, J BIOL CHEM, V265, P12796; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	49	100	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10319	10323						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037584				2022-12-25	WOS:A1991FP08600052
J	BOISSIER, F; AUGEGOUILLOU, C; SCHAEFFER, E; ZAKIN, MM				BOISSIER, F; AUGEGOUILLOU, C; SCHAEFFER, E; ZAKIN, MM			THE ENHANCER OF THE HUMAN TRANSFERRIN GENE IS ORGANIZED IN 2 STRUCTURAL AND FUNCTIONAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC ENHANCER; ALPHA-FETOPROTEIN GENE; SV40 ENHANCER; ALPHA-1-ANTITRYPSIN GENE; TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; BINDING; EXPRESSION; ELEMENTS; PROMOTERS	We previously identified a 300-base pair long enhancer, located 3.6 kilobases upstream of the cap site of the human transferrin gene. A 5' deletion up to position 86 of the enhancer resulted in complete loss of the enhancer activity. Here we show by competition footprint analysis, gel retardation assays, and transient expression studies in hepatoma and HeLa cells that the enhancer is composed of two distinct structural and functional domains, A (nucleotides 1-86) and B (nucleotides 87-291). Each domain is a proto-enhancer of a different type. Domain A is a proto-enhancer that, when multimerized, is able by itself to stimulate transcription from the heterologous SV40 promoter, both in Hep3B and HeLa cells. It contains the octanucleotide TGTTTGCT sequence and is the binding site of two liver-specific nuclear factors and of a different HeLa nuclear factor. Domain B contains four binding sites interacting with several liver nuclear proteins. In order to bind, any of these proteins requires the presence of all the others. This domain is able to block the activity of a downstream negative element, but it has no enhancer activity by itself. In the presence of the transferrin promoter, full enhancer activity requires the association of the two domains A and B.	INST PASTEUR,EXPRESS GENES EUCARYOTES LAB,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			GOUILLOU, Corinne AUGE/T-2346-2018	GOUILLOU, Corinne AUGE/0000-0002-3340-5560				BRUNEL F, 1988, J BIOL CHEM, V263, P10180; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CILIBERTO G, 1985, CELL, V41, P531, DOI 10.1016/S0092-8674(85)80026-X; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GALAS D, 1981, NUCLEIC ACIDS RES, V5, P3157; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GRAYSON DR, 1988, MOL CELL BIOL, V8, P1055, DOI 10.1128/MCB.8.3.1055; GUILLOU F, 1991, IN PRESS J BIOL CHEM, V266; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; SCHAEFFER E, 1989, J BIOL CHEM, V264, P7153; SCHAFFNER G, 1988, J MOL BIOL, V201, P81, DOI 10.1016/0022-2836(88)90440-8; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCOTT RW, 1983, MOL CELL BIOL, V3, P1295, DOI 10.1128/MCB.3.7.1295; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; WATANABE K, 1987, J BIOL CHEM, V262, P4812; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	25	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9822	9828						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033069				2022-12-25	WOS:A1991FM45900073
J	FRATTALI, AL; TREADWAY, JL; PESSIN, JE				FRATTALI, AL; TREADWAY, JL; PESSIN, JE			EVIDENCE SUPPORTING A PASSIVE ROLE FOR THE INSULIN-RECEPTOR TRANSMEMBRANE DOMAIN IN INSULIN-DEPENDENT SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR-I; STRUCTURAL BASIS; NEU ONCOGENE; ACTIVATION; BINDING; SUBUNIT; PHOSPHORYLATION; MECHANISM	We previously have demonstrated that intramolecular interactions between alpha-beta-alpha-beta-subunits are necessary for insulin-dependent activation of the protein kinase domain within a single alpha-2-beta-2 heterotetrameric insulin-receptor complex (Wilden, P. A., Morrison, B. D., and Pessin, J. E. (1989) Biochemistry 28, 785-792). To evaluate the role of the beta-subunit transmembrane domain in the insulin-dependent signalling mechanism, mutant human insulin receptors containing a series of nested transmembrane domain deletions (amino acids 941-945) were generated and stable Chinese hamster ovary-transfected cell lines were obtained. In addition, a substitution of Val-938 for Glu (E/V938) similar to the oncogenic mutation found in the neu transmembrane domain was also introduced into the insulin receptor. Scatchard analysis of insulin binding to the stable Chinese hamster ovary cell lines expressing either wild type or mutant insulin receptors indicated equivalent receptor number (2-4 x 10(6)/cell) and similar high affinity binding constants (K(d) 0.1-0.3 nM). I-125-Insulin affinity cross-linking demonstrated that all of the expressed insulin receptors were assembled and processed into alpha-2-beta-2 heterotetrameric complexes. Surprisingly, all the mutant insulin receptors retained insulin-stimulated autophosphorylation both in vivo and in vitro. Furthermore, endogenous substrate phosphorylation in vivo as well as insulin-stimulated thymidine incorporation into DNA were unaffected by the transmembrane domain mutations. These data demonstrate that marked structural alterations in the insulin receptor transmembrane domain do not interfere with insulin-dependent signal transduction.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NIDDK NIH HHS [DK 33823, DK 25295] Funding Source: Medline; NIGMS NIH HHS [GM07228] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, P30DK025295, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOYLE TR, 1985, J BIOL CHEM, V260, P8593; COCHET C, 1988, J BIOL CHEM, V263, P3290; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P109; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; IZUMI T, 1987, J BIOL CHEM, V262, P1282; JONG SMJ, 1991, J VIROL, V65, P180, DOI 10.1128/JVI.65.1.180-189.1991; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1985, ANNU REV MED, V36, P429; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; PESSIN JE, 1989, MOLECULAR AND CELLULAR BIOLOGY OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS, P261; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; Sambrook J, 1989, MOL CLONING LABORATO; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SIEFERT RA, 1989, J BIOL CHEM, V264, P8771; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILDEN PA, 1989, BIOCHEMISTRY-US, V28, P9734, DOI 10.1021/bi00451a029; WILDEN PA, 1989, BIOCHEMISTRY-US, V28, P785, DOI 10.1021/bi00428a056; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	36	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9829	9834						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033070				2022-12-25	WOS:A1991FM45900074
J	KRAUSE, KH; MILOS, M; LUANRILLIET, Y; LEW, DP; COX, JA				KRAUSE, KH; MILOS, M; LUANRILLIET, Y; LEW, DP; COX, JA			THERMODYNAMICS OF CATION BINDING TO RABBIT SKELETAL-MUSCLE CALSEQUESTRIN - EVIDENCE FOR DISTINCT CA-2+-BINDING AND MG-2+-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE CARDIAC CALSEQUESTRIN; AMINO-ACID SEQUENCE; SARCOPLASMIC-RETICULUM; CALCIUM-BINDING; PROTEIN INTERACTIONS; MAGNESIUM-BINDING; POSTULATED ROLE; PURIFICATION; CALMODULIN; IDENTIFICATION	Ca2+ binding to rabbit skeletal calsequestrin was studied at physiological ionic strength by equilibrium flow dialysis, Hummel-Dryer gel filtration and microcalorimetry. 31 Ca2+-binding sites with a mean dissociation constant (K(D)) of 0.79 mM were titrated in the absence, and 23 sites with a K(D) of 0.88 mM in the presence of 3 mM Mg2+. No cooperativity was observed. For Mg2+ binding, the combination of gel filtration and microcalorimetry yielded a stoichiometry of 26 Mg2+/protein with a K(D) of 2 mM. 1 mM Ca2+ decreased the stiochiometry to 20 Mg2+/protein. Binding of Ca2+ in the absence and presence of 3 mM Mg2+ was accompanied by a release of 2.0 and 2.7 H+/protein, respectively. Mg2+ binding did not lead to a significant proton release suggesting a qualitative difference in the Ca2+- and Mg2+-binding sites. After correction for proton release, the enthalpy change for Ca2+ binding was very low (-1.5 kJ/protein in the absence, and -15 kJ/protein in the presence of 3 mM Mg2+). The entropy change (+59 J/K.site in the absence and +56 J/K.site in the presence of Mg2+) was therefore virtually the sole driving force for Ca2+ binding. Mg2+ binding is slightly more exothermic (-12.6 kJ/protein), but, as for Ca2+, the entropy change (+50 J/K.site) constituted the major driving force of the reaction. A fluorimetric study indicates that the conformation of tryptophan in Mg2+-saturated calsequestrin was clearly different from that in the Ca2+-saturated protein, but that the (Ca2+ + Mg2+)-saturated protein was not distinct from the Ca2+-saturated protein. Thus, in addition to the thermodynamic characterization of the Ca2+/calsequestrin interaction, our data indicate that Ca2+ and Mg2+ do not bind to the same sites on calsequestrin. The data also predict considerable proton fluxes upon Ca2+-Mg2+ exchange in vivo.	UNIV GENEVA, DEPT BIOCHEM, 30 QUAI ERNEST ANSERMET, CH-1211 GENEVA 4, SWITZERLAND; UNIV GENEVA, HOP CANTONAL, DIV INFECT DIS, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva; University of Geneva			Milos, Mladen/D-4966-2017; Krause, Karl-Heinz/E-8030-2011	Milos, Mladen/0000-0001-9439-9400; Krause, Karl-Heinz/0000-0002-9033-6768				AARON BMB, 1984, J BIOL CHEM, V259, P1876; BERES L, 1971, BIOCHEMISTRY-US, V10, P2120; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALA SE, 1983, J BIOL CHEM, V258, P1932; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1197; COLLINS JH, 1990, BIOCHEM BIOPH RES CO, V167, P189, DOI 10.1016/0006-291X(90)91749-I; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; COX JA, 1990, J BIOL CHEM, V265, P6633; Cox JA, 1990, STIMULUS RESPONSE CO, P83; COZENS B, 1984, J BIOL CHEM, V259, P6248; DAMIANI E, 1990, BIOCHEM BIOPH RES CO, V172, P1253, DOI 10.1016/0006-291X(90)91584-F; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; IKEMOTO N, 1974, J BIOL CHEM, V249, P2357; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IMAIZUMI M, 1990, J BIOCHEM-TOKYO, V107, P127, DOI 10.1093/oxfordjournals.jbchem.a122995; KRAUSE KH, 1987, J CLIN INVEST, V80, P107, DOI 10.1172/JCI113035; KRAUSE KH, 1989, J BIOL CHEM, V264, P4269; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MACLENNAN DH, 1974, J BIOL CHEM, V249, P980; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MAMARBACHI A, 1987, CELL CALCIUM, V8, P473, DOI 10.1016/0143-4160(87)90030-3; MAURER A, 1985, P NATL ACAD SCI USA, V82, P4036, DOI 10.1073/pnas.82.12.4036; MAURER A, 1988, METHOD ENZYMOL, V157, P321; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; OBERDORF JA, 1988, J BIOL CHEM, V263, P6806; OHNISHI M, 1987, BIOCHIM BIOPHYS ACTA, V915, P180, DOI 10.1016/0167-4838(87)90298-6; OHNISHI M, 1987, BIOCHEMISTRY-US, V26, P7458, DOI 10.1021/bi00397a039; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SLUPSKY JR, 1987, BIOCHEMISTRY-US, V26, P6539, DOI 10.1021/bi00394a038; SOMLYO AV, 1985, J BIOL CHEM, V260, P6801; WILLIAMS RW, 1986, J BIOL CHEM, V261, P2408; WRIGHT DL, 1965, ANAL CHEM, V37, P884, DOI 10.1021/ac60226a025	40	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9453	9459						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033046				2022-12-25	WOS:A1991FM45900022
J	SANDY, JD; NEAME, PJ; BOYNTON, RE; FLANNERY, CR				SANDY, JD; NEAME, PJ; BOYNTON, RE; FLANNERY, CR			CATABOLISM OF AGGRECAN IN CARTILAGE EXPLANTS - IDENTIFICATION OF A MAJOR CLEAVAGE SITE WITHIN THE INTERGLOBULAR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ARTICULAR-CARTILAGE; BINDING REGION; LINK PROTEIN; PROTEOGLYCAN; METALLOPROTEINASE; DEGRADATION; STROMELYSIN; RAT	The catabolism of aggrecan has been studied in calf articular cartilage explant cultures. The chondroitin sulfate-rich, high buoyant density products that accumulate in culture medium have been purified, and NH2-terminal sequence data have been obtained. Aggrecan released from the tissue in the presence or absence of interleukin-1-alpha, whether analyzed before or after reduction and alkylation, exhibited only one major and one minor NH2-terminal sequence. The major sequence, ARGXVILXAKPDF, shows very high similarity to a region of the interglobular domain (between the G1 and G2 domains) of both human and rat aggrecan. The minor sequence, VEVS, was that previously described for the NH2 terminus of the intact core protein. These results indicate that catabolism of aggrecan in cartilage explants involves proteolytic cleavage within a conserved region of the interglobular domain and that this results in the separation of the G1 domain from the remainder of the molecule. A major product of this process is a large nonaggregating species that consists of an NH2-terminal sequence beginning with ARG (and composed of about 100 residues of the interglobular domain) that is attached to an intact G2 domain followed by an extended section of the chondroitin sulfate-bearing domain toward the COOH terminus.	UNIV S FLORIDA,INST BIOMOLEC SCI,TAMPA,FL 33612; SHRINERS HOSP CRIPPLED CHILDREN,TAMPA UNIT,TAMPA,FL 33612	State University System of Florida; University of South Florida	SANDY, JD (corresponding author), UNIV S FLORIDA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035322, R01AR038580] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 35322, AR 38580] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		DINGLE JT, 1979, BIOCHEM J, V184, P177, DOI 10.1042/bj1840177; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE K, 1990, BIOCHEM SOC T, V18, P200, DOI 10.1042/bst0180200; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; HEINEGARD D, 1972, BIOCHIM BIOPHYS ACTA, V285, P181, DOI 10.1016/0005-2795(72)90190-0; MURPHY G, 1990, BIOCHEM SOC T, V18, P812, DOI 10.1042/bst0180812; NGUYEN Q, 1989, BIOCHEM J, V259, P61, DOI 10.1042/bj2590061; PERIN JP, 1983, INT J BIOL MACROMOL, V5, P57, DOI 10.1016/0141-8130(83)90080-6; RATCLIFFE A, 1986, BIOCHEM J, V238, P571, DOI 10.1042/bj2380571; ROUGHLEY PJ, 1985, BIOCHEM J, V231, P129, DOI 10.1042/bj2310129; SANDY JD, 1987, BIOCHIM BIOPHYS ACTA, V931, P255, DOI 10.1016/0167-4889(87)90214-X; SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304-4165(78)90308-2; SANDY JD, 1990, J BIOL CHEM, V266, P8198; TEAHAN J, 1989, BIOCHEMISTRY-US, V28, P8497, DOI 10.1021/bi00447a034; WOOD DD, 1983, ARTHRITIS RHEUM, V26, P975, DOI 10.1002/art.1780260806	17	261	267	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8683	8685						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026585				2022-12-25	WOS:A1991FM03800010
J	TAYLOR, MG; MASSEY, V				TAYLOR, MG; MASSEY, V			6-MERCAPTO-FAD AND 6-THIOCYANATO-FAD AS ACTIVE-SITE PROBES OF PHENOL HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; PSEUDOMONAS-FLUORESCENS; GLUTATHIONE-REDUCTASE; TRICHOSPORON-CUTANEUM; TERTIARY STRUCTURE; FLAVIN ENZYMES; FLAVOPROTEINS; PROTEIN; BINDING; DEHYDROGENASE	Recently, the synthesis and properties of several 6-substituted flavins as active site probes for flavoproteins have been reported (Ghisla, S., Massey, V., and Yagi, K. (1986) Biochemistry 25, 3282-3289). Here, we report results of experiments in which 6-thiocyanato-FAD and 6-mercapto-FAD have been substituted for the native flavin of phenol hydroxylase. The 6-SCN-FAD enzyme was converted spontaneously to the 6-mercaptoflavin form probably due to dissociation of flavin, followed by attack of external protein thiols. The pK(a) values of uncomplexed and phenol-bound 6-mercapto-FAD enzyme were determined. Both the spontaneously formed 6-mercapto-FAD enzyme and the enzyme reconstituted with preformed 6-mercapto-FAD were treated with a variety of thiol-specific reagents, and reaction rates were followed by spectroscopic means. Comparison with the corresponding rates found with free flavin suggested a high degree of accessibility to the flavin 6-position. Accessibility was somewhat decreased in the presence of phenol. Upon treatment with low concentrations of methyl methanethiolsulfonate or N-ethylmaleimide (NEM), extremely rapid spectral changes were apparent. The former reaction, however, was reversed spontaneously within 2 h. Reaction with NEM was biphasic, with spectral changes consistent with the mechanism previously proposed (Steenkamp, D. J., McIntire, W., and Kenney, W. C. (1978) J. Biol. Chem. 253, 2818-2824), followed by a small absorbance decrease due to protein conformational changes. The NEM reaction is unusual, being easily reversed by addition of excess dithiothreitol.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSENIS C, 1964, BIOCHIM BIOPHYS ACTA, V92, P440, DOI 10.1016/0926-6569(64)90003-3; BEATY NB, 1981, J BIOL CHEM, V256, P4611; BRUICE TC, 1980, ACCOUNTS CHEM RES, V13, P256, DOI 10.1021/ar50152a002; BURNETT RM, 1974, J BIOL CHEM, V249, P4383; CLAIBORNE A, 1982, J BIOL CHEM, V257, P174; DANNA JA, 1971, BIOCHEMISTRY-US, V10, P57; DETMER K, 1984, J BIOL CHEM, V259, P1265; DETMER KM, 1984, FLAVINS FLAVOPROTEIN, P765; ENTSCH B, 1980, J BIOL CHEM, V255, P1420; FITZPATRICK PF, 1985, J BIOL CHEM, V260, P8483; GHISLA S, 1986, BIOCHEMISTRY-US, V25, P3282, DOI 10.1021/bi00359a030; GHISLA S, 1986, BIOCHEM J, V239, P1; HEMMERICH P, 1977, FEBS LETT, V84, P5, DOI 10.1016/0014-5793(77)81047-8; HOFSTEENGE J, 1980, EUR J BIOCHEM, V113, P141; KAZARINOFF MN, 1974, BIOCHIM BIOPHYS ACTA, V359, P282, DOI 10.1016/0005-2795(74)90226-8; KRAUTHSIEGEL RL, 1985, EUR J BIOCHEM, V148, P335, DOI 10.1111/j.1432-1033.1985.tb08844.x; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; LIU TY, 1977, PROTEINS, V3, P239; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MANSTEIN DJ, 1986, J BIOL CHEM, V261, P6169; MASSEY V, 1986, BIOCHEMISTRY-US, V25, P8095, DOI 10.1021/bi00372a045; MASSEY V, 1986, BIOCHEMISTRY-US, V25, P8103, DOI 10.1021/bi00372a046; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1984, J BIOL CHEM, V259, P9667; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MASSEY V, 1982, FLAVINS FLAVOPROTEIN, P83; MAYER EJ, 1981, ANAL BIOCHEM, V116, P227, DOI 10.1016/0003-2697(81)90348-1; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P289, DOI 10.1016/0005-2744(71)90207-5; NEUJAHR HY, 1975, EUR J BIOCHEM, V58, P351, DOI 10.1111/j.1432-1033.1975.tb02381.x; NEUJAHR HY, 1973, EUR J BIOCHEM, V35, P386, DOI 10.1111/j.1432-1033.1973.tb02851.x; NEUJAHR HY, 1988, FEBS LETT, V242, P75; POWLOWSKI J, 1989, J BIOL CHEM, V264, P16008; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; TAYLOR MG, 1990, J BIOL CHEM, V265, P13687; TSIBRIS JCM, 1964, J BIOL CHEM, V241, P1138; VANDERLAAN JM, 1986, THESIS RIJKSUNIVERSI; VISSER J, 1970, BIOCHIM BIOPHYS ACTA, V206, P224, DOI 10.1016/0005-2744(70)90106-3; WALSH C, 1980, ACCOUNTS CHEM RES, V13, P148, DOI 10.1021/ar50149a004; WEIJER WJ, 1983, EUR J BIOCHEM, V133, P109, DOI 10.1111/j.1432-1033.1983.tb07435.x; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; WIERENGA RK, 1979, J MOL BIOL, V131, P55, DOI 10.1016/0022-2836(79)90301-2; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5	43	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8281	8290						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022645				2022-12-25	WOS:A1991FK44100053
J	CALI, JJ; HSIEH, CL; FRANCKE, U; RUSSELL, DW				CALI, JJ; HSIEH, CL; FRANCKE, U; RUSSELL, DW			MUTATIONS IN THE BILE-ACID BIOSYNTHETIC ENZYME STEROL 27-HYDROXYLASE UNDERLIE CEREBROTENDINOUS XANTHOMATOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HUMAN ADRENODOXIN; LDL RECEPTOR; CHOLIC-ACID; DNA; GENE; 26-HYDROXYLATION; FRAGMENTS; BINDING; C27-STEROIDS	The sterol storage disorder cerebrotendinous xanthomatosis (CTX) is characterized by abnormal deposition of cholesterol and cholestanol in multiple tissues. Deposition in the central nervous system leads to neurological dysfunction marked by dementia, spinal cord paresis, and cerebellar ataxia. Deposition in other tissues causes tendon xanthomas, premature atherosclerosis, and cataracts. In two unrelated patients with CTX, we have identified different point mutations in the gene (CYP27) encoding sterol 27-hydroxylase, a key enzyme in the bile acid biosynthesis pathway. Transfection of mutant cDNAs into cultured cells results in the synthesis of immunoreactive sterol 27-hydroxylase protein with greatly diminished enzyme activity. We have localized the CYP27 gene to the q33-qter interval of human chromosome 2, and to mouse chromosome 1, in agreement with the autosomal recessive inheritance pattern of CTX. These findings underscore the essential role played by sterols in the central nervous system and suggest that mutations in other sterol metabolizing enzymes may contribute to diseases with neurological manifestations.	STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University	CALI, JJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Russell, David/0000-0002-0277-403X	NHLBI NIH HHS [P01 HL020948, HL-20948] Funding Source: Medline; NIGMS NIH HHS [GM-26105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO MA, 1988, IMMUNOGENETICS, V27, P91, DOI 10.1007/BF00351081; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARTON DE, 1989, GENOMICS, V5, P91, DOI 10.1016/0888-7543(89)90091-8; BERGINER VM, 1981, AM J MED GENET, V10, P151, DOI 10.1002/ajmg.1320100209; BJORKHEM I, 1983, J CLIN INVEST, V71, P142, DOI 10.1172/JCI110742; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BJORKHEM I, 1989, METABOLIC BASIS INHE, P1283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DANIELSSON H, 1973, BILE ACIDS, P1; ESSER V, 1988, J BIOL CHEM, V263, P13282; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HARLAN WR, 1968, NEW ENGL J MED, V278, P416, DOI 10.1056/NEJM196802222780803; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KOOPMAN BJ, 1988, J INHERIT METAB DIS, V11, P56, DOI 10.1007/BF01800057; LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; LYON MF, 1990, MOUSE GENOME, V87, P28; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MENKES JH, 1968, ARCH NEUROL-CHICAGO, V19, P47, DOI 10.1001/archneur.1968.00480010065004; MIKI H, 1986, CLIN CHIM ACTA, V160, P255, DOI 10.1016/0009-8981(86)90192-0; MOREL Y, 1988, AM J HUM GENET, V43, P52; MYANT NB, 1981, BIOL CHOLESTEROL REL, P1; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NORTON WT, 1976, BASIC NEUROCHEMISTRY, P74; OFTEBRO H, 1980, J CLIN INVEST, V65, P1418, DOI 10.1172/JCI109806; Pastershank S P, 1974, J Can Assoc Radiol, V25, P282; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALEN G, 1987, NEW ENGL J MED, V316, P1233, DOI 10.1056/NEJM198705143162002; SALEN G, 1975, BIOCHEM MED METAB B, V14, P57, DOI 10.1016/0006-2944(75)90020-4; SALEN G, 1979, J CLIN INVEST, V63, P38, DOI 10.1172/JCI109275; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETOGUCHI T, 1974, J CLIN INVEST, V53, P1393, DOI 10.1172/JCI107688; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; SOLISH SB, 1988, P NATL ACAD SCI USA, V85, P7104, DOI 10.1073/pnas.85.19.7104; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TULS J, 1989, J BIOL CHEM, V264, P16421; VANBOGAERT L, 1937, UNE FORME CEREBRALE, P1; WIKVALL K, 1984, J BIOL CHEM, V259, P3800; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	46	356	368	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7779	7783						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019602				2022-12-25	WOS:A1991FJ34200074
J	HWANG, DS; KAGUNI, JM				HWANG, DS; KAGUNI, JM			DNAK PROTEIN STIMULATES A MUTANT FORM OF DNAA PROTEIN IN ESCHERICHIA-COLI DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; NORMAL GROWTH TEMPERATURES; BACTERIOPHAGE-LAMBDA; CHROMOSOME-REPLICATION; NUCLEOPROTEIN STRUCTURES; AUTO-REGULATION; AUTOPHOSPHORYLATING ACTIVITY; DELTA-DNAK52 MUTANTS; PLASMID MAINTENANCE; INITIATION PROTEIN	Two proteins have been identified which stimulate a mutant form of dnaA protein in replication of plasmids containing the chromosomal origin, oriC. One of these is dnaK protein by the criteria of (i) absence of stimulatory activity in enzyme fractions from dnaK mutants, (ii) elevated levels of stimulatory activity in fractions from a dnaK protein overproducer, (iii) comigration of the stimulatory protein with authentic dnaK protein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and (iv) replacement of this stimulatory protein by dnaK protein in stimulation assays. The stimulatory effect of dnaK protein on dnaA46 protein in replication suggests that this interaction, occurring prior to its action in DNA replication, may regulate its activity.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University				Kaguni, Jon/0000-0002-3096-4447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33992, R01 GM033992] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ATLUNG T, 1985, MOL GEN GENET, V200, P442, DOI 10.1007/BF00425729; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BITTNER M, 1981, GENE, V15, P319, DOI 10.1016/0378-1119(81)90175-X; BOCHNER BR, 1986, J BACTERIOL, V168, P931, DOI 10.1128/jb.168.2.931-935.1986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAUN RE, 1987, J BACTERIOL, V169, P3898, DOI 10.1128/jb.169.9.3898-3903.1987; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; BREMER H, 1985, J BACTERIOL, V164, P922, DOI 10.1128/JB.164.2.922-924.1985; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COOPER S, 1968, J MOL BIOL, V31, P519, DOI 10.1016/0022-2836(68)90425-7; DESCHAIES RJ, 1988, NATURE, V332, P800; DODSON M, 1989, J BIOL CHEM, V264, P10719; DONACHIE WD, 1968, NATURE, V219, P1077, DOI 10.1038/2191077a0; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Georgopoulos C., 1971, BACTERIOPHAGE LAMBDA, P553; GEORGOPOULOS CP, 1977, MOL GEN GENET, V151, P35, DOI 10.1007/BF00446910; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HUGHES P, 1988, CELL, V55, P343, DOI 10.1016/0092-8674(88)90057-8; HWANG DS, 1988, J BIOL CHEM, V263, P10633; HWANG DS, 1990, J BIOL CHEM, V265, P19244; HWANG DS, 1988, J BIOL CHEM, V263, P10625; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KAGUNI JM, 1981, P NATL ACAD SCI USA, V76, P6250; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; KIM MH, 1981, P NATL ACAD SCI-BIOL, V78, P6784, DOI 10.1073/pnas.78.11.6784; KUCHERER C, 1986, MOL GEN GENET, V205, P115, DOI 10.1007/BF02428040; KUNG FC, 1978, J BACTERIOL, V133, P755, DOI 10.1128/JB.133.2.755-762.1978; LEONARD AC, 1988, J BACTERIOL, V170, P1380, DOI 10.1128/jb.170.3.1380-1383.1988; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LOTHER H, 1985, EMBO J, V4, P555, DOI 10.1002/j.1460-2075.1985.tb03664.x; Miller J. H., 1972, EXPT MOL GENETICS, P433; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRITCHARD R H, 1969, Symposium of the Society for General Microbiology, V19, P263; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; STUITJE AR, 1986, NUCLEIC ACIDS RES, V14, P2333, DOI 10.1093/nar/14.5.2333; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; WADA M, 1986, J BACTERIOL, V168, P213, DOI 10.1128/jb.168.1.213-220.1986; WANG QP, 1989, J BIOL CHEM, V264, P7338; WANG QP, 1987, MOL GEN GENET, V209, P518, DOI 10.1007/BF00331158; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; ZYSKIND JW, 1977, J BACTERIOL, V129, P1466, DOI 10.1128/JB.129.3.1466-1475.1977	64	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7537	7541						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019584				2022-12-25	WOS:A1991FJ34200036
J	NIGGLI, V; KELLER, H				NIGGLI, V; KELLER, H			ON THE ROLE OF PROTEIN-KINASES IN REGULATING NEUTROPHIL ACTIN ASSOCIATION WITH THE CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC PEPTIDE; RABBIT NEUTROPHILS; FREE CALCIUM; LEU-PHE; STAUROSPORINE; PHOSPHORYLATION; POLYMERIZATION; POTENT; PURIFICATION; LEUKOCYTES	We have investigated the effect of staurosporine-type protein kinase inhibitors, displaying different enzyme specificity, on the association of actin with the neutrophil cytoskeleton. In resting cells, nanomolar concentrations of staurosporine induced a rapid increase in cytoskeleton-associated actin. Other inhibitors, more specific for protein kinase C (PKC) or kinases dependent on cyclic nucleotides, induced a much smaller response, indicating that inhibition of these enzymes is not involved in the staurosporine-dependent rise. Therefore, inhibition of an unknown staurosporine-sensitive enzyme, not identical with PKC or one of the cyclic nucleotide-dependent kinases, can trigger an increase in cytoskeletal actin. It is well known that chemotactic peptide induces a rapid rise in cytoskeletal actin, followed by a decrease at later times after the onset of activation. Preincubation with CGP 41 251, a relatively specific inhibitor for PKC, did not affect these two events at concentrations of the drug which, in separate experiments, inhibited markedly phorbol ester induced protein phosphorylation in intact neutrophils. Thus the chemotactic peptide-induced changes in the level of cytoskeletal actin appear to be independent of PKC activation.			NIGGLI, V (corresponding author), UNIV BERN,DEPT PATHOL,MURTENSTR 31,CH-3010 BERN,SWITZERLAND.							AMREIN PC, 1980, BLOOD, V56, P442; ANDREWS PC, 1983, BLOOD, V61, P333; BADWEY JA, 1989, BIOCHEM BIOPH RES CO, V158, P1029, DOI 10.1016/0006-291X(89)92825-8; BENGTSSON T, 1986, EUR J CELL BIOL, V42, P338; BENGTSSON T, 1988, J BIOL CHEM, V263, P17385; BIRRELL GB, 1989, J CELL PHYSIOL, V141, P74, DOI 10.1002/jcp.1041410112; BLACKBURN WD, 1987, BIOCHEM BIOPH RES CO, V144, P1229, DOI 10.1016/0006-291X(87)91442-2; BOYUM A, 1968, SCAND J CLIN LAB S97, V21, P1; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; FERRANTE A, 1980, J IMMUNOL METHODS, V36, P109, DOI 10.1016/0022-1759(80)90036-8; HEDBERG KK, 1990, EXP CELL RES, V188, P199, DOI 10.1016/0014-4827(90)90160-C; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5030; HORN W, 1986, BIOCHEM BIOPH RES CO, V139, P1169, DOI 10.1016/S0006-291X(86)80300-X; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KELLER HU, 1990, J CELL SCI, V96, P99; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MOLSKI TFP, 1987, CELL MOTIL CYTOSKEL, V8, P1, DOI 10.1002/cm.970080102; NIGGLI V, 1989, Experientia (Basel), V45, pA39; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; RAO KMK, 1982, J IMMUNOL, V129, P1605; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SHAAFI RI, 1983, BIOCHEM BIOPH RES CO, V114, P638, DOI 10.1016/0006-291X(83)90828-8; SHAAFI RI, 1986, J CELL BIOL, V102, P1459, DOI 10.1083/jcb.102.4.1459; SHAAFI RI, 1987, BIOCHEM BIOPH RES CO, V145, P934, DOI 10.1016/0006-291X(87)91055-2; SHETERLINE P, 1986, J MUSCLE RES CELL M, V7, P405, DOI 10.1007/BF01753583; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THERRIEN S, 1989, J CELL BIOL, V109, P1125, DOI 10.1083/jcb.109.3.1125; WHITE JR, 1982, BIOCHEM BIOPH RES CO, V108, P1144, DOI 10.1016/0006-291X(82)92120-9	31	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7927	7932						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019607				2022-12-25	WOS:A1991FJ34200094
J	ATTRI, AK; LEWIS, MS; KORN, ED				ATTRI, AK; LEWIS, MS; KORN, ED			THE FORMATION OF ACTIN OLIGOMERS STUDIED BY ANALYTICAL ULTRACENTRIFUGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA PROFILIN; ATP HYDROLYSIS; STEADY-STATE; F-ACTIN; POLYMERIZATION; MECHANISM; PROTEINS; KINETICS; EXCHANGE; INHIBITION	The small oligomers formed from Mg-G-actin under favorable conditions were studied by sedimentation velocity ultracentrifugation. The critical concentration of actin at pH 7.8 in the presence of 100-mu-M MgCl2 and 200-mu-M ATP was 12.5 +/- 2.8-mu-M. Under these conditions, about 15% of 7.5-mu-M Mg-actin was converted to oligomers of subunit size four to eight in 5 h at 20-degrees-C. In 100-mu-M MgCl2 and no free ATP, the critical concentration was about 6.5-mu-M, and about 22% of 7.5-mu-M Mg-actin was converted to dimers in 80 min. There were no detectable higher oligomers or F-actin present in either case. As determined by the analysis of ATP hydrolysis, most, if not all, of the oligomer subunits contained ATP. When 28.5-mu-M actin was polymerized to steady state in 100-mu-M MgCl2 and 200-mu-M ATP, about 50% of the actin was present as F-actin, consistent with the critical concentration (approximately 12.5-mu-M), about 50% as oligomers as large as seven subunits, and only about 5% as monomers. When solutions containing oligomers were diluted the oligomers dissociated. Alternatively, when the MgCl2 concentration was raised to 1 mM, the solutions containing oligomers polymerized more rapidly than monomeric Mg-G-actin and to the same final steady state. These data are entirely consistent with the condensation-elongation model for helical polymerization proposed by Oosawa and Kasai (Oosawa, F., and Kasai, M. (1962) J. Mol. Biol. 4, 10-21) according to which, under certain conditions, substantial amounts of short linear and helical oligomers should be formed below the critical concentration and linear oligomers should coexist with monomers and F-actin at steady state.	NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	ATTRI, AK (corresponding author), NHLBI,CELL BIOL LAB,BETHESDA,MD 20892, USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				BRENNER SL, 1980, J BIOL CHEM, V255, P841; BRENNER SL, 1983, J BIOL CHEM, V258, P5013; BUBB MR, 1991, J BIOL CHEM, V266, P3820; COOPER JA, 1983, BIOCHEMISTRY-US, V22, P2193, DOI 10.1021/bi00278a021; FRIEDEN C, 1983, P NATL ACAD SCI-BIOL, V80, P6513, DOI 10.1073/pnas.80.21.6513; FRIEDEN C, 1985, ANNU REV BIOPHYS BIO, V14, P189, DOI 10.1146/annurev.bb.14.060185.001201; GERSHMAN LC, 1984, BIOCHEMISTRY-US, V23, P2199, DOI 10.1021/bi00305a015; GODDETTE DW, 1986, J BIOL CHEM, V261, P2605; GRAZI E, 1989, J MUSCLE RES CELL M, V10, P275, DOI 10.1007/BF01758423; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; IKKAI T, 1966, BIOCHEMISTRY-US, V5, P1551, DOI 10.1021/bi00869a015; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL AA, 1985, J BIOL CHEM, V260, P132; LAMBOOY PK, 1986, J BIOL CHEM, V261, P7150; LAMBOOY PK, 1988, J BIOL CHEM, V263, P12831; LANNI F, 1984, BIOPHYS J, V46, P97, DOI 10.1016/S0006-3495(84)84002-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, P NATL ACAD SCI USA, V84, P3151, DOI 10.1073/pnas.84.10.3151; MCCLURE JA, 1983, J BIOL CHEM, V258, P4570; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MOCKRIN SC, 1983, J BIOL CHEM, V258, P3215; NEWMAN J, 1985, BIOCHEMISTRY-US, V24, P1538, DOI 10.1021/bi00327a037; OOI T, 1961, J BIOCHEM-TOKYO, V50, P128, DOI 10.1093/oxfordjournals.jbchem.a127420; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Oosawa F, 1971, SUBUNITS BIOL SYST A, P261; OOSAWA F, 1983, MUSCLE NONMUSCLE MOT, V1, P151; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SPUDICH JA, 1971, J BIOL CHEM, V246, P4865; TOBACMAN LS, 1983, J BIOL CHEM, V258, P8806; TOBACMAN LS, 1982, J BIOL CHEM, V257, P4166; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; VILLARIAS MA, 1985, BIOCHEMISTRY-US, V24, P1544; WEGNER A, 1982, BIOCHEMISTRY-US, V21, P1909, DOI 10.1021/bi00537a032	40	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6815	6824						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016296				2022-12-25	WOS:A1991FG72700029
J	DAGNINO, L; BENNETT, LL; PATERSON, ARP				DAGNINO, L; BENNETT, LL; PATERSON, ARP			SODIUM-DEPENDENT NUCLEOSIDE TRANSPORT IN MOUSE LEUKEMIA L1210-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; MAMMALIAN-CELLS; NITROBENZYLTHIOINOSINE; L1210; SENSITIVITY; SPECIFICITY; MEMBRANE; KINETICS; BINDING; SYSTEM	Nucleoside permeation in L1210/AM cells is mediated by (a) equilibrative (facilitated diffusion) transporters of two types and by (b) a concentrative Na+-dependent transport system of low sensitivity to nitrobenzylthioinosine and dipyridamole, classical inhibitors of equilibrative nucleoside transport. In medium containing 10-mu-M dipyridamole and 20-mu-M adenosine, the equilibrative nucleoside transport systems of L1210/AM cells were substantially inhibited and the unimpaired activity of the Na+-dependent nucleoside transport system resulted in the cellular accumulation of free adenosine to 86-mu-M in 5 min, a concentration three times greater than the steady-state levels of adenosine achieved without dipyridamole. Uphill adenosine transport was not observed when extracellular Na+ was replaced by Li+, K+, Cs+, or N-methyl-D-glucammonium ions, or after treatment of the cells with nystatin, a Na+ ionophore. These findings show that concentrative nucleoside transport activity in L1210/AM cells required an inward transmembrane Na+ gradient. Treatment of cells in sodium medium with 2 mM furosemide in the absence or presence of 2 mM ouabain inhibited Na+-dependent adenosine transport by 50 and 75%, respectively. However, because treatment of cells with either agent in Na+-free medium decreased adenosine transport by only 25%, part of this inhibition may be secondary to the effects of furosemide and ouabain on the ionic content of the cells. Substitution of extracellular Cl- by SO4(-2) or SCN- had no effect on the concentrative influx of adenosine.	UNIV ALBERTA,CANC RES GRP,MCEACHERN LAB,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,DEPT PHARMACOL,EDMONTON T6G 2H7,ALBERTA,CANADA; SO RES INST,BIRMINGHAM,AL 35255	University of Alberta; University of Alberta				Dagnino, Lina/0000-0003-1483-5159				BELT JA, 1983, MOL PHARMACOL, V24, P479; BELT JA, 1988, J BIOL CHEM, V263, P13819; BELT JA, 1985, BIOCHEM J, V232, P681, DOI 10.1042/bj2320681; BENNETT LL, 1982, P AM ASSOC CANC RES, V23, P6; CASS CE, 1974, BIOCHIM BIOPHYS ACTA, V345, P1, DOI 10.1016/0005-2736(74)90239-9; DAGNINO L, 1987, P AM ASSOC CANC RES, V28, P15; DAGNINO L, 1988, THESIS U ALBERTA EDM; DAGNINO L, 1990, CANCER RES, V50, P6544; DAHLIGHARLEY E, 1981, BIOCHEM J, V200, P295, DOI 10.1042/bj2000295; DARNOWSKI JW, 1987, CANCER RES, V47, P2614; DRACH JC, 1973, ANAL BIOCHEM, V52, P633, DOI 10.1016/0003-2697(73)90071-7; GATI WP, 1989, RED BLOOD CELL MEMBR, P635; HARLEY ER, 1982, CANCER RES, V42, P1289; HLADKY SB, 1984, RED CELL MEMBRANES M, P335; JAKOBS ES, 1986, BIOCHEM BIOPH RES CO, V140, P1028, DOI 10.1016/0006-291X(86)90738-2; JARVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132, DOI 10.1016/0005-2736(89)90533-6; KAUNITZ JD, 1982, P NATL ACAD SCI-BIOL, V79, P2315, DOI 10.1073/pnas.79.7.2315; KIMMICH GA, 1979, AM J PHYSIOL, V237, pC56, DOI 10.1152/ajpcell.1979.237.1.C56; LYNCH TP, 1978, BIOCHEM PHARMACOL, V27, P1303, DOI 10.1016/0006-2952(78)90473-2; PATERSON ARP, 1981, PHARMACOL THERAPEUT, V12, P515, DOI 10.1016/0163-7258(81)90096-6; PATERSON ARP, 1987, TOPICS PERSPECTIVES, P89; PLAGEMANN PGW, 1984, BIOCHIM BIOPHYS ACTA, V773, P39, DOI 10.1016/0005-2736(84)90548-0; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; RANDERATH K, 1966, THIN LAYER CHROMATOG, P219; SPECTOR R, 1984, J NEUROCHEM, V42, P1048, DOI 10.1111/j.1471-4159.1984.tb12709.x; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; WOHLHUETER RM, 1978, J MEMBRANE BIOL, V42, P247, DOI 10.1007/BF01870361	27	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6308	6311						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007583				2022-12-25	WOS:A1991FE37300047
J	FORCHHAMMER, K; BOCK, A				FORCHHAMMER, K; BOCK, A			SELENOCYSTEINE SYNTHASE FROM ESCHERICHIA-COLI - ANALYSIS OF THE REACTION SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOSERYL-TRANSFER RNA; INSERTS SELENOCYSTEINE; MAMMALIAN-CELLS; NONSENSE CODON; SERINE; IDENTIFICATION; PROTEIN; UGA; RECOGNIZES	The product of the selA gene, selenocysteine synthase, is a pyridoxal 5-phosphate-containing enzyme which catalyzes the conversion of seryl-tRNA(UCA)Sec into selenocysteyl-tRNA(UCA)Sec. Reduction of the aldimine group of pyridoxal 5-phosphate inactivates the enzyme. When reacted with seryl-tRNA(UCA)Sec as sole substrate, pyruvate (and possibly also ammonia) is released; in the presence of a high concentration of potassium borohydride, alanyl-tRNA(UCA)Sec is formed from seryl-tRNA(UCA)Sec. These results support the notion that the formyl group of pyridoxal phosphate forms a Schiff base with the alpha-amino group of L-serine with the subsequent 2,3-elimination of a water molecule and the generation of an aminoacrylyl-tRNA(UCA)Sec intermediate. ATP is not required for this reaction step, but it is necessary for the conversion of aminoacrylyl-tRNA into selenocysteyl-tRNA(UCA)Sec which, in addition, requires the SELD protein and reduced selenium. Selenocysteine synthase forms a stable complex with seryl-tRNA(UCA)Sec with one tRNA molecule bound per two 50-kDa monomers. The enzyme does not interact with serine-inserting tRNA species. Taken together, the results show that biosynthesis of selenocysteine takes place in the enzyme-bound state and involves the dehydration of L-serine esterified to tRNA in a first step formally followed by the 2,3-addition of HSe- which is provided by the SELD protein in an ATP-dependent reaction in the form of a reactive selenium donor molecule.	UNIV MUNICH,LEHRSTUHL MIKROBIOL,MARIA WARD STR 1A,W-8000 MUNICH 19,GERMANY	University of Munich								BRAUNSTE.AE, 1971, BIOCHIM BIOPHYS ACTA, V242, P247, DOI 10.1016/0005-2744(71)90105-7; BRZOVIC P, 1990, BIOCHEMISTRY-US, V29, P442, DOI 10.1021/bi00454a020; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; DIAMOND A, 1981, CELL, V25, P497, DOI 10.1016/0092-8674(81)90068-4; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; HATFIELD D, 1982, P NATL ACAD SCI-BIOL, V79, P6215, DOI 10.1073/pnas.79.20.6215; HEIDER J, 1989, NUCLEIC ACIDS RES, V17, P2529, DOI 10.1093/nar/17.7.2529; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; MEHLITZ A, 1963, CHEM ZTG, V87, P573; MIZUTANI T, 1989, FEBS LETT, V247, P345, DOI 10.1016/0014-5793(89)81367-5; MIZUTANI T, 1986, FEBS LETT, V207, P162, DOI 10.1016/0014-5793(86)80032-1; SUNDE RA, 1987, J BIOL CHEM, V262, P933	16	156	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6324	6328						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007585				2022-12-25	WOS:A1991FE37300050
J	ALTMANN, SW; JOHNSON, GD; PRYSTOWSKY, MB				ALTMANN, SW; JOHNSON, GD; PRYSTOWSKY, MB			SINGLE PROLINE SUBSTITUTIONS IN PREDICTED ALPHA-HELICES OF MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RESULT IN A LOSS IN BIOACTIVITY AND ALTERED GLYCOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOROTHIOATE-MODIFIED DNA; GM-CSF; MOLECULAR-CLONING; SECONDARY-STRUCTURE; CELL LINES; EXPRESSION; PROTEINS; CDNA; IDENTIFICATION; GROWTH	Contributions of alpha-helices to biological activity in murine granulocyte-macrophage colony-stimulating factor were analyzed using site-directed mutagenesis and protein expression in COS-1 cells. A series of single proline substitutions were made for residues within the four predicted alpha-helices as a means of disrupting local helical secondary structure. Mutations in three of the four helices resulted in marked reductions in bioactivity. Five mutants E21P, L56P, E60P, L63P, and L107P showed 10(2)-10(4)-fold reduction in bioactivity as well as hyperglycosylation. The same Pro substitutions made on non-N-glycosylated molecules had a similar loss in bioactivity implying that a Pro-induced structural change and not hyperglycosylation was responsible for the major decrease in bioactivity. Additional amino acid substitutions at these residues which conserved charge or hydrophobicity, or replaced the original residue with an Ala, verified that conformational changes in the protein structure were specifically due to steric constraints imposed by the Pro residue rather than loss of important side chain functions.	UNIV PENN,DEPT PATHOL & LAB MED,547 CLIN RES BLDG,422 CURIE BLVD,PHILADELPHIA,PA 19104; SMITHKLINE BEECHAM,DEPT MOLEC GENET,SWEDELAND,PA 19406	University of Pennsylvania; GlaxoSmithKline					NATIONAL CANCER INSTITUTE [T32CA009171, R01CA048648] Funding Source: NIH RePORTER; NCI NIH HHS [CA 48648, CA 09171-14] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUSUBEL FM, CURRENT PROTOCOLS MO, V1; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BROWN CB, 1990, J IMMUNOL, V144, P2184; CALTABIANO MM, 1989, GENE, V85, P479, DOI 10.1016/0378-1119(89)90442-3; CEBON J, 1988, BLOOD, V72, P1340; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; DEBON J, 1990, J BIOL CHEM, V265, P4483; DONAHUE RE, 1988, SCIENCE, V241, P1820, DOI 10.1126/science.3051378; FLEISCHMANN J, 1986, BLOOD, V68, P708; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLDWASSER E, 1983, NORMAL NEOPLASTIC HE, P301; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; Ihle J N, 1985, Prog Clin Biol Res, V184, P85; JAFFE BD, 1988, ONCOGENE, V2, P167; KAUSHANSKY K, 1987, BIOCHEMISTRY-US, V26, P4861, DOI 10.1021/bi00389a038; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KAUSHANSKY K, 1990, INT J CELL CLONING, V8, pS26; LABRANCHE CC, 1990, ARCH BIOCHEM BIOPHYS, V276, P153, DOI 10.1016/0003-9861(90)90022-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALONDE JM, 1989, J MOL BIOL, V205, P783, DOI 10.1016/0022-2836(89)90323-9; LEE F, 1985, P NATL ACAD SCI USA, V82, P4360, DOI 10.1073/pnas.82.13.4360; LEONG SR, 1989, VET IMMUNOL IMMUNOP, V21, P261, DOI 10.1016/0165-2427(89)90036-6; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MESSING J, 1983, METHOD ENZYMOL, V101, P20; METCALF D, 1986, BLOOD, V67, P257; MIYATAKE S, 1985, EMBO J, V4, P2562; MOONEN P, 1987, P NATL ACAD SCI USA, V84, P4428, DOI 10.1073/pnas.84.13.4428; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NICOLA NA, 1985, NATURE, V314, P625, DOI 10.1038/314625a0; Parry D A, 1988, J Mol Recognit, V1, P107, DOI 10.1002/jmr.300010302; PRYSTOWSKY MB, 1982, J IMMUNOL, V129, P2337; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOLI D, 1987, J IMMUNOL, V139, P3348; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; SPEAR BT, 1985, J EXP MED, V162, P1802, DOI 10.1084/jem.162.6.1802; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0; WEISBART RH, 1985, NATURE, V314, P361, DOI 10.1038/314361a0; WINGFIELD P, 1988, EUR J BIOCHEM, V173, P65, DOI 10.1111/j.1432-1033.1988.tb13967.x; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WONG GG, 1985, CANCER CELL, V3, P235	50	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5333	5341						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	2002066				2022-12-25	WOS:A1991FC21700095
J	QURESHI, SA; CAO, XM; SUKHATME, VP; FOSTER, DA				QURESHI, SA; CAO, XM; SUKHATME, VP; FOSTER, DA			V-SRC ACTIVATES MITOGEN-RESPONSIVE TRANSCRIPTION FACTOR EGR-1 VIA SERUM RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE EARLY GENES; FINGER-ENCODING GENE; C-FOS; 3T3 CELLS; MAMMALIAN-CELLS; GROWTH-FACTORS; CHLORAMPHENICOL ACETYLTRANSFERASE; DIFFERENTIAL EXPRESSION; PROTEIN; BINDING	Activating the protein-tyrosine kinase activity of v-Src in murine fibroblasts leads to increased expression of Egr-1, a mitogen-responsive transcription factor. v-Src-induced expression of Egr-1 is independent of protein synthesis and is controlled at the level of transcription. Target sequences responsive to v-Src-induced signals were investigated using deletion mutant analysis of the Egr-1 promoter. Upstream Egr-1 promoter sequences linked to a reporter gene were cotransfected with a v-Src expression vector into NIH 3T3 cells. v-Src-enhanced gene expression from the Egr-1 promoter was dependent upon the presence of CC(A/T)6GG elements. The CC(A/T)6GG motif forms the core element of serum response elements (SREs) and is the binding site for serum response factor. The Egr-1 promoter sequences responsive to v-Src contained four SREs. Sequential deletion of these SREs reduced v-Src responsiveness to basal transcription levels. A single SRE from this region was able to confer v-Src responsiveness to a heterologous promoter, and a mutation to the CC(A/T)6GG box of this SRE abolished v-Src-enhanced gene expression. Thus, an early response of v-Src-induced intracellular signaling is the transcriptional activation of a growth factor-responsive transcription factor via an SRE.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, DEPT MED BIOL, NEW YORK, NY 10021 USA; UNIV CHICAGO, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); University of Chicago; Howard Hughes Medical Institute; University of Chicago			Sukhatme, Vikas/W-2776-2019		NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DAVIS LG, 1986, BASIC METHODS MOL BI, P84; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAY GM, 1988, J BIOL CHEM, V263, P10714; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HATCH CL, 1987, ANAL BIOCHEM, V162, P283, DOI 10.1016/0003-2697(87)90038-8; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, IN PRESS ONCOGENE; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WELHAM MJ, 1990, ONCOGENE, V5, P161; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	43	96	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10802	10806						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040600				2022-12-25	WOS:A1991FQ77400018
J	SEN, K; NIKAIDO, H				SEN, K; NIKAIDO, H			TRIMERIZATION OF AN INVITRO SYNTHESIZED OMPF PORIN OF ESCHERICHIA-COLI OUTER-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; SPHEROPLASTS; EXPORT	The assembly of outer membrane proteins of Escherichia coli was examined using the OmpF porin as a model. Since this protein is made as a precursor, which is processed to a protein of M(r) 37,000 before being assembled into trimers in the outer membrane, we synthesized a modified OmpF, which lacked 16 out of 22 amino acid residues from its signal sequence, in a coupled transcription-translation system. This modified protein resembled the unfolded, monomeric OmpF in its electrophoretic behavior, but much of the protein apparently existed in a more tightly folded conformation as it was recognized by a monoclonal antibody specific to a surface epitope of the native, trimeric OmpF porin. At least some conformers of this protein could be further incorporated into outer membrane or lipopolysaccharide bilayers, and assembled into trimers. The trimers formed were trypsin-resistant and heat-stable in sodium dodecyl sulfate up to 70-degrees-C, thus showing the characteristics of the native trimeric protein. These results extend our earlier observation that OmpF monomer secreted by spheroplasts of E. coli can be trimerized in vitro (Sen, K., and Nikaido, H (1990) Proc. Natl. Acad. Sci. U. S. A 87, 743-747) and show that the trimerization can occur, albeit at a low efficiency, with porin monomers synthesized in vitro, presumably not contaminated by membrane fragments or other components of the cell envelope. However, comparison of trimerization efficiency of the nascent in vitro product with that of the same product already exposed to aqueous medium, as well as with that of the spheroplast-secreted product, leads us to the working hypothesis that the trimerization process in intact cells is accelerated either by accessory components or by the conformational changes accompanying the secretion through the cytoplasmic membrane and that the reactions observed in this study represent only part of the physiological process.			SEN, K (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009644, R01AI009644] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09644] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAVOIL P, 1977, MOL GEN GENET, V158, P23, DOI 10.1007/BF00455116; BENSON S, 1985, ANN REV BIOCH, V154, P101; DECOCK H, 1990, J BIOL CHEM, V265, P4646; DECOCK H, 1990, BIOCHIMIE, V72, P177, DOI 10.1016/0300-9084(90)90143-5; EMR SD, 1982, J BIOL CHEM, V257, P5852; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOLOMB M, 1974, J BIOL CHEM, V249, P2858; KLEBBA PE, 1990, J BIOL CHEM, V265, P6800; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MASUYAMA S, 1984, J BACTERIOL, V158, P1041; METCALFE M, 1980, FEMS MICROBIOL LETT, V7, P111, DOI 10.1111/j.1574-6941.1980.tb01587.x; Miller J.H., 1972, EXPT MOL GENETICS; MUTOH N, 1982, FEBS LETT, V137, P171, DOI 10.1016/0014-5793(82)80341-4; NIKAIDO H, 1990, EXPERIENTIA, V46, P174; RANDALL LL, 1987, ANNU REV MICROBIOL, V41, P507; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; REID J, 1988, J BIOL CHEM, V263, P7753; REYNOLDS RL, 1988, THESIS U CALIFORNIA; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; TABOR S, 1985, P NATL ACAD SCI USA, V76, P4350	23	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11295	11300						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040634				2022-12-25	WOS:A1991FQ77400091
J	MATSUDA, J; OKABE, S; HASHIMOTO, T; YAMADA, Y				MATSUDA, J; OKABE, S; HASHIMOTO, T; YAMADA, Y			MOLECULAR-CLONING OF HYOSCYAMINE 6-BETA-HYDROXYLASE, A 2-OXOGLUTARATE-DEPENDENT DIOXYGENASE, FROM CULTURED ROOTS OF HYOSCYAMUS-NIGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N SYNTHETASE GENE; DEACETOXYCEPHALOSPORIN-C SYNTHETASE; PROLYL 4-HYDROXYLASE; STREPTOMYCES-CLAVULIGERUS; ESCHERICHIA-COLI; MESSENGER-RNA; SEQUENCE DETERMINATION; ASPERGILLUS-NIDULANS; NUCLEOTIDE-SEQUENCE; ALPHA-SUBUNIT	Roots of several solanaceous plants produce anticholinergic alkaloids, hyoscyamine and scopolamine. Hyoscyamine 6-beta-hydroxylase, a 2-oxoglutarate-dependent dioxygenase (EC 1.14.11.11), catalyzes hydroxylation of hyoscyamine in the biosynthetic pathway leading to scopolamine. We report here on the isolation of cDNA clones encoding the hydroxylase from a cDNA library made from mRNA of the cultured roots of Hyoscyamus niger. The library was screened with three synthetic oligonucleotides that encode amino acid sequences of internal peptide fragments of the purified hydroxylase. Nucleotide sequence analysis of the cloned cDNA revealed an open reading frame that encodes 344 amino acids (M(r) = 38,999). All 12 internal peptide fragments determined in the purified enzyme were found in the amino acid sequence deduced from the cDNA. With computer-aided comparison to other proteins we found that the hydroxylase is homologous to two synthases involved in the biosynthesis of beta-lactam antibiotics in some microorganisms and the gene products of tomato pTOM 13 cDNA and maize A2 locus which had been proposed to catalyze oxidative reactions in the biosynthesis of ethylene and anthocyan, respectively. RNA blotting hybridization showed that mRNA of the hydroxylase is abundant in cultured roots and present in plant roots, but absent in leaves, stems, and cultured cells of H. niger.	KYOTO UNIV, FAC AGR, DEPT AGR CHEM, KYOTO 606, JAPAN	Kyoto University								BALDWIN JE, 1988, NAT PROD REP, V5, P129, DOI 10.1039/np9880500129; BASSUK JA, 1989, P NATL ACAD SCI USA, V86, P7382, DOI 10.1073/pnas.86.19.7382; CARR LG, 1986, GENE, V48, P257, DOI 10.1016/0378-1119(86)90084-3; COHEN G, 1990, TRENDS BIOTECHNOL, V8, P105, DOI 10.1016/0167-7799(90)90148-Q; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEAN C, 1986, NUCLEIC ACIDS RES, V14, P2229, DOI 10.1093/nar/14.5.2229; DEIKMAN J, 1988, EMBO J, V7, P3315, DOI 10.1002/j.1460-2075.1988.tb03202.x; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; HASHIMOTO T, 1991, J BIOL CHEM, V266, P4648; HASHIMOTO T, 1987, AGR BIOL CHEM TOKYO, V51, P2769; HASHIMOTO T, 1987, EUR J BIOCHEM, V164, P277, DOI 10.1111/j.1432-1033.1987.tb11055.x; HASHIMOTO T, 1986, PLANT PHYSIOL, V81, P619, DOI 10.1104/pp.81.2.619; HASHIMOTO T, 1986, J PLANT PHYSIOL, V124, P61, DOI 10.1016/S0176-1617(86)80178-X; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HOFFMAN NE, 1982, PLANT PHYSIOL, V69, P317, DOI 10.1104/pp.69.2.317; HOLDSWORTH MJ, 1987, NUCLEIC ACIDS RES, V15, P731, DOI 10.1093/nar/15.2.731; HOLDSWORTH MJ, 1987, NUCLEIC ACIDS RES, V15, P10600, DOI 10.1093/nar/15.24.10600; JENSEN SE, 1985, J ANTIBIOT, V38, P263, DOI 10.7164/antibiotics.38.263; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KOVACEVIC S, 1989, J BACTERIOL, V171, P754, DOI 10.1128/jb.171.2.754-760.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEETE E, 1990, PLANTA MED, V56, P339, DOI 10.1055/s-2006-960979; LESKIW BK, 1988, GENE, V62, P187, DOI 10.1016/0378-1119(88)90557-4; MENSSEN A, 1990, EMBO J, V9, P3051, DOI 10.1002/j.1460-2075.1990.tb07501.x; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAMON D, 1987, GENE, V57, P171, DOI 10.1016/0378-1119(87)90120-X; Sambrook J, 1989, MOL CLONING LABORATO; SAMSON SM, 1985, NATURE, V318, P191, DOI 10.1038/318191a0; SAMSON SM, 1987, P NATL ACAD SCI USA, V84, P5705, DOI 10.1073/pnas.84.16.5705; SAMSON SM, 1987, BIO-TECHNOL, V5, P1207, DOI 10.1038/nbt1187-1207; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIFFMAN D, 1988, MOL GEN GENET, V214, P562, DOI 10.1007/BF00330495; SHIFFMAN D, 1990, NUCLEIC ACIDS RES, V18, P660, DOI 10.1093/nar/18.3.660; Waller G.R, 1978, ALKALOID BIOL METABO, P121; WEIGEL BJ, 1988, J BACTERIOL, V170, P3817, DOI 10.1128/jb.170.9.3817-3826.1988; YAMADA Y, 1990, P JPN ACAD B-PHYS, V66, P73, DOI 10.2183/pjab.66.73	38	176	189	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9460	9464						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033047				2022-12-25	WOS:A1991FM45900023
J	RUDNICK, DA; MCWHERTER, CA; ROCQUE, WJ; LENNON, PJ; GETMAN, DP; GORDON, JI				RUDNICK, DA; MCWHERTER, CA; ROCQUE, WJ; LENNON, PJ; GETMAN, DP; GORDON, JI			KINETIC AND STRUCTURAL EVIDENCE FOR A SEQUENTIAL ORDERED BI BI MECHANISM OF CATALYSIS BY SACCHAROMYCES-CEREVISIAE MYRISTOYL-COA - PROTEIN N-MYRISTOYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE AMINOPEPTIDASE; ESCHERICHIA-COLI; MEMBRANE ASSOCIATION; BOVINE LIVER; ACID; ACYLATION; ANALOG; ACYLTRANSFERASE; TRANSFORMATION; SPECIFICITIES	The mechanism of catalysis of Escherichia coli-derived Saccharomyces cerevisiae myristoyl-CoA: protein N-myristoyltransferase (NMT) has been characterized. Previous studies indicated that a high affinity reaction intermediate forms between NMT and myristoyl-CoA in the absence of a peptide substrate. This complex has been further characterized using S-(2-oxo)pentadecyl-CoA, a nonhydrolyzable myristoyl-CoA analog. Binding studies involving this analog, as well as myristoylpeptide and CoA, have indicated that the CoA moiety of the acyl substrate is retained in the acyl-NMT complex prior to peptide addition. These structural data, along with kinetic studies of myristoylpeptide and CoA product inhibition, indicate that the mechanism of catalysis of NMT is ordered Bi Bi, with myristoyl-CoA binding to NMT occurring prior to peptide binding and CoA release taking place before release of acyl peptide. Further analyses of the interactions between NMT, acyl peptide, and CoA demonstrate that NMT is able to deacylate a myristoylpeptide in the presence of CoA.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,660 S EUCLID AVE,BOX 8103,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; MONSANTO CORP RES,ST LOUIS,MO 63198	Washington University (WUSTL); Washington University (WUSTL); Monsanto					NIAID NIH HHS [AI27179, AI30188] Funding Source: Medline; NIGMS NIH HHS [GM07200] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; CHANG YH, 1990, J BIOL CHEM, V265, P19892; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CZUBA B, 1980, J BIOL CHEM, V255, P5296; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DESILVA AM, 1990, J CELL BIOL, V111, P401; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, IN PRESS J BIOL CHEM, V266; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1988, J BIOL CHEM, V263, P2127; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KISHORE NS, 1991, IN PRESS J BIOL CHEM; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; NANDI DL, 1979, J BIOL CHEM, V254, P7230; PAIGE LA, 1989, J MED CHEM, V32, P1665, DOI 10.1021/jm00128a001; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1991, IN PRESS LIPID MODIF; Rudolph F B, 1979, Methods Enzymol, V63, P411; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; Segel I.H., 1975, ENZYME KINETICS; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	36	124	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9732	9739						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033063				2022-12-25	WOS:A1991FM45900062
J	SAWHNEY, RS; HERING, TM; SANDELL, LJ				SAWHNEY, RS; HERING, TM; SANDELL, LJ			BIOSYNTHESIS OF SMALL PROTEOGLYCAN-II (DECORIN) BY CHONDROCYTES AND EVIDENCE FOR A PROCORE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; SKIN PROTEODERMATAN SULFATE; SWARM RAT CHONDROSARCOMA; CARTILAGE LINK PROTEINS; CELL-FREE TRANSLATION; SMOOTH-MUSCLE CELLS; CHONDROITIN SULFATE; CORE PROTEIN; ENDOPLASMIC-RETICULUM; ARTICULAR-CARTILAGE	We have studied the biosynthesis of cartilage dermatan sulfate proteoglycan II (DS-PGII) (decorin) using in vitro translation of mRNA to determine the size of the primary gene product and by radiolabeling the protein in the presence of tunicamycin to inhibit the addition of Asn-linked oligosaccharides. Pulse-chase experiments were performed to examine post-translational processing and secretion. Inhibitors of oligosaccharide processing were used to determine whether DS-PGII molecules containing partially processed oligosaccharides could become proteoglycans and be secreted. Cell-free translation of sucrose gradient-fractionated RNA and subsequent immunoprecipitation of the core protein confirmed that the functional translated mRNA is in the size range of the two mRNA species observed by hybridization of chondrocyte RNA with a bone PGII cloned probe and that the translation product is a single protein with an apparent molecular mass of 42 kDa. Digestion of the intact proteoglycan (average molecular mass = 103 kDa) with chondroitinase ABC or AC results in an approximately 48-49-kDa product. Chondrocytes treated with tunicamycin to inhibit Asn-linked oligosaccharide addition synthesize and secrete a glycosaminoglycan (GAG)-substituted proteoglycan (average molecular mass = 86 kDa), yielding a 42-kDa core protein after chondroitinase ABC digestion, showing that Asn-linked oligosaccharides are not required for the addition of GAG chains or secretion. Following a short pulse (10 min) of [H-3]leucine, three glycosylated forms of the DS-PGII core protein were observed, one of which is likely to be the precursor form of PGII predicted by the implied protein sequence of both bovine and human cDNA clones. Following the apparent cleavage of the propeptide, GAG-substituted intracellular core protein is detectable. Susceptibility to endoglycosidase H indicates that approximately one-third of the secreted core protein contains exclusively complex-type Asn-linked oligosaccharides and approximately two-thirds contain high mannose as well as complex-type oligosaccharides. Secreted DS-PGII appears to be fully substituted with three Asn-linked oligosaccharide chains. Inhibitors of oligosaccharide processing, however, permitted secretion of GAG-substituted DS-PGII that was fully (three chains) or incompletely (one or two chains) substituted with partially processed Asn-linked carbohydrate chains. By comparison of chondrocyte DS-PGII with fibroblast DS-PGII, we conclude that the addition and processing of Asn-linked carbohydrate chains are directed by the amino acid sequence of the core protein. The results reported here also suggest that the addition of xylose, the initial step in GAG chain synthesis, occurs early in biosynthesis and is determined by the primary amino acid sequence of the core protein. The temporal sequence of proteoglycan biosynthesis was found to be: 1) translation of mRNA and addition of Asn-linked carbohydrate chains, 2) removal of the precursor (pro) sequence and addition of the GAG linkage region to appropriate serine residues, 3) elongation of GAG chains and processing of Asn-linked oligosaccharides to the complex form, and 4) secretion.	VET ADM MED CTR, DEPT ORTHOPAED ORT112, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT MED, CHICAGO, IL 60612 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT BIOCHEM, CHICAGO, IL 60612 USA; UNIV WASHINGTON, DEPT ORTHOPAED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Rush University; Rush University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NEI NIH HHS [R03EY067735] Funding Source: Medline; NIADDK NIH HHS [R23AM34142] Funding Source: Medline; NIAMS NIH HHS [R01AR36994] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R23AM034142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036994] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alwine J C, 1979, Methods Enzymol, V68, P220; AVRAHAM S, 1988, J BIOL CHEM, V263, P7292; AXELSSON I, 1975, BIOCHEM J, V145, P491, DOI 10.1042/bj1450491; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURDON MA, 1990, EXTRACELLULAR MATRIX, P157; BRENNAN MJ, 1984, J BIOL CHEM, V259, P3742; CAMPBELL MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P275, DOI 10.1016/0003-9861(84)90350-3; CHANG Y, 1983, J BIOL CHEM, V258, P5679; CHEN KF, 1984, J HISTOCHEM CYTOCHEM, V32, P347, DOI 10.1177/32.4.6200530; COSTER L, 1981, BIOCHEM J, V193, P143, DOI 10.1042/bj1930143; COSTER L, 1987, J BIOL CHEM, V262, P3809; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DORFMAN A, 1981, PROTEOGLYCAN BIOSYNT, P115; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; GLOSSL J, 1986, J BIOL CHEM, V261, P1920; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; GROSS V, 1983, J BIOL CHEM, V258, P2203; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; HEINEGARD D, 1981, BIOCHEM J, V197, P355, DOI 10.1042/bj1970355; HERING TM, 1990, J BIOL CHEM, V265, P2375; HERING TM, 1988, J BIOL CHEM, V263, P1030; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; KIMURA JH, 1987, METHOD ENZYMOL, V144, P372; KINSELLA MG, 1988, J BIOL CHEM, V263, P19222; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARJAVA H, 1988, BIOCHEM J, V256, P35, DOI 10.1042/bj2560035; LOHMANDER LS, 1986, ARCH BIOCHEM BIOPHYS, V250, P211, DOI 10.1016/0003-9861(86)90719-8; LOHMANDER LS, 1989, J BIOL CHEM, V264, P18775; Maniatis T, 1982, MOL CLONING LABORATO; MEEK RL, 1982, J BIOL CHEM, V257, P2245; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; PEARSON CH, 1983, J BIOL CHEM, V258, P5101; RATCLIFFE A, 1985, J CELL BIOL, V101, P2355, DOI 10.1083/jcb.101.6.2355; RAUCH U, 1986, BIOCHEM J, V238, P465, DOI 10.1042/bj2380465; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROLLINS BJ, 1982, GLYCOCONJUGATES, V3, P289; ROMERO PA, 1985, FEBS LETT, V183, P29, DOI 10.1016/0014-5793(85)80947-9; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; ROSENBERG LC, 1986, CIBA F SYMP, V124, P47; ROUGHLEY PJ, 1989, BIOCHEM J, V262, P823, DOI 10.1042/bj2620823; SANDELL LJ, 1988, EUR J CELL BIOL, V46, P253; SCHWARTZ NB, 1975, FEBS LETT, V49, P342, DOI 10.1016/0014-5793(75)80781-2; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SCOTT PG, 1990, CONNECT TISSUE RES, V24, P225, DOI 10.3109/03008209009152151; SPIRO RC, 1989, J BIOL CHEM, V264, P1779; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; VOGEL KG, 1986, J BIOL CHEM, V261, P1334; VOGEL KG, 1985, J BIOL CHEM, V260, P9298; VOGEL KG, 1990, T ORTHOP RES SOC, V15, P41; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	61	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9231	9240						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026622				2022-12-25	WOS:A1991FM03800086
J	GILLESGONZALEZ, MA; ENGELMAN, DM; KHORANA, HG				GILLESGONZALEZ, MA; ENGELMAN, DM; KHORANA, HG			STRUCTURE-FUNCTION STUDIES OF BACTERIORHODOPSIN-XV - EFFECTS OF DELETIONS IN LOOP-B-C AND LOOP-E-F ON BACTERIORHODOPSIN CHROMOPHORE AND STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE-PROTEIN; PURPLE MEMBRANE; GENE; DNA; RENATURATION; EXPRESSION; RECONSTITUTION; DENATURATION; POLYPEPTIDE	Bacteriorhodopsin mutants containing deletions in loop B-C, DELTA-Thr67-Glu74 or DELTA-Gly65-Gln75, or a deletion in the loop E-F, DELTA-Glu161-Ala168, were prepared. Following their expression in Escherichia coli, the mutant proteins were purified to homogeneity and refolded with retinal in detergent-phospholipid mixtures. The mutants containing deletions in the loop B-C were normal at 4-degrees-C but showed the following changes at 20-degrees-C. 1) The lambda-max shifted from 540 to below 510 nm; 2) the rates of bleaching by hydroxylamine in the dark increased; and 3) the rate and steady state of proton pumping decreased. Deletion of the eight amino acids in loop E-F did not affect wild-type behavior. However, all the mutant proteins were more prone to thermal and sodium dodecyl sulfate denaturation than the wild-type bacteriorhodopsin. These observations show that the structures of the B-C and E-F loops are not essential for correct folding of bacteriorhodopsin, but they contribute to the stability of the folded protein.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Yale University					NIAID NIH HHS [AI 11479] Funding Source: Medline; NIGMS NIH HHS [GM28289, 5 PO1 GM 22778] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028289, R37GM028289, P01GM022778] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BAYLEY H, 1981, P NATL ACAD SCI-BIOL, V78, P2225, DOI 10.1073/pnas.78.4.2225; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; DUNN R, 1981, P NATL ACAD SCI-BIOL, V78, P6744, DOI 10.1073/pnas.78.11.6744; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2023, DOI 10.1073/pnas.77.4.2023; FIMMEL S, 1989, BIOCHIM BIOPHYS ACTA, V978, P231, DOI 10.1016/0005-2736(89)90120-X; FUCHS R, 1983, METHOD ENZYMOL, V100, P2; GUARENTE L, 1980, CELL, V20, P543, DOI 10.1016/0092-8674(80)90640-6; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989; HUANG KS, 1981, J BIOL CHEM, V256, P3802; HUANG KS, 1982, J BIOL CHEM, V257, P13616; KARNIK SS, 1987, J BIOL CHEM, V262, P9255; KHORANA HG, 1979, P NATL ACAD SCI USA, V76, P5046, DOI 10.1073/pnas.76.10.5046; KIMURA K, 1982, J BIOL CHEM, V257, P2859; LIAO MJ, 1984, J BIOL CHEM, V259, P4194; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; LONDON E, 1982, J BIOL CHEM, V257, P7003; MCCOY JM, 1983, J BIOL CHEM, V258, P8456; OESTERHELT D, 1974, FEBS LETT, V44, P257, DOI 10.1016/0014-5793(74)81152-X; OVCHINNIKOV YA, 1979, FEBS LETT, V100, P219, DOI 10.1016/0014-5793(79)80338-5; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; RACKER E, 1974, J BIOL CHEM, V249, P662; REHOREK M, 1979, BIOCHEMISTRY-US, V18, P4977, DOI 10.1021/bi00589a027; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH M, 1979, CELL, V16, P753, DOI 10.1016/0092-8674(79)90091-6; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3	30	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8545	8550						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022666				2022-12-25	WOS:A1991FK44100088
J	HAZUDA, DJ; STRICKLER, J; SIMON, P; YOUNG, PR				HAZUDA, DJ; STRICKLER, J; SIMON, P; YOUNG, PR			STRUCTURE-FUNCTION MAPPING OF INTERLEUKIN-1 PRECURSORS - CLEAVAGE LEADS TO A CONFORMATIONAL CHANGE IN THE MATURE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-1-ALPHA; ESCHERICHIA-COLI HEMOLYSIN; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; GROWTH-FACTOR; PURIFICATION; CLONING; 1-BETA; CDNA; EXPRESSION	The two interleukin 1 (IL-1) genes (IL-1-alpha and beta) encode 31-kDa precursor molecules, which are cleaved upon secretion to generate the mature, active, carboxyl-terminal 17-kDa proteins. The IL-1-beta-precursor is inactive, whereas the IL-1-alpha-precursor is as active as the mature IL-1-alpha. In this report, we demonstrate that when either of the recombinant precursors is processed to the mature form, the mature region undergoes a conformational change from a proteinase K-sensitive structure to one that is proteinase K-insensitive. In addition, cysteine residues that are exposed to solvent in the IL-1-beta-precursor become buried in the mature protein. Limited structure-activity mapping of the IL-1-beta-precursor indicates that the amino-terminal 76 residues are responsible for the conformational change, whereas the most dramatic change in biological activity occurs after further removal of residues 77-94. These findings suggest that the altered structure of the mature region in precursor IL-1s has been conserved for some function. Denaturation/renaturation experiments implicate the precursor domain in protein folding, and by analogy with signal-directed secretory proteins, the unique conformation of the precursors may play a role in IL-1 secretion.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MACROMOLEC SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT DEPT IMMUNOL,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; AURON PE, 1987, J IMMUNOL, V138, P1447; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BALDARI C, 1987, EMBO J, V6, P229, DOI 10.1002/j.1460-2075.1987.tb04743.x; BEUSCHER HU, 1988, J BIOL CHEM, V263, P4023; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BOMFORD R, 1987, IMMUNOLOGY, V62, P543; CRAIG S, 1987, BIOCHEMISTRY-US, V26, P3570, DOI 10.1021/bi00386a048; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; FELMLEE T, 1985, J BACTERIOL, V163, P88, DOI 10.1128/JB.163.1.88-93.1985; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GIRI JG, 1985, J IMMUNOL, V134, P343; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GUBLER U, 1986, J IMMUNOL, V136, P2492; HASSELL AM, 1989, J BIOL CHEM, V264, P4948; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HORUK R, 1987, J BIOL CHEM, V262, P16275; HUANG JJ, 1987, FEBS LETT, V223, P294, DOI 10.1016/0014-5793(87)80307-1; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KOBAYASHI Y, 1990, J BIOCHEM-TOKYO, V107, P666, DOI 10.1093/oxfordjournals.jbchem.a123105; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; LILLQUIST JS, 1988, J IMMUNOL, V141, P1975; LIMJUCO G, 1986, P NATL ACAD SCI USA, V83, P3972, DOI 10.1073/pnas.83.11.3972; LIVI GP, 1990, GENE, V88, P297, DOI 10.1016/0378-1119(90)90048-V; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MASUI Y, 1989, THERAPEUTIC PEPTIDES, P167; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MEYERS CA, 1987, J BIOL CHEM, V262, P11176; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; NEURATH H, 1976, P NATL ACAD SCI USA, V73, P3825, DOI 10.1073/pnas.73.11.3825; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SIMON PL, 1985, J IMMUNOL METHODS, V84, P85, DOI 10.1016/0022-1759(85)90417-X; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; STEINER DF, 1968, P NATL ACAD SCI USA, V60, P622, DOI 10.1073/pnas.60.2.622; STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205; SUTTLES J, 1990, J IMMUNOL, V144, P175; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; YOUNG PR, 1989, PROTEIN ENG, V2, P545, DOI 10.1093/protein/2.7.545; YOUNG PR, 1988, PROG LEUK BIOL, V8, P83	52	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7081	7086						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016316				2022-12-25	WOS:A1991FG72700068
J	HAUGEJORDEN, SM; SRINIVASAN, M; GREEN, M				HAUGEJORDEN, SM; SRINIVASAN, M; GREEN, M			ANALYSIS OF THE RETENTION SIGNALS OF 2 RESIDENT LUMINAL ENDOPLASMIC-RETICULUM PROTEINS BY INVITRO MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ER PROTEINS; SECRETION	Protein disulfide isomerase (PDI, ERp59), ERp72, and ERp61 are luminal proteins of the endoplasmic reticulum (ER) that are characterized by the presence of sequences corresponding to the active site regions of PDI. Each one of these proteins possesses a different COOH-terminal tetrapeptide ER retention signal. In order to investigate what other tetrapeptide sequences could serve as retention signals and to determine to what extent the function of the retention signal is modulated by the protein carrying the signal, we have constructed a set of mutants of two of these resident ER proteins, PDI and ERp72. In each of these proteins, the wild type tetrapeptide sequences were replaced by each member of the set of the 12 possible combinations consisting of (K,R,Q)-(D,E)-(D,E)-L. Analysis of the efficiency of retention of the variant proteins when each was transiently expressed in COS cells showed that the retention efficiencies vary with both the COOH-terminal sequence and with the protein that carries this sequence.	ST LOUIS UNIV,SCH MED,DEPT MICROBIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104	Saint Louis University								ANDRES DA, 1990, J BIOL CHEM, V265, P5952; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; COLEMAN J, 1985, CELL, V43, P351, DOI 10.1016/0092-8674(85)90040-6; FLIEGEL L, 1990, J BIOL CHEM, V265, P15496; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; TOMIZAWA HH, 1962, J BIOL CHEM, V237, P3393; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0	14	57	58	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6015	6018						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007562				2022-12-25	WOS:A1991FE37300003
J	MUTA, T; MIYATA, T; MISUMI, Y; TOKUNAGA, F; NAKAMURA, T; TOH, Y; IKEHARA, Y; IWANAGA, S				MUTA, T; MIYATA, T; MISUMI, Y; TOKUNAGA, F; NAKAMURA, T; TOH, Y; IKEHARA, Y; IWANAGA, S			LIMULUS FACTOR-C - AN ENDOTOXIN-SENSITIVE SERINE PROTEASE ZYMOGEN WITH A MOSAIC STRUCTURE OF COMPLEMENT-LIKE, EPIDERMAL GROWTH FACTOR-LIKE, AND LECTIN-LIKE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TACHYPLEUS-TRIDENTATUS HEMOCYTES; HORSESHOE-CRAB HEMOCYTES; RECEPTOR CDNA; LIPOPOLYSACCHARIDE; PURIFICATION; IDENTIFICATION; POLYPHEMUS; AMEBOCYTES; ACTIVATION	Factor C is an endotoxin-sensitive, intracellular serine protease zymogen which initiates the coagulation cascade system in the limulus hemolymph. We have determined the entire amino acid sequence of factor C using recombinant DNA technique. The zymogen consisted of 994 amino acid residues with a calculated molecular mass of 109,648 Da. Most interestingly, factor C has five repeating units ("Sushi" domain or short consensus repeat) of about 60 amino acid residues each, which have been found in many proteins participating in the mammalian complement system. In addition to a typical serine protease domain in the carboxyl-terminal portion, characteristic segments with an epidermal growth factor-like, a lectin-like, a cysteine-rich, and a proline-rich domain were also found, revealing a unique mosaic protein structure. The serine protease domain was most analogous to human thrombin. Factor C was identified to localize in large granules in the cell, indicating that it is released from the cell by lipopolysaccharide stimulation. Furthermore, we identified a transcript possibly derived by alternative splicing of factor C mRNA, which encodes a protein sharing the amino-terminal portion of factor C. We suggest that factor C, a newly discovered type of serine protease zymogen, is a "coagulation-complement factor" which may play important roles in both hemostasis and host defense mechanisms.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; FUKUOKA UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 81401,JAPAN	Kyushu University; Kyushu University; Fukuoka University				Tokunaga, Fuminori/0000-0003-3626-9119				BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Brehelin M., 1986, IMMUNITY INVERTEBRAT; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; HOJRUP P, 1987, BIOCHEM J, V245, P887, DOI 10.1042/bj2450887; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAUFFMAN DL, 1965, J MOL BIOL, V12, P929, DOI 10.1016/S0022-2836(65)80340-0; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; MACKINNON CM, 1987, EUR J BIOCHEM, V169, P547, DOI 10.1111/j.1432-1033.1987.tb13644.x; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MIYATA T, 1984, J BIOL CHEM, V259, P8924; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; MURAMOTO K, 1986, BIOCHIM BIOPHYS ACTA, V874, P285, DOI 10.1016/0167-4838(86)90027-0; MURER EH, 1975, J CELL PHYSIOL, V86, P533, DOI 10.1002/jcp.1040860310; NAKAMURA T, 1988, J BIOCHEM, V103, P370, DOI 10.1093/oxfordjournals.jbchem.a122276; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1988, EUR J BIOCHEM, V176, P89, DOI 10.1111/j.1432-1033.1988.tb14254.x; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Ornberg R.L., 1979, Progress in Clinical and Biological Research, V29, P125; PERKINS SJ, 1988, BIOCHEMISTRY-US, V27, P4004, DOI 10.1021/bi00411a017; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SPIESS M, 1985, J BIOL CHEM, V260, P1979; TAKEYA H, 1988, J BIOL CHEM, V263, P14868; TOKUNAGA F, 1987, EUR J BIOCHEM, V167, P405, DOI 10.1111/j.1432-1033.1987.tb13352.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	34	153	165	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6554	6561						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007602				2022-12-25	WOS:A1991FE37300082
J	TANG, BZ; NAZAR, RN				TANG, BZ; NAZAR, RN			STRUCTURE OF THE YEAST RIBOSOMAL 5-S RNA-BINDING PROTEIN-YL3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE RIBOSOMES; TRANSCRIPTION FACTOR TFIIIA; ESCHERICHIA-COLI RIBOSOMES; GLOBULAR PROTEINS; XENOPUS-LAEVIS; DNA; SEQUENCE; GENE; L5	A gene coding for the 5 S rRNA-binding protein (YL3) in yeast (Saccharomyces cerevisiae) was isolated using a polymerase chain reaction-amplified gene probe. The DNA sequence contains no introns and codes for a 297 amino acid (M(r) = 33,741) protein. Although the protein is just 1 residue longer than in rat, unlike the high sequence homology in the 5 S rRNAs from the same organisms, only about 45% of the amino acid residues are conserved with surprisingly little homology in the carboxyl-terminal end. Nevertheless, comparative studies indicate that a number of structural features are conserved including small repeats in the primary structure and a number of helical estimates in the higher order structure. One of the sequence repeats also appears to be present in the carboxyl-terminal end of the eukaryotic transcription factor TFIIIA suggesting an evolutionary relationship in these 5 S RNA-binding proteins.			TANG, BZ (corresponding author), UNIV GUELPH,DEPT MOLEC BIOL & GENET,GUELPH N1G 2W1,ONTARIO,CANADA.							BITAR KG, 1975, H-S Z PHYSIOL CHEM, V356, P1343, DOI 10.1515/bchm2.1975.356.2.1343; BLATTNER FR, 1977, SCIENCE, V196, P161, DOI 10.1126/science.847462; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; BROSIUS J, 1975, FEBS LETT, V56, P359, DOI 10.1016/0014-5793(75)81127-6; CHAN YL, 1987, J BIOL CHEM, V262, P12879; CHEN R, 1976, FEBS LETT, V69, P240, DOI 10.1016/0014-5793(76)80695-3; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Cryer D R, 1975, Methods Cell Biol, V12, P39; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRETT RA, 1981, TRENDS BIOCHEM SCI, V6, P137, DOI 10.1016/0968-0004(81)90051-7; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MCDOUGALL J, 1983, J BIOL CHEM, V258, P5256; NAZAR RN, 1979, EUR J BIOCHEM, V102, P573, DOI 10.1111/j.1432-1033.1979.tb04274.x; NAZAR RN, 1982, CELL NUCLEUS, V11, P1; NAZAR RN, 1983, NUCLEIC ACIDS RES, V11, P3155, DOI 10.1093/nar/11.10.3155; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; ROSE GD, 1978, NATURE, V272, P586, DOI 10.1038/272586a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHASTRY BS, 1984, J BIOL CHEM, V259, P1373; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; TSO JY, 1986, NUCLEIC ACIDS RES, V14, P2187, DOI 10.1093/nar/14.5.2187; VANRYK DI, 1990, J BIOL CHEM, V265, P8377; WORMINGTON WM, 1989, MOL CELL BIOL, V9, P5281, DOI 10.1128/MCB.9.12.5281; YAGUCHI M, 1984, EUR J BIOCHEM, V139, P451, DOI 10.1111/j.1432-1033.1984.tb08026.x	27	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6120	6123						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007570				2022-12-25	WOS:A1991FE37300021
J	LEE, JH; LI, YC; DOERRE, S; SISTA, P; BALLARD, DW; GREENE, WC; FRANZA, BR				LEE, JH; LI, YC; DOERRE, S; SISTA, P; BALLARD, DW; GREENE, WC; FRANZA, BR			A MEMBER OF THE SET OF KAPPA-B BINDING-PROTEINS, HIVEN86A, IS A PRODUCT OF THE HUMAN C-REL PROTOONCOGENE	ONCOGENE			English	Note							RECEPTOR-ALPHA-GENE; TRANSCRIPTION FACTOR; CELLULAR PROTEINS; T-CELLS; ENHANCER; NUCLEAR; EXPRESSION; TRANSACTIVATION; ACTIVATION; SEQUENCES	HIVEN86A is an inducible member of a set of cellular proteins that specifically bind to the kappa-B enhancer (Franza et al., 1987; Franza, 1988; Franza, 1990; Ballard et al., 1989; Bohnlein et al., 1988). This enhancer motif has been detected in numerous cellular and viral transcription control domains (Boshart et al., 1985; Sen & Baltimore, 1986; Nabel & Baltimore, 1987). Recently, cDNAs have been cloned (Kieran et al., 1990; Baldwin & Sharp, 1987) that encode the 50 kD DNA binding subunit of murine NF-kappa-B (for review: Leonardo & Baltimore, 1989) and the closely related human kappa binding factor (KBF-1) (Kimura et al., 1986; Baldwin & Sharp, 1987). A 350 amino acid domain at the N-terminus of these proteins was found to be homologous with the v-rel oncogene from the avian reticuloendotheliosis virus, strain T (REV-T), as well as a maternal effect gene, dorsal (Kieran et al., 1990; Ghosh et al., 1990). Dorsal is known to activate transcription of certain Drosophila genes (Rushlow et al., 1987). The v-Rel oncoprotein has been identified as a transcriptional activator (Gelinas & Temin, 1988; Hannink & Temin, 1989; Bull et al., 1990) in certain assay systems and shown to be induced by the tumor promoter, phorbol 12-myristate 13-acetate (PMA) in avian cells (for review: Rice & Gilden, 1988). HIVEN86A is also inducible by PMA (Franza et al., 1987; Franza, 1988; Franza, 1990). We now demonstrate that the protein product of the human c-rel proto-oncogene is structurally identical to HIVEN86A.	COLD SPRING HARBOR LAB,BUNGTOWN RD,POB 100,COLD SPRING HARBOR,NY 11724; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Cold Spring Harbor Laboratory; Duke University; Howard Hughes Medical Institute								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; FRANZA BR, 1988, CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, P159; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; FRANZA BR, 1990, HUMAN RETROVIRUSES, P181; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonardo MJ, 1998, CELL, V58, P227; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; RICE NR, 1988, ONCOGENE HDB, P495; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6	27	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					665	667						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030915				2022-12-25	WOS:A1991FR93900024
J	WINGATE, VPM; RYAN, CA				WINGATE, VPM; RYAN, CA			A NOVEL FRUIT-EXPRESSED TRYPSIN INHIBITOR-I GENE FROM A WILD-SPECIES OF TOMATO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE AMMONIA-LYASE; MOLECULAR CHARACTERIZATION; PROTEINASE-INHIBITORS; MESSENGER-RNA; RIPENING GENE; ETHYLENE; LEAVES; PLANTS; MECHANISM; ELICITOR	A member of the proteinase inhibitor I gene family encoding an inhibitor I protein with a novel trypsin-specific reactive site was isolated from the wild tomato species Lycopersicon peruvianum (L.) Mill. (LA107). The nucleotide sequence of the gene was identical to a previously isolated cDNA clone from L. peruvianum fruit (Wingate, V. P. M., Broadway, R. M., and Ryan, C. A. (1989) J. Biol. Chem. 264, 17734-17738) with the exception of one nucleotide 3 base pairs upstream from the 5' terminus of the cDNA. S1 nuclease protection experiments and RNA blot hybridization analysis show that the gene is developmentally regulated in L. peruvianum fruit and is not the same inhibitor I gene that is wound inducible in leaves. Nucleotide sequences are present in the 5'-flanking sequences of the fruit-specific L. peruvianum gene inhibitor I gene which share similarity with regulatory sequences that have been associated with the regulation of several known elicitor- and ethylene-inducible genes. However, the L. peruvianum motifs are not identical with those of other genes and are probably not functional. Because inhibitor I genes are not expressed or are expressed in very low levels in modern tomato fruit before the onset of ripening but expressed at high levels in fruit of the wild L. peruvianum species, a unique fruit-specific signaling system must therefore be present in L. peruvianum fruit for the transcriptional regulation of the inhibitor I gene which is not present in the fruit of the modern tomato, L. esculentum.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University								CLEVELAND TE, 1987, PLANT MOL BIOL, V8, P199, DOI 10.1007/BF00015028; DEIKMAN J, 1988, EMBO J, V7, P3315, DOI 10.1002/j.1460-2075.1988.tb03202.x; Favaloro J, 1980, Methods Enzymol, V65, P718; GRAHAM JS, 1985, J BIOL CHEM, V260, P6555; GRAHAM JS, 1986, PLANTA, V169, P399, DOI 10.1007/BF00392137; HILDER VA, 1987, NATURE, V330, P160, DOI 10.1038/330160a0; JOHNSON R, 1989, P NATL ACAD SCI USA, V86, P9871, DOI 10.1073/pnas.86.24.9871; LASKOWSKI M, 1987, COLD SPRING HARB SYM, V52, P545, DOI 10.1101/SQB.1987.052.01.062; LAWTON MA, 1983, EUR J BIOCHEM, V130, P131, DOI 10.1111/j.1432-1033.1983.tb07127.x; LEE JS, 1986, P NATL ACAD SCI USA, V83, P7277, DOI 10.1073/pnas.83.19.7277; LINCOLN JE, 1987, P NATL ACAD SCI USA, V84, P2793, DOI 10.1073/pnas.84.9.2793; LOIS R, 1989, EMBO J, V8, P1641, DOI 10.1002/j.1460-2075.1989.tb03554.x; MANIATIS T, 1982, MOL CLONING LABORATO, P150; MARGOSSIAN LJ, 1988, P NATL ACAD SCI USA, V85, P8012, DOI 10.1073/pnas.85.21.8012; NELSON CE, 1980, P NATL ACAD SCI-BIOL, V77, P1975, DOI 10.1073/pnas.77.4.1975; PALM CJ, 1990, P NATL ACAD SCI USA, V87, P603, DOI 10.1073/pnas.87.2.603; PEARCE G, 1988, PLANTA, V175, P527, DOI 10.1007/BF00393075; RODGERS SO, 1988, PLANT MOL BIOL A, V6, P1; RYAN CA, 1966, BIOCHEMISTRY-US, V5, P1592, DOI 10.1021/bi00869a020; RYAN CA, 1989, BIOESSAYS, V10, P20, DOI 10.1002/bies.950100106; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SVENSSON B, 1986, CARLSBERG RES COMMUN, V51, P493, DOI 10.1007/BF02906891; THORNBURG RW, 1987, P NATL ACAD SCI USA, V84, P744, DOI 10.1073/pnas.84.3.744; WINGATE VPM, 1989, J BIOL CHEM, V264, P17734	24	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5814	5818						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005119				2022-12-25	WOS:A1991FD37000072
J	PRZYWARA, DA; BHAVE, SV; BHAVE, A; WAKADE, TD; WAKADE, AR				PRZYWARA, DA; BHAVE, SV; BHAVE, A; WAKADE, TD; WAKADE, AR			STIMULATED RISE IN NEURONAL CALCIUM IS FASTER AND GREATER IN THE NUCLEUS THAN THE CYTOSOL	FASEB JOURNAL			English	Article						CALCIUM; GENE REGULATION; INDO-1; NUCLEUS; SYMPATHETIC NEURONS	SYMPATHETIC NEURONS; TYROSINE-HYDROXYLASE; CA-2+; CHANNELS; EXPRESSION; RELEASE; GROWTH	Calcium is an important regulator of a variety of neuronal activities including gene expression. However, it is not clear how Ca2+ influx affects intracellular Ca2+ concentration ([Ca2+]i) in the nucleus. We have taken advantage of laser photometry, the Ca2+-sensitive dye Indo-1 that allows ratio imaging, and confocal microscopy to eliminate the influences of unequal cell geometry and dye distribution. We show that Ca2+ influx into sympathetic neurons causes a significantly greater and faster increase in [Ca2+]i in the nucleus than in the cytosol. The differential increase in nuclear [Ca2+]i was apparent when Ca2+ entered from the extracellular medium during K+ deplarization, ionomycin or acetylcholine treatment, and brief periods of electrical stimulation. When intracellular Ca2+ was mobilized by caffeine the rise in nuclear [Ca2+]i was again greater than in any other region of the neuron. The increased nuclear Ca2+ levels were uniform throughout the nucleus and not associated with the nuclear envelope. The differential rise in nuclear Ca2+ was eliminated by acridine orange binding to nucleic acids. Nonexcitable cells (astrocytes, oligodendrocytes, and fibroblasts) did not show differential distribution of Ca2+ after ionomycin treatment. These results support the idea that activity-dependent gene regulation in sympathetic neurons may be mediated by changes in Ca2+ concentration at the level of the chromatin material.	WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,540 E CANFIELD,DETROIT,MI 48201	Wayne State University			Bhave, Sanjiv/K-2398-2012					AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEROD A, 1987, P NATL ACAD SCI USA, V84, P1699, DOI 10.1073/pnas.84.6.1699; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLACK IB, 1985, BRAIN RES, V339, P151, DOI 10.1016/0006-8993(85)90635-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MELDOLESI J, 1988, TRENDS NEUROSCI, V11, P449, DOI 10.1016/0166-2236(88)90197-X; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; PATTERSON PH, 1978, ANNU REV NEUROSCI, V1, P1, DOI 10.1146/annurev.ne.01.030178.000245; PRZYWARA DA, 1991, IN PRESS J PHYSL LON; WAKADE AR, 1982, EXP CELL RES, V140, P71, DOI 10.1016/0014-4827(82)90157-4; WAKADE AR, 1990, J NEUROCHEM, V54, P1281, DOI 10.1111/j.1471-4159.1990.tb01960.x; WAKADE TD, 1990, J NEUROCHEM, V55, P1806, DOI 10.1111/j.1471-4159.1990.tb04972.x; WALICKE PA, 1981, J NEUROSCI, V1, P343	21	90	90	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					217	222		10.1096/fasebj.5.2.2004666	http://dx.doi.org/10.1096/fasebj.5.2.2004666			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	2004666				2022-12-25	WOS:A1991EZ00200012
J	BEZOUSKA, K; CRICHLOW, GV; ROSE, JM; TAYLOR, ME; DRICKAMER, K				BEZOUSKA, K; CRICHLOW, GV; ROSE, JM; TAYLOR, ME; DRICKAMER, K			EVOLUTIONARY CONSERVATION OF INTRON POSITION IN A SUBFAMILY OF GENES ENCODING CARBOHYDRATE-RECOGNITION DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT APOPROTEIN; MANNOSE-BINDING PROTEINS; CHICKEN HEPATIC LECTIN; LIVER ASIALOGLYCOPROTEIN RECEPTOR; MULTIPLE SEQUENCE ALIGNMENT; PROTEOGLYCAN CORE PROTEIN; AMINO-ACID-SEQUENCE; TRANSMEMBRANE ORIENTATION; GLYCOPROTEIN RECEPTOR; MOLECULAR-CLONING	The structure of the gene encoding a chicken liver receptor, the chicken hepatic lectin, which mediates endocytosis of glycoproteins has been established. The coding sequence is divided into six exons separated by five introns. The first three exons correspond to separate functional domains of the receptor polypeptide (cytoplasmic tail, transmembrane sequence, and extracellular neck region), while the final three exons encode the Ca2+-dependent carbohydrate-recognition domain. These results, as well as computer-assisted multiple sequence comparisons, establish this receptor as the evolutionary homolog of the mammalian asialoglycoprotein receptors. It is interesting that the chicken receptor falls into a subfamily of proteins along with the mammalian asialoglycoprotein receptors, since the saccharide-binding specificity of the chicken receptor resembles more closely that of a different set of calcium-dependent animal lectins, which includes the mannose-binding proteins. The portions of the genes encoding the carbohydrate-recognition domains of these proteins lack introns. The results suggest that divergence of intron-containing and intron-lacking carbohydrate-recognition domains preceded shuffling events in which other functional domains were associated with the carbohydrate-recognition domains. This was followed by further divergence, generating a variety of saccharide-binding specificities.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA	Columbia University					NATIONAL CENTER FOR RESEARCH RESOURCES [U41RR004154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04154] Funding Source: Medline; NIGMS NIH HHS [GM42628] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; CHIACCHIA KB, 1984, J BIOL CHEM, V259, P5440; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COLLINS T, 1991, J BIOL CHEM, V266, P2466; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DOWBENKO DJ, 1991, GENOMICS, V9, P270, DOI 10.1016/0888-7543(91)90252-A; DRICKAMER K, 1987, KIDNEY INT, V32, pS167; DRICKAMER K, 1982, J BIOL CHEM, V257, P5156; DRICKAMER K, 1989, CIBA F SYMP, V145, P45; DRICKAMER K, 1981, J BIOL CHEM, V256, P5827; DRICKAMER K, 1987, J BIOL CHEM, V262, P2582; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DYBVIG K, 1983, NUCLEIC ACIDS RES, V11, P8495, DOI 10.1093/nar/11.23.8495; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HACHE RJG, 1983, J BIOL CHEM, V258, P4556; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOYLE GW, 1991, J BIOL CHEM, V266, P1850; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; II M, 1990, J BIOL CHEM, V265, P11295; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; KAWASAKI T, 1977, J BIOL CHEM, V252, P6536; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE YM, 1991, J BIOL CHEM, V266, P2715; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; LOEB JA, 1987, J BIOL CHEM, V262, P3022; Maniatis T., 1982, MOL CLONING; MAROTEAUX L, 1983, NUCLEIC ACIDS RES, V11, P1227, DOI 10.1093/nar/11.5.1227; MELLOW TE, 1988, J BIOL CHEM, V263, P5468; ORD DC, 1990, J BIOL CHEM, V265, P7760; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKDER SK, 1983, J BIOL CHEM, V258, P2520; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUTER U, 1987, NUCLEIC ACIDS RES, V15, P7295, DOI 10.1093/nar/15.18.7295; TANAKA T, 1988, J BIOL CHEM, V263, P15831; TAYLOR ME, 1986, CLIN SCI, V70, P539, DOI 10.1042/cs0700539; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; VERREY F, 1990, CELL REGUL, V1, P471, DOI 10.1091/mbc.1.6.471; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	50	96	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11604	11609						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050668				2022-12-25	WOS:A1991FT76200031
J	TSERNG, KY; JIN, SJ				TSERNG, KY; JIN, SJ			NADPH-DEPENDENT REDUCTIVE METABOLISM OF CIS-5 UNSATURATED FATTY-ACIDS - A REVISED PATHWAY FOR THE BETA-OXIDATION OF OLEIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; DICARBOXYLIC-ACIDS; IDENTIFICATION; PEROXISOMES; DEGRADATION; HYDRATASES; ENZYMES; CELLS	Cis-5 double bond in a fatty acid or when encountered through the beta-oxidation of an odd-numbered double-bond unsaturated fatty acid presents as a metabolic block to the further beta-oxidation. Cis-5-fatty acyl-CoA cannot beta-oxidized to cis-3-enoyl-CoA as suggested by the conventional pathway. Instead, this metabolic block can only be removed through an NADPH-dependent reduction of 5-enoyl-CoA, possibly mediated by a 5-enoyl-CoA reductase. In the case of oleic acid two cycles of beta-oxidation yield cis-5-tetradecenoyl-CoA. This intermediate is then reduced to tetradecanoyl-CoA, which is metabolized further via normal beta-oxidation cycles. The conventional pathway through cis-3-dodecenoyl-CoA does not operate in rat liver.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University	TSERNG, KY (corresponding author), VET ADM MED CTR,MED RES SERV,10701 E BLVD,CLEVELAND,OH 44106, USA.							BREMER J, 1972, BIOCHIM BIOPHYS ACTA, V280, P515, DOI 10.1016/0005-2760(72)90131-2; CLOUET P, 1989, BIOCHEM J, V263, P867, DOI 10.1042/bj2630867; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; DICZFALUSY U, 1990, BIOCHIM BIOPHYS ACTA, V1043, P182, DOI 10.1016/0005-2760(90)90294-8; HADJIAGAPIOU C, 1990, J BIOL CHEM, V265, P4369; HAGVE TA, 1986, BIOCHIM BIOPHYS ACTA, V875, P165, DOI 10.1016/0005-2760(86)90165-7; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HILTUNEN JK, 1983, BIOCHIM BIOPHYS ACTA, V752, P223, DOI 10.1016/0005-2760(83)90116-9; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; HOVIK R, 1987, BIOCHEM J, V247, P531, DOI 10.1042/bj2470531; JIN SJ, 1989, J LIPID RES, V30, P1611; JIN SJ, 1990, BIOCHEMISTRY-US, V29, P8540, DOI 10.1021/bi00489a006; KILPONEN JM, 1990, BIOCHEM J, V209, P223; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; MATHUR SN, 1990, J BIOL CHEM, V265, P21048; OSMUNDSEN H, 1982, BIOCHEM J, V208, P749, DOI 10.1042/bj2080749; OSMUNDSEN H, 1985, BIOCHEM J, V230, P329, DOI 10.1042/bj2300329; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SMELAND TE, 1989, BIOCHEM BIOPH RES CO, V160, P988, DOI 10.1016/S0006-291X(89)80098-1; STANLEY KK, 1975, BIOCHEM J, V150, P77, DOI 10.1042/bj1500077; STOFFEL W, 1965, H-S Z PHYSIOL CHEM, V341, P76, DOI 10.1515/bchm2.1965.341.1.76; Stoffel W., 1979, METHOD ENZYMOL, V14, P99; TSERNG KY, 1990, J LIPID RES, V31, P763; TSERNG KY, 1991, BIOCHEMISTRY-US, V30, P2508, DOI 10.1021/bi00223a030; WATMOUGH NJ, 1989, BIOCHEM J, V262, P261, DOI 10.1042/bj2620261; YANG SY, 1986, J BIOL CHEM, V261, P2238	28	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11614	11620						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	2050669				2022-12-25	WOS:A1991FT76200033
J	STUKENBERG, PT; STUDWELLVAUGHAN, PS; ODONNELL, M				STUKENBERG, PT; STUDWELLVAUGHAN, PS; ODONNELL, M			MECHANISM OF THE SLIDING BETA-CLAMP OF DNA POLYMERASE-III HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; EPSTEIN-BARR VIRUS; ESCHERICHIA-COLI; INITIATION COMPLEX; ACCESSORY PROTEINS; PRIMED TEMPLATE; ATP ACTIVATION; REPLICATION; SUBUNIT; PURIFICATION	DNA polymerase III holoenzyme (holoenzyme), the multiprotein replicase of Escherichia coli, is essentially unlimited in processive DNA synthesis. Processive activity can be reconstituted from two components. One component, the beta-preinitiation complex, is a beta-dimer clamped onto primed DNA. The beta-preinitiation complex is formed by the five-protein gamma-complex, which hydrolyzes ATP to chaperone-beta onto primed DNA. The other component is the alpha-epsilon-polymerase. The alpha-epsilon-polymerase itself is not processive, but is endowed with extremely high processive activity upon assembly with the beta-preinitiation complex. Here we examine the mechanism by which the beta-preinitiation complex confers processivity onto the alpha-epsilon-polymerase. We find the beta-preinitiation complex to be mobile on DNA. Diffusion of beta on DNA is specific to duplex DNA, is bidirectional, does not require ATP, and appears to diffuse linearly along the duplex. Furthermore, beta-directly binds the alpha-epsilon polymerase through contact with alpha, the DNA polymerase subunit. Hence, the high processivity of the holoenzyme is rooted in a "sliding clamp" of beta on DNA that tethers the polymerase to the primed template. Implications for transcription and translation are discussed.			STUKENBERG, PT (corresponding author), CORNELL UNIV,MED CTR,COLL MED,HOWARD HUGHES MED INST,HEARST MICROBIOL DEPT,NEW YORK,NY 10021, USA.			Stukenberg, Todd/0000-0002-6788-2111	NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; FAY PJ, 1981, J BIOL CHEM, V256, P976; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KORNBERG A, 1982, DNA REPLICATION S, P532; KOZAK M, 1983, MICROBIOL REV, V47, P1; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6547; MAKI S, 1988, J BIOL CHEM, V263, P6561; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MOK M, 1987, J BIOL CHEM, V262, P16644; MUNN M, 1986, THESIS U CALIFORNIA; NOSSAL NG, 1984, BACTERIOPHAGE T4, P71; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; RAY DS, 1969, J MOL BIOL, V43, P631, DOI 10.1016/0022-2836(69)90364-7; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; STUDWELL PS, 1990, UCLA SYM BI, V127, P153; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	37	343	352	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11328	11334						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040637				2022-12-25	WOS:A1991FQ77400095
J	TRAXINGER, RR; MARSHALL, S				TRAXINGER, RR; MARSHALL, S			COORDINATED REGULATION OF GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE ACTIVITY BY INSULIN, GLUCOSE, AND GLUTAMINE - ROLE OF HEXOSAMINE BIOSYNTHESIS IN ENZYME REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-6-PHOSPHATE-DEHYDROGENASE MESSENGER-RNA; PRIMARY CULTURED ADIPOCYTES; TRANSPORT SYSTEM; RAT HEPATOCYTES; PROTEIN-BIOSYNTHESIS; GLYCOGEN-SYNTHASE; DEHYDROGENASE; RESISTANCE; METABOLISM; KINETICS	We reported previously that glutamine:F-6-P amidotransferase (GFAT) plays an integral role in the development of insulin resistance by directing the flow of incoming glucose into the hexosamine biosynthesis pathway. To determine whether the enzymatic activity of GFAT is altered during desensitization of the glucose transport system, we treated isolated rat adipocytes with various combinations of insulin, glucose, and glutamine. Treatment with insulin or glucose alone (or in combination) failed to reduce cytosolic GFAT activity after 4 h, whereas combined treatment with all three components elicited a progressive loss of GFAT activity that was rapid (t1/2 of 2 h) and extensive (70% loss). A pronounced loss of GFAT activity was also seen in cells exposed to glucosamine, an agent known to directly enter the hexosamine pathway (55% loss at 4 h, ED50 of 360-mu-M). Moreover, a close correlation was observed between the induction of desensitization and the loss of GFAT activity as a function of glucose, insulin, glutamine, and glucosamine concentrations. When total intracellular hexosamine products were measured, we found that hexosamine formation was unaltered by insulin or glucose (or a combination) but was elevated by >4-fold in the presence of insulin, glucose, and glutamine (t1/2 of 22 min), a condition known to cause both desensitization and loss of GFAT activity. Additional studies indicated that the loss of GFAT activity under desensitizing conditions is not due to allosteric regulation since removal of potential allosteric factors from the cytosol of desensitized cells by G-25 column chromatography failed to restore enzyme activity. Overall, these studies indicate that 1) GFAT is an insulin-regulated enzyme; however, control of enzyme activity is not due to a direct action of insulin, but rather is mediated by insulin-induced enhancement of glucose uptake; 2) the routing of incoming glucose through the hexosamine pathway and the formation of hexosamine products appears to regulate GFAT activity; and 3) the progressive loss of GFAT activity over several hours is probably not due to allosteric regulation.	UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,800 MADISON AVE,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008206, R01DK038754] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05-5423] Funding Source: Medline; NIDDK NIH HHS [DK38754, DK08206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER M, 1985, J BIOL CHEM, V260, P1978; ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; BATES CJ, 1966, J BIOL CHEM, V241, P1705; BEKESI JG, 1969, J BIOL CHEM, V244, P5663; BEUTLER HO, 1983, METHODS ENZYMATIC AN; CALLAHAN M, 1981, ANAL BIOCHEM, V115, P347, DOI 10.1016/0003-2697(81)90016-6; CIMBALA MA, 1985, MOL BASIS INSULIN AC, P385; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; DELGIACCO R, 1964, J BIOL CHEM, V239, P2400; Denton R M, 1979, Essays Biochem, V15, P37; FRITZ RS, 1986, BIOCHEM J, V237, P617, DOI 10.1042/bj2370617; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1986, DIABETES, V35, P258, DOI 10.2337/diabetes.35.3.258; GHOSH S, 1960, J BIOL CHEM, V235, P1265; GRANNER D, 1990, J BIOL CHEM, V265, P10173; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; KORNFELD S, 1966, EXP CELL RES, V41, P592, DOI 10.1016/S0014-4827(66)80109-X; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; LAWRENCE JC, 1983, J BIOL CHEM, V258, P710; LAWRENCE JC, 1983, J BIOL CHEM, V259, P7975; LOOSE DS, 1985, MOL BASIS INSULIN AC, P347; MARSHALL S, 1987, ENDOCRINOLOGY, V121, P1116, DOI 10.1210/endo-121-3-1116; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MARSHALL S, 1989, J BIOL CHEM, V264, P2029; MARSHALL S, 1983, DIABETES, V32, P319, DOI 10.2337/diab.32.4.319; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MESSINA JL, 1990, HDB EXPT PHARM INSUL, P399; MOLNAR J, 1964, J BIOL CHEM, V239, P3157; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; RODBELL M, 1964, J BIOL CHEM, V239, P375; SAGGERSON ED, 1985, NEW PERSPECTIVES ADI, P87; SHIJO L, 1969, J BIOCHEM-TOKYO, V66, P175; SPIEGELMAN BM, 1980, J BIOL CHEM, V255, P8811; STUMPO DJ, 1984, EUR J BIOCHEM, V144, P497, DOI 10.1111/j.1432-1033.1984.tb08493.x; TRAXINGER RR, 1989, J BIOL CHEM, V264, P8156; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; VILLARPALASI C, 1960, BIOCHIM BIOPHYS ACTA, V39, P171, DOI 10.1016/0006-3002(60)90142-6; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276; WINBERRY L, 1977, J BIOL CHEM, V252, P7796; WINTERBURN PJ, 1971, BIOCHEM J, V121, P711, DOI 10.1042/bj1210711; WINTERBURN PJ, 1970, NATURE, V228, P1311, DOI 10.1038/2281311a0; YOSHIMOTO K, 1983, BIOCHIM BIOPHYS ACTA, V741, P143, DOI 10.1016/0167-4781(83)90021-0; ZALKIN H, 1985, METHOD ENZYMOL, V113, P278	46	129	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10148	10154						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037571				2022-12-25	WOS:A1991FP08600026
J	IDRISS, JM; JONAS, AJ				IDRISS, JM; JONAS, AJ			VITAMIN-B12 TRANSPORT BY RAT-LIVER LYSOSOMAL MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; AMINO-ACID TRANSPORT; ACETYL-D-GLUCOSAMINE; TRANSCOBALAMIN-II; CYSTINE TRANSPORT; METHYLMALONIC ACIDURIA; ESCHERICHIA-COLI; SIALIC-ACID; METABOLISM; PROTEIN	Vitamin B-12 (hydroxycobalamin) is endocytosed by mammalian cells as a complex with transcobalamin II and then processed to free B-12 in lysosomes. The mechanism by which free B-12 becomes available for subsequent cellular metabolism has been uncertain. Lysosomal transport of cyanocobalamin (B-12) was examined using membrane vesicles prepared from Percoll gradient purified lysosomes. B-12 uptake by vesicles was dependent upon pH and was inhibited by the protonophore CCCP. Transport exhibited saturation kinetics with a K(m) of 3.5-mu-M and temperature dependence with a Q10 of 1.8. Uptake of B-12 was dependent upon divalent cations and was inhibited by EDTA. Preparation of vesicles in the presence of 100-mu-M B-12 resulted in stimulation of uptake consistent with a mechanism of countertransport. Excess cyanocobalamin, adenosylcobalamin, methylcobalamin, or cobinamide dicyanide inhibited uptake of B-12. Trans-stimulation studies showed that only the first three compounds are actually transported species with cyanocobalamin as the preferred substrate. We conclude that lysosomes have a specific transport system for vitamin B-12 that results in release of this enzyme cofactor to the cytoplasm.	UNIV CALIF LOS ANGELES, HARBOR MED CTR, DIV MED GENET, TORRANCE, CA 90502 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037403] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37403] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RH, 1978, J CLIN INVEST, V61, P47, DOI 10.1172/JCI108924; BERLINER N, 1981, METABOLISM, V30, P230, DOI 10.1016/0026-0495(81)90146-3; BERNAR J, 1986, J BIOL CHEM, V261, P7107; BONNETT R, 1963, CHEM REV, V63, P573, DOI 10.1021/cr60226a002; COLLARINI EJ, 1989, BIOCHIM BIOPHYS ACTA, V987, P139, DOI 10.1016/0005-2736(89)90536-1; DIGROLAM.PM, 1971, J BACTERIOL, V106, P745, DOI 10.1128/JB.106.3.745-750.1971; DIMASI DR, 1973, J BACTERIOL, V115, P506, DOI 10.1128/JB.115.2.506-513.1973; FENTON WA, 1989, METABOLIC BASIS INHE, P2065; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; HALL CA, 1966, P SOC EXP BIOL MED, V123, P55, DOI 10.3181/00379727-123-31400; JONAS AJ, 1986, BIOCHEM BIOPH RES CO, V137, P175, DOI 10.1016/0006-291X(86)91192-7; JONAS AJ, 1990, J BIOL CHEM, V265, P17545; JONAS AJ, 1982, J BIOL CHEM, V257, P13185; JONAS AJ, 1986, BIOCHEM J, V236, P671, DOI 10.1042/bj2360671; JONAS AJ, 1990, BIOCHEM J, V268, P41, DOI 10.1042/bj2680041; JONAS AJ, 1990, BIOCHEM J, V272, P323, DOI 10.1042/bj2720323; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; JONAS AJ, 1987, J BIOL CHEM, V262, P16391; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MANCINI GMS, 1990, J BIOL CHEM, V265, P12380; MORIYAMA Y, 1984, J BIOCHEM-TOKYO, V95, P995, DOI 10.1093/oxfordjournals.jbchem.a134726; NEWMARK P, 1970, ARCH BIOCHEM BIOPHYS, V141, P121, DOI 10.1016/0003-9861(70)90114-1; OKHUMA S, 1982, P NATL ACAD SCI USA, V79, P2758; PISONI RL, 1991, J BIOL CHEM, V266, P979; PISONI RL, 1987, J BIOL CHEM, V262, P15011; PISONI RL, 1987, J BIOL CHEM, V262, P6010; PISONI RL, 1985, J BIOL CHEM, V260, P4791; PLETSCH QA, 1972, ARCH BIOCHEM BIOPHYS, V151, P157, DOI 10.1016/0003-9861(72)90484-5; ROSENBLATT DS, 1986, PEDIATRICS, V78, P51; ROSENBLATT DS, 1985, SCIENCE, V228, P1319, DOI 10.1126/science.4001945; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SENNETT C, 1981, ANNU REV BIOCHEM, V50, P1053, DOI 10.1146/annurev.bi.50.070181.005201; TAYLOR RT, 1972, ARCH BIOCHEM BIOPHYS, V148, P366, DOI 10.1016/0003-9861(72)90154-3; WATKINS D, 1986, AM J HUM GENET, V39, P404; YOUNGDAHLTURNER P, 1979, EXP CELL RES, V118, P127, DOI 10.1016/0014-4827(79)90590-1; YOUNGDAHLTURNER P, 1978, J CLIN INVEST, V61, P133, DOI 10.1172/JCI108911	36	30	30	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9438	9441						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033045				2022-12-25	WOS:A1991FM45900019
J	KISHORE, NS; LU, TB; KNOLL, LJ; KATOH, A; RUDNICK, DA; MEHTA, PP; DEVADAS, B; HUHN, M; ATWOOD, JL; ADAMS, SP; GOKEL, GW; GORDON, JI				KISHORE, NS; LU, TB; KNOLL, LJ; KATOH, A; RUDNICK, DA; MEHTA, PP; DEVADAS, B; HUHN, M; ATWOOD, JL; ADAMS, SP; GOKEL, GW; GORDON, JI			THE SUBSTRATE-SPECIFICITY OF SACCHAROMYCES-CEREVISIAE MYRISTOYL-COA-PROTEIN N-MYRISTOYLTRANSFERASE - ANALYSIS OF MYRISTIC ACID ANALOGS CONTAINING OXYGEN, SULFUR, DOUBLE-BONDS, TRIPLE BONDS, AND OR AN AROMATIC RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; FATTY-ACIDS; MEMBRANE ASSOCIATION; ESCHERICHIA-COLI; WITTIG REACTION; ACYLATION; REPLICATION; TRANSFERASE; ENZYMOLOGY; SEQUENCE	We have explored the acyl-CoA substrate specificity of Saccharomyces cerevisiae myristoyl-CoA: protein N-myristoyltransferase (NMT) by synthesizing 81 fatty acid analogs and surveying their activity in a coupled in vitro assay containing Pseudomonas acyl-CoA synthetase and Escherichia coli-derived yeast NMT. Single oxygen or sulfur substitution for C-3 through C-13 is well tolerated by both enzymes. Detailed kinetic analyses suggest that the acyl-CoA and peptide-binding sites of NMT are relatively insensitive to placement of single group 6B heteroatoms. By contrast, di-oxygen-substituted analogs were very poor substrates, producing dramatic reductions in the affinity of NMTs peptide-binding site for a synthetic octapeptide substrate derived from the NH2-terminal sequence of a known N-myristoylprotein, the gag polyprotein precursor of human immunodeficiency virus 1 (HIV-1). This observation provides an example of binding site cooperativity in NMT. Replacement of one oxygen with sulfur at either the 6, 9, or 12 position of dioxatetradecanoic acids results in a general increase in peptide catalytic efficiency (V(max)/K(m)). An analysis of five fatty acids from octanoic to dodecanoic having terminal phenyl groups indicated that the best substrate was 10-phenyldecanoic acid even though Corey-Pauling-Koltun molecular models indicate that it has a length equivalent to that of tridecanoic acid. Six analogs having an equivalent length of 13 carbon atoms were subsequently prepared in which the phenyl group was systematically moved one methylene group closer to carboxyl. Movement of the phenyl just one carbon closer to carboxyl (producing 9-(p-methylphenyl) nonanoic acid) decreases peptide catalytic efficiency (V(max/K(m)) severalfold compared to 10-phenyldecanoic acid. 10-(4-Tolyl)decanoic acid has the same relative positions of phenyl and carboxyl as 10-phenyldecanoic acid even though a methyl group is present on the phenyl ring. It produces peptide K(m) and V(max) values that are the same as 10-phenyldecanoic acid. Substitution of either oxygen or sulfur for a methylene group fails to override the effects noted when the phenyl group position is altered in the C-14 equivalent fatty acid series. Several fatty acids of differing chain lengths with cyclohexyl-, 2-furyl, and 2-thienyl groups at their omega-termnius had activity profiles that paralleled those of the comparable phenyl-substituted compounds. Myristic acid analogs with triple bonds (beginning at positions 2 through 13), cis-double bonds (positions 3 through 13) and trans-double bond isomers (E5, E6, and E7) were also tested. Evaluation of the alkynyl analog series revealed that 5-tetradecynoic acid (Y5) was not a substrate for NMT even though the corresponding Y4 and Y6 compounds had activities comparable to myristate. Y5 does not appear to bind to the acyltransferase. By contrast, Z5 was a superior substrate compared to all the other 10 cis-double isomers tested. E5 was inferior to E6 and E7, both of which were comparable to myristate in acylpeptide formation. Unexpectedly, addition of Z6 to the in vitro NMT assay system yielded two acyl peptide products, one that comigrated on C-18 reverse-phase HPLC with Z6 and the other with purified E6. A comparable phenomenon was not observed with other Z isomers or with E6. Control experiments indicated that this apparent isomerization wsa not due to the Pseudomonas acyl-CoA synthetase present in the coupled assay system. Together the data suggest that the acyl chain of myristoyl-CoA is present in a bent conformation in the acyl-CoA-binding site of S. cerevisiae NMT. The site appears to possess a complex measuring device that can sense distance along the chain from carboxyl to the omega-end of the fatty acid as well as steric volume at the omega-terminus. The overall shape of this sensor may be conical with the cone and the terminal carbons coaxial. In this proposed model, the relative sensitivity to chain length versus steric volume would be determined by the acuteness of the "cone."	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACEUT,ST LOUIS,MO 63110; MONSANTO CO,ST LOUIS,MO 63198; UNIV MIAMI,DEPT CHEM,CORAL GABLES,FL 33124; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; UNIV ALABAMA,DEPT CHEM,TUSCALOOSA,AL 35487	Washington University (WUSTL); Monsanto; University of Miami; Washington University (WUSTL); University of Alabama System; University of Alabama Tuscaloosa					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30188, AI-27179] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG VW, 1975, TETRAHEDRON LETT, P373; BAKER CD, 1963, J CHEM SOC, P489, DOI 10.1039/jr9630000489; BESTMAN HJ, 1967, J LIEBIG ANN CHEM, V709, P105; BJOSTAD LB, 1981, J BIOL CHEM, V256, P7936; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; COMEAU D, 1972, B SOC CHIM FR, P4163; DAWSON MI, 1977, J ORG CHEM, V47, P2783; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DZHEMILEV U M, 1980, Khimiya Prirodnykh Soedinenii, P97; FAWCETT CH, 1954, PROC R SOC SER B-BIO, V142, P60, DOI 10.1098/rspb.1954.0006; FAWCETT CH, 1952, P R SOC LOND B, V170, P887; FURUKAWA K, 1973, NIPPON KAGAKU KAISHI, P758, DOI 10.1246/nikkashi.1973.758; GILMAN NW, 1974, CHEM PHYS LIPIDS, V13, P239, DOI 10.1016/0009-3084(74)90023-1; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GUNSTONE FD, 1977, CHEM PHYS LIPIDS, V18, P115, DOI 10.1016/0009-3084(77)90031-7; HASE J, 1954, Pharm Bull, V2, P368; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1988, J BIOL CHEM, V263, P2127; HEUCKEROTH RO, 1990, J LIPID RES, V31, P1121; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; Hirsch J. A., 1967, TOP STEREOCHEM, V3, P199, DOI [10.1002/9780470147108.ch4, DOI 10.1002/9780470147108.CH4]; HUHTASAARI M, 1983, ACTA CHEM SCAND B, V37, P537, DOI 10.3891/acta.chem.scand.37b-0537; HUISGEN R, 1954, LIEBIGS ANN CHEM, V586, P52; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; KATOH A, 1991, J ORG CHEM, V56, P731, DOI 10.1021/jo00002a046; KOVALEVA AS, 1974, ZH ORG KHIM+, V10, P696; MAGERLEIN MJ, 1976, Patent No. 3962293; MARCH J, 1985, ADV ORGANIC CHEM; MARYANOFF BE, 1981, TETRAHEDRON LETT, V22, P4185, DOI 10.1016/S0040-4039(01)82099-2; MARYANOFF BE, 1985, J AM CHEM SOC, V107, P217, DOI 10.1021/ja00287a040; MINKIN VI, 1970, DIPOLE MOMENTS ORGAN, P88; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; OGURA K, 1981, TETRAHEDRON LETT, P4499; PAIGE LA, 1989, J MED CHEM, V32, P1667; Pauling L., 1960, NATURE CHEM BOND, V3rd; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAPA D, 1947, J AM CHEM SOC, V69, P3018; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RUDNICK DA, 1990, J BIOL CHEM, V265, P1370; RUDNICK DA, 1991, IN PRESS J BIOL CHEM; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SANDERSON RT, 1983, J AM CHEM SOC, V105, P2259, DOI 10.1021/ja00346a026; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; SHIRLEY DA, 1951, J AM CHEM SOC, V73, P2963, DOI 10.1021/ja01150a536; SINGH A, 1986, SYNTHETIC COMMUN, V16, P847, DOI 10.1080/00397918608059667; SMITH B, 1954, ACTA CHEM SCAND, V8, P1111, DOI 10.3891/acta.chem.scand.08-1111; SPENCER GF, 1971, LIPIDS, V6, P712, DOI 10.1007/BF02531295; TAYLOR WR, 1950, J AM CHEM SOC, V72, P4263, DOI 10.1021/ja01165a123; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	56	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8835	8855						21	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026598				2022-12-25	WOS:A1991FM03800034
J	TAKIGUCHI, M; MORI, M				TAKIGUCHI, M; MORI, M			INVITRO ANALYSIS OF THE RAT LIVER-TYPE ARGINASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; UREA-CYCLE ENZYMES; PHOSPHATE SYNTHETASE-I; MESSENGER-RNA LEVELS; GENE-EXPRESSION; HEPATOMA-CELLS; NUCLEAR FACTOR; ALBUMIN GENE; MONOLAYER-CULTURES; LEUCINE ZIPPER	Genes for urea cycle enzymes including liver-type arginase are expressed mainly in the liver and are regulated developmentally, nutritionally, and hormonally in a coordinated manner. The promoter region of the rat arginase gene was investigated with an in vitro transcription system using nuclear extracts prepared from rat tissues. Accurate initiation of the transcription in liver nuclear extracts was confirmed by run-off analysis and S1 nuclease mapping. The arginase promoter was transcribed more efficiently in liver nuclear extracts than in brain extracts, reproducing the in vivo tissue specificity qualitatively. Analysis of deletion mutants of the 5'-flanking region in liver nuclear extracts revealed a positive regulatory region spanning nucleotides -90 to -51 relative to the transcription start site. Overlapping this region, two protected areas were detected by DNase I footprinting. Competition analysis with synthetic oligonucleotides showed that the more downstream protected area was occupied, in a mutually exclusive manner, by two factors each related to CTF/NF-1 and Sp1. The other more upstream protected area was recognized by a factor related to the liver-enriched transcription factor C/EBP, which was recently shown to interact with regulatory regions of two other urea cycle enzyme genes.			TAKIGUCHI, M (corresponding author), KUMAMOTO UNIV,SCH MED,INST MED GENET,KUHONJI 4-24-1,KUMAMOTO 862,JAPAN.							ADCOCK MW, 1984, J BIOL CHEM, V259, P3471; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNEL F, 1988, J BIOL CHEM, V263, P10180; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4202; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GEBHARDT R, 1979, EUR J BIOCHEM, V97, P29, DOI 10.1111/j.1432-1033.1979.tb13082.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAGGERTY DF, 1982, J BIOL CHEM, V257, P2246; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAMERS WH, 1985, EUR J BIOCHEM, V146, P475, DOI 10.1111/j.1432-1033.1985.tb08675.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LI Y, 1988, MOL CELL BIOL, V8, P4362, DOI 10.1128/MCB.8.10.4362; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN RC, 1982, J BIOL CHEM, V257, P5061; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; MORI M, 1981, J BIOL CHEM, V256, P4127; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V269, P175, DOI 10.1016/0003-9861(89)90097-0; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; NEBES VL, 1988, MOL ENDOCRINOL, V2, P444, DOI 10.1210/mend-2-5-444; OHTAKE A, 1988, J BIOL CHEM, V263, P2245; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; SCHIMKE RT, 1962, J BIOL CHEM, V237, P459; SCHIMKE RT, 1962, J BIOL CHEM, V237, P1921; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; TAKIGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8789, DOI 10.1093/nar/16.18.8789; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; TSUTSUMI K, 1989, MOL CELL BIOL, V9, P4923, DOI 10.1128/MCB.9.11.4923; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEIL PA, 1979, CELL, V18, P469; XANTHOPOULOS KG, 1989, P NATL ACAD SCI USA, V86, P4117, DOI 10.1073/pnas.86.11.4117	56	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9186	9193						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026618				2022-12-25	WOS:A1991FM03800080
J	TRINCHERA, M; CARRETTONI, D; GHIDONI, R				TRINCHERA, M; CARRETTONI, D; GHIDONI, R			A PART OF GLUCOSYLCERAMIDE FORMED FROM EXOGENOUS LACTOSYLCERAMIDE IS NOT DEGRADED TO CERAMIDE BUT RECYCLED AND GLYCOSYLATED IN THE GOLGI-APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR-PRODUCT RELATIONSHIP; NORMAL RAT-LIVER; HUMAN-FIBROBLASTS; GM1 GANGLIOSIDE; SIALIC-ACID; PLASMA-MEMBRANE; CELLS; BIOSYNTHESIS; METABOLISM; TRANSPORT	The subcellular fate of glucosylceramide (GlcCer) formed from exogenous lactosylceramide (LacCer) in rat liver is investigated. LacCer radiolabeled on different positions of the molecule was intravenously administered to rats as a liposomal dispersion. A Golgi apparatus fraction 140-fold enriched in specific markers and constituted by intact cisternal stacks, as well as the lysosomal and plasma membrane fractions concurrently prepared from the same homogenate, were then studied in order to determine the time course of radioactive glycosphingolipids. LacCer quickly decreased with time in the plasma membrane, whereas in the lysosomes it increased up to 4 h and decreased thereafter. In both fractions results were regardless of the labeling position. In the Golgi apparatus, LacCer increased up to 12 h and then decreased. In this fraction, the radioactivity values of [Glc-H-3]LacCer were over twice those of [Gal-H-3]LacCer. GlcCer was found only after [Glc-H-3]LacCer administration. In the lysosomes, its time course provided a peak similar in shape but delayed in timing with respect to that of LacCer. Conversely, in the Golgi apparatus GlcCer was earlier formed, but earlier consumed, than LacCer. Gangliosides increased in the Golgi apparatus until 4 h and then decreased after 12 h, whereas in the plasma membrane they were progressively accumulated. In both fractions the amount of [Glc-H-3]gangliosides was over twice that of [Gal-H-3]gangliosides. Since we demonstrated that the sugars released in the course of LacCer degradation (LacCer --> galactose + GlcCer --> glucose + ceramide) are not incorporated into glycoconjugates, we conclude that a part of GlcCer formed during the lysosomal degradation of LacCer actually reaches the Golgi apparatus where it undergoes successive glycosylation.	UNIV MILAN,DEPT MED CHEM & BIOCHEM,VIA SALDINI 50,I-20133 MILAN,ITALY	University of Milan				GHIDONI, RICCARDO/0000-0002-6300-5867				AKHTAR M, 1980, J CLIN PATHOL, V33, P1214, DOI 10.1136/jcp.33.12.1214; BARTON NW, 1975, J BIOL CHEM, V250, P3966; BASU M, 1987, METHOD ENZYMOL, V138, P575; BERGERON JJ, 1973, J CELL BIOL, V59, P73, DOI 10.1083/jcb.59.1.73; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BREW K, 1975, J BIOL CHEM, V250, P1434; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CAHAN LD, 1982, P NATL ACAD SCI-BIOL, V79, P7629, DOI 10.1073/pnas.79.24.7629; CHATTERJEE S, 1986, J BIOL CHEM, V261, P3480; CHATTERJEE S, 1988, NATO ASI SER H, V150, P613; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DUBOIS G, 1980, ANAL BIOCHEM, V102, P313, DOI 10.1016/0003-2697(80)90159-1; EMMELOT P, 1964, BIOCHIM BIOPHYS ACTA, V90, P126, DOI 10.1016/0304-4165(64)90125-4; FISHMAN JB, 1986, J BIOL CHEM, V261, P1896; FORSTER S, 1986, TRENDS BIOCHEM SCI, V11, P365; Gazzotti G, 1984, GLYCOCONJUGATE J, V1, P111, DOI 10.1007/bf01213725; GHIDONI R, 1989, J NEUROCHEM, V53, P1567, DOI 10.1111/j.1471-4159.1989.tb08553.x; GHIDONI R, 1980, J BIOL CHEM, V255, P6990; GHIDONI R, 1986, BIOCHEM J, V237, P147, DOI 10.1042/bj2370147; GHIDONI R, 1987, BIOCHEM J, V247, P157, DOI 10.1042/bj2470157; GROSSE E, 1984, BIOCHIM BIOPHYS ACTA, V805, P354, DOI 10.1016/0167-4889(84)90018-1; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; KEENAN TW, 1974, J BIOL CHEM, V249, P310; KOK JW, 1989, P NATL ACAD SCI USA, V86, P9896, DOI 10.1073/pnas.86.24.9896; KREISEL W, 1988, J BIOL CHEM, V263, P11736; LESKAWA KC, 1984, ANAL BIOCHEM, V140, P172, DOI 10.1016/0003-2697(84)90149-0; LI SC, 1975, J BIOL CHEM, V250, P6786; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKITA A, 1985, NEW COMPREHENSIVE BI, V10, P1; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MCMASTER MC, 1975, J LABELLED COMPD RAD, V23, P353; MORRE DJ, 1983, EUR J CELL BIOL, V31, P263; MORRE DM, 1988, EUR J CELL BIOL, V46, P307; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; ROKUKAWA C, 1982, J BIOCHEM-TOKYO, V92, P1481, DOI 10.1093/oxfordjournals.jbchem.a134072; ROME LH, 1986, BIOCHEM J, V235, P707, DOI 10.1042/bj2350707; SAITO M, 1985, J BIOL CHEM, V260, P2295; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SORIANO P, 1983, P NATL ACAD SCI-BIOL, V80, P7128, DOI 10.1073/pnas.80.23.7128; SPANJER HH, 1983, BIOCHIM BIOPHYS ACTA, V734, P40, DOI 10.1016/0005-2736(83)90072-X; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; TAKI T, 1978, J BIOCHEM-TOKYO, V83, P1517, DOI 10.1093/oxfordjournals.jbchem.a132062; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; TOKORO T, 1987, J LIPID RES, V28, P968; TRINCHERA M, 1988, BIOCHEM J, V252, P375, DOI 10.1042/bj2520375; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; TRINCHERA M, 1990, FEBS LETT, V260, P23, DOI 10.1016/0014-5793(90)80056-O; TRINCHERA M, 1990, BIOCHEM J, V266, P363, DOI 10.1042/bj2660363; TRINCHERA M, 1991, BIOCHEMISTRY-US, V30, P2719, DOI 10.1021/bi00224a021; TRINCHERA M, 1990, J BIOCHEM-TOKYO, V107, P619, DOI 10.1093/oxfordjournals.jbchem.a123096; TRINCHERA M, 1990, BIOCHEM J, V266, P103, DOI 10.1042/bj2660103; USUKI S, 1988, J BIOL CHEM, V263, P6847; YAMADA H, 1984, J BIOCHEM, V95, P1155, DOI 10.1093/oxfordjournals.jbchem.a134704; ZANETTA JP, 1972, J CHROMATOGR, V69, P291, DOI 10.1016/S0021-9673(00)92897-8; 1977, LIPIDS, V12, P455	57	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9093	9099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026613				2022-12-25	WOS:A1991FM03800067
J	UZAN, G; PRENANT, M; PRANDINI, MH; MARTIN, F; MARGUERIE, G				UZAN, G; PRENANT, M; PRANDINI, MH; MARTIN, F; MARGUERIE, G			TISSUE-SPECIFIC EXPRESSION OF THE PLATELET GPIIB GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROLEUKEMIA CELL-LINE; HEMATOPOIETIC STEM-CELLS; DNA-BINDING PROTEIN; HUMAN MEGAKARYOCYTES; GLYCOPROTEIN-IIB; NUCLEAR FACTOR; IMMUNOGLOBULIN GENES; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; HEL CELLS	One of the major objectives in the study of thrombogenesis is to determine the mechanisms by which a hematopoietic progenitor is activated and committed to the megakaryocytic lineage. Recent development of primary cultures of human megakaryocytes and the molecular cloning of genes that are specific to this lineage offer the possibility of getting some insights into the genetic mechanisms that control megakaryocytopoiesis. One gene of interest is the glycoprotein IIb (GPIIb) gene; GPIIb, the alpha-subunit of the platelet cytoadhesin GPIIb-IIIa, is produced in megakaryocytes at an early stage of the differentiation, whereas the other subunit of this complex, GPIIIa, is expressed in other cells. For these reasons, the 5'-flanking region of the GPIIb gene was used to identify the regions that interact with DNA-binding nuclear factors. A fragment extending from -643 to +33 is capable of controlling the tissue-specific expression of the CAT gene in transfection experiments. Within this region, we have identified several sequences that are implicated in DNA protein interactions as shown in DNAse I footprints and gel mobility shift assays. One region, centered at -54, is similar to a nuclear factor E1-binding site, and a region located at position -233 contains a CCAAT motif. Two domains centered at positions -345 and -540, respectively, bind proteins that are present in megakaryocytic cells and nonrelated cells as well. Finally, two other domains, located at positions -460 and -510, interact with proteins that are only present in megakaryocytic cells. In addition, deletion of the region containing these two domains results in a significant decrease of the promoter activity. It is very likely that these domains bind megakaryocyte-specific nuclear proteins acting as positive transcription factors.			UZAN, G (corresponding author), CEN,DEPT BIOL MOLEC & STRUCT,HEMATOL LAB,INSERM,U217,F-38041 GRENOBLE,FRANCE.		Uzan, Georges/M-8199-2018	Uzan, Georges/0000-0002-0178-5386				BERRIDGE MV, 1985, BLOOD, V66, P76; BERTHIER R, 1987, EXP HEMATOL, V15, P750; BRANDT J, 1988, J CLIN INVEST, V82, P1017, DOI 10.1172/JCI113658; BRAY PF, 1987, J CLIN INVEST, V80, P1812, DOI 10.1172/JCI113277; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DELUCA M, 1984, BIOCHEM BIOPH RES CO, V123, P764, DOI 10.1016/0006-291X(84)90295-X; DOI T, 1987, MOL CELL BIOL, V7, P898, DOI 10.1128/MCB.7.2.898; DUPERRAY A, 1987, J CELL BIOL, V104, P1665, DOI 10.1083/jcb.104.6.1665; DUPERRAY A, 1989, BLOOD, V74, P1603; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRACHET P, 1990, MOL BIOL REP, V14, P27, DOI 10.1007/BF00422712; FRASER JK, 1986, BLOOD, V68, P762; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GREENBERG SM, 1988, BLOOD, V72, P1968; HALLIGAN BD, 1987, P NATL ACAD SCI USA, V84, P7019, DOI 10.1073/pnas.84.20.7019; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KANZ L, 1988, EXP HEMATOL, V16, P741; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LEVENE RB, 1985, J EXP MED, V161, P457, DOI 10.1084/jem.161.3.457; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P1311; MARGUERIE G, 1987, PLATELETS BIOL PATHO, V3, P85; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PHILLIPS DR, 1988, BLOOD, V71, P831; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1987, PERSPECTIVES INFLAMM, P267; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RABELLINO EM, 1981, J EXP MED, V154, P88, DOI 10.1084/jem.154.1.88; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIGNEURIN D, 1987, EXP HEMATOL, V15, P822; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; UZAN G, 1988, EUR J BIOCHEM, V171, P87, DOI 10.1111/j.1432-1033.1988.tb13762.x; VANCONG N, 1988, HUM GENET, V80, P389; VINCI G, 1984, BRIT J HAEMATOL, V56, P589, DOI 10.1111/j.1365-2141.1984.tb02184.x; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	51	95	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8932	8939						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026605				2022-12-25	WOS:A1991FM03800044
J	HELIN, K; BEGUINOT, L				HELIN, K; BEGUINOT, L			INTERNALIZATION AND DOWN-REGULATION OF THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR ARE REGULATED BY THE CARBOXYL-TERMINAL TYROSINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; EGF-RECEPTOR; MEDIATED ENDOCYTOSIS; AUTOPHOSPHORYLATION SITES; KINASE-ACTIVITY; LIGAND; CELLS; IDENTIFICATION; DEGRADATION; HEPATOCYTES	The C terminus of the epidermal growth factor receptor (EGF-R) contains three tyrosines (Y1068, Y1148, and Y1173) which correspond to the major autophosphorylation sites. To investigate the role of the tyrosines in internalization and down-regulation of the EGF-R, mutational analysis was performed with receptors in which 1, 2, or all 3 tyrosines were changed to phenylalanines. The triple point mutant EGF-R, expressed in NIH-3T3, exhibited low autophosphorylation in vivo, low biological and reduced kinase activities. Single and double point mutants were down-regulated, as well as wild type EGF-R in response to EGF showing a half-life of about 1 h. Degradation of the triple point mutant, however, was impaired and resulted in a half-life of 4 h in the presence of EGF. EGF-dependent down-regulation of surface receptors was decreased in the triple point mutant EGF-R as was internalization and degradation of EGF. The specific rate of internalization of the triple point mutant was reduced. By contrast, intracellular processing of ligand previously internalized at 20-degrees-C was similar between wild type and mutant receptors. Taken together the data indicate that the delay in degradation observed in cells expressing the triple point mutant EGF-R can be attributed mainly to a slower removal from the cell surface. Our results show that in the full-length EGF-R all three C-terminal tyrosines are necessary for rapid internalization, suggesting that autophosphorylation is required for efficient EGF-dependent receptor endocytosis.			HELIN, K (corresponding author), UNIV COPENHAGEN,INST MICROBIOL,DK-1353 COPENHAGEN,DENMARK.		Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; 				BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BEGUINOT L, 1986, J BIOL CHEM, V261, P1801; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1984, J BIOL CHEM, V259, P2553; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GLADHAUG IP, 1988, J BIOL CHEM, V263, P12199; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KORK M, 1985, P NATL ACAD SCI US A, V82, P6172; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; PANDIELLA A, 1989, TRENDS PHARMACOL SCI, V10, P411; Pastan I., 1985, ENDOCYTOSIS, V1-44; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TESLENKO LV, 1987, FEBS LETT, V221, P105, DOI 10.1016/0014-5793(87)80361-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILLINGHAM MC, 1982, J CELL BIOL, V94, P207, DOI 10.1083/jcb.94.1.207; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	44	83	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8363	8368						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022652				2022-12-25	WOS:A1991FK44100063
J	BODE, BP; KILBERG, MS				BODE, BP; KILBERG, MS			AMINO ACID-DEPENDENT INCREASE IN HEPATIC SYSTEM-N ACTIVITY IS LINKED TO CELL SWELLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; L-GLUTAMINE TRANSPORT; PERFUSED RAT-LIVER; MONOLAYER-CULTURE; HEPATOCYTES; METABOLISM; FLUXES; HISTIDINE; ALANINE; WATER	Treatment of cultured rat hepatocytes with certain amino acids stimulates the activity of the System N transporter. The present report investigates the mechanism by which the stimulatory amino acids elicit their effect. Activation of System N-mediated transport by amino acids is rapid, cycloheximide-insensitive, and involves neither trans-stimulation nor recruitment of additional carriers to the plasma membrane. In addition, the activation is Na+-dependent, supporting the related observation that the most effective stimulatory amino acids are substrates of Na+-dependent transport Systems A, ASC, and N whereas substrates of Na+-independent System L and non-amino acid metabolites are ineffective. The data suggest that active accumulation of amino acids via Na+-dependent carriers is necessary for the activation to occur. The amino acid-dependent stimulation is blocked in a concentration-dependent manner by increasing extracellular K+. Treatment of hepatocytes with an amino acid such as asparagine causes cell swelling and stimulation of System N activity; both of these effects are reduced by hypertonic media. Furthermore, swelling of rat hepatocytes with hypotonic media mimics the System N-stimulatory effects of asparagine. Among the Na+-dependent amino acid transport systems present in rat hepatocytes, System N is stimulated preferentially by amino acid-containing or hypotonic media. Collectively, these results demonstrate that cell swelling is a prerequisite for the amino acid-dependent activation of the hepatic System N transporter.	UNIV FLORIDA, J HILLIS MILLER HLTH CTR,SCH MED, DEPT BIOCHEM & MOLEC BIOL,BOX J245, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida					NIDDK NIH HHS [DK-31580] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031580] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACQUET A, 1990, J BIOL CHEM, V265, P955; CARIAPPA R, 1990, J BIOL CHEM, V265, P1470; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CORASANTI JG, 1990, AM J PHYSIOL, V258, pG290, DOI 10.1152/ajpgi.1990.258.2.G290; FAFOURNOUX P, 1989, J BIOL CHEM, V264, P4805; GAZZOLA GC, 1980, J BIOL CHEM, V255, P929; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GEBHARDT R, 1987, EUR J BIOCHEM, V166, P339, DOI 10.1111/j.1432-1033.1987.tb13520.x; HADDAD P, 1989, AM J PHYSIOL, V257, pG357, DOI 10.1152/ajpgi.1989.257.3.G357; HAUSSINGER D, 1990, EUR J BIOCHEM, V188, P689, DOI 10.1111/j.1432-1033.1990.tb15451.x; HAUSSINGER D, 1985, EUR J BIOCHEM, V152, P597, DOI 10.1111/j.1432-1033.1985.tb09237.x; HAUSSINGER D, 1990, HEPATOLOGY, V11, P243, DOI 10.1002/hep.1840110214; HAUSSINGER D, 1989, METABOLISM, V38, P14, DOI 10.1016/0026-0495(89)90133-9; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; HUNDAL HS, 1987, J PHYSIOL-LONDON, V393, P283, DOI 10.1113/jphysiol.1987.sp016824; KARL PI, 1989, PEDIATR RES, V25, P19, DOI 10.1203/00006450-198901000-00005; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; KRISTENSEN LO, 1984, BIOCHEM J, V221, P265, DOI 10.1042/bj2210265; KRISTENSEN LO, 1986, AM J PHYSIOL, V251, pG575, DOI 10.1152/ajpgi.1986.251.5.G575; LANG F, 1989, PFLUG ARCH EUR J PHY, V413, P209, DOI 10.1007/BF00583532; LAZARUS P, 1986, BIOCHIM BIOPHYS ACTA, V856, P488, DOI 10.1016/0005-2736(86)90140-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PRPIC V, 1984, J BIOL CHEM, V259, P1382; REMESY C, 1988, J NUTR, V118, P569, DOI 10.1093/jn/118.5.569; SCHENERMAN MA, 1986, BIOCHIM BIOPHYS ACTA, V856, P428, DOI 10.1016/0005-2736(86)90133-1; SOUBA WW, 1985, JPEN-PARENTER ENTER, V9, P608, DOI 10.1177/0148607185009005608; VADGAMA JV, 1983, J BIOL CHEM, V258, P6422; WEISSBACH L, 1984, J CELL PHYSIOL, V121, P133, DOI 10.1002/jcp.1041210116	31	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7376	7381						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019573				2022-12-25	WOS:A1991FJ34200013
J	LIGHT, A; ALOBEIDI, AM				LIGHT, A; ALOBEIDI, AM			FURTHER EVIDENCE FOR INDEPENDENT FOLDING OF DOMAINS IN SERINE PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; REDUCED RIBONUCLEASE; BOVINE TRYPSINOGEN; POLYPEPTIDE-CHAIN; PROTEIN; CHYMOTRYPSIN; DISULFIDE; MECHANISM; PATHWAY	The folding pathway of pancreatic serine proteases was clarified from kinetic studies on the refolding of the glutathione-mixed disulfide derivative of bovine neochymotrypsinogen. Neochymotrypsinogen is prepared from a limited proteolysis of native chymotrypsinogen A by cleavage at Tyr146-Thr147 (Duda and Light (1982) J. Biol. Chem. 257, 9866-9871). The mixed disulfide methodology (Odorzynski and Light (1979) J. Biol. Chem. 254, 4291-4295) was necessary to successfully refold chymotrypsinogen and neochymotrypsinogen. Mixtures of the chromatographically purified amino- and carboxyl-terminal polypeptides of neochymotrypsinogen, as the mixed disulfide derivatives, were refolded at varying molar ratios of the polypeptides. The regeneration of native structure was followed as a function of time from activity measurements and from the regain of the molecular weight of the zymogen. The rate data fit first-order kinetics. The kinetic analysis is compatible with a folding mechanism that supports (a) independent folding of the amino- and carboxyl-terminal domains; (b) identical rates of folding of each domain; and (c) the rate-limiting step is the formation of the interdomain disulfide. The formation of a stable complex of the folded domains was favored by complementary hydrophobic and hydrogen bonding interactions and the formation of the last disulfide bond. The geometric arrangement of the active site residues was regained and the zymogen could be converted to the active enzyme, namely, alpha-chymotrypsin.			LIGHT, A (corresponding author), PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907, USA.							ALOBEIDI AM, 1988, J BIOL CHEM, V263, P8642; ALOBEIDI AM, 1989, THESIS PURDUE U; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; BRADSHAW RA, 1967, J BIOL CHEM, V242, P3789; Creighton T. E., 1983, PROTEINS STRUCTURES, P1; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CREIGHTON TE, 1975, J MOL BIOL, V95, P167, DOI 10.1016/0022-2836(75)90389-7; CREIGHTON TE, 1977, J MOL BIOL, V113, P329, DOI 10.1016/0022-2836(77)90145-0; CREIGHTON TE, 1977, J MOL BIOL, V113, P295, DOI 10.1016/0022-2836(77)90143-7; CREIGHTON TE, 1987, PROTEIN ENG, V83, P83; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V5, pD99; DUDA CT, 1982, J BIOL CHEM, V257, P9866; HARRISON SC, 1985, P NATL ACAD SCI USA, V82, P4028, DOI 10.1073/pnas.82.12.4028; HIGAKI JN, 1986, J BIOL CHEM, V261, P606; HIGAKI JN, 1986, REFOLDING BOVINE TRY; HOLLECKER M, 1983, J MOL BIOL, V168, P409, DOI 10.1016/S0022-2836(83)80026-6; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JAENICKE R, 1980, PROTEIN FOLDING, P1; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KRAUT J, 1971, ENZYMES, V3, P165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; LIGHT A, 1987, BIOCHEMISTRY-US, V26, P5556, DOI 10.1021/bi00391a051; LIGHT A, 1985, Biotechniques, V3, P298; LIGHT A, 1986, PROTEIN STRUCTURE FO, P163; LIGHT A, 1991, HPLC PEPTIDES PROTEI; MOORE WG, 1981, THESIS PURDUE U; NEURATH H, 1986, CHEM SCRIPTA B, V27, P221; ODORZYNSKI TW, 1979, J BIOL CHEM, V254, P4291; PTITSYN OB, 1981, FEBS LETT, V131, P197, DOI 10.1016/0014-5793(81)80367-5; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROVERY M, 1957, BIOCHIM BIOPHYS ACTA, V23, P608, DOI 10.1016/0006-3002(57)90383-9; SHARMA SK, 1978, BIOCHIM BIOPHYS ACTA, V527, P465, DOI 10.1016/0005-2744(78)90360-1; VALENZUELA P, 1973, J BIOL CHEM, V248, P4909; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697; Wilcox P. E., 1970, METHODS ENZYMOLOGY, P64, DOI [10.1016/0076-6879(70)19007-0, DOI 10.1016/0076-6879(70)19007-0]	41	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7694	7698						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019593				2022-12-25	WOS:A1991FJ34200060
J	MALIK, MN; FENKO, MD; SHEIKH, AM				MALIK, MN; FENKO, MD; SHEIKH, AM			HIGH-MOLECULAR-WEIGHT GLYCOSYLATED PROTEASE IN CALF BRAIN - PURIFICATION AND PARTIAL CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; MULTICATALYTIC PROTEINASE; RABBIT RETICULOCYTE; NEUTRAL PROTEINASE; MYOSIN; FORMS	A high molecular weight protease has been purified to homogeneity from calf brain cytosol. The purification procedure involves ammonium sulfate fractionation of the cytosol followed by chromatography on DEAE-Sephacel, hydroxylapatite, concanavalin A-Sepharose 4B and Sephacryl S-300. The molecular weight of the native protease was estimated to be M(r) = 465,000 by high pressure liquid chromatography. It is composed of a closely moving doublet of M(r) = 165,000 and 155,000, as determined on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. It degrades [methyl-C-14]alpha-casein with a broad pH optimum of 6.8-8.5.[methyl-C-14]bovine serum albumin and I-125-bovine serum albumin are hydrolyzed to the same extent as [methyl-C-14]alpha-casein, whereas [methyl-C-14]methemoglobin is hydrolyzed to half the extent of [methyl-C-14]alpha-casein. Divalent cations, nucleotides, and known protease inhibitors (phenylmethylsulfonyl fluoride, p-chloromercuribenzoate, iodoacetic acid, N-ethylmaleimide, leupeptin, antipain, pepstatin, and hemin) have no effect on the activity of the protease. The protease is glycosylated and appears to aggregate readily. Aggregation may be reversed by treating the protease with certain organic solvents. The protease seems to maintain full activity after heat treatment. Electron microscopic data reveals a spherical structure of 20-nm diameter.			MALIK, MN (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABILITIES,NEURONAL PROTEASES & CYTOSKELETAL PROT LAB,STATEN ISL,NY 10314, USA.							ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; DAHLMANN B, 1985, BIOCHEM J, V228, P161, DOI 10.1042/bj2280161; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; HOUGH R, 1987, J BIOL CHEM, V262, P8303; ISHIURA S, 1986, J BIOCHEM, V100, P753, DOI 10.1093/oxfordjournals.jbchem.a121768; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; MALIK MN, 1987, BIOCHIM BIOPHYS ACTA, V916, P135, DOI 10.1016/0167-4838(87)90220-2; MALIK MN, 1983, J NEUROCHEM, V40, P1620, DOI 10.1111/j.1471-4159.1983.tb08135.x; MALIK MN, 1983, J BIOL CHEM, V258, P8955; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; NEESER JR, 1984, ANAL BIOCHEM, V142, P58, DOI 10.1016/0003-2697(84)90516-5; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; Rivett A.J., 1990, Essays in Biochemistry, V25, P39; RIVETT AJ, 1988, ARCH BIOCHEM BIOPHYS, V268, P1; SAITOH Y, 1989, J BIOCHEM-TOKYO, V105, P254, DOI 10.1093/oxfordjournals.jbchem.a122649; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TONG SW, 1983, J BIOL CHEM, V258, P3100	17	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6594	6599						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007605				2022-12-25	WOS:A1991FE37300087
J	WICK, KL; MATTHEWS, KS				WICK, KL; MATTHEWS, KS			INTERACTIONS BETWEEN LAC REPRESSOR PROTEIN AND SITE-SPECIFIC BROMODEOXYURIDINE-SUBSTITUTED OPERATOR DNA - ULTRAVIOLET FOOTPRINTING AND PROTEIN-DNA CROSS-LINK FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE CONTROL REGIONS; LACTOSE REPRESSOR; BINDING; DIGESTION; MUTATIONS; INVIVO; LIGHT; CORE	Specific contacts between the lac repressor and operator have been explored using 5-bromodeoxyuridine-substituted DNA. Substitution of BrdU for single thymidine positions in a synthetic 40-base pair operator provides substrate for ultraviolet irradiation; upon irradiation, strand scission occurs at the BrdU residues. When bound, lac repressor protein provides protection against UV-induced breakage depending on the nature of the sites and type of interaction. We have confirmed 13 unique sites of inducer-sensitive protection along the operator sequence using this method compared to complete substitution with BrdU; differences were observed at two positions for singly substituted versus completely substituted DNAs (Ogata, R., and Gilbert, W. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 4973-4976). The ability of these photosensitive DNAs to form short range cross-links to bound protein has been used to determine the efficiency with which cross-linked protein-DNA complexes are generated at each individual site of BrdU substitution. Five sites of high efficiency cross-linking to the repressor protein have been identified. At one site, cross-linking without protection from strand scission was observed; this result suggests an unusual mechanism of strand scission and/or cross-linking at this site. Comparison of the UV protection results and the cross-linking data show that these processes provide complementary tools for identifying and analyzing individual protein-DNA contacts.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TD, 1991, J BIOL CHEM, V266, P6113; BARBIER B, 1984, BIOCHEMISTRY-US, V23, P2933, DOI 10.1021/bi00308a013; BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BETZ JL, 1986, GENE, V50, P123, DOI 10.1016/0378-1119(86)90317-3; CARUTHERS MH, 1983, COLD SPRING HARB SYM, V47, P411; CULARD F, 1982, FEBS LETT, V146, P153, DOI 10.1016/0014-5793(82)80724-2; CULARD F, 1981, NUCLEIC ACIDS RES, V9, P5175, DOI 10.1093/nar/9.19.5175; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; DEVLIEG J, 1989, PROTEINS, V6, P104, DOI 10.1002/prot.340060203; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; GILBERT W, 1975, PROTEIN LIGAND INTER, P193; GOEDDEL DV, 1978, J MOL BIOL, V123, P661, DOI 10.1016/0022-2836(78)90211-5; GOEDDEL DV, 1977, NUCLEIC ACIDS RES, V4, P3039, DOI 10.1093/nar/4.9.3039; GOEDDEL DV, 1978, P NATL ACAD SCI USA, V75, P3578, DOI 10.1073/pnas.75.8.3578; HOTZ G, 1967, MOL GEN GENET, V99, P5, DOI 10.1007/BF00306453; HSIEH WT, 1981, J BIOL CHEM, V256, P4856; HUTCHINSON F, 1973, Q REV BIOPHYS, V6, P201, DOI 10.1017/S0033583500001141; KOHNLEIN W, 1969, RADIAT RES, V39, P745, DOI 10.2307/3572950; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LIN S, 1971, BIOCHEM BIOPH RES CO, V45, P1542, DOI 10.1016/0006-291X(71)90195-1; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; LIN SY, 1972, P NATL ACAD SCI USA, V69, P2574, DOI 10.1073/pnas.69.9.2574; Maniatis T., 1982, MOL CLONING; MANLY SP, 1984, J MOL BIOL, V179, P335, DOI 10.1016/0022-2836(84)90069-X; MANLY SP, 1984, J MOL BIOL, V179, P315, DOI 10.1016/0022-2836(84)90068-8; MAQUAT LE, 1980, J MOL BIOL, V139, P537, DOI 10.1016/0022-2836(80)90145-X; Miller J. H., 1980, OPERON; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; REZNIKOFF WS, 1984, MICROBE 1984 2, P195; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROSENBERG JM, 1977, NUCLEIC ACIDS RES, V4, P567, DOI 10.1093/nar/4.3.567; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SHALLOWAY D, 1980, CELL, V20, P411, DOI 10.1016/0092-8674(80)90627-3; SMITH KC, 1969, BIOCHEM BIOPH RES CO, V34, P354, DOI 10.1016/0006-291X(69)90840-7; SMITH TF, 1971, J MOL BIOL, V59, P273, DOI 10.1016/0022-2836(71)90051-9; WACKER A, 1964, PHOTOCHEM PHOTOBIOL, V3, P369, DOI 10.1111/j.1751-1097.1964.tb08160.x; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	42	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6106	6112						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007568				2022-12-25	WOS:A1991FE37300019
J	STIMPFEL, TM; GERSHEY, EL				STIMPFEL, TM; GERSHEY, EL			SELECTING ANESTHETIC AGENTS FOR HUMAN SAFETY AND ANIMAL RECOVERY SURGERY	FASEB JOURNAL			English	Article						SAFETY; ANESTHESIA; ANIMAL; EXPOSURE	KETAMINE; XYLAZINE	This review provides information to scientists performing animal surgery with recommendations for choosing an appropriate anesthetic agent. The human health risks from exposure to various anesthetic agents as well as methods to minimize exposure are discussed. In brief, methoxyflurane, used with precautions, is recommended for rodent bench-top surgery. When a precision vaporizer is available, isoflurane is usually the agent of choice. Other agents, including injectables, are considered.	ROCKEFELLER UNIV,SAFETY LAB,1230 YORK AVE,NEW YORK,NY 10021; MILES INC,W HAVEN,CT 06516	Rockefeller University								GREEN CJ, 1981, LAB ANIM, V15, P163, DOI 10.1258/002367781780959107; MULDER JK, 1979, VET MED SMALL ANIM C, V74, P569; VANPELT LF, 1977, J AM VET MED ASSOC, V171, P842; WATERMAN AE, 1978, BRIT J ANAESTH, V50, P885, DOI 10.1093/bja/50.9.885	4	27	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1991	5	7					2099	2104		10.1096/fasebj.5.7.2010062	http://dx.doi.org/10.1096/fasebj.5.7.2010062			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	2010062				2022-12-25	WOS:A1991FF44200013
J	VARLEY, JM; BRAMMAR, WJ; LANE, DP; SWALLOW, JE; DOLAN, C; WALKER, RA				VARLEY, JM; BRAMMAR, WJ; LANE, DP; SWALLOW, JE; DOLAN, C; WALKER, RA			LOSS OF CHROMOSOME-17P13 SEQUENCES AND MUTATION OF P53 IN HUMAN BREAST CARCINOMAS	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; MONOCLONAL-ANTIBODY; PROTO-ONCOGENE; ALLELE LOSS; SHORT ARM; SV40-TRANSFORMED CELLS; COLORECTAL CARCINOMAS; INCREASED EXPRESSION; TRANSFORMED-CELLS	DNAs from ninety seven primary breast carcinoma biopsies have been examined for loss of sequences on 17p13. In addition, immunohistochemical analysis has been carried out on the majority of these cases to determine whether p53 gene expression can be detected. Detection of p53 expression is taken to indicate mutation of p53 leading to stabilisation of the protein and thus detectable levels of p53 in the cell. In 86% of breast carcinoma samples where both allele loss and expression data were available, loss of sequences on 17p13 and/or expression of p53 was detected. Alterations to p53, whether loss of one allele or mutation, are therefore by far the most common changes so far detected in primary human breast tumours. In three cases where expression of p53 could be detected by immunohistochemistry, the precise mutation to p53 was identified. All three mutations fall within the regions which are highly conserved in p53, encoded by exons 5 to 8. Two are single base changes leading to missense mutations, and the third is a single base-pair deletion. The expression of the latter gene would result in production of a truncated protein which should lack normal biological activities.	UNIV LEICESTER,DEPT PATHOL,LEICESTER LE1 7RH,ENGLAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND	University of Leicester	VARLEY, JM (corresponding author), UNIV LEICESTER,ICI PLC UNIV JOINT LAB,LEICESTER LE1 7RH,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ADDISON C, 1990, ONCOGENE, V5, P423; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BENCHIMOL S, 1985, SOMAT CELL MOLEC GEN, V11, P505, DOI 10.1007/BF01534845; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BENDAVID Y, 1988, ONCOGENE, V3, P179; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; Crawford L V, 1984, Mol Biol Med, V2, P261; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DANG CV, 1989, J BIOL CHEM, V264, P18019; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FULTS D, 1989, CANCER RES, V49, P6572; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; LANE DP, 1985, PROC R SOC SER B-BIO, V226, P25, DOI 10.1098/rspb.1985.0077; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MARSHAL R, 1990, BLOOD, V75, P180; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; Nakamura Y, 1988, GENOMICS, V2, P302, DOI 10.1016/0888-7543(88)90018-3; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROGERS J, 1983, NATURE, V305, P101, DOI 10.1038/305101a0; ROSEN PP, 1987, BREAST DISEASES; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOGUCHIDA J, 1989, CANCER RES, V49, P6247; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VARLEY JM, 1987, ONCOGENE, V1, P423; VARLEY JM, 1989, HORM RES, V32, P250, DOI 10.1159/000181357; VARLEY JM, 1988, ONCOGENE, V3, P87; VARLEY JM, 1989, ONCOGENE, V4, P725; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITTAKER JL, 1986, INT J CANCER, V38, P651, DOI 10.1002/ijc.2910380506; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	83	262	262	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					413	421						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011397				2022-12-25	WOS:A1991FT34400010
J	LAUBER, ME; BENGTSON, T; WATERMAN, MR; SIMPSON, ER				LAUBER, ME; BENGTSON, T; WATERMAN, MR; SIMPSON, ER			REGULATION OF CYP11A (P450SCC) AND CYP17 (P45017-ALPHA) GENE-EXPRESSION IN BOVINE LUTEAL CELLS IN PRIMARY CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-CLEAVAGE CYTOCHROME-P-450; RAT GRANULOSA-CELLS; CORPUS-LUTEUM; CORPORA-LUTEA; GROWTH-FACTOR; 17-ALPHA-HYDROXYLASE CYTOCHROME-P-450; CYCLIC-AMP; LUTEINIZING-HORMONE; RESPONSIVE ELEMENT; MENSTRUAL-CYCLE	Cholesterol side chain cleavage cytochrome P450 (P450scc) and 17-alpha-hydroxylase cytochrome P450 (P450(17-alpha)) are key enzymes involved in steroid hormone biosynthesis. The 5'-flanking regions of the corresponding bovine genes have recently been characterized in the adrenal-derived Y1 cell line and specific DNA sequences, required for basal and cAMP-dependent gene expression, were identified. In order to investigate the molecular mechanisms controlling P450scc and P450(17-alpha) gene expression throughout the ovarian cycle, we devised an electroporation protocol to transfect bovine luteal cells in primary culture with specific chimeric DNA constructs. Transfection of such cells with reporter gene constructs containing 186 base pairs (bp) or more of the CYP11A (P450scc) 5'-regulatory region resulted in cAMP-responsive reporter gene expression. Reporter gene constructs containing 101 bp or less of this regulatory region were expressed neither in the presence nor in the absence of forskolin. Thus, expression of the CYP11A gene in bovine luteal cells in primary culture appears to be controlled by a cis-acting element located between -186 to -101 bp. Transfection of bovine luteal cells in primary culture with reporter gene constructs containing increasing deletions of the bovine CYP17 (P450(17-alpha)) 5'-regulatory region clearly demonstrated that none of the sequences were capable of promoting significant reporter gene expression, neither in the presence nor absence of forskolin. Since no 17-alpha-hydroxylase activity and no specific mRNA encoding P450(17-alpha) have been detected in the bovine corpus luteum, the failure of expression of the P450(17-alpha) reporter gene constructs mimics that of the endogenous gene. These results demonstrate that the regulation of CYP11A gene expression in bovine luteal cells is carried out by the same cis-acting element (-183/-101) which serves this role in the adrenal Y1 cell line. On the other hand, expression of the CYP17 gene in bovine luteal cells appears to be completely repressed, due to the absence of specific positive transcription factor(s) or the presence of negative regulatory factor(s). Thus, transfection experiments using bovine luteal cells in primary culture represent a first step towards the elucidation of molecular mechanisms underlying the regulation of cytochrome P450 gene expression throughout the ovarian cycle.	UNIV TEXAS, SW MED CTR, CECIL H & IDA GREEN CTR REPROD BIOL SCI, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OBSTET GYNECOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NICHD NIH HHS [HD 13234] Funding Source: Medline; NIDDK NIH HHS [DK 28350] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; ALILA HW, 1984, BIOL REPROD, V31, P1015, DOI 10.1095/biolreprod31.5.1015; BENHAIM A, 1990, MOL CELL ENDOCRINOL, V68, P105, DOI 10.1016/0303-7207(90)90182-8; BHASKER CR, 1989, ARCH BIOCHEM BIOPHYS, V271, P479, DOI 10.1016/0003-9861(89)90298-1; BRENTANO ST, 1990, MOL ENDOCRINOL, V4, P1972, DOI 10.1210/mend-4-12-1972; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS JS, 1989, J STEROID BIOCHEM, V32, P643, DOI 10.1016/0022-4731(89)90508-6; DODSON WC, 1987, ENDOCRINOLOGY, V120, P512, DOI 10.1210/endo-120-2-512; DOODY KJ, 1990, J CLIN ENDOCR METAB, V70, P1041, DOI 10.1210/jcem-70-4-1041; DOODY KJ, 1990, IN PRESSJ MOL ENDOCR; FITZ TA, 1982, BIOL REPROD, V27, P703, DOI 10.1095/biolreprod27.3.703; Fordis C M, 1987, Methods Enzymol, V151, P382; GOSPODAROWICZ D, 1979, ENDOCRINOLOGY, V104, P757, DOI 10.1210/endo-104-3-757; HANSEL W, 1987, AUST J BIOL SCI, V40, P331, DOI 10.1071/BI9870331; HANSEL W, 1972, AM ZOOL, V12, P225; IRELAND JJ, 1980, J DAIRY SCI, V63, P155, DOI 10.3168/jds.S0022-0302(80)82901-8; JONES PBC, 1982, J BIOL CHEM, V257, P1268; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; LAUBER ME, 1991, J REPROD FERTIL, P57; LUND J, 1990, J BIOL CHEM, V265, P3304; MARSH JM, 1976, BIOL REPROD, V14, P30, DOI 10.1095/biolreprod14.1.30; MCNATTY KP, 1979, J CLIN ENDOCR METAB, V49, P687, DOI 10.1210/jcem-49-5-687; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; RODGERS RJ, 1987, MOL ENDOCRINOL, V1, P274, DOI 10.1210/mend-1-3-274; RODGERS RJ, 1986, ENDOCRINOLOGY, V118, P1366, DOI 10.1210/endo-118-4-1366; RODGERS RJ, 1986, J REPROD FERTIL, V78, P639, DOI 10.1530/jrf.0.0780639; RODGERS RJ, 1986, J REPROD FERTIL, V78, P627, DOI 10.1530/jrf.0.0780627; SASANO H, 1989, J REPROD FERTIL, V85, P163; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; STIRLING D, 1990, J BIOL CHEM, V265, P5; THORNEYCROFT IH, 1971, AM J OBSTET GYNECOL, V111, P947, DOI 10.1016/0002-9378(71)90951-3; URSELY J, 1979, J ENDOCRINOL, V83, P303, DOI 10.1677/joe.0.0830303; VELDHUIS JD, 1986, J BIOL CHEM, V261, P2499; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILTBANK MC, 1989, BIOL REPROD, V40, P1194, DOI 10.1095/biolreprod40.6.1194; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074	38	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11170	11175						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040624				2022-12-25	WOS:A1991FQ77400073
J	OGISHIMA, T; SHIBATA, H; SHIMADA, H; MITANI, F; SUZUKI, H; SARUTA, T; ISHIMURA, Y				OGISHIMA, T; SHIBATA, H; SHIMADA, H; MITANI, F; SUZUKI, H; SARUTA, T; ISHIMURA, Y			ALDOSTERONE SYNTHASE CYTOCHROME-P-450 EXPRESSED IN THE ADRENALS OF PATIENTS WITH PRIMARY ALDOSTERONISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYACRYLAMIDE GELS; PEPTIDE-SYNTHESIS; CORTEX; MITOCHONDRIA; PROTEINS; CLONING; CDNA	A human cytochrome P-450 with aldosterone synthase activity was purified from the mitochondria of an aldosterone-producing adenoma. It was recognized by an anti-bovine cytochrome P-450(11-beta) IgG and by a specific antibody raised against a portion of the CYP11B2 gene product, one of the two putative proteins encoded by human cytochrome P-450(11-beta)-related genes (Mornet, E., Dupont, J., Vitek, A., and White, P. C. (1989) J. Biol. Chem. 264, 20961-20967). A similar and probably the same aldosterone synthase cytochrome P-450 was detected in the adrenal of a patient with idiopathic hyperaldosteronism. These aldosterone synthases were distinguishable from cytochrome P-450(11-beta), the product of another cytochrome P-450(11-beta)-related gene, i.e. CYP11B1, by their catalytic, molecular, and immunological properties and also by their localization. The latter enzyme was unable to produce aldosterone and did not react with the specific antibody against the CYPllB2 gene product. It was present both in tumor and non-tumor portions of the adrenals carrying the adenoma and in normal adrenal cortex. On the other hand, aldosterone synthase cytochrome P-450 localized in the tumor portion of the adrenals or in the adrenal of a patient with idiopathic hyperaldosteronism. Thus aldosterone synthase cytochrome P-450, a distinct species from cytochrome P-450(11-beta), is responsible for the biosynthesis of aldosterone in the human, at least in patients suffering from primary aldosteronism.	KEIO UNIV,DEPT BIOCHEM,35 SHINANOMACHI,SHINJUKU KU,TOKYO 160,JAPAN; KEIO UNIV,SCH MED,DEPT INTERNAL MED,TOKYO 160,JAPAN	Keio University; Keio University								ATHERTON E, 1981, J CHEM SOC PERK T 1, P538, DOI 10.1039/p19810000538; BRAND PH, 1986, ADRENAL GLAND, P201; ERICKSON PF, 1982, J IMMUNOL METHODS, V51, P241, DOI 10.1016/0022-1759(82)90263-0; FUJII N, 1987, CHEM PHARM BULL, V35, P3880; IKUSHIRO S, 1989, BIOCHIM BIOPHYS ACTA, V984, P50, DOI 10.1016/0005-2736(89)90341-6; IMAI M, 1990, FEBS LETT, V263, P299, DOI 10.1016/0014-5793(90)81398-8; IWAI K, 1988, ANAL BIOCHEM, V171, P277, DOI 10.1016/0003-2697(88)90486-1; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KAWAMOTO T, 1990, BIOCHEM BIOPH RES CO, V173, P309, DOI 10.1016/S0006-291X(05)81058-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITANI F, 1982, J HISTOCHEM CYTOCHEM, V30, P1066, DOI 10.1177/30.10.6813370; MORNET E, 1989, J BIOL CHEM, V264, P20961; MOROHASHI K, 1990, J BIOCHEM, V107, P635, DOI 10.1093/oxfordjournals.jbchem.a123099; MULLER J, 1988, MONOGR ENDOCRINOL, V29, P269; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OGISHIMA T, 1989, J BIOL CHEM, V264, P10935; OGISHIMA T, 1989, J BIOCHEM-TOKYO, V105, P497, DOI 10.1093/oxfordjournals.jbchem.a122694; OGISHIMA T, 1990, SEIKAGAKU, V62, P866; SHIBATA H, 1991, IN PRESS ENDOCRINOLO; SUGANO S, 1989, ANAL BIOCHEM, V182, P327, DOI 10.1016/0003-2697(89)90603-9; WADA A, 1985, J BIOCH, V98, P246	21	136	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10731	10734						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040591				2022-12-25	WOS:A1991FQ77400006
J	RAJ, NBK; AU, WC; PITHA, PM				RAJ, NBK; AU, WC; PITHA, PM			IDENTIFICATION OF A NOVEL VIRUS-RESPONSIVE SEQUENCE IN THE PROMOTER OF MURINE INTERFERON-ALPHA GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED NUCLEAR FACTORS; RNA POLYMERASE-II; IFN-BETA GENES; REGULATORY ELEMENTS; TRANSCRIPTION FACTOR; DIFFERENTIAL EXPRESSION; SIGNAL-TRANSDUCTION; STIMULATED GENES; INDUCTION	We have previously shown that the infection of mouse L-cells with Newcastle disease virus activates transcription of the alpha-4 but not the alpha-6 interferon gene and that the induction is mediated by a 35-base pair inducible element (IE) found in the alpha-4 promoter (-109 to -75). In the present study, we show that the inactivity of the alpha-6 promoter can be mapped to 2 out of 6 nucleotides in which the alpha-6 differs from alpha-4 IE. The symmetrical sequence, GTAAAGAAAGT (-103 to -93), present in the alpha-4 IE is essential for its inducibility and binding of nuclear protein(s) to the alpha-4 IE.	JOHNS HOPKINS UNIV, CTR ONCOL, 418 N BOND ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University					NCRR NIH HHS [SO7 RR05378] Funding Source: Medline; NIAID NIH HHS [AI19737] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019737, R21AI019737] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADERKA D, 1986, J IMMUNOL, V136, P2938; BISAT F, 1988, NUCLEIC ACIDS RES, V16, P6067, DOI 10.1093/nar/16.13.6067; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GODING CR, 1987, NUCLEIC ACIDS RES, V15, P7761, DOI 10.1093/nar/15.19.7761; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KELLER AD, 1988, P NATL ACAD SCI USA, V85, P3309, DOI 10.1073/pnas.85.10.3309; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P825, DOI 10.1093/nar/13.3.825; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P805, DOI 10.1093/nar/13.3.805; KELLEY KA, 1985, VIROLOGY, V147, P382, DOI 10.1016/0042-6822(85)90140-0; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MANIATIS T, 1988, HARVEY LECT, V82, P71; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOSCA JD, 1985, J VIROL, V56, P867, DOI 10.1128/JVI.56.3.867-878.1985; MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279; MOUNTS P, 1989, BIOTECHNIQUES, V7, P356; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RAJ NBK, 1989, J BIOL CHEM, V264, P11149; RAJ NBK, 1985, J INTERFERON RES, V5, P493, DOI 10.1089/jir.1985.5.493; RAJ NBK, 1981, P NATL ACAD SCI-BIOL, V78, P7426, DOI 10.1073/pnas.78.12.7426; RAJ NBK, 1989, J BIOL CHEM, V264, P16658; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; RYALS J, 1985, CELL, V41, P497, DOI 10.1016/S0092-8674(85)80023-4; SHUTTLEWORTH J, 1983, EUR J BIOCHEM, V133, P399, DOI 10.1111/j.1432-1033.1983.tb07476.x; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WHITTEMORE LA, 1990, P NATL ACAD SCI USA, V87, P7799, DOI 10.1073/pnas.87.20.7799; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; XANTHOUDAKIS S, 1989, J BIOL CHEM, V264, P1139; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	53	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11360	11365						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040641				2022-12-25	WOS:A1991FQ77400100
J	TOMME, P; CHAUVAUX, S; BEGUIN, P; MILLET, J; AUBERT, JP; CLAEYSSENS, M				TOMME, P; CHAUVAUX, S; BEGUIN, P; MILLET, J; AUBERT, JP; CLAEYSSENS, M			IDENTIFICATION OF A HISTIDYL RESIDUE IN THE ACTIVE-CENTER OF ENDOGLUCANASE-D FROM CLOSTRIDIUM-THERMOCELLUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; SCHIZOPHYLLUM-COMMUNE; CELLULOSE DEGRADATION; TRICHODERMA-REESEI; ESCHERICHIA-COLI; PROTEINS; GENE; DNA; CRYSTALLIZATION; INHIBITORS	Diethylpyrocarbonate modification of endoglucanase D from Clostridium thermocellum, cloned in Escherichia coli, resulted in a rapid but partial (maximally 70-80%) loss of activity. The second-order rate constant of inactivation proved to be exceptionally high (3210 M-1 . min-1). A 3-fold reduction of the k(cat) and a 2-fold increase of the K(m) for 2'-chloro-4'-nitrophenyl beta-cellobioside were observed. Spectrophotometric analysis indicate the presence of one rapidly (k = 0.45 min-1) and two slower (k = 0.23 min-1) reacting histidyl residues. In the presence of 50 mM methyl beta-cellotrioside, the rate of inactivation was reduced 16-fold, and the kinetics of modification were compatible with the protection of 1 histidyl residue. Since peptide analysis was inconclusive, identification of the critical residue was attempted by site-directed mutagenesis. Each of the 12 histidyl residues present in the endoglucanase D sequence was mutated into either Ala or Ser. Seven of the mutant enzymes had specific activities lower than 50% of the wild-type. Only in the case of the Ser-516 mutant, however, was the residual activity not affected by diethyl pyrocarbonate. These findings suggest an important functional or structural role for His-516 in the wild-type enzyme.	STATE UNIV GHENT, BIOCHEM LAB, KL LEDEGANCKSTR, B-9000 GHENT, BELGIUM; INST PASTEUR, DEPT BIOTECHNOL, CNRS, UNITE PHYSIOL CELLULAIRE, F-75724 PARIS 15, FRANCE; INST PASTEUR, DEPT BIOTECHNOL, CNRS, URA 1300, F-75724 PARIS 15, FRANCE	Ghent University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Beguin, Pierre/0000-0002-5372-6281				BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BEAVEN GH, 1952, ADV PROTEIN CHEM, V7, P319, DOI 10.1016/S0065-3233(08)60022-4; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; BURNSTEIN Y, 1974, BIOCHEMISTRY-US, V65, P495; CHAUVAUX S, 1990, BIOCHEM J, V265, P261, DOI 10.1042/bj2650261; CLAEYSSENS M, 1989, FEMS S, V43, P393; CLARKE AJ, 1986, BIOCHIM BIOPHYS ACTA, V870, P401, DOI 10.1016/0167-4838(86)90247-5; CLARKE AJ, 1985, EUR J BIOCHEM, V149, P233, DOI 10.1111/j.1432-1033.1985.tb08917.x; CLARKE AJ, 1987, BIOCHIM BIOPHYS ACTA, V912, P424, DOI 10.1016/0167-4838(87)90048-3; CORNET P, 1983, BIO-TECHNOL, V1, P589, DOI 10.1038/nbt0983-589; DEBOECK H, 1984, J BIOL CHEM, V259, P7067; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; GREPINET O, 1988, J BACTERIOL, V170, P4576, DOI 10.1128/jb.170.10.4576-4581.1988; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HALL J, 1988, MOL GEN GENET, V213, P112, DOI 10.1007/BF00333406; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JOLIFF G, 1986, J MOL BIOL, V189, P249, DOI 10.1016/0022-2836(86)90396-7; JOLIFF G, 1986, NUCLEIC ACIDS RES, V14, P8605, DOI 10.1093/nar/14.21.8605; JOLIFF G, 1986, BIO-TECHNOL, V4, P896, DOI 10.1038/nbt1086-896; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamed R, 1983, BIOTECHNOL BIOENG S, V13, P163; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V2, P105; MEINKE A, 1991, J BACTERIOL, V173, P308, DOI 10.1128/jb.173.1.308-314.1991; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Miles E W, 1977, Methods Enzymol, V47, P431; OVADI J, 1967, Acta Biochimica et Biophysica Academiae Scientiarum Hungaricae, V2, P455; Riordan J F, 1972, Methods Enzymol, V25, P515, DOI 10.1016/S0076-6879(72)25048-0; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHINA M, 1985, ANAL BIOCHEM, V151, P327; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TEATHER RM, 1982, APPL ENVIRON MICROB, V43, P777, DOI 10.1128/AEM.43.4.777-780.1982; TOMME P, 1989, FEBS LETT, V243, P239, DOI 10.1016/0014-5793(89)80136-X; TOMME P, 1988, METHOD ENZYMOL, V160, P187; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKER ML, 1987, PLANT MOL BIOL, V9, P197, DOI 10.1007/BF00166456; VANGRYSPERRE W, 1988, BIOCHEM J, V250, P153, DOI 10.1042/bj2500153; VANTILBEURGH H, 1985, FEBS LETT, V187, P283, DOI 10.1016/0014-5793(85)81260-6; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	46	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10313	10318						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037583				2022-12-25	WOS:A1991FP08600051
J	HARTMANN, K; RAUCH, J; URBAN, J; PARCZYK, K; DIEL, P; PILARSKY, C; APPEL, D; HAASE, W; MANN, K; WELLER, A; KOCHBRANDT, C				HARTMANN, K; RAUCH, J; URBAN, J; PARCZYK, K; DIEL, P; PILARSKY, C; APPEL, D; HAASE, W; MANN, K; WELLER, A; KOCHBRANDT, C			MOLECULAR-CLONING OF GP 80, A GLYCOPROTEIN COMPLEX SECRETED BY KIDNEY-CELLS INVITRO AND INVIVO - A LINK TO THE REPRODUCTIVE-SYSTEM AND TO THE COMPLEMENT CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; POLARIZED EPITHELIAL-CELL; SULFATED GLYCOPROTEIN-2; POLYACRYLAMIDE GELS; SERUM PROTEIN-40,40; MESSENGER-RNA; NUCLEIC-ACIDS; TESTIS FLUID; SURFACE; MDCK	cDNA clones coding for the gp 80 heterodimeric glycoprotein complex secreted constitutively at the apical surface of Madin-Darby canine kidney (MDCK) cells have been isolated from MDCK cDNA libraries in lambda-gt11 and lambda-gt10. The cloned sequences encode a polypeptide chain of 445 amino acids. The deduced amino acid sequence of the gp 80 protein reveals 80% homology to rat SGP-2, a major secretory protein of the testes epithelium and 83% homology to SP-40,40, a human complement-associated protein. SGP-2 and SP-40,40 have been proposed to be serum and seminal forms of the same protein. The sequence homology as well as the results of Southern and Northern blot analyses and immunological studies suggest that gp 80 is the canine homolog of the rat SGP-2 and the human SP-40,40. The protein is expressed in the embryonic kidney already early during organogenesis. In the adult kidney the protein has been localized along the luminal surfaces of the proximal and distal tubule and the collecting duct cells.	UNIV FRANKFURT, INST BIOCHEM, MOLEK GENET ABT, ROBERT MAYER STR 7-9, W-6000 FRANKFURT, GERMANY; MAX PLANCK INST BIOPHYS, W-6000 FRANKFURT, GERMANY; MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; MAX PLANCK GESELL, FRIEDRICH MIESCHER LAB, W-7400 TUBINGEN, GERMANY	Goethe University Frankfurt; Max Planck Society; Max Planck Society; Eberhard Karls University of Tubingen; Max Planck Society			Mann, Karlheinz/C-4254-2008	Pilarsky, Christian/0000-0002-7968-3283				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; Cereijido M, 1981, Ann N Y Acad Sci, V372, P422, DOI 10.1111/j.1749-6632.1981.tb15492.x; CHENG CY, 1988, BIOCHEMISTRY-US, V27, P4079, DOI 10.1021/bi00411a026; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; ENFIELD DL, 1975, P NATL ACAD SCI USA, V72, P16, DOI 10.1073/pnas.72.1.16; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HU NT, 1982, GENE, V17, P271; JAGUS R, 1987, METHOD ENZYMOL, V152, P567; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; KLOPPEL TM, 1986, HEPATOLOGY, V6, P587, DOI 10.1002/hep.1840060407; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABEIT S, 1987, METHOD ENZYMOL, V155, P166; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Maniatis T., 1982, MOL CLONING; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; McRoberts J. A., 1981, FUNCTIONALLY DIFFERE, P117; MECHLER BM, 1977, METHOD ENZYMOL, V152, P241; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MISFELDT DS, 1976, P NATL ACAD SCI USA, V73, P1212, DOI 10.1073/pnas.73.4.1212; PALMER DJ, 1990, J BIOL CHEM, V265, P6617; PARCZYK K, 1989, EUR J CELL BIOL, V48, P353; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PICCIONI R, 1982, METHODS CHLOROPLAST, P985; PODACK ER, 1977, J IMMUNOL, V119, P2024; RINDLER MJ, 1979, J CELL BIOL, V81, P635, DOI 10.1083/jcb.81.3.635; RINDLER MJ, 1988, J CELL BIOL, V107, P471, DOI 10.1083/jcb.107.2.471; RINDLER MJ, 1982, J BIOL CHEM, V257, P2254; ROSENIOR J, 1987, BIOL REPROD, V36, P1313, DOI 10.1095/biolreprod36.5.1313; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SIMMONS NL, 1984, FED PROC, V43, P2225; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGO T, 1984, J BIOL CHEM, V259, P5705; SYLVESTER SR, 1984, BIOL REPROD, V31, P1087, DOI 10.1095/biolreprod31.5.1087; SZTUL ES, 1983, J CELL BIOL, V97, P1582, DOI 10.1083/jcb.97.5.1582; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; TSURUTA JK, 1990, BIOCHEM J, V268, P571, DOI 10.1042/bj2680571; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YANG CPH, 1981, ANN NY ACAD SCI, V372, P470; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	61	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9924	9931						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033078				2022-12-25	WOS:A1991FM45900087
J	MITCHELL, RN; SHAW, AC; WEAVER, YK; LEDER, P; ABBAS, AK				MITCHELL, RN; SHAW, AC; WEAVER, YK; LEDER, P; ABBAS, AK			CYTOPLASMIC TAIL DELETION CONVERTS MEMBRANE IMMUNOGLOBULIN TO A PHOSPHATIDYLINOSITOL-LINKED FORM LACKING SIGNALING AND EFFICIENT ANTIGEN INTERNALIZATION FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE AMINO-ACID; GLYCOSYL-PHOSPHATIDYLINOSITOL; LYMPHOCYTES-B; RNA; PROTEINS; ANCHOR; SUBSTITUTIONS; HETEROGENEITY; ENDOCYTOSIS; EXPRESSION	Membrane-bound immunoglobulin (mIg) is the antigen receptor on B lymphocytes mediating early events in antigen presentation and signal transduction. Wild-type human mIgM constructs transfected into the murine B-cell lymphoma A20 are expressed as transmembrane proteins with antigen presentation and signaling functions comparable to the endogenous mIgG2A; the transfected wild-type mIgM is internalized rapidly after anti-Ig cross-linking. Transfected constructs lacking the normal three-amino acid cytoplasmic tail are expressed exclusively as phosphatidylinositol-linked proteins, lack both antigen presentation and signal transduction functions, and are internalized slowly following anti-Ig binding. The molecular mass of the cytoplasmic tail-deleted phosphatidylinositol-linked Ig molecule is consistent with cleavage of the transmembrane residues during processing. Cytoplasmic domains may therefore regulate the mode of expression of membrane proteins and thereby influence their functional capabilities.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	MITCHELL, RN (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,75 FRANCIS ST,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022802] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22802] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGER J, 1988, J BIOL CHEM, V263, P10016; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; DANNER D, 1985, P NATL ACAD SCI USA, V82, P8658, DOI 10.1073/pnas.82.24.8658; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GOUD B, 1984, EXP CELL RES, V153, P218, DOI 10.1016/0014-4827(84)90463-4; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HARLOW E, 1988, ANTIBODIES LAB MANUA, P626; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; PIERRES M, 1987, EUR J IMMUNOL, V17, P1781, DOI 10.1002/eji.1830171216; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; PRESKY DH, 1990, J IMMUNOL, V144, P860; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; REISER H, 1986, CELL, V47, P365, DOI 10.1016/0092-8674(86)90593-3; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; ROGERS J, 1984, ADV IMMUNOL, V35, P39, DOI 10.1016/S0065-2776(08)60573-8; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; THILO L, 1985, BIOCHIM BIOPHYS ACTA, V822, P243, DOI 10.1016/0304-4157(85)90010-3; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x	29	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8856	8860						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026599				2022-12-25	WOS:A1991FM03800035
J	MUNCHPETERSEN, B; CLOOS, L; TYRSTED, G; ERIKSSON, S				MUNCHPETERSEN, B; CLOOS, L; TYRSTED, G; ERIKSSON, S			DIVERGING SUBSTRATE-SPECIFICITY OF PURE HUMAN THYMIDINE KINASE-1 AND KINASE-2 AGAINST ANTIVIRAL DIDEOXYNUCLEOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN-LYMPHOCYTES; VIRUS REVERSE-TRANSCRIPTASE; PERIPHERAL-BLOOD MONOCYTES; HUMAN DEOXYCYTIDINE KINASE; ACUTE MYELOCYTIC-LEUKEMIA; CYTO-TOXICITY; BLAST CELLS; ANTI-HIV; PURIFICATION; GENE	The two thymidine (dThd) kinases in human cells, the cytosolic, S-phase-specific TK1 and the mitochondrial, constitutively expressed TK2 were purified to homogeneity as judged from sodium dodecyl sulfate-gel electrophoresis. The substrate specificity of TK1 and TK2 toward natural substrates and important nucleoside analogues was compared. With TK1, the K(m) values for 5-fluorodeoxyuridine (FdUrd), 3'-azido-2',3'-dideoxythymidine (AZT), and 3'-fluoro-2',3'-dideoxythymidine (FLT) were 2.2, 0.6, and 2.1-mu-M as compared to 0.5-mu-M for dThd and 9-mu-M for deoxyuridine (dUrd). With TK2, dUrd, deoxycytidine (dCyd), and 5-fluorodeoxyuridine (FdUrd) were efficiently phosphorylated, but with distinctly different kinetics: Michaelis-Menten kinetics with dCyd, dUrd, and FdUrd; negative cooperativity with dThd. Negative cooperativity was also observed with AZT, although this drug was a very poor substrate for TK2 with a V(max) of 5-6% of that with dThd. FLT, 2',3'-dideoxycytidine (ddCyd), and arabinofuranosylcytosine (araC) were not substrates for TK2, and 2',3'-didehydrodideoxy-thymidine (D4T) was not a substrate for TK1 or TK2. On the other hand, AZT, FLT, and D4T were competitive inhibitors with K(i) values of 0.6, 6, and 2073-mu-M for TK1, and 2, 10, and 78-mu-M for TK2, respectively. The much lower tolerance for modifications of the deoxyribose moiety of TK2 as compared to TK1 is important for the design of new antiviral nucleoside analogues intended for use in cells with different expression of TK1 and TK2.	KAROLINSKA INST,DEPT BIOCHEM 1,MED NOBEL INST,S-10401 STOCKHOLM 60,SWEDEN; UNIV COPENHAGEN,PANUM INST,DEPT BIOCHEM C,DK-2200 COPENHAGEN,DENMARK	Karolinska Institutet; University of Copenhagen								AHMED NK, 1983, INT J BIOCHEM, V15, P1469, DOI 10.1016/0020-711X(83)90080-0; ARNER ESJ, 1988, EXP CELL RES, V178, P335, DOI 10.1016/0014-4827(88)90403-X; BALZARINI J, 1989, J BIOL CHEM, V264, P6127; BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P2847, DOI 10.1016/0006-2952(88)90049-4; BALZARINI J, 1987, MOL PHARMACOL, V32, P162; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHENG YC, 1977, BIOCHIM BIOPHYS ACTA, V481, P481, DOI 10.1016/0005-2744(77)90281-9; COLOMA J, 1984, H-S Z PHYSIOL CHEM, V365, P457, DOI 10.1515/bchm2.1984.365.1.457; ELLIMS PH, 1980, J BIOL CHEM, V255, P1290; ELLIMS PH, 1981, CANCER RES, V41, P691; ELLIMS PH, 1982, MOL CELL BIOCHEM, V45, P113; ELLIMS PH, 1981, BIOCHIM BIOPHYS ACTA, V60, P238; ELSEVIER SM, 1974, NATURE, V251, P633, DOI 10.1038/251633a0; ENGAN T, 1983, J BIOL CHEM, V258, P7000; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HO HT, 1989, ANTIMICROB AGENTS CH, V33, P833; IVES DH, 1969, ANAL BIOCHEM, V28, P192, DOI 10.1016/0003-2697(69)90170-5; JOHNSON MA, 1989, MOL PHARMACOL, V36, P291; KARLSSON A, 1989, EUR J BIOCHEM, V186, P689, DOI 10.1111/j.1432-1033.1989.tb15261.x; KARLSTROM AR, 1986, ANTIMICROB AGENTS CH, V29, P171, DOI 10.1128/AAC.29.1.171; KIERDASZUK B, 1990, BIOCHEMISTRY-US, V29, P4109, DOI 10.1021/bi00469a013; KIT S, 1974, BIOCHEM GENET, V11, P231, DOI 10.1007/BF00486058; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; KREIDBERG JA, 1986, MOL CELL BIOL, V6, P2903, DOI 10.1128/MCB.6.8.2903; LAKE RS, 1980, MUTAT RES, V74, P357, DOI 10.1016/0165-1161(80)90194-6; LEE LS, 1976, J BIOL CHEM, V251, P2600; LEE LS, 1976, BIOCHEMISTRY-US, V15, P3686, DOI 10.1021/bi00662a007; MATTHES E, 1988, BIOCHEM BIOPH RES CO, V153, P825, DOI 10.1016/S0006-291X(88)81170-7; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MUNCHPETERSEN B, 1984, MOL CELL BIOCHEM, V64, P173; MUNCHPETERSEN B, 1977, BIOCHIM BIOPHYS ACTA, V478, P364, DOI 10.1016/0005-2787(77)90152-6; NAWATA H, 1975, J BIOCHEM-TOKYO, V78, P1215, DOI 10.1093/oxfordjournals.jbchem.a131019; PERNO CF, 1988, J EXP MED, V168, P1111, DOI 10.1084/jem.168.3.1111; SAKAMOTO S, 1984, CARCINOGENESIS, V5, P183, DOI 10.1093/carcin/5.2.183; SASVARISZEKELY M, 1985, ACTA BIOCHIM BIOPHYS, V20, P163; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHOWS TB, 1979, CYTOGENET CELL GENET, V25, P96, DOI 10.1159/000131404; STARNES MC, 1987, J BIOL CHEM, V262, P988; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; TAMIYA N, 1989, BIOCHIM BIOPHYS ACTA, V995, P28, DOI 10.1016/0167-4838(89)90229-X; TAYLOR AT, 1972, J BIOL CHEM, V247, P1930; WILLECKE K, 1977, SOMAT CELL GENET, V3, P237, DOI 10.1007/BF01538743	45	251	259	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9032	9038						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026611				2022-12-25	WOS:A1991FM03800058
J	WANG, CLA; WANG, LWC; XU, S; LU, RC; SAAVEDRAALANIS, V; BRYAN, J				WANG, CLA; WANG, LWC; XU, S; LU, RC; SAAVEDRAALANIS, V; BRYAN, J			LOCALIZATION OF THE CALMODULIN-BINDING AND THE ACTIN-BINDING SITES OF CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; CHICKEN GIZZARD CALDESMON; SKELETAL F-ACTIN; MOLECULAR-WEIGHT; ATPASE ACTIVITY; CROSS-LINKING; HEAVY-MEROMYOSIN; THIN-FILAMENTS; C-TERMINUS; PROTEIN	Expression of the C-terminal third of chicken gizzard caldesmon in Escherichia coli, using the Nagai vector (Nagai, K., and Thogersen, H. V. (1987) Methods Enzmol. 153, 461-481), produces a cII-caldesmon fusion protein (27 kDa) with caldesmon sequence beginning at Lys579. Degradation during purification yields five peptides with molecular masses of 24, 22, 19 (two peptides), and 15 kDa. The 24-kDa peptide begins at Phe581; the 22-kDa peptide begins at Leu597, the two 19-kDa peptides begin at Phe581 and Val629, respectively; the 15-kDa peptide also begins at Val629. We estimate that the 15-kDa and one of the 19-kDa peptides end near Leu710. Site-directed mutagenesis was used to produce truncated peptides with known C termini; one peptide (17 kDa) terminates at Asn675. Digestion of the fragments with chymotrypsin generates a second 15-kDa fragment that begins at Ser666 (15K'). All of the peptides, with the exception of 15K', bind Ca2+-calmodulin-Sepharose and share a common 37-amino acid peptide between Val629 and Ser666, suggesting this contains the calmodulin binding site. Comparison with published sequences (Takagi, T., Yazawa, M., Ueno, T., Suzuki, S., and Yagi, K. (1989) J. Biochem. (Tokyo) 106, 778-783 and Bartegi, A., Fattoum, A., Derancourt, J., and Kassab, R. (1990) J. Biol. Chem. 265, 15231-15238) for other calmodulin-binding fragments further restricts the binding site to 7 residues, Trp-Glu-Lys-Gly-Asn-Val-Phe, between Trp659 and Ser666. All of the fragments, except the two 15-kDa peptides, co-sediment with F-actin, indicating that there are two segments in the C-terminal third of caldesmon that can interact with F-actin: one between Leu597 and Val629, the other between Arg711 and Pro756. Although separated in the primary sequence, these domains may interact with the calmodulin-binding region in the folded structure.	BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor University	WANG, CLA (corresponding author), BOSTON BIOMED RES INST,DEPT MUSCLE RES,20 STANTFORD ST,BOSTON,MA 02114, USA.				NCRR NIH HHS [RR03370] Funding Source: Medline; NHLBI NIH HHS [HL41411] Funding Source: Medline; NIAMS NIH HHS [AR28401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR028401] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BERTRAND R, 1989, EUR J BIOCHEM, V181, P747, DOI 10.1111/j.1432-1033.1989.tb14787.x; BRYAN J, 1989, Journal of Cell Biology, V109, p189A; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1989, J MUSCLE RES CELL M, V10, P95, DOI 10.1007/BF01739964; BRYAN J, 1990, ANN NY ACAD SCI, V559, P100; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1988, CELL BIOPHYS, V12, P73, DOI 10.1007/BF02918351; DASGUPTA G, 1989, J MOL BIOL, V207, P833, DOI 10.1016/0022-2836(89)90249-0; DINGUS J, 1986, J CELL BIOL, V102, P1748, DOI 10.1083/jcb.102.5.1748; DRISKA S, 1975, ARCH BIOCHEM BIOPHYS, V167, P203, DOI 10.1016/0003-9861(75)90457-9; Fiske CH, 1925, J BIOL CHEM, V66, P375; FUJI T, 1990, J BIOCHEM-TOKYO, V107, P133, DOI 10.1093/oxfordjournals.jbchem.a122996; FUJII T, 1987, J BIOL CHEM, V262, P2757; FUJII T, 1988, J BIOCHEM-TOKYO, V104, P734, DOI 10.1093/oxfordjournals.jbchem.a122542; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASH JA, 1986, J BIOL CHEM, V261, P6155; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P20; LYNCH WP, 1987, J BIOL CHEM, V262, P7429; MABUCHI K, 1991, IN PRESS J MUSCLE RE; MAKUCH R, 1989, FEBS LETT, V247, P411, DOI 10.1016/0014-5793(89)81381-X; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MORNET D, 1988, BIOCHEM BIOPH RES CO, V155, P808, DOI 10.1016/S0006-291X(88)80567-9; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NGAI PK, 1984, J BIOL CHEM, V259, P3656; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; PATCHELL VB, 1989, BIOCHEM SOC T, V17, P901, DOI 10.1042/bst0170901; PRITCHARD K, 1986, CELL CALCIUM, V7, P309, DOI 10.1016/0143-4160(86)90035-7; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SKRIPNIKOVA EV, 1989, FEBS LETT, V257, P380, DOI 10.1016/0014-5793(89)81577-7; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAKAGI T, 1989, J BIOCHEM-TOKYO, V106, P778, DOI 10.1093/oxfordjournals.jbchem.a122930; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WANG CLA, 1990, BIOPHYS J, V57, pA162; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; WANG CLA, 1988, BIOPHYS J, V53, pA433; YAMASHIRO S, 1988, Journal of Cell Biology, V107, p681A; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144	58	107	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9166	9172						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026616				2022-12-25	WOS:A1991FM03800077
J	MAIORINO, M; CHU, FF; URSINI, F; DAVIES, KJA; DOROSHOW, JH; ESWORTHY, RS				MAIORINO, M; CHU, FF; URSINI, F; DAVIES, KJA; DOROSHOW, JH; ESWORTHY, RS			PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE-PEROXIDASE IS THE 18-KDA SELENOPROTEIN EXPRESSED IN HUMAN TUMOR-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; LIPID-PEROXIDATION; RAT-LIVER; PROTECTION; PROTEINS; TISSUES	Human tumor cell lines cultured in Se-75-containing media demonstrate four major Se-75-labeled cellular proteins (57, 22, 18, and 12 kDa) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. Among these selenoproteins, an enzymatic activity is known only for the 22-kDa protein, since this protein has been identified as the monomer of glutathione peroxidase. However, all tested cell lines also contained a peroxidase activity with phospholipid hydroperoxides that is completely accounted for by the other selenoenzyme, phospholipid hydroperoxide glutathione peroxidase (PHGPX) (Ursini, F., Maiorino, M., and Gregolin, C. (1985) Biochim. Biophys. Acta 839, 62-70). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography of Se-75-labeled proteins separated by gel permeation chromatography supported the identification of PHGPX as the monomeric protein matching the 18 kDa band. This paper is the first report on the identification of PHGPX in human cells.	UNIV SO CALIF,INST TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,DEPT BIOCHEM,LOS ANGELES,CA 90033; CITY HOPE NATL MED CTR,DEPT MED ONCOL & THERAPEUT RES,DUARTE,CA 91010	University of Southern California; University of Southern California; City of Hope	MAIORINO, M (corresponding author), UNIV PADUA,DIPARTIMENTO CHIM BIOL,V TRIESTE 75,I-35121 PADUA,ITALY.		Esworthy, Steve/AAN-3152-2020	Esworthy, Steve/0000-0002-4111-3349; Davies, Kelvin/0000-0001-7790-3003	NCI NIH HHS [CA35572, CA31788] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031788] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1980, ENZYMATIC BASIS DETO; BANSAL MP, 1989, CARCINOGENESIS, V10, P541, DOI 10.1093/carcin/10.3.541; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Burk R.F, 1978, FUNCTIONS GLUTATHION, P114; BURK RF, 1978, J BIOL CHEM, V253, P43; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; CHU FF, 1990, NUCLEIC ACIDS RES, V18, P1531, DOI 10.1093/nar/18.6.1531; DANIELSON KG, 1986, CANCER RES, V46, P4582; DARLINGTON GJ, 1986, IN VITRO CELL DEV, V123, P349; FLOHE L, 1989, COENZYME COFACTORS, V3, P643; GROSSMANN A, 1983, EUR J BIOCHEM, V135, P549, DOI 10.1111/j.1432-1033.1983.tb07687.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MAIORINO M, 1986, ARCH BIOCHEM BIOPHYS, V251, P600, DOI 10.1016/0003-9861(86)90369-3; MAIORINO M, 1989, LIPIDS, V24, P721, DOI 10.1007/BF02535211; MORRISON DG, 1988, CARCINOGENESIS, V9, P1801, DOI 10.1093/carcin/9.10.1801; MOSIALOU E, 1989, ARCH BIOCHEM BIOPHYS, V275, P289, DOI 10.1016/0003-9861(89)90375-5; PROHASKA JR, 1980, BIOCHIM BIOPHYS ACTA, V611, P87, DOI 10.1016/0005-2744(80)90045-5; THOMAS JP, 1990, J BIOL CHEM, V265, P454; THOMAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1045, P252, DOI 10.1016/0005-2760(90)90128-K; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; URSINI F, 1991, IN PRESS OXIDATIVE S; WARHOLM M, 1981, METHOD ENZYMOL, V77, P325; WENDEL A, 1990, BIOCHIM BIOPHYS ACTA, V1036, P88; ZHANG LP, 1989, BIOCHIM BIOPHYS ACTA, V1006, P140, DOI 10.1016/0005-2760(89)90336-6	27	110	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7728	7732						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019596				2022-12-25	WOS:A1991FJ34200065
J	PERDEW, GH; WHITELAW, ML				PERDEW, GH; WHITELAW, ML			EVIDENCE THAT THE 90-KDA HEAT-SHOCK PROTEIN (HSP90) EXISTS IN CYTOSOL IN HETEROMERIC COMPLEXES CONTAINING HSP70 AND 3 OTHER PROTEINS WITH MR OF 63,000, 56,000, AND 50,000	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROID-BINDING-COMPONENT; STEROID-HORMONE ANTAGONISTS; CHEMICAL CROSS-LINKING; MW 90,000 HSP-90; GLUCOCORTICOID-RECEPTOR; PROGESTERONE-RECEPTOR; UNCOATING ATPASE; STRESS PROTEINS; AH RECEPTOR; ASSOCIATION	Monoclonal antibody (mAb) 8D3 and 3G3 are unique antibodies capable of precipitating both free 90-kDa heat shock protein (HSP90) and HSP90-protein complexes. Immunoprecipitation of [S-35]methionine-labeled Hepa 1c1c7 cytosolic extracts were performed using mAb 8D3 or 3G3. The resulting immunoprecipitates can be dissociated from the mAb with a 500 mM NaCl wash. These washes were subjected to both sodium dodecyl sulfate-polyacrylamide gel electrophoresis and two-dimensional gel electrophoresis. Five major protein spots were detected in addition to HSP90 with the following relative molecular weights: 68,000, 63,000, 56,000, 50,000, and 188,000. On Western blots mAb 3G3 was capable of specifically binding to HSP90. Each of these proteins was localized on two-dimensional gels. Using one-dimensional gel electrophoresis and immunochemical localization on Western blots, the p68 spot was identified as HSP70, and the p56 spot was found to cross-react with polyclonal antibody JP-1 raised against a 59-kDa protein. This 59-kDa protein has been found previously to be associated with several steroid hormone receptors in rabbit uterine cytosol. Immunoprecipitation of [P-32]orthophosphate-labeled Hepa 1c1c7 cytosol with mAb 8D3 or 3G3 revealed two major phosphorylated proteins with relative molecular weights of 90,000 and 50,000. The identities of p63 and p188 are currently unknown. This is the first report examining the major proteins that are complexed with HSP90 in mammalian cells.			PERDEW, GH (corresponding author), PURDUE UNIV,DEPT FOODS & NUTR,W LAFAYETTE,IN 47907, USA.				NIEHS NIH HHS [ES-04869] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES004869, R01ES004869] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARANYI P, 1988, BIOCHEMISTRY-US, V27, P1330, DOI 10.1021/bi00404a036; BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BECKMANN RP, 1990, SCIENCE, V248, P820; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRUGGE JS, 1982, NATURE, V295, P250, DOI 10.1038/295250a0; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BRUGGE JS, 1983, ONCOGENES RETROVIRUS, P135; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DAHMER MK, 1984, ANN REV PHYSL, V46, P76; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DENIS M, 1989, CANCER RES, V49, pS2275; DENIS M, 1987, J BIOL CHEM, V262, P11803; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; GEARING A, 1985, J IMMUNOL METHODS, V76, P332; GILMORE TD, 1982, MOL CELL BIOL, V2, P199, DOI 10.1128/MCB.2.2.199; GREEN LAD, 1989, J BIOL CHEM, V264, P15210; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; IWASAKI M, 1989, BIOCHIM BIOPHYS ACTA, V992, P1, DOI 10.1016/0304-4165(89)90043-3; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANE RD, 1985, J IMMUNOL METHODS, V81, P223, DOI 10.1016/0022-1759(85)90207-8; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEFEBVRE P, 1988, BIOCHEM BIOPH RES CO, V150, P1221, DOI 10.1016/0006-291X(88)90759-0; LEFEBVRE P, 1988, BIOCHEMISTRY-US, V27, P9186, DOI 10.1021/bi00426a017; LEFEBVRE P, 1989, BIOCHEM BIOPH RES CO, V159, P677, DOI 10.1016/0006-291X(89)90048-X; LEGAGNEUX V, 1988, FEBS LETT, V231, P417, DOI 10.1016/0014-5793(88)80862-7; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; PERDEW GH, 1983, ANAL BIOCHEM, V135, P453, DOI 10.1016/0003-2697(83)90711-X; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1986, J BIOL CHEM, V261, P6352; RATAJCZAK T, 1988, BIOCHEM BIOPH RES CO, V151, P1156, DOI 10.1016/S0006-291X(88)80487-X; REDMOND T, 1989, EUR J CELL BIOL, V50, P66; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROSE DW, 1989, J BIOL CHEM, V264, P6239; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SMITH DF, 1990, J BIOL CHEM, V265, P3996; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; YONEZAWA N, 1988, EUR J BIOCHEM, V177, P1, DOI 10.1111/j.1432-1033.1988.tb14337.x; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	47	168	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6708	6713						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016286				2022-12-25	WOS:A1991FG72700012
J	WESSELS, MR; DIFABIO, JL; BENEDI, VJ; KASPER, DL; MICHON, F; BRISSON, JR; JELINKOVA, J; JENNINGS, HJ				WESSELS, MR; DIFABIO, JL; BENEDI, VJ; KASPER, DL; MICHON, F; BRISSON, JR; JELINKOVA, J; JENNINGS, HJ			STRUCTURAL DETERMINATION AND IMMUNOCHEMICAL CHARACTERIZATION OF THE TYPE-V GROUP-B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROVISIONAL TYPE-V; ANTIGEN; IV; IA; SEROTYPES; DISEASE	The type V capsular polysaccharide of group B Streptococcus has been isolated and purified, and its repeating unit structure determined. The native type V polysaccharide contains D-glucose, D-galactose, 2-acetamido-2-deoxy-D-glucose, and sialic acid in a molar ratio of 3:2:1:1. Methylation analysis and H-1 NMR and C-13 NMR analysis of the native type V polysaccharide and of its specifically degraded products permitted the determination of the repeating unit structure of the type V polysaccharide: [GRAPHICS] The type V polysaccharide has certain structural features in common with other group B streptococcal capsular polysaccharides but is antigenically distinct: no immunologic cross-reactivity was observed between type V and types Ia, Ib, II, III, or IV polysaccharides. Studies of antibody binding to the partially degraded forms of the type V polysaccharide indicated that the native epitope is complex, involving most if not all of the sugar residues of the repeating unit.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV INFECT DIS, BOSTON, MA 02215 USA; NATL RES COUNCIL CANADA, DIV BIOL SCI, OTTAWA K1A 0R6, ONTARIO, CANADA; INST HYG & EPIDEMIOL, CS-10042 PRAGUE 10, CZECHOSLOVAKIA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Research Council Canada	WESSELS, MR (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.				NIAID NIH HHS [AI23339, AI28040] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023339, R01AI028040, R37AI023339] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; ANTHONY BF, 1977, ANNU REV MED, V28, P355, DOI 10.1146/annurev.me.28.020177.002035; Baker C J, 1980, Adv Intern Med, V25, P475; BERMAN E, 1983, CARBOHYD RES, V118, P9, DOI 10.1016/0008-6215(83)88030-6; BOYER KM, 1983, J INFECT DIS, V148, P795, DOI 10.1093/infdis/148.5.795; DIFABIO JL, 1989, CAN J CHEM, V67, P877; DILLON HC, 1987, J PEDIATR-US, V110, P31, DOI 10.1016/S0022-3476(87)80283-4; DMITRIEV BA, 1975, EUR J BIOCHEM, V50, P539, DOI 10.1111/j.1432-1033.1975.tb09894.x; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; JELINKOVA J, 1985, J CLIN MICROBIOL, V21, P361; JENNINGS HJ, 1980, CAN J BIOCHEM CELL B, V58, P112, DOI 10.1139/o80-016; JENNINGS HJ, 1983, J BIOL CHEM, V258, P1793; JENNINGS HJ, 1983, BIOCHEMISTRY-US, V22, P1258, DOI 10.1021/bi00274a042; JENNINGS HJ, 1981, BIOCHEMISTRY-US, V20, P4511, DOI 10.1021/bi00519a001; KANE JA, 1978, INFECT IMMUN, V19, P983, DOI 10.1128/IAI.19.3.983-991.1978; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; MOLINARI A, 1987, FEMS MICROBIOL LETT, V41, P69; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; RYC M, 1988, J MED MICROBIOL, V25, P147, DOI 10.1099/00222615-25-2-147; SCHIFFERLE RE, 1985, J IMMUNOL, V135, P4164; WESSELS MR, 1987, P NATL ACAD SCI USA, V84, P9170, DOI 10.1073/pnas.84.24.9170; WESSELS MR, 1989, INFECT IMMUN, V57, P1089, DOI 10.1128/IAI.57.4.1089-1094.1989; WESSELS MR, 1987, J BIOL CHEM, V262, P8262; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	24	68	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6714	6719						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016287				2022-12-25	WOS:A1991FG72700013
J	BOSCOBOINIK, D; SZEWCZYK, A; HENSEY, C; AZZI, A				BOSCOBOINIK, D; SZEWCZYK, A; HENSEY, C; AZZI, A			INHIBITION OF CELL-PROLIFERATION BY ALPHA-TOCOPHEROL - ROLE OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PHORBOL ESTERS; VITAMIN-E; RAPIDLY STIMULATE; PHOSPHOLIPASE-C; DOWN-REGULATION; 80,000 PROTEIN; GROWTH; PHOSPHORYLATION; BINDING	The effect of alpha-tocopherol (vitamin E) on the proliferation of vascular smooth muscle cells (A7r5), human osteosarcoma cells (Saos-2), fibroblasts (Balb/3T3), and neuroblastoma cells (NB2A) has been studied. The proliferation of vascular smooth muscle cells was inhibited by physiologically relevant concentrations of alpha-tocopherol, neuroblastoma cells were only sensitive to higher alpha-tocopherol concentrations, and proliferation of the other cell lines was not inhibited. The inhibition of smooth muscle cell proliferation was specific for alpha-tocopherol. Trolox, phytol, and alpha-tocopherol esters had no effect. Proliferation of smooth muscle cells stimulated by platelet-derived growth factor or endothelin was completely sensitive to alpha-tocopherol. If smooth muscle cells were stimulated by fetal calf serum, proliferation was 50% inhibited by alpha-tocopherol. No effect of alpha-tocopherol was observed when proliferation of smooth muscle cells was stimulated by bombesin and lysophosphatidic acid. The possibility of an involvement of protein kinase C in the cell response to alpha-tocopherol was suggested by experiments with the isolated enzyme and supported by the 2- to 3-fold stimulation of phorbol ester binding induced by alpha-tocopherol in sensitive cells. Moreover, alpha-tocopherol also caused inhibition of protein kinase C translocation induced by phorbol esters and inhibition of the phosphorylation of its 80-kDa protein substrate in smooth muscle cells. A model is discussed by which alpha-tocopherol inhibits cell proliferation by interacting with the cytosolic protein kinase C, thus preventing its membrane translocation and activation.	UNIV BERN, INST BIOCHEM & MOLEK BIOL, BUHLSTR 28, CH-3012 BERN, SWITZERLAND; NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT BIOCHEM, DUBLIN 4, IRELAND	University of Bern; University College Dublin			Hensey, Carmel/L-7456-2013	Hensey, Carmel/0000-0003-3319-4094; Szewczyk, Adam/0000-0001-5519-260X				ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; DOUGHERTY RW, 1986, J BIOL CHEM, V261, P4097; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; GRIENDLING KK, 1989, J BIOL CHEM, V264, P8237; GROVE DS, 1988, BIOCHEM BIOPH RES CO, V151, P94, DOI 10.1016/0006-291X(88)90563-3; HIROTA K, 1985, J BIOL CHEM, V260, P3243; HUANG FL, 1987, J BIOL CHEM, V262, P15714; KAPLOWITZ N, 1989, ANN NY ACAD SCI, V570, P85; KARIYA K, 1989, BIOCHEM BIOPH RES CO, V161, P1020, DOI 10.1016/0006-291X(89)91345-4; KARIYA K, 1987, ATHEROSCLEROSIS, V63, P251, DOI 10.1016/0021-9150(87)90128-6; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V156, P846, DOI 10.1016/S0006-291X(88)80921-5; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TS, 1989, BIOCHEM BIOPH RES CO, V162, P381, DOI 10.1016/0006-291X(89)92008-1; MAHONEY CW, 1988, BIOCHEM BIOPH RES CO, V154, P694, DOI 10.1016/0006-291X(88)90195-7; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NIKI E, 1986, CLIN NUTR ASPECTS VI, P3; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; OWENS GK, 1985, CIRC RES, V57, P695, DOI 10.1161/01.RES.57.5.695; PACKER L, 1989, ANN NY ACAD SCI, V570, P1; REDDANNA P, 1989, ANN NY ACAD SCI, V570, P136; REGAZZI R, 1986, INT J CANCER, V37, P731, DOI 10.1002/ijc.2910370514; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; STAHELIN HB, 1989, ANN NY ACAD SCI, V570, P391; TAPLEY PM, 1984, BIOCHEM BIOPH RES CO, V122, P158, DOI 10.1016/0006-291X(84)90453-4; TAPPEL AL, 1972, ANN NY ACAD SCI, V203, P12, DOI 10.1111/j.1749-6632.1972.tb27851.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; URANO S, 1988, BIOCHEM BIOPH RES CO, V150, P469, DOI 10.1016/0006-291X(88)90544-X; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4	41	470	476	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6188	6194						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007576				2022-12-25	WOS:A1991FE37300031
J	KUGE, O; NISHIJIMA, M; AKAMATSU, Y				KUGE, O; NISHIJIMA, M; AKAMATSU, Y			A CLONED GENE ENCODING PHOSPHATIDYLSERINE DECARBOXYLASE COMPLEMENTS THE PHOSPHATIDYLSERINE BIOSYNTHETIC DEFECT OF A CHINESE-HAMSTER OVARY CELL MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; MAMMALIAN-CELLS; DNA; PROTEIN; CLONING; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLCHOLINE; TRANSLOCATION	A phosphatidylserine-auxotrophic mutant of cultured Chinese hamster ovary cells, PSA-3, manifests a defect in phosphatidylserine synthase I activity (Kuge, O., Nishijima, M., and Akamatsu, Y. (1986) J. Biol. Chem. 261, 5790-5794). We cloned a Chinese hamster gene, designated pssC, which was able to transform the PSA-3 cell line to a phosphatidylserine prototroph. The resultant transformant contained phosphatidylserine in normal amounts but remained defective in phosphatidylserine synthase I activity, indicating that pssC is a suppressor gene. Using the genomic fragment of pssC as a probe, a cDNA clone of pssC was isolated, and its nucleotide sequence was determined. A computer search through a protein data bank revealed that pssC had homology with the Escherichia coli psd gene encoding the proenzyme of phosphatidylserine decarboxylase at the amino acid level. Introduction of the cloned pssC gene into PSA-3 resulted in a 2-fold increase in phosphatidylserine decarboxylase activity. When the pssC cDNA was placed downstream of the yeast GAL1 promoter and introduced into yeast Saccharomyces cerevisiae cells, the phosphatidylserine decarboxylase activity increased in a galactose-dependent manner. These results indicate that pssC encodes phosphatidylserine decarboxylase. The mechanism by which pssC complements the defect of PSA-3 in phosphatidylserine biosynthesis is discussed.			KUGE, O (corresponding author), NATL INST HLTH,DEPT CHEM,SHINAGAWA KU,TOKYO 141,JAPAN.			Kuge, Osamu/0000-0003-4962-3519				BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ESKO JD, 1983, J BIOL CHEM, V258, P3051; GERLACH E, 1963, BIOCHEM Z, V337, P477; GROSVELD FG, 1981, GENE, V13, P227, DOI 10.1016/0378-1119(81)90028-7; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; KESZENMANPEREYRA D, 1988, CURR GENET, V13, P21, DOI 10.1007/BF00365751; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; LEWIS WH, 1980, SOMAT CELL GENET, V6, P333, DOI 10.1007/BF01542787; LI QX, 1988, J BIOL CHEM, V263, P11516; LI QX, 1990, J BIOL CHEM, V265, P4111; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; ORLANDO P, 1980, J LIPID RES, V21, P1053; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; RECSEI PA, 1983, P NATL ACAD SCI-BIOL, V80, P973, DOI 10.1073/pnas.80.4.973; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATRE M, 1978, J BIOL CHEM, V253, P479; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946	40	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6370	6376						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007589				2022-12-25	WOS:A1991FE37300056
J	RAY, K; WANG, XK; ZHAO, M; COOKE, NE				RAY, K; WANG, XK; ZHAO, M; COOKE, NE			THE RAT VITAMIN-D BINDING-PROTEIN (GC-GLOBULIN) GENE - STRUCTURAL-ANALYSIS, FUNCTIONAL AND EVOLUTIONARY CORRELATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; SERUM-ALBUMIN GENE; GROUP-SPECIFIC COMPONENT; LIVER-SPECIFIC FACTOR; MESSENGER-RNA; NUCLEAR FACTOR; ALPHA-1-FETOPROTEIN GENE; DEVELOPMENTAL REGULATION; INVITRO TRANSCRIPTION; NUCLEOTIDE-SEQUENCE	The complete rat vitamin D binding protein (DBP) gene has been cloned and characterized. Genomic mapping suggests that there is only one copy of this gene in the haploid genome. The gene spans 35 kilobase pairs and contains 13 exons. All exons, exon/intron borders, and 2196 base pairs of 5'-flanking region have been sequenced. The transcription cap site, determined by primer extension analysis, is 62 base pairs upstream from the start of translation and predicts that an unusual TGTAAA motif may serve as a surrogate TATA. The promoter region contains about 50% nucleotide sequence similarity to the corresponding region of the partially characterized human DBP gene and is uniquely interrupted by a repetitive element. Although lacking in overall sequence similarity to the albumin (ALB) and alpha-fetoprotein (AFP) genes, the 5'-flanking region of the DBP gene contains a number of conserved segments which may correspond to critical proximal promoter elements in this gene family. The location of the introns in the coding region of the DBP gene is highly conserved when compared with the ALB and AFP genes. Detailed comparison of exon size and content confirms the previous prediction that the smaller size of the DBP protein results from loss of internal exons 12 and 13 from the DBP progenitor gene during its evolutionary divergence from ALB and AFP.	UNIV PENN,SCH MED,DEPT MED,700 CLIN RES BLDG,422 CURIE BLVD,PHILADELPHIA,PA 19104; UNIV PENN,DEPT HUMAN GENET,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Ray, Kunal/E-6515-2011	Ray, Kunal/0000-0001-9989-1760	NIGMS NIH HHS [GM32035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELANGER L, 1975, NATURE, V256, P657, DOI 10.1038/256657a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOUILLON R, 1978, J BIOL CHEM, V253, P4426; BOUILLON R, 1978, ENDOCRINOLOGY, V102, P1710; BROWN JR, 1976, FED PROC, V35, P2141; CAMPER SA, 1989, PROG NUCLEIC ACID RE, V36, P131; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVE H, 1973, ISRAEL J MED SCI, V9, P1133; COOKE NE, 1987, CYTOGENET CELL GENET, V44, P98, DOI 10.1159/000132351; COOKE NE, 1986, HUM GENET, V73, P225, DOI 10.1007/BF00401232; COOKE NE, 1986, J BIOL CHEM, V261, P3441; COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; COOKE NE, 1982, NATURE, V297, P603, DOI 10.1038/297603a0; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DZIADEK MA, 1983, EMBO J, V2, P549, DOI 10.1002/j.1460-2075.1983.tb01461.x; EIFERMAN FA, 1981, NATURE, V294, P713, DOI 10.1038/294713a0; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRAIN M, 1990, MOL CELL BIOL, V10, P991, DOI 10.1128/MCB.10.3.991; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; GIBBS PEM, 1987, MOL BIOL EVOL, V4, P364; GITLIN D, 1972, CANCER RES, V32, P979; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUERTIN M, 1983, BIOCHEMISTRY-US, V22, P4296, DOI 10.1021/bi00287a021; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; GUOTH M, 1990, ENDOCRINOLOGY, V127, P2313, DOI 10.1210/endo-127-5-2313; HADDAD JG, 1976, J CLIN INVEST, V58, P1217, DOI 10.1172/JCI108575; HADDAD JG, 1990, P NATL ACAD SCI USA, V87, P1381, DOI 10.1073/pnas.87.4.1381; HADDAD JG, 1976, J CLIN ENDOCR METAB, V43, P86, DOI 10.1210/jcem-43-1-86; HADDAD JG, 1976, J BIOL CHEM, V251, P4803; HADDAD JG, 1984, VITAMIN D; HAMADA H, 1984, MOL CELL BIOL, V4, P2610, DOI 10.1128/MCB.4.12.2610; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HARPER KD, 1987, J CLIN INVEST, V79, P1365, DOI 10.1172/JCI112963; HAY AWM, 1976, COMP BIOCHEM PHYS B, V53, P167, DOI 10.1016/0305-0491(76)90029-8; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; JAGODZINSKI LL, 1981, P NATL ACAD SCI-BIOL, V78, P3521, DOI 10.1073/pnas.78.6.3521; JOSEESTANYOL M, 1988, J BIOL CHEM, V263, P10865; KEW RR, 1988, J CLIN INVEST, V82, P364, DOI 10.1172/JCI113596; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; LAW SW, 1981, NATURE, V291, P201, DOI 10.1038/291201a0; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIEBHABER SA, 1981, J CLIN INVEST, V68, P439, DOI 10.1172/JCI110273; LIND SE, 1986, J CLIN INVEST, V78, P736, DOI 10.1172/JCI112634; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; Maniatis T, 1989, DECONTAMINATION DILU; MCLEOD JF, 1989, J BIOL CHEM, V264, P21760; MCLEOD JF, 1986, ENDOCRINOLOGY, V119, P77, DOI 10.1210/endo-119-1-77; MCLEOD JF, 1989, J BIOL CHEM, V264, P1260; MIKKELSEN M, 1977, HUM HERED, V27, P105, DOI 10.1159/000152857; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUGLIA L, 1984, NUCLEIC ACIDS RES, V12, P6751, DOI 10.1093/nar/12.17.6751; NAHON JL, 1987, J BIOL CHEM, V262, P12479; NAKABAYASHI H, 1989, J BIOL CHEM, V264, P266; NESTLER JE, 1987, ENDOCRINOLOGY, V120, P1996, DOI 10.1210/endo-120-5-1996; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PAGE G, 1986, NUCLEIC ACIDS RES, V14, P899, DOI 10.1093/nar/14.2.899; PETRINI M, 1985, J BIOL CHEM, V260, P1804; PETRINI M, 1983, NATURE, V306, P73, DOI 10.1038/306073a0; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROBZYK P, 1989, J BONE MIN METAB, V4, pS262; ROMEROHERRERA AE, 1973, NATURE, V246, P389, DOI 10.1038/246389a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER JM, 1990, P NATL ACAD SCI USA, V87, P5474, DOI 10.1073/pnas.87.14.5474; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SARGENT TD, 1981, P NATL ACAD SCI-BIOL, V78, P243, DOI 10.1073/pnas.78.1.243; SARGENT TD, 1981, MOL CELL BIOL, V1, P871, DOI 10.1128/MCB.1.10.871; SAWADAISHI K, 1988, MOL CELL BIOL, V8, P5179, DOI 10.1128/MCB.8.12.5179; SCHORPP M, 1988, J MOL BIOL, V199, P83, DOI 10.1016/0022-2836(88)90380-4; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SCOTT RW, 1983, MOL CELL BIOL, V3, P1295, DOI 10.1128/MCB.3.7.1295; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SMITHIES O, 1955, BIOCHEM J, V61, P629, DOI 10.1042/bj0610629; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TELLAM RL, 1989, TRENDS BIOCHEM SCI, V14, P130, DOI 10.1016/0968-0004(89)90142-4; TURCOTTE B, 1985, NUCLEIC ACIDS RES, V13, P2387, DOI 10.1093/nar/13.7.2387; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; YANG F, 1985, P NATL ACAD SCI USA, V82, P7994, DOI 10.1073/pnas.82.23.7994; YANG F, 1987, GENE, V54, P285, DOI 10.1016/0378-1119(87)90499-9; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; YOUNG PR, 1982, NUCLEIC ACIDS RES, V10, P3099, DOI 10.1093/nar/10.10.3099	89	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6221	6229						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007578				2022-12-25	WOS:A1991FE37300036
J	HAZEN, SL; FORD, DA; GROSS, RW				HAZEN, SL; FORD, DA; GROSS, RW			ACTIVATION OF A MEMBRANE-ASSOCIATED PHOSPHOLIPASE-A2 DURING RABBIT MYOCARDIAL-ISCHEMIA WHICH IS HIGHLY SELECTIVE FOR PLASMALOGEN SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST ATOM BOMBARDMENT; CANINE MYOCARDIUM; ARACHIDONIC-ACID; HUMAN-PLATELETS; RAT-HEART; METABOLISM; ACCUMULATION; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPASE	Recently, the prototype of a novel class of calcium-independent plasmalogen-selective phospholipase A2 activities was identified in the cytosolic fraction of canine myocardium (Wolf, R. A., and Gross, R. W. (1985) J. Biol. Chem. 260, 7295-7303) and subsequently purified and characterized (Hazen, S. L., Stuppy, R. J., and Gross, R. W. (1990) J. Biol. Chem. 265, 10622-10630). We now demonstrate that 15 min of myocardial ischemia utilizing a rabbit Langendorf perfused heart model results in a 10-fold increase in membrane-associated calcium-independent phospholipase A2 activity whose detection is entirely dependent upon utilization of plasmalogen substrate. Ischemia-induced phospholipase activity was identified as a membrane bound member of this class of phospholipases A2 by demonstration of: 1) concomitant production of lysoplasmenylcholine and sn-2 fatty acid from plasmenylcholine substrate; 2) maximal enzymatic activity in the absence of calcium ion; and 3) a 16-fold higher maximum reaction velocity utilizing plasmenylcholine compared to phosphatidylcholine substrate at multiple surface concentrations. Ischemia-induced phospholipase A2 activity was specifically localized to the microsomal fraction and could not be solubilized by sonication, salt treatment, exposure to chelators, or utilization of submicellar concentrations of detergent. The appearance of microsomal phospholipase A2 activity did not require ischemia-induced transcription or translation since identical increases in enzymic activity were obtained in hearts previously treated with actinomycin D and cycloheximide. Collectively, these results demonstrate that a membrane-associated calcium-independent phospholipase A2 that selectively hydrolyzes plasmalogen molecular species is the likely enzymic mediator of accelerated phospholipid catabolism during early myocardial ischemia.	WASHINGTON UNIV,SCH MED,DIV MOLEC & CELLULAR CARDIOVASC BIOCHEM,660 S EUCLID AVE,BOX 8020,ST LOUIS,MO 63110	Washington University (WUSTL)			Hazen, Stanley L/ABD-5845-2021; Ford, David/D-1819-2018	Ford, David/0000-0002-0029-1560	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034839] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34839] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARSMAN AJ, 1985, BIOCHIM BIOPHYS ACTA, V837, P288, DOI 10.1016/0005-2760(85)90052-9; AYANOGLU E, 1984, J AM CHEM SOC, V106, P5246, DOI 10.1021/ja00330a035; BENTHAM JM, 1987, BASIC RES CARDIOL, V82, P127; BILLS TK, 1977, J CLIN INVEST, V60, P1, DOI 10.1172/JCI108745; BROEKMAN MJ, 1980, J CLIN INVEST, V66, P275, DOI 10.1172/JCI109854; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHIEN KR, 1981, CIRC RES, V48, P711, DOI 10.1161/01.RES.48.5.711; CHIEN KR, 1984, CIRC RES, V54, P313, DOI 10.1161/01.RES.54.3.313; CORR PB, 1984, CIRC RES, V55, P135, DOI 10.1161/01.RES.55.2.135; CORR PB, 1982, AM J PHYSIOL, V243, pH187, DOI 10.1152/ajpheart.1982.243.2.H187; CREER MH, 1985, J CHROMATOGR, V338, P61, DOI 10.1016/0378-4347(85)80070-0; DAS DK, 1986, AM J PHYSIOL, V251, pH71, DOI 10.1152/ajpheart.1986.251.1.H71; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DENNIS EA, 1973, ARCH BIOCHEM BIOPHYS, V158, P485, DOI 10.1016/0003-9861(73)90540-7; EDGAR AD, 1982, J NEUROCHEM, V39, P1111, DOI 10.1111/j.1471-4159.1982.tb11503.x; FORD DA, 1989, CIRC RES, V64, P173, DOI 10.1161/01.RES.64.1.173; FRANSON RC, 1983, J MOL CELL CARDIOL, V15, P189, DOI 10.1016/0022-2828(83)90298-5; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GROSS RW, 1980, J CHROMATOGR, V197, P79, DOI 10.1016/S0021-9673(00)80538-5; GROSS RW, 1982, J BIOL CHEM, V257, P6702; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; GRYNBERG A, 1988, BIOCHIM BIOPHYS ACTA, V958, P24, DOI 10.1016/0005-2760(88)90242-1; HAJDU S, 1957, J PHARMACOL EXP THER, V120, P99; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HIRASHIMA Y, 1989, MOL CHEM NEUROPATHOL, V10, P87, DOI 10.1007/BF03159716; JARVIS AA, 1984, J BIOL CHEM, V259, P5188; MIYAZAKI Y, 1990, AM J PHYSIOL, V259, pC325, DOI 10.1152/ajpcell.1990.259.2.C325; NEELY JR, 1973, AM J PHYSIOL, V225, P651; PORCELLATI G, 1978, P EUROPEAN SOC NEURO, V1, P285; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; SCHON R, 1965, ANAL BIOCHEM, V12, P413, DOI 10.1016/0003-2697(65)90208-3; SHAIKH NA, 1981, CIRC RES, V49, P316, DOI 10.1161/01.RES.49.2.316; VANBILSEN M, 1989, CIRC RES, V64, P304, DOI 10.1161/01.RES.64.2.304; VANDERVUSSE GJ, 1982, CIRC RES, V50, P538, DOI 10.1161/01.RES.50.4.538; WOLF RA, 1985, J BIOL CHEM, V260, P7295	35	173	189	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5629	5633						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005103				2022-12-25	WOS:A1991FD37000043
J	HERNANDEZ, VJ; BREMER, H				HERNANDEZ, VJ; BREMER, H			ESCHERICHIA-COLI PPGPP SYNTHETASE-II ACTIVITY REQUIRES SPOT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA SYNTHESIS; GUANOSINE 5'-DIPHOSPHATE 3'-DIPHOSPHATE; RATE-DEPENDENT REGULATION; DIFFERENTIAL STRINGENT CONTROL; RIBONUCLEIC-ACID; PROTEIN-SYNTHESIS; SYNTHESIS INVITRO; GENE-PRODUCT; RELA GENE; B-R	Escherichia coli has two enzymes catalyzing the synthesis of guanosine tetraphosphate (ppGpp), designated ppGpp synthetase I (PSI = RelA) and II (PSII), whose activities are regulated differently. Until now, the gene for PSII had not been identified. Here, an E. coli relA1 strain that expresses lacZ from an rrnB P1 promoter was used to screen mutants with increased beta-galactosidase activity on 5-bromo-4-chloro-3-indoyl beta-D-galactoside indicator plates at 30-degrees-C. About 15% of the mutants obtained in this manner had reduced levels of ppGpp at 30-degrees-C and no detectable ppGpp at 43-degrees-C. These mutants did not form colonies at 42-degrees-C on minimal medium plates and had elevated ribosome concentrations and higher growth rates at 30-degrees-C. Genetic mapping by phage P1 transduction and complementation analyses showed that the mutations were located in spoT and that they were recessive. Specific inhibition of SpoT-dependent ppGpp degradation activity with picolinic acid showed that two of the mutants tested were deficient in ppGpp synthesis activity. These results indicate that spoT is required for PSII activity, suggesting that spoT encodes both ppGpp degradation and synthesis activities and that these two functions can be affected independently by mutation.			HERNANDEZ, VJ (corresponding author), UNIV TEXAS, MOLEC & CELL BIOL PROGRAM, F031, RICHARDSON, TX 75083 USA.							ALFOLDI L, 1962, J MOL BIOL, V5, P348, DOI 10.1016/S0022-2836(62)80077-1; AN G, 1979, J BACTERIOL, V137, P1100, DOI 10.1128/JB.137.3.1100-1110.1979; ATHERLY AG, 1979, J BACTERIOL, V138, P530, DOI 10.1128/JB.138.2.530-534.1979; BARACCHINI E, 1988, MOL GEN GENET, V213, P379, DOI 10.1007/BF00339606; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BRUNSCHEDE H, 1977, J BACTERIOL, V129, P1020, DOI 10.1128/JB.129.2.1020-1033.1977; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASHEL M, 1970, J BIOL CHEM, V245, P2309; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; CHASHEL M, 1969, NATURE, V221, P838, DOI 10.1038/221838a0; CHURCHWARD G, 1981, J BACTERIOL, V145, P1232, DOI 10.1128/JB.145.3.1232-1238.1981; COCHRAN JW, 1974, J BIOL CHEM, V249, P353; DICKSON RR, 1989, J BACTERIOL, V171, P4862, DOI 10.1128/jb.171.9.4862-4870.1989; ENGEL JA, 1979, REGULATION MACROMOLE, P25; FEHR S, 1981, J BACTERIOL, V145, P68, DOI 10.1128/JB.145.1.68-73.1981; FIIL N, 1969, J MOL BIOL, V45, P195, DOI 10.1016/0022-2836(69)90099-0; FRIESEN JD, 1975, J BIOL CHEM, V250, P304; FRIESEN JD, 1976, J BACTERIOL, V127, P917, DOI 10.1128/JB.127.2.917-922.1976; FRIESEN JD, 1978, CELL, V15, P1187, DOI 10.1016/0092-8674(78)90045-4; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GENTRY DR, 1986, GENE, V48, P33, DOI 10.1016/0378-1119(86)90349-5; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HASELTINE WA, 1973, P NATL ACAD SCI USA, V70, P1564, DOI 10.1073/pnas.70.5.1564; HEINEMEYER EA, 1977, FEBS LETT, V84, P357, DOI 10.1016/0014-5793(77)80724-2; HELMSTETTER CE, 1967, J MOL BIOL, V24, P417, DOI 10.1016/0022-2836(67)90228-8; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; JOHNSON GS, 1979, J BIOL CHEM, V254, P5483; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; LAFFLER T, 1974, CELL, V1, P27, DOI 10.1016/0092-8674(74)90151-2; LAGOSKY PA, 1980, J BACTERIOL, V144, P499, DOI 10.1128/JB.144.2.499-508.1980; LAGOSKY PA, 1981, J BIOL CHEM, V256, P1651; LAMOND AI, 1985, CELL, V40, P319, DOI 10.1016/0092-8674(85)90146-1; LITTLE R, 1983, J BACTERIOL, V154, P787, DOI 10.1128/JB.154.2.787-792.1983; LITTLE R, 1982, ANAL BIOCHEM, V126, P381, DOI 10.1016/0003-2697(82)90531-0; LITTLE R, 1983, J BACTERIOL, V155, P1162, DOI 10.1128/JB.155.3.1162-1170.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; METZGER S, 1989, J BIOL CHEM, V264, P21146; METZGER S, 1989, J BIOL CHEM, V264, P9122; METZGER S, 1988, J BIOL CHEM, V263, P15699; Miller JH., 1972, EXPT MOL GENETICS; NIERLICH DP, 1972, J MOL BIOL, V7, P119; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; PEDERSEN FS, 1973, NATURE-NEW BIOL, V243, P13; RICHTER D, 1979, EUR J BIOCHEM, V99, P57, DOI 10.1111/j.1432-1033.1979.tb13230.x; RICHTER D, 1979, RIBOSOMES STRUCTURE, P743; RYALS J, 1982, J BACTERIOL, V151, P1425, DOI 10.1128/JB.151.3.1425-1432.1982; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; RYALS J, 1982, J BACTERIOL, V150, P168, DOI 10.1128/JB.150.1.168-179.1982; SARMIENTOS P, 1983, P NATL ACAD SCI-BIOL, V80, P7010, DOI 10.1073/pnas.80.22.7010; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SARUBBI E, 1988, MOL GEN GENET, V213, P214, DOI 10.1007/BF00339584; SARUBBI E, 1989, J BIOL CHEM, V264, P15074; SHEN V, 1977, J BACTERIOL, V130, P1098, DOI 10.1128/JB.130.3.1098-1108.1977; SHEPHERD NS, 1980, J BACTERIOL, V141, P1098, DOI 10.1128/JB.141.3.1098-1108.1980; Silhavy T. J., 1984, EXPT GENE FUSIONS, P107; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; SY J, 1973, P NATL ACAD SCI USA, V70, P306, DOI 10.1073/pnas.70.2.306; SY J, 1977, P NATL ACAD SCI USA, V74, P5529, DOI 10.1073/pnas.74.12.5529; SY J, 1979, REGULATION MACROMOLE, P95; TRAVERS A, 1976, MOL GEN GENET, V147, P225, DOI 10.1007/BF00267575; TRAVERS AA, 1980, J MOL BIOL, V141, P91, DOI 10.1016/S0022-2836(80)80030-1; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VANOOYEN AJJ, 1975, NATURE, V254, P530, DOI 10.1038/254530a0; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; XIAO H, 1991, J BIOL CHEM, V266, P5980; ZACHARIAS M, 1989, EMBO J, V8, P3357, DOI 10.1002/j.1460-2075.1989.tb08498.x	69	117	119	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5991	5999						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005135				2022-12-25	WOS:A1991FD37000097
J	BOHNET, S; ROGERS, L; SASAKI, G; KOLATTUKUDY, PE				BOHNET, S; ROGERS, L; SASAKI, G; KOLATTUKUDY, PE			ESTRADIOL INDUCES PROLIFERATION OF PEROXISOME-LIKE MICROBODIES AND THE PRODUCTION OF 3-HYDROXY FATTY-ACID DIESTERS, THE FEMALE PHEROMONES, IN THE UROPYGIAL GLANDS OF MALE AND FEMALE MALLARDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERM CASTRATED MICE; MALE PEKING DUCKS; PREPUTIAL GLAND; SEX STEROIDS; SEBUM SECRETION; THYROID-HORMONE; WAX ESTERS; RAT-KIDNEY; ESTROGEN; BIOSYNTHESIS	During the mating season the female mallards produce sex pheromones, diesters of 3-hydroxy fatty acids, in their uropygial glands. Subcellular fractionation by sucrose and Nycodenz density gradient centrifugations and electron microscopic examination of the fractions showed that diesters of 3-hydroxy acids and the enzymes that catalyze the formation and esterification of the 3-hydroxy fatty acids are located in the catalase-containing fractions, probably peroxisomes, whereas monoester synthesizing activities are located in the endoplasmic reticulum. Fatty acyl-CoA reductase that would provide fatty alcohol needed for the synthesis of monoester and diester waxes was found both in the peroxisomal and endoplasmic reticulum fraction. Upon daily intramuscular injection of estradiol into the females in the nonmating season, the short chain monoester waxes of the uropygial glands were replaced by long chain monoester waxes, and subsequently the monoester waxes were replaced by diester waxes. Injection of thyroxine with estradiol hastened the induction of the compositional changes including diester synthesis. Similar changes, including the synthesis of the female pheromones, were induced in the uropygial glands by the hormone treatment of males that do not normally produce diesters at any time during their life cycle. The structure and composition of the diesters induced by hormone treatment of both males and females were identical to those of the female pheromones produced during their mating season. Electron microscopic examination of diaminobenzidine-treated glands showed that peroxisomes proliferated in the gland of the females in the mating season and in the estradiol-treated males that produce the diesters.	OHIO STATE UNIV,OHIO STATE BIOTECHNOL CTR,206 RIGHTMIRE HALL,1060 CARMACK RD,COLUMBUS,OH 43210	University System of Ohio; Ohio State University			kolattukudy, pappachan e/A-1350-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018278] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-18278] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASEN AJ, 1971, LIPIDS, V6, P502, DOI 10.1007/BF02531236; APPELKVIST EL, 1987, PEROXISOMES BIOL MED, P53; BRAIN PF, 1985, IRCS MED SCI-BIOCHEM, V13, P242; BRAIN PF, 1985, IRCS MED SCI-BIOCHEM, V13, P240; BRAIN PF, 1985, IRCS MED SCI-BIOCHEM, V13, P238; EBLING FJ, 1974, J INVEST DERMATOL, V62, P161, DOI 10.1111/1523-1747.ep12676781; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRATER G, 1979, HELV CHIM ACTA, V62, P2825, DOI 10.1002/hlca.19790620832; FUJIMOTO N, 1988, BIOCHEM BIOPH RES CO, V152, P44, DOI 10.1016/S0006-291X(88)80677-6; HAJRA AK, 1985, ANAL BIOCHEM, V148, P233, DOI 10.1016/0003-2697(85)90651-7; HUMPHREYS TN, 1973, J ENDOCRINOL, V58, P353; Jacob J., 1978, P165; JACOB J, 1979, BIOCHEM SYST ECOL, V7, P149, DOI 10.1016/0305-1978(79)90024-3; JAHN R, 1984, P NATL ACAD SCI-BIOL, V81, P1684, DOI 10.1073/pnas.81.6.1684; JALLAGEAS M, 1979, GEN COMP ENDOCR, V37, P44, DOI 10.1016/0016-6480(79)90044-3; JALLAGEAS M, 1978, GEN COMP ENDOCR, V36, P201, DOI 10.1016/0016-6480(78)90023-0; Kolattukudy P E, 1981, Methods Enzymol, V72, P714; KOLATTUKUDY PE, 1987, ARCH BIOCHEM BIOPHYS, V252, P121, DOI 10.1016/0003-9861(87)90015-4; KOLATTUKUDY PE, 1985, J BIOL CHEM, V260, P789; KOLATTUKUDY PE, 1985, J LIPID RES, V26, P989; KOLATTUKUDY PE, 1970, LIPIDS, V5, P398, DOI 10.1007/BF02532105; KOLATTUKUDY PE, 1974, LIPIDS, V9, P290, DOI 10.1007/BF02532208; KOLATTUKUDY PE, 1978, ARCH BIOCHEM BIOPHYS, V191, P244, DOI 10.1016/0003-9861(78)90087-5; KOLATTUKUDY PE, 1987, J LIPID RES, V28, P582; Kolattukudy PE, 1987, PEROXISOMES BIOL MED, P18; KOLATTUKUDY PE, 1976, CHEM BIOL NATURAL WA; KRISANS SK, 1987, PEROXISOMES BIOL MED, P40; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUECKLER MM, 1983, J BIOL CHEM, V258, P1781; MUECKLER MM, 1984, J BIOL CHEM, V259, P2302; NOVIKOFF AB, 1969, J HISTOCHEM CYTOCHEM, V17, P675, DOI 10.1177/17.10.675; PEDERSEN JJ, 1987, PEROXISOMES BIOL MED, P67; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; RABERT U, 1987, PEROXISOMES BIOL MED, P32; RAO MS, 1987, PEROXISOMES BIOL MED, P263; REDDY JK, 1987, PEROXISOMES BIOL MED, P255; RILEY DA, 1988, J HISTOCHEM CYTOCHEM, V36, P633, DOI 10.1177/36.6.3367048; ROGERS L, 1982, J BIOL CHEM, V257, P880; SASAKI GC, 1988, DNA-J MOLEC CELL BIO, V7, P449, DOI 10.1089/dna.1.1988.7.449; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHARP PJ, 1986, J EXP ZOOL, V238, P409, DOI 10.1002/jez.1402380314; SHUSTER S, 1974, J INVEST DERMATOL, V62, P172, DOI 10.1111/1523-1747.ep12676782; SMALL GM, 1980, LIFE SCI, V27, P1743, DOI 10.1016/0024-3205(80)90441-5; STEWART ME, 1983, DERMATOL CLIN, V1, P335, DOI 10.1016/S0733-8635(18)31019-2; ZAAR K, 1985, EUR J CELL BIOL, V38, P322	46	53	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9795	9804						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033066				2022-12-25	WOS:A1991FM45900070
J	ECKHARDT, AE; TIMPTE, CS; ABERNETHY, JL; ZHAO, Y; HILL, RL				ECKHARDT, AE; TIMPTE, CS; ABERNETHY, JL; ZHAO, Y; HILL, RL			PORCINE SUBMAXILLARY MUCIN CONTAINS A CYSTINE-RICH, CARBOXYL-TERMINAL DOMAIN IN ADDITION TO A HIGHLY REPETITIVE, GLYCOSYLATED DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; INTEGUMENTARY MUCIN; GEL-ELECTROPHORESIS; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; GLAND APOMUCIN; GLYCOPROTEINS; PROTEINS; CDNA; DNA	The sequence of a 3.65-kilobase cDNA encoding a large portion of the polypeptide chain of porcine submaxillary mucin (apomucin) has been completed. The encoded polypeptide contains 1150 residues with the carboxyl-terminal 240 residues forming a globular domain that is rich in half-cystine, but deficient in sites for oligosaccharide attachment. The remaining 910 residues preceding the half-cystine-rich domain appear devoid of secondary structures, but they are rich in serine and threonine to which the O-linked oligosaccharides are bound. The first 391 residues of apomucin contain several tandemly repeated, identical sequences of 81 residues. Blots of genomic DNA partially digested with restriction nucleases show that at least 25 of these identical repeats are present in apomucin. The amino acid composition of apomucin isolated in the absence of protease inhibitors was shown earlier (Eckhardt, A. E., Timpte, C. S., Abernethy, J. L., Toumadje, A., Johnson, W. C., Jr., and Hill, R. L. (1987) J. Biol. Chem. 282, 11339-11344) to be devoid of half-cystine. In contrast, the amino acid composition of mucin purified in the presence of protease inhibitors contains half-cystine in amounts predicted by the cDNA sequence and also suggests that this mucin has about 25 tandem repeats. Thus, apomucin contains at least 2800 amino acid residues. Moreover, immunoblots of apomucin prepared in the presence or the absence of protease inhibitors, with antibodies specific for the half-cystine-rich domains or the tandem repeat sequences, show that the half-cystine-rich domain is absent in apomucin unless protease inhibitors are present throughout. Both types of mucin, however, contain the highly repetitive sequences. The molecular weight of undegraded apomucin has not been established exactly, but gel filtration in 6 M guanidine hydrochloride suggests that it is considerably higher than 250,000. RNA blot analysis shows that apomucin mRNA is large and polydisperse in accord with the message size necessary to synthesize the large apomucin polypeptide. These structural features of apomucin suggest a model for the structure of the mucin molecule that correlates well with its reported properties.			ECKHARDT, AE (corresponding author), DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA.				NIGMS NIH HHS [GM07184, GM25766] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025766, T32GM007184, R37GM025766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN A, 1983, TRENDS BIOCHEM SCI, V8, P169, DOI 10.1016/0968-0004(83)90166-4; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BLANKENSHIP DT, 1989, ANAL BIOCHEM, V178, P227, DOI 10.1016/0003-2697(89)90629-5; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CARLSTEDT I, 1983, BIOCHEM J, V211, P13, DOI 10.1042/bj2110013; CASTRO B, 1975, TETRAHEDRON LETT, P1219; Chaplin M.F., 1986, MASS SPECTROM, P1; DESALEGUI M, 1969, ARCH BIOCHEM BIOPHYS, V129, P49, DOI 10.1016/0003-9861(69)90148-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; ECKHARDT AE, 1990, GLYCOCONJUGATE J, V7, P386; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Garnier J., 1989, PREDICTION PROTEIN S, P417; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GUM JR, 1989, J BIOL CHEM, V264, P6480; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7440; HAUSER F, 1990, EXP CELL RES, V189, P157, DOI 10.1016/0014-4827(90)90230-8; HILL RL, 1987, PEDIATR PULMONARY S, V1, P105; HIRS CHW, 1967, METHOD ENZYMOL, V11, P199; Hirs CHW, 1967, METHOD ENZYMOL, P59, DOI [10.1016/S0076-6879(67)11008-2, DOI 10.1016/S0076-6879(67)11008-2]; HOFFMANN W, 1988, J BIOL CHEM, V263, P7686; HUDSON D, 1988, J ORG CHEM, V53, P617, DOI 10.1021/jo00238a026; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAISER K, 1985, DNA CLONING PRACTICA, V1, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MAHONEY WC, 1980, J BIOL CHEM, V255, P1199; Maniatis T., 1982, MOL CLONING; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NUTT E, 1988, J BIOL CHEM, V263, P10162; Prevelige P., 1989, PREDICTION PROTEIN S, P391; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAIKHEL NV, 1987, P NATL ACAD SCI USA, V84, P6745, DOI 10.1073/pnas.84.19.6745; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROUSSEL P, 1988, BIOCHIMIE, V70, P1471, DOI 10.1016/0300-9084(88)90284-2; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SHOGREN RL, 1984, J BIOL CHEM, V259, P4657; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; WILLIAMS DB, 1984, J BIOL CHEM, V259, P5105	46	109	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9678	9686						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033060				2022-12-25	WOS:A1991FM45900054
J	JHUN, E; JHUN, BH; JONES, LR; JUNG, CY				JHUN, E; JHUN, BH; JONES, LR; JUNG, CY			DIRECT EFFECTS OF IONIZING-RADIATION ON INTEGRAL MEMBRANE-PROTEINS - NONCOVALENT ENERGY-TRANSFER REQUIRES SPECIFIC INTERPEPTIDE INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; ERYTHROCYTE GLUCOSE TRANSPORTER; INACTIVATION ANALYSIS; MOLECULAR-WEIGHT; SKELETAL-MUSCLE; PUMP PROTEIN; TARGET SIZE; CA-2+ PUMP; PHOSPHOLAMBAN; SEQUENCE	The 12 transmembrane alpha-helices (TMHs) of human erythrocyte glucose transporter were individually cut by pepsin digestion as membrane-bound 2.5-3.5-kDa peptide fragments. Radiation-induced chemical degradation of these fragments showed an average target size of 34 kDa. This is 10-12 x larger than the average size of an individual TMH, demonstrating that a significant energy transfer occurs among these TMHs in the absence of covalent linkage. Heating this TMH preparation at 100-degrees-C for 15 min reduced the target size to 5 kDa or less, suggesting that the noncovalent energy transfer requires specific helix-helix interactions. Purified phospholamban, a small (6-kDa) integral membrane protein containing a single TMH, formed a pentameric assembly in sodium dodecyl sulfate. The chemical degradation target size of this phospholamban pentamer was 5-6 kDa, illustrating that not all integral membrane protein assemblies permit intersubunit energy transfer. These findings together with other published observations suggest strongly that significant noncovalent energy transfer can occur within the tertiary and quaternary structure of membrane proteins and that as yet undefined proper molecular interactions are required for such covalent energy transfer. Our results with pepsin-digested glucose transporter also illustrate the importance of the interhelical interaction as a predominating force in maintaining the tertiary structure of a transmembrane protein.	VET ADM MED CTR,BIOPHYS LAB,3495 BAILEY AVE,BUFFALO,NY 14215; SUNY BUFFALO,DEPT BIOPHYS SCI,BUFFALO,NY 14215; INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013376] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28556, HL 06308] Funding Source: Medline; NIDDK NIH HHS [DK13376] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVERY J, 1964, ELECTRONIC ASPECTS B, P29; BOWMAN BJ, 1985, J BIOL CHEM, V260, P8726; BRETSCHER MS, 1985, SCI AM, V253, P100, DOI 10.1038/scientificamerican1085-100; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P1997; CHEN JJ, 1987, P NATL ACAD SCI USA, V84, P4113; CUPPOLETTI J, 1985, J BIOL CHEM, V260, P5714; DAVYDOV AS, 1976, PHYS STATUS SOLIDI B, V75, P735, DOI 10.1002/pssb.2220750238; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FRIEDRICH P, 1984, SUPRAMOLECULAR ENZYM, P62; FUROISCORBIN S, 1987, BIOCHIM BIOPHYS ACTA, V902, P31, DOI 10.1016/0005-2736(87)90133-7; HYMEL L, 1984, J BIOL CHEM, V259, P4890; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1981, J BIOL CHEM, V256, P1809; JUNG CY, 1984, MOL CHEM CHARACTERIZ, P193; KEMPNER ES, 1979, ANAL BIOCHEM, V92, P2, DOI 10.1016/0003-2697(79)90617-1; KEMPNER ES, 1990, J BIOL CHEM, V265, P15776; KEMPNER ES, 1989, BIOPHYS J, V55, P159, DOI 10.1016/S0006-3495(89)82787-0; KEPNER GR, 1968, BIOCHIM BIOPHYS ACTA, V163, P188, DOI 10.1016/0005-2736(68)90097-7; KIRKWOOD JG, 1952, P NATL ACAD SCI USA, V38, P8630; KOHLMILLER NA, 1979, J BIOL CHEM, V254, P7302; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; LEMAIRE M, 1990, BIOCHEM J, V267, P431, DOI 10.1042/bj2670431; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MANALAN AS, 1982, J BIOL CHEM, V257, P52; MCINTYRE JO, 1983, J BIOL CHEM, V258, P953; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OTTOLENGHI P, 1983, J BIOL CHEM, V258, P4895; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RAMJEESINGH M, 1984, BIOCHIM BIOPHYS ACTA, V769, P381, DOI 10.1016/0005-2736(84)90321-3; RAMPAL AL, 1986, BIOCHIM BIOPHYS ACTA, V859, P135, DOI 10.1016/0005-2736(86)90208-7; SACCOMANI G, 1981, J BIOL CHEM, V256, P7727; SIMMERMAN HKB, 1989, BIOCHIM BIOPHYS ACTA, V997, P322, DOI 10.1016/0167-4838(89)90203-3; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SOLOMONSON LP, 1987, J BIOL CHEM, V262, P8934; TAKAHASHI M, 1985, J BIOL CHEM, V260, P551; VAIDHYANATHAN VS, 1987, TARGET SIZE ANAL MEM, P153; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	41	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9403	9407						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033040				2022-12-25	WOS:A1991FM45900013
J	SCARBOROUGH, RM; ROSE, JW; HSU, MA; PHILLIPS, DR; FRIED, VA; CAMPBELL, AM; NANNIZZI, L; CHARO, IF				SCARBOROUGH, RM; ROSE, JW; HSU, MA; PHILLIPS, DR; FRIED, VA; CAMPBELL, AM; NANNIZZI, L; CHARO, IF			BARBOURIN - A GPIIB-IIIA-SPECIFIC INTEGRIN ANTAGONIST FROM THE VENOM OF SISTRURUS-M-BARBOURI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ASP-CONTAINING PEPTIDE; PLATELET-AGGREGATION; GLYCOPROTEIN-IIB; VONWILLEBRAND-FACTOR; SYNTHETIC PEPTIDES; POTENT INHIBITOR; ECHIS-CARINATUS; CELL-ADHESION; VIPER VENOMS; SNAKE-VENOM	Sixty-two snake venoms were screened to identify those which specifically inhibit the adhesive protein binding function of the glycoprotein (GP) IIb-IIIa complex, the receptor-mediating platelet aggregation. Although 52 of these venoms inhibited GPIIb-IIIa, only one of these, from the southeastern pigmy rattlesnake, Sistrurus m. barbouri, was specific for GPIIb-IIIa versus other integrins. The peptide responsible for this activity, termed barbourin, was sequenced and found to be highly homologous to other peptides of the viper venom GPIIb-IIIa antagonist family but was the first member which did not contain the Arg-Gly-Asp (RGD) amino acid sequence, believed to be required for inhibition of receptor function. Instead, barbourin contains the sequence, Lys-Gly-Asp (KGD). The conservative Lys for Arg substitution appears to be the sole structural feature which imparts integrin specificity to barbourin, since venom peptide analogs with Lys substitutions were also specific for GPIIb-IIIa. Thus, barbourin represents a new structural model useful for designing potent and GPIIb-IIIa-specific compounds that may have therapeutic value as platelet aggregation inhibitors.	ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital	SCARBOROUGH, RM (corresponding author), COR THERAPEUT INC, 256 E GRAND AVE, SUITE 80 S, SAN FRANCISCO, CA 94080 USA.							ALI FE, 1990, PEPTIDES CHEM STRUCT, P94; CHAO BH, 1989, P NATL ACAD SCI USA, V86, P8050, DOI 10.1073/pnas.86.20.8050; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; FITZGERALD LA, 1985, J BIOL CHEM, V260, P893; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GARSKY VM, 1989, P NATL ACAD SCI USA, V86, P4022, DOI 10.1073/pnas.86.11.4022; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; HUANG TF, 1987, J BIOL CHEM, V262, P16157; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Iwanaga S., 1979, HDB EXPT PHARMACOLOG, V52, P61; KNUDSEN KA, 1988, EXP CELL RES, V179, P42, DOI 10.1016/0014-4827(88)90346-1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUSIAL J, 1990, CIRCULATION, V82, P261, DOI 10.1161/01.CIR.82.1.261; PHILLIPS DR, 1988, BLOOD, V71, P831; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RUCINSKI B, 1990, BIOCHIM BIOPHYS ACTA, V1054, P257, DOI 10.1016/0167-4889(90)90096-V; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; RUGGERI ZM, 1989, CIRCULATION, V80, P1920, DOI 10.1161/01.CIR.80.6.1920; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEBUSKI RJ, 1990, CIRCULATION, V82, P169, DOI 10.1161/01.CIR.82.1.169; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; WHEBUSKI RJ, 1989, J BIOL CHEM, V264, P21550; WILLIAMS J, 1990, BIOCHIM BIOPHYS ACTA, V1039, P81, DOI 10.1016/0167-4838(90)90229-9	33	359	394	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9359	9362						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033037				2022-12-25	WOS:A1991FM45900006
J	SHALHOUB, V; JACKSON, ME; LIAN, JB; STEIN, GS; MARKS, SC				SHALHOUB, V; JACKSON, ME; LIAN, JB; STEIN, GS; MARKS, SC			GENE-EXPRESSION DURING SKELETAL DEVELOPMENT IN 3 OSTEOPETROTIC RAT MUTATIONS - EVIDENCE FOR OSTEOBLAST ABNORMALITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NODULES FORMED INVITRO; OP OP MOUSE; BONE-RESORPTION; CONGENITAL OSTEOPETROSIS; IA RAT; ALKALINE-PHOSPHATASE; OSTEOCLAST FORMATION; PARATHYROID-HORMONE; TOOTHLESS RAT	Osteopetrosis is a group of metabolic bone diseases characterized by reductions in osteoclast development and/or function. These aspects of osteoclast biology are known to be influenced by osteoblasts and their products. To ascertain whether osteoblast dysfunction contributes to aberrations in the structural and functional properties of osteoclasts in osteopetrosis, we systematically examined gene expression as reflected by mRNA levels for a series of cell growth- and tissue-related genes associated with the osteoblast phenotype during skeletal development in normal and mutant rats of three different osteopetrotic stocks. We show that the methods used permit the reproducible isolation of undegraded total cellular RNA from bone and that mRNA levels can be reliably quantitated in these preparations. Each osteopetrotic mutation exhibits a distinct aberrant pattern of osteoblast gene expression that may be correlated with and explain some abnormalities in extracellular matrix composition, mineralization, osteoclast development, and effects of elevated serum levels of 1-alpha,25-dihydroxyvitamin D3, depending upon the mutation. Normal rats show minor variations in gene expression that reflect the genetic background (stock). This, the first comprehensive molecular analysis of osteoblast gene expression in osteopetrosis, suggests that some osteopetroses, particularly in the toothless rat, are associated with and potentially related to mechanisms associated with aberrations in osteoblast function. More generally, the present studies demonstrate alterations in gene expression as reflected by mRNA levels that are associated with functional properties of the osteoblast, particularly those contributing to the recruitment and/or differentiation of osteoclasts, thereby influencing skeletal modeling.	UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,55 LAKE AVE N,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035166, R01AR033920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE007444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE007444] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 35166, AR33920] Funding Source: Medline; NIDCR NIH HHS [DE 07444] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980; ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BHARGAVA U, 1988, BONE, V9, P155, DOI 10.1016/8756-3282(88)90005-1; BOSKEY AL, 1985, CALCIFIED TISSUE INT, V37, P287, DOI 10.1007/BF02554876; CHAMBERS TJ, 1982, J CELL SCI, V57, P247; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EKRYLANDER B, 1989, BONE MINER, V5, P309, DOI 10.1016/0169-6009(89)90009-3; ESCAROTCHARRIER B, 1983, J CELL BIOL, V96, P639; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIX R, 1989, CALCIFIED TISSUE INT, V44, P356, DOI 10.1007/BF02556317; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FELIX R, 1990, J BONE MINER RES, V5, P781; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GRIMES S, 1987, EXP CELL RES, V173, P534, DOI 10.1016/0014-4827(87)90293-X; HARRISON JR, 1989, ENDOCRINOLOGY, V125, P327, DOI 10.1210/endo-125-1-327; KOHNO K, 1984, J BIOL CHEM, V259, P3668; KURIHARA N, 1990, J IMMUNOL, V144, P4226; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; LIAN JB, 1990, ENDOCRINOLOGY, V126, P955, DOI 10.1210/endo-126-2-955; LINDUNGER A, 1990, BONE MINER, V10, P109, DOI 10.1016/0169-6009(90)90086-U; MARKS CR, 1984, METAB BONE DIS RELAT, V5, P259, DOI 10.1016/0221-8747(84)90068-7; Marks S C Jr, 1989, Connect Tissue Res, V21, P107, DOI 10.3109/03008208909050001; MARKS S C JR, 1987, Applied Pathology, V5, P172; MARKS SC, 1976, AM J ANAT, V146, P331, DOI 10.1002/aja.1001460308; MARKS SC, 1983, J ORAL PATHOL MED, V12, P226, DOI 10.1111/j.1600-0714.1983.tb00337.x; MARKS SC, 1977, AM J ANAT, V149, P289, DOI 10.1002/aja.1001490212; MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110; MARKS SC, 1976, J ORAL PATHOL MED, V5, P149, DOI 10.1111/j.1600-0714.1976.tb01760.x; MARKS SC, 1988, AM J ANAT, V183, P1, DOI 10.1002/aja.1001830102; MARKS SC, 1973, AM J ANAT, V138, P165, DOI 10.1002/aja.1001380204; MARKS SC, 1989, AM J ANAT, V186, P325, DOI 10.1002/aja.1001860402; MARKS SC, 1984, CLIN ORTHOP RELAT R, V189, P239; MARX SJ, 1988, J BONE MINER RES, V3, P481; MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V119, P1654, DOI 10.1210/endo-119-4-1654; MILHAUD G, 1975, CR ACAD SCI D NAT, V280, P2485; MILLER SC, 1982, CALCIFIED TISSUE INT, V34, P422, DOI 10.1007/BF02411278; MOUTIER R, 1976, J HERED, V67, P189, DOI 10.1093/oxfordjournals.jhered.a108705; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; NODA M, 1987, J BONE MINER RES, V2, P161; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OSIER LK, 1987, BONE MINER, V3, P35; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PRINCE CW, 1987, COLLAGEN REL RES, V7, P305; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; SCHEVEN BAA, 1990, BONE, V11, P53, DOI 10.1016/8756-3282(90)90072-7; SCHOFIELD BH, 1974, CALC TISS RES, V14, P153, DOI 10.1007/BF02060291; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SEIFERT MF, 1988, AM J ANAT, V183, P158, DOI 10.1002/aja.1001830206; SEIFERT MF, 1985, EXPERIENTIA, V41, P192, DOI 10.1007/BF02002613; SEIFERT MF, 1990, AM J PHYSIOL, V258, pE377, DOI 10.1152/ajpendo.1990.258.2.E377; SEIFERT MF, 1991, IN PRESS CLIN ORTHOP; SHALHOUB V, 1989, BIOCHEMISTRY-US, V28, P5318, DOI 10.1021/bi00439a002; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; VANDEWIJNGAERT FP, 1989, BONE, V10, P61, DOI 10.1016/8756-3282(89)90148-8; WEINREB M, 1990, J BONE MINER RES, V5, P831; WEIR EC, 1989, ENDOCRINOLOGY, V124, P899, DOI 10.1210/endo-124-2-899; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; YOON K, 1987, BIOCHEM BIOPH RES CO, V148, P1129, DOI 10.1016/S0006-291X(87)80250-4; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zar JH, 1974, BIOSTAT ANAL, P236; ZERWEKH JE, 1987, BONE MINER, V2, P193	64	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9847	9856						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033073				2022-12-25	WOS:A1991FM45900077
J	STROUD, MR; LEVERY, SB; NUDELMAN, ED; SALYAN, MEK; TOWELL, JA; ROBERTS, CE; WATANABE, M; HAKOMORI, S				STROUD, MR; LEVERY, SB; NUDELMAN, ED; SALYAN, MEK; TOWELL, JA; ROBERTS, CE; WATANABE, M; HAKOMORI, S			EXTENDED TYPE-1 CHAIN GLYCOSPHINGOLIPIDS - DIMERIC LEA (III4V4FUC2LC6) AS HUMAN TUMOR-ASSOCIATED ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; ADENOCARCINOMA COLO-205 CELLS; HUMAN-ERYTHROCYTE MEMBRANES; H-1-NMR ANALYSIS; GLYCOLIPIDS; CANCER; CARCINOMA; FUCOLIPIDS; GANGLIOSIDES; BIOSYNTHESIS	Glycolipid extracts from various human cancer tissues and cell lines showed the presence of a slow-migrating glycolipid component which was strongly reactive with monoclonal antibody (mAb) NCC-ST-421 (raised against human gastric adenocarcinoma) and weakly cross-reactive with anti-Le(a) mAbs. The slow-migrating glycolipid was isolated from human colonic adenocarcinoma cell line Colo205 grown in nude mice, and was purified by high-performance liquid chromatography followed by preparative thin-layer chromatography. Its structure was elucidated by sequential enzymatic degradation and thin-layer chromatography immunostaining of the degradation products with various mAbs, H-1 NMR spectroscopy, positive-ion fast atom bombardment mass spectrometry, and methylation analysis. The major slow-migrating component reacting with mAb ST-421 was identified as dimeric Le(a), with the structure as follows. Gal-beta-1 --> 3GlcNAc-beta-1 --> 3Gal-beta-1 --> 3GlcNAc-beta-1 --> 3Gal-beta-1 --> 4Glc-beta-1 --> 1Cer [GRAPHICS] Antigens containing this structure and various analogous structures (including enzymatically synthesized Le(a)/Le(x) hybrid antigen) were tested with ST-421. While the mAb was equally reactive with dimeric Le(a) and Le(a)/Le(x), only the former was chemically detectable as the slow-migrating glycolipid from the tumor extract. St-421 showed less reactivity with simple Le(a) (III4FucLc4) or extended Le(a) (V4FucLc6, and/or IV3Gal-beta-1 --> 3[Fuc-alpha-1 --> 4]GlcNAcnLc4), and was not reactive with Le(x)/Le(x) (dimeric Le(x). It was concluded, therefore, that the major tumor-associated slow-migrating glycolipid reacting with ST-421 has the dimeric Le(a) structure shown above. Since extension of lacto-series structure has been shown to be limited to type 2 chain in normal cells and tissues, extended elongation of type 1 chain as shown in this structure represents a novel tumor-associated epitope.	UNIV WASHINGTON, SEATTLE, WA 98119 USA	University of Washington; University of Washington Seattle	STROUD, MR (corresponding author), BIOMEMBRANE INST, SEATTLE, WA 98119 USA.				NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barber M., 1988, RAPID COMMUN MASS SP, V2, P18; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DABROWSKI J, 1981, ARCH BIOCHEM BIOPHYS, V210, P405, DOI 10.1016/0003-9861(81)90203-4; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; EGGE H, 1987, MASS SPECTROM REV, V6, P331, DOI 10.1002/mas.1280060302; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHI Y, 1984, J BIOL CHEM, V259, P4681; Hakomori S, 1970, Biochim Biophys Acta, V202, P225, DOI 10.1016/0005-2760(70)90244-4; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAKOMORI SI, 1967, J IMMUNOL, V98, P31; HAKOMORI SI, 1975, BIOCHIM BIOPHYS ACTA, V417, P55, DOI 10.1016/0304-419X(75)90008-6; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P633, DOI 10.1016/0003-9861(89)90479-7; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P14, DOI 10.1016/0003-9861(89)90410-4; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; ISOBE R, 1987, TRAC-TREND ANAL CHEM, V6, P78, DOI 10.1016/0165-9936(87)87037-1; KAIZU T, 1986, J BIOL CHEM, V261, P1254; KANNAGI R, 1985, J BIOL CHEM, V260, P6410; KANNAGI R, 1982, J BIOL CHEM, V257, P4438; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KANNAGI R, 1983, CANCER RES, V43, P4997; LAINE RA, 1981, ANAL BIOCHEM, V116, P383, DOI 10.1016/0003-2697(81)90376-6; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; LEVERY SB, 1986, CARBOHYD RES, V151, P311, DOI 10.1016/S0008-6215(00)90351-3; LEVERY SB, 1988, CARBOHYD RES, V178, P121, DOI 10.1016/0008-6215(88)80106-X; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MARTENSSON S, 1988, CANCER RES, V48, P2125; MCNEIL M, 1977, CARBOHYD RES, V56, P239, DOI 10.1016/S0008-6215(00)83346-7; MEILI J, 1984, ORG MASS SPECTROM, V19, P581, DOI 10.1002/oms.1210191111; MIYAKE M, 1989, CANCER RES, V49, P5689; PETTIJOHN DE, 1987, CANCER RES, V47, P1161; SEMPLE TU, 1978, CANCER RES, V38, P1345; STELLNER K, 1973, BIOCHEMISTRY-US, V12, P656, DOI 10.1021/bi00728a014; WATANABE K, 1976, J EXP MED, V144, P644, DOI 10.1084/jem.144.3.644; WATANABE K, 1979, J BIOL CHEM, V254, P8223; WATANABE M, 1985, JPN J CANCER RES, V76, P43; YANG HJ, 1971, J BIOL CHEM, V246, P1192; YOUNG WW, 1981, J BIOL CHEM, V256, P967	42	65	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8439	8446						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022659				2022-12-25	WOS:A1991FK44100073
J	BODWELL, JE; ORTI, E; COULL, JM; PAPPIN, DJC; SMITH, LI; SWIFT, F				BODWELL, JE; ORTI, E; COULL, JM; PAPPIN, DJC; SMITH, LI; SWIFT, F			IDENTIFICATION OF PHOSPHORYLATED SITES IN THE MOUSE GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; FUNCTIONAL DOMAINS; WEHI-7 CELLS; ACTIVATION; BINDING; PURIFICATION; EXPRESSION; COMPLEXES; HORMONE; SUBUNIT	Glucocorticoid receptors in vivo are phosphorylated in the absence of hormone and become hyperphosphorylated in the presence of glucocorticoid agonist but not antagonists (Orti, E., Mendel, D. B., Smith, L. I., and Munck, A. (1989) J. Biol. Chem. 264, 9728-9731). As a preliminary step to elucidating the functional significance of receptor phosphorylation, we have identified seven phosphorylated sites on the mouse receptor. Tryptic phosphopeptides from P-32-labeled receptors were purified from glucocorticoid-treated mouse thymoma cells (WEHI-7) and from stably transfected Chinese hamster ovary cells (WCL2) that express large numbers of mouse receptors. Phosphopeptide maps of receptors from these two cell types were almost indistinguishable. Solid phase sequencing revealed phosphorylation at serines 122, 150, 212, 220, 234, and 315 and threonine 159. Serines 122, 150, 212, 220, and 234 and the sequences surrounding them are conserved in the homologous regions of the rat and human receptors, but threonine 159 and serine 315 have no homologues in the human receptor. The seven phosphorylated sites are in the amino-terminal domain of the receptor. All but serine 315 are within transactivation domains identified in the human and/or rat receptors. Serines 212, 220, and 234 are in a highly acidic region that in the mouse receptor is necessary for full transcription initiation activity and reduces nonspecific DNA binding. Serines 212, 220, and 234 and threonine 159 are in consensus sequences for proline-directed kinase and/or p34cdc2 kinase. Serine 122 is in a consensus sequence for casein kinase II whereas serines 150 and 315 do not appear to be in any known kinase consensus sequence. The location of many of these sites suggests a role of phosphorylation in transactivation.	MILLIGEN BIOSEARCH,BURLINGTON,MA 01803		BODWELL, JE (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHYSIOL,HANOVER,NH 03756, USA.			Pappin, Darryl/0000-0002-8981-8401	NCI NIH HHS [CA 23108] Funding Source: Medline; NIDDK NIH HHS [DK 03535] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003535] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1989, METHODS PROTEIN SEQU, P79; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BODWELL JE, 1981, BIOCHEMISTRY-US, V20, P2767, DOI 10.1021/bi00513a010; BURNSTEIN KL, 1989, ANNU REV PHYSIOL, V51, P683, DOI 10.1146/annurev.ph.51.030189.003343; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; COULL JM, 1991, IN PRESS ANAL BIOCH; DALMAN FC, 1988, J BIOL CHEM, V263, P12259; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DENNER LA, 1990, J BIOL CHEM, V265, P16548; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOECK W, 1990, J BIOL CHEM, V265, P5403; HOLBROOK NJ, 1983, J BIOL CHEM, V258, P6477; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MENDEL DB, 1987, J BIOL CHEM, V262, P5644; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ORTI E, 1989, J BIOL CHEM, V264, P231; ORTI E, 1989, J BIOL CHEM, V264, P9728; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; RAAKA BM, 1983, J BIOL CHEM, V258, P417; RAO KVS, 1987, BIOCHEM BIOPH RES CO, V144, P512, DOI 10.1016/S0006-291X(87)80539-9; SHERMAN MR, 1984, ANNU REV PHYSIOL, V46, P83; SMITH LI, 1988, BIOCHEMISTRY-US, V27, P3747, DOI 10.1021/bi00410a034; SMITH LI, 1989, BIOCHEMISTRY-US, V28, P4490, DOI 10.1021/bi00436a055; SODERLING TR, 1982, J CHROMATOGR, V253, P243, DOI 10.1016/S0021-9673(01)88382-5; STONE KL, 1990, LABORATORY METHODOLO; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; VEDECKIS WV, 1983, BIOCHEMISTRY-US, V22, P1983, DOI 10.1021/bi00277a038; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WETTENHALL REH, 1991, IN PRESS METHODS ENZ; WILKINSON JM, 1986, PRACTICAL PROTEIN CH, P122; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	38	194	197	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7549	7555						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019585				2022-12-25	WOS:A1991FJ34200038
J	EPPERLY, BR; DEKKER, EE				EPPERLY, BR; DEKKER, EE			L-THREONINE DEHYDROGENASE FROM ESCHERICHIA-COLI - IDENTIFICATION OF AN ACTIVE-SITE CYSTEINE RESIDUE AND METAL-ION STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALCOHOL-DEHYDROGENASE; PURIFICATION; ACTIVATION; K-12; ACID	Pure L-threonine dehydrogenase from Escherichia coli is a tetrameric protein (M(r) = 148,000) with 6 half-cystine residues/subunit; its catalytic activity as isolated is stimulated 5-10-fold by added Mn2+ or Cd2+. The peptide containing the 1 cysteine/subunit which reacts selectively with iodoacetate, causing complete loss of enzymatic activity, has been isolated and sequenced; this cysteine residue occupies position 38. Neutron activation and atomic absorption analyses of threonine dehydrogenase as isolated in homogeneous form now show that it contains 1 mol of Zn2+/mol of enzyme subunit. Removal of the Zn2+ with 1,10-phenanthroline demonstrates a good correlation between the remaining enzymatic activity and the zinc content. Complete removal of the Zn2+ yields an unstable protein, but the native metal ion can be exchanged by either Zn-65(2+), Co2+, or Cd2+ with no change in specific catalytic activity. Mn2+ added to and incubated with the native enzyme, the ZN-65(2+)-, the Co2+-, or the Cd2+- substituted form of the enzyme stimulates dehydrogenase activity to the same extent. These studies along with previously observed structural homologies further establish threonine dehydrogenase of E. coli as a member of the zinc-containing long chain alcohol/polyol dehydrogenases; it is unique among these enzymes in that its activity is stimulated by Mn2+ or Cd2+.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIDDK NIH HHS [DK-03718] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003718] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON I, 1981, BIOCHEMISTRY-US, V20, P3433, DOI 10.1021/bi00515a020; AOYAMA Y, 1981, J BIOL CHEM, V256, P2367; ARONSON BD, 1989, J BIOL CHEM, V264, P5226; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BORRAS T, 1989, BIOCHEMISTRY-US, V28, P6133, DOI 10.1021/bi00441a001; BOYLAN SA, 1981, J BIOL CHEM, V256, P1809; Branden C.-I., 1975, ENZYMES, V11, P103; CRAIG PA, 1986, BIOCHEMISTRY-US, V25, P1870, DOI 10.1021/bi00356a005; CRAIG PA, 1990, BIOCHIM BIOPHYS ACTA, V1037, P30, DOI 10.1016/0167-4838(90)90098-Z; CRAIG PA, 1988, BIOCHIM BIOPHYS ACTA, V957, P222, DOI 10.1016/0167-4838(88)90276-2; DALE RA, 1978, BIOCHIM BIOPHYS ACTA, V544, P496, DOI 10.1016/0304-4165(78)90324-0; DRUM DE, 1969, BIOCHEMISTRY-US, V8, P3792, DOI 10.1021/bi00837a045; Eklund H., 1987, BIOL MACROMOL, V3, P73; EPPERLY BR, 1989, J BIOL CHEM, V264, P18296; JEFFERY J, 1981, EUR J BIOCHEM, V120, P229, DOI 10.1111/j.1432-1033.1981.tb05693.x; JENDROSSEK D, 1988, J BACTERIOL, V170, P5248, DOI 10.1128/jb.170.11.5248-5256.1988; KOMATSUBARA S, 1978, J BACTERIOL, V135, P318, DOI 10.1128/JB.135.2.318-323.1978; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANCINI MA, 1989, CURR MICROBIOL, V18, P105, DOI 10.1007/BF01570833; MARET W, 1988, METHOD ENZYMOL, V158, P79, DOI 10.1016/0076-6879(88)58049-7; MARET W, 1989, BIOCHEMISTRY-US, V28, P9944, DOI 10.1021/bi00452a011; PERETZ M, 1989, BIOCHEMISTRY-US, V28, P6549, DOI 10.1021/bi00442a004; RAVNIKAR PD, 1987, J BACTERIOL, V169, P2611, DOI 10.1128/jb.169.6.2611-2617.1987; RAY M, 1985, J BIOL CHEM, V260, P5913; SCHWARZENBACH G, 1969, COMPLEXOMETRIC TITRA, P29; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SYTKOWSKI AJ, 1978, BIOCHEMISTRY-US, V17, P2850, DOI 10.1021/bi00607a024; SYTKOWSKI AJ, 1979, BIOCHEMISTRY-US, V18, P4095, DOI 10.1021/bi00586a006; TARR GE, 1986, ICROCHARACTERIZATION, P155; TRESSEL T, 1986, J BIOL CHEM, V261, P6428; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VLAHOS CJ, 1986, J BIOL CHEM, V261, P1049; Weber K, 1972, Methods Enzymol, V26, P3	33	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6086	6092						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007567				2022-12-25	WOS:A1991FE37300016
J	HEUSEL, JW; HANSON, RD; SILVERMAN, GA; LEY, TJ				HEUSEL, JW; HANSON, RD; SILVERMAN, GA; LEY, TJ			STRUCTURE AND EXPRESSION OF A CLUSTER OF HUMAN HEMATOPOIETIC SERINE PROTEASE GENES FOUND ON CHROMOSOME-14Q11.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXIC LYMPHOCYTES; CELL-SPECIFIC EXPRESSION; NATURAL-KILLER CELLS; HUMAN CATHEPSIN-G; MAST-CELL; MOLECULAR-CLONING; GENOMIC ORGANIZATION; GEL-ELECTROPHORESIS; ESTERASE GENE; DNA-MOLECULES	We previously identified a cluster of hematopoietic serine protease genes on chromosome 14 at band q11.2. This cluster contains the cathepsin G gene and the two related cathepsin G-like genes CGL-1 and CGL-2. The CGL-1 gene is identical with the cytotoxic T cell serine protease CSP-B (also called SECT, and in mice, CCP1, granzyme B, or CTLA-1). In this report, we determined that CGL-2 is identical with a recently described gene called h-CCPX. The coding sequences of CG, CGL-1, and CGL-2 are 65-75% identical at the DNA level. The intervening sequences are much less conserved, except for introns 3 of the CGL-1 and CGL-2 genes, which are 93% identical. Each of the genes has the same overall organization, with 5 exons and 4 introns, very short 5' untranslated regions, and identical splice phases for all of the introns. Cathepsin G is expressed at high levels in promyelocytes/promonocytes, and CGL-1/CSP-B is expressed at high levels in activated cytolytic T cells, lymphokine-activated killer (LAK), and natural killer (NK) cells. CGL-2/h-CCPX is expressed at much lower levels in activated peripheral blood lymphocytes, LAK and NK cells. To begin to define the regulatory elements that target expression of each of these genes to their specific lineages at specific times, the 5' flanking region of each gene was sequenced. The 5' flanking regions are minimally related and have few conserved consensus elements. Further experiments will be required to determine the critical cis-acting regulatory sequences required for tissue- and development-specific expression of each of these genes.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT GENET,ST LOUIS,MO 63110; CHILDRENS HOSP ST LOUIS,DEPT PEDIAT,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); St. Louis Children's Hospital			Heusel, Jon/AAC-8050-2021; Silverman, Gary/AAJ-1269-2020		NCI NIH HHS [CA 49712] Funding Source: Medline; NICHD NIH HHS [HD07271] Funding Source: Medline; NIDDK NIH HHS [DK 38682] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038682, R01DK038682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BELL GI, 1984, J BIOL CHEM, V259, P4265; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CAPUTO A, 1988, J BIOL CHEM, V263, P6363; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HADDAD P, 1990, GENE, V87, P265, DOI 10.1016/0378-1119(90)90311-E; HADDAD P, 1991, IN PRESS INT IMMUNOL; HANSON RD, 1990, MOL CELL BIOL, V10, P5655, DOI 10.1128/MCB.10.11.5655; HANSON RD, 1990, J BIOL CHEM, V265, P1524; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HOHN PA, 1989, J BIOL CHEM, V264, P13412; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; KLEIN JL, 1989, GENOMICS, V5, P110, DOI 10.1016/0888-7543(89)90093-1; KLEIN JL, 1990, TISSUE ANTIGENS, V35, P220, DOI 10.1111/j.1399-0039.1990.tb01787.x; LANIER LL, 1988, ISI ATLAS-IMMUNOL, V1, P15; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LEY TJ, 1989, J CLIN INVEST, V83, P1032, DOI 10.1172/JCI113944; LOBE CG, 1989, NUCLEIC ACIDS RES, V17, P5765, DOI 10.1093/nar/17.14.5765; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; Maniatis T., 1982, MOL CLONING; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MEIER M, 1990, BIOCHEMISTRY-US, V29, P4042, DOI 10.1021/bi00469a003; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; NAGLER A, 1989, J IMMUNOL, V143, P3183; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PHILLIPS JH, 1987, J CLIN ONCOL, V5, P1933, DOI 10.1200/JCO.1987.5.12.1933; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGERS J, 1985, NATURE, V315, P458, DOI 10.1038/315458a0; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SARID J, 1989, J BIOL CHEM, V264, P1022; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SILVERMAN GA, 1989, P NATL ACAD SCI USA, V86, P7485, DOI 10.1073/pnas.86.19.7485; STANWAY G, 1984, P NATL ACAD SCI-BIOL, V81, P1539, DOI 10.1073/pnas.81.5.1539; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5651, DOI 10.1021/bi00619a011; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VOLLRATH D, 1987, NUCLEIC ACIDS RES, V15, P7865, DOI 10.1093/nar/15.19.7865; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001; YOUNG JDE, 1986, CELL, V47, P183, DOI 10.1016/0092-8674(86)90441-1	55	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6152	6158						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007574				2022-12-25	WOS:A1991FE37300026
J	GREENBERG, AS; EGAN, JJ; WEK, SA; GARTY, NB; BLANCHETTEMACKIE, EJ; LONDOS, C				GREENBERG, AS; EGAN, JJ; WEK, SA; GARTY, NB; BLANCHETTEMACKIE, EJ; LONDOS, C			PERILIPIN, A MAJOR HORMONALLY REGULATED ADIPOCYTE-SPECIFIC PHOSPHOPROTEIN ASSOCIATED WITH THE PERIPHERY OF LIPID STORAGE DROPLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GENE-EXPRESSION; ADIPOSE CONVERSION; PHOSPHORYLATION; CELLS; INSULIN; DIFFERENTIATION; METABOLISM; GLUCAGON; OBESITY	The lipid fraction ("fat cake") of rat epididymal adipocytes contains a prominent phosphoprotein (62 kDa(app) by sodium dodecyl sulfate-polyacrylamide gel electrophoresis) that is multiply phosphorylated by cAMP-dependent protein kinase in vivo, at which point it migrates as a 65/67-kDa(app) doublet by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and is by far the most heavily radiolabeled protein in the cell. Western blot analysis of various tissues with immunopurified antibodies purified from antisera raised against the 62-kDa species suggests that the protein is specific for adipocytes. This protein, which we term perilipin, is found in differentiated cultured 3T3-L1 adipocytes, but not in their precursor 3T3-L1 fibroblasts. Immunocytochemical studies with specific antiserum shows that the perilipin is closely associated with the periphery of lipid storage droplets in cultured adipocytes. Given its adipocyte specificity, acute regulation by hormones, and subcellular location, we speculate that perilipin plays a role in the specialized lipid storage function of adipocytes.	NIDDKD, MEMBRANE REGULAT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	GREENBERG, AS (corresponding author), NIDDKD, ENDOCRINOL SECT, CELLULAR & DEV BIOL LAB, BLDG 6, RM B1-16, BETHESDA, MD 20892 USA.							ACHTSTAETTER T, 1986, METHOD ENZYMOL, V134, P355; AMENDE LM, 1986, CELL TISSUE RES, V247, P85; AUSIELLO D, 1976, BIOCHIM BIOPHYS ACTA, V451, P372, DOI 10.1016/0304-4165(76)90132-X; AVRUCH J, 1978, J BIOL CHEM, V253, P4754; BENJAMIN WB, 1978, J BIOL CHEM, V253, P1700; BLANCHETTEMACKI.EJ, 1984, INT J OBESITY, V8, P67; CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CUSHMAN SW, 1970, J CELL BIOL, V46, P326, DOI 10.1083/jcb.46.2.326; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; FAUST IM, 1977, SCIENCE, V197, P393, DOI 10.1126/science.877564; FLIER JS, 1989, RECENT PROG HORM RES, V45, P567; FORN J, 1976, ARCH BIOCHEM BIOPHYS, V176, P721, DOI 10.1016/0003-9861(76)90216-2; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; Fredrickson D. S., 1978, METABOLIC BASIS INHE, P604; GARRISON JC, 1978, J BIOL CHEM, V253, P7091; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; HUANG CK, 1983, BIOCHIM BIOPHYS ACTA, V760, P126, DOI 10.1016/0304-4165(83)90133-2; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KOROSCIL TM, 1981, J BIOL CHEM, V256, P6700; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LECAM A, 1982, J BIOL CHEM, V257, P8376; LECOCQ R, 1979, EUR J BIOCHEM, V102, P147, DOI 10.1111/j.1432-1033.1979.tb06274.x; MINOR LK, 1989, J LIPID RES, V30, P189; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; RINGOLD GM, 1988, RECENT PROG HORM RES, V44, P115; RODBELL M, 1964, J BIOL CHEM, V239, P375; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHOFF PK, 1987, BIOL REPROD, V37, P1037, DOI 10.1095/biolreprod37.4.1037; SIMPSON IA, 1982, ANAL BIOCHEM, V119, P424, DOI 10.1016/0003-2697(82)90608-X; SLAVIN BG, 1979, ANAT RECORD, V195, P63, DOI 10.1002/ar.1091950106; SPIEGELMAN BM, 1988, J CELL BIOL, V107, P829, DOI 10.1083/jcb.107.3.829; SPIEGELMAN BM, 1988, TRENDS GENET, V4, P203, DOI 10.1016/0168-9525(88)90077-7; SPRUILL WA, 1983, P NATL ACAD SCI-BIOL, V80, P993, DOI 10.1073/pnas.80.4.993; WILLIAMS ML, 1988, J INHERIT METAB DIS, V11, P131, DOI 10.1007/BF01799862; WOOD EM, 1967, ANAT REC, V157, P437, DOI 10.1002/ar.1091570304	39	644	673	3	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11341	11346						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040638				2022-12-25	WOS:A1991FQ77400097
J	BERTAGNOLLI, BL; HAGER, LP				BERTAGNOLLI, BL; HAGER, LP			ACTIVATION OF ESCHERICHIA-COLI PYRUVATE OXIDASE ENHANCES THE OXIDATION OF HYDROXYETHYLTHIAMIN PYROPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL MEMBRANE ENZYME; LIPID-BINDING SITE; THIAMIN PYROPHOSPHATE; PROTEASE ACTIVATION; AFFINITY; DECARBOXYLATION; INTERMEDIATE; PHOSPHOLIPIDS; KINASE; FORM	The catalytic efficiency (k(cat)/K(m)) of Escherichia coli flavin pyruvate oxidase can be stimulated 450-fold either by the addition of lipid activators or by limited proteolytic hydrolysis. Previous studies have shown that a functional lipid binding site is a mandatory prerequisite for the in vivo functioning of this enzyme (Grabau, C., and Cronan, J. E., Jr. (1986) Biochemistry 25, 3748-3751). The effect of activation on the transient state kinetics of partial reactions in the overall oxidative conversion of pyruvate to acetate and CO2 has now been examined. The rate of decarboxylation of pyruvate to form CO2 and hydroxyethylthiamin pyrophosphate for both activated and unactivated forms of the enzyme is identical within experimental error. The decarboxylation step was measured using substrate concentrations of the enzyme in the absence of an electron acceptor. The pseudo-first order rate constant for the decarboxylation step is 60-80 s-1. The rate of oxidation of hydroxyethylthiamin pyrophosphate and concomitant enzyme-bound flavin reduction was analyzed by stopped-flow methods utilizing synthetic hydroxyethylthiamin pyrophosphate. The pseudo-first order rate for this step with unactivated enzyme was 2.85 s-1 and increased 145-fold for lipid-activated enzyme to 413 s-1 and 61-fold for the proteolytically activated enzyme to 173 s-1. The analysis of a third reaction step, the reoxidation of enzyme-bound FADH, was also investigated by stopped-flow techniques utilizing ferricyanide as the electron acceptor. The rate of oxidation of enzyme.FADH is very fast for both unactivated (1041 s-1) and activated enzyme (645 s-1). The data indicate that the FAD reduction step is the rate-limiting step in the overall reaction for unactivated enzyme. Alternatively, the rate-limiting step in the overall reaction with the activated enzyme shifts to one of the partial steps in the decarboxylation reaction.			BERTAGNOLLI, BL (corresponding author), UNIV ILLINOIS,ROGER ADAMS LAB,DEPT BIOCHEM,URBANA,IL 61801, USA.				NIGMS NIH HHS [GM07768] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABITA JP, 1984, J BIOL CHEM, V259, P4560; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; BLAKE R, 1978, J BIOL CHEM, V253, P1963; BLAKE R, 1982, FLAVINS FLAVOPRTEINS, P864; BLAKE RC, 1977, THESIS U ILLINOIS CH; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROSBY J, 1970, J AM CHEM SOC, V92, P5707, DOI 10.1021/ja00722a027; CUNNINGHAM CC, 1975, J BIOL CHEM, V250, P7139; CUNNINGHAM CC, 1971, J BIOL CHEM, V246, P1575; DEEB SS, 1964, J BIOL CHEM, V239, P1024; EDSALL JT, 1958, BIOPHYSICAL CHEM, V1, P584; GRABAU C, 1986, BIOCHEMISTRY-US, V25, P3748, DOI 10.1021/bi00361a003; GRABAU C, 1984, J BACTERIOL, V160, P1088, DOI 10.1128/JB.160.3.1088-1092.1984; GRABAU C, 1986, NUCLEIC ACIDS RES, V14, P5549; GRUYS KJ, 1987, BIOCHEMISTRY-US, V26, P7575, DOI 10.1021/bi00398a007; HAGER LP, 1957, J BIOL CHEM, V229, P251; HAMILTON SE, 1986, BIOCHEMISTRY-US, V25, P8178, DOI 10.1021/bi00373a009; HO C, 1968, J BIOL CHEM, V238, P3499; INOUE M, 1977, J BIOL CHEM, V252, P7610; JEAN Y, 1982, CHEM PHYS, V65, P107, DOI 10.1016/0301-0104(82)85060-X; KLUGER R, 1981, J AM CHEM SOC, V103, P884, DOI 10.1021/ja00394a027; KUO DJ, 1983, J BIOL CHEM, V258, P3415; MATHER MW, 1985, J BIOL CHEM, V260, P395; MATHER MW, 1985, J BIOL CHEM, V260, P6148; OBRIEN TA, 1979, BIOCHEMISTRY-US, V18, P804, DOI 10.1021/bi00572a010; OBRIEN TA, 1977, BIOCHEMISTRY-US, V16, P3105, DOI 10.1021/bi00633a010; OBRIEN TA, 1980, J BIOL CHEM, V255, P3302; OBRIEN TA, 1976, BIOCHIM BIOPHYS ACTA, V452, P13, DOI 10.1016/0005-2744(76)90054-1; RAJ T, 1977, BIOCHIM BIOPHYS ACTA, V481, P42, DOI 10.1016/0005-2744(77)90135-8; RECNY MA, 1985, J BIOL CHEM, V260, P4287; RECNY MA, 1982, J BIOL CHEM, V257, P2878; RECNY MA, 1983, J BIOL CHEM, V258, P5189; RECNY MA, 1983, THESIS U ILLINOIS CH; RUSSELL P, 1977, J BIOL CHEM, V252, P7883; RUSSELL P, 1977, J BIOL CHEM, V252, P7877; SCHROCK HL, 1977, J BIOL CHEM, V252, P5990; SCHROCK HL, 1980, BIOCHIM BIOPHYS ACTA, V614, P215, DOI 10.1016/0005-2744(80)90182-5; STEVENS DJ, 1980, J BIOL CHEM, V255, P379; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; WILLIAMS FR, 1966, ARCH BIOCHEM BIOPHYS, V116, P168, DOI 10.1016/0003-9861(66)90025-7	40	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10168	10173						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037573				2022-12-25	WOS:A1991FP08600029
J	ROBEY, RB; KWON, HM; HANDLER, JS; GARCIAPEREZ, A; BURG, MB				ROBEY, RB; KWON, HM; HANDLER, JS; GARCIAPEREZ, A; BURG, MB			INDUCTION OF GLYCINEBETAINE UPTAKE INTO XENOPUS OOCYTES BY INJECTION OF POLY(A)+ RNA FROM RENAL-CELLS EXPOSED TO HIGH EXTRACELLULAR NACL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE RIBONUCLEIC-ACID; MAJOR ORGANIC OSMOLYTES; MESSENGER-RNA; ALDOSE REDUCTASE; MEDULLARY CELLS; LAEVIS OOCYTES; MOLECULAR-CLONING; OSMOTIC-STRESS; EXPRESSION; RAT	Madin-Darby canine kidney (MDCK) cells accumulate glycinebetaine via Na+-dependent transport in response to hypertonic stress. When extracellular tonicity is increased by the addition of NaCl, V(max) for glycinebetaine transport increases without an associated change in K(m), consistent with an increase in the number of functioning transporters. To test whether increased transport activity results from increased gene expression, we injected poly(A)+ RNA (mRNA) from MDCK cells into Xenopus oocytes and assayed for glycinebetaine uptake in ovo. RNA-induced Na+-dependent uptake is observed in oocytes injected with mRNA from cells exposed to high extracellular NaCl, but not in oocytes injected with either water or mRNA from cells maintained in isotonic medium. Unfractionated mRNA induces glycinebetaine uptake in ovo at a rate which is approximately 3-fold higher than in water-injected controls. Size-fractionated mRNA (median size 2.8 kilobases) induces uptake at a rate which is approximately 7-fold higher than controls. Such RNA-induced transport activity in ovo is consistent with heterologous expression of Na+/glycinebetaine cotransporters encoded by renal mRNA. Increased transporter mRNA in cells exposed to hypertonicity probably underlies the pattern of expression observed in ovo. This can account for the observed rise in MDCK cell glycinebetaine transport during hypertonic stress.	NHLBI,KIDNEY & ELECTROLYTE LAB,BLDG 10,RM 6N307,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV NEPHROL,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University			Robey, R. Brooks/J-7099-2013	Robey, R. Brooks/0000-0001-5059-3965				[Anonymous], PHYSL BIOCH DROUGHT; AOSHIMA H, 1988, ARCH BIOCHEM BIOPHYS, V265, P73, DOI 10.1016/0003-9861(88)90372-4; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BAGNASCO SM, 1987, P NATL ACAD SCI USA, V84, P1718, DOI 10.1073/pnas.84.6.1718; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COWLEY BD, 1990, AM J PHYSIOL, V258, pF154, DOI 10.1152/ajprenal.1990.258.1.F154; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; DUCHEMIN AM, 1990, MOL BRAIN RES, V8, P235, DOI 10.1016/0169-328X(90)90022-6; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GROSSMAN EB, 1989, AM J PHYSIOL, V256, pF107; GULLANS SR, 1988, AM J PHYSIOL, V255, pF626, DOI 10.1152/ajprenal.1988.255.4.F626; GURDON JB, 1971, NATURE, V233, P177, DOI 10.1038/233177a0; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; KWON HM, 1991, AM J PHYSIOL, V260, pF258, DOI 10.1152/ajprenal.1991.260.2.F258; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LONGONI S, 1988, AM J PHYSIOL, V255, pC870, DOI 10.1152/ajpcell.1988.255.6.C870; MERRIAM RW, 1971, EXP CELL RES, V68, P75, DOI 10.1016/0014-4827(71)90588-X; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; MORIYAMA T, 1990, AM J PHYSIOL, V259, pF847, DOI 10.1152/ajprenal.1990.259.5.F847; MORIYAMA T, 1991, IN PRESS AM J PHYSL; NAKANISHI T, 1989, P NATL ACAD SCI USA, V86, P6002, DOI 10.1073/pnas.86.15.6002; NAKANISHI T, 1990, AM J PHYSIOL, V258, pF1061, DOI 10.1152/ajprenal.1990.258.4.F1061; NAKANISHI T, 1988, AM J PHYSIOL, V255, pC181, DOI 10.1152/ajpcell.1988.255.2.C181; ORON Y, 1987, SCIENCE, V238, P1406, DOI 10.1126/science.2825350; PALMER LG, 1990, J GEN PHYSIOL, V96, P23, DOI 10.1085/jgp.96.1.23; PRINCE WS, 1990, J BIOL CHEM, V265, P17673; ROBEY RB, 1990, FASEB J, V4, pA1960; SEIFTER JL, 1990, J AM SOC NEPHROL, V1, P707; SMARDO FM, 1990, FASEB J, V4, pA2096; SOREQ H, 1985, CRC CR REV BIOCH MOL, V18, P199, DOI 10.3109/10409238509085134; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; VILIJN F, 1989, J BIOL CHEM, V264, P11901; WALLACE RA, 1973, J EXP ZOOL, V184, P321, DOI 10.1002/jez.1401840305; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745; WIRTHENSOHN G, 1982, BIOCH KIDNEY FUNCTIO, P119; WRIGHT S H, 1989, FASEB Journal, V3, pA858; YANCEY PH, 1988, J COMP PHYSIOL B, V158, P369, DOI 10.1007/BF00695336; YANCEY PH, 1989, AM J PHYSIOL, V257, pF602, DOI 10.1152/ajprenal.1989.257.4.F602; YANCEY PH, 1990, AM J PHYSIOL, V258, pR198, DOI 10.1152/ajpregu.1990.258.1.R198; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	46	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10400	10405						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	2037590				2022-12-25	WOS:A1991FP08600063
J	CREMERS, HCJC; BATLEY, M; REDMOND, JW; WIJFJES, AHM; LUGTENBERG, BJJ; WIJFFELMAN, CA				CREMERS, HCJC; BATLEY, M; REDMOND, JW; WIJFJES, AHM; LUGTENBERG, BJJ; WIJFFELMAN, CA			DISTRIBUTION OF O-ACETYL GROUPS IN THE EXOPOLYSACCHARIDE SYNTHESIZED BY RHIZOBIUM-LEGUMINOSARUM STRAINS IS NOT DETERMINED BY THE SYM PLASMID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC EXTRACELLULAR POLYSACCHARIDES; HOST-SYMBIONT INTERACTIONS; NODULATION GENES; STRUCTURAL FEATURES; TRIFOLII; MUTANTS; ABILITY; PRL1JI; SPECIFICITY; BINDING	The patterns of O-acetylation of the exopolysaccharide (EPS) from the Sym plasmid-cured derivatives of Rhizobium leguminosarum bv. trifolii strain LPR5, R. leguminosarum bv. trifolii strain ANU843 and R. leguminosarum bv. viciae strain 248 were determined by H-1 and C-13 NMR spectroscopy. Beside a site indicative of the chromosomal background, these strains have one site of O-acetylation in common, namely residue b of the repeating unit (Fig. 1). The O-acetyl esterification pattern of EPS of the Sym plasmid-cured derivatives of strains LPR5, ANU843, and 248 was not altered by the introduction of a R. leguminosarum bv. viciae Sym plasmid or a R. leguminosarum bv. trifolii Sym plasmid. The induction of nod gene expression by growth of the bacteria in the presence of Vicia sativa plants or by the presence of the flavonoid naringenin, produced no significant changes in either amount or sites of O-acetyl substitution. Furthermore, no such changes were found in the EPS from a Rhizobium strain in which the nod genes are constitutively expressed. The substitution pattern of the exopolysaccharide from R. leguminosarum is, therefore, determined by the bacterial genome and is not influenced by genes present on the Sym plasmid. This conclusion is inconsistent with the suggestion of Philip-Hollingsworth et al. (Philip-Hollingsworth, S., Hollingsworth, R. I., Dazzo, F. B., Djordjevic, M. A., and Rolfe, B. G. (1989) J. Biol. Chem. 264, 5710-5714) that nod genes of R. leguminosarum bv. trifolii, by influencing the acetylation pattern of EPS, determine the host specificity of nodulation.	UNIV ZEIDEN,DEPT PLANT MOLEC BIOL,2311 VJ LEIDEN,NETHERLANDS; MACQUARIE UNIV,SCH CHEM,SYDNEY,NSW 2104,AUSTRALIA	Macquarie University				Batley, Michael/0000-0001-9191-4286				BERGEY D, 1983, BERGEYS MANUAL DETER, V1; Berkeley, 1979, MICROBIAL POLYSACCHA, P1; BUCHANANWOLLASTON V, 1979, J GEN MICROBIOL, V112, P135, DOI 10.1099/00221287-112-1-135; CREMERS HCJ, 1988, NITROGEN FIXATION 10, P484; CREMERS HCJ, 1991, IN PRESS CARBOHYDR R; CREMERS HCJC, 1989, PLANT MOL BIOL, V13, P163, DOI 10.1007/BF00016135; CREMERS HCJC, 1990, J BIOL CHEM, V265, P21122; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5632; DJORDJEVIC MA, 1985, MOL GEN GENET, V200, P463, DOI 10.1007/BF00425732; DJORDJEVIC MA, 1987, EMBO J, V6, P1173, DOI 10.1002/j.1460-2075.1987.tb02351.x; DJORDJEVIC SP, 1986, CARBOHYD RES, V148, P87, DOI 10.1016/0008-6215(86)80039-8; DJORDJEVIC SP, 1987, J BACTERIOL, V169, P53, DOI 10.1128/jb.169.1.53-60.1987; DOWNIE JA, 1985, MOL GEN GENET, V198, P255, DOI 10.1007/BF00383003; EICH G, 1982, J AM CHEM SOC, V104, P3731, DOI 10.1021/ja00377a036; HOLLINGSWORTH RI, 1988, CARBOHYD RES, V172, P97, DOI 10.1016/S0008-6215(00)90845-0; HOLZWARTH G, 1979, CARBOHYD RES, V76, P277, DOI 10.1016/0008-6215(79)80030-0; HOOYKAAS PJJ, 1981, NATURE, V291, P351, DOI 10.1038/291351a0; JOHNSTON AWB, 1978, NATURE, V276, P634, DOI 10.1038/276634a0; KUO MS, 1986, CARBOHYD RES, V145, P247, DOI 10.1016/S0008-6215(00)90433-6; LIE TA, 1984, PLANT SOIL, V82, P415, DOI 10.1007/BF02184279; MCNEIL M, 1986, CARBOHYD RES, V146, P307, DOI 10.1016/0008-6215(86)85048-0; PHILIPHOLLINGSWORTH S, 1989, J BIOL CHEM, V264, P1461; PHILIPHOLLINGSWORTH S, 1989, J BIOL CHEM, V264, P5710; PRIEM WJE, 1984, FEMS MICROBIOL LETT, V25, P247; ROBERTSEN BK, 1981, PLANT PHYSIOL, V67, P389, DOI 10.1104/pp.67.3.389; ROLFE BG, 1982, PLANT SCI LETT, V19, P227; SKORUPSKA A, 1985, ARCH MICROBIOL, V143, P307, DOI 10.1007/BF00411255; SPAINK HP, 1989, EMBO J, V8, P2811, DOI 10.1002/j.1460-2075.1989.tb08427.x; SPAINK HP, 1987, NATURE, V328, P337, DOI 10.1038/328337a0; SPAINK HP, 1989, J BACTERIOL, V171, P4045, DOI 10.1128/jb.171.7.4045-4053.1989; VANBRUSSEL AAN, 1982, PLANT SCI LETT, V27, P317, DOI 10.1016/0304-4211(82)90134-1; VANBRUSSEL AAN, 1977, J GEN MICROBIOL, V101, P51, DOI 10.1099/00221287-101-1-51; VANBRUSSEL AAN, 1986, J BACTERIOL, V165, P517, DOI 10.1128/jb.165.2.517-522.1986; VINCENT JM, 1970, HDB BLACKWELL SCI PU, V15; WIJFFELMAN CA, 1985, ARCH MICROBIOL, V143, P225, DOI 10.1007/BF00411240; ZAAT SAJ, 1987, J BACTERIOL, V169, P198, DOI 10.1128/jb.169.1.198-204.1987	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9556	9564						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033052				2022-12-25	WOS:A1991FM45900036
J	KAJIMOTO, Y; ROTWEIN, P				KAJIMOTO, Y; ROTWEIN, P			STRUCTURE OF THE CHICKEN INSULIN-LIKE GROWTH FACTOR-I GENE REVEALS CONSERVED PROMOTER ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; IGF-I; DNA FRAGMENTS; NUCLEOTIDE-SEQUENCE; EXPRESSION; HORMONE; RNA; RAT; TRANSCRIPTION; ORGANIZATION	Insulin-like growth factor I plays a major role in cellular growth by mediating many of the actions of growth hormone. In mammals, IGF-I gene expression is complicated, as the single-copy gene is transcribed and processed into multiple mRNAs that encode at least two peptide precursors. Recent cDNA cloning studies have suggested that in chickens the organization of the gene might be simpler, and that comparative mapping might define essential features of IGF-I that are common to vertebrates. To achieve this goal, we have cloned and characterized the chicken IGF-I gene. The chicken gene is more compact than its mammalian homologues. It is composed of 4 exons which are distributed over 50 kilobases (kb) of chromosomal DNA and are transcribed and processed into mRNAs of 1.9 and 2.6 kb. As in the rat and human genes, the mature 70-amino acid IGF-I molecule is encoded within exons 2 and 3, while exons 1 and 4 contain NH2- and COOH-terminal extension peptides, respectively, and untranslated sequences. Both ends of the chicken gene are structurally heterogeneous. IGF-I mRNAs were found to have two regions of polyadenylation which mapped to exon 4 and were separated by approximately 0.7 kb. At the 5' end, several transcription initiation sites were identified within a 74-nucleotide portion of exon 1 that was found to be highly conserved between chicken and mammalian IGF-I genes. To test promoter function, chimeric genes were constructed linking fragments of chicken IGF-I 5'-flanking DNA to a promoterless reporter plasmid. Hybrid genes containing at least 0.6 kb of IGF-I enhanced expression of luciferase after transfection into SK-N-MC cells, a human line that synthesizes IGF-I mRNA. These observations represent the first thorough characterization of an IGF-I gene and provide an impetus for discerning the mechanisms by which IGF-I expression is regulated during growth, development, and differentiation.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,BOX 8127,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020579, P60DK020579, R01DK037449] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20579, DK37449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BORTZ JD, 1988, J CELL BIOL, V107, P811, DOI 10.1083/jcb.107.2.811; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUCCI C, 1989, NUCLEIC ACIDS RES, V17, P3596, DOI 10.1093/nar/17.9.3596; CANCELA L, 1990, J BIOL CHEM, V265, P15040; CAO QP, 1989, MOL ENDOCRINOL, V3, P2005, DOI 10.1210/mend-3-12-2005; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DEPAGTERHOLTHUIZEN P, 1986, FEBS LETT, V195, P179, DOI 10.1016/0014-5793(86)80156-9; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EMLER CA, 1987, ENDOCRINOLOGY, V120, P832, DOI 10.1210/endo-120-2-832; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; KAJIMOTO Y, 1990, MOL ENDOCRINOL, V4, P217, DOI 10.1210/mend-4-2-217; KAJIMOTO Y, 1989, MOL ENDOCRINOL, V3, P1907, DOI 10.1210/mend-3-12-1907; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LUO JM, 1989, ENDOCRINOLOGY, V125, P165, DOI 10.1210/endo-125-1-165; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURPHY LJ, 1988, ENDOCRINOLOGY, V122, P325, DOI 10.1210/endo-122-1-325; NAGAOKA I, 1990, J CLIN INVEST, V85, P448, DOI 10.1172/JCI114458; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; OLIVER JE, 1989, ENDOCRINOLOGY, V124, P2671, DOI 10.1210/endo-124-6-2671; ONEILL IE, 1990, MOL CELL ENDOCRINOL, V70, P41, DOI 10.1016/0303-7207(90)90057-F; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; ROGERS SA, 1989, P NATL ACAD SCI USA, V86, P6363, DOI 10.1073/pnas.86.16.6363; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROTWEIN P, 1987, ENDOCRINOLOGY, V121, P2141, DOI 10.1210/endo-121-6-2141; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; Sambrook J, 1989, MOL CLONING LABORATO; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; Woo S L, 1979, Methods Enzymol, V68, P389; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	51	86	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9724	9731						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033062				2022-12-25	WOS:A1991FM45900061
J	REILLY, CF; MCFALL, RC				REILLY, CF; MCFALL, RC			PLATELET-DERIVED GROWTH-FACTOR AND TRANSFORMING GROWTH-FACTOR-BETA REGULATE PLASMINOGEN-ACTIVATOR INHIBITOR-1 SYNTHESIS IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; EXTRACELLULAR-MATRIX; MYOCARDIAL-INFARCTION; LUNG FIBROBLASTS; TYPE-1; PURIFICATION; PROTEIN; PLASMA; INDUCTION; LIPOPOLYSACCHARIDE	Bovine vascular smooth muscle cells (SMC) were examined for production of plasminogen activator inhibitor-1 (PAI-1) which may play a key role in regulating the fibrinolytic system. Growth-arrested SMC released active PAI (101 arbitrary units (AU)/10(6) cells/24 h) and a latent form of PAI (880 AU/10(6) cells/24 h) into the conditioned medium (CM). The levels of PAI were significant since 880 AU of PAI could inhibit approximately 1-mu-g of tissue plasminogen activator. The extracellular matrix of SMC also contained PAI activity; however, the level was 17-fold less than that observed in the CM. SMC-PAI was a rapid inhibitor of tissue plasminogen activator (k(ass) > 10(7) M-1 s-1) and was identified as a 45-kDa protein immunologically related to endothelial cell PAI-1. PAI-1 comprised 20 and 30%, respectively, of the newly synthesized protein detected in the CM and extracellular matrix of SMC. The SMC growth modulators, platelet-derived growth factor and transforming growth factor-beta, induced PAI-1 activity and protein synthesis by 2- and 3-fold, respectively, in a dose- and time-dependent manner. The increases in PAI-1 activity and protein synthesis were ascribed to elevated levels of PAI-1 mRNA as judged by Northern blot analysis of total RNA prepared from control and platelet-derived growth factor- and transforming growth factor-beta-treated cells. Increases in PAI-1 mRNA levels were evident 1 h after growth factor treatment and were maximal after 4 h. PAI-1 mRNA levels were unaffected by cycloheximide treatment. The results indicate that SMC synthesize and release PAI-1 which could regulate the normal fibrinolytic environment of the arterial wall. During atherosclerosis or after vascular injury increases in platelet-derived or locally produced mitogens may stimulate further PAI-1 synthesis and generate a prothrombotic state.			REILLY, CF (corresponding author), MERCK SHARP & DOHME LTD, DEPT PHARMACOL, W42-300, West Point, PA 19486 USA.							ALMER LO, 1987, THROMB RES, V47, P335, DOI 10.1016/0049-3848(87)90147-2; ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; ASSOIAN RK, 1984, NATURE, V309, P804, DOI 10.1038/309804a0; ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; BOOYSE FM, 1975, THROMB DIATH HAEMOST, V34, P825, DOI 10.1055/s-0038-1654001; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; EMEIS JJ, 1986, J EXP MED, V163, P1260, DOI 10.1084/jem.163.5.1260; ERICKSON LA, 1984, ANAL BIOCHEM, V137, P454, DOI 10.1016/0003-2697(84)90113-1; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; HAMSTEN A, 1987, LANCET, V2, P3; HEGT VN, 1974, NATURE, V248, P75, DOI 10.1038/248075a0; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; JUHANVAGUE I, 1987, THROMB HAEMOSTASIS, V57, P67; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; KLUFT C, 1985, SCAND J CLIN LAB INV, V45, P605, DOI 10.3109/00365518509155267; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KOOISTRA T, 1986, BIOCHEM J, V239, P497, DOI 10.1042/bj2390497; KRUITHOF EKO, 1987, BLOOD, V70, P1645; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LAUG WE, 1989, THROMB HAEMOSTASIS, V61, P517; LAUG WE, 1985, THROMB HAEMOSTASIS, V53, P165; LEVIN EG, 1986, BLOOD, V67, P1309; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P936; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PARAMO JA, 1985, BRIT MED J, V291, P573, DOI 10.1136/bmj.291.6495.573; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; REILLY CF, 1989, BIOCHEM BIOPH RES CO, V160, P1047, DOI 10.1016/S0006-291X(89)80108-1; REILLY CF, 1989, J BIOL CHEM, V264, P6990; REILLY CF, 1988, J CELL PHYSIOL, V136, P23, DOI 10.1002/jcp.1041360104; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHWARTZ CJ, 1988, SEMIN THROMB HEMOST, V14, P189, DOI 10.1055/s-2007-1002775; SPRENGERS ED, 1987, BLOOD, V69, P381; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914	48	131	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9419	9427						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	2033043				2022-12-25	WOS:A1991FM45900016
J	HUANG, JM; WEI, YF; KIM, YH; OSTERBERG, L; MATTHEWS, HR				HUANG, JM; WEI, YF; KIM, YH; OSTERBERG, L; MATTHEWS, HR			PURIFICATION OF A PROTEIN HISTIDINE KINASE FROM THE YEAST SACCHAROMYCES-CEREVISIAE - THE 1ST MEMBER OF THIS CLASS OF PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LABILE HISTONE PHOSPHATES; ESCHERICHIA-COLI; GEL-ELECTROPHORESIS; RAT-LIVER; PHOSPHOTRANSFERASE SYSTEM; BACTERIAL CHEMOTAXIS; NUCLEAR PROTEINS; SUGAR-TRANSPORT; RNA-POLYMERASE; DIVERSE FAMILY	An enzyme of molecular weight 32,000 comprising a single subunit has been isolated from whole cell extracts of the yeast Saccharomyces cerevisiae. In vitro, the enzyme transfers the gamma-phosphate of ATP to a protein substrate, histone H4, to produce an alkalistable phosphorylation. Modification of the substrate histidine with diethylpyrocarbonate prevented phosphorylation. Phosphoamino acid analysis of the phosphorylated substrate showed the presence of 1-phosphohistidine. Hence, the isolated enzyme is a protein histidine kinase. A novel assay for acid-labile alkalistable protein phosphorylation was used in the purification of the kinase activity to a final specific activity of 2,700 nmol/15 min/mg. The purified enzyme phosphorylates specifically histidine 75 in histone H4 and does not phosphorylate histidine 18 nor histidine residues in any other core histone. Steady state kinetic data are consisten with an ordered sequential reaction with K(m) values for Mg-ATP and histone H4 of 60 and 17-mu-M, respectively. The protein histidine kinase requires a divalent cation such as Mg2+, Co2+, or Mn2+ but will not use Ca2+, Zn2+, Cu2+, Fe2+, spermine, or spermidine. This is the first purification of an enzyme that catalyzes N-linked phosphorylation in proteins.			HUANG, JM (corresponding author), UNIV CALIF DAVIS, DEPT BIOL CHEM, DAVIS, CA 95616 USA.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON B, 1971, J BIOL CHEM, V246, P7023; BIEBER LL, 1966, J BIOL CHEM, V241, P5375; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BOYER PD, 1962, J BIOL CHEM, V237, P3306; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; CARLOMAGNO L, 1985, ANAL BIOCHEM, V149, P344, DOI 10.1016/0003-2697(85)90580-9; CHEN CC, 1977, BIOCHEMISTRY-US, V16, P4852, DOI 10.1021/bi00641a016; CHEN CC, 1974, BIOCHEMISTRY-US, V13, P3785, DOI 10.1021/bi00715a026; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; DELANGE RJ, 1969, J BIOL CHEM, V244, P319; Drapeau G R, 1977, Methods Enzymol, V47, P189; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; GALABRU J, 1987, J BIOL CHEM, V262, P15538; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEGDE AN, 1987, FEBS LETT, V217, P74, DOI 10.1016/0014-5793(87)81246-2; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; HOPPE J, 1979, EUR J BIOCHEM, V93, P141, DOI 10.1111/j.1432-1033.1979.tb12804.x; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG JM, 1990, ANAL BIOCHEM, V188, P114, DOI 10.1016/0003-2697(90)90537-J; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; HULTQUIST DE, 1966, BIOCHEMISTRY-US, V5, P322, DOI 10.1021/bi00865a041; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JACKSON V, 1975, J BIOL CHEM, V250, P4856; KURODA Y, 1982, ARCH BIOCHEM BIOPHYS, V213, P271, DOI 10.1016/0003-9861(82)90462-3; LAMBERT SF, 1986, EUR J BIOCHEM, V160, P191, DOI 10.1111/j.1432-1033.1986.tb09957.x; Light A, 1972, Methods Enzymol, V25, P253, DOI 10.1016/S0076-6879(72)25022-4; MAGASANIK B, 1989, BIOCHIMIE, V71, P1005, DOI 10.1016/0300-9084(89)90104-1; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARKOVITS J, 1989, CANCER RES, V49, P5111; MASARACCHIA RA, 1977, J BIOL CHEM, V252, P7109; MATTHEWS HR, 1968, J CHROMATOGR, V36, P302, DOI 10.1016/S0021-9673(01)92946-2; MATTHEWS HR, 1984, MOL CELL BIOCHEM, V59, P81; Matthews HR, 1985, ENZYMOLOGY POSTTRANS, V2, P125; MATTOO RL, 1984, ANAL BIOCHEM, V139, P1, DOI 10.1016/0003-2697(84)90383-X; Miles E W, 1977, Methods Enzymol, V47, P431; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NIEDBALSKI J, 1986, FASEB J, V45, P1801; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NORMAN AW, 1965, BIOCHEM BIOPH RES CO, V20, P703, DOI 10.1016/0006-291X(65)90073-2; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; PESIS KH, 1988, FEBS LETT, V239, P151, DOI 10.1016/0014-5793(88)80563-5; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; REITZER LJ, 1989, J BACTERIOL, V171, P5512, DOI 10.1128/jb.171.10.5512-5522.1989; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; ROBERTSON EF, 1988, J BIOL CHEM, V263, P2477; ROSE ZB, 1970, ARCH BIOCHEM BIOPHYS, V140, P508, DOI 10.1016/0003-9861(70)90095-0; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; Sheridan R. C., 2007, INORG SYN, P23; SIKORSKA M, 1982, BIOCHIM BIOPHYS ACTA, V703, P171, DOI 10.1016/0167-4838(82)90045-0; SMITH DL, 1973, NATURE, V246, P103, DOI 10.1038/246103a0; SMITH DL, 1974, BIOCHEMISTRY-US, V13, P3780, DOI 10.1021/bi00715a025; SMITH LS, 1976, BIOCHEM BIOPH RES CO, V71, P459, DOI 10.1016/0006-291X(76)90809-3; SMITH MM, 1983, J MOL BIOL, V169, P663, DOI 10.1016/S0022-2836(83)80164-8; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SWANSON ME, 1983, J BIOL CHEM, V258, P3242; TAYLOR SS, 1986, ANN NY ACAD SCI, V478, P191, DOI 10.1111/j.1749-6632.1986.tb15531.x; TAYLOR SS, 1987, BIOESSAYS, V7, P24, DOI 10.1002/bies.950070106; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; TAYLOR SS, 1988, COLD SPRING HARB SYM, V53, P121, DOI 10.1101/SQB.1988.053.01.018; VENER AV, 1986, BIOORG KHIM+, V12, P200; WALINDER O, 1968, J BIOL CHEM, V243, P2793; WALINDER O, 1968, J BIOL CHEM, V243, P3947; WEI YF, 1989, ARCH BIOCHEM BIOPHYS, V268, P546, DOI 10.1016/0003-9861(89)90321-4; WEI YF, 1990, ANAL BIOCHEM, V190, P188, DOI 10.1016/0003-2697(90)90179-D; WEI YF, 1990, IN PRESS METHODS ENZ; WEI YF, 1990, THESIS U CALIFORNIA; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZETTERQV.O, 1967, BIOCHIM BIOPHYS ACTA, V141, P523, DOI 10.1016/0304-4165(67)90181-X; ZETTERQV.O, 1966, BIOCHIM BIOPHYS ACTA, V113, P520, DOI 10.1016/S0926-6593(66)80010-3	82	68	69	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9023	9031						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026610				2022-12-25	WOS:A1991FM03800057
J	MAJUMDAR, S; ROSSI, MW; FUJIKI, T; PHILLIPS, WA; DISA, S; QUEEN, CF; JOHNSTON, RB; ROSEN, OM; CORKEY, BE; KORCHAK, HM				MAJUMDAR, S; ROSSI, MW; FUJIKI, T; PHILLIPS, WA; DISA, S; QUEEN, CF; JOHNSTON, RB; ROSEN, OM; CORKEY, BE; KORCHAK, HM			PROTEIN-KINASE-C ISOTYPES AND SIGNALING IN NEUTROPHILS - DIFFERENTIAL SUBSTRATE SPECIFICITIES OF A TRANSLOCATABLE, CALCIUM-DEPENDENT AND PHOSPHOLIPID-DEPENDENT BETA-PROTEIN KINASE-C AND A NOVEL CALCIUM-INDEPENDENT, PHOSPHOLIPID-DEPENDENT PROTEIN-KINASE WHICH IS INHIBITED BY LONG-CHAIN FATTY ACYL COENZYME-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PHORBOL ESTER RECEPTOR; METHIONYL-LEUCYL-PHENYLALANINE; NADPH-OXIDASE; STIMULATED NEUTROPHILS; RESPIRATORY BURST; DISTINCT FORMS; DE-GRANULATION; RAT-BRAIN; ACTIVATION	Neutrophils possess a classical Ca2+, phosphatidyl serine (PS) and diglyceride (DG)-dependent protein kinase C (beta-PKC) which was translocatable from cytosol to membrane in response to elevated Ca2+ in the physiologic range or to pretreatment with phorbol myristate acetate (PMA). The translocatable beta-PKC was purified from neutrophil membranes prepared in the presence of Ca2+, eluted with EGTA and subjected to hydroxyapatite chromatography. An 80-kDa protein possessing Ca/DG/PS-dependent histone phosphorylating activity was recognized by a monoclonal antibody to beta-PKC but not to alpha-PKC or gamma-PKC. A cytosolic kinase activity remaining after Ca2+-induced translocation of beta-PKC was dependent on PS and DG but did not require Ca2+. This novel Ca2+-independent, PS/DG-dependent kinase, termed nPKC, eluted from hydroxyapatite between alpha-PKC and beta-PKC, ran as a 76-kDa band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and was reactive to a polyclonal consensus antibody but not to monoclonal antibodies to alpha-PKC, beta-PKC, or gamma-PKC. Long chain fatty acyl-CoA, but not the corresponding free fatty acids, inhibited nPKC in the 1-10-mu-M range. The chemotactic peptide fMet-Leu-Phe triggered prompt but transient increases in neutrophil long chain fatty acid acyl-CoA, suggesting that nPKC is regulated by fatty acyl-CoA as well as DG during neutrophil activation. Purified beta-PKC phosphorylated a number of cytosolic proteins in a Ca2+-dependent manner, including a major 47-kDa cytosolic protein, which may be implicated in superoxide anion generation. In contrast, nPKC did not phosphorylate the 47-kDa protein, but phosphorylated numerous cytosolic proteins in a Ca2+-independent manner, including a 66-kDa protein which was not phosphorylated by beta-PKC. Differences in location, substrate specificity, and cofactor dependence between nPKC and beta-PKC suggest these kinases may play selective roles in the activation sequence of the neutrophil.	UNIV PENN, SCH MED, DEPT BIOCHEM BIOPHYS, PHILADELPHIA, PA 19104 USA; BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA	University of Pennsylvania; Boston University	MAJUMDAR, S (corresponding author), UNIV PENN, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA.		Phillips, Wayne A/H-8070-2013; Corkey, Barbara/E-7712-2015	Phillips, Wayne A/0000-0002-7961-638X; Corkey, Barbara/0000-0002-5467-1630	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024782, R01AI024840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS017752] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 24782, AI 24840] Funding Source: Medline; NINDS NIH HHS [NS17752] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKITA Y, 1990, J BIOL CHEM, V265, P354; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BALAZOVICH KJ, 1986, J IMMUNOL, V137, P1665; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRONFMAN M, 1988, BIOCHEM BIOPH RES CO, V152, P987, DOI 10.1016/S0006-291X(88)80381-4; BUYON JP, 1990, J IMMUNOL, V144, P191; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; CORKEY BE, 1990, PROG CLIN BIOL RES, V321, P217; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; COX CC, 1986, J IMMUNOL, V136, P4611; DELLABIANCA V, 1986, BIOCHEM BIOPH RES CO, V135, P556; FABBRO D, 1985, ARCH BIOCHEM BIOPHYS, V239, P102, DOI 10.1016/0003-9861(85)90816-1; FUJITA I, 1984, BIOCHEM BIOPH RES CO, V120, P318, DOI 10.1016/0006-291X(84)91256-7; GENNARO R, 1985, FEBS LETT, V180, P185, DOI 10.1016/0014-5793(85)81068-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GSCHWENDT M, 1989, J CELL BIOCHEM, V40, P295, DOI 10.1002/jcb.240400306; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; HEYWORTH PG, 1989, J BIOL CHEM, V264, P14935; HONEYCUTT PJ, 1986, J BIOL CHEM, V261, P5900; HORN W, 1986, BIOCHEM BIOPH RES CO, V139, P1169, DOI 10.1016/S0006-291X(86)80300-X; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KORCHAK HM, 1984, J BIOL CHEM, V259, P4076; KORCHAK HM, 1983, P NATL ACAD SCI-BIOL, V80, P4968, DOI 10.1073/pnas.80.16.4968; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; KUO JF, 1985, ADV INFLAMMAT RES, V10, P63; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASCU I, 1988, BIOCHEM BIOPH RES CO, V156, P1020, DOI 10.1016/S0006-291X(88)80946-X; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; Martell A. E., 1974, CRITICAL STABILITY C, V2; MAY WS, 1985, NATURE, V317, P549, DOI 10.1038/317549a0; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MELLONI E, 1986, J BIOL CHEM, V261, P4101; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SEIFERT R, 1987, BIOCHEM BIOPH RES CO, V149, P762, DOI 10.1016/0006-291X(87)90433-5; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SHOYAB M, 1985, ARCH BIOCHEM BIOPHYS, V236, P435, DOI 10.1016/0003-9861(85)90644-7; STASIA MJ, 1987, BIOCHEM BIOPH RES CO, V147, P428, DOI 10.1016/S0006-291X(87)80139-0; STASIA MJ, 1990, FEBS LETT, V274, P61, DOI 10.1016/0014-5793(90)81329-M; TAKAI Y, 1985, J CELL BIOCHEM, V29, P143, DOI 10.1002/jcb.240290209; TAUBER AI, 1987, BLOOD, V69, P711; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERKEST V, 1988, BIOCHEM BIOPH RES CO, V152, P825, DOI 10.1016/S0006-291X(88)80112-8; WALSH CE, 1983, BIOCHIM BIOPHYS ACTA, V750, P32, DOI 10.1016/0005-2760(83)90201-1; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; WISE BC, 1983, BIOCHEM PHARMACOL, V32, P1259, DOI 10.1016/0006-2952(83)90280-0; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; WOLF M, 1985, J BIOL CHEM, V260, P5718; WOLFSON M, 1985, J IMMUNOL, V135, P2057; WOOTEN MW, 1988, BIOCHEM BIOPH RES CO, V153, P67, DOI 10.1016/S0006-291X(88)81190-2; WYNKOOP EM, 1986, BIOCHEM J, V236, P829, DOI 10.1042/bj2360829	69	179	179	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9285	9294						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026625				2022-12-25	WOS:A1991FM03800093
J	BROOKS, AR; BLACKHART, BD; HAUBOLD, K; LEVYWILSON, B				BROOKS, AR; BLACKHART, BD; HAUBOLD, K; LEVYWILSON, B			CHARACTERIZATION OF TISSUE-SPECIFIC ENHANCER ELEMENTS IN THE 2ND INTRON OF THE HUMAN APOLIPOPROTEIN-B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERSENSITIVE SITES; MAMMALIAN-CELLS; MESSENGER-RNA; TRANSCRIPTION; EXPRESSION; DNA; ALPHA-1-ANTITRYPSIN; REGION; TRANSTHYRETIN; PROMOTER	We report the identification and characterization of tissue-specific transcriptional enhancer elements that influence the expression of the human apolipoprotein B gene. A 704-base pair PstI fragment comprising sequences from the first and second introns of the human apolipoprotein B gene (positions +360 to +1064) possesses tissue-specific transcriptional enhancer elements when assayed in transient transfection experiments using either the apolipoprotein B or thymidine kinase promoter. The majority of the enhancer activity, which was observed in transcriptionally active HepG2 and CaCo-2 cells, but not in transcriptionally inactive Chinese hamster ovary or HeLa cells, was subsequently localized to a 443-base pair SmaI-PvuII fragment (positions +621 to +1064) within the second intron of the apolipoprotein B gene. Gel retention experiments demonstrated that sequence motifs within this region interact with a number of nuclear proteins from HepG2, CaCo-2, and HeLa cells. The actual sequence elements that bound to nuclear proteins from HepG2 cells were identified by DNase I footprinting. Deletion experiments were performed to distinguish those protein-binding regions involved in the enhancer effect. Our data demonstrate that sequences between positions +806 and +940 are essential for this enhancer activity. This segment contains one large 97-base pair footprint, whose sequence has been conserved between the human and mouse genes. Binding sites for the liver-specific transcription factors HNF-1 and HNF-3 are present within this footprint.	GLADSTONE FDN LABS CARDIOVASC DIS,CARDIOVAS RES INST,POB 40608,SAN FRANCISCO,CA 94140; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BLACKHART BD, 1986, J BIOL CHEM, V261, P5364; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CARLSSON P, 1989, GENE, V77, P113, DOI 10.1016/0378-1119(89)90365-X; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DAS HK, 1988, J BIOL CHEM, V263, P11452; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ELGIN SCR, 1981, CELL, V27, P413, DOI 10.1016/0092-8674(81)90381-0; EMORINE L, 1983, NATURE, V304, P447, DOI 10.1038/304447a0; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAYSON DR, 1988, SCIENCE, V239, P786, DOI 10.1126/science.3257586; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HIGUCHI K, 1988, J BIOL CHEM, V263, P18530; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KARDASSIS D, 1990, MOL CELL BIOL, V10, P2653, DOI 10.1128/MCB.10.6.2653; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LEVYWILSON B, 1988, MOL CELL BIOL, V8, P71, DOI 10.1128/MCB.8.1.71; LUCERO MA, 1989, NUCLEIC ACIDS RES, V17, P2283, DOI 10.1093/nar/17.6.2283; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; METZGER S, 1990, J BIOL CHEM, V265, P9978; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; MULLER MM, 1988, EUR J BIOCHEM, V176, P485, DOI 10.1111/j.1432-1033.1988.tb14306.x; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; PARSLOW TG, 1983, NUCLEIC ACIDS RES, V11, P4775, DOI 10.1093/nar/11.14.4775; PARSLOW TG, 1982, NATURE, V299, P449, DOI 10.1038/299449a0; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	46	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7848	7859						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019605				2022-12-25	WOS:A1991FJ34200083
J	CARSON, GR; KUESTNER, RE; AHMED, A; PETTEY, CL; CONCINO, MF				CARSON, GR; KUESTNER, RE; AHMED, A; PETTEY, CL; CONCINO, MF			6 CHAINS OF THE HUMAN T-CELL ANTIGEN RECEPTOR.CD3 COMPLEX ARE NECESSARY AND SUFFICIENT FOR PROCESSING THE RECEPTOR HETERODIMER TO THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD3-ZETA CHAIN; CD3 COMPLEX; ZETA-CHAIN; EXPRESSION; DNA; RECONSTITUTION; SEQUENCE; SUBUNIT; PROTEIN; GENE	The T cell antigen receptor (TCR) plays a key role in the process of antigen recognition. It is a complex of at least seven peptide chains (alpha-beta-gamma-delta-epsilon-zeta-zeta). It is found on the surface of mature T cells and functions in antigen binding in the presence of the major histocompatibility complex. It has been known for some time that physical associations between the CD3 proteins and the TCR chains are essential for efficient transport of either component to the surface of T cells. For example, T cells that lack either the alpha, beta, or delta-chains synthesize partial complexes that are eventually degraded. cDNAs encoding the six chains of receptor have become available recently. We have used transfection techniques to generate a panel of Chinese hamster ovary cells that contain partial receptor complexes of known composition and also cells that express all six subunits of the TCR.CD3 complex. Cells in this panel were analyzed for the ability to form alpha-beta-heterodimers and also an ability to transport the synthesized chains to the plasma membrane. These studies have allowed us to define the minimum requirements for TCR.CD3 expression on the cell surface.			CARSON, GR (corresponding author), T CELL SCI INC,PROT EXPRESS GRP,38 SIDNEY ST,CAMBRIDGE,MA 02139, USA.							ALARCON B, 1988, J BIOL CHEM, V263, P2953; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; GEISLER C, 1989, J IMMUNOL, V143, P4069; GOLD DP, 1986, NATURE, V321, P431, DOI 10.1038/321431a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KLAUSNER R D, 1989, New Biologist, V1, P3; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; Maniatis T., 1982, MOL CLONING; MAX EE, 1981, J BIOL CHEM, V256, P5116; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PETTEY CL, 1987, J BIOL CHEM, V262, P4854; RICCIARDI RP, 1979, P NATL ACAD SCI USA, V76, P4927, DOI 10.1073/pnas.76.10.4927; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	27	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7883	7887						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019606				2022-12-25	WOS:A1991FJ34200088
J	CHEN, CM; CHIANG, SY; YEH, NH				CHEN, CM; CHIANG, SY; YEH, NH			INCREASED STABILITY OF NUCLEOLIN IN PROLIFERATING CELLS BY INHIBITION OF ITS SELF-CLEAVING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; SEQUENCE; ACID; RNA; DNA; PHOSPHOPROTEIN; LOCALIZATION; GLYCINE; CDNA; C23	Nucleolin is the major nucleolar phosphoprotein of exponentially growing eukaryotic cells and is presumably involved in pre-rRNA transcription and ribosome biogenesis. Monoclonal antibodies against nucleolin were selected by a differential dot-immunobinding assay. Nucleolin expression during T lymphocyte activation was monitored by the specific antibody. Results showed that nucleolin fluctuated in parallel to DNA synthesis. The intact 105-kDa nucleolin molecule was the major species in actively dividing cells, whereas the degraded forms were relatively abundant in non-dividing cells. These results imply that stability of nucleolin molecule is cell proliferation-dependent. When affinity purified nucleolin containing undetectable contaminants was incubated at 37-degrees-C, the majority of 105-kDa nucleolin was cleaved by 6 h and completely degraded within 24 h. This purified nucleolin was further separated from possible copurified protease, if any, on a reducing sodium dodecyl sulfate-polyacrylamide gel. After renaturation, the 105-kDa nucleolin immobilized in the gel was also cleaved at 37-degrees-C. These data have confirmed that nucleolin protein autocatalyzes its own degradation. The self-cleaving activity of nucleolin was inhibited by nuclear extracts prepared from proliferating cells. Apparently, a proteolytic inhibitor(s) in the nuclei of proliferating cells stabilized the nucleolin molecule. It provides an unique regulatory mechanism for nucleolin expression.	NATL YANG MING MED COLL,INST MICROBIOL & IMMUNOL,TAIPEI,TAIWAN	National Yang Ming Chiao Tung University								BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BOURBON HM, 1988, J MOL BIOL, V200, P627, DOI 10.1016/0022-2836(88)90476-7; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; BUGLER B, 1987, J BIOL CHEM, V262, P10922; DEMARTINO GN, 1986, J BIOL CHEM, V261, P2047; EGYHAZI E, 1988, EXP CELL RES, V178, P264, DOI 10.1016/0014-4827(88)90397-7; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; FREEMAN JW, 1985, MOL CELL BIOCHEM, V68, P87; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3345, DOI 10.1021/bi00283a007; ORRICK LR, 1973, P NATL ACAD SCI USA, V70, P1316, DOI 10.1073/pnas.70.5.1316; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; RAO SVV, 1982, J BIOL CHEM, V257, P5035; SAPP M, 1985, J BIOL CHEM, V260, P1550; SAPP M, 1989, EUR J BIOCHEM, V179, P541, DOI 10.1111/j.1432-1033.1989.tb14581.x; SAPP M, 1986, NUCLEIC ACIDS RES, V14, P6803, DOI 10.1093/nar/14.17.6803; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; SUZUKI N, 1985, J BIOL CHEM, V260, P8050; YEH NH, 1988, CHIN J MICROBIOL IMM, V21, P210	25	125	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7754	7758						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019600				2022-12-25	WOS:A1991FJ34200070
J	EDELBERG, JM; PIZZO, SV				EDELBERG, JM; PIZZO, SV			APPENDIXES - KINETIC-MODELS FOR THE ANALYSIS OF MODULATION AND SUPPRESSION OF IRREVERSIBLE ENZYMATIC INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									DUKE UNIV,MED CTR,DEPT PATHOL,BOX 3712,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University								Salvesen, 1986, PROTEINASE INHIBITOR, P23	1	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7494	7495						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019580				2022-12-25	WOS:A1991FJ34200029
J	NAITO, K; FUJIKAWA, K				NAITO, K; FUJIKAWA, K			ACTIVATION OF HUMAN BLOOD-COAGULATION FACTOR-XI INDEPENDENT OF FACTOR-XII - FACTOR-XI IS ACTIVATED BY THROMBIN AND FACTOR-XIA IN THE PRESENCE OF NEGATIVELY CHARGED SURFACES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAGEMAN-FACTOR; FACTOR-VII; PLASMA PREKALLIKREIN; TISSUE FACTOR; PROTEIN-C; AUTOACTIVATION; BINDING; QUANTITIES; INITIATION; INHIBITOR	Human blood coagulation factor XI was activated by either autoactivation or thrombin. These reactions occurred only in the presence of negatively charged materials, such as dextran sulfate (approximately M(r) 500,000), sulfatide, and heparin. During the activation, factor XI was cleaved at a single Arg-Ile bond by thrombin or factor XIa to produce an amino-terminal 50-kDa heavy chain and a carboxyl-terminal 35-kDa light chain. This activation pattern is identical to that produced by factor XIIa. The addition of a small amount of thrombin and sulfatide to factor XII-deficient plasma produced shorter clotting times than when these agents were added to factor XI/factor XII combined-deficient plasma. These results suggest that the activation of factor XI by thrombin and possibly the autoactivation of factor XI proceed in plasma to lead fibrin clot formation. These reactions may have a role on an appropriate negatively charged surface in normal hemostasis.			NAITO, K (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; ASAKAI R, 1989, P NATL ACAD SCI USA, V86, P7667, DOI 10.1073/pnas.86.20.7667; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; COCHRANE CG, 1982, ADV IMMUNOL, V33, P241, DOI 10.1016/S0065-2776(08)60837-8; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON NL, 1983, J BIOL CHEM, V258, P2238; ESMON NL, 1982, J BIOL CHEM, V257, P859; FOSTER D, 1984, P NATL ACAD SCI-BIOL, V81, P4766, DOI 10.1073/pnas.81.15.4766; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FUJIKAWA K, 1981, METHOD ENZYMOL, V80, P198; FUJIKAWA K, 1989, METABOLIC BASIS INHE, V2, P2189; GRIEP MA, 1985, BIOCHEMISTRY-US, V24, P4124, DOI 10.1021/bi00336a047; HOJIMA Y, 1980, THROMB RES, V20, P149, DOI 10.1016/0049-3848(80)90381-3; KATO H, 1981, METHOD ENZYMOL, V80, P172; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P959, DOI 10.1021/bi00403a018; MEIJERS JCM, 1988, REGULATION BLOOD COA, P93; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; RAPAPORT SI, 1961, BLOOD, V18, P149, DOI 10.1182/blood.V18.2.149.149; Ratnoff O D, 1979, Curr Top Hematol, V2, P1; SAITO H, 1987, SEMIN THROMB HEMOST, V13, P36, DOI 10.1055/s-2007-1003474; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SILVERBERG M, 1980, J BIOL CHEM, V255, P7281; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; TANS G, 1987, J BIOL CHEM, V262, P11308; TANS G, 1983, J BIOL CHEM, V258, P8215; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	39	359	367	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7353	7358						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019570				2022-12-25	WOS:A1991FJ34200009
J	ANDREANI, CL; PAYNE, DW; PACKMAN, JN; RESNICK, CE; HURWITZ, A; ADASHI, EY				ANDREANI, CL; PAYNE, DW; PACKMAN, JN; RESNICK, CE; HURWITZ, A; ADASHI, EY			CYTOKINE-MEDIATED REGULATION OF OVARIAN-FUNCTION - TUMOR-NECROSIS-FACTOR-ALPHA INHIBITS GONADOTROPIN-SUPPORTED OVARIAN ANDROGEN BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT GRANULOSA-CELLS; MACROPHAGES	Resident ovarian macrophages have been implicated in the regulation of ovarian function, presumably through local paracrine secretion of regulatory molecules (i.e. cytokines). One such macrophage product, tumor necrosis factor (TNF)-alpha, has been shown to attenuate the gonadotropin-dependent differentiation of the somatic ovarian (estrogen-producing) granulosa cell. This study examines the possibility that TNF-alpha may also regulate the adjacent androgen-producing theca interstitial cell. The basal accumulation of androsterone (the major androgenic steroid), synthesized by whole ovarian dispersates from immature rats, remained unchanged following treatment with TNF-alpha (30 ng/ml) alone. In contrast, concurrent treatment with increasing concentrations of TNF-alpha (0.03-30 ng/ml), yielded dose-dependent inhibition of the human chorionic gonadotropin (1 ng/ml)-stimulated accumulation of androsterone. This reversible and immunoneutralizable effect of TNF-alpha was characterized by a minimal effective dose of 0.1 ng/ml, a median inhibitory dose of 0.9 ng/ml, a maximal inhibitory effect of 90%, and a minimal time requirement of less-than-or-equal-to 48 h. Comparable results were obtained when using highly purified theca interstitial cells, thereby indicating that TNF-alpha is capable of exerting a direct inhibitory effect at the level of the ovarian androgen-producing cell. TNF-alpha action was not accounted for by alterations in the plated viable cell mass. Instead, treatment with TNF-alpha resulted in significant inhibition of the human chorionic gonadotropin-supported accumulation of cAMP, the putative second messenger of gonadotropin hormonal action. TNF-alpha action at sites distal to cAMP generation was associated with profound inhibition of the conversion of the [H-3]pregnanolone (3-alpha-hydroxy,5-alpha-pregnane-20-one) and [H-3]17-alpha-hydroxypregnanolone (3-alpha, 17-alpha-dihydroxy,5-alpha-pregnane-20-one) substrates to androsterone, suggesting stimulation of 20-alpha-hydroxysteroid dehydrogenase activity, inhibition of 17-alpha-hydroxylase/17:20 lyase activity, or both. Taken together, these findings indicate that TNF-alpha, acting at relatively low concentrations, is capable of inhibiting gonadotropin-supported ovarian androgen biosynthesis by selectively modulating the activity of relevant key steroidogenic enzymes. As such, these observations suggest that the theca interstitial cell is a site of TNF-alpha reception and action and the TNF-alpha, possibly of resident ovarian macrophage origin, may partake in the regulation of ovarian androgen production, an effect due in part to inhibition of the activity of the key steroidogenic enzymes 17-alpha-hydroxylase/17:20 lyase.	UNIV MARYLAND, SCH MED,DEPT OBSTET & GYNECOL, DIV REPROD ENDOCRINOL,405 W REDWOOD ST, 3RD FLOOR, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019998] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-00697, HD-19998] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADASHI EY, 1990, AM J OBSTET GYNECOL, V162, P889, DOI 10.1016/0002-9378(90)91289-O; ADASHI EY, 1989, J BIOL CHEM, V264, P11591; ADASHI EY, 1989, ENDOCRINOLOGY, V124, P2043; BULMER D, 1964, J ANAT, V98, P313; DARBON JM, 1989, BIOCHEM BIOPH RES CO, V163, P1038, DOI 10.1016/0006-291X(89)92326-7; EMOTO N, 1988, BIOCHEM BIOPH RES CO, V153, P792, DOI 10.1016/S0006-291X(88)81165-3; GOLDRING NB, 1985, J BIOL CHEM, V260, P913; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; HALME J, 1985, J CLIN ENDOCR METAB, V61, P912, DOI 10.1210/jcem-61-5-912; HERNANDEZ ER, 1988, ENDOCRINOLOGY, V122, P1603, DOI 10.1210/endo-122-4-1603; HUME DA, 1984, P NATL ACAD SCI-BIOL, V81, P4174, DOI 10.1073/pnas.81.13.4174; KIRSCH TM, 1981, BIOL REPROD, V25, P629, DOI 10.1095/biolreprod25.3.629; KIRSCH TM, 1983, ENDOCRINOLOGY, V113, P1910, DOI 10.1210/endo-113-5-1910; MAGOFFIN DA, 1988, ENDOCRINOLOGY, V122, P2345, DOI 10.1210/endo-122-5-2345; PAYNE DW, 1985, J BIOL CHEM, V260, P3648; ROBY KF, 1989, SERONO SYMP, P273; ROBY KF, 1988, ENDOCRINOLOGY, V123, P2952, DOI 10.1210/endo-123-6-2952; ROBY KF, 1990, ENDOCRINOLOGY, V126, P2711, DOI 10.1210/endo-126-5-2711; ZOLTI M, 1990, FEBS LETT, V261, P253, DOI 10.1016/0014-5793(90)80565-Z	19	97	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6761	6766						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016291				2022-12-25	WOS:A1991FG72700021
J	ISHII, Y; LEHRER, SS				ISHII, Y; LEHRER, SS			2-SITE ATTACHMENT OF TROPONIN TO PYRENE-LABELED TROPOMYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; THIN FILAMENT; EXCIMER FLUORESCENCE; ACTIN INTERACTIONS; ALPHA-TROPOMYOSIN; T FRAGMENTS; BINDING; CONTRACTION; COMPONENTS; PROBE	The interaction of troponin (a complex of troponin T, troponin I, and troponin C) with tropomyosin (Tm) was studied using the fluorescence of pyrene-labeled Tm. Fluorescence titrations showed that an increase in salt concentration not only decreased the binding constant of troponin to Tm but also decreased the magnitude of the total pyrene fluorescence change. This indicates that the interaction of the part of troponin (TnT2) with the middle of Tm near Cys-190 is weakened at high ionic strength, while the other part (TnT1) maintains its binding with the C-terminal region of Tm. The temperature dependence of the pyrene excimer fluorescence of Tm showed that troponin stabilized the whole Tm molecule with much less effect on the stability of the middle region where the TnT2 binds. TnT1, the N-terminal chymotryptic fragment of troponin T (TnT), stabilized Tm in a similar manner to troponin by inhibiting dissociation of Tm chains in the main unfolding transition. Thus, these data indicate a loose interaction of the TnT2 part of troponin with the region of Tm near Cys-190 and a tight interaction of the TnT1 part with the C-terminal region of Tm. TnT alone interacted more strongly with Tm near Cys-190 than when in the troponin complex. This was indicated by the following observations in the Tm.TnT complex compared to the Tm.troponin complex: (i) a more hydrophobic environment of pyrene at Cys-190 of Tm; (ii) stabilization against the local unfolding of Tm near Cys-190; (iii) more fluorescence resonance energy transfer between Tm and TnT. These studies indicate a loose and flexible interaction of troponin with the middle region of Tm which may be important in Ca2+ regulation by troponin.Tm.	HARVARD UNIV,DEPT NEUROL,CAMBRIDGE,MA 02138	Harvard University	ISHII, Y (corresponding author), BOSTON BIOMED RES INST,DEPT MUSCLE RES,20 STANIFORD ST,BOSTON,MA 02114, USA.		Lehrer, Sherwin/ABF-7282-2021		NHLBI NIH HHS [HL-22461] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022461] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; BETTERIDGE DR, 1983, J MOL BIOL, V167, P481, DOI 10.1016/S0022-2836(83)80346-5; BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; BURTNICK LD, 1986, BIOCHEMISTRY-US, V25, P3875, DOI 10.1021/bi00361a020; BURTNICK LD, 1988, ARCH BIOCHEM BIOPHYS, V266, P622, DOI 10.1016/0003-9861(88)90295-0; CARR HJ, 1988, J MUSCLE RES CELL M, V9, P384, DOI 10.1007/BF01774065; EBASHI S, 1971, J BIOCHEM, V69, P441, DOI 10.1093/oxfordjournals.jbchem.a129486; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GRACEFFA P, 1980, J BIOL CHEM, V255, P1296; GREASER ML, 1973, J BIOL CHEM, V248, P2125; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; INGRAHAM RH, 1985, BIOCHEMISTRY-US, V24, P5221, DOI 10.1021/bi00340a040; ISHII Y, 1985, BIOCHEMISTRY-US, V24, P6631, DOI 10.1021/bi00344a050; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; ISHII Y, 1986, BIOPHYS J, V50, P75, DOI 10.1016/S0006-3495(86)83440-3; LAMKIN M, 1983, BIOCHEMISTRY-US, V22, P3053, DOI 10.1021/bi00282a005; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LEHRER SS, 1978, J MOL BIOL, V118, P209, DOI 10.1016/0022-2836(78)90413-8; LEHRER SS, 1989, FLUORESCENCE BIOMOLE, P423; LIN TI, 1983, BIOCHEM BIOPH RES CO, V114, P447, DOI 10.1016/0006-291X(83)90800-8; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MANI RS, 1974, BIOCHEMISTRY-US, V13, P5003, DOI 10.1021/bi00721a021; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; POTEKHIN SA, 1982, J MOL BIOL, V159, P519, DOI 10.1016/0022-2836(82)90299-6; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; TANOKURA M, 1984, J BIOCHEM, V95, P1417, DOI 10.1093/oxfordjournals.jbchem.a134749; TANOKURA M, 1983, J BIOCHEM, V93, P331, DOI 10.1093/oxfordjournals.jbchem.a134185; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; TAO T, 1979, BIOCHEMISTRY-US, V18, P2759, DOI 10.1021/bi00580a011; UENO H, 1984, BIOCHEMISTRY-US, V23, P4791, DOI 10.1021/bi00315a040; UENO H, 1978, J BIOCHEM-TOKYO, V84, P1009, DOI 10.1093/oxfordjournals.jbchem.a132182; VANEERD JP, 1973, BIOCHEMISTRY-US, V12, P4972, DOI 10.1021/bi00748a024; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WOODS EF, 1976, AUST J BIOL SCI, V29, P405, DOI 10.1071/BI9760405; YUKIOKA S, 1985, MACROMOLECULES, V18, P1083, DOI 10.1021/ma00148a006; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	45	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6894	6903						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016303				2022-12-25	WOS:A1991FG72700042
J	SERDA, RE; HENZL, MT				SERDA, RE; HENZL, MT			METAL ION-BINDING PROPERTIES OF AVIAN THYMIC HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN-CONTAINING PARVALBUMIN; CALCIUM-BINDING; SKELETAL-MUSCLE; TUMOR PROTEIN; RAT ONCOMODULIN; ENERGY-TRANSFER; STOPPED-FLOW; LUMINESCENCE; CALMODULIN; LOCALIZATION	Lanthanide ion luminescence studies and 45Ca2+(-) binding measurements were used to study the metal ion-binding properties of avian thymic hormone. The procedure used to isolate the protein-involving heat-treatment at 80-degrees-C, trichloroacetic acid precipitation,DEAE-agarose chromatography, and gel filtration-affords material that is deemed homogeneous by sodium dodecyl sulfate-polyacrylamide gel electrophoresis as well as the absence of a detectable tryptophan signal in the fluorescence emission spectrum. Avian thymic hormone exhibits a pI = 4.35 when subjected to isoelectric focusing through polyacrylamide gels. The two ion-binding sites are indistinguishable in their interactions with Ca2+ and Mg2+, displaying K(Ca) = 8 nM and K(Mg) = 68-mu-M. The Eu3+ 7F0 --> 5D0 excitation spectrum at pH 6 displays a peak at 5795.4 angstrom, with a shoulder at 5792.8 angstrom and is replaced at higher pH values by a broader spectrum with a maximum at 5784.8 angstrom and a shoulder at 5777.1 angstrom. The pK(a) governing this spectral interconversion is 8.21. All of these properties are very similar to those observed with other parvalbumins. However, polyclonal antibodies to avian thymic hormone do not cross-react with the parvalbumin from chicken leg muscle, as judged by Western blot analysis-further evidence that avian thymic hormone and the muscle-associated chicken parvalbumin are indeed distinct proteins.	NEW MEXICO STATE UNIV, DEPT CHEM, LAS CRUCES, NM 88003 USA	New Mexico State University								BARGER B, 1990, IN PRESS THYMUS; BERCHTOLD MW, 1982, EUR J BIOCHEM, V127, P381, DOI 10.1111/j.1432-1033.1982.tb06883.x; BERCHTOLD MW, 1982, BIOCHEMISTRY-US, V21, P6552, DOI 10.1021/bi00268a035; BREEN PJ, 1985, BIOCHEMISTRY-US, V24, P4991, DOI 10.1021/bi00340a005; BREEN PJ, 1985, BIOCHEMISTRY-US, V24, P4997, DOI 10.1021/bi00340a006; BREWER JM, 1989, BIOCHEM BIOPH RES CO, V160, P1155, DOI 10.1016/S0006-291X(89)80124-X; BREWER JM, 1990, FASEB J, V4, pA1828; BREWER LM, 1987, PLACENTA, V8, P351, DOI 10.1016/0143-4004(87)90063-4; BREWER LM, 1985, DEV BIOL, V112, P49, DOI 10.1016/0012-1606(85)90117-4; BUTTERWORTH PH, 1967, ARCH BIOCHEM BIOPHYS, V118, P716, DOI 10.1016/0003-9861(67)90409-2; CAPONY JP, 1976, EUR J BIOCHEM, V70, P123, DOI 10.1111/j.1432-1033.1976.tb10963.x; CAVE A, 1979, BIOCHIMIE, V61, P755, DOI 10.1016/S0300-9084(79)80270-9; CELIO MR, 1986, SCIENCE, V231, P995, DOI 10.1126/science.3945815; CELIO MR, 1981, NATURE, V293, P300, DOI 10.1038/293300a0; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; CORSON DC, 1983, BIOCHEMISTRY-US, V22, P5882, DOI 10.1021/bi00294a030; COX JA, 1990, J BIOL CHEM, V265, P6633; DEHORROCKS W, 1981, J AM CHEM SOC, V103, P2856, DOI 10.1021/ja00400a061; DONATO H, 1974, BIOCHEMISTRY-US, V13, P4575, DOI 10.1021/bi00719a016; DURKIN JP, 1983, CANCER RES, V43, P5390; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENFIELD DL, 1975, P NATL ACAD SCI USA, V72, P1309, DOI 10.1073/pnas.72.4.1309; GILLEN MF, 1988, CANCER LETT, V40, P151, DOI 10.1016/0304-3835(88)90005-5; GILLIS JM, 1985, BIOCHIM BIOPHYS ACTA, V811, P97, DOI 10.1016/0304-4173(85)90016-3; GOODMAN M, 1979, J MOL EVOL, V13, P331, DOI 10.1007/BF01731373; HAIECH J, 1979, BIOCHEMISTRY-US, V18, P2752, DOI 10.1021/bi00580a010; HANER M, 1984, ANAL BIOCHEM, V138, P229, DOI 10.1016/0003-2697(84)90793-0; HAPAK RC, 1989, J BIOL CHEM, V264, P18751; HAPAK RC, 1989, THESIS NEW MEXICO ST; HEIZMANN CW, 1979, J BIOL CHEM, V254, P4296; HEIZMANN CW, 1982, P NATL ACAD SCI-BIOL, V79, P7243, DOI 10.1073/pnas.79.23.7243; HEIZMANN CW, 1989, CALCIUM BINDING PROT, P57; HENZL MT, 1985, J BIOL CHEM, V260, P8447; HENZL MT, 1986, BIOCHIM BIOPHYS ACTA, V872, P16, DOI 10.1016/0167-4838(86)90142-1; HENZL MT, 1988, J BIOL CHEM, V263, P10674; HOFMANN T, 1988, EUR J BIOCHEM, V172, P307, DOI 10.1111/j.1432-1033.1988.tb13888.x; HORROCKS WD, 1979, SCIENCE, V206, P1194, DOI 10.1126/science.505007; HORROCKS WD, 1981, ACCOUNTS CHEM RES, V14, P384, DOI 10.1021/ar00072a004; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1980, CALCIUM CELL FUNCTIO, V1, P59; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lyle S.J., 1963, TALANTA, V10, P1177, DOI [DOI 10.1016/0039-9140(63)80170-8, 10.1016/0039-9140(63)80170-8]; MACMANUS JP, 1982, ONCODEV BIOL MED, V3, P79; MACMANUS JP, 1984, BIOCHEM J, V220, P261, DOI 10.1042/bj2200261; MACMANUS JP, 1984, CANCER LETT, V21, P309, DOI 10.1016/0304-3835(84)90010-7; MACMANUS JP, 1979, CANCER RES, V39, P3000; MACMANUS JP, 1985, CANCER LETT, V27, P145, DOI 10.1016/0304-3835(85)90103-X; MACMANUS JP, 1983, CALCIUM CELL FUNCTIO, V4, P411; MARTIN RB, 1983, CALCIUM BIOL, P237; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEANS AR, 1982, PHYSIOL REV, V62, P1, DOI 10.1152/physrev.1982.62.1.1; MOESCHLER HJ, 1980, EUR J BIOCHEM, V111, P73; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULQUEEN P, 1985, BIOCHEMISTRY-US, V24, P6639, DOI 10.1021/bi00344a051; MURTHY KK, 1984, THYMUS, V6, P43; MURTHY KK, 1984, CHEM REGULATION IMMU, P481; NELSON DJ, 1977, BIOINORG CHEM, V7, P325, DOI 10.1016/S0006-3061(00)81031-5; PALMISANO WA, 1990, BIOCHEM BIOPH RES CO, V167, P1286, DOI 10.1016/0006-291X(90)90663-8; PALMISANO WA, 1990, J BIOL CHEM, V265, P14450; PECHERE JF, 1971, BIOCHIM BIOPHYS ACTA, V236, P391, DOI 10.1016/0005-2795(71)90220-0; Potter J.D., 1977, CALCIUM BINDING PROT, P239; RHEE MJ, 1981, BIOCHEMISTRY-US, V20, P3328, DOI 10.1021/bi00515a002; RINALDI ML, 1982, BIOCHEMISTRY-US, V21, P4805, DOI 10.1021/bi00262a044; SIMONIDES WS, 1989, BIOCHIM BIOPHYS ACTA, V998, P137, DOI 10.1016/0167-4838(89)90265-3; SOMMER EW, 1989, FEBS LETT, V257, P307, DOI 10.1016/0014-5793(89)81558-3; SOWADSKI J, 1978, J MOL BIOL, V124, P123, DOI 10.1016/0022-2836(78)90151-1; STREHLER EE, 1977, FEBS LETT, V78, P127, DOI 10.1016/0014-5793(77)80289-5; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUHLFAUTH I, 1984, P NATL ACAD SCI-BIOL, V81, P4814, DOI 10.1073/pnas.81.15.4814; TREVINO CL, 1990, J BIOL CHEM, V265, P9694; WANG CLA, 1981, BIOCHEMISTRY-US, V20, P2439, DOI 10.1021/bi00512a012; WANG CLA, 1982, EUR J BIOCHEM, V124, P7, DOI 10.1111/j.1432-1033.1982.tb05900.x; WILLIAMS TC, 1986, BIOCHEMISTRY-US, V25, P1835, DOI 10.1021/bi00355a057; Wnuk W., 1982, CALCIUM CELL FUNCTIO, V2, P243	77	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7291	7299						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016329				2022-12-25	WOS:A1991FG72700100
J	MASUMOTO, N; TASAKA, K; KASAHARA, K; MIYAKE, A; TANIZAWA, O				MASUMOTO, N; TASAKA, K; KASAHARA, K; MIYAKE, A; TANIZAWA, O			PURIFICATION OF GONADOTROPES AND INTRACELLULAR FREE CALCIUM OSCILLATION - EFFECTS OF GONADOTROPIN-RELEASING-HORMONE AND INTERLEUKIN-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY CELLS; CA-2+ TRANSIENTS; INVITRO	The intracellular free calcium concentration ([Ca2+]i) in single gonadotropes was measured with a calcium-sensitive fluorescent dye indo-1 or fura-2 and a digital imaging fluorescence microscopic system to determine how interleukin-6 (IL-6) increases release of gonadotropins. IL-6 induced an increase in the basal [Ca2+]i or the amplitude of spontaneous oscillation of [Ca2+]i in gonadotropes in a mixed population. Gonadotropin-releasing hormone (Gn-RH) induced a biphasic increase in [Ca2+]i, a transient increase, and then a prolonged increase. These effects were inhibited by the absence of extracellular calcium or pretreatment with calcium channel blockers, cobalt or nifedipine. Next, purified gonadotropes were prepared by fluorescence-activated cell sorting and argon laser treatment of the cells. Gonadotropes labeled with anti-luteinizing hormone antibody were sorted by fluorescence-activated cell sorting and then cultured as monolayers for 24-48 h. In this way, gonadotropes were concentrated from 5-10% to 70-85% from whole pituitary cells. After relabeling with anti-luteinizing hormone antibody, 100% purified gonadotropes were obtained by killing other types of cells with an argon laser. Gonadotropin-releasing hormone induced almost the same responses of [Ca2+]i in the purified cell population as in the mixed cell population, but IL-6 did not affect [Ca2+]i in the purified gonadotropes. These results suggest that IL-6 affects calcium mobilization in gonadotropes indirectly via paracrine pathways.			MASUMOTO, N (corresponding author), OSAKA UNIV,SCH MED,DEPT OBSTET & GYNECOL,1-1-50 FUKUSHIMA,FUKUSHIMA KU,OSAKA 553,JAPAN.							CANONICO PL, 1985, ENDOCRINOLOGY, V116, P218, DOI 10.1210/endo-116-1-218; CROXTON TL, 1988, ENDOCRINOLOGY, V123, P1783, DOI 10.1210/endo-123-4-1783; DENEF C, 1982, INT REV CYTOL, V76, P225, DOI 10.1016/S0074-7696(08)61792-1; EDWARDS SA, 1983, MOL CELL ENDOCRINOL, V30, P21, DOI 10.1016/0303-7207(83)90198-3; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HOLL RW, 1988, J BIOL CHEM, V263, P9682; JIRIK FR, 1989, J IMMUNOL, V142, P144; JOHN PAS, 1986, ENDOCRINOLOGY, V119, P2783; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KISHIMOTO T, 1988, ANNU REV IMMUNOL, V6, P485, DOI 10.1146/annurev.iy.06.040188.002413; MASUMOTO N, 1990, J BIOL CHEM, V265, P22533; MOLLARD P, 1989, BIOCHEM BIOPH RES CO, V164, P1045, DOI 10.1016/0006-291X(89)91775-0; SCHINDLER M, 1985, CYTOMETRY, V6, P368, DOI 10.1002/cyto.990060415; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SPANGELO BL, 1989, ENDOCRINOLOGY, V125, P575, DOI 10.1210/endo-125-1-575; SPANGELO BL, 1990, ENDOCRINOLOGY, V126, P582, DOI 10.1210/endo-126-1-582; TASAKA K, 1991, OBSTET GYNECOL, V77, P101; TASAKA K, 1988, BIOCHEM BIOPH RES CO, V154, P398, DOI 10.1016/0006-291X(88)90699-7; THORNER MO, 1982, ENDOCRINOLOGY, V110, P1831, DOI 10.1210/endo-110-5-1831; VANKELECOM H, 1989, NEUROENDOCRINOLOGY, V49, P102, DOI 10.1159/000125097; WIER WG, 1987, SCIENCE, V235, P325, DOI 10.1126/science.3798114; YAMAGUCHI M, 1990, ACTA ENDOCRINOL-COP, V122, P201, DOI 10.1530/acta.0.1220201	23	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6485	6488						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007597				2022-12-25	WOS:A1991FE37300073
J	MUSTONEN, P; KINNUNEN, PKJ				MUSTONEN, P; KINNUNEN, PKJ			ACTIVATION OF PHOSPHOLIPASE-A2 BY ADRIAMYCIN INVITRO - ROLE OF DRUG-LIPID INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; NATURAL MEMBRANES; ARACHIDONIC-ACID; CYTO-TOXICITY; FATTY-ACIDS; CELLS; CARDIOLIPIN; PROSTAGLANDINS; PEROXIDATION; INHIBITION	To probe adriamycin-phospholipid interactions, the effects of this cytotoxin on the hydrolysis of a pyrene-labeled acidic alkyl-acyl phospholipid analog 1-octacosanyl-2-(6-pyren-1-yl)hexanoyl-sn-glycero-3-phosphatidylmethanol (C28-O-PHPM) by porcine pancreatic phospholipase A2 (PLA2) were studied. In the absence of added Ca2+ adriamycin caused a 3-4-fold activation of hydrolysis of this pyrenelipid whereas an inhibition of action of PLA2 on the corresponding phosphatidylcholine derivative C28-O-PHPC was observed. Under similar conditions adriamycin also enhanced the rate of hydrolysis of the pyrene-labeled diacyl lipid 1-palmitoyl - 2 - (pyren - 1 - yl)hexanoyl - sn - glycero - 3 - phosphatidylglycerol and inhibited the hydrolysis of PLA2 on the phosphatidylcholine derivative. Increasing calcium concentrations abolished the activating and most of the inhibitory effects of adriamycin with the above phospholipid substrates. Quenching of pyrene excimer fluorescence by adriamycin revealed efficient binding of the drug to acidic lipids. Addition of 1 mM calcium reduced fluorescence quenching by adriamycin maximally by approximately 90%. In comparison, quenching by adriamycin of pyrene-labeled phosphatidylcholine was much weaker and calcium had only an insignificant effect. Monolayer experiments at an air/water interface showed a rapid and surface pressure-dependent penetration of the drug into a film of C28-O-PHPM. Increase in surface pressure was reversed by 80% by the inclusion of 1 mM Ca2+ into the subphase. Penetration of adriamycin into a monolayer of C28-O-PHPC was much weaker. In agreement with earlier studies two types of binding of adriamycin to C28-O-PHPM are proposed.	UNIV HELSINKI,DEPT MED CHEM,SF-00100 HELSINKI 10,FINLAND	University of Helsinki								AUGER M, 1987, BIOCHEMISTRY-US, V26, P8513, DOI 10.1021/bi00400a003; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; CONSTANTINIDES PP, 1990, BIOPHYS CHEM, V35, P259, DOI 10.1016/0301-4622(90)80013-W; CONSTANTINIDES PP, 1986, J BIOL CHEM, V261, P196; DENNIS EA, 1987, BIO-TECHNOL, V5, P1294, DOI 10.1038/nbt1287-1294; Di MARCO A., 1963, TUMORI, V49, P235; DUPOUCEZANNE L, 1989, EUR J BIOCHEM, V181, P695, DOI 10.1111/j.1432-1033.1989.tb14779.x; EHRKE MJ, 1986, CANCER RES, V46, P54; FIALLO MML, 1986, BIOCHIM BIOPHYS ACTA, V854, P143; FULTON AM, 1987, J NATL CANCER I, V78, P735; GOLDMAN R, 1978, BIOCHIM BIOPHYS ACTA, V512, P254, DOI 10.1016/0005-2736(78)90251-1; GOODMAN J, 1977, BIOCHEM BIOPH RES CO, V77, P797, DOI 10.1016/S0006-291X(77)80048-X; GOORMAGHTIGH E, 1987, BIOCHEMISTRY-US, V26, P1789, DOI 10.1021/bi00380a043; GOORMAGHTIGH E, 1980, BIOCHIM BIOPHYS ACTA, V597, P1, DOI 10.1016/0005-2736(80)90145-5; GOORMAGHTIGH E, 1980, BIOCHEM PHARMACOL, V29, P3003, DOI 10.1016/0006-2952(80)90050-7; GOORMAGHTIGH E, 1990, BIOPHYS CHEM, V35, P247, DOI 10.1016/0301-4622(90)80012-V; GRIFFIN EA, 1986, BIOCHEMISTRY-US, V25, P7875, DOI 10.1021/bi00372a013; HALENDA SP, 1989, BIOCHEMISTRY-US, V28, P7356, DOI 10.1021/bi00444a031; HENRY N, 1985, BIOCHEMISTRY-US, V24, P7085, DOI 10.1021/bi00346a010; HONN KV, 1981, PROSTAG OTH LIPID M, V21, P833, DOI 10.1016/0090-6980(81)90240-9; HUART P, 1984, BIOCHIM BIOPHYS ACTA, V799, P199, DOI 10.1016/0304-4165(84)90296-4; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; JETT M, 1985, CANCER RES, V45, P4810; KARCZMAR GS, 1979, BIOCHIM BIOPHYS ACTA, V557, P306, DOI 10.1016/0005-2736(79)90329-8; KIGOSHI S, 1973, EXPERIENTIA, V29, P1408, DOI 10.1007/BF01922845; LEE AG, 1976, BIOCHIM BIOPHYS ACTA, V448, P34, DOI 10.1016/0005-2736(76)90074-2; LOTTA TI, 1990, CHEM PHYS LIPIDS, V52, P11, DOI 10.1016/0009-3084(90)90003-A; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MIMNAUGH EG, 1983, J PHARMACOL EXP THER, V226, P806; MIMNAUGH EG, 1985, BIOCHEM PHARMACOL, V34, P847, DOI 10.1016/0006-2952(85)90766-X; MIMNAUGH EG, 1985, CANCER RES, V45, P3296; MIMNAUGH EG, 1986, TOXICOL APPL PHARM, V61, P313; MURPHREE SA, 1981, BIOCHIM BIOPHYS ACTA, V649, P317, DOI 10.1016/0005-2736(81)90421-1; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHUCHI K, 1978, PROSTAG LEUKOTR ESS, V1, P433, DOI 10.1016/0161-4630(78)90114-3; OHUCHI K, 1978, PROSTAGLANDINS, V15, P723; OISHI K, 1988, J BIOL CHEM, V263, P6865; PALAYOOR ST, 1987, BIOCHEM BIOPH RES CO, V148, P718, DOI 10.1016/0006-291X(87)90935-1; POSADA J, 1989, CANCER RES, V49, P6634; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; SMABY JM, 1990, BIOPHYS J, V58, P195, DOI 10.1016/S0006-3495(90)82365-1; THUREN T, 1983, CHEM PHYS LIPIDS, V33, P283, DOI 10.1016/0009-3084(83)90079-8; THUREN T, 1984, BIOCHEMISTRY-US, V23, P5129, DOI 10.1021/bi00317a008; THUREN T, 1986, J MEMBRANE BIOL, V92, P1, DOI 10.1007/BF01869010; THUREN T, 1985, CLIN CHEM, V31, P714; THUREN T, 1990, CHEM PHYS LIPIDS, V53, P129, DOI 10.1016/0009-3084(90)90039-T; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; VANBOXTEL CJ, 1979, PHARMACOLOGY, V19, P5, DOI 10.1159/000137277; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; Verger R, 1980, Methods Enzymol, V64, P340; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WAITE M, 1987, PHOSPHOLIPASES HDB L, V5; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WISE BC, 1983, BIOCHEM PHARMACOL, V32, P1259, DOI 10.1016/0006-2952(83)90280-0	54	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6302	6307						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007582				2022-12-25	WOS:A1991FE37300046
J	SUN, SC; ASLING, B; FAYE, I				SUN, SC; ASLING, B; FAYE, I			ORGANIZATION AND EXPRESSION OF THE IMMUNORESPONSIVE LYSOZYME GENE IN THE GIANT SILK MOTH, HYALOPHORA-CECROPIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN LYSOZYME; CDNA SEQUENCES; DROSOPHILA; EVOLUTION; PROTEINS; PURIFICATION; HEMOLYMPH; IMMUNITY; LEADER	Lysozyme is one of the antibacterial proteins that are produced by the giant silk moth Hyalophora cecropia in response to bacterial infection or injury. As an essential step toward the understanding of the mechanisms involved in the immune response, we have isolated and characterized the lysozyme gene from Cecropia. The complete nucleotide sequence of the gene as well as the immediate flanking sequences have been determined. The gene includes three exons. Its first intron contains a repetitive sequence. In the evolutionary aspect, the Cecropia lysozyme gene and two vertebrate lysozyme genes have been found to maintain a similar organization pattern of exons. The lysozyme gene has been found to be strongly induced by lipopolysaccharides and a phorbol ester as well as bacteria. In the induction by bacteria, the lysozyme transcript appears at about 2 h, reaches to the maximum level at about 24 h, and then declines. Comparison of the 5'-flanking sequences with several other genes involved in the immune response of H. cecropia and Drosophila melanogaster revealed a kappa-B-like consensus sequence. This sequence is specifically recognized by a nuclear protein from the induced pupa.			SUN, SC (corresponding author), UNIV STOCKHOLM, DEPT MICROBIOL, S-10691 STOCKHOLM, SWEDEN.							BALDACCI P, 1981, NUCLEIC ACIDS RES, V9, P3575, DOI 10.1093/nar/9.15.3575; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; ENGSTROM A, 1985, EMBO J, V4, P2119, DOI 10.1002/j.1460-2075.1985.tb03901.x; FRITTON HP, 1983, NUCLEIC ACIDS RES, V11, P3467, DOI 10.1093/nar/11.11.3467; GARBER RL, 1983, EMBO J, V2, P2027, DOI 10.1002/j.1460-2075.1983.tb01696.x; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GILMAN M, 1987, CURRENT PROTOCOLS MO, P471; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HALL L, 1987, BIOCHEM J, V242, P735, DOI 10.1042/bj2420735; HULTMARK D, 1980, EUR J BIOCHEM, V106, P7, DOI 10.1111/j.1432-1033.1980.tb05991.x; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; IRWIN DM, 1989, J BIOL CHEM, V264, P11387; IRWIN DM, 1990, J BIOL CHEM, V265, P4944; JOLLES J, 1979, J MOL EVOL, V14, P267, DOI 10.1007/BF01732494; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI PC, 1988, P NATL ACAD SCI USA, V85, P6227; Maniatis T., 1982, MOL CLONING LAB MANU; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; POWNING RF, 1973, COMP BIOCHEM PHYSIOL, V45, P669, DOI 10.1016/0305-0491(73)90205-8; POWNING RF, 1976, COMP BIOCHEM PHYS B, V55, P221, DOI 10.1016/0305-0491(76)90234-0; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER PM, 1985, INSECT BIOCHEM, V15, P463, DOI 10.1016/0020-1790(85)90058-7; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SNYDER M, 1982, CELL, V29, P1027, DOI 10.1016/0092-8674(82)90466-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUN SC, 1991, IN PRESS EUR J BIOCH; TRENCZEK T, 1988, INSECT BIOCHEM, V18, P299, DOI 10.1016/0020-1790(88)90095-9; XANTHOPOULOS KG, 1988, EUR J BIOCHEM, V172, P371, DOI 10.1111/j.1432-1033.1988.tb13896.x	37	82	88	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6644	6649						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007608				2022-12-25	WOS:A1991FE37300094
J	BULLESBACH, EE; SCHWABE, C				BULLESBACH, EE; SCHWABE, C			TOTAL SYNTHESIS OF HUMAN RELAXIN AND HUMAN RELAXIN DERIVATIVES BY SOLID-PHASE PEPTIDE-SYNTHESIS AND SITE-DIRECTED CHAIN COMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETAMIDOMETHYL-CYSTEINE-PEPTIDES; S-TRITYL-CYSTEINE; HUMAN INSULIN; CIRCULAR-DICHROISM; RECEPTOR-BINDING; BIOLOGICAL-ACTIVITY; IODINE OXIDATION; RAT RELAXIN; BOND; HOMOLOGY	Human relaxin, a two-chain protein hormone, was synthesized by solid-phase peptide synthesis in combination with a novel thiol-protecting group strategy whereby the three disulfide bonds could be synthesized sequentially and without error. The final product was shown to be homogeneous by reversed-phase high performance liquid chromatography and electrophoresis and had the correct amino acid composition and sequence. Tryptic digestion and peptide mapping of the synthetic relaxin by reversed-phase high performance liquid chromatography resulted in a pattern identical with that produced by standard tryptic relaxin fragments synthetized by different methods. Three human relaxin derivatives containing oxidized methionine, formyltryptophan, and bis[Bl3,Bl7-citrulline]-relaxin, were produced and their biological activity and structural similarity to human relaxin was assessed. All derivatives, except those containing modified tryptophan residues, showed indistinguishable circular dichroic spectra, indicating that the modifications did not cause significant structural changes. However, only human relaxin and the tryptophan- and methionine-protected relaxin derivatives showed bioactivity. The derivative in which the two arginines in positions B13 and B17 had been replaced by the uncharged isosteric amino acid citrulline were biologically inactive. This observation confirms preliminary studies (Bullesbach, E. E. and Schwabe, C. (1988) Int. J. Pept. Protein Res. 32, 361-367) that suggested that these two conserved arginines located in the midregion of the relaxin B chain are essential for the function of the hormone.			BULLESBACH, EE (corresponding author), MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,CHARLESTON,SC 29425, USA.				NICHD NIH HHS [HD 23877] Funding Source: Medline; NIDDK NIH HHS [DK 38348] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038348] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler A J, 1973, Methods Enzymol, V27, P675; ALBERICIO F, 1989, INT J PEPT PROT RES, V34, P124; Atherton E., 1990, SOLID PHASE PEPTIDE; BARANY G, 1980, PEPTIDES, P1; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; BERNATOWICZ MS, 1986, INT J PEPT PROT RES, V28, P107; BEYERMAN HC, 1979, 6TH AM PEPT S, P333; BLUNDELL TL, 1980, NATURE, V287, P781, DOI 10.1038/287781a0; BULLESBACH EE, 1985, BIOCHEMISTRY-US, V24, P7717, DOI 10.1021/bi00347a032; BULLESBACH EE, 1980, H-S Z PHYSIOL CHEM, V361, P865, DOI 10.1515/bchm2.1980.361.1.865; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; CANOVADAVIS E, 1990, J CHROMATOGR, V508, P81, DOI 10.1016/S0021-9673(00)91242-1; CHU YC, 1987, BIOCHEMISTRY-US, V26, P6966, DOI 10.1021/bi00396a016; Cooper G J, 1989, Prog Growth Factor Res, V1, P99, DOI 10.1016/0955-2235(89)90004-5; DODSON GG, 1982, INT J BIOL MACROMOL, V4, P399, DOI 10.1016/0141-8130(82)90083-6; DU YC, 1982, INT J PEPT PROT RES, V20, P47; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERRAIOLO BL, 1989, ENDOCRINOLOGY, V125, P2922, DOI 10.1210/endo-125-6-2922; GATTNER HG, 1981, H-S Z PHYSIOL CHEM, V362, P1043, DOI 10.1515/bchm2.1981.362.2.1043; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; ISAACS N, 1978, NATURE, V271, P278, DOI 10.1038/271278a0; IWAI M, 1989, J BIOCHEM-TOKYO, V106, P949, DOI 10.1093/oxfordjournals.jbchem.a122978; IZEBOUD E, 1978, RECL TRAV CHIM PAY B, V97, P1; JHOTI H, 1987, FEBS LETT, V219, P419, DOI 10.1016/0014-5793(87)80264-8; JOHN MJ, 1981, ENDOCRINOLOGY, V108, P726, DOI 10.1210/endo-108-2-726; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KAMBER B, 1980, HELV CHIM ACTA, V63, P899, DOI 10.1002/hlca.19800630418; KEMP BE, 1984, VITAM HORM, V41, P79; LANDINI D, 1970, J AM CHEM SOC, V92, P7168; MacLennan A H, 1983, Clin Reprod Fertil, V2, P77; MARKUSSEN J, 1988, PROTEIN ENG, V2, P157, DOI 10.1093/protein/2.2.157; MORODER L, 1976, H-S Z PHYSIOL CHEM, V357, P1651, DOI 10.1515/bchm2.1976.357.2.1651; NAGASAWA H, 1987, PEPTIDE CHEM, P123; PREVIERO A, 1967, BIOCHIM BIOPHYS ACTA, V147, P453, DOI 10.1016/0005-2795(67)90005-0; RAWITCH AB, 1980, INT J BIOCHEM, V11, P357, DOI 10.1016/0020-711X(80)90306-7; ROSEN O, 1990, INT J PEPT PROT RES, V35, P545; RYLE AP, 1955, BIOCHEM J, V60, P541, DOI 10.1042/bj0600541; SAROSI P, 1983, ENDOCRINOLOGY, V112, P1860, DOI 10.1210/endo-112-5-1860; Savige W E, 1977, Methods Enzymol, V47, P453; SCHWABE C, 1977, SCIENCE, V197, P914, DOI 10.1126/science.887933; SCHWABE C, 1978, BIOCHEM BIOPH RES CO, V84, P374, DOI 10.1016/0006-291X(78)90180-8; Schwabe C, 1978, Recent Prog Horm Res, V34, P123; SCHWABE C, 1990, COMP BIOCHEM PHYS B, V96, P15, DOI 10.1016/0305-0491(90)90335-Q; SHERWOOD OD, 1979, ENDOCRINOLOGY, V104, P886, DOI 10.1210/endo-104-4-886; SIEBER P, 1978, H-S Z PHYSIOL CHEM, V359, P113; SIEBER P, 1977, HELV CHIM ACTA, V60, P27, DOI 10.1002/hlca.19770600105; SIEBER P, 1980, HELV CHIM ACTA, V63, P2358, DOI 10.1002/hlca.19800630826; SIEBER P, 1974, HELV CHIM ACTA, V57, P2617, DOI 10.1002/hlca.19740570839; SMIT AB, 1988, NATURE, V331, P535, DOI 10.1038/331535a0; STEINETZ BG, 1960, ENDOCRINOLOGY, V67, P102, DOI 10.1210/endo-67-1-102; STEWART DR, 1986, ENDOCRINOLOGY, V119, P1093, DOI 10.1210/endo-119-3-1093; Stewart JM, 1984, SOLID PHASE PEPTIDE; STULTS JT, 1990, BIOMED ENVIRON MASS, V19, P655, DOI 10.1002/bms.1200191105; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; WEISS G, 1989, BIOL REPROD, V40, P197, DOI 10.1095/biolreprod40.2.197; WEISS G, 1984, ANNU REV PHYSIOL, V46, P43; WOOD SP, 1975, EUR J BIOCHEM, V55, P531, DOI 10.1111/j.1432-1033.1975.tb02190.x	57	95	109	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10754	10761						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040595				2022-12-25	WOS:A1991FQ77400011
J	LI, YT; CARTER, BZ; RAO, BNN; SCHWEINGRUBER, H; LI, SC				LI, YT; CARTER, BZ; RAO, BNN; SCHWEINGRUBER, H; LI, SC			SYNTHESIS OF NEOGLYCOCONJUGATES USING OLIGOSACCHARIDE TRANSFERRING ACTIVITY OF CERAMIDE GLYCANASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LUMBRICUS-TERRESTRIS; TRANSGLYCOSYLATION; EARTHWORM; LEECH	Ceramide glycanase (CGase) isolated from the leech Macrobdella decora was found to transfer the oligosaccharide en bloc from various glycosphingolipids to suitable acceptors. For example, CGase transferred the intact II3NeuAcGgOse4 from G(M1) to 4-phenyl-1-butanol, 1,8-octanediol and various 1-alkanols having a chain length of six or more carbons. Among various 1-alkanols, 1-octanol was found to be the best acceptor. In an incubation mixture of 50-mu-l containing 30 nmol of G(M1), 50-mu-g of sodium cholate, 20-mu-l of 1-octanol, and 0.1 unit of CGase, the ratio between hydrolysis and transglycosylation was approximately 3:1. Negative fast atom bombardment-mass spectral analysis of the enzymatically synthesized octyl-II3NeuAcGgOse4 showed a mass ion at m/z 1109.7 for the parent ion, consistent with its expected mass. NMR analysis of the enzymatically synthesized octyl-II3NeuAcGgOse4 showed that the Glc residue is linked to the octanol through a beta-linkage. Vicinal coupling constants of the ring protons of the sugar residues indicate that their pyranose ring geometries are not affected by the transferase activity. CGase also transferred the oligosaccharide from G(M1) to CF3CO-NH(CH2)5CH2OH, (CH3)3CO-CO-NH(CH2)5CH2OH, (HOCH2)3C-NHCO-(CH2)4-COOMe, CH2 = CH-(CH2)7CH2OH and 1,2:3,4-di-O-isopropylidene-D-galactopyranose. The oligosaccharide transferring reaction carried out by CGase should become useful for the synthesis of neoglycoconjugates to study the biological functions expressed by glycan chains in glycosphingolipids.	GLYCOMED INC, ALAMEDA, CA 94501 USA		LI, YT (corresponding author), TULANE UNIV, SCH MED, DEPT BIOCHEM, 1430 TUANE AVE, NEW ORLEANS, LA 70112 USA.				NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDALES RM, 1989, J BIOL CHEM, V264, P19893; COTE GL, 1990, GLYCOCONJUGATE J, V7, P145, DOI 10.1007/BF01050377; EDELMAN J, 1956, ADV ENZYMOL REL S BI, V17, P189; FOLCH J, 1957, J BIOL CHEM, V226, P497; HARRIS G, 1954, CHEM IND-LONDON, P249; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; KITAMIKADO M, 1981, J BIOL CHEM, V256, P3906; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V96, P1156, DOI 10.1016/0006-291X(80)90073-X; LI SC, 1986, BIOCHEM BIOPH RES CO, V141, P346, DOI 10.1016/S0006-291X(86)80375-8; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; LI YT, 1989, METHOD ENZYMOL, V179, P479; ONG RL, 1986, ARCH BIOCHEM BIOPHYS, V245, P157, DOI 10.1016/0003-9861(86)90200-6; ZHOU B, 1989, J BIOL CHEM, V264, P12272	14	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10723	10726						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	2040590				2022-12-25	WOS:A1991FQ77400004
J	LIOCHEV, SI; FRIDOVICH, I				LIOCHEV, SI; FRIDOVICH, I			EFFECTS OF OVERPRODUCTION OF SUPEROXIDE-DISMUTASE ON THE TOXICITY OF PARAQUAT TOWARD ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE SODA; DEFENSE; COPPER; MUTANTS; CLONING; REGULON; AGENTS; K-12	Gross overproduction of the manganese-containing superoxide dismutase in Escherichia coli, by virtue of a multicopy plasmid bearing the sodA gene, decreases enumeration on paraquat-containing agar plates. This reflects growth inhibition, not lethality, since cells on these plates can be rescued by exclusion of dioxygen. Growth in liquid medium revealed that the control strain adapted to growth in the presence of paraquat more rapidly than did the overproducer. Glucose-6-phosphate dehydrogenase, taken as a representative of the superoxide-inducible soxR regulon, was induced during exposure to paraquat to a much greater extent in the control than in the superoxide dismutase-over-producing strain. These results support the view that overproduction of superoxide dismutase interferes with induction of the soxR regulon and thus prevents a balanced adaptation to the multiple aspects of the toxicity of aerobic paraquat.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University								ASNIS RE, 1955, J BIOL CHEM, V213, P77; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BLOCH CA, 1986, J BACTERIOL, V168, P795, DOI 10.1128/jb.168.2.795-798.1986; BOWLER C, 1990, J BACTERIOL, V172, P1539, DOI 10.1128/jb.172.3.1539-1546.1990; BOWLER C, 1989, P NATL ACAD SCI USA, V86, P3237, DOI 10.1073/pnas.86.9.3237; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; HASSAN HM, 1989, ADV GENET, V26, P65; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KAO SM, 1985, J BIOL CHEM, V260, P478; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MINAKAMI H, 1990, J BACTERIOL, V172, P691, DOI 10.1128/jb.172.2.691-695.1990; NATVIG DO, 1987, J BIOL CHEM, V262, P14697; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; TOUATI D, 1989, FREE RADICAL RES COM, V8, P1, DOI 10.3109/10715768909087967; TOUATI D, 1983, J BACTERIOL, V155, P1078, DOI 10.1128/JB.155.3.1078-1087.1983; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990	22	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8747	8750						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026591				2022-12-25	WOS:A1991FM03800020
J	PAYNE, MA; COOK, PF				PAYNE, MA; COOK, PF			APPENDIX - DERIVATION OF THE RATE-EQUATION FOR COMPETITIVE DOUBLE ACTIVATION BY EFFECTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									TEXAS HEART INST,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77025	Texas Heart Institute	PAYNE, MA (corresponding author), TEXAS HEART INST,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77025, USA.				NIGMS NIH HHS [GM 37057, GM 36799] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036799, R01GM037057] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHA S, 1968, J BIOL CHEM, V243, P820; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010	2	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8897	8898						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026601				2022-12-25	WOS:A1991FM03800039
J	SIMONET, WS; BUCAY, N; PITAS, RE; LAUER, SJ; TAYLOR, JM				SIMONET, WS; BUCAY, N; PITAS, RE; LAUER, SJ; TAYLOR, JM			MULTIPLE TISSUE-SPECIFIC ELEMENTS CONTROL THE APOLIPOPROTEIN E/C-I GENE LOCUS IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							E MESSENGER-RNA; CHOLESTEROL TRANSPORT; PERIPHERAL-TISSUES; A-I; EXPRESSION; PROTEIN; LIVER; SEQUENCE; CELLS	To investigate the mechanisms controlling tissue-specific expression of the human apolipoprotein (apo) E/C-I gene locus, human apoE and apoC-I gene constructs containing various lengths of the 5'-flanking or 3'-flanking region were used to create transgenic mice. Several essential tissue-specific regulatory elements were identified in the region between the apoE and the apoC-I genes, as well as in a distal domain found downstream of the apoC-I gene. Most notably, transcription of both the apoE and apoC-I genes in the liver, their major site of expression, required downstream regulatory elements, possibly located within a common regulatory domain more than 2 kilobases 3' of the apoC-I gene (about 14 kilobases downstream of the apoE gene promoter). In the region between the apoE and apoC-I genes, a single strong positive element directed apoE and apoC-I gene expression in the skin. The intergenic region also contained elements that stimulated apoE gene expression in the brain and silenced apoE gene expression only in the kidney. These results demonstrate that multiple independent regulatory elements control expression of the human apoE/C-I gene locus in various tissues. Transgenic mice expressing human apoC-I in the liver exhibited plasma triglyceride levels that were 2-3-fold higher than those in control mice, an effect not found when transgenic human apoE was produced. This result suggests that apoC-I may modulate the metabolism of triglyceride-rich lipoproteins.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94140	University of California System; University of California San Francisco	SIMONET, WS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,CARDIOVASC RES INST,GLADSTONE FDN LABS CARDIOVASC DIS,SAN FRANCISCO,CA 94140, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063, P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633, HL37063] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; DAS HK, 1985, J BIOL CHEM, V260, P6240; DRISCOLL DM, 1985, J BIOL CHEM, V260, P9031; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; GILMAN M, 1990, CURRENT PROTOCOLS MO; GORDON DA, 1989, J INVEST DERMATOL, V92, P96, DOI 10.1111/1523-1747.ep13071302; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAJACK RA, 1988, J CELL BIOL, V107, P1207, DOI 10.1083/jcb.107.3.1207; Maniatis T., 1982, MOL CLONING; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; PAIK YK, 1985, P NATL ACAD SCI USA, V82, P3445, DOI 10.1073/pnas.82.10.3445; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RALL SC, 1982, J BIOL CHEM, V257, P4171; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WALSH A, 1989, J BIOL CHEM, V264, P6488; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WERB Z, 1983, J BIOL CHEM, V258, P642; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x	27	119	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8651	8654						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	2026582				2022-12-25	WOS:A1991FM03800002
J	GOODWIN, LO; LEESMILLER, JP; LEONARD, MA; CHELEY, SB; HELFMAN, DM				GOODWIN, LO; LEESMILLER, JP; LEONARD, MA; CHELEY, SB; HELFMAN, DM			4 FIBROBLAST TROPOMYOSIN ISOFORMS ARE EXPRESSED FROM THE RAT ALPHA-TROPOMYOSIN GENE VIA ALTERNATIVE RNA SPLICING AND THE USE OF 2 PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; AMINO-ACID-SEQUENCE; TUMORIGENIC HUMAN-FIBROBLASTS; CHICKEN-EMBRYO FIBROBLASTS; NONMUSCLE TROPOMYOSIN; CULTURED-CELLS; MUSCLE TROPOMYOSIN; BETA-TROPOMYOSIN; MESSENGER-RNA; DIFFERENTIAL EXPRESSION	cDNA clones encoding four rat tropomyosin isoforms, termed TM-2, TM-3, TM-5a, and TM-5b, were isolated and characterized. All are derived from the alpha-tropomyosin gene via alternative RNA processing and the use of two alternate promoters. The cDNA sequences predict that TM-2 and TM-3 both contain 284 amino acids and differ from each other only at an internal region of the protein from amino acids 189 through 213, due to alternative splicing of exons 6a and 6b. TM-5a and TM-5b both contain 248 amino acids and differ from each other only at an internal exon encoding amino acids 153 through 177, also due to alternative splicing of exons 6a and 6b. The differences in the amino acid sequence encoded by these alternate exons affects the theoretical actin-binding pattern of the tropomyosins, such that TM-5b is expected to bind actin with greater affinity than TM-5a. TM-2 and TM-3 are transcribed from the upstream promoter, and TM-5a and TM-5b are transcribed from an internal promoter. In addition, all four isoforms contain the identical COOH-terminal coding region. RNA protection analyses revealed that the mRNA for each isoform is expressed in a number of different tissues and cell types, although the expression of some isoforms is restricted to particular cell types. Furthermore, the expression of mRNA encoding these isoforms was found to be altered in a number of different virally transformed cell lines. The changes in the expression of tropomyosin mRNAs in transformed cells reflect changes in the relative use of the two promoters, as well as the relative use of alternatively spliced exons 6a and 6b.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [P01CA046370, T32CA009311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043049] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09311-10, CA46370] Funding Source: Medline; NIGMS NIH HHS [GM43049] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERNSTEIN BW, 1982, CELL MOTIL CYTOSKEL, V2, P1, DOI 10.1002/cm.970020102; BRADAC JA, 1989, MOL CELL BIOL, V9, P185, DOI 10.1128/MCB.9.1.185; BROSCHAT KO, 1986, J BIOL CHEM, V261, P3350; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYTON L, 1988, J MOL BIOL, V201, P507, DOI 10.1016/0022-2836(88)90633-X; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COTE GP, 1981, J BIOL CHEM, V256, P7257; CUMMINS P, 1974, BIOCHEM J, V141, P43, DOI 10.1042/bj1410043; CUMMINS P, 1973, BIOCHEM J, V133, P765, DOI 10.1042/bj1330765; EDELMAN GM, 1976, P NATL ACAD SCI USA, V73, P2047, DOI 10.1073/pnas.73.6.2047; FATTOUM A, 1983, BIOCHEMISTRY-US, V22, P1187, DOI 10.1021/bi00274a031; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; GIOMETTI CS, 1981, J BIOL CHEM, V256, P1840; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANKE PD, 1988, MOL CELL BIOL, V8, P3591, DOI 10.1128/MCB.8.9.3591; HEGMANN TE, 1989, J CELL BIOL, V109, P1141, DOI 10.1083/jcb.109.3.1141; HELFMAN DM, 1984, J BIOL CHEM, V259, P4136; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1975, J CELL BIOL, V65, P549, DOI 10.1083/jcb.65.3.549; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEAVITT J, 1986, MOL CELL BIOL, V6, P2721, DOI 10.1128/MCB.6.7.2721; LEESMILLER JP, 1990, J MOL BIOL, V213, P399, DOI 10.1016/S0022-2836(05)80202-5; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; LEWIS WG, 1980, J BIOL CHEM, V255, P6854; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIN CS, 1988, MOL CELL BIOL, V8, P160, DOI 10.1128/MCB.8.1.160; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; LIN JJC, 1988, J CELL BIOL, V107, P563, DOI 10.1083/jcb.107.2.563; LIN JJC, 1984, CANCER CELL, V1, P57; MACLEOD AR, 1985, P NATL ACAD SCI USA, V82, P7835, DOI 10.1073/pnas.82.23.7835; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MACLEOD AR, 1987, J MOL BIOL, V194, P1, DOI 10.1016/0022-2836(87)90710-8; MAK AS, 1980, J BIOL CHEM, V255, P3647; MANIATIS T, 1982, CLONING MANUAL; MATSUDAIRA PT, 1982, J CELL BIOL, V92, P657, DOI 10.1083/jcb.92.3.657; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MATSUMURA F, 1985, J BIOL CHEM, V260, P3851; MATSUMURA F, 1983, J BIOL CHEM, V258, P6636; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARSONWHITE SH, 1987, J BIOL CHEM, V262, P15998; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; POLLACK R, 1975, P NATL ACAD SCI USA, V72, P994, DOI 10.1073/pnas.72.3.994; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; RUIZOPAZO N, 1985, NATURE, V315, P67, DOI 10.1038/315067a0; SANDERS C, 1985, J BIOL CHEM, V260, P7264; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSS JA, 1980, J CELL BIOL, V87, P633, DOI 10.1083/jcb.87.3.633; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; TAKENAGA K, 1988, MOL CELL BIOL, V8, P5561, DOI 10.1128/MCB.8.12.5561; TAKENAGA K, 1988, MOL CELL BIOL, V8, P3934, DOI 10.1128/MCB.8.9.3934; WANG E, 1976, P NATL ACAD SCI USA, V73, P4065, DOI 10.1073/pnas.73.11.4065; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; YAMASHIROMATSUMURA S, 1988, J CELL BIOL, V106, P1973, DOI 10.1083/jcb.106.6.1973; YAMAWAKIKATAOKA Y, 1985, J BIOL CHEM, V260, P4440; YAMAWAKIKATAOKA Y, 1987, J BIOL CHEM, V262, P10791; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	68	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8408	8415						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022655				2022-12-25	WOS:A1991FK44100069
J	MEYER, M; MALY, K; UBERALL, F; HOFLACHER, J; GRUNICKE, H				MEYER, M; MALY, K; UBERALL, F; HOFLACHER, J; GRUNICKE, H			STIMULATION OF K+ TRANSPORT-SYSTEMS BY HA-RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ASCITES TUMOR-CELLS; MITOGENIC RESPONSE; OUABAIN-RESISTANT; VOLUME REGULATION; NIH-3T3 CELLS; GROWTH-FACTOR; V-MOS; COTRANSPORT; ONCOGENE	The expression of Ha-ras in quiescent NIH3T3 cells carrying a glucocorticoid-inducible human Ha-ras gene (Val-Gly mutation at codon 12) stimulates total Rb-86+ influx. This effect is predominantly due to an elevated Rb-86+ uptake through an ouabain-resistant, furosemide-sensitive system. The ouabain-sensitive Na+/K+-ATPase is less affected. The transport which is resistant to both inhibitors is not altered by Ha-ras. Overexpression of the Ha-ras proto-oncogene causes only a marginal increase in total Rb-86+ uptake. The stimulation of the furosemide-sensitive influx by Ha-ras is paralleled by an increase in mean cell volume which can be inhibited by furosemide. A rapid stimulation of the furosemide-sensitive Rb+ influx is also observed after addition of bombesin to growth-arrested cells. Furosemide inhibits the mitogenic response after expression of Ha-ras or addition of bombesin. Both the Ha-ras and the bombesin-induced stimulation of the furosemide-sensitive Rb+ transport can be blocked by protein kinase C depletion or the protein kinase C inhibitor staurosporine. In contrast to bombesin-induced phosphatidylinositol-4,5-bisphosphate hydrolysis which is down-modulated by Ha-ras, the stimulation of the furosemide-sensitive Rb+ influx by bombesin is elevated in Ha-ras-expressing cells. This is in accordance with the increased mitogenic activity of bombesin in Ha-ras-expressing cells.	UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, FRITZ PREGLSTR 3, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck				Meyer, Markus/0000-0002-4398-5642				ATLAN H, 1984, J MEMBRANE BIOL, V81, P181, DOI 10.1007/BF01868712; BAKKERGRUNWALD T, 1978, BIOCHIM BIOPHYS ACTA, V513, P292, DOI 10.1016/0005-2736(78)90181-5; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DOPPLER W, 1987, GENE, V54, P147, DOI 10.1016/0378-1119(87)90357-X; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; HANCOCK JF, 1988, ONCOGENE, V3, P187; HOFFMANN EK, 1983, J MEMBRANE BIOL, V76, P269, DOI 10.1007/BF01870369; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HUANG M, 1988, J BIOL CHEM, V263, P17975; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZRIVAS A, 1982, P NATL ACAD SCI-BIOL, V79, P6275, DOI 10.1073/pnas.79.20.6275; MALY K, 1988, MOL CELL BIOL, V8, P4212, DOI 10.1128/MCB.8.10.4212; MALY K, 1988, ADV ENZYME REGUL, V27, P121; MALY K, 1989, J BIOL CHEM, V264, P11839; MARSHALL CJ, 1989, INT J CANCER, P29; MCROBERTS JA, 1982, J BIOL CHEM, V257, P2260; MORRIS JDH, 1989, ONCOGENE, V4, P27; OBRIEN TG, 1987, J CELL PHYSIOL, V130, P377, DOI 10.1002/jcp.1041300310; OBRIEN TG, 1988, BIOCHIM BIOPHYS ACTA, V945, P41, DOI 10.1016/0005-2736(88)90360-4; Palfrey H C, 1981, Ann N Y Acad Sci, V372, P291, DOI 10.1111/j.1749-6632.1981.tb15482.x; PANET R, 1980, J MEMBRANE BIOL, V52, P273, DOI 10.1007/BF01869195; PANET R, 1982, J MEMBRANE BIOL, V70, P165, DOI 10.1007/BF01870226; PANET R, 1983, J MEMBRANE BIOL, V75, P219, DOI 10.1007/BF01871952; PANET R, 1985, BIOCHIM BIOPHYS ACTA, V813, P141, DOI 10.1016/0005-2736(85)90355-4; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; Peferoen M, 1988, Methods Mol Biol, V3, P395, DOI 10.1385/0-89603-126-8:395; PRICE BD, 1989, BIOCHEM J, V260, P157, DOI 10.1042/bj2600157; PRICE BD, 1989, J BIOL CHEM, V264, P16638; ROZENGURT E, 1988, COLD SPRING HARB SYM, V53, P945, DOI 10.1101/SQB.1988.053.01.109; ROZENGURT E, 1981, ADV ENZYME REGUL, V19, P61; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SVANE PC, 1990, RENAL PHYSL BIOCH, V13, P177; TUPPER JT, 1977, J CELL PHYSIOL, V91, P429, DOI 10.1002/jcp.1040910313; UEBERSCHAR S, 1983, BIOCHIM BIOPHYS ACTA, V731, P243, DOI 10.1016/0005-2736(83)90015-9; WAKELAM MJO, 1989, BIOCHEM J, V259, P737, DOI 10.1042/bj2590737; WARNOCK DG, 1984, FED PROC, V43, P2473; WILEY JS, 1974, J CLIN INVEST, V53, P745, DOI 10.1172/JCI107613; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	45	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8230	8235						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022640				2022-12-25	WOS:A1991FK44100045
J	OIKAWA, S; INUZUKA, C; KUROKI, M; ARAKAWA, F; MATSUOKA, Y; KOSAKI, G; NAKAZATO, H				OIKAWA, S; INUZUKA, C; KUROKI, M; ARAKAWA, F; MATSUOKA, Y; KOSAKI, G; NAKAZATO, H			A SPECIFIC HETEROTYPIC CELL-ADHESION ACTIVITY BETWEEN MEMBERS OF CARCINOEMBRYONIC ANTIGEN FAMILY, W272 AND NCA, IS MEDIATED BY N-DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-REACTING ANTIGEN; CEA GENE FAMILY; MOLECULAR-CLONING; CDNA SEQUENCE; PROTEINS; MORPHOGENESIS; SURFACE; MUTANTS; CLONES	The Ca2+-independent homotypic and heterotypic cell adhesion activities of a carcinoembryonic antigen (CEA) family member, W272 (CGM6), whose cDNA has recently been isolated from libraries of human peripheral leukocytes of apparently normal subjects (Arakawa, F., Kuroki, Mo., Misumi, Y., Oikawa, S., Nakazato, H., and Matsuoka, Y. (1990) Biochem. Biophys. Res. Commun. 166, 1063-1071) and spleen of chronic myelogenous leukemia patients (Berling, B., Kolbinger, F., Grunert, F., Thompson, J. A., Brombacher, F., Buchegger, F., von Kleist, S., and Zimmermann, W. (1990) Cancer Res. 50, 6534-6539) has been examined. Chinese hamster ovary cells transfected with the cDNA for W272, CEA, nonspecific cross-reacting antigen (NCA), and various antigens containing chimeric N-domain have been used. The W272 producers did not show homotypic binding at all but bound only to the cells expressing NCA and a chimeric CEA whose N-domain is substituted by that of NCA, indicating the major contribution of N-domain of NCA in the specific binding. The importance of the N-terminal region of NCA N-domain for the W272-NCA binding has been shown by detailed analysis using COS-1 cells producing various NCA whose N-domain are chimera of that of NCA and CEA. The strict heterotypic nature of the W272-NCA adhesion strongly suggests that the cell adhesion activities exhibited by CEA family members are not the fortuitous activity but the specific one which have some important physiological roles.	SUNTORY INST BIOMED RES, MOLEC BIOL LAB, 1-1-1 WAKAYAMADAI, SHIMAMOTO, OSAKA 618, JAPAN; FUKUOKA UNIV, SCH MED, DEPT BIOCHEM 1, JONAN KU, FUKUOKA 81401, JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP, BUNKYO KU, TOKYO 113, JAPAN	Suntory Holdings Ltd; Fukuoka University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital								ARAKAWA F, 1990, BIOCHEM BIOPH RES CO, V166, P1063, DOI 10.1016/0006-291X(90)90975-S; BARNETT T, 1990, TUMOR BIOL, V11, P59; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BERLING B, 1990, CANCER RES, V50, P6534; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COURNOYER D, 1988, CANCER RES, V48, P3153; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDENBERG DM, 1981, CANCER RES, V41, P4354; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; KUROKI M, 1988, JPN J CANCER RES, V79, P82, DOI 10.1111/j.1349-7006.1988.tb00014.x; KUROKI M, 1990, BIOCHEM BIOPH RES CO, V166, P701, DOI 10.1016/0006-291X(90)90866-L; KUROKI M, 1982, JNCI-J NATL CANCER I, V69, P401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUOKA Y, 1983, J IMMUNOL METHODS, V58, P31, DOI 10.1016/0022-1759(83)90261-2; MATSUOKA Y, 1978, INT J CANCER, V21, P604, DOI 10.1002/ijc.2910210510; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; NAKAZATO H, 1989, CARCINOEMBRYONIC ANT, P75; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V144, P634, DOI 10.1016/S0006-291X(87)80013-X; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P511, DOI 10.1016/0006-291X(87)90304-4; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V146, P464, DOI 10.1016/0006-291X(87)90552-3; PAXTON RJ, 1987, P NATL ACAD SCI USA, V84, P920, DOI 10.1073/pnas.84.4.920; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SUZUKI R, 1983, J IMMUNOL, V130, P981; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TATARINOV Y S, 1970, Byulleten' Eksperimental'noi Biologii i Meditsiny, V69, P66; TAWARAGI Y, 1988, BIOCHEM BIOPH RES CO, V150, P89, DOI 10.1016/0006-291X(88)90490-1; THOMPSON JA, 1989, BIOCHEM BIOPH RES CO, V158, P996, DOI 10.1016/0006-291X(89)92821-0; THOMSON DMP, 1969, P NATL ACAD SCI USA, V64, P161, DOI 10.1073/pnas.64.1.161; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZIMMERMANN W, 1987, P NATL ACAD SCI USA, V84, P2960, DOI 10.1073/pnas.84.9.2960	40	117	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					7995	8001						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022629				2022-12-25	WOS:A1991FK44100009
J	SUZUKI, S; SUGAWARA, K; SATOH, Y; TOYOTA, T				SUZUKI, S; SUGAWARA, K; SATOH, Y; TOYOTA, T			INSULIN STIMULATES THE GENERATION OF 2 PUTATIVE INSULIN MEDIATORS, INOSITOL-GLYCAN AND DIACYLGLYCEROL IN BC3H-1 MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; POLAR HEAD GROUP; SENSITIVE GLYCOSYL-PHOSPHATIDYLINOSITOL; HEPATIC PLASMA-MEMBRANES; PYRUVATE-DEHYDROGENASE; GLUCOSE-TRANSPORT; RAT HEPATOCYTES; INCREASES; ADIPOCYTES; GLUCOSE-6-PHOSPHATASE	Recent evidence suggests that insulin induces hydrolysis of phosphatidylinositol-glycan (PI-G) and releases inositol-glycan (IG) and diacylglycerol (DAG). These two mediators are speculated to mediate different insulin actions. In this study, we examined metabolic labeling of PI-G in BC3H-1 myocytes with known precursors of PI-G. PI-G was metabolically labeled with [H-3]myo-inositol, [H-3]glucosamine, [H-3]galactose, [H-3]glycerol, and [H-3]myristic acid. The treatment of H-3-labeled PI-G with phosphatidylinositol-specific phospholipase C liberated [H-3]myo-inositol, [H-3]glucosamine, or [H-3]galactosamine-labeled IGs, and [H-3]glycerol or [H-3]myristic acid-labeled DAG. In BC3H-1 myocytes, insulin induced phosphodiesteratic hydrolysis of PI-G and stimulated generation of IGs and DAG. Released IGs were labeled with [H-3]myo-inositol, [H-3]glucosamine, and [H-3]galactose. Released DAG was labeled with [H-3]glycerol and [H-3]myristic acid. The IG had a dose-dependent insulin-like activity on glucose oxidation and lipogenesis without affecting glucose transport in rat adipocytes. Insulin increased H-3 radioactivities of IG and insulin-mimicking activities of IG. These results provided further evidence that hydrolysis of PI-G and generation of IGs and DAG might be early steps in some insulin actions.			SUZUKI, S (corresponding author), TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 3,SENDAI,MIYAGI 980,JAPAN.							ACEVEDODUNCAN M, 1989, FEBS LETT, V244, P174, DOI 10.1016/0014-5793(89)81186-X; ALEMANY S, 1987, NATURE, V330, P77, DOI 10.1038/330077a0; ALVAREZ JF, 1988, BIOCHEM BIOPH RES CO, V152, P1455, DOI 10.1016/S0006-291X(88)80449-2; CHAN BL, 1988, SCIENCE, V241, P1670, DOI 10.1126/science.2843987; COOPER DR, 1987, J BIOL CHEM, V262, P3633; CROFFORD OB, 1965, J BIOL CHEM, V240, P14; FARESE RV, 1988, BIOCHEM J, V256, P185, DOI 10.1042/bj2560185; FARESE RV, 1989, DIABETES METAB REV, V5, P455, DOI 10.1002/dmr.5610050504; FARESE RV, 1985, BIOCHEM J, V231, P269, DOI 10.1042/bj2310269; FARESE RV, 1984, J BIOL CHEM, V259, P7094; FARESE RV, 1988, BIOCHEM J, V256, P175, DOI 10.1042/bj2560175; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; HESKETH JE, 1988, FEBS LETT, V241, P115, DOI 10.1016/0014-5793(88)81042-1; JARETT L, 1979, SCIENCE, V206, P1407, DOI 10.1126/science.505013; KELLY KL, 1986, FEBS LETT, V209, P238, DOI 10.1016/0014-5793(86)81119-X; KELLY KL, 1987, P NATL ACAD SCI USA, V84, P6404, DOI 10.1073/pnas.84.18.6404; KENNINGTON AS, 1989, ANAL BIOCHEM, V181, P1, DOI 10.1016/0003-2697(89)90384-9; LARNER J, 1979, SCIENCE, V206, P1408, DOI 10.1126/science.228395; LARNER J, 1988, BIOCHEM BIOPH RES CO, V151, P1416, DOI 10.1016/S0006-291X(88)80520-5; LARNER J, 1988, DIABETES, V37, P265; LUTTRELL L, 1986, ENDOCRINOLOGY, V119, P331, DOI 10.1210/endo-119-1-331; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; MACICAO F, 1990, BIOCHEM J, V266, P909; MATO JM, 1987, BIOCHEM BIOPH RES CO, V146, P764, DOI 10.1016/0006-291X(87)90595-X; MATO JM, 1987, J BIOL CHEM, V262, P2131; MERIDA I, 1988, FEBS LETT, V236, P251, DOI 10.1016/0014-5793(88)80325-9; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; ROBERTSON DG, 1989, J BIOL CHEM, V264, P6773; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROMERO G, 1988, SCIENCE, V240, P509, DOI 10.1126/science.3282305; ROMERO G, 1990, P NATL ACAD SCI USA, V87, P1476, DOI 10.1073/pnas.87.4.1476; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUIZALBUSAC JM, 1989, FEBS LETT, V258, P281, DOI 10.1016/0014-5793(89)81674-6; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SALTIEL AR, 1987, BIOCHEM BIOPH RES CO, V149, P1084, DOI 10.1016/0006-291X(87)90519-5; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SALTIEL AR, 1987, ENDOCRINOLOGY, V120, P967, DOI 10.1210/endo-120-3-967; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STANDAERT ML, 1988, J BIOL CHEM, V263, P8696; STEVENS EVJ, 1987, ARCH BIOCHEM BIOPHYS, V258, P361, DOI 10.1016/0003-9861(87)90356-0; STRALFORS P, 1988, NATURE, V335, P554, DOI 10.1038/335554a0; SUZUKI S, 1987, J BIOL CHEM, V262, P3199; SUZUKI S, 1984, BIOCHEM BIOPH RES CO, V118, P40, DOI 10.1016/0006-291X(84)91064-7; SUZUKI S, 1984, ARCH BIOCHEM BIOPHYS, V235, P418, DOI 10.1016/0003-9861(84)90215-7; VILA MD, 1989, FEBS LETT, V244, P177, DOI 10.1016/0014-5793(89)81187-1; VILLALBA M, 1988, BIOCHIM BIOPHYS ACTA, V968, P69, DOI 10.1016/0167-4889(88)90045-6; WITTERS AR, 1988, P NATL ACAD SCI USA, V85, P5473	48	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8115	8121						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	2022633				2022-12-25	WOS:A1991FK44100028
J	SONG, KB; FREY, PA				SONG, KB; FREY, PA			MOLECULAR-PROPERTIES OF LYSINE-2,3-AMINOMUTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE 2,3-AMINOMUTASE; S-ADENOSYLMETHIONINE; CONFORMATION	Lysine-2,3-aminomutase purified from Clostridium subterminale SB4 is reported to exhibit an apparent subunit M(r) of 48,000, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the undenatured enzyme exhibits an apparent M(r) of 285,000, as determined by electrophoretic mobility and gel permeation chromatography (Chirpich, T. P., Zappia, V., Costilow, R. N., and Barker, H. A. (1970) J. Biol. Chem. 245, 1778-1789). The diffusion coefficient of the enzyme is 3.36 x 10(-7) cm2/s, as determined by quasielastic light scattering. The overall M(r) calculated from the diffusion coefficient and the published sedimentation coefficient is 259,000. Cross-linking experiments using glutaraldehyde and dithiobis(succinimidylpropionate) as cross-linking reagents indicate that the enzyme has a hexameric quaternary structure. The number of major cyanogen bromide peptides, compared with the methionine content of the enzyme, is consistent with the subunits being identical, and isoelectric focusing also is consistent with identical subunits. The circular dichroism of the enzyme indicates that it is a highly ordered structure, which is estimated to consist of 26% alpha-helix and 48% beta-sheet. The enzyme contains approximately six molecules of pyridoxal 5'-phosphate per hexamer, as determined by the phenylhydrazine method. The amino acid analysis of the enzyme, after perfomic acid oxidation, indicates that it contains approximately 13 cysteine residues per subunit. Six sulfhydryl groups per hexamer react readily with 5,5'-dithiobis-2-nitrobenzoate, indicating that one sulfhydryl group is accessible per subunit.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	SONG, KB (corresponding author), UNIV WISCONSIN, GRAD SCH, INST ENZYME RES, MADISON, WI 53705 USA.				NIDDK NIH HHS [DK28607] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028607, R37DK028607] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANIAK J, 1989, J BIOL CHEM, V264, P1357; CAJACOB CA, 1985, BIOCHEMISTRY-US, V24, P2425, DOI 10.1021/bi00331a006; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHIRPICH TP, 1970, J BIOL CHEM, V245, P1778; FREY PA, 1990, ANN NY ACAD SCI, V585, P368, DOI 10.1111/j.1749-6632.1990.tb28069.x; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MOORE S, 1963, J BIOL CHEM, V238, P235; MOSS M, 1987, J BIOL CHEM, V262, P14859; MOSS ML, 1990, J BIOL CHEM, V265, P18112; PETROVICH RM, 1991, J BIOL CHEM, V266, P7656; WADA H, 1961, J BIOL CHEM, V236, P2089; WANG LX, 1988, MACROMOLECULES, V21, P3498, DOI 10.1021/ma00190a026; ZAPPIA V, 1970, BIOCHIM BIOPHYS ACTA, V207, P505	13	40	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7651	7655						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	2019591				2022-12-25	WOS:A1991FJ34200053
J	HARRIS, RW; SIMS, PJ; TWETEN, RK				HARRIS, RW; SIMS, PJ; TWETEN, RK			KINETIC ASPECTS OF THE AGGREGATION OF CLOSTRIDIUM-PERFRINGENS THETA-TOXIN ON ERYTHROCYTE-MEMBRANES - A FLUORESCENCE ENERGY-TRANSFER STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOLYSIN-O; PERFRINGOLYSIN-O; ELECTRON-MICROSCOPY; CHOLESTEROL; CEREOLYSIN; EXOTOXINS; PROTEINS; GENE	Fluorescence resonance energy transfer was used to monitor aggregation kinetics of the "thiol-activated" cytolysin (perfringolysin O (PFO) or theta-toxin) of Clostridium perfringens on erythrocyte membranes. PFO was labeled with the isothiocyanate derivatives of either fluorescein or tetramethylrhodamine. No detectable change in the hemolytic activity of PFO was detected after modification with either fluorophore at a ratio of 1:2 fluorophore molecules/cytolysin molecule. Fluorescence energy transfer (FET) between the donor (fluorescein.PFO or PFO(D)) and the acceptor (tetramethylrhodamine.PFO or PFO(A)) was detected by both quenching of donor fluorescence (520 nm) and by enhancement of acceptor fluorescence (575 nm) upon aggregation of labeled cytolysin molecules. FET was only observed when PFO(D) and PFO(A) were incubated in the presence of membranes. FET was not observed when PFO(D) and PFO(A) were incubated in a membrane-free solution or when unlabeled toxin was substituted for PFO(A). FET was also found to be temperature-dependent. The temperature-dependent rates of change in FET upon mixing labeled toxin with erythrocyte membranes proceeded without a lag phase and displayed an activation energy of 18.7 kcal/mol. At all temperatures aggregation of PFO was virtually complete before the onset of hemolysis, the latter exhibiting a distinct lag phase. The lag period before onset of hemolysis was temperature-dependent and exhibited an activation energy of 23.2 kcal/mol. These results suggest that the aggregation of membrane-associated PFO is necessary to initiate the hemolytic process, and the lag phase which occurs before onset of hemolysis reflects the kinetics of PFO monomer to polymer conversion.	UNIV OKLAHOMA,HLTH SCI CTR,CTR MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73190; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036061, R37HL036061] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36061] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNHEIMER AW, 1947, J GEN PHYSIOL, V30, P337, DOI 10.1085/jgp.30.4.337; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; COWELL JL, 1978, ARCH BIOCHEM BIOPHYS, V190, P603, DOI 10.1016/0003-9861(78)90316-8; COWELL JL, 1978, BIOCHIM BIOPHYS ACTA, V507, P230, DOI 10.1016/0005-2736(78)90419-4; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; DUNCAN JL, 1974, INFECT IMMUN, V9, P1022, DOI 10.1128/IAI.9.6.1022-1027.1974; Fairclough R H, 1978, Methods Enzymol, V48, P347; HASE J, 1975, JPN J EXP MED, V45, P433; KEOUGH KMW, 1984, MEMBRANE FLUIDITY, P55; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSINGTAYLOR D, 1981, J CELL BIOL, V89, P362; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V558, P307, DOI 10.1016/0005-2736(79)90265-7; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V554, P68, DOI 10.1016/0005-2736(79)90007-5; NIEDERMEYER W, 1985, TOXICON, V23, P425, DOI 10.1016/0041-0101(85)90026-1; OHNOIWASHITA Y, 1986, BIOCHEMISTRY-US, V25, P6048, DOI 10.1021/bi00368a032; PRIGENT D, 1976, BIOCHIM BIOPHYS ACTA, V443, P288, DOI 10.1016/0005-2736(76)90511-3; SIMS PJ, 1984, BIOCHEMISTRY-US, V23, P3260, DOI 10.1021/bi00309a021; Smythe C.J., 1978, BACTERIAL TOXINS CEL, P129; STEVENS B, 1970, CHEM KINETICS; TWETEN RK, 1988, INFECT IMMUN, V56, P3235, DOI 10.1128/IAI.56.12.3235-3240.1988; TWETEN RK, 1988, INFECT IMMUN, V56, P3228, DOI 10.1128/IAI.56.12.3228-3234.1988	22	62	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6936	6941						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016307				2022-12-25	WOS:A1991FG72700048
J	KIM, SK; HOSOI, M; KIKUCHI, N; YAMAMOTO, K				KIM, SK; HOSOI, M; KIKUCHI, N; YAMAMOTO, K			AMINO-TERMINAL AMINO-ACID-SEQUENCE AND HETEROGENEITY IN GLYCOSYLATION OF RAT RENAL RENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUB-MAXILLARY GLAND; HOG KIDNEY; ISOELECTRIC HETEROGENEITY; COMPLETE PURIFICATION; PROTEINS; PEPTIDE; PURE; CHROMATOGRAPHY; INHIBITOR; CLONING	We isolated 7.4 mg of pure renin from 2 kg of rat kidneys using affinity chromatography on pepstatin-aminohexyl-Sepharose and an octapeptide renin inhibitor, H-77-Sepharose. Sodium dodecyl sulfate-poly-acrylamide gel electrophoresis showed that renin consists of two polypeptide chains linked by a disulfide bond, one of M(r) = 36,000 (heavy chain) and the other of M(r) = 3,000 (light chain). The amino-terminal 10-amino acid sequences of the heavy and the light chains were identical to the sequences beginning at Ser72 and Asp355, respectively, of the amino acid sequence of preprorenin deduced from the renin cDNA sequence. Amino acid sequencing of the carboxyl-terminal peptide of the heavy chain, generated by digestion with lysyl endopeptidase, showed that the carboxyl-terminal residue of the heavy chain is Phe. Thus, the propeptide of prorenin is cleaved after Thr71, followed by removal of two amino acids, Arg353 and Asn354, the result being formation of the heavy and light chains. Thus, the site of cleavage of rat prorenin is after a nonbasic amino acid, in contrast to the cleavage of the propeptide after a pair of basic amino acids in mouse submaxillary renin, human renal renin, and many secretory proteins. Treatment of renin with neuraminidase or glycopeptidase F had no apparent effect on the charge heterogeneity of renin. Glycosylation probably does not contribute to charge heterogeneity.	SHIONOGI & CO LTD,SHIONOGI RES LABS,OSAKA 553,JAPAN	Shionogi & Company Limited	KIM, SK (corresponding author), OSAKA CITY UNIV,SCH MED,DEPT PHARMACOL,1-4-54 ASAHIMACHI,ABENO KU,OSAKA 545,JAPAN.							BODANSZKY M, 1955, NATURE, V175, P685, DOI 10.1038/175685a0; BURNHAM CE, 1987, P NATL ACAD SCI USA, V84, P5605, DOI 10.1073/pnas.84.16.5605; COHEN S, 1972, BIOCHEMISTRY-US, V11, P4286, DOI 10.1021/bi00773a015; CORVOL P, 1983, HYPERTENSION S1, V5, P3; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DO YS, 1987, J BIOL CHEM, V262, P1037; DORER FE, 1984, HYPERTENSION, V6, P374, DOI 10.1161/01.HYP.6.3.374; DZAU VJ, 1979, BIOCHEMISTRY-US, V18, P5224, DOI 10.1021/bi00590a029; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; FIGUEIREDO AFS, 1983, BIOCHEMISTRY-US, V22, P5476, DOI 10.1021/bi00293a004; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; INAGAMI T, 1977, J BIOL CHEM, V252, P2978; KATZ SA, 1982, ENDOCRINOLOGY, V111, P814, DOI 10.1210/endo-111-3-814; KIM S, 1987, J HISTOCHEM CYTOCHEM, V35, P549, DOI 10.1177/35.5.3549890; KIM S, 1987, AM J PHYSIOL, V253, pE621, DOI 10.1152/ajpendo.1987.253.6.E621; KIM S, 1989, AM J PHYSIOL, V256, pE798, DOI 10.1152/ajpendo.1989.256.6.E798; KIM S, 1987, AM J PHYSIOL, V252, pE136, DOI 10.1152/ajpendo.1987.252.1.E136; KIM S, 1988, AM J PHYSIOL, V255, pE642, DOI 10.1152/ajpendo.1988.255.5.E642; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATOBA T, 1978, BIOCHIM BIOPHYS ACTA, V526, P560, DOI 10.1016/0005-2744(78)90146-8; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCINTYRE GD, 1983, BIOCHEM J, V211, P519, DOI 10.1042/bj2110519; MISONO KS, 1982, ARCH BIOCHEM BIOPHYS, V217, P574, DOI 10.1016/0003-9861(82)90539-2; MISONO KS, 1982, P NATL ACAD SCI-BIOL, V79, P4858, DOI 10.1073/pnas.79.16.4858; MISONO KS, 1982, J BIOL CHEM, V257, P7536; MURAKAMI K, 1975, BIOCHEM BIOPH RES CO, V62, P757, DOI 10.1016/0006-291X(75)90464-7; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; SESSLER FM, 1985, AM J PHYSIOL, V248, pE694, DOI 10.1152/ajpendo.1985.248.6.E694; SESSLER FM, 1986, AM J PHYSIOL, V250, pE551, DOI 10.1152/ajpendo.1986.250.5.E551; SHEEHAN JC, 1955, J AM CHEM SOC, V77, P1067, DOI 10.1021/ja01609a099; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; STEINER DF, 1984, J CELL BIOCHEM, V24, P121, DOI 10.1002/jcb.240240204; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; SZELKE M, 1982, NATURE, V299, P555, DOI 10.1038/299555a0; SZELKE M, 1982, HYPERTENSION, V4, P59, DOI 10.1161/01.HYP.4.3_Pt_2.59; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; YOKOSAWA H, 1980, J BIOL CHEM, V255, P3498	39	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7044	7050						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016314				2022-12-25	WOS:A1991FG72700063
J	SCHUMANN, WC; MAGNUSSON, I; CHANDRAMOULI, V; KUMARAN, K; WAHREN, J; LANDAU, BR				SCHUMANN, WC; MAGNUSSON, I; CHANDRAMOULI, V; KUMARAN, K; WAHREN, J; LANDAU, BR			METABOLISM OF [2-C-14]ACETATE AND ITS USE IN ASSESSING HEPATIC KREBS CYCLE ACTIVITY AND GLUCONEOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE; INVIVO; EXCHANGE; PATHWAYS; CARBON; ATOMS; GLUTAMINE; GLYCOGEN; HUMANS; LIVER	To examine the fate of the carbons of acetate and to evaluate the usefulness of labeled acetate in assessing intrahepatic metabolic processes during gluconeogenesis, [2-C-14]acetate, [2-C-14]ethanol, and [1-C-14]ethanol were infused into normal subjects fasted 60 h and given phenyl acetate. Distributions of C-14 in the carbons of blood glucose and glutamate from urinary phenylacetylglutamine were determined. With [2-C-14]acetate and [2-C-14]ethanol, carbon 1 of glucose had about twice as much C-14 as carbon 3. Carbon 2 of glutamate had about twice as much C-14 as carbon 1 and one-half to one-third as much as carbon 4. There was only a small amount in carbon 5. These distributions are incompatible with the metabolism of [2-C-14]acetate being primarily in liver. Therefore, [2-C-14]acetate cannot be used to study Krebs cycle metabolism in liver and in relationship to gluconeogenesis, as has been done. The distributions can be explained by: (a) fixation of (CO2)-C-14 from [2-C-14]acetate in the formation of the C-14-labeled glucose and glutamate in liver and (b) the formation of C-14-labeled glutamate in a second site, proposed to be muscle. [1,3-C-14]Acetone formation from the [2-C-14] acetate does not contribute to the distributions, as evidenced by the absence of C-14 in carbons 2-4 of glutamate after [1-C-14]ethanol administration.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN PHYSIOL,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,DEPT CLIN PHYSIOL,S-10401 STOCKHOLM 60,SWEDEN	Case Western Reserve University; Case Western Reserve University; Karolinska Institutet; Karolinska Institutet					NIDDK NIH HHS [DK-14507] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK014507, R01DK014507] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM S, 1952, J BIOL CHEM, V195, P567; ANTONY GJ, 1968, J LIPID RES, V9, P267; BERNSTEIN IA, 1957, METHOD ENZYMOL, V4, P561, DOI 10.1016/0076-6879(57)04071-9; BJORKMAN O, 1982, DIABETES, V31, P516, DOI 10.2337/diabetes.31.6.516; BULUS N, 1989, METABOLISM, V38, P1, DOI 10.1016/0026-0495(89)90131-5; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; DESROSIERS C, 1990, AM J PHYSIOL, V258, pE519, DOI 10.1152/ajpendo.1990.258.3.E519; FINK G, 1988, J BIOL CHEM, V263, P18036; FORSANDER O, 1960, H-S Z PHYSIOL CHEM, V318, P1, DOI 10.1515/bchm2.1960.318.1.1; GARBER AJ, 1976, J BIOL CHEM, V251, P836; GOEBEL R, 1982, FED PROC, V41, P96; HELLERSTEIN MK, 1989, CLIN RES, V37, pA130; HETENYI G, 1982, FED PROC, V41, P104; HETENYI G, 1983, BIOCHEM MED METAB B, V29, P372, DOI 10.1016/0006-2944(83)90073-X; HETENYI G, 1982, CAN J PHYSIOL PHARM, V60, P1603, DOI 10.1139/y82-237; HILL RJ, 1958, J BIOL CHEM, V230, P169; HOSTETLER KY, 1969, J BIOL CHEM, V244, P2075; JORFELDT L, 1978, METABOLISM, V27, P97, DOI 10.1016/0026-0495(78)90128-2; KADISH AH, 1968, CLIN CHEM, V14, P116; KALDERON B, 1987, FEBS LETT, V213, P209, DOI 10.1016/0014-5793(87)81493-X; KALDERON B, 1987, FEBS LETT, V220, P259, DOI 10.1016/0014-5793(87)80917-1; KAM W, 1978, J LIPID RES, V19, P591; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KATZ J, 1955, BIOCHIM BIOPHYS ACTA, V18, P87, DOI 10.1016/0006-3002(55)90012-3; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; KOEPPE RE, 1955, J BIOL CHEM, V216, P813; KOSUGI K, 1986, J BIOL CHEM, V261, P3179; LINDENEG O, 1964, CLIN SCI, V27, P427; LUNDQUIST F, 1962, J CLIN INVEST, V41, P955, DOI 10.1172/JCI104574; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MAGNUSSON I, 1987, J CLIN INVEST, V80, P1748, DOI 10.1172/JCI113267; NORSTEN C, 1990, BIOCHEM J, V265, P569, DOI 10.1042/bj2650569; PETERSEN KF, 1988, HEPATOLOGY, V8, P1237; RADZIUK J, 1989, AM J PHYSIOL, V257, pE158, DOI 10.1152/ajpendo.1989.257.2.E158; REMESY C, 1983, ANN NUTR METAB, V27, P57, DOI 10.1159/000176624; ROGNSTAD R, 1988, Medical Science Research, V16, P293; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; WEINMAN EO, 1967, PHYSIOL REV, V37, P252	39	93	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6985	6990						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	2016310				2022-12-25	WOS:A1991FG72700055
J	TANIYAMA, Y; KUROKI, R; OMURA, F; SEKO, C; KIKUCHI, M				TANIYAMA, Y; KUROKI, R; OMURA, F; SEKO, C; KIKUCHI, M			EVIDENCE FOR INTRAMOLECULAR DISULFIDE BOND SHUFFLING IN THE FOLDING OF MUTANT HUMAN LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUBTILISIN BPN'; STABILITY; PROTEIN; EXPRESSION; GENE; STABILIZATION; SECRETION; BINDING; YEAST	Our previous results using the Saccharomyces cerevisiae secretion system suggest that intramolecular exchange of disulfide bonds occurs in the folding pathway of human lysozyme in vivo (Taniyama, Y., Yamamoto, Y., Kuroki, R., and Kikuchi, M. (1990) J. Biol. Chem. 265, 7570-7575). Here we report on the results of introducing an artificial disulfide bond in mutants with 2 cysteine residues substituting for Ala83 and Asp91. The mutant (C83/91) protein was not detected in the culture medium of the yeast, probably because of incorrect folding. Thereupon, 2 cysteine residues Cys77 and Cys95 were replaced with Ala in the mutant C83/91, because a native disulfide bond Cys77-Cys95 was found not necessary for correct folding in vivo (Taniyama, Y., Yamamoto, Y., Nakao, M., Kikuchi, M., and Ikehara, M. (1988) Biochem. Biophys. Res. Commun. 152, 962-967). The resultant mutant (AC83/91) was secreted as two proteins (AC83/91-a and AC83/91-b) with different specific activities. Amino acid and peptide mapping analyses showed that two glutathiones appeared to be attached to the thiol groups of the cysteine residues introduced into AC83/91-a and that four disulfide bonds including an artificial disulfide bond existed in the AC83/91-b molecule. The presence of cysteine residues modified with glutathione may indicate that the non-native disulfide bond Cys83-Cys91 is not so easily formed as a native disulfide bond. These results suggest that the introduction of Cys83 and Cys91 may act to suppress the process of native disulfide bond formation through disulfide bond interchange in the folding of human lysozyme.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN									ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FETT JW, 1985, BIOCHEMISTRY-US, V24, P965, DOI 10.1021/bi00325a024; HAYAKAWA T, 1987, GENE, V56, P53; IKEHARA M, 1986, CHEM PHARM BULL, V34, P2202; INAKA K, 1990, Protein Engineering, V3, P325; JIGAMI Y, 1986, GENE, V43, P273, DOI 10.1016/0378-1119(86)90216-7; KIKUCHI M, 1990, EUR J BIOCHEM, V187, P315, DOI 10.1111/j.1432-1033.1990.tb15307.x; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHINSON C, 1989, BIOCHEMISTRY-US, V28, P4807, DOI 10.1021/bi00437a043; MIYANOHARA A, 1983, P NATL ACAD SCI-BIOL, V80, P1, DOI 10.1073/pnas.80.1.1; MURAKI M, 1986, AGR BIOL CHEM TOKYO, V50, P713, DOI 10.1080/00021369.1986.10867445; NANJO F, 1988, J BIOCHEM-TOKYO, V104, P255, DOI 10.1093/oxfordjournals.jbchem.a122453; NISHIKAWA S, 1990, PROTEIN ENG, V3, P443, DOI 10.1093/protein/3.5.443; PANTOLIANO MW, 1987, BIOCHEMISTRY-US, V26, P2077, DOI 10.1021/bi00382a002; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; SAUER RT, 1986, BIOCHEMISTRY-US, V25, P5992, DOI 10.1021/bi00368a024; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TANIYAMA Y, 1990, J BIOL CHEM, V265, P16767; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; VILLAFRANCA JE, 1987, BIOCHEMISTRY-US, V26, P2182, DOI 10.1021/bi00382a017; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WELLS JA, 1986, J BIOL CHEM, V261, P6564; WETZEL R, 1988, P NATL ACAD SCI USA, V85, P401, DOI 10.1073/pnas.85.2.401; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0	34	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6456	6461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	2007594				2022-12-25	WOS:A1991FE37300068
J	DREWES, G; FAULSTICH, H				DREWES, G; FAULSTICH, H			A REVERSIBLE CONFORMATIONAL TRANSITION IN MUSCLE ACTIN IS CAUSED BY NUCLEOTIDE EXCHANGE AND UNCOVERS CYSTEINE IN POSITION-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; AMINO-ACID SEQUENCE; ADP-ACTIN; METAL-ION; F-ACTIN; MONOMERIC ACTIN; ATP HYDROLYSIS; THIOL-GROUPS; POLYMERIZATION; BINDING	ATP-G-actin in the absence of excess ATP and divalent metal ions was treated with ADP in amounts large enough to ensure complete formation of ADP-G-actin. Under these conditions the monomer undergoes a very slow structural transition as seen by the exposure of 2.0 +/- 0.2 thiol groups per actin molecule. Once exposed, the second thiol group reacts with 5,5'-dithiobis-(2-nitrobenzoic acid) at a rate approximately 10-fold higher than that of cysteine 374. Labeling experiments with 2,4-dinitrophenyl [1-C-14]cysteinyl disulfide followed by digestion and peptide analysis showed (besides reaction with cysteine 374) nearly exclusive labeling of cysteine 10. Since this residue is completely shielded in ATP-G-actin, exchange of ATP for ADP must have caused a partial unfolding of the protein uncovering the side chain of this cysteine. The transition is reversible, because addition of ATP or of excess divalent metal ions restored the conformation with only cysteine 374 exposed. Reversibility of the transition allowed us to directly determine the relative affinities of ATP and ADP to monomeric actin in the absence of Me2+ ions. By determination of the 50% exposure value of cysteine 10 from either side of the equilibrium we found a value of K(ATP)/K(ADP) = 30. The rate of uncovering of the thiol of cysteine 10 at 0-degrees-C was distinctly slower (t1/2 = 9 h) than its reshielding by the addition of ATP (t1/2 = 3 h). The structural change was accompanied by a decrease in polymerization rate. Relative polymerization rates were determined as ATP-G(1S)-actin:ADP-G(approximately 1S)-actin:ADP-G(2S)-actin = 1.0:0.35:0.1. From the data presented here we conclude that preparations of ADP-G-actin remain undefined unless the number of thiol groups exposed has been determined.	MAX PLANCK INST MED RES,JAHNSTR 29,W-6900 HEIDELBERG 1,GERMANY	Max Planck Society				Drewes, Gerard/0000-0003-0575-6766				BARDEN JA, 1986, BIOCHEM INT, V12, P95; BARDEN JA, 1989, BIOCHEMISTRY-US, V28, P5995; BLACKHOLM H, 1981, BIOCHEM BIOPH RES CO, V103, P125, DOI 10.1016/0006-291X(81)91669-7; BRAUER M, 1986, BIOCHEMISTRY-US, V25, P2187, DOI 10.1021/bi00356a050; BROWN SS, 1979, J CELL BIOL, V83, P657, DOI 10.1083/jcb.83.3.657; CARLIER MF, 1986, J BIOL CHEM, V261, P778; COOPER JA, 1983, J MUSCLE RES CELL, V4, P235; DOSREMEDIOS CG, 1988, BIOPHYS J, V53, P28; DREWES G, 1990, ANAL BIOCHEM, V188, P109, DOI 10.1016/0003-2697(90)90536-I; DREWES G, 1990, J BIOL CHEM, V265, P3017; DUKE J, 1976, P NATL ACAD SCI USA, V73, P302, DOI 10.1073/pnas.73.2.302; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; ELZINGA M, 1975, J BIOL CHEM, V250, P5897; ELZINGA M, 1970, BIOCHEMISTRY-US, V9, P1365, DOI 10.1021/bi00808a010; ELZINGA M, 1972, COLD SPRING HARB SYM, V37, P1; FAULSTICH H, 1984, BIOCHEMISTRY-US, V23, P1608, DOI 10.1021/bi00303a004; FRIEDEN C, 1982, J BIOL CHEM, V257, P2882; GERSHMAN LC, 1989, BIOCHIM BIOPHYS ACTA, V995, P109, DOI 10.1016/0167-4838(89)90068-X; GRUBHOFER N, 1961, Z NATURFORSCH PT B, VB 16, P435; HAMBLY BD, 1986, BIOESSAYS, V4, P124, DOI 10.1002/bies.950040308; HIGASHI S, 1965, J MOL BIOL, V12, P843, DOI 10.1016/S0022-2836(65)80332-1; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1985, EMBO J, V4, P2113, DOI 10.1002/j.1460-2075.1985.tb03900.x; KABSCH W, 1989, CYTOSKELETAL EXTRACE, P42; KATZ AM, 1962, BIOCHIM BIOPHYS ACTA, V65, P82, DOI 10.1016/0006-3002(62)90151-8; KATZ AM, 1965, BIOCHEMISTRY-US, V4, P987, DOI 10.1021/bi00882a001; KEISER T, 1986, BIOCHEMISTRY-US, V25, P4899, DOI 10.1021/bi00365a026; KONNO K, 1985, P NATL ACAD SCI USA, V82, P7904, DOI 10.1073/pnas.82.23.7904; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAL AA, 1984, J BIOL CHEM, V259, P3061; LUSTY CJ, 1969, BIOCHEMISTRY-US, V8, P2933, DOI 10.1021/bi00835a036; MIKI M, 1990, EUR J BIOCHEM, V187, P155, DOI 10.1111/j.1432-1033.1990.tb15289.x; NEIDL C, 1979, EUR J BIOCHEM, V101, P163; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P1785, DOI 10.1021/bi00405a060; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P8613, DOI 10.1021/bi00423a016; OOSAWA M, 1986, J BIOCHEM, V100, P1001, DOI 10.1093/oxfordjournals.jbchem.a121778; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1983, ANAL BIOCHEM, V134, P406, DOI 10.1016/0003-2697(83)90316-0; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; SCHAFER A, 1975, FEBS LETT, V57, P51, DOI 10.1016/0014-5793(75)80150-5; SELDEN LA, 1987, FEBS LETT, V217, P89, DOI 10.1016/0014-5793(87)81249-8; SLEIGH RW, 1973, ARCH BIOCHEM BIOPHYS, V159, P792, DOI 10.1016/0003-9861(73)90520-1; STOURNARAS C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P86, DOI 10.1016/0167-4838(90)90105-O; STOURNARAS C, 1988, BIOCHEM BIOPH RES CO, V155, P962, DOI 10.1016/S0006-291X(88)80590-4; STRZELECKAGOLASZEWSKA H, 1989, EUR J BIOCHEM, V182, P299, DOI 10.1111/j.1432-1033.1989.tb14830.x; STRZELECKAGOLASZEWSKA H, 1978, EUR J BIOCHEM, V88, P229, DOI 10.1111/j.1432-1033.1978.tb12442.x; TONOMURA Y, 1961, J BIOCHEM-TOKYO, V50, P79, DOI 10.1093/oxfordjournals.jbchem.a127415; VALENTINRANC C, 1989, J BIOL CHEM, V264, P20871; WANGER M, 1983, FEBS LETT, V162, P112, DOI 10.1016/0014-5793(83)81059-X; WENDEL H, 1987, BIOCHIM BIOPHYS ACTA, V915, P205, DOI 10.1016/0167-4838(87)90301-3; WEST JJ, 1971, BIOCHEMISTRY-US, V10, P3547, DOI 10.1021/bi00795a009	53	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5508	5513						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005093				2022-12-25	WOS:A1991FD37000025
J	HILLE, R; ANDERSON, RF				HILLE, R; ANDERSON, RF			ELECTRON-TRANSFER IN MILK XANTHINE-OXIDASE AS STUDIED BY PULSE-RADIOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTION; MOLYBDENUM; MECHANISM; OXYGEN	Electron transfer within milk xanthine oxidase has been examined by the technique of pulse radiolysis. Radiolytically generated N-methylnicotinamide radical or 5-deazalumiflavin radical has been used to rapidly and selectively introduce reducing equivalents into the enzyme so that subsequent equilibration among the four redox-active centers of the enzyme (a molybdenum center, two iron-sulfur centers, and FAD) could be monitored spectrophotometrically. Experiments have been performed at pH 6 and 8.5, and a comprehensive scheme describing electron equilibration within the enzyme at both pH values has been developed. All rate constants ascribed to equilibration between specific pairs of centers in the enzyme are found to be rapid relative to enzyme turnover under the same conditions. Electron equilibration between the molybdenum center and one of the iron-sulfur centers of the enzyme (tentatively assigned Fe/S I) is particularly rapid, with a pH-independent first-order rate constant of approximately 8.5 x 10(3) s-1. The results unambiguously demonstrate the role of the iron-sulfur centers of xanthine oxidase in mediating electron transfer between the molybdenum and flavin centers of the enzyme.	MT VERNON HOSP,CANC RES CAMPAIGN,GRAY LAB,NORTHWOOD HA6 2JR,MIDDX,ENGLAND	University of Oxford	HILLE, R (corresponding author), OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210, USA.							ANDERSON RF, 1986, J BIOL CHEM, V261, P5870; ANDERSON RF, 1984, J CHEM SOC FARAD T 1, V80, P2693, DOI 10.1039/f19848002693; BHATTACHARYYA A, 1983, BIOCHEMISTRY-US, V22, P5270, DOI 10.1021/bi00292a005; BISBY RH, 1976, J CHEM SOC FARAD T 1, V72, P51, DOI 10.1039/f19767200051; BLIESE M, 1983, AUST J CHEM, V36, P1873, DOI 10.1071/CH9831873; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; EDMONDSON DE, 1987, FLAVINS FLAVOPROTEIN, P403; FARVER O, 1989, P NATL ACAD SCI USA, V86, P6968, DOI 10.1073/pnas.86.18.6968; HEELIS PF, 1989, INT J RADIAT BIOL, V55, P557, DOI 10.1080/09553008914550601; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1981, J BIOL CHEM, V256, P8933; HILLE R, 1985, J BIOL CHEM, V260, P569; HILLE R, 1982, J BIOL CHEM, V257, P8898; HILLE R, 1981, J BIOL CHEM, V256, P9090; HILLE R, 1986, J BIOL CHEM, V261, P1241; KNOX WE, 1946, J BIOL CHEM, V166, P391; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KOMAI H, 1971, FLAVINS FLAVOPROTEIN, P399; LAND EJ, 1968, BIOCHIM BIOPHYS ACTA, V162, P327, DOI 10.1016/0005-2728(68)90119-9; LOWE DJ, 1972, BIOCHEM J, V130, P239, DOI 10.1042/bj1300239; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MORRISON M, 1963, J BIOL CHEM, V238, P2847; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; OLSON JS, 1974, J BIOL CHEM, V249, P4350; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; SCHULER RH, 1980, J PHYS CHEM-US, V84, P2088, DOI 10.1021/j100453a020; SHARDY D, 1990, IN PRESS FLAVINS FLA	29	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5608	5615						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	2005100				2022-12-25	WOS:A1991FD37000040
